PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Matsuzaka, T; Shimano, H; Yahagi, N; Kato, T; Atsumi, A; Yamamoto, T; Inoue, N; Ishikawa, M; Okada, S; Ishigaki, N; Iwasaki, H; Iwasaki, Y; Karasawa, T; Kumadaki, S; Matsui, T; Sekiya, M; Ohashi, K; Hasty, AH; Nakagawa, Y; Takahashi, A; Suzuki, H; Yatoh, S; Sone, H; Toyoshima, H; Osuga, JI; Yamada, N				Matsuzaka, Takashi; Shimano, Hitoshi; Yahagi, Naoya; Kato, Toyonori; Atsumi, Ayaka; Yamamoto, Takashi; Inoue, Noriyuki; Ishikawa, Mayumi; Okada, Sumiyo; Ishigaki, Naomi; Iwasaki, Hitoshi; Iwasaki, Yuko; Karasawa, Tadayoshi; Kumadaki, Shin; Matsui, Toshiyuki; Sekiya, Motohiro; Ohashi, Ken; Hasty, Alyssa H.; Nakagawa, Yoshimi; Takahashi, Akimitsu; Suzuki, Hiroaki; Yatoh, Sigeru; Sone, Hirohito; Toyoshima, Hideo; Osuga, Jun-ichi; Yamada, Nobuhiro			Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance	NATURE MEDICINE			English	Article							STEAROYL-COA DESATURASE-1; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEINS; MICE LACKING; TRANSCRIPTION FACTOR; METABOLIC SYNDROME; LIPID-METABOLISM; LIVER-DISEASE; IKK-BETA; SENSITIVITY	Insulin resistance is often associated with obesity and can precipitate type 2 diabetes. To date, most known approaches that improve insulin resistance must be preceded by the amelioration of obesity and hepatosteatosis. Here, we show that this provision is not mandatory; insulin resistance and hyperglycemia are improved by the modification of hepatic fatty acid composition, even in the presence of persistent obesity and hepatosteatosis. Mice deficient for Elovl6, the gene encoding the elongase that catalyzes the conversion of palmitate to stearate, were generated and shown to become obese and develop hepatosteatosis when fed a high- fat diet or mated to leptin- deficient ob/ ob mice. However, they showed marked protection from hyperinsulinemia, hyperglycemia and hyperleptinemia. Amelioration of insulin resistance was associated with restoration of hepatic insulin receptor substrate- 2 and suppression of hepatic protein kinase C e activity resulting in restoration of Akt phosphorylation. Collectively, these data show that hepatic fatty acid composition is a new determinant for insulin sensitivity that acts independently of cellular energy balance and stress. Inhibition of this elongase could be a new therapeutic approach for ameliorating insulin resistance, diabetes and cardiovascular risks, even in the presence of a continuing state of obesity.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Internal Med Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Tsukuba; University of Tsukuba; University of Tokyo; Vanderbilt University	Shimano, H (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Internal Med Endocrinol & Metab, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/V-1761-2019; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014	Sone, Hirohito/0000-0003-1263-2817; Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045; Yahagi, Naoya/0000-0002-1823-1865; Karasawa, Tadayoshi/0000-0002-6738-2360				Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Hiraoka-Yamamoto J, 2004, CLIN EXP PHARMACOL P, V31, P107, DOI 10.1111/j.1440-1681.2004.04121.x; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Kato T, 2006, CELL METAB, V4, P143, DOI 10.1016/j.cmet.2006.06.009; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Maeda K, 2003, DIABETES, V52, P300, DOI 10.2337/diabetes.52.2.300; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Matsuzaka T, 2002, J LIPID RES, V43, P911; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakagawa Y, 2006, NAT MED, V12, P107, DOI 10.1038/nm1334; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Neumann-Haefelin C, 2004, DIABETES, V53, P528, DOI 10.2337/diabetes.53.3.528; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006; Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Torisu T, 2007, GENES CELLS, V12, P143, DOI 10.1111/j.1365-2443.2007.01044.x; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Wang Y, 2006, J LIPID RES, V47, P2028, DOI 10.1194/jlr.M600177-JLR200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	50	376	395	2	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1193	1202		10.1038/nm1662	http://dx.doi.org/10.1038/nm1662			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17906635				2022-12-27	WOS:000249980200035
J	Wang, Z; Nicholls, SJ; Rodriguez, ER; Kummu, O; Horkko, S; Barnard, J; Reynolds, WF; Topol, EJ; DiDonato, JA; Hazen, SL				Wang, Zeneng; Nicholls, Stephen J.; Rodriguez, E. Rene; Kummu, Outi; Horkko, Sohvi; Barnard, John; Reynolds, Wanda F.; Topol, Eric J.; DiDonato, Joseph A.; Hazen, Stanley L.			Protein carbamylation links inflammation, smoking, uremia and atherogenesis	NATURE MEDICINE			English	Article							APOLIPOPROTEIN-A-I; MYELOPEROXIDASE-CATALYZED OXIDATION; HEMOGLOBIN CARBAMYLATION; EOSINOPHIL PEROXIDASE; NITRIC-OXIDE; THIOCYANATE; CYANATE; EXPRESSION; ATHEROSCLEROSIS; CHLORINATION	Post- translational modification and functional impairment of proteins through carbamylation is thought to promote vascular dysfunction during end- stage renal disease. Cyanate, a reactive species in equilibrium with urea, carbamylates protein lysine residues to form epsilon-carbamyllysine (homocitrulline), altering protein structure and function. We now report the discovery of an alternative and quantitatively dominant mechanism for cyanate formation and protein carbamylation at sites of inflammation and atherosclerotic plaque: myeloperoxidase-catalyzed oxidation of thiocyanate, an anion abundant in blood whose levels are elevated in smokers. We also show that myeloperoxidase-catalyzed lipoprotein carbamylation facilitates multiple pro- atherosclerotic activities, including conversion of low-density lipoprotein into a ligand for macrophage scavenger receptor A1 recognition, cholesterol accumulation and foam-cell formation. In two separate clinical studies ( combined n = 1,000 subjects), plasma levels of protein-bound homocitrulline independently predicted increased risk of coronary artery disease, future myocardial infarction, stroke and death. We propose that protein carbamylation is a mechanism linking inflammation, smoking, uremia and coronary artery disease pathogenesis.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA; Univ Oulu, Dept Internal Med, Oulu, Finland; Univ Oulu, Bioctr Oulu, Oulu, Finland; Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland; Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Oulu; University of Oulu; University of Oulu; Cleveland Clinic Foundation	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hazens@ccf.org	Wang, Zeneng/AAK-6119-2021; Hazen, Stanley L/ABD-5845-2021	Kummu, Outi/0000-0003-0327-3496; Nicholls, Stephen/0000-0002-9668-4368; Topol, Eric/0000-0002-1478-4729	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [P01 HL077107, HL70621, P01 HL076491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076491, R01HL070621, P50HL077107] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Arlandson M, 2001, J BIOL CHEM, V276, P215, DOI 10.1074/jbc.M004881200; Asselbergs FW, 2004, AM J MED, V116, P429, DOI 10.1016/j.amjmed.2003.10.025; Baldus S, 2004, FREE RADICAL BIO MED, V37, P902, DOI 10.1016/j.freeradbiomed.2004.06.003; BOBB D, 1971, ANAL BIOCHEM, V40, P209, DOI 10.1016/0003-2697(71)90094-7; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Castellani LW, 2006, J LIPID RES, V47, P1366, DOI 10.1194/jlr.M600005-JLR200; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ERILL S, 1980, CLIN PHARMACOL THER, V27, P612, DOI 10.1038/clpt.1980.87; FLUCKIGER R, 1981, NEW ENGL J MED, V304, P823, DOI 10.1056/NEJM198104023041406; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HILL P, 1983, J CHRON DIS, V36, P439, DOI 10.1016/0021-9681(83)90136-4; HORKKO S, 1994, EUR J CLIN INVEST, V24, P105, DOI 10.1111/j.1365-2362.1994.tb00974.x; HORKKO S, 1992, KIDNEY INT, V41, P1175, DOI 10.1038/ki.1992.179; HUSGAFVELPURSIAINEN K, 1987, INT ARCH OCC ENV HEA, V59, P337, DOI 10.1007/BF00405277; KERSTEN HW, 1981, J DENT RES, V60, P831, DOI 10.1177/00220345810600041201; Kraus LM, 2001, KIDNEY INT, V59, pS102, DOI 10.1046/j.1523-1755.2001.59780102.x; Kumar AP, 2004, J BIOL CHEM, V279, P8300, DOI 10.1074/jbc.M311625200; Lhotta K, 1996, NEPHRON, V72, P442, DOI 10.1159/000188910; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McMillen TS, 2005, CIRCULATION, V111, P2798, DOI 10.1161/CIRCULATIONAHA.104.516278; Mun KC, 2000, BLOOD PURIFICAT, V18, P13, DOI 10.1159/000014403; Nicholls SJ, 2005, ARTERIOSCL THROM VAS, V25, P1102, DOI 10.1161/01.ATV.0000163262.83456.6d; Ok E, 2005, KIDNEY INT, V68, P173, DOI 10.1111/j.1523-1755.2005.00391.x; OLEA F, 1992, J ANAL TOXICOL, V16, P258, DOI 10.1093/jat/16.4.258; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; STARK GR, 1965, BIOCHEMISTRY-US, V4, P588, DOI 10.1021/bi00879a032; STARK GR, 1960, J BIOL CHEM, V235, P3177; STARK GR, 1963, J BIOL CHEM, V238, P214; STARK RG, 1964, J BIOL CHEM, V239, P1411; STIM J, 1995, KIDNEY INT, V48, P1605, DOI 10.1038/ki.1995.454; Stoves J, 2002, NEPHROL DIAL TRANSPL, V17, P2036, DOI 10.1093/ndt/17.11.2036; Sugiyama S, 2004, ARTERIOSCL THROM VAS, V24, P1309, DOI 10.1161/01.ATV.0000131784.50633.4f; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; vanDalen CJ, 1997, BIOCHEM J, V327, P487; Vita JA, 2004, CIRCULATION, V110, P1134, DOI 10.1161/01.CIR.0000140262.20831.8F; WEVER R, 1982, BIOCHIM BIOPHYS ACTA, V709, P212, DOI 10.1016/0167-4838(82)90463-0; Wu Z, 2007, NAT STRUCT MOL BIOL, V14, P861, DOI 10.1038/nsmb1284; Yang J, 2006, AM J PHYSIOL-HEART C, V291, pH3087, DOI 10.1152/ajpheart.00412.2006; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zheng L, 2005, J BIOL CHEM, V280, P38, DOI 10.1074/jbc.M407019200; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	47	516	534	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1176	1184		10.1038/nm1637	http://dx.doi.org/10.1038/nm1637			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17828273				2022-12-27	WOS:000249980200033
J	Baccala, R; Hoebe, K; Kono, DH; Beutler, B; Theofilopoulos, AN				Baccala, Roberto; Hoebe, Kasper; Kono, Dwight H.; Beutler, Bruce; Theofilopoulos, Argyrios N.			TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity	NATURE MEDICINE			English	Review							TOLL-LIKE RECEPTORS; PATTERN-RECOGNITION RECEPTORS; DENDRITIC CELL ACTIVATION; ANTIGEN-PRESENTING CELLS; LUPUS-ERYTHEMATOSUS; MURINE LUPUS; RIG-I; IMMUNE-RESPONSES; APOPTOTIC CELLS; MAMMALIAN DNA	We formulate a two-phase paradigm of autoimmunity associated with systemic lupus erythematosus, the archetypal autoimmune disease. The initial Toll-like receptor (TLR)-independent phase is mediated by dendritic cell uptake of apoptotic cell debris and associated nucleic acids, whereas the subsequent TLR-dependent phase serves an amplification function and is mediated by uptake of TLR ligands derived from self-antigens (principally nucleic acids) complexed with autoantibodies. Both phases depend on elaboration of type I interferons (IFNs), and therapeutic interruption of induction or activity of these cytokines in predisposed individuals might have a substantial mitigating effect in lupus and other autoimmune diseases.	Scripps Res Inst, Dept Immunol, La Jolla, CA 93037 USA	Scripps Research Institute	Baccala, R (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 93037 USA.	argyrio@scripps.edu		Hoebe, Kasper/0000-0002-3626-8098; Baccala, Roberto/0000-0002-3159-8469				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Andrade F, 2000, RHEUM DIS CLIN N AM, V26, P215, DOI 10.1016/S0889-857X(05)70136-8; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; Baccala R, 2005, IMMUNOL REV, V204, P9, DOI 10.1111/j.0105-2896.2005.00252.x; Bagavant H, 2004, SCAND J IMMUNOL, V60, P52, DOI 10.1111/j.0300-9475.2004.01463.x; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Bekeredjian-Ding IB, 2005, J IMMUNOL, V174, P4043, DOI 10.4049/jimmunol.174.7.4043; Berland R, 2006, IMMUNITY, V25, P429, DOI 10.1016/j.immuni.2006.07.014; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Bodano A, 2004, ARTHRITIS RHEUM, V50, P4070, DOI 10.1002/art.20721; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Boule MW, 2004, J EXP MED, V199, P1631, DOI 10.1084/jem.20031942; Braun D, 2003, J AUTOIMMUN, V20, P15, DOI 10.1016/S0896-8411(02)00109-9; Chen M, 2006, SCIENCE, V311, P1160, DOI 10.1126/science.1122545; Christensen SR, 2006, IMMUNITY, V25, P417, DOI 10.1016/j.immuni.2006.07.013; Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338; Cortez-Gonzalez X, 2006, DNA CELL BIOL, V25, P253, DOI 10.1089/dna.2006.25.253; Decker P, 2005, J IMMUNOL, V174, P3326, DOI 10.4049/jimmunol.174.6.3326; Denny MF, 2006, J IMMUNOL, V176, P2095, DOI 10.4049/jimmunol.176.4.2095; Dong L, 2005, ARTHRITIS RHEUM-US, V52, P651, DOI 10.1002/art.20810; Ehlers M, 2006, J EXP MED, V203, P553, DOI 10.1084/jem.20052438; Eriksson U, 2003, NAT MED, V9, P1484, DOI 10.1038/nm960; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Gaipl US, 2006, CURR TOP MICROBIOL, V305, P161, DOI 10.1007/3-540-29714-6_8; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Goodnow CC, 2005, NATURE, V435, P590, DOI 10.1038/nature03724; Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782; HANG L, 1983, J EXP MED, V157, P874, DOI 10.1084/jem.157.3.874; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hron JD, 2004, J IMMUNOL, V173, P2134, DOI 10.4049/jimmunol.173.3.2134; Ishii KJ, 2006, CURR PHARM DESIGN, V12, P4135, DOI 10.2174/138161206778743484; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janssen E, 2006, IMMUNITY, V24, P787, DOI 10.1016/j.immuni.2006.03.024; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245; KONO DH, 2004, SYSTEMIC LUPUS ERYTH, P225; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lang KS, 2006, J CLIN INVEST, V116, P2456, DOI 10.1172/JCI28349; Lang KS, 2005, NAT MED, V11, P138, DOI 10.1038/nm1176; Lartigue A, 2006, J IMMUNOL, V177, P1349, DOI 10.4049/jimmunol.177.2.1349; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Le Bon A, 2006, J IMMUNOL, V176, P2074, DOI 10.4049/jimmunol.176.4.2074; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Maldonado MA, 1999, J IMMUNOL, V162, P6322; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Martin DA, 2006, ARTHRITIS RHEUM-US, V54, P951, DOI 10.1002/art.21677; Martin DA, 2005, J EXP MED, V202, P1465, DOI 10.1084/jem.20052228; Mathian A, 2005, J IMMUNOL, V174, P2499, DOI 10.4049/jimmunol.174.5.2499; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012; Mohty M, 2003, J IMMUNOL, V171, P3385, DOI 10.4049/jimmunol.171.7.3385; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nordmark G, 2006, NAT CLIN PRACT RHEUM, V2, P262, DOI 10.1038/ncprheum0173; O'Neill LAJ, 2006, NAT IMMUNOL, V7, P1023, DOI 10.1038/ni1006-1023; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogden CA, 2006, CURR DIRECT AUTOIMMU, V9, P120; Okabe Y, 2005, J EXP MED, V202, P1333, DOI 10.1084/jem.20051654; Pawar RD, 2006, AM J PHYSIOL-RENAL, V291, pF509, DOI 10.1152/ajprenal.00453.2005; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Poole BD, 2006, AUTOIMMUNITY, V39, P63, DOI 10.1080/08916930500484849; Rezaei N, 2006, INT IMMUNOPHARMACOL, V6, P863, DOI 10.1016/j.intimp.2006.02.005; Ronnblom L, 2006, ARTHRITIS RHEUM-US, V54, P408, DOI 10.1002/art.21571; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; SANO H, 1982, J IMMUNOL, V128, P1341; Savarese E, 2006, BLOOD, V107, P3229, DOI 10.1182/blood-2005-07-2650; Schwarting A, 2005, J AM SOC NEPHROL, V16, P3264, DOI 10.1681/ASN.2004111014; Seya T, 2003, ANTICANCER RES, V23, P4369; Sigurdsson S, 2005, AM J HUM GENET, V76, P528, DOI 10.1086/428480; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Stewart TA, 2003, CYTOKINE GROWTH F R, V14, P139, DOI 10.1016/S1359-6101(02)00088-6; Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Takemura Y, 2007, J CLIN INVEST, V117, P375, DOI 10.1172/JCI29709; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Tsukumo SI, 2004, CLIN IMMUNOL, V113, P14, DOI 10.1016/j.clim.2004.05.009; Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696; Wagner H, 2006, ADV IMMUNOL, V91, P159, DOI 10.1016/S0065-2776(06)91004-9; Waldner H, 2004, J CLIN INVEST, V113, P990, DOI 10.1172/JCI200419388; Wenzel J, 2006, CLIN EXP DERMATOL, V31, P576, DOI 10.1111/j.1365-2230.2006.02150.x; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Wu XB, 2006, ARTHRITIS RHEUM-US, V54, P336, DOI 10.1002/art.21553; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoshida H, 2005, NAT IMMUNOL, V6, P49, DOI 10.1038/ni1146; Yu P, 2006, INT IMMUNOL, V18, P1211, DOI 10.1093/intimm/dxl067; Zhu JK, 2005, J CLIN INVEST, V115, P1869, DOI 10.1172/JCI23049; Zhuang HY, 2006, ARTHRITIS RHEUM-US, V54, P1573, DOI 10.1002/art.21800	100	369	393	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2007	13	5					543	551		10.1038/nm1590	http://dx.doi.org/10.1038/nm1590			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17479100				2022-12-27	WOS:000246302800020
J	Backer, MV; Levashova, Z; Patel, V; Jehning, BT; Claffey, K; Blankenberg, FG; Backer, JM				Backer, Marina V.; Levashova, Zoya; Patel, Vimalkumar; Jehning, Brian T.; Claffey, Kevin; Blankenberg, Francis G.; Backer, Joseph M.			Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; FUSION PROTEINS/; CLINICAL-TRIALS; EXPRESSION; THERAPY; BINDING; CANCER; CELLS; RADIOACTIVITY	We describe a new generation of protein-targeted contrast agents for multimodal imaging of the cell-surface receptors for vascular endothelial growth factor (VEGF). These receptors have a key role in angiogenesis and are important targets for drug development. Our probes are based on a single-chain recombinant VEGF expressed with a cysteine-containing tag that allows site-specific labeling with contrast agents for near-infrared fluorescence imaging, single-photon emission computed tomography or positron emission tomography. These probes retain VEGF activities in vitro and undergo selective and highly specific focal uptake into the vasculature of tumors and surrounding host tissue in vivo. The fluorescence contrast agent shows long-term persistence and co-localizes with endothelial cell markers, indicating that internalization is mediated by the receptors. We expect that multimodal imaging of VEGF receptors with these probes will be useful for clinical diagnosis and therapeutic monitoring, and will help to accelerate the development of new angiogenesis-directed drugs and treatments.	SibTech Inc, Newington, CT 06111 USA; Stanford Univ, MIPS, Dept Pediat, Palo Alto, CA 94304 USA; Stanford Univ, Dept Radiol, Div Nucl Med, Palo Alto, CA 94304 USA; Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	Stanford University; Stanford University; University of Connecticut	Backer, JM (corresponding author), SibTech Inc, 705 N Mt Rd, Newington, CT 06111 USA.	jbacker@sibtech.com	Backer, Joseph/AAF-8332-2020		NCI NIH HHS [1 P50 CA114747, R43 CA113080, CA064436] Funding Source: Medline; NIBIB NIH HHS [R21 EB001946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, P50CA114747, R43CA113080, R29CA064436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB001946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Backer MV, 2006, BIOMATERIALS, V27, P5452, DOI 10.1016/j.biomaterials.2006.06.025; Backer MV, 2005, MOL CANCER THER, V4, P1423, DOI 10.1158/1535-7163.MCT-05-0161; Backer MV, 2001, PROTEIN EXPRES PURIF, V23, P1, DOI 10.1006/prep.2001.1472; Backer MV, 2001, BIOCONJUGATE CHEM, V12, P1066, DOI 10.1021/bc015534j; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Blankenberg FG, 2004, J NUCL MED, V45, P1373; Blankenberg FG, 2006, EUR J NUCL MED MOL I, V33, P841, DOI 10.1007/s00259-006-0099-1; Chan C, 2005, J NUCL MED, V46, P1745; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Haubner R, 2004, CURR PHARM DESIGN, V10, P1439, DOI 10.2174/1381612043384745; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Koukourakis MI, 2000, CANCER RES, V60, P3088; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Li S, 2004, Q J NUCL MED MOL IM, V48, P198; Li S, 2003, ANN ONCOL, V14, P1274, DOI 10.1093/annonc/mdg344; Li SR, 2001, INT J CANCER, V91, P789, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.3.CO;2-B; Lu EX, 2003, CIRCULATION, V108, P97, DOI 10.1161/01.CIR.0000079100.38176.83; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; McCarty MF, 2003, TRENDS MOL MED, V9, P53, DOI 10.1016/S1471-4914(03)00002-9; Miller JC, 2005, JNCI-J NATL CANCER I, V97, P172, DOI 10.1093/jnci/dji023; Ono M, 2002, BIOCONJUGATE CHEM, V13, P491, DOI 10.1021/bc010043k; Ono M, 1999, BIOCONJUGATE CHEM, V10, P386, DOI 10.1021/bc980105f; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Wu Y, 2005, J NUCL MED, V46, P1707; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	31	198	207	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					504	509		10.1038/nm1522	http://dx.doi.org/10.1038/nm1522			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17351626				2022-12-27	WOS:000245543900041
J	Brooks, DG; Trifilo, MJ; Edelmann, KH; Teyton, L; McGavern, DB; Oldstone, MBA				Brooks, David G.; Trifilo, Matthew J.; Edelmann, Kurt H.; Teyton, Luc; McGavern, Dorian B.; Oldstone, Michael B. A.			Interleukin-10 determines viral clearance or persistence in vivo	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; ACTIVE ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; IL-10 PRODUCTION; IMMUNE-RESPONSES; INTERFERON-ALPHA; DISEASE PROGRESSION	Persistent viral infections are a major health concern. One obstacle inhibiting the clearance of persistent infections is functional inactivation of antiviral T cells. Although such immunosuppression occurs rapidly after infection, the mechanisms that induce the loss of T-cell activity and promote viral persistence are unknown. Herein we document that persistent viral infection in mice results in a significant upregulation of interleukin (IL)-10 by antigen-presenting cells, leading to impaired T-cell responses. Genetic removal of II10 resulted in the maintenance of robust effector T-cell responses, the rapid elimination of virus and the development of antiviral memory T-cell responses. Therapeutic administration of an antibody that blocks the IL-10 receptor restored T-cell function and eliminated viral infection. Thus, we identify a single molecule that directly induces immunosuppression leading to viral persistence and demonstrate that a therapy to neutralize IL-10 results in T-cell recovery and the prevention of viral persistence.	Scripps Res Inst, Viral Immunobiol Lab, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Harold L Dorris Neurol Res Inst, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Infectol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Brooks, DG (corresponding author), Scripps Res Inst, Viral Immunobiol Lab, Mol & Integrat Neurosci Dept, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dbrooks@scripps.edu	McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X; Brooks, David/0000-0001-7763-8764	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, T32AI007244, R01AI045927, R21AI062718, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45927, R01 AI045927, R01 AI009484, T32 AI007244, AI09484, R01 AI009484-36, R01 AI045927-07, AI062718-01, AI07244-22, R21 AI062718] Funding Source: Medline; NINDS NIH HHS [NS048866-01, R21 NS048866] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420415, 10.1172/JCI200420515]; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Borrow Persephone, 1997, P593; Brady MT, 2003, EUR J IMMUNOL, V33, P3448, DOI 10.1002/eji.200324251; Brooks DG, 2006, J CLIN INVEST, V116, P1675, DOI 10.1172/JCI26856; Brooks DG, 2005, J VIROL, V79, P10514, DOI 10.1128/JVI.79.16.10514-10527.2005; Cacciarelli TV, 1996, HEPATOLOGY, V24, P6, DOI 10.1053/jhep.1996.v24.pm0008707283; Carbonneil C, 2004, J IMMUNOL, V172, P7832, DOI 10.4049/jimmunol.172.12.7832; Clerici M, 1996, BLOOD, V88, P574, DOI 10.1182/blood.V88.2.574.bloodjournal882574; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dolganiuc A, 2003, J IMMUNOL, V170, P5615, DOI 10.4049/jimmunol.170.11.5615; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fuller MJ, 2004, J IMMUNOL, V172, P4204, DOI 10.4049/jimmunol.172.7.4204; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Ji JX, 2005, INT IMMUNOL, V17, P729, DOI 10.1093/intimm/dxh252; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; Lechmann M, 1999, J HEPATOL, V31, P971, DOI 10.1016/S0168-8278(99)80307-9; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lin MT, 1998, VIROLOGY, V245, P270, DOI 10.1006/viro.1998.9170; Marin-Serrano E, 2006, J VIRAL HEPATITIS, V13, P230, DOI 10.1111/j.1365-2893.2005.00679.x; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Orsilles MA, 2006, APMIS, V114, P55, DOI 10.1111/j.1600-0463.2006.apm_108.x; Ostrowski MA, 2001, J INFECT DIS, V184, P1268, DOI 10.1086/324005; Ou R, 2001, J VIROL, V75, P8407, DOI 10.1128/JVI.75.18.8407-8423.2001; Rico MA, 2001, HEPATOLOGY, V33, P295, DOI 10.1053/jhep.2001.21147; Rigopoulou EI, 2005, CLIN IMMUNOL, V117, P57, DOI 10.1016/j.clim.2005.06.003; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; SALVATO M, 1991, J VIROL, V65, P1863, DOI 10.1128/JVI.65.4.1863-1869.1991; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; Strestik BD, 2001, J GEN VIROL, V82, P1349, DOI 10.1099/0022-1317-82-6-1349; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; TISHON A, 1995, VIROLOGY, V212, P244, DOI 10.1006/viro.1995.1477; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Tsai SL, 1997, HEPATOLOGY, V25, P449; van der Most RG, 1998, VIROLOGY, V240, P158, DOI 10.1006/viro.1997.8934; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zuniga EI, 2004, NAT IMMUNOL, V5, P1227, DOI 10.1038/ni1136	48	710	744	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1301	1309		10.1038/nm1492	http://dx.doi.org/10.1038/nm1492			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17041596	Green Accepted			2022-12-27	WOS:000241844900028
J	Melkus, MW; Estes, JD; Padgett-Thomas, A; Gatlin, J; Denton, PW; Othieno, FA; Wege, AK; Haase, AT; Garcia, JV				Melkus, Michael W.; Estes, Jacob D.; Padgett-Thomas, Angela; Gatlin, Joel; Denton, Paul W.; Othieno, Florence A.; Wege, Anja K.; Haase, Ashley T.; Garcia, J. Victor			Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1	NATURE MEDICINE			English	Article							HUMAN CD34(+) CELLS; SCID-HU MOUSE; SHOCK-SYNDROME TOXIN-1; EPSTEIN-BARR-VIRUS; NOD/SCID MICE; T-CELLS; ENGRAFTMENT; INFECTION; BLOOD; MODEL	Here we show that transplantation of autologous human hematopoietic fetal liver CD34(+) cells into NOD/ SCID mice previously implanted with human fetal thymic and liver tissues results in long-term, systemic human T-cell homeostasis. In addition, these mice show systemic repopulation with human B cells, monocytes and macrophages, and dendritic cells (DCs). T cells in these mice generate human major histocompatibility complex class I- and class II-restricted adaptive immune responses to Epstein-Barr virus (EBV) infection and are activated by human DCs to mount a potent T-cell immune response to superantigens. Administration of the superantigen toxic shock syndrome toxin 1 (TSST-1) results in the specific systemic expansion of human V beta 2(+) T cells, release of human proinflammatory cytokines and localized, specific activation and maturation of human CD11c(+) dendritic cells. This represents the first demonstration of long-term systemic human T-cell reconstitution in vivo allowing for the manifestation of the differential response by human DCs to TSST-1.	Univ Texas, SW Med Ctr, Div Infect Dis, Dept Internal Med, Dallas, TX 75390 USA; Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Arena Pharmaceut Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities	Melkus, MW (corresponding author), Univ Texas, SW Med Ctr, Div Infect Dis, Dept Internal Med, Dallas, TX 75390 USA.			Denton, Paul/0000-0003-2458-8147	NCI NIH HHS [CA82055] Funding Source: Medline; NIAID NIH HHS [5T32 AI005284, R37 AI028246, AI39416, T32 AI07421] Funding Source: Medline; NICHD NIH HHS [HD011149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA082055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI005284, R37AI028246, T32AI007421, R01AI039416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKINA RK, 1994, BLOOD, V84, P1393; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; An DS, 1997, J VIROL, V71, P1397, DOI 10.1128/JVI.71.2.1397-1404.1997; Bente DA, 2005, J VIROL, V79, P13797, DOI 10.1128/JVI.79.21.13797-13799.2005; Cravens PD, 2005, STEM CELLS, V23, P264, DOI 10.1634/stemcells.2004-0116; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Gatlin J, 2001, HUM GENE THER, V12, P1079, DOI 10.1089/104303401750214294; Gatlin J, 2001, J VIROL, V75, P9995, DOI 10.1128/JVI.75.20.9995-9999.2001; Gimeno R, 2004, BLOOD, V104, P3886, DOI 10.1182/blood-2004-02-0656; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Islas-Ohlmayer M, 2004, J VIROL, V78, P13891, DOI 10.1128/JVI.78.24.13891-13900.2004; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; Kum WWS, 2001, INFECT IMMUN, V69, P7544, DOI 10.1128/IAI.69.12.7544-7549.2001; Makida R, 1996, MOL IMMUNOL, V33, P891, DOI 10.1016/0161-5890(96)84615-3; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Palucka AK, 2003, BLOOD, V102, P3302, DOI 10.1182/blood-2003-02-0384; Roos MTL, 2000, J INFECT DIS, V182, P451, DOI 10.1086/315737; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; VANDEKERCKHOVE BAE, 1991, J IMMUNOL, V146, P4173; Yahata T, 2002, J IMMUNOL, V169, P204, DOI 10.4049/jimmunol.169.1.204	25	472	477	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1316	1322		10.1038/nm1431	http://dx.doi.org/10.1038/nm1431			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057712				2022-12-27	WOS:000241844900030
J	Trautmann, L; Janbazian, L; Chomont, N; Said, EA; Gimmig, S; Bessette, B; Boulassel, MR; Delwart, E; Sepulveda, H; Balderas, RS; Routy, JP; Haddad, EK; Sekaly, RP				Trautmann, Lydie; Janbazian, Loury; Chomont, Nicolas; Said, Elias A.; Gimmig, Sylvain; Bessette, Benoit; Boulassel, Mohamed-Rachid; Delwart, Eric; Sepulveda, Homero; Balderas, Robert S.; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre			Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction	NATURE MEDICINE			English	Article							CHRONIC VIRAL-INFECTION; ANTIRETROVIRAL THERAPY; LYMPHOCYTES; ACTIVATION; PERFORIN; RECEPTOR; ANTIGEN; ESCAPE; PROLIFERATION; PERSISTENCE	The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L2(1-4), inhibits proliferation and cytokine production mediated by antibodies to CD3 (refs. 5-7). Blocking the PD-1 - PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8(+) T cells to undergo proliferation, cytokine production and cytotoxic activity and, consequently, results in reduced viral load(8). During chronic HIV infection, HIV-specific CD8(+) T cells are functionally impaired(9-11), showing a reduced capacity to produce cytokines and effector molecules as well as an impaired capacity to proliferate(12-15). Here, we found that PD-1 was upregulated on HIV-specific CD8(+) T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine production and proliferation of HIV-specific CD8(+) T cells. Notably, cytomegalovirus (CMV)-specific CD8(+) T cells from the same donors did not upregulate PD-1 and maintained the production of high levels of cytokines. Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8(+) T cells to survive and proliferate and led to an increased production of cytokines and cytotoxic molecules in response to cognate antigen. The accumulation of HIV-specific dysfunctional CD8(+) T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8(+) repertoire.	CR CHUM St Luc, Lab Immunol, Montreal, PQ H3X 1P1, Canada; Univ Montreal, Lab Immunol, Dept Microbiol & Immunol, Montreal, PQ, Canada; Univ Montreal, CR CHUM, INSERM, U743, Montreal, PQ H2X 1P1, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Royal Victoria Hosp, Immunodeficiency Serv, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Div Haematol, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; Blood Syst Res Inst, San Francisco, CA 94118 USA; BD Biosci, San Diego, CA 92121 USA	Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Vitalant; Vitalant Research Institute	Sekaly, RP (corresponding author), CR CHUM St Luc, Lab Immunol, 264 Rene Levesque Est, Montreal, PQ H3X 1P1, Canada.	rafick-pierre.sekaly@umontreal.ca	Chomont, Nicolas/ABG-2545-2020; Said, Elias/AAY-5557-2020	Chomont, Nicolas/0000-0001-9747-5018; Said, Elias/0000-0003-4224-6351; Delwart, Eric/0000-0002-6296-4484; Trautmann, Lydie/0000-0002-3012-0009				Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Almanzar G, 2005, J VIROL, V79, P3675, DOI 10.1128/JVI.79.6.3675-3683.2005; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Douek DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/jimmunol.168.6.3099; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Geels MJ, 2003, J VIROL, V77, P12430, DOI 10.1128/JVI.77.23.12430-12440.2003; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010; Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Wherry EJ, 2005, J VIROL, V79, P8960, DOI 10.1128/JVI.79.14.8960-8968.2005; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Yang OO, 2005, VIROLOGY, V332, P16, DOI 10.1016/j.virol.2004.11.028; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	29	1154	1226	0	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1198	1202		10.1038/nm1482	http://dx.doi.org/10.1038/nm1482			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16917489				2022-12-27	WOS:000241102200038
J	Murphy, GJ; Mostoslavsky, G; Kotton, DN; Mulligan, RC				Murphy, George J.; Mostoslavsky, Gustavo; Kotton, Darrell N.; Mulligan, Richard C.			Exogenous control of mammalian gene expression via modulation of translational termination	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; IN-VIVO; NONSENSE MUTATION; ESCHERICHIA-COLI; STOP CODON; AMINOGLYCOSIDE; SUPPRESSION; EFFICIENCY; RECEPTOR; VECTORS	Here, we describe a system for the exogenous control of gene expression in mammalian cells that relies on the control of translational termination. To achieve gene regulation, we modified protein-coding sequences by introduction of a translational termination codon just downstream from the initiator AUG codon. Translation of the resulting mRNA leads to potent reduction in expression of the desired gene product. Expression of the gene product can be controlled by treating cells that express the mRNA with either aminoglycoside antibiotics or several nonantibiotic compounds. We show that the extent of regulation of gene expression can be substantial (60-fold) and that regulation can be achieved in the case of a variety of different genes, in different cultured cell lines and in primary cells in vivo. This gene regulation strategy offers significant advantages over existing methods for controlling gene expression and should have both immediate experimental application and possible clinical application.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Div Mol Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Mulligan, RC (corresponding author), Harvard Univ, Sch Med, Dept Genet, 300 Longwood Ave, Boston, MA 02115 USA.	mulligan@receptor.med.harvard.edu		Kotton, Darrell/0000-0002-9604-8476; Mostoslavsky, Gustavo/0000-0002-0784-2169	NHLBI NIH HHS [5P0-HL54785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ainsworth C, 2005, NATURE, V438, P726, DOI 10.1038/438726a; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; BURKE JF, 1985, NUCLEIC ACIDS RES, V13, P6265, DOI 10.1093/nar/13.17.6265; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Howard MT, 2000, ANN NEUROL, V48, P164, DOI 10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.3.CO;2-2; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; Lai CH, 2004, P NATL ACAD SCI USA, V101, P15676, DOI 10.1073/pnas.0405155101; LOEBENBERG D, 1975, ANTIMICROB AGENTS CH, V7, P811, DOI 10.1128/AAC.7.6.811; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Nilsson M, 2003, BBA-GENE STRUCT EXPR, V1627, P1, DOI 10.1016/S0167-4781(03)00050-2; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PARROTT CL, 1992, J LIPID RES, V33, P361; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sangkuhl K, 2004, HUM MOL GENET, V13, P893, DOI 10.1093/hmg/ddh105; Suhr ST, 1998, P NATL ACAD SCI USA, V95, P7999, DOI 10.1073/pnas.95.14.7999; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Yen L, 2004, NATURE, V431, P471, DOI 10.1038/nature02844; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; 2004009533	30	45	48	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1093	1099		10.1038/nm1376	http://dx.doi.org/10.1038/nm1376			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892063				2022-12-27	WOS:000240373900035
J	Cupers, P; Sautter, J; Vanvossel, A				Cupers, Philippe; Sautter, Jurgen; Vanvossel, Alain			European Union research policy and funding for Alzheimer disease	NATURE MEDICINE			English	Editorial Material							DEMENTIA; BRAIN; COST		Commiss European Communities, Res Directorate Gen, Off CDMA 02 005, BE-1049 Brussels, Belgium		Cupers, P (corresponding author), Commiss European Communities, Res Directorate Gen, Off CDMA 02 005, BE-1049 Brussels, Belgium.	philippe.cupers@ec.europa.eu						Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berr C, 2005, EUR NEUROPSYCHOPHARM, V15, P463, DOI 10.1016/j.euroneuro.2005.04.003; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Jonsson L, 2005, EUR J NEUROL, V12, P50, DOI 10.1111/j.1468-1331.2005.01190.x; Lobo A, 2000, NEUROLOGY, V54, pS4; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x	6	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					774	775		10.1038/nm0706-774	http://dx.doi.org/10.1038/nm0706-774			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829944				2022-12-27	WOS:000238862800057
J	Manno, CS; Arruda, VR; Pierce, GF; Glader, B; Ragni, M; Rasko, J; Ozelo, MC; Hoots, K; Blatt, P; Konkle, B; Dake, M; Kaye, R; Razavi, M; Zajko, A; Zehnder, J; Nakai, H; Chew, A; Leonard, D; Wright, JF; Lessard, RR; Sommer, JM; Tigges, M; Sabatino, D; Luk, A; Jiang, HY; Mingozzi, F; Couto, L; Ertl, HC; High, KA; Kay, MA				Manno, CS; Arruda, VR; Pierce, GF; Glader, B; Ragni, M; Rasko, J; Ozelo, MC; Hoots, K; Blatt, P; Konkle, B; Dake, M; Kaye, R; Razavi, M; Zajko, A; Zehnder, J; Nakai, H; Chew, A; Leonard, D; Wright, JF; Lessard, RR; Sommer, JM; Tigges, M; Sabatino, D; Luk, A; Jiang, HY; Mingozzi, F; Couto, L; Ertl, HC; High, KA; Kay, MA			Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response	NATURE MEDICINE			English	Article							SUSTAINED PHENOTYPIC CORRECTION; LONG-TERM CORRECTION; GENE-TRANSFER; B DOGS; SKELETAL-MUSCLE; EXPRESSION; CANINE; VECTOR; THERAPY; DELIVERY	We have previously shown that a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B-1. We carried out a phase 1/2 dose-escalation clinical study to extend this approach to humans with severe hemophilia B. rAAV-2 vector expressing human F.IX was infused through the hepatic artery into seven subjects. The data show that: (i) vector infusion at doses up to 2 x 10(12) vg/kg was not associated with acute or long-lasting toxicity; (ii) therapeutic levels of F.IX were achieved at the highest dose tested; (iii) duration of expression at therapeutic levels was limited to a period of similar to 8 weeks; (iv) a gradual decline in F.IX was accompanied by a transient asymptomatic elevation of liver transaminases that resolved without treatment. Further studies suggested that destruction of transduced hepatocytes by cell-mediated immunity targeting antigens of the AAV capsid caused both the decline in F.IX and the transient transaminitis. We conclude that rAAV-2 vectors can transduce human hepatocytes in vivo to result in therapeutically relevant levels of F.IX, but that future studies in humans may require immunomodulation to achieve long-term expression.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Avigen Inc, Alameda, CA 94502 USA; Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Univ Pittsburgh, Med Ctr, Hemophilia Ctr Western Penn, Pittsburgh, PA 15213 USA; Royal Prince Albert Hosp, Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2042, Australia; Univ Estadual Campinas, BR-13083970 Campinas, SP, Brazil; Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA; Christiana Hosp, Newark, DE 19718 USA; Univ Penn, Sch Med, Presbyterian Med Ctr, Philadelphia, PA 19107 USA; Cornell Univ, Weill Med Coll, New York, NY 10012 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sydney; Centenary Institute; Universidade Estadual de Campinas; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; Cornell University; The Wistar Institute; Howard Hughes Medical Institute	High, KA (corresponding author), Childrens Hosp Philadelphia, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	high@email.chop.edu	Wilson, Matthew H/K-3193-2013; Ozelo, Margareth C/K-5819-2012; Rasko, John EJ/F-5754-2013; High, Katherine A./AAB-9322-2020	Ozelo, Margareth C/0000-0001-5938-0675; rasko, John/0000-0003-2975-807X; Ertl, Hildegund/0000-0001-9795-5206; Manno, Catherine/0000-0001-8029-0391; Kay, Mark/0000-0002-2799-2615; Jiang, Haiyan/0000-0002-5778-4008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071518, U01HL066948, P01HL064190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060580] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL064190, U01 HL66948, R01 HL71518] Funding Source: Medline; NIDDK NIH HHS [K01 DK60580] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Appay V, 2004, SEMIN IMMUNOL, V16, P205, DOI 10.1016/j.smim.2004.02.007; Arruda VR, 2005, BLOOD, V105, P3458, DOI 10.1182/blood-2004-07-2908; Arruda VR, 2001, MOL THER, V4, P586, DOI 10.1006/mthe.2001.0491; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Chao H, 1999, GENE THER, V6, P1695, DOI 10.1038/sj.gt.3301024; Couto L, 2004, HUM GENE THER, V15, P287, DOI 10.1089/104303404322886138; Currier JR, 2002, J IMMUNOL METHODS, V260, P157, DOI 10.1016/S0022-1759(01)00535-X; Hauck B, 2004, J VIROL, V78, P13678, DOI 10.1128/JVI.78.24.13678-13686.2004; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kreher CR, 2003, J IMMUNOL METHODS, V278, P79, DOI 10.1016/S0022-1759(03)00226-6; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; Le MT, 1997, BLOOD, V89, P1254, DOI 10.1182/blood.V89.4.1254; Ljung RCR, 1998, BRIT J HAEMATOL, V101, P215, DOI 10.1046/j.1365-2141.1998.00707.x; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; Miao CH, 2000, MOL THER, V1, P522, DOI 10.1006/mthe.2000.0075; Mount JD, 2002, BLOOD, V99, P2670, DOI 10.1182/blood.V99.8.2670; Nathwani AC, 2002, BLOOD, V100, P1662, DOI 10.1182/blood-2002-02-0589; NATHWANI AC, 2005, BLOOD           1201; Scallan CD, 2003, BLOOD, V102, P2031, DOI 10.1182/blood-2003-01-0292; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; Sommer JM, 2003, MOL THER, V7, P122, DOI 10.1016/S1525-0016(02)00019-9; Thomas CE, 2004, J VIROL, V78, P3110, DOI 10.1128/JVI.78.6.3110-3122.2004; Wang LL, 2000, MOL THER, V1, P154, DOI 10.1006/mthe.2000.0031; Wang LL, 2005, BLOOD, V105, P3079, DOI 10.1182/blood-2004-10-3867; Wright JF, 2005, MOL THER, V12, P171, DOI 10.1016/j.ymthe.2005.02.021	29	1441	1573	5	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					342	347		10.1038/nm1358	http://dx.doi.org/10.1038/nm1358			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474400				2022-12-27	WOS:000235802900035
J	Spiegel, AM; Nabel, EG				Spiegel, AM; Nabel, EG			NIH research on obesity and type 2 diabetes: providing the scientific evidence base for actions to improve health	NATURE MEDICINE			English	Editorial Material									NIDDK, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Spiegel, AM (corresponding author), NIDDK, NIH, Bldg 31,Room 9A52,31 Ctr Dr,MSC 2560, Bethesda, MD 20892 USA.	spiegela@extra.niddk.nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200334, ZIAHG200334] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))			0	8	10	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					67	69		10.1038/nm0106-67	http://dx.doi.org/10.1038/nm0106-67			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397572				2022-12-27	WOS:000234419000052
J	Sablina, AA; Budanov, AV; Ilyinskaya, GV; Agapova, LS; Kravchenko, JE; Chumakov, PM				Sablina, AA; Budanov, AV; Ilyinskaya, GV; Agapova, LS; Kravchenko, JE; Chumakov, PM			The antioxidant function of the p53 tumor suppressor	NATURE MEDICINE			English	Article							OXIDATIVE DNA-DAMAGE; ATM-DEFICIENT MICE; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; CALORIE RESTRICTION; P53-DEFICIENT MICE; CHECKPOINT CONTROL; MITOCHONDRIAL-DNA; GROWTH ARREST; HUMAN-CELLS	It is widely accepted that the p53 tumor suppressor restricts abnormal cells by induction of growth arrest or by triggering apoptosis. Here we show that, in addition, p53 protects the genome from oxidation by reactive oxygen species (ROS), a major cause of DNA damage and genetic instability. In the absence of severe stresses, relatively low levels of p53 are sufficient for upregulation of several genes with antioxidant products, which is associated with a decrease in intracellular ROS. Downregulation of p53 results in excessive oxidation of DNA, increased mutation rate and karyotype instability, which are prevented by incubation with the antioxidant N-acetylcysteine (NAC). Dietary supplementation with NAC prevented frequent lymphomas characteristic of Trp53-knockout mice, and slowed the growth of lung cancer xenografts deficient in p53. Our results provide a new paradigm for a nonrestrictive tumor suppressor function of p53 and highlight the potential importance of antioxidants in the prophylaxis and treatment of cancer.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Canc Res Ctr, Moscow 115478, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Univ Calif San Diego, La Jolla, CA 92093 USA	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of California System; University of California San Diego	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chumakp@ccf.org	Budanov, Andrei V/HGD-5487-2022; Chumakov, Peter M/E-7731-2014; Sablina, Anna/P-2818-2019; Sablina, Anna/B-2217-2017	Budanov, Andrei V/0000-0002-7943-1000; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Chumakov, Peter/0000-0002-8078-2908	NCI NIH HHS [R01 CA104903-02, R01 CA10490, R01 CA104903] Funding Source: Medline; NIA NIH HHS [R01 AG025278-01A1, R01 AG025278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Balansky R, 1996, CANCER RES, V56, P1642; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bishop AJR, 2003, CANCER RES, V63, P5335; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HAVRE PA, 1995, CANCER RES, V55, P4420; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2004, J NUTR, V134, p2482S, DOI 10.1093/jn/134.9.2482S; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KNAAP AGAC, 1975, MUTAT RES, V30, P97; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; OSOVSKAYA VS, 1995, MOL BIOL+, V29, P32; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reliene R, 2004, CANCER RES, V64, P5148, DOI 10.1158/0008-5472.CAN-04-0442; Schubert R, 2004, HUM MOL GENET, V13, P1793, DOI 10.1093/hmg/ddh189; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wahl GM, 1997, CANCER SURV, V29, P183; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	49	855	888	3	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1306	1313		10.1038/nm1320	http://dx.doi.org/10.1038/nm1320			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16286925	Green Accepted			2022-12-27	WOS:000233774400029
J	Cole, C; Qiao, J; Kottke, T; Diaz, RM; Ahmed, A; Sanchez-Perez, L; Brunn, G; Thompson, J; Chester, J; Vile, RG				Cole, C; Qiao, J; Kottke, T; Diaz, RM; Ahmed, A; Sanchez-Perez, L; Brunn, G; Thompson, J; Chester, J; Vile, RG			Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells	NATURE MEDICINE			English	Article							CANCER GENE-THERAPY; MURINE LEUKEMIA-VIRUS; THYMIDINE KINASE GENE; RETROVIRAL VECTORS; HEPARAN-SULFATE; IN-VIVO; ANTITUMOR LYMPHOCYTES; MAMMALIAN HEPARANASE; HIGH-TITER; EXPRESSION	Antigen-specific T cells circulate freely and accumulate specifically at sites of antigen expression. To enhance the survival and targeting of systemically delivered viral vectors, we exploited the observation that retroviral particles adhere nonspecifically, or 'hitchhike,' to the surface of T cells. Adoptive transfer of antigen-specific T cells, loaded with viruses encoding interleukin (IL)-12 or Herpes Simplex Virus thymidine kinase (HSVtk), cured established metastatic disease where adoptive T-cell transfer alone was not effective. Productive hand off correlated with local heparanase expression either from malignant tumor cells and/or as a result of T-cell activation by antigen, providing high levels of selectivity for viral transfer to metastatic tumors in vivo. Protection, concentration and targeting of viruses by adsorption to cell carriers represent a new technique for systemic delivery of vectors, in fully immunocompetent hosts, for a variety of diseases in which delivery of genes may be therapeutically beneficial.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Transplantat Biol, Rochester, MN 55905 USA; St James Univ Hosp, Div Canc Med Res, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Mayo Clinic; Mayo Clinic; Mayo Clinic; Cancer Research UK; Saint James's University Hospital; University of Leeds	Vile, RG (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	vile.richard@mayo.edu			NCI NIH HHS [1R01CA94180, 1R01CA107082] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107082, R01CA094180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Blomer U, 2005, GENE THER, V12, P67, DOI 10.1038/sj.gt.3302384; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Chernajovsky Y, 2004, NAT REV IMMUNOL, V4, P800, DOI 10.1038/nri1459; Chester J, 2002, NAT BIOTECHNOL, V20, P256, DOI 10.1038/nbt0302-256; Chong H, 1998, GENE THER, V5, P223, DOI 10.1038/sj.gt.3300584; Crittenden M, 2003, CANCER RES, V63, P3173; Daniels GA, 2004, NAT BIOTECHNOL, V22, P1125, DOI 10.1038/nbt1007; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Harrington K, 2002, HUM GENE THER, V13, P1263, DOI 10.1089/104303402760128504; Harrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Linardakis E, 2002, CANCER RES, V62, P5495; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Palmer DC, 2004, J IMMUNOL, V173, P7209, DOI 10.4049/jimmunol.173.12.7209; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; Pizzato M, 2001, GENE THER, V8, P1088, DOI 10.1038/sj.gt.3301494; Qiao J, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-237; Reiland J, 2004, J BIOL CHEM, V279, P8047, DOI 10.1074/jbc.M304872200; Robbins PF, 2004, J IMMUNOL, V173, P7125, DOI 10.4049/jimmunol.173.12.7125; Rosenberg SA, 2004, P NATL ACAD SCI USA, V101, P14639, DOI 10.1073/pnas.0405730101; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Tatsumi T, 2002, CANCER RES, V62, P5853; Todryk S, 1999, J IMMUNOL, V163, P1398; VILE R, 1994, GENE THER, V1, P307; Vile RG, 2000, GENE THER, V7, P2, DOI 10.1038/sj.gt.3301084; VILE RG, 1993, CANCER RES, V53, P3860; Vile RG, 1997, INT J CANCER, V71, P267; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; Walker SJ, 2002, J VIROL, V76, P6909, DOI 10.1128/JVI.76.14.6909-6918.2002; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Yee C, 2001, CURR OPIN IMMUNOL, V13, P141, DOI 10.1016/S0952-7915(00)00196-5; Yotnda P, 2004, BLOOD, V104, P2272, DOI 10.1182/blood-2003-11-3803	50	110	122	4	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1073	1081		10.1038/nm1297	http://dx.doi.org/10.1038/nm1297			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170322				2022-12-27	WOS:000232492500028
J	Liu, SL; Premont, RT; Kontos, CD; Zhu, SK; Rockey, DC				Liu, SL; Premont, RT; Kontos, CD; Zhu, SK; Rockey, DC			A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension	NATURE MEDICINE			English	Article							COUPLED RECEPTOR KINASE; GENE-TRANSFER; BETA-GAMMA; AKT; ACTIVATION; EXPRESSION; CAVEOLIN; LIVER; RAT; PHOSPHORYLATION	Nitric oxide ( NO) production by endothelial cell nitric oxide synthase ( eNOS) in sinusoidal endothelial cells is reduced in the injured liver and leads to intrahepatic portal hypertension. We sought to understand the mechanism underlying defective eNOS function. Phosphorylation of the serine- threonine kinase Akt, which activates eNOS, was substantially reduced in sinusoidal endothelial cells from injured livers. Overexpression of Akt in vivo restored phosphorylation of Akt and production of NO and reduced portal pressure in portal hypertensive rats. We found that Akt physically interacts with G- protein- coupled receptor kinase- 2 ( GRK2), and that this interaction inhibits Akt activity. Furthermore, GRK2 expression increased in sinusoidal endothelial cells from portal hypertensive rats and knockdown of GRK2 restored Akt phosphorylation and NO production, and normalized portal pressure. Finally, after liver injury, GRK2- deficient mice developed less severe portal hypertension than control mice. Thus, an important mechanism underlying impaired activity of eNOS in injured sinusoidal endothelial cells is defective phosphorylation of Akt caused by overexpression of GRK2 after injury.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rockey, DC (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	don.rockey@utsouthwestern.edu		Premont, Richard/0000-0002-8053-5026; Kontos, Christopher/0000-0002-8056-3115	NHLBI NIH HHS [HL 03557] Funding Source: Medline; NIDA NIH HHS [DA 16347] Funding Source: Medline; NIDDK NIH HHS [R01 DK 50574, R01 DK057830, R01 DK 57830] Funding Source: Medline; NIGMS NIH HHS [R01 GM 59989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057830, R01DK050574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dzimiri N, 2004, EUR J PHARMACOL, V489, P167, DOI 10.1016/j.ejphar.2004.03.015; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu SL, 2003, J BIOL CHEM, V278, P49929, DOI 10.1074/jbc.M306930200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; Ramos-Ruiz R, 2000, CIRCULATION, V101, P2083, DOI 10.1161/01.CIR.101.17.2083; Rockey DC, 1998, GASTROENTEROLOGY, V114, P344, DOI 10.1016/S0016-5085(98)70487-1; Shah V, 1999, GASTROENTEROLOGY, V117, P1222, DOI 10.1016/S0016-5085(99)70408-7; Teshima S, 2004, J HEPATOL, V40, P616, DOI 10.1016/j.jhep.2003.12.018; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; Williams ML, 2004, CIRCULATION, V109, P1590, DOI 10.1161/01.CIR.0000125521.40985.28; WOLFRUM S, 2004, ARTERIOSCLER THROMB; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; Yu Q, 2000, J CLIN INVEST, V105, P741, DOI 10.1172/JCI7997; Yu Q, 2002, AM J PHYSIOL-GASTR L, V282, pG565, DOI 10.1152/ajpgi.00512.2000	38	195	206	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					952	958		10.1038/nm1289	http://dx.doi.org/10.1038/nm1289			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16142243				2022-12-27	WOS:000231724700022
J	Kebir, H; Kreymborg, K; Ifergan, I; Dodelet-Devillers, A; Cayrol, R; Bernard, M; Giuliani, F; Arbour, N; Becher, B; Prat, A				Kebir, Hania; Kreymborg, Katharina; Ifergan, Igal; Dodelet-Devillers, Aurore; Cayrol, Romain; Bernard, Monique; Giuliani, Fabrizio; Arbour, Nathalie; Becher, Burkhard; Prat, Alexandre			Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; EXPRESSION; MIGRATION; CYTOKINE; IL-17; CELLS; TH1	T(H)17 lymphocytes appear to be essential in the pathogenesis of numerous inflammatory diseases. We demonstrate here the expression of IL- 17 and IL- 22 receptors on blood- brain barrier endothelial cells (BBB-ECs) in multiple sclerosis lesions, and show that IL- 17 and IL- 22 disrupt BBB tight junctions in vitro and in vivo. Furthermore, T(H)17 lymphocytes transmigrate efficiently across BBB-ECs, highly express granzyme B, kill human neurons and promote central nervous system inflammation through CD4(+) lymphocyte recruitment.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Study Brain Dis,Neuroimmunol Unit, Montreal, PQ H2L 4M1, Canada; Univ Zurich, Dept Neurol, Div Neuroimmunol, CH-8057 Zurich, Switzerland; Univ Alberta, Dept Med, Div Neurol, Edmonton, AB T6G 2G3, Canada	Universite de Montreal; University of Zurich; University of Alberta	Prat, A (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Study Brain Dis,Neuroimmunol Unit, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	a.prat@umontreal.ca	Becher, Burkhard/ABE-4225-2020; Ifergan, Igal/AAI-9734-2020; Ifergan, Igal/AAR-7849-2021	Becher, Burkhard/0000-0002-1541-7867; Ifergan, Igal/0000-0003-2945-2580; Kebir, Hania/0000-0001-6174-8846; Arbour, Nathalie/0000-0002-3718-1584; Prat, Alexandre/0000-0001-6188-0580	Canadian Institutes of Health Research [79785-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; Biernacki K, 2001, J NEUROPATH EXP NEUR, V60, P1127, DOI 10.1093/jnen/60.12.1127; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Prat A, 2005, J AUTOIMMUN, V24, P119, DOI 10.1016/j.jaut.2005.01.004; RENNO T, 1994, INT IMMUNOL, V6, P347, DOI 10.1093/intimm/6.3.347; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Uyttenhove C, 2006, EUR J IMMUNOL, V36, P2868, DOI 10.1002/eji.200636662; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	14	1143	1192	1	106	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1173	1175		10.1038/nm1651	http://dx.doi.org/10.1038/nm1651			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17828272	Green Accepted			2022-12-27	WOS:000249980200032
J	Kim, KD; Zhao, J; Auh, S; Yang, XM; Du, PS; Tang, H; Fu, YX				Kim, Kwang Dong; Zhao, Jie; Auh, Sogyong; Yang, Xuanming; Du, Peishuang; Tang, Hong; Fu, Yang-Xin			Adaptive immune cells temper initial innate responses	NATURE MEDICINE			English	Article							DENDRITIC CELLS; ANTIVIRAL IMMUNITY; RECEPTOR; MICE; INFECTION; MATURATION; NECROSIS; SHOCK	Toll- like receptors ( TLRs) recognize conserved microbial structures called pathogen- associated molecular patterns. Signaling from TLRs leads to upregulation of co- stimulatory molecules for better priming of T cells and secretion of inflammatory cytokines by innate immune cells(1-4). Lymphocyte-deficient hosts often die of acute infection, presumably owing to their lack of an adaptive immune response to effectively clear pathogens. However, we show here that an unleashed innate immune response due to the absence of residential T cells can also be a direct cause of death. Viral infection or administration of poly(I:C), a ligand for TLR3, led to cytokine storm in T-cell- or lymphocyte- deficient mice in a fashion dependent on NK cells and tumor necrosis factor. We have further shown, through the depletion of CD4(+) and CD8(+) cells in wild- type mice and the transfer of T lymphocytes into Rag- 1 deficient mice, respectively, that T cells are both necessary and sufficient to temper the early innate response. In addition to the effects of natural regulatory T cells, close contact of resting CD4(+)CD25(-)Foxp3(-) or CD8(+) T cells with innate cells could also suppress the cytokine surge by various innate cells in an antigen- independent fashion. Therefore, adaptive immune cells have an unexpected role in tempering initial innate responses.	Chinese Acad Sci, Ctr Infect & Immun, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Chinese Academy of Sciences; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Chicago	Fu, YX (corresponding author), Chinese Acad Sci, Ctr Infect & Immun, 15 Da Tun Rd, Beijing 100101, Peoples R China.	yfu@uchicago.edu		Yang, Xuanming/0000-0002-3261-8206; fu, yang-xin/0000-0001-8441-6617	NCI NIH HHS [R01 CA115540, R01 CA115540-03, CA115540] Funding Source: Medline; NIAID NIH HHS [R01 AI062026-08, R01 AI062026, R01 AI062026-07, AI062026, R01 AI062026-06] Funding Source: Medline; NIDDK NIH HHS [R01 DK058897-05, R01 DK058897, R01 DK058891, DK58891, R01 DK058897-06, R01 DK058897-07] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07281, T32 GM007281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058891, R01DK058897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andoniou CE, 2005, NAT IMMUNOL, V6, P1011, DOI 10.1038/ni1244; Andrews DM, 2003, NAT IMMUNOL, V4, P175, DOI 10.1038/ni880; El-Sawy T, 2004, AM J PATHOL, V165, P147, DOI 10.1016/S0002-9440(10)63283-X; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gazzinelli RT, 2006, NAT REV IMMUNOL, V6, P895, DOI 10.1038/nri1978; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Haring J, 2001, CURR OPIN MICROBIOL, V4, P462, DOI 10.1016/S1369-5274(00)00236-8; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; LAVI E, 1984, J VIROL, V51, P563, DOI 10.1128/JVI.51.2.563-566.1984; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Munz C, 2005, J EXP MED, V202, P203, DOI 10.1084/jem.20050810; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035	19	272	288	4	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1248	1252		10.1038/nm1633	http://dx.doi.org/10.1038/nm1633			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17891146	Bronze, Green Published, Green Accepted			2022-12-27	WOS:000249980200042
J	Connor, KM; SanGiovanni, JP; Lofqvist, C; Aderman, CM; Chen, J; Higuchi, A; Hong, S; Pravda, EA; Majchrzak, S; Carper, D; Hellstrom, A; Kang, JX; Chew, EY; Salem, N; Serhan, CN; Smith, LEH				Connor, Kip M.; SanGiovanni, John Paul; Lofqvist, Chatarina; Aderman, Christopher M.; Chen, Jing; Higuchi, Akiko; Hong, Song; Pravda, Elke A.; Majchrzak, Sharon; Carper, Deborah; Hellstrom, Ann; Kang, Jing X.; Chew, Emily Y.; Salem, Norman, Jr.; Serhan, Charles N.; Smith, Lois E. H.			Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis	NATURE MEDICINE			English	Article							NF-KAPPA-B; DOCOSAHEXAENOIC ACID; ISCHEMIC RETINOPATHY; RESOLVIN E1; IN-VIVO; INFLAMMATION; RECEPTOR; NEOVASCULARIZATION; INHIBITION; PROLIFERATION	Many sight-threatening diseases have two critical phases, vessel loss followed by hypoxia-driven destructive neovascularization. These diseases include retinopathy of prematurity and diabetic retinopathy, leading causes of blindness in childhood and middle age affecting over 4 million people in the United States. We studied the influence of omega-3- and omega-6-polyunsaturated fatty acids (PUFAs) on vascular loss, vascular regrowth after injury, and hypoxia-induced pathological neovascularization in a mouse model of oxygen-induced retinopathy. We show that increasing omega-3-PUFA tissue levels by dietary or genetic means decreased the avascular area of the retina by increasing vessel regrowth after injury, thereby reducing the hypoxic stimulus for neovascularization. The bioactive omega-3-PUFA-derived mediators neuroprotectinD1, resolvinD1 and resolvinE1 also potently protected against neovascularization. The protective effect of omega-3-PUFAs and their bioactive metabolites was mediated, in part, through suppression of tumor necrosis factor-alpha. This inflammatory cytokine was found in a subset of microglia that was closely associated with retinal vessels. These findings indicate that increasing the sources of omega-3-PUFA or their bioactive products reduces pathological angiogenesis. Western diets are often deficient in omega-3-PUFA, and premature infants lack the important transfer from the mother to the infant of omega-3-PUFA that normally occurs in the third trimester of pregnancy. Supplementing omega-3-PUFA intake may be of benefit in preventing retinopathy.	Harvard Univ, Sch Med, Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA; NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA; Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA 02115 USA; NIAAA, Lab Membrane Biochem & Biophys, Bethesda, MD 20892 USA; NEI, Off Director, Bethesda, MD 20892 USA; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci, Gothenburg, Sweden; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Gothenburg; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Gothenburg; Harvard University; Harvard Medical School; Massachusetts General Hospital	Smith, LEH (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.	lois.smith@childrens.harvard.edu	SanGiovanni, John Paul/AAU-3895-2020; Yan, Shuo/B-8381-2009; Majchrzak, Sharon/F-1830-2013; SanGiovanni, John Paul/A-7605-2008; Akın, Mustafa Senol/F-5143-2017	Majchrzak, Sharon/0000-0001-8934-7294; Akın, Mustafa Senol/0000-0003-0055-8277; Hellstrom, Ann/0000-0002-9259-1244; Lofqvist, Chatarina/0000-0003-4371-5164; Connor, Kip/0000-0002-2048-9080; SanGiovanni, John Paul/0000-0001-7199-7053	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY017789, R01EY008670, T32EY007145, R01EY017017, R21EY014811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R29GM038765, R37GM038765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000235] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NEI NIH HHS [EY14811, R01 EY008670, EY017017, T32 EY007145, R21 EY014811, 5 T32 EY07145, R01 EY017017, EY008670, 1F32 EY017789, F32 EY017789] Funding Source: Medline; NICHD NIH HHS [P01 HD18655, P30 HD018655] Funding Source: Medline; NIDCR NIH HHS [P50-DE016191, P50 DE016191] Funding Source: Medline; NIGMS NIH HHS [GM38765, R37 GM038765, R01 GM038765] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Calder PC, 2006, PROSTAG LEUKOTR ESS, V75, P197, DOI 10.1016/j.plefa.2006.05.012; Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Crawford MA, 1997, AM J CLIN NUTR, V66, P1032, DOI 10.1093/ajcn/66.4.1032S; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5; Goukassian DA, 2007, CIRCULATION, V115, P752, DOI 10.1161/CIRCULATIONAHA.106.647255; Grounds MD, 2005, CELL TISSUE RES, V320, P509, DOI 10.1007/s00441-005-1102-z; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a; Kermorvant-Duchemin E, 2005, NAT MED, V11, P1339, DOI 10.1038/nm1336; Kishore R, 2005, J CLIN INVEST, V115, P1785, DOI 10.1172/JCI22849; Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Moriguchi T, 2004, J LIPID RES, V45, P1437, DOI 10.1194/jlr.M400087-JLR200; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	30	516	556	1	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					868	873		10.1038/nm1591	http://dx.doi.org/10.1038/nm1591			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17589522	Green Accepted			2022-12-27	WOS:000247902800035
J	Nathan, C				Nathan, Carl			Aligning pharmaceutical innovation with medical need	NATURE MEDICINE			English	Editorial Material							DRUG DISCOVERY; GLOBAL HEALTH; ANTIBIOTICS; FRAMEWORK; BUSINESS; ACCESS; CANCER		Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Nathan, C (corresponding author), Cornell Univ, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	cnathan@med.cornell.edu						Abramowicz M, 2003, VANDERBILT LAW REV, V56, P115; Barton JH, 2005, JAMA-J AM MED ASSOC, V294, P2075, DOI 10.1001/jama.294.16.2075; Check E, 2006, NATURE, V444, P412, DOI 10.1038/444412b; Chirac P, 2006, LANCET, V367, P1560, DOI 10.1016/S0140-6736(06)68672-8; Clardy J, 2006, NAT BIOTECHNOL, V24, P1541, DOI 10.1038/nbt1266; Cuatrecasas P, 2006, J CLIN INVEST, V116, P2837, DOI 10.1172/JCI29999; Danzon Patricia M, 2003, Int J Health Care Finance Econ, V3, P183, DOI 10.1023/A:1025384819575; DUGGER C, 2006, NY TIMES        1201, pA9; Fenical W, 2006, NAT CHEM BIOL, V2, P666, DOI 10.1038/nchembio841; Fisher ES, 2006, NEW ENGL J MED, V355, P1845, DOI 10.1056/NEJMp068221; Fox JL, 2006, NAT BIOTECHNOL, V24, P1521, DOI 10.1038/nbt1206-1521; Hubbard T, 2004, PLOS BIOL, V2, P147, DOI 10.1371/journal.pbio.0020052; Katz ML, 2006, NAT BIOTECHNOL, V24, P1529, DOI 10.1038/nbt1206-1529; Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865; KREMER M, 2004, STRONG MED CREATING, P55; LANJOUW J, 2006, INNOVATIONS, V1, P108; Leaf C, 2004, FORTUNE, V149, P76; Lewis K, 2006, NAT BIOTECHNOL, V24, P1504, DOI 10.1038/nbt1206-1504; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Love JP, 2006, B WORLD HEALTH ORGAN, V84, P408; MacCoss M, 2004, SCIENCE, V303, P1810, DOI 10.1126/science.1096800; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Nathan C, 2005, NAT REV DRUG DISCOV, V4, P887, DOI 10.1038/nrd1878; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Outterson Kevin, 2005, Yale J Health Policy Law Ethics, V5, P193; Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Pisano GP, 2006, HARVARD BUS REV, V84, P114; Pogge TW, 2005, METAPHILOSOPHY, V36, P182, DOI 10.1111/j.1467-9973.2005.00362.x; Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837; Sporn MB, 2006, NAT CLIN PRACT ONCOL, V3, P364, DOI 10.1038/ncponc0536; Walsh C. T., 2005, TREATING INFECT DIS, P1	32	37	39	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					304	308		10.1038/nm0307-304	http://dx.doi.org/10.1038/nm0307-304			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342145				2022-12-27	WOS:000244715700042
J	Lo, YMD; Tsui, NBY; Chiu, RWK; Lau, TK; Leung, TN; Heung, MMS; Gerovassili, A; Jin, YJ; Nicolaides, KH; Cantor, CR; Ding, C				Lo, Y. M. Dennis; Tsui, Nancy B. Y.; Chiu, Rossa W. K.; Lau, Tze K.; Leung, Tse N.; Heung, Macy M. S.; Gerovassili, Ageliki; Jin, Yongjie; Nicolaides, Kypros H.; Cantor, Charles R.; Ding, Chunming			Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection	NATURE MEDICINE			English	Article							FREE FETAL DNA; MATERNAL PLASMA; MESSENGER-RNA; DOWN-SYNDROME; SERUM; DIAGNOSIS; BLOOD; CELLS; ORIGIN; GENE	Current methods for prenatal diagnosis of chromosomal aneuploidies involve the invasive sampling of fetal materials using procedures such as amniocentesis or chorionic villus sampling and constitute a finite risk to the fetus. Here, we outline a strategy for fetal chromosome dosage assessment that can be performed noninvasively through analysis of placental expressed mRNA in maternal plasma. We achieved noninvasive prenatal diagnosis of fetal trisomy 21 by determining the ratio between alleles of a single-nucleotide polymorphism (SNP) in PLAC4 mRNA, which is transcribed from chromosome 21 and expressed by the placenta, in maternal plasma. PLAC4 mRNA in maternal plasma was fetal derived and cleared after delivery. The allelic ratios in maternal plasma correlated with those in the placenta. Fetal trisomy 21 was detected noninvasively in 90% of cases and excluded in 96.5% of controls.	Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China; Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London SE5 9RS, England; Boston Univ, Bioinformat Program, Boston, MA 02118 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02118 USA	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Boston University; Boston University	Lo, YMD (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.	loym@cuhk.edu.hk	Lo, Yuk Ming Dennis/D-4468-2011; Ding, Chunming/B-2593-2008	Lo, Yuk Ming Dennis/0000-0001-8746-0293; Ding, Chunming/0000-0002-2063-5594; Lau, Tze Kin/0000-0002-0242-1410; Nicolaides, Kypros/0000-0003-1266-0711				Alfirevic Z, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003252, 10.1002/14651858]; Amor DJ, 2006, PRENATAL DIAG, V26, P443, DOI 10.1002/pd.1433; Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791; Bianchi DW, 2002, PRENATAL DIAG, V22, P609, DOI 10.1002/pd.347; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102; Ding CM, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-8; Farina A, 2003, CLIN CHEM, V49, P239, DOI 10.1373/49.2.239; Ferguson-Smith MA, 2003, P NATL ACAD SCI USA, V100, P4360, DOI 10.1073/pnas.0830966100; Jurinke C, 2004, MOL BIOTECHNOL, V26, P147, DOI 10.1385/MB:26:2:147; Kaiser J, 2005, SCIENCE, V309, P1476, DOI 10.1126/science.309.5740.1476; KIDO S, 1993, GENOMICS, V17, P256, DOI 10.1006/geno.1993.1317; Lee T, 2002, AM J OBSTET GYNECOL, V187, P1217, DOI 10.1067/mob.2002.127462; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lo YMD, 1999, CLIN CHEM, V45, P1747; Lui YNYN, 2002, CLIN CHEM, V48, P421; Malone FD, 2005, NEW ENGL J MED, V353, P2001, DOI 10.1056/NEJMoa043693; Ng EKO, 2003, P NATL ACAD SCI USA, V100, P4748, DOI 10.1073/pnas.0637450100; Oudejans CBM, 2003, CLIN CHEM, V49, P1445, DOI 10.1373/49.9.1445; Tsui NBY, 2004, J MED GENET, V41, P461, DOI 10.1136/jmg.2003.016881; Wapner R, 2003, NEW ENGL J MED, V349, P1405, DOI 10.1056/NEJMoa025273; Wapner RJ, 2005, SEMIN PERINATOL, V29, P401, DOI 10.1053/j.semperi.2006.01.003	25	285	407	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					218	223		10.1038/nm1530	http://dx.doi.org/10.1038/nm1530			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17206148				2022-12-27	WOS:000244031700032
J	O'Connor, KC; McLaughlin, KA; De Jager, PL; Chitnis, T; Bettelli, E; Xu, CQ; Robinson, WH; Cherry, SV; Bar-Or, A; Banwell, B; Fukaura, H; Fukazawa, T; Tenembaum, S; Wong, SJ; Tavakoli, NP; Idrissova, Z; Viglietta, V; Rostasy, K; Pohl, D; Dale, RC; Freedman, M; Steinman, L; Kuchroo, VK; Hafler, DA; Wucherpfennig, KW				O'Connor, Kevin C.; McLaughlin, Katherine A.; De Jager, Philip L.; Chitnis, Tanuja; Bettelli, Estelle; Xu, Chenqi; Robinson, William H.; Cherry, Sunil V.; Bar-Or, Amit; Banwell, Brenda; Fukaura, Hikoaki; Fukazawa, Toshiyuki; Tenembaum, Silvia; Wong, Susan J.; Tavakoli, Norma P.; Idrissova, Zhannat; Viglietta, Vissia; Rostasy, Kevin; Pohl, Daniela; Dale, Russell C.; Freedman, Mark; Steinman, Lawrence; Kuchroo, Vijay K.; Hafler, David A.; Wucherpfennig, Kai W.			Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein	NATURE MEDICINE			English	Article							ACUTE DISSEMINATED ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; BASIC-PROTEIN; ANTIMYELIN ANTIBODIES; FOLLOW-UP; DEMYELINATION; PLASMAPHERESIS; PREDICTION	The role of autoantibodies in the pathogenesis of multiple sclerosis (MS) and other demyelinating diseases is controversial, in part because widely used western blotting and ELISA methods either do not permit the detection of conformation-sensitive antibodies or do not distinguish them from conformation-independent antibodies. We developed a sensitive assay based on self-assembling radiolabeled tetramers that allows discrimination of antibodies against folded or denatured myelin oligodendrocyte glycoprotein (MOG) by selective unfolding of the antigen domain. The tetramer radioimmunoassay (RIA) was more sensitive for MOG autoantibody detection than other methodologies, including monomer-based RIA, ELISA or fluorescent-activated cell sorting (FACS). Autoantibodies from individuals with acute disseminated encephalomyelitis (ADEM) selectively bound the folded MOG tetramer, whereas sera from mice with experimental autoimmune encephalomyelitis induced with MOG peptide immunoprecipitated only the unfolded tetramer. MOG-specific autoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating that MOG is a more prominent target antigen in ADEM than MS.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; MIT, Cambridge Ctr 7, Cambridge, MA 02142 USA; Stanford Univ, Sch Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Hosp Sick Children, Dept Paediat Neurol, Toronto, ON M5G 1X8, Canada; Iwate Med Univ, Dept Neurol, Morioka, Iwate 0208505, Japan; Hokkaido Univ, Hokuyukai Neurol Hosp, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Dr JP Garrahan Natl Pediat Hosp, Dept Pediat Neurol, RA-1249 Buenos Aires, DF, Argentina; New York State Dept Hlth, Wadsworth Ctr, Diagnost Immunol Lab, Albany, NY 12201 USA; Kazakh Natl Med Univ, Dept Neurol, Alma Ata 050012, Kazakhstan; Univ Gottingen, Dept Pediat & Pediat Neurol, D-37075 Gottingen, Germany; Great Ormond St Hosp Sick Children, Dept Neurol, London WC1N 3JH, England; Ottawa Gen Hosp, Dept Neurol, Ottawa, ON K1H 8L6, Canada	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Stanford University; Stanford University; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Iwate Medical University; Hokkaido University; Hospital de Pediatria Doctor Juan Garrahan; State University of New York (SUNY) System; Wadsworth Center; Asfendiyarov Kazakh National Medical University; University of Gottingen; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Ottawa; Ottawa Hospital Research Institute	Wucherpfennig, KW (corresponding author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02115 USA.	Kai_Wucherpfennig@dfci.harvard.edu	Bar-Or, Amit/C-4213-2011; Idrissova, Zhannat/ABC-5245-2020	Idrissova, Zhannat/0000-0003-2500-7105; Steinman, Lawrence/0000-0002-2437-2250; Xu, Chenqi/0000-0002-4968-6782	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045757, P01AI039671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK061926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247, P01NS038037] Funding Source: NIH RePORTER; NIAID NIH HHS [P01AI39671, P01 AI039671, P01 AI045757] Funding Source: Medline; NIDDK NIH HHS [U01DK6192601] Funding Source: Medline; NINDS NIH HHS [R01 NS024247, P01 NS038037, P01NS38037, R01NS2424710] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker JM, 2004, J CLIN ENDOCR METAB, V89, P3896, DOI 10.1210/jc.2003-031887; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Brehm U, 1999, J NEUROIMMUNOL, V97, P9, DOI 10.1016/S0165-5728(99)00010-7; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Fossati-Jimack L, 1999, J EXP MED, V190, P1689, DOI 10.1084/jem.190.11.1689; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; HEMACHUDHA T, 1987, NEW ENGL J MED, V316, P369, DOI 10.1056/NEJM198702123160703; Hjelmstrom P, 1998, J IMMUNOL, V161, P4480; Idrissova ZR, 2003, EUR J NEUROL, V10, P537, DOI 10.1046/j.1468-1331.2003.00639.x; JAVIER RS, 1989, J NEUROL SCI, V93, P221, DOI 10.1016/0022-510X(89)90192-5; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KANTER DS, 1995, NEUROLOGY, V45, P824, DOI 10.1212/WNL.45.4.824; Khurana DS, 2005, PEDIATRICS, V116, P431, DOI 10.1542/peds.2004-2038; LaGasse JM, 2002, DIABETES CARE, V25, P505, DOI 10.2337/diacare.25.3.505; Lalive PH, 2006, P NATL ACAD SCI USA, V103, P2280, DOI 10.1073/pnas.0510672103; Lampasona V, 2004, NEUROLOGY, V62, P2092, DOI 10.1212/01.WNL.0000127615.15768.AE; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Lim ET, 2005, MULT SCLER J, V11, P492, DOI 10.1191/1352458505ms1187sr; LININGTON C, 1988, AM J PATHOL, V130, P443; LISAK RP, 1974, NEUROLOGY, V24, P560, DOI 10.1212/WNL.24.6.560; Marchioni E, 2005, NEUROLOGY, V65, P1057, DOI 10.1212/01.wnl.0000179302.93960.ad; Mathey E, 2004, EUR J IMMUNOL, V34, P2065, DOI 10.1002/eji.200425291; Menge T, 2005, ARCH NEUROL-CHICAGO, V62, P1673, DOI 10.1001/archneur.62.11.1673; O'Connor KC, 2005, J IMMUNOL, V175, P1974, DOI 10.4049/jimmunol.175.3.1974; Pohl-Koppe A, 1998, J NEUROIMMUNOL, V91, P19, DOI 10.1016/S0165-5728(98)00125-8; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016; THOMPSON EJ, 1979, BRIT MED J, V1, P16, DOI 10.1136/bmj.1.6155.16; von Budingen HC, 2004, EUR J IMMUNOL, V34, P2072, DOI 10.1002/eji.200425050; Wingerchuk Dean M, 2003, Curr Neurol Neurosci Rep, V3, P256, DOI 10.1007/s11910-003-0086-x	30	250	258	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					211	217		10.1038/nm1488	http://dx.doi.org/10.1038/nm1488			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17237795	Green Accepted			2022-12-27	WOS:000244031700031
J	Bohn, G; Allroth, A; Brandes, G; Thiel, J; Glocker, E; Schaffer, AA; Rathinam, C; Taub, N; Teis, D; Zeidler, C; Dewey, RA; Geffers, R; Buer, J; Huber, LA; Welte, K; Grimbacher, B; Klein, C				Bohn, Georg; Allroth, Anna; Brandes, Gudrun; Thiel, Jens; Glocker, Erik; Schaffer, Alejandro A.; Rathinam, Chozhavendan; Taub, Nicole; Teis, David; Zeidler, Cornelia; Dewey, Ricardo A.; Geffers, Robert; Buer, Jan; Huber, Lukas A.; Welte, Karl; Grimbacher, Bodo; Klein, Christoph			A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14	NATURE MEDICINE			English	Article							CHEDIAK-HIGASHI-SYNDROME; SEVERE CONGENITAL NEUTROPENIA; HERMANSKY-PUDLAK-SYNDROME; COLONY-STIMULATING FACTOR; GRANULE EXOCYTOSIS; GRISCELLI-SYNDROME; HUMAN-NEUTROPHILS; PROGENITOR CELLS; LINKAGE ANALYSIS; MYELOID CELLS	Lysosome-related organelles have versatile functions, including protein and lipid degradation, signal transduction and protein secretion. The molecular elucidation of rare congenital diseases affecting endosomal-lysosomal biogenesis has given insights into physiological functions of the innate and adaptive immune system. Here, we describe a previously unknown human primary immunodeficiency disorder and provide evidence that the endosomal adaptor protein p14, previously characterized as confining mitogen-activated protein kinase (MAPK) signaling to late endosomes, is crucial for the function of neutrophils, B cells, cytotoxic T cells and melanocytes. Combining genetic linkage studies and transcriptional profiling analysis, we identified a homozygous point mutation in the 3' untranslated region (UTR) of p14 (also known as MAPBPIP), resulting in decreased protein expression. In p14-deficient cells, the distribution of late endosomes was severely perturbed, suggesting a previously unknown role for p14 in endosomal biogenesis. These findings have implications for understanding endosomal membrane dynamics, compartmentalization of cell signal cascades, and their role in immunity.	Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Cell Biol, D-30625 Hannover, Germany; Univ Hosp Freiburg, Div Clin Immunol & Rheumatol, D-79106 Freiburg, Germany; Natl Inst Hlth, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20894 USA; Med Univ Innsbruck, Div Cell Biol, A-6020 Innsbruck, Austria; Helmholtz Ctr Infect Res, HCI, Array Facil & Mucosal Immun, D-38124 Braunschweig, Germany	Hannover Medical School; Hannover Medical School; University of Freiburg; National Institutes of Health (NIH) - USA; Medical University of Innsbruck; Helmholtz Association; Helmholtz-Center for Infection Research	Klein, C (corresponding author), Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	klein.christoph@mh-hannover.de	Schaffer, Alejandro/N-1222-2019; Huber, Lukas Alfons/AAM-3499-2021; Saborowski, Anna/GQH-4609-2022; Schaffer, Alejandro A/F-2902-2012	Saborowski, Anna/0000-0003-4857-4276; Buer, Jan/0000-0002-7602-1698; Teis, David/0000-0002-8181-0253; Dewey, Ricardo/0000-0003-1677-2745; Huber, Lukas Alfons/0000-0003-1116-2120; Schider, Nicole/0000-0002-3579-3667	NATIONAL LIBRARY OF MEDICINE [Z01LM000097, ZIALM000097] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; BAETZ K, 1995, J IMMUNOL, V154, P6122; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Carlsson G, 2004, BLOOD, V103, P3355, DOI 10.1182/blood-2003-04-1011; Chen JM, 2006, HUM GENET, V120, P1, DOI 10.1007/s00439-006-0180-7; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Fischer A, 2004, NAT IMMUNOL, V5, P23, DOI 10.1038/ni1023; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HAMERS MN, 1984, BLOOD, V64, P635, DOI 10.1182/blood.V64.3.635.635; Hino M, 2000, BRIT J HAEMATOL, V109, P314, DOI 10.1046/j.1365-2141.2000.02054.x; Huynh C, 2004, P NATL ACAD SCI USA, V101, P16795, DOI 10.1073/pnas.0405905101; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Jung J, 2006, BLOOD, V108, P362, DOI 10.1182/blood-2005-11-4377; KLEIN C, 1994, J PEDIATR-US, V125, P886, DOI 10.1016/S0022-3476(05)82003-7; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; KLEIN C, IN PRESS NAT GENET; Kollner I, 2006, BLOOD, V108, P493, DOI 10.1182/blood-2005-11-4689; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kurzbauer R, 2004, P NATL ACAD SCI USA, V101, P10984, DOI 10.1073/pnas.0403435101; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Price TH, 1996, BLOOD, V88, P335; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; Stinchcombe J, 2004, SCIENCE, V305, P55, DOI 10.1126/science.1095291; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; TEIS D, IN PRESS J CELL BIOL; Trambas CM, 2003, NAT IMMUNOL, V4, P399, DOI 10.1038/ni0503-399; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Zhuang DZ, 2006, J BIOL CHEM, V281, P10745, DOI 10.1074/jbc.M510924200	42	140	144	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					38	45		10.1038/nm1528	http://dx.doi.org/10.1038/nm1528			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17195838				2022-12-27	WOS:000243301800034
J	Roy, NS; Cleren, C; Singh, SK; Yang, L; Beal, MF; Goldman, SA				Roy, Neeta S.; Cleren, Carine; Singh, Shashi K.; Yang, Lichuan; Beal, M. Flint; Goldman, Steven A.			Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes	NATURE MEDICINE			English	Article							EMBRYONIC STEM-CELLS; PARKINSONS-DISEASE; IN-VITRO; PROTEOMIC ANALYSIS; NEURAL PRECURSORS; TYPE-1 ASTROCYTES; HUMAN BLASTOCYSTS; SUBSTANTIA-NIGRA; SPINAL-CORD; RAT MODELS	To direct human embryonic stem (HES) cells to a dopaminergic neuronal fate, we cocultured HES cells that were exposed to both sonic hedgehog and fibroblast growth factor 8 with telomerase-immortalized human fetal midbrain astrocytes. These astrocytes substantially potentiated dopaminergic neurogenesis by both WA09 and WA01 HES cells, biasing them to the A9 nigrostriatal phenotype. When transplanted into the neostriata of 6-hydroxydopamine-lesioned parkinsonian rats, the dopaminergic implants yielded a significant, substantial and long-lasting restitution of motor function. However, although rich in donor-derived tyrosine hydroxylase-expressing neurons, the grafts exhibited expanding cores of undifferentiated mitotic neuroepithelial cells, which can be tumorigenic. These results show the utility of recreating the cellular environment of the developing human midbrain while driving dopaminergic neurogenesis from HES cells, and they demonstrate the potential of the resultant cells to mediate substantial functional recovery in a model of Parkinson disease. Yet these data also mandate caution in the clinical application of HES cell-derived grafts, given their potential for phenotypic instability and undifferentiated expansion.	Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurosurg & Pediat, Rochester, NY 14642 USA	Cornell University; Cornell University; University of Rochester; University of Rochester	Roy, NS (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA.	ner2004@med.cornell.edu; steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303; Cleren, Carine/0000-0002-2451-8387				Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Buytaert-Hoefen KA, 2004, STEM CELLS, V22, P669, DOI 10.1634/stemcells.22-5-669; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Chang JW, 1999, NEUROSCIENCE, V88, P617, DOI 10.1016/S0306-4522(98)00217-6; Chung S, 2006, J NEUROCHEM, V97, P1467, DOI 10.1111/j.1471-4159.2006.03841.x; Egnaczyk GF, 2003, PROTEOMICS, V3, P689, DOI 10.1002/pmic.200300407; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Lafon-Cazal M, 2003, J BIOL CHEM, V278, P24438, DOI 10.1074/jbc.M211980200; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; McRitchie DA, 1996, J COMP NEUROL, V364, P121, DOI 10.1002/(SICI)1096-9861(19960101)364:1<121::AID-CNE11>3.0.CO;2-1; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Morga E, 1998, J NEUROIMMUNOL, V87, P179, DOI 10.1016/S0165-5728(98)00099-X; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; OLSSON M, 1995, J NEUROSCI, V15, P3863; Onofre GR, 2001, BRAZ J MED BIOL RES, V34, P251, DOI 10.1590/S0100-879X2001000200014; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reuss B, 2000, MOL CELL NEUROSCI, V16, P42, DOI 10.1006/mcne.2000.0857; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schwarting RKW, 1996, PROG NEUROBIOL, V50, P275, DOI 10.1016/S0301-0082(96)00040-8; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; TAKESHIMA T, 1994, J NEUROSCI, V14, P4769; Thompson L, 2005, J NEUROSCI, V25, P6467, DOI 10.1523/JNEUROSCI.1676-05.2005; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Yang LC, 2004, NEUROBIOL DIS, V17, P250, DOI 10.1016/j.nbd.2004.07.021; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Yoshida M, 2001, J NEUROSCI RES, V63, P284, DOI 10.1002/1097-4547(20010201)63:3<284::AID-JNR1022>3.0.CO;2-6; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	35	618	669	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1259	1268		10.1038/nm1495	http://dx.doi.org/10.1038/nm1495			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057709				2022-12-27	WOS:000241844900023
J	Wyss-Coray, T				Wyss-Coray, Tony			Inflammation in Alzheimer disease: driving force, bystander or beneficial response?	NATURE MEDICINE			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; OSTEOPETROTIC OP/OP MICE; TARGET GAMMA-SECRETASE; CENTRAL-NERVOUS-SYSTEM; MARROW-DERIVED CELLS; TRANSGENIC MICE; A-BETA; GENE-EXPRESSION; IN-VIVO	Alzheimer disease is a progressive dementia with unknown etiology that affects a growing number of the aging population. Increased expression of inflammatory mediators in postmortem brains of people with Alzheimer disease has been reported, and epidemiological studies link the use of anti-inflammatory drugs with reduced risk for the disorder. On the initial basis of this kind of evidence, inflammation has been proposed as a possible cause or driving force of Alzheimer disease. If true, this could have important implications for the development of new treatments. Alternatively, inflammation could simply be a by product of the disease process and may not substantially alter its course. Or components of the inflammatory response might even be beneficial and slow the disease. To address these possibilities, we need to determine whether inflammation in Alzheimer disease is an early event, whether it is genetically linked with the disease and whether manipulation of inflammatory pathways changes the course of the pathology. Although there is still little evidence that inflammation triggers or promotes Alzheimer disease, increasing evidence from mouse models suggests that certain inflammatory mediators are potent drivers of the disease. Related factors, on the other hand, elicit beneficial responses and can reduce disease.	Vet Adm Palo Alto Hlth Care Syst, Educ & Clin Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA	Stanford University	Wyss-Coray, T (corresponding author), Vet Adm Palo Alto Hlth Care Syst, Educ & Clin Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	twc@stanford.edu	Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831				ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Bernardo A, 2005, J NEUROCHEM, V92, P895, DOI 10.1111/j.1471-4159.2004.02932.x; Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; CHIANG CS, 1993, RADIOTHER ONCOL, V29, P60, DOI 10.1016/0167-8140(93)90174-7; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Craft JM, 2004, NEUROBIOL AGING, V25, P1283, DOI 10.1016/j.neurobiolaging.2004.01.006; Dickey CA, 2003, J NEUROSCI, V23, P5219; Du Y, 2001, NEUROLOGY, V57, P801, DOI 10.1212/WNL.57.5.801; DYSKEN MW, 1992, J PSYCHIATR RES, V26, P213, DOI 10.1016/0022-3956(92)90024-I; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EIKELENBOOM P, 1989, VIRCHOWS ARCH B, V56, P259; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gasparini L, 2004, J NEUROCHEM, V88, P337, DOI 10.1046/j.1471-4159.2003.02154.x; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GROOM GN, 1995, J NUCL MED, V36, P2207; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Ho L, 2001, NEUROSCI LETT, V310, P1, DOI 10.1016/S0304-3940(01)02044-4; Hoozemans JJM, 2005, CNS NEUROL DISORD-DR, V4, P307, DOI 10.2174/1568007054038201; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; Iqbal K, 2005, ANN NEUROL, V58, P748, DOI 10.1002/ana.20639; ITAGAKI S, 1988, NEUROSCI LETT, V91, P259, DOI 10.1016/0304-3940(88)90690-8; Kaku M, 2003, BRAIN RES PROTOC, V12, P104, DOI 10.1016/j.brainresprot.2003.09.001; Kanter JL, 2006, NAT MED, V12, P138, DOI 10.1038/nm1344; Katsel PL, 2005, INT REV NEUROBIOL, V63, P41, DOI 10.1016/S0074-7742(05)63003-6; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Li YK, 2003, J NEUROSCI, V23, P1605; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; Masliah E, 1996, J NEUROSCI, V16, P5795; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; McGowan E, 2006, TRENDS GENET, V22, P281, DOI 10.1016/j.tig.2006.03.007; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Miller RJ, 2005, NEURON, V47, P621, DOI 10.1016/j.neuron.2005.08.012; Moir RD, 2005, J BIOL CHEM, V280, P17458, DOI 10.1074/jbc.M414176200; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Morgan D, 2005, J NEUROPATH EXP NEUR, V64, P743, DOI 10.1097/01.jnen.0000178444.33972.e0; Mruthinti S, 2004, NEUROBIOL AGING, V25, P1023, DOI 10.1016/j.neurobiolaging.2003.11.001; Mucke L, 2000, AM J PATHOL, V157, P2003, DOI 10.1016/S0002-9440(10)64839-0; Nagasaka Y, 2005, P NATL ACAD SCI USA, V102, P14854, DOI 10.1073/pnas.0504178102; Nath A, 2003, NEUROMOL MED, V3, P29, DOI 10.1385/NMM:3:1:29; Nilsson LNG, 2001, J NEUROSCI, V21, P1444, DOI 10.1523/JNEUROSCI.21-05-01444.2001; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ono K, 1999, BIOCHEM BIOPH RES CO, V262, P610, DOI 10.1006/bbrc.1999.1223; PIRTTILA T, 1992, J NEUROL SCI, V107, P160, DOI 10.1016/0022-510X(92)90284-R; Quinn J, 2003, J NEUROIMMUNOL, V137, P32, DOI 10.1016/S0165-5728(03)00037-7; Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140; Richartz-Salzburger E, 2007, J PSYCHIATR RES, V41, P174, DOI 10.1016/j.jpsychires.2006.01.010; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schneider A, 2004, J BIOL CHEM, V279, P55833, DOI 10.1074/jbc.M409954200; Sheng JG, 2000, EXP NEUROL, V163, P388, DOI 10.1006/exnr.2000.7393; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shie FS, 2005, BRAIN PATHOL, V15, P134; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; SKIAS D, 1985, NEUROLOGY, V35, P1635, DOI 10.1212/WNL.35.11.1635; Stalder AK, 2005, J NEUROSCI, V25, P11125, DOI 10.1523/JNEUROSCI.2545-05.2005; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Sung S, 2004, AM J PATHOL, V165, P2197, DOI 10.1016/S0002-9440(10)63269-5; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; Tian J, 2003, NEUROSCI LETT, V352, P137, DOI 10.1016/j.neulet.2003.08.048; Togo T, 2002, J NEUROIMMUNOL, V124, P83, DOI 10.1016/S0165-5728(01)00496-9; Trieb K, 1996, NEUROBIOL AGING, V17, P541; van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001; Versijpt JJ, 2003, EUR NEUROL, V50, P39, DOI 10.1159/000070857; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wegiel J, 1998, BRAIN RES, V804, P135, DOI 10.1016/S0006-8993(98)00618-0; Weksler ME, 2002, EXP GERONTOL, V37, P943, DOI 10.1016/S0531-5565(02)00029-3; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7; Wu ZL, 2006, NEUROBIOL AGING, V27, P377, DOI 10.1016/j.neurobiolaging.2005.02.010; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2005, NAT MED, V11, P472, DOI 10.1038/nm0505-472; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Wyss-Coray T, 2001, NEUROBIOL AGING, V22, P967, DOI 10.1016/S0197-4580(01)00305-0; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yan Q, 2003, J NEUROSCI, V23, P7504; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	119	1003	1046	2	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1005	1015		10.1038/nml1484	http://dx.doi.org/10.1038/nml1484			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16960575				2022-12-27	WOS:000240373900023
J	Tapinos, N; Ohnishi, M; Rambukkana, A				Tapinos, Nikos; Ohnishi, Makoto; Rambukkana, Anura			ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; MYCOBACTERIUM-LEPRAE; SCHWANN-CELL; MYELINATION; NEUREGULIN; PATHWAY; CANCER; DEGENERATION; PREDILECTION; TRANSDUCTION	Demyelination is a common pathologic feature in many neurodegenerative diseases including infection with leprosy-causing Mycobacterium leprae(1-3). Because of the long incubation time and highly complex disease pathogenesis, the management of nerve damage in leprosy, as in other demyelinating diseases, is extremely difficult. Therefore, an important challenge in therapeutic interventions is to identify the molecular events that occur in the early phase before the progression of the disease. Here we provide evidence that M. leprae-induced demyelination(4,5) is a result of direct bacterial ligation to and activation of ErbB2 receptor tyrosine kinase (RTK) signaling without ErbB2-ErbB3 heterodimerization, a previously unknown mechanism that bypasses the neuregulin-ErbB3-mediated ErbB2 phosphorylation(6-9). MEK- dependent Erk1 and Erk2 (hereafter referred to as Erk1/2) signaling is identified as a downstream target of M. leprae-induced ErbB2 activation that mediates demyelination. Herceptin (trastuzumab), a therapeutic humanized ErbB2-specific antibody(9,10), inhibits M. leprae binding to and activation of ErbB2 and Erk1/2 in human primary Schwann cells, and the blockade of ErbB2 activity by the small molecule dual ErbB1-ErbB2 kinase inhibitor PKI-166 (ref. 11) effectively abrogates M. leprae induced myelin damage in in vitro and in vivo models. These results may have implications for the design of ErbB2 RTK - based therapies for both leprosy nerve damage and other demyelinating neurodegenerative diseases.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Rambukkana, A (corresponding author), Rockefeller Univ, Bronk Bldg,Rm 501,Box 172,1230 York Ave, New York, NY 10021 USA.	rambuka@rockefeller.edu	Scheltens, Philip/E-1205-2012	rambukkana, anura/0000-0002-6286-9145	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045187] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS45187] Funding Source: Medline; PHS HHS [R01 A145816] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen S, 2006, J NEUROSCI, V26, P3079, DOI 10.1523/JNEUROSCI.3785-05.2006; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Fregien NL, 2005, GLIA, V49, P24, DOI 10.1002/glia.20091; Garratt AN, 2000, J CELL BIOL, V148, P1035, DOI 10.1083/jcb.148.5.1035; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Guertin AD, 2005, J NEUROSCI, V25, P3478, DOI 10.1523/JNEUROSCI.3766-04.2005; Harrisingh MC, 2004, EMBO J, V23, P3061, DOI 10.1038/sj.emboj.7600309; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; JOB CK, 1989, INT J LEPROSY, V57, P532; JOHNSON PC, 1997, TXB NEUROPATHOLOGY, P1233; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Nagy P, 1999, J CELL SCI, V112, P1733; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Rambukkana A, 2004, CURR OPIN IMMUNOL, V16, P511, DOI 10.1016/j.coi.2004.05.021; Rambukkana A, 2002, SCIENCE, V296, P927, DOI 10.1126/science.1067631; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; STONER GL, 1979, LANCET, V2, P994; Tapinos N, 2005, P NATL ACAD SCI USA, V102, P9188, DOI 10.1073/pnas.0501196102; Truman RW, 2001, INT J LEPROSY, V69, P1; Tsiper MV, 2002, J CELL SCI, V115, P1005; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289	30	101	106	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					961	966		10.1038/nm1433	http://dx.doi.org/10.1038/nm1433			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892039				2022-12-27	WOS:000239626200029
J	Topczewska, JM; Postovit, LM; Margaryan, NV; Sam, A; Hess, AR; Wheaton, WW; Nickoloff, BJ; Topczewski, J; Hendrix, MJC				Topczewska, Jolanta M.; Postovit, Lynne-Marie; Margaryan, Naira V.; Sam, Anthony; Hess, Angela R.; Wheaton, William W.; Nickoloff, Brian J.; Topczewski, Jacek; Hendrix, Mary J. C.			Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness	NATURE MEDICINE			English	Article							VASCULOGENIC MIMICRY; STEM-CELLS; MALIGNANT-MELANOMA; TUMOR-CELLS; IN-VIVO; EXPRESSION; ZEBRAFISH; GROWTH; GENE; MICROENVIRONMENT	Bidirectional cellular communication is integral to both cancer progression and embryological development. In addition, aggressive tumor cells are phenotypically plastic, sharing many properties with embryonic cells. Owing to the similarities between these two types of cells, the developing zebrafish can be used as a biosensor for tumor-derived signals. Using this system, we show that aggressive melanoma cells secrete Nodal (a potent embryonic morphogen) and consequently can induce ectopic formation of the embryonic axis. We further show that Nodal is present in human metastatic tumors, but not in normal skin, and thus may be involved in melanoma pathogenesis. Inhibition of Nodal signaling reduces melanoma cell invasiveness, colony formation and tumorigenicity. Nodal inhibition also promotes the reversion of melanoma cells toward a melanocytic phenotype. These data suggest that Nodal signaling has a key role in melanoma cell plasticity and tumorigenicity, thereby providing a previously unknown molecular target for regulating tumor progression.	Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Dev Biol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Canc Biol & Epigenom, Chicago, IL 60614 USA; Loyola Univ, Med Ctr, Dept Pathol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago	Hendrix, MJC (corresponding author), Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Dev Biol, 2300 Childrens Pl,Box 222, Chicago, IL 60614 USA.	mjchendrix@childrensmemorial.org	Topczewski, Jacek/D-5895-2016	Topczewski, Jacek/0000-0001-6023-9556; Postovit, Lynne-Marie/0000-0002-8088-4197; Topczewska, Jolanta M/0000-0003-1876-5039	NATIONAL CANCER INSTITUTE [P01CA027502, R01CA059702, R37CA059702, P01CA059327, R01CA080318] Funding Source: NIH RePORTER; NCI NIH HHS [CA59327, CA27502, CA80318, CA59702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Branford WW, 2004, CURR BIOL, V14, pR341, DOI 10.1016/j.cub.2004.04.020; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Chen Y, 2001, NATURE, V411, P607, DOI 10.1038/35079121; Cheng SK, 2004, PLOS BIOL, V2, P215, DOI 10.1371/journal.pbio.0020030; Chu YW, 1996, AM J PATHOL, V148, P63; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; Gritsman K, 2000, DEVELOPMENT, V127, P921; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; Hatta K, 1996, DEV DYNAM, V205, P183, DOI 10.1002/(SICI)1097-0177(199602)205:2<183::AID-AJA9>3.0.CO;2-E; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; JUHASZ I, 1993, AM J PATHOL, V143, P528; Kim DS, 2004, INT J BIOCHEM CELL B, V36, P1482, DOI 10.1016/j.biocel.2003.10.023; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinez-Esparza M, 1999, CELL MOL BIOL, V45, P991; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; PIERCE GB, 1982, CANCER RES, V42, P1082; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; Takeuchi H, 2003, CANCER RES, V63, P441; THISSE C, 1993, DEVELOPMENT, V119, P1203; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	50	343	366	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					925	932		10.1038/nm1448	http://dx.doi.org/10.1038/nm1448			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892036				2022-12-27	WOS:000239626200023
J	Vandenberghe, LH; Wang, LL; Somanathan, S; Zhi, Y; Figueredo, J; Calcedo, R; Sanmiguel, J; Desai, RA; Chen, CS; Johnston, J; Grant, RL; Gao, GP; Wilson, JM				Vandenberghe, Luk H.; Wang, Lili; Somanathan, Suryanarayan; Zhi, Yan; Figueredo, Joanita; Calcedo, Roberto; Sanmiguel, Julio; Desai, Ravi A.; Chen, Christopher S.; Johnston, Julie; Grant, Rebecca L.; Gao, Guangping; Wilson, James M.			Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid	NATURE MEDICINE			English	Article							HUMAN GENE-THERAPY; SULFATE PROTEOGLYCAN; IDENTIFICATION; EPITOPES; TYPE-2; TRANSDUCTION; PRIMATES; VECTORS; PROTEIN	Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia B-1. To further investigate this kind of toxicity, we evaluated T-cell responses to AAV capsids after intramuscular injection of vectors into mice and nonhuman primates. High levels of T cells specific to capsids of vectors based on AAV2 and a phylogenetically related AAV variant were detected. Vectors from other AAV clades(2) such as AAV8 (ref. 3), however, did not lead to activation of capsid-specific T cells. Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG)(4-6). Evaluation of natural and engineered AAV variants showed direct correlations between heparin binding, uptake into human dendritic cells (DCs) and activation of capsid-specific T cells. The role of heparin binding in the activation of CD8(+) T cells may be useful in modulating the immunogenicity of antigens and improving the safety profile of existing AAV vectors for gene therapy.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Gene Therapy Program, Philadelphia, PA 19104 USA; Katholieke Univ Leuven, B-3000 Louvain, Belgium; Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA	University of Pennsylvania; KU Leuven; University of Pennsylvania	Wilson, JM (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Gene Therapy Program, 125 S 31st St, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	VANDENBERGHE, LUC H./ABH-1765-2020; Vandenberghe, Luk H/B-4678-2008; Vandenberghe, Luk H./J-6395-2014; Chen, Christopher S./ABD-8499-2021; Wilson, James M/F-9220-2011	VANDENBERGHE, LUC H./0000-0002-3508-4924; Vandenberghe, Luk H/0000-0002-3508-4924; Vandenberghe, Luk H./0000-0002-3508-4924; Chen, Christopher S./0000-0003-2445-8449; Wilson, James M/0000-0002-9630-3131; Wang, Lili/0000-0001-9347-3939; Desai, Ravi/0000-0002-4217-3351	NHLBI NIH HHS [P01-HL-05407] Funding Source: Medline; NIDDK NIH HHS [P30-DK-047757] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100; Gao GP, 2004, J VIROL, V78, P6381, DOI 10.1128/JVI.78.12.6381-6388.2004; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Kodaira Y, 2000, J IMMUNOL, V165, P1599, DOI 10.4049/jimmunol.165.3.1599; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Mueller YM, 2005, J VIROL, V79, P4877, DOI 10.1128/JVI.79.8.4877-4885.2005; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Reyes-Sandoval A, 2004, J VIROL, V78, P7392, DOI 10.1128/JVI.78.14.7392-7399.2004; Sabatino DE, 2005, MOL THER, V12, P1023, DOI 10.1016/j.ymthe.2005.09.009; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Simmons G, 2004, VIROLOGY, V318, P224, DOI 10.1016/j.virol.2003.09.016; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3; Xie Q, 2002, P NATL ACAD SCI USA, V99, P10405, DOI 10.1073/pnas.162250899; Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050	17	165	204	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					967	971		10.1038/nm1445	http://dx.doi.org/10.1038/nm1445			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16845388				2022-12-27	WOS:000239626200030
J	Hodes, RJ				Hodes, Richard J.			Public funding for Alzheimer disease research in the United States	NATURE MEDICINE			English	Editorial Material									NIA, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hodes, RJ (corresponding author), NIA, NIH, Room 5C35,31 Ctr Dr, Bethesda, MD 20892 USA.	hodesr@nia.nih.gov						Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; HOYERT DC, 2003, DEATHS FINAL DATA	2	14	16	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					770	773		10.1038/nm0706-770	http://dx.doi.org/10.1038/nm0706-770			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829943				2022-12-27	WOS:000238862800056
J	Yu, Y; Fan, JJ; Chen, XS; Wang, DR; Klein-Szanto, AJ; Campbell, RL; FitzGerald, GA; Funk, CD				Yu, Ying; Fan, Jinjin; Chen, Xin-Sheng; Wang, Dairong; Klein-Szanto, Andres J.; Campbell, Robert L.; FitzGerald, Garret A.; Funk, Colin D.			Genetic model of selective COX2 inhibition reveals novel heterodimer signaling	NATURE MEDICINE			English	Article							DUCTUS-ARTERIOSUS; CYCLOOXYGENASE-2; MICE; SYNTHASE-1; EXPRESSION; AGENTS; MOUSE; TRIAL	Selective inhibitors of cyclooxygenase-2 ( COX2) have attracted widespread media attention because of evidence of an elevated risk of cardiovascular complications in placebo-controlled trials, resulting in the market withdrawal of some members of this class(1-5). These drugs block the cyclooxygenase activity of prostaglandin H synthase-2 ( PGHS2), but do not affect the associated peroxidase function. They were developed with the rationale of conserving the anti-inflammatory and analgesic actions of traditional nonsteroidal anti-inflammatory drugs ( tNSAIDs) while sparing the ability of PGHS1-derived prostaglandins to afford gastric cytoprotection(1,2,6). PGHS1 and PGHS2 coexist in the vasculature and in macrophages, and are upregulated together in inflammatory tissues such as rheumatoid synovia(7) and atherosclerotic plaque(8). They are each believed to function as homodimers(6). Here, we developed a new genetic mouse model of selective COX2 inhibition using a gene-targeted point mutation, resulting in a Y385F substitution. Structural modeling and biochemical assays showed the ability of PGHS1 and PGHS2 to heterodimerize and form prostaglandins. The heterodimerization of PGHS1-PGHS2 may explain how the ductus arteriosus closes normally at birth in mice expressing PGHS2 Y385F, but not in PGHS2-null mice(9,10).	Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Queens University - Canada; Queens University - Canada	Funk, CD (corresponding author), Univ Penn, Inst Translat Med & Therapeut, 421 Curie Blvd,BRB 2-3, Philadelphia, PA 19104 USA.	funkc@post.queensu.ca	FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233; yu, ying/0000-0002-6476-1752; Campbell, Robert/0000-0002-5473-5876				Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Loftin CD, 2002, J CLIN INVEST, V110, P549, DOI 10.1172/JCI200214924; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith GCS, 1998, PHARMACOL REV, V50, P35; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Szewczuk LM, 2004, J BIOL CHEM, V279, P22727, DOI 10.1074/jbc.M314302200; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Yu Y, 2005, J CLIN INVEST, V115, P986, DOI 10.1172/JCI23683; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	30	57	58	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					699	704		10.1038/nm1412	http://dx.doi.org/10.1038/nm1412			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732282				2022-12-27	WOS:000238149200034
J	Miyahara, Y; Nagaya, N; Kataoka, M; Yanagawa, B; Tanaka, K; Hao, H; Ishino, K; Ishida, H; Shimizu, T; Kangawa, K; Sano, S; Okano, T; Kitamura, S; Mori, H				Miyahara, Y; Nagaya, N; Kataoka, M; Yanagawa, B; Tanaka, K; Hao, H; Ishino, K; Ishida, H; Shimizu, T; Kangawa, K; Sano, S; Okano, T; Kitamura, S; Mori, H			Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction	NATURE MEDICINE			English	Article							MARROW STROMAL CELLS; HUMAN ADIPOSE-TISSUE; HUMAN BONE-MARROW; TRANSPLANTATION; SHEETS; NEOVASCULARIZATION; DIFFERENTIATION; CARDIOMYOCYTES	Mesenchymal stem cells are multipotent cells that can differentiate into cardiomyocytes and vascular endothelial cells. Here we show, using cell sheet technology, that monolayered mesenchymal stem cells have multipotent and self-propagating properties after transplantation into infarcted rat hearts. We cultured adipose tissue-derived mesenchymal stem cells characterized by flow cytometry using temperature-responsive culture dishes. Four weeks after coronary ligation, we transplanted the monolayered mesenchymal stem cells onto the scarred myocardium. After transplantation, the engrafted sheet gradually grew to form a thick stratum that included newly formed vessels, undifferentiated cells and few cardiomyocytes. The mesenchymal stem cell sheet also acted through paracrine pathways to trigger angiogenesis. Unlike a fibroblast cell sheet, the monolayered mesenchymal stem cells reversed wall thinning in the scar area and improved cardiac function in rats with myocardial infarction. Thus, transplantation of monolayered mesenchymal stem cells may be a new therapeutic strategy for cardiac tissue regeneration.	Natl Cardiovasc Ctr, Dept Regenerat Med & Tissue Engn, Res Inst, Suita, Osaka 5658565, Japan; Natl Cardiovasc Ctr, Dept Pathol, Suita, Osaka 5658565, Japan; Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cardiovasc Surg, Okayama 7008555, Japan; Tokai Univ, Sch Med, Dept Physiol, Isehara, Kanagawa 2591193, Japan; Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, Tokyo 1628666, Japan; Natl Cardiovasc Ctr, Dept Biochem, Res Inst, Suita, Osaka 5658565, Japan; Natl Cardiovasc Ctr, Dept Cardiovasc Surg, Suita, Osaka 5658565, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Cardiac Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; Okayama University; Tokai University; Tokyo Women's Medical University; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan	Nagaya, N (corresponding author), Natl Cardiovasc Ctr, Dept Regenerat Med & Tissue Engn, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	nnagaya@ri.ncvc.go.jp	Miyahara, Yoshinori/W-1474-2019; Tatsuya, Shimizu/AAN-5675-2021; Okano, Teruo/J-4028-2012					Bel A, 2003, CIRCULATION, V108, P247, DOI 10.1161/01.cir.0000089040.11131.d4; Gaustad KG, 2004, BIOCHEM BIOPH RES CO, V314, P420, DOI 10.1016/j.bbrc.2003.12.109; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Hirose M, 2000, BIOMACROMOLECULES, V1, P377, DOI 10.1021/bm0002961; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kushida A, 1999, J BIOMED MATER RES, V45, P355, DOI 10.1002/(SICI)1097-4636(19990615)45:4<355::AID-JBM10>3.0.CO;2-7; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100; Liu JB, 2004, AM J PHYSIOL-HEART C, V287, pH501, DOI 10.1152/ajpheart.00019.2004; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; NISHIKIMI T, 1992, AM J PHYSIOL, V262, pR198, DOI 10.1152/ajpregu.1992.262.2.R198; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Rangappa S, 2003, ANN THORAC SURG, V75, P775, DOI 10.1016/S0003-4975(02)04568-X; Reinlib L, 2000, CIRCULATION, V101, pE182; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Schuster MD, 2004, AM J PHYSIOL-HEART C, V287, pH525, DOI 10.1152/ajpheart.00058.2004; Shimizu T, 2002, CIRC RES, V90, pE40, DOI 10.1161/hh0302.105722; Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; Skobel E, 2004, TISSUE ENG, V10, P849, DOI 10.1089/1076327041348491; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; VANDEBERG JS, 1984, AM J PATHOL, V114, P187; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	30	931	1019	6	187	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					459	465		10.1038/nm1391	http://dx.doi.org/10.1038/nm1391			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16582917	Green Submitted			2022-12-27	WOS:000236581300036
J	Bentires-Alj, M; Gil, SG; Chan, R; Wang, ZGC; Wang, YP; Imanaka, N; Harris, LN; Richardson, A; Neel, BG; Gu, HH				Bentires-Alj, M; Gil, SG; Chan, R; Wang, ZGC; Wang, YP; Imanaka, N; Harris, LN; Richardson, A; Neel, BG; Gu, HH			A role for the scaffolding adapter GAB2 in breast cancer	NATURE MEDICINE			English	Article							TYROSINE PHOSPHATASE; PROTEIN GAB2; GENE; MUTATIONS; TUMORS; TRANSFORMATION; EXPRESSION; PTPN11; PHOSPHORYLATION; PROLIFERATION	The scaffolding adapter GAB2 maps to a region (11q13-14) commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and primary tumors, but its functional role in mammary carcinogenesis has remained unexplored. We found that overexpression of GAB2 (Grb2-associated binding protein 2) increases proliferation of MCF10A mammary cells in three-dimensional culture. Coexpression of GAB2 with antiapoptotic oncogenes causes lumenal filling, whereas coexpression with Neu (also known as ErbB2 and HER2) results in an invasive phenotype. These effects of GAB2 are mediated by hyperactivation of the Shp2-Erk pathway. Furthermore, overexpression of Gab2 potentiates, whereas deficiency of Gab2 ameliorates, Neu-evoked breast carcinogenesis in mice. Finally, GAB2 is amplified in some GAB2-overexpressing human breast tumors. Our data suggest that GAB2 may be a key gene within an 11q13 amplicon in human breast cancer and propose a role for overexpression of GAB2 in mammary carcinogenesis. Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrat Genoproteom, B-4000 Liege, Belgium; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Liege; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Bentires-Alj, M (corresponding author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, NRB 1030,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mbentire@bidmc.harvard.edu	Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127	NIAID NIH HHS [AI 51612] Funding Source: Medline; NIDDK NIH HHS [DK50693] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050693] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; RICHARDSON A, IN PRESS CANC CELL; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Yamada K, 2001, CYTOGENET CELL GENET, V94, P39, DOI 10.1159/000048780; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	155	166	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					114	121		10.1038/nm1341	http://dx.doi.org/10.1038/nm1341			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16369543				2022-12-27	WOS:000234419000060
J	Floto, RA; Clatworthy, MR; Heilbronn, KR; Rosner, DR; MacAry, PA; Rankin, A; Lehner, PJ; Ouwehand, WH; Allen, JM; Watkins, NA; Smith, KGC				Floto, RA; Clatworthy, MR; Heilbronn, KR; Rosner, DR; MacAry, PA; Rankin, A; Lehner, PJ; Ouwehand, WH; Allen, JM; Watkins, NA; Smith, KGC			Loss of function of a lupus-associated Fc gamma RIIb polymorphism through exclusion from lipid rafts	NATURE MEDICINE			English	Article							RECEPTOR IIB; ERYTHEMATOSUS; SUSCEPTIBILITY; AUTOIMMUNITY; TRAFFICKING; CELLS; GENE	Dysfunction of receptors for IgG (Fc gamma Rs) has been thought to be involved in the pathogenesis of systemic lupus erythematosus (SLE). We show that a recently described SLE-associated polymorphism of Fc gamma RIIb (Fc gamma RIIbT(232)), encoding a single transmembrane amino acid substitution, is functionally impaired. Fc gamma RIIbT(232) is unable to inhibit activatory receptors because it is excluded from sphingolipid rafts, resulting in the unopposed proinflammatory signaling thought to promote SLE.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Cambridge; University of Cambridge; University of Cambridge; University of London; University College London	Floto, RA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England.	arf27@cam.ac.uk		MacAry, Paul/0000-0002-1139-8996; Lehner, Paul Joseph/0000-0001-9383-1054; Smith, Kenneth/0000-0003-3829-4326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Brauweiler AM, 2004, IMMUNOL LETT, V92, P75, DOI 10.1016/j.imlet.2003.11.028; Cameron AJM, 2002, IMMUNOL LETT, V83, P171, DOI 10.1016/S0165-2478(02)00118-9; Chu ZT, 2004, TISSUE ANTIGENS, V63, P21, DOI 10.1111/j.1399-0039.2004.00142.x; Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1	15	237	261	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1056	1058		10.1038/nm1288	http://dx.doi.org/10.1038/nm1288			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170323				2022-12-27	WOS:000232492500025
J	Southern, E				Southern, E			Tools for genomics	NATURE MEDICINE			English	Editorial Material							FIELD GEL-ELECTROPHORESIS; MOUSE SATELLITE DNA; XENOPUS-LAEVIS; COMPLEMENTARY OLIGONUCLEOTIDES; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC ACID; BASE SEQUENCE; HYBRIDIZATION; ARRAYS; RNA		Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Southern, E (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ed.southern@bioch.ox.ac.uk						ANAND R, 1988, GENOMICS, V3, P177, DOI 10.1016/0888-7543(88)90077-8; ANAND R, 1990, GEL ELECTROPHORESIS, P101; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ARNHEIM N, 1977, CELL, V11, P363, DOI 10.1016/0092-8674(77)90053-8; BIRNSTIEL M, 1968, NATURE, V219, P454, DOI 10.1038/219454a0; BISHOP JO, 1969, BIOCHEM J, V113, P805, DOI 10.1042/bj1130805; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROWNLEE GG, 1967, J MOL BIOL, V23, P337, DOI 10.1016/S0022-2836(67)80109-8; FORD PJ, 1973, NATURE-NEW BIOL, V241, P7, DOI 10.1038/newbio241007a0; FORD PJ, 1971, NATURE, V233, P561, DOI 10.1038/233561a0; GILLESPIE D, 1965, J MOL BIOL, V12, P829, DOI 10.1016/S0022-2836(65)80331-X; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HATCH FT, 1970, BIOCHIM BIOPHYS ACTA, V224, P291, DOI 10.1016/0005-2787(70)90651-9; HUGHES TR, 2001, NATURE, V409, P922; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JONES KW, 1970, NATURE, V225, P912, DOI 10.1038/225912a0; KELLY TJ, 1970, J MOL BIOL, V51, P393, DOI 10.1016/0022-2836(70)90150-6; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; MESELSON M, 1958, COLD SPRING HARB SYM, V23, P9, DOI 10.1101/SQB.1958.023.01.004; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; Roeder RG, 2003, NAT MED, V9, P1239, DOI 10.1038/nm938; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHEPINOV MS, 1997, NUCLEIC ACIDS RES, V25, P1155; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHINNICK TM, 1975, NUCLEIC ACIDS RES, V2, P1911, DOI 10.1093/nar/2.10.1911; Sohail M, 2001, NUCLEIC ACIDS RES, V29, P2041, DOI 10.1093/nar/29.10.2041; Sohail M, 1999, RNA, V5, P646, DOI 10.1017/S1355838299982195; Southern E, 1997, U. S. Patent, Patent No. [5,700,637, 5700637]; SOUTHERN EM, 1973, COLD SPRING HARB SYM, V38, P429, DOI 10.1101/SQB.1974.038.01.046; SOUTHERN EM, 1970, NATURE, V227, P794, DOI 10.1038/227794a0; SOUTHERN EM, 1975, J MOL BIOL, V94, P51, DOI 10.1016/0022-2836(75)90404-0; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; Southern EM, 2000, TRENDS BIOCHEM SCI, V25, P585, DOI 10.1016/S0968-0004(00)01702-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSURUI H, 1988, NUCLEIC ACIDS S SER, V19, P49; TYLERSMITH C, 1987, J MOL BIOL, V195, P457, DOI 10.1016/0022-2836(87)90175-6; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; WALKER PMB, 1956, EXP CELL RES, V10, P155, DOI 10.1016/0014-4827(56)90081-7	45	3	3	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1029	1034		10.1038/nm1005-1029	http://dx.doi.org/10.1038/nm1005-1029			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211028				2022-12-27	WOS:000232492500014
J	Barber, DF; Bartolome, A; Hernandez, C; Flores, JM; Redondo, C; Fernandez-Arias, C; Camps, M; Ruckle, T; Schwarz, MK; Rodriguez, S; Martinez-A, C; Balomenos, D; Rommel, C; Carrera, AC				Barber, DF; Bartolome, A; Hernandez, C; Flores, JM; Redondo, C; Fernandez-Arias, C; Camps, M; Ruckle, T; Schwarz, MK; Rodriguez, S; Martinez-A, C; Balomenos, D; Rommel, C; Carrera, AC			PI3K gamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus	NATURE MEDICINE			English	Article							PATHOGENIC T-CELLS; PERIPHERAL-BLOOD; MURINE LUPUS; ERYTHEMATOSUS; MICE; INFLAMMATION; LYMPHOCYTES; EXPRESSION; NEPHRITIS; ISOFORMS	Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell - mediated B- cell activation, which results in glomerulonephritis and renal failure. Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects. Here we examine the use of inhibitors of phosphoinositide 3- kinase (PI3K) gamma, a lipid kinase that regulates inflammation, in the MRL- Ipr mouse model of SLE. Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that PI3K gamma may be a useful target in the treatment of chronic inflammation.	Univ Autonoma Madrid, Dept Immunol & Oncol, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Anim Facil, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Complutense Madrid, Sch Vet, Dept Anim Med & Surg, E-28040 Madrid, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; Serono Int SA, Serono Pharmaceut Res Inst, CH-1211 Geneva, Switzerland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Complutense University of Madrid; Hospital Universitario Ramon y Cajal; Merck & Company; Serono International S.A.	Carrera, AC (corresponding author), Univ Autonoma Madrid, Dept Immunol & Oncol, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain.	acarrera@cnb.uam.es	Balomenos, Dimitrios/I-3850-2015; Barber, Domingo F./G-1257-2010; Fernandez-Arias, Cristina/D-1618-2018	Balomenos, Dimitrios/0000-0002-1252-0850; Barber, Domingo F./0000-0001-8824-5405; Flores, Juana M/0000-0002-7995-4426; Fernandez Arias, Cristina/0000-0002-3883-8795; Camps, Montserrat/0000-0002-9849-8657; Carrera, Ana/0000-0002-3999-5434				Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; CERVERA R, 2003, J RHEUMATOL, V6, P150; Chatham WW, 2001, LUPUS, V10, P140, DOI 10.1191/096120301675075008; Dai CS, 2001, CHINESE MED J-PEKING, V114, P864; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; INGHIRAMI G, 1988, CLIN EXP RHEUMATOL, V6, P269; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; Lang TJ, 2003, J IMMUNOL, V171, P5795, DOI 10.4049/jimmunol.171.11.5795; Neidhart M, 1996, SCHWEIZ MED WSCHR, V126, P1922; Niculescu F, 2003, ARTHRITIS RHEUM, V48, P1071, DOI 10.1002/art.10900; RODRIGUEZBORLAD.L, 2000, FASEB J, V14, P895; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SINGER GG, 1994, CURR OPIN IMMUNOL, V6, P913, DOI 10.1016/0952-7915(94)90013-2; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Wakeland EK, 1999, CURR OPIN IMMUNOL, V11, P701, DOI 10.1016/S0952-7915(99)00039-4	15	267	380	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2005	11	9					933	935		10.1038/nm1291	http://dx.doi.org/10.1038/nm1291			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127435				2022-12-27	WOS:000231724700019
J	Camps, M; Ruckle, T; Ji, H; Ardissone, V; Rintelen, F; Shaw, J; Ferrandi, C; Chabert, C; Gillieron, C; Francon, B; Martin, T; Gretener, D; Perrin, D; Leroy, D; Vitte, PA; Hirsch, E; Wymann, MP; Cirillo, R; Schwarz, MK; Rommel, C				Camps, M; Ruckle, T; Ji, H; Ardissone, V; Rintelen, F; Shaw, J; Ferrandi, C; Chabert, C; Gillieron, C; Francon, B; Martin, T; Gretener, D; Perrin, D; Leroy, D; Vitte, PA; Hirsch, E; Wymann, MP; Cirillo, R; Schwarz, MK; Rommel, C			Blockade of PI3K gamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; PHOSPHOINOSITIDE 3-KINASE; B-CELL; EMBRYONIC LETHALITY; MONOCLONAL-ANTIBODY; MAST-CELLS; NEUTROPHILS; P110-DELTA; SUBUNIT; MICE	Phosphoinositide 3- kinases ( PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease- relevant target validation. Here we describe the identification and development of specific, selective and orally active small- molecule inhibitors of PI3K gamma ( encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3K gamma as a therapeutic target. We also describe that oral treatment with a PI3K gamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3K gamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.	Serono Int SA, Serono Pharmaceut Res Inst, Geneva, Switzerland; Serono Int SA, LCG RBM, I-10010 Colleretto Giacosa, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; Univ Basel, Dept Clin & Biol Sci, Inst Biochem & Genet, Biomed Ctr, CH-4058 Basel, Switzerland	Merck & Company; Serono International S.A.; Merck & Company; Serono International S.A.; University of Turin; University of Basel	Rommel, C (corresponding author), Serono Int SA, Serono Pharmaceut Res Inst, 14,Chemin Aulx,1288 Plan Ouates, Geneva, Switzerland.	christian.rommel@serono.com	Hirsch, Emilio/F-4848-2013; Wymann, Matthias P/C-3227-2008	Hirsch, Emilio/0000-0002-9073-6024; Wymann, Matthias P/0000-0003-3349-4281; Camps, Montserrat/0000-0002-9849-8657				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; CAMPS M, 2002, Patent No. 2002101084; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHATHAM WW, 1993, ARTHRITIS RHEUM, V36, P51; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Henderson RB, 2003, BLOOD, V102, P328, DOI 10.1182/blood-2002-10-3228; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Johnson Z, 2004, BIOCHEM SOC T, V32, P366, DOI 10.1042/BST0320366; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KERWAR SS, 1983, ARTHRITIS RHEUM, V26, P1120, DOI 10.1002/art.1780260910; KITSIS E, 1991, CLIN ORTHOP RELAT R, P63; Kowanko IC, 1996, J CLIN IMMUNOL, V16, P216, DOI 10.1007/BF01541227; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MOHR W, 1984, RHEUMATOL INT, V5, P39, DOI 10.1007/BF00541364; Nandakumar KS, 2003, AM J PATHOL, V163, P1827, DOI 10.1016/S0002-9440(10)63542-0; Okkenhaug K, 2002, SCIENCE, V297, P1031; RUECKLE T, 2004, Patent No. 2004007491; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SEKI N, 1988, J IMMUNOL, V140, P1477; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; STUART JM, 1984, ANNU REV IMMUNOL, V2, P199, DOI 10.1146/annurev.iy.02.040184.001215; Szekanecz Z, 2003, SEMIN IMMUNOL, V15, P15, DOI 10.1016/S1044-5323(02)00124-0; TERATO K, 1992, J IMMUNOL, V148, P2103; TRENTHAM DE, 1982, ARTHRITIS RHEUM, V25, P911, DOI 10.1002/art.1780250801; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Weiss-Haljiti C, 2004, J BIOL CHEM, V279, P43273, DOI 10.1074/jbc.M402924200; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; YOSHINO S, 1992, J EXP MED, V175, P907, DOI 10.1084/jem.175.4.907	42	634	757	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					936	943		10.1038/nm1284	http://dx.doi.org/10.1038/nm1284			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127437				2022-12-27	WOS:000231724700020
J	Trkola, A; Kuster, H; Rusert, P; Joos, B; Fischer, M; Leemann, C; Manrique, A; Huber, M; Rehr, M; Oxenius, A; Weber, R; Stiegler, G; Vcelar, B; Katinger, H; Aceto, L; Gunthard, HF				Trkola, A; Kuster, H; Rusert, P; Joos, B; Fischer, M; Leemann, C; Manrique, A; Huber, M; Rehr, M; Oxenius, A; Weber, R; Stiegler, G; Vcelar, B; Katinger, H; Aceto, L; Gunthard, HF			Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; CROSS-CLADE NEUTRALIZATION; PBL-SCID MICE; PHASE-I; MACAQUE MONKEYS; CHIMERIC VIRUS; INFECTION; ESCAPE; GLYCOPROTEIN	To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1-infected individuals undergoing interruption of antiretroviral treatment ( ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound during the passive immunization. Rebound in antibody-treated acutely infected individuals upon cessation of ART was substantially later than in a control group of 12 individuals with acute infection. Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail. By providing further direct evidence of the potency, breadth and titers of neutralizing antibodies that are required for in vivo activity, these data underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.	Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; ETH Honggerberg, Inst Microbiol, CH-8093 Zurich, Switzerland; Polymun Sci, A-1190 Vienna, Austria	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Trkola, A (corresponding author), Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Ramistr 100, CH-8091 Zurich, Switzerland.	alexandra.trkola@usz.ch; huldrych.guenthard@usz.ch	Joos, Beda/D-5547-2009; Huber, Michael/B-8509-2015; Weber, Rainer/D-5175-2012; Oxenius, Annette/G-7794-2015; Kuster, Herbert/A-3912-2013; Trkola, Alexandra/K-2115-2012; gunthard, huldrych f/F-1724-2011	Joos, Beda/0000-0002-3082-8875; Huber, Michael/0000-0002-0384-0000; Trkola, Alexandra/0000-0003-1013-876X; gunthard, huldrych f/0000-0002-1142-6723; Kuster, Herbert/0000-0001-6873-0091; Manrique, Amapola/0000-0003-3982-398X; Rehr, Manuela/0000-0001-5604-510X				Andrus L, 1998, J INFECT DIS, V177, P889, DOI 10.1086/515251; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012; Armbruster C, 2004, J ANTIMICROB CHEMOTH, V54, P915, DOI 10.1093/jac/dkh428; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Calarota Sandra A, 2003, AIDS, V17 Suppl 4, pS73, DOI 10.1097/00002030-200317004-00009; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005; Cavacini LA, 1998, AIDS RES HUM RETROV, V14, P545, DOI 10.1089/aid.1998.14.545; Fagard C, 2003, AIDS, V17, P1487, DOI 10.1097/00002030-200307040-00009; Fagard C, 2003, ARCH INTERN MED, V163, P1220, DOI 10.1001/archinte.163.10.1220; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Gibaldi M., 1975, PHARMACOKINETICS, P329; GUNTHARD HF, 1994, J INFECT DIS, V170, P1384, DOI 10.1093/infdis/170.6.1384; Haigwood Nancy L, 2003, AIDS, V17 Suppl 4, pS67, DOI 10.1097/00002030-200317004-00008; Haigwood NL, 2004, J VIROL, V78, P5983, DOI 10.1128/JVI.78.11.5983-5995.2004; JACOBSON JM, 1993, J INFECT DIS, V168, P298, DOI 10.1093/infdis/168.2.298; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; Montefiori DC, 2001, J VIROL, V75, P10200, DOI 10.1128/JVI.75.21.10200-10207.2001; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; PANTALEO G, 1995, EUR J IMMUNOL, V25, P226, DOI 10.1002/eji.1830250137; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Parren PWHI, 1999, AIDS, V13, pS137; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rusert P, 2004, VIROLOGY, V326, P113, DOI 10.1016/j.virol.2004.05.022; RUSERT P, IN PRESS J VIROL; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Schockmel GA, 1997, J ACQ IMMUN DEF SYND, V14, P179, DOI 10.1097/00042560-199702010-00013; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Smith DE, 2004, AIDS, V18, P709, DOI 10.1097/00002030-200403260-00001; Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; VITTECOQ D, 1995, P NATL ACAD SCI USA, V92, P1195, DOI 10.1073/pnas.92.4.1195; WATKINS BA, 1993, J VIROL, V67, P7493, DOI 10.1128/JVI.67.12.7493-7500.1993; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	49	405	437	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					615	622		10.1038/nm1244	http://dx.doi.org/10.1038/nm1244			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880120				2022-12-27	WOS:000229589800027
J	Frappart, PO; Tong, WM; Demuth, I; Radovanovic, I; Herceg, Z; Aguzzi, A; Digweed, M; Wang, ZQ				Frappart, PO; Tong, WM; Demuth, I; Radovanovic, I; Herceg, Z; Aguzzi, A; Digweed, M; Wang, ZQ			An essential function for NBS1 in the prevention of ataxia and cerebellar defects	NATURE MEDICINE			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-LIGASE-IV; TARGETED DISRUPTION; EMBRYONIC LETHALITY; GENOME STABILITY; NERVOUS-SYSTEM; MRE11 COMPLEX; ATM-DEFICIENT; SYNDROME GENE; MURINE MODEL	Nijmegen breakage syndrome (NBS), ataxia telangiectasia and ataxia telangiectasia-like disorder (ATLD) show overlapping phenotypes such as growth retardation, microcephaly, cerebellar developmental defects and ataxia. However, the molecular pathogenesis of these neurological defects remains elusive. Here we show that inactivation of the Nbn gene ( also known as Nbs1) in mouse neural tissues results in a combination of the neurological anomalies characteristic of NBS, ataxia telangiectasia and ATLD, including microcephaly, growth retardation, cerebellar defects and ataxia. Loss of Nbn causes proliferation arrest of granule cell progenitors and apoptosis of postmitotic neurons in the cerebellum. Furthermore, Nbn-deficient neuroprogenitors show proliferation defects ( but not increased apoptosis) and contain more chromosomal breaks, which are accompanied by ataxia telangiectasia mutated protein (ATM)-mediated p53 activation. Notably, depletion of p53 substantially rescues the neurological defects of Nbn mutant mice. This study gives insight into the physiological function of NBS1 ( the Nbn gene product) and the function of the DNA damage response in the neurological anomalies of NBS, ataxia telangiectasia and ATLD.	Int Agcy Res Canc, F-69008 Lyon, France; Humboldt Univ, Inst Human Genet, D-13353 Berlin, Germany; Univ Spital Zurich, Inst Neuropathol, CH-809 Zurich, Switzerland	World Health Organization; International Agency for Research on Cancer (IARC); Humboldt University of Berlin	Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr	Aguzzi, Adriano/A-3351-2008; Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523; Aguzzi, Adriano/0000-0002-0344-6708; FRAPPART, PIERRE-OLIVIER/0000-0002-8142-3878				Abner CW, 2004, DNA REPAIR, V3, P1141, DOI 10.1016/j.dnarep.2004.03.009; Allen DR, 2001, GENE DEV, V15, P554, DOI 10.1101/gad.869001; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Dumon-Jones V, 2003, CANCER RES, V63, P7263; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Herson PS, 2003, NAT NEUROSCI, V6, P378, DOI 10.1038/nn1025; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee Y, 2002, CANCER RES, V62, P6395; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; McConnell MJ, 2004, J NEUROSCI, V24, P8090, DOI 10.1523/JNEUROSCI.2263-04.2004; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	38	134	144	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					538	544		10.1038/nm1228	http://dx.doi.org/10.1038/nm1228			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15821748				2022-12-27	WOS:000228915000026
J	Holmgren, J; Czerkinsky, C				Holmgren, J; Czerkinsky, C			Mucosal immunity and vaccines	NATURE MEDICINE			English	Review							ORAL CHOLERA VACCINE; REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GUT INTRAEPITHELIAL LYMPHOCYTES; IMMUNIZATION INDUCES MUCOSAL; VI CAPSULAR POLYSACCHARIDE; VIRUS-LIKE PARTICLES; TOXIN B-SUBUNIT; ANTIBODY-RESPONSES; SUBLINGUAL IMMUNOTHERAPY	There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens. Mucosally induced tolerance also seems to be a promising form of immunomodulation for treating certain autoimmune diseases and allergies. Here we review the properties of the mucosal immune system and discuss advances in the development of mucosal vaccines for protection against infections and for treatment of various inflammatory disorders.	Univ Gothenburg, Dept Med Microbiol & Immunol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Goteborg Univ Vaccine Res Inst GUVAX, SE-40530 Gothenburg, Sweden; Fac Med Pasteur, INSERM, Unite 721, F-06107 Nice, France	University of Gothenburg; University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Holmgren, J (corresponding author), Univ Gothenburg, Dept Med Microbiol & Immunol, SE-40530 Gothenburg, Sweden.	jan.holmgren@microbio.gu.se	CZERKINSKY, CECIL/G-6520-2015; Liu, Xia/L-9425-2013	Holmgren, Jan/0000-0003-1784-5918				ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; ALI M, IN PRESS LANCET; [Anonymous], 2001, Wkly Epidemiol Rec, V76, P117; Asano T, 2004, CLIN EXP IMMUNOL, V136, P284, DOI 10.1111/j.1365-2249.2004.02440.x; Belshe Robert, 2004, Expert Rev Vaccines, V3, P643, DOI 10.1586/14760584.3.6.643; Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610; Bilsborough J, 2004, GASTROENTEROLOGY, V127, P300, DOI 10.1053/j.gastro.2004.01.028; BOWEN JC, 1994, IMMUNOLOGY, V81, P338; BuzoniGatel D, 1997, J IMMUNOL, V158, P5883; Campbell DJ, 2003, SEMIN IMMUNOL, V15, P277, DOI 10.1016/j.smim.2003.08.005; Chaillous L, 2000, LANCET, V356, P545, DOI 10.1016/S0140-6736(00)02579-4; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; De Vos Beatrice, 2004, Pediatr Infect Dis J, V23, pS179, DOI 10.1097/01.inf.0000142370.16514.4a; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Eriksson K, 1998, INFECT IMMUN, V66, P5889, DOI 10.1128/IAI.66.12.5889-5896.1998; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; FRANCO MA, 1995, J VIROL, V69, P7800, DOI 10.1128/JVI.69.12.7800-7806.1995; Gockel CM, 2000, MOL IMMUNOL, V37, P537, DOI 10.1016/S0161-5890(00)00074-2; Goodrich ME, 1998, CYTOKINE, V10, P948, DOI 10.1006/cyto.1998.0385; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Guerrero RA, 2001, J VIROL, V75, P9713, DOI 10.1128/JVI.75.20.9713-9722.2001; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Hanninen A, 2000, IMMUNOL REV, V173, P109, DOI 10.1034/j.1600-065X.2000.917303.x; Harandi Ali M, 2004, Curr Opin Investig Drugs, V5, P141; Harandi AM, 2001, J VIROL, V75, P6705, DOI 10.1128/JVI.75.14.6705-6709.2001; Holmgren J, 2003, VACCINE, V21, pS89, DOI 10.1016/S0264-410X(03)00206-8; HOLMGREN J, 2004, NEW GENERATION VACCI, P499; Holmgren Jan, 2003, Expert Rev Vaccines, V2, P205, DOI 10.1586/14760584.2.2.205; HORNQUIST CE, 1995, J IMMUNOL, V155, P2877; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Ishikawa H, 1999, IMMUNOL RES, V20, P243, DOI 10.1007/BF02790407; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jertborn M, 2001, INFECT IMMUN, V69, P4125, DOI 10.1128/IAI.69.6.4125-4128.2001; Johansson EL, 2004, VACCINE, V22, P984, DOI 10.1016/j.vaccine.2003.09.002; Johansson EL, 2001, INFECT IMMUN, V69, P7481, DOI 10.1128/IAI.69.12.7481-7486.2001; Johansson M, 1997, INFECT IMMUN, V65, P1032, DOI 10.1128/IAI.65.3.1032-1044.1997; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Klavinskis LS, 1996, J IMMUNOL, V157, P2521; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Klugman KP, 1996, VACCINE, V14, P435, DOI 10.1016/0264-410X(95)00186-5; Kozlowski PA, 1997, INFECT IMMUN, V65, P1387, DOI 10.1128/IAI.65.4.1387-1394.1997; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5; Lu XH, 2002, VACCINE, V20, P1019, DOI 10.1016/S0264-410X(01)00452-2; Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323; Lycke N, 2004, CELL MICROBIOL, V6, P23, DOI 10.1046/j.1462-5822.2003.00338.x; LYCKE N, 1987, SCAND J IMMUNOL, V25, P413, DOI 10.1111/j.1365-3083.1987.tb02208.x; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Mastrandrea F, 2004, AM J CLIN DERMATOL, V5, P281, DOI 10.2165/00128071-200405050-00001; McCluskie MJ, 2001, CRIT REV IMMUNOL, V21, P103; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Mestecky J, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P1; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Nardelli-Haefliger D, 2003, JNCI-J NATL CANCER I, V95, P1128, DOI 10.1093/jnci/djg018; NGAN J, 1978, J IMMUNOL, V120, P861; Niikura M, 2002, VIROLOGY, V293, P273, DOI 10.1006/viro.2001.1240; Phipps PA, 2003, EUR J IMMUNOL, V33, P224, DOI 10.1002/immu.200390025; Pizza M, 2001, VACCINE, V19, P2534, DOI 10.1016/S0264-410X(00)00137-7; Plant A, 2004, CURR TOP MED CHEM, V4, P509, DOI 10.2174/1568026043451230; Polanski M, 1997, J AUTOIMMUN, V10, P339, DOI 10.1006/jaut.1997.0148; Postlethwaite A E, 2001, Curr Rheumatol Rep, V3, P64, DOI 10.1007/s11926-001-0052-z; QUIDING M, 1991, J CLIN INVEST, V88, P143, DOI 10.1172/JCI115270; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Richie E, 2000, VACCINE, V18, P2399, DOI 10.1016/S0264-410X(00)00006-2; Roelofs-Haarhuis K, 2004, J IMMUNOL, V173, P1043, DOI 10.4049/jimmunol.173.2.1043; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sanchez J, 2002, J BIOL CHEM, V277, P33369, DOI 10.1074/jbc.M112337200; Schoen C, 2004, INT J MED MICROBIOL, V294, P319, DOI 10.1016/j.ijmm.2004.03.001; Shi W, 2001, J VIROL, V75, P10139, DOI 10.1128/JVI.75.21.10139-10148.2001; Simmons CP, 2001, J IMMUNOL, V166, P1106, DOI 10.4049/jimmunol.166.2.1106; Staats HF, 2001, J IMMUNOL, V167, P5386, DOI 10.4049/jimmunol.167.9.5386; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; Stanford M, 2004, CLIN EXP IMMUNOL, V137, P201, DOI 10.1111/j.1365-2249.2004.02520.x; Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656; Stoel M, 2005, J IMMUNOL, V174, P1046, DOI 10.4049/jimmunol.174.2.1046; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Svennerholm AM, 2004, BEST PRACT RES CL GA, V18, P421, DOI 10.1016/j.bpg.2003.11.004; Tamura S, 1997, VACCINE, V15, P225, DOI 10.1016/S0264-410X(96)00135-1; Tarkowski A, 1999, ARTHRITIS RHEUM, V42, P1628, DOI 10.1002/1529-0131(199908)42:8<1628::AID-ANR10>3.0.CO;2-T; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x; Vrtala S, 2004, METHODS, V32, P313, DOI 10.1016/j.ymeth.2003.08.016; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wu HY, 2003, IMMUNOL RES, V28, P265, DOI 10.1385/IR:28:3:265; Yang HH, 2001, B WORLD HEALTH ORGAN, V79, P625; Yuan Q, 2004, J PEDIATR GASTR NUTR, V38, P463, DOI 10.1097/00005176-200405000-00001; ZHAORI G, 1988, J INFECT DIS, V158, P160, DOI 10.1093/infdis/158.1.160	100	1065	1145	7	139	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S45	S53		10.1038/nm1213	http://dx.doi.org/10.1038/nm1213			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812489	Bronze			2022-12-27	WOS:000228339600010
J	Saito, T; Iwata, N; Tsubuki, S; Takaki, Y; Takano, J; Huang, SM; Suemoto, T; Higuchi, M; Saido, TC				Saito, T; Iwata, N; Tsubuki, S; Takaki, Y; Takano, J; Huang, SM; Suemoto, T; Higuchi, M; Saido, TC			Somatostatin regulates brain amyloid beta peptide A beta(42) through modulation of proteolytic degradation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; MOUSE HIPPOCAMPUS; PRIMARY NEURONS; A-BETA; NEPRILYSIN; EXPRESSION; CLEARANCE; IMMUNOREACTIVITY; ENDOPEPTIDASE; LOCALIZATION	Expression of somatostatin in the brain declines during aging in various mammals including apes and humans(1,2). A prominent decrease in this neuropeptide also represents a pathological characteristic of Alzheimer disease(3,4). Using in vitro and in vivo paradigms, we show that somatostatin regulates the metabolism of amyloid beta peptide (A beta), the primary pathogenic agent of Alzheimer disease, in the brain through modulating proteolytic degradation catalyzed by neprilysin. Among various effector candidates, only somatostatin upregulated neprilysin activity in primary cortical neurons. A genetic deficiency of somatostatin altered hippocampal neprilysin activity and localization, and increased the quantity of a hydrophobic 42-mer form of A beta, A beta(42), in a manner similar to presenilin gene mutations that cause familial Alzheimer disease. These results indicate that the aging-induced downregulation of somatostatin expression may be a trigger for A beta accumulation leading to late-onset sporadic Alzheimer disease, and suggest that somatostatin receptors may be pharmacological-target candidates for prevention and treatment of Alzheimer disease.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	RIKEN	Iwata, N (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	iwatan@brain.riken.go.jp; saido@brain.riken.go.jp	Sado, Takaomi/AAN-2759-2021; Saito, Takashi/G-2563-2015; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saito, Takashi/0000-0002-9659-9251; Saido, Takaomi C/0000-0003-1970-6903				BACK SA, 1989, J NEUROSCI, V9, P4439; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; Doggrell SA, 2004, EXPERT OPIN INV DRUG, V13, P69, DOI 10.1517/13543784.13.1.69; GARCIAJIMENEZ A, 2002, BRAIN AGING, V2, P7; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hama E, 2004, J BIOL CHEM, V279, P30259, DOI 10.1074/jbc.M401891200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hayashi M, 1997, BRAIN RES, V749, P283, DOI 10.1016/S0006-8993(96)01317-0; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jinno S, 2003, J COMP NEUROL, V461, P333, DOI 10.1002/cne.10700; Joshi DD, 2001, BLOOD, V98, P2697, DOI 10.1182/blood.V98.9.2697; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Turner A.J., 2004, ABETA METABOLISM ALZ, P419; van de Nes JAP, 2002, ACTA NEUROPATHOL, V104, P351, DOI 10.1007/s00401-002-0551-7; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wang TL, 1998, CARDIOVASC RES, V40, P557, DOI 10.1016/S0008-6363(98)00192-8; Wolfe M., 2003, ABETA METABOLISM ALZ, P33; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Zeyda T, 2001, BRAIN RES, V906, P107, DOI 10.1016/S0006-8993(01)02563-X	29	277	291	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					434	439		10.1038/nm1206	http://dx.doi.org/10.1038/nm1206			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778722				2022-12-27	WOS:000228180500036
J	Kuhn, B; del Monte, F; Hajjar, RJ; Chang, YS; Lebeche, D; Arab, S; Keating, MT				Kuhn, Bernhard; del Monte, Federica; Hajjar, Roger J.; Chang, Yuh-Shin; Lebeche, Djamel; Arab, Shima; Keating, Mark T.			Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair	NATURE MEDICINE			English	Article							MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; DNA-SYNTHESIS; HEART; KINASE; GROWTH; BINUCLEATION; INHIBITION; PROTEIN	Adult mammalian hearts respond to injury with scar formation and not with cardiomyocyte proliferation, the cellular basis of regeneration. Although cardiogenic progenitor cells may maintain myocardial turnover, they do not give rise to a robust regenerative response. Here we show that extracellular periostin induced reentry of differentiated mammalian cardiomyocytes into the cell cycle. Periostin stimulated mononucleated cardiomyocytes to go through the full mitotic cell cycle. Periostin activated alpha(V), beta(1), beta(3) and beta(5) integrins located in the cardiomyocyte cell membrane. Activation of phosphatidylinositol-3-OH kinase was required for periostin-induced reentry of cardiomyocytes into the cell cycle and was sufficient for cell-cycle reentry in the absence of periostin. After myocardial infarction, periostin-induced cardiomyocyte cell-cycle reentry and mitosis were associated with improved ventricular remodeling and myocardial function, reduced fibrosis and infarct size, and increased angiogenesis. Thus, periostin and the pathway that it regulates may provide a target for innovative strategies to treat heart failure.	Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Kuhn, B (corresponding author), Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.	bernhard.kuhn@cardio.chboston.org; mark.keating@novartis.com	del Monte, Federica/AAB-3982-2019; del Monte, Federica/AAF-3961-2020	del Monte, Federica/0000-0001-9506-9665	NHLBI NIH HHS [HL080498, R01 HL078691, K08 HL085143, HL071763, HL057263, K01 HL076659, HL083156, K08 HL069842] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057263, R01HL078691, R01HL083156, R01HL080498, R01HL071763, K08HL069842, R29HL057263, K01HL076659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Butcher JT, 2007, DEV BIOL, V302, P256, DOI 10.1016/j.ydbio.2006.09.048; Chen XW, 2007, CIRC RES, V100, P536, DOI 10.1161/01.RES.0000259560.39234.99; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Engel FB, 2006, P NATL ACAD SCI USA, V103, P15546, DOI 10.1073/pnas.0607382103; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Gilbert ME, 2005, TOXICOL SCI, V86, P365, DOI 10.1093/toxsci/kfi156; Goetsch SC, 2003, PHYSIOL GENOMICS, V14, P261, DOI 10.1152/physiolgenomics.00056.2003; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Katsuragi N, 2004, CIRCULATION, V110, P1806, DOI 10.1161/01.CIR.0000142607.33398.54; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KATZBERG AA, 1977, AM J ANAT, V149, P489, DOI 10.1002/aja.1001490406; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lebeche D, 2001, J RENIN-ANGIO-ALDO S, V2, pS154, DOI 10.1177/14703203010020012701; Lindner V, 2005, ARTERIOSCL THROM VAS, V25, P77, DOI 10.1161/01.ATV.0000149141.81230.c6; Litvin J, 2006, CARDIOVASC PATHOL, V15, P24, DOI 10.1016/j.carpath.2005.09.001; Litvin J, 2005, ANAT REC PART A, V287A, P1205, DOI 10.1002/ar.a.20237; Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115; Ma HL, 2004, AM J PHYSIOL-CELL PH, V286, pC556, DOI 10.1152/ajpcell.00328.2003; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nakajima H, 2004, CIRC RES, V94, P1606, DOI 10.1161/01.RES.0000132279.99249.f4; Nakazawa T, 2004, J ORTHOP RES, V22, P520, DOI 10.1016/j.orthres.2003.10.007; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Pasumarthi KBS, 2005, CIRC RES, V96, P110, DOI 10.1161/01.RES.0000152326.91223.4F; Prunier F, 2007, AM J PHYSIOL-HEART C, V292, pH522, DOI 10.1152/ajpheart.00357.2006; Ren J, 2007, J MOL CELL CARDIOL, V42, P367, DOI 10.1016/j.yjmcc.2006.11.002; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shiojima I, 2006, GENE DEV, V20, P3347, DOI 10.1101/gad.1492806; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Srivastava D, 2006, CELL, V126, P1037, DOI 10.1016/j.cell.2006.09.003; Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939; Sun M, 2003, CIRCULATION, V107, P1046, DOI 10.1161/01.CIR.0000051363.86009.3C; Tai IT, 2005, CARCINOGENESIS, V26, P908, DOI 10.1093/carcin/bgi034; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Tatsuka M, 1998, CANCER RES, V58, P4811; Wang DJ, 2003, HYPERTENSION, V42, P88, DOI 10.1161/01.HYP.0000074905.22908.A6; Woo YJ, 2006, CIRCULATION, V114, pI206, DOI 10.1161/CIRCULATIONAHA.105.000455; Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590; ZarainHerzberg A, 1996, MOL CELL BIOCHEM, V164, P285, DOI 10.1007/BF00408669	48	492	528	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					962	969		10.1038/nm1619	http://dx.doi.org/10.1038/nm1619			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17632525				2022-12-27	WOS:000248674600027
J	Gao, Q; Mezei, G; Nie, YZ; Rao, Y; Choi, CS; Bechmann, I; Leranth, C; Toran-Allerand, D; Priest, CA; Roberts, JL; Gao, XB; Mobbs, C; Shulman, GI; Diano, S; Horvath, TL				Gao, Qian; Mezei, Gabor; Nie, Yongzhan; Rao, Yan; Choi, Cheol Soo; Bechmann, Ingo; Leranth, Csaba; Toran-Allerand, Dominique; Priest, Catherine A.; Roberts, James L.; Gao, Xiao-Bing; Mobbs, Charles; Shulman, Gerald I.; Diano, Sabrina; Horvath, Tamas L.			Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals	NATURE MEDICINE			English	Article							RECEPTOR-CONTAINING NEURONS; ARCUATE NUCLEUS; RAT HYPOTHALAMUS; WEIGHT-GAIN; BODY-WEIGHT; FOOD-INTAKE; DISRUPTION; MUTATION; CYCLE; RNA	Metabolic hormones, such as leptin, alter the input organization of hypothalamic circuits(1-3), resulting in increased proopiomelanocortin (POMC) tone, followed by decreased food intake and adiposity. The gonadal steroid estradiol can also reduce appetite and adiposity(4,5), and it influences synaptic plasticity(6). Here we report that estradiol (E2) triggers a robust increase in the number of excitatory inputs to POMC neurons in the arcuate nucleus of wild-type rats and mice. This rearrangement of synapses in the arcuate nucleus is leptin independent because it also occurred in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice, and was paralleled by decreased food intake and body weight gain as well as increased energy expenditure. However, estrogen-induced decrease in body weight was dependent on Stat3 activation in the brain. These observations support the notion that synaptic plasticity of arcuate nucleus feeding circuits is an inherent element in body weight regulation and offer alternative approaches to reducing adiposity under conditions of failed leptin receptor signaling.	Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med & Cellular & Mol Physiol, New Haven, CT 06520 USA; Goethe Univ Frankfurt, Inst Clin Neuroanat, D-60596 Frankfurt, Germany; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; Mt Sinai Sch Med, Neurobiol Aging Labs, New York, NY 10029 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA	Yale University; Yale University; Goethe University Frankfurt; Columbia University; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio; Yale University; Yale University	Horvath, TL (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.	qian.gao@yale.edu; tamas.horvath@yale.edu	Gao, Xiao-Bing/C-3121-2011; Shulman, Gerald I./P-7176-2019; Roberts, James/AAI-3283-2020	Gao, Xiao-Bing/0000-0002-2035-4936; Shulman, Gerald I./0000-0003-1529-5668; Roberts, James/0000-0002-2671-3207; Mobbs, Charles/0000-0002-5815-8711	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U2CDK059635, K01DK061478, R01DK040936, R01DK074386, U24DK059635, R01DK070723, R01DK070039, R01DK061619, R01DK060711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-060711, DK061619, DK061478, DK-070723, DK-059635, DK-070039, DK-074386, R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; BROWN TJ, 1992, BRAIN RES, V578, P129, DOI 10.1016/0006-8993(92)90239-6; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Diano S, 1998, BRAIN RES, V812, P256, DOI 10.1016/S0006-8993(98)00936-6; Diano S, 1997, ENDOCRINOLOGY, V138, P778, DOI 10.1210/en.138.2.778; DUBUC PU, 1985, P SOC EXP BIOL MED, V180, P468; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Flanagan-Cato LM, 2001, PHYSIOL BEHAV, V72, P549, DOI 10.1016/S0031-9384(01)00411-5; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Geary N, 2001, ENDOCRINOLOGY, V142, P4751, DOI 10.1210/en.142.11.4751; Horvath TL, 2005, CELL METAB, V1, P279, DOI 10.1016/j.cmet.2005.03.003; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Meli R, 2004, ENDOCRINOLOGY, V145, P3115, DOI 10.1210/en.2004-0129; Naftolin F, 1996, ENDOCRINOLOGY, V137, P5576, DOI 10.1210/en.137.12.5576; Osterlund M, 1998, MOL BRAIN RES, V54, P175, DOI 10.1016/S0169-328X(97)00351-3; Parker GC, 2001, PHYSIOL BEHAV, V74, P399, DOI 10.1016/S0031-9384(01)00599-6; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Polidori C, 2002, PEPTIDES, V23, P1697, DOI 10.1016/S0196-9781(02)00112-2; Qiu J, 2006, J NEUROSCI, V26, P5649, DOI 10.1523/JNEUROSCI.0327-06.2006; Roesch DM, 2006, PHYSIOL BEHAV, V87, P39, DOI 10.1016/j.physbeh.2005.08.035; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Sternson SM, 2005, NAT NEUROSCI, V8, P1356, DOI 10.1038/nn1550; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; WADE GN, 1985, INT J OBESITY, V9, P83	30	321	327	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					89	94		10.1038/nm1525	http://dx.doi.org/10.1038/nm1525			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17195839				2022-12-27	WOS:000243301800041
J	Mruk, DD; Wong, CH; Silvestrini, B; Cheng, CY				Mruk, Dolores D.; Wong, Ching-Hang; Silvestrini, Bruno; Cheng, C. Yan			A male contraceptive targeting germ cell adhesion	NATURE MEDICINE			English	Article							FOLLICLE-STIMULATING-HORMONE; FREE ALPHA-SUBUNIT; N-TERMINAL SERINE; SEMINIFEROUS EPITHELIUM; PERIODATE-OXIDATION; JUNCTION DYNAMICS; ECTOPLASMIC SPECIALIZATION; CARBOHYDRATE RESIDUES; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING	Throughout spermatogenesis, developing germ cells remain attached to Sertoli cells via testis- specific anchoring junctions. If adhesion between these cell types is compromised, germ cells detach from the seminiferous epithelium and infertility often results. Previously, we reported that Adjudin is capable of inducing germ cell loss from the epithelium. In a small subset of animals, however, oral administration of Adjudin (50 mg per kg body weight (b. w.) for 29 d) resulted in adverse effects such as liver inflammation and muscle atrophy. Here, we report a novel approach in which Adjudin is specifically targeted to the testis by conjugating Adjudin to a recombinant follicle-stimulating hormone (FSH) mutant, which serves as its 'carrier'. Using this approach, infertility was induced in adult rats when 0.5 mu g Adjudin per kg b. w. was administered intraperitoneally, which was similar to results when 50 mg per kg b. w. was given orally. This represents a substantial increase in Adjudin's selectivity and efficacy as a male contraceptive.	Ctr Biomed Res, Populat Council, New York, NY 10021 USA; Univ Roma La Sapienza, I-00185 Rome, Italy	Population Council; Sapienza University Rome	Mruk, DD (corresponding author), Ctr Biomed Res, Populat Council, 1230 York Ave, New York, NY 10021 USA.	d-mruk@popcbr.rockefeller.edu; y-cheng@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U01 HD045908, U54 HD029990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beardsley A, 2003, BIOL REPROD, V68, P1299, DOI 10.1095/biolreprod.102.009811; BISHOP LA, 1995, ENDOCRINOLOGY, V136, P2635, DOI 10.1210/en.136.6.2635; BISHOP LA, 1994, MOL ENDOCRINOL, V8, P722, DOI 10.1210/me.8.6.722; BLITHE DL, 1995, ENDOCRINOLOGY, V136, P903, DOI 10.1210/en.136.3.903; Braghiroli L, 1998, BIOL REPROD, V59, P111, DOI 10.1095/biolreprod59.1.111; Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Cheng CY, 2001, BIOL REPROD, V65, P449, DOI 10.1095/biolreprod65.2.449; CLAMP JR, 1965, BIOCHEM J, V94, P17, DOI 10.1042/bj0940017; FLACK MR, 1994, J BIOL CHEM, V269, P14015; Gaertner HF, 1996, BIOCONJUGATE CHEM, V7, P38, DOI 10.1021/bc950074d; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; GEOGHEGAN KF, 1993, BIOCONJUGATE CHEM, V4, P537, DOI 10.1021/bc00024a017; Grima J, 2001, BIOL REPROD, V64, P1500, DOI 10.1095/biolreprod64.5.1500; GRISWOLD MD, 1995, J STEROID BIOCHEM, V53, P215, DOI 10.1016/0960-0760(95)00049-6; Lee NPY, 2004, J ANDROL, V25, P200; Lui WY, 2003, BIOL REPROD, V68, P2189, DOI 10.1095/biolreprod.102.011379; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2004, TRENDS ENDOCRIN MET, V15, P439, DOI 10.1016/j.tem.2004.09.009; O'Donnell L, 2000, BIOL REPROD, V63, P99, DOI 10.1095/biolreprod63.1.99; Rosenthal CS, 2000, WOMEN POLIT, V21, P21, DOI 10.1300/J014v21n02_02; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Toyama Yoshiro, 2003, Anatomical Science International, V78, P1, DOI 10.1046/j.0022-7722.2003.00034.x; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; Walker WH, 2005, REPRODUCTION, V130, P15, DOI 10.1530/rep.1.00358; Wong CH, 2005, ENDOCRINOLOGY, V146, P1192, DOI 10.1210/en.2004-1275; Zhang JY, 2005, J CELL PHYSIOL, V204, P470, DOI 10.1002/jcp.20303	30	83	92	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1323	1328		10.1038/nm1420	http://dx.doi.org/10.1038/nm1420			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072312				2022-12-27	WOS:000241844900031
J	Goldstein, JL				Goldstein, Joseph L.			Venture science: climbing the ladder to telomerase, cognitive therapy and in situ hybridization	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1129	1132		10.1038/nm1006-1129	http://dx.doi.org/10.1038/nm1006-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024207				2022-12-27	WOS:000241102200026
J	Vilcheze, C; Wang, F; Arai, M; Hazbon, MH; Colangeli, R; Kremer, L; Weisbrod, TR; Alland, D; Sacchettini, JC; Jacobs, WR				Vilcheze, Catherine; Wang, Feng; Arai, Masayoshi; Hazbon, Manzour Hernando; Colangeli, Roberto; Kremer, Laurent; Weisbrod, Torin R.; Alland, David; Sacchettini, James C.; Jacobs, William R., Jr.			Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid	NATURE MEDICINE			English	Article							BOVIS BCG; ETHIONAMIDE; RESISTANCE; GENE; REDUCTASE; SYNTHASE	Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial. Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis. The inhA(S94A) allele was sufficient to confer clinically relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis. This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymatic and X-ray crystallographic analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Infect Dis, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Ruy V Lourenco Ctr Study Emerging & Reemerging Pa, Newark, NJ 07103 USA; Univ Montpellier 2, CNRS, Lab Dynam Mol Interact Membranaires, UMR 5539, F-34095 Montpellier 05, France	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University College Station; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jacobsw@hhmi.org	Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; Hazbon, Manzour Hernando/0000-0001-6967-815X; Wang, Feng/0000-0003-2980-4646; ROBERTO, COLANGELI/0000-0003-3263-7404; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI46669, AI43268] Funding Source: Medline; NIGMS NIH HHS [1P50GM6241] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043268, R21AI043268, R01AI046669] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Ramaswamy SV, 2003, ANTIMICROB AGENTS CH, V47, P1241, DOI 10.1128/AAC.47.4.1241-1250.2003; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005; Wilming M, 1999, ANGEW CHEM INT EDIT, V38, P2588, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2588::AID-ANIE2588>3.0.CO;2-8; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	15	230	248	2	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1027	1029		10.1038/nm1466	http://dx.doi.org/10.1038/nm1466			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906155				2022-12-27	WOS:000240373900026
J	Tran, MH; Pearson, MS; Jeffrey, MB; Smyth, DJ; Jones, MK; Duke, M; Don, TA; McManus, DP; Correa-Oliveira, R; Loukas, A				Tran, Mai H.; Pearson, Mark S.; Jeffrey, M. Bethony; Smyth, Danielle J.; Jones, Malcolm K.; Duke, Mary; Don, Tegan A.; McManus, Donald P.; Correa-Oliveira, Rodrigo; Loukas, Alex			Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis	NATURE MEDICINE			English	Article							RURAL AREA; ENDEMIC AREA; IRRADIATED CERCARIAE; INTERFERON-GAMMA; IMMUNE-RESPONSE; INFECTION; ANTIBODY; BRAZIL; INDIVIDUALS; EXPOSURE	Schistosomes are blood-dwelling flukes that infect 200 million people worldwide and are responsible for hundreds of thousands of deaths annually(1). Using a signal sequence trap, we cloned from Schistosoma mansoni two cDNAs, Sm-tsp-1 and Sm-tsp-2, encoding the tetraspanin (TSP) integral membrane proteins TSP-1 and TSP-2. We raised antibodies to recombinant TSP fusion proteins and showed that both proteins are exposed on the surface of S. mansoni. Recombinant TSP-2, but not TSP-1, is strongly recognized by IgG1 and IgG3 ( but not IgE) from naturally resistant individuals but is not recognized by IgG from chronically infected or unexposed individuals. Vaccination of mice with the recombinant proteins followed by challenge infection with S. mansoni resulted in reductions of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for mean adult worm burdens and liver egg burdens, respectively, over two independent trials. Fecal egg counts were reduced by 65-69% in both test groups. TSP-2 in particular provided protection in excess of the 40% benchmark set by the World Health Organization for progression of schistosome vaccine antigens into clinical trials. When coupled with its selective recognition by naturally resistant people, TSP-2 seems to be an effective vaccine antigen against S. mansoni.	Queensland Inst Med Res, Helminth Biol Lab, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; George Washington Univ, Dept Microbiol Trop Med & Immunol, Washington, DC 20037 USA; Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil	QIMR Berghofer Medical Research Institute; George Washington University; Fundacao Oswaldo Cruz	Loukas, A (corresponding author), Queensland Inst Med Res, Helminth Biol Lab, Div Infect Dis & Immunol, 300 Herston Rd, Brisbane, Qld 4006, Australia.	alex.loukas@qimr.edu.au	McManus, Donald P./G-2678-2013; Pearson, Mark S/O-5636-2014; Jones, Malcolm K/A-1097-2009; Loukas, Alex/B-7355-2014; McManus, Don/AAC-5394-2020	Jones, Malcolm K/0000-0002-0035-6141; Loukas, Alex/0000-0002-0896-8441; McManus, Don/0000-0001-6443-1449; Smyth, Danielle/0000-0001-6080-2679; Pearson, Mark/0000-0002-0002-1544	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5; Bergquist NR, 2005, TRENDS PARASITOL, V21, P112, DOI 10.1016/j.pt.2005.01.001; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Bethony J, 2004, TROP MED INT HEALTH, V9, P381, DOI 10.1111/j.1365-3156.2004.01203.x; Bethony J, 2002, AM J TROP MED HYG, V67, P336, DOI 10.4269/ajtmh.2002.67.336; Bethony J, 1999, J INFECT DIS, V180, P1665, DOI 10.1086/315069; Bethony J, 2001, TROP MED INT HEALTH, V6, P136, DOI 10.1046/j.1365-3156.2001.00685.x; Braschi S, 2005, MOL CELL PROTEOMICS; Brito CFA, 2000, SCAND J IMMUNOL, V51, P595; Correa-Oliveira R, 2000, PARASITOL TODAY, V16, P397, DOI 10.1016/S0169-4758(00)01740-3; CORREAOLIVEIRA R, 1989, T ROY SOC TROP MED H, V83, P798, DOI 10.1016/0035-9203(89)90334-9; de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000; El-Sayed NMA, 2004, TRENDS PARASITOL, V20, P154, DOI 10.1016/j.pt.2004.02.002; Gazzinelli A, 2001, TROP MED INT HEALTH, V6, P126, DOI 10.1046/j.1365-3156.2001.00684.x; HARN DA, 1984, J EXP MED, V159, P1371, DOI 10.1084/jem.159.5.1371; HARN DA, 1985, J IMMUNOL, V135, P2115; Hoffmann KF, 2002, ADV PARASIT, V52, P265, DOI 10.1016/S0065-308X(02)52014-5; JAMES SL, 1983, PARASITE IMMUNOL, V5, P567, DOI 10.1111/j.1365-3024.1983.tb00773.x; JAMES SL, 1981, CELL IMMUNOL, V65, P75, DOI 10.1016/0008-8749(81)90053-8; Jones MK, 2004, BIOESSAYS, V26, P752, DOI 10.1002/bies.20058; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Kloos H, 2006, ACTA TROP, V97, P31, DOI 10.1016/j.actatropica.2005.08.006; Kloos H, 2004, MEM I OSWALDO CRUZ, V99, P673, DOI 10.1590/S0074-02762004000700002; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; LEWIS FA, 1981, INFECT IMMUN, V32, P260, DOI 10.1128/IAI.32.1.260-267.1981; Loukas A, 2001, INFECT IMMUN, V69, P3646, DOI 10.1128/IAI.69.6.3646-3651.2001; MINARD P, 1978, AM J TROP MED HYG, V27, P76, DOI 10.4269/ajtmh.1978.27.76; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; SHER A, 1978, J EXP MED, V148, P46, DOI 10.1084/jem.148.1.46; SILVA EE, 1993, J IMMUNOL, V151, P7057; Smyth D, 2003, INFECT IMMUN, V71, P2548, DOI 10.1128/IAI.71.5.2548-2554.2003; STEK M, 1981, SCIENCE, V212, P1518, DOI 10.1126/science.7233238; van Balkom BWM, 2005, J PROTEOME RES, V4, P958, DOI 10.1021/pr050036w; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; VIANA IRC, 1994, T ROY SOC TROP MED H, V88, P466, DOI 10.1016/0035-9203(94)90436-7; VIANA IRC, 1995, PARASITE IMMUNOL, V17, P297, DOI 10.1111/j.1365-3024.1995.tb00895.x; Williams GM, 2002, ACTA TROP, V82, P253, DOI 10.1016/S0001-706X(02)00017-7; World Health Organization, 2002, PREV CONTR SCHIST SO	38	292	312	0	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					835	840		10.1038/nm1430	http://dx.doi.org/10.1038/nm1430			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16783371				2022-12-27	WOS:000238862800072
J	Tappe, A; Klugmann, M; Luo, C; Hirlinger, D; Agarwal, N; Benrath, J; Ehrengruber, MU; During, MJ; Kuner, R				Tappe, Anke; Klugmann, Matthias; Luo, Ceng; Hirlinger, David; Agarwal, Nitin; Benrath, Justus; Ehrengruber, Markus U.; During, Matthew J.; Kuner, Rohini			Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain	NATURE MEDICINE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; IP3 RECEPTORS; NEURONS; ACTIVATION; EXPRESSION; PLASTICITY; CHANNELS; COMPLEX; FAMILY; BINDS	Glutamatergic signaling and intracellular calcium mobilization in the spinal cord are crucial for the development of nociceptive plasticity, which is associated with chronic pathological pain(1,2). Long-form Homer proteins anchor glutamatergic receptors to sources of calcium influx and release at synapses(3-5), which is antagonized by the short, activity-dependent splice variant Homer1a. We show here that Homer1a operates in a negative feedback loop to regulate the excitability of the pain pathway in an activity-dependent manner. Homer1a is rapidly and selectively upregulated in spinal cord neurons after peripheral inflammation in an NMDA receptor-dependent manner. Homer1a strongly attenuates calcium mobilization as well as MAP kinase activation induced by glutamate receptors and reduces synaptic contacts on spinal cord neurons that process pain inputs. Preventing activity-induced upregulation of Homer1a using shRNAs in mice in vivo exacerbates inflammatory pain. Thus, activity-dependent uncoupling of glutamate receptors from intracellular signaling mediators is a novel, endogenous physiological mechanism for counteracting sensitization at the first, crucial synapse in the pain pathway. Furthermore, we observed that targeted gene transfer of Homer1a to specific spinal segments in vivo reduces inflammatory hyperalgesia. Thus, Homer1 function is crucially involved in pain plasticity and constitutes a promising therapeutic target for the treatment of chronic inflammatory pain.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand; Med Univ Vienna, Dept Anesthesiol & Gen Intens Care, A-1090 Vienna, Austria; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland	Ruprecht Karls University Heidelberg; University of Auckland; Medical University of Vienna; University of Zurich	Kuner, R (corresponding author), Univ Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de	During, Matthew/AAC-1388-2020; Kuner, Rohini/AGU-0204-2022					Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Bottai D, 2002, J NEUROSCI, V22, P167, DOI 10.1523/JNEUROSCI.22-01-00167.2002; During Matthew J, 2003, Methods Mol Med, V76, P221; Ehrengruber MU, 2004, MOL NEUROBIOL, V29, P213, DOI 10.1385/MN:29:3:213; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hartmann B, 2004, NEURON, V44, P637, DOI 10.1016/j.neuron.2004.10.029; Hennou S, 2003, EUR J NEUROSCI, V18, P811, DOI 10.1046/j.1460-9568.2003.02812.x; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Klugmann M, 2005, MOL CELL NEUROSCI, V28, P347, DOI 10.1016/j.mcn.2004.10.002; Sandkuhler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	20	102	107	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					677	681		10.1038/nm1406	http://dx.doi.org/10.1038/nm1406			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715092				2022-12-27	WOS:000238149200030
J	Watt, MJ; Dzamko, N; Thomas, WG; Rose-John, S; Ernst, M; Carling, D; Kemp, BE; Febbraio, MA; Steinberg, GR				Watt, Matthew J.; Dzamko, Nicolas; Thomas, Walter G.; Rose-John, Stefan; Ernst, Matthias; Carling, David; Kemp, Bruce E.; Febbraio, Mark A.; Steinberg, Gregory R.			CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK	NATURE MEDICINE			English	Article							CILIARY NEUROTROPHIC FACTOR; FATTY-ACID OXIDATION; LEPTIN SENSITIVITY; PROTEIN-KINASE; RECEPTOR; EXPRESSION; WEIGHT; MICE; IDENTIFICATION; LOCALIZATION	Ciliary neurotrophic factor (CNTF) induces weight loss and improves glucose tolerance in humans and rodents. CNTF is thought to act centrally by inducing hypothalamic neurogenesis to modulate food intake and peripherally by altering hepatic gene expression, in a manner similar to that of leptin. Here, we show that CNTF signals through the CNTFR alpha-IL-6R-gp130 beta receptor complex to increase fatty-acid oxidation and reduce insulin resistance in skeletal muscle by activating AMP-activated protein kinase (AMPK), independent of signaling through the brain. Thus, our findings further show that the antiobesogenic effects of CNTF in the periphery result from direct effects on skeletal muscle, and that these peripheral effects are not suppressed by diet-induced or genetic models of obesity, an essential requirement for the therapeutic treatment of obesity-related diseases.	RMIT Univ, Sch Med Sci, Cellulalr & Mol Metab Lab, Bundoora, Vic 3083, Australia; Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; Baker Heart Res Inst, Mol Endocrinol Lab, Melbourne, Vic 3008, Australia; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany; Royal Melbourne Hosp, Ludwig Inst Canc Res, Colon Mol & Cell Biol Lab, Melbourne, Vic 3050, Australia; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Cellular Stress Grp, Med Res Council Clin Sci Ctr, London W12 0NN, England; Commonwealth Sci & Ind Res Org Hlth Sci & Nutr, Parkville, Vic 3052, Australia	Royal Melbourne Institute of Technology (RMIT); St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; Baker Heart and Diabetes Institute; University of Kiel; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Febbraio, MA (corresponding author), RMIT Univ, Sch Med Sci, Cellulalr & Mol Metab Lab, POB 71, Bundoora, Vic 3083, Australia.	mark.febbraio@rmit.edu.au	Watt, Matthew J/B-2089-2014; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Febbraio, Mark/AAE-9632-2019; Dzamko, Nicolas/AAD-6922-2019; Thomas, Walter/I-2208-2015; Carling, David/F-1943-2014; Ernst, Matthias/D-5111-2012; Rose-John, Stefan/A-7998-2010	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Thomas, Walter/0000-0003-0685-2952; Carling, David/0000-0002-2316-1830; Ernst, Matthias/0000-0002-6399-1177; Rose-John, Stefan/0000-0002-7519-3279; Steinberg, Gregory/0000-0001-5425-8275; Febbraio, Mark/0000-0002-9296-4418; Dzamko, Nicolas/0000-0002-9121-0294	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V5, P1967; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; Bluher S, 2004, DIABETES, V53, P2787, DOI 10.2337/diabetes.53.11.2787; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Lee MY, 1997, NEUROSCIENCE, V77, P233, DOI 10.1016/S0306-4522(96)00476-9; MacLennan AJ, 1996, J NEUROSCI, V16, P621; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Petersen EW, 2005, AM J PHYSIOL-ENDOC M, V288, pE155, DOI 10.1152/ajpendo.00257.2004; PREISS J, 1986, J BIOL CHEM, V261, P8597; Schuster B, 2003, J BIOL CHEM, V278, P9528, DOI 10.1074/jbc.M210044200; Shibata R, 2003, HUM GENE THER, V14, P601, DOI 10.1089/104303403321618128; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Sleeman MW, 2003, P NATL ACAD SCI USA, V100, P14297, DOI 10.1073/pnas.2335926100; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Steinberg GR, 2002, J BIOL CHEM, V277, P8854, DOI 10.1074/jbc.M107683200; Steinberg GR, 2004, AM J PHYSIOL-ENDOC M, V286, pE57, DOI 10.1152/ajpendo.00302.2003; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V282, pE593, DOI 10.1152/ajpendo.00303.2001; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Watt MJ, 2004, FASEB J, V18, P1445, DOI 10.1096/fj.03-1067fje; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Ziotopoulou M, 2000, DIABETES, V49, P1890, DOI 10.2337/diabetes.49.11.1890; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	49	235	241	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					541	548		10.1038/nm1383	http://dx.doi.org/10.1038/nm1383			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604088				2022-12-27	WOS:000238149100038
J	Frentsch, M; Arbach, O; Kirchhoff, D; Moewes, B; Worm, M; Rothe, M; Scheffold, A; Thiel, A				Frentsch, M; Arbach, O; Kirchhoff, D; Moewes, B; Worm, M; Rothe, M; Scheffold, A; Thiel, A			Direct access to CD4(+) T cells specific for defined antigens according to CD154 expression	NATURE MEDICINE			English	Article							FLOW-CYTOMETRIC METHOD; HUMAN CYTOMEGALOVIRUS; CD40 LIGAND; MOLECULES; RECEPTOR; SUPERANTIGENS; LYMPHOCYTES; INDUCTION; PROTEINS; TRAP	The direct assessment of T helper (T-H)-cell responses specific for antigens is essential to evaluate pathogenic and protective immunity. Presently, analysis and isolation of antigen-specific T-H cells is restricted to cells that produce cytokines, or can be performed only with a rare selection of specific peptide major histocompatibility complex class II (MHC II) multimers. Here we report a new method that enables the assessment and isolation of T-H cells specific for a defined antigen according to CD154 expression induced after stimulation in vitro. We show that antigen-induced CD154 expression is highly sensitive and specific for human and mouse antigen-specific T-H cells. Moreover, the isolation of antigen-specific CD154(+) T-H cells necessitates only surface staining with antibodies, thereby enabling the fast generation of antigen-specific T-H cell lines. Our approach allows assessment of T-H cells with a defined specificity for the combined quantitative and qualitative analysis of T-H-cell immunity as well as for the isolation of specific T-H cells for targeted cellular immunotherapies.	Deutsch Rheuma Forschungszentrum, Clin Immunol Grp, D-10117 Berlin, Germany; Deutsch Rheuma Forschungszentrum, Immunomodulat Grp, D-10117 Berlin, Germany; Clin Dermatol Venerol & Allergol, D-10117 Berlin, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Deutsches Rheuma-Forschungszentrum (DRFZ)	Thiel, A (corresponding author), Deutsch Rheuma Forschungszentrum, Clin Immunol Grp, Schumannstr 21-22, D-10117 Berlin, Germany.	thiel@drfz.de	Scheffold, Alexander/S-2090-2016; Thiel, Andreas/F-1539-2013	Scheffold, Alexander/0000-0002-0626-343X; Thiel, Andreas/0000-0002-5515-4002; Worm, Margitta/0000-0002-3449-1245				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BENINGA J, 1995, J GEN VIROL, V76, P153, DOI 10.1099/0022-1317-76-1-153; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Casares S, 2002, NAT IMMUNOL, V3, P383, DOI 10.1038/ni770; Casares S, 2001, PROTEIN ENG, V14, P195, DOI 10.1093/protein/14.3.195; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; Hackett CJ, 2002, NAT IMMUNOL, V3, P887, DOI 10.1038/ni1002-887; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; Kahi S, 1998, CLIN DIAGN LAB IMMUN, V5, P745, DOI 10.1128/CDLI.5.6.745-748.1998; Lindgren H, 2001, J IMMUNOL, V166, P4578, DOI 10.4049/jimmunol.166.7.4578; Ludewig B, 1996, EUR J IMMUNOL, V26, P3137, DOI 10.1002/eji.1830261246; MAINO VC, 1995, CYTOMETRY, V20, P127, DOI 10.1002/cyto.990200205; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Michalek J, 2003, P NATL ACAD SCI USA, V100, P1180, DOI 10.1073/pnas.0337543100; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; Suni MA, 1998, J IMMUNOL METHODS, V212, P89, DOI 10.1016/S0022-1759(98)00004-0; Thiel A, 2004, CLIN IMMUNOL, V111, P155, DOI 10.1016/j.clim.2003.12.017; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996; YELLIN MJ, 1994, J IMMUNOL, V152, P598	26	355	374	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1118	1124		10.1038/nm1292	http://dx.doi.org/10.1038/nm1292			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16186818				2022-12-27	WOS:000232492500035
J	Tian, GF; Azmi, H; Takano, T; Xu, QW; Peng, WG; Lin, J; Oberheim, N; Lou, NH; Wang, XH; Zielke, HR; Kang, J; Nedergaard, M				Tian, GF; Azmi, H; Takano, T; Xu, QW; Peng, WG; Lin, J; Oberheim, N; Lou, NH; Wang, XH; Zielke, HR; Kang, J; Nedergaard, M			An astrocytic basis of epilepsy	NATURE MEDICINE			English	Article							DEPENDENT GLUTAMATE RELEASE; FIELD BURST ACTIVITY; EPILEPTIFORM ACTIVITY; ANTIEPILEPTIC DRUGS; IN-VIVO; EXTRACELLULAR GLUTAMATE; CALCIUM-CHANNELS; MODULATION; NEURONS; BRAIN	Hypersynchronous neuronal firing is a hallmark of epilepsy, but the mechanisms underlying simultaneous activation of multiple neurons remains unknown. Epileptic discharges are in part initiated by a local depolarization shift that drives groups of neurons into synchronous bursting. In an attempt to define the cellular basis for hypersynchronous bursting activity, we studied the occurrence of paroxysmal depolarization shifts after suppressing synaptic activity using tetrodotoxin ( TTX) and voltage- gated Ca2+ channel blockers. Here we report that paroxysmal depolarization shifts can be initiated by release of glutamate from extrasynaptic sources or by photolysis of caged Ca2+ in astrocytes. Two- photon imaging of live exposed cortex showed that several antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability of astrocytes to transmit Ca2+ signaling. Our results show an unanticipated key role for astrocytes in seizure activity. As such, these findings identify astrocytes as a proximal target for the treatment of epileptic disorders.	Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Aging & Dev Biol, Rochester, NY 14642 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA	University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; New York Medical College; University System of Maryland; University of Maryland Baltimore; New York Medical College	Tian, GF (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Aging & Dev Biol, 601 Elmwood Ave, Rochester, NY 14642 USA.	guo-feng_tian@urmc.rochester.edu		Takano, Takahiro/0000-0002-6235-6673; Wang, Xiaohai/0000-0001-5814-4072	NICHD NIH HHS [HD16596] Funding Source: Medline; NINDS NIH HHS [NS38073, R01 NS038073, NS39997, R01 NS030007, R01 NS039997, NS30007] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039997, R01NS038073, R29NS030007, R01NS030007] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Ayala GX, 2003, NEUROPHARMACOLOGY, V45, P649, DOI 10.1016/S0028-3908(03)00230-2; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bikson M, 1999, J NEUROPHYSIOL, V82, P2262, DOI 10.1152/jn.1999.82.5.2262; Boothe DM, 1998, VET CLIN N AM-SMALL, V28, P411, DOI 10.1016/S0195-5616(98)82011-1; Carmignoto G, 1998, J NEUROSCI, V18, P4637; CONTINA ML, 2000, J NEUROSCI, V20, P2835; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Drew GM, 2004, NEUROPHARMACOLOGY, V46, P927, DOI 10.1016/j.neuropharm.2004.01.015; Duffy S, 1999, Adv Neurol, V79, P573; Elmslie KS, 2003, J BIOENERG BIOMEMBR, V35, P477, DOI 10.1023/B:JOBB.0000008021.55853.18; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Grimaldi M, 2001, J NEUROSCI, V21, P3135, DOI 10.1523/JNEUROSCI.21-09-03135.2001; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Heinemann U, 1986, Adv Neurol, V44, P641; Heinemann U, 1999, Adv Neurol, V79, P583; Hirase H, 2004, NEUROSCIENCE, V128, P209, DOI 10.1016/j.neuroscience.2004.07.002; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Jones MS, 2002, J NEUROPHYSIOL, V88, P1016, DOI 10.1152/jn.2002.88.2.1016; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Luhmann HJ, 2000, EUR J NEUROSCI, V12, P2757, DOI 10.1046/j.1460-9568.2000.00156.x; Meldrum BS, 1996, EPILEPSIA, V37, pS4, DOI 10.1111/j.1528-1157.1996.tb06038.x; Mena FV, 2000, J NEUROSCI RES, V60, P632, DOI 10.1002/(SICI)1097-4547(20000601)60:5<632::AID-JNR8>3.0.CO;2-3; MILES R, 1983, NATURE, V306, P371, DOI 10.1038/306371a0; NAJM IM, 2001, TREATMENT EPILEPSY P, P33; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Obrenovitch TP, 1996, J NEUROCHEM, V66, P2446; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rogawski MA, 2004, NAT MED, V10, P685, DOI 10.1038/nm1074; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Schneiderman JH, 1997, NEUROSCIENCE, V81, P1111, DOI 10.1016/S0306-4522(97)00209-1; Schuchmann S, 2002, NEUROBIOL DIS, V11, P96, DOI 10.1006/nbdi.2002.0533; Stout C, 2003, GLIA, V43, P265, DOI 10.1002/glia.10257; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Tashiro A, 2002, J NEUROBIOL, V50, P45, DOI 10.1002/neu.10019; Urenjak J, 2000, J NEUROCHEM, V75, P2427, DOI 10.1046/j.1471-4159.2000.0752427.x; VALIANTE TA, 1995, J NEUROSCI, V15, P6946; YAMAGUCHI S, 1992, EPILEPSY RES, V11, P9, DOI 10.1016/0920-1211(92)90016-M; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	49	606	632	3	84	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2005	11	9					973	981		10.1038/nm1277	http://dx.doi.org/10.1038/nm1277			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116433	Green Accepted			2022-12-27	WOS:000231724700025
J	Jo, D; Liu, DY; Yao, S; Collins, RD; Hawiger, J				Jo, D; Liu, DY; Yao, S; Collins, RD; Hawiger, J			Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis	NATURE MEDICINE			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN-B; TUMOR-NECROSIS-FACTOR; LETHAL SHOCK; CYTOKINE SIGNALING-1; FUNCTIONAL PEPTIDES; ENDOTOXIC-SHOCK; NUCLEAR IMPORT; CONCANAVALIN-A; HEPATIC-INJURY; LIVER-INJURY	Suppressor of cytokine signaling (SOCS) 3 attenuates proinflammatory signaling mediated by the signal transducer and activator of transcription (STAT) family of proteins. But acute inflammation can occur after exposure to pathogen-derived inducers staphylococcal enterotoxin B (SEB) and lipopolysaccharide (LPS), or the lectin concanavalin A (ConA), suggesting that physiologic levels of SOCS3 are insufficient to stem proinflammatory signaling under pathogenic circumstances. To test this hypothesis, we developed recombinant cell-penetrating forms of SOCS3 (CP-SOCS3) for intracellular delivery to counteract SEB-, LPS- and ConA-induced inflammation. We found that CP-SOCS3 was distributed in multiple organs within 2 h and persisted for at least 8 h in leukocytes and lymphocytes. CP-SOCS3 protected animals from lethal effects of SEB and LPS by reducing production of inflammatory cytokines and attenuating liver apoptosis and hemorrhagic necrosis. It also reduced ConA-induced liver apoptosis. Thus, replenishing the intracellular stores of SOCS3 with CP-SOCS3 effectively suppresses the devastating effects of acute inflammation.	Vanderbilt Univ, Sch Med, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Dept Microbiol & Immunol, 1161 21st Ave S,A-5321 MCN, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu			NCI NIH HHS [2P30 CA 68485] Funding Source: Medline; NHLBI NIH HHS [HL 69542, HL 68744, HL 62356] Funding Source: Medline; NIDDK NIH HHS [5P30DK058404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062356, P01HL068744, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Arad G, 2000, NAT MED, V6, P414, DOI 10.1038/74672; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Jo D, 2003, J CELL BIOCHEM, V89, P674, DOI 10.1002/jcb.10542; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lin Q, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-25; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Liu DY, 2004, J BIOL CHEM, V279, P19239, DOI 10.1074/jbc.M313442200; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; O'Keefe GM, 2001, J IMMUNOL, V166, P2260, DOI 10.4049/jimmunol.166.4.2260; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200; Yasuda S, 2002, J ENDOTOXIN RES, V8, P253, DOI 10.1179/0968051025000461; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	29	214	247	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					892	898		10.1038/nm1269	http://dx.doi.org/10.1038/nm1269			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16007096				2022-12-27	WOS:000230964700036
J	Jones, SM; Feldmann, H; Stroher, U; Geisbert, JB; Fernando, L; Grolla, A; Klenk, HD; Sullivan, NJ; Volchkov, VE; Fritz, EA; Daddario, KM; Hensley, LE; Jahrling, PB; Geisbert, TW				Jones, SM; Feldmann, H; Stroher, U; Geisbert, JB; Fernando, L; Grolla, A; Klenk, HD; Sullivan, NJ; Volchkov, VE; Fritz, EA; Daddario, KM; Hensley, LE; Jahrling, PB; Geisbert, TW			Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS VIRUSES; HEMORRHAGIC-FEVER; GLYCOPROTEINS; CHILDREN; DISEASE	Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.	Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 3R2, Canada; USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA; Univ Marburg, Inst Virol, D-35037 Marburg, Germany; NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA; Univ Lyon 1, INSERM, U412, Filovirus Lab, F-69007 Lyon, France; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Public Health Agency of Canada; University of Manitoba; University of Manitoba; Philipps University Marburg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Uniformed Services University of the Health Sciences - USA	Feldmann, H (corresponding author), Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.	Heinz_Feldmann@hc-sc.gc.ca	Volchkov, Viktor/M-7846-2014	Volchkov, Viktor/0000-0001-7896-8706; Hensley, Lisa/0000-0003-1188-4342	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005082, ZIAAI005082, Z01AI005081, Z01AI005079, ZIAAI005079, ZIAAI005081, Z01AI005080, ZIAAI005080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; BRANDT CD, 1969, AM J EPIDEMIOL, V90, P484, DOI 10.1093/oxfordjournals.aje.a121094; BUKREYEV AA, 1995, ARCH VIROL, V140, P1589, DOI 10.1007/BF01322532; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P308; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert Thomas W, 2003, Expert Rev Vaccines, V2, P777, DOI 10.1586/14760584.2.6.777; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Ignatyev GM, 1996, J BIOTECHNOL, V44, P111, DOI 10.1016/0168-1656(95)00104-2; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; JAHRLING PB, 1999, MANUAL CLIN MICROBIO, P1125; Piedra PA, 1998, PEDIATRICS, V101, P1013, DOI 10.1542/peds.101.6.1013; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; Sanchez A, 2001, FIELDS VIROLOGY, P1279; Schlereth B, 2000, J VIROL, V74, P4652, DOI 10.1128/JVI.74.10.4652-4657.2000; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; SMITH DH, 1982, LANCET, V1, P816; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; WAGNER RR, 1996, FIELDS VIROLOGY, V1	27	477	532	1	107	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					786	790		10.1038/nm1258	http://dx.doi.org/10.1038/nm1258			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15937495	Bronze			2022-12-27	WOS:000230304200036
J	Pipper, J; Inoue, M; Ng, LFP; Neuzil, P; Zhang, Y; Novak, L				Pipper, Juergen; Inoue, Masafumi; Ng, Lisa F-P; Neuzil, Pavel; Zhang, Yi; Novak, Lukas			Catching bird flu in a droplet	NATURE MEDICINE			English	Article							INFLUENZA-A H5N1; AVIAN INFLUENZA; MICROFLUIDIC SYSTEMS; CHIP; LAB; VIRUS; ASIA; PCR	It is assumed that a timely mass administration of antiviral drugs, backed by quarantines and social distancing, could contain a nascent influenza epidemic at its source, provided that the first clusters of cases were localized within a short time. However, effective routine surveillance may be impossible in countries lacking basic public health resources. For a global containment strategy to be successful, low- cost, easy-to- use handheld units that permit decentralized testing would be vital. Here we present a microfluidic platform that can detect the highly pathogenic avian influenza virus H5N1 in a throat swab sample by using magnetic forces to manipulate a free droplet containing superparamagnetic particles. In a sequential process, the viral RNA is isolated, purified, preconcentrated by 50,000% and subjected to ultrafast real- time RT-PCR. Compared to commercially available tests, the bioassay is equally sensitive and is 440% faster and 2,000 - 5,000% cheaper.	Inst Bioengn & Nanotechnol, Singapore 138669, Singapore; Inst Mol & Cell Biol, Singapore 138673, Singapore; Genome Inst Singapore, Singapore 138672, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Institute of Bioengineering & Nanotechnology (IBN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Pipper, J (corresponding author), Inst Bioengn & Nanotechnol, 31 Biopolis Way,Nanos 04-01, Singapore 138669, Singapore.	j.pipper@ibn.a-star.edu.sg	Neuzil, Pavel/B-9981-2012; Neuzil, Pavel/ABC-5530-2020; Zhang, Yi/F-5817-2010; Novak, Lukas/A-7903-2008	Neuzil, Pavel/0000-0001-9040-281X; Zhang, Yi/0000-0002-1239-3441; Ng, Lisa/0000-0003-4071-5222				Abbott A, 2004, NATURE, V427, P472, DOI 10.1038/427472a; Auroux PA, 2004, LAB CHIP, V4, P534, DOI 10.1039/b408850f; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Daw R, 2006, NATURE, V442, P367, DOI 10.1038/442367a; de Mello AJ, 2003, LAB CHIP, V3, p11N, DOI 10.1039/b301019h; deMello AJ, 2006, NATURE, V442, P394, DOI 10.1038/nature05062; Enserink M, 2006, SCIENCE, V311, P314, DOI 10.1126/science.311.5759.314; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Gascoyne PRC, 2004, LAB CHIP, V4, P299, DOI 10.1039/b404130e; Guttenberg Z, 2005, LAB CHIP, V5, P308, DOI 10.1039/b412712a; Ho D, 2005, NATURE, V435, P421, DOI 10.1038/435421a; Holmes EC, 2005, SCIENCE, V309, P989, DOI 10.1126/science.1117128; Lehmann U, 2006, ANGEW CHEM INT EDIT, V45, P3062, DOI 10.1002/anie.200503624; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; Melzak KA, 1996, J COLLOID INTERF SCI, V181, P635, DOI 10.1006/jcis.1996.0421; Mukhopadhyay R, 2006, ANAL CHEM, V78, P1401, DOI 10.1021/ac069373u; Neuzil P, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl416; Normile D, 2006, SCIENCE, V311, P315, DOI 10.1126/science.311.5759.315; Novak L, 2007, LAB CHIP, V7, P27, DOI 10.1039/b611745g; Pamme N, 2006, LAB CHIP, V6, P24, DOI 10.1039/b513005k; Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554; Srinivasan V, 2004, ANAL CHIM ACTA, V507, P145, DOI 10.1016/j.aca.2003.12.030; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058; *WHO, 2007, WHO PAND INFL DRAFT; Wilschut J, 2006, INFLUENZA, P49; Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	28	177	188	1	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1259	1263		10.1038/nm1634	http://dx.doi.org/10.1038/nm1634			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17891145	Green Published, Bronze			2022-12-27	WOS:000249980200044
J	Nagaraj, S; Gupta, K; Pisarev, V; Kinarsky, L; Sherman, S; Kang, L; Herber, DL; Schneck, J; Gabrilovich, DI				Nagaraj, Srinivas; Gupta, Kapil; Pisarev, Vladimir; Kinarsky, Leo; Sherman, Simon; Kang, Loveleen; Herber, Donna L.; Schneck, Jonathan; Gabrilovich, Dmitry I.			Altered recognition of antigen is a mechanism of CD8(+) T cell tolerance in cancer	NATURE MEDICINE			English	Article							MYELOID SUPPRESSOR-CELLS; NITRIC-OXIDE; IN-VIVO; IMMUNE DYSFUNCTION; DENDRITIC CELLS; PEROXYNITRITE; ACTIVATION; INHIBITION; ANERGY; MICE	Antigen-specific CD8(+) T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape. Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide-major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex. This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation. Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact. Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC. These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.	Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33647 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Univ Nebraska Med Ctr, Omaha, NE 68198 USA; Eppley Canc Ctr, Omaha, NE 68198 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Johns Hopkins University; University of Nebraska System; University of Nebraska Medical Center	Gabrilovich, DI (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33647 USA.	dmitry.gabrilovich@moffitt.org	Pisarev, Vladimir M./E-1373-2012; Bharadwaj, Srinivas Nagaraj/I-4947-2012; Gabrilovich, Dmitry/ABE-7122-2020	Pisarev, Vladimir M./0000-0002-5729-9846; 	NCI NIH HHS [R01 CA084488, R01CA 84488, R01 CA084488-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Appleman LJ, 2001, J MOL MED, V78, P673, DOI 10.1007/s001090000180; Atochina O, 2001, J IMMUNOL, V167, P4293, DOI 10.4049/jimmunol.167.8.4293; Balavoine GGA, 1999, NITRIC OXIDE-BIOL CH, V3, P40, DOI 10.1006/niox.1999.0206; Bronte V, 2001, J IMMUNOTHER, V24, P431, DOI 10.1097/00002371-200111000-00001; Cuenca A, 2003, CANCER RES, V63, P9007; De Santo C, 2005, P NATL ACAD SCI USA, V102, P4185, DOI 10.1073/pnas.0409783102; Drake DR, 2005, J IMMUNOL, V175, P1507, DOI 10.4049/jimmunol.175.3.1507; DUTZ JP, 1994, MOL IMMUNOL, V31, P967, DOI 10.1016/0161-5890(94)90091-4; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398; Haqqani AS, 2002, J BIOL CHEM, V277, P3614, DOI 10.1074/jbc.M105730200; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Kusmartsev S, 2003, J LEUKOCYTE BIOL, V74, P186, DOI 10.1189/jlb.0103010; Kusmartsev S, 2003, CANCER RES, V63, P4441; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619; Makarenkova VP, 2006, J IMMUNOL, V176, P2085, DOI 10.4049/jimmunol.176.4.2085; Melani C, 2003, BLOOD, V102, P2138, DOI 10.1182/blood-2003-01-0190; Mencacci A, 2002, J IMMUNOL, V169, P3180, DOI 10.4049/jimmunol.169.6.3180; Nikitina EY, 2002, GENE THER, V9, P345, DOI 10.1038/sj.gt.3301670; Pandit R, 2000, ANN OTO RHINOL LARYN, V109, P749, DOI 10.1177/000348940010900809; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Quinn MT, 2005, NEUTROPHILS: NEW OUTLOOK FOR OLD CELLS, 2ND EDITION, P35, DOI 10.1142/9781860946059_0002; Quint P, 2006, FREE RADICAL BIO MED, V40, P453, DOI 10.1016/j.freeradbiomed.2005.08.045; Regoli F, 1999, TOXICOL APPL PHARM, V156, P96, DOI 10.1006/taap.1999.8637; Schmielau J, 2001, CANCER RES, V61, P4756; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Sinha P, 2005, CANCER IMMUNOL IMMUN, V54, P1137, DOI 10.1007/s00262-005-0703-4; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Udaka K, 1996, J IMMUNOL, V157, P670; Wilkinson IB, 2002, BRIT J CLIN PHARMACO, V53, P189, DOI 10.1046/j.1365-2125.2002.1528adoc.x; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505; Zingarelli B, 1998, INT J MOL MED, V1, P787	43	769	816	0	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					828	835		10.1038/nm1609	http://dx.doi.org/10.1038/nm1609			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17603493	Green Accepted			2022-12-27	WOS:000247902800029
J	Morse, SS				Morse, Stephen S.			The US pandemic influenza implementation plan at six months	NATURE MEDICINE			English	Editorial Material							A VIRUS; VACCINE; IMMUNOGENICITY; SAFETY		Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Ctr Publ Hlth Preparedness, Natl Ctr Disaster Preparedness, New York, NY 10032 USA	Columbia University; Columbia University	Morse, SS (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Rosenfield Bldg,722 W 168th St,1021, New York, NY 10032 USA.	ssm20@columbia.edu			NIAID NIH HHS [5U54AI057158] Funding Source: Medline; PHS HHS [U90/CCU224241, A1010-21/21] Funding Source: Medline; NCPDCID CDC HHS [U01/CI000442] Funding Source: Medline; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [U01CI000442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NCPDCID CDC HHS; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARY JM, 2005, GREAT INFLUENZA; Bui HH, 2007, P NATL ACAD SCI USA, V104, P246, DOI 10.1073/pnas.0609330104; Crosby AW, 2003, AMERICAS FORGOTTEN P, V2nd; De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Inglesby TV, 2006, BIOSECUR BIOTERROR, V4, P366, DOI 10.1089/bsp.2006.4.366; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; Kong WP, 2006, P NATL ACAD SCI USA, V103, P15987, DOI 10.1073/pnas.0607564103; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989; Morse SS, 1996, HEALTH POLICY, V38, P135, DOI 10.1016/0168-8510(96)00863-9; Morse SS, 2006, SCIENCE, V314, P929, DOI 10.1126/science.1135823; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Mozdzanowska K, 2003, VACCINE, V21, P2616, DOI 10.1016/S0264-410X(03)00040-9; Neustadt R., 2005, SWINE FLUE AFFAIR DE; Olson DR, 2005, P NATL ACAD SCI USA, V102, P11059, DOI 10.1073/pnas.0408290102; Subbarao K, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030040; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; Zhu QY, 2006, NEW ENGL J MED, V354, P2731, DOI 10.1056/NEJMc066058	21	8	8	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					681	684		10.1038/nm1597	http://dx.doi.org/10.1038/nm1597			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17554335	Bronze, Green Published			2022-12-27	WOS:000247084300029
J	Lesniewski, LA; Hosch, SE; Neels, JG; Luca, C; Pashmforoush, M; Lumeng, CN; Chiang, SH; Scadeng, M; Saltiel, AR; Olefsky, JM				Lesniewski, Lisa A.; Hosch, Sarah E.; Neels, Jaap G.; de Luca, Carl; Pashmforoush, Mohammad; Lumeng, Carey N.; Chiang, Shian-Huey; Scadeng, Miriam; Saltiel, Alan R.; Olefsky, Jerrold M.			Bone marrow-specific Cap gene deletion protects against high-fat diet-induced insulin resistance	NATURE MEDICINE			English	Article							STIMULATED GLUCOSE-TRANSPORT; C-CBL; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; CSF-1 RECEPTOR; DEFICIENT MICE; OBESITY; APS	Cbl-associated protein (Cap) is a member of a phosphatidylinositol 3-kinase-independent pathway for insulin-stimulated translocation of the glucose transporter GLUT4. Despite this positive role of Cap in glucose uptake, here we show that deletion of the gene encoding Cap (official gene name: Sorbs1) protects against high-fat diet (HFD)-induced insulin resistance in mice while also having an opposite, insulin-sensitizing effect, accompanied by reduced tissue markers of inflammation. Given the emerging role of chronic inflammation in insulin resistance and the macrophage in initiating this inflammatory process, we considered that Sorbs1 deletion from macrophages may have resulted in the observed protection from HFD-induced insulin resistance. Using bone marrow transplantation to generate functional Sorbs1-null macrophages, we show that the insulin-sensitive phenotype can be transferred to wild-type mice by transplantation of Sorbs1-null bone marrow. These studies show that macrophages are an important cell type in the induction of insulin resistance and that Cap has a modulatory role in this function.	Univ Calif San Diego, Dept Endocrinol & Metab, La Jolla, CA 92093 USA; Inst Med Genet, Los Angeles, CA 90033 USA; Univ Michigan, Inst Life Sci, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat & Commun Dis, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Saltiel, Alan/L-3632-2019; Lesniewski, Lisa A/B-2443-2012; Saltiel, Alan R/A-1282-2007; Neels, Jaap G/F-5534-2010	Neels, Jaap G/0000-0002-5900-8395; LESNIEWSKI, LISA/0000-0002-2138-1450; Scadeng, Miriam/0000-0002-9593-2956; Saltiel, Alan/0000-0002-9726-9828; Lumeng, Carey/0000-0003-0303-6204	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060591, F32DK072815, R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK078851, DK 60591, F32 DK076313, F32 DK072815, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Alcazar O, 2004, BIOCHEM BIOPH RES CO, V317, P285, DOI 10.1016/j.bbrc.2004.03.038; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Caveggion E, 2003, J CELL PHYSIOL, V195, P276, DOI 10.1002/jcp.10236; Chen AR, 2005, OBES RES, V13, P1311, DOI 10.1038/oby.2005.159; Erdreich-Epstein A, 1999, J LEUKOCYTE BIOL, V65, P523, DOI 10.1002/jlb.65.4.523; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; Molero JC, 2006, DIABETES, V55, P708, DOI 10.2337/diabetes.55.03.06.db05-0312; Molero JC, 2004, J CLIN INVEST, V114, P1326, DOI [10.1172/JCI200421480, 10.1172/JCI21480]; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	27	91	92	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					455	462		10.1038/nm1550	http://dx.doi.org/10.1038/nm1550			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17351624				2022-12-27	WOS:000245543900034
J	Matsumoto, Y; Marusawa, H; Kinoshita, K; Endo, Y; Kou, T; Morisawa, T; Azuma, T; Okazaki, IM; Honjo, T; Chiba, T				Matsumoto, Yuko; Marusawa, Hiroyuki; Kinoshita, Kazuo; Endo, Yoko; Kou, Tadayuki; Morisawa, Toshiyuki; Azuma, Takeshi; Okazaki, Il-Mi; Honjo, Tasuku; Chiba, Tsutomu			Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium	NATURE MEDICINE			English	Article							NF-KAPPA-B; CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; P53 MUTATIONS; CELL-LINES; AID; CANCER; DNA; PROTEIN; MICE	Infection with Helicobacter pylori (H. pylori) is a risk factor for the development of gastric cancer. Here we show that infection of gastric epithelial cells with 'cag' pathogenicity island (cagPAI)-positive H. pylori induced aberrant expression of activation-induced cytidine deaminase (AID), a member of the cytidine-deaminase family that acts as a DNA- and RNA-editing enzyme, via the I kappa B kinase-dependent nuclear factor-kappa B activation pathway. H. pylori-mediated upregulation of AID resulted in the accumulation of nucleotide alterations in the TP53 tumor suppressor gene in gastric cells in vitro. Our findings provide evidence that aberrant AID expression caused by H. pylori infection might be a mechanism of mutation accumulation in the gastric mucosa during H. pylori-associated gastric carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Shiga Med Ctr Res Inst, Shiga 5248524, Japan; Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kobe University; Kyoto University	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	chiba@kuhp.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Marusawa, Hiroyuki/0000-0002-4286-2712; Okazaki, Il-mi/0000-0001-8644-0100				Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585; Babbage G, 2006, CANCER RES, V66, P3996, DOI 10.1158/0008-5472.CAN-05-3704; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; BLASER MJ, 1995, CANCER RES, V55, P2111; Cascalho M, 2004, J IMMUNOL, V172, P6513, DOI 10.4049/jimmunol.172.11.6513; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chiba T, 2006, J GASTROENTEROL, V41, P1, DOI 10.1007/s00535-005-1743-4; CRABTREE JE, 1993, GUT, V34, P1339, DOI 10.1136/gut.34.10.1339; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Fenoglio-Preiser CM, 2003, HUM MUTAT, V21, P258, DOI 10.1002/humu.10180; Glickman J N, 2001, Gastrointest Endosc Clin N Am, V11, P717; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Iwai A, 2003, J GASTROENTEROL, V38, P751, DOI 10.1007/s00535-003-1141-8; Kanda N, 2006, AM J PHYSIOL-GASTR L, V290, pG519, DOI 10.1152/ajpgi.00113.2005; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Lossos IS, 2004, LEUKEMIA, V18, P1775, DOI 10.1038/sj.leu.2403488; Marusawa H, 2001, MICROBIOL IMMUNOL, V45, P483, DOI 10.1111/j.1348-0421.2001.tb02648.x; Matsumoto Y, 2005, HELICOBACTER, V10, P407, DOI 10.1111/j.1523-5378.2005.00349.x; Morgan C, 2003, BRIT J CANCER, V89, P1314, DOI 10.1038/sj.bjc.6601302; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 2001, AM J PHYSIOL-GASTR L, V280, pG525, DOI 10.1152/ajpgi.2001.280.4.G525; Peek RM, 1995, LAB INVEST, V73, P760; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Uchida K, 2001, INFECT IMMUN, V69, P6749, DOI 10.1128/IAI.69.11.6749-6754.2001; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; 1994, IACR MONOGR EVAL CAR, V61, P1	45	370	389	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					470	476		10.1038/nm1566	http://dx.doi.org/10.1038/nm1566			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17401375	Green Submitted			2022-12-27	WOS:000245543900036
J	Lam, TKT; Gutierrez-Juarez, R; Pocai, A; Bhanot, S; Tso, P; Schwartz, GJ; Rossetti, L				Lam, Tony K. T.; Gutierrez-Juarez, Roger; Pocai, Alessandro; Bhanot, Sanjay; Tso, Patrick; Schwartz, Gary J.; Rossetti, Luciano			Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins	NATURE MEDICINE			English	Article							STEAROYL-COA DESATURASE-1; B-CONTAINING LIPOPROTEINS; FRUCTOSE-FED HAMSTER; INSULIN-RESISTANCE; TRANSFER PROTEIN; APOLIPOPROTEIN-B; FATTY-ACIDS; HYPOTHALAMIC NEURONS; PLASMA-LIPOPROTEINS; OBESITY	Increased production of very low-density lipoprotein (VLDL) is a critical feature of the metabolic syndrome. Here we report that a selective increase in brain glucose lowered circulating triglycerides (TG) through the inhibition of TG-VLDL secretion by the liver. We found that the effect of glucose required its conversion to lactate, leading to activation of ATP-sensitive potassium channels and to decreased hepatic activity of stearoyl-CoA desaturase-1 (SCD1). SCD1 catalyzed the synthesis of oleyl-CoA from stearoyl-CoA. Curtailing the liver activity of SCD1 was sufficient to lower the hepatic levels of oleyl-CoA and to recapitulate the effects of central glucose administration on VLDL secretion. Notably, portal infusion of oleic acid restored hepatic oleyl-CoA to control levels and negated the effects of both central glucose and SCD1 deficiency on TG-VLDL secretion. These central effects of glucose (but not those of lactate) were rapidly lost in diet-induced obesity. These findings indicate that a defect in brain glucose sensing could play a critical role in the etiology of the metabolic syndrome.	Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Diabet Res Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA; Univ Cincinnati, Dept Pathol, Cincinnati, OH 45237 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Isis Pharmaceuticals Inc; University System of Ohio; University of Cincinnati	Rossetti, L (corresponding author), Albert Einstein Coll Med, Diabet Res Ctr, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu	Adiels, Martin/C-9278-2011		NIA NIH HHS [AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK48321, DK47208, DK45024, DK 20541, F32-DK072876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020541, R01DK045024, R01DK047208, P60DK020541, R37DK048321, F32DK072876, R29DK045024, R01DK048321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adeli K, 2001, TRENDS CARDIOVAS MED, V11, P170, DOI 10.1016/S1050-1738(01)00084-6; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; Borg MA, 1997, J CLIN INVEST, V99, P361, DOI 10.1172/JCI119165; Carpentier A, 2002, J BIOL CHEM, V277, P28795, DOI 10.1074/jbc.M204568200; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; DAVIS JD, 1981, SCIENCE, V212, P81, DOI 10.1126/science.7193909; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; FRANCONE OL, 1992, AM J PHYSIOL, V263, pE615, DOI 10.1152/ajpendo.1992.263.4.E615; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gill JMR, 2004, ATHEROSCLEROSIS, V176, P49, DOI 10.1016/j.atherosclerosis.2004.04.022; Ginsberg HN, 2002, CIRCULATION, V106, P2137, DOI 10.1161/01.CIR.0000035280.64322.31; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Hollenbeck Clarie B., 1993, American Journal of Clinical Nutrition, V58, p800S, DOI 10.1093/ajcn/58.5.800S; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; KALOPISSIS AD, 1981, BIOCHEM J, V198, P373, DOI 10.1042/bj1980373; Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI 10.1056/NEJMoa020194; Lam TKT, 2005, SCIENCE, V309, P943, DOI 10.1126/science.1112085; Lam TKT, 2005, NAT NEUROSCI, V8, P579, DOI 10.1038/nn1456; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Levin BE, 2004, DIABETES, V53, P2521, DOI 10.2337/diabetes.53.10.2521; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Morgan K, 2004, J BIOL CHEM, V279, P31139, DOI 10.1074/jbc.M400458200; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Olofsson SO, 2005, J INTERN MED, V258, P395, DOI 10.1111/j.1365-2796.2005.01556.x; OTVOS JD, 1991, CLIN CHEM, V37, P377; OTVOS JD, 1992, CLIN CHEM, V38, P1632; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Pellerin L, 2004, SCIENCE, V305, P50, DOI 10.1126/science.1100428; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Qiu W, 2005, BIOCHEMISTRY-US, V44, P3041, DOI 10.1021/bi047803+; Qiu W, 2004, DIABETES, V53, P3057, DOI 10.2337/diabetes.53.12.3057; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; VERSCHOOR L, 1985, HORM METAB RES, V17, P285, DOI 10.1055/s-2007-1013520; Vikramadithyan RK, 2005, J CLIN INVEST, V115, P2434, DOI 10.1172/JCI24819; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; WOODS SC, 1978, SCIENCE, V202, P1209, DOI 10.1126/science.725595; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277	50	124	124	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					171	180		10.1038/nm1540	http://dx.doi.org/10.1038/nm1540			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17273170				2022-12-27	WOS:000244031700026
J	Leen, AM; Myers, GD; Sili, U; Huls, MH; Weiss, H; Leung, KS; Carrum, G; Krance, RA; Chang, CC; Molldrem, JJ; Gee, AP; Brenner, MK; Heslop, HE; Rooney, CM; Bollard, CM				Leen, Ann M.; Myers, G. Doug; Sili, Uluhan; Huls, M. Helen; Weiss, Heidi; Leung, Kathryn S.; Carrum, George; Krance, Robert A.; Chang, Chung-Che; Molldrem, Jeffrey J.; Gee, Adrian P.; Brenner, Malcolm K.; Heslop, Helen E.; Rooney, Cliona M.; Bollard, Catherine M.			Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals	NATURE MEDICINE			English	Article							ALLOGENEIC BONE-MARROW; STEM-CELL TRANSPLANTATION; EXTENSIVE CROSS-REACTIVITY; LYMPHOPROLIFERATIVE DISEASE; ADOPTIVE TRANSFER; CYTOMEGALOVIRUS-INFECTION; ADENOVIRUS; GENE; RECIPIENTS; THERAPY	Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4(+) and CD8(+) T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.	Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Virol, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA; Cornell Univ, TMHRI, Methodist Hosp, Dept Pathol,Weill Med Coll, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; UTMD Anderson Cancer Center	Bollard, CM (corresponding author), Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.	cmbollar@txccc.org	Wilson, Matthew H/K-3193-2013; Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019; Rooney, Cliona/ABD-5475-2021; Sili, Uluhan/AAE-4280-2020	Sili, Uluhan/0000-0002-9939-9298	NCI NIH HHS [P01 CA094237] Funding Source: Medline; NCRR NIH HHS [U42 RR16578, RR00188] Funding Source: Medline; NHLBI NIH HHS [N01HB37163-C001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bollard CM, 2004, J EXP MED, V200, P1623, DOI 10.1084/jem.20040890; Bollard CM, 2004, BIOL BLOOD MARROW TR, V10, P143, DOI 10.1016/j.bbmt.2003.09.017; Bunde T, 2005, J EXP MED, V201, P1031, DOI 10.1084/jem.20042384; BUSSON P, 1995, J GEN VIROL, V76, P139, DOI 10.1099/0022-1317-76-1-139; Chakrabarti S, 2002, BLOOD, V100, P1619, DOI 10.1182/blood-2002-02-0377; Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357; Cobbold M, 2005, J EXP MED, V202, P379, DOI 10.1084/jem.20040613; Einsele H, 2002, BLOOD, V99, P3916, DOI 10.1182/blood.V99.11.3916; Gottschalk S, 2001, BLOOD, V97, P835, DOI 10.1182/blood.V97.4.835; Gustafsson A, 2000, BLOOD, V95, P807, DOI 10.1182/blood.V95.3.807.003k24_807_814; Heemskerk B, 2003, J VIROL, V77, P6562, DOI 10.1128/JVI.77.11.6562-6566.2003; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Khanna R, 2000, ANNU REV MICROBIOL, V54, P19, DOI 10.1146/annurev.micro.54.1.19; Leen AM, 2004, BLOOD, V104, P2432, DOI 10.1182/blood-2004-02-0646; Leen AM, 2004, BLOOD, V103, P1011, DOI 10.1182/blood-2003-07-2449; Lion T, 2003, BLOOD, V102, P1114, DOI 10.1182/blood-2002-07-2152; Myers GD, 2005, BONE MARROW TRANSPL, V36, P1001, DOI 10.1038/sj.bmt.1705164; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; RIDDELL SR, 1992, SCIENCE, V257, P238; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Sili U, 2003, J IMMUNOTHER, V26, P241, DOI 10.1097/00002371-200305000-00008; Smith CA, 1998, HUM GENE THER, V9, P1419, DOI 10.1089/hum.1998.9.10-1419; Wadell G, 1980, Ann N Y Acad Sci, V354, P16, DOI 10.1111/j.1749-6632.1980.tb27955.x; Wagner HJ, 2004, BLOOD, V103, P3979, DOI 10.1182/blood-2003-12-4287; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang Q, 2001, J EXP MED, V194, P1721, DOI 10.1084/jem.194.12.1721; Wherry EJ, 2002, ADV EXP MED BIOL, V512, P165; Yotnda P, 2001, GENE THER, V8, P930, DOI 10.1038/sj.gt.3301488	32	427	444	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1160	1166		10.1038/nm1475	http://dx.doi.org/10.1038/nm1475			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998485				2022-12-27	WOS:000241102200032
J	Skokowa, J; Cario, G; Uenalan, M; Schambach, A; Germeshausen, M; Battmer, K; Zeidler, C; Lehmann, U; Eder, M; Baum, C; Grosschedl, R; Stanulla, M; Scherr, M; Welte, K				Skokowa, Julia; Cario, Gunnar; Uenalan, Murat; Schambach, Axel; Germeshausen, Manuela; Battmer, Karin; Zeidler, Cornelia; Lehmann, Ulrich; Eder, Matthias; Baum, Christopher; Grosschedl, Rudolf; Stanulla, Martin; Scherr, Michaela; Welte, Karl			LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia	NATURE MEDICINE			English	Article							COLONY-STIMULATING-FACTOR; BINDING PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA; PROGENITOR CELLS; COLORECTAL-CANCER; GENE-EXPRESSION; BETA-CATENIN; C-MYC; MUTATIONS	We demonstrate here that lymphoid enhancer-binding factor 1 (LEF-1) mediates the proliferation, survival and differentiation of granulocyte progenitor cells. We initially documented the importance of this transcription factor in the bone marrow of individuals with severe congenital neutropenia (CN) with a 'differentiation block' at the promyelocytic stage of myelopoiesis(1). LEF-1 expression was greatly reduced or even absent in CN arrested promyelocytes, resulting in defective expression of the LEF-1 target genes CCND1, MYC and BIRC5, encoding cyclin D1 (ref. 2), c-Myc(3) and survivin(4), respectively. In contrast, healthy individuals showed highest LEF-1 expression in promyelocytes. Reconstitution of LEF-1 in early hematopoietic progenitors of two individuals with CN corrected the defective myelopoiesis and resulted in the differentiation of these progenitors into mature granulocytes. Repression of endogenous LEF-1 by specific short hairpin RNA inhibited proliferation and induced apoptosis of CD34(+) progenitors from healthy individuals and of cells from two myeloid lines (HL-60 and K562). C/EBP alpha, a key transcription factor in granulopoiesis(5,6), was directly regulated by LEF-1. These observations indicate that LEF-1 is an instructive factor regulating neutrophilic granulopoiesis whose absence plays a critical role in the defective maturation program of myeloid progenitors in individuals with CN.	Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Hematol Hemostaseol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany; Max Planck Inst Immunobiol, Dept Cellular & Mol Immunol, D-79108 Freiburg, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School; Max Planck Society	Welte, K (corresponding author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	skokowa.julia@mh-hannover.de; Welte.Karl.H@mh-hannover.de	Schambach, Axel/C-5491-2011; Skokowa, Julia/AAU-3622-2021; Stanulla, Martin/N-4674-2017; Stanulla, Martin/D-2528-2010; Cario, Gunnar/D-2535-2010	Skokowa, Julia/0000-0002-4399-2324; Stanulla, Martin/0000-0002-3834-0727; 				Cammenga J, 2003, BLOOD, V101, P2206, DOI 10.1182/blood-2002-05-1546; Cario G, 2005, BRIT J HAEMATOL, V129, P275, DOI 10.1111/j.1365-2141.2005.05428.x; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Konishi N, 1999, BLOOD, V94, P4077, DOI 10.1182/blood.V94.12.4077.424k04_4077_4083; Liu F, 2005, DEVELOPMENT, V132, P5375, DOI 10.1242/dev.02152; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Nawshad A, 2003, J CELL BIOL, V163, P1291, DOI 10.1083/jcb.200306024; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rosenberg PS, 2006, BLOOD, V107, P4628, DOI 10.1182/blood-2005-11-4370; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; WELTE K, 1990, BLOOD, V75, P1056; Welte K, 2006, SEMIN HEMATOL, V43, P189, DOI 10.1053/j.seminhematol.2006.04.004; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406	36	152	156	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1191	1197		10.1038/nm1484	http://dx.doi.org/10.1038/nm1484			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17063141				2022-12-27	WOS:000241102200037
J	Contoli, M; Message, SD; Laza-Stanca, V; Edwards, MR; Wark, PAB; Bartlett, NW; Kebadze, T; Mallia, P; Stanciu, LA; Parker, HL; Slater, L; Lewis-Antes, A; Kon, OM; Holgate, ST; Davies, DE; Kotenko, SV; Papi, A; Johnston, SL				Contoli, Marco; Message, Simon D.; Laza-Stanca, Vasile; Edwards, Michael R.; Wark, Peter A. B.; Bartlett, Nathan W.; Kebadze, Tatiana; Mallia, Patrick; Stanciu, Luminita A.; Parker, Hayley L.; Slater, Louise; Lewis-Antes, Anita; Kon, Onn M.; Holgate, Stephen T.; Davies, Donna E.; Kotenko, Sergei V.; Papi, Alberto; Johnston, Sebastian L.			Role of deficient type III interferon-lambda production in asthma exacerbations	NATURE MEDICINE			English	Article							BRONCHIAL EPITHELIAL-CELLS; IFN-LAMBDA; RHINOVIRUS; INFECTIONS; INDUCTION; COHORT; VIRUS	Rhinoviruses are the major cause of asthma exacerbations, and asthmatics have increased susceptibility to rhinovirus and risk of invasive bacterial infections. Here we show deficient induction of interferon-lambda s by rhinovirus in asthmatic primary bronchial epithelial cells and alveolar macrophages, which was highly correlated with severity of rhinovirus-induced asthma exacerbation and virus load in experimentally infected human volunteers. Induction by lipopolysaccharide in asthmatic macrophages was also deficient and correlated with exacerbation severity. These results identify previously unknown mechanisms of susceptibility to infection in asthma and suggest new approaches to prevention and/or treatment of asthma exacerbations.	Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mechan Asthma, London W2 1PG, England; Univ Ferrara, Res Ctr Asthma, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Ferrara, COPD, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Southampton, Southampton Gen Hosp, Brooke Labs, Sch Med, Southampton SO16 6YD, Hants, England; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; St Marys NHS Trust, London W2 1NY, England	Imperial College London; Imperial College London; University of Ferrara; University of Ferrara; University of Southampton; Rutgers State University New Brunswick; Rutgers State University Medical Center	Johnston, SL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Davies, Donna E/H-2993-2012; Wark, Peter/G-7037-2013; Stanciu, Luminita A/B-8384-2012; Johnston, Sebastian Lennox/I-2423-2012; Papi, alberto/AAC-1888-2019; Contoli, Marco/K-3947-2018	Wark, Peter/0000-0001-5676-6126; Johnston, Sebastian Lennox/0000-0003-3009-9200; Contoli, Marco/0000-0002-2731-5809; Davies, Donna/0000-0002-5117-2991; PAPI, ALBERTO/0000-0002-6924-4500; Edwards, Michael Robert/0000-0001-6837-0532; Bartlett, Nathan/0000-0002-2715-5163; Kon, Onn Min/0000-0003-2647-4688	MRC [G19/34] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051139, R01AI057468] Funding Source: NIH RePORTER; Medical Research Council [G19/34, G0800766] Funding Source: Medline; NIAID NIH HHS [AI051139, R01 AI051139, AI057468, R01 AI057468] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carr DJJ, 2005, J VIROL, V79, P9341, DOI 10.1128/JVI.79.14.9341-9345.2005; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	14	775	820	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1023	1026		10.1038/nm1462	http://dx.doi.org/10.1038/nm1462			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906156				2022-12-27	WOS:000240373900025
J	Lautrette, A; Li, SQ; Alili, R; Sunnarborg, SW; Burtin, M; Lee, DC; Friedlander, G; Terzi, F				Lautrette, A; Li, SQ; Alili, R; Sunnarborg, SW; Burtin, M; Lee, DC; Friedlander, G; Terzi, F			Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach	NATURE MEDICINE			English	Article							EPIDERMAL-GROWTH-FACTOR; ALPHA CONVERTING-ENZYME; SMOOTH-MUSCLE-CELLS; RENAL-DISEASE; TYROSINE KINASE; TRANSGENIC MICE; TGF-ALPHA; TRANSACTIVATION; PROGRESSION; INJURY	Mechanisms of progression of chronic renal diseases, a major healthcare burden, are poorly understood. Angiotensin II (AngII), the major renin-angiotensin system effector, is known to be involved in renal deterioration, but the molecular pathways are still unknown. Here, we show that mice overexpressing a dominant negative isoform of epidermal growth factor receptor (EGFR) were protected from renal lesions during chronic AngII infusion. Transforming growth factor-alpha (TGF-alpha) and its sheddase, TACE (also known as ADAM17), were induced by AngII treatment, TACE was redistributed to apical membranes and EGFR was phosphorylated. AngII-induced lesions were substantially reduced in mice lacking TGF-alpha or in mice given a specific TACE inhibitor. Pharmacologic inhibition of AngII prevented TGF-alpha and TACE accumulation as well as renal lesions after nephron reduction. These findings indicate a crucial role for AngII-dependent EGFR transactivation in renal deterioration and identify in TACE inhibitors a new therapeutic strategy for preventing progression of chronic renal diseases.	Univ Paris 05, Hop Necker Enfants Malad, INSERM U426, IFR 94, F-75015 Paris, France; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Terzi, F (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, INSERM U426, IFR 94, 149 Rue Sevres, F-75015 Paris, France.	terzi@necker.fr	Terzi, Fabiola/N-5482-2018	Friedlander, Gerard/0000-0002-6854-4261	NATIONAL CANCER INSTITUTE [R01CA043793, R01CA085410] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793, CA85410] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALADIB W, 1990, BONE MINER, V9, P59, DOI 10.1016/0169-6009(90)90100-T; Anderson S, 1996, EXP NEPHROL, V4, P34; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS30; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Brewster UC, 2004, AM J MED, V116, P263, DOI 10.1016/j.amjmed.2003.09.034; BREYER MD, 1990, AM J PHYSIOL, V259, pF553, DOI 10.1152/ajprenal.1990.259.4.F553; CREELY JJ, 1990, AM J PATHOL, V136, P1247; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Dell KM, 2001, KIDNEY INT, V60, P1240, DOI 10.1046/j.1523-1755.2001.00963.x; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; EARP HS, 1995, J BIOL CHEM, V270, P28440; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Francois H, 2004, FASEB J, V18, P926, DOI 10.1096/fj.03-0702fje; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; HOSTETTER TH, 1995, ANNU REV PHYSIOL, V57, P263, DOI 10.1146/annurev.ph.57.030195.001403; IVANYI B, 1991, HISTOCHEMISTRY, V95, P351, DOI 10.1007/BF00266962; LAFAYETTE RA, 1992, J CLIN INVEST, V90, P766, DOI 10.1172/JCI115949; Laverman GD, 2002, J RENIN-ANGIO-ALDO S, V3, P205, DOI 10.3317/jraas.2002.042; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LOWDEN DA, 1994, J LAB CLIN MED, V124, P386; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; Mackenzie HS, 1999, J AM SOC NEPHROL, V10, pS283; Navis G, 1996, DRUG SAFETY, V15, P200, DOI 10.2165/00002018-199615030-00005; NORMAN J, 1987, AM J PHYSIOL, V253, pF299, DOI 10.1152/ajprenal.1987.253.2.F299; NOUWEN EJ, 1994, KIDNEY INT, V45, P1510, DOI 10.1038/ki.1994.198; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Pei Y, 1997, J CLIN INVEST, V100, P814, DOI 10.1172/JCI119596; Pillebout E, 2003, J CLIN INVEST, V112, P843, DOI 10.1172/JCI200317647; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Siragy HM, 2004, SEMIN NEPHROL, V24, P93, DOI 10.1016/j.semnephrol.2003.11.009; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Sweeney WE, 2000, KIDNEY INT, V57, P33, DOI 10.1046/j.1523-1755.2000.00829.x; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Terzi F, 1997, J CLIN INVEST, V100, P1520, DOI 10.1172/JCI119675; Terzi F, 1998, KIDNEY INT, pS68; Wong RWC, 2000, J BIOL CHEM, V275, P18297, DOI 10.1074/jbc.M001965200; Zoja C, 2004, CURR OPIN NEPHROL HY, V13, P31, DOI 10.1097/00041552-200401000-00005	49	274	287	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					867	874		10.1038/nm1275	http://dx.doi.org/10.1038/nm1275			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16041383				2022-12-27	WOS:000230964700032
J	Klyubin, I; Walsh, DM; Lemere, CA; Cullen, WK; Shankar, GM; Betts, V; Spooner, ET; Jiang, LY; Anwyl, R; Selkoe, DJ; Rowan, MJ				Klyubin, I; Walsh, DM; Lemere, CA; Cullen, WK; Shankar, GM; Betts, V; Spooner, ET; Jiang, LY; Anwyl, R; Selkoe, DJ; Rowan, MJ			Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo	NATURE MEDICINE			English	Article							LONG-TERM POTENTIATION; REVERSIBLE MEMORY LOSS; ALZHEIMERS-DISEASE; MOUSE MODEL; PEPTIDE; BRAIN; IMMUNIZATION; FIBRILLOGENESIS; ANTIBODY; ACTIVATION	One of the most clinically advanced forms of experimental disease-modifying treatment for Alzheimer disease is immunization against the amyloid beta protein (A beta)(1-7), but how this may prevent cognitive impairment is unclear(8-13). We hypothesized that antibodies to A beta could exert a beneficial action by directly neutralizing potentially synaptotoxic soluble A beta species(14-16) in the brain. Intracerebroventricular injection of naturally secreted human A beta inhibited long-term potentiation (LTP), a correlate of learning and memory(17), in rat hippocampus in vivo but a monoclonal antibody to A beta completely prevented the inhibition of LTP when injected after A beta. Size fractionation showed that A beta oligomers, not monomers or fibrils, were responsible for inhibiting LTP, and an A beta antibody again prevented such inhibition. Active immunization against A beta was partially effective, and the effects correlated positively with levels of antibodies to A beta oligomers. The ability of exogenous and endogenous antibodies to rapidly neutralize soluble A beta oligomers that disrupt synaptic plasticity in vivo suggests that treatment with such antibodies might show reversible cognitive deficits in early Alzheimer disease.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland	Harvard University; Harvard Medical School; Trinity College Dublin; Trinity College Dublin; Harvard University; Brigham & Women's Hospital; University College Dublin; Trinity College Dublin	Rowan, MJ (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	mrowan@tcd.ie		Rowan, Michael Joseph/0000-0002-3867-9536	NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG06173] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Chauhan NB, 2001, J NEUROSCI RES, V66, P231, DOI 10.1002/jnr.1215; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 2002, NEUROBIOL AGING, V23, P991, DOI 10.1016/S0197-4580(02)00127-6; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; McGeer PL, 2003, NEUROBIOL AGING, V24, P391, DOI 10.1016/S0197-4580(02)00157-4; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morris RGM, 2003, PHILOS T R SOC B, V358, P773, DOI 10.1098/rstb.2002.1264; Nicoll JAR, 2004, NAT MED, V10, P118, DOI 10.1038/nm0204-118; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Robinson SR, 2004, NEUROBIOL AGING, V25, P609, DOI 10.1016/j.neurobiolaging.2003.12.020; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wilcock DM, 2004, NEUROBIOL DIS, V15, P11, DOI 10.1016/j.nbd.2003.09.015; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195	30	424	493	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					556	561		10.1038/nm1234	http://dx.doi.org/10.1038/nm1234			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834427				2022-12-27	WOS:000228915000029
J	Genove, G; DeMarco, U; Xu, HY; Goins, WF; Ahrens, ET				Genove, G; DeMarco, U; Xu, HY; Goins, WF; Ahrens, ET			A new transgene reporter for in vivo magnetic resonance imaging	NATURE MEDICINE			English	Article							FERRITIN H-CHAIN; GENE-EXPRESSION; IRON-UPTAKE; CELLS; OVEREXPRESSION; RELAXATION	We report a new platform technology for visualizing transgene expression in living subjects using magnetic resonance imaging (MRI). Using a vector, we introduced an MRI reporter, a metalloprotein from the ferritin family, into specific host tissues. The reporter is made superparamagnetic as the cell sequesters endogenous iron from the organism. In this new approach, the cells construct the MRI contrast agent in situ using genetic instructions introduced by the vector. No exogenous metal-complexed contrast agent is required, thereby simplifying intracellular delivery. We used a replication-defective adenovirus vector to deliver the ferritin transgenes. Following focal inoculation of the vector into the mouse brain, we monitored the reporter activity using in vivo time-lapse MRI. We observed robust contrast in virus-transduced neurons and glia for several weeks. This technology is adaptable to monitor transgene expression in vivo in many tissue types and has numerous biomedical applications, such as visualizing preclinical therapeutic gene delivery.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ahrens, ET (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	eta@andrew.cmu.edu	Goins, William/GLT-6681-2022; Genove, Guillem/F-1158-2011	Goins, William/0000-0001-7744-9891; Genove, Guillem/0000-0002-8558-3107	NIAMS NIH HHS [P50-AR049617] Funding Source: Medline; NIBIB NIH HHS [P41-EB001977, R01-EB003453] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001977, R01EB003453] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Ahrens ET, 2003, MAGN RESON MED, V49, P1006, DOI 10.1002/mrm.10465; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; BULTE JWM, 1994, J MAGN RESON IMAGING, V4, P497, DOI 10.1002/jmri.1880040343; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dhenain M, 1997, NEUROBIOL AGING, V18, P517, DOI 10.1016/S0197-4580(97)00105-X; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Gottesfeld Z, 1996, MAGN RESON MED, V35, P514, DOI 10.1002/mrm.1910350410; Kircher MF, 2003, CANCER RES, V63, P6838; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KORETSKY AP, 1990, P NATL ACAD SCI USA, V87, P3112, DOI 10.1073/pnas.87.8.3112; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; OKON E, 1994, LAB INVEST, V71, P895; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; STOLZ JF, 1986, NATURE, V321, P849, DOI 10.1038/321849a0; Vymazal J, 1996, MAGN RESON MED, V36, P61, DOI 10.1002/mrm.1910360111; Vymazal J, 1996, MAGN RESON MED, V35, P56, DOI 10.1002/mrm.1910350108; Vymazal J, 1998, J INORG BIOCHEM, V71, P153, DOI 10.1016/S0162-0134(98)10047-8; Walter G, 2000, P NATL ACAD SCI USA, V97, P5151, DOI 10.1073/pnas.97.10.5151; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; WELCH S, 1992, TRANSFERRIN IRON CAR; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513	25	331	358	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					450	454		10.1038/nm1208	http://dx.doi.org/10.1038/nm1208			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15778721				2022-12-27	WOS:000228180500039
J	Melendez, AJ; Harnett, MM; Pushparaj, PN; Wong, WF; Tay, HK; McSharry, CP; Harnett, W				Melendez, Alirio J.; Harnett, Margaret M.; Pushparaj, Peter N.; Wong, Ws Fred; Tay, Hwee Kee; McSharry, Charles P.; Harnett, William			Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes	NATURE MEDICINE			English	Article							KINASE-C-ALPHA; NF-KAPPA-B; CYTOKINE PRODUCTION; SECRETED PRODUCT; TNF-ALPHA; ACTIVATION; EXPRESSION; PATHWAYS; IGE; LIPOPOLYSACCHARIDE	Atopic allergy is characterized by an increase in IgE antibodies that signal through the high-affinity Fc epsilon receptor (Fc epsilon RI) to induce the release of inflammatory mediators from mast cells. For unknown reasons, the prevalence of allergic diseases has recently increased steeply in the developed world(1). However, this increase has not been mirrored in developing countries(2), even though IgE concentrations are often greatly elevated in individuals from these countries, owing to nonspecific IgE induction by universally present parasitic worms(3). Here we offer one explanation for this paradox based on the properties of ES-62, a molecule secreted by filarial nematodes(4). We found that highly purified, endotoxin-free ES-62 directly inhibits the Fc epsilon RI-induced release of allergy mediators from human mast cells by selectively blocking key signal transduction events, including phospholipase D-coupled, sphingosine kinase-mediated calcium mobilization and nuclear factor-kappa B activation. ES-62 mediates these effects by forming a complex with Toll-like receptor 4, which results in the sequestration of protein kinase C-alpha (PKC-alpha). This causes caveolae/lipid raft-mediated, proteasome-independent degradation of PKC-alpha, a molecule important for the coupling of Fc epsilon RI to phospholipase D and mast cell activation. We also show that ES-62 is able to protect mice from mast cell-dependent hypersensitivity in the skin and lungs, indicating that it has potential as a novel therapeutic for allergy.	Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0NR, Lanark, Scotland; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore; Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow G12 8TA, Lanark, Scotland; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117597, Singapore	University of Strathclyde; National University of Singapore; University of Glasgow; National University of Singapore	Harnett, W (corresponding author), Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.	w.harnett@strath.ac.uk	Pushparaj, Peter Natesan/H-9871-2012; Wong, Wai Shui Fred/D-8205-2013	Pushparaj, Peter Natesan/0000-0001-7574-1880; Harnett, William/0000-0001-9545-9401; McSharry, Charles/0000-0003-4758-9038; Wong, Wai Shiu Fred/0000-0001-7010-3759	Medical Research Council [G0700794] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abdel-Raheem IT, 2005, BRIT J PHARMACOL, V145, P415, DOI 10.1038/sj.bjp.0706207; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; BURNEY PGJ, 1997, ASTHMA, P35; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Goodridge HS, 2005, IMMUNOLOGY, V115, P296, DOI 10.1111/j.1365-2567.2005.02167.x; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Goodridge HS, 2001, J IMMUNOL, V167, P940, DOI 10.4049/jimmunol.167.2.940; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Harnett W, 2004, IMMUNOL LETT, V94, P27, DOI 10.1016/j.imlet.2004.04.008; Harnett W, 2003, CURR PROTEIN PEPT SC, V4, P59, DOI 10.2174/1389203033380368; Jeong HJ, 2002, CELL SIGNAL, V14, P633, DOI 10.1016/S0898-6568(02)00005-0; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LAL RB, 1987, J IMMUNOL, V138, P3454; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Li GM, 2005, CELL IMMUNOL, V238, P10, DOI 10.1016/j.cellimm.2005.12.001; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; McInnes IB, 2003, J IMMUNOL, V171, P2127, DOI 10.4049/jimmunol.171.4.2127; McKay DM, 2006, PARASITOLOGY, V132, P1, DOI 10.1017/S003118200500884X; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Nigo YI, 2006, P NATL ACAD SCI USA, V103, P2286, DOI 10.1073/pnas.0510685103; Powner DJ, 2002, MOL BIOL CELL, V13, P1252, DOI 10.1091/mbc.01-05-0235; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391; Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35	29	163	173	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1375	1381		10.1038/nm1654	http://dx.doi.org/10.1038/nm1654			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17952092				2022-12-27	WOS:000250736900032
J	Umetani, M; Domoto, H; Gormley, AK; Yuhanna, IS; Cummins, CL; Javitt, NB; Korach, KS; Shaul, PW; Mangelsdorf, DJ				Umetani, Michihisa; Domoto, Hideharu; Gormley, Andrew K.; Yuhanna, Ivan S.; Cummins, Carolyn L.; Javitt, Norman B.; Korach, Kenneth S.; Shaul, Philip W.; Mangelsdorf, David J.			27-hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen	NATURE MEDICINE			English	Article							CORONARY-HEART-DISEASE; NITRIC-OXIDE; OXIDATION-PRODUCTS; RECEPTOR-ALPHA; PLUS PROGESTIN; FATTY STREAKS; REENDOTHELIALIZATION; CHOLESTEROL; CONTROVERSIES; OXYSTEROLS	The cardioprotective effects of estrogen are mediated by receptors expressed in vascular cells. Here we show that 27- hydroxycholesterol ( 27HC), an abundant cholesterol metabolite that is elevated with hypercholesterolemia and found in atherosclerotic lesions, is a competitive antagonist of estrogen receptor action in the vasculature. 27HC inhibited both the transcription- mediated and the non- transcription- mediated estrogen- dependent production of nitric oxide by vascular cells, resulting in reduced estrogen- induced vasorelaxation of rat aorta. Furthermore, increasing 27HC levels in mice by diet- induced hypercholesterolemia, pharmacologic administration or genetic manipulation ( by knocking out the gene encoding the catabolic enzyme CYP7B1) decreased estrogen- dependent expression of vascular nitric oxide synthase and repressed carotid artery reendothelialization. As well as antiestrogenic effects, there were proestrogenic actions of 27HC that were cell- type specific, indicating that 27HC functions as an endogenous selective estrogen receptor modulator ( SERM). Taken together, these studies point to 27HC as a contributing factor in the loss of estrogen protection from vascular disease.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University; New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu	Umetani, Michi/AAP-3964-2020	Umetani, Michi/0000-0001-8474-7088; Mangelsdorf, David/0000-0002-4355-0796; Cummins, Carolyn/0000-0001-7603-6577; Korach, Kenneth/0000-0002-7765-418X; Javitt, Norman B/0000-0001-9265-3508	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL87564] Funding Source: Medline; NIDDK NIH HHS [U19DK62434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Brouchet L, 2001, CIRCULATION, V103, P423; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Clark James H, 2006, Nucl Recept Signal, V4, pe023; Clarkson TB, 2005, MATURITAS, V51, P64, DOI 10.1016/j.maturitas.2005.02.016; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Couse JF, 2003, MOL ENDOCRINOL, V17, P1039, DOI 10.1210/me.2002-0398; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; Garcia-Cruset S, 2001, FREE RADICAL RES, V35, P31, DOI 10.1080/10715760100300571; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Hanke H, 1999, ATHEROSCLEROSIS, V147, P123, DOI 10.1016/S0021-9150(99)00182-3; Herrington DM, 2002, CIRCULATION, V105, P2962, DOI 10.1161/01.CIR.0000019406.74017.B2; Hodgin JB, 2002, ENDOCRINOLOGY, V143, P4495, DOI 10.1210/en.2002-220844; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Iwakura A, 2003, CIRCULATION, V108, P3115, DOI 10.1161/01.CIR.0000106906.56972.83; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Karas RH, 2004, CLIN OBSTET GYNECOL, V47, P489, DOI 10.1097/00003081-200406000-00024; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; Lund EG, 2003, METHOD ENZYMOL, V364, P24; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Omoto Y, 2005, P NATL ACAD SCI USA, V102, P2814, DOI 10.1073/pnas.0500198102; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; RAVI J, 1994, AM J HYPERTENS, V7, P1065, DOI 10.1093/ajh/7.12.1065; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rosenfeld ME, 2002, ATHEROSCLEROSIS, V164, P251, DOI 10.1016/S0021-9150(02)00178-8; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Seetharam D, 2006, CIRC RES, V98, P63, DOI 10.1161/01.RES.0000199272.59432.5b; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Takahashi K, 2003, J ENDOCRINOL, V178, P319, DOI 10.1677/joe.0.1780319; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0; Yu LQ, 2004, J LIPID RES, V45, P889, DOI 10.1194/jlr.M300461-JLR200; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	49	283	288	1	33	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1185	1192		10.1038/nm1641	http://dx.doi.org/10.1038/nm1641			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17873880				2022-12-27	WOS:000249980200034
J	Barnett, BP; Arepally, A; Karmarkar, PV; Qian, D; Gilson, WD; Walczak, P; Howland, V; Lawler, L; Lauzon, C; Stuber, M; Kraitchman, DL; Bulte, JWM				Barnett, Brad P.; Arepally, Aravind; Karmarkar, Parag V.; Qian, Di; Gilson, Wesley D.; Walczak, Piotr; Howland, Valerie; Lawler, Leo; Lauzon, Cal; Stuber, Matthias; Kraitchman, Dara L.; Bulte, Jeff W. M.			Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells	NATURE MEDICINE			English	Article							STEM-CELLS; PORCINE ISLETS; TRANSPLANTATION; NANOPARTICLES; INJECTION; REJECTION; TRACKING; ALGINATE; MODEL; MRI	In type I diabetes mellitus, islet transplantation provides a moment-to-moment fine regulation of insulin. Success rates vary widely, however, necessitating suitable methods to monitor islet delivery, engraftment and survival. Here magnetic resonance-trackable magnetocapsules have been used simultaneously to immunoprotect pancreatic beta-cells and to monitor, non-invasively in real-time, hepatic delivery and engraftment by magnetic resonance imaging (MRI). Magnetocapsules were detected as single capsules with an altered magnetic resonance appearance on capsule rupture. Magnetocapsules were functional in vivo because mouse beta-cells restored normal glycemia in streptozotocin-induced diabetic mice and human islets induced sustained C-peptide levels in swine. In this large-animal model, magnetocapsules could be precisely targeted for infusion by using magnetic resonance fluoroscopy, whereas MRI facilitated monitoring of liver engraftment over time. These findings are directly applicable to ongoing improvements in islet cell transplantation for human diabetes, particularly because our magnetocapsules comprise clinically applicable materials.	Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21212 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Cellular Imaging Sect, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Arepally, A (corresponding author), Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St,Blalock 644, Baltimore, MD 21212 USA.	aarepal@jhmi.edu	Stuber, Matthias/B-2949-2010; Barnett, Brad/AAY-2578-2020; Walczak, Piotr/B-8707-2008; Barnett, Bradley/AAN-1628-2020; Bulte, Jeff W.M./A-3240-2008	Stuber, Matthias/0000-0001-9843-2028; Walczak, Piotr/0000-0002-3733-3322; Barnett, Bradley/0000-0002-8301-404X; Bulte, Jeff W.M./0000-0003-1202-1610	NIBIB NIH HHS [K08 EB004348, R01 EB007825] Funding Source: Medline; NINDS NIH HHS [R01 NS045062] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007825, K08EB004348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045062] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arepally A, 2006, RADIOLOGY, V238, P113, DOI 10.1148/radiol.2381041533; Ault A, 2003, LANCET, V361, P2054; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Cunningham CH, 2005, MAGNET RESON MED, V53, P999, DOI 10.1002/mrm.20477; de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154; Elliott RB, 2005, TRANSPL P, V37, P3505, DOI 10.1016/j.transproceed.2005.09.038; Evgenov NV, 2006, DIABETES, V55, P2419, DOI 10.2337/db06-0484; Evgenov NV, 2006, NAT MED, V12, P144, DOI 10.1038/nm1316; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Hunkeler D, 2001, ANN NY ACAD SCI, V944, P456; Jacobson RM, 2005, VACCINE, V23, P2315, DOI 10.1016/j.vaccine.2005.01.025; Jirak D, 2004, MAGN RESON MED, V52, P1228, DOI 10.1002/mrm.20282; Karmarkar PV, 2004, MAGN RESON MED, V51, P1163, DOI 10.1002/mrm.20086; Kostura L, 2004, NMR BIOMED, V17, P513, DOI 10.1002/nbm.925; Kriz J, 2005, TRANSPLANTATION, V80, P1596, DOI 10.1097/01.tp.0000183959.73681.b9; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Oca-Cossio J, 2004, BIOCHEM BIOPH RES CO, V319, P569, DOI 10.1016/j.bbrc.2004.04.195; Orive G, 2003, NAT MED, V9, P104, DOI 10.1038/nm0103-104; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shapiro EM, 2006, MAGN RESON MED, V55, P242, DOI 10.1002/mrm.20718; Shen F, 2005, HUM GENE THER, V16, P971, DOI 10.1089/hum.2005.16.971; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; STUBER M, 2006, J CARDIOVASC MAGN R, V8, P13; Tai JH, 2006, DIABETES, V55, P2931, DOI 10.2337/db06-0393; Toso C, 2005, CELL TRANSPLANT, V14, P159, DOI 10.3727/000000005783983223; Toso C, 2003, TRANSPLANT INT, V16, P405, DOI 10.1007/s00147-003-0555-9; Walczak P, 2005, MAGN RESON MED, V54, P769, DOI 10.1002/mrm.20701; White SA, 2000, CELL TRANSPLANT, V9, P19, DOI 10.1177/096368970000900103; ZHOU D, 1994, TRANSPLANT P, V26, P1091	30	183	186	3	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					986	991		10.1038/nm1581	http://dx.doi.org/10.1038/nm1581			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17660829				2022-12-27	WOS:000248674600031
J	Dierks, C; Grbic, J; Zirlik, K; Beigi, R; Englund, NP; Guo, GR; Veelken, H; Engelhardt, M; Mertelsmann, R; Kelleher, JF; Schultz, P; Warmuth, M				Dierks, Christine; Grbic, Jovana; Zirlik, Katja; Beigi, Ronak; Englund, Nathan P.; Guo, Gui-Rong; Veelken, Hendrik; Engelhardt, Monika; Mertelsmann, Roland; Kelleher, Joseph F.; Schultz, Peter; Warmuth, Markus			Essential role of stromally induced hedgehog signaling in B-cell malignancies	NATURE MEDICINE			English	Article							SONIC HEDGEHOG; C-MYC; ACTIVATION; GROWTH; MICE; PROLIFERATION; REQUIREMENT; EXPRESSION; DEFICIENT; MUTATIONS	Interaction of cancer cells with their microenvironment generated by stromal cells is essential for tumor cell survival and influences the localization of tumor growth. Here we demonstrate that hedgehog ligands secreted by bone-marrow, nodal and splenic stromal cells function as survival factors for malignant lymphoma and plasmacytoma cells derived from transgenic E mu-Myc mice or isolated from humans with these malignancies. Hedgehog pathway inhibition in lymphomas induced apoptosis through downregulation of Bc12, but was independent of p53 or Bmi1 expression. Blockage of hedgehog signaling in vivo inhibited expansion of mouse lymphoma cells in a syngeneic mouse model and reduced tumor mass in mice with fully developed disease. Our data indicate that stromally induced hedgehog signaling may provide an important survival signal for B- and plasma-cell malignancies in vitro and in vivo. Disruption of this interaction by hedgehog pathway inhibition could provide a new strategy in lymphoma and multiple myeloma therapy.	Novartis Res Fdn, Kinase Biol In Vivo Oncol, Dept Pharmacol, Genom Inst, San Diego, CA 92121 USA; Novartis Res Fdn, Dept Med Chem, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, San Diego, CA 92121 USA; Univ Freiburg, Dept Hematol Oncol, D-79111 Freiburg, Germany; Novartis Inst BioMed Res, Cambridge, MA 02139 USA	Novartis; Novartis; Scripps Research Institute; University of Freiburg; Novartis	Dierks, C (corresponding author), Novartis Res Fdn, Kinase Biol In Vivo Oncol, Dept Pharmacol, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	chdierks@yahoo.de; mwarmuth@gnf.org	Dierks, Christine/L-4358-2013	Veelken, Hendrik/0000-0002-9108-3125				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Dyer MA, 2001, DEVELOPMENT, V128, P1717; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Gering M, 2005, DEV CELL, V8, P389, DOI 10.1016/j.devcel.2005.01.010; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobune M, 2004, BLOOD, V104, P1002, DOI 10.1182/blood-2003-09-3347; Lee J, 1997, DEVELOPMENT, V124, P2537; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Moller C, 2003, LEUKEMIA, V17, P203, DOI 10.1038/sj.leu.2402717; MULLER JR, 1995, CANCER RES, V55, P5012; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park SS, 2005, CANCER RES, V65, P1306, DOI 10.1158/0008-5472.CAN-04-0268; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Stewart GA, 2002, J IMMUNOL, V169, P5451, DOI 10.4049/jimmunol.169.10.5451; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tassone P, 2005, CLIN CANCER RES, V11, P4251, DOI 10.1158/1078-0432.CCR-04-2611; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	46	266	287	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					944	951		10.1038/nm1614	http://dx.doi.org/10.1038/nm1614			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17632527				2022-12-27	WOS:000248674600025
J	Idzko, M; Hammad, H; van Nimwegen, M; Kool, M; Willart, MAM; Muskens, F; Hoogsteden, HC; Luttmann, W; Ferrari, D; Di Virgilio, F; Virchow, JC; Lambrecht, BN				Idzko, Marco; Hammad, Hamida; van Nimwegen, Menno; Kool, Mirjam; Willart, Monique A. M.; Muskens, Femke; Hoogsteden, Henk C.; Luttmann, Werner; Ferrari, Davide; Di Virgilio, Francesco; Virchow, J. Christian, Jr.; Lambrecht, Bart N.			Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells	NATURE MEDICINE			English	Article							NUCLEOTIDE RECEPTORS; PLATELET ACTIVATION; ADENINE-NUCLEOTIDES; ALLERGEN CHALLENGE; EPITHELIAL-CELLS; IMMUNE-RESPONSE; TH2 RESPONSES; LUNG; RELEASE; ADENOSINE	Extracellular ATP serves as a danger signal to alert the immune system of tissue damage by acting on P2X or P2Y receptors. Here we show that allergen challenge causes acute accumulation of ATP in the airways of asthmatic subjects and mice with experimentally induced asthma. All the cardinal features of asthma, including eosinophilic airway inflammation, Th2 cytokine production and bronchial hyper-reactivity, were abrogated when lung ATP levels were locally neutralized using apyrase or when mice were treated with broad-spectrum P2-receptor antagonists. In addition to these effects of ATP in established inflammation, Th2 sensitization to inhaled antigen was enhanced by endogenous or exogenous ATP. The adjuvant effects of ATP were due to the recruitment and activation of lung myeloid dendritic cells that induced Th2 responses in the mediastinal nodes. Together these data show that purinergic signaling has a key role in allergen-driven lung inflammation that is likely to be amenable to therapeutic intervention.	Univ Hosp Freiburg, Dept Pulm Med, D-79106 Freiburg, Germany; Erasmus Univ, Ctr Med, Dept Pulm Med, NL-3000 DR Rotterdam, Netherlands; Univ Hosp Rostock, Dept Pulm Med, D-18055 Rostock, Germany; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, ICSI, I-44100 Ferrara, Italy	University of Freiburg; Erasmus University Rotterdam; University of Rostock; University of Ferrara; University of Ferrara	Idzko, M (corresponding author), Univ Hosp Freiburg, Dept Pulm Med, Killianstr 5, D-79106 Freiburg, Germany.	marco.idzko@uniklinik-freiburg.de; b.lambrecht@erasmusmc.nl	Ferrari, Davide/F-5644-2015; Lambrecht, Bart N/K-2484-2014; DI VIRGILIO, Francesco/O-4634-2019; Hammad, Hamida/J-9391-2015; Di Virgilio, Francesco/J-3754-2018	Ferrari, Davide/0000-0002-5727-9204; Lambrecht, Bart N/0000-0003-4376-6834; DI VIRGILIO, Francesco/0000-0003-3566-1362; Hammad, Hamida/0000-0003-3762-8603; Di Virgilio, Francesco/0000-0003-3566-1362				Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Adriaensen D, 2004, CURR OPIN PHARMACOL, V4, P207, DOI 10.1016/j.coph.2004.01.010; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio Francesco, 2005, Purinergic Signal, V1, P205, DOI 10.1007/s11302-005-6312-z; Douillet CD, 2006, AM J PHYSIOL-LUNG C, V291, pL734, DOI 10.1152/ajplung.00389.2005; Ferrari D, 2006, J LEUKOCYTE BIOL, V79, P7, DOI 10.1189/jlb.0505286; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Granstein RD, 2005, J IMMUNOL, V174, P7725, DOI 10.4049/jimmunol.174.12.7725; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Hollander GA, 1999, TRANSPL P, V31, p25S, DOI 10.1016/S0041-1345(98)02078-8; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Idzko M, 2003, BRIT J PHARMACOL, V138, P1244, DOI 10.1038/sj.bjp.0705145; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; la Sala A, 2002, BLOOD, V99, P1715, DOI 10.1182/blood.V99.5.1715; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; la Sala A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/jlb.0802418; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Laubinger W, 2006, EUR J PHARMACOL, V543, P1, DOI 10.1016/j.ejphar.2006.06.029; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mizumoto N, 2002, NAT MED, V8, P358, DOI 10.1038/nm0402-358; Mohsenin A, 2006, CURR OPIN PULM MED, V12, P54, DOI 10.1097/01.mcp.0000199002.46038.cb; Muller T, 2005, AM J RESP CELL MOL, V33, P601, DOI 10.1165/rcmb.2005-0181OC; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Pelleg Amir, 2002, Am J Ther, V9, P454, DOI 10.1097/00045391-200209000-00014; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Pitchford SC, 2006, CLIN EXP ALLERGY, V36, P399, DOI 10.1111/j.1365-2222.2006.02462.x; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; van den Berge M, 2004, J ALLERGY CLIN IMMUN, V114, P737, DOI 10.1016/j.jaci.2004.05.071; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	49	465	487	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					913	919		10.1038/nm1617	http://dx.doi.org/10.1038/nm1617			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17632526				2022-12-27	WOS:000248674600021
J	Gao, BB; Clermont, A; Rook, S; Fonda, SJ; Srinivasan, VJ; Wojtkowski, M; Fujimoto, JG; Avery, RL; Arrigg, PG; Bursell, SE; Aiello, LP; Feener, EP				Gao, Ben-Bo; Clermont, Allen; Rook, Susan; Fonda, Stephanie J.; Srinivasan, Vivek J.; Wojtkowski, Maciej; Fujimoto, James G.; Avery, Robert L.; Arrigg, Paul G.; Bursell, Sven-Erik; Aiello, Lloyd Paul; Feener, Edward P.			Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DIABETIC-RETINOPATHY; MACULAR EDEMA; PIGMENT EPITHELIUM; BLOOD-FLOW; BRADYKININ; CELLS; PROLYLCARBOXYPEPTIDASE; ACETAZOLAMIDE; PROGRESSION	Excessive retinal vascular permeability contributes to the pathogenesis of proliferative diabetic retinopathy and diabetic macular edema, leading causes of vision loss in working-age adults. Using mass spectroscopy-based proteomics, we detected 117 proteins in human vitreous and elevated levels of extracellular carbonic anhydrase-I (CA-I) in vitreous from individuals with diabetic retinopathy, suggesting that retinal hemorrhage and erythrocyte lysis contribute to the diabetic vitreous proteome. Intravitreous injection of CA-I in rats increased retinal vessel leakage and caused intraretinal edema. CA-I-induced alkalinization of vitreous increased kallikrein activity and its generation of factor XIIa, revealing a new pathway for contact system activation. CA-I-induced retinal edema was decreased by complement 1 inhibitor, neutralizing antibody to prekallikrein and bradykinin receptor antagonism. Subdural infusion of CA-I in rats induced cerebral vascular permeability, suggesting that extracellular CA-I could have broad relevance to neurovascular edema. Inhibition of extracellular CA-I and kallikrein-mediated innate inflammation could provide new therapeutic opportunities for the treatment of hemorrhage-induced retinal and cerebral edema.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA; Santa Barbara Cottage Hosp Eye Ctr, Santa Barbara, CA 93103 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Santa Barbara Cottage Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Feener, EP (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	edward.feener@joslin.harvard.edu	Wojtkowski, Maciej/D-6822-2014	Wojtkowski, Maciej/0000-0003-0599-0878	NATIONAL EYE INSTITUTE [R01EY014106, R01EY011289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK060165] Funding Source: NIH RePORTER; NEI NIH HHS [EY011289, EY014106] Funding Source: Medline; NIDDK NIH HHS [DK 36836, DK 60165] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Anderson NL, 2004, MOL CELL PROTEOMICS, V3, P311, DOI 10.1074/mcp.M300127-MCP200; [Anonymous], 1991, Ophthalmology, V98, P786; Carugati A, 2001, MOL IMMUNOL, V38, P161, DOI 10.1016/S0161-5890(01)00040-2; Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907; Giusti Cristiano, 2001, International Ophthalmology, V24, P79, DOI 10.1023/A:1016354517304; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Henricsson M, 1999, ACTA OPHTHALMOL SCAN, V77, P218, DOI 10.1034/j.1600-0420.1999.770221.x; Houle S, 2003, HYPERTENSION, V41, P611, DOI 10.1161/01.HYP.0000054971.03046.9B; Iwaki T, 2006, THROMB HAEMOSTASIS, V95, P1003, DOI 10.1160/TH06-03-0128; Joseph K, 2005, ADV IMMUNOL, V86, P159, DOI 10.1016/S0065-2776(04)86005-X; Kakoki M, 2004, P NATL ACAD SCI USA, V101, P13302, DOI 10.1073/pnas.0405449101; Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552; Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464; Knudsen ST, 2002, DIABETES CARE, V25, P2328, DOI 10.2337/diacare.25.12.2328; KROGSAA B, 1981, ACTA OPHTHALMOL, V59, P689, DOI 10.1111/j.1755-3768.1981.tb08735.x; Lattanzio R, 2002, EUR J OPHTHALMOL, V12, P482, DOI 10.1177/112067210201200606; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Nagelhus EA, 2005, P NATL ACAD SCI USA, V102, P8030, DOI 10.1073/pnas.0503021102; Nakanishi T, 2002, J CHROMATOGR B, V776, P89, DOI 10.1016/S1570-0232(02)00078-8; Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4; Ouchi M, 2005, EXP EYE RES, V81, P176, DOI 10.1016/j.exer.2005.01.020; PLEHWE WE, 1989, BRIT J OPHTHALMOL, V73, P255, DOI 10.1136/bjo.73.4.255; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; RASSAM SMB, 1993, EYE, V7, P697, DOI 10.1038/eye.1993.159; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shariat-Madar Z, 2004, BLOOD, V103, P4554, DOI 10.1182/blood-2003-07-2510; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; Srinivas SP, 2002, INVEST OPHTH VIS SCI, V43, P3273; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stefansson E, 1999, INVEST OPHTH VIS SCI, V40, P2756; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; VELOSO D, 1987, BLOOD, V70, P1053; VORSTRUP S, 1984, J CLIN INVEST, V74, P1634, DOI 10.1172/JCI111579; Weber A, 2004, J MED CHEM, V47, P550, DOI 10.1021/jm030912m; Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476; WISTRAND PJ, 1986, INVEST OPHTH VIS SCI, V27, P419; Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023; WOLFENSBERGER TJ, 1994, INVEST OPHTH VIS SCI, V35, P3401; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200; Yang ZL, 2005, HUM MOL GENET, V14, P255, DOI 10.1093/hmg/ddi023	47	227	261	2	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					181	188		10.1038/nm1534	http://dx.doi.org/10.1038/nm1534			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17259996				2022-12-27	WOS:000244031700027
J	Chen, K; Li, FH; Li, J; Cai, HB; Strom, S; Bisello, A; Kelley, DE; Friedman-Einat, M; Skibinski, GA; McCrory, MA; Szalai, AJ; Zhao, AZ				Chen, K; Li, FH; Li, J; Cai, HB; Strom, S; Bisello, A; Kelley, DE; Friedman-Einat, M; Skibinski, GA; McCrory, MA; Szalai, AJ; Zhao, AZ			Induction of leptin resistance through direct interaction of C-reactive protein with leptin	NATURE MEDICINE			English	Article							OBESE SUBJECTS; PLASMA LEPTIN; SERUM LEPTIN; BOUND LEPTIN; WEIGHT-LOSS; INFLAMMATION; INTERLEUKIN-6; RECEPTOR; HUMANS; MICE	The mechanisms underlying leptin resistance are still being defined. We report here the presence in human blood of several serum leptin-interacting proteins (SLIPs), isolated by leptin-affinity chromatography and identified by mass spectrometry and immunochemical analysis. We confirmed that one of the major SLIPs is C-reactive protein (CRP). In vitro, human CRP directly inhibits the binding of leptin to its receptors and blocks its ability to signal in cultured cells. In vivo, infusion of human CRP into ob/ob mice blocked the effects of leptin upon satiety and weight reduction. In mice that express a transgene encoding human CRP, the actions of human leptin were completely blunted. We also found that physiological concentrations of leptin can stimulate expression of CRP in human primary hepatocytes. Recently, human CRP has been correlated with increased adiposity and plasma leptin. Thus, our results suggest a potential mechanism contributing to leptin resistance, by which circulating CRP binds to leptin and attenuates its physiological functions.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Div Endocrinol & Bone Metab, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Obes & Nutr Res Ctr, Pittsburgh, PA 15261 USA; Agr Res Org, Inst Anim Sci, Volcani Ctr, IL-50250 Bet Dagan, Israel; Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Alabama System; University of Alabama Birmingham	Zhao, AZ (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, 3500 Terrace St,BST-S-326, Pittsburgh, PA 15261 USA.	azhao@pitt.edu	Cai, Huaibin/H-3359-2013	Cai, Huaibin/0000-0002-8596-6108; Friedman-Einat, Miriam/0000-0002-9451-1025; Szalai, Alexander J/0000-0001-6638-579X; Skibinski, Gregory/0000-0002-1454-8179	NIDDK NIH HHS [1R01DK064383-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064383] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Aronson D, 2004, INT J OBESITY, V28, P674, DOI 10.1038/sj.ijo.0802609; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; Chan JL, 2005, J CLIN ENDOCR METAB, V90, P1618, DOI 10.1210/jc.2004-1921; DEBEER FC, 1982, IMMUNOLOGY, V45, P55; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Friedman-Einat M, 2003, REGUL PEPTIDES, V111, P77, DOI 10.1016/S0167-0115(02)00259-8; Gura T, 1999, SCIENCE, V286, P881; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Huan JN, 2003, J BIOL CHEM, V278, P45638, DOI 10.1074/jbc.M304165200; Hukshorn CJ, 2004, J CLIN ENDOCR METAB, V89, P1773, DOI 10.1210/jc.2003-030803; Hukshorn CJ, 2002, INT J OBESITY, V26, P504, DOI 10.1038/sj.ijo.0801952; Kazumi T, 2003, METABOLISM, V52, P1113, DOI 10.1016/S0026-0495(03)00184-7; Kostrubsky VE, 2000, DRUG METAB DISPOS, V28, P1192; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LENNIE TA, 1995, AM J PHYSIOL-REG I, V269, pR1024, DOI 10.1152/ajpregu.1995.269.5.R1024; Maachi M, 2004, INT J OBESITY, V28, P993, DOI 10.1038/sj.ijo.0802718; Mackintosh RM, 2001, OBES RES, V9, P462, DOI 10.1038/oby.2001.60; McCarthy DO, 2000, RES NURS HEALTH, V23, P222, DOI 10.1002/1098-240X(200006)23:3<222::AID-NUR6>3.0.CO;2-3; McConway MG, 2000, ANN CLIN BIOCHEM, V37, P717, DOI 10.1258/0004563001899771; Mistrik P, 2004, ANAL BIOCHEM, V327, P271, DOI 10.1016/j.ab.2004.01.022; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Pignatti P, 2003, CLIN EXP IMMUNOL, V131, P355, DOI 10.1046/j.1365-2249.2003.02052.x; Rais G, 2002, CLIN CHEM, V48, P591; Ridker PM, 2004, AM HEART J, V148, pS19, DOI 10.1016/j.ahj.2004.04.028; Schulze MB, 2004, DIABETES CARE, V27, P889, DOI 10.2337/diacare.27.4.889; Schwartz MW, 1997, DIABETES CARE, V20, P1476, DOI 10.2337/diacare.20.9.1476; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Shamsuzzaman ASM, 2004, CIRCULATION, V109, P2181, DOI 10.1161/01.CIR.0000127960.28627.75; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Szalai AJ, 2002, IMMUNOL RES, V26, P279, DOI 10.1385/IR:26:1-3:279; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TSENG J, 1988, MOL IMMUNOL, V25, P679, DOI 10.1016/0161-5890(88)90103-4; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; ZAHEDI K, 1991, INFLAMMATION, V15, P1, DOI 10.1007/BF00917905; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223	45	234	256	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					425	432		10.1038/nm1372	http://dx.doi.org/10.1038/nm1372			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16582918				2022-12-27	WOS:000236581300031
J	Ott, MG; Schmidt, M; Schwarzwaelder, K; Stein, S; Siler, U; Koehl, U; Glimm, H; Kuhlcke, K; Schilz, A; Kunkel, H; Naundorf, S; Brinkmann, A; Deichmann, A; Fischer, M; Ball, C; Pilz, I; Dunbar, C; Du, Y; Jenkins, NA; Copeland, NG; Luthi, U; Hassan, M; Thrasher, AJ; Hoelzer, D; von Kalle, C; Seger, R; Grez, M				Ott, MG; Schmidt, M; Schwarzwaelder, K; Stein, S; Siler, U; Koehl, U; Glimm, H; Kuhlcke, K; Schilz, A; Kunkel, H; Naundorf, S; Brinkmann, A; Deichmann, A; Fischer, M; Ball, C; Pilz, I; Dunbar, C; Du, Y; Jenkins, NA; Copeland, NG; Luthi, U; Hassan, M; Thrasher, AJ; Hoelzer, D; von Kalle, C; Seger, R; Grez, M			Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; NADPH OXIDASE ACTIVITY; ASPERGILLUS-FUMIGATUS; CD34(+) CELLS; HOST-DEFENSE; LIPOSOMAL BUSULFAN; CORD BLOOD; NEUTROPHILS; PHARMACOKINETICS; TRANSPLANTATION	Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid but not myeloid immunodeficiencies. Here we report on two adults who received gene therapy after nonmyeloablative bone marrow conditioning for the treatment of X-linked chronic granulomatous disease (X-CGD), a primary immunodeficiency caused by a defect in the oxidative antimicrobial activity of phagocytes resulting from mutations in gp91(phox). We detected substantial gene transfer in both individuals' neutrophils that lead to a large number of functionally corrected phagocytes and notable clinical improvement. Large-scale retroviral integration site-distribution analysis showed activating insertions in MDS1-EVI1, PRDM16 or SETBP1 that had influenced regulation of long-term hematopoiesis by expanding gene-corrected myelopoiesis three- to four-fold in both individuals. Although insertional influences have probably reinforced the therapeutic efficacy in this trial, our results suggest that gene therapy in combination with bone marrow conditioning can be successfully used to treat inherited diseases affecting the myeloid compartment such as CGD.	Inst Biomed Res, D-60596 Frankfurt, Germany; Univ Hosp, Dept Hematol Oncol, D-60590 Frankfurt, Germany; Univ Hosp, Dept Internal Med 1, D-79106 Freiburg, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; Univ Childrens Hosp, Div Hematol Immunol, CH-8032 Zurich, Switzerland; Univ Hosp, D-60590 Frankfurt, Germany; EUFETS AG, D-55743 Idar Oberstein, Germany; NHLBI, Hematol Branch, Bethesda, MD 20892 USA; NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; Univ Zurich, Cent Lab Electron Microscopy, CH-8006 Zurich, Switzerland; Karolinska Inst, Div Hematol, Dept Med, SE-17177 Stockholm, Sweden; Inst Child Hlth, Mol Immunol Unit, London WC1H 1EH, England; Cincinnati Childrens Res Fdn, Mol & Gene Therapy Program, Cincinnati, OH 45229 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Freiburg; University Children's Hospital Zurich; Goethe University Frankfurt; Goethe University Frankfurt Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zurich; Karolinska Institutet; University of London; University College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Grez, M (corresponding author), Inst Biomed Res, Georg Speyer Haus,Paul Ehrlich Str 42, D-60596 Frankfurt, Germany.	christof.kalle@nct-heidelberg.de; grez@em.uni-frankfurt.de	Hassan, Moustapha/H-9260-2015; Wilson, Matthew H/K-3193-2013	Hassan, Moustapha/0000-0003-1927-5859; Dunbar, Cynthia/0000-0002-7645-838X; Ball, Claudia/0000-0002-1749-3791; Koehl, Ulrike/0000-0002-8159-9160; Stein, Stefan/0000-0003-1473-9706; Siler, Ulrich/0000-0002-2458-2629; Thrasher, Adrian/0000-0002-6097-6115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002339, ZIAHL002339] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Barese CN, 2004, EXPERT OPIN BIOL TH, V4, P1423, DOI 10.1517/14712598.4.9.1423; Baum C, 2004, MOL THER, V9, P5, DOI 10.1016/j.ymthe.2003.10.013; BAUM C, 1995, J VIROL, V69, P7541, DOI 10.1128/JVI.69.12.7541-7547.1995; Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Buonamici S, 2003, BLOOD CELL MOL DIS, V31, P206, DOI 10.1016/S1079-9796(03)00159-1; Calmels B, 2005, BLOOD, V106, P2530, DOI 10.1182/blood-2005-03-1115; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dinauer MC, 1999, BLOOD, V94, P914, DOI 10.1182/blood.V94.3.914.415a11_914_922; Dinauer MC, 2001, BLOOD, V97, P3738, DOI 10.1182/blood.V97.12.3738; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Dunbar CE, 1998, HUM GENE THER, V9, P2629, DOI 10.1089/10430349850019463; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Glimm H, 2005, BLOOD, V106, P893, DOI 10.1182/blood-2004-07-2859; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; HAMERS MN, 1984, BLOOD, V64, P635, DOI 10.1182/blood.V64.3.635.635; Hassan M, 1998, CANCER CHEMOTH PHARM, V42, P471, DOI 10.1007/s002800050847; Hassan Z, 2001, BONE MARROW TRANSPL, V27, P479, DOI 10.1038/sj.bmt.1702823; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; JOHNSTON RB, 1985, J PEDIATR-US, V106, P50, DOI 10.1016/S0022-3476(85)80463-7; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Malech HL, 2004, JPN J INFECT DIS, V57, pS27; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MILLS EL, 1980, J CLIN INVEST, V66, P332, DOI 10.1172/JCI109861; REX JH, 1990, J INFECT DIS, V162, P523, DOI 10.1093/infdis/162.2.523; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; Rosen-Wolff A, 2001, ANN HEMATOL, V80, P113, DOI 10.1007/s002770000230; Sadat MA, 2003, HUM GENE THER, V14, P651, DOI 10.1089/104303403321618164; Schmidt M, 2003, NAT MED, V9, P463, DOI 10.1038/nm844; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Thrasher AJ, 2005, BLOOD, V105, P4255, DOI 10.1182/blood-2004-12-4837; von Kalle C, 2004, SEMIN HEMATOL, V41, P303, DOI 10.1053/j.seminhematol.2004.07.007; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Wolach B, 2005, BLOOD, V105, P61, DOI 10.1182/blood-2004-02-0675; Yamauchi A, 2001, MICROBIOL IMMUNOL, V45, P249, DOI 10.1111/j.1348-0421.2001.tb02614.x	47	874	909	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					401	409		10.1038/nm1393	http://dx.doi.org/10.1038/nm1393			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16582916				2022-12-27	WOS:000236581300028
J	Yanez-Munoz, RJ; Balaggan, KS; MacNeil, A; Howe, SJ; Schmidt, M; Smith, AJ; Buch, P; MacLaren, RE; Anderson, PN; Barker, SE; Duran, Y; Bartholomae, C; von Kalle, C; Heckenlively, JR; Kinnon, C; Ali, RR; Thrasher, AJ				Yanez-Munoz, RJ; Balaggan, KS; MacNeil, A; Howe, SJ; Schmidt, M; Smith, AJ; Buch, P; MacLaren, RE; Anderson, PN; Barker, SE; Duran, Y; Bartholomae, C; von Kalle, C; Heckenlively, JR; Kinnon, C; Ali, RR; Thrasher, AJ			Effective gene therapy with nonintegrating lentiviral vectors	NATURE MEDICINE			English	Article							RETINAL-PIGMENT EPITHELIUM; TYPE-1 INTEGRASE MUTANTS; RCS RAT MODEL; IN-VIVO; RETINITIS-PIGMENTOSA; STABLE TRANSDUCTION; NONDIVIDING CELLS; ADULT-RAT; EXPRESSION; DNA	Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis(1). This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction(4-6). With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.	Inst Canc Res, Ctr Med Oncol, London EC1M 6BQ, England; Barts & London Queen Marys Sch Med & Dent, Ctr Clin, John Vane Sci Ctr, London EC1M 6BQ, England; UCL, Inst Ophthalmol, Div Mol Therapy, London EC1V 9EL, England; Univ Hosp Freiburg, Dept Internal Med 1, D-79106 Freiburg, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Cincinnati Childrens Res Fdn, Mol & Gene Therapy Program, Cincinnati, OH 45229 USA; Kellogg Eye Ctr, Ann Arbor, MI 48105 USA; Hosp Sick Children, Dept Immunol, Great Ormond St Hosp Children NHS Trust, London WC1N 3JH, England; UCL, Inst Child Hlth, Mol Immunol Unit, London WC1N 1EH, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Queen Mary University London; University of London; University College London; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of London; University College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Yanez-Munoz, RJ (corresponding author), Guys Hosp, Kings Coll London Sch Med, Nucl Biol Grp, Dept Med & Mol Genet, London SE1 9RT, England.	rafael.yanez@genetics.kcl.ac.uk; r.ali@ucl.ac.uk	Kinnon, Christine/A-1585-2010; Smith, Alexander/A-5142-2009; Howe, Steven J/C-4801-2008	Howe, Steven J/0000-0003-2940-2874; MacLaren, Robert/0000-0002-3096-4682; Thrasher, Adrian/0000-0002-6097-6115; Yanez-Munoz, Rafael J/0000-0001-7113-1938; Ali, Robin/0000-0003-3126-6517	Medical Research Council [G0601588] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abordo-Adesida E, 2005, HUM GENE THER, V16, P741, DOI 10.1089/hum.2005.16.741; Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bemelmans AP, 2005, J GENE MED, V7, P1367, DOI 10.1002/jgm.788; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988; Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Gruter O, 2005, GENE THER, V12, P942, DOI 10.1038/sj.gt.3302485; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; HSU TW, 1978, J VIROL, V28, P810, DOI 10.1128/JVI.28.3.810-818.1978; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Loewen N, 2003, J GENE MED, V5, P1009, DOI 10.1002/jgm.447; Lu R, 2004, J VIROL, V78, P658, DOI 10.1128/JVI.78.2.658-668.2004; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pang JJ, 2005, MOL VIS, V11, P152; Park F, 2000, BLOOD, V96, P1173, DOI 10.1182/blood.V96.3.1173.015k34_1173_1176; Pierson TC, 2002, J VIROL, V76, P4138, DOI 10.1128/JVI.76.8.4138-4144.2002; Saenz DT, 2004, J VIROL, V78, P2906, DOI 10.1128/JVI.78.6.2906-2920.2004; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; SHANK PR, 1978, CELL, V15, P1383, DOI 10.1016/0092-8674(78)90063-6; Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8; Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460; Vargas J, 2004, HUM GENE THER, V15, P361, DOI 10.1089/104303404322959515	30	351	374	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					348	353		10.1038/nm1365	http://dx.doi.org/10.1038/nm1365			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491086				2022-12-27	WOS:000235802900036
J	Mandavilli, A				Mandavilli, A			Dominique Toran-Allerand	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2005	11	10					1022	1022		10.1038/nm1005-1022	http://dx.doi.org/10.1038/nm1005-1022			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211025	Bronze			2022-12-27	WOS:000232492500011
J	Bins, AD; Jorritsma, A; Wolkers, MC; Hung, CF; Wu, TC; Schumacher, TNM; Haanen, JBAG				Bins, AD; Jorritsma, A; Wolkers, MC; Hung, CF; Wu, TC; Schumacher, TNM; Haanen, JBAG			A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression	NATURE MEDICINE			English	Article							CYTOTOXIC T-CELLS; INFLUENZA-VIRUS; TUMOR-ANTIGEN; GENE-TRANSFER; CLASS-II; MICE; INFECTION; RESPONSES; HEMAGGLUTININ; ACTIVATION	Induction of immunity after DNA vaccination is generally considered a slow process. Here we show that DNA delivery to the skin results in a highly transient pulse of antigen expression. Based on this information, we developed a new rapid and potent intradermal DNA vaccination method. By short-interval intradermal DNA delivery, robust T-cell responses, of a magnitude sufficient to reject established subcutaneous tumors, are generated within 12 d. Moreover, this vaccination strategy confers protecting humoral immunity against influenza A infection within 2 weeks after the start of vaccination. The strength and speed of this newly developed strategy will be beneficial in situations in which immunity is required in the shortest possible time.	Netherlands Canc Inst, Dept Immunol, NL-1066 CX Amsterdam, Netherlands; Johns Hopkins Univ, Sch Med, Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	Netherlands Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine	Haanen, JBAG (corresponding author), Netherlands Canc Inst, Dept Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.haanen@nki.nl	Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022	Schumacher, Ton/0000-0003-0517-8804; Haanen, John/0000-0001-5884-7704; Bins, Adriaan/0000-0002-9794-6526; Wolkers, Monika/0000-0003-3242-1363				Cappello P, 2003, CANCER RES, V63, P2518; Chen CH, 2000, CANCER RES, V60, P1035; Ciernik IF, 1996, HUM GENE THER, V7, P893, DOI 10.1089/hum.1996.7.8-893; De Marco F, 2003, ANTICANCER RES, V23, P1449; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; EPSTEIN SL, 1993, J IMMUNOL, V150, P5484; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Kalat M, 2002, CANCER RES, V62, P5489; Kirman JR, 2003, INFECT IMMUN, V71, P575, DOI 10.1128/IAI.71.1.575-579.2003; Lin KY, 1996, CANCER RES, V56, P21; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Rice J, 2002, J IMMUNOL, V169, P3908, DOI 10.4049/jimmunol.169.7.3908; SCHERLE PA, 1992, J IMMUNOL, V148, P212; Smerdou C, 1999, CURR OPIN MOL THER, V1, P244; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VIRELIZIER JL, 1975, J IMMUNOL, V115, P434; Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Wolkers MC, 2002, J IMMUNOL, V168, P4998, DOI 10.4049/jimmunol.168.10.4998; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463	26	134	153	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					899	904		10.1038/nm1264	http://dx.doi.org/10.1038/nm1264			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	15965482	Bronze			2022-12-27	WOS:000230964700037
J	Guan, YF; Hao, CM; Cha, DR; Rao, R; Lu, WD; Kohan, DE; Magnuson, MA; Redha, R; Zhang, YH; Breyer, MD				Guan, YF; Hao, CM; Cha, DR; Rao, R; Lu, WD; Kohan, DE; Magnuson, MA; Redha, R; Zhang, YH; Breyer, MD			Thiazolidinediones expand body fluid volume through PPAR gamma stimulation of ENaC-mediated renal salt absorption	NATURE MEDICINE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; TRANSGENIC MICE; COLLECTING DUCT; HEART-FAILURE; IN-VIVO; EXPRESSION; CHANNEL; INSULIN; GENE; ROSIGLITAZONE	Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-gamma (PPAR gamma, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Pparg(flox/flox) mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaC gamma) expression through a PPAR gamma-dependent pathway. These studies identify Scnn1g as a PPAR gamma target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, MCN S3223, Nashville, TN 37232 USA; Univ Utah, Sch Med, Dept Nephrol, Med Ctr, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Breyer, MD (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, 21st Ave S Garland Ave, Nashville, TN 37232 USA.	matthew.breyer@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097, R01DK065074, U24DK059637, P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37097, DK38226, DK59637, R01 DK65074-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakawa K, 1998, BRIT J PHARMACOL, V125, P429, DOI 10.1038/sj.bjp.0702066; Ave P, 1997, TRANSGENIC RES, V6, P37, DOI 10.1023/A:1018401015497; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Friedrich B, 2003, PFLUG ARCH EUR J PHY, V445, P693, DOI 10.1007/s00424-002-0993-8; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; HERRING SW, 1982, J BIOL CHEM, V257, P4882; Hong GZ, 2003, FASEB J, V17, P1966, DOI 10.1096/fj.03-0181fje; Hummler E, 2003, CURR HYPERTENS REP, V5, P11, DOI 10.1007/s11906-003-0005-1; Hummler E, 2002, GENESIS, V32, P169, DOI 10.1002/gene.10041; Jones JR, 2002, GENESIS, V32, P134, DOI 10.1002/gene.10042; King KA, 2004, AM J HEALTH-SYST PH, V61, P390, DOI 10.1093/ajhp/61.4.390; Kleyman TR, 1999, SEMIN NEPHROL, V19, P524; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC447, DOI 10.1152/ajpcell.00385.2002; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Mudaliar Sunder, 2003, Endocr Pract, V9, P406; Nelson RD, 1998, AM J PHYSIOL-CELL PH, V275, pC216, DOI 10.1152/ajpcell.1998.275.1.C216; Nesto R, 2004, DIABETIC MED, V21, P810, DOI 10.1111/j.1464-5491.2004.01296.x; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Page RLP, 2003, PHARMACOTHERAPY, V23, P945, DOI 10.1592/phco.23.7.945.32721; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Schafer JA, 2002, AM J PHYSIOL-RENAL, V283, pF221, DOI 10.1152/ajprenal.00068.2002; Schreyer SA, 2003, ATHEROSCLEROSIS, V171, P49, DOI 10.1016/j.atherosclerosis.2003.07.010; Song J, 2004, J PHARMACOL EXP THER, V308, P426, DOI 10.1124/jpet.103.058008; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; Stricklett PK, 1999, EXP NEPHROL, V7, P67; Suzuki Jun, 2004, Nihon Yakurigaku Zasshi, V123, P281; Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; Volk KA, 2005, J BIOL CHEM, V280, P18348, DOI 10.1074/jbc.M413689200; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Weisz OA, 2003, AM J PHYSIOL-RENAL, V285, pF833, DOI 10.1152/ajprenal.00088.2003; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	39	462	489	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					861	866		10.1038/nm1278	http://dx.doi.org/10.1038/nm1278			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16007095				2022-12-27	WOS:000230964700031
J	Kuba, K; Imai, Y; Rao, SA; Gao, H; Guo, F; Guan, B; Huan, Y; Yang, P; Zhang, YL; Deng, W; Bao, LL; Zhang, BL; Liu, G; Wang, Z; Chappell, M; Liu, YX; Zheng, DX; Leibbrandt, A; Wada, T; Slutsky, AS; Liu, DP; Qin, CA; Jiang, CY; Penninger, JM				Kuba, K; Imai, Y; Rao, SA; Gao, H; Guo, F; Guan, B; Huan, Y; Yang, P; Zhang, YL; Deng, W; Bao, LL; Zhang, BL; Liu, G; Wang, Z; Chappell, M; Liu, YX; Zheng, DX; Leibbrandt, A; Wada, T; Slutsky, AS; Liu, DP; Qin, CA; Jiang, CY; Penninger, JM			A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; HONG-KONG; CARBOXYPEPTIDASE; IDENTIFICATION; REPLICATION; EXPRESSION; RECEPTOR; CLONING; MICE	During several months of 2003, a newly identified illness termed severe acute respiratory syndrome (SARS) spread rapidly through the world(1-3). A new coronavirus (SARS-CoV) was identified as the SARS pathogen(4-7) which triggered severe pneumonia and acute, often lethal, lung failure(8). Moreover, among infected individuals influenza such as the Spanish flu(9,10) and the emergence of new respiratory disease viruses(11,12) have caused high lethality resulting from acute lung failure(13). In cell lines, angiotensin-converting enzyme 2 (ACE2) has been identified as a potential SARS-CoV receptor(14). The high lethality of SARS-CoV infections, its enormous economic and social impact, fears of renewed outbreaks as well as the potential misuse of such viruses as biologic weapons make it paramount to understand the pathogenesis of SARS-CoV. Here we provide the first genetic proof that ACE2 is a crucial SARS-CoV receptor in vivo. SARS-CoV infections and the Spike protein of the SARS-CoV reduce ACE2 expression. Notably, injection of SARS-CoV Spike into mice worsens acute lung failure in vivo that can be attenuated by blocking the renin-angiotensin pathway. These results provide a molecular explanation why SARS-CoV infections cause severe and often lethal lung failure and suggest a rational therapy for SARS and possibly other respiratory disease viruses.	Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, Beijing 100005, Peoples R China; Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100005, Peoples R China; Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Wake Forest Univ, Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Interdept Div Crit Care, Toronto, ON M5B 1W8, Canada	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Wake Forest University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Jiang, CY (corresponding author), Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, 5 Dongdan Santiao, Beijing 100005, Peoples R China.	jiang@pumc.edu	Liu, Geoffrey/N-4421-2016; Slutsky, Arthur S/A-6013-2008; Imai, Yumiko/GXW-1144-2022; Rao, Shuan/V-3653-2019; Slutsky, Arthur/M-3325-2019; Penninger, Josef/I-6860-2013	Slutsky, Arthur S/0000-0002-6063-3876; Rao, Shuan/0000-0002-5268-7006; Zheng, Dexian/0000-0003-3966-1212; Penninger, Josef/0000-0002-8194-3777; Guo, Feng/0000-0002-4506-7618				CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Imai Y, 2001, J APPL PHYSIOL, V91, P1836, DOI 10.1152/jappl.2001.91.4.1836; IMAI Y, IN PRESS NATURE; INAGAMI T, 1995, ADV EXP MED BIOL, V377, P311; Itoyama S, 2004, BIOCHEM BIOPH RES CO, V323, P1124, DOI 10.1016/j.bbrc.2004.08.208; JEFFERS SA, 2004, P NATL ACAD SCI USA, V20, P20; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; MYINT SH, 1994, REV MED VIROL, V4, P35, DOI 10.1002/rmv.1980040108; Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;119::AID-RMV272&gt;3.0.CO;2-O; Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; *SARS EP WORK GROU, 2003, WHO CONS DOC EP SEV; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; *WHO, 2004, CONF HUM CAS AV INFL; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; Zou Ke, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P495	30	2183	2326	13	133	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					875	879		10.1038/nm1267	http://dx.doi.org/10.1038/nm1267			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16007097	Bronze, Green Published			2022-12-27	WOS:000230964700033
J	Kroemer, G; Martin, SJ				Kroemer, G; Martin, SJ			Caspase-independent cell death	NATURE MEDICINE			English	Review							APOPTOSIS-INDUCING FACTOR; TUMOR-NECROSIS-FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; CATHEPSIN-B; OMI/HTRA2 PROTEASE; BH3-ONLY PROTEINS; IMMUNE-SYSTEM; CYTOCHROME-C; IN-VIVO; ACTIVATION	Caspase activation has been frequently viewed as synonymous with apoptotic cell death; however, caspases can also contribute to processes that do not culminate in cell demise. Moreover, inhibition of caspases can have cytoprotective effects. In a number of different models, caspase inhibition does not maintain cellular viability and instead shifts the morphology of death from apoptosis to nonapoptotic pathways. Here, we explore the contribution of caspases to cell death, either as upstream signals or as downstream effectors contributing to apoptotic morphology, as well as alternative strategies for cell death inhibition. Such alternative strategies may either target catabolic hydrolases or be aimed at preventing mitochondrial membrane permeabilization and its upstream triggers.	Inst Gustave Roussy, UMR8125, CNRS, F-94805 Villejuif, France; Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Trinity College Dublin	Kroemer, G (corresponding author), Inst Gustave Roussy, UMR8125, CNRS, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405; Martin, Seamus/0000-0002-8539-3143				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Benchoua A, 2004, J CEREBR BLOOD F MET, V24, P1272, DOI 10.1097/01.WCB.0000140272.54583.FB; Black S, 2004, CELL DEATH DIFFER, V11, P90, DOI 10.1038/sj.cdd.4401307; Boyce M, 2004, CELL DEATH DIFFER, V11, P29, DOI 10.1038/sj.cdd.4401339; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Cilenti L, 2005, AM J PHYSIOL-RENAL, V288, pF371, DOI 10.1152/ajprenal.00154.2004; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fukuda H, 2004, CELL DEATH DIFFER, V11, P1166, DOI 10.1038/sj.cdd.4401472; Garnier P, 2003, J NEUROSCI, V23, P7967; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KROEMER G, 2005, IN PRESS CELL DEATH; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liu HR, 2005, CIRCULATION, V111, P90, DOI 10.1161/01.CIR.0000151613.90994.17; Liu N, 2004, NAT IMMUNOL, V5, P919, DOI 10.1038/ni1107; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; MATSUMORI Y, 2005, J CEREB BLOOD FLOW M; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; McLaughlin B, 2004, APOPTOSIS, V9, P111, DOI 10.1023/B:APPT.0000018793.10779.dc; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Muntener K, 2004, J BIOL CHEM, V279, P41012, DOI 10.1074/jbc.M405333200; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nussbaum AK, 2004, J IMMUNOL, V173, P6611, DOI 10.4049/jimmunol.173.11.6611; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Rustin P, 2003, EXPERT OPIN INV DRUG, V12, P569, DOI 10.1517/eoid.12.4.569.23756; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stavrovskaya IG, 2004, J EXP MED, V200, P211, DOI 10.1084/jem.20032053; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang BL, 2004, CHINESE J ORG CHEM, V24, P973; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhivotovsky B, 2003, ESSAYS BIOCHEM, V39, P25, DOI 10.1042/bse0390025; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	84	548	577	1	36	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2005	11	7					725	730		10.1038/nm1263	http://dx.doi.org/10.1038/nm1263			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	16015365				2022-12-27	WOS:000230304200028
J	Lechler, RI; Sykes, M; Thomson, AW; Turka, LA				Lechler, RI; Sykes, M; Thomson, AW; Turka, LA			Organ transplantation - how much of the promise has been realized?	NATURE MEDICINE			English	Review							T-CELL-ACTIVATION; RENAL-ALLOGRAFT REJECTION; DONOR BONE-MARROW; LONG-TERM ACCEPTANCE; MONOCLONAL-ANTIBODY; MIXED CHIMERISM; DENDRITIC CELLS; B-CELLS; LYMPHOHEMATOPOIETIC CHIMERISM; INDOLEAMINE 2,3-DIOXYGENASE	Since the introduction of organ transplantation into medical practice, progress and optimism have been abundant. Improvements in immunosuppressive drugs and ancillary care have led to outstanding short-term ( 1 - 3-year) patient and graft survival rates. This success is mitigated by several problems, including poor long-term (> 5-year) graft survival rates, the need for continual immunosuppressive medication and the discrepancy between the demand for organs and the supply. Developing methods to induce transplant tolerance, as a means to improve graft outcomes and eliminate the requirement for immunosuppression, and expanding the pool of organs for transplantation are the major challenges of the field.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Kings Coll London, Guys Kings & St Thomass Med Sch, London SE1 9RT, England; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02129 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA	University of Pennsylvania; University of London; King's College London; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Turka, LA (corresponding author), Univ Penn, Dept Med, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	turka@mail.med.upenn.edu						Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Armstrong N, 1998, TRANSPLANTATION, V66, P5, DOI 10.1097/00007890-199807150-00002; BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; Cascalho M, 2001, IMMUNITY, V14, P437, DOI 10.1016/S1074-7613(01)00124-8; Cecka J Michael, 2002, Clin Transpl, P1; Dai ZH, 1998, J IMMUNOL, V161, P1659; Durham MM, 2000, J IMMUNOL, V165, P1, DOI 10.4049/jimmunol.165.1.1; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Fan XH, 2004, NAT MED, V10, P1227, DOI 10.1038/nm1126; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Ge Q, 2002, P NATL ACAD SCI USA, V99, P2989, DOI 10.1073/pnas.052714099; Gloor JM, 2003, AM J TRANSPLANT, V3, P1017, DOI 10.1034/j.1600-6143.2003.00180.x; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; Gudmundsdottir H, 2001, J IMMUNOL, V167, P3699, DOI 10.4049/jimmunol.167.7.3699; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; Harper Ann M, 2002, Clin Transpl, P79; Heeger PS, 1999, J IMMUNOL, V163, P2267; Holcombe H, 2002, J IMMUNOL, V169, P4982, DOI 10.4049/jimmunol.169.9.4982; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kawai T, 1999, TRANSPLANTATION, V68, P1767, DOI 10.1097/00007890-199912150-00022; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 2003, TRANSPLANTATION, V76, P120, DOI 10.1097/01.TP.0000071362.99021.D9; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; KIRK AD, 2002, AM J TRANSPL S3, V2, P379; Knechtle SJ, 2004, SURGERY, V136, P754, DOI 10.1016/j.surg.2004.06.015; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kurtz J, 2004, BLOOD, V103, P4336, DOI 10.1182/blood-2003-08-2642; Kuwaki K, 2005, NAT MED, V11, P29, DOI 10.1038/nm1171; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Levisetti MG, 1997, J IMMUNOL, V159, P5187; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LOMBARDI G, 1990, INT IMMUNOL, V2, P9, DOI 10.1093/intimm/2.1.9; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; Medawar PB, 1944, J ANAT, V78, P176; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P1289, DOI 10.1111/j.1600-6143.2004.00515.x; Merrill John P, 1955, SURG FORUM, V6, P432; Mirenda V, 2004, J AM SOC NEPHROL, V15, P987, DOI 10.1097/01.ASN.0000119575.98696.1D; Montgomery SP, 2002, TRANSPLANTATION, V74, P1365, DOI 10.1097/00007890-200211270-00002; MOSES RD, 1989, TRANSPLANTATION, V48, P769, DOI 10.1097/00007890-198911000-00009; Munn DH, 2004, J IMMUNOL, V172, P4100, DOI 10.4049/jimmunol.172.7.4100; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733; Ohdan H, 2001, XENOTRANSPLANTATION, V8, P227, DOI 10.1034/j.1399-3089.2001.00006.x; Oike F, 2002, TRANSPLANT P, V34, P1521, DOI 10.1016/S0041-1345(02)02980-9; OPELZ G, 1985, TRANSPLANTATION, V40, P240, DOI 10.1097/00007890-198509000-00003; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; Ozkaynak E, 2002, J IMMUNOL, V169, P6546, DOI 10.4049/jimmunol.169.11.6546; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Pearl JP, 2005, AM J TRANSPLANT, V5, P465, DOI 10.1111/j.1600-6143.2005.00759.x; PEARSON TC, 1992, TRANSPLANTATION, V54, P475, DOI 10.1097/00007890-199209000-00018; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Rothstein DM, 2003, IMMUNOL REV, V196, P85, DOI 10.1046/j.1600-065X.2003.00088.x; Russell PS, 2001, J IMMUNOL, V167, P5731, DOI 10.4049/jimmunol.167.10.5731; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Scobie L, 2004, J VIROL, V78, P2502, DOI 10.1128/JVI.78.5.2502-2509.2004; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Starzl TE, 2003, LANCET, V361, P1502, DOI 10.1016/S0140-6736(03)13175-3; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007; Tryphonopoulos P, 2005, AM J TRANSPLANT, V5, P608, DOI 10.1111/j.1600-6143.2004.00743.x; Waldmann H, 2001, IMMUNITY, V14, P399, DOI 10.1016/S1074-7613(01)00120-0; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Yamada K, 2005, NAT MED, V11, P32, DOI 10.1038/nm1172; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335; Zheng XX, 2003, IMMUNITY, V19, P503, DOI 10.1016/S1074-7613(03)00259-0	90	293	311	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					605	613		10.1038/nm1251	http://dx.doi.org/10.1038/nm1251			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15937473				2022-12-27	WOS:000229589800026
J	Munoz-Elias, EJ; McKinney, JD				Munoz-Elias, EJ; McKinney, JD			Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence	NATURE MEDICINE			English	Article							ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; GLYOXYLATE CYCLE; PYRUVATE-KINASE; GENE-EXPRESSION; PATHOGENICITY; MACROPHAGES; PERSISTENCE; BOVIS; MICE	Genes involved in fatty acid catabolism have undergone extensive duplication in the genus Mycobacterium, which includes the etiologic agents of leprosy and tuberculosis. Here, we show that prokaryotic- and eukaryotic-like isoforms of the glyoxylate cycle enzyme isocitrate lyase (ICL) are jointly required for fatty acid catabolism and virulence in Mycobacterium tuberculosis. Although deletion of icl1 or icl2, the genes that encode ICL1 and ICL2, respectively, had little effect on bacterial growth in macrophages and mice, deletion of both genes resulted in complete impairment of intracellular replication and rapid elimination from the lungs. The feasibility of targeting ICL1 and ICL2 for chemical inhibition was shown using a dual-specific ICL inhibitor, which blocked growth of M. tuberculosis on fatty acids and in macrophages. The absence of ICL orthologs in mammals should facilitate the development of glyoxylate cycle inhibitors as new drugs for the treatment of tuberculosis.	Rockefeller Univ, Lab Infect Biol, New York, NY 10021 USA	Rockefeller University	McKinney, JD (corresponding author), Rockefeller Univ, Lab Infect Biol, 1230 York Ave, New York, NY 10021 USA.	mckinney@rockefeller.edu			NIAID NIH HHS [P01 AI046392-050001, AI 46392] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046392] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bentrup KHZ, 1999, J BACTERIOL, V181, P7161; Blokpoel MCJ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni023; Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065; Britton KL, 2000, STRUCTURE, V8, P349, DOI 10.1016/S0969-2126(00)00117-9; Chang DE, 2004, P NATL ACAD SCI USA, V101, P7427, DOI 10.1073/pnas.0307888101; Charpentier E, 2000, MICROBES INFECT, V2, P1855, DOI 10.1016/S1286-4579(00)01345-9; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Claes WA, 2002, J BACTERIOL, V184, P2728, DOI 10.1128/JB.184.10.2728-2739.2002; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Collins DM, 2002, MICROBIOL-SGM, V148, P3019, DOI 10.1099/00221287-148-10-3019; Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Fischer E, 2003, J BIOL CHEM, V278, P46446, DOI 10.1074/jbc.M307968200; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003; Idnurm A, 2002, EUKARYOT CELL, V1, P719, DOI 10.1128/EC.1.5.719-724.2002; Keating LA, 2005, MOL MICROBIOL, V56, P163, DOI 10.1111/j.1365-2958.2005.04524.x; KONDO E, 1976, JPN J MED SCI BIOL, V29, P109, DOI 10.7883/yoken1952.29.109; KORNBERG HL, 1957, NATURE, V179, P988, DOI 10.1038/179988a0; Liu KY, 2003, MICROBIOL-SGM, V149, P1829, DOI 10.1099/mic.0.26234-0; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Luttik MAH, 2000, J BACTERIOL, V182, P7007, DOI 10.1128/JB.182.24.7007-7013.2000; McDERMOTT WALSH, 1958, YALE JOUR BIOL AND MED, V30, P257; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Nishino H, 1997, NEUROSCI RES, V27, P343, DOI 10.1016/S0168-0102(97)01170-X; Pavelka MS, 1999, J BACTERIOL, V181, P4780, DOI 10.1128/JB.181.16.4780-4789.1999; PERTIERRA AG, 1977, J BACTERIOL, V129, P1208, DOI 10.1128/JB.129.3.1208-1214.1977; Peters-Wendisch PG, 1998, MICROBIOL-UK, V144, P915, DOI 10.1099/00221287-144-4-915; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RANES MG, 1990, J BACTERIOL, V172, P2793, DOI 10.1128/jb.172.5.2793-2797.1990; Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; SEGAL W, 1956, J BACTERIOL, V72, P132, DOI 10.1128/JB.72.2.132-141.1956; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; Smith H, 2000, PHILOS T R SOC B, V355, P551, DOI 10.1098/rstb.2000.0597; Solomon PS, 2004, MOL MICROBIOL, V53, P1065, DOI 10.1111/j.1365-2958.2004.04178.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TABUCHI T, 1975, AGR BIOL CHEM TOKYO, V39, P2035, DOI 10.1080/00021369.1975.10861896; Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100; VANNI P, 1970, COMP BIOCH PHYSL, V958, P431; Vereecke D, 2002, J BACTERIOL, V184, P1112, DOI 10.1128/jb.184.4.1112-1120.2002; Wang ZY, 2003, MOL MICROBIOL, V47, P1601, DOI 10.1046/j.1365-2958.2003.03412.x; Wendisch VF, 2000, J BACTERIOL, V182, P3088, DOI 10.1128/JB.182.11.3088-3096.2000	48	550	576	2	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					638	644		10.1038/nm1252	http://dx.doi.org/10.1038/nm1252			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895072	Green Accepted			2022-12-27	WOS:000229589800030
J	Kerschensteiner, M; Schwab, ME; Lichtman, JW; Misgeld, T				Kerschensteiner, M; Schwab, ME; Lichtman, JW; Misgeld, T			In vivo imaging of axonal degeneration and regeneration in the injured spinal cord	NATURE MEDICINE			English	Article							WALLERIAN DEGENERATION; TRANSGENIC MICE; SYSTEM; LESION; RAT	The poor response of central axons to transection underlies the bleak prognosis following spinal cord injury. Here, we monitor individual fluorescent axons in the spinal cords of living transgenic mice over several days after spinal injury. We find that within 30 min after trauma, axons die back hundreds of micrometers. This acute form of axonal degeneration is similar in mechanism to the more delayed Wallerian degeneration of the disconnected distal axon, but acute degeneration affects the proximal and distal axon ends equally. In vivo imaging further shows that many axons attempt regeneration within 6-24 h after lesion. This growth response, although robust, seems to fail as a result of the inability of axons to navigate in the proper direction. These results suggest that time-lapse imaging of spinal cord injury may provide a powerful analytical tool for assessing the pathogenesis of spinal cord injury and for evaluating therapies that enhance regeneration.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; ETH, Dept Biol, Brain Res Inst, Dept Neuromorphol, CH-8057 Zurich, Switzerland; Univ Zurich, CH-8057 Zurich, Switzerland	Harvard University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Misgeld, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	tmisgeld@mcb.harvard.edu	Schwab, Martin E/B-6818-2016					Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; CAJAL SRY, 1991, DEGENERATION REGENER, pCH4; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FIRKINS SS, 1993, EXP NEUROL, V120, P1, DOI 10.1006/exnr.1993.1036; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Houle JD, 2001, EXP NEUROL, V169, P208, DOI 10.1006/exnr.2001.7645; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Nguyen QT, 2002, NAT NEUROSCI, V5, P861, DOI 10.1038/nn905; Pan YA, 2003, J NEUROSCI, V23, P11479; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Steward O, 2003, J COMP NEUROL, V459, P1, DOI 10.1002/cne.10593; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Walsh MK, 2003, NEURON, V37, P67, DOI 10.1016/S0896-6273(02)01142-X; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	23	408	420	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					572	577		10.1038/nm1229	http://dx.doi.org/10.1038/nm1229			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15821747				2022-12-27	WOS:000228915000032
J	Takayama, K; Yuhki, K; Ono, K; Fujino, T; Hara, A; Yamada, T; Kuriyama, S; Karibe, H; Okada, Y; Takahata, O; Taniguchi, T; Iijima, T; Iwasaki, H; Narumiya, S; Ushikubi, F				Takayama, K; Yuhki, K; Ono, K; Fujino, T; Hara, A; Yamada, T; Kuriyama, S; Karibe, H; Okada, Y; Takahata, O; Taniguchi, T; Iijima, T; Iwasaki, H; Narumiya, S; Ushikubi, F			Thromboxane A(2) and prostaglandin F-2 alpha mediate inflammatory tachycardia	NATURE MEDICINE			English	Article							MICE LACKING; ENDOTOXIN; FAILURE	Systemic inflammation induces various adaptive responses including tachycardia. Although inflammation-associated tachycardia has been thought to result from increased sympathetic discharge caused by inflammatory signals of the immune system(1), definitive proof has been lacking. Prostanoids, including prostaglandin (PG) D-2, PGE(2), PGF(2 alpha), PGI(2) and thromboxane (TX) A(2), exert their actions through specific receptors: DP, EP (EP1, EP2, EP3, EP4), FP, IP and TP, respectively(2). Here we have examined the roles of prostanoids in inflammatory tachycardia using mice that lack each of these receptors individually. The TXA(2) analog I-BOP and PGF(2 alpha) each increased the beating rate of the isolated atrium of wild-type mice in vitro through interaction with TP and FP receptors, respectively. The cytokine- induced increase in beating rate was markedly inhibited in atria from mice lacking either TP or FP receptors. The tachycardia induced in wild-type mice by injection of lipopolysaccharide (LPS) was greatly attenuated in TP-deficient or FP-deficient mice and was completely absent in mice lacking both TP and FP. The beta-blocker propranolol did not block the LPS-induced increase in heart rate in wildtype animals. Our results show that inflammatory tachycardia is caused by a direct action on the heart of TXA(2) and PGF(2 alpha) formed under systemic inflammatory conditions.	Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Anesthesiol, Asahikawa, Hokkaido 0788510, Japan; Akita Univ, Sch Med, Dept Pharmacol, Akita 0108543, Japan; Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Asahikawa Medical College; Asahikawa Medical College; Akita University; Asahikawa Medical College; Kyoto University	Ushikubi, F (corresponding author), Asahikawa Med Coll, Dept Pharmacol, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	ushikubi@asahikawa-med.ac.jp	Yamada, Takehiro/A-5201-2012; Yamada, Takehiro/GVS-0279-2022					Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Court O, 2002, CRIT CARE, V6, P500, DOI 10.1186/cc1822; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Verheijck EE, 2001, CARDIOVASC RES, V52, P40, DOI 10.1016/S0008-6363(01)00364-9; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058	21	115	120	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					562	566		10.1038/nm1231	http://dx.doi.org/10.1038/nm1231			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834430	Green Submitted			2022-12-27	WOS:000228915000030
J	Goldstein, JL				Goldstein, Joseph L.			Creation and revelation: two different routes to advancement in the biomedical sciences	NATURE MEDICINE			English	Editorial Material																			0	6	7	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1151	1154		10.1038/nm1642	http://dx.doi.org/10.1038/nm1642			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17917663				2022-12-27	WOS:000249980200027
J	Vogl, T; Tenbrock, K; Ludwig, S; Leukert, N; Ehrhardt, C; van Zoelen, MAD; Nacken, W; Foell, D; van der Poll, T; Sorg, C; Roth, J				Vogl, Thomas; Tenbrock, Klaus; Ludwig, Stephan; Leukert, Nadja; Ehrhardt, Christina; van Zoelen, Marieke A. D.; Nacken, Wolfgang; Foell, Dirk; van der Poll, Tom; Sorg, Clemens; Roth, Johannes			Mrp8 and Mrp14 are endogenous activators of Toll- like receptor 4, promoting lethal, endotoxin-induced shock	NATURE MEDICINE			English	Article							CALCIUM-BINDING PROTEINS; SEVERE SEPSIS; GENE-EXPRESSION; S100 PROTEINS; RECEPTOR; INNATE; MIGRATION; ALPHA; RESPONSIVENESS; PHAGOCYTES	To identify new components that regulate the inflammatory cascade during sepsis, we characterized the functions of myeloidrelated protein-8 (Mrp8, S100A8) and myeloid-related protein-14 (Mrp14, S100A9), two abundant cytoplasmic proteins of phagocytes. We now demonstrate that mice lacking Mrp8-Mrp14 complexes are protected from endotoxin-induced lethal shock and Escherichia coli-induced abdominal sepsis. Both proteins are released during activation of phagocytes, and Mrp8-Mrp14 complexes amplify the endotoxin-triggered inflammatory responses of phagocytes. Mrp8 is the active component that induces intracellular translocation of myeloid differentiation primary response protein 88 and activation of interleukin-1 receptor-associated kinase-1 and nuclear factor-kappa B, resulting in elevated expression of tumor necrosis factor-alpha (TNF-alpha). Using phagocytes expressing a nonfunctional Toll- like receptor 4 (TLR4), HEK293 cells transfected with TLR4, CD14 and MD2, and by surface plasmon resonance studies in vitro, we demonstrate that Mrp8 specifically interacts with the TLR4-MD2 complex, thus representing an endogenous ligand of TLR4. Therefore Mrp8-Mrp14 complexes are new inflammatory components that amplify phagocyte activation during sepsis upstream of TNF alpha-dependent effects.	Univ Munster, Inst Expt Dermatol, D-48129 Munster, Germany; Univ Munster, Interdisciplinary Ctr Clin Res, D-48129 Munster, Germany; Univ Munster, Dept Pediat, D-48129 Munster, Germany; Univ Munster, Inst Mol Virol, D-48129 Munster, Germany; Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun, NL-1105 AZ Amsterdam, Netherlands	University of Munster; University of Munster; University of Munster; University of Munster; University of Amsterdam; Academic Medical Center Amsterdam	Roth, J (corresponding author), Univ Munster, Inst Expt Dermatol, D-48129 Munster, Germany.	rothj@uni-muenster.de		Ludwig, Stephan/0000-0003-4490-3052				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427; Brandl K, 2005, J ENDOTOXIN RES, V11, P197, DOI 10.1179/096805105X58670; Clark MA, 1998, CRIT CARE MED, V26, P1650, DOI 10.1097/00003246-199810000-00016; Corr M, 2005, ARTHRITIS RHEUM, V52, P2233, DOI 10.1002/art.21214; Ehrhardt C., 2006, SIGNAL TRANSDUCT BAN, V6, P179, DOI [10.1002/sita.200500073, DOI 10.1002/SITA.200500073]; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Foell D, 2004, ARTHRITIS RHEUM-US, V50, P3762, DOI 10.1002/art.20631; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; Fuellen G, 2003, TRENDS IMMUNOL, V24, P622, DOI 10.1016/j.it.2003.10.004; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lolis E, 2003, NAT REV DRUG DISCOV, V2, P635, DOI 10.1038/nrd1153; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Nacken W, 2000, EUR J BIOCHEM, V267, P560, DOI 10.1046/j.1432-1327.2000.01040.x; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Passey RJ, 1999, J IMMUNOL, V163, P2209; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rammes A, 1997, J BIOL CHEM, V272, P9496; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; ROTH J, 1993, BLOOD, V82, P1875; Sampson B, 2002, LANCET, V360, P1742, DOI 10.1016/S0140-6736(02)11683-7; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tenbrock K, 2003, J IMMUNOL, V170, P2971, DOI 10.4049/jimmunol.170.6.2971; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602; Viemann D, 2005, BLOOD, V105, P2955, DOI 10.1182/blood-2004-07-2520; Viemann D, 2004, BLOOD, V103, P3365, DOI 10.1182/blood-2003-09-3296; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 1999, J AM SOC MASS SPECTR, V10, P1124; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051	46	971	1034	1	67	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1042	1049		10.1038/nm1638	http://dx.doi.org/10.1038/nm1638			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17767165				2022-12-27	WOS:000249353100031
J	Darrah, PA; Patel, DT; De Luca, PM; Lindsay, RWB; Davey, DF; Flynn, BJ; Hoff, ST; Andersen, P; Reed, SG; Morris, SL; Roederer, M; Seder, RA				Darrah, Patricia A.; Patel, Dipti T.; De Luca, Paula M.; Lindsay, Ross W. B.; Davey, Dylan F.; Flynn, Barbara J.; Hoff, Soren T.; Andersen, Peter; Reed, Steven G.; Morris, Sheldon L.; Roederer, Mario; Seder, Robert A.			Multifunctional T(H)1 cells define a correlate of vaccine-mediated protection against Leishmania major	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CD8(+) T-CELLS; INTERFERON-GAMMA; MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSE; FLOW-CYTOMETRY; MEMORY CD4(+); NITRIC-OXIDE; IN-VIVO; INFECTION	CD4(+) T cells have a crucial role in mediating protection against a variety of pathogens through production of specific cytokines. However, substantial heterogeneity in CD4(+) T-cell cytokine responses has limited the ability to define an immune correlate of protection after vaccination. Here, using multiparameter flow cytometry to assess the immune responses after immunization, we show that the degree of protection against Leishmania major infection in mice is predicted by the frequency of CD4(+) T cells simultaneously producing interferon-gamma, interleukin-2 and tumor necrosis factor. Notably, multifunctional effector cells generated by all vaccines tested are unique in their capacity to produce high amounts of interferon-gamma. These data show that the quality of a CD4(+) T-cell cytokine response can be a crucial determinant in whether a vaccine is protective, and may provide a new and useful prospective immune correlate of protection for vaccines based on T-helper type 1 (T(H)1) cells.	NIAID, Cellular Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen S, Denmark; Infect Dis Res Inst, Seattle, WA 98104 USA; US FDA, Ctr Biol Evaluat & Res, Lab Mycobacterial Dis & Cellular Immunol, Bethesda, MD 20892 USA; NIAID, Vaccine Res Ctr, ImmunoTechnol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Statens Serum Institut; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIAID, Cellular Immunol Sect, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.	rseder@mail.nih.gov	Roederer, Mario/G-1887-2011	Andersen, Peter/0000-0002-5869-2551	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005017, Z01AI005021, ZIAAI005021, Z01AI005016, ZIAAI005018, ZIAAI005017, ZIAAI005016, Z01AI005018] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; Barouch DH, 2006, J PATHOL, V208, P283, DOI 10.1002/path.1874; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Blackwell JM, 1996, PARASITOLOGY, V112, pS67, DOI 10.1017/S0031182000076678; BLOOM BR, 1994, IMMUNOBIOLOGY, V191, P526, DOI 10.1016/S0171-2985(11)80459-6; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Elias D, 2005, T ROY SOC TROP MED H, V99, P363, DOI 10.1016/j.trstmh.2004.08.006; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Gicheru MM, 2001, INFECT IMMUN, V69, P245, DOI 10.1128/IAI.69.1.245-251.2001; Hayashi N, 2002, P NATL ACAD SCI USA, V99, P6187, DOI 10.1073/pnas.092129899; Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042; Jelley-Gibbs DM, 2005, J EXP MED, V202, P697, DOI 10.1084/jem.20050227; Jelley-Gibbs DM, 2005, J EXP MED, V201, P1101, DOI 10.1084/jem.20041852; Leal IS, 2001, IMMUNOLOGY, V104, P157, DOI 10.1046/j.1365-2567.2001.01305.x; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; LIEW FY, 1990, J IMMUNOL, V145, P4306; Modabber F, 1995, ANN TROP MED PARASIT, V89, P83, DOI 10.1080/00034983.1995.11813017; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oliveira MR, 2005, PARASITOLOGY, V131, P477, DOI 10.1017/S0031182005008073; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007; Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009; Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Scott P, 2003, IMMUNOL RES, V27, P489, DOI 10.1385/IR:27:2-3:489; Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Skeiky YAW, 2002, VACCINE, V20, P3292, DOI 10.1016/S0264-410X(02)00302-X; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967; von Stebut E, 2002, J INVEST DERMATOL, V119, P621, DOI 10.1046/j.1523-1747.2002.01850.x; Wang J, 2004, J IMMUNOL, V173, P6357, DOI 10.4049/jimmunol.173.10.6357; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108	49	1058	1088	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					843	850		10.1038/nm1592	http://dx.doi.org/10.1038/nm1592			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17558415	Bronze			2022-12-27	WOS:000247902800031
J	Mandavilli, A				Mandavilli, Apoorva			Peter Doherty	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2007	13	6					655	655		10.1038/nm0607-655	http://dx.doi.org/10.1038/nm0607-655			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17554322				2022-12-27	WOS:000247084300009
J	Care, A; Catalucci, D; Felicetti, F; Bonci, D; Addario, A; Gallo, P; Bang, ML; Segnalini, P; Gu, YS; Dalton, ND; Elia, L; Latronico, MVG; Hoydal, M; Autore, C; Russo, MA; Dorn, GW; Ellingsen, O; Ruiz-Lozano, P; Peterson, KL; Croce, CM; Peschle, C; Condorelli, G				Care, Alessandra; Catalucci, Daniele; Felicetti, Federica; Bonci, Desiree; Addario, Antonio; Gallo, Paolo; Bang, Marie-Louise; Segnalini, Patrizia; Gu, Yusu; Dalton, Nancy D.; Elia, Leonardo; Latronico, Michael V. G.; Hoydal, Morten; Autore, Camillo; Russo, Matteo A.; Dorn, Gerald W., II; Ellingsen, Oyvind; Ruiz-Lozano, Pilar; Peterson, Kirk L.; Croce, Carlo M.; Peschle, Cesare; Condorelli, Gianluigi			MicroRNA-133 controls cardiac hypertrophy	NATURE MEDICINE			English	Article							IN-VIVO; CELL-GROWTH; EXPRESSION; HEART	Growing evidence indicates that microRNAs (miRNAs or miRs) are involved in basic cell functions and oncogenesis. Here we report that miR-133 has a critical role in determining cardiomyocyte hypertrophy. We observed decreased expression of both miR-133 and miR-1, which belong to the same transcriptional unit, in mouse and human models of cardiac hypertrophy. In vitro overexpression of miR-133 or miR-1 inhibited cardiac hypertrophy. In contrast, suppression of miR-133 by 'decoy' sequences induced hypertrophy, which was more pronounced than that after stimulation with conventional inducers of hypertrophy. In vivo inhibition of miR-133 by a single infusion of an antagomir caused marked and sustained cardiac hypertrophy. We identified specific targets of miR-133: RhoA, a GDP-GTP exchange protein regulating cardiac hypertrophy; Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis. Our data show that miR-133, and possibly miR-1, are key regulators of cardiac hypertrophy, suggesting their therapeutic application in heart disease.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Univ Calif San Diego, Dept Med, Div Cardiol, La Jolla, CA 92093 USA; IRCCS Multimedia, I-20099 Milan, Italy; San Raffaele Biomed Sci Pk, I-00128 Rome, Italy; Norwegian Univ Sci & Technol, N-7491 Trondheim, Norway; Univ Roma La Sapienza, Fac Med 2, I-00161 Rome, Italy; IRCCS, I-00163 Rome, Italy; Univ Cincinnati, Div Cardiol, Cincinnati, OH 45267 USA; Burnham Inst Med Res, La Jolla, CA 92037 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Istituto Superiore di Sanita (ISS); University of California System; University of California San Diego; IRCCS Multimedica; Norwegian University of Science & Technology (NTNU); Sapienza University Rome; University System of Ohio; University of Cincinnati; Sanford Burnham Prebys Medical Discovery Institute; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Peschle, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	cesare.peschle@iss.it; gcondorelli@ucsd.edu	gu, yu/GSD-4507-2022; Bang, Marie-Louise/B-5683-2015; Young, Richard A/F-6495-2012; Catalucci, Daniele/AAA-6056-2022; Addario, Antonio/AAC-4707-2022; Felicetti, Federica/N-7077-2017; CARE', Alessandra/H-5090-2016; Høydal, Morten A/K-2806-2012; Latronico, Michael/AAB-3691-2019; Bonci, Desiree/K-6488-2016; Catalucci, Daniele/B-6745-2015; Elia, Leonardo/A-3749-2016; Russo, Matteo/AAD-7733-2021; Condorelli, Gianluigi/Q-6736-2017	Bang, Marie-Louise/0000-0001-8859-5034; Young, Richard A/0000-0001-8855-8647; Catalucci, Daniele/0000-0001-7041-6114; Addario, Antonio/0000-0001-8527-8738; Felicetti, Federica/0000-0003-4628-0696; CARE', Alessandra/0000-0003-4106-3342; Høydal, Morten A/0000-0003-1804-2578; Bonci, Desiree/0000-0002-2472-5140; Catalucci, Daniele/0000-0001-7041-6114; Elia, Leonardo/0000-0001-5011-0206; Latronico, Michele/0000-0003-4017-5764; autore, camillo/0000-0002-6542-7342; Condorelli, Gianluigi/0000-0003-0481-6843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078797, R01HL063168] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL63168, HL078797-01A1] Funding Source: Medline; PHS HHS [HLO65484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergemann AD, 2005, TRENDS GENET, V21, P188, DOI 10.1016/j.tig.2005.01.008; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Ikeda Y, 2003, GENE THER, V10, P1161, DOI 10.1038/sj.gt.3301973; Iwatate M, 2003, GENE THER, V10, P1814, DOI 10.1038/sj.gt.3302077; Kattman SJ, 2006, DEV CELL, V11, P723, DOI 10.1016/j.devcel.2006.10.002; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Nagai T, 2003, BIOCHEM BIOPH RES CO, V305, P806, DOI 10.1016/S0006-291X(03)00838-6; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sayed D, 2007, CIRC RES, V100, P416, DOI 10.1161/01.RES.0000257913.42552.23; Shiojima I, 2006, GENE DEV, V20, P3347, DOI 10.1101/gad.1492806; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Wisloff U, 2001, AM J PHYSIOL-HEART C, V280, pH1301, DOI 10.1152/ajpheart.2001.280.3.H1301; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	29	1418	1548	1	110	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					613	618		10.1038/nm1582	http://dx.doi.org/10.1038/nm1582			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17468766				2022-12-27	WOS:000246302800029
J	Grohmann, U; Volpi, C; Fallarino, F; Bozza, S; Bianchi, R; Vacca, C; Orabona, C; Belladonna, ML; Ayroldi, E; Nocentini, G; Boon, L; Bistoni, F; Fioretti, MC; Romani, L; Riccardi, C; Puccetti, P				Grohmann, Ursula; Volpi, Claudia; Fallarino, Francesca; Bozza, Silvia; Bianchi, Roberta; Vacca, Carmine; Orabona, Ciriana; Belladonna, Maria L.; Ayroldi, Emira; Nocentini, Giuseppe; Boon, Louis; Bistoni, Francesco; Fioretti, Maria C.; Romani, Luigina; Riccardi, Carlo; Puccetti, Paolo			Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy	NATURE MEDICINE			English	Article							PLASMACYTOID DENDRITIC CELLS; KAPPA-B ACTIVATION; REGULATORY T-CELLS; TRYPTOPHAN CATABOLISM; INDOLEAMINE 2,3-DIOXYGENASE; IMMUNOSUPPRESSIVE PATHWAY; CUTTING EDGE; CO-STIMULATION; RECEPTOR; TOLERANCE	Glucocorticoid-induced tumor necrosis factor receptor (GITR) on T cells and its natural ligand, GITRL, on accessory cells contribute to the control of immune homeostasis. Here we show that reverse signaling through GITRL after engagement by soluble GITR initiates the immunoregulatory pathway of tryptophan catabolism in mouse plasmacytoid dendritic cells, by means of noncanonical NF-kappa B-dependent induction of indoleamine 2,3-dioxygenase (IDO). The synthetic glucocorticoid dexamethasone administered in vivo activated IDO through the symmetric induction of GITR in CD4+ T cells and GITRL in plasmacytoid dendritic cells. The drug exerted IDO-dependent protection in a model of allergic airway inflammation. Modulation of tryptophan catabolism via the GITR-GITRL coreceptor system might represent an effective therapeutic target in immune regulation. Induction of IDO could be an important mechanism underlying the anti-inflammatory action of corticosteroids.	Univ Perugia, Dept Expt Med & Biochem Sci, I-06126 Perugia, Italy; Univ Perugia, Dept Clin & Expt Med, I-06126 Perugia, Italy; Bioceros BV, NL-3584 CM Utrecht, Netherlands	University of Perugia; University of Perugia; Bioceros B.V.	Puccetti, P (corresponding author), Univ Perugia, Dept Expt Med & Biochem Sci, I-06126 Perugia, Italy.	plopcc@tin.it	Boon, Laurence/HCI-3629-2022; Riccardi, Carlo/N-4610-2014; Romani, Luigina/O-9987-2018; Vacca, Carmine/AAE-7046-2019; Grohmann, Ursula/T-6545-2019; Orabona, Ciriana/L-8725-2015; Fallarino, Francesca/O-3358-2013; Nocentini, Giuseppe/B-9412-2013; Nocentini, Giuseppe/GZB-0146-2022	Riccardi, Carlo/0000-0001-9257-3997; Vacca, Carmine/0000-0002-3799-8164; Orabona, Ciriana/0000-0003-3113-0572; Fallarino, Francesca/0000-0002-8501-2136; Nocentini, Giuseppe/0000-0002-5209-0488; Grohmann, Ursula/0000-0001-7952-1850; Belladonna, Maria Laura/0000-0001-6522-0870; Bianchi, Roberta/0000-0001-5914-4701; Puccetti, Paolo/0000-0001-6674-2128; Boon, Louis/0000-0002-0937-9171; VOLPI, CLAUDIA/0000-0002-3967-7954; Ayroldi, Emira/0000-0002-9073-7297; Romani, Luigina/0000-0002-1356-525X				Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Bluestone JA, 2005, CURR OPIN IMMUNOL, V17, P638, DOI 10.1016/j.coi.2005.09.002; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chen X, 2004, EUR J IMMUNOL, V34, P859, DOI 10.1002/eji.200324506; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fallarino F, 2006, EUR J IMMUNOL, V36, P8, DOI 10.1002/eji.200535667; Fallarino F, 2005, INT IMMUNOL, V17, P1429, DOI 10.1093/intimm/dxh321; Fallarino F, 2004, J IMMUNOL, V173, P3748, DOI 10.4049/jimmunol.173.6.3748; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Gurtner GJ, 2003, GASTROENTEROLOGY, V125, P1762, DOI 10.1053/j.gastro.2003.08.031; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Judson M A, 2001, Expert Opin Pharmacother, V2, P1065, DOI 10.1517/14656566.2.7.1065; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Kinoshita D, 2006, J IMMUNOL, V176, P3995, DOI 10.4049/jimmunol.176.7.3995; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Montagnoli C, 2006, J IMMUNOL, V176, P1712, DOI 10.4049/jimmunol.176.3.1712; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Orabona C, 2006, BLOOD, V107, P2846, DOI 10.1182/blood-2005-10-4077; Orabona C, 2004, NAT IMMUNOL, V5, P1134, DOI 10.1038/ni1124; Romani L, 2006, TRENDS MICROBIOL, V14, P183, DOI 10.1016/j.tim.2006.02.003; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Romani L, 2006, BLOOD, V108, P2265, DOI 10.1182/blood-2006-02-004762; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Seo SK, 2004, NAT MED, V10, P1088, DOI 10.1038/nm1107; Shevach EM, 2006, NAT REV IMMUNOL, V6, P613, DOI 10.1038/nri1867; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Vacca C, 2005, MICROBES INFECT, V7, P1040, DOI 10.1016/j.micinf.2005.03.030; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Yang CH, 2005, J BIOL CHEM, V280, P31530, DOI 10.1074/jbc.M503120200	50	264	281	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					579	586		10.1038/nm1563	http://dx.doi.org/10.1038/nm1563			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17417651				2022-12-27	WOS:000246302800025
J	Xanthou, G; Alissafi, T; Semitekolou, M; Simoes, DCM; Economidou, E; Gaga, M; Lambrecht, BN; Lloyd, CM; Panoutsakopoulou, V				Xanthou, Georgina; Alissafi, Themis; Semitekolou, Maria; Simoes, Davina C. M.; Economidou, Erasmia; Gaga, Mina; Lambrecht, Bart N.; Lloyd, Clare M.; Panoutsakopoulou, Vily			Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets	NATURE MEDICINE			English	Article							LYMPH-NODES; T-CELLS; BACTERIAL-INFECTION; GENETIC-RESISTANCE; EPITHELIAL-CELLS; IN-VIVO; ASTHMA; INFLAMMATION; CYTOKINE; ANTIGEN	Osteopontin (Opn) is important for T helper type 1 (T(H)1) immunity and autoimmunity. However, the role of this cytokine in T(H)2-mediated allergic disease as well as its effects on primary versus secondary antigenic encounters remain unclear. Here we demonstrate that OPN is expressed in the lungs of asthmatic individuals and that Opn-s, the secreted form of Opn, exerts opposing effects on mouse T(H)2 effector responses and subsequent allergic airway disease: pro-inflammatory at primary systemic sensitization, and anti-inflammatory during secondary pulmonary antigenic challenge. These effects of Opn-s are mainly mediated by the regulation of T(H)2-suppressing plasmacytoid dendritic cells (DCs) during primary sensitization and T(H)2-promoting conventional DCs during secondary antigenic challenge. Therapeutic administration of recombinant Opn during pulmonary secondary antigenic challenge decreased established T(H)2 responses and protected mice from allergic disease. These effects on T(H)2 allergic responses suggest that Opn-s is an important therapeutic target and provide new insight into its role in immunity.	Acad Athens, Fdn Biomed Res, Cellular Immunol Lab, Div Cell Biol,Ctr Basic Res, Athens 11527, Greece; Natl & Kapodistrian Univ Athens, Sch Med, M Simou & GP Livanos Labs, Dept Crit Care & Pulm Med, Athens 10675, Greece; Sotiria Athens Chest Hosp, Asthma Ctr, Athens 11527, Greece; Sotiria Athens Chest Hosp, Resp Med Dept 7, Athens 11527, Greece; Erasmus Univ, Med Ctr, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands; Univ London Imperial Coll Sci & Technol, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England	Academy of Athens; Athens Medical School; National & Kapodistrian University of Athens; Erasmus University Rotterdam; Erasmus MC; Imperial College London	Panoutsakopoulou, V (corresponding author), Acad Athens, Fdn Biomed Res, Cellular Immunol Lab, Div Cell Biol,Ctr Basic Res, 4 Soranou Efessiou St, Athens 11527, Greece.	vpan@bioacademy.gr	Lambrecht, Bart N/K-2484-2014; Xanthou, Georgina/AAH-8682-2019; Alissafi, Themis/HDM-5785-2022; Gaga, Mina/AAP-8348-2020	Lambrecht, Bart N/0000-0003-4376-6834; Alissafi, Themis/0000-0002-4002-6008; Simoes, Davina Camargo Madeira/0000-0002-7262-1784; Semitekolou, Maria/0000-0002-0318-6774; Lloyd, Clare/0000-0001-8977-6726; Gaga, Mina/0000-0002-9949-6012; Panoutsakopoulou, Vily/0000-0002-1569-1508	Wellcome Trust [057704, 087618] Funding Source: Medline; Medical Research Council [G0400503B] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Begum MD, 2007, MICROBIOL IMMUNOL, V51, P135, DOI 10.1111/j.1348-0421.2007.tb03884.x; Blasius AL, 2006, J IMMUNOL, V177, P3260, DOI 10.4049/jimmunol.177.5.3260; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; D'Alfonso S, 2005, ARTHRITIS RHEUM, V52, P539, DOI 10.1002/art.20808; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Gassler N, 2002, SCAND J GASTROENTERO, V37, P1286, DOI 10.1080/003655202761020560; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Haeryfar SMM, 2005, TRENDS IMMUNOL, V26, P311, DOI 10.1016/j.it.2005.04.002; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096; Kawamura K, 2005, CLIN DIAGN LAB IMMUN, V12, P206, DOI 10.1128/CDLI.12.1.206-212.2005; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Liu AH, 2002, ALLERGY ASTHMA PROC, V23, P289; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; MOSMANN TR, 1986, J IMMUNOL, V136, P2357; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Niino M, 2003, J NEUROIMMUNOL, V136, P125, DOI 10.1016/S0165-5728(03)00004-3; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Panoutsakopoulou V, 2001, IMMUNITY, V15, P137, DOI 10.1016/S1074-7613(01)00172-8; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; Renkl AC, 2005, BLOOD, V106, P946, DOI 10.1182/blood-2004-08-3228; Rimoldi M, 2005, BLOOD, V106, P2818, DOI 10.1182/blood-2004-11-4321; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; Shinohara ML, 2005, P NATL ACAD SCI USA, V102, P17101, DOI 10.1073/pnas.0508666102; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Wang J, 2005, J ALLERGY CLIN IMMUN, V115, P1318, DOI 10.1016/j.jaci.2005.02.021; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Weiss JM, 2001, J EXP MED, V194, P1219, DOI 10.1084/jem.194.9.1219; Xu GW, 2005, J CLIN INVEST, V115, P1060	50	148	155	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					570	578		10.1038/nm1580	http://dx.doi.org/10.1038/nm1580			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17435770	Green Accepted			2022-12-27	WOS:000246302800024
J	Harper, C				Harper, Claire			Tuberculosis, a neglected opportunity?	NATURE MEDICINE			English	Article									Wood Mackenzie, Edinburgh EH2 4NS, Midlothian, Scotland		Harper, C (corresponding author), Wood Mackenzie, Kintore House,74-77 Queen St, Edinburgh EH2 4NS, Midlothian, Scotland.	claire.harper@woodmac.com						*COLL CTR CHRON CO, 2006, TUB GUID; DIX K, 2007, INFECT CONTROL TODAY; Gurwitz JH, 2006, NEW ENGL J MED, V354, P1413, DOI 10.1056/NEJMe068051; Spigelman M, 2006, LANCET, V367, P945, DOI 10.1016/S0140-6736(06)68388-8; *WHO, 2006, WHO REP; *WHO, 2006, WHO FACTSH, V104; 2006, PROGR REPORT; 2001, EC TB DRUG DEV; 2006, NY TIMES        0914; 2006, TUBERCULOSIS DIS REP	10	23	24	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					309	312		10.1038/nm0307-309	http://dx.doi.org/10.1038/nm0307-309			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342146				2022-12-27	WOS:000244715700043
J	Obeid, M; Tesniere, A; Ghiringhelli, F; Fimia, GM; Apetoh, L; Perfettini, JL; Castedo, M; Mignot, G; Panaretakis, T; Casares, N; Metivier, D; Larochette, N; van Endert, P; Ciccosanti, F; Piacentini, M; Zitvogel, L; Kroemer, G				Obeid, Michel; Tesniere, Antoine; Ghiringhelli, Francois; Fimia, Gian Maria; Apetoh, Lionel; Perfettini, Jean-Luc; Castedo, Maria; Mignot, Gregoire; Panaretakis, Theoharis; Casares, Noelia; Metivier, Didier; Larochette, Nathanael; van Endert, Peter; Ciccosanti, Fabiola; Piacentini, Mauro; Zitvogel, Laurence; Kroemer, Guido			Calreticulin exposure dictates the immunogenicity of cancer cell death	NATURE MEDICINE			English	Article							DENDRITIC CELLS; APOPTOTIC CELLS; ENDOPLASMIC-RETICULUM; SURFACE CALRETICULIN; DYING CELLS; TUMOR; CLEARANCE; ANTIGEN; CHAPERONE; BINDING	Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and mitomycin C do not induce immunogenic cell death. Here we show that anthracyclins induce the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knockdown of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase 1/GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase 1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anticancer immune responses and delineate a possible strategy for immunogenic chemotherapy.	INSERM, U848, F-94805 Villejuif, France; Inst Gustave Roussy, F-94805 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94805 Villejuif, France; INSERM, U805, F-94805 Villejuif, France; Natl Inst Infect Dis Lazzaro Spallanzani, I-00149 Rome, Italy; Hop Necker Enfants Malad, INSERM, U580, F-75015 Paris, France; Univ Paris 05, F-75015 Paris, France; Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); IRCCS Lazzaro Spallanzani; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Rome Tor Vergata	Obeid, M (corresponding author), INSERM, U848, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		van Endert, Peter/R-4606-2017; LAROCHETTE, Nathanael/R-4298-2017; Casares, Noelia/AAA-5568-2019; KROEMER, Guido/B-4263-2013; PERFETTINI, Jean-Luc/N-4699-2017; Fimia, Gian Maria/K-3232-2016; Kroemer, Guido/AAY-9859-2020; Ciccosanti, Fabiola/B-5284-2017; Apetoh, Lionel/G-3310-2014; OBEID, Michel/HCI-9145-2022; Mignot, Grégoire/R-4976-2017	van Endert, Peter/0000-0003-3782-0750; LAROCHETTE, Nathanael/0000-0002-7936-678X; Casares, Noelia/0000-0003-3817-6434; KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Fimia, Gian Maria/0000-0003-4438-3325; Ciccosanti, Fabiola/0000-0003-0481-6878; Apetoh, Lionel/0000-0002-2774-438X; Mignot, Grégoire/0000-0002-0682-0152; Panaretakis, Theocharis/0000-0001-5754-6950; ZITVOGEL, laurence/0000-0003-1596-0998; ghiringhelli, francois/0000-0002-5465-8305				Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Blacher NE, 2005, PLOS BIOL, V3, P1070, DOI 10.1371/journal.pbio.0030185; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cheng WF, 2006, CANCER GENE THER, V13, P873, DOI 10.1038/sj.cgt.7700956; Culina S, 2004, J BIOL CHEM, V279, P54210, DOI 10.1074/jbc.M410841200; Gaipl US, 2006, CURR TOP MICROBIOL, V305, P161, DOI 10.1007/3-540-29714-6_8; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Hsieh CJ, 2004, VACCINE, V22, P3993, DOI 10.1016/j.vaccine.2004.03.057; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kim SJ, 2006, BIOCHEM BIOPH RES CO, V339, P463, DOI 10.1016/j.bbrc.2005.11.040; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Lake RA, 2006, NEW ENGL J MED, V354, P2503, DOI 10.1056/NEJMcibr061443; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Steinman RM, 2004, SCIENCE, V305, P197, DOI 10.1126/science.1099688; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856; Yoshida H, 2005, NATURE, V437, P754, DOI 10.1038/nature03964; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	35	2072	2198	25	335	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					54	61		10.1038/nm1523	http://dx.doi.org/10.1038/nm1523			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17187072				2022-12-27	WOS:000243301800036
J	Tegeder, I; Costigan, M; Griffin, RS; Abele, A; Belfer, I; Schmidt, H; Ehnert, C; Nejim, J; Marian, C; Scholz, J; Wu, TX; Allchorne, A; Diatchenko, L; Binshtok, AM; Goldman, D; Adolph, J; Sama, S; Atlas, SJ; Carlezon, WA; Parsegian, A; Lotsch, J; Fillingim, RB; Maixner, W; Geisslinger, G; Max, MB; Woolf, CJ				Tegeder, Irmgard; Costigan, Michael; Griffin, Robert S.; Abele, Andrea; Belfer, Inna; Schmidt, Helmut; Ehnert, Corina; Nejim, Jemiel; Marian, Claudiu; Scholz, Joachim; Wu, Tianxia; Allchorne, Andrew; Diatchenko, Luda; Binshtok, Alexander M.; Goldman, David; Adolph, Jan; Sama, Swetha; Atlas, Steven J.; Carlezon, William A.; Parsegian, Aram; Loetsch, Joern; Fillingim, Roger B.; Maixner, William; Geisslinger, Gerd; Max, Mitchell B.; Woolf, Clifford J.			GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence	NATURE MEDICINE			English	Article							PERIPHERAL-NERVE INJURY; MAINE LUMBAR SPINE; NITRIC-OXIDE; DORSAL-HORN; I GENE; LAPAROSCOPIC CHOLECYSTECTOMY; NONSURGICAL MANAGEMENT; GABAERGIC INHIBITION; NEUROPATHIC PAIN; PROTEIN	We report that GTP cyclohydrolase (GCH1), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, is a key modulator of peripheral neuropathic and inflammatory pain. BH4 is an essential cofactor for catecholamine, serotonin and nitric oxide production. After axonal injury, concentrations of BH4 rose in primary sensory neurons, owing to upregulation of GCH1. After peripheral inflammation, BH4 also increased in dorsal root ganglia (DRGs), owing to enhanced GCH1 enzyme activity. Inhibiting this de novo BH4 synthesis in rats attenuated neuropathic and inflammatory pain and prevented nerve injury-evoked excess nitric oxide production in the DRG, whereas administering BH4 intrathecally exacerbated pain. In humans, a haplotype of the GCH1 gene (population frequency 15.4%) was significantly associated with less pain following diskectomy for persistent radicular low back pain. Healthy individuals homozygous for this haplotype exhibited reduced experimental pain sensitivity, and forskolinstimulated immortalized leukocytes from haplotype carriers upregulated GCH1 less than did controls. BH4 is therefore an intrinsic regulator of pain sensitivity and chronicity, and the GTP cyclohydrolase haplotype is a marker for these traits.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Frankfurt, Pharmazentrum, Inst Klin Pharmakol, Zentrum Arzneimittelforsch Entwicklung & Sicherhe, D-60590 Frankfurt, Germany; NIAAA, Neurogenet Lab, Dept Hlth & Human Serv, NIH, Rockville, MD 20852 USA; Natl Inst Dent & Craniofacial Res, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Ctr Neurosensory Disorders, Sch Dent, Chapel Hill, NC 27599 USA; Univ Florida, Coll Dent, Gainesville, FL 32608 USA; Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Clin Epidemiol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Belmont, MA 02478 USA; Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; Goethe University Frankfurt; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill; State University System of Florida; University of Florida; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Woolf, CJ (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, 149 13th St,Room 4309, Charlestown, MA 02129 USA.	cwoolf@partners.org	Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020; Fillingim, Roger/K-3569-2019; Woolf, Clifford/A-9784-2010; Tegeder, Irmgard/AAM-2266-2020; Tegeder, Irmgard/AAM-2246-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Binshtok, Alexander/0000-0002-3620-8116; /0000-0002-4162-3947; Fillingim, Roger/0000-0002-7699-8183; Lotsch, Jorn/0000-0002-5818-6958	NIAAA NIH HHS [Z01 AA000301] Funding Source: Medline; NIDCR NIH HHS [DE07509, Z01 DE00366, DE16558] Funding Source: Medline; NINDS NIH HHS [NS045685, NS038253, NS052623, NS039518] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016558, P01DE007509, Z01DE000366, P50DE007509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038253, R01NS039518, R03NS052623, R37NS039518, P01NS045685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000281, Z01AA000301, Z01AA000303, Z01AA000302] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Atlas SJ, 1996, SPINE, V21, P1777, DOI 10.1097/00007632-199608010-00011; Atlas SJ, 2005, SPINE, V30, P927, DOI 10.1097/01.brs.0000158954.68522.2a; Baba H, 2003, MOL CELL NEUROSCI, V24, P818, DOI 10.1016/S1044-7431(03)00236-7; Bauer M, 2002, J NEUROCHEM, V82, P1300, DOI 10.1046/j.1471-4159.2002.01074.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bisgaard T, 2005, SCAND J GASTROENTERO, V40, P1358, DOI 10.1080/00365520510023675; Bonafe L, 2001, AM J HUM GENET, V69, P269, DOI 10.1086/321970; Choi HJ, 2000, MOL PHARMACOL, V58, P633, DOI 10.1124/mol.58.3.633; Costigan M, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-16; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Frank S, 1998, J INVEST DERMATOL, V111, P1058, DOI 10.1046/j.1523-1747.1998.00434.x; Hagenah J, 2005, NEUROLOGY, V64, P908, DOI 10.1212/01.WNL.0000152839.50258.A2; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hastie BA, 2005, PAIN, V116, P227, DOI 10.1016/j.pain.2005.04.016; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; Hirayama K, 2001, J NEUROCHEM, V79, P576, DOI 10.1046/j.1471-4159.2001.00583.x; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Kapatos G, 2000, J BIOL CHEM, V275, P5947, DOI 10.1074/jbc.275.8.5947; Kolinsky MA, 2004, J BIOL CHEM, V279, P40677, DOI 10.1074/jbc.M405370200; KOSHIMURA K, 1994, J NEUROCHEM, V63, P649; Lewin MR, 1999, NAT NEUROSCI, V2, P18, DOI 10.1038/4520; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MacGregor AJ, 2004, ARTHRIT RHEUM-ARTHR, V51, P160, DOI 10.1002/art.20236; Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433; Maita N, 2002, P NATL ACAD SCI USA, V99, P1212, DOI 10.1073/pnas.022646999; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; MILSTIEN S, 1983, BIOCHEM BIOPH RES CO, V115, P888, DOI 10.1016/S0006-291X(83)80018-7; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Mogil JS, 2003, P NATL ACAD SCI USA, V100, P4867, DOI 10.1073/pnas.0730053100; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Pan ZH, 1996, P NATL ACAD SCI USA, V93, P15423, DOI 10.1073/pnas.93.26.15423; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005; Shiraki T, 1996, BIOCHEM BIOPH RES CO, V221, P181, DOI 10.1006/bbrc.1996.0566; Tegeder I, 2004, P NATL ACAD SCI USA, V101, P3253, DOI 10.1073/pnas.0304076101; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Wood JN, 2004, J NEUROBIOL, V61, P55, DOI 10.1002/neu.20094; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Xie LJ, 1998, J BIOL CHEM, V273, P21091, DOI 10.1074/jbc.273.33.21091; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	49	410	434	2	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1269	1277		10.1038/nm1490	http://dx.doi.org/10.1038/nm1490			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057711				2022-12-27	WOS:000241844900024
J	Jung, CR; Hwang, KS; Yoo, J; Cho, WK; Kim, JM; Kim, WH; Im, DS				Jung, Cho-Rok; Hwang, Kyung-Sun; Yoo, Jinsang; Cho, Won-Kyung; Kim, Jin-Man; Kim, Woo Ho; Im, Dong-Soo			E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis	NATURE MEDICINE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; UBIQUITIN CARRIER PROTEIN; HIPPEL-LINDAU PROTEIN; SUPPRESSOR PROTEIN; SOLID TUMOR; MOLECULAR-BASIS; CELL-GROWTH; IN-VIVO; VHL; COMPLEX	The von Hippel-Lindau tumor suppressor, pVHL, forms part of an E3 ubiquitin ligase complex that targets specific substrates for degradation, including hypoxia-inducible factor-1 alpha (HIF-1 alpha), which is involved in tumor progression and angiogenesis. It remains unclear, however, how pVHL is destabilized. Here we show that E2-EPF ubiquitin carrier protein (UCP) associates with and targets pVHL for ubiquitin-mediated proteolysis in cells, thereby stabilizing HIF-1 alpha. UCP is detected coincidently with HIF-1 alpha in human primary liver, colon and breast tumors, and metastatic cholangiocarcinoma and colon cancer cells. UCP level correlates inversely with pVHL level in most tumor cell lines. In vitro and in vivo, forced expression of UCP boosts tumor-cell proliferation, invasion and metastasis through effects on the pVHL-HIF pathway. Our results suggest that UCP helps stabilize HIF-1 alpha and may be a new molecular target for therapeutic intervention in human cancers.	Korea Res Inst Biosci & Biotechnol, Gene Therapy Res Unit, Taejon 305333, South Korea; Chung Nam Natl Univ, Dept Pathol, Sch Med, Taejon 301721, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Seoul National University (SNU)	Im, DS (corresponding author), Korea Res Inst Biosci & Biotechnol, Gene Therapy Res Unit, Taejon 305333, South Korea.	imdongsu@kribb.re.kr	Kim, Wooho/G-3703-2011	, cho-rok/0000-0002-4474-6563; KIM, JIN MAN/0000-0003-0905-9730				Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cho WK, 2004, MOL THER, V10, P938, DOI 10.1016/j.ymthe.2004.07.023; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jung CR, 2006, HEPATOLOGY, V43, P1042, DOI 10.1002/hep.21137; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lee DH, 2003, CANCER RES, V63, P4648; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; LIU Z, 1992, J BIOL CHEM, V267, P15829; Los M, 1996, LAB INVEST, V75, P231; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakyo T, 2002, BBA-BIOMEMBRANES, V1567, P165, DOI 10.1016/S0005-2736(02)00613-2; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwartz AL, 1999, ANNU REV MED, V50, P57; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; Zhong H, 2002, CANCER LETT, V181, P233, DOI 10.1016/S0304-3835(02)00053-8; Zhong H, 1999, CANCER RES, V59, P5830	49	98	105	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					809	816		10.1038/nm1440	http://dx.doi.org/10.1038/nm1440			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819549				2022-12-27	WOS:000238862800068
J	Netea, MG; Joosten, LAB; Lewis, E; Jensen, DR; Voshol, PJ; Kullberg, BJ; Tack, CJ; van Krieken, H; Kim, SH; Stalenhoef, AF; Van de Loo, FA; Verschueren, I; Pulawa, L; Akira, S; Eckel, RH; Dinarello, CA; Van den Berg, W; Van der Meer, JWM				Netea, MG; Joosten, LAB; Lewis, E; Jensen, DR; Voshol, PJ; Kullberg, BJ; Tack, CJ; van Krieken, H; Kim, SH; Stalenhoef, AF; Van de Loo, FA; Verschueren, I; Pulawa, L; Akira, S; Eckel, RH; Dinarello, CA; Van den Berg, W; Van der Meer, JWM			Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance	NATURE MEDICINE			English	Article							IFN-GAMMA PRODUCTION; CYTOKINE; IL-18; INHIBITION; TRANSDUCER; DISRUPTION; ACTIVATOR; STRESS; STAT3; SERUM	Here we report the presence of hyperphagia, obesity and insulin resistance in knockout mice deficient in IL-18 or IL-18 receptor, and in mice transgenic for expression of IL-18 binding protein. Obesity of II18(-/-) mice resulted from accumulation of fat tissue based on increased food intake. II18(-/-) mice also had hyperinsulinemia, consistent with insulin resistance and hyperglycemia. Insulin resistance was secondary to obesity induced by increased food intake and occurred at the liver level as well as at the muscle and fat-tissue level. The molecular mechanisms responsible for the hepatic insulin resistance in the II18(-/-) mice involved an enhanced expression of genes associated with gluconeogenesis in the liver of II18(-/-) mice, resulting from defective phosphorylation of STAT3. Recombinant IL-18 ( rIL-18) administered intracerebrally inhibited food intake. In addition, rIL-18 reversed hyperglycemia in II18(-/-) mice through activation of STAT3 phosphorylation. These findings indicate a new role of IL-18 in the homeostasis of energy intake and insulin sensitivity.	Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands; Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80262 USA; Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Rheumatol Res & Adv Therapeut, NL-6500 HB Nijmegen, Netherlands; Radboud Univ, Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Univ Colorado, Hlth Sci Ctr, Div Endocrinol, Aurora, CO 80045 USA; Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands	Radboud University Nijmegen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Radboud University Nijmegen; Radboud University Nijmegen; Osaka University; University of Colorado System; University of Colorado Anschutz Medical Campus; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Netea, MG (corresponding author), Dept Internal Med, Geert Grootepl 8, NL-6500 HB Nijmegen, Netherlands.	m.netea@aig.umcn.nl	LEWIS, ELI C/F-1552-2012; Kullberg, BJ/C-8520-2013; van Krieken, Joannes H J M/D-4138-2009; van de Loo, Fons AJ/A-3425-2014; Akira, Shizuo/C-3134-2009; Netea, Mihai/N-5155-2014; Joosten, Leo AB/H-3138-2015; Dinarello, Charles/C-8524-2013; Stalenhoef, A.F.H./H-8094-2014; van den Berg, W.B./H-8010-2014; Tack, Cees J/A-2368-2014; van der Meer, Jos W.M./C-8521-2013	LEWIS, ELI C/0000-0002-4189-2207; Kullberg, BJ/0000-0002-6813-8167; van Krieken, Joannes H J M/0000-0001-6544-1040; van de Loo, Fons AJ/0000-0002-5851-099X; Joosten, Leo AB/0000-0001-6166-9830; van der Meer, Jos W.M./0000-0001-5120-3690				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Blaskovich MA, 2003, CANCER RES, V63, P1270; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Escobar-Morreale HF, 2004, J CLIN ENDOCR METAB, V89, P806, DOI 10.1210/jc.2003-031365; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gorogawa S, 2004, BIOCHEM BIOPH RES CO, V319, P1159, DOI 10.1016/j.bbrc.2004.05.095; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Joosten LAB, 2000, J IMMUNOL, V165, P6553, DOI 10.4049/jimmunol.165.11.6553; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Moriwaki Y, 2003, METABOLISM, V52, P605, DOI 10.1053/meta.2003.50096; Netea MG, 2000, J IMMUNOL, V164, P2644, DOI 10.4049/jimmunol.164.5.2644; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Pocai A, 2005, DIABETES, V54, P3182, DOI 10.2337/diabetes.54.11.3182; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Voshol PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/diabetes.50.11.2585; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	25	323	329	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					650	656		10.1038/nm1415	http://dx.doi.org/10.1038/nm1415			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732281				2022-12-27	WOS:000238149200026
J	Hering, BJ; Wijkstrom, M; Graham, ML; Harstedt, M; Aasheim, TC; Jie, T; Ansite, JD; Nakano, M; Cheng, J; Li, W; Moran, K; Christians, U; Finnegan, C; Mills, CD; Sutherland, DE; Bansal-Pakala, P; Murtaugh, MP; Kirchhof, N; Schuurman, HJ				Hering, BJ; Wijkstrom, M; Graham, ML; Harstedt, M; Aasheim, TC; Jie, T; Ansite, JD; Nakano, M; Cheng, J; Li, W; Moran, K; Christians, U; Finnegan, C; Mills, CD; Sutherland, DE; Bansal-Pakala, P; Murtaugh, MP; Kirchhof, N; Schuurman, HJ			Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates	NATURE MEDICINE			English	Article							COSTIMULATORY BLOCKADE; REJECTION; SURVIVAL; CELL; TRANSPLANTATION; LEFLUNOMIDE; RECOGNITION; XENOGRAFTS; EXPRESSION; INDUCTION	Cell-based diabetes therapy requires an abundant cell source. Here, we report reversal of diabetes for more than 100 d in cynomolgus macaques after intraportal transplantation of cultured islets from genetically unmodified pigs without GaI-specific antibody manipulation. Immunotherapy with CD25-specific and CD154-specific monoclonal antibodies, FTY720 (or tacrolimus), everolimus and leflunomide suppressed indirect activation of T cells, elicitation of non-GaI pig-specific IgG antibody, intragraft expression of proinflammatory cytokines and invasion of infiltrating mononuclear cells into islets.	Univ Minnesota, Diabet Inst Immunol & Transplantat, Dept Surg, Minneapolis, MN 55455 USA; Immerge BioTherapeut Inc, Charlestown, MA 02129 USA; Univ Colorado, Hlth Sci Ctr, Dept Anesthesia, Denver, CO 80262 USA; Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Dept Vet Populat Med, Vet Med Ctr 225, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hering, BJ (corresponding author), Univ Minnesota, Diabet Inst Immunol & Transplantat, Dept Surg, 424 Harvard St SE, Minneapolis, MN 55455 USA.	bhering@umn.edu	Sano, Michael/E-1715-2011; Graham, Melanie L/M-2536-2017	Graham, Melanie L/0000-0002-2475-6975				GILL RG, 1992, TRANSPLANT P, V24, P642; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Hancock WW, 1997, TRANSPLANTATION, V64, P696, DOI 10.1097/00007890-199709150-00006; Kirchhof N, 2004, XENOTRANSPLANTATION, V11, P396, DOI 10.1111/j.1399-3089.2004.00157.x; Kuwaki K, 2005, NAT MED, V11, P29, DOI 10.1038/nm1171; Manna SK, 2000, J IMMUNOL, V165, P5962, DOI 10.4049/jimmunol.165.10.5962; Nyqvist D, 2005, DIABETES, V54, P2287, DOI 10.2337/diabetes.54.8.2287; Olack B, 2000, J IMMUNOL, V165, P1294, DOI 10.4049/jimmunol.165.3.1294; Rayat GR, 2003, DIABETES, V52, P1433, DOI 10.2337/diabetes.52.6.1433; Rayat GR, 2003, J ENDOCRINOL, V177, P127, DOI 10.1677/joe.0.1770127; Rijkelijkhuizen JKRA, 2003, TRANSPLANTATION, V76, P1359, DOI 10.1097/01.TP.0000085290.60182.6B; Rogers NJ, 2000, NAT IMMUNOL, V1, P163, DOI 10.1038/77853; Schuler W, 2004, TRANSPLANTATION, V77, P717, DOI 10.1097/01.TP.0000116563.72763.83; Wijkstrom M, 2004, TRANSPLANTATION, V77, P827, DOI 10.1097/01.TP.0000116390.76425.20; Yamada A, 2001, J IMMUNOL, V167, P5522, DOI 10.4049/jimmunol.167.10.5522	15	400	421	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					301	303		10.1038/nm1369	http://dx.doi.org/10.1038/nm1369			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491083				2022-12-27	WOS:000235802900027
J	Kawano, T; Anrather, J; Zhou, P; Park, L; Wang, G; Frys, KA; Kunz, A; Cho, SH; Orio, M; Iadecola, C				Kawano, T; Anrather, J; Zhou, P; Park, L; Wang, G; Frys, KA; Kunz, A; Cho, SH; Orio, M; Iadecola, C			Prostaglandin E-2 EP1 receptors: downstream effectors of COX-2 neurotoxicity	NATURE MEDICINE			English	Article							NA+/CA2+ EXCHANGER; CEREBRAL-ISCHEMIA; NEURONS; PGE(2); OVERLOAD; INJURY; NEUROPROTECTION; EXCITOTOXICITY; PHARMACOLOGY; CONTRIBUTES	Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostanoid synthesis, has been implicated in the neurotoxicity resulting from hypoxia-ischemia, and its inhibition has therapeutic potential for ischemic stroke. However, COX-2 inhibitors increase the risk of cardiovascular complications. We therefore sought to identify the downstream effectors of COX-2 neurotoxicity, and found that prostaglandin E-2 EP1 receptors are essential for the neurotoxicity mediated by COX-2-derived prostaglandin E-2. EP1 receptors disrupt Ca2+ homeostasis by impairing Na+-Ca2+ exchange, a key mechanism by which neurons cope with excess Ca2+ accumulation after an excitotoxic insult. Thus, EP1 receptors contribute to neurotoxicity by augmenting the Ca2+ dysregulation underlying excitotoxic neuronal death. Pharmacological inhibition or gene inactivation of EP1 receptors ameliorates brain injury induced by excitotoxicity, oxygen glucose deprivation and middle cerebral artery (MCA) occlusion. An EP1 receptor inhibitor reduces brain injury when administered 6 hours after MCA occlusion, suggesting that EP1 receptor inhibition may be a viable therapeutic option in ischemic stroke.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY 10021 USA	Cornell University	Iadecola, C (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, 411 E 69th St, New York, NY 10021 USA.	coi2001@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X; PARK, LAIBAIK/0000-0001-7601-663X	NINDS NIH HHS [NS34179, NS35806] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034179, R37NS034179, R01NS035806] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad AS, 2005, BRAIN RES, V1066, P71, DOI 10.1016/j.brainres.2005.10.068; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Audoly LP, 1999, AM J PHYSIOL-HEART C, V277, pH924, DOI 10.1152/ajpheart.1999.277.3.H924; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bilak M, 2004, ANN NEUROL, V56, P240, DOI 10.1002/ana.20179; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Choi DW, 2005, NATURE, V433, P696, DOI 10.1038/433696a; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Hallinan EA, 1996, J MED CHEM, V39, P609, DOI 10.1021/jm950454k; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; KHODOROV B, 1993, FEBS LETT, V324, P271, DOI 10.1016/0014-5793(93)80132-E; Kiedrowski L, 1999, MOL PHARMACOL, V56, P619, DOI 10.1124/mol.56.3.619; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Nogawa S, 1997, J NEUROSCI, V17, P2746; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Suganami T, 2003, HYPERTENSION, V42, P1183, DOI 10.1161/01.HYP.0000101689.64849.97; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U	30	317	329	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					225	229		10.1038/nm1362	http://dx.doi.org/10.1038/nm1362			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16432513				2022-12-27	WOS:000235160600028
J	Komatsu, M; Ruoslahti, E				Komatsu, M; Ruoslahti, E			R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis	NATURE MEDICINE			English	Article							INTEGRIN ACTIVATION; SKELETAL MYOGENESIS; IN-VITRO; CELLS; PROLIFERATION; ADHESION; PATHWAY; PROTEIN; INJURY; DISRUPTION		Burnham Inst Med Res, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst Med Res, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham.org		Komatsu, Masanobu/0000-0001-7548-137X	NATIONAL CANCER INSTITUTE [P01CA082713, P30CA030199, R01CA098162, R01CA079984, T32CA009579] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09579, P01 CA82713, P30 CA 30199, R01 CA098162, R01 CA79984] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Carmeliet P, 1998, CARDIOVASC RES, V39, P8, DOI 10.1016/S0008-6363(98)00108-4; CLOWES AW, 1983, LAB INVEST, V49, P327; Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jin G, 2000, J SURG RES, V94, P124, DOI 10.1006/jsre.2000.6014; Koyama N, 1996, AM J PATHOL, V148, P749; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; Moiseeva EP, 2001, CARDIOVASC RES, V52, P372, DOI 10.1016/S0008-6363(01)00399-6; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ratajska A, 2001, HISTOCHEM CELL BIOL, V116, P79; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; SAEZ R, 1994, ONCOGENE, V9, P2977; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Suzuki J, 2000, ONCOGENE, V19, P1138, DOI 10.1038/sj.onc.1203402; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WEISSBERG PL, 1993, CARDIOVASC RES, V27, P1191, DOI 10.1093/cvr/27.7.1191; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	30	96	100	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1346	1350		10.1038/nm1324	http://dx.doi.org/10.1038/nm1324			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16286923				2022-12-27	WOS:000233774400034
J	Fatkenheuer, G; Pozniak, AL; Johnson, MA; Plettenberg, A; Staszewski, S; Hoepelman, AIM; Saag, MS; Goebel, FD; Rockstroh, JK; Dezube, BJ; Jenkins, TM; Medhurst, C; Sullivan, JF; Ridgway, C; Abel, S; James, IT; Youle, M; van der Ryst, E				Fatkenheuer, G; Pozniak, AL; Johnson, MA; Plettenberg, A; Staszewski, S; Hoepelman, AIM; Saag, MS; Goebel, FD; Rockstroh, JK; Dezube, BJ; Jenkins, TM; Medhurst, C; Sullivan, JF; Ridgway, C; Abel, S; James, IT; Youle, M; van der Ryst, E			Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1	NATURE MEDICINE			English	Article							IN-VITRO; INHIBITOR; DELETION; SAFETY; ADULTS; GENE; AIDS	We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >= 1.6 log(10) copies/ml at all twice daily doses >= 100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.	Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England; Univ Cologne, Div Infect Dis, Dept Internal Med, D-50924 Cologne, Germany; Chelsea & Westminster Hosp, London SW10 974, England; Royal Free Hosp, Dept Thorac Med, London NW3 2QG, England; St Georg Hosp, Ifi Inst Interdisziplinare Infektiol & Immunol, D-20099 Hamburg, Germany; Klinikum Johann Wolfgang Goethe Univ, Zentrum Inneren Med, D-60596 Frankfurt, Germany; Univ Utrecht Hosp, Head Div Infect Dis & AIDS, NL-3508 GA Utrecht, Netherlands; Univ Alabama, Birmingham, AL 35294 USA; Univ Munich, Med Poliklin, Munich, Germany; Univ Bonn, D-53105 Bonn, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Pfizer; University of Cologne; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Asklepios Klinik St. Georg; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Utrecht University; Utrecht University Medical Center; University of Alabama System; University of Alabama Birmingham; University of Munich; University of Bonn; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	van der Ryst, E (corresponding author), Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England.	Elna.Van.Der.Ryst@pfizer.com						Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DORR PK, IN PRESS ANTIMICROB; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004; Lalezari J, 2005, AIDS, V19, P1443, DOI 10.1097/01.aids.0000183633.06580.8a; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; Maggiolo Franco, 2002, HIV Clin Trials, V3, P371, DOI 10.1310/98B3-PWG8-PMYW-W5BP; McCallister S, 2004, JAIDS-J ACQ IMM DEF, V35, P376, DOI 10.1097/00126334-200404010-00007; MEYER L, 1997, AIDS, V11, P73; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; Struble K, 2005, AIDS, V19, P747, DOI 10.1097/01.aids.0000168968.34810.ca; Takashima K, 2001, ANTIMICROB AGENTS CH, V45, P3538, DOI 10.1128/AAC.45.12.3538-3543.2001	14	423	439	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1170	1172		10.1038/nm1319	http://dx.doi.org/10.1038/nm1319			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16205738				2022-12-27	WOS:000233115400028
J	Beilke, JN; Kuhl, NR; Van Kaer, L; Gill, RG				Beilke, JN; Kuhl, NR; Van Kaer, L; Gill, RG			NK cells promote islet allograft tolerance via a perforin-dependent mechanism	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; REGULATORY T-CELLS; DENDRITIC CELLS; IN-VIVO; TRANSPLANTATION TOLERANCE; IMMUNE-RESPONSES; MUTANT MICE; ACTIVATION; DEFICIENT; INDUCTION	Although major histocompatibility complex (MHC) class II-restricted CD4 T cells are well appreciated for their contribution to peripheral tolerance to tissue allografts, little is known regarding MHC class I-dependent reactivity in this process. Here we show a crucial role for host MHC class I-dependent NK cell reactivity for allograft tolerance in mice induced through either costimulation blockade using CD154-specific antibody therapy or by targeting LFA-1 (also known as CD11a). Tolerance induction absolutely required host expression of MHC class I, but was independent of CD8 T cell-dependent immunity. Rather, tolerance required innate immunity involving NK1.1(+) cells, but was independent of CD1d-restricted NKT cells. Therefore, NK cells seem to be generally required for induction of tolerance to islet allografts. Additional studies indicate that CD154-specific antibody-induced allograft tolerance is perforin dependent. Notably, NK cells that are perforin competent are sufficient to restore allograft tolerance in perforin-deficient recipients. Together, these results show an obligatory role for NK cells, through perforin, for induction of tolerance to islet allografts.	Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80010 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University	Gill, RG (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, 1775 Ursula St,Box B-140, Aurora, CO 80010 USA.	ron.g.gill@uchsc.edu	Van Kaer, Luc/H-1033-2015; Gill, Ronald/GWM-5338-2022	Van Kaer, Luc/0000-0001-5275-2309; 				Bose A, 2003, J IMMUNOL, V170, P1611, DOI 10.4049/jimmunol.170.4.1611; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Ciubotariu R, 1998, J IMMUNOL, V161, P5193; Coudert RD, 2002, J IMMUNOL, V169, P2979, DOI 10.4049/jimmunol.169.6.2979; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Dowdell KC, 2003, J IMMUNOL, V171, P234, DOI 10.4049/jimmunol.171.1.234; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; Fort MM, 1998, J IMMUNOL, V161, P3256; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Kondo T, 2000, TRANSPLANTATION, V69, P969; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Le Moine A, 2003, AM J TRANSPLANT, V3, P101, DOI 10.1034/j.1600-6143.2002.00026.x; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Maier S, 2001, NAT MED, V7, P557, DOI 10.1038/87880; Matsuda JL, 2003, P NATL ACAD SCI USA, V100, P8395, DOI 10.1073/pnas.1332805100; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Nicolls MR, 2002, J IMMUNOL, V169, P4831, DOI 10.4049/jimmunol.169.9.4831; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; Pietra G, 2003, EUR J IMMUNOL, V33, P3427, DOI 10.1002/eji.200324515; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114; Seino K, 2001, P NATL ACAD SCI USA, V98, P2577, DOI 10.1073/pnas.041608298; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Sonoda KH, 2002, J IMMUNOL, V168, P2028, DOI 10.4049/jimmunol.168.4.2028; Sun WJ, 2004, IMMUNOL LETT, V94, P191, DOI 10.1016/j.imlet.2004.05.001; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; Van Kaer L, 2004, IMMUNOL RES, V30, P139, DOI 10.1385/IR:30:2:139; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vankayalapati R, 2004, J IMMUNOL, V172, P130, DOI 10.4049/jimmunol.172.1.130; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zhai YA, 2003, J IMMUNOL, V170, P3024, DOI 10.4049/jimmunol.170.6.3024; Zhou J, 2001, J IMMUNOL, V167, P107, DOI 10.4049/jimmunol.167.1.107	40	156	161	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1059	1065		10.1038/nm1296	http://dx.doi.org/10.1038/nm1296			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155578				2022-12-27	WOS:000232492500026
J	Mandavilli, A				Mandavilli, A			Profile - Michael Malim	NATURE MEDICINE			English	Biographical-Item																		MALIM M, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2005	11	6					586	586		10.1038/nm0605-586	http://dx.doi.org/10.1038/nm0605-586			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15937460	Bronze			2022-12-27	WOS:000229589800010
J	Recher, M; Lang, KS; Navarini, A; Hunziker, L; Lang, PA; Fink, K; Freigang, S; Georgiev, P; Hangartner, L; Zellweger, R; Bergthaler, A; Hegazy, AN; Eschli, B; Theocharides, A; Jeker, LT; Merkler, D; Odermatt, B; Hersberger, M; Hengartner, H; Zinkernagel, RM				Recher, Mike; Lang, Karl S.; Navarini, Alexander; Hunziker, Lukas; Lang, Philipp A.; Fink, Katja; Freigang, Stefan; Georgiev, Panco; Hangartner, Lars; Zellweger, Raphael; Bergthaler, Andreas; Hegazy, Ahmed N.; Eschli, Bruno; Theocharides, Alexandre; Jeker, Lukas T.; Merkler, Doron; Odermatt, Bernhard; Hersberger, Martin; Hengartner, Hans; Zinkernagel, Rolf M.			Extralymphatic virus sanctuaries as a consequence of potent T-cell activation	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ANTIVIRAL IMMUNE-RESPONSES; CHRONIC VIRAL-INFECTION; HIV-1 INFECTION; INFLUENZA-VIRUS; MICE; DISEASE; PERSISTENT; IMMUNOPATHOLOGY; REPLICATION	T helper cells can support the functions of CD8(+) T cells against persistently infecting viruses such as murine lymphocytic choriomeningitis virus (LCMV), cytomegalovirus, hepatitis C virus and HIV. These viruses often resist complete elimination and remain detectable at sanctuary sites, such as the kidneys and other extralymphatic organs. The mechanisms underlying this persistence are not well understood. Here we show that mice with potent virus-specific T-cell responses have reduced levels and delayed formation of neutralizing antibodies, and these mice fail to clear LCMV from extralymphatic epithelia. Transfer of virus-specific B cells but not virus-specific T cells augmented virus clearance from persistent sites. Virus elimination from the kidneys was associated with the formation of IgG deposits in the interstitial space, presumably from kidney-infiltrating B cells. CD8(+) T cells in the kidneys of mice that did not clear virus from this site were activated but showed evidence of exhaustion. Thus, we conclude that in this model of infection, site-specific virus persistence develops as a consequence of potent immune activation coupled with reductions in virus-specific neutralizing antibodies. Our results suggest that sanctuary-site formation depends both on organ anatomy and on the induction of different adaptive immune effector mechanisms. Boosting T-cell responses alone may not reduce virus persistence.	Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Dept Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland; German Rheumatol Res Ctr, D-10117 Berlin, Germany; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel, Ctr Biomed, CH-4058 Basel, Switzerland; Univ Childrens Hosp Basel, CH-4058 Basel, Switzerland; Univ Gottingen, Dept Neuropathol, Gottingen, Germany; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland	University of Zurich; University of Basel; University of Zurich; University Zurich Hospital; Deutsches Rheuma-Forschungszentrum (DRFZ); University of Basel; University of Basel; University of Basel; University of Gottingen; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Recher, M (corresponding author), Univ Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	rechermike@bluewin.ch	Bergthaler, Andreas/ABG-5047-2020; Navarini, Alexander/C-5504-2014; Hangartner, Lars/H-3503-2011; Fink, Katja/AAI-1881-2021; Hangartner, Lars/AAS-1320-2021; Freigang, Stefan/A-8682-2013; Lang, Karl S/R-2505-2016; Merkler, Doron/N-9157-2016	Bergthaler, Andreas/0000-0003-0597-1976; Navarini, Alexander/0000-0001-7059-632X; Fink, Katja/0000-0002-3571-0390; Hangartner, Lars/0000-0002-3165-2058; Freigang, Stefan/0000-0003-4438-7828; Merkler, Doron/0000-0002-0247-2007; Lang, Karl/0000-0001-9783-7605; Hersberger, Martin/0000-0002-4472-329X; Hegazy, Ahmed N./0000-0002-2946-8251; Hunziker, Lukas/0000-0003-0081-8518; Jeker, Lukas/0000-0002-3359-8796; Recher, Mike/0000-0002-9121-6936; Theocharides, Alexandre/0000-0002-1535-8692				AHMED R, 1987, J VIROL, V61, P3920, DOI 10.1128/JVI.61.12.3920-3929.1987; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Andreansky S, 2004, P NATL ACAD SCI USA, V101, P2017, DOI 10.1073/pnas.0307320101; Arrieta JJ, 2001, AM J PATHOL, V158, P259, DOI 10.1016/S0002-9440(10)63964-8; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Becker JL, 1999, J CLIN INVEST, V104, P1673, DOI 10.1172/JCI7286; Bronke C, 2005, IMMUNOL LETT, V97, P215, DOI 10.1016/j.imlet.2004.11.004; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; Crotty S, 2006, BLOOD, V108, P3085, DOI 10.1182/blood-2006-04-018929; Fischer SA, 2006, NEW ENGL J MED, V354, P2235, DOI 10.1056/NEJMoa053240; Flodstrom M, 2002, NAT IMMUNOL, V3, P373, DOI 10.1038/ni771; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Hangartner L, 2003, P NATL ACAD SCI USA, V100, P12883, DOI 10.1073/pnas.2135542100; Harada Y, 2003, J EXP MED, V197, P1779, DOI 10.1084/jem.20021457; Hilleman MR, 2004, P NATL ACAD SCI USA, V101, P14560, DOI 10.1073/pnas.0404758101; Junt T, 2002, J IMMUNOL, V168, P6032, DOI 10.4049/jimmunol.168.12.6032; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Lang KS, 2005, NAT MED, V11, P138, DOI 10.1038/nm1176; Lauterbach H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-53; Legrand E, 1997, AIDS RES HUM RETROV, V13, P1383, DOI 10.1089/aid.1997.13.1383; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; Lo AWI, 2006, J PATHOL, V208, P142, DOI 10.1002/path.1897; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Matter M, 2006, J EXP MED, V203, P2145, DOI 10.1084/jem.20060651; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Ramos-Casals M, 2004, J RHEUMATOL, V31, P495; Recher M, 2004, NAT IMMUNOL, V5, P934, DOI 10.1038/ni1102; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400; Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101; Stewart JP, 1998, J EXP MED, V187, P1941, DOI 10.1084/jem.187.12.1941; Thomson M, 2003, J VIROL, V77, P862, DOI 10.1128/JVI.77.2.862-870.2003; Wang XTZ, 2003, IMMUNITY, V18, P631, DOI 10.1016/S1074-7613(03)00116-X; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wolf DG, 2003, BLOOD, V101, P463, DOI 10.1182/blood-2002-07-1982; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502	43	47	47	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1316	1323		10.1038/nm1670	http://dx.doi.org/10.1038/nm1670			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17982463	Bronze, Green Published			2022-12-27	WOS:000250736900024
J	Weber, MS; Prod'homme, T; Youssef, S; Dunn, SE; Rundle, CD; Lee, L; Patarroyo, JC; Stuve, O; Sobel, RA; Steinman, L; Zamvil, SS				Weber, Martin S.; Prod'homme, Thomas; Youssef, Sawsan; Dunn, Shannon E.; Rundle, Cynthia D.; Lee, Linda; Patarroyo, Juan C.; Stuve, Olaf; Sobel, Raymond A.; Steinman, Lawrence; Zamvil, Scott S.			Type II monocytes modulate T cell-mediated central nervous system autoimmune disease	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; REMITTING MULTIPLE-SCLEROSIS; TRANSCRIPTION FACTOR FOXP3; GLATIRAMER ACETATE; COPOLYMER 1; DEVELOPMENTAL PATHWAYS; IL-10 PRODUCTION; DENDRITIC CELLS; IN-VIVO	Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis ( MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-beta, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of T(H)2 cells and CD4(+) CD25(+) FoxP3(+) regulatory T cells (T-reg) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed T(H)17 cell development and promoted both T(H)2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA; Stanford Univ, Dept Neurol & Neurol Sci, Interdept Program Immunol, Stanford, CA 94305 USA; Vet Affairs N Texas Hlth Care Syst, Neurol Sect, Dallas, TX USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; Stanford University	Zamvil, SS (corresponding author), Univ Calif San Francisco, Dept Neurol, 513 Parnassus Ave,S-268, San Francisco, CA 94143 USA.	zamvil@ucsf.neuroimmunol.org	Weber, Martin/GPW-6095-2022	Sobel, Raymond/0000-0002-0477-9002; Steinman, Lawrence/0000-0002-2437-2250	NIAID NIH HHS [R01 AI059709] Funding Source: Medline; NINDS NIH HHS [R01 NS046721, NS06414] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046721] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aharoni R, 2000, P NATL ACAD SCI USA, V97, P11472, DOI 10.1073/pnas.97.21.11472; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Arnon R, 2004, P NATL ACAD SCI USA, V101, P14593, DOI 10.1073/pnas.0404887101; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chen M, 2001, MULT SCLER, V7, P209, DOI 10.1191/135245801680209303; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Dhib-Jalbut S, 2002, NEUROLOGY, V58, pS3, DOI 10.1212/WNL.58.8_suppl_4.S3; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; Farina C, 2005, LANCET NEUROL, V4, P567, DOI 10.1016/S1474-4422(05)70167-8; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; FRIDKISHARELI M, 1994, P NATL ACAD SCI USA, V91, P4872, DOI 10.1073/pnas.91.11.4872; Frisullo G, 2006, J NEUROSCI RES, V84, P1027, DOI 10.1002/jnr.20995; Gur C, 2006, CLIN IMMUNOL, V118, P307, DOI 10.1016/j.clim.2005.10.004; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hong J, 2005, P NATL ACAD SCI USA, V102, P6449, DOI 10.1073/pnas.0502187102; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jee Y, 2006, INT IMMUNOL, V18, P537, DOI 10.1093/intimm/dxh394; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kim HJ, 2004, J IMMUNOL, V172, P7144, DOI 10.4049/jimmunol.172.11.7144; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; LISAK RP, 1983, J NEUROL SCI, V62, P281, DOI 10.1016/0022-510X(83)90205-8; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nestle FO, 2000, ONCOGENE, V19, P6673, DOI 10.1038/sj.onc.1204095; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Neuhaus O, 2001, NEUROLOGY, V56, P702, DOI 10.1212/WNL.56.6.702; Putheti P, 2003, J NEUROIMMUNOL, V144, P125, DOI 10.1016/j.jneuroim.2003.08.001; Ranger AM, 1996, INT IMMUNOL, V8, P1549, DOI 10.1093/intimm/8.10.1549; Salama AD, 2003, J EXP MED, V198, P71, DOI 10.1084/jem.20022119; Shimoda M, 2006, J IMMUNOL, V176, P6503, DOI 10.4049/jimmunol.176.11.6503; Stasiolek M, 2006, BRAIN, V129, P1293, DOI 10.1093/brain/awl043; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Stuve O, 2006, J CLIN INVEST, V116, P1037, DOI 10.1172/JCI25805; Takahashi K, 2007, PLOS MED, V4, P675, DOI 10.1371/journal.pmed.0040124; Teitelbaum D, 1996, J NEUROIMMUNOL, V64, P209, DOI 10.1016/0165-5728(95)00180-8; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Tran EH, 1998, J IMMUNOL, V161, P3767; VanDeusen JB, 2006, EUR J IMMUNOL, V36, P623, DOI 10.1002/eji.200535241; Vieira PL, 2003, J IMMUNOL, V170, P4483, DOI 10.4049/jimmunol.170.9.4483; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Weber MS, 2004, BRAIN, V127, P1370, DOI 10.1093/brain/awh163; Wesemann DR, 2003, J IMMUNOL, V171, P5313, DOI 10.4049/jimmunol.171.10.5313; Zamora A, 2002, AUTOIMMUNITY, V35, P21, DOI 10.1080/08916930290005873; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; Zhang MF, 2000, J NEUROIMMUNOL, V103, P189, DOI 10.1016/S0165-5728(99)00239-8; Ziemssen T, 2002, BRAIN, V125, P2381, DOI 10.1093/brain/awf252	50	353	368	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2007	13	8					935	943		10.1038/nm1620	http://dx.doi.org/10.1038/nm1620			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17676050				2022-12-27	WOS:000248674600024
J	Bernhagen, J; Krohn, R; Lue, H; Gregory, JL; Zernecke, A; Koenen, RR; Dewor, M; Georgiev, I; Schober, A; Leng, L; Kooistra, T; Fingerle-Rowson, G; Ghezzi, P; Kleemann, R; McColl, SR; Bucala, R; Hickey, MJ; Weber, C				Bernhagen, Juergen; Krohn, Regina; Lue, Hongqi; Gregory, Julia L.; Zernecke, Alma; Koenen, Rory R.; Dewor, Manfred; Georgiev, Ivan; Schober, Andreas; Leng, Lin; Kooistra, Teake; Fingerle-Rowson, Guenter; Ghezzi, Pietro; Kleemann, Robert; McColl, Shaun R.; Bucala, Richard; Hickey, Michael J.; Weber, Christian			MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment	NATURE MEDICINE			English	Article							MIGRATION INHIBITORY FACTOR; DEFICIENT MICE; ATHEROSCLEROTIC PLAQUES; LESION PROGRESSION; MONOCYTE ARREST; CC CHEMOKINES; EXPRESSION; DISEASE; CYTOKINES; BINDING	The cytokine macrophage migration inhibitory factor (MIF) plays a critical role in inflammatory diseases and atherogenesis. We identify the chemokine receptors CXCR2 and CXCR4 as functional receptors for MIF. MIF triggered G(alpha i)- and integrin-dependent arrest and chemotaxis of monocytes and T cells, rapid integrin activation and calcium influx through CXCR2 or CXCR4. MIF competed with cognate ligands for CXCR4 and CXCR2 binding, and directly bound to CXCR2. CXCR2 and CD74 formed a receptor complex, and monocyte arrest elicited by MIF in inflamed or atherosclerotic arteries involved both CXCR2 and CD74. In vivo, Mif deficiency impaired monocyte adhesion to the arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte recruitment required II8rb (which encodes Cxcr2). Blockade of Mif but not of canonical ligands of Cxcr2 or Cxcr4 in mice with advanced atherosclerosis led to plaque regression and reduced monocyte and T-cell content in plaques. By activating both CXCR2 and CXCR4, MIF displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis. Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition.	Univ Aachen, Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Biochem Mol & Cell Biol,Inst Biochem, D-52074 Aachen, Germany; Univ Aachen, Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Mol Cardiovasc Res, D-52074 Aachen, Germany; Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic 3168, Australia; Univ Munich, Med Policlin, D-80336 Munich, Germany; Yale Univ, Sch Med, Anlyan Ctr, Dept Med Pathol Epidemiol & Publ Hlth, New Haven, CT 06520 USA; TNO Qual Life, Gaubius Lab Biosci, Dept Vasc & Metab Dis, NL-2301 CE Leiden, Netherlands; Univ Hosp Cologne, Med Clin 1, Dept Hematol & Oncol, D-50937 Cologne, Germany; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Leiden Univ, Dept Vasc Surg, NL-2333 CK Leiden, Netherlands; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Monash University; University of Munich; Yale University; Netherlands Organization Applied Science Research; University of Cologne; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Leiden University; Leiden University - Excl LUMC; University of Adelaide	Bernhagen, J (corresponding author), Univ Aachen, Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Biochem Mol & Cell Biol,Inst Biochem, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de; cweber@ukaachen.de	Hickey, Michael J./A-5429-2012; Gregory, Julia L/K-8726-2012; Ghezzi, Pietro/A-4995-2010; Schober, Andreas/B-2866-2013; Gregory, Julia/AAW-6017-2020; Koenen, Rory/H-4172-2012; Weber, Christian/AAW-2153-2020	Hickey, Michael J./0000-0003-2354-357X; Schober, Andreas/0000-0001-7798-136X; Gregory, Julia/0000-0003-2408-677X; Koenen, Rory/0000-0002-9955-9730; Weber, Christian/0000-0003-4610-8714; Ghezzi, Pietro/0000-0003-0911-8358; Leng, Lin/0000-0002-0605-358X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43210] Funding Source: Medline; NIAMS NIH HHS [AR49610] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BenBaruch A, 1997, CYTOKINE, V9, P37, DOI 10.1006/cyto.1996.0133; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Boisvert WA, 2006, AM J PATHOL, V168, P1385, DOI 10.2353/ajpath.2006.040748; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Degryse B, 2003, FEBS LETT, V553, P11, DOI 10.1016/S0014-5793(03)01027-5; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Gregory JL, 2004, ARTHRITIS RHEUM-US, V50, P3023, DOI 10.1002/art.20470; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; HAYASHI S, 1995, J IMMUNOL, V154, P814; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kleemann R, 2002, J INTERF CYTOK RES, V22, P351, DOI 10.1089/107999002753675785; Kong YZ, 2005, ATHEROSCLEROSIS, V178, P207, DOI 10.1016/j.atherosclerosis.2004.08.030; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; Laudanna C, 2006, THROMB HAEMOSTASIS, V95, P5, DOI 10.1160/TH05-07-0482; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin SG, 2000, CIRC RES, V87, P1202, DOI 10.1161/01.RES.87.12.1202; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Murphy PM, 2000, PHARMACOL REV, V52, P145; Navab M, 2004, CURR OPIN LIPIDOL, V15, P645, DOI 10.1097/00041433-200412000-00004; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Roscic-Mrkic B, 2003, BLOOD, V102, P1169, DOI 10.1182/blood-2003-02-0488; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Schrans-Stassen BHGJ, 2005, ANTIOXID REDOX SIGN, V7, P1211, DOI 10.1089/ars.2005.7.1211; Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Verschuren L, 2005, ARTERIOSCL THROM VAS, V25, P161, DOI 10.1161/01.ATV.0000148866.29829.19; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Weber C, 2006, TRENDS IMMUNOL, V27, P268, DOI 10.1016/j.it.2006.04.002; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38	50	925	965	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2007	13	5					587	596		10.1038/nm1567	http://dx.doi.org/10.1038/nm1567			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17435771				2022-12-27	WOS:000246302800026
J	Lee, SH; Rho, J; Jeong, D; Sul, JY; Kim, T; Kim, N; Kang, JS; Miyamoto, T; Suda, T; Lee, SK; Pignolo, RJ; Koczon-Jaremko, B; Lorenzo, J; Choi, Y				Lee, Seoung-Hoon; Rho, Jaerang; Jeong, Daewon; Sul, Jai-Yoon; Kim, Taesoo; Kim, Nacksung; Kang, Ju-Seob; Miyamoto, Takeshi; Suda, Toshio; Lee, Sun-Kyeong; Pignolo, Robert J.; Koczon-Jaremko, Boguslawa; Lorenzo, Joseph; Choi, Yongwon			v-ATPase V-0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation	NATURE MEDICINE			English	Article							GENE-EXPRESSION; C-SUBUNIT; CELL; DIFFERENTIATION; ISOFORMS	Matrix-producing osteoblasts and bone-resorbing osteoclasts maintain bone homeostasis. Osteoclasts are multinucleated, giant cells of hematopoietic origin formed by the fusion of mononuclear pre-osteoclasts derived from myeloid cells(1,2). Fusion-mediated giant cell formation is critical for osteoclast maturation; without it, bone resorption is inefficient(2,3). To understand how osteoclasts differ from other myeloid lineage cells, we previously compared global mRNA expression patterns in these cells and identified genes of unknown function predominantly expressed in osteoclasts, one of which is the d2 isoform of vacuolar (H+) ATPase (v-ATPase) V-0 domain (Atp6v0d2)(4-7). Here we show that inactivation of Atp6v0d2 in mice results in markedly increased bone mass due to defective osteoclasts and enhanced bone formation. Atp6v0d2 deficiency did not affect differentiation or the v-ATPase activity of osteoclasts. Rather, Atp6v0d2 was required for efficient pre-osteoclast fusion. Increased bone formation was probably due to osteoblast-extrinsic factors, as Atp6v02 was not expressed in osteoblasts and their differentiation ex vivo was not altered in the absence of Atp6v02. Our results identify Atp6v0d2 as a regulator of osteoclast fusion and bone formation, and provide genetic data showing that it is possible to simultaneously inhibit osteoclast maturation and stimulate bone formation by therapeutically targeting the function of a single gene.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Keio Univ, Sch Med, Dept Cell Differentiat & Orthoped Surg, Shinjuku Ku, Tokyo 1608582, Japan; Univ Connecticut, Ctr Hlth, Dept Med, Div Endocrinol, Farmington, CT 06030 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Yeungnam Univ, Coll Med, Dept Microbiol, Taegu 705717, South Korea; Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju 501746, South Korea; Hanyang Univ, Dept Pharmacol, Coll Med, Seoul 133791, South Korea; Hanyang Univ, Inst Biomed Sci, Seoul 133791, South Korea	University of Pennsylvania; University of Pennsylvania; Keio University; University of Connecticut; University of Pennsylvania; Yeungnam University; Chonnam National University; Hanyang University; Hanyang University	Choi, Y (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	ychoi3@mail.med.upenn.edu	Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771; Rho, Jaerang/0000-0002-0019-4939				Abe E, 1999, CALCIFIED TISSUE INT, V64, P508, DOI 10.1007/s002239900641; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007; Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345; Lee SK, 2006, J BONE MINER RES, V21, P695, DOI 10.1359/JBMR.060117; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P46396, DOI 10.1074/jbc.M303924200; Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Suda T, 1997, METHOD ENZYMOL, V282, P223; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Takami M, 1999, CELL TISSUE RES, V298, P327, DOI 10.1007/s004419900092; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Verrier S, 2004, BONE, V35, P34, DOI 10.1016/j.bone.2003.12.029; Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645	22	418	438	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1403	1409		10.1038/nm1514	http://dx.doi.org/10.1038/nm1514			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17128270				2022-12-27	WOS:000242618200021
J	Hahn, CG; Wang, HY; Cho, DS; Talbot, K; Gur, RE; Berrettini, WH; Bakshi, K; Kamins, J; Borgmann-Winter, KE; Siegel, SJ; Gallop, RJ; Arnold, SE				Hahn, Chang-Gyu; Wang, Hoau-Yan; Cho, Dan-Sung; Talbot, Konrad; Gur, Raquel E.; Berrettini, Wade H.; Bakshi, Kalindi; Kamins, Joshua; Borgmann-Winter, Karin E.; Siegel, Steven J.; Gallop, Robert J.; Arnold, Steven E.			Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia	NATURE MEDICINE			English	Article							PREFRONTAL CORTEX; SUSCEPTIBILITY; EXPRESSION; PROTEINS; ERBB4; GENES	Recent molecular genetics studies implicate neuregulin 1 (NRG1) and its receptor erbB in the pathophysiology of schizophrenia(1-3). Among NRG1 receptors, erbB4 is of particular interest because of its crucial roles in neurodevelopment and in the modulation of N-methyl-D-aspartate ( NMDA) receptor signaling(4-6). Here, using a new postmortem tissue-stimulation approach, we show a marked increase in NRG1-induced activation of erbB4 in the prefrontal cortex in schizophrenia. Levels of NRG1 and erbB4, however, did not differ between schizophrenia and control groups. To evaluate possible causes for this hyperactivation of erbB4 signaling, we examined the association of erbB4 with PSD-95 (postsynaptic density protein of 95 kDa), as this association has been shown to facilitate activation of erbB4. Schizophrenia subjects showed substantial increases in erbB4-PSD-95 interactions. We found that NRG1 stimulation suppresses NMDA receptor activation in the human prefrontal cortex, as previously reported in the rodent cortex. NRG1-induced suppression of NMDA receptor activation was more pronounced in schizophrenia subjects than in controls, consistent with enhanced NRG1-erbB4 signaling seen in this illness. Therefore, these findings suggest that enhanced NRG1 signaling may contribute to NMDA hypofunction in schizophrenia.	Univ Penn, Dept Psychiat, Cellular & Mol Neuropathol Program, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA; CUNY, Sch Med, Dept Physiol & Pharmacol, New York, NY 10031 USA; W Chester Univ, Dept Math, Appl Stat Program, W Chester, PA 19380 USA	University of Pennsylvania; Pennsylvania Medicine; City University of New York (CUNY) System; Pennsylvania State System of Higher Education (PASSHE); West Chester University of Pennsylvania	Hahn, CG (corresponding author), Univ Penn, Dept Psychiat, Cellular & Mol Neuropathol Program, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA.	hahnc@mail.med.upenn.edu	Arnold, Steven E/J-7546-2012; Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996; Siegel, Steven/0000-0001-8058-9713	NIMH NIH HHS [MH63946, MH64045] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH063946, P50MH064045] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anton ES, 2004, NAT NEUROSCI, V7, P1319, DOI 10.1038/nn1345; Arnold SE, 2005, PROG BRAIN RES, V147, P319, DOI 10.1016/S0079-6123(04)47023-X; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Clinton SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1353, DOI 10.1038/sj.npp.1300451; Corvin AP, 2004, MOL PSYCHIATR, V9, P208, DOI 10.1038/sj.mp.4001412; Coyle JT, 2003, ANN NY ACAD SCI, V1003, P318, DOI 10.1196/annals.1300.020; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Gu ZL, 2005, J NEUROSCI, V25, P4974, DOI 10.1523/JNEUROSCI.1086-05.2005; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Hashimoto R, 2004, MOL PSYCHIATR, V9, P299, DOI 10.1038/sj.mp.4001434; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Kwon OB, 2005, J NEUROSCI, V25, P9378, DOI 10.1523/JNEUROSCI.2100-05.2005; Lemke G, 2001, ANNU REV NEUROSCI, V24, P87, DOI 10.1146/annurev.neuro.24.1.87; Moghaddam B, 2003, NEURON, V40, P881, DOI 10.1016/S0896-6273(03)00757-8; Okada M, 2004, HIPPOCAMPUS, V14, P337, DOI 10.1002/hipo.10185; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Stefansson H, 2004, ANN MED, V36, P62, DOI 10.1080/07853890310017585; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Toyooka K, 2002, J NEUROCHEM, V83, P797, DOI 10.1046/j.1471-4159.2002.01181.x; Wang HY, 1996, BIOL PSYCHIAT, V40, P568, DOI 10.1016/0006-3223(95)00611-7; WANG HY, 1994, NEUROSCI LETT, V173, P37, DOI 10.1016/0304-3940(94)90144-9; Williams NM, 2003, MOL PSYCHIATR, V8, P485, DOI 10.1038/sj.mp.4001348	27	438	464	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					824	828		10.1038/nm1418	http://dx.doi.org/10.1038/nm1418			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767099				2022-12-27	WOS:000238862800070
J	Chromek, M; Slamova, Z; Bergman, P; Kovacs, L; Podracka, L; Ehren, I; Hokfelt, T; Gudmundsson, GH; Gallo, RL; Agerberth, B; Brauner, A				Chromek, Milan; Slamova, Zuzana; Bergman, Peter; Kovacs, Laszlo; Podracka, L'udmila; Ehren, Ingrid; Hokfelt, Tomas; Gudmundsson, Gudmundur H.; Gallo, Richard L.; Agerberth, Birgitta; Brauner, Annelie			The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection	NATURE MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; INNATE IMMUNITY; DEFENSE PEPTIDES; LL-37; EXPRESSION; BETA-DEFENSIN-1; BLADDER; HCAP-18; MICE; DIFFERENTIATION	The urinary tract functions in close proximity to the outside environment, yet must remain free of microbial colonization to avoid disease. The mechanisms for establishing an antimicrobial barrier in this area are not completely understood. Here, we describe the production and function of the cathelicidin antimicrobial peptides LL-37, its precursor hCAP-18 and its ortholog CRAMP in epithelial cells of human and mouse urinary tract, respectively. Bacterial contact with epithelial cells resulted in rapid production and secretion of the respective peptides, and in humans LL-37/hCAP-18 was released into urine. Epithelium-derived cathelicidin substantially contributed to the protection of the urinary tract against infection, as shown using CRAMP-deficient and neutrophil-depleted mice. In addition, clinical E. coli strains that were more resistant to LL-37 caused more severe urinary tract infections than did susceptible strains. Thus, cathelicidin seems to be a key factor in mucosal immunity of the urinary tract.	Karolinska Univ Hosp, Dept Clin Microbiol, Microbiol & Tumorbiol Ctr, SE-17176 Stockholm, Sweden; Karolinska Inst, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; Karolinska Univ Hosp, Dept Urol, SE-17176 Stockholm, Sweden; Comenius Univ, Sch Med, Dept Pediat, Bratislava, Slovakia; Safarik Univ, Sch Med, Dept Pediat, Kosice 04066, Slovakia; Univ Iceland, Inst Biol, IS-101 Reykjavik, Iceland; Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Comenius University Bratislava; University of Pavol Jozef Safarik Kosice; University of Iceland; University of California System; University of California San Diego	Brauner, A (corresponding author), Karolinska Univ Hosp, Dept Clin Microbiol, Microbiol & Tumorbiol Ctr, SE-17176 Stockholm, Sweden.	Annelie.Brauner@ki.se	Gudmundsson, Gudmundur H/K-9178-2015; Chromek, Milan/AAD-9116-2022; Gallo, Richard L/A-8931-2009; Chromek, Milan/ABE-7455-2020	Gudmundsson, Gudmundur H/0000-0001-5793-0565; Chromek, Milan/0000-0002-8941-057X; Gallo, Richard L/0000-0002-1401-7861; Ehren, Ingrid/0000-0001-7995-1252; Podracka, Ludmila/0000-0002-6633-0251; Bergman, Peter/0000-0003-3306-3713				Abrink M, 2000, KIDNEY INT, V57, P2004, DOI 10.1046/j.1523-1755.2000.00050.x; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Bates JM, 2004, KIDNEY INT, V65, P791, DOI 10.1111/j.1523-1755.2004.00452.x; Bergman P, 2005, CELL MICROBIOL, V7, P1009, DOI 10.1111/j.1462-5822.2005.00530.x; Black CA, 1998, INFECT IMMUN, V66, P1273, DOI 10.1128/IAI.66.3.1273-1275.1998; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; Braff MH, 2005, INFECT IMMUN, V73, P6771, DOI 10.1128/IAI.73.10.6771-6781.2005; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Chromek M, 2003, PEDIATR RES, V53, P698, DOI 10.1203/01.PDR.0000057575.86337.CB; COX CE, 1961, J UROLOGY, V86, P739, DOI 10.1016/S0022-5347(17)65257-1; Dorschner RA, 2006, FASEB J, V20, P35, DOI 10.1096/fj.05-4406com; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; FLIEDNER M, 1986, J PEDIATR-US, V109, P416, DOI 10.1016/S0022-3476(86)80110-X; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GORDON DM, 1992, MOL MICROBIOL, V6, P555, DOI 10.1111/j.1365-2958.1992.tb01500.x; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Justice SS, 2004, P NATL ACAD SCI USA, V101, P1333, DOI 10.1073/pnas.0308125100; Khalil A, 1997, J UROLOGY, V158, P1576, DOI 10.1016/S0022-5347(01)64282-4; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Morrison G, 2002, INFECT IMMUN, V70, P3053, DOI 10.1128/IAI.70.6.3053-3060.2002; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; NORDEN CW, 1968, J CLIN INVEST, V47, P2689, DOI 10.1172/JCI105952; Pestonjamasp VK, 2001, PEPTIDES, V22, P1643, DOI 10.1016/S0196-9781(01)00499-5; Rossi MR, 2001, ENVIRON HEALTH PERSP, V109, P801, DOI 10.1289/ehp.01109801; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; TODD JH, 1996, HUMAN CELL CULTURE P, P431; Tollin M, 2003, PEPTIDES, V24, P523, DOI 10.1016/S0196-9781(03)00114-1; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zucht H D, 1998, Eur J Med Res, V3, P315	45	455	477	1	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					636	641		10.1038/nm1407	http://dx.doi.org/10.1038/nm1407			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16751768				2022-12-27	WOS:000238149200024
J	Hasegawa, H; Sawa, H; Lewis, MJ; Orba, Y; Sheehy, N; Yamamoto, Y; Ichinohe, T; Tsunetsugu-Yokota, Y; Katano, H; Takahashi, H; Matsuda, J; Sata, T; Kurata, T; Nagashima, K; Hall, WW				Hasegawa, H; Sawa, H; Lewis, MJ; Orba, Y; Sheehy, N; Yamamoto, Y; Ichinohe, T; Tsunetsugu-Yokota, Y; Katano, H; Takahashi, H; Matsuda, J; Sata, T; Kurata, T; Nagashima, K; Hall, WW			Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I	NATURE MEDICINE			English	Article							NF-KAPPA-B; CELL LEUKEMIA; HTLV-I; SIGNALING PATHWAYS; MOUSE MODEL; EXPRESSION; NEUROFIBROMATOSIS; TRANSFORMATION; ACTIVATION; INFECTION	Adult T-cell leukemia-lymphoma (ATLL) is a group of T-cell malignancies caused by infection with human T-lymphotropic virus type I (HTLV-I). Although the pathogenesis of ATLL remains incompletely understood, the viral regulatory protein Tax is centrally involved in cellular transformation. Here we describe the generation of HTLV-I Tax transgenic mice using the Lck proximal promoter to restrict transgene expression to developing thymocytes. After prolonged latency periods, transgenic mice developed diffuse large-cell lymphomas and leukemia with clinical, pathological and immunological features characteristic of acute ATLL. Transgenic mice were functionally immunocompromised and they developed opportunistic infections. Fulminant disease also developed rapidly in SCID mice after engraftment of lymphomatous cells from transgenic mice. Flow cytometry showed that the cells were CD4(-) and CD8(-), but CD44(+), CD25(+) and cytoplasmic CD3(+). This phenotype is indicative of a thymus-derived pre-T-cell phenotype, and disease development was associated with the constitutive activation of NF-kappa B. Our model accurately reproduces human disease and will provide a tool for analysis of the molecular events in transformation and for the development of new therapeutics.	Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland; Natl Inst Infect Dis, Dept Pathol, Tokyo 2080011, Japan; Hokkaido Univ, Res Ctr Zoonosis Control, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608338, Japan; Hokkaido Univ, Res Ctr Zoonosis Control, Dept Mol Pathobiol, Kita Ku, Sapporo, Hokkaido 0608338, Japan; 21st Century COE Program Zoonosis Control, Kita Ku, Sapporo, Hokkaido 0608338, Japan; Univ Calif Los Angeles, Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA; Natl Inst Biomed Innovat, Osaka 5670085, Japan; Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan	University College Dublin; National Institute of Infectious Diseases (NIID); Hokkaido University; Hokkaido University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institute of Health Sciences - Japan; National Institute of Infectious Diseases (NIID)	Hall, WW (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland.	william.hall@ucd.ie	Sawa, Hirofumi/F-6954-2012; Hasegawa, Hideki/C-7978-2014; Sawa, Hirofumi/AAW-8816-2021; Orba, Yasuko/F-6888-2012	Sawa, Hirofumi/0000-0003-2569-2755; Katano, Harutaka/0000-0002-5332-4434; Sheehy, Noreen/0000-0001-5004-0228				CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Ciminale V, 2000, LEUKEMIA RES, V24, P353, DOI 10.1016/S0145-2126(99)00193-9; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GREEN JE, 1992, AM J PATHOL, V140, P1401; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hall WW, 2005, ONCOGENE, V24, P5965, DOI 10.1038/sj.onc.1208975; HATTORI T, 1991, LANCET, V337, P76, DOI 10.1016/0140-6736(91)90737-A; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; KAMIHIRA S, 1993, LEUKEMIA LYMPHOMA, V12, P123, DOI 10.3109/10428199309059580; Kannagi M, 2004, TRENDS MICROBIOL, V12, P346, DOI 10.1016/j.tim.2004.05.005; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Mori N, 1999, BLOOD, V93, P2360; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Noguchi A, 2004, EXP ANIM TOKYO, V53, P103, DOI 10.1538/expanim.53.103; Ohata J, 1999, INT J HEMATOL, V69, P92; Rezuke WN, 1997, CLIN CHEM, V43, P1814; Shimauchi T, 2005, BRIT J DERMATOL, V152, P350, DOI 10.1111/J.1365-2133.2004.06281.X; Staal FJT, 2001, STEM CELLS, V19, P165, DOI 10.1634/stemcells.19-3-165; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUZUSHIMA H, 1994, LEUKEMIA LYMPHOMA, V13, P257, DOI 10.3109/10428199409056289; SUZUSHIMA H, 1993, BLOOD, V81, P1032; TAKATSUKI K, 1985, CANCER RES, V45, P4644; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; YAMADA Y, 1985, J CLIN ONCOL, V3, P782, DOI 10.1200/JCO.1985.3.6.782; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	29	211	217	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					466	472		10.1038/nm1389	http://dx.doi.org/10.1038/nm1389			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550188				2022-12-27	WOS:000236581300037
J	Lee, JS; Heo, J; Libbrecht, L; Chu, IS; Kaposi-Novak, P; Calvisi, DF; Mikaelyan, A; Roberts, LR; Demetris, AJ; Sun, ZT; Nevens, F; Roskams, T; Thorgeirsson, SS				Lee, JS; Heo, J; Libbrecht, L; Chu, IS; Kaposi-Novak, P; Calvisi, DF; Mikaelyan, A; Roberts, LR; Demetris, AJ; Sun, ZT; Nevens, F; Roskams, T; Thorgeirsson, SS			A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells	NATURE MEDICINE			English	Article							COMPARATIVE FUNCTIONAL GENOMICS; GENE-EXPRESSION; SIGNALING PATHWAY; LIVER-TUMOR; C-JUN; CLASSIFICATION; EZRIN; PREDICTION; PHENOTYPE; EFFICIENT	The variability in the prognosis of individuals with hepatocellular carcinoma (HCC) suggests that HCC may comprise several distinct biological phenotypes. These phenotypes may result from activation of different oncogenic pathways during tumorigenesis and/or from a different cell of origin. Here we address whether the transcriptional characteristics of HCC can provide insight into the cellular origin of the tumor. We integrated gene expression data from rat fetal hepatoblasts and adult hepatocytes with HCC from human and mouse models. Individuals with HCC who shared a gene expression pattern with fetal hepatoblasts had a poor prognosis. The gene expression program that distinguished this subtype from other types of HCC included markers of hepatic oval cells, suggesting that HCC of this subtype may arise from hepatic progenitor cells. Analyses of gene networks showed that activation of AP-1 transcription factors in this newly identified HCC subtype might have key roles in tumor development.	NCI, Expt Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; Katholieke Univ Leuven, Dept Morphol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Mol Pathol, B-3000 Louvain, Belgium; Korea Res Inst Biosci & Biotechnol, Natl Genome Informat Ctr, Taejon 305333, South Korea; Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplant Inst, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); KU Leuven; KU Leuven; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, 37 Convent Dr,Room 4146, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov		Roberts, Lewis/0000-0001-7885-8574; Roskams, Tania/0000-0002-2816-1530	NATIONAL CANCER INSTITUTE [Z01SC010385] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Curto M, 2004, CANCER CELL, V5, P113, DOI 10.1016/S1535-6108(04)00031-5; Dabeva MD, 2003, SEMIN LIVER DIS, V23, P349; DURNEZ A, IN PRESS HEPATOLOGY; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; EL SH, 1999, NEW ENGL J MED, V340, P745; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gouillat C, 1999, J AM COLL SURGEONS, V189, P282, DOI 10.1016/S1072-7515(99)00142-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Jothy S, 2003, CLIN EXP METASTAS, V20, P195, DOI 10.1023/A:1022931016285; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kitano H, 2003, NATURE, V426, P125, DOI 10.1038/426125a; Kondo K, 2005, J HEPATO-BILIARY-PAN, V12, P399, DOI 10.1007/s00534-005-1009-9; Lee JS, 2005, CARCINOGENESIS, V26, P1013, DOI 10.1093/carcin/bgi030; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2005, SEMIN LIVER DIS, V25, P125, DOI 10.1055/s-2005-871192; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Libbrecht L, 2000, J HEPATOL, V33, P76, DOI 10.1016/S0168-8278(00)80162-2; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Petkov PM, 2004, HEPATOLOGY, V39, P617, DOI 10.1002/hep.20088; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Robrechts C, 1998, LIVER, V18, P288; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SARRAF C, 1994, AM J PATHOL, V145, P1114; Thorgeirsson SS, 2003, SEMIN LIVER DIS, V23, P303; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; Wu PC, 1996, AM J PATHOL, V149, P1167; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	40	749	787	0	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					410	416		10.1038/nm1377	http://dx.doi.org/10.1038/nm1377			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16532004				2022-12-27	WOS:000236581300029
J	Hao, E; Tyrberg, B; Itkin-Ansari, P; Lakey, JRT; Geron, I; Monosov, EZ; Barcova, M; Mercola, M; Levine, F				Hao, E; Tyrberg, B; Itkin-Ansari, P; Lakey, JRT; Geron, I; Monosov, EZ; Barcova, M; Mercola, M; Levine, F			Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas	NATURE MEDICINE			English	Article							HUMAN-FETAL PANCREAS; ISLET PRECURSOR CELLS; STEM-CELLS; PROGENITOR CELLS; IN-VITRO; ENDOCRINE PANCREAS; NESTIN EXPRESSION; ENDOTHELIAL-CELLS; POSITIVE CELLS; RAT PANCREAS	The nature and even existence of adult pancreatic endocrine stem or progenitor cells is a subject of controversy in the field of beta-cell replacement for diabetes. One place to search for such cells is in the nonendocrine fraction of cells that remain after islet isolation, which consist of a mixture of epithelia and mesenchyme. Culture in G418 resulted in elimination of the mesenchymal cells, leaving a highly purified population of nonendocrine pancreatic epithelial cells (NEPECs). To evaluate their differentiation potential, NEPECs were heritably marked and transplanted under the kidney capsule of immunodeficient mice. When cotransplanted with fetal pancreatic cells, NEPECs were capable of endocrine differentiation. We found no evidence of beta-cell replication or cell fusion that could have explained the appearance of insulin positive cells from a source other than NEPECs. Nonendocrine-to-endocrine differentiation of NEPECs supports the existence of endocrine stem or progenitor cells within the epithelial compartment of the adult human pancreas.	Univ Calif San Diego, Rebecca & John Moores UCSD Canc Ctr, La Jolla, CA 92093 USA; Burnham Inst, Stem Cells & Regenerat Program, La Jolla, CA 92037 USA; Univ Alberta, Clin Islet Isolat Lab, Edmonton, AB T6G 2N8, Canada	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of Alberta	Levine, F (corresponding author), Univ Calif San Diego, Rebecca & John Moores UCSD Canc Ctr, 9500 Gilman Dr,MC 0816, La Jolla, CA 92093 USA.	flevine@ucsd.edu	; Levine, Fred/L-2693-2013	Tyrberg, Bjorn/0000-0003-0976-1220; Levine, Fred/0000-0002-7336-2526				Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152; Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; BEATTIE GM, 1994, CELL TRANSPLANT, V3, P421, DOI 10.1177/096368979400300509; Bogdani M, 2003, DIABETOLOGIA, V46, P830, DOI 10.1007/s00125-003-1118-4; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Delacour A, 2004, MECH DEVELOP, V121, P3, DOI 10.1016/j.mod.2003.11.004; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Esni F, 2004, MECH DEVELOP, V121, P15, DOI 10.1016/j.mod.2003.08.010; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Gao R, 2005, DIABETOLOGIA, V48, P2296, DOI 10.1007/s00125-005-1935-8; Gao R, 2003, DIABETES, V52, P2007, DOI 10.2337/diabetes.52.8.2007; Gershengorn MC, 2004, SCIENCE, V306, P2261, DOI 10.1126/science.1101968; Guz Y, 2001, ENDOCRINOLOGY, V142, P4956, DOI 10.1210/en.142.11.4956; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; Halban PA, 2004, NAT CELL BIOL, V6, P1021, DOI 10.1038/ncb1104-1021; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; Heimberg H, 2000, DIABETES, V49, P571, DOI 10.2337/diabetes.49.4.571; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Hirshberg B, 2003, DIABETES CARE, V26, P3288, DOI 10.2337/diacare.26.12.3288; Humphrey RK, 2003, DIABETES, V52, P2519, DOI 10.2337/diabetes.52.10.2519; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Klein T, 2003, J HISTOCHEM CYTOCHEM, V51, P697, DOI 10.1177/002215540305100601; Lardon J, 2004, VIRCHOWS ARCH, V444, P61, DOI 10.1007/s00428-003-0930-z; Lardon J, 2002, HISTOCHEM CELL BIOL, V117, P535, DOI 10.1007/s00418-002-0412-4; Lechner A, 2004, DIABETES, V53, P616, DOI 10.2337/diabetes.53.3.616; Lechner A, 2002, BIOCHEM BIOPH RES CO, V293, P670, DOI 10.1016/S0006-291X(02)00275-9; Leibowitz G, 1999, DIABETES, V48, P745, DOI 10.2337/diabetes.48.4.745; Levine F, 2004, NEW ENGL J MED, V351, P1024, DOI 10.1056/NEJMcibr041779; Rajagopal J, 2003, SCIENCE, V299, P363; SANDLER S, 1987, DIABETES, V36, P1401, DOI 10.2337/diabetes.36.12.1401; SARVETNICK NE, 1992, ADV EXP MED BIOL, V321, P85; Scharfmann R, 2000, DIABETOLOGIA, V43, P1083, DOI 10.1007/s001250051498; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Street Cale N, 2004, Rev Diabet Stud, V1, P66, DOI 10.1900/RDS.2004.1.66; TUCH BE, 1984, DIABETES, V33, P1180, DOI 10.2337/diabetes.33.12.1180; Tyrberg B, 2001, GEN COMP ENDOCR, V122, P238, DOI 10.1006/gcen.2001.7638; Wang S, 1997, CELL TRANSPLANT, V6, P59, DOI 10.1016/S0963-6897(96)00120-0; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	46	178	208	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					310	316		10.1038/nm1367	http://dx.doi.org/10.1038/nm1367			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491084				2022-12-27	WOS:000235802900030
J	L'Heureux, N; Dusserre, N; Konig, G; Victor, B; Keire, P; Wight, TN; Chronos, NAF; Kyles, AE; Gregory, CR; Hoyt, G; Robbins, RC; McAllister, TN				L'Heureux, N; Dusserre, N; Konig, G; Victor, B; Keire, P; Wight, TN; Chronos, NAF; Kyles, AE; Gregory, CR; Hoyt, G; Robbins, RC; McAllister, TN			Human tissue-engineered blood vessels for adult arterial revascularization	NATURE MEDICINE			English	Article							CULTURED VASCULAR CELLS; MECHANICAL-PROPERTIES; SMOOTH-MUSCLE; IN-VITRO; INVITRO; MODEL; ULTRASOUND; COLLAGEN; GRAFTS	There is a crucial need for alternatives to native vein or artery for vascular surgery. The clinical efficacy of synthetic, allogeneic or xenogeneic vessels has been limited by thrombosis, rejection, chronic inflammation and poor mechanical properties. Using adult human fibroblasts extracted from skin biopsies harvested from individuals with advanced cardiovascular disease, we constructed tissue-engineered blood vessels (TEBVs) that serve as arterial bypass grafts in long-term animal models. These TEBVs have mechanical properties similar to human blood vessels, without relying upon synthetic or exogenous scaffolding. The TEBVs are antithrombogenic and mechanically stable for 8 months in vivo. Histological analysis showed complete tissue integration and formation of vasa vasorum. The endothelium was confluent and positive for von Willebrand factor. A smooth muscle-specific alpha-actin-positive cell population developed within the TEBV, suggesting regeneration of a vascular media. Electron microscopy showed an endothelial basement membrane, elastogenesis and a complex collagen network. These results indicate that a completely biological and clinically relevant TEBV can be assembled exclusively from an individual's own cells.	Cytograft Tissue Engn Inc, Novato, CA 94949 USA; Capitol Cardiovasc Imaging Ctr, Sacramento, CA 95816 USA; Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA 98101 USA; Amer Cardiovasc Res Inst, Atlanta, GA 30342 USA; Univ Calif Davis, Dept Surg & Radiol Sci, Sch Vet Med, Davis, CA 95616 USA; Stanford Univ, Dept Cardiothorac Surg, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA	Benaroya Research Institute; Virginia Mason Medical Center; University of California System; University of California Davis; Stanford University	L'Heureux, N (corresponding author), Cytograft Tissue Engn Inc, 3 Hamilton Landing,Suite 220, Novato, CA 94949 USA.	nico@cytograft.com; todd@cytograft.com	Dusserre, Nathalie/AAG-9108-2019; L'Heureux, Nicolas/K-8669-2015	Dusserre, Nathalie/0000-0002-4699-3365; L'Heureux, Nicolas/0000-0001-8602-3948	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL064462] Funding Source: NIH RePORTER; NHLBI NIH HHS [R44 HL064462-02A1, 2R44HL64462, R44 HL064462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berglund JD, 2003, BIOMATERIALS, V24, P1241, DOI 10.1016/S0142-9612(02)00506-9; CAMBRIA RP, 1987, ANN SURG, V205, P167, DOI 10.1097/00000658-198702000-00011; Chamiot-Clerc P, 1998, CARDIOVASC RES, V37, P811, DOI 10.1016/S0008-6363(97)00267-8; Chue WL, 2004, J VASC SURG, V39, P859, DOI 10.1016/j.jvs.2003.03.003; Davis C, 2003, J THROMB HAEMOST, V1, P1699, DOI 10.1046/j.1538-7836.2003.00292.x; DOBRIN PB, 1984, ANN BIOMED ENG, V12, P497, DOI 10.1007/BF02363919; GIRERD XJ, 1992, J HYPERTENS, V10, pS111; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; Grenier G, 2003, IN VITRO CELL DEV-AN, V39, P131; Kakisis JD, 2005, J VASC SURG, V41, P349, DOI 10.1016/j.jvs.2004.12.026; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Lamm P, 2001, CIRCULATION, V104, pI108; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; Michel M, 1999, IN VITRO CELL DEV-AN, V35, P318; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 1999, SCIENCE, V286, P1493, DOI 10.1126/science.286.5444.1493; Poh M, 2005, LANCET, V365, P2122, DOI 10.1016/S0140-6736(05)66735-9; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; van Andel CJ, 2003, ANN THORAC SURG, V76, P58, DOI 10.1016/S0003-4975(03)00263-7; VAN SJ, 1990, J THORAC CARDIOVASC, V99, P703; VANDERLUGT A, 1995, EUR J VASC ENDOVASC, V9, P394, DOI 10.1016/S1078-5884(05)80006-1; Varty K, 1996, BRIT J SURG, V83, P1375, DOI 10.1002/bjs.1800831015; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421	26	653	682	1	208	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					361	365		10.1038/nm1364	http://dx.doi.org/10.1038/nm1364			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491087	Green Accepted			2022-12-27	WOS:000235802900038
J	Lewis, JD; Destito, G; Zijlstra, A; Gonzalez, MJ; Quigley, JP; Manchester, M; Stuhlmann, H				Lewis, JD; Destito, G; Zijlstra, A; Gonzalez, MJ; Quigley, JP; Manchester, M; Stuhlmann, H			Viral nanoparticles as tools for intravital vascular imaging	NATURE MEDICINE			English	Article							COWPEA MOSAIC-VIRUS; 2.8 ANGSTROM RESOLUTION; IN-VIVO; CRYSTAL-STRUCTURE; PLANT-VIRUSES; ANGIOGENESIS; PEPTIDES; SURFACE; CELLS	A significant impediment to the widespread use of noninvasive in vivo vascular imaging techniques is the current lack of suitable intravital imaging probes. We describe here a new strategy to use viral nanoparticles as a platform for the multivalent display of fluorescent dyes to image tissues deep inside living organisms. The bioavailable cowpea mosaic virus (CPMV) can be fluorescently labeled to high densities with no measurable quenching, resulting in exceptionally bright particles with in vivo dispersion properties that allow high-resolution intravital imaging of vascular endothelium for periods of at least 72 h. We show that CPMV nanoparticles can be used to visualize the vasculature and blood flow in living mouse and chick embryos to a depth of up to 500 mu m. Furthermore, we show that the intravital visualization of human fibrosarcoma-mediated tumor angiogenesis using fluorescent CPMV provides a means to identify arterial and venous vessels and to monitor the neovascularization of the tumor microenvironment.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Div Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Ctr Integrat Mol Biosci, Scripps Res Inst, La Jolla, CA 92037 USA; Univ Studi Magna Graecia Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Manchester, M (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	marim@scripps.edu; hstuhlm@scripps.edu	zijlstra, andries/G-4564-2013	zijlstra, andries/0000-0001-8460-8803; Stuhlmann, Heidi/0000-0001-7217-768X; Manchester, Marianne/0000-0002-7143-5744	NATIONAL CANCER INSTITUTE [R01CA055852, R01CA112075, R01CA105412] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065738, R21HL072270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047823] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112075, R01 CA105412, CA112075, N01-CO-27181, R01 CA055852, R01 CA55852] Funding Source: Medline; NHLBI NIH HHS [R01 HL065738, R21 HL072270-02, R01 HL065738-04, R21 HL072270-03, R01 HL65738, R21 HL72270, R21 HL072270] Funding Source: Medline; NIAID NIH HHS [AI47823, R01 AI047823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brennan FR, 2001, MOL BIOTECHNOL, V17, P15, DOI 10.1385/MB:17:1:15; Chatterji A, 2004, BIOCONJUGATE CHEM, V15, P807, DOI 10.1021/bc0402888; Chatterji A, 2004, CHEM BIOL, V11, P855, DOI 10.1016/j.chembiol.2004.04.011; DESSENS JT, 1993, J GEN VIROL, V74, P889, DOI 10.1099/0022-1317-74-5-889; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; Gref R, 1997, Pharm Biotechnol, V10, P167; Hahm B, 2004, VIROLOGY, V323, P292, DOI 10.1016/j.virol.2004.03.011; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Johnson J, 1997, ANNU REV PHYTOPATHOL, V35, P67, DOI 10.1146/annurev.phyto.35.1.67; Jones EAV, 2002, GENESIS, V34, P228, DOI 10.1002/gene.10162; Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d; Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lee PJ, 2003, METHOD ENZYMOL, V373, P214; Lin TW, 1999, VIROLOGY, V265, P20, DOI 10.1006/viro.1999.0038; Lin TW, 1996, FOLD DES, V1, P179, DOI 10.1016/S1359-0278(96)00030-2; LOMONOSSOFF GP, 1983, EMBO J, V2, P2253, DOI 10.1002/j.1460-2075.1983.tb01731.x; LOMONOSSOFF GP, 1991, PROG BIOPHYS MOL BIO, V55, P107, DOI 10.1016/0079-6107(91)90003-B; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Nicholas BL, 2002, VACCINE, V20, P2727, DOI 10.1016/S0264-410X(02)00200-1; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; Porta C, 2003, VIROLOGY, V310, P50, DOI 10.1016/S0042-6822(03)00140-5; Rae CS, 2005, VIROLOGY, V343, P224, DOI 10.1016/j.virol.2005.08.017; Reddy VS, 2001, J VIROL, V75, P11943, DOI 10.1128/JVI.75.24.11943-11947.2001; RIZZO V, 1993, MICROVASC RES, V46, P320, DOI 10.1006/mvre.1993.1056; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e; Wang Q, 2002, CHEM BIOL, V9, P805, DOI 10.1016/S1074-5521(02)00165-5; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; Yang CS, 2004, ANAL CHEM, V76, P4465, DOI 10.1021/ac035491v; Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200	33	295	305	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					354	360		10.1038/nm1368	http://dx.doi.org/10.1038/nm1368			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16501571	Green Accepted			2022-12-27	WOS:000235802900037
J	Mills, PB; Struys, E; Jakobs, C; Plecko, B; Baxter, P; Baumgartner, M; Willemsen, MAAP; Omran, H; Tacke, U; Uhlenberg, B; Weschke, B; Clayton, PT				Mills, PB; Struys, E; Jakobs, C; Plecko, B; Baxter, P; Baumgartner, M; Willemsen, MAAP; Omran, H; Tacke, U; Uhlenberg, B; Weschke, B; Clayton, PT			Mutations in antiquitin in individuals with pyridoxine-dependent seizures	NATURE MEDICINE			English	Article							ALDEHYDE DEHYDROGENASES; EPILEPSY; ACID; PURIFICATION; PHOSPHATE; PROTEIN; GENE	We show here that children with pyridoxine-dependent seizures (PDS) have mutations in the ALDH7A1 gene, which encodes antiquitin; these mutations abolish the activity of antiquitin as a Delta(1)-piperideine-6-carboxylate (P6C)-alpha-aminoadipic semialdehyde (alpha-AASA) dehydrogenase. The accumulating P6C inactivates pyridoxal 5'-phosphate (PLP) by forming a Knoevenagel condensation product. Measurement of urinary alpha-AASA provides a simple way of confirming the diagnosis of PDS and ALDH7A1 gene analysis provides a means for prenatal diagnosis.	UCL, Great Ormond St Hosp Children Children, Natl Hlth Serv Trust, Inst Child Hlth, London, England; Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, NL-1081 HV Amsterdam, Netherlands; Univ Hosp Graz, Dept Pediat, A-8036 Graz, Austria; Sheffields Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England; Univ Childrens Hosp, Div Metab & Mol Pediat, CH-8032 Zurich, Switzerland; Univ Nijmegen, Med Ctr, Dept Pediat Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Freiburg, Dept Neuropediat, D-79106 Freiburg, Germany; Charite Univ Med Berlin, Dept Neuropediat, D-13353 Berlin, Germany	University of London; University College London; Vrije Universiteit Amsterdam; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University Children's Hospital Zurich; Radboud University Nijmegen; University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Clayton, PT (corresponding author), UCL, Great Ormond St Hosp Children Children, Natl Hlth Serv Trust, Inst Child Hlth, 30 Guilford St, London, England.	clayton@ich.ucl.ac.uk	Baumgartner, Matthias/Q-2855-2017; Willemsen, Michel A.A.P./H-8119-2014; Clayton, Peter T/C-1523-2008	Baumgartner, Matthias/0000-0002-9270-0826; Weschke, Bernhard/0000-0003-4533-0743; Mills, Philippa/0000-0002-9704-1268; Plecko, Barbara/0000-0002-3203-1325; Omran, Heymut/0000-0003-0282-6765; Clayton, Peter/0000-0001-7592-4302				Baxter P, 2001, VITAMIN RESPONSIVE C, P109; Cormier-Daire V, 2000, AM J HUM GENET, V67, P991, DOI 10.1086/303087; Farrant RD, 2001, J BIOL CHEM, V276, P15107, DOI 10.1074/jbc.M010860200; Kure S, 1998, J HUM GENET, V43, P128, DOI 10.1007/s100380050053; LEE P, 1994, GENOMICS, V21, P371, DOI 10.1006/geno.1994.1279; Mann CJ, 1999, PROTEIN SCI, V8, P1922, DOI 10.1110/ps.8.10.1922; Nabbout R, 1999, ARCH DIS CHILD-FETAL, V81, pF125, DOI 10.1136/fn.81.2.F125; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Plecko B, 2000, ANN NEUROL, V48, P121, DOI 10.1002/1531-8249(200007)48:1<121::AID-ANA20>3.0.CO;2-V; Rodriguez-Zavala J, 2001, CHEM-BIOL INTERACT, V130, P151, DOI 10.1016/S0009-2797(00)00230-1; Tang WK, 2002, FEBS LETT, V516, P183, DOI 10.1016/S0014-5793(02)02553-X; TSAI CH, 1974, J BIOL CHEM, V249, P5790; Wang HS, 2005, ARCH DIS CHILD, V90, P512, DOI 10.1136/adc.2003.045963; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007	15	366	379	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					307	309		10.1038/nm1366	http://dx.doi.org/10.1038/nm1366			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16491085				2022-12-27	WOS:000235802900029
J	Nakagawa, Y; Shimano, H; Yoshikawa, T; Ide, T; Tamura, M; Furusawa, M; Yamamoto, T; Inoue, N; Matsuzaka, T; Takahashi, A; Hasty, AH; Suzuki, H; Sone, H; Toyoshima, H; Yahagi, N; Yamada, N				Nakagawa, Y; Shimano, H; Yoshikawa, T; Ide, T; Tamura, M; Furusawa, M; Yamamoto, T; Inoue, N; Matsuzaka, T; Takahashi, A; Hasty, AH; Suzuki, H; Sone, H; Toyoshima, H; Yahagi, N; Yamada, N			TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes	NATURE MEDICINE			English	Article							ELEMENT-BINDING PROTEIN-1; LOOP-HELIX PROTEIN; HEXOKINASE II GENE; LIVER; MICE; RESISTANCE; PROMOTER; RECEPTOR; EXPRESSION; SREBPS	Using an expression cloning strategy, we have identified TFE3, a basic helix-loop-helix protein, as a transactivator of metabolic genes that are regulated through an E-box in their promoters. Adenovirus-mediated expression of TFE3 in hepatocytes in culture and in vivo strongly activated expression of IRS-2 and Akt and enhanced phosphorylation of insulin-signaling kinases such as Akt, glycogen synthase kinase 3 beta and p70S6 kinase. TFE3 also induced hexokinase II (HK2) and insulin-induced gene 1 (INSIG1). These changes led to metabolic consequences, such as activation of glycogen and protein synthesis, but not lipogenesis, in liver. Collectively, plasma glucose levels were markedly reduced both in normal mice and in different mouse models of diabetes, including streptozotocin-treated, db/db and KK mice. Promoter analyses showed that IRS2, HK2 and INSIG1 are direct targets of TFE3. Activation of insulin signals in both insulin depletion and resistance suggests that TFE3 could be a therapeutic target for diabetes.	Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Tsukuba; University of Tsukuba; Vanderbilt University	Shimano, H (corresponding author), Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Yahagi, Naoya/D-2360-2014; Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/V-1761-2019; Hasty, Alyssa/AAA-2757-2020; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Sone, Hirohito/0000-0003-1263-2817; Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045; 				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Grinberg AV, 2003, J BIOL CHEM, V278, P11227, DOI 10.1074/jbc.M211734200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heikkinen S, 2000, MAMM GENOME, V11, P91, DOI 10.1007/s003350010019; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Riu E, 2003, FASEB J, V17, P1715, DOI 10.1096/fj.02-1163fje; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	36	91	95	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					107	113		10.1038/nm1334	http://dx.doi.org/10.1038/nm1334			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327801				2022-12-27	WOS:000234419000059
J	Yamamoto, K; Sokabe, T; Matsumoto, T; Yoshimura, K; Shibata, M; Ohura, N; Fukuda, T; Sato, T; Sekine, K; Kato, S; Isshiki, M; Fujita, T; Kobayashi, M; Kawamura, K; Masuda, H; Kamiya, A; Ando, J				Yamamoto, K; Sokabe, T; Matsumoto, T; Yoshimura, K; Shibata, M; Ohura, N; Fukuda, T; Sato, T; Sekine, K; Kato, S; Isshiki, M; Fujita, T; Kobayashi, M; Kawamura, K; Masuda, H; Kamiya, A; Ando, J			Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice	NATURE MEDICINE			English	Article							FLUID SHEAR-STRESS; ENDOTHELIAL-CELLS; NITRIC-OXIDE; P2X RECEPTORS; ATP; ACTIVATION; MUSCLE; CHANNELS; SYNTHASE; RELEASE	The structure and function of blood vessels adapt to environmental changes such as physical development and exercise(1-3). This phenomenon is based on the ability of the endothelial cells to sense and respond to blood flow(4-6); however, the underlying mechanisms remain unclear. Here we show that the ATP-gated P2X4 ion channel(7,8), expressed on endothelial cells and encoded by P2rx4 in mice, has a key role in the response of endothelial cells to changes in blood flow. P2rx4(-/-) mice do not have normal endothelial cell responses to flow, such as influx of Ca2+ and subsequent production of the potent vasodilator nitric oxide (NO). Additionally, vessel dilation induced by acute increases in blood flow is markedly suppressed in P2rx4(-/-) mice. Furthermore, P2rx4(-/-) mice have higher blood pressure and excrete smaller amounts of NO products in their urine than do wild-type mice. Moreover, no adaptive vascular remodeling, that is, a decrease in vessel size in response to a chronic decrease in blood flow, was observed in P2rx4(-/-) mice. Thus, endothelial P2X4 channels are crucial to flow-sensitive mechanisms that regulate blood pressure and vascular remodeling.	Univ Tokyo, Dept Biomed Engn, Grad Sch Med, Tokyo 1130033, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Univ Tokyo, Dept Nephrol & Endocrinol, Grad Sch Med, Tokyo 1138655, Japan; Akita Univ, Sch Med, Dept Pathol 2, Akita 0108543, Japan; Nihon Univ, Interdisciplinary Sci Ctr, Tokyo 1020074, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Akita University; Nihon University	Ando, J (corresponding author), Univ Tokyo, Dept Biomed Engn, Grad Sch Med, Tokyo 1130033, Japan.	joji@m.u-tokyo.ac.jp		Sekine, Keisuke/0000-0001-5133-0876; Sokabe, Takaaki/0000-0003-1280-9424				Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Glass R, 2001, J ANAT, V198, P569, DOI 10.1046/j.1469-7580.2001.19850569.x; GUYTON JR, 1985, AM J PHYSIOL, V248, P540; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; KAMIYA A, 1980, AM J PHYSIOL, V239, P14; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; KOLLER A, 1994, AM J PHYSIOL, V267, pH326, DOI 10.1152/ajpheart.1994.267.1.H326; Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812, DOI 10.1161/01.ATV.9.6.812; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Ray FR, 2002, ATHEROSCLEROSIS, V162, P55, DOI 10.1016/S0021-9150(01)00681-5; Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Vlaskovska M, 2001, J NEUROSCI, V21, P5670, DOI 10.1523/JNEUROSCI.21-15-05670.2001; Yamamoto K, 2000, CIRC RES, V87, P385; Yamamoto K, 2000, AM J PHYSIOL-HEART C, V279, pH285, DOI 10.1152/ajpheart.2000.279.1.H285	30	259	270	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					133	137		10.1038/nm1338	http://dx.doi.org/10.1038/nm1338			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327800				2022-12-27	WOS:000234419000063
J	Iannacone, M; Sitia, G; Isogawa, M; Marchese, P; Castro, MG; Lowenstein, PR; Chisari, FV; Ruggeri, ZM; Guidotti, LG				Iannacone, M; Sitia, G; Isogawa, M; Marchese, P; Castro, MG; Lowenstein, PR; Chisari, FV; Ruggeri, ZM; Guidotti, LG			Platelets mediate cytotoxic T lymphocyte-induced liver damage	NATURE MEDICINE			English	Article							HEPATITIS-B-VIRUS; IN-VIVO; CELLS	We found that platelet depletion reduces intrahepatic accumulation of virus-specific cytotoxic T lymphocytes ( CTLs) and organ damage in mouse models of acute viral hepatitis. Transfusion of normal but not activation-blocked platelets in platelet-depleted mice restored accumulation of CTLs and severity of disease. In contrast, anticoagulant treatment that prevented intrahepatic fibrin deposition without reducing platelet counts did not avert liver injury. Thus, activated platelets contribute to CTL-mediated liver immunopathology independently of procoagulant function.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; San Raffaele Sci Inst, Immunopathogenesis Liver Infect Unit, I-20132 Milan, Italy; Cedars Sinai Med Ctr, Board Governors, Gene Therapeut Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Scripps Research Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Guidotti, LG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	guidotti@scripps.edu	Iannacone, Matteo/I-8507-2018; Guidotti, Luca G. G/I-8542-2018; Chisari, Francis V/A-3086-2008; Castro, Maria/ABC-5182-2021; Isogawa, Masanori/AAN-8969-2021; Sitia, Giovanni/U-2114-2019; Sitia, Giovanni/K-1036-2016	Iannacone, Matteo/0000-0002-9370-2671; Guidotti, Luca G. G/0000-0002-0205-2678; Castro, Maria/0000-0003-2237-2756; Isogawa, Masanori/0000-0001-8730-4303; Sitia, Giovanni/0000-0003-1024-9128; Sitia, Giovanni/0000-0003-1024-9128; Chisari, Francis/0000-0002-4832-1044	NATIONAL CANCER INSTITUTE [R01CA040489, R37CA040489] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, P01HL078784, P01HL031950, R01HL042846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057711, U01NS052465, R21NS054143, R01NS054193, R01NS061107, R01NS042893] Funding Source: NIH RePORTER; NCI NIH HHS [CA40489, R37 CA040489, R01 CA040489] Funding Source: Medline; NHLBI NIH HHS [HL31950, R01 HL042846, HL78784, P01 HL078784, R37 HL042846, HL42846, P01 HL031950] Funding Source: Medline; NIAID NIH HHS [R01 AI040696, AI40696] Funding Source: Medline; NINDS NIH HHS [U01 NS052465-01A2, R21 NS054143, R01 NS042893, R01 NS057711, R01 NS061107-01A1, R01 NS042893-01A1, R01 NS054193, R21 NS054143-01A2, U01 NS052465, R01 NS061107, R01 NS054193-01A1, R01 NS057711-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO K, 1994, J IMMUNOL, V152, P3245; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Kakimi K, 2001, J EXP MED, V194, P1755, DOI 10.1084/jem.194.12.1755; McClary H, 2000, J VIROL, V74, P2255, DOI 10.1128/JVI.74.5.2255-2264.2000; Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836; Sitia G, 2004, J CLIN INVEST, V113, P1158, DOI 10.1172/JCI200421087; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x; Wilson JM, 2001, ADV DRUG DELIVER REV, V46, P205, DOI 10.1016/S0169-409X(00)00125-3	12	248	261	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1167	1169		10.1038/nm1317	http://dx.doi.org/10.1038/nm1317			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16258538	Green Accepted			2022-12-27	WOS:000233115400027
J	Wei, FY; Nagashima, K; Ohshima, T; Saheki, Y; Lu, YF; Matsushita, M; Yamada, Y; Mikoshiba, K; Seino, Y; Matsui, H; Tomizawa, K				Wei, FY; Nagashima, K; Ohshima, T; Saheki, Y; Lu, YF; Matsushita, M; Yamada, Y; Mikoshiba, K; Seino, Y; Matsui, H; Tomizawa, K			Cdk5-dependent regulation of glucose-stimulated insulin secretion	NATURE MEDICINE			English	Article							CYCLIN-DEPENDENT KINASE-5; DIFFERENTIAL GENE-EXPRESSION; CHANNEL ACTIVITY; MIN6 SUBLINES; ACTIVATOR; PHOSPHORYLATION; CDK5; P35; EXOCYTOSIS; SUBUNIT	Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications(1). Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (K-ATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often associated with the side effect of hypoglycemia. Here we show that inhibition of the activity of cyclin-dependent kinase 5 (Cdk5) enhanced insulin secretion under conditions of stimulation by high glucose but not low glucose in MIN6 cells and pancreatic islets. The role of Cdk5 in regulation of insulin secretion was confirmed in pancreatic beta cells deficient in p35, an activator of Cdk5. p35-knockout mice also showed enhanced insulin secretion in response to a glucose challenge. Cdk5 kinase inhibition enhanced the inward whole-cell Ca2+ channel current and increased Ca2+ influx across the L-type voltage-dependent Ca2+ channel ( L-VDCC) upon stimulation with high glucose in beta cells, but had no effect on Ca2+ influx without glucose stimulation. The inhibitory regulation by Cdk5 on the L-VDCC was attributed to the phosphorylation of loop II-III of the alpha(1C) subunit of L-VDCC at Ser783, which prevented the binding to SNARE proteins and subsequently resulted in a decrease of the activity of L-VDCC. These results suggest that Cdk5/p35 may be a drug target for the regulation of glucose-stimulated insulin secretion.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama 7008558, Japan; Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto 6068507, Japan; RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Prot Therapy, Preventure Program, Off Technol Transfer, Okayama 7008558, Japan	Okayama University; Kyoto University; RIKEN; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015; Wei, Fan-Yan/AAD-8461-2021; Mikoshiba, Katsuhiko/N-7943-2015; Saheki, Yasunori/D-5430-2016	Tomizawa, Kazuhito/0000-0002-5663-2627; Saheki, Yasunori/0000-0002-1229-6668; Wei, Fan-Yan/0000-0002-4843-724X				Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Lilla V, 2003, ENDOCRINOLOGY, V144, P1368, DOI 10.1210/en.2002-220916; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P188; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	22	149	190	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1104	1108		10.1038/nm1299	http://dx.doi.org/10.1038/nm1299			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155576				2022-12-27	WOS:000232492500032
J	Chiarle, R; Simmons, WJ; Cai, HY; Dhall, G; Zamo', A; Raz, R; Karras, JG; Levy, DE; Inghirami, G				Chiarle, R; Simmons, WJ; Cai, HY; Dhall, G; Zamo', A; Raz, R; Karras, JG; Levy, DE; Inghirami, G			Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target	NATURE MEDICINE			English	Article							ABL KINASE-ACTIVITY; CYCLIN D1 PROMOTER; CONSTITUTIVE ACTIVATION; ANAPLASTIC LYMPHOMA; NPM-ALK; CELL LYMPHOMA; EXPRESSION; INHIBITION; APOPTOSIS; GROWTH	Anaplastic large cell lymphomas (ALCLs) are caused by chromosomal translocations that juxtapose the anaplastic lymphoma kinase (ALK) proto-oncogene to a dimerization partner, resulting in constitutive expression of ALK and ALK tyrosine kinase activity. One substrate of activated ALK in human ALCLs is the transcription factor Stat3, and its phosphorylation is accurately recapitulated in a new nucleophosmin (NPM)-ALK transgenic mouse model of lymphomagenesis. Here we show by gene targeting that Stat3 is required for the transformation of mouse embryonic fibroblasts in vitro, for the development of B-cell lymphoma in transgenic mice and for the growth and survival of both human and mouse NPM-ALK-transformed B and T cells. Ablation of Stat3 expression by antisense oligonucleotides significantly ( P < 0.0001) impaired the growth of human and mouse NPM-ALK tumors in vivo. Pharmacological ablation of Stat3 represents a new candidate approach for the treatment of human lymphoma.	NYU, Dept Pathol, Sch Med, New York, NY 10016 USA; NYU, Inst Canc, Sch Med, New York, NY 10016 USA; Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy; NYU, Dept Pediat Oncol, Sch Med, New York, NY 10016 USA; Univ Verona, Dept Pathol, I-37100 Verona, Italy; ISIS Pharmaceut, Carlsbad, CA 92008 USA	New York University; New York University; University of Turin; University of Turin; New York University; University of Verona; Isis Pharmaceuticals Inc	Inghirami, G (corresponding author), NYU, Dept Pathol, Sch Med, 550 1st Ave, New York, NY 10016 USA.	inghig01@med.nyu.edu	Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019; Zamò, Alberto/ABF-4436-2020	Levy, David/0000-0002-7320-7788; Zamo, Alberto/0000-0001-6203-7966; CHIARLE, Roberto/0000-0003-1564-8531				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Cessna MH, 2002, MODERN PATHOL, V15, P931, DOI 10.1097/01.MP.0000026615.04130.1F; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 1999, J IMMUNOL, V163, P194; De Paepe P, 2003, BLOOD, V102, P2638, DOI 10.1182/blood-2003-04-1050; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS NL, 1994, BLOOD, V84, P1361; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Huang M, 2002, ONCOGENE, V21, P8804, DOI 10.1038/sj.onc.1206028; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Liang Y, 2004, DIABETES, V53, pA134, DOI 10.2337/diabetes.53.2.410; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; SCHLESSINGER K, IN PRESS CANC RES; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Sloop KW, 2004, J CLIN INVEST, V113, P1571, DOI 10.1172/JCI200420911; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152	41	336	347	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					623	629		10.1038/nm1249	http://dx.doi.org/10.1038/nm1249			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895073				2022-12-27	WOS:000229589800028
J	Davies, JE; Wang, L; Garcia-Oroz, L; Cook, LJ; Vacher, C; O'Donovan, DG; Rubinsztein, DC				Davies, JE; Wang, L; Garcia-Oroz, L; Cook, LJ; Vacher, C; O'Donovan, DG; Rubinsztein, DC			Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice	NATURE MEDICINE			English	Article							REDUCE AGGREGATE FORMATION; CELL-DEATH; HUNTINGTONS-DISEASE; MODEL; MINOCYCLINE; PHENOTYPE; GENE; EXPANSIONS; CHAPERONES; APOPTOSIS	The muscular dystrophies are a heterogeneous group of disorders for which there are currently no cures. Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset, progressive disease that generally presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness. OPMD is caused by the abnormal expansion of a (GCG)(n) trinucleotide repeat in the coding region of the poly-(A) binding protein nuclear 1 (PABPN1) gene(1). In unaffected individuals, (GCG)(6) codes for the first six alanines in a homopolymeric stretch of ten alanines. In most individuals with OPMD this (GCG)(6) repeat is expanded to (GCG)(8-13), leading to a stretch of 12 - 17 alanines in mutant PABPN1. PABPN1 with an expanded polyalanine tract forms aggregates consisting of tubular filaments within the nuclei of skeletal muscle fibers(2-4). We have developed a transgenic mouse model of OPMD that manifests progressive muscle weakness accompanied by intranuclear aggregates and TUNEL-stained nuclei in skeletal muscle fibers. The onset and severity of these abnormalities were substantially delayed and attenuated by doxycycline treatment, which may exert its therapeutic effect by reducing aggregates and by distinct antiapoptotic properties. Doxycycline may represent a safe and feasible therapeutic for this disease.	Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.	dcr1000@hermes.cam.ac.uk	Rubinsztein, David C/C-3472-2011	Davies, Janet/0000-0002-8853-8328				Abu-Baker A, 2003, HUM MOL GENET, V12, P2609, DOI 10.1093/hmg/ddg293; Albrecht AN, 2004, HUM MOL GENET, V13, P2351, DOI 10.1093/hmg/ddh277; Bao YP, 2004, J MED GENET, V41, P47, DOI 10.1136/jmg.2003.014548; Bao YP, 2002, J BIOL CHEM, V277, P12263, DOI 10.1074/jbc.M109633200; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Girgenrath M, 2004, J CLIN INVEST, V114, P1635, DOI 10.1172/JCI200422928; Hino H, 2004, HUM MOL GENET, V13, P181, DOI 10.1093/hmg/ddh017; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TOME FMS, 1997, NEUROMUSCUL DISOR S1, V7, P63; Uyama E, 2000, MUSCLE NERVE, V23, P1549, DOI 10.1002/1097-4598(200010)23:10<1549::AID-MUS11>3.0.CO;2-0; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	22	109	111	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					672	677		10.1038/nm1242	http://dx.doi.org/10.1038/nm1242			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15864313				2022-12-27	WOS:000229589800035
J	Mandavilli, A				Mandavilli, A			Woo-Suk Hwang	NATURE MEDICINE			English	Biographical-Item																		2004, SCIENCE, V303, P1663	1	8	8	1	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2005	11	5					464	464		10.1038/nm0505-464	http://dx.doi.org/10.1038/nm0505-464			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15875043	Bronze			2022-12-27	WOS:000228915000009
J	Lin, JM; Patel, SR; Cheng, X; Cho, EA; Levitan, I; Ullenbruch, M; Phan, SH; Park, JM; Dressler, GR				Lin, JM; Patel, SR; Cheng, X; Cho, EA; Levitan, I; Ullenbruch, M; Phan, SH; Park, JM; Dressler, GR			Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease	NATURE MEDICINE			English	Article							BONE MORPHOGENETIC PROTEIN-7; TGF-BETA; MESENCHYMAL TRANSITION; EMBRYONIC-DEVELOPMENT; FIBROSIS; CHORDIN; KIDNEY; INJURY; GENE; IDENTIFICATION	The bone morphogenetic proteins (BMPs) profoundly affect embryonic development, differentiation and disease. BMP signaling is suppressed by cysteine-rich domain proteins, such as chordin, that sequester ligands from the BMP receptor. We describe a novel protein, KCP, with 18 cysteine-rich domains. Unlike chordin, KCP enhances BMP signaling in a paracrine manner. Smad1-dependent transcription and phosphorylated Smad1 (P-Smad1) levels are increased, as KCP binds to BMP7 and enhances binding to the type I receptor. In vivo, Kcp(-/-) mice are viable and fertile. Because BMPs have a pivotal role in renal disease, we examined the phenotype of Kcp(-/-) mice in two different models of renal injury. Kcp(-/-) animals show reduced levels of P-Smad1, are more susceptible to developing renal interstitial fibrosis, are more sensitive to tubular injury and show substantial pathology after recovery. The data indicate an important role for KCP in attenuating the pathology of renal fibrotic disease.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dressler, GR (corresponding author), Univ Michigan, Dept Pathol, 1301 Catherine St, Ann Arbor, MI 48109 USA.	dressler@umich.edu	Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NHLBI NIH HHS [HL52285] Funding Source: Medline; NIDDK NIH HHS [DK02803, DK062914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062914, K08DK002803] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Almanzar MM, 1998, J AM SOC NEPHROL, V9, P1456; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Capdevila J, 1999, CURR OPIN GENET DEV, V9, P427, DOI 10.1016/S0959-437X(99)80065-3; Chevalier RL, 1999, PEDIATR NEPHROL, V13, P612, DOI 10.1007/s004670050756; Christian JL, 2000, CURR OPIN CELL BIOL, V12, P244, DOI 10.1016/S0955-0674(99)00082-4; Coles E, 2004, DEVELOPMENT, V131, P5309, DOI 10.1242/dev.01419; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523-1755.2002.00103.x; Herzlinger D, 2002, J CLIN INVEST, V110, P305, DOI 10.1172/JCI200216377; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; JOYNER AL, 1993, GENE TARGETING PRACT, P33; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Klahr S, 2003, KIDNEY INT, V64, pS105, DOI 10.1046/j.1523-1755.64.s87.16.x; Kopp JB, 2000, KIDNEY INT, V58, P2237, DOI 10.1046/j.1523-1755.2000.00402.x; Kopp JB, 1996, LAB INVEST, V74, P991; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; Larrain J, 2000, DEVELOPMENT, V127, P821; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Matsui M, 2000, P NATL ACAD SCI USA, V97, P5291, DOI 10.1073/pnas.090020497; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; PHAN SH, 1980, AM REV RESPIR DIS, V121, P501, DOI 10.1164/arrd.1980.121.3.501; Safirstein R, 1999, KIDNEY INT, V56, P1599, DOI 10.1046/j.1523-1755.1999.00718.x; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zwijsen A, 2003, FEBS LETT, V546, P133, DOI 10.1016/S0014-5793(03)00566-0	37	144	155	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					387	393		10.1038/nm1217	http://dx.doi.org/10.1038/nm1217			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793581				2022-12-27	WOS:000228180500029
J	Starr, A				Starr, Albert			The artificial heart valve	NATURE MEDICINE			English	Editorial Material							REPLACEMENT; PROSTHESIS; EXPERIENCE		Providence St Vincent Med Ctr, Portland, OR 97225 USA		Starr, A (corresponding author), Providence St Vincent Med Ctr, 9155 SW Barnes Rd,Suite 240, Portland, OR 97225 USA.	astarr@starrwood.com						Gao GQ, 2004, J HEART VALVE DIS, V13, P91; GIBBON J H Jr, 1954, Minn Med, V37, P171; GLADWELL M, 2002, TIPPING POINT HOW LI; Gladwell M., 2005, BLINK POWER THINKING; GRUNKEMEIER GL, 1988, CAN J CARDIOL, V4, P381; HUFNAGEL CA, 1958, ANN SURG, V147, P636, DOI 10.1097/00000658-195805000-00007; KIRKLIN JW, 1960, CIRCULATION, V21, P578, DOI 10.1161/01.CIR.21.4.578; LILLEHEI CW, 1958, J THORAC SURG, V35, P154; Maeda J., 2006, LAWS SIMPLICITY; MERENDINO KA, 1961, PROSTHETIC VALVES CA; Paladugu R, 2002, WORLD J SURG, V26, P1099, DOI 10.1007/s00268-002-6376-7; STARR A, 1961, ANN SURG, V154, P726, DOI 10.1097/00000658-196110000-00017; STARR A, 1960, SURG FORUM, V11, P258; Taleb N. N., 2010, BLACK SWAN, DOI DOI 10.1176/PS.2009.60.11.1564; TEPLY JF, 1981, ANN THORAC SURG, V32, P111, DOI 10.1016/S0003-4975(10)61017-X	15	12	12	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1160	1164		10.1038/nm1644	http://dx.doi.org/10.1038/nm1644			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17917665				2022-12-27	WOS:000249980200029
J	Ohashi, K; Yokoyama, T; Yamato, M; Kuge, H; Kanehiro, H; Tsutsumi, M; Amanuma, T; Iwata, H; Yang, J; Okano, T; Nakajima, Y				Ohashi, Kazuo; Yokoyama, Takashi; Yamato, Masayuki; Kuge, Hiroyuki; Kanehiro, Hiromichi; Tsutsumi, Masahiro; Amanuma, Toshihiro; Iwata, Hiroo; Yang, Joseph; Okano, Teruo; Nakajima, Yoshiyuki			Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets	NATURE MEDICINE			English	Article							HEPATOCYTE TRANSPLANTATION; CELL SHEETS; MICE	Hepatic tissue engineering using primary hepatocytes has been considered a valuable new therapeutic modality for several classes of liver diseases. Recent progress in the development of clinically feasible liver tissue engineering approaches, however, has been hampered mainly by insufficient cell-to-cell contact of the engrafted hepatocytes. We developed a method to engineer a uniformly continuous sheet of hepatic tissue using isolated primary hepatocytes cultured on temperature-responsive surfaces. Sheets of hepatic tissue transplanted into the subcutaneous space resulted in efficient engraftment to the surrounding cells, with the formation of two-dimensional hepatic tissues that stably persisted for longer than 200 d. The engineered hepatic tissues also showed several characteristics of liver-specific functionality. Additionally, when the hepatic tissue sheets were layered in vivo, three-dimensional miniature liver systems having persistent survivability could be also engineered. This technology for liver tissue engineering is simple, minimally invasive and free of potentially immunogenic biodegradable scaffolds.	Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan; Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, Tokyo 1628666, Japan; Nihon Noyaku Co Ltd, Osaka 5860094, Japan; Saiseikai Chuwa Hosp, Dept Pathol, Nara 6330054, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan	Nara Medical University; Tokyo Women's Medical University; Kyoto University	Ohashi, K (corresponding author), Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ohashi@abmes.twmu.ac.jp	Okano, Teruo/J-4028-2012					Bumgardner GL, 1998, TRANSPLANTATION, V65, P47, DOI 10.1097/00007890-199801150-00010; Dhawan A, 2004, TRANSPLANTATION, V78, P1812, DOI 10.1097/01.TP.0000146386.77076.47; Dhawan A, 2006, J INHERIT METAB DIS, V29, P431, DOI 10.1007/s10545-006-0245-8; Fox IJ, 2006, AM J TRANSPLANT, V6, P5, DOI 10.1111/j.1600-6143.2005.01188.x; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Gouon-Evans V, 2006, NAT BIOTECHNOL, V24, P1402, DOI 10.1038/nbt1258; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Harimoto M, 2002, J BIOMED MATER RES, V62, P464, DOI 10.1002/jbm.10228; Hirose M, 2000, BIOMACROMOLECULES, V1, P377, DOI 10.1021/bm0002961; JOLLEY ME, 1981, CLIN CHEM, V27, P1190; Kuge H, 2006, CELL TRANSPLANT, V15, P1, DOI 10.3727/000000006783982214; Lee HM, 2003, TISSUE ENG, V9, P1227, DOI 10.1089/10763270360728134; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Muraca M, 2002, LANCET, V359, P317, DOI 10.1016/S0140-6736(02)07529-3; Nahmias Y, 2006, HEPATOLOGY, V43, P257, DOI 10.1002/hep.21016; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Ohashi K, 2005, CELL TRANSPLANT, V14, P621, DOI 10.3727/000000005783982620; Ohashi K, 2005, HEPATOLOGY, V41, P132, DOI 10.1002/hep.20484; Ohashi K, 2000, NAT MED, V6, P327; Ohashi K, 2002, TRANSPLANT P, V34, P1431, DOI 10.1016/S0041-1345(02)02916-0; Ohashi K, 2001, J MOL MED, V79, P617, DOI 10.1007/s001090100260; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Shimizu T, 2002, CIRC RES, V90, pE40, DOI 10.1161/hh0302.105722; Stephenne X, 2006, GASTROENTEROLOGY, V130, P1317, DOI 10.1053/j.gastro.2006.01.008; Strom S, 2003, GASTROENTEROLOGY, V124, P568, DOI 10.1053/gast.2003.50072; YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571; Yang J, 2005, BIOMATERIALS, V26, P6415, DOI 10.1016/j.biomaterials.2005.04.061; Yokoyama T, 2006, AM J TRANSPLANT, V6, P50, DOI 10.1111/j.1600-6143.2005.01155.x	29	404	432	3	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					880	885		10.1038/nm1576	http://dx.doi.org/10.1038/nm1576			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17572687				2022-12-27	WOS:000247902800037
J	Cohen, B; Ziv, K; Plaks, V; Israely, T; Kalchenko, V; Harmelin, A; Benjamin, LE; Neeman, M				Cohen, Batya; Ziv, Keren; Plaks, Vicki; Israely, Tomer; Kalchenko, Vyacheslav; Harmelin, Alon; Benjamin, Laura E.; Neeman, Michal			MRI detection of transcriptional regulation of gene expression in transgenic mice	NATURE MEDICINE			English	Article							H-FERRITIN; TRANSFERRIN RECEPTOR; IRON CONCENTRATION; MARKER GENE; REPORTER; CHAIN; NMR; ANGIOGENESIS; RELAXATION; OVERLOAD	Ferritin, the iron storage protein, was recently suggested to be a candidate reporter for the detection of gene expression by magnetic resonance imaging (MRI). Here we report the generation of TET:EGFP-HAferritin (tet-hfer) transgenic mice, in which tissue-specific inducible transcriptional regulation of expression of the heavy chain of ferritin could be detected in vivo by MRI. We show organ specificity by mating the tet-hfer mice with transgenic mice expressing tetracycline transactivator (tTA) in liver hepatocytes and in vascular endothelial cells. Tetracycline-regulated overexpression of ferritin resulted in specific alterations of the transverse relaxation rate (R-2) of water. Transgene-dependent changes in R-2 were detectable by MRI in adult mice, and we also found fetal developmental induction of transgene expression in utero. Thus, the tet-hfer MRI reporter mice provide a new transgenic mouse platform for in vivo molecular imaging of reporter gene expression by MRI during both embryonic and adult life.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Weizmann Institute of Science; Weizmann Institute of Science; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Neeman, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	michal.neeman@weizmann.ac.il	Neeman, Michal/AAH-9602-2019; Kalchenko, Vyacheslav/F-2924-2012; Neeman, Michal/A-8264-2008	Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X; Kalchenko, Vyacheslav/0000-0002-3166-7049				Alfke H, 2003, RADIOLOGY, V228, P488, DOI 10.1148/radiol.2282012006; BAUMINGER ER, 1993, BIOCHEM J, V296, P709, DOI 10.1042/bj2960709; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Cohen B, 2005, NEOPLASIA, V7, P109, DOI 10.1593/neo.04436; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Deans AE, 2006, MAGN RESON MED, V56, P51, DOI 10.1002/mrm.20914; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Genove G, 2005, NAT MED, V11, P450, DOI 10.1038/nm1208; Gilad AA, 2007, NAT BIOTECHNOL, V25, P217, DOI 10.1038/nbt1277; Giordani A, 2000, J PHOTOCH PHOTOBIO B, V54, P43, DOI 10.1016/S1011-1344(99)00154-2; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gossuin Y, 2004, NMR BIOMED, V17, P427, DOI 10.1002/nbm.903; Gottesfeld Z, 1996, MAGN RESON MED, V35, P514, DOI 10.1002/mrm.1910350410; Grabill C, 2003, BRAIN RES, V971, P95, DOI 10.1016/S0006-8993(03)02366-7; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hardy PA, 2005, J MAGN RESON IMAGING, V21, P118, DOI 10.1002/jmri.20244; Kakhlon O, 2001, BIOCHEM J, V356, P311, DOI 10.1042/0264-6021:3560311; Kato J, 2001, AM J HUM GENET, V69, P191, DOI 10.1086/321261; Kim I, 2005, BLOOD, V106, P903, DOI 10.1182/blood-2004-12-4960; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KORETSKY A, 1996, P INT SOC MAGNETIC R, V4, P69; Li ZJ, 2005, HUM GENE THER, V16, P1429, DOI 10.1089/hum.2005.16.1429; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Moore A, 2001, RADIOLOGY, V221, P244, DOI 10.1148/radiol.2211001784; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Plaks V, 2006, MAGN RESON MED, V55, P1013, DOI 10.1002/mrm.20881; Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008-5472.CAN-03-1816; Sheehan D, 1980, THEORY PRACTICE HIST, P217; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Vymazal J, 1996, MAGN RESON MED, V36, P61, DOI 10.1002/mrm.1910360111; Vymazal J, 1998, J INORG BIOCHEM, V71, P153, DOI 10.1016/S0162-0134(98)10047-8; Walter G, 2000, P NATL ACAD SCI USA, V97, P5151, DOI 10.1073/pnas.97.10.5151; Weissleder R, 1997, RADIOLOGY, V204, P425, DOI 10.1148/radiology.204.2.9240530; Wilkinson J, 2006, BIOCHEM J, V395, P501, DOI 10.1042/BJ20060063; Wood JC, 2004, MAGNET RESON MED, V51, P607, DOI 10.1002/mrm.10735; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yu JX, 2006, BIOORGAN MED CHEM, V14, P326, DOI 10.1016/j.bmc.2005.08.021	43	155	167	2	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					498	503		10.1038/nm1497	http://dx.doi.org/10.1038/nm1497			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17351627				2022-12-27	WOS:000245543900040
J	Opar, A				Opar, Alisa			Menno de Jong	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					7	7		10.1038/nm0107-7	http://dx.doi.org/10.1038/nm0107-7			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17206114	Green Published			2022-12-27	WOS:000243301800009
J	Potti, A; Dressman, HK; Bild, A; Riedel, RF; Chan, G; Sayer, R; Cragun, J; Cottrill, H; Kelley, MJ; Petersen, R; Harpole, D; Marks, J; Berchuck, A; Ginsburg, GS; Febbo, P; Lancaster, J; Nevins, JR				Potti, Anil; Dressman, Holly K.; Bild, Andrea; Riedel, Richard F.; Chan, Gina; Sayer, Robyn; Cragun, Janiel; Cottrill, Hope; Kelley, Michael J.; Petersen, Rebecca; Harpole, David; Marks, Jeffrey; Berchuck, Andrew; Ginsburg, Geoffrey S.; Febbo, Phillip; Lancaster, Johnathan; Nevins, Joseph R.			RETRACTED: Genomic signatures to guide the use of chemotherapeutics (Retracted article. See vol. 17, pg. 135, 2011)	NATURE MEDICINE			English	Article; Retracted Publication							ACUTE LYMPHOBLASTIC-LEUKEMIA; METASTATIC BREAST-CANCER; PACLITAXEL SENSITIVITY; THERAPEUTIC RESPONSE; EXPRESSION PATTERNS; SINGLE-AGENT; LUNG-CANCER; PREDICTION; RESISTANCE; MARKER	Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.	Duke Univ, Duke Inst Gen Sci & Policy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Univ S Florida, Div Gynecol Surg Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Duke University; Duke University	Nevins, JR (corresponding author), Duke Univ, Duke Inst Gen Sci & Policy, Box 3383, Durham, NC 27710 USA.	nevin001@mc.duke.edu	Kelley, Michael/AAC-8939-2019; Riedel, Richard/HHM-4275-2022	Kelley, Michael/0000-0001-9523-6080; 	NATIONAL CANCER INSTITUTE [R01CA106520, U54CA112952] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA106520, U54 CA112952-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blagosklonny MV, 2005, CELL CYCLE, V4, P1693, DOI 10.4161/cc.4.12.2259; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Broxterman HJ, 2005, DRUG RESIST UPDATE, V8, P183, DOI 10.1016/j.drup.2005.07.002; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; DeVita V. T., 2005, CANC PRINCIPLES PRAC; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emi M, 2005, BREAST CANCER RES, V7, pR940, DOI 10.1186/bcr1323; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Herbst RS, 2006, J CLIN ONCOL, V24, P190, DOI 10.1200/JCO.2005.04.8678; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Minna JD, 2004, SCIENCE, V304, P1458, DOI 10.1126/science.1099578; Modi S, 2005, CANCER INVEST, V23, P483, DOI 10.1080/07357900500201301; Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158/1535-7163.MCT-04-0282; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	25	435	480	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1294	1300		10.1038/nm1491	http://dx.doi.org/10.1038/nm1491			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057710				2022-12-27	WOS:000241844900027
J	Venkatesha, S; Toporsian, M; Lam, C; Hanai, J; Mammoto, T; Kim, YM; Bdolah, Y; Lim, KH; Yuan, HT; Libermann, TA; Stillman, IE; Roberts, D; D'Amore, PA; Epstein, FH; Sellke, FW; Romero, R; Sukhatme, VP; Letarte, M; Karumanchi, SA				Venkatesha, Shivalingappa; Toporsian, Mourad; Lam, Chun; Hanai, Jun-ichi; Mammoto, Tadanori; Kim, Yeon M.; Bdolah, Yuval; Lim, Kee-Hak; Yuan, Hai-Tao; Libermann, Towia A.; Stillman, Isaac E.; Roberts, Drucilla; D'Amore, Patricia A.; Epstein, Franklin H.; Sellke, Frank W.; Romero, Roberto; Sukhatme, Vikas P.; Letarte, Michelle; Karumanchi, S. Ananth			Soluble endoglin contributes to the pathogenesis of preeclampsia	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; ELEVATED LIVER-ENZYMES; BETA BINDING-PROTEIN; HUMAN CYTOTROPHOBLASTS; PLASMA; PATHOPHYSIOLOGY; ANGIOGENESIS; HYPERTENSION; PROSTACYCLIN	Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality. Maternal endothelial dysfunction mediated by excess placenta-derived soluble VEGF receptor 1 ( sVEGFR1 or sFlt1) is emerging as a prominent component in disease pathogenesis. We report a novel placenta-derived soluble TGF-beta coreceptor, endoglin ( sEng), which is elevated in the sera of preeclamptic individuals, correlates with disease severity and falls after delivery. sEng inhibits formation of capillary tubes in vitro and induces vascular permeability and hypertension in vivo. Its effects in pregnant rats are amplified by coadministration of sFlt1, leading to severe preeclampsia including the HELLP ( hemolysis, elevated liver enzymes, low platelets) syndrome and restriction of fetal growth. sEng impairs binding of TGF-beta 1 to its receptors and downstream signaling including effects on activation of eNOS and vasodilation, suggesting that sEng leads to dysregulated TGF-beta signaling in the vasculature. Our results suggest that sEng may act in concert with sFlt1 to induce severe preeclampsia.	Beth Israel Deaconess Med Ctr, Dept Med, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Ctr Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Heart & Stroke Fdn, Richard Lewar Ctr Excellence, Toronto, ON M5G 1X8, Canada; NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Wayne State Univ, Sch Med, Detroit, MI 48201 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Wayne State University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Karumanchi, SA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Ctr Vasc Biol, Boston, MA 02215 USA.	sananth@bidmc.harvard.edu	Libermann, Towia/F-9866-2010; Sukhatme, Vikas/W-2776-2019; D'Amore, Patricia A/G-5660-2017; Stillman, Isaac E/ABC-7278-2020; Karumanchi, Subbian Ananth/AAI-1694-2021; Roberts, Drucilla/AAB-6379-2022; Romero, Roberto/A-5268-2019	D'Amore, Patricia A/0000-0001-9652-8974; Romero, Roberto/0000-0002-4448-5121; Toporsian, Mourad/0000-0002-8430-2094; Libermann, Towia/0000-0002-4006-8179	NHLBI NIH HHS [HL079594] Funding Source: Medline; NIDDK NIH HHS [DK064255] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002400] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOG, 2002, OBSTET GYNECOL, V99, P869; Ahmad S, 2004, CIRC RES, V95, P884, DOI 10.1161/01.RES.0000147365.86159.f5; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bdolah Y, 2004, SEMIN NEPHROL, V24, P548, DOI 10.1016/S0270-9295(04)00125-1; Benian A, 2002, OBSTET GYNECOL, V100, P327, DOI 10.1016/S0029-7844(02)02077-X; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BROWN MA, 1989, CLIN SCI, V77, P599, DOI 10.1042/cs0770599; Caniggia I, 1997, ENDOCRINOLOGY, V138, P4977, DOI 10.1210/en.138.11.4977; Chaiworapongsa T, 2004, AM J OBSTET GYNECOL, V190, P1541, DOI 10.1016/j.ajog.2004.03.043; Chaiworapongsa T, 2005, J MATERN-FETAL NEO M, V17, P3, DOI 10.1080/14767050400028816; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fonsatti E, 2003, CURR DRUG TARGETS, V4, P291, DOI 10.2174/1389450033491073; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hennessy A, 2002, CLIN EXP PHARMACOL P, V29, P968, DOI 10.1046/j.1440-1681.2002.03763.x; Hertig A, 2004, CLIN CHEM, V50, P1702, DOI 10.1373/clinchem.2004.036715; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lowe DT, 2000, NITRIC OXIDE-BIOL CH, V4, P441, DOI 10.1006/niox.2000.0296; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mills JL, 1999, JAMA-J AM MED ASSOC, V282, P356, DOI 10.1001/jama.282.4.356; Muy-Rivera M, 2004, AM J HYPERTENS, V17, P334, DOI 10.1016/j.amjhyper.2003.12.010; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROMERO R, 1989, AM J PERINAT, V6, P32, DOI 10.1055/s-2007-999540; Saura M, 2002, CIRC RES, V91, P806, DOI 10.1161/01.RES.0000040397.23817.E5; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; STJACQUES S, 1994, BIOL REPROD, V51, P405, DOI 10.1095/biolreprod51.3.405; Tatsumi M, 2000, THROMB RES, V98, P451, DOI 10.1016/S0049-3848(00)00190-0; Taylor RN, 2003, AM J OBSTET GYNECOL, V188, P177, DOI 10.1067/mob.2003.111; Toporsian M, 2005, CIRC RES, V96, P684, DOI 10.1161/01.res.0000159936.38601.22; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	50	1334	1392	1	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					642	649		10.1038/nm1429	http://dx.doi.org/10.1038/nm1429			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16751767				2022-12-27	WOS:000238149200025
J	Yamada, T; Kawano, H; Koshizuka, Y; Fukuda, T; Yoshimura, K; Kamekura, S; Saito, T; Ikeda, T; Kawasaki, Y; Azuma, Y; Ikegawa, S; Hoshi, K; Chung, UI; Nakamura, K; Kato, S; Kawaguchi, H				Yamada, Takashi; Kawano, Hirotaka; Koshizuka, Yu; Fukuda, Toru; Yoshimura, Kimihiro; Kamekura, Satoru; Saito, Taku; Ikeda, Toshiyuki; Kawasaki, Yosuke; Azuma, Yoshiaki; Ikegawa, Shiro; Hoshi, Kazuto; Chung, Ung-il; Nakamura, Kozo; Kato, Shigeaki; Kawaguchi, Hiroshi			Carminerin contributes to chondrocyte calcification during endochondral ossification	NATURE MEDICINE			English	Article							DIFFERENTIATION; EXPRESSION; PROTEIN; PC-1; CARTILAGE; PATHWAYS; ROLES; STEPS	Endochondral ossification is an essential process not only for physiological skeletal development and growth, but also for pathological disorders. We recently identified a novel cartilage-specific molecule, carminerin ( also known as cystatin 10 and encoded by Cst10), which is upregulated in synchrony with cartilage maturation and stimulates the later differentiation of cultured chondrocytes(1). Although carminerin-deficient ( Cst10(-/-)) mice developed and grew normally, they had a microscopic decrease in the calcification of hypertrophic chondrocytes at the growth plate. When we created experimental models of pathological endochondral ossification, we observed suppression of chondrocyte calcification during formation of osteoarthritic osteophytes, age-related ectopic ossification and healing of bone fractures in Cst10(-/-) mice. Cultured Cst10(-/-) chondrocytes showed a reduction in calcification with activation of an SRY site in the promoter of the gene encoding nucleotide pyrophosphatase phosphodiesterase 1 ( NPP1, encoded by Enpp1). Functional NPP1 is required for carminerin deficiency to suppress the pathological endochondral ossifications listed above. Carminerin is the first cartilage-specific protein that contributes to chondrocyte calcification during endochondral ossification under physiological and pathological conditions through the transcriptional inhibition of NPP1.	Univ Tokyo, Fac Med, Dept Sensory & Motor Syst Med, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; RIKEN, Inst Phys & Chem Res, Tokyo 1068639, Japan; Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan	University of Tokyo; University of Tokyo; RIKEN	Kawaguchi, H (corresponding author), Univ Tokyo, Fac Med, Dept Sensory & Motor Syst Med, Hongo 7-3-1, Tokyo 1138655, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp	Ikeda, Toshiyuki/GVS-5588-2022; Saito, Takashi/C-9684-2009; Ikegawa, Shiro/N-6895-2015	Saito, Takashi/0000-0001-9495-3547; Ikegawa, Shiro/0000-0003-0316-2147				Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; Goldfine ID, 1999, ANN NY ACAD SCI, V892, P204, DOI 10.1111/j.1749-6632.1999.tb07797.x; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004; Koshizuka Y, 2003, J BIOL CHEM, V278, P48259, DOI 10.1074/jbc.M211639200; Laroche M, 2001, JOINT BONE SPINE, V68, P211, DOI 10.1016/S1297-319X(01)00274-3; LOTZ M, 1995, P NATL ACAD SCI USA, V92, P10364, DOI 10.1073/pnas.92.22.10364; MANKIN HJ, 1981, J BONE JOINT SURG AM, V63, P131, DOI 10.2106/00004623-198163010-00017; Nakamichi Y, 2003, MOL CELL BIOL, V23, P636, DOI 10.1128/MCB.23.2.636-644.2003; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; OYAJOBI BO, 1994, J BONE MINER RES, V9, P99; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Ryan LM, 2001, ARTHRITIS RES, V3, P77, DOI 10.1186/ar143; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Solan JL, 1996, J BONE MINER RES, V11, P183; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; WOLBACH SB, 1947, J BONE JOINT SURG, V29, P171	22	47	49	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					665	670		10.1038/nm1409	http://dx.doi.org/10.1038/nm1409			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680148				2022-12-27	WOS:000238149200028
J	Mandavilli, A				Mandavilli, A			Hui Zhen Sheng - Profile	NATURE MEDICINE			English	Biographical-Item																			0	8	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					265	265		10.1038/nm0306-265	http://dx.doi.org/10.1038/nm0306-265			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16520761				2022-12-27	WOS:000235802900012
J	Amino, R; Thiberge, S; Martin, B; Celli, S; Shorte, S; Frischknecht, F; Menard, R				Amino, R; Thiberge, S; Martin, B; Celli, S; Shorte, S; Frischknecht, F; Menard, R			Quantitative imaging of Plasmodium transmission from mosquito to mammal	NATURE MEDICINE			English	Article							ANOPHELES-STEPHENSI; BERGHEI SPOROZOITES; MALARIA PARASITES; LYMPH-NODES; VACCINE; YOELII; DYNAMICS; IMMUNITY; PROTEIN; BITE	Plasmodium, the parasite that causes malaria, is transmitted by a mosquito into the dermis and must reach the liver before infecting erythrocytes and causing disease. We present here a quantitative, real-time analysis of the fate of parasites transmitted in a rodent system. We show that only a proportion of the parasites enter blood capillaries, whereas others are drained by lymphatics. Lymph sporozoites stop at the proximal lymph node, where most are degraded inside dendritic leucocytes, but some can partially differentiate into exoerythrocytic stages. This previously unrecognized step of the parasite life cycle could influence the immune response of the host, and may have implications for vaccination strategies against the preerythrocytic stages of the parasite.	Inst Pasteur, Unite Biol & Genet Paludisme, F-75724 Paris 15, France; Inst Pasteur, Grp Dynam Reponses Immunes, F-75724 Paris 15, France; Inst Pasteur, Plate Forme Imagerie Dynam, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Amino, R (corresponding author), Univ Fed Sao Paulo, Dept Bioquim, Rua Tres Maio 100, BR-04044020 Sao Paulo, Brazil.	roti@ecb.epm.br; freddy.frischknecht@med.uni-heidelberg.de; rmenard@pasteur.fr	Celli, Susanna/M-7138-2014	Frischknecht, Friedrich/0000-0002-8332-6668; Thiberge, Sabine/0000-0001-5507-0602; Shorte, Spencer/0000-0002-2125-8663				Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; BOYD MARK F., 1939, AMER JOUR TROP MED, V19, P27; CHAROENVIT Y, 1995, EXP PARASITOL, V80, P419, DOI 10.1006/expr.1995.1054; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Frischknecht F, 2004, CELL MICROBIOL, V6, P687, DOI 10.1111/j.1462-5822.2004.00395.x; Good MF, 2005, TRENDS IMMUNOL, V26, P295, DOI 10.1016/j.it.2005.04.005; Gruner AC, 2005, MOL BIOCHEM PARASIT, V142, P184, DOI 10.1016/j.molbiopara.2005.03.019; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Krettli AU, 2000, INFECT IMMUN, V68, P3064, DOI 10.1128/IAI.68.5.3064-3065.2000; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Matsuoka H, 2002, PARASITOL INT, V51, P17, DOI 10.1016/S1383-5769(01)00095-2; MEIS JFGM, 1988, ADV PARASIT, V27, P1, DOI 10.1016/S0065-308X(08)60352-8; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188; Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N; Sacci JB, 2005, MOL BIOCHEM PARASIT, V142, P177, DOI 10.1016/j.molbiopara.2005.03.018; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; Sumen C, 2004, IMMUNITY, V21, P315, DOI 10.1016/S1074-7613(04)00237-7; Tongren JE, 2004, TRENDS PARASITOL, V20, P604, DOI 10.1016/j.pt.2004.09.005; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; Vaughan JA, 1999, INFECT IMMUN, V67, P4285, DOI 10.1128/IAI.67.8.4285-4289.1999	23	376	391	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					220	224		10.1038/nm1350	http://dx.doi.org/10.1038/nm1350			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429144				2022-12-27	WOS:000235160600027
J	Day, SM; Westfall, MV; Fomicheva, EV; Hoyer, K; Yasuda, S; La Cross, NC; D'Alecy, LG; Ingwall, JS; Metzger, JM				Day, SM; Westfall, MV; Fomicheva, EV; Hoyer, K; Yasuda, S; La Cross, NC; D'Alecy, LG; Ingwall, JS; Metzger, JM			Histidine button engineered into cardiac troponin I protects the ischemic and failing heart	NATURE MEDICINE			English	Article							GENE-TRANSFER; MYOFILAMENT TENSION; CONTRACTILE FAILURE; CHIMERA ANALYSIS; PH SENSITIVITY; MOUSE MODEL; ADULT; REPERFUSION; EXPRESSION; MICE	The myofilament protein troponin I (TnI) has a key isoform-dependent role in the development of contractile failure during acidosis and ischemia. Here we show that cardiac performance in vitro and in vivo is enhanced when a single histidine residue present in the fetal cardiac TnI isoform is substituted into the adult cardiac TnI isoform at codon 164. The most marked effects are observed under the acute challenges of acidosis, hypoxia, ischemia and ischemia-reperfusion, in chronic heart failure in transgenic mice and in myocytes from failing human hearts. In the isolated heart, histidine-modified TnI improves systolic and diastolic function and mitigates reperfusion-associated ventricular arrhythmias. Cardiac performance is markedly enhanced in transgenic hearts during reperfusion despite a high-energy phosphate content similar to that in nontransgenic hearts, providing evidence for greater energetic economy. This pH-sensitive 'histidine button' engineered in TnI produces a titratable molecular switch that 'senses' changes in the intracellular milieu of the cardiac myocyte and responds by preferentially augmenting acute and long-term function under pathophysiological conditions. Myofilament-based inotropy may represent a therapeutic avenue to improve myocardial performance in the ischemic and failing heart.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Cardiac Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,NMR Lab Physiol Chem, Boston, MA 02115 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Metzger, JM (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1150 W Med Ctr Dr,7301 MSRB 3, Ann Arbor, MI 48109 USA.	metzgerj@umich.edu		Westfall, Margaret/0000-0001-9491-0125	NHLBI NIH HHS [HL52320, HL059301, HL63985, HL67254] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067254, P50HL052320, R01HL063985, R01HL059301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; Chaudhary KW, 2004, J AM COLL CARDIOL, V44, P837, DOI 10.1016/j.jacc.2004.05.049; Coutu P, 2004, CIRC RES, V94, P1235, DOI 10.1161/01.RES.0000126923.46786.FD; Cross HR, 1998, CIRC RES, V83, P1215, DOI 10.1161/01.RES.83.12.1215; Cross HR, 2003, AM J PHYSIOL-HEART C, V284, pH683, DOI 10.1152/ajpheart.00567.2002; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; Deedwania PC, 2003, CIRCULATION, V107, P1719, DOI 10.1161/01.CIR.0000014688.12415.C0; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; Dewald O, 2003, P NATL ACAD SCI USA, V100, P2700, DOI 10.1073/pnas.0438035100; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Gould KE, 2002, AM J PHYSIOL-HEART C, V282, pH615, DOI 10.1152/ajpheart.00206.2001; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; Heerdt PM, 2000, CIRCULATION, V102, P2713, DOI 10.1161/01.CIR.102.22.2713; Jain M, 2004, CIRCULATION, V109, P898, DOI 10.1161/01.CIR.0000112605.43318.CA; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LEE JA, 1991, J CLIN INVEST, V88, P361, DOI 10.1172/JCI115311; Metzger JM, 2004, CIRC RES, V94, P146, DOI 10.1161/01.RES.0000110083.17024.60; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; MUNDINAWEILENMA.C, 1996, AM J PHYSIOL, V39, pC107; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Naito H, 2000, EUR J PHARMACOL, V388, P171, DOI 10.1016/S0014-2999(99)00845-6; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; Pieske B, 1999, CIRC RES, V85, P38; Piper HM, 2003, ANN THORAC SURG, V75, pS644, DOI 10.1016/S0003-4975(02)04686-6; Robbins J, 2000, ANNU REV PHYSIOL, V62, P261, DOI 10.1146/annurev.physiol.62.1.261; Rossman EI, 2004, J MOL CELL CARDIOL, V36, P33, DOI 10.1016/j.yjmcc.2003.09.001; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Sakamoto J, 1999, BASIC RES CARDIOL, V94, P489, DOI 10.1007/s003950050165; Saupe KW, 1998, CIRC RES, V82, P898; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Steg PG, 2004, CIRCULATION, V109, P494, DOI 10.1161/01.CIR.0000109691.16944.DA; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003; Wainwright CL, 2002, BRIT J PHARMACOL, V135, P1882, DOI 10.1038/sj.bjp.0704646; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; Westfall MV, 2001, BIOPHYS J, V80, p356A; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	50	89	90	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					181	189		10.1038/nm1346	http://dx.doi.org/10.1038/nm1346			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429145				2022-12-27	WOS:000235160600022
J	Diamond, B				Diamond, B			Aaron Marcus	NATURE MEDICINE			English	Biographical-Item																		MARCUS AJ, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2005	11	8					816	816		10.1038/nm0805-816	http://dx.doi.org/10.1038/nm0805-816			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16079866	Bronze			2022-12-27	WOS:000230964700011
J	Jenkins, BJ; Grail, D; Nheu, T; Najdovska, M; Wang, B; Waring, P; Inglese, M; McLoughlin, RM; Jones, SA; Topley, N; Baumann, H; Judd, LM; Giraud, AS; Boussioutas, A; Zhu, HJ; Ernst, M				Jenkins, BJ; Grail, D; Nheu, T; Najdovska, M; Wang, B; Waring, P; Inglese, M; McLoughlin, RM; Jones, SA; Topley, N; Baumann, H; Judd, LM; Giraud, AS; Boussioutas, A; Zhu, HJ; Ernst, M			Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling	NATURE MEDICINE			English	Article							GROWTH-FACTOR; NECK-CANCER; IN-VIVO; EXPRESSION; GENE; SMAD7; IL-6; INHIBITION; CYTOKINE; CELLS	The latent transcription factor Stat3 is activated by gp130, the common receptor for the interleukin (IL)-6 cytokine family and other growth factor and cytokine receptors. Ligand-induced dimerization of gp130 leads to activation of the Stat1, Stat3 and Shp2-Ras-Erk signaling pathways. Here we assess genetically the contribution of exaggerated Stat3 activation to the phenotype of gp130(Y757F/Y757F) mice, in which a knock-in mutation disrupts the negative feedback mechanism on gp130-dependent Stat signaling. Compared to gp130(Y757F/Y757F) mice, reduced Stat3 activation in gp130(Y757F/Y757F) Stat3(+/-) mice increased their lifespan, prevented splenomegaly, normalized exaggerated hepatic acute-phase response and lymphocyte trafficking, and suppressed the growth of spontaneously arising gastric adenomas in young mice. These lesions share histological features of gastric polyps in aging mice with monoallelic null mutations in Smad4, which encodes the common transducer for transforming growth factor (TGF)-beta signaling. Indeed, hyperactivation of Stat3 desensitizes gp130(Y757F/Y757F) cells to the cytostatic effect of TGF-beta through transcriptional induction of inhibitory Smad7, thereby providing a novel link for cross-talk between Stat and Smad signaling in gastric homeostasis.	Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic 30025, Australia; Univ Cardiff Wales, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales; Univ Cardiff Wales, Sch Med, Inst Nephrol, Cardiff CF14 4XN, Wales; Roswell Pk Canc Inst, MRC 308, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Melbourne, Dept Med, Footscray, Vic 3011, Australia	Ludwig Institute for Cancer Research; Peter Maccallum Cancer Center; Cardiff University; Cardiff University; Roswell Park Cancer Institute; University of Melbourne	Ernst, M (corresponding author), Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.	matthias.ernst@ludwig.edu.au	jenkins, brendan/A-2401-2009; Ernst, Matthias/D-5111-2012; jenkins, brendan/J-7854-2012; Jones, Simon Arnett/Q-7017-2018	Ernst, Matthias/0000-0002-6399-1177; Boussioutas, Alex/0000-0002-8109-6897; McLoughlin, Rachel/0000-0003-4553-018X; Jenkins, Brendan/0000-0002-7552-4656; Zhu, Hong-Jian/0000-0002-1478-995X; Judd, Louise/0000-0003-3613-4839; Jones, Simon Arnett/0000-0001-7297-9711				Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Boivin GP, 1996, LAB INVEST, V74, P513; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Boussioutas A, 2003, CANCER RES, V63, P2569; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hohenstein P, 2003, GENE CHROMOSOME CANC, V36, P273, DOI 10.1002/gcc.10169; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; HOWLETT M, IN PRESS GASTROENTER; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Jenkins BJ, 2005, BLOOD, V105, P3512, DOI 10.1182/blood-2004-09-3751; Jenkins BJ, 2004, MOL CELL BIOL, V24, P1453, DOI 10.1128/MCB.24.4.1453-1463.2004; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kanai M, 2003, ONCOGENE, V22, P548, DOI 10.1038/sj.onc.1206109; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Takaku K, 1999, CANCER RES, V59, P6113; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Xie W, 2002, CANCER RES, V62, P497; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	46	243	258	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					845	852		10.1038/nm1282	http://dx.doi.org/10.1038/nm1282			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16041381				2022-12-27	WOS:000230964700029
J	Kaufmann, SHE; McMichael, AJ				Kaufmann, SHE; McMichael, AJ			Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; HEPARIN-BINDING HEMAGGLUTININ; CALMETTE-GUERIN STRAINS; MYCOBACTERIUM-TUBERCULOSIS; PROTECTIVE EFFICACY; IMMUNE-RESPONSES; ENHANCED IMMUNOGENICITY; BOOST VACCINATION; INTERFERON-GAMMA	Human immunodeficiency virus (HIV) and Mycobacterium tuberculosis annually cause 3 million and 2 million deaths, respectively. Last year, 600,000 individuals, doubly infected with HIV and M. tuberculosis, died. Since World War 1, approximately 150 million people have succumbed to these two infections-more total deaths than in all wars in the last 2,000 years. Although the perceived threats of new infections such as SARS, new variant Creutzfeldt-Jakob disease and anthrax are real, these outbreaks have caused less than 1,000 deaths globally, a death toll AIDS and tuberculosis exact every 2 h. In 2003, 40 million people were infected with HIV, 2 billion with M. tuberculosis, and 15 million with both. Last year, 5 million and 50 million were newly infected with HIV or M. tuberculosis, respectively, with 2 million new double infections. Better control measures are urgently needed.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	Max Planck Society; University of Oxford	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268				Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/00002030-200307040-00012; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altman JD, 2004, NAT MED, V10, P229, DOI 10.1038/nm0304-229; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; [Anonymous], 2004, 2004 REP GLOB AIDS E; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Beignon AS, 2003, NAT IMMUNOL, V4, P939, DOI 10.1038/ni1003-939; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Boon C, 2002, J BACTERIOL, V184, P6760, DOI 10.1128/JB.184.24.6760-6767.2002; Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Brooks JV, 2001, INFECT IMMUN, V69, P2714, DOI 10.1128/IAI.69.4.2714-2717.2001; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; CALMETTE A, 1928, SCHUTZIMPFUNG GEGEN; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Chan J, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P437; Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Dascher CC, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P475; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; FINE PEM, 1989, REV INFECT DIS, V11, pS353; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Glynn JR, 2002, EMERG INFECT DIS, V8, P843; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; GUIERIA I, 1996, NAT MED, V2, P334; Haase AT, 2001, AIDS, V15, pS10, DOI 10.1097/00002030-200102001-00013; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; Hess J, 1998, P NATL ACAD SCI USA, V95, P5299, DOI 10.1073/pnas.95.9.5299; Hingley-Wilson SM, 2003, NAT IMMUNOL, V4, P949, DOI 10.1038/ni981; Hisert KB, 2004, INFECT IMMUN, V72, P5315, DOI 10.1128/IAI.72.9.5315-5321.2004; Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397; Huang XL, 2003, J INFECT DIS, V187, P315, DOI 10.1086/346054; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; KAMATH AT, IN PRESS VACCINE; Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631; Kaufmann SHE, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P465; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KAUFMANN SHE, IN PRESS MICROBES IN; KAUFMANN SHE, 2004, NOVEL VACCINATION ST; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Kremer L, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P287; Kremer M, 2004, STRONG MED CREATING; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; Liu HY, 2002, J IMMUNOL, V168, P3477, DOI 10.4049/jimmunol.168.7.3477; Liu MA, 1998, NAT MED, V4, P515, DOI 10.1038/nm0598supp-515; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147; Luo Y, 2001, CLIN EXP IMMUNOL, V123, P264, DOI 10.1046/j.1365-2249.2001.01428.x; MacGregor RR, 2000, J INFECT DIS, V181, P406, DOI 10.1086/315199; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Markovic I, 2004, CURR HIV RES, V2, P223, DOI 10.2174/1570162043351327; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; McDermott AB, 2004, J VIROL, V78, P3140, DOI 10.1128/JVI.78.6.3140-3144.2004; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001; Mollenkopf HJ, 2004, INFECT IMMUN, V72, P6471, DOI 10.1128/IAI.72.11.6471-6479.2004; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Murray PJ, 1996, P NATL ACAD SCI USA, V93, P934, DOI 10.1073/pnas.93.2.934; Nabel GJ, 2002, VACCINE, V20, P1945, DOI 10.1016/S0264-410X(02)00074-9; Naegeli O, 1900, ARCH PATHOL ANAT PH, V160, P426; Nishimura Y, 2003, P NATL ACAD SCI USA, V100, P15131, DOI 10.1073/pnas.2436476100; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; OHagan DT, 2004, NOVEL VACCINATION ST, P147, DOI 10.1002/3527601449.ch8; Okkels Limei Meng, 2003, Current Pharmaceutical Biotechnology, V4, P69, DOI 10.2174/1389201033377931; Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001; Orme IM, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P561; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Paris R, 2004, TISSUE ANTIGENS, V64, P251, DOI 10.1111/j.1399-0039.2004.00270.x; Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Russell DG, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P427; Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772; Skeiky YAW, 2004, J IMMUNOL, V172, P7618, DOI 10.4049/jimmunol.172.12.7618; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; Stebbings RJ, 2002, VIROLOGY, V296, P338, DOI 10.1006/viro.2002.1379; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7; Temmerman S, 2004, NAT MED, V10, P935, DOI 10.1038/nm1090; Tryniszewska E, 2002, J IMMUNOL, V169, P5347, DOI 10.4049/jimmunol.169.9.5347; Ulrichs T, 2004, J PATHOL, V204, P217, DOI 10.1002/path.1628; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wangoo A, 2000, CLIN EXP IMMUNOL, V119, P92, DOI 10.1046/j.1365-2249.2000.01100.x; White RG, 2004, JAIDS-J ACQ IMM DEF, V37, P1500, DOI 10.1097/01.qai.0000127062.94627.31; *WHO, 2004, GLOB ATL INF DIS; *WHO, 2004, GLOB TUB CONTR SURV; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268; World Health Organization, 2004, WORLD HLTH REP 2004; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598	125	212	220	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S33	S44		10.1038/nm1221	http://dx.doi.org/10.1038/nm1221			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812488	Bronze, Green Published			2022-12-27	WOS:000228339600009
J	Zheng, L; Dai, HF; Zhou, M; Li, M; Singh, P; Qiu, JZ; Tsark, W; Huang, Q; Kernstine, K; Zhang, XM; Lin, DX; Shen, BH				Zheng, Li; Dai, Huifang; Zhou, Mian; Li, Mei; Singh, Purnima; Qiu, Junzhuan; Tsark, Walter; Huang, Qin; Kernstine, Kemp; Zhang, Xuemei; Lin, Dongxin; Shen, Binghui			Fen1 mutations result in autoimmunity, chronic inflammation and cancers	NATURE MEDICINE			English	Article							NF-KAPPA-B; APOPTOTIC DNA-DEGRADATION; FLAP ENDONUCLEASE-1; LUNG-CANCER; SACCHAROMYCES-CEREVISIAE; IMMUNE-RESPONSES; EXCISION-REPAIR; NZB/W MICE; CELLS; ACTIVATION	Functional deficiency of the FEN1 gene has been suggested to cause genomic instability and cancer predisposition. We have identified a group of FEN1 mutations in human cancer specimens. Most of these mutations abrogated two of three nuclease activities of flap endonuclease 1 ( FEN1). To demonstrate the etiological significance of these somatic mutations, we inbred a mouse line harboring the E160D mutation representing mutations identified in human cancers. Selective elimination of nuclease activities led to frequent spontaneous mutations and accumulation of incompletely digested DNA fragments in apoptotic cells. The mutant mice were predisposed to autoimmunity, chronic inflammation and cancers. The mutator phenotype results in the initiation of cancer, whereas chronic inflammation promotes the cancer progression. The current work exemplifies the approach of studying the mechanisms of individual polymorphisms and somatic mutations in cancer development, and may serve as a reference in developing new therapeutic regimens through the suppression of inflammatory responses.	City Hope Natl Med Ctr, Dept Radiat Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Div Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Div Pathol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Div Surg, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; Chinese Acad Med Sci, Inst Canc, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China	City of Hope; City of Hope; City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Chinese Academy of Medical Sciences - Peking Union Medical College	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Radiat Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bshen@coh.org	zhang, xuemei/F-3818-2010	Shen, Binghui/0000-0002-4408-407X; Singh, Purnima/0000-0002-4968-7398	NATIONAL CANCER INSTITUTE [R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA073764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bielas JH, 2006, P NATL ACAD SCI USA, V103, P18238, DOI 10.1073/pnas.0607057103; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fournie GJ, 1996, CLIN EXP IMMUNOL, V104, P236, DOI 10.1046/j.1365-2249.1996.26736.x; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kalinowska M, 2005, APOPTOSIS, V10, P821, DOI 10.1007/s10495-005-0410-9; Kikuchi K, 2005, MOL CELL BIOL, V25, P6948, DOI 10.1128/MCB.25.16.6948-6955.2005; Koay MA, 2001, INFECT IMMUN, V69, P5991, DOI 10.1128/IAI.69.10.5991-5996.2001; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LAMBERT PH, 1968, J EXP MED, V127, P507, DOI 10.1084/jem.127.3.507; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee SO, 2005, PROSTATE, V64, P160, DOI 10.1002/pros.20218; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Lutz HU, 2006, MOL IMMUNOL, V43, P2, DOI 10.1016/j.molimm.2005.06.020; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Moller B, 1996, J INFECT DIS, V174, P557, DOI 10.1093/infdis/174.3.557; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Okabe Y, 2005, J EXP MED, V202, P1333, DOI 10.1084/jem.20051654; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Parrish JZ, 2003, EMBO J, V22, P3451, DOI 10.1093/emboj/cdg320; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Romanelli RG, 2006, AM J PHYSIOL-GASTR L, V290, pG120, DOI 10.1152/ajpgi.00350.2004; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Zeng DF, 2003, J CLIN INVEST, V112, P1211, DOI 10.1172/JCI200317165; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	49	174	188	3	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2007	13	7					812	819		10.1038/nm1599	http://dx.doi.org/10.1038/nm1599			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17589521				2022-12-27	WOS:000247902800027
J	Ohsawa, I; Ishikawa, M; Takahashi, K; Watanabe, M; Nishimaki, K; Yamagata, K; Katsura, K; Katayama, Y; Asoh, S; Ohta, S				Ohsawa, Ikuroh; Ishikawa, Masahiro; Takahashi, Kumiko; Watanabe, Megumi; Nishimaki, Kiyomi; Yamagata, Kumi; Katsura, Ken-ichiro; Katayama, Yasuo; Asoh, Sadamitsu; Ohta, Shigeo			Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals	NATURE MEDICINE			English	Article							TRANSIENT FOCAL ISCHEMIA; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; CELL-DEATH; MITOCHONDRIA; BRAIN; DEFICIENCY; CALCIUM; DISEASE; INJURY	Acute oxidative stress induced by ischemia-reperfusion or inflammation causes serious damage to tissues, and persistent oxidative stress is accepted as one of the causes of many common diseases including cancer. We show here that hydrogen (H-2) has potential as an antioxidant in preventive and therapeutic applications. We induced acute oxidative stress in cultured cells by three independent methods. H-2 selectively reduced the hydroxyl radical, the most cytotoxic of reactive oxygen species (ROS), and effectively protected cells; however, H-2 did not react with other ROS, which possess physiological roles. We used an acute rat model in which oxidative stress damage was induced in the brain by focal ischemia and reperfusion. The inhalation of H-2 gas markedly suppressed brain injury by buffering the effects of oxidative stress. Thus H-2 can be used as an effective antioxidant therapy; owing to its ability to rapidly diffuse across membranes, it can reach and react with cytotoxic ROS and thus protect against oxidative damage.	Inst Dev & Aging Sci, Dept Biochem & Cell Biol, Grad Sch Med, Nippon Med Sch,Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan; Nippon Med Sch, Dept Internal Med, Bunkyo Ku, Tokyo 1138602, Japan	Nippon Medical School; Nippon Medical School	Ohta, S (corresponding author), Inst Dev & Aging Sci, Dept Biochem & Cell Biol, Grad Sch Med, Nippon Med Sch,Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.	ohta@nms.ac.jp						Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Chinopoulos C, 2006, FEBS J, V273, P433, DOI 10.1111/j.1742-4658.2005.05103.x; FALICK AM, 1965, J CHEM PHYS, V42, P1837, DOI 10.1063/1.1696199; Ferrari R, 2004, CURR PHARM DESIGN, V10, P1699, DOI 10.2174/1381612043384718; Fontanari P, 2000, EUR J APPL PHYSIOL, V81, P325, DOI 10.1007/s004210050050; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; James AM, 2005, MECH AGEING DEV, V126, P982, DOI 10.1016/j.mad.2005.03.026; Kamiya H, 2004, BIOL PHARM BULL, V27, P475, DOI 10.1248/bpb.27.475; Labiche Lise A, 2004, NeuroRx, V1, P46, DOI 10.1007/BF03206567; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10; Murad F, 2004, BIOSCIENCE REP, V24, P452, DOI 10.1007/s10540-005-2741-8; Murakami K, 1998, J NEUROSCI, V18, P205; Nito C, 2004, BRAIN RES, V1008, P179, DOI 10.1016/j.brainres.2004.02.031; Ohsawa I, 2003, J NEUROCHEM, V84, P1110, DOI 10.1046/j.1471-4159.2003.01619.x; Ohta S, 2003, CURR MED CHEM, V10, P2485, DOI 10.2174/0929867033456440; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Reddy PH, 2006, J NEUROCHEM, V96, P1, DOI 10.1111/j.1471-4159.2005.03530.x; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Takada J, 2003, EXP GERONTOL, V38, P423, DOI 10.1016/S0531-5565(02)00241-3; Tomizawa S, 2005, NEUROSCI RES, V53, P304, DOI 10.1016/j.neures.2005.08.002; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; Wright E, 2006, INT J CLIN PRACT, V60, P308, DOI 10.1111/j.1368-5031.2006.00825.x; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06	31	1454	1728	37	468	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					688	694		10.1038/nm1577	http://dx.doi.org/10.1038/nm1577			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17486089				2022-12-27	WOS:000247084300031
J	Pamplona, A; Ferreira, A; Balla, J; Jeney, V; Balla, G; Epiphanio, S; Chora, A; Rodrigues, CD; Gregoire, IP; Cunha-Rodrigues, M; Portugal, S; Soares, MP; Mota, MM				Pamplona, Ana; Ferreira, Ana; Balla, Jozsef; Jeney, Viktoria; Balla, Gyoergy; Epiphanio, Sabrina; Chora, Angelo; Rodrigues, Cristina D.; Gregoire, Isabel Pombo; Cunha-Rodrigues, Margarida; Portugal, Silvia; Soares, Miguel P.; Mota, Maria M.			Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE BIOAVAILABILITY; MONOCLONAL-ANTIBODY; ALPHA PROMOTER; CELLS; SUSCEPTIBILITY; POLYMORPHISM; EXPRESSION; FERRITIN; MEDIATOR	Cerebral malaria claims more than 1 million lives per year. We report that heme oxygenase-1 (HO-1, encoded by Hmox1) prevents the development of experimental cerebral malaria (ECM). BALB/c mice infected with Plasmodium berghei ANKA upregulated HO-1 expression and activity and did not develop ECM. Deletion of Hmox1 and inhibition of HO activity increased ECM incidence to 83% and 78%, respectively. HO-1 upregulation was lower in infected C57BL/6 compared to BALB/c mice, and all infected C57BL/6 mice developed ECM (100% incidence). Pharmacological induction of HO-1 and exposure to the end-product of HO-1 activity, carbon monoxide (CO), reduced ECM incidence in C57BL/6 mice to 10% and 0%, respectively. Whereas neither HO-1 nor CO affected parasitemia, both prevented blood-brain barrier (BBB) disruption, brain microvasculature congestion and neuroinflammation, including CD8(+) T-cell brain sequestration. These effects were mediated by the binding of CO to hemoglobin, preventing hemoglobin oxidation and the generation of free heme, a molecule that triggers ECM pathogenesis.	Inst Gulbenkian Ciencias, P-278156 Oeiras, Portugal; Univ Lisbon, Unidade Malaria, Inst Mol Med, Fac Med, P-1649028 Lisbon, Portugal; Univ Debrecen, Dept Med, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Neonatol, H-4032 Debrecen, Hungary; Univ Debrecen, Hlth Sci Ctr, H-4032 Debrecen, Hungary	Instituto Gulbenkian de Ciencia; Universidade de Lisboa; University of Debrecen; University of Debrecen; University of Debrecen	Soares, MP (corresponding author), Inst Gulbenkian Ciencias, P-278156 Oeiras, Portugal.	mpsoares@igc.gulbenkian.pt; mmota@fm.ul.pt	Jeney, Viktória/AAF-5355-2019; Ferreira Chora, Angelo/AAZ-6503-2021; Jeney, Viktoria/A-6779-2011; Pamplona, Ana/J-4465-2013; Epiphanio, Sabrina/C-7572-2012; Pamplona, Ana/U-2126-2019; Soares, Miguel P/G-4188-2011; Mota, Maria/AAF-2048-2019	Ferreira Chora, Angelo/0000-0002-7941-7196; Pamplona, Ana/0000-0001-5338-2768; Epiphanio, Sabrina/0000-0001-6094-9750; Ferreira, Ana/0000-0002-9171-6068; Mota, Maria Manuel/0000-0002-2858-1041; Jeney, Viktoria/0000-0003-4942-7091; Portugal, Silvia/0000-0003-4567-9101; Soares, Miguel/0000-0002-9314-4833; Balla, Jozsef/0000-0001-7923-2645				Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; BALLA G, 1992, J BIOL CHEM, V267, P18148; Balla J, 2005, MOL NUTR FOOD RES, V49, P1030, DOI 10.1002/mnfr.200500076; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Basilico N, 1997, FEBS LETT, V409, P297, DOI 10.1016/S0014-5793(97)00533-4; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; CLARK IA, 1994, PARASITOL TODAY, V10, P417, DOI 10.1016/0169-4758(94)90170-8; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Favre N, 1999, MICROBES INFECT, V1, P961, DOI 10.1016/S1286-4579(99)80513-9; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Good MF, 2005, ANNU REV IMMUNOL, V23, P69, DOI 10.1146/annurev.immunol.23.021704.115638; Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499; GRAU GE, 1991, EUR J IMMUNOL, V21, P2265, DOI 10.1002/eji.1830210939; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; Hansen DS, 2003, IMMUNITY, V18, P391, DOI 10.1016/S1074-7613(03)00052-9; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Schluesener HJ, 2001, ACTA NEUROPATHOL, V101, P65; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Takeda M, 2005, JPN J INFECT DIS, V58, P268; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; THUMWOOD CM, 1988, PARASITOLOGY, V96, P579, DOI 10.1017/S0031182000080203; van der Heyde HC, 2001, INFECT IMMUN, V69, P3460, DOI 10.1128/IAI.69.5.3460-3465.2001; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Yanez DM, 1996, J IMMUNOL, V157, P1620; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	42	423	427	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					703	710		10.1038/nm1586	http://dx.doi.org/10.1038/nm1586			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17496899				2022-12-27	WOS:000247084300033
J	Barberi, T; Bradbury, M; Dincer, Z; Panagiotakos, G; Socci, ND; Studer, L				Barberi, Tiziano; Bradbury, Michelle; Dincer, Zehra; Panagiotakos, Georgia; Socci, Nicholas D.; Studer, Lorenz			Derivation of engraftable skeletal myoblasts from human embryonic stem cells	NATURE MEDICINE			English	Article							DEFINITIVE ENDODERM; PARAXIAL MESODERM; MUSCLE-CELLS; DIFFERENTIATION; GENERATION; ANTIGEN; LINE	Human embryonic stem cells (hESCs) are a promising source for cell therapy in degenerative diseases. A key step in establishing the medical potential of hESCs is the development of techniques for the conversion of hESCs into tissue-restricted precursors suitable for transplantation. We recently described the derivation of multipotent mesenchymal precursors from hESCs. Nevertheless, our previous study was limited by the requirement for mouse feeders and the lack of in vivo data. Here we report a stroma-free induction system for deriving mesenchymal precursors. Selective culture conditions and fluorescence-activated cell sorting (FACS)-mediated purification yielded multipotent mesenchymal precursors and skeletal myoblasts. Skeletal muscle cells undergo in vitro maturation resulting in myotube formation and spontaneous twitching. We found that hESC-derived skeletal myoblasts were viable after transplantation into the tibialis anterior muscle of SCID/Beige mice, as assessed by bioluminescence imaging. Lack of teratoma formation and evidence of long-term myoblast engraftment suggests considerable potential for future therapeutic applications.	Sloan Kettering Inst, Dept Radiol, New York, NY 10021 USA; Sloan Kettering Inst, Computat Biol Ctr, New York, NY 10021 USA; Sloan Kettering Inst, Dev Biol Program, Div Neurosurg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Barberi, T (corresponding author), Beckman Res Inst City Hope, Div Neurosci, Duarte, CA 91010 USA.	tbarberi@coh.org; studerl@mskcc.org	Studer, Lorenz/ABH-1491-2021; Dincer, Zehra/U-6023-2019	Studer, Lorenz/0000-0003-0741-7987; PANAGIOTAKOS, GEORGIA/0000-0001-9444-2480				Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; De Angelis MGC, 2003, EXP CELL RES, V290, P207, DOI 10.1016/S0014-4827(03)00314-8; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Guettier-Sigrist S, 2000, EXP CELL RES, V259, P204, DOI 10.1006/excr.2000.4968; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Lanctot C, 1997, DEVELOPMENT, V124, P2807; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631; Minguillon C, 2005, DEV CELL, V8, P75, DOI 10.1016/j.devcel.2004.11.013; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Saito D, 2006, DEV BIOL, V292, P79, DOI 10.1016/j.ydbio.2006.01.002; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Trounson A, 2006, ENDOCR REV, V27, P208, DOI 10.1210/er.2005-0016; WALSH FS, 1981, NATURE, V289, P60, DOI 10.1038/289060a0; Xu CH, 2004, STEM CELLS, V22, P972, DOI 10.1634/stemcells.22-6-972; Xu KL, 2001, MOL THER, V3, P97, DOI 10.1006/mthe.2000.0238; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	25	236	256	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					642	648		10.1038/nm1533	http://dx.doi.org/10.1038/nm1533			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17417652				2022-12-27	WOS:000246302800034
J	Maresz, K; Pryce, G; Ponomarev, ED; Marsicano, G; Croxford, JL; Shriver, LP; Ledent, C; Cheng, XD; Carrier, EJ; Mann, MK; Giovannoni, G; Pertwee, RG; Yamamura, T; Buckley, NE; Hillard, CJ; Lutz, B; Baker, D; Dittel, BN				Maresz, Katarzyna; Pryce, Gareth; Ponomarev, Eugene D.; Marsicano, Giovanni; Croxford, J. Ludovic; Shriver, Leah P.; Ledent, Catherine; Cheng, Xiaodong; Carrier, Erica J.; Mann, Monica K.; Giovannoni, Gavin; Pertwee, Roger G.; Yamamura, Takashi; Buckley, Nancy E.; Hillard, Cecilia J.; Lutz, Beat; Baker, David; Dittel, Bonnie N.			Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB(1) on neurons and CB(2) on autoreactive T cells	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; MICROGLIAL CELLS; SELECTIVE ANTAGONIST; IMMUNE MODULATION; ENCEPHALOMYELITIS; 2-ARACHIDONOYLGLYCEROL; IDENTIFICATION; ACTIVATION; POTENT	The cannabinoid system is immunomodulatory and has been targeted as a treatment for the central nervous system (CNS) autoimmune disease multiple sclerosis. Using an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we investigated the role of the CB(1) and CB(2) cannabinoid receptors in regulating CNS autoimmunity. We found that CB(1) receptor expression by neurons, but not T cells, was required for cannabinoid-mediated EAE suppression. In contrast, CB(2) receptor expression by encephalitogenic T cells was critical for controlling inflammation associated with EAE. CB(2)-deficient T cells in the CNS during EAE exhibited reduced levels of apoptosis, a higher rate of proliferation and increased production of inflammatory cytokines, resulting in severe clinical disease. Together, our results demonstrate that the cannabinoid system within the CNS plays a critical role in regulating autoimmune inflammation, with the CNS directly suppressing T-cell effector function via the CB(2) receptor.	BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA; UCL, Inst Neurol, Dept Neuroinflammat, London WC1N 1PJ, England; Johannes Gutenberg Univ Mainz, Dept Physiol Chem, D-55099 Mainz, Germany; Natl Inst Neurosci, Dept Immunol, Tokyo 1870802, Japan; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Univ Libre Bruxelles, Inst Rech Interdisciplinaire Biol Humaine & Mol, B-1070 Brussels, Belgium; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Univ Aberdeen, Dept Biomed Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA	Versiti Blood Center of Wisconsin; University of London; University College London; Johannes Gutenberg University of Mainz; National Center for Neurology & Psychiatry - Japan; Medical College of Wisconsin; Universite Libre de Bruxelles; Medical College of Wisconsin; University of Aberdeen; California State University System; California State Polytechnic University Pomona	Dittel, BN (corresponding author), BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA.	bonnie.dittel@bcw.edu	Hillard, Cecilia J/O-6693-2018; Marsicano, Giovanni/I-9603-2016; Lutz, Beat/AFK-6229-2022; Lutz, Beat/AAG-4538-2022; Pertwee, Roger Guy/E-1312-2011; Ponomarev, Eugene D./K-1546-2013	Ponomarev, Eugene D./0000-0002-0871-8522; Marsicano, Giovanni/0000-0003-3804-1951; Pertwee, Roger/0000-0003-3227-2783	Multiple Sclerosis Society [835] Funding Source: Medline; NIDA NIH HHS [DA09155] Funding Source: Medline; NINDS NIH HHS [R01 NS041314, R01 NS046662] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041314, R01NS046662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009155] Funding Source: NIH RePORTER	Multiple Sclerosis Society(National Multiple Sclerosis Society); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Dittel BN, 1999, J IMMUNOL, V162, P6392; Do Y, 2004, J IMMUNOL, V173, P2373, DOI 10.4049/jimmunol.173.4.2373; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Ponomarev ED, 2005, J IMMUNOL, V174, P4678, DOI 10.4049/jimmunol.174.8.4678; Ponomarev ED, 2004, J IMMUNOL, V173, P1587, DOI 10.4049/jimmunol.173.3.1587; Ponomarev ED, 2007, J IMMUNOL, V178, P39, DOI 10.4049/jimmunol.178.1.39; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Witting A, 2006, P NATL ACAD SCI USA, V103, P6362, DOI 10.1073/pnas.0510418103; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101	30	273	292	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					492	497		10.1038/nm1561	http://dx.doi.org/10.1038/nm1561			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17401376				2022-12-27	WOS:000245543900039
J	Leopold, JA; Dam, A; Maron, BA; Scribner, AW; Liao, R; Handy, DE; Stanton, RC; Pitt, B; Loscalzo, J				Leopold, Jane A.; Dam, Aamir; Maron, Bradley A.; Scribner, Anne W.; Liao, Ronglih; Handy, Diane E.; Stanton, Robert C.; Pitt, Bertram; Loscalzo, Joseph			Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; CONGESTIVE-HEART-FAILURE; EARLY REPRESSOR ICER; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; ANGIOTENSIN-II; NO SYNTHASE; CELLS; CAMP; SPIRONOLACTONE	Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO center dot). Here we show that aldosterone (10(-9) - 10(-7) mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO center dot levels - similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMP-response element modulator (CREM) to inhibit cyclic AMP-response element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Renal Sect, Boston, MA 02215 USA; Univ Michigan, Sch Med, Taubman Med Ctr, Div Cardiol, Ann Arbor, MI 48109 USA	Boston University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Michigan System; University of Michigan	Leopold, JA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Med Div, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	jleopold@partners.org	Stanton, Robert C/AAG-7584-2020; Loscalzo, Joseph/ABD-8980-2021	Stanton, Robert C/0000-0002-3056-1277; 	NHLBI NIH HHS [R01 HL073756-01, N01HV28178, HV28178, HL04399, R01 HL067297, P50 HL055993, R01 HL073756, P01 HL81587, R01 HL071775-01A1, K08 HL004399-01, P50 HL055993-10, HL58976, U01 HL108630, N01 HV028178, R01 HL058976, R01 HL071775, HL073756, R01 HL067297-01A2, K08 HL004399, R01 HL058976-08, HL071775, HL067297, HL081110, R37 HL061795, K02 HL081110-01, HL61828, K02 HL081110] Funding Source: Medline; NIDDK NIH HHS [DK053480-05, R01 DK054380, R01 DK054380-04S1] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067297, K02HL081110, P01HL081587, R01HL071775, R01HL028178, K08HL004399, R01HL058976, R37HL061795, U01HL108630, R01HL073756, P50HL055993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054380, R01DK053480] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abiose AK, 2004, AM J CARDIOL, V93, P1564, DOI 10.1016/j.amjcard.2004.03.015; Blacher J, 1997, AM J HYPERTENS, V10, P1326, DOI 10.1016/S0895-7061(97)90502-1; Boissel JP, 2004, BIOCHEMISTRY-US, V43, P7197, DOI 10.1021/bi0302191; Booth RE, 2002, ADV PHYSIOL EDUC, V26, P8, DOI 10.1152/advan.00051.2001; Cai S, 2005, DIABETOLOGIA, V48, P1933, DOI 10.1007/s00125-005-1857-5; CRISS WE, 1969, BIOCHIM BIOPHYS ACTA, V184, P486, DOI 10.1016/0304-4165(69)90262-1; Davies JI, 2004, DIABETOLOGIA, V47, P1687, DOI 10.1007/s00125-004-1510-8; Ding B, 2005, P NATL ACAD SCI USA, V102, P14771, DOI 10.1073/pnas.0506489102; Ding H, 2005, BRIT J PHARMACOL, V146, P1110, DOI 10.1038/sj.bjp.0706417; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Duprez DA, 1998, EUR HEART J, V19, P1371, DOI 10.1053/euhj.1998.1099; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; Farquharson CAJ, 2000, CIRCULATION, V101, P594, DOI 10.1161/01.CIR.101.6.594; Forgione MA, 2003, J AM COLL CARDIOL, V41, p249A; Garnier A, 2004, CIRCULATION, V110, P1819, DOI 10.1161/01.CIR.0000142858.44680.27; Guo L, 2002, BIOCHEMISTRY-US, V41, P14726, DOI 10.1021/bi026110v; Hou JH, 2002, J AM SOC NEPHROL, V13, P1190, DOI 10.1097/01.ASN.0000013702.73570.3B; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Leopold JA, 2000, AM J PHYSIOL-HEART C, V279, pH2477, DOI 10.1152/ajpheart.2000.279.5.H2477; Leopold JA, 2003, J BIOL CHEM, V278, P32100, DOI 10.1074/jbc.M301293200; Leopold JA, 2003, ARTERIOSCL THROM VAS, V23, P411, DOI 10.1161/01.ATV.0000056744.26901.BA; Leopold JA, 2001, FASEB J, V15, P1771, DOI 10.1096/fj.00-0893fje; LIEW CC, 1969, CAN J PHYSIOL PHARM, V47, P193, DOI 10.1139/y69-033; Macdonald JE, 2004, HEART, V90, P765, DOI 10.1136/hrt.2003.017368; Macho B, 2003, METHOD ENZYMOL, V370, P396; Manna PR, 2002, MOL ENDOCRINOL, V16, P184, DOI 10.1210/me.16.1.184; Massaad C, 1999, MOL ENDOCRINOL, V13, P57, DOI 10.1210/me.13.1.57; Matsui R, 2005, CIRCULATION, V112, P257, DOI 10.1161/CIRCULATIONAHA.104.499095; Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B; Mioduszewska B, 2003, J NEUROCHEM, V87, P1313, DOI 10.1046/j.1471-4159.2003.02116.x; Nagata D, 2006, HYPERTENSION, V48, P165, DOI 10.1161/01.HYP.0000226054.53527.bb; Nishizaka MK, 2004, CIRCULATION, V109, P2857, DOI 10.1161/01.CIR.0000129307.26791.8E; Rousseau MF, 2002, J AM COLL CARDIOL, V40, P1596, DOI 10.1016/S0735-1097(02)02382-3; Schafer A, 2003, CARDIOVASC RES, V58, P655, DOI 10.1016/S0008-6363(03)00333-X; Shepard JD, 2005, J NEUROSCI, V25, P4073, DOI 10.1523/JNEUROSCI.0122-05.2005; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; Struthers AD, 2004, MOL CELL ENDOCRINOL, V217, P239, DOI 10.1016/j.mce.2003.10.024; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Virdis A, 2003, ARTERIOSCL THROM VAS, V23, P1352, DOI 10.1161/01.ATV.0000083297.47245.DA; Weber KT, 2003, J LAB CLIN MED, V142, P71, DOI 10.1016/S0022-2143(03)00062-3; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050; Xu YZ, 2005, AM J PHYSIOL-RENAL, V289, pF1040, DOI 10.1152/ajprenal.00076.2005; Zhang MX, 2005, P NATL ACAD SCI USA, V102, P16967, DOI 10.1073/pnas.0503853102; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhang YY, 2002, BIOCHEM J, V361, P267, DOI 10.1042/0264-6021:3610267; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhang ZQ, 2000, J BIOL CHEM, V275, P40042, DOI 10.1074/jbc.M007505200	48	264	267	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					189	197		10.1038/nm1545	http://dx.doi.org/10.1038/nm1545			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17273168	Green Accepted			2022-12-27	WOS:000244031700028
J	Vilimas, T; Mascarenhas, J; Palomero, T; Mandal, M; Buonamici, S; Meng, FY; Thompson, B; Spaulding, C; Macaroun, S; Alegre, ML; Kee, BL; Ferrando, A; Miele, L; Aifantis, I				Vilimas, Tomas; Mascarenhas, Joaquina; Palomero, Teresa; Mandal, Malay; Buonamici, Silvia; Meng, Fanyong; Thompson, Benjamin; Spaulding, Christina; Macaroun, Sami; Alegre, Maria-Luisa; Kee, Barbara L.; Ferrando, Adolfo; Miele, Lucio; Aifantis, Iannis			Targeting the NF-kappa B signaling pathway in Notch1-induced T-cell leukemia	NATURE MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; CANCER DEVELOPMENT; NOTCH; ACTIVATION; LEUKEMIA/LYMPHOMA; LINEAGE; GENE; EXPRESSION	T-cell acute lymphoblastic leukemia (T-ALL), unlike other ALL types, is only infrequently associated with chromosomal aberrations, but it was recently shown that most individuals with T-ALL carry activating mutations in the NOTCH1 gene. However, the signaling pathways and target genes responsible for Notch1-induced neoplastic transformation remain undefined. We report here that constitutively active Notch1 activates the NF-kappa B pathway transcriptionally and via the I kappa B kinase (IKK) complex, thereby causing increased expression of several well characterized target genes of NF-kappa B in bone marrow hematopoietic stem cells and progenitors. Our observations demonstrate that the NF-kappa B pathway is highly active in established human T-ALL and that inhibition of the pathway can efficiently restrict tumor growth both in vitro and in vivo. These findings identify NF-kappa B as one of the major mediators of Notch1-induced transformation and suggest that the NF-kappa B pathway is a potential target of future therapies of T-ALL.	Univ Chicago, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA; Loyola Univ, Med Ctr, Inst Oncol, Maywood, IL 60153 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; Loyola University Chicago; Columbia University; New York University; University of Chicago	Aifantis, I (corresponding author), Univ Chicago, Dept Med, Rheumatol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	iannis.aifantis@med.nyu.edu	Ferrando, Adolfo A/Q-7026-2016	Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [R01CA105129, R01CA084065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA105129, R01CA84065] Funding Source: Medline; NIA NIH HHS [P01AG025531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Allman D, 2001, J EXP MED, V194, P99, DOI 10.1084/jem.194.1.99; Aster JC, 2005, INT J HEMATOL, V82, P295, DOI 10.1532/IJH97.05096; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Borowski C, 2004, J EXP MED, V199, P607, DOI 10.1084/jem.20031973; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Campese AF, 2006, BLOOD, V108, P305, DOI 10.1182/blood-2006-01-0143; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338; El Abdaloussi E, 2006, NAT IMMUNOL, V7, P418, DOI 10.1038/ni1313; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Mandal M, 2005, J EXP MED, V201, P603, DOI 10.1084/jem.20041924; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Spano JP, 2005, B CANCER, V92, P945; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035	45	255	268	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					70	77		10.1038/nm1524	http://dx.doi.org/10.1038/nm1524			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17173050				2022-12-27	WOS:000243301800038
J	Roeder, I; Horn, M; Glauche, I; Hochhaus, A; Mueller, MC; Loeffler, M				Roeder, Ingo; Horn, Matthias; Glauche, Ingmar; Hochhaus, Andreas; Mueller, Martin C.; Loeffler, Markus			Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications	NATURE MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELL ORGANIZATION; ABL TYROSINE KINASE; POSITIVE CELLS; RESISTANCE; INTERFERON; INHIBITOR; THERAPY; STI571; PROGENITORS	Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib represents a successful application of molecularly targeted cancer therapy. A rapid hematologic and cytogenetic response can be induced in the majority of people, even in advanced disease. However, complete eradication of malignant cells, which are characterized by the expression of the BCR-ABL1 fusion protein, is rare. Reasons for the persistence of the malignant clone are currently not known and provide a substantial challenge for clinicians and biologists. Based on a mathematical modeling approach that quantitatively explains a broad range of phenomena, we show for two independent datasets that clinically observed BCR-ABL1 transcript dynamics during imatinib treatment of CML can consistently be explained by a selective functional effect of imatinib on proliferative leukemia stem cells. Our results suggest the general potential of imatinib to induce a complete elimination of the malignant clone. Moreover, we predict that the therapeutic benefit of imatinib can, under certain circumstances, be accelerated by combination with proliferation-stimulating treatment strategies.	Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04107 Leipzig, Germany; Heidelberg Univ, Med Klin 3, Fak Klin Med Mannheim, D-68305 Mannheim, Germany	Leipzig University	Roeder, I (corresponding author), Univ Leipzig, Inst Med Informat Stat & Epidemiol, Haertelstr 16-18, D-04107 Leipzig, Germany.	ingo.roeder@imise.uni-leipzig.de		Hochhaus, Andreas/0000-0003-0626-0834				Catlin SN, 2005, BLOOD, V106, P2688, DOI 10.1182/blood-2005-03-1240; Cortes J, 2005, CLIN CANCER RES, V11, P3425, DOI 10.1158/1078-0432.CCR-04-2139; Deininger MWN, 2004, CANCER CELL, V6, P108, DOI 10.1016/j.ccr.2004.08.006; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES C, 1993, LEUKEMIA LYMPHOMA, V11, P245, DOI 10.3109/10428199309047894; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hehlmann R, 2000, ANN HEMATOL, V79, P345, DOI 10.1007/s002770000167; Hochhaus A, 2004, LEUKEMIA, V18, P1321, DOI 10.1038/sj.leu.2403426; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; ICHIMARU M, 1991, J RADIAT RES, V32, P14, DOI 10.1269/jrr.32.SUPPLEMENT2_14; Jorgensen HG, 2005, CANCER, V103, P210, DOI 10.1002/cncr.20742; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Lahaye T, 2005, CANCER-AM CANCER SOC, V103, P1659, DOI 10.1002/cncr.20922; Loeffler M, 2002, CELLS TISSUES ORGANS, V171, P8, DOI 10.1159/000057688; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Muller MC, 2003, LEUKEMIA, V17, P2392, DOI 10.1038/sj.leu.2403157; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; Roeder I, 2005, BLOOD, V105, P609, DOI 10.1182/blood-2004-01-0282; Roeder I, 2002, EXP HEMATOL, V30, P853, DOI 10.1016/S0301-472X(02)00832-9; Topaly J, 2002, BRIT J CANCER, V86, P1487, DOI 10.1038/sj.bjc.6600242; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683	26	252	261	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1181	1184		10.1038/nm1487	http://dx.doi.org/10.1038/nm1487			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013383				2022-12-27	WOS:000241102200035
J	Rossi, AG; Sawatzky, DA; Walker, A; Ward, C; Sheldrake, TA; Riley, NA; Caldicott, A; Martinez-Losa, M; Walker, TR; Duffin, R; Gray, M; Crescenzi, E; Martin, MC; Brady, HJ; Savill, JS; Dransfield, I; Haslett, C				Rossi, Adriano G.; Sawatzky, Deborah A.; Walker, Annemieke; Ward, Carol; Sheldrake, Tara A.; Riley, Nicola A.; Caldicott, Alison; Martinez-Losa, Magdalena; Walker, Trevor R.; Duffin, Rodger; Gray, Mohini; Crescenzi, Elvira; Martin, Morag C.; Brady, Hugh J.; Savill, John S.; Dransfield, Ian; Haslett, Christopher			Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis	NATURE MEDICINE			English	Article							NF-KAPPA-B; HUMAN NEUTROPHILS; IN-VIVO; DOWN-REGULATION; R-ROSCOVITINE; BACTERIAL LIPOPOLYSACCHARIDE; INDUCIBLE CYCLOOXYGENASE; SELICICLIB CYC202; AGING NEUTROPHILS; MULTIPLE-MYELOMA	Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of inflammation. Here we report that human neutrophils contain functionally active cyclin-dependent kinases (CDKs), and that structurally diverse CDK inhibitors induce caspase-dependent apoptosis and override powerful anti-apoptosis signals from survival factors such as granulocyte - macrophage colony-stimulating factor (GM-CSF). We show that the CDK inhibitor R-roscovitine (Seliciclib or CYC202) markedly enhances resolution of established neutrophil-dependent inflammation in carrageenan-elicited acute pleurisy, bleomycininduced lung injury, and passively induced arthritis in mice. In the pleurisy model, the caspase inhibitor zVAD-fmk prevents R-roscovitine - enhanced resolution of inflammation, indicating that this CDK inhibitor augments inflammatory cell apoptosis. We also provide evidence that R-roscovitine promotes apoptosis by reducing concentrations of the anti-apoptotic protein Mcl-1. Thus, CDK inhibitors enhance the resolution of established inflammation by promoting apoptosis of inflammatory cells, thereby demonstrating a hitherto unrecognized potential for the treatment of inflammatory disorders.	Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland; UCL, Great Ormond St Hosp Children NHS Trust, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England	University of Edinburgh; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Rossi, AG (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	a.g.rossi@ed.ac.uk		Martin, Morag/0000-0002-8667-6057; CRESCENZI, ELVIRA/0000-0002-9258-8053; Duffin, Rodger/0000-0002-3425-9745; Dransfield, Ian/0000-0001-5848-7059; Brady, Hugh/0000-0002-3152-067X	Medical Research Council [G0601481] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azambuja E, 2005, PULM PHARMACOL THER, V18, P363, DOI 10.1016/j.pupt.2005.01.007; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Cailhier JFO, 2006, AM J RESP CRIT CARE, V173, P540, DOI 10.1164/rccm.200504-538OC; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Paepe ME, 2004, AM J PHYSIOL-LUNG C, V287, pL730, DOI 10.1152/ajplung.00120.2004; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 2003, FASEB J, V17, P2269, DOI 10.1096/fj.02-1162fje; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HASLETT C, 1985, AM J PATHOL, V119, P101; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Klausen P, 2004, J LEUKOCYTE BIOL, V75, P569, DOI 10.1189/jlb.1003474; Kobayashi SD, 2005, J LEUKOCYTE BIOL, V78, P1408, DOI 10.1189/jlb.0605289; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Monaco EA, 2003, CURR MED CHEM, V10, P367, DOI 10.2174/0929867033368277; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Pinho V, 2005, J LEUKOCYTE BIOL, V77, P800, DOI 10.1189/jlb.0704386; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Riley Nicola A., 2006, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V5, P3, DOI 10.2174/187152306775537319; Rosales JL, 2004, J BIOL CHEM, V279, P53932, DOI 10.1074/jbc.M408467200; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Tsukahara Y, 2003, J CELL BIOCHEM, V89, P848, DOI 10.1002/jcb.10526; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Williams O, 2000, EUR J IMMUNOL, V30, P709; Zhang XQ, 2004, J LEUKOCYTE BIOL, V75, P358, DOI 10.1189/jlb.0903412	50	400	420	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1056	1064		10.1038/nm1468	http://dx.doi.org/10.1038/nm1468			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16951685				2022-12-27	WOS:000240373900030
J	Ochi, H; Abraham, M; Ishikawa, H; Frenkel, D; Yang, KY; Basso, AS; Wu, H; Chen, ML; Gandhi, R; Miller, A; Maron, R; Weiner, HL				Ochi, Hirofumi; Abraham, Michal; Ishikawa, Hiroki; Frenkel, Dan; Yang, Kaiyong; Basso, Alexandre S.; Wu, Henry; Chen, Mei-Ling; Gandhi, Roopali; Miller, Ariel; Maron, Ruth; Weiner, Howard L.			Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4(+) CD25(-)LAP(+) T cells	NATURE MEDICINE			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NONOBESE DIABETIC MICE; NOD MICE; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES; SELF-TOLERANCE; ACTIVATION	A major goal of immunotherapy for autoimmune diseases and transplantation is induction of regulatory T cells that mediate immunologic tolerance. The mucosal immune system is unique, as tolerance is preferentially induced after exposure to antigen, and induction of regulatory T cells is a primary mechanism of oral tolerance. Parenteral administration of CD3-specific monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We found that orally administered CD3-specific antibody is biologically active in the gut and suppresses autoimmune encephalomyelitis both before induction of disease and at the height of disease. Orally administered CD3-specific antibody induces CD4(+)CD25(-)LAP(+) regulatory T cells that contain latency-associated peptide ( LAP) on their surface and that function in vitro and in vivo through a TGF-beta-dependent mechanism. These findings identify a new immunologic approach that is widely applicable for the treatment of human autoimmune conditions.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Carmel Hosp, Dept Neurol, Neuroimmunol Unit, IL-34362 Haifa, Israel	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Clalit Health Services; Carmel Medical Center	Weiner, HL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu	Basso, Alexandre S/K-2281-2012	Basso, Alexandre S/0000-0002-3302-4792; Miller, Ariel/0000-0001-5843-6841				Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; CHATENOUD L, 1986, J IMMUNOL, V137, P830; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HAFLER DA, 1988, J IMMUNOL, V141, P131; Herold KC, 2005, DIABETES, V54, P1763, DOI 10.2337/diabetes.54.6.1763; Herold KC, 2003, J CLIN INVEST, V111, P409, DOI 10.1172/JCI200316090; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HEROLD KC, 1992, DIABETES, V41, P385, DOI 10.2337/diabetes.41.3.385; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Jorritsma PJ, 2003, J IMMUNOL, V170, P2427, DOI 10.4049/jimmunol.170.5.2427; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; LIDER O, 1989, J IMMUNOL, V142, P748; Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30; Maron R, 1999, J AUTOIMMUN, V12, P251, DOI 10.1006/jaut.1999.0278; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1993, J IMMUNOL, V151, P7307; Mottram PL, 2002, TRANSPL IMMUNOL, V10, P63, DOI 10.1016/S0966-3274(02)00050-3; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; SAYEGH MH, 1992, P NATL ACAD SCI USA, V89, P7762, DOI 10.1073/pnas.89.16.7762; Slavin AJ, 2001, INT IMMUNOL, V13, P825, DOI 10.1093/intimm/13.6.825; Tran GT, 2001, INT IMMUNOL, V13, P1109, DOI 10.1093/intimm/13.9.1109; Utset TO, 2002, J RHEUMATOL, V29, P1907; von Herrath MG, 2002, J IMMUNOL, V168, P933, DOI 10.4049/jimmunol.168.2.933; WEINSHENKER BG, 1991, NEUROLOGY, V41, P1047, DOI 10.1212/WNL.41.7.1047; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; Zhang XM, 2006, INT IMMUNOL, V18, P495, DOI 10.1093/intimm/dxh390; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	42	196	212	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					627	635		10.1038/nm1408	http://dx.doi.org/10.1038/nm1408			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715091				2022-12-27	WOS:000238149200023
J	Jiang, DH; Liang, JR; Fan, J; Yu, S; Chen, SP; Luo, Y; Prestwich, GD; Mascarenhas, MM; Garg, HG; Quinn, DA; Homer, RJ; Goldstein, DR; Bucala, R; Lee, PJ; Medzhitov, R; Noble, PW				Jiang, DH; Liang, JR; Fan, J; Yu, S; Chen, SP; Luo, Y; Prestwich, GD; Mascarenhas, MM; Garg, HG; Quinn, DA; Homer, RJ; Goldstein, DR; Bucala, R; Lee, PJ; Medzhitov, R; Noble, PW			Regulation of lung injury and repair by Toll-like receptors and hyaluronan	NATURE MEDICINE			English	Article							NF-KAPPA-B; BLEOMYCIN-INDUCED PNEUMONOPATHY; MURINE MACROPHAGES; PULMONARY-FIBROSIS; CASPASE INHIBITOR; EPITHELIAL-CELLS; IMMUNE-RESPONSE; FAS LIGAND; EXPRESSION; MICE	Mechanisms that regulate inflammation and repair after acute lung injury are incompletely understood. The extracellular matrix glycosaminoglycan hyaluronan is produced after tissue injury and impaired clearance results in unremitting inflammation. Here we report that hyaluronan degradation products require MyD88 and both Toll-like receptor ( TLR) 4 and TLR2 in vitro and in vivo to initiate inflammatory responses in acute lung injury. Hyaluronan fragments isolated from serum of individuals with acute lung injury stimulated macrophage chemokine production in a TLR4- and TLR2-dependent manner. Myd88(-/-) and Tlr4(-/-)Tlr2(-/-) mice showed impaired transepithelial migration of inflammatory cells but decreased survival and enhanced epithelial cell apoptosis after lung injury. Lung epithelial cell-specific overexpression of high-molecular-mass hyaluronan was protective against acute lung injury. Furthermore, epithelial cell-surface hyaluronan was protective against apoptosis, in part, through TLR-dependent basal activation of NF-kappa B. Hyaluronan-TLR2 and hyaluronan-TLR4 interactions provide signals that initiate inflammatory responses, maintain epithelial cell integrity and promote recovery from acute lung injury.	Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84132 USA; Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Yale Univ, Sch Med, Cardiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University; Utah System of Higher Education; University of Utah; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Noble, PW (corresponding author), Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Med Sect, 333 Cedar St, New Haven, CT 06520 USA.	paul.noble@yale.edu	Liang, Carol Jiurong/AAI-4963-2021; homer, robert/P-3884-2019; Jiang, Dianhua/B-1421-2009	homer, robert/0000-0002-2055-5885; Jiang, Dianhua/0000-0002-4508-3829; Liang, Jiurong/0000-0001-5179-5016; Goldstein, Daniel/0000-0001-6695-979X	NHLBI NIH HHS [HL57486] Funding Source: Medline; NIAID NIH HHS [AI52487] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON IYR, 1974, AM J PATHOL, V77, P185; Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Armstrong L, 2004, AM J RESP CELL MOL, V31, P241, DOI 10.1165/rcmb.2004-0078OC; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; CLARK JM, 1971, PHARMACOL REV, V23, P37; Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 1998, J IMMUNOL, V160, P3023; Jameson JM, 2005, J EXP MED, V201, P1269, DOI 10.1084/jem.20042057; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; Kuwano K, 2001, AM J PHYSIOL-LUNG C, V280, pL316, DOI 10.1152/ajplung.2001.280.2.L316; Luo Y, 1999, BIOCONJUGATE CHEM, V10, P755, DOI 10.1021/bc9900338; Mascarenhas MM, 2004, AM J RESP CELL MOL, V30, P51, DOI 10.1165/rcmb.2002-0167OC; Mehrad B, 1999, J IMMUNOL, V163, P6086; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; RICE WR, 2002, IN VITRO AM J PHYSL, V283, pL256; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; VAN AD, 1996, SCIENCE, V274, P787; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; Zhang XY, 2000, AM J RESP CRIT CARE, V162, P1561, DOI 10.1164/ajrccm.162.4.9908093; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200	40	1071	1118	2	135	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1173	1179		10.1038/nm1315	http://dx.doi.org/10.1038/nm1315			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16244651				2022-12-27	WOS:000233115400029
J	Liu, BH; Wang, JM; Chan, KM; Tjia, WM; Deng, W; Guan, XY; Huang, JD; Li, KM; Chau, PY; Chen, DJ; Pei, DQ; Pendas, AM; Cadinanos, J; Lopez-Otin, C; Tse, HF; Hutchison, C; Chen, JJ; Cao, YH; Cheah, KSE; Tryggvason, K; Zhou, ZJ				Liu, BH; Wang, JM; Chan, KM; Tjia, WM; Deng, W; Guan, XY; Huang, JD; Li, KM; Chau, PY; Chen, DJ; Pei, DQ; Pendas, AM; Cadinanos, J; Lopez-Otin, C; Tse, HF; Hutchison, C; Chen, JJ; Cao, YH; Cheah, KSE; Tryggvason, K; Zhou, ZJ			Genomic instability in laminopathy-based premature aging	NATURE MEDICINE			English	Article							HUTCHINSON-GILFORD PROGERIA; DOUBLE-STRAND BREAKS; LAMIN-A; DNA-DAMAGE; CELLULAR SENESCENCE; ZMPSTE24; MICE; RECOMBINATION; METALLOPROTEINASE	Premature aging syndromes often result from mutations in nuclear proteins involved in the maintenance of genomic integrity. Lamin A is a major component of the nuclear lamina and nuclear skeleton. Truncation in lamin A causes Hutchinson-Gilford progerial syndrome (HGPS), a severe form of early-onset premature aging. Lack of functional Zmpste24, a metalloproteinase responsible for the maturation of prelamin A, also results in progeroid phenotypes in mice and humans. We found that Zmpste24-deficient mouse embryonic fibroblasts (MEFs) show increased DNA damage and chromosome aberrations and are more sensitive to DNA-damaging agents. Bone marrow cells isolated from Zmpste24(-/-) mice show increased aneuploidy and the mice are more sensitive to DNA- damaging agents. Recruitment of p53 binding protein 1 (53BP1) and Rad51 to sites of DNA lesion is impaired in Zmpste24(-/-) MEFs and in HGPS fibroblasts, resulting in delayed checkpoint response and defective DNA repair. Wild-type MEFs ectopically expressing unprocessible prelamin A show similar defects in checkpoint response and DNA repair. Our results indicate that unprocessed prelamin A and truncated lamin A act dominant negatively to perturb DNA damage response and repair, resulting in genomic instability which might contribute to laminopathy-based premature aging.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Diego, Dept Mol Med, La Jolla, CA 92093 USA; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Oviedo, Dept Bioquim & Biol Mol, Inst Oncol, E-33006 Oviedo, Spain; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Durham, Dept Biol & Biomed Sci, Durham DH1 3HP, England; Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; Karolinska Inst, Microbiol & Tumor Ctr, S-17177 Stockholm, Sweden	University of Hong Kong; University of California System; University of California San Diego; University of Hong Kong; University of Hong Kong; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities; University of Oviedo; University of Hong Kong; Durham University; Mayo Clinic; Karolinska Institutet	Zhou, ZJ (corresponding author), Univ Hong Kong, Dept Biochem, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	zhongjun@hkucc.hku.hk	Deng, Wen/C-4154-2009; Deng, Wen/M-5208-2019; Liu, Baohua/C-9594-2014; zhou, zhongjun/D-4818-2012; Chan, Kui Ming June/G-4330-2013; Liu, Baohua/AAH-3685-2020; López-Otín, Carlos/AAB-2106-2020; Liu, Baohua/C-4191-2009; Tse, Hung-Fat/C-4426-2009; Pendas, Alberto M/L-1017-2014; Guan, Xin-Yuan/A-3639-2009; Zhou, Zhongjun/C-4476-2009; /C-4277-2009; /A-3639-2009	Liu, Baohua/0000-0002-1599-8059; Liu, Baohua/0000-0002-1599-8059; López-Otín, Carlos/0000-0001-6964-1904; Tse, Hung-Fat/0000-0002-9578-7808; Guan, Xin-Yuan/0000-0002-4485-6017; Zhou, Zhongjun/0000-0001-7092-8128; CHAN, Kui Ming/0000-0001-6430-3340; Cadinanos, Juan/0000-0001-7561-7759; Pendas, Alberto M/0000-0001-9264-3721; /0000-0001-7531-2816; /0000-0003-1874-9805				Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Busuttil RA, 2004, ANN NY ACAD SCI, V1019, P245, DOI 10.1196/annals.1297.041; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; GOLDMAN AE, 1992, J CELL BIOL, V119, P725, DOI 10.1083/jcb.119.4.725; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Karanjawala ZE, 2004, MECH AGEING DEV, V125, P405, DOI 10.1016/j.mad.2004.04.003; Li XT, 2003, NUCLEIC ACIDS RES, V31, P6674, DOI 10.1093/nar/gkg844; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; LUZI P, 1994, CYTOMETRY, V18, P79, DOI 10.1002/cyto.990180205; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Mukherjee AB, 1998, MECH AGEING DEV, V103, P209, DOI 10.1016/S0047-6374(98)00041-4; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	25	470	489	4	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					780	785		10.1038/nm1266	http://dx.doi.org/10.1038/nm1266			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980864				2022-12-27	WOS:000230304200035
J	Pashine, A; Valiante, NM; Ulmer, JB				Pashine, A; Valiante, NM; Ulmer, JB			Targeting the innate immune response with improved vaccine adjuvants	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; DENDRITIC CELLS SERVE; BACTERIAL FIMBRIAE; IN-VIVO; RECOGNITION; PEPTIDOGLYCAN; SYSTEM; CPG; ACTIVATION; EVOLUTION	Despite two centuries of vaccine use, only a few adjuvants and delivery systems are licensed for human use. This is partly because traditional vaccines based on attenuated live organisms already have them-their invasiveness provides efficient delivery to antigen-presenting cells and various naturally occurring components of the pathogens stimulate the innate immune system. But consideration of these immune potentiators and delivery systems has become important to the development of new subunit vaccines consisting of isolated antigens. Here we consider rational approaches to the discovery and development of immunostimulatory compounds and vaccine formulations that target innate immune responses.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Ulmer, JB (corresponding author), Chiron Corp, 4560 Horton St, Emeryville, CA 94608 USA.	jeffrey_ulmer@chiron.com						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Asai Y, 2001, INFECT IMMUN, V69, P7387, DOI 10.1128/IAI.69.12.7387-7395.2001; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chernysh S, 2002, P NATL ACAD SCI USA, V99, P12628, DOI 10.1073/pnas.192301899; Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/00001432-200306000-00003; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; Grohmann U, 1997, ADV EXP MED BIOL, V417, P579; GUPTA RK, 1995, VACCINE, V13, P1276; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hengge UR, 2003, BRIT J DERMATOL, V149, P15, DOI 10.1046/j.0366-077X.2003.05623.x; Hilleman MR, 2000, VACCINE, V18, P1436, DOI 10.1016/S0264-410X(99)00434-X; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kieny MP, 2004, AM J PUBLIC HEALTH, V94, P1931, DOI 10.2105/AJPH.94.11.1931; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; Lindblad EB, 2004, VACCINE, V22, P3658, DOI 10.1016/j.vaccine.2004.03.032; Liu Bailing, 2004, Am J Pharmacogenomics, V4, P263, DOI 10.2165/00129785-200404040-00006; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mason KA, 2005, CLIN CANCER RES, V11, P361; Mayordomo JI, 1997, STEM CELLS, V15, P94, DOI 10.1002/stem.150094; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; O'Hagan D.T., 2004, NEW GENERATION VACCI, P259; O'Hagan DT, 2004, VACCINE, V23, P672, DOI 10.1016/j.vaccine.2004.06.037; O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176; Ogawa T, 2002, EUR J IMMUNOL, V32, P2543, DOI 10.1002/1521-4141(200209)32:9<2543::AID-IMMU2543>3.0.CO;2-2; OTT G, 2001, VACCINE ADJUVANTS PR, P211; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pink J Richard, 2004, Vaccine, V22, P2097, DOI 10.1016/j.vaccine.2004.01.021; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Roberts TL, 2005, J IMMUNOL, V174, P605, DOI 10.4049/jimmunol.174.2.605; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x	49	398	440	0	56	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4		S			S63	S68		10.1038/nm1210	http://dx.doi.org/10.1038/nm1210			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812492	Bronze			2022-12-27	WOS:000228339600012
J	da Silva, FP; Aloulou, M; Skurnik, D; Benhamou, M; Andremont, A; Velasco, IT; Chiamolera, M; Verbeek, JS; Launay, P; Monteiro, RC				da Silva, Fabiano Pinheiro; Aloulou, Meryem; Skurnik, David; Benhamou, Marc; Andremont, Antoine; Velasco, Irineu T.; Chiamolera, Murilo; Verbeek, J. Sjef; Launay, Pierre; Monteiro, Renato C.			CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation	NATURE MEDICINE			English	Article							DEFICIENT MICE; RECEPTOR MARCO; RESPONSES; MACROPHAGES; MONOCYTES; DAP12; COMPLEXES; INFECTION; 3-KINASE; SHOCK	Sepsis, a leading cause of death worldwide, involves proinflammatory responses and inefficient bacterial clearance(1,2). Phagocytic cells play a crucial part in the prevention of sepsis by clearing bacteria through host innate receptors(3). Here we show that the FcR gamma adaptor, an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal transduction subunit of the Fc receptor family, has a deleterious effect on sepsis. FcR gamma(-/-) mice show increased survival during peritonitis, owing to markedly increased E. coli phagocytosis and killing and to lower production of the proinflammatory cytokine tumor necrosis factor (TNF)-alpha. The FcR gamma-associated receptor that inhibits E. coli phagocytosis is Fc gamma RIII (also called CD16), and its absence protects mice from sepsis. Fc gamma RIII binds E. coli, and this interaction induces FcR gamma phosphorylation, recruitment of the tyrosine phosphatase SHP-1 and phosphatidylinositide-3 kinase (PI3K) dephosphorylation. Decreased PI3K activity inhibits E. coli phagocytosis and increases TNF-alpha production through Toll-like receptor 4. We identified the phagocytic receptor negatively regulated by FcR gamma on macrophages as the class A scavenger receptor MARCO. E. coli-Fc gamma RIII interaction induces the recruitment of SHP-1 to MARCO, thereby inhibiting E. coli phagocytosis. Thus, by binding FccRIII, E. coli triggers an inhibitory FcR gamma pathway that both impairs MARCO-mediated bacterial clearance and activates TNF-a secretion.	Univ Paris 07, INSERM, U699, F-75018 Paris, France; Univ Paris 07, Bichat Med Sch, F-75018 Paris, France; Univ Sao Paulo, Dept Emergency Med, BR-01246903 Sao Paulo, Brazil; Univ Paris 07, Bichat Claude Bernard Hosp, Dept Bacteriol, F-75018 Paris, France; Univ Paris 07, EA 6934, F-75018 Paris, France; Univ Sao Paulo, Div Rheumatol, BR-01246903 Sao Paulo, Brazil; Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; Equipe Avenir Inst Natl Sante & Rech Med, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universidade de Sao Paulo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universidade de Sao Paulo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Institut National de la Sante et de la Recherche Medicale (Inserm)	Monteiro, RC (corresponding author), Univ Paris 07, INSERM, U699, 16 Rue Henri Huchard, F-75018 Paris, France.	monteiro@bichat.inserm.fr	da Silva, Fabiano Pinheiro/F-3464-2011; chiamolera, murilo/T-7817-2019; Aloulou, Meryem/AAA-6713-2020; Launay, Pierre/AAH-7076-2019; Monteiro, Renato C/U-8633-2017	da Silva, Fabiano Pinheiro/0000-0003-2673-2202; Aloulou, Meryem/0000-0003-4590-230X; Monteiro, Renato C/0000-0001-5202-5646; Benhamou, Marc/0000-0001-7763-3795				Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Celli J, 2001, EMBO J, V20, P1245, DOI 10.1093/emboj/20.6.1245; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Daeron M, 2006, ADV IMMUNOL, V89, P39, DOI 10.1016/S0065-2776(05)89002-9; Dubois MJ, 2006, NAT MED, V12, P549, DOI 10.1038/nm1397; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; Kraal G, 2000, MICROBES INFECT, V2, P313, DOI 10.1016/S1286-4579(00)00296-3; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; LEIJH PCJ, 1979, J CLIN INVEST, V63, P772, DOI 10.1172/JCI109362; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Opal SM, 2001, CRIT CARE MED, V29, P13, DOI 10.1097/00003246-200101000-00003; Pasquier B, 2005, IMMUNITY, V22, P31, DOI 10.1016/j.immuni.2004.11.017; Pinheiro-da-Silva F, 2006, SHOCK, V25, P61, DOI 10.1097/01.shk.0000196496.72553.78; SALMON JE, 1987, J EXP MED, V166, P1798, DOI 10.1084/jem.166.6.1798; Sano H, 1998, J BIOL CHEM, V273, P8630, DOI 10.1074/jbc.273.15.8630; Skinner NA, 2005, CLIN EXP IMMUNOL, V141, P270, DOI 10.1111/j.1365-2249.2005.02839.x; Skrzeczynska J, 2002, SCAND J IMMUNOL, V55, P629, DOI 10.1046/j.1365-3083.2002.01092.x; SUNG SSJ, 1985, J IMMUNOL, V135, P1981; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Turnbull IR, 2005, J EXP MED, V202, P363, DOI 10.1084/jem.20050986; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; van der Laan LJW, 1999, J IMMUNOL, V162, P939; Williams DL, 2004, J IMMUNOL, V172, P449, DOI 10.4049/jimmunol.172.1.449	30	98	99	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1368	1374		10.1038/nm1665	http://dx.doi.org/10.1038/nm1665			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17934470				2022-12-27	WOS:000250736900031
J	Ballabh, P; Xu, HM; Hu, FR; Braun, A; Smith, K; Rivera, A; Lou, NH; Ungvari, Z; Goldman, SA; Csiszar, A; Nedergaard, M				Ballabh, Praveen; Xu, Hongmin; Hu, Furong; Braun, Alex; Smith, Kira; Rivera, Aracelie; Lou, Nanhong; Ungvari, Zoltan; Goldman, Steven A.; Csiszar, Anna; Nedergaard, Maiken			Angiogenic inhibition reduces germinal matrix hemorrhage	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; INTRAVENTRICULAR HEMORRHAGE; CYCLOOXYGENASE-2 INHIBITORS; IN-VIVO; SUPPRESS ANGIOGENESIS; CEREBRAL-CORTEX; BLOOD-VESSELS; WHITE-MATTER; ANGIOPOIETIN-2; EXPRESSION	The germinal matrix of premature infants is selectively vulnerable to hemorrhage within the first 48 h of life. To assess the role of vascular immaturity in germinal matrix hemorrhage (GMH), we evaluated germinal matrix angiogenesis in human fetuses and premature infants, as well as in premature rabbit pups, and noted active vessel remodeling in all three. Vascular endothelial growth factor (VEGF), angiopoietin-2 and endothelial cell proliferation were present at consistently higher levels in the germinal matrix relative to the white matter anlagen and cortical mantle. On that basis, we asked whether prenatal treatment with either of two angiogenic inhibitors, the COX-2 inhibitor celecoxib, or the VEGFR2 inhibitor ZD6474, could suppress the incidence of GMH in premature rabbit pups. Celecoxib treatment decreased angiopoietin-2 and VEGF levels as well as germinal matrix endothelial proliferation. Furthermore, treatment with celecoxib or ZD6474 substantially decreased the incidence of GMH. Thus, by suppressing germinal matrix angiogenesis, prenatal celecoxib or ZD6474 treatment may be able to reduce both the incidence and severity of GMH in susceptible premature infants.	Westchester Med Ctr, New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; Westchester Med Ctr, New York Med Coll, Dept Anat & Cell Biol, Valhalla, NY 10595 USA; Westchester Med Ctr, New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; Westchester Med Ctr, New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA; Univ Rochester, Dept Neurosurg, Rochester, NY USA; Univ Rochester, Dept Neurol, Rochester, NY USA; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center; University of Rochester; University of Rochester; University of Rochester	Ballabh, P (corresponding author), Westchester Med Ctr, New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.	pballabh@msn.com	Ungvari, Zoltan/GZK-8127-2022; Ungvari, Zoltan/ADU-0095-2022	Goldman, Steven/0000-0002-5498-4303	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029813] Funding Source: NIH RePORTER; NINDS NIH HHS [NS050586, R01NS29813] Funding Source: Medline; PHS HHS [R0130007] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alvarez-Soria MA, 2006, ANN RHEUM DIS, V65, P998, DOI 10.1136/ard.2005.046920; Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531; BALCOM RJ, 1993, PEDIATRICS, V91, P540; Ballabh P, 2005, PEDIATR RES, V58, P791, DOI 10.1203/01.PDR.0000180535.14093.FB; Ballabh P, 2004, PEDIATR RES, V56, P117, DOI 10.1203/01.PDR.0000130472.30874.FF; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; BEVERLEY DW, 1984, BRIT J OBSTET GYNAEC, V91, P1007, DOI 10.1111/j.1471-0528.1984.tb03679.x; *BOULD COMM, 1970, ANAT REC, V28, P3019; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; CONNER ES, 1983, J NEUROSURG, V58, P204, DOI 10.3171/jns.1983.58.2.0204; Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026; du Plessis AJ, 2002, CURR OPIN NEUROL, V15, P151, DOI 10.1097/00019052-200204000-00005; El-Rayes BF, 2004, MOL CANCER THER, V3, P1421; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fukuda R, 2003, CANCER RES, V63, P2330; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hartleroad JY, 2005, BIOL NEONATE, V87, P246, DOI 10.1159/000083588; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Heuchan AM, 2002, ARCH DIS CHILD-FETAL, V86, P86; Isobe K, 2002, COMP BIOCHEM PHYS A, V132, P133, DOI 10.1016/S1095-6433(01)00539-6; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; KEY G, 1993, LAB INVEST, V68, P629; Leahy KM, 2002, CANCER RES, V62, P625; LORENZO AV, 1982, J NEUROSURG, V56, P404, DOI 10.3171/jns.1982.56.3.0404; Lukiw WJ, 2003, INVEST OPHTH VIS SCI, V44, P4163, DOI 10.1167/iovs.02-0655; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Masferrer JL, 2000, CANCER RES, V60, P1306; Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462; Muscara MN, 2000, BRIT J PHARMACOL, V129, P1423, DOI 10.1038/sj.bjp.0703232; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Sakai M, 2001, MOL HUM REPROD, V7, P595, DOI 10.1093/molehr/7.6.595; Sanborn R, 2005, SEMIN ONCOL, V32, P69, DOI 10.1053/j.seminoncol.2004.09.035; Sawaoka H, 1999, LAB INVEST, V79, P1469; Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Stika CS, 2002, AM J OBSTET GYNECOL, V187, P653, DOI 10.1067/mob.2002.125281; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tommiska V, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e2; TSIANTOS A, 1974, J PEDIATR-US, V85, P854, DOI 10.1016/S0022-3476(74)80360-4; Vates GE, 2005, J NEUROSURG, V103, P136, DOI 10.3171/jns.2005.103.1.0136; Virgintino D, 2003, HISTOCHEM CELL BIOL, V119, P227, DOI 10.1007/s00418-003-0510-y; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wong CG, 2001, CURR EYE RES, V22, P140, DOI 10.1076/ceyr.22.2.140.5528; Wu YL, 2005, BIOMED PHARMACOTHER, V59, pS289, DOI 10.1016/S0753-3322(05)80048-4; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhu YQ, 2005, STROKE, V36, P1533, DOI 10.1161/01.STR.0000170712.46106.2e	48	105	107	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					477	485		10.1038/nm1558	http://dx.doi.org/10.1038/nm1558			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17401377				2022-12-27	WOS:000245543900037
J	Trivedi, CM; Luo, Y; Yin, Z; Zhang, MZ; Zhu, WT; Wang, T; Floss, T; Goettlicher, M; Noppinger, PR; Wurst, W; Ferrari, VA; Abrams, CS; Gruber, PJ; Epstein, JA				Trivedi, Chinmay M.; Luo, Yang; Yin, Zhan; Zhang, Maozhen; Zhu, Wenting; Wang, Tao; Floss, Thomas; Goettlicher, Martin; Noppinger, Patricia Ruiz; Wurst, Wolfgang; Ferrari, Victor A.; Abrams, Charles S.; Gruber, Peter J.; Epstein, Jonathan A.			Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity	NATURE MEDICINE			English	Article							HISTONE DEACETYLASE INHIBITORS; GLYCOGEN-SYNTHASE KINASE-3-BETA; HEART-FAILURE; CLASS-I; GENE; EXPRESSION; AKT; ACETYLATION; HOP; IDENTIFICATION	In the adult heart, a variety of stresses induce re-expression of a fetal gene program in association with myocyte hypertrophy and heart failure. Here we show that histone deacetylase-2 (Hdac2) regulates expression of many fetal cardiac isoforms. Hdac2 deficiency or chemical histone deacetylase ( HDAC) inhibition prevented the re-expression of fetal genes and attenuated cardiac hypertrophy in hearts exposed to hypertrophic stimuli. Resistance to hypertrophy was associated with increased expression of the gene encoding inositol polyphosphate-5-phosphatase f (Inpp5f) resulting in constitutive activation of glycogen synthase kinase 3b (Gsk3b) via inactivation of thymoma viral proto-oncogene (Akt) and 3-phosphoinositide- dependent protein kinase-1 (Pdk1). In contrast, Hdac2 transgenic mice had augmented hypertrophy associated with inactivated Gsk3b. Chemical inhibition of activated Gsk3b allowed Hdac2-deficient adults to become sensitive to hypertrophic stimulation. These results suggest that Hdac2 is an important molecular target of HDAC inhibitors in the heart and that Hdac2 and Gsk3b are components of a regulatory pathway providing an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA; Tech Univ Munich, D-85764 Neuherberg, Germany; GSF Natl Res Ctr Environm & Hlth, Dept Toxicol, D-85764 Neuherberg, Germany; Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-10115 Berlin, Germany; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Cardiac Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Epstein, JA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 1156 Basic Res Bldg 2,421 Curie Blvd, Philadelphia, PA 19104 USA.	epsteinj@mail.med.upenn.edu	Zhu, Wenting/A-2718-2012; Göttlicher, Martin/M-7342-2014; Zhu, Wendy/G-3079-2010; Noppinger, Patricia Ruiz/AAH-1753-2019	Göttlicher, Martin/0000-0003-0619-2181; Noppinger, Patricia Ruiz/0000-0001-5617-8965; Wurst, Wolfgang/0000-0003-4422-7410; Epstein, Jonathan/0000-0001-8637-4465; Ferrari, Victor/0000-0001-8696-3243; Trivedi, Chinmay/0000-0002-3544-0474	NHLBI NIH HHS [R01 HL071546] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Baldinu P, 2004, HUM MUTAT, V23, P318, DOI 10.1002/humu.20015; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Choi JD, 2005, MOL CELL BIOL, V25, P5514, DOI 10.1128/MCB.25.13.5514-5522.2005; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724; Kong YL, 2006, CIRCULATION, V113, P2579, DOI 10.1161/CIRCULATIONAHA.106.625467; Kook H, 2003, TRENDS CARDIOVAS MED, V13, P261, DOI 10.1016/S1050-1738(03)00107-5; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002; Minagawa T, 2001, J BIOL CHEM, V276, P22011, DOI 10.1074/jbc.M101579200; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Peiffer-Schneider S, 1998, GENOMICS, V52, P9, DOI 10.1006/geno.1998.5399; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhou R, 2003, MAGN RESON MED, V49, P760, DOI 10.1002/mrm.10423	41	359	378	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					324	331		10.1038/nm1552	http://dx.doi.org/10.1038/nm1552			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17322895				2022-12-27	WOS:000244715700045
J	Park, BK; Zhang, HL; Zeng, QH; Dai, JL; Keller, ET; Giordano, T; Gu, KN; Shah, V; Pei, L; Zarbo, RJ; McCauley, L; Shi, ST; Chen, SQ; Wang, CY				Park, Bae Keun; Zhang, Honglai; Zeng, Qinghua; Dai, Jinlu; Keller, Evan T.; Giordano, Thomas; Gu, Keni; Shah, Veena; Pei, Lei; Zarbo, Richard J.; McCauley, Laurie; Shi, Songtao; Chen, Shaoqiong; Wang, Cun-Yu			NF-kappa B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; MARROW CULTURES; TUMOR-GROWTH; IN-VIVO; INFLAMMATION; INHIBITION; PATHOGENESIS; ACTIVATION; EXPRESSION; THERAPY	Advanced breast cancers frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are poorly understood. Here we report that nuclear factor-kappa B (NF-kappa B) plays a crucial role in the osteolytic bone metastasis of breast cancer by stimulating osteoclastogenesis. Using an in vivo bone metastasis model, we found that constitutive NF-kappa B activity in breast cancer cells is crucial for the bone resorption characteristic of osteolytic bone metastasis. We identified the gene encoding granulocyte macrophage-colony stimulating factor (GM-CSF) as a key target of NF-kappa B and found that it mediates osteolytic bone metastasis of breast cancer by stimulating osteoclast development. Moreover, we observed that the expression of GM-CSF correlated with NF-kappa B activation in bone-metastatic tumor tissues from individuals with breast cancer. These results uncover a new and specific role of NF-kappa B in osteolytic bone metastasis through GM-CSF induction, suggesting that NF-kappa B is a potential target for the treatment of breast cancer and the prevention of skeletal metastasis.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Henry Ford Hlth Syst, Dept Pathol, Detroit, MI 48202 USA; Univ Michigan, Sch Med & Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan; University of Southern California	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu	Dai, Jin/GVT-2414-2022; McCauley, Laurie/G-4041-2012; Keller, Evan T/M-1446-2016	Dai, Jin/0000-0003-3063-746X; Keller, Evan T/0000-0002-7592-7535; Giordano, Thomas/0000-0003-0641-8873	NCI NIH HHS [CA100849, CA093900, P01 CA093900] Funding Source: Medline; NIDCR NIH HHS [DE015618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA093900, R01CA100849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471-4906(02)02260-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232; Horak CE, 2005, CANCER CELL, V8, P93, DOI 10.1016/j.ccr.2005.07.013; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002-9440(10)65301-1; Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	46	264	281	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					62	69		10.1038/nm1519	http://dx.doi.org/10.1038/nm1519			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159986				2022-12-27	WOS:000243301800037
J	Blackburn, EH; Greider, CW; Szostak, JW				Blackburn, Elizabeth H.; Greider, Carol W.; Szostak, Jack W.			Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging	NATURE MEDICINE			English	Editorial Material							DOMINANT DYSKERATOSIS-CONGENITA; RIBOSOMAL-RNA GENES; REVERSE-TRANSCRIPTASE; TERMINAL TRANSFERASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; MOLECULAR-STRUCTURE; DNA-SEQUENCES; EST GENES; IN-VITRO		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Simches Res Ctr, Ctr Computat & Integrat Biol, Boston, MA 02114 USA	University of California System; University of California San Francisco; Johns Hopkins University; Harvard University; Harvard Medical School	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 600 16th St,MC 2200, San Francisco, CA 94158 USA.	elizabeth.blackburn@ucsf.edu; cgreider@jhmi.edu; szostak@molbio.mgh.harvard.edu	daehun, lee/H-2435-2013	Greider, Carol/0000-0002-5494-8126				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Armanios M, 2005, P NATL ACAD SCI USA, V102, P15960, DOI 10.1073/pnas.0508124102; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1982, COLD SPRING HARB SYM, V47, P1195, DOI 10.1101/SQB.1983.047.01.135; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOSWELL RE, 1982, P NATL ACAD SCI-BIOL, V79, P3255, DOI 10.1073/pnas.79.10.3255; Chen JL, 2004, TRENDS BIOCHEM SCI, V29, P183, DOI 10.1016/j.tibs.2004.02.003; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; DAWSON DS, 1986, SCIENCE, V234, P713, DOI 10.1126/science.3535068; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; EMERY HS, 1981, CELL, V26, P411, DOI 10.1016/0092-8674(81)90210-5; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JOHNSON EM, 1980, CELL, V22, P875, DOI 10.1016/0092-8674(80)90564-4; KATZEN AL, 1981, CELL, V24, P313, DOI 10.1016/0092-8674(81)90321-4; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; Kornberg Arthur, 1974, DNA SYNTHESIS; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; McCLINTOCK B., 1931, MISSOURI AGRIC EXP STA RES BULL, V163, P1; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Muller H, 1938, COLLECTING NET, V13, P181; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PAN WC, 1981, CELL, V23, P459, DOI 10.1016/0092-8674(81)90141-0; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; YAO MC, 1979, COLD SPRING HARB SYM, V43, P1293, DOI 10.1101/SQB.1979.043.01.147; YAO MC, 1981, J CELL BIOL, V90, P515, DOI 10.1083/jcb.90.2.515; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	58	620	643	8	190	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1133	1138		10.1038/nm1006-1133	http://dx.doi.org/10.1038/nm1006-1133			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024208				2022-12-27	WOS:000241102200027
J	Mi, QS; Deng, ZB; Joshi, SK; Wang, ZZ; Zhou, L; Eckenrode, S; Joshi, R; Ly, D; Yi, B; Delovitch, TL; She, JX				Mi, Qing-Sheng; Deng, Zhong-Bin; Joshi, Sunil K.; Wang, Zai-Zhao; Zhou, Li; Eckenrode, Sarah; Joshi, Ratanmani; Ly, Dalam; Yi, Bing; Delovitch, Terry L.; She, Jin-Xiong			RETRACTED: The autoimmune regulator (Aire) controls iNKT cell development and maturation (Retracted Article. See vol 12, pg 1100, 2006)	NATURE MEDICINE			English	Article; Retracted Publication							DEFICIENT MICE; NKT CELLS; T-CELLS; TYPE-1; EXPRESSION; TOLERANCE; LINEAGE; PROTEIN; THYMUS; MOUSE	The mechanism underlying the autoimmune polyglandular syndrome type-1 ( APS1) has been attributed to defective T-cell negative selection resulting from reduced expression and presentation of autoantigens in thymic medullary epithelial cells ( MECs). It has also been postulated that Aire is involved in development of regulatory T cells, although supporting evidence is lacking. Here we show that expression of Aire in MECs is required for development of iNKT cells, suggesting a role for iNKT cells in APS1.	Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Med, Dermatol Sect, Augusta, GA 30912 USA; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5K8, Canada; Univ Western Ontario, Robarts Res Inst, Lab Autoimmune Diabet, London, ON N6A 5K8, Canada	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Mi, QS (corresponding author), Med Coll Georgia, Ctr Biotechnol & Genom Med, 1120 15th St, Augusta, GA 30912 USA.	qmi@mail.mcg.edu; jshe@mail.mcg.edu		Ly, Dalam/0000-0002-1177-0225				Anderson MS, 2005, IMMUNITY, V23, P227, DOI 10.1016/j.immuni.2005.07.005; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; Kuroda N, 2005, J IMMUNOL, V174, P1862, DOI 10.4049/jimmunol.174.4.1862; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6; Matsuda JL, 2005, CURR OPIN IMMUNOL, V17, P122, DOI 10.1016/j.coi.2005.01.002; Mi QS, 2004, DIABETES, V53, P1303, DOI 10.2337/diabetes.53.5.1303; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Ruan QG, 2004, CLIN LAB MED, V24, P305, DOI 10.1016/j.cll.2004.01.008; Sivakumar V, 2003, J EXP MED, V197, P1613, DOI 10.1084/jem.20022234; Wagner MJD, 2005, J IMMUNOL, V174, P6764, DOI 10.4049/jimmunol.174.11.6764; Wei DG, 2005, J EXP MED, V202, P239, DOI 10.1084/jem.20050413; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	15	5	6	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					624	626		10.1038/nm1424	http://dx.doi.org/10.1038/nm1424			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732280				2022-12-27	WOS:000238149200022
J	Decramer, S; Wittke, S; Mischak, H; Zurbig, P; Walden, M; Bouissou, F; Bascands, JL; Schanstra, JP				Decramer, S; Wittke, S; Mischak, H; Zurbig, P; Walden, M; Bouissou, F; Bascands, JL; Schanstra, JP			Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis	NATURE MEDICINE			English	Article							CAPILLARY-ELECTROPHORESIS; MASS-SPECTROMETRY; BIOMARKERS; NEPHROPATHY; DISCOVERY; COLLAGEN; TOOL	We analyzed urinary polypeptides from individuals with neonatal ureteropelvic junction (UPJ) obstruction to predict which individuals with this condition will evolve toward obstruction that needs surgical correction. We identified polypeptides that enabled diagnosis of the severity of obstruction and validated these biomarkers in urine collected in a prospective blinded study. Using these noninvasive biomarkers, we were able to predict, several months in advance and with 94% precision, the clinical evolution of neonates with UPJ obstruction.	INSERM, U388, F-31432 Toulouse, France; Univ Toulouse 3, Inst Louis Bugnard, IFR31, F-31432 Toulouse, France; CHU Toulouse, Nephropediat Unit, Hop Enfants, F-31059 Toulouse 9, France; Mosaiques Diagnost & Therapeut AG, D-30625 Hannover, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Schanstra, JP (corresponding author), INSERM, U388, 1 Ave Jean Poulhes, F-31432 Toulouse, France.	schans@toulouse.inserm.fr	Bascands, Jean-loup/G-3260-2013; Schanstra, Joost P/X-7724-2018; Mischak, Harald/E-8685-2011	Schanstra, Joost P/0000-0002-7471-372X; Zurbig, Petra/0000-0003-3465-2173; Bascands, Jean-loup/0000-0002-1667-5913; Decramer, Stephane/0000-0001-6984-762X; Wittke, Stefan/0000-0002-2133-3360; Mischak, Harald/0000-0003-0323-0306				Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; Chevalier RL, 2004, J UROLOGY, V172, P852, DOI 10.1097/01.ju.0000129542.22043.ef; Chevalier Robert L., 2003, Pediatric Nephrology, V18, P576; Cochrane AL, 2005, J AM SOC NEPHROL, V16, P3623, DOI 10.1681/ASN.2004090771; CSAICSICH D, CURR OPIN UROL, V14, P213; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Haubitz M, 2005, KIDNEY INT, V67, P2313, DOI 10.1111/j.1523-1755.2005.00335.x; Kaiser T, 2004, BLOOD, V104, P340, DOI 10.1182/blood-2004-02-0518; Kolch W, 2005, MASS SPECTROM REV, V24, P959, DOI 10.1002/mas.20051; Kolch W, 2004, RAPID COMMUN MASS SP, V18, P2365, DOI 10.1002/rcm.1633; Theodorescu D, 2005, ELECTROPHORESIS, V26, P2797, DOI 10.1002/elps.200400208; Wittke S, 2005, ELECTROPHORESIS, V26, P1476, DOI 10.1002/elps.200410140	13	199	210	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					398	400		10.1038/nm1384	http://dx.doi.org/10.1038/nm1384			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550189				2022-12-27	WOS:000236581300027
J	Fiedler, U; Reiss, Y; Scharpfenecker, M; Grunow, V; Koidl, S; Thurston, G; Gale, NW; Witzenrath, M; Rosseau, S; Suttorp, N; Sobke, A; Herrmann, M; Preissner, KT; Vajkoczy, P; Augustin, HG				Fiedler, U; Reiss, Y; Scharpfenecker, M; Grunow, V; Koidl, S; Thurston, G; Gale, NW; Witzenrath, M; Rosseau, S; Suttorp, N; Sobke, A; Herrmann, M; Preissner, KT; Vajkoczy, P; Augustin, HG			Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation	NATURE MEDICINE			English	Article							TIE-2 LIGAND ANGIOPOIETIN-2; ANGIOGENESIS; EXPRESSION; GROWTH; VASCULATURE; INHIBITION; PROTECTS; RECEPTOR; TISSUES; LEAKAGE	The angiopoietins Ang-1 and Ang-2 have been identified as ligands of the receptor tyrosine kinase Tie-2 (refs. 1,2). Paracrine Ang-1-mediated activation of Tie-2 acts as a regulator of vessel maturation and vascular quiescence(3,4). In turn, the antagonistic ligand Ang-2 acts by an autocrine mechanism(5-7) and is stored in endothelial Weibel-Palade bodies from where it can be rapidly released upon stimulation(8). The rapid release of Ang-2 implies functions of the angiopoietin-Tie system beyond its established role during vascular morphogenesis as a regulator of rapid vascular responses. Here we show that mice deficient in Ang-2 (encoded by the gene Angpt2) cannot elicit an inflammatory response in thioglycollate-induced or Staphylococcus aureus-induced peritonitis, or in the dorsal skinfold chamber model. Recombinant Ang-2 restores the inflammation defect in Angpt2(-/-) mice. Intravital microscopy showed normal TNF-alpha-induced leukocyte rolling in the vasculature of Angpt2(-/-) mice, but rolling cells did not firmly adhere to activated endothelium. Cellular experiments showed that Ang-2 promotes adhesion by sensitizing endothelial cells toward TNF-alpha and modulating TNF-alpha-induced expression of endothelial cell adhesion molecules. Together, these findings identify Ang-2 as an autocrine regulator of endothelial cell inflammatory responses. Ang-2 thereby acts as a switch of vascular responsiveness exerting a permissive role for the activities of proinflammatory cytokines.	Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Humboldt Univ, Charite, Dept Internal Med Infect Dis, D-13353 Berlin, Germany; Univ Saarland Hosp, Dept Med Microbiol & Hyg, D-66421 Homburg, Germany; Univ Giessen, Dept Biochem, D-35392 Giessen, Germany; Univ Heidelberg, Univ Clin Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany	Regeneron; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universitatsklinikum des Saarlandes; Justus Liebig University Giessen; Ruprecht Karls University Heidelberg	Augustin, HG (corresponding author), Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany.	augustin@angiogenese.de	Rosseau, Simone/AAO-1201-2020; Augustin, Hellmut/AAA-5246-2020; Herrmann, Mathias/B-6475-2013	Augustin, Hellmut/0000-0002-7173-4242; Herrmann, Mathias/0000-0003-2638-2257; Suttorp, Norbert/0000-0002-3958-1151; Thurston, Gavin/0000-0002-4105-5919				Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Eberhard A, 2000, CANCER RES, V60, P1388; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Folkman J, 1992, Semin Cancer Biol, V3, P65; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; Jeon BH, 2003, CIRC RES, V92, P586, DOI 10.1161/01.RES.0000066881.04116.45; Lehr HA, 1999, METHOD ENZYMOL, V300, P462; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F; Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030; Pitera JE, 2004, AM J PATHOL, V165, P1895, DOI 10.1016/S0002-9440(10)63242-7; Ramsauer M, 2002, J CLIN INVEST, V110, P1615, DOI 10.1172/JCI200217326; Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Vajkoczy P, 1998, J CEREBR BLOOD F MET, V18, P510, DOI 10.1097/00004647-199805000-00006; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Zhang L, 2003, CANCER RES, V63, P3403	27	698	729	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					235	239		10.1038/nm1351	http://dx.doi.org/10.1038/nm1351			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462802				2022-12-27	WOS:000235160600030
J	Shibata, R; Sato, K; Pimentel, DR; Takemura, Y; Kihara, S; Ohashi, K; Funahashi, T; Ouchi, N; Walsh, K				Shibata, R; Sato, K; Pimentel, DR; Takemura, Y; Kihara, S; Ohashi, K; Funahashi, T; Ouchi, N; Walsh, K			Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2 dependent mechanisms	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; ADIPOSE-SPECIFIC PROTEIN; CORONARY-ARTERY-DISEASE; FATTY-ACID OXIDATION; ISCHEMIA/REPERFUSION INJURY; MICE LACKING; STIMULATES ANGIOGENESIS; PLASMA-CONCENTRATIONS; ENDOTHELIAL-CELLS; GLUCOSE-UPTAKE	Obesity-related disorders are associated with the development of ischemic heart disease. Adiponectin is a circulating adipose-derived cytokine that is downregulated in obese individuals and after myocardial infarction. Here, we examine the role of adiponectin in myocardial remodeling in response to acute injury. Ischemia-reperfusion in adiponectin-deficient (APN-KO) mice resulted in increased myocardial infarct size, myocardial apoptosis and tumor necrosis factor (TNF)-alpha expression compared with wild-type mice. Administration of adiponectin diminished infarct size, apoptosis and TNF-alpha production in both APN-KO and wildtype mice. In cultured cardiac cells, adiponectin inhibited apoptosis and TNF-alpha production. Dominant negative AMP-activated protein kinase ( AMPK) reversed the inhibitory effects of adiponectin on apoptosis but had no effect on the suppressive effect of adiponectin on TNF-alpha production. Adiponectin induced cyclooxygenase (COX)-2-dependent synthesis of prostaglandin E-2 in cardiac cells, and COX-2 inhibition reversed the inhibitory effects of adiponectin on TNF-alpha production and infarct size. These data suggest that adiponectin protects the heart from ischemia-reperfusion injury through both AMPK- and COX-2-dependent mechanisms.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Med Ctr, Cardiovasc Med Sect, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Myocardial Biol Unit, Boston, MA 02118 USA; Osaka Univ, Dept Internal Med & Mol Sci, Grad Sch Med, Suita, Osaka 5650871, Japan	Boston University; Boston University; Boston University; Osaka University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.	kxwalsh@bu.edu	OUCHI, Noriyuki/I-7306-2014	Walsh, Kenneth/0000-0001-7580-2276; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL077774, T32HL007224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL077774-01A1, R01 HL077774, P01 HL066957, HL77774, HL07224, P01 HL066957-040004, T32 HL007224, HL66957] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197, R01 AR040197-15, AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, R37 AG015052, R01 AG015052-04, R01 AG015052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Arnaud C, 2003, CARDIOVASC RES, V58, P582, DOI 10.1016/S0008-6363(03)00295-5; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bolli R, 2002, CARDIOVASC RES, V55, P506, DOI 10.1016/S0008-6363(02)00414-5; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Camitta MGW, 2001, CIRCULATION, V104, P2453, DOI 10.1161/hc4401.098429; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; Hohlfeld T, 2000, J MOL CELL CARDIOL, V32, P285, DOI 10.1006/jmcc.1999.1072; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Iwashima Y, 2004, HYPERTENSION, V43, P1318, DOI 10.1161/01.HYP.0000129281.03801.4b; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Kojima S, 2003, HEART, V89, P667, DOI 10.1136/heart.89.6.667; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Li QH, 2003, CIRC RES, V92, P741, DOI 10.1161/01.RES.0000065441.72685.29; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maekawa N, 2002, J AM COLL CARDIOL, V39, P1229, DOI 10.1016/S0735-1097(02)01738-2; Meja KK, 1997, BRIT J PHARMACOL, V122, P149, DOI 10.1038/sj.bjp.0701360; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2003, CIRCULATION, V107, P671, DOI 10.1161/01.CIR.0000055188.83694.B3; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; PRUIMBOOM WM, 1994, IMMUNOL LETT, V41, P255, DOI 10.1016/0165-2478(94)90142-2; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sugano M, 2004, MOL CELL BIOCHEM, V266, P127, DOI 10.1023/B:MCBI.0000049149.03964.c9; Wagner DR, 1998, CIRC RES, V82, P47; Wolk R, 2003, CIRCULATION, V108, P2206, DOI 10.1161/01.CIR.0000095270.85646.E8; Xiao CY, 2004, CIRCULATION, V109, P2462, DOI 10.1161/01.CIR.0000128046.54681.97; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	50	816	884	0	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1096	1103		10.1038/nm1295	http://dx.doi.org/10.1038/nm1295			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155579	Green Accepted			2022-12-27	WOS:000232492500031
J	Badovinac, VP; Messingham, KAN; Jabbari, A; Haring, JS; Harty, JT				Badovinac, VP; Messingham, KAN; Jabbari, A; Haring, JS; Harty, JT			Accelerated CD8(+) T-cell memory and prime-boost response after dendritic-cell vaccination	NATURE MEDICINE			English	Article							CUTTING EDGE; LISTERIA-MONOCYTOGENES; SELECTIVE EXPRESSION; PROTECTIVE IMMUNITY; VIRAL-INFECTION; EXPANSION; EFFECTOR; RECEPTOR; NAIVE; DIFFERENTIATION	Efficient boosting of memory T- cell numbers to protective levels generally requires a relatively long interval between immunizations. Decreasing this interval could be crucial in biodefense and cancer immunotherapy, in which rapid protective responses are essential. Here, we show that vaccination with peptide- coated dendritic cells (DCs) generated CD8(+) T cells with the phenotype and function of memory cells within 4 - 6 d. These early memory CD8(+) T cells underwent vigorous secondary expansion in response to a variety of booster immunizations, leading to elevated numbers of effector and memory T cells and enhanced protective immunity. Coinjection of CpG oligodeoxynucleotides, potent inducers of inflammation that did not alter the duration of DC antigen display, prevented the rapid generation of memory T cells in wild- type mice but not in mice lacking the interferon (IFN)-gamma receptor. These data show that DC vaccination stimulates a pathway of accelerated generation of memory T cells, and suggest that events of inflammation, including the action of IFN-gamma on the responding T cells, control the rate of development of memory CD8(+) T cells.	Univ Iowa, Dept Microbiol, Iowa City, IA 52240 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Med Labs 1190, Iowa City, IA 52240 USA	University of Iowa; University of Iowa	Harty, JT (corresponding author), Univ Iowa, Dept Microbiol, 3-512 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52240 USA.	john-harty@uiowa.edu	Messingham, Kelly/AAD-8388-2020; badovinac, Vladimir/O-7760-2015	Messingham, Kelly/0000-0003-4630-0722; Jabbari, Ali/0000-0002-8559-7314; Harty, John/0000-0001-7266-2802; Badovinac, Vladimir/0000-0003-3180-2439	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042767, R01AI046653, R37AI042767, R01AI050073, T32AI007511, R21AI042767] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50073, AI46653, T32AI007511, AI42767, T32AI0726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An LL, 1996, INFECT IMMUN, V64, P1685, DOI 10.1128/IAI.64.5.1685-1693.1996; Badovinac VP, 2003, J IMMUNOL, V170, P4933, DOI 10.4049/jimmunol.170.10.4933; Badovinac VP, 2003, IMMUNITY, V18, P463, DOI 10.1016/S1074-7613(03)00079-7; Badovinac VP, 2003, NAT IMMUNOL, V4, P212, DOI 10.1038/ni0303-212; Badovinac VP, 2004, NAT IMMUNOL, V5, P809, DOI 10.1038/ni1098; Badovinac VP, 2000, J IMMUNOL METHODS, V238, P107, DOI 10.1016/S0022-1759(00)00153-8; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Badovinac VP, 2002, NAT IMMUNOL, V3, P619, DOI 10.1038/ni804; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bouwer HGA, 1996, INFECT IMMUN, V64, P3728, DOI 10.1128/IAI.64.9.3728-3735.1996; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Edelson BT, 1999, J IMMUNOL, V163, P4087; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Hamilton SE, 2004, NAT IMMUNOL, V5, P159, DOI 10.1038/ni1026; Hamilton SE, 2002, J IMMUNOL, V169, P4936, DOI 10.4049/jimmunol.169.9.4936; Haring JS, 2005, J IMMUNOL, V174, P6791, DOI 10.4049/jimmunol.174.11.6791; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Huster KM, 2004, P NATL ACAD SCI USA, V101, P5610, DOI 10.1073/pnas.0308054101; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kerksiek KM, 1999, J EXP MED, V190, P195, DOI 10.1084/jem.190.2.195; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; Paczesny S, 2004, J EXP MED, V199, P1503, DOI 10.1084/jem.20032118; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Roberts AD, 2004, J IMMUNOL, V172, P6533, DOI 10.4049/jimmunol.172.11.6533; SALLUSTO F, 2004, ANNU REV IMMUNOL, V22, P683; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wong P, 2004, J IMMUNOL, V172, P7239, DOI 10.4049/jimmunol.172.12.7239; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009	50	316	338	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					748	756		10.1038/nm1257	http://dx.doi.org/10.1038/nm1257			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951824				2022-12-27	WOS:000230304200031
J	Foti, D; Chiefari, E; Fedele, M; Iuliano, R; Brunetti, L; Paonessa, F; Manfioletti, G; Barbetti, F; Brunetti, A; Croce, CM; Fusco, A; Brunetti, A				Foti, D; Chiefari, E; Fedele, M; Iuliano, R; Brunetti, L; Paonessa, F; Manfioletti, G; Barbetti, F; Brunetti, A; Croce, CM; Fusco, A; Brunetti, A			Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice	NATURE MEDICINE			English	Article							GROWTH-FACTOR-I; RECEPTOR GENE; GLUCOSE-TRANSPORTER; BETA-CELL; PROTEINS; KNOCKOUT; TRANSCRIPTION; EXPRESSION; INDUCTION; PROMOTER	Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally. Although genetics and environmental factors seem to have a role, the cause of this metabolic disorder is largely unknown. Here we report a genetic flaw that markedly reduced the intracellular expression of the high mobility group A1 (HMGA1) protein, and adversely affected insulin receptor expression in cells and tissues from four subjects with insulin resistance and type 2 diabetes. Restoration of HMGA1 protein expression in subjects' cells enhanced INSR gene transcription, and restored cell-surface insulin receptor protein expression and insulin-binding capacity. Loss of Hmga1 expression, induced in mice by disrupting the Hmga1 gene, considerably decreased insulin receptor expression in the major targets of insulin action, largely impaired insulin signaling and severely reduced insulin secretion, causing a phenotype characteristic of human type 2 diabetes.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Inst Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Biotecnol Avanzate, CEINGE, NOGEC, I-80131 Naples, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy; Univ Naples Federico II, Ist Biostrutture & Bioimmagini, CNR, I-80131 Naples, Italy; Osped Bambino Gesu, IRCCS, I-00100 Rome, Italy; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II; IRCCS Bambino Gesu; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Brunetti, A (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, Via T Campanella 115, I-88100 Catanzaro, Italy.	brunetti@unicz.it	Chiefari, Eusebio/Y-2558-2019; Foti, Daniela P/K-8038-2016; Barbetti, Fabrizio/AAK-9106-2021; Brunetti, Antonio/K-7756-2016; Barbetti, Fabrizio/I-7351-2018; Young, Richard A/F-6495-2012; Brunetti, Arturo/AAE-5261-2019; Fedele, Monica/C-1417-2015	Chiefari, Eusebio/0000-0001-5329-3124; Barbetti, Fabrizio/0000-0003-4687-980X; Barbetti, Fabrizio/0000-0003-4687-980X; Young, Richard A/0000-0001-8855-8647; Brunetti, Arturo/0000-0001-7057-3494; Fedele, Monica/0000-0002-9171-1312; Brunetti, Antonio/0000-0003-1533-8779; Fusco, Alfredo/0000-0003-3332-5197; Paonessa, Francesco/0000-0002-4729-0928; Foti, Daniela/0000-0002-9536-5736; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601	Telethon [GGP04245, GTF04002] Funding Source: Medline	Telethon(Fondazione Telethon)		Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; BILAN PJ, 1991, ADV EXP MED BIOL, V293, P273; Borrmann L, 2001, ONCOGENE, V20, P4537, DOI 10.1038/sj.onc.1204577; Brunetti A, 1996, J CLIN INVEST, V97, P258, DOI 10.1172/JCI118400; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; EIZIRIK DL, 1994, P NATL ACAD SCI USA, V91, P9253, DOI 10.1073/pnas.91.20.9253; Fidanza V, 1996, CANCER RES, V56, P1179; Foti D, 2003, MOL CELL BIOL, V23, P2720, DOI 10.1128/MCB.23.8.2720-2732.2003; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sandhu MS, 2002, LANCET, V359, P1740, DOI 10.1016/S0140-6736(02)08655-5; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	33	173	176	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2005	11	7					765	773		10.1038/nm1254	http://dx.doi.org/10.1038/nm1254			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15924147				2022-12-27	WOS:000230304200033
J	Stroh, M; Zimmer, JP; Duda, DG; Levchenko, TS; Cohen, KS; Brown, EB; Scadden, DT; Torchilin, VP; Bawendi, MG; Fukumura, D; Jain, RK				Stroh, M; Zimmer, JP; Duda, DG; Levchenko, TS; Cohen, KS; Brown, EB; Scadden, DT; Torchilin, VP; Bawendi, MG; Fukumura, D; Jain, RK			Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo	NATURE MEDICINE			English	Article							CRANIAL WINDOWS; TAT PEPTIDE; CELLS; ANGIOGENESIS; NANOCRYSTALS; VESSELS; CANCER; MICROSCOPY; TARGETS; MICE	A solid tumor is an organ composed of cancer and host cells embedded in an extracellular matrix and nourished by blood vessels. A prerequisite to understanding tumor pathophysiology is the ability to distinguish and monitor each component in dynamic studies. Standard fluorophores hamper simultaneous intravital imaging of these components. Here, we used multiphoton microscopy techniques and transgenic mice that expressed green fluorescent protein, and combined them with the use of quantum dot preparations. We show that these fluorescent semiconductor nanocrystals can be customized to concurrently image and differentiate tumor vessels from both the perivascular cells and the matrix. Moreover, we used them to measure the ability of particles of different sizes to access the tumor. Finally, we successfully monitored the recruitment of quantum dot - labeled bone marrow - derived precursor cells to the tumor vasculature. These examples show the versatility of quantum dots for studying tumor pathophysiology and creating avenues for treatment.	Massachusetts Gen Hosp, EL Steele Lab Tumor Biol, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Northeastern University; Harvard University; Massachusetts General Hospital	Jain, RK (corresponding author), Massachusetts Gen Hosp, EL Steele Lab Tumor Biol, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Duda, Dan G/H-8523-2014; Jain, Rakesh K/I-1384-2017	Duda, Dan G/0000-0001-7065-8797; Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [R01CA085140, R24CA085140, P01CA080124, F32CA103386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001961] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA103386-02, P01 CA080124-08, F32 CA103386, F32 CA 103386, R01 CA085140, R24 CA 85140, P01 CA080124, R24 CA085140, R01 CA085140-09, P01 CA 80124] Funding Source: Medline; NIBIB NIH HHS [5R01 EB 001951-06, R01 EB001961-06, R01 EB001961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bestvater F, 2002, J MICROSC-OXFORD, V208, P108, DOI 10.1046/j.1365-2818.2002.01074.x; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan Y, 2004, ADV MATER, V16, P2092, DOI 10.1002/adma.200400237; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Fisher BR, 2004, J PHYS CHEM B, V108, P143, DOI 10.1021/jp035756+; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jain RK, 2004, NAT BIOTECHNOL, V22, P959, DOI 10.1038/nbt0804-959; Jain RK, 2003, CANCER CELL, V3, P515, DOI 10.1016/S1535-6108(03)00138-7; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; LEUNIG M, 1992, CANCER RES, V52, P6553; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; MELDER RJ, 1995, MICROVASC RES, V50, P35, DOI 10.1006/mvre.1995.1036; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Steckel JS, 2004, ANGEW CHEM INT EDIT, V43, P2154, DOI 10.1002/anie.200453728; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; YUAN F, 1994, CANCER RES, V54, P4564; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	30	357	390	5	93	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					678	682		10.1038/nm1247	http://dx.doi.org/10.1038/nm1247			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880117	Green Accepted			2022-12-27	WOS:000229589800036
J	Weckmann, M; Collison, A; Simpson, JL; Kopp, MV; Wark, PAB; Smyth, MJ; Yagita, H; Matthaei, KI; Hansbro, N; Whitehead, B; Gibson, PG; Foster, PS; Mattes, J				Weckmann, Markus; Collison, Adam; Simpson, Jodie L.; Kopp, Matthias V.; Wark, Peter A. B.; Smyth, Mark J.; Yagita, Hideo; Matthaei, Klaus I.; Hansbro, Nicole; Whitehead, Bruce; Gibson, Peter G.; Foster, Paul S.; Mattes, Joerg			Critical link between TRAIL and CCL20 for the activation of T(H)2 cells and the expression of allergic airway disease	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; DENDRITIC CELLS; IN-VIVO; EXPERIMENTAL ASTHMA; TUMOR-METASTASIS; INHALED ANTIGEN; ATOPIC ASTHMA; HYPERREACTIVITY; INFLAMMATION; IL-13	The role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in immune responses mediated by T-helper 2 (T(H)2) lymphocytes is unknown. Here we characterize the development of allergic airway disease in TRAIL-deficient (Tnfsf10(-/-)) mice and in mice exposed to short interfering RNA targeting TRAIL. We show that TRAIL is abundantly expressed in the airway epithelium of allergic mice and that inhibition of signaling impairs production of the chemokine CCL20 and homing of myeloid dendritic cells and T cells expressing CCR6 and CD4 to the airways. Attenuated homing limits TH2 cytokine release, inflammation, airway hyperreactivity and expression of the transcriptional activator STAT6. Activation of STAT6 by interleukin-13 restores airway hyperreactivity in Tnfsf10(-/-) mice. Recombinant TRAIL induces pathognomic features of asthma and stimulates the production of CCL20 in primary human bronchial epithelium cells. TRAIL is also increased in sputum of asthmatics. The function of TRAIL in the airway epithelium identifies this molecule as a target for the treatment of asthma.	Univ Freiburg, Dept Paediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Newcastle, Fac Hlth, Sch Biomed Sci, CARD, Newcastle, NSW 2301, Australia; Hunter Med Res Inst, Newcastle, NSW 2301, Australia; Hunter Med Res Inst, Dept Resp & Sleep Med, Newcastle, NSW 2305, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; John Hunter Childrens Hosp, Dept Paediat, Newcastle, NSW 2305, Australia	University of Freiburg; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Peter Maccallum Cancer Center; Juntendo University; Australian National University; John Curtin School of Medical Research	Mattes, J (corresponding author), Univ Freiburg, Dept Paediat & Adolescent Med, D-79106 Freiburg, Germany.	joerg.mattes@newcastle.edu.au	Foster, Paul/G-5057-2013; Wark, Peter/G-7037-2013; Weckmann, Markus/GXG-3428-2022; Klaus, Matthaei/D-8691-2011; Smyth, Mark J/H-8709-2014; MATTES, JOERG/M-5179-2019; SIMPSON, JODIE LOUISE/G-7639-2013; gibson, peter/G-6194-2014; Collison, Adam/G-7718-2013	Wark, Peter/0000-0001-5676-6126; Weckmann, Markus/0000-0001-5342-979X; Smyth, Mark J/0000-0001-7098-7240; SIMPSON, JODIE LOUISE/0000-0002-3626-680X; gibson, peter/0000-0001-5865-489X; Collison, Adam/0000-0002-3074-3046				Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Begue B, 2006, GASTROENTEROLOGY, V130, P1962, DOI 10.1053/j.gastro.2006.03.022; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Daigle I, 2001, SWISS MED WKLY, V131, P231; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Le Borgne M, 2006, IMMUNITY, V24, P191, DOI 10.1016/j.immuni.2006.01.005; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Lundy SK, 2005, J IMMUNOL, V174, P2054, DOI 10.4049/jimmunol.174.4.2054; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2001, J IMMUNOL, V167, P1683, DOI 10.4049/jimmunol.167.3.1683; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Robertson NM, 2002, J IMMUNOL, V169, P5986, DOI 10.4049/jimmunol.169.10.5986; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366; Zhang XR, 2003, CELL DEATH DIFFER, V10, P203, DOI 10.1038/sj.cdd.4401138; Zhang YY, 2004, JNCI-J NATL CANCER I, V96, P201, DOI 10.1093/jnci/djh024; 1987, AM REV RESP DIS, V136, P225	50	98	103	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1308	1315		10.1038/nm1660	http://dx.doi.org/10.1038/nm1660			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17934471				2022-12-27	WOS:000250736900023
J	Yamasaki, K; Di Nardo, A; Bardan, A; Murakami, M; Ohtake, T; Coda, A; Dorschner, RA; Bonnart, C; Descargues, P; Hovnanian, A; Morhenn, VB; Gallo, RL				Yamasaki, Kenshi; Di Nardo, Anna; Bardan, Antonella; Murakami, Masamoto; Ohtake, Takaaki; Coda, Alvin; Dorschner, Robert A.; Bonnart, Chrystelle; Descargues, Pascal; Hovnanian, Alain; Morhenn, Vera B.; Gallo, Richard L.			Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea	NATURE MEDICINE			English	Article							ANTIMICROBIAL PEPTIDE; STRATUM-CORNEUM; DEFENSE; LL-37; IDENTIFICATION; EXPRESSION; DERMATITIS; WOUNDS; GENE; MICE	Acne rosacea is an inflammatory skin disease that affects 3% of the US population over 30 years of age and is characterized by erythema, papulopustules and telangiectasia(1-3). The etiology of this disorder is unknown, although symptoms are exacerbated by factors that trigger innate immune responses, such as the release of cathelicidin antimicrobial peptides(4). Here we show that individuals with rosacea express abnormally high levels of cathelicidin in their facial skin and that the proteolytically processed forms of cathelicidin peptides found in rosacea are different from those present in normal individuals. These cathelicidin peptides are a result of a post-translational processing abnormality associated with an increase in stratum corneum tryptic enzyme ( SCTE) in the epidermis. In mice, injection of the cathelicidin peptides found in rosacea, addition of SCTE, and increasing protease activity by targeted deletion of the serine protease inhibitor gene Spink5 each increases inflammation in mouse skin. The role of cathelicidin in enabling SCTE-mediated inflammation is verified in mice with a targeted deletion of Camp, the gene encoding cathelicidin. These findings confirm the role of cathelicidin in skin inflammatory responses and suggest an explanation for the pathogenesis of rosacea by demonstrating that an exacerbated innate immune response can reproduce elements of this disease.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; VA San Diego Hlth Care Syst, San Diego, CA 92161 USA; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Med, Asahikawa, Hokkaido 0788510, Japan; INSERM, U563, F-31000 Toulouse, France; Univ Toulouse 3, F-31000 Toulouse, France; CHU Toulouse, Dept Genet, F-31000 Toulouse, France	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Asahikawa Medical College; Asahikawa Medical College; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@ucsd.edu	BONNART, Chrystelle/A-1309-2011; di nardo, anna/AAI-1629-2020; Gallo, Richard L/A-8931-2009; Yamasaki, Kenshi/C-8905-2018; Hovnanian, Alain/I-4711-2017	di nardo, anna/0000-0002-5575-9968; Gallo, Richard L/0000-0002-1401-7861; Yamasaki, Kenshi/0000-0002-5495-4956; Hovnanian, Alain/0000-0003-3412-7512; Coda, Alvin/0000-0002-8509-8590	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052453, R01AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI052453] Funding Source: Medline; NIAMS NIH HHS [R01-AR45676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Acharya MR, 2004, DRUG RESIST UPDATE, V7, P195, DOI 10.1016/j.drup.2004.04.002; Braff MH, 2005, J IMMUNOL, V174, P4271, DOI 10.4049/jimmunol.174.7.4271; BRINNEL H, 1989, ARCH DERMATOL RES, V281, P66, DOI 10.1007/BF00424276; Chang CI, 2005, INFECT IMMUN, V73, P5053, DOI 10.1128/IAI.73.8.5053-5064.2005; Crawford GH, 2004, J AM ACAD DERMATOL, V51, P327, DOI 10.1016/j.jaad.2004.03.030; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; KELLY AP, 1996, PINCIPLES PRACTICE D; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Komatsu N, 2005, J INVEST DERMATOL, V125, P1182, DOI 10.1111/j.0022-202X.2005.23933.x; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; STRAUS J, 1991, DERMATOLOGY, P337; van Dijk A, 2005, VET IMMUNOL IMMUNOP, V106, P321, DOI 10.1016/j.vetimm.2005.03.003; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	30	526	579	5	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					975	980		10.1038/nm1616	http://dx.doi.org/10.1038/nm1616			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17676051				2022-12-27	WOS:000248674600029
J	Goga, A; Yang, D; Tward, AD; Morgan, DO; Bishop, JM				Goga, Andrei; Yang, Dun; Tward, Aaron D.; Morgan, David O.; Bishop, J. Michael			Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC	NATURE MEDICINE			English	Article							CELL-CYCLE PROGRESSION; C-MYC; MITOCHONDRIAL APOPTOSIS; CYTOCHROME-C; N-MYC; SURVIVIN; PATHWAY; CANCER; MUTANT; CHECKPOINT	Tumor cells have a dysregulated cell cycle that may render their proliferation especially sensitive to the inhibition of cyclin-dependent kinases (CDKs), important regulators of cell cycle progression. We examined the effects of CDK1 inhibition in the context of different oncogenic signals. Cells transformed with MYC, but not cells transformed by a panel of other activated oncogenes, rapidly underwent apoptosis when treated with small-molecule CDK1 inhibitors. The inhibitor of apoptosis protein BIRC5 (survivin), a known CDK1 target, is required for the survival of cells over-expressing MYC. Inhibition of CDK1 rapidly downregulates survivin expression and induces MYC-dependent apoptosis. CDK1 inhibitor treatment of MYC-dependent mouse lymphoma and hepatoblastoma tumors decreased tumor growth and prolonged their survival. As there are no effective small-molecule inhibitors that selectively target the MYC pathway, we propose that CDK1 inhibition might therefore be useful in the treatment of human malignancies that overexpress MYC.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goga, A (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA.	andrei.goga@ucsf.edu		Morgan, David/0000-0001-8753-4416	NATIONAL CANCER INSTITUTE [K08CA104032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069901] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA104032] Funding Source: Medline; NIGMS NIH HHS [R01 GM069901, R01 GM69901] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Altieri DC, 2006, CURR OPIN CELL BIOL, V18, P609, DOI 10.1016/j.ceb.2006.08.015; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hirose Y, 2001, CANCER RES, V61, P5843; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Klefstrom J, 2002, J BIOL CHEM, V277, P43224, DOI 10.1074/jbc.M206967200; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VANROY FM, 1986, CANCER RES, V46, P4787; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	246	250	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2007	13	7					820	827		10.1038/nm1606	http://dx.doi.org/10.1038/nm1606			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17589519				2022-12-27	WOS:000247902800028
J	Amadi-Obi, A; Yu, CR; Liu, XB; Mahdi, RM; Clarke, GL; Nussenblatt, RB; Gery, I; Lee, YS; Egwuagu, CE				Amadi-Obi, Ahjoku; Yu, Cheng-Rong; Liu, Xuebin; Mahdi, Rashid M.; Clarke, Grace Levy; Nussenblatt, Robert B.; Gery, Igal; Lee, Yun Sang; Egwuagu, Charles E.			T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE UVEITIS; BEHCETS-DISEASE; T-CELLS; FAMILY CYTOKINES; TH1; INDUCTION; INTERLEUKIN-12; INFLAMMATION; SUPPRESSORS; ARTHRITIS	T-helper type 17 cells (T(H)17) are implicated in rodent models of immune- mediated diseases. Here we report their involvement in human uveitis and scleritis, and validate our findings in experimental autoimmune uveoretinitis (EAU), a model of uveitis. T(H)17 cells were present in human peripheral blood mononuclear cells (PBMC), and were expanded by interleukin (IL)- 2 and inhibited by interferon (IFN)-alpha. Their numbers increased during active uveitis and scleritis and decreased following treatment. IL-17 was elevated in EAU and upregulated tumor necrosis factor (TNF)- a in retinal cells, suggesting a mechanism by which T(H)17 may contribute to ocular pathology. Furthermore, IL-27 was constitutively expressed in retinal ganglion and photoreceptor cells, was upregulated by IFN-gamma and inhibited proliferation of T(H)17. These findings suggest that T(H)1 cells may mitigate uveitis by antagonizing the T(H)17 phenotype through the IFN-gamma mediated induction of IL- 27 in target tissue. The finding that IL-2 promotes T(H)17 expansion provides explanations for the efficacy of IL- 2R antibody therapy in uveitis, and suggests that antagonism of T(H)17 by IFN-gamma and/ or IL- 27 could be used for the treatment of chronic inflammation.	NEI, NIH, Mol Immunol Sect, Bethesda, MD 20892 USA; NEI, NIH, Clin Immunol Sect, Bethesda, MD 20892 USA; NEI, NIH, Expt Immunol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, NIH, Mol Immunol Sect, Bethesda, MD 20892 USA.	egwuaguc@nei.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [Z01EY000464, Z01EY000356, Z01EY000262] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 EY000262-12] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; Calguneri M, 2003, ANN RHEUM DIS, V62, P492, DOI 10.1136/ard.62.5.492; CASPI RR, 1988, J IMMUNOL, V140, P1490; Caspi RR, 1996, J IMMUNOL, V157, P2668; Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652; Crane IJ, 2006, J LEUKOCYTE BIOL, V79, P435, DOI 10.1189/jlb.0305130; Cua DJ, 2006, NAT IMMUNOL, V7, P557, DOI 10.1038/ni0606-557; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Deuter CME, 2004, OPHTHALMOLOGE, V101, P129, DOI 10.1007/s00347-003-0927-7; Egwuagu CE, 2005, J AUTOIMMUN, V24, P39, DOI 10.1016/j.jaut.2004.11.006; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Hamzaoui K, 2002, SCAND J RHEUMATOL, V31, P205, DOI 10.1080/030097402320318387; HEN Z, 2006, P NATL ACAD SCI USA, V103, P8137; Hofmann Hans-Dieter, 2005, V1, P58; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Li JF, 2005, J NEUROL SCI, V232, P3, DOI 10.1016/j.jns.2004.12.013; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; NUSSENBLATT RB, 1991, INVEST OPHTH VIS SCI, V32, P3131; Nussenblatt RB, 2003, J AUTOIMMUN, V21, P283, DOI 10.1016/S0896-8411(03)00113-6; Nussenblatt RB, 1999, P NATL ACAD SCI USA, V96, P7462, DOI 10.1073/pnas.96.13.7462; Nussenblatt Robert B, 2002, Int Rev Immunol, V21, P273, DOI 10.1080/08830180212067; Okhravi N, 2005, SURV OPHTHALMOL, V50, P351, DOI 10.1016/j.survophthal.2005.04.001; Owaki T, 2005, J IMMUNOL, V175, P2191, DOI 10.4049/jimmunol.175.4.2191; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Saruhan-Direskeneli G, 2003, J NEUROIMMUNOL, V145, P127, DOI 10.1016/j.jneuroim.2003.08.040; Sonobe Y, 2005, BRAIN RES, V1040, P202, DOI 10.1016/j.brainres.2005.01.100; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Takase H, 2005, J NEUROIMMUNOL, V168, P118, DOI 10.1016/j.jneuroim.2005.07.021; Tarrant TK, 1998, J IMMUNOL, V161, P122; Tarrant TK, 1999, J EXP MED, V189, P219, DOI 10.1084/jem.189.2.219; Tato CM, 2006, J EXP MED, V203, P809, DOI 10.1084/jem.20060522; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Villarino AV, 2006, J IMMUNOL, V176, P237, DOI 10.4049/jimmunol.176.1.237; Villarino AV, 2004, ARTHRITIS RES THER, V6, P225, DOI 10.1186/ar1227; Watford WT, 2004, IMMUNOL REV, V202, P139, DOI 10.1111/j.0105-2896.2004.00211.x; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377; Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737	46	639	691	5	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					711	718		10.1038/nm1585	http://dx.doi.org/10.1038/nm1585			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17496900				2022-12-27	WOS:000247084300034
J	Ju, ZY; Jiang, H; Jaworski, M; Rathinam, C; Gompf, A; Klein, C; Trumpp, A; Rudolph, KL				Ju, Zhenyu; Jiang, Hong; Jaworski, Maike; Rathinam, Chozhavendan; Gompf, Anne; Klein, Christoph; Trumpp, Andreas; Rudolph, K. Lenhard			Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment	NATURE MEDICINE			English	Article							BONE-MARROW; LIFE-SPAN; B-CELL; MICE; PROGENITOR; CANCER; LONGEVITY	Cell-intrinsic checkpoints limit the proliferative capacity of primary cells in response to telomere dysfunction. It is not known, however, whether telomere dysfunction contributes to cell-extrinsic alterations that impair stem cell function and organ homeostasis. Here we show that telomere dysfunction provokes defects of the hematopoietic environment that impair B lymphopoiesis but increase myeloid proliferation in aging telomerase knockout (Terc(-/-)) mice. Moreover, the dysfunctional environment limited the engraftment of transplanted wild-type hematopoietic stem cells (HSCs). Dysfunction of the hematopoietic environment was age dependent and correlated with progressive telomere shortening in bone marrow stromal cells. Telomere dysfunction impaired mesenchymal progenitor cell function, reduced the capacity of bone marrow stromal cells to maintain functional HSCs, and increased the expression of various cytokines, including granulocyte colony-stimulating factor (G-CSF), in the plasma of aging mice. Administration of G-CSF to wild-type mice mimicked some of the defects seen in aging Terc(-/)-mice, including impairment of B lymphopoiesis and HSC engraftment. Conversely, inhibition of G-CSF improved HSC engraftment in aged Terc(-/)-mice. Taken together, these results show that telomere dysfunction induces alterations of the environment that can have implications for organismal aging and cell transplantation therapies.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Ecole Polytech Fed Lausanne, Genet & Stem Cell Lab, Swiss Inst Expt Canc Res, ISREC,Sch Life Sci, CH-1015 Lausanne, Switzerland; Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany	Hannover Medical School; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Hannover Medical School	Rudolph, KL (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany.	rudolph.lenhard@MH-Hannover.de	Trumpp, Andreas/Z-2141-2019	Trumpp, Andreas/0000-0002-6212-3466; Rudolph, Karl Lenhard/0000-0002-4839-2862				Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331; Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Caruso C, 2004, ANN NY ACAD SCI, V1028, P1, DOI 10.1196/annals.1322.001; Choudhury AR, 2007, NAT GENET, V39, P99, DOI 10.1038/ng1937; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Davis T, 2006, REJUV RES, V9, P402, DOI 10.1089/rej.2006.9.402; Djojosubroto MW, 2003, MOL CELLS, V15, P164; DRIZE N, 1993, EXP HEMATOL, V21, P1289; Hardy Richard R, 2004, Methods Mol Biol, V271, P1; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; HORNSBY PJ, 2003, METH MOL B, V240, P147; Lieber MR, 2004, NAT REV MOL CELL BIO, V5, P69, DOI 10.1038/nrm1281; Min HY, 2006, J IMMUNOL, V176, P1007, DOI 10.4049/jimmunol.176.2.1007; Min HY, 2005, IMMUNOL REV, V205, P7, DOI 10.1111/j.0105-2896.2005.00263.x; NEBEN S, 1993, BLOOD, V81, P1960; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saba H I, 2001, Cancer Control, V8, P79; Shay JW, 2000, NAT BIOTECHNOL, V18, P22, DOI 10.1038/71872; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Van Zant G, 2003, EXP HEMATOL, V31, P659, DOI 10.1016/S0301-472X(03)00088-2; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; ZATZ MM, 1985, GERONTOLOGY, V31, P263, DOI 10.1159/000212709	30	207	220	2	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					742	747		10.1038/nm1578	http://dx.doi.org/10.1038/nm1578			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17486088				2022-12-27	WOS:000247084300039
J	Berdeaux, R; Goebel, N; Banaszynski, L; Takemori, H; Wandless, T; Shelton, GD; Montminy, M				Berdeaux, Rebecca; Goebel, Naomi; Banaszynski, Laura; Takemori, Hiroshi; Wandless, Thomas; Shelton, G. Diane; Montminy, Marc			SIK1 is a class IIHDAC kinase that promotes survival of skeletal myocytes	NATURE MEDICINE			English	Article							ELEMENT-BINDING PROTEIN; CREB COACTIVATOR TORC2; TRANSCRIPTION FACTOR; MICE LACKING; NUCLEAR EXPORT; MUSCLE; GENE; PHOSPHORYLATION; CAMP; ACTIVATION	During physical exercise, increases in motor neuron activity stimulate the expression of muscle-specific genes through the myocyte enhancer factor 2 (MEF2) family of transcription factors. Elevations in intracellular calcium increase MEF2 activity via the phosphorylation-dependent inactivation of class II histone deacetylases (HDACs). In studies to determine the role of the cAMP responsive element binding protein (CREB) in skeletal muscle, we found that mice expressing a dominant-negative CREB transgene (M-ACREB mice) exhibited a dystrophic phenotype along with reduced MEF2 activity. Class II HDAC phosphorylation was decreased in M-ACREB myofibers due to a reduction in amounts of Snf1lk (encoding salt inducible kinase, SIK1), a CREB target gene that functions as a class II HDAC kinase. Inhibiting class II HDAC activity either by viral expression of Snf1lk or by the administration of a small molecule antagonist improved the dystrophic phenotype in M-ACREB mice, pointing to an important role for the SIK1-HDAC pathway in regulating muscle function.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Stanford Univ, Stanford, CA 94305 USA; Natl Inst Biomed Innovat, Lab Cell Signaling & Metab, Osaka 5670085, Japan; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Salk Institute; Stanford University; National Institute of Health Sciences - Japan; University of California System; University of California San Diego	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Banaszynski, Laura/B-9612-2009	Berdeaux, Rebecca/0000-0002-9929-1711	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK070502] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK070502, F32 DK070502-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Belfield JL, 2006, J BIOL CHEM, V281, P27724, DOI 10.1074/jbc.M601485200; Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mikkelsen UR, 2006, AM J PHYSIOL-REG I, V290, pR265, DOI 10.1152/ajpregu.00392.2005; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; RUIZ JC, 1994, MECH DEVELOP, V48, P153, DOI 10.1016/0925-4773(94)90056-6; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Takemori H, 2002, J BIOL CHEM, V277, P42334, DOI 10.1074/jbc.M204602200; Talanian JL, 2006, AM J PHYSIOL-REG I, V291, pR1094, DOI 10.1152/ajpregu.00130.2006; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Watchko JF, 2002, J APPL PHYSIOL, V93, P407, DOI 10.1152/japplphysiol.01242.2001; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	41	210	224	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					597	603		10.1038/nm1573	http://dx.doi.org/10.1038/nm1573			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17468767				2022-12-27	WOS:000246302800027
J	Lee, SH; Goswami, S; Grudo, A; Song, LZ; Bandi, V; Goodnight-White, S; Green, L; Hacken-Bitar, J; Huh, J; Bakaeen, F; Coxson, HO; Cogswell, S; Storness-Bliss, C; Corry, DB; Kheradmand, F				Lee, Seung-Hyo; Goswami, Sangeeta; Grudo, Ariel; Song, Li-zhen; Bandi, Venkata; Goodnight-White, Sheila; Green, Linda; Hacken-Bitar, Joan; Huh, Joseph; Bakaeen, Faisal; Coxson, Harvey O.; Cogswell, Sebastian; Storness-Bliss, Claudine; Corry, David B.; Kheradmand, Farrah			Antielastin autoimmunity in tobacco smoking-induced emphysema	NATURE MEDICINE			English	Article							DISEASE; ELASTIN; AIRWAYS; HEALTH	Chronic obstructive pulmonary disease and emphysema are common destructive inflammatory diseases that are leading causes of death worldwide. Here we show that emphysema is an autoimmune disease characterized by the presence of antielastin antibody and T-helper type 1 (T(H)1) responses, which correlate with emphysema severity. These findings link emphysema to adaptive immunity against a specific lung antigen and suggest the potential for autoimmune pathology of other elastin-rich tissues such as the arteries and skin of smokers.	Baylor Coll Med, Dept Med, Sect Pulm & Crit Care, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Michael E DeBakey VA Med Ctr, Dept Pathol, Houston, TX 77030 USA; Michael E DeBakey VA Med Ctr, Dept Radiol, Houston, TX 77030 USA; Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V6Z 1Y6, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of British Columbia	Kheradmand, F (corresponding author), Baylor Coll Med, Dept Med, Sect Pulm & Crit Care, Houston, TX 77030 USA.	dcorry@bcm.tmc.edu; farrahk@bcm.tmc.edu	Coxson, Harvey O/A-9861-2017; Lee, Seung-Hyo/B-9922-2015; Lee, Seung Hyo/C-1689-2011	Coxson, Harvey O/0000-0001-5750-9711; Lee, Seung-Hyo/0000-0003-0010-4072; Goswami, Sangeeta/0000-0001-9201-4503				Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Cosio MG, 1999, AM J RESP CRIT CARE, V160, pS21, DOI 10.1164/ajrccm.160.supplement_1.7; Coxson HO, 2005, ACAD RADIOL, V12, P1457, DOI 10.1016/j.acra.2005.08.013; Critchley JA, 2003, JAMA-J AM MED ASSOC, V290, P86, DOI 10.1001/jama.290.1.86; DeMeo DL, 2004, AM J RESP CRIT CARE, V170, P1294, DOI 10.1164/rccm.200404-524OC; Grumelli S, 2004, PLOS MED, V1, P75, DOI 10.1371/journal.pmed.0010008; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Houghton AM, 2006, J CLIN INVEST, V116, P753, DOI 10.1172/JCI25617; Patel BD, 2006, THORAX, V61, P568, DOI 10.1136/thx.2005.053827; Pepine CJ, 2006, J AM COLL CARDIOL, V47, P547, DOI 10.1016/j.jacc.2005.09.031; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Winkleby MA, 1998, JAMA-J AM MED ASSOC, V280, P356, DOI 10.1001/jama.280.4.356	15	391	435	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					567	569		10.1038/nm1583	http://dx.doi.org/10.1038/nm1583			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17450149				2022-12-27	WOS:000246302800023
J	Sakuma, R; Noser, JA; Ohmine, S; Ikeda, Y				Sakuma, Ryuta; Noser, Josh A.; Ohmine, Seiga; Ikeda, Yasuhiro			Rhesus monkey TRIM5 alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTIOUS MOLECULAR CLONE; RETROVIRUS RESTRICTION; CELL TROPISM; OLD-WORLD; GENE; PROTEIN; REPLICATION; GENERATION; MUTANT	Mammalian cells have developed diverse strategies to restrict retroviral infection(1-5). Retroviruses have therefore evolved to counteract such restriction factors, in order to colonize their hosts(4,6). Tripartite motif-containing 5 isoform-alpha (TRIM5 alpha) protein from rhesus monkey (TRIM5 alpha rh) restricts human immunodeficiency virus type 1 (HIV-1) infection at a postentry, preintegration stage in the viral life cycle, by recognizing the incoming capsid and promoting its premature disassembly(7,8). TRIM5 alpha comprises an RBCC (RING, B-box 2 and coiled-coil motifs) domain and a B30.2(SPRY) domain. Sequences in the B30.2( SPRY) domain dictate the potency and specificity of the restriction(8-11). As TRIM5 alpha rh targets incoming mature HIV-1 capsid, but not precursor Gag(12), it was assumed that TRIM5 alpha rh did not affect HIV-1 production. Here we provide evidence that TRIM5 alpha rh, but not its human ortholog (TRIM5 alpha hu), blocks HIV-1 production through rapid degradation of HIV-1 Gag polyproteins. The specificity for this restriction is determined by sequences in the RBCC domain. Our observations suggest that TRIM5 alpha rh interacts with HIV-1 Gag during or before Gag assembly through a mechanism distinct from the well-characterized postentry restriction. This finding demonstrates a cellular factor blocking HIV-1 production by actively degrading a viral protein. Further understanding of this previously unknown restriction mechanism may reveal new targets for future anti-HIV-1 therapy.	Mayo Clin, Coll Med, Program Mol Med, Rochester, MN 55905 USA	Mayo Clinic	Ikeda, Y (corresponding author), Mayo Clin, Coll Med, Program Mol Med, Rochester, MN 55905 USA.	ikeda.yasuhiro@mayo.edu	Liu, FL/D-1795-2009					ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Hatziioannou T, 2006, SCIENCE, V314, P95, DOI 10.1126/science.1130994; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Kamada K, 2006, P NATL ACAD SCI USA, V103, P16959, DOI 10.1073/pnas.0608289103; Keckesova Z, 2004, P NATL ACAD SCI USA, V101, P10780, DOI 10.1073/pnas.0402474101; LUCIW PA, 1992, AIDS RES HUM RETROV, V8, P395, DOI 10.1089/aid.1992.8.395; Morner A, 1999, J VIROL, V73, P2343; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Neil Stuart J. D., 2006, PLoS Pathogens, V2, DOI 10.1371/jounral.ppat.0020039; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Perez-Caballero D, 2005, J VIROL, V79, P8969, DOI 10.1128/JVI.79.14.8969-8978.2005; Sayah DM, 2004, NATURE, V430, P569, DOI 10.1038/nature02777; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SIMM M, 1995, J VIROL, V69, P4582, DOI 10.1128/JVI.69.7.4582-4586.1995; Soares MA, 1997, VIROLOGY, V228, P394, DOI 10.1006/viro.1996.8387; Song B, 2005, J VIROL, V79, P3930, DOI 10.1128/JVI.79.7.3930-3937.2005; Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yap MW, 2005, CURR BIOL, V15, P73, DOI 10.1016/j.cub.2004.12.042; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	30	86	95	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2007	13	5					631	635		10.1038/nm1562	http://dx.doi.org/10.1038/nm1562			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17435772				2022-12-27	WOS:000246302800032
J	Roussel, R; Mentre, F; Bouchemal, N; Hadjadj, S; Lievre, M; Chatellier, G; Menard, J; Panhard, X; Le Henanff, A; Marre, M; Le Moyec, L				Roussel, Ronan; Mentre, France; Bouchemal, Nadia; Hadjadj, Samy; Lievre, Michel; Chatellier, Gilles; Menard, Joel; Panhard, Xaviere; Le Henanff, Anne; Marre, Michel; Le Moyec, Laurence		DIABHYCAR Study Grp	NMR-based prediction of cardiovascular risk in diabetes	NATURE MEDICINE			English	Editorial Material							DISEASE		INSERM, U695, F-75018 Paris, France; Univ Paris 07, Unite Format & Rech Med Xavier Bichat, F-75018 Paris, France; Hop Bichat Claude Bernard, AP HP, Dept Endocrinol Diabetol & Nutr, F-75018 Paris, France; INSERM, U738, F-75018 Paris, France; Hop Bichat Claude Bernard, AP HP, Dept Epidemiol Biostat & Rech Clin, F-75018 Paris, France; Univ Paris 13, Unite Mixte Rech 7033, CNRS, F-93000 Bobigny, France; Univ Paris 06, F-93000 Bobigny, France; Univ Poitiers, Univ Hosp, Ctr Hosp, F-86021 Poitiers, France; INSERM, Equipe Rech Mixte 324, F-86021 Poitiers, France; Univ Lyon 1, Fac Med Laennec, F-69000 Lyon, France; George Pompidou European Hosp, AP HP, Dept Biostat, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite Paris 13; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Roussel, R (corresponding author), INSERM, U695, F-75018 Paris, France.	ronan.roussel@bch.aphp.fr	Mentre, France/AFU-8218-2022	Mentre, France/0000-0002-7045-1275; Marre, Michel/0000-0002-3071-1837				Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Kirschenlohr HL, 2006, NAT MED, V12, P705, DOI 10.1038/nm1432; Le Moyec L, 2005, NMR BIOMED, V18, P421, DOI 10.1002/nbm.974; Marre M, 2004, BRIT MED J, V328, P495, DOI 10.1136/bmj.37970.629537.0D; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167	5	14	17	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					399	400		10.1038/nm0407-399	http://dx.doi.org/10.1038/nm0407-399			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17415367	Green Accepted, Green Submitted			2022-12-27	WOS:000245543900011
J	Brunham, LR; Kruit, JK; Pape, TD; Timmins, JM; Reuwer, AQ; Vasanji, Z; Marsh, BJ; Rodrigues, B; Johnson, JD; Parks, JS; Verchere, CB; Hayden, MR				Brunham, Liam R.; Kruit, Janine K.; Pape, Terry D.; Timmins, Jenelle M.; Reuwer, Anne Q.; Vasanji, Zainisha; Marsh, Brad J.; Rodrigues, Brian; Johnson, James D.; Parks, John S.; Verchere, C. Bruce; Hayden, Michael R.			beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL EFFLUX; LIPID-ACCUMULATION; HDL CHOLESTEROL; FATTY-ACIDS; EXOCYTOSIS; APOPTOSIS; PATHWAY; BINDING; MICE	Type 2 diabetes is characterized by both peripheral insulin resistance and reduced insulin secretion by beta-cells. The reasons for beta-cell dysfunction in this disease are incompletely understood but may include the accumulation of toxic lipids within this cell type. We examined the role of Abca1, a cellular cholesterol transporter, in cholesterol homeostasis and insulin secretion in beta-cells. Mice with specific inactivation of Abca1 in beta-cells had markedly impaired glucose tolerance and defective insulin secretion but normal insulin sensitivity. Islets isolated from these mice showed altered cholesterol homeostasis and impaired insulin secretion in vitro. We found that rosiglitazone, an activator of the peroxisome proliferator-activated receptor-gamma, which upregulates Abca1 in beta-cells, requires beta-cell Abca1 for its beneficial effects on glucose tolerance. These experiments establish a new role for Abca1 in beta-cell cholesterol homeostasis and insulin secretion, and suggest that cholesterol accumulation may contribute to beta-cell dysfunction in type 2 diabetes.	Univ British Columbia, Child & Family Res Inst, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Wake Forest Univ, Sch Med, Dept Pathol, Sect Lipid Sci, Winston Salem, NC 27157 USA; Univ British Columbia, Child & Family Res Inst, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z4, Canada	Child & Family Research Institute; University of British Columbia; Wake Forest University; Child & Family Research Institute; University of British Columbia; University of Queensland; University of British Columbia	Verchere, CB (corresponding author), Univ British Columbia, Child & Family Res Inst, Dept Med Genet, Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	verchere@interchange.ubc.ca; mrh@cmmt.ubc.ca	Marsh, Brad/A-4981-2008; Hayden, Michael R/D-8581-2011; Kruit, Janine/AGI-8582-2022	Hayden, Michael R/0000-0001-5159-1419; Kruit, Janine/0000-0002-5414-0485; Rodrigues, Brian/0000-0002-0129-4261; Johnson, James/0000-0002-7523-9433; Maijer-Reuwer, Anne/0000-0003-3016-5749	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belmonte SA, 2005, DEV BIOL, V285, P393, DOI 10.1016/j.ydbio.2005.07.001; Brunham LR, 2006, ANNU REV NUTR, V26, P105, DOI 10.1146/annurev.nutr.26.061505.111214; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Chintagari NR, 2006, AM J RESP CELL MOL, V34, P677, DOI 10.1165/rcmb.2005-0418OC; Cnop M, 2000, AM J PATHOL, V156, P237, DOI 10.1016/S0002-9440(10)64724-4; Cnop M, 2002, ENDOCRINOLOGY, V143, P3449, DOI 10.1210/en.2002-220273; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Daimon M, 2005, BIOCHEM BIOPH RES CO, V329, P205, DOI 10.1016/j.bbrc.2005.01.119; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Gerin I, 2005, J BIOL CHEM, V280, P23024, DOI 10.1074/jbc.M412564200; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Grupping AY, 1997, ENDOCRINOLOGY, V138, P4064, DOI 10.1210/en.138.10.4064; Heaps CL, 2005, AM J PHYSIOL-HEART C, V288, pH568, DOI 10.1152/ajpheart.00157.2004; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2001, J LIPID RES, V42, P1173; PERLEY MJ, 1967, J CLIN INVEST, V46, P1954, DOI 10.1172/JCI105685; Plesner A, 2005, DIABETES, V54, P2533, DOI 10.2337/diabetes.54.9.2533; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roehrich ME, 2003, J BIOL CHEM, V278, P18368, DOI 10.1074/jbc.M300102200; Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA; Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	39	317	326	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					340	347		10.1038/nm1546	http://dx.doi.org/10.1038/nm1546			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17322896				2022-12-27	WOS:000244715700047
J	Steinman, L				Steinman, Lawrence			A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage	NATURE MEDICINE			English	Review							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; IFN-GAMMA; INTERFERON-GAMMA; IL-6-DEFICIENT MICE; HUMAN KERATINOCYTES; INDUCED ARTHRITIS	For over 35 years, immunologists have divided T-helper (T-H) cells into functional subsets. T-helper type 1 (T(H)1) cells - long thought to mediate tissue damage - might be involved in the initiation of damage, but they do not sustain or play a decisive role in many commonly studied models of autoimmunity, allergy and microbial immunity. A major role for the cytokine interleukin-17 (IL-17) has now been described in various models of immune-mediated tissue injury, including organ-specific autoimmunity in the brain, heart, synovium and intestines, allergic disorders of the lung and skin, and microbial infections of the intestines and the nervous system. A pathway named T(H)17 is now credited for causing and sustaining tissue damage in these diverse situations. The T(H)1 pathway antagonizes the T(H)17 pathway in an intricate fashion. The evolution of our understanding of the T(H)17 pathway illuminates a shift in immunologists' perspectives regarding the basis of tissue damage, where for over 20 years the role of T(H)1 cells was considered paramount.	Stanford Univ, Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Interdepartmental Program Immunol, Stanford, CA 94305 USA	Stanford University	Steinman, L (corresponding author), Stanford Univ, Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Interdepartmental Program Immunol, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250				Aarvak T, 1999, J IMMUNOL, V162, P1246; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; BENACERRAF B, 1963, ANNU REV MICROBIOL, V17, P263, DOI 10.1146/annurev.mi.17.100163.001403; Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; BILLIAU A, 1988, J IMMUNOL, V140, P1506; CANTOR H, 1975, CELL IMMUNOL, V15, P180, DOI 10.1016/0008-8749(75)90174-4; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; Chen Q, 2006, NAT IMMUNOL, V7, P1299, DOI 10.1038/ni1406; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; CHER DJ, 1987, J IMMUNOL, V138, P3688; Coffman RL, 2006, NAT IMMUNOL, V7, P539, DOI 10.1038/ni0606-539; COFFMAN RL, 1986, J IMMUNOL, V136, P949; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Di Marco R, 2001, J NEUROIMMUNOL, V116, P168, DOI 10.1016/S0165-5728(01)00301-0; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Ferber IA, 1996, J IMMUNOL, V156, P5; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FONG TAT, 1989, J IMMUNOL, V143, P2887; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; JACOB CO, 1989, J IMMUNOL, V142, P1500; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; KLEIN J, 1982, NATURE, V300, P12, DOI 10.1038/300012a0; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; NAKAJIMA H, 1991, AGENTS ACTIONS, V34, P63, DOI 10.1007/BF01993239; Okuda Y, 2000, J NEUROIMMUNOL, V105, P120, DOI 10.1016/S0165-5728(00)00192-2; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; Rangachari M, 2006, J EXP MED, V203, P2009, DOI 10.1084/jem.20052222; Samoilova EB, 1998, J IMMUNOL, V161, P6480; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Shinohara ML, 2005, P NATL ACAD SCI USA, V102, P17101, DOI 10.1073/pnas.0508666102; Steinman L, 2005, NAT REV DRUG DISCOV, V4, P510, DOI 10.1038/nrd1752; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Steinman L, 2003, J EXP MED, V197, P1065, DOI 10.1084/jem.20030320; STEINMETZ M, 1982, NATURE, V300, P35, DOI 10.1038/300035a0; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Tartour E, 1999, CANCER RES, V59, P3698; Tato CM, 2006, NATURE, V441, P166, DOI 10.1038/441166a; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; VOLLMER TL, 1987, J IMMUNOL, V138, P3737; VOORTHUIS JAC, 1990, CLIN EXP IMMUNOL, V81, P183; WAKSMAN BH, 1962, MEDICINE, V41, P93, DOI 10.1097/00005792-196205000-00001; Willenborg DO, 1996, J IMMUNOL, V157, P3223; WILLIAMS R, 2006, J EXP MED, V203, P2567; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0	77	1015	1094	2	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					139	145		10.1038/nm1551	http://dx.doi.org/10.1038/nm1551			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17290272				2022-12-27	WOS:000244031700021
J	Gall, JG				Gall, Joseph G.			Through the looking glass	NATURE MEDICINE			English	Editorial Material							RIBOSOMAL-RNA GENES; DROSOPHILA-MELANOGASTER; LAMPBRUSH CHROMOSOMES; DNA; TETRAHYMENA; LOCALIZATION		Carnegie Inst, Dept Embryol, Baltimore, MD 21218 USA	Carnegie Institution for Science	Gall, JG (corresponding author), Carnegie Inst, Dept Embryol, 3520 San Martin Dr, Baltimore, MD 21218 USA.	gall@ciwemb.edu	Vadi, Valentina/AAT-7748-2020; Gall, Joseph/AAF-6789-2020	Vadi, Valentina/0000-0001-5856-6195; 				BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; COONS AH, 1950, J EXP MED, V91, P1, DOI 10.1084/jem.91.1.1; GALL JG, 1971, CHROMOSOMA, V33, P319; GALL JG, 1963, NATURE, V198, P36, DOI 10.1038/198036a0; GALL JG, 1969, P NATL ACAD SCI USA, V63, P378, DOI 10.1073/pnas.63.2.378; GALL JG, 1962, P NATL ACAD SCI USA, V48, P562, DOI 10.1073/pnas.48.4.562; GALL JG, 1974, P NATL ACAD SCI USA, V71, P3078, DOI 10.1073/pnas.71.8.3078; GALL JG, 1968, P NATL ACAD SCI USA, V60, P553, DOI 10.1073/pnas.60.2.553; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; MACGREGOR HC, 1962, Q J MICROSC SCI, V103, P173; McCLINTOCK BARBARA, 1934, ZEITSCHR ZELLJORSCH U MIKROSK ANAT, V21, P294, DOI 10.1007/BF00374060; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; PARDUE ML, 1970, CHROMOSOMA, V29, P268, DOI 10.1007/BF00325943; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; TAYLOR JH, 1957, P NATL ACAD SCI USA, V43, P122, DOI 10.1073/pnas.43.1.122; Waddington C. H., 1939, INTRO MODERN GENETIC; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition	23	2	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1142	1145		10.1038/nm1006-1142	http://dx.doi.org/10.1038/nm1006-1142			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024210				2022-12-27	WOS:000241102200029
J	Fichtner-Feigl, S; Strober, W; Kawakami, K; Puri, RK; Kitani, A				Fichtner-Feigl, S; Strober, W; Kawakami, K; Puri, RK; Kitani, A			IL-13 signaling through the IL-13 alpha 2 receptor is involved in induction of TGF-beta 1 production and fibrosis	NATURE MEDICINE			English	Article							GROWTH FACTOR-BETA-1 GENE; NK-T-CELLS; PULMONARY-FIBROSIS; ULCERATIVE-COLITIS; OXAZOLONE COLITIS; TISSUE FIBROSIS; ALPHA-2 CHAIN; IN-VIVO; MICE; INTERLEUKIN-13	Interleukin (IL)-13 is a major inducer of fibrosis in many chronic infectious and autoimmune diseases. In studies of the mechanisms underlying such induction, we found that IL-13 induces transforming growth factor (TGF)-beta(1) in macrophages through a two-stage process involving, first, the induction of a receptor formerly considered to function only as a decoy receptor, IL-13R alpha(2). Such induction requires IL-13 (or IL-4) and tumor necrosis factor (TNF)-alpha. Second, it involves IL-13 signaling through IL-13R alpha(2) to activate an AP-1 variant containing c-jun and Fra-2, which then activates the TGFB1 promoter. In vivo, we found that prevention of IL-13R alpha(2) expression reduced production of TGF-beta(1) in oxazolone-induced colitis and that prevention of IL-13Ra2 expression, Il13ra2 gene silencing or blockade of IL-13R alpha(2) signaling led to marked downregulation of TGF-beta(1) production and collagen deposition in bleomycin-induced lung fibrosis. These data suggest that IL-13R alpha(2) signaling during prolonged inflammation is an important therapeutic target for the prevention of TGF-beta(1)-mediated fibrosis.	NIAID, NIH, Mucosal Immun Sect, Lab Host Def, Bethesda, MD 20892 USA; Univ Regensburg, Dept Surg, Med Ctr, D-93053 Regensburg, Germany; US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Regensburg; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Strober, W (corresponding author), NIAID, NIH, Mucosal Immun Sect, Lab Host Def, Bldg 10-CRC 5W3864,10 Ctr Dr, Bethesda, MD 20892 USA.	wstrober@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000432, Z01AI000432] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; de Lalla C, 2004, J IMMUNOL, V173, P1417, DOI 10.4049/jimmunol.173.2.1417; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Ha H, 2001, KIDNEY INT, V59, P463, DOI 10.1046/j.1523-1755.2001.059002463.x; Hasegawa M, 1997, J RHEUMATOL, V24, P328; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Jo N, 2002, CURR EYE RES, V24, P465, DOI 10.1076/ceyr.24.6.465.8600; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kitani A, 2000, J EXP MED, V192, P41, DOI 10.1084/jem.192.1.41; Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917; Kraus J, 2002, FASEB J, V16, P304, DOI 10.1096/fj.02-0482fje; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V300, P464, DOI 10.1016/S0006-291X(02)02807-3; WOOLEY PH, 1993, J IMMUNOL, V151, P6602; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Wu ZL, 2004, CELL BIOCHEM FUNCT, V22, P237, DOI 10.1002/cbf.1096; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Wynn TA, 2004, HEPATOLOGY, V39, P676, DOI 10.1002/hep.20102; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhang K, 1997, J IMMUNOL, V158, P954; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001; Zheng T, 2003, J ALLERGY CLIN IMMUN, V111, P720, DOI 10.1067/mai.2003.1383	44	661	715	1	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					99	106		10.1038/nm1332	http://dx.doi.org/10.1038/nm1332			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327802				2022-12-27	WOS:000234419000058
J	Ciuffi, A; Llano, M; Poeschla, E; Hoffmann, C; Leipzig, J; Shinn, P; Ecker, JR; Bushman, F				Ciuffi, A; Llano, M; Poeschla, E; Hoffmann, C; Leipzig, J; Shinn, P; Ecker, JR; Bushman, F			A role for LEDGF/p75 in targeting HIV DNA integration	NATURE MEDICINE			English	Article							HUMAN GENOME; HUMAN-CELLS; TRANSCRIPTION; IDENTIFICATION; PROTEINS; REVEALS; DOMAIN	HIV DNA integration is favored in active genes, but the underlying mechanism is unclear. Cellular lens epithelium-derived growth factor (LEDGF/p75) binds both chromosomal DNA and HIV integrase, and might therefore direct integration by a tethering interaction. We analyzed HIV integration in cells depleted for LEDGF/p75, and found that integration was (i) less frequent in transcription units, (ii) less frequent in genes regulated by LEDGF/p75 and (iii) more frequent in GC-rich DNA. LEDGF is thus the first example of a cellular protein controlling the location of HIV integration in human cells.	Mayo Clin & Mayo Fdn, Coll Med, Program Mol Med, Rochester, MN 55905 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Salk Inst Biol Studies, Genom Anal Lab, La Jolla, CA 92037 USA	Mayo Clinic; University of Pennsylvania; Salk Institute	Poeschla, E (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	poeschla.eric@mayo.edu; bushman@mail.med.upenn.edu	Ciuffi, Angela/K-5798-2017; Ecker, Joseph R/B-9144-2008; Hoffmann, Christian/C-1298-2015	Ciuffi, Angela/0000-0003-2333-513X; Ecker, Joseph R/0000-0001-5799-5895; Hoffmann, Christian/0000-0003-1736-8007; Leipzig, Jeremy/0000-0001-7224-9620	NIAID NIH HHS [AI52845, AI47536, R01 AI052845, AI34786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052845, R21AI047536, R01AI034786, R01AI047536] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSHMAN F, 2005, NAT REV MICRO; Cherepanov P, 2004, J BIOL CHEM, V279, P48883, DOI 10.1074/jbc.M406307200; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Lewinski MK, 2005, J VIROL, V79, P6610, DOI 10.1128/JVI.79.11.6610-6619.2005; Llano M, 2004, J BIOL CHEM, V279, P55570, DOI 10.1074/jbc.M408508200; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Narezkina A, 2004, J VIROL, V78, P11656, DOI 10.1128/JVI.78.21.11656-11663.2004; Sandmeyer S, 2003, P NATL ACAD SCI USA, V100, P5586, DOI 10.1073/pnas.1031802100; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Vanegas M, 2005, J CELL SCI, V118, P1733, DOI 10.1242/jcs.02299; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413	16	462	475	0	19	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2005	11	12					1287	1289		10.1038/nm1329	http://dx.doi.org/10.1038/nm1329			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16311605				2022-12-27	WOS:000233774400024
J	Mizukami, Y; Jo, WS; Duerr, EM; Gala, M; Li, JN; Zhang, XB; Zimmer, MA; Iliopoulos, O; Zukerberg, LR; Kohgo, Y; Lynch, MP; Rueda, BR; Chung, DC				Mizukami, Y; Jo, WS; Duerr, EM; Gala, M; Li, JN; Zhang, XB; Zimmer, MA; Iliopoulos, O; Zukerberg, LR; Kohgo, Y; Lynch, MP; Rueda, BR; Chung, DC			Induction of interleukin-8 preserves the angiogenic response in HIF-1 alpha-deficient colon cancer cells	NATURE MEDICINE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; NF-KAPPA-B; TUMOR-GROWTH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; OXYGEN; HIF-1; RAS; TUMORIGENESIS	Hypoxia inducible factor- 1 ( HIF- 1) is considered a crucial mediator of the cellular response to hypoxia through its regulation of genes that control angiogenesis(1-4). It represents an attractive therapeutic target(5,6) in colon cancer, one of the few tumor types that shows a clinical response to antiangiogenic therapy(7). But it is unclear whether inhibition of HIF- 1 alone is sufficient to block tumor angiogenesis(8,9). In HIF- 1 alpha knockdown DLD- 1 colon cancer cells ( DLD- 1(HIF- kd)), the hypoxic induction of vascular endothelial growth factor ( VEGF) was only partially blocked. Xenografts remained highly vascularized with microvessel densities identical to DLD- 1 tumors that had wild- type HIF- 1 alpha ( DLD- 1(HIF-wt)). In addition to the preserved expression of VEGF, the proangiogenic cytokine interleukin ( IL)- 8 was induced by hypoxia in DLD- 1(HIF-kd) but not DLD- 1(HIF- wt) cells. This induction was mediated by the production of hydrogen peroxide and subsequent activation of NF-kappa B. Furthermore, the KRAS oncogene, which is commonly mutated in colon cancer, enhanced the hypoxic induction of IL- 8. A neutralizing antibody to IL- 8 substantially inhibited angiogenesis and tumor growth in DLD- 1HIF- kd but not DLD-1(HIF-) (wt) xenografts, verifying the functional significance of this IL- 8 response. Thus, compensatory pathways can be activated to preserve the tumor angiogenic response, and strategies that inhibit HIF- 1 alpha may be most effective when IL- 8 is simultaneously targeted.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Oncol Unit, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Asahikawa Med Coll, Dept Internal Med 3, Asahikawa, Hokkaido 0788510, Japan; Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Asahikawa Medical College; Harvard University; Massachusetts General Hospital	Chung, DC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 50 Blossom St, Boston, MA 02114 USA.	chung.daniel@mgh.harvard.edu	Kohgo, Yutaka/AAN-4863-2020; Mizukami, Yusuke/AAB-1777-2019; Mizukami, Yusuke/AAU-1767-2021	Mizukami, Yusuke/0000-0002-1068-7024	NCI NIH HHS [CA92594, CA104574, CA098333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104574, R01CA092594, R01CA098333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Beasley NJP, 2002, CANCER RES, V62, P2493; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Koshiji M, 2004, CELL CYCLE, V3, P853; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Ofori-Darko E, 2000, INFECT IMMUN, V68, P3657, DOI 10.1128/IAI.68.6.3657-3666.2000; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	30	345	397	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					992	997		10.1038/nm1294	http://dx.doi.org/10.1038/nm1294			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127434	Green Submitted			2022-12-27	WOS:000231724700028
J	Brockstedt, DG; Bahjat, KS; Giedlin, MA; Liu, W; Leong, M; Luckett, W; Gao, Y; Schnupf, P; Kapadia, D; Castro, G; Lim, JYH; Sampson-Johannes, A; Herskovits, AA; Stassinopoulos, A; Bouwer, HGA; Hearst, JE; Portnoy, DA; Cook, DN; Dubensky, TW				Brockstedt, DG; Bahjat, KS; Giedlin, MA; Liu, W; Leong, M; Luckett, W; Gao, Y; Schnupf, P; Kapadia, D; Castro, G; Lim, JYH; Sampson-Johannes, A; Herskovits, AA; Stassinopoulos, A; Bouwer, HGA; Hearst, JE; Portnoy, DA; Cook, DN; Dubensky, TW			Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity	NATURE MEDICINE			English	Article							RECOMBINANT LISTERIA-MONOCYTOGENES; HUMAN DENDRITIC CELLS; MEDIATED-IMMUNITY; ESTABLISHED TUMORS; CANCER VACCINES; CLASS-I; INFECTION; INDUCTION; PATHOGENESIS; SYSTEM	We developed a new class of vaccines, based on killed but metabolically active (KBMA) bacteria, that simultaneously takes advantage of the potency of live vaccines and the safety of killed vaccines. We removed genes required for nucleotide excision repair (uvrAB), rendering microbial-based vaccines exquisitely sensitive to photochemical inactivation with psoralen and long-wavelength ultraviolet light. Colony formation of the nucleotide excision repair mutants was blocked by infrequent, randomly distributed psoralen crosslinks, but the bacterial population was able to express its genes, synthesize and secrete proteins. Using the intracellular pathogen Listeria monocytogenes as a model platform, recombinant psoralen-inactivated Lm Delta uvrAB vaccines induced potent CD4(+) and CD8(+) T-cell responses and protected mice against virus challenge in an infectious disease model and provided therapeutic benefit in a mouse cancer model. Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of the pathogen itself may have broad use for the treatment of infectious disease and cancer.	Cerus Corp, Concord, CA 94520 USA; Oregon Hlth Sci Univ, Dept Mol & Cell Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Cerus Corporation; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Berkeley	Dubensky, TW (corresponding author), Cerus Corp, 2411 Stanwell Dr, Concord, CA 94520 USA.	tom_dubensky@cerus.com	Schnupf, Pamela/G-6040-2017	Schnupf, Pamela/0000-0003-4292-1257				AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976; Auerbuch V, 2003, MOL MICROBIOL, V49, P1361, DOI 10.1046/j.1365-2958.2003.03639.x; BERCHE P, 1987, J IMMUNOL, V138, P2266; Brockstedt DG, 1999, CLIN IMMUNOL, V92, P67, DOI 10.1006/clim.1999.4724; Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BUSCH DHC, 2000, CURRENT PROTOCOLS IM, V3, P9; CAMILLI A, 1993, MOL MICROBIOL, V8, P143, DOI 10.1111/j.1365-2958.1993.tb01211.x; Carrero JA, 2004, J EXP MED, V200, P535, DOI 10.1084/jem.20040769; Geginat G, 2001, J IMMUNOL, V166, P1877, DOI 10.4049/jimmunol.166.3.1877; Gunn GR, 2001, J IMMUNOL, V167, P6471, DOI 10.4049/jimmunol.167.11.6471; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Janion C, 2001, ACTA BIOCHIM POL, V48, P599; Jensen ER, 1997, J VIROL, V71, P8467, DOI 10.1128/JVI.71.11.8467-8474.1997; Kolb-Maurer A, 2003, FEMS IMMUNOL MED MIC, V35, P255, DOI 10.1016/S0928-8244(02)00470-4; Kolb-Maurer A, 2000, INFECT IMMUN, V68, P3680, DOI 10.1128/IAI.68.6.3680-3688.2000; Lauer P, 2002, J BACTERIOL, V184, P4177, DOI 10.1128/JB.184.15.4177-4186.2002; Lauvau G, 2001, SCIENCE, V294, P1735, DOI 10.1126/science.1064571; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; Liau LM, 2002, CANCER RES, V62, P2287; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MALARKANNAN S, 2000, METHOD MOL BIOL, V156, P1; O'Connell RM, 2004, J EXP MED, V200, P437, DOI 10.1084/jem.20040712; O'Riordan M, 2002, P NATL ACAD SCI USA, V99, P13861, DOI 10.1073/pnas.202476699; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PAN ZK, 1995, CANCER RES, V55, P4776; Paterson Y, 1996, CURR OPIN IMMUNOL, V8, P664, DOI 10.1016/S0952-7915(96)80083-5; Peters C, 2003, J IMMUNOL, V170, P5176, DOI 10.4049/jimmunol.170.10.5176; Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009; Rappuoli R, 2004, NAT MED, V10, P1177, DOI 10.1038/nm1129; Reuveny S, 2001, INFECT IMMUN, V69, P2888, DOI 10.1128/IAI.69.5.2888-2893.2001; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; SHEN H, 1995, P NATL ACAD SCI USA, V92, P3987, DOI 10.1073/pnas.92.9.3987; Shen ZH, 1997, J IMMUNOL, V158, P2723; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Starks H, 2004, J IMMUNOL, V173, P420, DOI 10.4049/jimmunol.173.1.420; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; WILSON EB, 1905, J EXP ZOOL, V2, P4; Wollowitz S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29495; 2001, CLIN TOXICOLOGY, V39, P85	46	101	132	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					853	860		10.1038/nm1276	http://dx.doi.org/10.1038/nm1276			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16041382				2022-12-27	WOS:000230964700030
J	Edghill-Smith, Y; Golding, H; Manischewitz, J; King, LR; Scott, D; Bray, M; Nalca, A; Hooper, JW; Whitehouse, CA; Schmitz, JE; Reimann, KA; Franchini, G				Edghill-Smith, Y; Golding, H; Manischewitz, J; King, LR; Scott, D; Bray, M; Nalca, A; Hooper, JW; Whitehouse, CA; Schmitz, JE; Reimann, KA; Franchini, G			Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus	NATURE MEDICINE			English	Article							INFECTION; RESPONSES; MICE	Vaccination with live vaccinia virus affords long- lasting protection against variola virus, the agent of smallpox. Its mode of protection in humans, however, has not been clearly defined. Here we report that vaccinia- specific B-cell responses are essential for protection of macaques from monkeypox virus, a variola virus ortholog. Antibody- mediated depletion of B cells, but not CD4(+) or CD8(+) T cells, abrogated vaccine- induced protection from a lethal intravenous challenge with monkeypox virus. In addition, passive transfer of human vaccinia-neutralizing antibodies protected nonimmunized macaques from severe disease. Thus, vaccines able to induce long- lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax).	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Bethesda, MD 20892 USA; US FDA, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NIAID, Biodef Clin Res Branch, Off Clin Res, Bethesda, MD 20892 USA; So Res Inst, Frederick, MD 21701 USA; USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Viral Pathogenesis, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov	Schmitz, Joern/A-4929-2018; Hooper, Jay/K-2362-2017; Nalca, Aysegul/L-8149-2019	Schmitz, Joern/0000-0001-8803-0922; Hooper, Jay/0000-0002-4475-0415; Nalca, Aysegul/0000-0001-8581-7535	NATIONAL CANCER INSTITUTE [Z01BC005688, ZIABC005688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR016001, RR016001] Funding Source: Medline; NIAID NIH HHS [AI040101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Bray M, 2004, CLIN INFECT DIS, V38, P882, DOI 10.1086/381976; Bray M, 2003, CLIN INFECT DIS, V36, P766, DOI 10.1086/374244; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P642; Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V23, P537; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; DUNCAN SA, 1992, J VIROL, V66, P1610, DOI 10.1128/JVI.66.3.1610-1621.1992; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Edghill-Smith Y, 2005, J INFECT DIS, V191, P372, DOI 10.1086/427265; Edghill-Smith Y, 2003, J INFECT DIS, V188, P1181, DOI 10.1086/378518; ENGELSTAD M, 1992, VIROLOGY, V188, P801, DOI 10.1016/0042-6822(92)90535-W; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HIRT P, 1986, J VIROL, V58, P757, DOI 10.1128/JVI.58.3.757-764.1986; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7; ISAACS SN, 1992, J VIROL, V66, P7217, DOI 10.1128/JVI.66.12.7217-7224.1992; Jezek Z, 1988, HUMAN MONKEYPOX; Kemper Alex R, 2002, Eff Clin Pract, V5, P84; Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004; LADNYI ID, 1972, B WORLD HLTH ORG, V55, P613; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; Manischewitz J, 2003, J INFECT DIS, V188, P440, DOI 10.1086/376557; MARENNIKOVA SS, 1989, ACTA VIROL, V33, P246; Moss B, 1996, Adv Exp Med Biol, V397, P7; Mourad GJ, 1998, TRANSPLANTATION, V65, P632, DOI 10.1097/00007890-199803150-00006; REFF ME, 1994, BLOOD, V83, P435; Roper RL, 1996, J VIROL, V70, P3753, DOI 10.1128/JVI.70.6.3753-3762.1996; SALK J, 1977, SCIENCE, V195, P834, DOI 10.1126/science.320661; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Schmitz JE, 2003, J VIROL, V77, P2165, DOI 10.1128/JVI.77.3.2165-2173.2003; Schmitz JE, 1999, AM J PATHOL, V154, P1923, DOI 10.1016/S0002-9440(10)65450-8; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916; Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101; Zaucha GM, 2001, LAB INVEST, V81, P1581, DOI 10.1038/labinvest.3780373	35	223	227	7	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					740	747		10.1038/nm1261	http://dx.doi.org/10.1038/nm1261			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951823				2022-12-27	WOS:000230304200030
J	Scheuner, D; Mierde, DV; Song, B; Flamez, D; Creemers, JWM; Tsukamoto, K; Ribick, M; Schuit, FC; Kaufman, RJ				Scheuner, D; Mierde, DV; Song, B; Flamez, D; Creemers, JWM; Tsukamoto, K; Ribick, M; Schuit, FC; Kaufman, RJ			Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis	NATURE MEDICINE			English	Article							UNFOLDED-PROTEIN RESPONSE; WOLCOTT-RALLISON-SYNDROME; RAT PANCREATIC-ISLETS; PROINSULIN BIOSYNTHESIS; REGULATED PROTEINS; EIF2-ALPHA KINASE; INSULIN RELEASE; ER STRESS; MICE; GENE	Type 2 diabetes is a disorder of hyperglycemia resulting from failure of beta cells to produce adequate insulin to accommodate an increased metabolic demand. Here we show that regulation of mRNA translation through phosphorylation of eukaryotic initiation factor 2 (eIF2 alpha) is essential to preserve the integrity of the endoplasmic reticulum (ER) and to increase insulin production to meet the demand imposed by a high-fat diet. Accumulation of unfolded proteins in the ER activates phosphorylation of eIF2a at Ser51 and inhibits translation. To elucidate the role of this pathway in beta- cell function we studied glucose homeostasis in Eif2s1(tm1Rjk) mutant mice, which have an alanine substitution at Ser51. Heterozygous (Eif2s1(+/tm1Rjk)) mice became obese and diabetic on a high-fat diet. Profound glucose intolerance resulted from reduced insulin secretion accompanied by abnormal distension of the ER lumen, defective trafficking of proinsulin, and a reduced number of insulin granules in beta cells. We propose that translational control couples insulin synthesis with folding capacity to maintain ER integrity and that this signal is essential to prevent diet- induced type 2 diabetes.	Katholieke Univ Leuven, Gene Express Unit, Dept Mol Cell Biol, B-3000 Louvain, Belgium; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Vrije Univ Brussels, Diabet Res Ctr, B-1090 Brussels, Belgium; Katholieke Univ Leuven, Dept Menselijke Erfelijkheid, Louvain, Belgium; Vlaams Interunib, Inst Biotechnol, B-3000 Louvain, Belgium; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	KU Leuven; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Vrije Universiteit Brussel; KU Leuven; University of Michigan System; University of Michigan	Schuit, FC (corresponding author), Katholieke Univ Leuven, Gene Express Unit, Dept Mol Cell Biol, Herestr 49, B-3000 Louvain, Belgium.	frans.schuit@med.kuleuven.be; kaufmanr@umich.edu			NIDDK NIH HHS [DK42394, R01 DK042394, R37 DK042394] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042394, R01DK042394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Flamez D, 1998, DIABETES, V47, P646, DOI 10.2337/diabetes.47.4.646; GRIMALDI KA, 1987, BIOCHEM J, V245, P557, DOI 10.1042/bj2450557; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinke SA, 2004, J PHYSIOL-LONDON, V558, P369, DOI 10.1113/jphysiol.2004.064881; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Jorns A, 1997, J ENDOCRINOL, V155, P283, DOI 10.1677/joe.0.1550283; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; WILLIAMS BRG, 2001, SIGNAL INTEGRATION P; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	43	300	318	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					757	764		10.1038/nm1259	http://dx.doi.org/10.1038/nm1259			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980866	Green Published			2022-12-27	WOS:000230304200032
J	Hsieh, PCH; Segers, VFM; Davis, ME; MacGillivray, C; Gannon, J; Molkentin, JD; Robbins, J; Lee, RT				Hsieh, Patrick C. H.; Segers, Vincent F. M.; Davis, Michael E.; MacGillivray, Catherine; Gannon, Joseph; Molkentin, Jeffery D.; Robbins, Jeffrey; Lee, Richard T.			Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury	NATURE MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CARDIAC-MUSCLE; BONE-MARROW; REGENERATION; MULTIPOTENT; PROTEIN	An emerging concept is that the mammalian myocardium has the potential to regenerate, but that regeneration might be too inefficient to repair the extensive myocardial injury that is typical of human disease(1-8). However, the degree to which stem cells or precursor cells contribute to the renewal of adult mammalian cardiomyocytes remains controversial. Here we report evidence that stem cells or precursor cells contribute to the replacement of adult mammalian cardiomyocytes after injury but do not contribute significantly to cardiomyocyte renewal during normal aging. We generated double-transgenic mice to track the fate of adult cardiomyocytes in a 'pulsechase' fashion: after a 4-OH-tamoxifen pulse, green fluorescent protein (GFP) expression was induced only in cardiomyocytes, with 82.7% of cardiomyocytes expressing GFP. During normal aging up to one year, the percentage of GFP(+) cardiomyocytes remained unchanged, indicating that stem or precursor cells did not refresh uninjured cardiomyocytes at a significant rate during this period of time. By contrast, after myocardial infarction or pressure overload, the percentage of GFP(+) cardiomyocytes decreased from 82.8% in heart tissue from sham-treated mice to 67.5% in areas bordering a myocardial infarction, 76.6% in areas away from a myocardial infarction, and 75.7% in hearts subjected to pressure overload, indicating that stem cells or precursor cells had refreshed the cardiomyocytes.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Cambridge, MA 02139 USA; Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Harvard University; Brigham & Women's Hospital; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Lee, RT (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Cambridge, MA 02139 USA.	rlee@partners.org	Segers, Vincent F/J-1191-2019; Hsieh, Patrick Ching-Ho/H-5108-2015	Segers, Vincent F/0000-0001-7796-2222; Hsieh, Patrick C.H./0000-0002-8910-3596; Lee, Richard/0000-0003-4687-1381; Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [F32 HL073574, F32 HL073574-03, R01 HL081404, R01HL081404] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073574, R01HL081404] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER RO, 1974, NATURE, V248, P145, DOI 10.1038/248145a0; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Oh H, 2004, ANN NY ACAD SCI, V1015, P182, DOI 10.1196/annals.1302.015; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Winitsky SO, 2005, PLOS BIOL, V3, P662, DOI 10.1371/journal.pbio.0030087; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326	15	563	585	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2007	13	8					970	974		10.1038/nm1618	http://dx.doi.org/10.1038/nm1618			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17660827	Green Accepted			2022-12-27	WOS:000248674600028
J	Alexander, JJ; Umino, Y; Everhart, D; Chang, B; Min, SH; Li, QH; Timmers, AM; Hawes, NL; Pang, JJ; Barlow, RB; Hauswirth, WW				Alexander, John J.; Umino, Yumiko; Everhart, Drew; Chang, Bo; Min, Seok H.; Li, Qiuhong; Timmers, Adrian M.; Hawes, Norman L.; Pang, Ji-jing; Barlow, Robert B.; Hauswirth, William W.			Restoration of cone vision in a mouse model of achromatopsia	NATURE MEDICINE			English	Article							LOCUS-CONTROL REGION; MOLECULAR-GENETICS; PIGMENT GENES; HUMAN RED; MUTATIONS; EXPRESSION; CNGB3; GNAT2	Loss of cone function in the central retina is a pivotal event in the development of severe vision impairment for many prevalent blinding diseases. Complete achromatopsia is a genetic defect resulting in cone vision loss in 1 in 30,000 individuals. Using adeno-associated virus (AAV) gene therapy, we show that it is possible to target cones and rescue both the cone-mediated electroretinogram response and visual acuity in the Gnat2(cpfl3) mouse model of achromatopsia.	Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; SUNY Upstate Med Univ, Ctr Vis Res, Dept Ophthalmol, Syracuse, NY 13210 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Jackson Laboratory; State University System of Florida; University of Florida	Hauswirth, WW (corresponding author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.	hauswrth@eye.ufl.edu	Alexander, John/GVS-7271-2022	Chang, Bo/0000-0001-8259-7290	NEI NIH HHS [P30 EY021721, EY007132, R56 EY000667, EY008571, EY007758, EY00667, T32 EY007132, P30 EY008571, F32 EY017246, EY011123, R01 EY000667, R01 EY011123, R01 EY007758, EY017246] Funding Source: Medline; NINDS NIH HHS [P01 NS036302, NS36302] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008571, R56EY000667, R01EY007758, R01EY011123, R01EY000667, T32EY007132, P30EY021721, F32EY017246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036302] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chang B, 2006, INVEST OPHTH VIS SCI, V47, P5017, DOI 10.1167/iovs.05-1468; Deeb SS, 2004, VISUAL NEUROSCI, V21, P191, DOI 10.1017/S0952523804213244; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Johnson S, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011437; Kohl S, 2005, EUR J HUM GENET, V13, P302, DOI 10.1038/sj.ejhg.5201269; Kohl S, 2002, AM J HUM GENET, V71, P422, DOI 10.1086/341835; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; Roca A, 2004, NEUROSCIENCE, V129, P779, DOI 10.1016/j.neuroscience.2004.08.021; Shaaban SA, 1998, INVEST OPHTH VIS SCI, V39, P1036; Smallwood PM, 2002, P NATL ACAD SCI USA, V99, P1008, DOI 10.1073/pnas.022629799; Umino Y, 2006, P NATL ACAD SCI USA, V103, P19541, DOI 10.1073/pnas.0604478104; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; Zhu XM, 2002, MOL VIS, V8, P462	13	172	191	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					685	687		10.1038/nm1596	http://dx.doi.org/10.1038/nm1596			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17515894	Green Accepted			2022-12-27	WOS:000247084300030
J	Ziouzenkova, O; Orasanu, G; Sharlach, M; Akiyama, TE; Berger, JP; Viereck, J; Hamilton, JA; Tang, GW; Dolnikowski, GG; Vogel, S; Duester, G; Plutzky, J				Ziouzenkova, Ouliana; Orasanu, Gabriela; Sharlach, Molly; Akiyama, Taro E.; Berger, Joel P.; Viereck, Jason; Hamilton, James A.; Tang, Guangwen; Dolnikowski, Gregory G.; Vogel, Silke; Duester, Gregg; Plutzky, Jorge			Retinaldehyde represses adipogenesis and diet-induced obesity	NATURE MEDICINE			English	Article							RETINOL-BINDING-PROTEIN; INSULIN-RESISTANCE; BETA-CAROTENE; VITAMIN-A; ACID; ADIPONECTIN; INHIBITION; FAT; RETINOL-BINDING-PROTEIN-4; DIFFERENTIATION	The metabolism of vitamin A and the diverse effects of its metabolites are tightly controlled by distinct retinoid-generating enzymes, retinoid-binding proteins and retinoid-activated nuclear receptors. Retinoic acid regulates differentiation and metabolism by activating the retinoic acid receptor and retinoid X receptor (RXR), indirectly influencing RXR heterodimeric partners. Retinoic acid is formed solely from retinaldehyde (Rald), which in turn is derived from vitamin A. Rald currently has no defined biologic role outside the eye. Here we show that Rald is present in rodent fat, binds retinol-binding proteins (CRBP1, RBP4), inhibits adipogenesis and suppresses peroxisome proliferator-activated receptor-c and RXR responses. In vivo, mice lacking the Rald-catabolizing enzyme retinaldehyde dehydrogenase 1 (Raldh1) resisted diet-induced obesity and insulin resistance and showed increased energy dissipation. In ob/ob mice, administrating Rald or a Raldh inhibitor reduced fat and increased insulin sensitivity. These results identify Rald as a distinct transcriptional regulator of the metabolic responses to a high-fat diet.	Harvard Univ, Sch Med, Div Cardiovasc, Brigham & Womens Hosp, Boston, MA 02115 USA; Merck Res Labs, Rahway, NJ 07065 USA; Boston Univ, Dept Physiol & Biophys, Boston, MA 02118 USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; Burnham Inst, OncoDev Biol Program, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Merck & Company; Boston University; Tufts University; United States Department of Agriculture (USDA); Columbia University; Sanford Burnham Prebys Medical Discovery Institute	Plutzky, J (corresponding author), Harvard Univ, Sch Med, Div Cardiovasc, Brigham & Womens Hosp, Boston, MA 02115 USA.	jplutzky@rics.bwh.harvard.edu	Dolnikowski, Gregory G/C-4354-2008; Ziouzenkova, Ouliana/B-3690-2012; Plutzky, Jorge/V-3410-2019; Eckhardt, Erik/G-1567-2010; Ziouzenkova, Ouliana/AAM-1971-2020	Dolnikowski, Gregory G/0000-0001-5886-2656; Ziouzenkova, Ouliana/0000-0003-2449-2591; Hamilton, James/0000-0002-4747-7071; Duester, Gregg/0000-0003-4335-3650	NEI NIH HHS [R01 EY013969-05A2, R01 EY013969] Funding Source: Medline; NHLBI NIH HHS [P01 HL48743, R01 HL071745, P01 HL048743] Funding Source: Medline; NICHD NIH HHS [K12 HD051959-01, K12 HD051959] Funding Source: Medline; NIDDK NIH HHS [5P30DK046200, P30 DK046200] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD051959] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071745, P01HL048743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; BERNI R, 1993, FASEB J, V7, P1179, DOI 10.1096/fasebj.7.12.8375617; Cavasotto CN, 2004, J MED CHEM, V47, P4360, DOI 10.1021/jm030651g; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Fliers E, 2003, J NEUROENDOCRINOL, V15, P1005, DOI 10.1046/j.1365-2826.2003.01096.x; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Hallsten K, 2002, DIABETES, V51, P3479, DOI 10.2337/diabetes.51.12.3479; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kikonyogo A, 1999, EUR J BIOCHEM, V262, P704, DOI 10.1046/j.1432-1327.1999.00415.x; Koch SSC, 1999, J MED CHEM, V42, P742, DOI 10.1021/jm980621r; Kubota N, 2006, J BIOL CHEM, V281, P8748, DOI 10.1074/jbc.M505649200; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; Lee S, 2006, DIABETES CARE, V29, P51, DOI 10.2337/diacare.29.1.51; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Molotkov A, 2003, J BIOL CHEM, V278, P36085, DOI 10.1074/jbc.M303709200; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Paydas S, 2003, LEUKEMIA LYMPHOMA, V44, P547, DOI 10.1080/1042819021000055101; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Redlich CA, 1999, ATHEROSCLEROSIS, V143, P427, DOI 10.1016/S0021-9150(98)00303-7; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; Ress NB, 2003, TOXICOL SCI, V71, P198, DOI 10.1093/toxsci/71.2.198; Sell H, 2004, ENDOCRINOLOGY, V145, P3925, DOI 10.1210/en.2004-0321; Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590; Szatmari I, 2006, J EXP MED, V203, P2351, DOI 10.1084/jem.20060141; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Xie YS, 1998, PROTEIN EXPRES PURIF, V14, P31, DOI 10.1006/prep.1998.0944; Xue JC, 1996, MOL CELL BIOL, V16, P1567; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100	43	300	312	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					695	702		10.1038/nm1587	http://dx.doi.org/10.1038/nm1587			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17529981	Green Accepted			2022-12-27	WOS:000247084300032
J	Berner, V; Liu, H; Zhou, Q; Alderson, KL; Sun, K; Weiss, JM; Back, TC; Longo, DL; Blazar, BR; Wiltrout, RH; Welniak, LA; Redelman, D; Murphy, WJ				Berner, Vanessa; Liu, Haiyan; Zhou, Qing; Alderson, Kory L.; Sun, Kai; Weiss, Jonathan M.; Back, Timothy C.; Longo, Dan L.; Blazar, Bruce R.; Wiltrout, Robert H.; Welniak, Lisbeth A.; Redelman, Doug; Murphy, William J.			IFN-gamma mediates CD4(+) T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy	NATURE MEDICINE			English	Article							HOMEOSTATIC PROLIFERATION; CD8-T-CELL MEMORY; INTERFERON-GAMMA; CD4-T-CELL HELP; ACUTE INFECTION; LYMPHOCYTES; EXPRESSION; GENERATION; DEATH; MICE	Protective cell-mediated immune responses in cancer are critically dependent on T-helper type 1 (T(H)1) cytokines such as interferon-gamma (IFN-gamma). We have previously shown that the combination of CD40 stimulation and interleukin- 2 (IL-2) leads to synergistic antitumor responses in several models of advanced metastatic disease. We now report that after this treatment and other immunotherapy regimens, the CD4(+)T- cell population, in contrast to CD8(+)T cells, did not significantly increase but rather exhibited a substantial level of apoptosis that was dependent on IFN-gamma. Mice immunized with tumor cells and treated with an immunotherapy regimen that was initially protective were later unable to mount effective memory responses compared with immunized mice not receiving immunotherapy. Immunotherapy given to tumor-bearing Ifngr(-/-) mice resulted in restoration of secondary responses. Thus, although immunotherapeutic regimens inducing strong IFN-gamma responses can lead to successful early antitumor efficacy, they may also impair the development of durable antitumor responses.	Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA; Univ Nevada, Dept Physiol & Cell Biol, Reno, NV 89557 USA; Natl Canc Inst, Ctr Canc Res, Expt Immunol Lab, Frederick, MD 21702 USA; NIA, Baltimore, MD 21224 USA; Univ Minnesota, Div Bone Marrow Transplantat, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Div Bone Marrow Transplantat, Dept Pediat, Minneapolis, MN 55455 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Murphy, WJ (corresponding author), Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA.	wmurphy@medicine.nevada.edu	Liu, Haiyan/ABD-8689-2021; Longo, Dan L./F-6022-2011	Liu, Haiyan/0000-0002-4652-469X; 	NCI NIH HHS [R01 CA095572, N01-CO-12400, R01 CA72669, R01 CA095572-04A1, R01 CA95572] Funding Source: Medline; NCRR NIH HHS [P20 RR16464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095572, Z01BC009262, R01CA072669] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abdalla AO, 2003, SCAND J IMMUNOL, V58, P601, DOI 10.1111/j.1365-3083.2003.01348.x; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Elsasser-Beile U, 2000, BRIT J CANCER, V83, P637, DOI 10.1054/bjoc.2000.1275; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Hamilton SE, 2006, NAT IMMUNOL, V7, P475, DOI 10.1038/ni1326; Honeychurch J, 2003, BLOOD, V102, P1449, DOI 10.1182/blood-2002-12-3717; Hunter KW, 2004, IMMUNOL LETT, V93, P71, DOI 10.1016/j.imlet.2004.02.006; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Murphy WJ, 2003, J IMMUNOL, V170, P2727, DOI 10.4049/jimmunol.170.5.2727; Schluns KS, 2002, J IMMUNOL, V168, P4827, DOI 10.4049/jimmunol.168.10.4827; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Sobek V, 2002, EUR J IMMUNOL, V32, P2490, DOI 10.1002/1521-4141(200209)32:9<2490::AID-IMMU2490>3.0.CO;2-G; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; Switaj T, 2004, CLIN CANCER RES, V10, P4165, DOI 10.1158/1078-0432.CCR-04-0022; Wigginton JM, 2001, J CLIN INVEST, V108, P51; Yang YG, 1998, J CLIN INVEST, V102, P2126, DOI 10.1172/JCI4992; ZHOU Q, IN PRESS J IMMUNOL	25	128	131	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					354	360		10.1038/nm1554	http://dx.doi.org/10.1038/nm1554			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17334371				2022-12-27	WOS:000244715700049
J	Lymperopoulos, A; Rengo, G; Funakoshi, H; Eckhart, AD; Koch, WJ				Lymperopoulos, Anastasios; Rengo, Giuseppe; Funakoshi, Hajime; Eckhart, Andrea D.; Koch, Walter J.			Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure	NATURE MEDICINE			English	Article							PLASMA NOREPINEPHRINE; CARDIAC-FUNCTION; RECEPTOR KINASE; IN-VIVO; ALPHA(2)-ADRENOCEPTOR SUBTYPES; CATECHOLAMINE RELEASE; MYOCARDIAL-INFARCTION; CHROMAFFIN CELLS; NERVOUS-SYSTEM; BETA-ARRESTINS	Cardiac overstimulation by the sympathetic nervous system (SNS) is a salient characteristic of heart failure, reflected by elevated circulating levels of catecholamines. The success of beta-adrenergic receptor (bAR) antagonists in heart failure argues for SNS hyperactivity being pathogenic; however, sympatholytic agents targeting alpha(2)AR-mediated catecholamine inhibition have been unsuccessful. By investigating adrenal adrenergic receptor signaling in heart failure models, we found molecular mechanisms to explain the failure of sympatholytic agents and discovered a new strategy to lower SNS activity. During heart failure, there is substantial alpha(2)AR dysregulation in the adrenal gland, triggered by increased expression and activity of G protein-coupled receptor kinase 2 (GRK2). Adrenal gland-specific GRK2 inhibition reversed a2AR dysregulation in heart failure, resulting in lowered plasma catecholamine levels, improved cardiac bAR signaling and function, and increased sympatholytic efficacy of a a2AR agonist. This is the first demonstration, to our knowledge, of a molecular mechanism for SNS hyperactivity in heart failure, and our study identifies adrenal GRK2 activity as a new sympatholytic target.	Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, George Zallie & Family Lab Cardiovasc Gene Therap, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Eugene Feiner Lab Vasc Biol & Trombosis, Dept Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Koch, WJ (corresponding author), Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA.	walter.koch@jefferson.edu	Lymperopoulos, Tasos/AAA-4366-2020; Rengo, Giuseppe/AAA-2870-2021; Rengo, Giuseppe/K-4963-2016	Rengo, Giuseppe/0000-0002-9701-0437; Rengo, Giuseppe/0000-0002-9701-0437; Lymperopoulos, Anastasios/0000-0001-9817-6319	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061690, P01HL075443, R01HL056205] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL075443, R01 HL56205, R01 HL61690] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal A, 2001, J AM COLL CARDIOL, V37, P1246, DOI 10.1016/S0735-1097(01)01121-4; Brede M, 2003, MOL ENDOCRINOL, V17, P1640, DOI 10.1210/me.2003-0035; Brede M, 2002, CIRCULATION, V106, P2491, DOI 10.1161/01.CIR.0000036600.39600.66; Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001; BYLUND DB, 1994, PHARMACOL REV, V46, P121; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Floras JS, 2002, CIRCULATION, V105, P1753, DOI 10.1161/01.CIR.0000013788.71817.16; Guyenet PG, 1997, AM J PHYSIOL-REG I, V273, pR1580, DOI 10.1152/ajpregu.1997.273.5.R1580; Harding VB, 2001, P NATL ACAD SCI USA, V98, P5809, DOI 10.1073/pnas.091102398; Hata JA, 2004, J MOL CELL CARDIOL, V37, P11, DOI 10.1016/j.yjmcc.2004.03.014; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115; Iaccarino G, 2005, EUR HEART J, V26, P1752, DOI 10.1093/eurheartj/ehi429; Iaccarino G, 1999, HYPERTENSION, V33, P396, DOI 10.1161/01.HYP.33.1.396; Iaccarino G, 1998, CIRCULATION, V98, P1783, DOI 10.1161/01.CIR.98.17.1783; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Lang CC, 1997, HYPERTENSION, V30, P392, DOI 10.1161/01.HYP.30.3.392; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Most P, 2004, J CLIN INVEST, V114, P1550, DOI 10.1172/JCI200421454; Neumeister A, 2005, PHARMACOGENET GENOM, V15, P143, DOI 10.1097/01213011-200503000-00002; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Pleger ST, 2005, MOL THER, V12, P1120, DOI 10.1016/j.ymthe.2005.08.002; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; Rich MW, 1997, J AM GERIATR SOC, V45, P968, DOI 10.1111/j.1532-5415.1997.tb02968.x; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Small KM, 2003, ANNU REV PHARMACOL, V43, P381, DOI 10.1146/annurev.pharmtox.43.100901.135823; Swedberg K, 2002, CIRCULATION, V105, P1797, DOI 10.1161/01.CIR.0000014212.04920.62; Swedberg K, 2000, J AM COLL CARDIOL, V35, P398, DOI 10.1016/S0735-1097(99)00565-3; Uhlen S, 1998, EUR J PHARMACOL, V343, P93, DOI 10.1016/S0014-2999(97)01521-5; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; WILSON SP, 1983, J NEUROSCI, V3, P1971; YOUNG JB, 1998, WILLIAMS TXB ENDOCRI, P665; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	40	185	191	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					315	323		10.1038/nm1553	http://dx.doi.org/10.1038/nm1553			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17322894				2022-12-27	WOS:000244715700044
J	Spira, A; Beane, JE; Shah, V; Steiling, K; Liu, G; Schembri, F; Gilman, S; Dumas, YM; Calner, P; Sebastiani, P; Sridhar, S; Beamis, J; Lamb, C; Anderson, T; Gerry, N; Keane, J; Lenburg, ME; Brody, JS				Spira, Avrum; Beane, Jennifer E.; Shah, Vishal; Steiling, Katrina; Liu, Gang; Schembri, Frank; Gilman, Sean; Dumas, Yves-Martine; Calner, Paul; Sebastiani, Paola; Sridhar, Sriram; Beamis, John; Lamb, Carla; Anderson, Timothy; Gerry, Norman; Keane, Joseph; Lenburg, Marc E.; Brody, Jerome S.			Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer	NATURE MEDICINE			English	Article							CELL; CLASSIFICATION; INTERLEUKIN-8; BRONCHOSCOPY; PROGNOSIS; REVEALS	Lung cancer is the leading cause of death from cancer in the US and the world(1). The high mortality rate (80-85% within 5 years) results, in part, from a lack of effective tools to diagnose the disease at an early stage2-4. Given that cigarette smoke creates a field of injury throughout the airway(5-11), we sought to determine if gene expression in histologically normal large-airway epithelial cells obtained at bronchoscopy from smokers with suspicion of lung cancer could be used as a lung cancer biomarker. Using a training set (n = 77) and gene-expression profiles from Affymetrix HG-U133A microarrays, we identified an 80-gene biomarker that distinguishes smokers with and without lung cancer. We tested the biomarker on an independent test set (n = 52), with an accuracy of 83% (80% sensitive, 84% specific), and on an additional validation set independently obtained from five medical centers (n = 35). Our biomarker had B90% sensitivity for stage 1 cancer across all subjects. Combining cytopathology of lower airway cells obtained at bronchoscopy with the biomarker yielded 95% sensitivity and a 95% negative predictive value. These findings indicate that gene expression in cytologically normal large-airway epithelial cells can serve as a lung cancer biomarker, potentially owing to a cancer-specific airway-wide response to cigarette smoke.	Boston Univ, Med Ctr, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Bioinformat Program, Boston, MA 02118 USA; Lahey Clin Fdn, Dept Med, Div Pulm, Burlington, MA 01805 USA; St James Hosp, Dublin 8, Ireland; Trinity Coll Dublin, Dublin, Ireland; Boston Univ, Med Ctr, Sch Publ Hlth, Boston, MA 02118 USA; Caritas St Elizabeths Med Ctr, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02135 USA; Boston Univ, Dept Genet & Genom, Boston, MA 02118 USA	Boston University; Boston University; Lahey Hospital & Medical Center; Trinity College Dublin; Trinity College Dublin; Boston University; St. Elizabeth's Medical Center; Tufts University; Boston University	Spira, A (corresponding author), Boston Univ, Med Ctr, Ctr Pulm, 715 Albany St, Boston, MA 02118 USA.	aspira@bu.edu	Lenburg, Marc/B-8027-2008; Keane, Joseph/AAX-6658-2021	Lenburg, Marc/0000-0002-5760-4708; Keane, Joseph/0000-0001-5313-385X; Brody, Jerome/0000-0002-2824-802X; Liu, Gang/0000-0001-9270-6796; Schembri, Frank/0000-0002-8172-710X; sebastiani, paola/0000-0001-6419-1545; Steiling, Katrina/0000-0001-9663-2093; Beane-Ebel, Jennifer/0000-0002-6699-2132; Spira, Avrum/0000-0003-1467-0489	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010377] Funding Source: NIH RePORTER; NCI NIH HHS [R21CA10650] Funding Source: Medline; NIEHS NIH HHS [ES10377] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arimura Y, 2004, ANTICANCER RES, V24, P4051; AUERBACH O, 1970, ARCH ENVIRON HEALTH, V21, P754, DOI 10.1080/00039896.1970.10667329; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gudmundsson G, 1999, EXP LUNG RES, V25, P217; Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763; Hirsch FR, 2002, EUR RESPIR J, V19, P1151, DOI 10.1183/09031936.02.00294102; Jett JR, 2005, CLIN CANCER RES, V11, p4988S, DOI 10.1158/1078-0432.CCR-05-9000; Kamio T, 2003, BLOOD, V102, P3317, DOI 10.1182/blood-2002-12-3656; MacRedmond R, 2006, THORAX, V61, P54, DOI 10.1136/thx.2004.037580; Mazzone P, 2002, CLIN CHEST MED, V23, P137, DOI 10.1016/S0272-5231(03)00065-0; Miyazu YM, 2005, CANCER RES, V65, P9623, DOI 10.1158/0008-5472.CAN-05-0976; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Postmus PE, 2005, CHEST, V128, P16, DOI 10.1378/chest.128.1.16; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Powell CA, 1999, CLIN CANCER RES, V5, P2025; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Salomaa ER, 2005, CHEST, V128, P2282, DOI 10.1378/chest.128.4.2282; Schreiber G, 2003, CHEST, V123, p115S, DOI 10.1378/chest.123.1_suppl.115S; Shimada K, 2005, BRIT J CANCER, V92, P1915, DOI 10.1038/sj.bjc.6602594; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Wachi S, 2005, BIOINFORMATICS, V21, P4205, DOI 10.1093/bioinformatics/bti688; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8	30	401	424	2	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					361	366		10.1038/nm1556	http://dx.doi.org/10.1038/nm1556			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17334370				2022-12-27	WOS:000244715700050
J	Yang, ZM; Chang, YJ; Yu, IC; Yeh, SY; Wu, CC; Miyamoto, H; Merry, DE; Sobue, G; Chen, LM; Chang, SS; Chang, CS				Yang, Zhiming; Chang, Yu-Jia; Yu, I-Chen; Yeh, Shuyuan; Wu, Cheng-Chia; Miyamoto, Hiroshi; Merry, Diane E.; Sobue, Gen; Chen, Lu-Min; Chang, Shu-Shi; Chang, Chawnshang			ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor	NATURE MEDICINE			English	Article							TRANSGENIC MOUSE MODEL; MOTOR-NEURON DEGENERATION; PROSTATE-CANCER; NUCLEAR INCLUSIONS; HSP90 INHIBITOR; LATE-ONSET; POLYGLUTAMINE; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; CELLS; MICE	Motor neuron degeneration resulting from the aggregation of the androgen receptor with an expanded polyglutamine tract (AR-polyQ) has been linked to the development of spinal and bulbar muscular atrophy (SBMA or Kennedy disease). Here we report that adding 5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one (ASC-J9) disrupts the interaction between AR and its coregulators, and also increases cell survival by decreasing AR-polyQ nuclear aggregation and increasing AR-polyQ degradation in cultured cells. Intraperitoneal injection of ASC-J9 into AR-polyQ transgenic SBMA mice markedly improved disease symptoms, as seen by a reduction in muscular atrophy. Notably, unlike previous approaches in which surgical or chemical castration was used to reduce SBMA symptoms, ASC-J9 treatment ameliorated SBMA symptoms by decreasing AR-97Q aggregation and increasing VEGF164 expression with little change of serum testosterone. Moreover, mice treated with ASC-J9 retained normal sexual function and fertility. Collectively, our results point to a better therapeutic and preventative approach to treating SBMA, by disrupting the interaction between AR and AR coregulators.	Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; Zhejiang Univ, Hangzhou 310009, Peoples R China; 2nd Hosp, Hangzhou 310009, Peoples R China; Taipei Med Univ & Hosp, Taipei 110, Taiwan; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Nagoya Univ, Nagoya, Aichi 4668550, Japan; China Med Univ & Hosp, Taichung 404, Taiwan	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Zhejiang University; Taipei Medical University; Taipei Medical University Hospital; Jefferson University; Nagoya University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, CS (corresponding author), Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@URMC.rochester.edu	Yang, Zhiming/C-3812-2012	Miyamoto, Hiroshi/0000-0001-7610-7769; Wu, Cheng-Chia/0000-0002-5908-0143; Yu, I-Chen/0000-0001-5270-9888; Chang, Yu-Jia/0000-0003-3978-3244; Chang, Chawnshang/0000-0001-8510-3516	NIDDK NIH HHS [DK067686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Beauchemin AMJ, 2001, BRAIN RES BULL, V56, P285, DOI 10.1016/S0361-9230(01)00583-4; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hostein I, 2001, CANCER RES, V61, P4003; Katsuno M, 2004, NEURON, V41, P677, DOI 10.1016/S0896-6273(04)00110-2; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kennedy WR, 1998, NEUROLOGY, V50, P583, DOI 10.1212/WNL.50.3.583; LA SA, 1991, NATURE, V352, P77; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Mandrusiak LM, 2003, HUM MOL GENET, V12, P1497, DOI 10.1093/hmg/ddg161; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; Ohtsu H, 2002, J MED CHEM, V45, P5037, DOI 10.1021/jm020200g; Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008-5472.CAN-04-4458; RINGEL SP, 1978, MUSCLE NERVE, V1, P297, DOI 10.1002/mus.880010406; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Solit DB, 2002, CLIN CANCER RES, V8, P986; Sopher BL, 2004, NEURON, V41, P687, DOI 10.1016/S0896-6273(04)00082-0; Tarlac V, 2003, J NEUROSCI RES, V74, P406, DOI 10.1002/jnr.10746; Terao S, 1996, ACTA NEUROPATHOL, V92, P109, DOI 10.1007/s004010050497; Thin TH, 2002, J BIOL CHEM, V277, P36499, DOI 10.1074/jbc.M202824200; Walcott JL, 2002, J BIOL CHEM, V277, P50855, DOI 10.1074/jbc.M209466200; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	37	129	142	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					348	353		10.1038/nm1547	http://dx.doi.org/10.1038/nm1547			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17334372				2022-12-27	WOS:000244715700048
J	Beck, AT				Beck, Aaron T.			How an anomalous finding led to a new system of psychotherapy	NATURE MEDICINE			English	Editorial Material							COGNITIVE-BEHAVIOR THERAPY; DYSFUNCTIONAL ATTITUDES; MAJOR DEPRESSION; MEDICATIONS; PREVENTION		Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania	Beck, AT (corresponding author), Univ Penn, Dept Psychiat, 3535 Market St, Philadelphia, PA 19104 USA.	abeck@mail.med.upenn.edu						Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; DeRubeis RJ, 1999, AM J PSYCHIAT, V156, P1007; Gloaguen V, 1998, J AFFECT DISORDERS, V49, P59, DOI 10.1016/S0165-0327(97)00199-7; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Hollon SD, 2005, ARCH GEN PSYCHIAT, V62, P417, DOI 10.1001/archpsyc.62.4.417; Meyer JH, 2004, ARCH GEN PSYCHIAT, V61, P1271, DOI 10.1001/archpsyc.61.12.1271; Meyer JH, 2003, AM J PSYCHIAT, V160, P90, DOI 10.1176/appi.ajp.160.1.90	8	13	14	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1139	1141		10.1038/nm1006-1139	http://dx.doi.org/10.1038/nm1006-1139			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024209				2022-12-27	WOS:000241102200028
J	de Jong, MD; Simmons, CP; Thanh, TT; Hien, VM; Smith, GJD; Chau, TNB; Hoang, DM; Chau, NVV; Khanh, TH; Dong, VC; Qui, PT; Van Cam, B; Ha, DQ; Guan, Y; Peiris, JSM; Chinh, NT; Hien, TT; Farrar, J				de Jong, Menno D.; Simmons, Cameron P.; Thanh, Tran Tan; Hien, Vo Minh; Smith, Gavin J. D.; Chau, Tran Nguyen Bich; Hoang, Dang Minh; Chau, Nguyen Van Vinh; Khanh, Truong Huu; Dong, Vo Cong; Qui, Phan Tu; Van Cam, Bach; Ha, Do Quang; Guan, Yi; Peiris, J. S. Malik; Chinh, Nguyen Tran; Hien, Tran Tinh; Farrar, Jeremy			Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia	NATURE MEDICINE			English	Article							BRONCHIAL EPITHELIAL-CELLS; CYTOKINE RESPONSES; HIGH VIRULENCE; HUMAN-DISEASE; VIRUS; INFECTION; MICE; A/VIETNAM/1203/04; MACROPHAGES; ADAPTATION	Avian influenza A (H5N1) viruses cause severe disease in humans(1,2), but the basis for their virulence remains unclear. In vitro and animal studies indicate that high and disseminated viral replication is important for disease pathogenesis(3-5). Laboratory experiments suggest that virus-induced cytokine dysregulation may contribute to disease severity(6-9). To assess the relevance of these findings for human disease, we performed virological and immunological studies in 18 individuals with H5N1 and 8 individuals infected with human influenza virus subtypes. Influenza H5N1 infection in humans is characterized by high pharyngeal virus loads and frequent detection of viral RNA in rectum and blood. Viral RNA in blood was present only in fatal H5N1 cases and was associated with higher pharyngeal viral loads. We observed low peripheral blood T-lymphocyte counts and high chemokine and cytokine levels in H5N1-infected individuals, particularly in those who died, and these correlated with pharyngeal viral loads. Genetic characterization of H5N1 viruses revealed mutations in the viral polymerase complex associated with mammalian adaptation and virulence. Our observations indicate that high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment.	Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; Hosp Trop Dis, Ho Chi Minh City, Vietnam; Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Pediat Hosp 1, Ho Chi Minh City, Vietnam; Pediat Hosp 2, Ho Chi Minh City, Vietnam	University of Oxford; University of Hong Kong	de Jong, MD (corresponding author), Univ Oxford, Clin Res Unit, 190 Ben Ham Tu, Ho Chi Minh City, Vietnam.	dejongmd@gmail.com	Simmons, Cameron P/ABA-3896-2021; Farrar, Jeremy J./HGA-7610-2022; Peiris, Joseph Sriyal Malik/C-4380-2009	Simmons, Cameron P/0000-0002-9039-7392; Tran Tan, Thanh/0000-0002-8096-7750; Farrar, Jeremy/0000-0002-2700-623X; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Guan, Yi/0000-0001-6057-9243; Smith, Gavin JD/0000-0001-5031-468X	Wellcome Trust [074636] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; CHEN H, 2006, P NATL ACAD SCI US; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chotpitayasunondh T, 2005, EMERG INFECT DIS, V11, P201, DOI 10.3201/eid1102.041061; Chutinimitkul S, 2006, EMERG INFECT DIS, V12, P1041, DOI 10.3201/eid1206.060227; de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Gabriel G, 2005, P NATL ACAD SCI USA, V102, P18590, DOI 10.1073/pnas.0507415102; Govorkova EA, 2005, J VIROL, V79, P2191, DOI 10.1128/JVI.79.4.2191-2198.2005; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; JORENS PG, 1992, CYTOKINE, V4, P592, DOI 10.1016/1043-4666(92)90025-M; Lipatov AS, 2005, J GEN VIROL, V86, P1121, DOI 10.1099/vir.0.80663-0; Maines TR, 2005, J VIROL, V79, P11788, DOI 10.1128/JVI.79.18.11788-11800.2005; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Openshaw PJM, 2004, CLIN EXP IMMUNOL, V136, P11, DOI 10.1111/j.1365-2249.2004.02448.x; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Salomon R, 2006, J EXP MED, V203, P689, DOI 10.1084/jem.20051938; Sauty A, 1999, J IMMUNOL, V162, P3549; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Smith GJD, 2006, VIROLOGY, V350, P258, DOI 10.1016/j.virol.2006.03.048; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Tumpey TM, 2000, J VIROL, V74, P6105, DOI 10.1128/JVI.74.13.6105-6116.2000; Yen HL, 2005, J INFECT DIS, V192, P665, DOI 10.1086/432008; Zhou JF, 2006, J INFECT DIS, V193, P945, DOI 10.1086/500954	29	1403	1466	1	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1203	1207		10.1038/nm1477	http://dx.doi.org/10.1038/nm1477			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16964257	Green Published, Green Accepted			2022-12-27	WOS:000241102200039
J	Randall, JB; Munsell, LY; Morris, JC; Swarm, R; Yarasheski, KE; Holtzman, DM				Bateman, Randall J.; Munsell, Ling Y.; Morris, John C.; Swarm, Robert; Yarasheski, Kevin E.; Holtzman, David M.			Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; GAMMA-SECRETASE INHIBITOR; MUSCLE PROTEIN-METABOLISM; ALZHEIMERS-DISEASE; A-BETA; MOUSE MODEL; GENE; PLASMA; TRANSPORT; INSERTION	Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-b (A beta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce A beta indicate dysregulation of production or clearance of A beta. Whether dysregulation of A beta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, > 99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of A beta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.	Washington Univ, Sch Med, Dept Neurol, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Randall, JB (corresponding author), Washington Univ, Sch Med, Dept Neurol, Alzheimer Dis Res Ctr, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	batemanr@neuro.wustl.edu	Yarasheski, Kevin/AAC-7450-2021; Morris, John C/A-1686-2012	Yarasheski, Kevin/0000-0001-5436-2451; Bateman, Randall/0000-0002-7729-1702	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681, K08AG027091] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000036, P41 RR000954, M01 RR00036, RR000954] Funding Source: Medline; NIA NIH HHS [L30 AG024455, K08 AG027091-01, P50 AG05681, P50 AG005681, L30 AG024455-01, K08 AG027091] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-05S2, P30 DK056341-06, P30 DK056341, DK056341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cirrito JR, 2003, J NEUROSCI, V23, P8844; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Elias N, 2000, ARTERIOSCL THROM VAS, V20, P1309, DOI 10.1161/01.ATV.20.5.1309; Fishman RA., 1992, CEREBROSPINAL FLUID; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Merchak A, 2000, J MASS SPECTROM, V35, P734, DOI 10.1002/1096-9888(200006)35:6<734::AID-JMS2>3.0.CO;2-H; OWEN F, 1989, LANCET, V1, P51; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Poduslo JF, 2001, NEUROBIOL DIS, V8, P555, DOI 10.1006/nbdi.2001.0402; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saido TC, 2003, ABETA METABOLISM ALZ; SANPIETRO A, 1953, J BIOL CHEM, V201, P457; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; Williams MA, 2002, NEUROLOGY, V58, P1859, DOI 10.1212/WNL.58.12.1859; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Wolfe RR, 2005, CURR OPIN CLIN NUTR, V8, P61, DOI 10.1097/00075197-200501000-00009; Wolfe RR., 2005, ISOTOPE TRACERS META, V2; Yarasheski KE, 1998, AM J PHYSIOL-ENDOC M, V275, pE577, DOI 10.1152/ajpendo.1998.275.4.E577; Yarasheski KE, 2003, J GERONTOL A-BIOL, V58, P918; YARASHESKI KE, 1992, BIOL MASS SPECTROM, V21, P486, DOI 10.1002/bms.1200211004; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582	27	422	447	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					856	861		10.1038/nm1438	http://dx.doi.org/10.1038/nm1438			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799555	Green Accepted			2022-12-27	WOS:000238862800076
J	Ferby, I; Reschke, M; Kudlacek, O; Knyazev, P; Pante, G; Amann, K; Sommergruber, W; Kraut, N; Ullrich, A; Fassler, R; Klein, R				Ferby, Ingvar; Reschke, Markus; Kudlacek, Oliver; Knyazev, Pjotr; Pante, Guido; Amann, Kerstin; Sommergruber, Wolfgang; Kraut, Norbert; Ullrich, Axel; Faessler, Reinhard; Klein, R. diger			Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; ENDOGENOUS INHIBITOR; TARGETED DISRUPTION; TYROSINE KINASE; TRANSGENIC MICE; CELL-MIGRATION; FACTOR-ALPHA; EXPRESSION; GENE; DIFFERENTIATION	The growing number of recently identified negative feedback regulators of receptor tyrosine kinases (RTKs) highlights the importance of signal attenuation and modulation for correct signaling outcome. Mitogen-inducible gene 6 (Mig6 also known as RALT or Gene 33) is a multiadaptor protein thought to be involved in the regulation of RTK and stress signaling(1-3). Here, we show that deletion of the mouse gene encoding Mig6 (designated Errfi1, which stands for ERBB receptor feedback inhibitor 1) causes hyperactivation of endogenous epidermal growth factor receptor (EGFR) and sustained signaling through the mitogen-activated protein kinase (MAPK) pathway, resulting in overproliferation and impaired differentiation of epidermal keratinocytes. Furthermore, Errfi1(-/-) mice develop spontaneous tumors in various organs and are highly susceptible to chemically induced formation of skin tumors. A tumor-suppressive role for Mig6 is supported by our finding that MIG6 is downregulated in various human cancers. Inhibition of endogenous Egfr signaling with the Egfr inhibitor gefitinib (Iressa) or replacement of wild-type Egfr with the kinase-deficient protein encoded by the hypomorphic Egfr(wa 2) allele completely rescued skin defects in Erffi1(-/-) mice. Carcinogen-induced tumors displayed by Errfi1(-/-) mice were highly sensitive to gefitinib. These results indicate that Mig6 is a specific negative regulator of Egfr signaling in skin morphogenesis and is a novel tumor suppressor of Egfr-dependent carcinogenesis.	Max Planck Inst Neurobiol, Dept Mol Neurobiol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Biol Mol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; Boehringer Ingelheim Austria GmbH, A-1121 Vienna, Austria	Max Planck Society; Max Planck Society; Max Planck Society; University of Erlangen Nuremberg; Boehringer Ingelheim	Klein, R (corresponding author), Max Planck Inst Neurobiol, Dept Mol Neurobiol, Klopferspitz 18, D-82152 Martinsried, Germany.	rklein@neuro.mpg.de	Klein, Ruediger/C-6147-2008; Ferby, Ingvar/B-7895-2008	Klein, Ruediger/0000-0002-3109-0163; Ferby, Ingvar/0000-0002-3435-1728; Kudlacek, Oliver/0000-0002-3086-8551	Worldwide Cancer Research [09-0228] Funding Source: Medline	Worldwide Cancer Research		Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Ballaro C, 2005, EMBO REP, V6, P755, DOI 10.1038/sj.embor.7400458; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CHU DTW, 1988, J BIOL CHEM, V263, P13007; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Dlugosz AA, 1997, CANCER RES, V57, P3180; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Koshikawa K, 2004, HEPATO-GASTROENTEROL, V51, P186; Krampert M, 2005, J BIOL CHEM, V280, P23844, DOI 10.1074/jbc.M412212200; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013; Savontaus M, 1996, AM J PATHOL, V149, P2169; Shen-Ong GL, 2003, CANCER RES, V63, P3296; Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhang YW, 2005, P NATL ACAD SCI USA, V102, P11740, DOI 10.1073/pnas.0505171102	30	196	206	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					568	573		10.1038/nm1401	http://dx.doi.org/10.1038/nm1401			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16648858				2022-12-27	WOS:000238149100041
J	Weathington, NM; van Houwelingen, AH; Noerager, BD; Jackson, PL; Kraneveld, AD; Galin, FS; Folkerts, G; Nijkamp, FP; Blalock, JE				Weathington, NM; van Houwelingen, AH; Noerager, BD; Jackson, PL; Kraneveld, AD; Galin, FS; Folkerts, G; Nijkamp, FP; Blalock, JE			A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation	NATURE MEDICINE			English	Article							SMOKE-INDUCED EMPHYSEMA; NEUTROPHIL CHEMOATTRACTANT; CHEMOTACTIC ACTIVITY; INTERLEUKIN-8; COLLAGEN; CHEMOKINES; PROLINE; ANALOGS; CORNEA; COPD	We describe the tripeptide neutrophil chemoattractant N-acetyl Pro-Gly-Pro (PGP), derived from the breakdown of extracellular matrix (ECM), which shares sequence and structural homology with an important domain on alpha chemokines. PGP caused chemotaxis and production of superoxide through CXC receptors, and administration of peptide caused recruitment of neutrophils (PMNs) into lungs of control, but not CXCR2-deficient mice. PGP was generated in mouse lung after exposure to lipopolysaccharide, and in vivo and in vitro blockade of PGP with monoclonal antibody suppressed PMN responses as much as chemokine-specific monoclonal antibody. Extended PGP treatment caused alveolar enlargement and right ventricular hypertrophy in mice. PGP was detectable in substantial concentrations in a majority of bronchoalveolar lavage samples from individuals with chronic obstructive pulmonary disease, but not control individuals. Thus, PGP's activity links degradation of ECM with neutrophil recruitment in airway inflammation, and PGP may be a biomarker and therapeutic target for neutrophilic inflammatory diseases.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, NL-3584 CA Utrecht, Netherlands	University of Alabama System; University of Alabama Birmingham; Utrecht University	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 1918 Univ Blvd, Birmingham, AL 35294 USA.	blalock@uab.edu	Kraneveld, Aletta D/J-3351-2016	Kraneveld, Aletta D/0000-0001-9819-383X; Blalock, J. Edwin/0000-0001-5303-8123	NHLBI NIH HHS [T32HL007553, HL68806] Funding Source: Medline; NIEHS NIH HHS [F30 ES13874] Funding Source: Medline; NIGMS NIH HHS [T32 GM008361, T32 GM63490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553, R01HL068806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES013874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063490, T32GM008361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137; Adair-Kirk TL, 2003, J IMMUNOL, V171, P398, DOI 10.4049/jimmunol.171.1.398; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Beeh KM, 2003, CHEST, V123, P1240, DOI 10.1378/chest.123.4.1240; Belvisi MG, 2003, INFLAMM RES, V52, P95, DOI 10.1007/s000110300020; Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340; Brown J.H., 2001, GOODMAN GILMANS PHAR, V10th ed., P10; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHANG C, 1970, P SOC EXP BIOL MED, V134, P22; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736; Downs JT, 2001, J IMMUNOL METHODS, V247, P25, DOI 10.1016/S0022-1759(00)00302-1; Feniger-Barish R, 2003, BIOCHEMISTRY-US, V42, P2874, DOI 10.1021/bi026783d; Foronjy RF, 2003, AM J PHYSIOL-LUNG C, V284, pL727, DOI 10.1152/ajplung.00349.2002; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haddox JL, 1999, INVEST OPHTH VIS SCI, V40, P2427; Hauert AB, 2002, INT J BIOCHEM CELL B, V34, P838, DOI 10.1016/S1357-2725(02)00010-9; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; KOBZIK L, 1999, ROBBINS PATHOLOGIC B; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LASKIN DL, 1986, J LEUKOCYTE BIOL, V39, P255, DOI 10.1002/jlb.39.3.255; Lee YC, 2001, BIOPOLYMERS, V58, P548, DOI 10.1002/1097-0282(200105)58:6<548::AID-BIP1030>3.0.CO;2-B; Mahler DA, 2004, CHEST, V126, P926, DOI 10.1378/chest.126.3.926; Miller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7; Nishimura T, 2003, CIRCULATION, V108, P1640, DOI 10.1161/01.CIR.0000087592.47401.37; Otterness IG, 1999, MATRIX BIOL, V18, P331, DOI 10.1016/S0945-053X(99)00026-8; PFISTER RR, 1993, INVEST OPHTH VIS SCI, V34, P2297; PFISTER RR, 1995, INVEST OPHTH VIS SCI, V36, P1306; PFISTER RR, 1988, INVEST OPHTH VIS SCI, V29, P955; Pfister RR, 1998, INVEST OPHTH VIS SCI, V39, P1744; POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; RILEY DJ, 1988, EXP LUNG RES, V14, P549, DOI 10.3109/01902148809087827; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Selman M, 1996, AM J PHYSIOL-LUNG C, V271, pL734, DOI 10.1152/ajplung.1996.271.5.L734; SENIOR RM, 1989, AM J RESP CELL MOL, V1, P479, DOI 10.1165/ajrcmb/1.6.479; Senior RM, 1998, AM J RESP CRIT CARE, V157, pS139, DOI 10.1164/ajrccm.157.4.nhlbi-12; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Turino GM, 2002, CHEST, V122, P1058, DOI 10.1378/chest.122.3.1058; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Weathington NM, 2005, CURR TOP MEMBR, V55, P49, DOI 10.1016/S1063-5823(04)55002-0; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	50	350	365	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					317	323		10.1038/nm1361	http://dx.doi.org/10.1038/nm1361			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474398				2022-12-27	WOS:000235802900031
J	Dzhala, VI; Talos, DM; Sdrulla, DA; Brumback, AC; Mathews, GC; Benke, TA; Delpire, E; Jensen, FE; Staley, KJ				Dzhala, VI; Talos, DM; Sdrulla, DA; Brumback, AC; Mathews, GC; Benke, TA; Delpire, E; Jensen, FE; Staley, KJ			NKCC1 transporter facilitates seizures in the developing brain	NATURE MEDICINE			English	Article							CLINICAL NEONATAL SEIZURES; POSTNATAL RAT BRAINS; K-CL COTRANSPORTERS; NA-K-2CL COTRANSPORTER; EXCITATORY ACTIONS; NEURONAL COMMUNICATION; DEVELOPMENTAL-CHANGES; EPILEPTIFORM ACTIVITY; IN-VITRO; GABA	During development, activation of Cl--permeable GABA(A) receptors ( GABA(A)-R) excites neurons as a result of elevated intracellular Cl- levels and a depolarized Cl- equilibrium potential ( E-Cl). GABA becomes inhibitory as net outward neuronal transport of Cl- develops in a caudal- rostral progression. In line with this caudal- rostral developmental pattern, GABAergic anticonvulsant compounds inhibit motor manifestations of neonatal seizures but not cortical seizure activity. The Na+-K+-2Cl(-) cotransporter ( NKCC1) facilitates the accumulation of Cl- in neurons. The NKCC1 blocker bumetanide shifted ECl negative in immature neurons, suppressed epileptiform activity in hippocampal slices in vitro and attenuated electrographic seizures in neonatal rats in vivo. Bumetanide had no effect in the presence of the GABAA-R antagonist bicuculline, nor in brain slices from NKCC1-knockout mice. NKCC1 expression level versus expression of the Cl--extruding transporter ( KCC2) in human and rat cortex showed that Cl- transport in perinatal human cortex is as immature as in the rat. Our results provide evidence that NKCC1 facilitates seizures in the developing brain and indicate that bumetanide should be useful in the treatment of neonatal seizures.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pediat, Denver, CO 80262 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Boston Children's Hospital; Harvard Medical School; Vanderbilt University; Vanderbilt University	Staley, KJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA.	kevin.staley@uchsc.edu	Brumback, Audrey C./A-8499-2008; Mathews, Gregory C/A-9660-2009	Brumback, Audrey C./0000-0002-4904-4368; Benke, Timothy/0000-0002-6969-5061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034700, R01NS040109, R01NS034700, R56NS031718, R29NS031718, R01NS031718, R01NS034360, R01NS036758, P01NS038475] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-43368] Funding Source: Medline; NINDS NIH HHS [NS38475, NS36758, R56 NS031718, NS34700, NS34360, NS31718, NS40109] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baram TZ, 2003, ANN NEUROL, V54, P701, DOI 10.1002/ana.10833; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Brunquell PJ, 2002, J PEDIATR-US, V140, P707, DOI 10.1067/mpd.2002.124773; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; CONNELL J, 1989, ARCH DIS CHILD-FETAL, V64, P459, DOI 10.1136/adc.64.4_Spec_No.459; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Dzhala VI, 2004, J NEUROSCI, V24, P8896, DOI 10.1523/JNEUROSCI.3112-04.2004; Dzhala VI, 2003, J NEUROSCI, V23, P1840; Dzhala VI, 2003, J NEUROSCI, V23, P7873; Haglund MM, 2005, J NEUROPHYSIOL, V94, P907, DOI 10.1152/jn.00944.2004; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Hesdorffer DC, 2001, ANN NEUROL, V50, P458, DOI 10.1002/ana.1136; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; Holmes GL, 2004, MENT RETARD DEV D R, V10, P101, DOI 10.1002/mrdd.20019; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; JENSEN FE, 1992, EPILEPSIA, V33, P971, DOI 10.1111/j.1528-1157.1992.tb01746.x; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kanaka C, 2001, NEUROSCIENCE, V104, P933, DOI 10.1016/S0306-4522(01)00149-X; Khalilov I, 1999, DEV NEUROSCI-BASEL, V21, P310, DOI 10.1159/000017380; Khazipov R, 2004, EUR J NEUROSCI, V19, P590, DOI 10.1111/j.0953-816X.2003.03152.x; Leinekugel X, 2002, SCIENCE, V296, P2049, DOI 10.1126/science.1071111; Lopez AAB, 1997, NEW MEX HIST REV, V72, P272; Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.0.CO;2-5; Owens DF, 1996, J NEUROSCI, V16, P6414; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Painter MJ, 1999, NEW ENGL J MED, V341, P485, DOI 10.1056/NEJM199908123410704; PAINTER MJ, 1986, PEDIATR CLIN N AM, V33, P91; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Plotkin MD, 1997, J NEUROBIOL, V33, P781, DOI 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NEU6>3.0.CO;2-5; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Ronen GM, 1999, J PEDIATR-US, V134, P71, DOI 10.1016/S0022-3476(99)70374-4; Sanchez RM, 2005, J NEUROSCI, V25, P3442, DOI 10.1523/JNEUROSCI.0204-05.2005; Sankar R, 2005, NEUROLOGY, V64, P776, DOI 10.1212/01.WNL.0000157320.78071.6D; SCHER MS, 1993, PEDIATRICS, V91, P128; Scher MS, 2003, PEDIATR NEUROL, V28, P277, DOI 10.1016/S0887-8994(02)00621-5; Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5; STALEY K, 1992, NEUROSCI LETT, V146, P105, DOI 10.1016/0304-3940(92)90183-8; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; Stein V, 2004, J COMP NEUROL, V468, P57, DOI 10.1002/cne.10983; Stringer JL, 1997, BRAIN RES, V745, P328, DOI 10.1016/S0006-8993(96)01253-X; Sullivan JE, 1996, CLIN PHARMACOL THER, V60, P405, DOI 10.1016/S0009-9236(96)90197-6; Sung KW, 2000, J NEUROSCI, V20, P7531; SWANN JW, 2002, PROG BRAIN RES, V147, P347; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; Ulfig N, 1998, CELL TISSUE RES, V291, P433, DOI 10.1007/s004410051013; Wang C, 2002, DEV BRAIN RES, V139, P59, DOI 10.1016/S0165-3806(02)00536-9; Yamada J, 2004, J PHYSIOL-LONDON, V557, P829, DOI 10.1113/jphysiol.2004.062471	50	682	702	1	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1205	1213		10.1038/nm1301	http://dx.doi.org/10.1038/nm1301			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227993				2022-12-27	WOS:000233115400033
J	Kusano, KF; Pola, R; Murayama, T; Curry, C; Kawamoto, A; Iwakura, A; Shintani, S; Ii, M; Asai, J; Tkebuchava, T; Thorne, T; Takenaka, H; Aikawa, R; Goukassian, D; von Samson, P; Hamada, H; Yoon, YS; Silver, M; Eaton, E; Ma, H; Heyd, L; Kearney, M; Munger, W; Porter, JA; Kishore, R; Losordo, DW				Kusano, KF; Pola, R; Murayama, T; Curry, C; Kawamoto, A; Iwakura, A; Shintani, S; Ii, M; Asai, J; Tkebuchava, T; Thorne, T; Takenaka, H; Aikawa, R; Goukassian, D; von Samson, P; Hamada, H; Yoon, YS; Silver, M; Eaton, E; Ma, H; Heyd, L; Kearney, M; Munger, W; Porter, JA; Kishore, R; Losordo, DW			Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; MOTOR-NEURON INDUCTION; FLOOR PLATE; TRANSPLANTATION; CARDIOMYOCYTES; ANGIOGENESIS; INFARCTION; EXPRESSION; INJURY; BLIND	Sonic hedgehog ( Shh) is a crucial regulator of organ development during embryogenesis. We investigated whether intramyocardial gene transfer of naked DNA encoding human Shh ( phShh) could promote a favorable effect on recovery from acute and chronic myocardial ischemia in adult animals, not only by promoting neovascularization, but by broader effects, consistent with the role of this morphogen in embryogenesis. After Shh gene transfer, the hedgehog pathway was upregulated in mammalian fibroblasts and cardiomyocytes. This resulted in preservation of left ventricular function in both acute and chronic myocardial ischemia by enhanced neovascularization, and reduced fibrosis and cardiac apoptosis. Shh gene transfer also enhanced the contribution of bone marrow-derived endothelial progenitor cells to myocardial neovascularization. These data suggest that Shh gene therapy may have considerable therapeutic potential in individuals with acute and chronic myocardial ischemia by triggering expression of multiple trophic factors and engendering tissue repair in the adult heart.	Tufts Univ, Sch Med, St Elizabeth Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Cattolica Sacro Cuore, A Gemelli Univ Hosp, Dept Med, Sch Med, I-00168 Rome, Italy; Curis Inc, Cambridge, MA 02138 USA	St. Elizabeth's Medical Center; Tufts University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Losordo, DW (corresponding author), Tufts Univ, Sch Med, St Elizabeth Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA.	douglas.losordo@tufts.edu	Losordo, Douglas W/F-9782-2011; Asai, Jun/AAD-4796-2020	Asai, Jun/0000-0002-7610-0820; Goukassian, David/0000-0001-5270-5270; Losordo, Douglas/0000-0002-6857-7506; Pola, Roberto/0000-0001-5224-2931; Kawamoto, Atsuhiko/0000-0002-2733-8015	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL053354, R01HL057516, R01HL080137, R37HL053354, R01HL063414] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53354, HL 57516, HL P01 66957, HL 63414, HL 80137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Aikawa R, 2000, CIRCULATION, V102, P2873; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; Fortuin FD, 2003, AM J CARDIOL, V92, P436, DOI 10.1016/S0002-9149(03)00661-1; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gepstein L, 1998, CIRCULATION, V98, P2055, DOI 10.1161/01.CIR.98.19.2055; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Goukassian DA, 2003, CIRC RES, V93, P162, DOI 10.1161/01.RES.0000082980.94211.3A; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KASS DA, 1987, CIRCULATION, V76, P1422, DOI 10.1161/01.CIR.76.6.1422; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Vale PR, 2001, CIRCULATION, V103, P2138; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zardoya R, 1996, TRENDS GENET, V12, P496, DOI 10.1016/S0168-9525(96)20014-9	39	249	267	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1197	1204		10.1038/nm1313	http://dx.doi.org/10.1038/nm1313			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16244652				2022-12-27	WOS:000233115400032
J	Pentz, RD; Cohen, CB; Wicclair, M; DeVita, MA; Flamm, AL; Youngner, SJ; Hamric, AB; McCabe, MS; Glover, JJ; Kittiko, WJ; Kinlaw, K; Keller, J; Asch, A; Kavanagh, JJ; Arap, W				Pentz, RD; Cohen, CB; Wicclair, M; DeVita, MA; Flamm, AL; Youngner, SJ; Hamric, AB; McCabe, MS; Glover, JJ; Kittiko, WJ; Kinlaw, K; Keller, J; Asch, A; Kavanagh, JJ; Arap, W			Ethics guidelines for research with the recently dead	NATURE MEDICINE			English	Editorial Material							CANCER; OVERSIGHT; POLICY	The objective of the multidisciplinary expert Consensus Panel on Research with the Recently Dead ( CPRRD) was to craft ethics guidelines for research with the recently dead. The CPRRD recommends that research with the recently dead: ( i) receive scientific and ethical review and oversight; ( ii) involve the community of potential research subjects; ( iii) be coordinated with organ procurement organizations; ( iv) not conflict with organ donation or required autopsy; ( v) use procedures respectful of the dead; ( vi) be restricted to one procedure per day; ( vii) preferably be authorized by first-person consent, though both general advance research directives and surrogate consent are acceptable; ( viii) protect confidentiality; ( ix) not impose costs on subjects' estates or next of kin and not involve payment; ( x) clearly explain ultimate disposition of the body.	Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA; Georgetown Univ, Kennedy Inst Eth, Washington, DC USA; Univ Pittsburgh, Ctr Bioeth & Hlth Law, Pittsburgh, PA 15213 USA; W Virginia Univ, Dept Philosophy, Morgantown, WV 26506 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Bioeth, Cleveland, OH 44106 USA; Univ Virginia, Sch Nursing, Charlottesville, VA 22908 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Colorado, Ctr Bioeth & Humanities, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO 80262 USA; Childrens Oncol Grp, Arcadia, CA 91066 USA; Emory Univ, Ctr Eth, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Atlanta, GA 30322 USA; Yeshiva Univ, Wurzweiler Sch Social Work, New York, NY 10033 USA	Emory University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; West Virginia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Case Western Reserve University; University of Virginia; Memorial Sloan Kettering Cancer Center; University of Colorado System; University of Colorado Denver; Children's Oncology Group (COG); Emory University; Emory University; Yeshiva University	Pentz, RD (corresponding author), Emory Univ, Winship Canc Ctr, 1365 C Clifton Rd NE,C30008, Atlanta, GA 30322 USA.	rebecca.pentz@emoryhealthcare.org			NATIONAL CANCER INSTITUTE [R13CA108423] Funding Source: NIH RePORTER; NCI NIH HHS [1R13CA108423] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKABAYASHI A, 1991, BIOLAW, V2, pS531; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Aziz M. Ashraf, 2002, Anatomical Record, V269, P20, DOI 10.1002/ar.10046; BAKER R, 1989, ANN INTERN MED, V110, P88, DOI 10.7326/0003-4819-110-1-88_1; Bartucci M R, 1987, J Neurosci Nurs, V19, P305; BATTEN HL, 1987, HEALTH AFFAIR, V6, P35, DOI 10.1377/hlthaff.6.2.35; BEYLEVELD D, 2001, HUMAN DIGNIT BIOETHI; BOYCE N, 2004, US NEWS WORLD R 0112; BRANDT AM, 1996, KENNEDY INST ETHIC J, V6, P242; BRODER JM, 2004, NY TIMES        0312; Browne D C, 2001, Matern Child Health J, V5, P215, DOI 10.1023/A:1013077404562; Carson Ronald A, 1981, IRB, V3, P5, DOI 10.2307/3563807; Churchill Larry R, 2003, IRB, V25, P1, DOI 10.2307/3564297; Cohen CB, 2002, KENNEDY INST ETHIC J, V12, P47, DOI 10.1353/ken.2002.0002; COLLER BS, 1988, ANN INTERN MED, V109, P635, DOI 10.7326/0003-4819-109-8-635; COLLER BS, 1989, CLIN RES, V37, P487; Corbie-Smith G, 2003, J GEN INTERN MED, V18, P531, DOI 10.1046/j.1525-1497.2003.21061.x; Couzin J, 2003, SCIENCE, V299, P29; DEFRIAS EC, 1980, J PEDIATR, V96, P153; DICKSON D, 1988, SCIENCE, V239, P1370, DOI 10.1126/science.3347837; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; FEINBERG J, 1985, HASTINGS CENT REP, V15, P31, DOI 10.2307/3561915; FIRESTONE D, 2002, NY TIMES        0217; Gaylin Willard, 1974, Harpers (N Y N Y), V249, P23; Ghorpade A, 2005, J NEUROIMMUNOL, V163, P135, DOI 10.1016/j.jneuroim.2005.01.021; Guterman Lila, 2003, Chron High Educ, V49, pA13; KOLFF J, 1984, J THORAC CARDIOV SUR, V87, P825; KOTULAK R, 2003, CHICAGO TRIBUNE 0515; LAPUMA J, 1988, ANN INTERN MED, V109, P606, DOI 10.7326/0003-4819-109-8-606; MAUGH TJ, 1979, SCIENCE, V206, P5; Metcalf P., 1991, CELEBRATIONS DEATH A; National Bioethics Advisory Commission, 2001, ETH POL ISS RES INV; Nelkin D, 1998, AM J LAW MED, V24, P261; PELLETIER M, 1992, J ADV NURS, V17, P90, DOI 10.1111/j.1365-2648.1992.tb01822.x; PENTZ RD, 2003, HASTINGS CENT REP, V33, P2; Regehr C, 2004, J CLIN NURS, V13, P430, DOI 10.1111/j.1365-2702.2004.00905.x; Robertson John A, 1980, IRB, V2, P4, DOI 10.2307/3563921; Schold C, 2003, CRIT CARE MED, V31, pS391, DOI 10.1097/01.CMM.0000065204.84978.27; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shapiro R.S., 2002, CURR OPIN ORGAN TRAN, V7, P375; Sharp RR, 2000, J LAW MED ETHICS, V28, P41, DOI 10.1111/j.1748-720X.2000.tb00315.x; Siminoff L A, 1997, Crit Care Nurs Clin North Am, V9, P85; Sullivan M, 2001, HEALTH EDUC BEHAV, V28, P130, DOI 10.1177/109019810102800202; WADE N, 2002, NY TIMES        0212; Wendler D, 2001, JAMA-J AM MED ASSOC, V285, P329, DOI 10.1001/jama.285.3.329; Wicclair MR, 2004, KENNEDY INST ETHIC J, V14, P143, DOI 10.1353/ken.2004.0025; Yasko LL, 2004, CAMB Q HEALTHC ETHIC, V13, P327; YOUNGNER SJ, 1985, NEW ENGL J MED, V313, P321, DOI 10.1056/NEJM198508013130510	48	70	70	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1145	1149		10.1038/nm1105-1145	http://dx.doi.org/10.1038/nm1105-1145			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16270065				2022-12-27	WOS:000233115400018
J	Sharkey, RM; Cardillo, TM; Rossi, EA; Chang, CH; Karacay, H; McBride, WJ; Hansen, HJ; Horak, ID; Goldenberg, DM				Sharkey, RM; Cardillo, TM; Rossi, EA; Chang, CH; Karacay, H; McBride, WJ; Hansen, HJ; Horak, ID; Goldenberg, DM			Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody	NATURE MEDICINE			English	Article							CARCINOEMBRYONIC ANTIGEN; RADIOIMMUNOTHERAPY; CANCER; LOCALIZATION; TOMOGRAPHY; AGENTS; CARCINOMA; MINIBODY; FRAGMENT; DIVALENT	Here we describe molecular imaging of cancer using signal amplification of a radiotracer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen ( CEA), which subsequently also captures a radioactive hapten-peptide. Human colon cancer xenografts as small as similar to 0.15 g were disclosed in nude mice within 1 h of giving the radiotracer, with tumor/blood ratios increased by >= 40-fold ( similar to 10:1 at 1 h, similar to 100:1 at 24 h), compared to a Tc-99m-labeled CEA-specific F( ab') used clinically for colorectal cancer detection, while also increasing tumor uptake tenfold ( similar to 20% injected dose/g) under optimal conditions. This technology could be adapted to other antibodies and imaging modalities.	Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA; Immunomed Inc, Morris Plains, NJ 07950 USA; IBC Pharmaceut Inc, Morris Plains, NJ 07950 USA		Goldenberg, DM (corresponding author), Garden State Canc Ctr, Ctr Mol Med & Immunol, 520 Belleville Ave, Belleville, NJ 07109 USA.	dmg.gscancer@att.net			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002114] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB002114] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Boerman OC, 2003, J NUCL MED, V44, P400; Breitz HB, 2000, J NUCL MED, V41, P131; Chang CH, 2002, MOL CANCER THER, V1, P553; DELALOYE B, 1986, J CLIN INVEST, V77, P301, DOI 10.1172/JCI112291; Forero A, 2004, BLOOD, V104, P227, DOI 10.1182/blood-2003-09-3284; Goel A, 2001, J NUCL MED, V42, P1519; Goldenberg D. M., 1992, International Journal of Biological Markers, V7, P183; GOLDENBERG DM, 1972, SCIENCE, V175, P1117, DOI 10.1126/science.175.4026.1117; Goldenberg DM, 1997, CANCER-AM CANCER SOC, V80, P2431, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2431::AID-CNCR15>3.0.CO;2-D; GOLDENBERG DM, 1992, J NUCL MED, V33, P803; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; Griffiths GL, 2004, J NUCL MED, V45, P30; HALPERN SE, 1988, RADIOLOGY, V168, P529, DOI 10.1148/radiology.168.2.3393677; HANSEN HJ, 1990, CANCER RES, V50, pS794; Kasina S, 1998, BIOCONJUGATE CHEM, V9, P108, DOI 10.1021/bc970047i; Kenanova V, 2005, CANCER RES, V65, P622; LARSON SM, 1992, J NUCL MED, V33, P2020; LEDOUSSAL JM, 1989, J NUCL MED, V30, P1358; Lewis MR, 2003, J NUCL MED, V44, P1284; LOSMAN MJ, 1994, INT J CANCER, V56, P580, DOI 10.1002/ijc.2910560419; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; Moffat FL, 1996, J CLIN ONCOL, V14, P2295, DOI 10.1200/JCO.1996.14.8.2295; Revets H, 2005, EXPERT OPIN BIOL TH, V5, P111, DOI 10.1517/14712598.5.1.111; Robinson MK, 2005, CANCER RES, V65, P1471, DOI 10.1158/0008-5472.CAN-04-2008; Rossi EA, 2005, CLIN CANCER RES, V11, p7122S, DOI 10.1158/1078-0432.CCR-1004-0020; Rossi EA, 2003, CLIN CANCER RES, V9, p3886S; Sharkey RM, 2003, CLIN CANCER RES, V9, p3897S; Sharkey RM, 2003, CANCER RES, V63, P354; *US FOOD DRUG ADM, 2002, GUID IND REV EST SAF; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Wong JYC, 2004, CLIN CANCER RES, V10, P5014, DOI 10.1158/1078-0432.CCR-03-0576; Yazaki PJ, 2001, BIOCONJUGATE CHEM, V12, P220, DOI 10.1021/bc000092h	32	113	120	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1250	1255		10.1038/nm1322	http://dx.doi.org/10.1038/nm1322			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16258537				2022-12-27	WOS:000233115400039
J	Waza, M; Adachi, H; Katsuno, M; Minamiyama, M; Sang, C; Tanaka, F; Inukai, A; Doyu, M; Sobue, G				Waza, M; Adachi, H; Katsuno, M; Minamiyama, M; Sang, C; Tanaka, F; Inukai, A; Doyu, M; Sobue, G			17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration	NATURE MEDICINE			English	Article							BULBAR MUSCULAR-ATROPHY; TRANSGENIC MOUSE MODEL; RECESSIVE BULBOSPINAL NEURONOPATHY; ANDROGEN RECEPTOR PROTEIN; HUNTINGTONS-DISEASE; PROTEASOMAL DEGRADATION; PHENOTYPIC-EXPRESSION; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONES; THERAPEUTIC APPROACH	Heat-shock protein 90 (Hsp90) functions as part of a multichaperone complex that folds, activates and assembles its client proteins. Androgen receptor (AR), a pathogenic gene product in spinal and bulbar muscular atrophy (SBMA), is one of the Hsp90 client proteins. We examined the therapeutic effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a potent Hsp90 inhibitor, and its ability to degrade polyglutamine-expanded mutant AR. Administration of 17-AAG markedly ameliorated motor impairments in the SBMA transgenic mouse model without detectable toxicity, by reducing amounts of monomeric and aggregated mutant AR. The mutant AR showed a higher affinity for Hsp90-p23 and preferentially formed an Hsp90 chaperone complex as compared to wild-type AR; mutant AR was preferentially degraded in the presence of 17-AAG in both cells and transgenic mice as compared to wild-type AR. 17-AAG also mildly induced Hsp70 and Hsp40. 17-AAG would thus provide a new therapeutic approach to SBMA and probably to other related neurodegenerative diseases.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	KATSUNO, MASAHISA/I-7502-2014; Adachi, Hiroaki/AAM-7812-2020	KATSUNO, MASAHISA/0000-0001-9453-9311; Adachi, Hiroaki/0000-0002-9302-4663				Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381; Adachi H, 2003, J NEUROSCI, V23, P2203; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Beliakoff J, 2003, CLIN CANCER RES, V9, P4961; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517; Egorin MJ, 2001, CANCER CHEMOTH PHARM, V47, P291, DOI 10.1007/s002800000242; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Ishigaki S, 2002, J NEUROCHEM, V82, P576, DOI 10.1046/j.1471-4159.2002.00998.x; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LA SA, 1991, NATURE, V352, P77; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Murphy P, 2002, J NEUROSCI RES, V67, P461, DOI 10.1002/jnr.10139; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neckers L, 2002, CLIN CANCER RES, V8, P962; Page J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P308; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Solit DB, 2002, CLIN CANCER RES, V8, P986; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Tanaka F, 1996, HUM MOL GENET, V5, P1253, DOI 10.1093/hmg/5.9.1253; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	50	301	319	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1088	1095		10.1038/nm1298	http://dx.doi.org/10.1038/nm1298			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16155577				2022-12-27	WOS:000232492500030
J	Neelapu, SS; Kwak, LW; Kobrin, CB; Reynolds, CW; Janik, JE; Dunleavy, K; White, T; Harvey, L; Pennington, R; Stetler-Stevenson, M; Jaffe, ES; Steinberg, SM; Gress, R; Hakim, F; Wilson, WH				Neelapu, SS; Kwak, LW; Kobrin, CB; Reynolds, CW; Janik, JE; Dunleavy, K; White, T; Harvey, L; Pennington, R; Stetler-Stevenson, M; Jaffe, ES; Steinberg, SM; Gress, R; Hakim, F; Wilson, WH			Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; DOSE-ADJUSTED EPOCH; RESPONSES; INDUCTION; MEMORY; GENERATION; RITUXIMAB; VARIANTS; MICE	The role of B cells in T- cell priming is unclear, and the effects of B- cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell - dependent immunity by competing with antigen- presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/ or inducing T- cell tolerance(1-4), results from others suggest that B cells are necessary for priming as well as generation of T- cell memory(5-7). We assessed immune responses to a wellcharacterized idiotype vaccine in individuals with severe B- cell depletion but normal T cells after CD20- specific antibody based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor- specific responses were detectable but delayed, and they correlated with peripheral blood B- cell recovery. In contrast, vigorous CD4(+) and CD8(+) antitumor type I T- cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B- cell depletion does not impair T- cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B- cell depletion; however, vaccine boosts after B- cell recovery may be necessary for optimal humoral responses.	NCI, Expt & Transplantat Immunol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, SAIC, Frederick, MD 21702 USA; NCI, Off Sci Operat, Frederick, MD 21702 USA; NCI, Biostat & Data Management Sect, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kwak, LW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA.	lkwak@mdanderson.org	Stetler-Stevenson, Maryalice/AAV-7393-2020; Jaffe, Elaine/G-8981-2014	Kwak, Larry/0000-0002-1884-5349	NATIONAL CANCER INSTITUTE [ZIASC000550, ZIABC010603, Z01SC000550, Z01BC010603] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen NS, 2000, BLOOD, V96, P2219; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; CARROLL WL, 1986, J IMMUNOL METHODS, V89, P61, DOI 10.1016/0022-1759(86)90032-3; Cheson, 2000, J CLIN ONCOL, V18, P2351; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Hennessy BT, 2004, LANCET ONCOL, V5, P341, DOI 10.1016/S1470-2045(04)01490-1; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kneitz C, 2002, IMMUNOBIOLOGY, V206, P519, DOI 10.1078/0171-2985-00200; Kobrin CB, 2001, J IMMUNOL, V166, P2235, DOI 10.4049/jimmunol.166.4.2235; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; Linton PJ, 2000, J IMMUNOL, V165, P5558, DOI 10.4049/jimmunol.165.10.5558; Little RF, 2003, BLOOD, V101, P4653, DOI 10.1182/blood-2002-11-3589; Malyguine Anatoli, 2004, J Transl Med, V2, P9, DOI 10.1186/1479-5876-2-9; Mattis AE, 1997, J IMMUNOL METHODS, V204, P135, DOI 10.1016/S0022-1759(97)00047-1; Neelapu SS, 2004, CLIN CANCER RES, V10, P8309, DOI 10.1158/1078-0432.CCR-04-1071; Neelapu SS, 2001, J CANCER RES CLIN, V127, pR14, DOI 10.1007/BF01470994; Paroli M, 2002, BLOOD, V99, P2131, DOI 10.1182/blood.V99.6.2131; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Rosenberg SA, 2004, J AM COLL SURGEONS, V198, P685, DOI 10.1016/j.jamcollsurg.2004.01.025; Schroder C, 2003, TRANSPL IMMUNOL, V12, P19, DOI 10.1016/S0966-3274(03)00059-5; SCHULTZE JL, 1995, P NATL ACAD SCI USA, V92, P8200, DOI 10.1073/pnas.92.18.8200; Shen H, 2003, J IMMUNOL, V170, P1443, DOI 10.4049/jimmunol.170.3.1443; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Vigouroux S, 2004, BLOOD, V104, P26, DOI 10.1182/blood-2004-01-0182; Wilson WH, 2002, SEMIN ONCOL, V29, P41, DOI 10.1053/sonc.2002.30151; Yang X, 1998, J IMMUNOL, V161, P1439	31	87	95	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					986	991		10.1038/nm1290	http://dx.doi.org/10.1038/nm1290			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116429				2022-12-27	WOS:000231724700027
J	Castor, A; Nilsson, L; Astrand-Grundstrom, I; Buitenhuis, M; Ramirez, C; Anderson, K; Strombeck, B; Garwicz, S; Bekassy, AN; Schmiegelow, K; Lausen, B; Hokland, P; Lehmann, S; Juliusson, G; Johansson, B; Jacobsen, SEW				Castor, A; Nilsson, L; Astrand-Grundstrom, I; Buitenhuis, M; Ramirez, C; Anderson, K; Strombeck, B; Garwicz, S; Bekassy, AN; Schmiegelow, K; Lausen, B; Hokland, P; Lehmann, S; Juliusson, G; Johansson, B; Jacobsen, SEW			Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; PHILADELPHIA-CHROMOSOME; MYELODYSPLASTIC SYNDROMES; PROGENITOR/STEM CELLS; MYELOGENOUS LEUKEMIA; CHILDREN; IDENTIFICATION; EXPRESSION; CANCER	The cellular targets of primary mutations and malignant transformation remain elusive in most cancers. Here, we show that clinically and genetically different subtypes of acute lymphoblastic leukemia ( ALL) originate and transform at distinct stages of hematopoietic development. Primary ETV6-RUNX1 ( also known as TEL-AML1) fusions and subsequent leukemic transformations were targeted to committed B-cell progenitors. Major breakpoint BCR-ABL1 fusions ( encoding P210 BCR-ABL1) originated in hematopoietic stem cells (HSCs), whereas minor BCR-ABL1 fusions ( encoding P190 BCR-ABL1) had a B-cell progenitor origin, suggesting that P190 and P210 BCR-ABL1 ALLs represent largely distinct tumor biological and clinical entities. The transformed leukemia-initiating stem cells in both P190 and P210 BCR-ABL1 ALLs had, as in ETV6-RUNX1 ALLs, a committed B progenitor phenotype. In all patients, normal and leukemic repopulating stem cells could successfully be separated prospectively, and notably, the size of the normal HSC compartment in ETV6-RUNX1 and P190 BCR-ABL1 ALLs was found to be unaffected by the expansive leukemic stem cell population.	Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden; Univ Lund Hosp, Dept Pediat, Hematol Oncol Sect, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Hematol, S-22185 Lund, Sweden; Univ Med Ctr, Dept Pulm Dis, Utrecht, Netherlands; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Hosp, Pediat Clin 2, Juliane Marie Ctr, Rigshosp, Copenhagen, Denmark; Arhus Amtssygehus, Dept Hematol, Aarhus, Denmark; Karolinska Inst, Huddinge Hosp, Dept Hematol, S-14186 Stockholm, Sweden	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Utrecht University; Utrecht University Medical Center; Lund University; Skane University Hospital; Rigshospitalet; University of Copenhagen; Aarhus University; Karolinska Institutet	Jacobsen, SEW (corresponding author), Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden.	sten.jacobsen@med.lu.se	Jacobsen, Sten Eirik W/D-3974-2018; , Anders/V-6166-2019	Jacobsen, Sten Eirik W/0000-0002-1362-3659; Hokland, Peter/0000-0002-1177-9756				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Costello RT, 2000, CANCER RES, V60, P4403; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Darzynkiewicz Z, 2001, METHOD CELL BIOL, V63, P527; Dorrell C, 2000, BLOOD, V95, P102; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Faderl Stefan, 2002, Rev Clin Exp Hematol, V6, P142, DOI 10.1046/j.1468-0734.2002.00066.x; FIALKOW PJ, 1978, J CLIN INVEST, V62, P815, DOI 10.1172/JCI109193; George AA, 2001, BLOOD, V97, P3925, DOI 10.1182/blood.V97.12.3925; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hotfilder M, 2002, BLOOD, V100, P640, DOI 10.1182/blood.V100.2.640; JACKSON GH, 1992, BRIT J HAEMATOL, V81, P77, DOI 10.1111/j.1365-2141.1992.tb08175.x; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; Maloney KW, 1999, LEUKEMIA, V13, P1708, DOI 10.1038/sj.leu.2401548; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Petzer AL, 1996, BLOOD, V88, P2162, DOI 10.1182/blood.V88.6.2162.bloodjournal8862162; Pui Ching-Hon, 2002, Rev Clin Exp Hematol, V6, P161, DOI 10.1046/j.1468-0734.2002.00067.x; Quijano CA, 1997, LEUKEMIA, V11, P1508, DOI 10.1038/sj.leu.2400754; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Schenk TM, 1998, LEUKEMIA, V12, P666, DOI 10.1038/sj.leu.2400986; Tajima F, 2001, BLOOD, V97, P2618, DOI 10.1182/blood.V97.9.2618; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Zanjani ED, 2003, EXP HEMATOL, V31, P406, DOI 10.1016/S0301-472X(03)00051-1; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	49	245	261	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					630	637		10.1038/nm1253	http://dx.doi.org/10.1038/nm1253			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15908956				2022-12-27	WOS:000229589800029
J	Wang, X; Huang, DY; Huong, SM; Huang, ES				Wang, X; Huang, DY; Huong, SM; Huang, ES			Integrin alpha v beta 3 is a coreceptor for human cytomegalovirus	NATURE MEDICINE			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; MOLECULAR-MECHANISMS; HERPESVIRUS ENTRY; LIPID RAFTS; VIRUS ENTRY; PROTEIN; INFECTION; ASSOCIATION; RECRUITMENT	Human cytomegalovirus ( HCMV) is a widespread opportunistic pathogen that causes birth defects in newborns and severe disease in immunocompromised individuals. The broad tropism of HCMV infection suggests that it uses multiple receptors. We recently showed that the epidermal growth factor receptor ( EGFR) serves as a receptor for HCMV. Here we show that HCMV also uses integrin alpha v beta 3 as a coreceptor. Upon infection, HCMV glycoproteins gB and gH independently bind to EGFR and alpha v beta 3, respectively, to initiate viral entry and signaling. alpha v beta 3 then translocates to lipid rafts where it interacts with EGFR to induce coordinated signaling. The coordination between EGFR and alpha v beta 3 is essential for the early events of HCMV infection, including viral entry, RhoA downregulation, stress-fiber disassembly and viral nuclear trafficking. Our findings support a model in which EGFR and alpha v beta 3 work together as coreceptors for HCMV entry and signaling. This discovery is fundamental to understanding HCMV pathogenesis and developing treatment strategies targeted to viral receptors.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Huang, ES (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,Lineberger Bldg, Chapel Hill, NC 27599 USA.	eshuang@med.unc.edu			NCI NIH HHS [CA19014, P01 CA019014-27A10024, P01 CA019014] Funding Source: Medline; NIAID NIH HHS [R01 AI047678-05, AI47468] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cinati J, 2004, TRENDS MOL MED, V10, P19, DOI 10.1016/j.molmed.2003.11.002; Cudmore S, 1997, TRENDS MICROBIOL, V5, P142, DOI 10.1016/S0966-842X(97)01011-1; Di Pasquale G, 2003, NAT MED, V9, P1306, DOI 10.1038/nm929; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; Feire AL, 2004, P NATL ACAD SCI USA, V101, P15470, DOI 10.1073/pnas.0406821101; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Flint S.J., 2000, PRINCIPLES VIROLOGY, P101; Fortunato EA, 2000, TRENDS MICROBIOL, V8, P111, DOI 10.1016/S0966-842X(00)01699-1; Fuller AO, 2002, FRONT BIOSCI, V7, pD390, DOI 10.2741/perez; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; HUANG ES, 1973, J VIROL, V12, P1473, DOI 10.1128/JVI.12.6.1473-1481.1973; Huang ES, 1993, MOL ASPECTS HUMAN CY, P1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; JONES NL, 1986, EUR J CELL BIOL, V41, P304; Kalejta RF, 2002, FRONT BIOSCI-LANDMRK, V7, pD295, DOI 10.2741/kalejta; KEAY S, 1992, J VIROL, V66, P4834, DOI 10.1128/JVI.66.8.4834-4838.1992; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Lukac DM, 1999, J VIROL, V73, P2825, DOI 10.1128/JVI.73.4.2825-2831.1999; MACHER AM, 1983, NEW ENGL J MED, V309, P1454; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; MILLER N, 1988, J VIROL, V62, P2366, DOI 10.1128/JVI.62.7.2366-2372.1988; Mocarski E.S., 2001, FIELDS VIROLOGY, V4th Edn, P2629; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; Nemerow GR, 2002, NAT CELL BIOL, V4, pE69, DOI 10.1038/ncb0402-e69; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shen YQ, 1997, P NATL ACAD SCI USA, V94, P3341, DOI 10.1073/pnas.94.7.3341; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Terry-Allison T, 1998, J VIROL, V72, P5802, DOI 10.1128/JVI.72.7.5802-5810.1998; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wu E, 2004, J VIROL, V78, P3897, DOI 10.1128/JVI.78.8.3897-3905.2004; Yurochko AD, 1997, J VIROL, V71, P5051, DOI 10.1128/JVI.71.7.5051-5059.1997	50	214	224	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					515	521		10.1038/nm1236	http://dx.doi.org/10.1038/nm1236			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834425	Green Accepted, Green Submitted			2022-12-27	WOS:000228915000023
J	Wolfrum, C; Poy, MN; Stoffel, M				Wolfrum, C; Poy, MN; Stoffel, M			Apolipoprotein M is required for pre beta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis	NATURE MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; GENE-EXPRESSION; A-I; PLASMA; ACYLTRANSFERASE; PROTEINS; LESIONS; ARTERY; MICE	High-density lipoproteins (HDLs) are considered antiatherogenic because they mediate reverse cholesterol transport from the periphery to the liver for excretion and degradation. Here we show that mice deficient in apolipoprotein M ( apoM), a component of the HDL particle, accumulated cholesterol in large HDL particles (HDL1) while the conversion of HDL to pre beta-HDL was impaired. Accordingly, apoM-deficient mice lacked pre beta-HDL, a subclass of lipid-poor apolipoproteins that serves as a key acceptor of peripheral cellular cholesterol. This deficiency led to a markedly reduced cholesterol efflux from macrophages to apoM-deficient HDL compared to normal HDL in vitro. Overexpression of apoM in Ldlr(-/-) mice protected against atherosclerosis when the mice were challenged with a cholesterol-enriched diet, showing that apoM is important for the formation of pre-HDL and cholesterol efflux to HDL, and thereby inhibits formation of atherosclerotic lesions.	Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA	Rockefeller University	Stoffel, M (corresponding author), Rockefeller Univ, Lab Metab Dis, 1230 York Ave, New York, NY 10021 USA.	stoffel@rockefeller.edu	Poy, Matthew/F-6914-2017	Poy, Matthew/0000-0002-4904-2426; Stoffel, Markus/0000-0003-1304-5817; Wolfrum, Christian/0000-0002-3862-6805	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00102] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashavaid T F, 2003, J Assoc Physicians India, V51, P345; Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; Isomaa B, 1998, DIABETOLOGIA, V41, P467, DOI 10.1007/s001250050931; Law S W, 1986, Adv Exp Med Biol, V201, P151; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; OConnor PM, 1997, ANAL BIOCHEM, V251, P234, DOI 10.1006/abio.1997.2258; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; Richter S, 2003, DIABETES, V52, P2989, DOI 10.2337/diabetes.52.12.2989; Rye KA, 2002, BIOCHEMISTRY-US, V41, P12538, DOI 10.1021/bi025998k; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Silver DL, 2000, ANN NY ACAD SCI, V902, P103; SPARKS DL, 1989, J LIPID RES, V30, P1491; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	27	250	301	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					418	422		10.1038/nm1211	http://dx.doi.org/10.1038/nm1211			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793583				2022-12-27	WOS:000228180500033
J	Li, YX; Migueles, SA; Welcher, B; Svehla, K; Phogat, A; Louder, MK; Wu, XL; Shaw, GM; Connors, M; Wyatt, RT; Mascola, JR				Li, Yuxing; Migueles, Stephen A.; Welcher, Brent; Svehla, Krisha; Phogat, Adhuna; Louder, Mark K.; Wu, Xueling; Shaw, George M.; Connors, Mark; Wyatt, Richard T.; Mascola, John R.			Broad HIV-1 neutralization mediated by CD4-binding site antibodies	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEINS; GP120; SERA	We have identified several patient sera showing potent and broad HIV-1 neutralization. Using antibody adsorption and elution from selected gp120 variants, the neutralizing specificities of the two most broadly reactive sera were mapped to the primary receptor CD4-binding region of HIV-1 gp120. Novel antibodies to the CD4-binding site are elicited in some HIV-1-infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens.	Natl Inst Hlth, Vaccine Res Ctr, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Dept Med & Microbiol, Birmingham, AL 35294 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham	Wyatt, RT (corresponding author), Natl Inst Hlth, Vaccine Res Ctr, Bethesda, MD 20892 USA.	richardwyatt@nih.gov	Mascola, John/AAI-7193-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000855, Z01AI005089, U19AI067854, Z01AI005091, Z01AI005095] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [U19 AI067854-03, U19 AI067854] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06; Haynes BF, 2006, EXPERT REV VACCINES, V5, P578; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Stamatos NM, 1998, J VIROL, V72, P9656, DOI 10.1128/JVI.72.12.9656-9667.1998; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; THALI M, 1991, J VIROL, V65, P5007, DOI 10.1128/JVI.65.9.5007-5012.1991; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580	15	335	359	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1032	1034		10.1038/nm1624	http://dx.doi.org/10.1038/nm1624			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17721546	Green Accepted			2022-12-27	WOS:000249353100029
J	Sun, JS; Sukhova, GK; Wolters, PJ; Yang, M; Kitamoto, S; Libby, P; MacFarlane, LA; Clair, JMS; Shi, GP				Sun, Jiusong; Sukhova, Galina K.; Wolters, Paul J.; Yang, Min; Kitamoto, Shiro; Libby, Peter; MacFarlane, Lindsey A.; Clair, Jon Mallen-St; Shi, Guo-Ping			Mast cells promote atherosclerosis by releasing proinflammatory cytokines	NATURE MEDICINE			English	Article							CATHEPSIN-S; REDUCES ATHEROSCLEROSIS; CYSTEINE PROTEASE; DEFICIENT MICE; IN-VIVO; EXPRESSION; GENE; ACTIVATION; CHYMASE; TISSUE	Mast cells contribute importantly to allergic and innate immune responses by releasing various preformed and newly synthesized mediators(1,2). Previous studies have shown mast cell accumulation in human atherosclerotic lesions(3). This report establishes the direct participation of mast cells in atherogenesis in low-density lipoprotein receptor -deficient (Ldlr(-/-)) mice4. Atheromata from compound mutant Ldlr(-/-) Kit(W)-(sh/W-sh) mice(5) showed decreased lesion size, lipid deposition, T-cell and macrophage numbers, cell proliferation and apoptosis, but increased collagen content and fibrous cap development. In vivo, adoptive transfer of syngeneic wild-type or tumor necrosis factor (TNF)-alpha-deficient mast cells restored atherogenesis to Ldlr(-/-)Kit(W-sh/W-sh) mice. Notably, neither interleukin (IL)-6-nor interferon (IFN)-gamma-deficient mast cells did so, indicating that the inhibition of atherogenesis in Ldlr(-/-)Kit(W-sh/W-sh) mice resulted from the absence of mast cells and mast cell-derived IL-6 and IFN-gamma. Compared with wild-type or TNF-a-deficient mast cells, those lacking IL-6 or IFN-gamma did not induce expression of proatherogenic cysteine proteinase cathepsins from vascular cells in vitro or affect cathepsin and matrix metalloproteinase activities in atherosclerotic lesions, implying that mast cell -derived IL-6 and IFN-gamma promote atherogenesis by augmenting the expression of matrix-degrading proteases. These observations establish direct participation of mast cells and mast cell -derived IL-6 and IFN-gamma in mouse atherogenesis and provide new mechanistic insight into the pathogenesis of this common disease.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Nanfang Hosp, Dept Rheumatol, Guangzhou 510515, Peoples R China; Nanfang Med Univ, Guangzhou 510515, Peoples R China	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Southern Medical University - China; Southern Medical University - China	Shi, GP (corresponding author), Brigham & Womens Hosp, Dept Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	gshi@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021; Wolters, Paul/A-7181-2009	Libby, Peter/0000-0002-1502-502X; 	NHLBI NIH HHS [R01 HL075026, HL67249, HL67283, HL75026, HL56985, HL60942] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056985, R01HL067249, R01HL075026, R01HL060942, R01HL067283] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIONDILLO DE, 1994, AM J PHYSIOL, V267, P564; Bradding P, 1996, CLIN EXP ALLERGY, V26, P13, DOI 10.1111/j.1365-2222.1996.tb00051.x; CONSTANTINIDES P, 1953, SCIENCE, V117, P505, DOI 10.1126/science.117.3045.505; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; DUTTLINGER R, 1995, P NATL ACAD SCI USA, V92, P3754, DOI 10.1073/pnas.92.9.3754; Faggioli L, 1997, EUR J IMMUNOL, V27, P3022, DOI 10.1002/eji.1830271140; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; GURISH MF, 2001, J EXP MED, V194, P1; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Jeziorska M, 1997, J PATHOL, V182, P115, DOI 10.1002/(SICI)1096-9896(199705)182:1<115::AID-PATH806>3.0.CO;2-9; Johnson JL, 1998, ARTERIOSCL THROM VAS, V18, P1707, DOI 10.1161/01.ATV.18.11.1707; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Kitamoto S, 2007, CIRCULATION, V115, P2065, DOI 10.1161/CIRCULATIONAHA.107.688523; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; TONO T, 1992, BLOOD, V80, P1448; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x	30	339	366	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2007	13	6					719	724		10.1038/nm1601	http://dx.doi.org/10.1038/nm1601			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17546038				2022-12-27	WOS:000247084300035
J	Nishie, W; Sawamura, D; Goto, M; Ito, K; Shibaki, A; McMillan, JR; Sakai, K; Nakamura, H; Olasz, E; Yancey, KB; Akiyama, M; Shimizu, H				Nishie, Wataru; Sawamura, Daisuke; Goto, Maki; Ito, Kei; Shibaki, Akihiko; McMillan, James R.; Sakai, Kaori; Nakamura, Hideki; Olasz, Edit; Yancey, Kim B.; Akiyama, Masashi; Shimizu, Hiroshi			Humanization of autoantigen	NATURE MEDICINE			English	Article							BENIGN EPIDERMOLYSIS-BULLOSA; PEMPHIGOID ANTIGEN BPAG2; AUTOIMMUNE-DISEASES; PASSIVE TRANSFER; ANIMAL-MODELS; AUTOANTIBODIES; COL17A1; BP180; MICE; ANTIBODIES	Transmissibility of characteristic lesions to experimental animals may help us understand the pathomechanism of human autoimmune disease. Here we show that human autoimmune disease can be reproduced using genetically engineered model mice. Bullous pemphigoid ( BP) is the most common serious autoimmune blistering skin disease, with a considerable body of indirect evidence indicating that the underlying autoantigen is collagen XVII (COL17). Passive transfer of human BP autoantibodies into mice does not induce skin lesions, probably because of differences between humans and mice in the amino acid sequence of the COL17 pathogenic epitope. We injected human BP autoantibody into Col17-knockout mice rescued by the human ortholog. This resulted in BP-like skin lesions and a human disease phenotype. Humanization of autoantigens is a new approach to the study of human autoimmune diseases.	Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA	Hokkaido University; Medical College of Wisconsin	Shimizu, H (corresponding author), Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp	Akiyama, Masashi/I-1122-2012; Shimizu, Hiroshi/A-5193-2012; Nishie, Wataru/A-5236-2012; McMillan, James R/C-6657-2009		NIAMS NIH HHS [R01 AR048982] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048982] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; ANHALT GJ, 1981, J CLIN INVEST, V68, P1097, DOI 10.1172/JCI110333; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Gatalica B, 1997, AM J HUM GENET, V60, P352; Gregersen JW, 2004, TISSUE ANTIGENS, V63, P383, DOI 10.1111/j.0001-2815.2004.00243.x; ISHIKO A, 1993, J CLIN INVEST, V91, P1608, DOI 10.1172/JCI116368; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Laczko I, 2000, J PEPT SCI, V6, P378, DOI 10.1002/1099-1387(200008)6:8<378::AID-PSC265>3.0.CO;2-Q; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; Shimizu H, 1998, J INVEST DERMATOL, V111, P887, DOI 10.1046/j.1523-1747.1998.00363.x; Taneja V, 2001, NAT IMMUNOL, V2, P781, DOI 10.1038/ni0901-781; Wen L, 2000, J EXP MED, V191, P97, DOI 10.1084/jem.191.1.97; Zillikens D, 1997, J INVEST DERMATOL, V109, P573, DOI 10.1111/1523-1747.ep12337492; Zillikens D, 2001, J PATHOL, V193, P117	17	223	231	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					378	383		10.1038/nm1496	http://dx.doi.org/10.1038/nm1496			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17322897				2022-12-27	WOS:000244715700053
J	Kollet, O; Dar, A; Shivtiel, S; Kalinkovich, A; Lapid, K; Sztainberg, Y; Tesio, M; Samstein, RM; Goichberg, P; Spiegel, A; Elson, A; Lapidot, T				Kollet, Orit; Dar, Ayelet; Shivtiel, Shoham; Kalinkovich, Alexander; Lapid, Kfir; Sztainberg, Yejezkel; Tesio, Melania; Samstein, Robert M.; Goichberg, Polina; Spiegel, Asaf; Elson, Ari; Lapidot, Tsvee			Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; COLONY-STIMULATING FACTOR; STEM-CELL; BONE-MARROW; MATRIX DEGRADATION; MESSENGER-RNA; IN-VITRO; RESORPTION; MMP-9; EXPRESSION	Here we investigated the potential role of bone-resorbing osteoclasts in homeostasis and stress-induced mobilization of hematopoietic progenitors. Different stress situations induced activity of osteoclasts ( OCLs) along the stem cell-rich endosteum region of bone, secretion of proteolytic enzymes and mobilization of progenitors. Specific stimulation of OCLs with RANKL recruited mainly immature progenitors to the circulation in a CXCR4- and MMP-9-dependent manner; however, RANKL did not induce mobilization in young female PTP epsilon-knockout mice with defective OCL bone adhesion and resorption. Inhibition of OCLs with calcitonin reduced progenitor egress in homeostasis, G-CSF mobilization and stress situations. RANKL-stimulated bone-resorbing OCLs also reduced the stem cell niche components SDF-1, stem cell factor ( SCF) and osteopontin along the endosteum, which was associated with progenitor mobilization. Finally, the major bone-resorbing proteinase, cathepsin K, also cleaved SDF-1 and SCF. Our findings indicate involvement of OCLs in selective progenitor recruitment as part of homeostasis and host defense, linking bone remodeling with regulation of hematopoiesis.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lapidot, T (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	Tsvee.Lapidot@weizmann.ac.il	Lapid, Kfir/C-5265-2014; Lapidot, Tsvee/A-1812-2010; Kollet, Orit/A-6861-2008	Lapid, Kfir/0000-0002-8898-8695; TESIO, Melania/0000-0001-9291-0797; Elson, Ari/0000-0001-9808-9135; Samstein, Robert/0000-0001-6860-2401				AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331; Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Armbrust T, 2002, LIVER, V22, P486, DOI 10.1034/j.1600-0676.2002.01731.x; BLAVIER L, 1995, J CELL SCI, V108, P3649; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03-04-0207; Christopherson KW, 2003, BLOOD, V101, P4680, DOI 10.1182/blood-2002-12-3893; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; Crestani B, 2002, LAB INVEST, V82, P1015, DOI 10.1097/01.LAB.0000024361.92500.19; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; Fujii K, 2004, BRIT J HAEMATOL, V124, P190, DOI 10.1046/j.1365-2141.2003.04745.x; Goto T, 2003, J ELECTRON MICROSC, V52, P551, DOI 10.1093/jmicro/52.6.551; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445; Grassi F, 2003, HISTOCHEM CELL BIOL, V120, P391, DOI 10.1007/s00418-003-0587-3; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Janowska-Wieczorek ANNA, 2000, Hematology, V4, P515; JOHNELL O, 1977, CALC TISS RES, V23, P241, DOI 10.1007/BF02012792; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Matsuda-Hashii Y, 2004, EXP HEMATOL, V32, P955, DOI 10.1016/j.exphem.2004.06.012; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MERRY K, 1993, J CELL SCI, V104, P1013; MOLENDIJK WJ, 1986, CELL TISSUE KINET, V19, P407, DOI 10.1111/j.1365-2184.1986.tb00738.x; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; OKADA Y, 1995, LAB INVEST, V72, P311; Perez-Amodio S, 2004, J BONE MINER RES, V19, P1722, DOI 10.1359/JBMR.040509; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Pruijt JFM, 1999, P NATL ACAD SCI USA, V96, P10863, DOI 10.1073/pnas.96.19.10863; Rothe L, 1998, ENDOCRINOLOGY, V139, P4353, DOI 10.1210/en.139.10.4353; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Takamatsu Y, 1998, BLOOD, V92, P3465, DOI 10.1182/blood.V92.9.3465.421k35_3465_3473; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vaaraniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Watanabe T, 2003, INT J HEMATOL, V77, P75, DOI 10.1007/BF02982606; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404; Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756-3282(02)00688-9	50	565	592	2	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					657	664		10.1038/nm1417	http://dx.doi.org/10.1038/nm1417			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715089				2022-12-27	WOS:000238149200027
J	Baral, TN; Magez, S; Stijlemans, B; Conrath, K; Vanhollebeke, B; Pays, E; Muyldermans, S; De Baetselier, P				Baral, Toya Nath; Magez, Stefan; Stijlemans, Benoit; Conrath, Katja; Vanhollebeke, Benoit; Pays, Etienne; Muyldermans, Serge; De Baetselier, Patrick			Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor	NATURE MEDICINE			English	Article							VARIANT SURFACE GLYCOPROTEIN; SLEEPING-SICKNESS; BRUCEI-RHODESIENSE; HUMAN SERUM; APOLIPOPROTEIN L; ANTIGENIC VARIATION; LYTIC FACTOR; RESISTANCE; IDENTIFICATION; ANTIBODIES	High systemic drug toxicity and increasing prevalence of drug resistance hampers efficient treatment of human African trypanosomiasis (HAT). Hence, development of new highly specific trypanocidal drugs is necessary. Normal human serum (NHS) contains apolipoprotein L-I (apoL-I), which lyses African trypanosomes except resistant forms such as Trypanosoma brucei rhodesiense(1). T. b. rhodesiense expresses the apoL-I neutralizing serum resistance-associated (SRA) protein(2), endowing this parasite with the ability to infect humans and cause HAT. A truncated apoL-I (Tr-apoL-I) has been engineered by deleting its SRA-interacting domain, which makes it lytic for T. b. rhodesiense(1). Here, we conjugated Tr-apoL-I with a single-domain antibody (nanobody) that efficiently targets conserved cryptic epitopes of the variant surface glycoprotein (VSG) of trypanosomes(3) to generate a new manmade type of immunotoxin with potential for trypanosomiasis therapy. Treatment with this engineered conjugate resulted in clear curative and alleviating effects on acute and chronic infections of mice with both NHS-resistant and NHS-sensitive trypanosomes.	Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, Lab Cellulaire Mol Immunol, B-1050 Brussels, Belgium; Univ Libre Bruxelles, IBMM, Mol Parasitol Lab, B-6041 Gosselies, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite Libre de Bruxelles	Baral, TN (corresponding author), Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, Lab Cellulaire Mol Immunol, Pleinlaan 2, B-1050 Brussels, Belgium.	tbaral@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Magez, Stefan/AAC-5682-2021; Muyldermans, Serge V/C-6418-2016; De Baetselier, Patrick/D-3866-2014; Stijlemans, Benoit/AAD-9122-2021	Muyldermans, Serge/0000-0002-3678-3575; Magez, Stefan/0000-0003-3760-7968; Muyldermans, Serge V/0000-0002-3678-3575; Stijlemans, Benoit/0000-0003-0082-9751; Vanhollebeke, Benoit/0000-0002-0353-365X				BACCHI CJ, 1993, PARASITOL TODAY, V9, P190, DOI 10.1016/0169-4758(93)90145-6; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; Chisi J E, 2004, East Afr Med J, V81, P505; Conrath K, 2005, J MOL BIOL, V350, P112, DOI 10.1016/j.jmb.2005.04.050; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Cortez-Retamozo V, 2002, INT J CANCER, V98, P456, DOI 10.1002/ijc.10212; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; Duchateau PN, 2000, J LIPID RES, V41, P1231; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Horn D, 2004, CURR MOL MED, V4, P563, DOI 10.2174/1566524043360078; Hutchinson OC, 2003, LANCET INFECT DIS, V3, P42, DOI 10.1016/S1473-3099(03)00488-2; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; Magez S, 1999, INFECT IMMUN, V67, P3128, DOI 10.1128/IAI.67.6.3128-3132.1999; Magez S, 2004, J INFECT DIS, V189, P527, DOI 10.1086/381151; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Muyldermans S, 2001, J Biotechnol, V74, P277; Naessens J, 2005, CLIN EXP IMMUNOL, V139, P405, DOI 10.1111/j.1365-2249.2004.02717.x; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Vanhamme L, 2004, INT J PARASITOL, V34, P887, DOI 10.1016/j.ijpara.2004.04.008; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; Welburn SC, 2001, TRENDS PARASITOL, V17, P19, DOI 10.1016/S1471-4922(00)01839-0; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	30	124	155	1	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					580	584		10.1038/nm1395	http://dx.doi.org/10.1038/nm1395			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604085				2022-12-27	WOS:000238149100043
J	Liu, YW; Teige, I; Birnir, B; Issazadeh-Navikas, S				Liu, Yawei; Teige, Ingrid; Birnir, Bryndis; Issazadeh-Navikas, Shohreh			Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GROWTH-FACTOR-BETA; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MHC CLASS-I; TGF-BETA; ALLERGIC ENCEPHALOMYELITIS; NEUROTROPHIC FACTOR; NEGATIVE REGULATOR; LEUKOCYTE INTEGRIN	Neurons have been neglected as cells with a major immune-regulatory function because they do not express major histocompatibility complex class II. Our data show that neurons are highly immune regulatory, having a crucial role in governing T-cell response and central nervous system (CNS) inflammation. Neurons induce the proliferation of activated CD4+ T cells through B7-CD28 and transforming growth factor (TGF)-beta 1-TGF-beta receptor signaling pathways, resulting in amplification of T-cell receptor signaling through phosphorylated ZAP-70, interleukin (IL)-2 and IL- 9. The interaction between neurons and T cells results in the conversion of encephalitogenic T cells to CD25(+) TGF-beta 1(+)CTLA-4(+)FoxP3(+) T regulatory (T-reg) cells that suppress encephalitogenic T cells and inhibit experimental autoimmune encephalomyelitis. Suppression is dependent on cytotoxic T lymphocyte antigen (CTLA)-4 but not TGF-beta 1. Autocrine action of TGF-beta 1, however, is important for the proliferative arrest of T-reg cells. Blocking the B7 and TGF-beta pathways prevents the CNS-specific generation of Treg cells. These findings show that generation of neuron-dependent Treg cells in the CNS is instrumental in regulating CNS inflammation.	Lund Univ, Inst Expt Med Sci, Neuroinflammat Unit, S-22184 Lund, Sweden; Lund Univ, Clin Res Ctr, Dept Clin Sci, S-20502 Malmo, Sweden	Lund University; Lund University	Issazadeh-Navikas, S (corresponding author), Lund Univ, Inst Expt Med Sci, Neuroinflammat Unit, BMC,I13,, S-22184 Lund, Sweden.	shohreh.issazadeh@med.lu.se	Issazadeh-Navikas, Shohreh/AAI-7900-2021	Birnir, Bryndis/0000-0002-1763-0266				Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Estevez AG, 1998, J NEUROSCI, V18, P3708; Flugel A, 2000, BRAIN PATHOL, V10, P353; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hurwitz AA, 2002, P NATL ACAD SCI USA, V99, P3013, DOI 10.1073/pnas.042684699; Issazadeh S, 1998, J IMMUNOL, V161, P1104; Issazadeh S, 1999, J IMMUNOL, V162, P761; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Issazadeh S, 1996, J NEUROIMMUNOL, V69, P103; Issazadeh S, 1997, EUR J IMMUNOL, V27, P1584, DOI 10.1002/eji.1830270640; Karandikar NJ, 1996, J EXP MED, V184, P783, DOI 10.1084/jem.184.2.783; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kullberg MC, 2005, EUR J IMMUNOL, V35, P2886, DOI 10.1002/eji.200526106; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MAEHLEN J, 1989, J NEUROIMMUNOL, V23, P125, DOI 10.1016/0165-5728(89)90031-3; Medana I, 2001, J IMMUNOL, V167, P674, DOI 10.4049/jimmunol.167.2.674; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Mott RT, 2004, GLIA, V46, P369, DOI 10.1002/glia.20009; Nakada M, 1999, J ALLERGY CLIN IMMUN, V104, P222, DOI 10.1016/S0091-6749(99)70139-9; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Teige A, 2004, J IMMUNOL, V172, P186, DOI 10.4049/jimmunol.172.1.186; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001; Tian L, 1997, J IMMUNOL, V158, P928; Tian L, 2000, EUR J IMMUNOL, V30, P810, DOI 10.1002/1521-4141(200003)30:3<810::AID-IMMU810>3.3.CO;2-O; Vahlenkamp TW, 2004, VET IMMUNOL IMMUNOP, V98, P203, DOI 10.1016/j.vetimm.2003.12.006; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WEKERLE H, 1987, J EXP BIOL, V132, P43; Zhang XS, 2005, J IMMUNOL, V175, P2931, DOI 10.4049/jimmunol.175.5.2931	45	231	238	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					518	525		10.1038/nm1402	http://dx.doi.org/10.1038/nm1402			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633347				2022-12-27	WOS:000238149100035
J	Zimmermann, WH; Melnychenko, I; Wasmeier, G; Didie, M; Naito, H; Nixdorff, U; Hess, A; Budinsky, L; Brune, K; Michaelis, B; Dhein, S; Schwoerer, A; Ehmke, H; Eschenhagen, T				Zimmermann, WH; Melnychenko, I; Wasmeier, G; Didie, M; Naito, H; Nixdorff, U; Hess, A; Budinsky, L; Brune, K; Michaelis, B; Dhein, S; Schwoerer, A; Ehmke, H; Eschenhagen, T			Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; CARDIAC-MUSCLE; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; CARDIOMYOCYTES; TRANSPLANTATION; SURVIVAL; REPAIR; DIFFERENTIATION; REGENERATION	The concept of regenerating diseased myocardium by implantation of tissue-engineered heart muscle is intriguing, but convincing evidence is lacking that heart tissues can be generated at a size and with contractile properties that would lend considerable support to failing hearts. Here we created large (thickness/ diameter, 1-4 mm/15 mm), force-generating engineered heart tissue from neonatal rat heart cells. Engineered heart tissue formed thick cardiac muscle layers when implanted on myocardial infarcts in immune-suppressed rats. When evaluated 28 d later, engineered heart tissue showed undelayed electrical coupling to the native myocardium without evidence of arrhythmia induction. Moreover, engineered heart tissue prevented further dilation, induced systolic wall thickening of infarcted myocardial segments and improved fractional area shortening of infarcted hearts compared to controls (sham operation and noncontractile constructs). Thus, our study provides evidence that large contractile cardiac tissue grafts can be constructed in vitro, can survive after implantation and can support contractile function of infarcted hearts.	Univ Hamburg Eppendorf, Med Ctr, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Med Clin 2, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; Univ Leipzig, Dept Cardiac Surg, Ctr Heart, D-04289 Leipzig, Germany; Univ Hamburg Eppendorf, Med Ctr, Inst Vegetat Physiol & Pathophysiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Eschenhagen, T (corresponding author), Univ Hamburg Eppendorf, Med Ctr, Inst Expt & Clin Pharmacol, Martinistr 52, D-20246 Hamburg, Germany.	w.zimmermann@uke.uni-hamburg.de; t.eschenhagen@uke.uni-hamburg.de	Zimmermann, Wolfram-Hubertus H/I-6838-2012; Nixdorff, Uwe/ABC-3298-2020	Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040; Budinsky, Lubos/0000-0003-2171-0098				Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; DHEIN S, 1993, CIRCULATION, V87, P617, DOI 10.1161/01.CIR.87.2.617; Eschenhagen T, 1997, FASEB J, V11, P683, DOI 10.1096/fasebj.11.8.9240969; Eschenhagen T, 2005, CIRC RES, V97, P1220, DOI 10.1161/01.RES.0000196562.73231.7d; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leor J, 2000, CIRCULATION, V102, P56; Li RK, 1999, CIRCULATION, V100, P63; Li RK, 1997, CIRCULATION, V96, P179; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Muller-Ehmsen J, 2002, CIRCULATION, V105, P1720, DOI 10.1161/01.CIR.0000013782.76324.92; Murry CE, 2005, CIRCULATION, V112, P3174, DOI 10.1161/CIRCULATIONAHA.105.546218; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zimmermann WH, 2002, CIRCULATION, V106, pI151, DOI 10.1161/01.cir.0000032876.55215.10; Zimmermann WH, 2000, BIOTECHNOL BIOENG, V68, P106	30	732	767	2	130	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					452	458		10.1038/nm1394	http://dx.doi.org/10.1038/nm1394			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16582915				2022-12-27	WOS:000236581300035
J	Back, SA; Tuohy, TMF; Chen, HQ; Wallingford, N; Craig, A; Struve, J; Luo, NL; Banine, F; Liu, Y; Chang, A; Trapp, BD; Bebo, BF; Rao, MS; Sherman, LS				Back, SA; Tuohy, TMF; Chen, HQ; Wallingford, N; Craig, A; Struve, J; Luo, NL; Banine, F; Liu, Y; Chang, A; Trapp, BD; Bebo, BF; Rao, MS; Sherman, LS			Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS LESIONS; PRECURSOR CELLS; CD44 EXPRESSION; DENDRITIC CELLS; WHITE-MATTER; SPINAL-CORD; T-CELLS; ASTROCYTES; ADULT; BRAIN	Demyelination is the hallmark of numerous neurodegenerative conditions, including multiple sclerosis. Oligodendrocyte progenitors ( OPCs), which normally mature into myelin- forming oligodendrocytes, are typically present around demyelinated lesions but do not remyelinate affected axons. Here, we find that the glycosaminoglycan hyaluronan accumulates in demyelinated lesions from individuals with multiple sclerosis and in mice with experimental autoimmune encephalomyelitis. A high molecular weight ( HMW) form of hyaluronan synthesized by astrocytes accumulates in chronic demyelinated lesions. This form of hyaluronan inhibits remyelination after lysolecithin- induced white matter demyelination. OPCs accrue and do not mature into myelin- forming cells in demyelinating lesions where HMW hyaluronan is present. Furthermore, the addition of HMW hyaluronan to OPC cultures reversibly inhibits progenitor- cell maturation, whereas degrading hyaluronan in astrocyte- OPC cocultures promotes oligodendrocyte maturation. HMW hyaluronan may therefore contribute substantially to remyelination failure by preventing the maturation of OPCs that are recruited to demyelinating lesions.	Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Neurol, Sch Med, Portland, OR 97239 USA; NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Oregon Hlth Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cleveland Clinic Foundation; Oregon Health & Science University	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu	Tuohy, Therese/A-8665-2009; Wallingford, Nicholas/J-1367-2018	Wallingford, Nicholas/0000-0003-2279-0480	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001517] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT001517] Funding Source: Medline; NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS39550] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; AKIYAMA H, 1993, BRAIN RES, V632, P249, DOI 10.1016/0006-8993(93)91160-T; Alfei L, 1999, EUR J HISTOCHEM, V43, P29; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Blakemore WF, 2003, EXP NEUROL, V184, P955, DOI 10.1016/S0014-4886(03)00347-9; Bouvier-Labit C, 2002, J NEURO-ONCOL, V60, P127, DOI 10.1023/A:1020630732625; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Chari DM, 2002, MULT SCLER J, V8, P271, DOI 10.1191/1352458502ms842oa; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; De Groot C J, 2001, Prog Brain Res, V132, P533; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; GIRGRAH N, 1991, J NEUROPATH EXP NEUR, V50, P779, DOI 10.1097/00005072-199111000-00009; HAEGEL H, 1993, J CELL BIOL, V122, P1067, DOI 10.1083/jcb.122.5.1067; Ito M, 2001, J NEUROPATH EXP NEUR, V60, P1004, DOI 10.1093/jnen/60.10.1004; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; JENKINS HG, 1988, J NEUROCHEM, V51, P1641, DOI 10.1111/j.1471-4159.1988.tb01135.x; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Lassmann H, 2001, CURR OPIN NEUROL, V14, P253, DOI 10.1097/00019052-200106000-00001; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Liu Y, 2002, GLIA, V40, P25, DOI 10.1002/glia.10111; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARRET S, 1994, J NEUROCHEM, V62, P1285; MERRILL JE, 1984, SCIENCE, V224, P1428, DOI 10.1126/science.6610212; MORETTO G, 1993, J NEUROPATH EXP NEUR, V52, P419, DOI 10.1097/00005072-199307000-00009; Moseley R, 1997, BBA-MOL BASIS DIS, V1362, P221, DOI 10.1016/S0925-4439(97)00083-5; Mummert ME, 2002, J IMMUNOL, V169, P4322, DOI 10.4049/jimmunol.169.8.4322; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Perosa SR, 2002, EPILEPSIA, V43, P159, DOI 10.1046/j.1528-1157.43.s.5.30.x; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Sherman L, 1995, J NEURO-ONCOL, V26, P171, DOI 10.1007/BF01052620; STRUVE J, IN PRESS GLIA; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuohy TMF, 2004, GLIA, V47, P335, DOI 10.1002/glia.20042; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; Wang H, 2001, STROKE, V32, P1020, DOI 10.1161/01.STR.32.4.1020; Wang MJ, 2004, J NEUROIMMUNOL, V146, P50, DOI 10.1016/j.jneuroim.2003.10.034; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wolswijk G, 1998, J NEUROSCI, V18, P601; Zhang SC, 1998, J NEUROCYTOL, V27, P475, DOI 10.1023/A:1006953023845	46	443	450	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					966	972		10.1038/nm1279	http://dx.doi.org/10.1038/nm1279			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16086023				2022-12-27	WOS:000231724700024
J	Reeves, PM; Bommarius, B; Lebeis, S; McNulty, S; Christensen, J; Swimm, A; Chahroudi, A; Chavan, R; Feinberg, MB; Veach, D; Bornmann, W; Sherman, M; Kalman, D				Reeves, PM; Bommarius, B; Lebeis, S; McNulty, S; Christensen, J; Swimm, A; Chahroudi, A; Chavan, R; Feinberg, MB; Veach, D; Bornmann, W; Sherman, M; Kalman, D			Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases	NATURE MEDICINE			English	Article							ACTIN-BASED MOTILITY; VACCINIA VIRUS; INTRACELLULAR MOVEMENT; BCR-ABL; PROTEIN; MICROTUBULES; SMALLPOX; COMPLEX; FORM; RESISTANCE	The Poxviridae family members vaccinia and variola virus enter mammalian cells, replicate outside the nucleus and produce virions that travel to the cell surface along microtubules, fuse with the plasma membrane and egress from infected cells toward apposing cells on actin-filled membranous protrusions. We show that cell- associated enveloped virions (CEV) use Abl- and Src-family tyrosine kinases for actin motility, and that these kinases act in a redundant fashion, perhaps permitting motility in a greater range of cell types. Additionally, release of CEV from the cell requires Abl- but not Src- family tyrosine kinases, and is blocked by STI-571 ( Gleevec), an Abl- family kinase inhibitor used to treat chronic myelogenous leukemia in humans. Finally, we show that STI-571 reduces viral dissemination by five orders of magnitude and promotes survival in infected mice, suggesting possible use for this drug in treating smallpox or complications associated with vaccination. This therapeutic approach may prove generally efficacious in treating microbial infections that rely on host tyrosine kinases, and, because the drug targets host but not viral molecules, this strategy is much less likely to engender resistance compared to conventional antimicrobial therapies.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA; Aarhus Univ, Dept Epidemiol, NANEA, Inst Publ Hlth, DK-8000 Aarhus, Denmark; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Organ Chem Sect, Houston, TX 77030 USA	Emory University; Emory University; Aarhus University; Emory University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kalman, D (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St,Whitehead Res Bldg 144, Atlanta, GA 30322 USA.	dkalman@emory.edu	Reeves, Patrick/I-1066-2018; Swimm, Alyson/D-1025-2013	Reeves, Patrick/0000-0001-8202-0723; Veach, Darren/0000-0002-8201-622X; Bommarius, Bettina/0000-0002-1283-0218; Swimm, Alyson/0000-0001-9975-0247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046007, R01AI056067] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIAID NIH HHS [P01 AI046007, R01 AI056067, P01 AI 46007, R01-AI056067-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amorosa VK, 2003, CLIN INFECT DIS, V37, P426, DOI 10.1086/375823; [Anonymous], 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 1997, DECONVOLUTION IMAGES; APPLEYARD G, 1971, J GEN VIROL, V13, P9, DOI 10.1099/0022-1317-13-1-9; Baker R, 2003, ANTIVIR RES, V57, P13, DOI 10.1016/S0166-3542(02)00196-1; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLASCO R, 1993, J VIROL, V67, P3319, DOI 10.1128/JVI.67.6.3319-3325.1993; Boulter E A, 1973, Prog Med Virol, V16, P86; Carter GC, 2003, J GEN VIROL, V84, P2443, DOI 10.1099/vir.0.19271-0; CHAHROUDI A, 2005, IN PRESS J VIROL; Kohn William G, 2003, MMWR Recomm Rep, V52, P1; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Dorsey JF, 2000, CANCER RES, V60, P3127; DRUCKER BJ, 2001, HEMATOL-AM SOC HEMAT, P87; Esposito JJ, 2001, FIELDS VIROLOGY, P2885; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gould IM, 2002, CURR OPIN INFECT DIS, V15, P395, DOI 10.1097/00001432-200208000-00007; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Hollinshead M, 2001, J CELL BIOL, V154, P389, DOI 10.1083/jcb.200104124; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ichihashi Y, 1996, VIROLOGY, V220, P491, DOI 10.1006/viro.1996.0337; IDEMYOR V, 1993, ANN PHARMACOTHER, V27, P1285, DOI 10.1177/106002809302701023; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Law M, 2002, J GEN VIROL, V83, P209, DOI 10.1099/0022-1317-83-1-209; Law M, 2001, VIROLOGY, V280, P132, DOI 10.1006/viro.2000.0750; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Moss B, 2001, FIELDS VIROLOGY, P2849; Nagar B, 2002, CANCER RES, V62, P4236; *NAT RES COUNC, 1999, ASS FUT SC NEEDS LIV, V126; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Newsome TP, 2004, SCIENCE, V306, P124, DOI 10.1126/science.1101509; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Ramirez JC, 2003, ARCH VIROL, V148, P827, DOI 10.1007/s00705-003-0006-z; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Smith JN, 2003, J BACTERIOL, V185, P1357, DOI 10.1128/JB.185.4.1357-1366.2003; Swimm A, 2004, MOL BIOL CELL, V15, P3520, DOI 10.1091/mbc.E04-02-0093; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Vanderplasschen A, 1998, P NATL ACAD SCI USA, V95, P7544, DOI 10.1073/pnas.95.13.7544; Ward BM, 2003, J VIROL, V77, P4113, DOI 10.1128/JVI.77.7.4113-4126.2003; Ward BM, 2001, J VIROL, V75, P11651, DOI 10.1128/JVI.75.23.11651-11663.2001; Ward BM, 2001, J VIROL, V75, P4802, DOI 10.1128/JVI.75.10.4802-4813.2001; Wisniewski D, 2002, CANCER RES, V62, P4244; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424	59	168	182	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					731	739		10.1038/nm1265	http://dx.doi.org/10.1038/nm1265			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15980865				2022-12-27	WOS:000230304200029
J	Jackson, SP; Schoenwaelder, SM; Goncalves, I; Nesbitt, WS; Yap, CL; Wright, CE; Kenche, V; Anderson, KE; Dopheide, SM; Yuan, YP; Sturgeon, SA; Prabaharan, H; Thompson, PE; Smith, GD; Shepherd, PR; Daniele, N; Kulkarni, S; Abbott, B; Saylik, D; Jones, C; Lu, L; Giuliano, S; Hughan, SC; Angus, JA; Robertson, AD; Salem, HH				Jackson, SP; Schoenwaelder, SM; Goncalves, I; Nesbitt, WS; Yap, CL; Wright, CE; Kenche, V; Anderson, KE; Dopheide, SM; Yuan, YP; Sturgeon, SA; Prabaharan, H; Thompson, PE; Smith, GD; Shepherd, PR; Daniele, N; Kulkarni, S; Abbott, B; Saylik, D; Jones, C; Lu, L; Giuliano, S; Hughan, SC; Angus, JA; Robertson, AD; Salem, HH			PI 3-kinase p110 beta: a new target for antithrombotic therapy	NATURE MEDICINE			English	Article							VON-WILLEBRAND-FACTOR; HIGH-SHEAR RATE; PHOSPHOINOSITIDE 3-KINASES; INTEGRIN ALPHA(IIB)BETA(3); PLATELET-ADHESION; TISSUE FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GLYCOPROTEIN IB/V/IX; THROMBUS FORMATION; CORONARY-ARTERIES	Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, precipitating diseases such as acute myocardial infarction and ischemic stroke. Rheological disturbances ( high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110 beta isoform in regulating the formation and stability of integrin alpha(IIb)beta(3) adhesion bonds, necessary for shear activation of platelets. Isoform-selective PI3K p110 beta inhibitors have been developed which prevent formation of stable integrin alpha(IIb)beta(3) adhesion contacts, leading to defective platelet thrombus formation. In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time. These studies define PI3K p110 beta as an important new target for antithrombotic therapy.	Monash Univ, Australian Ctr Blood Dis, Prahran, Vic 3181, Australia; Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Kinacia Pty Ltd, Richmond, Vic 3121, Australia	Monash University; University of Melbourne; University of London; University College London	Jackson, SP (corresponding author), Monash Univ, Australian Ctr Blood Dis, 6th Floor Burnet Bldg,AMREP,89 Commercial Rd, Prahran, Vic 3181, Australia.	shaun.jackson@med.monash.edu.au	Schoenwaelder, Simone/E-9506-2011; Angus, James/F-6666-2014; Abbott, Belinda/AGJ-1760-2022; Goncalves, Isaac/AAO-8371-2020; Abbott, Belinda M/B-1278-2012; Danièle, Nathalie/J-7432-2013; Abbott, Belinda/AAH-5100-2019; Wright, Christine/B-2509-2012	Angus, James/0000-0002-0605-9682; Abbott, Belinda/0000-0003-1643-245X; Abbott, Belinda M/0000-0003-1643-245X; Nesbitt, Warwick/0000-0001-5644-7053; LU, SAI/0000-0002-6368-3721; Jackson, Shaun/0000-0002-4750-1991; Anderson, Karen/0000-0002-7394-6660; Thompson, Philip/0000-0002-5910-7625; Daniele, Nathalie/0000-0002-7985-2788; Kenche, Vijaya/0000-0003-4424-4886; Wright, Christine/0000-0002-3339-040X; Schoenwaelder, Simone/0000-0003-0465-5840				Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; BANG CJ, 1991, HAEMOSTASIS, V21, P155; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; BUSH LR, 1990, FASEB J, V4, P3087, DOI 10.1096/fasebj.4.13.2210155; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; FOLTS JD, 1991, CIRCULATION, V83, P2122, DOI 10.1161/01.CIR.83.6.2122; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; Goncalves I, 2003, J BIOL CHEM, V278, P34812, DOI 10.1074/jbc.M306504200; GONCALVES I, 2005, J BIOL CHEM     0208, DOI DOI 10.1074/JBC.M410235200; Goto S, 2002, CIRCULATION, V105, P2531, DOI 10.1161/01.CIR.0000016703.93845.AF; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; HERBERT JM, 1993, THROMB RES, V71, P433, DOI 10.1016/0049-3848(93)90117-7; Jackson SP, 2003, NAT REV DRUG DISCOV, V2, P775, DOI 10.1038/nrd1198; Jackson SP, 2004, BIOCHEM SOC T, V32, P387, DOI 10.1042/BST0320387; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JACKSON SP, 2004, Patent No. 4177; Jander S, 2001, STROKE, V32, P850, DOI 10.1161/01.STR.32.4.850; Kasirer-Friede A, 2004, BLOOD, V103, P3403, DOI 10.1182/blood-2003-10-3664; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Okkenhaug K, 2002, SCIENCE, V297, P1031; Resendiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SADHU C, 2003, Patent No. 6518277; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; TRONY J, 1993, AM J PHYSIOL, V265, pH1787; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Zhang J, 2002, BIOCHEM BIOPH RES CO, V296, P178, DOI 10.1016/S0006-291X(02)00744-1	47	490	552	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2005	11	5					507	514		10.1038/nm1232	http://dx.doi.org/10.1038/nm1232			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834429				2022-12-27	WOS:000228915000022
J	Silvestre, JS; Thery, C; Hamard, G; Boddaert, J; Aguilar, B; Delcayre, A; Houbron, C; Tamarat, R; Blanc-Brude, O; Heeneman, S; Clergue, M; Duriez, M; Merval, R; Levy, B; Tedgui, A; Amigorena, S; Mallat, Z				Silvestre, JS; Thery, C; Hamard, G; Boddaert, J; Aguilar, B; Delcayre, A; Houbron, C; Tamarat, R; Blanc-Brude, O; Heeneman, S; Clergue, M; Duriez, M; Merval, R; Levy, B; Tedgui, A; Amigorena, S; Mallat, Z			Lactadherin promotes VEGF-dependent neovascularization	NATURE MEDICINE			English	Article							DEVELOPMENTAL ENDOTHELIAL LOCUS-1; APOPTOTIC CELLS; MOUSE DEVELOPMENT; HUMAN-MILK; IN-VIVO; PROTEIN; GROWTH; ANGIOGENESIS; INTEGRIN; MEMBRANE	Vascular endothelial growth factor (VEGF)-induced blood vessel growth is involved in both physiological and pathological angiogenesis and requires integrin-mediated signaling. We now show that an integrin-binding protein initially described in milk-fat globule, MFG-E8 (also known as lactadherin), is expressed in and around blood vessels and has a crucial role in VEGF-dependent neovascularization in the adult mouse. Using neutralizing antibodies and lactadherin-deficient animals, we show that lactadherin interacts with alpha v beta 3 and alpha v beta 5 integrins and alters both VEGF-dependent Akt phosphorylation and neovascularization. In the absence of VEGF, lactadherin administration induced alpha v beta 3- and alpha v beta 5-dependent Akt phosphorylation in endothelial cells in vitro and strongly improved postischemic neovascularization in vivo. These results show a crucial role for lactadherin in VEGF-dependent neovascularization and identify lactadherin as an important target for the modulation of neovascularization.	Univ Paris 07, Hop Lariboisiere, Cardiovasc Res Ctr, INSERM,Lariboisiere U689, F-75475 Paris, France; INSERM, U653, F-75249 Paris, France; Inst Curie, F-75249 Paris, France; Inst Cochin Genet Mol, INSERM, U567, Plate Forme Recombinaison Homologue, F-75014 Paris, France; Anosys Inc, Menlo Pk, CA 94025 USA; Inst Radioprotect & Surete Nucl, F-92262 Fontenay Aux Roses, France; Cardiovasc Res Inst Maastricht, Dept Pathol, NL-6229 HX Maastricht, Netherlands	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Maastricht University	Mallat, Z (corresponding author), Univ Paris 07, Hop Lariboisiere, Cardiovasc Res Ctr, INSERM,Lariboisiere U689, 41 Bvd Chapelle, F-75475 Paris, France.	mallat@larib.inserm.fr	Mallat, Ziad/D-4041-2012; Silvestre, Jean-Sebastien/K-7695-2017; thery, clotilde/F-6373-2013; BLANC-BRUDE, Olivier/O-8629-2017	Mallat, Ziad/0000-0003-0443-7878; Silvestre, Jean-Sebastien/0000-0003-3962-2205; thery, clotilde/0000-0001-8294-6884; Amigorena, Sebastian/0000-0001-8583-8416; BLANC-BRUDE, Olivier/0000-0002-4015-0615				Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Ho HKV, 2004, CIRCULATION, V109, P1314, DOI 10.1161/01.CIR.0000118465.36018.2D; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Miyasaka K, 2004, EUR J IMMUNOL, V34, P1414, DOI 10.1002/eji.200424930; Newburg DS, 1998, LANCET, V351, P1160, DOI 10.1016/S0140-6736(97)10322-1; Oshima K, 1999, BIOCHEM BIOPH RES CO, V254, P522, DOI 10.1006/bbrc.1998.0107; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Silvestre JS, 2003, CIRC RES, V93, P114, DOI 10.1161/01.RES.0000081594.21764.44; Silvestre JS, 2001, CIRC RES, V89, P259, DOI 10.1161/hh1501.094269; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Sullivan CJ, 2002, J APPL PHYSIOL, V93, P2009, DOI 10.1152/japplphysiol.00451.2002; Tamarat R, 2002, LAB INVEST, V82, P747, DOI 10.1097/01.LAB.0000017372.76297.EB; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Yang HT, 1996, CIRC RES, V79, P62, DOI 10.1161/01.RES.79.1.62; Zhong JP, 2003, J CLIN INVEST, V112, P30, DOI 10.1172/JCI200317034	30	244	260	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					499	506		10.1038/nm1233	http://dx.doi.org/10.1038/nm1233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834428				2022-12-27	WOS:000228915000021
J	Zhang, Q; Wang, HY; Liu, XB; Wasik, MA				Zhang, Qian; Wang, Hong Y.; Liu, Xiaobin; Wasik, Mariusz A.			STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression	NATURE MEDICINE			English	Article							MALIGNANT T-LYMPHOCYTES; NON-HODGKINS-LYMPHOMA; HUMAN BREAST-CANCER; SIGNAL TRANSDUCER; CELL LYMPHOMA; NPM-ALK; TRANSCRIPTION FACTORS; ACTIVATION; GENE; PROLIFERATION	Although STAT5A and STAT5B have some nonredundant functional properties, their distinct contributions to carcinogenesis are not clearly defined. Here we report that STAT5A expression is selectively inhibited by DNA methylation of the STAT5A gene promoter region in cells expressing the oncogenic tyrosine kinase NPM1-ALK ( also known as NPM-ALK). The DNA methylation is induced by NPM1-ALK itself via STAT3, and is associated with binding to the promoter of the gene encoding MeCP2 capping protein and with lack of binding of the STAT5A gene transcription activator SP1. Reversal of methylation by the DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine restores SP1 binding and STAT5A gene expression. Notably, the induced or exogenously expressed STAT5A protein binds to the enhancer and intron 14 of the NPM1-ALK gene and triggers selective suppression of NPM1-ALK expression. These results show that NPM1-ALK induces epigenetic silencing of STAT5A gene and that STAT5A protein can act as a key tumor suppressor by reciprocally inhibiting expression of NPM1-ALK.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Zhang, Q (corresponding author), Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	qian2@mail.med.upenn.edu			NCI NIH HHS [R01-CA89194, R01-CA96856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089194, R01CA096856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosio R, 2002, GENE, V285, P311, DOI 10.1016/S0378-1119(02)00421-3; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bondarenko VA, 2003, BIOCHEM CELL BIOL, V81, P241, DOI 10.1139/o03-051; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Crispi S, 2004, FEBS LETT, V562, P27, DOI 10.1016/S0014-5793(04)00166-8; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fujioka H, 2002, CHEM IMMUNOL, V80, P1; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Hehlmann R, 2005, ANN HEMATOL, V84, P487, DOI 10.1007/s00277-005-1039-z; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lai SY, 2005, ONCOGENE, V24, P4442, DOI 10.1038/sj.onc.1208635; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; SHIOTA M, 1994, ONCOGENE, V9, P1567; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wasik Mariusz A, 2002, Am J Clin Pathol, V118 Suppl, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377	44	98	100	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2007	13	11					1341	1348		10.1038/nm1659	http://dx.doi.org/10.1038/nm1659			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17922009				2022-12-27	WOS:000250736900027
J	Wagner, KW; Punnoose, EA; Januario, T; Lawrence, DA; Pitti, RM; Lancaster, K; Lee, D; von Goetz, M; Yee, SF; Totpal, K; Huw, L; Katta, V; Cavet, G; Hymowitz, SG; Amler, L; Ashkenazi, A				Wagner, Klaus W.; Punnoose, Elizabeth A.; Januario, Thomas; Lawrence, David A.; Pitti, Robert M.; Lancaster, Kate; Lee, Dori; von Goetz, Melissa; Yee, Sharon Fong; Totpal, Klara; Huw, Ling; Katta, Viswanatham; Cavet, Guy; Hymowitz, Sarah G.; Amler, Lukas; Ashkenazi, Avi			Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL	NATURE MEDICINE			English	Article							SIALYL-LEWIS-X; CANCER-CELLS; MUCIN-TYPE; GLYCAN BIOSYNTHESIS; INDUCED APOPTOSIS; TARGETING DEATH; ASSOCIATION; RESISTANCE; CASPASE-8; COMPLEX	dApo2L/TRAIL stimulates cancer cell death through the proapoptotic receptors DR4 and DR5, but the determinants of tumor susceptibility to this ligand are not fully defined. mRNA expression of the peptidyl O-glycosyltransferase GALNT14 correlated with Apo2L/ TRAIL sensitivity in pancreatic carcinoma, non-small-cell lung carcinoma and melanoma cell lines, and up to 30% of samples from various human malignancies showed GALNT14 overexpression. RNA interference of GALNT14 reduced cellular Apo2L/ TRAIL sensitivity, whereas overexpression increased responsiveness. Biochemical analysis of DR5 identified several ectodomain O-(N-acetyl galactosamine-galactose-sialic acid) structures. Sequence comparison predicted conserved extracellular DR4 and DR5 O- glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling. O- glycosylation promoted ligand-stimulated clustering of DR4 and DR5, which mediated recruitment and activation of the apoptosis-initiating protease caspase-8. These results uncover a new link between death-receptor O- glycosylation and apoptotic signaling, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Diagnost, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Dev, San Francisco, CA 94080 USA; Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Dalton WS, 2006, SCIENCE, V312, P1165, DOI 10.1126/science.1125948; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Foster MM, 2003, CANCER RES, V63, P2775; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hang HC, 2005, BIOORGAN MED CHEM, V13, P5021, DOI 10.1016/j.bmc.2005.04.085; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; TAKADA A, 1993, CANCER RES, V53, P354; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Wang H, 2003, BIOCHEM BIOPH RES CO, V300, P738, DOI 10.1016/S0006-291X(02)02908-X; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	37	454	474	1	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1070	1077		10.1038/nm1627	http://dx.doi.org/10.1038/nm1627			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17767167				2022-12-27	WOS:000249353100034
J	Bachmaier, K; Toya, S; Gao, XP; Triantafillou, T; Garrean, S; Park, GY; Frey, RS; Vogel, S; Minshall, R; Christman, JW; Tiruppathi, C; Malik, AB				Bachmaier, Kurt; Toya, Sophie; Gao, Xiaopei; Triantafillou, Thomas; Garrean, Sean; Park, Gye Young; Frey, Randall S.; Vogel, Stephen; Minshall, Richard; Christman, John W.; Tiruppathi, Chinnaswamy; Malik, Asrar B.			E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury	NATURE MEDICINE			English	Article							NF-KAPPA-B; NEGATIVE REGULATION; C-CBL; RECEPTOR; MICE; EXPRESSION; ACTIVATION; PROTEIN; SEPSIS; ALPHA	The E3 ubiquitin ligase Cblb has a crucial role in the prevention of chronic inflammation and autoimmunity. Here we show that Cblb also has an unexpected function in acute lung inflammation. Cblb attenuates the sequestration of inflammatory cells in the lungs after administration of lipopolysaccharide (LPS). In a model of polymicrobial sepsis in which acute lung inflammation depends on the LPS receptor (Toll-like receptor 4, TLR-4), the loss of Cblb expression accentuates acute lung inflammation and reduces survival. Loss of Cblb significantly increases sepsis-induced release of inflammatory cytokines and chemokines. Cblb controls the association between TLR4 and the intracellular adaptor MyD88. Expression of wild-type Cblb, but not expression of a Cblb mutant that lacks E3 ubiquitin ligase function, prevents the activity of a reporter gene for the transcription factor nuclear factor-kappa B (NF-kappa B) in monocytes that have been challenged with LPS. The downregulation of TLR4 expression on the cell surface of neutrophils is impaired in the absence of Cblb. Our data reveal that Cblb regulates the TLR4-mediated acute inflammatory response that is induced by sepsis.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Dept Med, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Ctr Lung & Vasc Biol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bachmaier, K (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, E403,Med Sci Bldg,MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	kbachmai@uic.edu	Bachmaier, Kurt/B-6331-2014; Bachmaier, Kurt/AHC-5491-2022	Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [T32 HL 07829, P01 HL77806, P01 HL60678] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL077806, T32HL007829, P01HL060678] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alves JC, 2006, CRIT CARE MED, V34, P461, DOI 10.1097/01.CCM.0000198527.71819.E1; Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510; Ankermann T, 2005, CRIT CARE MED, V33, P1384, DOI 10.1097/01.CCM.0000166371.18066.5E; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; Blackwell TS, 2000, AM J RESP CRIT CARE, V162, P1095, DOI 10.1164/ajrccm.162.3.9906129; Bosco MC, 2000, J IMMUNOL, V164, P3283, DOI 10.4049/jimmunol.164.6.3283; Brueckmann M, 2004, INFLAMM RES, V53, P528, DOI 10.1007/s00011-004-1291-z; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chuang TH, 2004, NAT IMMUNOL, V5, P495, DOI 10.1038/ni1066; Deng JC, 2006, J CLIN INVEST, V116, P2532, DOI 10.1172/JCI28054; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Iwata A, 2003, J IMMUNOL, V171, P3136, DOI 10.4049/jimmunol.171.6.3136; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeon MS, 2004, IMMUNITY, V21, P167, DOI 10.1016/j.immuni.2004.07.013; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KEANE MM, 1995, ONCOGENE, V10, P2367; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levy H, 2005, CRIT CARE, V9, pR502, DOI 10.1186/cc3778; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007; Matsuda N, 2005, MOL PHARMACOL, V67, P1018, DOI 10.1124/mol.104.005926; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Neumann B, 1996, J IMMUNOL, V156, P1587; Richards GA, 2005, CLIN MICROBIOL INFEC, V11, P18, DOI 10.1111/j.1469-0691.2005.01266.x; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; SHANLEY TP, 1995, J IMMUNOL, V154, P4793; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	50	66	69	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					920	926		10.1038/nm1607	http://dx.doi.org/10.1038/nm1607			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17618294				2022-12-27	WOS:000248674600022
J	Zeisberg, EM; Tarnavski, O; Zeisberg, M; Dorfman, AL; McMullen, JR; Gustafsson, E; Chandraker, A; Yuan, XL; Pu, WT; Roberts, AB; Neilson, EG; Sayegh, MH; Izumo, S; Kalluri, R				Zeisberg, Elisabeth M.; Tarnavski, Oleg; Zeisberg, Michael; Dorfman, Adam L.; McMullen, Julie R.; Gustafsson, Erika; Chandraker, Anil; Yuan, Xueli; Pu, William T.; Roberts, Anita B.; Neilson, Eric G.; Sayegh, Mohamed H.; Izumo, Seigo; Kalluri, Raghu			Endothelial-to-mesenchymal transition contributes to cardiac fibrosis	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; NITRIC-OXIDE SYNTHESIS; LONG-TERM BLOCKADE; DIASTOLIC DYSFUNCTION; TGF-BETA; CELL-TRANSFORMATION; EMBRYONIC HEART; GENE-EXPRESSION; CRE RECOMBINASE; TRANSGENIC MICE	Cardiac fibrosis, associated with a decreased extent of microvasculature and with disruption of normal myocardial structures, results from excessive deposition of extracellular matrix, which is mediated by the recruitment of fibroblasts. The source of these fibroblasts is unclear and specific anti-fibrotic therapies are not currently available. Here we show that cardiac fibrosis is associated with the emergence of fibroblasts originating from endothelial cells, suggesting an endothelial-mesenchymal transition (EndMT) similar to events that occur during formation of the atrioventricular cushion in the embryonic heart. Transforming growth factor-beta 1 (TGF-beta 1) induced endothelial cells to undergo EndMT, whereas bone morphogenic protein 7 (BMP-7) preserved the endothelial phenotype. The systemic administration of recombinant human BMP-7 (rhBMP-7) significantly inhibited EndMT and the progression of cardiac fibrosis in mouse models of pressure overload and chronic allograft rejection. Our findings show that EndMT contributes to the progression of cardiac fibrosis and that rhBMP-7 can be used to inhibit EndMT and to intervene in the progression of chronic heart disease associated with fibrosis.	Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Cardiol, Dept Med, Div Cardiovasc, Boston, MA 02215 USA; Lund Univ, Dept Expt Pathol, S-22185 Lund, Sweden; Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02215 USA; Childrens Hosp, Boston, MA 02215 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37215 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA; Harvard Mit Div Hlth Sci & Technol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Novartis; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Lund University; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Harvard University; Harvard Medical School; Harvard University	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Zeisberg, Elisabeth/ABG-4970-2021; Chandraker, Anil/L-3908-2019; Pu, William/AAJ-8301-2020; Kalluri, Raghu/E-2677-2015	Pu, William/0000-0002-4551-8079; Kalluri, Raghu/0000-0002-2190-547X; Sayegh, Mohamed/0000-0002-2847-588X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL082436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046282, K08DK074558, R01DK062987, R01DK061688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013913] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 F32 HL082436-01] Funding Source: Medline; NIAAA NIH HHS [AA13913] Funding Source: Medline; NIDDK NIH HHS [DK55001, DK62987, DK-46282, 5K08DK074558-01, DK61688] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Boyer AS, 1999, DEV BIOL, V208, P530, DOI 10.1006/dbio.1999.9211; Camenisch TD, 2002, DEV BIOL, V248, P170, DOI 10.1006/dbio.2002.0731; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523-1755.2002.00103.x; Gustafsson E, 2001, J CELL SCI, V114, P671; Hocht-Zeisberg E, 2004, EUR HEART J, V25, P749, DOI 10.1016/j.ehj.2004.01.017; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; JALIL JE, 1989, CIRC RES, V64, P1041, DOI 10.1161/01.RES.64.6.1041; Kass DA, 2004, CIRC RES, V94, P1533, DOI 10.1161/01.RES.0000129254.25507.d6; KORHONEN J, 1994, ONCOGENE, V9, P395; Kuwahara F, 2002, CIRCULATION, V106, P130, DOI 10.1161/01.CIR.0000020689.12472.E0; Lang HN, 2001, DEV BIOL, V234, P120, DOI 10.1006/dbio.2001.0248; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; LEFER AM, 1992, J MOL CELL CARDIOL, V24, P585, DOI 10.1016/0022-2828(92)91043-5; Liebner S, 2004, J CELL BIOL, V166, P359, DOI 10.1083/jcb.200403050; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; Lips DJ, 2004, BASIC RES CARDIOL, V99, P351, DOI 10.1007/s00395-004-0476-5; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MAESHIMA Y, 2001, J BIOL CHEM, V7, P7; Mandelbrot DA, 2001, J CLIN INVEST, V107, P881, DOI 10.1172/JCI11710; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Maresh JG, 2004, ARTERIOSCL THROM VAS, V24, P1836, DOI 10.1161/01.ATV.0000143097.90868.c8; Maric C, 1997, ANAT EMBRYOL, V195, P503, DOI 10.1007/s004290050070; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Nakajima Y, 2000, ANAT RECORD, V258, P119, DOI 10.1002/(SICI)1097-0185(20000201)258:2<119::AID-AR1>3.0.CO;2-U; Nicoletti A, 1999, CARDIOVASC RES, V41, P532, DOI 10.1016/S0008-6363(98)00305-8; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Perrino C, 2006, J CLIN INVEST, V116, P1547, DOI 10.1172/JCI25397; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Ramsdell AF, 1998, ACTA ANAT, V162, P1; Razeghi P, 2007, CARDIOVASC RES, V74, P133, DOI 10.1016/j.cardiores.2006.12.021; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Sugimoto H, 2006, P NATL ACAD SCI USA, V103, P7321, DOI 10.1073/pnas.0601436103; Takemoto M, 1997, HYPERTENSION, V30, P1621, DOI 10.1161/01.HYP.30.6.1621; Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003; Tokumasa A, 2004, BIOCHEM BIOPH RES CO, V317, P377, DOI 10.1016/j.bbrc.2004.03.047; Tomita H, 1998, HYPERTENSION, V32, P273, DOI 10.1161/01.HYP.32.2.273; Vasan RS, 2001, NEW ENGL J MED, V344, P56, DOI 10.1056/NEJM200101043440111; Verheule S, 2004, CIRC RES, V94, P1458, DOI 10.1161/01.RES.0000129579.59664.9d; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Weber KT, 1997, CIRCULATION, V96, P2488; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zeisberg EM, 2005, J CLIN INVEST, V115, P1522, DOI 10.1172/JCI23769; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	50	1547	1636	6	161	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2007	13	8					952	961		10.1038/nm1613	http://dx.doi.org/10.1038/nm1613			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17660828				2022-12-27	WOS:000248674600026
J	Hernando, E; Charytonowicz, E; Dudas, ME; Menendez, S; Matushansky, I; Mills, J; Socci, ND; Behrendt, N; Ma, L; Maki, RG; Pandolfi, PP; Cordon-Cardo, C				Hernando, Eva; Charytonowicz, Elizabeth; Dudas, Maria E.; Menendez, Silvia; Matushansky, Igor; Mills, Joslyn; Socci, Nicholas D.; Behrendt, Nille; Ma, Li; Maki, Robert G.; Pandolfi, Pier Paolo; Cordon-Cardo, Carlos			The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE; TUBEROUS SCLEROSIS; SYNOVIAL SARCOMA; CANCER; GENE; MICE; TSC2; PHOSPHORYLATION; TUMORIGENESIS; DEFICIENT	We analyzed the PI3K-AKT signaling cascade in a cohort of sarcomas and found a marked induction of insulin receptor substrate-2 (IRS2) and phosphorylated AKT and a concomitant upregulation of downstream effectors in most leiomyosarcomas. To determine the role of aberrant PI3K-AKT signaling in leiomyosarcoma pathogenesis, we genetically inactivated Pten in the smooth muscle cell lineage by cross-breeding Pten(loxP/loxP) mice with Tagln-cre mice. Mice carrying homozygous deletion of Pten alleles developed widespread smooth muscle cell hyperplasia and abdominal leiomyosarcomas, with a very rapid onset and elevated incidence (similar to 80%) compared to other animal models. Constitutive mTOR activation was restricted to the leiomyosarcomas, revealing the requirement for additional molecular events besides Pten loss. The rapamycin derivative everolimus substantially decelerated tumor growth on Tagln-cre/ Pten(loxP/loxP) mice and prolonged their lifespan. Our data show a new and critical role for the AKT-mTOR pathway in smooth muscle transformation and leiomyosarcoma genesis, and support treatment of selected sarcomas by the targeting of this pathway with new compounds or combinations of these with conventional chemotherapy agents.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), NYU, Sch Med, Dept Pathol, Expt Pathol Program, New York, NY 10016 USA.	p-pandolfi@ski.mskcc.org; cc2791@columbia.edu	Maki, Robert G/J-9145-2019; Maki, Robert G./AAI-2793-2020; Ma, Li/GQR-1313-2022	Maki, Robert G/0000-0002-9853-2528; Ma, Li/0000-0001-9965-989X; Hernando, Eva/0000-0003-1023-0312	NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA47179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499; Hornick Jason L, 2003, Ann Diagn Pathol, V7, P60, DOI 10.1053/adpa.2003.50010; Hu J, 2005, CANCER GENET CYTOGEN, V161, P20, DOI 10.1016/j.cancergencyto.2005.01.011; Lepore JJ, 2005, GENESIS, V41, P179, DOI 10.1002/gene.20112; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Politi K, 2004, AM J PATHOL, V164, P325, DOI 10.1016/S0002-9440(10)63122-7; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Rieske P, 1999, J EXP CLIN CANC RES, V18, P403; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Sun Y, 2006, ONCOGENE, V25, P1042, DOI 10.1038/sj.onc.1209143; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tos APD, 1996, AM J PATHOL, V148, P1037; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xie YT, 1999, CANCER RES, V59, P3588; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	29	212	223	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					748	753		10.1038/nm1560	http://dx.doi.org/10.1038/nm1560			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17496901				2022-12-27	WOS:000247084300040
J	Putz, MM; Midgley, CM; Law, M; Smith, GL				Puetz, Mike M.; Midgley, Claire M.; Law, Mansun; Smith, Geoffrey L.			Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination	NATURE MEDICINE			English	Article							PROTECTION; IMMUNITY; PROTEIN; HUMANS; TARGET; MICE	Smallpox was eradicated without an adequate understanding of how vaccination induced protection. In response to possible bioterrorism with smallpox, the UK government vaccinated similar to 300 health care workers with vaccinia virus (VACV) strain Lister. Antibody responses were analyzed using ELISA for multiple surface antigens of the extracellular enveloped virus (EEV) and the intracellular mature virus (IMV), plaque reduction neutralization and a fluorescence-based flow cytometric neutralization assay. Antibody depletion experiments showed that the EEV surface protein B5 is the only target responsible for EEV neutralization in vaccinated humans, whereas multiple IMV surface proteins, including A27 and H3, are targets for IMV-neutralizing antibodies. These data suggest that it would be unwise to exclude the B5 protein from a future smallpox vaccine. Repeated vaccination provided significantly higher B5-specific and thus EEV-neutralizing antibody responses. These data provide a benchmark against which new, safer smallpox vaccines and residual immunity can be compared.	Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, London W2 1PG, England	Imperial College London	Smith, GL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, St Marys Campus, London W2 1PG, England.	glsmith@imperial.ac.uk	Smith, Geoffrey L/G-2894-2012; Law, Mansun/A-3899-2008	Smith, Geoffrey L/0000-0002-3730-9955; Law, Mansun/0000-0002-8934-9756	MRC [G0501257] Funding Source: UKRI; Medical Research Council [G0501257] Funding Source: Medline; NIAID NIH HHS [R41AI058365] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI058365] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aldaz-Carroll L, 2005, VIROLOGY, V341, P59, DOI 10.1016/j.virol.2005.07.006; Auckland C, 2005, VACCINE, V23, P4185, DOI 10.1016/j.vaccine.2004.10.052; Bell E, 2004, VIROLOGY, V325, P425, DOI 10.1016/j.virol.2004.05.004; Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Boulter E A, 1973, Prog Med Virol, V16, P86; Carter GC, 2005, J GEN VIROL, V86, P1279, DOI 10.1099/vir.0.80831-0; Carter GC, 2003, J GEN VIROL, V84, P2443, DOI 10.1099/vir.0.19271-0; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Davies DH, 2005, J VIROL, V79, P11724, DOI 10.1128/JVI.79.18.11724-11733.2005; Davies DH, 2005, P NATL ACAD SCI USA, V102, P547, DOI 10.1073/pnas.0408782102; Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261; Fang M, 2005, J IMMUNOL, V175, P6829, DOI 10.4049/jimmunol.175.10.6829; Fenner F., 1988, SMALLPOX ITS ERADICA, P121; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; Kidokoro M, 2005, P NATL ACAD SCI USA, V102, P4152, DOI 10.1073/pnas.0406671102; Law M, 2006, P NATL ACAD SCI USA, V103, P5989, DOI 10.1073/pnas.0601025103; Law M, 2005, J GEN VIROL, V86, P991, DOI 10.1099/vir.0.80660-0; Law M, 2001, VIROLOGY, V280, P132, DOI 10.1006/viro.2000.0750; MCCARTHY K., 1958, JOUR HYGIENE, V56, P466; Pulford DJ, 2004, VACCINE, V22, P3358, DOI 10.1016/j.vaccine.2004.02.034; Putz MM, 2005, J GEN VIROL, V86, P2955, DOI 10.1099/vir.0.81265-0; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Su HP, 2005, P NATL ACAD SCI USA, V102, P4240, DOI 10.1073/pnas.0501103102; Viner KM, 2005, MICROBES INFECT, V7, P579, DOI 10.1016/j.micinf.2005.02.004	30	94	96	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1310	1315		10.1038/nm1457	http://dx.doi.org/10.1038/nm1457			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17086190				2022-12-27	WOS:000241844900029
J	Jin, LQ; Hope, KJ; Zhai, QL; Smadja-Joffe, F; Dick, JE				Jin, Liqing; Hope, Kristin J.; Zhai, Qiongli; Smadja-Joffe, Florence; Dick, John E.			Targeting of CD44 eradicates human acute myeloid leukemic stem cells	NATURE MEDICINE			English	Article							PRIMITIVE HEMATOPOIETIC-CELLS; BONE-MARROW; ADHESION MOLECULES; NOD/SCID MICE; SCID MICE; IN-VITRO; DIFFERENTIATION; TRANSPLANTATION; IDENTIFICATION; PROGENITORS	The long-term survival of patients with acute myeloid leukemia (AML) is dismally poor. A permanent cure of AML requires elimination of leukemic stem cells (LSCs), the only cell type capable of initiating and maintaining the leukemic clonal hierarchy. We report a therapeutic approach using an activating monoclonal antibody directed to the adhesion molecule CD44. In vivo administration of this antibody to nonobese diabetic-severe combined immune-deficient mice transplanted with human AML markedly reduced leukemic repopulation. Absence of leukemia in serially transplanted mice demonstrated that AML LSCs are directly targeted. Mechanisms underlying this eradication included interference with transport to stem cell-supportive microenvironmental niches and alteration of AML-LSC fate, identifying CD44 as a key regulator of AML LSCs. The finding that AML LSCs require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML LSCs and may be applicable to other types of cancer stem cells.	Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada; Hop St Louis, INSERM, U718, F-75475 Paris, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dick, JE (corresponding author), Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto Med Discovery Tower,101 Coll St,Suite 8-3, Toronto, ON M5G 1L7, Canada.	jdick@uhnres.utoronto.ca		Dick, John/0000-0002-9527-8317; Hope, Kristin/0000-0003-1449-4948				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Bendall LJ, 2000, LEUKEMIA, V14, P1239, DOI 10.1038/sj.leu.2401830; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cancelas JA, 2006, NAT MED, V12, P278, DOI 10.1038/nm0306-278; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Guan Y, 2000, LEUKEMIA, V14, P2135, DOI 10.1038/sj.leu.2401975; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; KORTLEPEL K, 1993, LEUKEMIA, V7, P1174; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LIESVELD JL, 1991, EXP HEMATOL, V19, P63; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Madlambayan GJ, 2005, EXP HEMATOL, V33, P1229, DOI 10.1016/j.exphem.2005.05.018; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Mazurier F, 2004, BLOOD, V103, P545, DOI 10.1182/blood-2003-05-1558; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Nilsson SK, 2003, BLOOD, V101, P856, DOI 10.1182/blood-2002-05-1344; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SINGH S, 2003, CANCER RES, V63, P5281; Tallman Martin S, 2005, Hematology Am Soc Hematol Educ Program, P143; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	37	913	1001	6	123	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1167	1174		10.1038/nm1483	http://dx.doi.org/10.1038/nm1483			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998484				2022-12-27	WOS:000241102200033
J	Kerkela, R; Grazette, L; Yacobi, R; Iliescu, C; Patten, R; Beahm, C; Walters, B; Shevtsov, S; Pesant, S; Clubb, FJ; Rosenzweig, A; Salomon, RN; Van Etten, RA; Alroy, J; Durand, JB; Force, T				Kerkela, Risto; Grazette, Luanda; Yacobi, Rinat; Iliescu, Cezar; Patten, Richard; Beahm, Cara; Walters, Brian; Shevtsov, Sergei; Pesant, Stephanie; Clubb, Fred J.; Rosenzweig, Anthony; Salomon, Robert N.; Van Etten, Richard A.; Alroy, Joseph; Durand, Jean-Bernard; Force, Thomas			Cardiotoxicity of the cancer therapeutic agent imatinib mesylate	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM STRESS; ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; HER2-POSITIVE BREAST-CANCER; UNFOLDED PROTEIN RESPONSE; CHRONIC MYELOID-LEUKEMIA; NEURONAL CELL-DEATH; N-TERMINAL KINASE; C-ABL; ADJUVANT CHEMOTHERAPY	Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction. Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco-(endo-) plasmic reticulum, findings suggestive of a toxic myopathy. With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death. Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death. Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.	Thomas Jefferson Univ, Jefferson Med Coll, Ctr Translat Med, Philadelphia, PA 19107 USA; Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Pathol, Boston, MA 02111 USA; MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Houston, TX 77030 USA; Texas Heart Inst, Dept Cardiovasc Pathol, Houston, TX 77030 USA; Tufts Univ, Cummings Sch Vet Med, North Grafton, MA 01536 USA	Jefferson University; Tufts Medical Center; Tufts University; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Texas Heart Institute; Tufts University	Force, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Ctr Translat Med, 1025 Walnut St, Philadelphia, PA 19107 USA.	thomas.force@jefferson.edu	Grazette, Luanda/AAJ-5965-2020; Rosenzweig, Anthony/AAD-7893-2019	Force, Thomas/0000-0002-0450-8659	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cohen MH, 2002, CLIN CANCER RES, V8, P935; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Deng XZ, 2004, NAT GENET, V36, P906, DOI 10.1038/ng1396; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Grazette LP, 2004, J AM COLL CARDIOL, V44, P2231, DOI 10.1016/j.jacc.2004.08.066; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; KHAN MA, 1995, PROG NEUROBIOL, V46, P541, DOI 10.1016/0301-0082(95)00015-N; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504; McLeod CJ, 2005, TRENDS CARDIOVAS MED, V15, P118, DOI 10.1016/j.tcm.2005.05.001; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Okada M, 2004, BLOOD, V103, P2299, DOI 10.1182/blood-2003-05-1605; Pattacini L, 2004, LEUKEMIA RES, V28, P191, DOI 10.1016/S0145-2126(03)00218-2; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sanbe A, 2005, P NATL ACAD SCI USA, V102, P13592, DOI 10.1073/pnas.0503324102; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Van Etten RA, 2004, LEUKEMIA RES, V28, pS21, DOI 10.1016/j.leukres.2003.10.005; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vasan RS, 2000, AM HEART J, V139, P412, DOI 10.1016/S0002-8703(00)90084-X; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	49	880	930	3	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					908	916		10.1038/nm1446	http://dx.doi.org/10.1038/nm1446			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862153	Green Published			2022-12-27	WOS:000239626200021
J	Norton, L; Massague, J				Norton, Larry; Massague, Joan			Is cancer a disease of self-seeding?	NATURE MEDICINE			English	Editorial Material							GENE-EXPRESSION SIGNATURE; STEM-CELLS; BREAST; TUMOR; BEVACIZUMAB; METASTASIS; SURVIVAL	The high cell density, rapid growth rate and large population size of cancer are conventionally attributed to a pathologically high ratio of cell production to cell death. Yet these features might also or instead result from inappropriate cell movement, already understood to underlie invasion and metastasis. This integrating concept could induce a broadening of our existing anticancer pharmacopoeia, which, with mitosis as its predominant target, is now seldom curative.	Cornell Univ, Weill Coll Med, New York, NY 10021 USA; Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Norton, L (corresponding author), Cornell Univ, Weill Coll Med, New York, NY 10021 USA.	nortonpub@mskcc.org		Massague, Joan/0000-0001-9324-8408; Norton, Larry/0000-0003-3701-9250	NCI NIH HHS [P01-CA94060-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; DANG CT, 2003, CANC MED, P645; *E COOP ONC GROUP, 2004, CLIN LUNG CANC, V6, P276; Foekens JA, 2006, J CLIN ONCOL, V24, P1665, DOI 10.1200/JCO.2005.03.9115; Folkman J, 2003, CANC MED, P161; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; NORTON L, 1990, PROG CLIN BIOL RES, V354, P109; Norton L, 2001, ONCOLOGIST, V6, P30; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019; Schneider BS, 1996, P ROY SOC B-BIOL SCI, V263, P129, DOI 10.1098/rspb.1996.0020; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967	25	267	271	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					875	878		10.1038/nm0806-875	http://dx.doi.org/10.1038/nm0806-875			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892025				2022-12-27	WOS:000239626200011
J	McLaurin, J; Kierstead, ME; Brown, ME; Hawkes, CA; Lambermon, MHL; Phinney, AL; Darabie, AA; Cousins, JE; French, JE; Lan, MF; Chen, FS; Wong, SSN; Mount, HTJ; Fraser, PE; Westaway, D; St George-Hyslop, P				McLaurin, JoAnne; Kierstead, Meredith E.; Brown, Mary E.; Hawkes, Cheryl A.; Lambermon, Mark H. L.; Phinney, Amie L.; Darabie, Audrey A.; Cousins, Julian E.; French, Janet E.; Lan, Melissa F.; Chen, Fusheng; Wong, Sydney S. N.; Mount, Howard T. J.; Fraser, Paul E.; Westaway, David; St George-Hyslop, Peter			Cyclohexanehexol inhibitors of A beta aggregation prevent and reverse Alzheimer phenotype in a mouse model	NATURE MEDICINE			English	Article							AMYLOID PEPTIDES; TRANSGENIC MICE; DISEASE; PROTEIN; INOSITOL; IMMUNIZATION; ANTIBODIES; MEMBRANES; PLAQUES; NEUROPATHOLOGY	When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid b peptide ( Ab) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease-like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Ab pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease-like phenotype, support the idea that the accumulation of Ab oligomers has a central role in the pathogenesis of Alzheimer disease.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Univ Hlth Network, Toronto Western Hosp, Res Inst, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	j.mclaurin@utoronto.ca	Mount, Howard/B-4097-2013					Auton M, 2005, P NATL ACAD SCI USA, V102, P15065, DOI 10.1073/pnas.0507053102; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Frenkel D, 2000, P NATL ACAD SCI USA, V97, P11455, DOI 10.1073/pnas.97.21.11455; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; HACCOU P, 1995, STAT ANAL BEHAV DATA, P120; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hu L, 2003, NEUROSCIENCE, V121, P421, DOI 10.1016/S0306-4522(03)00394-4; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mount HTJ, 2004, J NEUROCHEM, V88, P1449, DOI 10.1046/j.1471-4159.2003.02278.x; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Phinney AL, 1999, NEUROSCIENCE, V90, P1207, DOI 10.1016/S0306-4522(98)00645-9; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SHETTY HU, 1994, BIOL MASS SPECTROM, V23, P440, DOI 10.1002/bms.1200230710; SPECTOR R, 1988, NEUROCHEM RES, V13, P785, DOI 10.1007/BF00971603; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; Vaucher E, 2002, EXP NEUROL, V175, P398, DOI 10.1006/exnr.2002.7915; Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	35	293	321	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					801	808		10.1038/nm1423	http://dx.doi.org/10.1038/nm1423			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767098				2022-12-27	WOS:000238862800067
J	Mount, C; Downton, C				Mount, Claire; Downton, Christian			Alzheimer disease: progress or profit?	NATURE MEDICINE			English	Article							CHOLINESTERASE-INHIBITORS; METAANALYSIS		Wood Mackenzie, London EC2N 1HN, England		Mount, C (corresponding author), Wood Mackenzie, London EC2N 1HN, England.	claire.mount@woodmac.com						*ALZH ASS FACT SHE, 2005, FDA APPR CHOL INH; *ALZH DIS INT, 1999, FACTSH 3 PREV DEM; *ALZH DIS RES, 2003, 108 C 1 SESS, pS566; Beckett L. A., 2001, ALZ DIS ASSOC DIS, V15, P169, DOI DOI 10.1097/00002093-200110000-00002; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005593; Farlow MR, 2002, INT J CLIN PRACT, P37; Filonenko V. S, 2003, SOL SYS RES, V37, P2; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; HODES, 2006, NAT MED, P770; Lanctot KL, 2003, CAN MED ASSOC J, V169, P557; *LEW GROUP, 2004, SAV LIV SAV MON DIV; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; NICOLL JA, 2003, NAT MED, V9, P389; Schechter LE, 2005, J PHARMACOL EXP THER, V314, P1274, DOI 10.1124/jpet.105.086363; TABET N, 2000, COCHRANE DB SYST REV, V4, P2854; Tariot PN, 2003, ALZ DIS ASSOC DIS, V17, pS105, DOI 10.1097/00002093-200307004-00005; Vas C.J., 2001, ALZHEIMERS DIS BRAIN	17	216	233	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					780	784		10.1038/nm0706-780	http://dx.doi.org/10.1038/nm0706-780			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829947				2022-12-27	WOS:000238862800063
J	Brown, BD; Venneri, MA; Zingale, A; Sergi, LS; Naldini, L				Brown, Brian D.; Venneri, Mary Anna; Zingale, Anna; Sergi, Lucia Sergi; Naldini, Luigi			Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer	NATURE MEDICINE			English	Article							IMMUNE-RESPONSE; THERAPEUTIC-EFFICACY; LENTIVIRAL VECTORS; HEMOPHILIA-A; FACTOR-IX; CELLS; MICE; IDENTIFICATION; TARGETS; ANTIGEN	MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by repressing translation of target cellular transcripts. Increasing evidence indicates that miRNAs have distinct expression profiles and play crucial roles in numerous cellular processes, although the extent of miRNA regulation is not well known. By challenging mice with lentiviral vectors encoding target sequences of endogenous miRNAs, we show the efficiency of miRNAs in sharply segregating gene expression among different tissues. Transgene expression from vectors incorporating target sequences for mir-142-3p was effectively suppressed in intravascular and extravascular hematopoietic lineages, whereas expression was maintained in nonhemato-poietic cells. This expression profile, which could not be attained until now, enabled stable gene transfer in immunocompetent mice, thus overcoming a major hurdle to successful gene therapy. Our results provide novel in situ evidence of miRNA regulation and demonstrate a new paradigm in vector design with applications for genetic engineering and therapeutic gene transfer.	San Raffaele Telethon Inst Gene Therapy, HSR TIGET, I-20132 Milan, Italy; Vita Salute Raffaele Univ, San Raffaele Sci Inst, I-20132 Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy, HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.	naldini.luigi@hsr.it	Naldini, Luigi/E-9083-2012	lucia, Sergi Sergi/0000-0002-8631-7433; VENNERI, MARY ANNA/0000-0002-0687-8135; NALDINI, Luigi/0000-0002-7835-527X	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brown BD, 2004, J THROMB HAEMOST, V2, P111, DOI 10.1111/j.1538-7836.2004.00552.x; Brown BD, 2004, BLOOD, V103, P804, DOI 10.1182/blood-2003-05-1426; Brown BD, 2002, BLOOD, V100, P1133, DOI 10.1182/blood-2001-11-0067; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; De Geest BR, 2003, BLOOD, V101, P2551, DOI 10.1182/blood-2002-07-2146; De Palma M, 2005, BLOOD, V105, P2307, DOI 10.1182/blood-2004-03-0798; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Follenzi A, 2004, BLOOD, V103, P3700, DOI 10.1182/blood-2003-09-3217; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; High K, 2005, J THROMB HAEMOST, V3, P1682, DOI 10.1111/j.1538-7836.2005.01460.x; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Mingozzi F, 2003, J CLIN INVEST, V111, P1347, DOI 10.1172/JCI200316887; Onoe T, 2005, J IMMUNOL, V175, P139, DOI 10.4049/jimmunol.175.1.139; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Steiniger B, 2003, J HISTOCHEM CYTOCHEM, V51, P655, DOI 10.1177/002215540305100511; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	30	382	464	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2006	12	5					585	591		10.1038/nm1398	http://dx.doi.org/10.1038/nm1398			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633348				2022-12-27	WOS:000238149100044
J	Yazaki, Y; Kadowaki, T				Yazaki, Y; Kadowaki, T			Combating diabetes and obesity in Japan	NATURE MEDICINE			English	Editorial Material									Natl Hosp Org, Meguro Ku, Tokyo 1528621, Japan; Univ Tokyo, Dept Metab Dis, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Yazaki, Y (corresponding author), Natl Hosp Org, Meguro Ku, 2-5-21, Tokyo 1528621, Japan.	yazaki-yoshio@nho.hosp.go.jp						KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; Mandavilli A, 2004, NAT MED, V10, P325, DOI 10.1038/nm0404-325; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	3	40	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					73	74		10.1038/nm0106-73	http://dx.doi.org/10.1038/nm0106-73			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397574				2022-12-27	WOS:000234419000054
J	Kortylewski, M; Kujawski, M; Wang, TH; Wei, S; Zhang, SM; Pilon-Thomas, S; Niu, GL; Kay, H; Mule, J; Kerr, WG; Jove, R; Pardoll, D; Yu, H				Kortylewski, M; Kujawski, M; Wang, TH; Wei, S; Zhang, SM; Pilon-Thomas, S; Niu, GL; Kay, H; Mule, J; Kerr, WG; Jove, R; Pardoll, D; Yu, H			Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity	NATURE MEDICINE			English	Article							DENDRITIC CELL-DIFFERENTIATION; TUMOR-CELLS; IN-VIVO; NK CELLS; CANCER; MACROPHAGES; RESPONSES; ANTIGEN; MICE; ENTEROCOLITIS	The immune system can act as an extrinsic suppressor of tumors. Therefore, tumor progression depends in part on mechanisms that downmodulate intrinsic immune surveillance. Identifying these inhibitory pathways may provide promising targets to enhance antitumor immunity. Here, we show that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis. We observed a markedly enhanced function of dendritic cells, T cells, natural killer (NK) cells and neutrophils in tumor-bearing mice with Stat3(-/-) hematopoietic cells, and showed that tumor regression requires immune cells. Targeting Stat3 with a small-molecule drug induces T cell- and NK cell-dependent growth inhibition of established tumors otherwise resistant to direct killing by the inhibitor. Our findings show that Stat3 signaling restrains natural tumor immune surveillance and that inhibiting hematopoietic Stat3 in tumor-bearing hosts elicits multicomponent therapeutic antitumor immunity.	H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21231 USA; Univ S Florida, Coll Publ Hlth, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; Johns Hopkins University; State University System of Florida; University of South Florida	Pardoll, D (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	dmpardol@jhmi.edu; hyu@coh.org	Kortylewski, Marcin/H-8052-2019; Kerr, William G/B-8616-2015	Kortylewski, Marcin/0000-0002-6003-1816; Kerr, William G/0000-0002-4720-7135; YU, Hua/0000-0003-0931-1000	NCI NIH HHS [R01 CA089693, P01 CA082533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089693, P01CA082533, R29CA075243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almand B, 2000, CLIN CANCER RES, V6, P1755; Alonzi T, 2004, CYTOKINE, V26, P45, DOI 10.1016/j.cyto.2003.12.002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Furumoto K, 2000, INT J CANCER, V87, P665, DOI 10.1002/1097-0215(20000901)87:5<665::AID-IJC8>3.0.CO;2-F; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; Guiducci C, 2005, CANCER RES, V65, P3437, DOI 10.1158/0008-5472.CAN-04-4262; Halak BK, 1999, CANCER RES, V59, P911; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Ho WY, 2003, CANCER CELL, V3, P431, DOI 10.1016/S1535-6108(03)00113-2; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Laouar Y, 2003, IMMUNITY, V19, P903, DOI 10.1016/S1074-7613(03)00332-7; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Melani C, 2003, BLOOD, V102, P2138, DOI 10.1182/blood-2003-01-0190; Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464; Niu GL, 1999, CANCER RES, V59, P5059; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Sotomayor EM, 2001, BLOOD, V98, P1070, DOI 10.1182/blood.V98.4.1070; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Spiotto MT, 2002, IMMUNITY, V17, P737, DOI 10.1016/S1074-7613(02)00480-6; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Turkson J, 2004, MOL CANCER THER, V3, P1533; Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Wang JW, 2002, SCIENCE, V295, P2094, DOI 10.1126/science.1068438; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu P, 2005, J EXP MED, V201, P779, DOI 10.1084/jem.20041684	46	744	810	3	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1314	1321		10.1038/nm1325	http://dx.doi.org/10.1038/nm1325			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16288283				2022-12-27	WOS:000233774400030
J	Yoshimura, K; Aoki, H; Ikeda, Y; Fujii, K; Akiyama, N; Furutani, A; Hoshii, Y; Tanaka, N; Ricci, R; Ishihara, T; Esato, K; Hamano, K; Matsuzaki, M				Yoshimura, K; Aoki, H; Ikeda, Y; Fujii, K; Akiyama, N; Furutani, A; Hoshii, Y; Tanaka, N; Ricci, R; Ishihara, T; Esato, K; Hamano, K; Matsuzaki, M			Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; IV COLLAGENASE EXPRESSION; FACTOR-KAPPA-B; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; GENE-THERAPY; RAT MODEL; DOXYCYCLINE; JNK; MICE	Abdominal aortic aneurysm (AAA) is a common disease among elderly people that, when surgical treatment is inapplicable, results in progressive expansion and rupture of the aorta with high mortality. Although nonsurgical treatment for AAA is much awaited, few options are available because its molecular pathogenesis remains elusive. Here, we identify JNK as a proximal signaling molecule in the pathogenesis of AAA. Human AAA tissue showed a high level of phosphorylated JNK. We show that JNK programs a gene expression pattern in different cell types that cooperatively enhances the degradation of the extracellular matrix while suppressing biosynthetic enzymes of the extracellular matrix. Selective inhibition of JNK in vivo not only prevented the development of AAA but also caused regression of established AAA in two mouse models. Thus, JNK promotes abnormal extracellular matrix metabolism in the tissue of AAA and may represent a therapeutic target.	Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Cardiovasc Surg, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Pathol 1, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Radiol, Ube, Yamaguchi 7558505, Japan; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Yamaguchi Univ, Sch Med, Dept Cardiovasc Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University; Yamaguchi University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Yamaguchi University	Aoki, H (corresponding author), Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	haoki@yamaguchi-u.ac.jp	Ricci, Romeo/K-3009-2013	Ricci, Romeo/0000-0002-9766-4369; Ikeda, Yasuhiro/0000-0002-2970-7304				Adachi M, 2003, FEBS LETT, V554, P77, DOI 10.1016/S0014-5793(03)01109-8; Allaire E, 1998, J CLIN INVEST, V102, P1413, DOI 10.1172/JCI2909; Allaire E, 2004, ANN SURG, V239, P417, DOI 10.1097/01.sla.0000114131.79899.82; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Baxter BT, 2002, J VASC SURG, V36, P1, DOI 10.1067/mva.2002.125018; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bigatel DA, 1999, J VASC SURG, V29, P130, DOI 10.1016/S0741-5214(99)70354-X; Bode MK, 2002, EUR J VASC ENDOVASC, V23, P413, DOI 10.1053/ejvs.2002.1606; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; BUTH J, 2005, VASCULAR SURG, P1452; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; CURCI JA, 2001, CURRENT THERAPY VASC, P199; Dai JP, 2005, CIRCULATION, V112, P1008, DOI 10.1161/CIRCULATIONAHA.104.523357; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Huffman MD, 2000, SURGERY, V128, P429, DOI 10.1067/msy.2000.107379; Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04-0929; Krettek A, 2003, ARTERIOSCL THROM VAS, V23, P582, DOI 10.1161/01.ATV.0000064372.78561.A5; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; Mosorin M, 2001, J VASC SURG, V34, P606, DOI 10.1067/mva.2001.117891; Nakashima H, 2004, CIRCULATION, V109, P132, DOI 10.1161/01.CIR.0000105725.61763.A2; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Parodi FE, 2005, J VASC SURG, V41, P479, DOI 10.1016/j.jvs.2004.12.030; Patel MI, 1996, J VASC SURG, V24, P82, DOI 10.1016/S0741-5214(96)70148-9; Petrinec D, 1996, J VASC SURG, V23, P336, DOI 10.1016/S0741-5214(96)70279-3; Prall AK, 2002, J VASC SURG, V35, P923, DOI 10.1067/mva.2002.123757; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Ricci R, 2004, SCIENCE, V306, P1558, DOI 10.1126/science.1101909; ROWE DW, 1977, J BIOL CHEM, V252, P939; SATO H, 1993, ONCOGENE, V8, P395; SCHLUMBERGER W, 1991, ARTERIOSCLER THROMB, V11, P1660, DOI 10.1161/01.ATV.11.6.1660; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Takagi Y, 2002, NEUROSURGERY, V51, P997, DOI 10.1097/00006123-200210000-00027; Upchurch GR, 2005, CIRCULATION, V112, P939, DOI 10.1161/CIRCULATIONAHA.105.558767; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; ZEMPO N, 1994, J VASC SURG, V20, P209, DOI 10.1016/0741-5214(94)90008-6	44	342	360	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1330	1338		10.1038/nm1335	http://dx.doi.org/10.1038/nm1335			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16311603				2022-12-27	WOS:000233774400032
J	Rapoport, AP; Stadtmauer, EA; Aqui, N; Badros, A; Cotte, J; Chrisley, L; Veloso, E; Zheng, ZH; Westphal, S; Mair, R; Chi, N; Ratterree, B; Pochran, MF; Natt, S; Hinkle, J; Sickles, C; Sohal, A; Ruehle, K; Lynch, C; Zhang, L; Porter, DL; Luger, S; Guo, CF; Fang, HB; Blackwelder, W; Hankey, K; Mann, D; Edelman, R; Frasch, C; Levine, BL; Cross, A; June, CH				Rapoport, AP; Stadtmauer, EA; Aqui, N; Badros, A; Cotte, J; Chrisley, L; Veloso, E; Zheng, ZH; Westphal, S; Mair, R; Chi, N; Ratterree, B; Pochran, MF; Natt, S; Hinkle, J; Sickles, C; Sohal, A; Ruehle, K; Lynch, C; Zhang, L; Porter, DL; Luger, S; Guo, CF; Fang, HB; Blackwelder, W; Hankey, K; Mann, D; Edelman, R; Frasch, C; Levine, BL; Cross, A; June, CH			Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer	NATURE MEDICINE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; PROTECTIVE ANTIBODY-RESPONSES; STEM-CELL; STREPTOCOCCUS-PNEUMONIAE; CLONAL EXPANSION; IMMUNOGENICITY; TRANSPLANTATION; POLYSACCHARIDE; INDUCTION; THERAPY	Immunodeficiency is a barrier to successful vaccination in individuals with cancer and chronic infection. We performed a randomized phase 1/2 study in lymphopenic individuals after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for myeloma. Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations improved the severe immunodeficiency associated with high-dose chemotherapy and led to the induction of clinically relevant immunity in adults within a month after transplantation. Immune assays showed accelerated restoration of CD4 T-cell numbers and function. Early T-cell infusions also resulted in significantly improved T-cell proliferation in response to antigens that were not contained in the vaccine, as assessed by responses to staphylococcal enterotoxin B and cytomegalovirus antigens ( P < 0.05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; US FDA, Ctr Biol Evolut & Res, Rockville, MD 20852 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania; Pennsylvania Medicine; US Food & Drug Administration (FDA)	Rapoport, AP (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	arapoport@umn.edu; cjune@mail.med.upenn.edu	Levine, Bruce L/D-1688-2009	Sabins, Nina/0000-0001-7983-8962; June, Carl/0000-0003-0241-3557	NCI NIH HHS [R21 CA101356-2] Funding Source: Medline; NHLBI NIH HHS [T32 HL007775] Funding Source: Medline; NIAID NIH HHS [N01-AI-85342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA101356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085342] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANIAN R, 1992, BLOOD, V80, P887; ANDERSON KC, 1990, BLOOD, V76, P235; Antin JH, 2005, BIOL BLOOD MARROW TR, V11, P213, DOI 10.1016/j.bbmt.2004.12.330; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Borrello I, 2000, BLOOD, V95, P3011; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Concepcion NF, 2001, CLIN DIAGN LAB IMMUN, V8, P266, DOI 10.1128/CDLI.8.2.266-272.2001; Dhodapkar MV, 2002, P NATL ACAD SCI USA, V99, P13009, DOI 10.1073/pnas.202491499; Dummer W, 2002, J CLIN INVEST, V110, P185, DOI 10.1172/JCI200215175; Eaton SM, 2004, J EXP MED, V200, P1613, DOI 10.1084/jem.20041395; Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Fernandez JD, 2005, VACCINE, V23, P1917, DOI 10.1016/j.vaccine.2004.10.024; Gandhi MK, 2001, BONE MARROW TRANSPL, V28, P775, DOI 10.1038/sj.bmt.1703239; Guillaume T, 1998, BLOOD, V92, P1471, DOI 10.1182/blood.V92.5.1471; GUINAN EC, 1994, TRANSPLANTATION, V57, P677, DOI 10.1097/00007890-199403150-00009; Hakim FT, 2005, J CLIN INVEST, V115, P930, DOI 10.1172/JCI200522492; Heitger A, 2002, BLOOD, V99, P4053, DOI 10.1182/blood.V99.11.4053; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5; Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531; JONES RJ, 1989, LANCET, V1, P754; Kamboj KK, 2003, J INFECT DIS, V187, P1629, DOI 10.1086/374785; Kirschner D, 1998, J MATH BIOL, V37, P235, DOI 10.1007/s002850050127; Laport GG, 2003, BLOOD, V102, P2004, DOI 10.1182/blood-2003-01-0095; Levine BL, 1997, J IMMUNOL, V159, P5921; Levine BL, 2002, NAT MED, V8, P47, DOI 10.1038/nm0102-47; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Lottenbach KR, 1999, INFECT IMMUN, V67, P4935, DOI 10.1128/IAI.67.9.4935-4938.1999; Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832; Noonan K, 2005, CANCER RES, V65, P2026, DOI 10.1158/0008-5472.CAN-04-3337; Nordoy T, 2001, BONE MARROW TRANSPL, V28, P681, DOI 10.1038/sj.bmt.1703228; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Porrata LF, 2001, BLOOD, V98, P579, DOI 10.1182/blood.V98.3.579; Powers DC, 1996, J INFECT DIS, V173, P1014, DOI 10.1093/infdis/173.4.1014; Rapoport AP, 2004, BONE MARROW TRANSPL, V33, P53, DOI 10.1038/sj.bmt.1704317; Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200; Shelly MA, 1997, INFECT IMMUN, V65, P242, DOI 10.1128/IAI.65.1.242-247.1997; Shelly MA, 2001, SCAND J INFECT DIS, V33, P542, DOI 10.1080/00365540110026502; Shinefield HR, 1999, PEDIATR INFECT DIS J, V18, P757, DOI 10.1097/00006454-199909000-00004; Singhal S, 1999, BONE MARROW TRANSPL, V23, P637, DOI 10.1038/sj.bmt.1701640; Teshima T, 2001, CANCER RES, V61, P162; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; Vavassori M, 1996, J IMMUNOL, V157, P5739; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873	47	242	275	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1230	1237		10.1038/nm1310	http://dx.doi.org/10.1038/nm1310			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227990	Bronze			2022-12-27	WOS:000233115400036
J	Larche, M; Wraith, DC				Larche, M; Wraith, DC			Peptide-based therapeutic vaccines for allergic and autoimmune diseases	NATURE MEDICINE			English	Review							MYELIN BASIC-PROTEIN; T-CELL EPITOPE; GRASS-POLLEN IMMUNOTHERAPY; COLLAGEN-INDUCED ARTHRITIS; LATE ASTHMATIC REACTIONS; IMMATURE DENDRITIC CELLS; BEE VENOM IMMUNOTHERAPY; AMINO-ACID COPOLYMERS; PHASE-II TRIAL; MULTIPLE-SCLEROSIS	Allergic and autoimmune diseases are forms of immune hypersensitivity that increasingly cause chronic ill health. Most current therapies treat symptoms rather than addressing underlying immunological mechanisms. The ability to modify antigen-specific pathogenic responses by therapeutic vaccination offers the prospect of targeted therapy resulting in long-term clinical improvement without nonspecific immune suppression. Examples of specific immune modulation can be found in nature and in established forms of immune desensitization. Understanding and exploiting common mechanisms such as the ability to induce antigen-specific regulatory cells should allow the development of effective therapeutic strategies for both forms of immunopathology. Targeting pathogenic T cells using vaccines consisting of synthetic peptides representing T cell epitopes is one such strategy that is currently being evaluated with encouraging results. Future challenges in the development of therapeutic vaccines include selection of appropriate antigens and peptides, optimization of peptide dose and route of administration and identifying strategies to induce bystander suppression.	Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Clin Immunol, Fac Med, London SW3 6LY, England; Univ Bristol, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	Imperial College London; University of Bristol	Larche, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Clin Immunol, Fac Med, Dovehouse St, London SW3 6LY, England.	m.larche@imperial.ac.uk	Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593; Wraith, David/0000-0003-2147-5614				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; ALEXANDER C, IN PRESS ALLERGY; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Alpan O, 2004, NAT IMMUNOL, V5, P615, DOI 10.1038/ni1077; AlSabbagh A, 1996, CELL IMMUNOL, V171, P111, DOI 10.1006/cimm.1996.0180; Anderton SM, 1997, BIOCHEM SOC T, V25, P659, DOI 10.1042/bst0250659; Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Anderton SM, 1998, EUR J IMMUNOL, V28, P1251, DOI 10.1002/(SICI)1521-4141(199804)28:04<1251::AID-IMMU1251>3.0.CO;2-O; Anderton SM, 1998, CIBA F SYMP, V215, P120; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Balandina A, 2005, BLOOD, V105, P735, DOI 10.1182/blood-2003-11-3900; Bali D, 1999, GENES IMMUN, V1, P28, DOI 10.1038/sj.gene.6363635; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Barrett JH, 1999, ARTHRITIS RHEUM, V42, P1219, DOI 10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Chai JG, 2004, BLOOD, V103, P3951, DOI 10.1182/blood-2003-11-3763; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Chu CQ, 1999, J AUTOIMMUN, V12, P35, DOI 10.1006/jaut.1998.0255; Cookson W, 2002, IMMUNOL REV, V190, P195, DOI 10.1034/j.1600-065X.2002.19015.x; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; Dakin R, 1829, AM J MED SCI, V4, P98; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; de Kleer IM, 2004, J IMMUNOL, V172, P6435, DOI 10.4049/jimmunol.172.10.6435; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Hanninen A, 2001, DIABETES, V50, P771, DOI 10.2337/diabetes.50.4.771; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; Jeannin P, 1998, J IMMUNOL, V160, P3555; Johnson KP, 2005, ACTA NEUROL SCAND, V111, P42, DOI 10.1111/j.1600-0404.2004.00351.x; Johnson KP, 2003, MULT SCLER, V9, P585, DOI 10.1191/1352458503ms961oa; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Karachunski PI, 1997, J CLIN INVEST, V100, P3027, DOI 10.1172/JCI119857; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LIU GY, 1995, INT IMMUNOL, V7, P1255, DOI 10.1093/intimm/7.8.1255; Liu JQ, 1998, INT IMMUNOL, V10, P1139, DOI 10.1093/intimm/10.8.1139; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Maron R, 1999, J AUTOIMMUN, V12, P251, DOI 10.1006/jaut.1999.0278; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; Mathisen PM, 1997, J EXP MED, V186, P159, DOI 10.1084/jem.186.1.159; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Merriman TR, 1995, CURR OPIN IMMUNOL, V7, P786, DOI 10.1016/0952-7915(95)80049-2; Metzler B, 1999, IMMUNOLOGY, V97, P257; Metzler B, 2000, IMMUNOL INVEST, V29, P61, DOI 10.3109/08820130009105145; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Munari L., 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD004678, 10.1002/14651858.CD004678]; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Nicholson LB, 1997, P NATL ACAD SCI USA, V94, P9279, DOI 10.1073/pnas.94.17.9279; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Nussenblatt RB, 1997, AM J OPHTHALMOL, V123, P583, DOI 10.1016/S0002-9394(14)71070-0; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; Paas-Rozner M, 2001, P NATL ACAD SCI USA, V98, P12642, DOI 10.1073/pnas.221456798; Pedotti R, 2003, TRENDS IMMUNOL, V24, P479, DOI 10.1016/S1471-4906(03)00233-3; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Prakken BJ, 1997, P NATL ACAD SCI USA, V94, P3284, DOI 10.1073/pnas.94.7.3284; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shen CR, 2003, BLOOD, V102, P3800, DOI 10.1182/blood-2002-07-2125; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Southwood S, 1998, J IMMUNOL, V160, P3363; Staines NA, 1996, CLIN EXP IMMUNOL, V103, P368; Stern JNH, 2004, P NATL ACAD SCI USA, V101, P11743, DOI 10.1073/pnas.0403832101; Stern JNH, 2005, P NATL ACAD SCI USA, V102, P1620, DOI 10.1073/pnas.0409022102; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; THURAU SR, 1991, J AUTOIMMUN, V4, P507, DOI 10.1016/0896-8411(91)90162-6; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERHOEF A, IN PRESS PLOS MED; VIDARD L, 1994, P NATL ACAD SCI USA, V91, P5627, DOI 10.1073/pnas.91.12.5627; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Williams NA, 1999, IMMUNOL TODAY, V20, P95, DOI 10.1016/S0167-5699(98)01397-8; Wraith DC, 2004, CURR OPIN IMMUNOL, V16, P695, DOI 10.1016/j.coi.2004.09.015; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; Zou LP, 1999, J NEUROIMMUNOL, V94, P109, DOI 10.1016/S0165-5728(98)00232-X	128	247	276	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S69	S76		10.1038/nm1226	http://dx.doi.org/10.1038/nm1226			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812493				2022-12-27	WOS:000228339600013
J	Apetoh, L; Ghiringhelli, F; Tesniere, A; Obeid, M; Ortiz, C; Criollo, A; Mignot, G; Maiuri, MC; Ullrich, E; Saulnier, P; Yang, H; Amigorena, S; Ryffel, B; Barrat, FJ; Saftig, P; Levi, F; Lidereau, R; Nogues, C; Mira, JP; Chompret, A; Joulin, V; Clavel-Chapelon, F; Bourhis, J; Andre, F; Delaloge, S; Tursz, T; Kroemer, G; Zitvogel, L				Apetoh, Lionel; Ghiringhelli, Francois; Tesniere, Antoine; Obeid, Michel; Ortiz, Carla; Criollo, Alfredo; Mignot, Gregoire; Maiuri, M. Chiara; Ullrich, Evelyn; Saulnier, Patrick; Yang, Huan; Amigorena, Sebastian; Ryffel, Bernard; Barrat, Franck J.; Saftig, Paul; Levi, Francis; Lidereau, Rosette; Nogues, Catherine; Mira, Jean-Paul; Chompret, Agnes; Joulin, Virginie; Clavel-Chapelon, Francoise; Bourhis, Jean; Andre, Fabrice; Delaloge, Suzette; Tursz, Thomas; Kroemer, Guido; Zitvogel, Laurence			Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy	NATURE MEDICINE			English	Article							DENDRITIC CELLS; APOPTOTIC CELLS; ANTIGEN PRESENTATION; INNATE IMMUNITY; NECROTIC CELLS; PROTEIN HMGB1; T-CELLS; TOLL-LIKE-RECEPTOR-4; DEATH; IMMUNOGENICITY	Conventional cancer treatments rely on radiotherapy and chemotherapy. Such treatments supposedly mediate their effects via the direct elimination of tumor cells. Here we show that the success of some protocols for anticancer therapy depends on innate and adaptive antitumor immune responses. We describe in both mice and humans a previously unrecognized pathway for the activation of tumor antigen-specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs). During chemotherapy or radiotherapy, DCs require signaling through TLR4 and its adaptor MyD88 for efficient processing and cross-presentation of antigen from dying tumor cells. Patients with breast cancer who carry a TLR4 loss-of-function allele relapse more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele. These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death.	Inst Gustave Roussy, F-94805 Villejuif, France; Univ Paris Sud, Le Kremlin Bicetre, France; Inst Natl Sante & Rech Med, Immunol & Immunotherapie Tumeurs U805, F-94805 Villejuif, France; IGR, Ctr Invest Biotherapies CBT507, F-94805 Villejuif, France; Inst Natl Sante & Rech Med, U848 Apoptosis Canc & Immun, F-94805 Villejuif, France; Univ Naples Federico 2, Fac Sci Biotecnol, Dipartimento Farmacol Sperimentale, I-80135 Naples, Italy; IGR, Lab Rech Tranlationnelle, F-94805 Villejuif, France; Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA; Inst Curie, Inst Nat Sante & Rech Med U653, F-75248 Paris 05, France; Ctr Natl Rech Sci IEM2815, F-45071 Orleans, France; Dynavax Technol Corp, Berkeley, CA 94710 USA; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Hop Paul Brousse, Inst Natl Sante & Rech Med U776 Biol Rhythms & Ca, F-94807 Villejuif, France; Ctr Rene Huguenin, FNCLCC, Inst Natl Sante & Rech med U735, F-92210 St Cloud, France; Univ Paris 05, Fac Med Rene Descartes, Dept Biol Cellulaire,Inst Natl Sante & Rech Med, Inst Cochin,CNRS,UMR 8104,U567, F-75014 Paris, France; IGR, Dept Med, F-94805 Villejuif, France; IGR, Dept Radiotherapy, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Naples Federico II; UNICANCER; Gustave Roussy; Northwell Health; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Kiel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Zitvogel, L (corresponding author), Inst Gustave Roussy, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; zitvogel@igr.fr	Mignot, Grégoire/R-4976-2017; OBEID, Michel/HCI-9145-2022; Apetoh, Lionel/AIC-2384-2022; Apetoh, Lionel/G-3310-2014; Saftig, Paul/A-7966-2010; ANDRE, Fabrice/AAL-2683-2020; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Clavel-Chapelon, Francoise/G-6733-2014	Mignot, Grégoire/0000-0002-0682-0152; Apetoh, Lionel/0000-0002-2774-438X; Apetoh, Lionel/0000-0002-2774-438X; ANDRE, Fabrice/0000-0001-5795-8357; KROEMER, Guido/0000-0002-9334-4405; Bourhis, Jean/0000-0001-5162-1171; Criollo, Alfredo/0000-0002-2737-7751; JOULIN, Virginie/0000-0003-1091-7819; Amigorena, Sebastian/0000-0001-8583-8416; ZITVOGEL, laurence/0000-0003-1596-0998; Ullrich, Evelyn/0000-0001-8530-1192; ghiringhelli, francois/0000-0002-5465-8305				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cheng I, 2007, CANCER EPIDEM BIOMAR, V16, P352, DOI 10.1158/1055-9965.EPI-06-0429; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; Dumitriu IE, 2007, J LEUKOCYTE BIOL, V81, P84, DOI 10.1189/jlb.0306171; Erridge C, 2003, J EXP MED, V197, P1787, DOI 10.1084/jem.20022078; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; GORLA R, 1994, AIDS RES HUM RETROV, V10, P1097, DOI 10.1089/aid.1994.10.1097; Granda TG, 2002, BRIT J CANCER, V86, P999, DOI 10.1038/sj.bjc.6600168; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Janssen E, 2006, IMMUNITY, V24, P787, DOI 10.1016/j.immuni.2006.03.024; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Ronchetti A, 1999, J LEUKOCYTE BIOL, V66, P247, DOI 10.1002/jlb.66.2.247; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shiratsuchi A, 2004, J IMMUNOL, V172, P2039, DOI 10.4049/jimmunol.172.4.2039; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; van der Graaf C, 2005, CYTOKINE, V30, P264, DOI 10.1016/j.cyto.2005.02.001; van Rijn BB, 2004, J IMMUNOL METHODS, V289, P81, DOI 10.1016/j.jim.2004.03.013; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Yarovinsky F, 2006, IMMUNITY, V25, P655, DOI 10.1016/j.immuni.2006.07.015	48	2187	2270	14	295	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1050	1059		10.1038/nm1622	http://dx.doi.org/10.1038/nm1622			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17704786				2022-12-27	WOS:000249353100032
J	Buonpane, RA; Churchill, HRO; Moza, B; Sundberg, EJ; Peterson, ML; Schlievert, PM; Kranz, DM				Buonpane, Rebecca A.; Churchill, Hywyn R. O.; Moza, Beenu; Sundberg, Eric J.; Peterson, Marnie L.; Schlievert, Patrick M.; Kranz, David M.			Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists	NATURE MEDICINE			English	Article							TOXIC-SHOCK-SYNDROME; T-CELL-ACTIVATION; ANTIBODY FRAGMENTS; PYROGENIC EXOTOXIN; SUPERANTIGENS; LIBRARIES; INVOLVEMENT; ENDOTOXIN; DISPLAY	Exotoxins of Staphylococcus aureus belong to a family of bacterial proteins that act as superantigens by activating a large subset of the T-cell population, causing massive release of inflammatory cytokines. This cascade can ultimately result in toxic shock syndrome and death. Therapeutics targeting the early stage of the pathogenic process, when the superantigen binds to its receptor, could limit the severity of disease. We engineered picomolar binding affinity agents to neutralize the potent toxin staphylococcal enterotoxin B (SEB). A single immunoglobulin-like domain of the T-cell receptor (variable region, Vb) was subjected to multiple rounds of directed evolution using yeast display. Soluble forms of the engineered Vb proteins produced in Escherichia coli were effective inhibitors of SEB-mediated T-cell activation and completely neutralized the lethal activity of SEB in animal models. These Vb proteins represent an easily produced potential treatment for diseases mediated by bacterial superantigens.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Minnesota, Sch Med, Dept Expt & Clin Pharmacol, Coll Pharm, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA	University of Illinois System; University of Illinois Urbana-Champaign; Boston Biomedical Research Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kranz, DM (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.	d-kranz@uiuc.edu	Jalali, Beenu Moza/H-7224-2017	Jalali, Beenu Moza/0000-0003-0954-3485; Buonpane, Rebecca/0000-0002-8158-8074; Sundberg, Eric/0000-0003-0478-3033; Schlievert, Patrick/0000-0001-8314-9369	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER; NIAID NIH HHS [AI064611] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07283] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews MM, 2001, CLIN INFECT DIS, V32, P1470, DOI 10.1086/320170; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Buonpane RA, 2005, J MOL BIOL, V353, P308, DOI 10.1016/j.jmb.2005.08.041; Burnett JC, 2005, NAT REV DRUG DISCOV, V4, P281, DOI 10.1038/nrd1694; CRASS BA, 1986, J CLIN MICROBIOL, V23, P1138, DOI 10.1128/JCM.23.6.1138-1139.1986; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007; HOO WS, 1993, J IMMUNOL, V150, P4331; Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126; Horn DL, 2000, CLIN INFECT DIS, V31, P851, DOI 10.1086/318127; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kieke MC, 2001, J MOL BIOL, V307, P1305, DOI 10.1006/jmbi.2001.4560; LEE VTP, 1992, J INFECT DIS, V166, P911, DOI 10.1093/infdis/166.4.911; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; Olafsen T, 2005, CANCER RES, V65, P5907, DOI 10.1158/0008-5472.CAN-04-4472; PARSONNET J, 1987, INFECT IMMUN, V55, P1070, DOI 10.1128/IAI.55.5.1070-1076.1987; Razai A, 2005, J MOL BIOL, V351, P158, DOI 10.1016/j.jmb.2005.06.003; REED L. J., 1938, AMER JOUR HYG, V27, P493; Roggiani M, 1997, INFECT IMMUN, V65, P2868, DOI 10.1128/IAI.65.7.2868-2875.1997; SCHLIEVERT PM, 1982, INFECT IMMUN, V36, P123, DOI 10.1128/IAI.36.1.123-128.1982; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; STONE RL, 1987, J INFECT DIS, V155, P682, DOI 10.1093/infdis/155.4.682; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141	26	68	74	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2007	13	6					725	729		10.1038/nm1584	http://dx.doi.org/10.1038/nm1584			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17515896				2022-12-27	WOS:000247084300036
J	El Khoury, J; Toft, M; Hickman, SE; Means, TK; Terada, K; Geula, C; Luster, AD				El Khoury, Joseph; Toft, Michelle; Hickman, Suzanne E.; Means, Terry K.; Terada, Kinya; Geula, Changiz; Luster, Andrew D.			Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease	NATURE MEDICINE			English	Article							AMYLOID-BETA-PROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; MOUSE MODEL; REACTIVE MICROGLIA; SCAVENGER RECEPTOR; APOLIPOPROTEIN-E; PLAQUE-FORMATION; GAMMA-SECRETASE	Microglia are the principal immune cells of the brain. In Alzheimer disease, these brain mononuclear phagocytes are recruited from the blood and accumulate in senile plaques. However, the role of microglia in Alzheimer disease has not been resolved. Microglia may be neuroprotective by phagocytosing amyloid-beta (A beta), but their activation and the secretion of neurotoxins may also cause neurodegeneration. Ccr2 is a chemokine receptor expressed on microglia, which mediates the accumulation of mononuclear phagocytes at sites of inflammation. Here we show that Ccr2 deficiency accelerates early disease progression and markedly impairs microglial accumulation in a transgenic mouse model of Alzheimer disease (Tg2576). Alzheimer disease mice deficient in Ccr2 accumulated Ab earlier and died prematurely, in a manner that correlated with Ccr2 gene dosage, indicating that absence of early microglial accumulation leads to decreased A beta clearance and increased mortality. Thus, Ccr2-dependent microglial accumulation plays a protective role in the early stages of Alzheimer disease by promoting Ab clearance.	Ctr Immunol & Inflammat Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan; Beth Israel Deaconess Med Ctr, Lab Neurodegenerat & Aging Res, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Okayama University; Harvard University; Beth Israel Deaconess Medical Center	El Khoury, J (corresponding author), Ctr Immunol & Inflammat Dis, Div Rheumatol Allergy & Immunol, 149 13th St, Charlestown, MA 02129 USA.	jelkhoury@partners.org; luster.andrew@mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				Babcock AA, 2003, J NEUROSCI, V23, P7922; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bennett JL, 2003, J NEUROVIROL, V9, P623, DOI 10.1080/714044484; Benzing WC, 1999, NEUROBIOL AGING, V20, P581, DOI 10.1016/S0197-4580(99)00065-2; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Charo IF, 2003, MICROCIRCULATION, V10, P259, DOI 10.1038/sj.mn.7800191; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; ElKhoury J, 1996, NATURE, V382, P716; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Frautschy SA, 1998, AM J PATHOL, V152, P307; Fryer JD, 2003, J NEUROSCI, V23, P7889; Ghiso J, 2001, J ALZHEIMERS DIS, V3, P65, DOI 10.3233/JAD-2001-3110; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang DR, 2005, FASEB J, V19, P761, DOI 10.1096/fj.04-3104com; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kuo YM, 2000, MOL MED, V6, P430, DOI 10.1007/BF03401785; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; Meda L, 1996, J IMMUNOL, V157, P1213; Miao J, 2005, AM J PATHOL, V167, P505, DOI 10.1016/S0002-9440(10)62993-8; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Robbins EM, 2006, J NEUROSCI, V26, P365, DOI 10.1523/JNEUROSCI.3854-05.2006; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Smits HA, 2002, J NEUROIMMUNOL, V127, P160, DOI 10.1016/S0165-5728(02)00112-1; Stalder AK, 2005, J NEUROSCI, V25, P11125, DOI 10.1523/JNEUROSCI.2545-05.2005; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weldon DT, 1998, J NEUROSCI, V18, P2161; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	50	675	697	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					432	438		10.1038/nm1555	http://dx.doi.org/10.1038/nm1555			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17351623				2022-12-27	WOS:000245543900031
J	Rousseaux, C; Thuru, X; Gelot, A; Barnich, N; Neut, C; Dubuquoy, L; Dubuquoy, C; Merour, E; Geboes, K; Chamaillard, M; Ouwehand, A; Leyer, G; Carcano, D; Colombel, JF; Ardid, D; Desreumaux, P				Rousseaux, Christel; Thuru, Xavier; Gelot, Agathe; Barnich, Nicolas; Neut, Christel; Dubuquoy, Laurent; Dubuquoy, Caroline; Merour, Emilie; Geboes, Karen; Chamaillard, Mathias; Ouwehand, Arthur; Leyer, Greg; Carcano, Didier; Colombel, Jean-Frederic; Ardid, Denis; Desreumaux, Pierre			Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors	NATURE MEDICINE			English	Article							IRRITABLE-BOWEL-SYNDROME; COLON; HYPERSENSITIVITY; EXPRESSION	Abdominal pain is common in the general population and, in patients with irritable bowel syndrome, is attributed to visceral hypersensitivity. We found that oral administration of specific Lactobacillus strains induced the expression of mu-opioid and cannabinoid receptors in intestinal epithelial cells, and mediated analgesic functions in the gut-similar to the effects of morphine. These results suggest that the microbiology of the intestinal tract influences our visceral perception, and suggest new approaches for the treament of abdominal pain and irritable bowel syndrome.	Hop Swynghedauw, INSERM, U795, F-59037 Lille, France; Univ Lille 2, Hop Swynghedauw, F-59037 Lille, France; Hop Huriez, Digest Tract Dis & Nutr Dept, F-59037 Lille, France; INSERM, U766, F-63001 Clermont Ferrand, France; Univ Clermont Ferrand 1, Lab Pharmacol Med, Unite Format & Rech Med, F-63001 Clermont Ferrand, France; Inst Univ & Technol Biol, F-63172 Aubiere, France; Fac Med & Pharm, Lab Pathogenie Bacterienne Intestinale, Ctr Biomed Rech & Valorisat, F-63001 Clermont Ferrand, France; Katholieke Univ Leuven, Dept Pathol & Gastroenterol, B-3000 Louvain, Belgium; Danisco Cultures Div, F-75017 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); KU Leuven	Desreumaux, P (corresponding author), Hop Swynghedauw, INSERM, U795, Rue A Verhaeghe, F-59037 Lille, France.	pdesreumaux@hotmail.com	Dubuquoy, laurent/J-4978-2015; Chamaillard, Mathias/L-6542-2013; GELOT, Agathe/K-5552-2015; ardid, denis/K-2234-2015; Dubuquoy, Laurent/N-1623-2019; Neut, Christel/S-2521-2018; Desreumaux, Pierre F/R-6877-2018; Thuru, Xavier/F-7695-2018; Neut, Christel/AAA-5153-2021; Geboes, Karen P/E-1752-2018	Dubuquoy, laurent/0000-0003-3596-5497; Chamaillard, Mathias/0000-0002-0243-9717; Neut, Christel/0000-0002-2036-6152; Desreumaux, Pierre F/0000-0002-6127-5281; Thuru, Xavier/0000-0002-0998-4160; Geboes, Karen P/0000-0002-1003-666X; Ouwehand, Arthur/0000-0001-8348-0633; Barnich, Nicolas/0000-0001-9465-7844				Altermann E, 2005, P NATL ACAD SCI USA, V102, P3906, DOI 10.1073/pnas.0409188102; Bourdu S, 2005, GASTROENTEROLOGY, V128, P1996, DOI 10.1053/j.gastro.2005.03.082; Cervero F, 1999, LANCET, V353, P2145, DOI 10.1016/S0140-6736(99)01306-9; D'Argenio G, 2006, FASEB J, V20, P568, DOI 10.1096/fj.05-4943fje; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Kajander K, 2005, ALIMENT PHARM THER, V22, P387, DOI 10.1111/j.1365-2036.2005.02579.x; Kamiya T, 2006, GUT, V55, P191, DOI 10.1136/gut.2005.070987; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Philippe D, 2006, GUT, V55, P815, DOI 10.1136/gut.2005.080887; Philippe D, 2003, J CLIN INVEST, V111, P1329, DOI 10.1172/JCI200316750; Sanders ME, 2001, J DAIRY SCI, V84, P319, DOI 10.3168/jds.S0022-0302(01)74481-5; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Verdu EF, 2006, GUT, V55, P182, DOI 10.1136/gut.2005.066100; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026	15	526	569	2	69	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					35	37		10.1038/nm1521	http://dx.doi.org/10.1038/nm1521			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159985				2022-12-27	WOS:000243301800033
J	Ni, YX; Zhao, XH; Bao, GB; Zou, L; Teng, L; Wang, Z; Song, M; Xiong, JX; Bai, Y; Pei, G				Ni, Yanxiang; Zhao, Xiaohui; Bao, Guobin; Zou, Lin; Teng, Lin; Wang, Zhu; Song, Min; Xiong, Jiaxiang; Bai, Yun; Pei, Gang			Activation of beta(2)-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; A-BETA; TRANSGENIC MICE; ENDOCYTIC PATHWAY; PRESENILIN; BRAIN; STRESS; OLIGOMERIZATION; TRAFFICKING	Amyloid plaque is the hallmark and primary cause of Alzheimer disease. Mutations of presenilin-1, the gamma-secretase catalytic subunit, can affect amyloid-beta (A beta) production and Alzheimer disease pathogenesis. However, it is largely unknown whether and how c-secretase activity and amyloid plaque formation are regulated by environmental factors such as stress, which is mediated by receptors including beta(2)-adrenergic receptor (beta(2)-AR). Here we report that activation of beta(2)-AR enhanced gamma-secretase activity and thus A beta production. This enhancement involved the association of beta(2)-AR with presenilin-1 and required agonist-induced endocytosis of beta(2)-AR and subsequent trafficking of gamma-secretase to late endosomes and lysosomes, where A beta production was elevated. Similar effects were observed after activation of delta-opioid receptor. Furthermore, chronic treatment with beta(2)-AR agonists increased cerebral amyloid plaques in an Alzheimer disease mouse model. Thus, beta(2)-AR activation can stimulate c-secretase activity and amyloid plaque formation, which suggests that abnormal activation of beta(2)-AR might contribute to A beta accumulation in Alzheimer disease pathogenesis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Mol Cell Biol Lab, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Third Mil Med Univ, Dept Med Genet, Chongqing 400038, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Army Medical University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Mol Cell Biol Lab, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	gpei@sibs.ac.cn	Zhao, Xiaohui/G-7626-2012; Wang, Zhu/H-3844-2013					Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Cai DM, 2006, P NATL ACAD SCI USA, V103, P1941, DOI 10.1073/pnas.0510708103; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Ferry B, 1999, BIOL PSYCHIAT, V46, P1140, DOI 10.1016/S0006-3223(99)00157-2; FOLLESA P, 1993, MOL PHARMACOL, V43, P132; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Guo DF, 2001, CELL RES, V11, P165, DOI 10.1038/sj.cr.7290083; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Langui D, 2004, AM J PATHOL, V165, P1465, DOI 10.1016/S0002-9440(10)63405-0; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ramsden M, 2003, J NEUROCHEM, V87, P1052, DOI 10.1046/j.1471-4159.2003.02114.x; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RussoNeustadt A, 1997, J NEUROSCI, V17, P5573; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanzi RE, 2005, NAT NEUROSCI, V8, P977, DOI 10.1038/nn0805-977; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Walters MR, 2003, J CARDIOVASC PHARM, V42, P266, DOI 10.1097/00005344-200308000-00017; Wang YP, 2004, CELL RES, V14, P467, DOI 10.1038/sj.cr.7290249; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilson RS, 2003, NEUROLOGY, V61, P1479, DOI 10.1212/01.WNL.0000096167.56734.59; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yin DL, 2000, J EXP MED, V191, P1423, DOI 10.1084/jem.191.8.1423	49	173	191	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1390	1396		10.1038/nm1485	http://dx.doi.org/10.1038/nm1485			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115048				2022-12-27	WOS:000242618200019
J	Yun, SH; Tearney, GJ; Vakoc, BJ; Shishkov, M; Oh, WY; Desjardins, AE; Suter, MJ; Chan, RC; Evans, JA; Jang, IK; Nishioka, NS; de Boer, JF; Bouma, BE				Yun, Seok H.; Tearney, Guillermo J.; Vakoc, Benjamin J.; Shishkov, Milen; Oh, Wang Y.; Desjardins, Adrien E.; Suter, Melissa J.; Chan, Raymond C.; Evans, John A.; Jang, Ik-Kyung; Nishioka, Norman S.; de Boer, Johannes F.; Bouma, Brett E.			Comprehensive volumetric optical microscopy in vivo	NATURE MEDICINE			English	Article							COHERENCE TOMOGRAPHY; ATHEROSCLEROTIC PLAQUES; LASER; ESOPHAGUS; DYSPLASIA; DIAGNOSIS	Comprehensive volumetric microscopy of epithelial, mucosal and endothelial tissues in living human patients would have a profound impact in medicine by enabling diagnostic imaging at the cellular level over large surface areas. Considering the vast area of these tissues with respect to the desired sampling interval, achieving this goal requires rapid sampling. Although noninvasive diagnostic technologies are preferred, many applications could be served by minimally invasive instruments capable of accessing remote locations within the body. We have developed a fiber-optic imaging technique termed optical frequency-domain imaging (OFDI) that satisfies these requirements by rapidly acquiring high-resolution, cross-sectional images through flexible, narrow-diameter catheters. Using a prototype system, we show comprehensive microscopy of esophageal mucosa and of coronary arteries in vivo. Our pilot study results suggest that this technology may be a useful clinical tool for comprehensive diagnostic imaging for epithelial disease and for evaluating coronary pathology and iatrogenic effects.	Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Biophys Program, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Gastroenterol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Cardiol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Bouma, BE (corresponding author), Harvard Univ, Sch Med, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA.	bouma@helix.mgh.harvard.edu	de Boer, Johannes F/B-7590-2012; Jovani, Manol/AAF-5333-2020; Oh, Wang-Yuhl/C-2055-2011	de Boer, Johannes F/0000-0003-1253-4950; 	NCI NIH HHS [R01 CA103769, R33 CA110130, R33 CA110130-02, R01 CA103769-03] Funding Source: Medline; NCRR NIH HHS [R01 RR0119768, R01 RR019768-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL076398-03, R01 HL076398, R01 HL070039-03, R01 HL070039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103769, R33CA110130] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR019768] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076398, R01HL070039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boppart SA, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2008974; Bouma BE, 2000, GASTROINTEST ENDOSC, V51, P467, DOI 10.1016/S0016-5107(00)70449-4; Bouma BE, 2003, HEART, V89, P317, DOI 10.1136/heart.89.3.317; Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067; Evans JA, 2006, CLIN GASTROENTEROL H, V4, P38, DOI 10.1016/S1542-3565(05)00746-9; FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Jang IK, 2005, CIRCULATION, V111, P1551, DOI 10.1161/01.CIR.0000159354.43778.69; Jang IK, 2002, J AM COLL CARDIOL, V39, P604, DOI 10.1016/S0735-1097(01)01799-5; Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050; KINGSLEY SA, 1985, ELECTRON LETT, V21, P434, DOI 10.1049/el:19850309; Kobayashi K, 1998, GASTROINTEST ENDOSC, V47, P515, DOI 10.1016/S0016-5107(98)70254-8; Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; MacNeill BD, 2004, J AM COLL CARDIOL, V44, P972, DOI 10.1016/j.jacc.2004.05.066; Pfau PR, 2003, GASTROINTEST ENDOSC, V58, P196, DOI 10.1067/mge.2003.344; Poneros JM, 2001, GASTROENTEROLOGY, V120, P7, DOI 10.1053/gast.2001.20911; Rajadhyaksha M, 1999, J INVEST DERMATOL, V113, P293, DOI 10.1046/j.1523-1747.1999.00690.x; Tearney GJ, 2003, CIRCULATION, V107, P113, DOI 10.1161/01.CIR.0000044384.41037.43; Tearney GJ, 1997, AM J GASTROENTEROL, V92, P1800; Vakoc BJ, 2005, OPT EXPRESS, V13, P5483, DOI 10.1364/OPEX.13.005483; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Yabushita H, 2002, CIRCULATION, V106, P1640, DOI 10.1161/01.CIR.0000029927.92825.F6; Yang CH, 2004, OPT LETT, V29, P1396, DOI 10.1364/OL.29.001396; Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953; Yun SH, 2003, OPT LETT, V28, P1981, DOI 10.1364/OL.28.001981; Zhang J, 2004, OPT EXPRESS, V12, P6033, DOI 10.1364/OPEX.12.006033	29	333	351	3	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1429	1433		10.1038/nm1450	http://dx.doi.org/10.1038/nm1450			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115049	Green Accepted			2022-12-27	WOS:000242618200025
J	Cheng, T; Petraglia, AL; Li, Z; Thiyagarajan, M; Zhong, ZH; Wu, ZH; Liu, D; Maggirwar, SB; Deane, R; Fernandez, JA; LaRue, B; Griffin, JH; Chopp, M; Zlokovic, BV				Cheng, Tong; Petraglia, Anthony L.; Li, Zhang; Thiyagarajan, Meenakshisundaram; Zhong, Zhihui; Wu, Zhenhua; Liu, Dong; Maggirwar, Sanjay B.; Deane, Rashid; Fernandez, Jose A.; LaRue, Barbra; Griffin, John H.; Chopp, Michael; Zlokovic, Berislav V.			Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; FACTOR-KAPPA-B; ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; NEURONAL DAMAGE; EMBOLIC STROKE; RAT MODEL; RECEPTOR; APOPTOSIS; BARRIER	Brain hemorrhage is a serious complication of tissue plasminogen activator (tPA) therapy for ischemic stroke. Here we report that activated protein C (APC), a plasma serine protease with systemic anticoagulant, anti- inflammatory and antiapoptotic activities, and direct vasculoprotective and neuroprotective activities, blocks tPA- mediated brain hemorrhage after transient brain ischemia and embolic stroke in rodents. We show that APC inhibits a pro- hemorrhagic tPA- induced, NF-kappa B-dependent matrix metalloproteinase-9 pathway in ischemic brain endothelium in vivo and in vitro by acting through protease-activated receptor 1. The present findings suggest that APC may improve thrombolytic therapy for stroke, in part, by reducing tPA- mediated hemorrhage.	Univ Rochester, Med Ctr, Frank P Smith Lab Neurosci & Neurosurg Res, Dept Neurosurg, Rochester, NY 14642 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI 48202 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Rochester; Henry Ford Health System; Henry Ford Hospital; University of Rochester; Scripps Research Institute	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Lab Neurosci & Neurosurg Res, Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu	Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063290] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Fernandez JA, 2003, BLOOD CELL MOL DIS, V30, P271, DOI 10.1016/S1079-9796(03)00034-2; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Laderoute KR, 2005, SEMIN CELL DEV BIOL, V16, P502, DOI 10.1016/j.semcdb.2005.03.005; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nurmi A, 2004, J NEUROCHEM, V91, P755, DOI 10.1111/j.1471-4159.2004.02756.x; Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754; Zlokovic BV, 2006, NAT MED, V12, P390, DOI 10.1038/nm0406-390; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	42	216	224	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1278	1285		10.1038/nm1498	http://dx.doi.org/10.1038/nm1498			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072311				2022-12-27	WOS:000241844900025
J	Yan, M; Kanbe, E; Peterson, LF; Boyapati, A; Miao, Y; Wang, Y; Chen, IM; Chen, ZX; Rowley, JD; Willman, CL; Zhang, DE				Yan, Ming; Kanbe, Eiki; Peterson, Luke F.; Boyapati, Anita; Miao, Yuqin; Wang, Yang; Chen, I-Ming; Chen, Zixing; Rowley, Janet D.; Willman, Cheryl L.; Zhang, Dong-Er			A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; AML1-ETO FUSION PROTEIN; EMBRYONIC LETHALITY; MURINE MODEL; EXPRESSION; HEMATOPOIESIS; PROGENITORS; MICE; ABNORMALITIES; TRANSLOCATION	The t(8; 21)(q22; q22) translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML), identified in 15% of all cases of AML, including 40-50% of FAB M2 subtype and rare cases of M0, M1 and M4 subtypes(1-4). The most commonly known AML1-ETO fusion protein (full-length AML1-ETO) from this translocation has 752 amino acids and contains the N-terminal portion of RUNX1 (also known as AML1, CBF alpha 2 or PEBP2 alpha B), including its DNA binding domain, and almost the entire RUNX1T1 (also known as MTG8 or ETO) protein(5). Although alterations of gene expression and hematopoietic cell proliferation have been reported in the presence of AML1-ETO, its expression does not lead to the development of leukemia(6-9). Here, we report the identification of a previously unknown alternatively spliced isoform of the AML1-ETO transcript, AML1-ETO9a, that includes an extra exon, exon 9a, of the ETO gene. AML1-ETO9a encodes a C-terminally truncated AML1-ETO protein of 575 amino acids. Expression of AML1-ETO9a leads to rapid development of leukemia in a mouse retroviral transduction transplantation model. More importantly, coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage. These results indicate that fusion proteins from alternatively spliced isoforms of a chromosomal translocation may work together to induce cancer development.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China; Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Scripps Research Institute; Soochow University - China; University of New Mexico; University of Chicago	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu			NCI NIH HHS [CA104509, CA096735] Funding Source: Medline; NHLBI NIH HHS [F32HL079900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104509, R01CA096735] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL079900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; KITA K, 1994, LEUKEMIA LYMPHOMA, V13, P229, DOI 10.3109/10428199409056286; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Langabeer SE, 1997, BRIT J HAEMATOL, V99, P925, DOI 10.1046/j.1365-2141.1997.4663270.x; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Peterson LF, 2005, MOL CELL BIOL, V25, P10205, DOI 10.1128/MCB.25.23.10205-10219.2005; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Rege K, 2000, LEUKEMIA LYMPHOMA, V40, P67, DOI 10.3109/10428190009054882; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Rowe D, 2000, BRIT J HAEMATOL, V111, P1051, DOI 10.1046/j.1365-2141.2000.02474.x; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	30	205	216	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					945	949		10.1038/nm1443	http://dx.doi.org/10.1038/nm1443			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892037				2022-12-27	WOS:000239626200026
J	Sauzeau, V; Sevilla, MA; Rivas-Elena, JV; de Alava, E; Montero, MJ; Lopez-Novoa, JM; Bustelo, XR				Sauzeau, Vincent; Sevilla, Maria A.; Rivas-Elena, Juan V.; de Alava, Enrique; Montero, Maria J.; Lopez-Novoa, Jose M.; Bustelo, Xose R.			Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction	NATURE MEDICINE			English	Article							ELEVATED HEART-RATE; HYPERTENSION; FAMILY; REQUIREMENT; PROTEINS	Although much is known about environmental factors that predispose individuals to hypertension and cardiovascular disease, little information is available regarding the genetic and signaling events involved(1-3). Indeed, few genes associated with the progression of these pathologies have been discovered despite intensive research in animal models and human populations(1-3). Here we identify Vav3, a GDP-GTP exchange factor that stimulates Rho and Rac GTPases(4), as an essential factor regulating the homeostasis of the cardiovascular system. Vav3-deficient mice exhibited tachycardia, systemic arterial hypertension and extensive cardiovascular remodeling. These mice also showed hyperactivity of sympathetic neurons from the time of birth. The high catecholamine levels associated with this condition led to the activation of the renin-angiotensin system, increased levels of kidney-related hormones and the progressive loss of cardiovascular and renal homeostasis. Pharmacological studies with drugs targeting sympathetic and renin-angiotensin responses confirmed the causative role and hierarchy of these events in the development of the Vav3-null mouse phenotype. These observations uncover the crucial role of Vav3 in the regulation of the sympathetic nervous system (SNS) and cardiovascular physiology, and reveal a signaling pathway that could be involved in the pathophysiology of human disease states involving tachycardia and sympathetic hyperactivity with unknown etiologies(2,5,6).	Univ Salamanca, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; Univ Salamanca, Red Temat Cooperat, Ctr Canc, CSIC, E-37007 Salamanca, Spain; Univ Salamanca, Dept Fisiol & Farmacol, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	IBIS, SARCOMAS/O-1893-2015; Montero, María José MJ/C-3084-2018; Lopez-Novoa, Jose M/A-3672-2008; Sevilla, M Angeles/J-8146-2017; Sauzeau, Vincent/D-3548-2015; de Alava, Enrique/GOH-0368-2022; Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Montero, María José MJ/0000-0003-2125-0378; Sevilla, M Angeles/0000-0003-2960-8514; de Alava, Enrique/0000-0001-8400-046X; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Sauzeau, Vincent/0000-0002-6187-0312; Lopez-Novoa, Jose M./0000-0002-6211-7269	NCI NIH HHS [R01 CA073735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beevers G, 2001, BRIT MED J, V322, P912, DOI 10.1136/bmj.322.7291.912; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Carrasco GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8; CHEVILLARD C, 1988, EUR J PHARMACOL, V147, P23, DOI 10.1016/0014-2999(88)90629-2; DiBona GF, 2004, HYPERTENSION, V43, P147, DOI 10.1161/01.HYP.0000113047.47711.fa; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Flores O, 1998, EXP NEPHROL, V6, P39; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Jerkic M, 2004, FASEB J, V18, P609, DOI 10.1096/fj.03-0197fje; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Palatini P, 2006, DRUGS, V66, P133, DOI 10.2165/00003495-200666020-00001; Palatini P, 2004, CLIN EXP HYPERTENS, V26, P637, DOI 10.1081/CEH-200031959; Palatini P, 1999, AM J HYPERTENS, V12, p3S, DOI 10.1016/S0895-7061(98)00207-6; Palatini P, 1999, Curr Hypertens Rep, V1, P219, DOI 10.1007/s11906-999-0024-7; Remuzzi G, 2002, NAT REV DRUG DISCOV, V1, P986, DOI 10.1038/nrd962; Schmieder RE, 2000, J HUM HYPERTENS, V14, P597, DOI 10.1038/sj.jhh.1001044; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Takahashi N, 1999, J AM SOC NEPHROL, V10, P1598; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Valdivielso JM, 2001, AM J PHYSIOL-REG I, V280, pR771, DOI 10.1152/ajpregu.2001.280.3.R771	24	85	86	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					841	845		10.1038/nm1426	http://dx.doi.org/10.1038/nm1426			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767097	Green Accepted, Green Submitted			2022-12-27	WOS:000238862800073
J	Choi, JM; Ahn, MH; Chae, WJ; Jung, YG; Park, JC; Song, HM; Kim, YE; Shin, JA; Park, CS; Park, JW; Park, TK; Lee, JH; Seo, BF; Kim, KD; Kim, ES; Lee, DH; Lee, SK; Lee, SK				Choi, Je-Min; Ahn, Mi-Hyun; Chae, Wook-Jin; Jung, Yung-Gook; Park, Jae-Chul; Song, Hyun-Mi; Kim, Young-Eun; Shin, Jung-Ah; Park, Choon-Sik; Park, Jung-Won; Park, Tae-Kwann; Lee, Jung-Hoon; Seo, Byung-Fhy; Kim, Kyun-Do; Kim, Eun-Sung; Lee, Dong-Ho; Lee, Seung-Kyou; Lee, Sang-Kyou			Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; IN-VIVO; TYROSINE PHOSPHATASE; INHIBITORY RECEPTORS; MAMMALIAN-CELLS; ASTHMA; MOUSE; ACTIVATION; MODEL	CTLA-4 is a negative regulator of T-cell activation, and its inhibitory effects can be accomplished either by competition with CD28 or by transmitting negative signals through its intracellular domain. To utilize the cytoplasmic domain of CTLA-4 to suppress allergic inflammation, we fused it to a novel protein-transduction domain in the human transcriptional factor Hph-1. Transduction efficiency was verified in vitro and in vivo after ocular, intranasal and intradermal administration. After transduction into T cells, the Hph-1 ctCTLA-4 fusion protein inhibited the production of interleukin (IL)-2, and downregulated CD69 and CD25. Intranasal administration of Hph-1-ctCTLA-4 resulted in markedly reduced infiltration of inflammatory cells, secretion of T helper type 2 (T(H)2) cytokines, serum IgE levels and airway hyper-responsiveness in a mouse model of allergic airway inflammation. These results indicated that Hph-1-ctCTLA-4 constitutes an effective immunosuppressive protein drug for potential use in the treatment of allergic asthma, via nasal administration.	Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Genome Res Ctr Allergy & Resp Dis, Puchon 420767, South Korea; Yonsei Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Dept Ophthalmol, Puchon 420767, South Korea; Chungnam Natl Univ Hosp, Dept Dermatol, Taejon 301721, South Korea; Amorepacific Co, R&D Ctr, Skin Res Inst, Yongin 449729, South Korea; ForHumanTech Co Ltd, Suwon, South Korea	Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Chungnam National University; Chungnam National University Hospital; Samsung	Lee, SK (corresponding author), Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea.	sjrlee@yonsei.ac.kr		Park, Tae Kwann/0000-0001-9689-4384; Park, Jung-Won/0000-0003-0249-8749; Choi, Je-Min/0000-0002-9482-710X; Park, Choon-Sik/0000-0003-2977-0255				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busch R, 2004, J IMMUNOL METHODS, V286, P97, DOI 10.1016/j.jim.2003.12.012; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chikuma S, 2005, J IMMUNOL, V175, P177, DOI 10.4049/jimmunol.175.1.177; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Krautwald S, 2004, J BIOL CHEM, V279, P44005, DOI 10.1074/jbc.M401327200; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Myou S, 2003, J IMMUNOL, V171, P4379, DOI 10.4049/jimmunol.171.8.4379; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Schneider H, 2000, BIOCHEM BIOPH RES CO, V269, P279, DOI 10.1006/bbrc.2000.2234; Schneider H, 2001, EUR J IMMUNOL, V31, P2042, DOI 10.1002/1521-4141(200107)31:7<2042::AID-IMMU2042>3.0.CO;2-D; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; TEFT WA, 2005, ANNU REV IMMUNOL; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Veldhoen M, 2005, EUR J IMMUNOL, V35, P207, DOI 10.1002/eji.200425542; Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yi LA, 2004, INT IMMUNOL, V16, P539, DOI 10.1093/intimm/dxh055; Zhang JY, 1999, J IMMUNOL, V163, P3012	30	112	118	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2006	12	5					574	579		10.1038/nm1385	http://dx.doi.org/10.1038/nm1385			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604087				2022-12-27	WOS:000238149100042
J	Alter, J; Lou, F; Rabinowitz, A; Yin, HF; Rosenfeld, J; Wilton, SD; Partridge, TA; Lu, QL				Alter, J; Lou, F; Rabinowitz, A; Yin, HF; Rosenfeld, J; Wilton, SD; Partridge, TA; Lu, QL			Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology	NATURE MEDICINE			English	Article							ANTISENSE; EXON	For the majority of Duchenne muscular dystrophy (DMD) mutations, antisense oligonucleotide (AON)-mediated exon skipping has the potential to restore a functional protein. Here we show that weekly intravenous injections of morpholino phosphorodiamidate (morpholino) AONs induce expression of functional levels of dystrophin in body-wide skeletal muscles of the dystrophic mdx mouse, with resulting improvement in muscle function. Although the level of dystrophin expression achieved varies considerably between muscles, antisense therapy may provide a realistic hope for the treatment of a majority of individuals with DMD.	Carolinas Med Ctr, Neuromuscular ALS Ctr, Muscular Dystrophy Lab, Charlotte, NC 28231 USA; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Nedlands, WA 6009, Australia	Carolinas Medical Center; Imperial College London; University of Hertfordshire; University of Western Australia	Lu, QL (corresponding author), Carolinas Med Ctr, Neuromuscular ALS Ctr, Muscular Dystrophy Lab, 1000 Blythe Blvd, Charlotte, NC 28231 USA.	qi.lu@carolinashealthcare.org	lu, qi/HHS-2115-2022	Wilton, Steve/0000-0002-9400-893X				Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Bruno IG, 2004, HUM MOL GENET, V13, P2409, DOI 10.1093/hmg/ddh272; Dickson G, 2002, NEUROMUSCULAR DISORD, V12, pS67, DOI 10.1016/S0960-8966(02)00085-8; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196; Goyenvalle A, 2004, SCIENCE, V306, P1796, DOI 10.1126/science.1104297; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x; Laing N G, 1993, Mol Cell Biol Hum Dis Ser, V3, P37; Lu QL, 2005, P NATL ACAD SCI USA, V102, P198, DOI 10.1073/pnas.0406700102; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187	15	402	460	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					175	177		10.1038/nm1345	http://dx.doi.org/10.1038/nm1345			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444267				2022-12-27	WOS:000235160600020
J	Kerjaschki, D; Huttary, N; Raab, I; Regele, H; Bojarski-Nagy, K; Bartel, G; Krober, SM; Greinix, H; Rosenmaier, A; Karlhofer, F; Wick, N; Mazal, PR				Kerjaschki, D; Huttary, N; Raab, I; Regele, H; Bojarski-Nagy, K; Bartel, G; Krober, SM; Greinix, H; Rosenmaier, A; Karlhofer, F; Wick, N; Mazal, PR			Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants	NATURE MEDICINE			English	Article							MACROPHAGES; ANGIOGENESIS; INFLAMMATION; METASTASIS	De novo lymphangiogenesis influences the course of different human diseases as diverse as chronic renal transplant rejection(1) and tumor metastasis(2,3). The cellular mechanisms of lymphangiogenesis in human diseases are currently unknown, and could involve division of local preexisting endothelial cells or incorporation of circulating progenitors. We analyzed renal tissues of individuals with gender-mismatched transplants who had transplant rejection and high rates of overall lymphatic endothelial proliferation as well as massive chronic inflammation. Donor-derived cells were detected by in situ hybridization of the Y chromosome. We compared these tissues with biopsies of essentially normal skin and intestine, and two rare carcinomas with low rates of lymphatic endothelial proliferation that were derived from individuals with gender-mismatched bone marrow transplants. Here, we provide evidence for the participation of recipient-derived lymphatic progenitor cells in renal transplants. In contrast, lymphatic vessels of normal tissues and those around post-transplant carcinomas did not incorporate donor-derived progenitors. This indicates a stepwise mechanism of inflammation-associated de novo lymphangiogenesis, implying that potential lymphatic progenitor cells derive from the circulation, transmigrate through the connective tissue stroma, presumably in the form of macrophages, and finally incorporate into the growing lymphatic vessel.	Med Univ Vienna, Allgemeines Krankenhaus, Dept Pathol, A-1090 Vienna, Austria; Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany; Austrian Bone Marrow Donor Registry, A-1080 Vienna, Austria; Med Univ Vienna, Allgemeines Krankenhaus, Dept Dermatol, A-1090 Vienna, Austria	Medical University of Vienna; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Medical University of Vienna	Kerjaschki, D (corresponding author), Med Univ Vienna, Allgemeines Krankenhaus, Dept Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	dontscho.kerjaschki@meduniwien.ac.at	Bartel, Gregor/C-6654-2008	bond, gregor/0000-0003-0440-3053; Mazal, Peter/0000-0002-9586-6231				Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; He YL, 2004, CANCER RES, V64, P3737, DOI 10.1158/0008-5472.CAN-04-0088; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Ito WD, 2003, ENDOTHELIUM-J ENDOTH, V10, P233, DOI 10.1080/713715240; Jackson DG, 2004, APMIS, V112, P526, DOI 10.1111/j.1600-0463.2004.apm11207-0811.x; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Mazal PR, 2002, NEW ENGL J MED, V347, P653, DOI 10.1056/NEJMoa013413; PLUNKETT ML, 1987, J EXP MED, V165, P664, DOI 10.1084/jem.165.3.664; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051	20	274	295	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2006	12	2					230	234		10.1038/nm1340	http://dx.doi.org/10.1038/nm1340			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16415878				2022-12-27	WOS:000235160600029
J	Veazey, RS; Springer, MS; Marx, PA; Dufour, J; Klasse, PJ; Moore, JP				Veazey, RS; Springer, MS; Marx, PA; Dufour, J; Klasse, PJ; Moore, JP			Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor	NATURE MEDICINE			English	Article							INFECTION; PREVENTION; TRANSMISSION	Pre-exposure oral prophylaxis with antiviral drugs is a potential method for preventing transmission of human immunodeficiency virus type 1 (HIV-1). We show that oral delivery of CMPD167, a small molecule that binds to the CCR5 coreceptor, for 10-14 d can protect a substantial proportion of macaques from vaginal infection with a CCR5-using virus (SHIV-162P3). The macaques that became infected despite receiving CMPD167 had reduced plasma viremia levels during the earliest stages of infection.	Tulane Natl Primate Res Ctr, Covington, LA 70433 USA; Merck Res Labs, Rahway, NJ 07065 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Tulane University; Merck & Company; Cornell University	Moore, JP (corresponding author), Tulane Natl Primate Res Ctr, 18703 3 Rivers Rd, Covington, LA 70433 USA.	jpm2003@med.cornell.edu	Klasse, P.J./AEX-0142-2022	Klasse, P.J./0000-0001-8222-278X				*AIDS VACC ADV COA, 2005, WILL PILL DAY PREV H; Barber Chris G, 2004, Curr Opin Investig Drugs, V5, P851; Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Seibert C, 2004, CURR PHARM DESIGN, V10, P2041, DOI 10.2174/1381612043384312; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998; Veazey RS, 2005, NAT MED, V11, P469, DOI 10.1038/nm0505-469; Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266; VEAZEY RS, 2005, NATURE; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; Wolinsky SM, 2004, VIROLOGY, V328, P19, DOI 10.1016/j.virol.2004.07.021; Youle M, 2003, AIDS, V17, P937, DOI 10.1097/00002030-200304110-00027	14	79	81	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1293	1294		10.1038/nm1321	http://dx.doi.org/10.1038/nm1321			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16273102				2022-12-27	WOS:000233774400026
J	Deng, GM; Zheng, LX; Chan, FKM; Lenardo, M				Deng, GM; Zheng, LX; Chan, FKM; Lenardo, M			Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; THERAPEUTIC TARGET; BACTERIAL-DNA; CPG MOTIFS; IN-VIVO; TNF; MICE; JOINT	Tumor necrosis factor (TNF)-alpha has an important role in the pathogenesis of autoimmune and inflammatory diseases such as rheumatoid and septic arthritis. The biological effects of TNF-alpha are mediated by binding to TNF receptors TNFR1 ( also known as P60) or TNFR2 ( also known as P80). The pre-ligand assembly domain (PLAD) is a portion of the extracellular region of TNFRs that mediates receptor-chain association essential for signaling. We found that soluble versions of PLAD, especially those derived from P60, block the biochemical effects of TNF-alpha in vitro and potently inhibit arthritis in animal models. Thus, targeting the PLAD may have clinical value in the treatment of human arthritis and other disorders involving receptors of the TNFR superfamily.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Massachusetts System; University of Massachusetts Worcester	Lenardo, M (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10,Room 11N311,10 Ctr Dr,MSC 1892, Bethesda, MD 20892 USA.	lenardo@nih.gov	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021	Chan, Francis Ka-Ming/0000-0002-4803-8353; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000717, Z01AI000717] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chan FKM, 2000, ANN RHEUM DIS, V59, P50, DOI 10.1136/ard.59.suppl_1.i50; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Deng GM, 2000, ARTHRITIS RHEUM-US, V43, P2283, DOI 10.1002/1529-0131(200010)43:10<2283::AID-ANR16>3.0.CO;2-9; Deng GM, 1999, NAT MED, V5, P702, DOI 10.1038/9554; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gomez-Reino JJ, 2003, ARTHRITIS RHEUM-US, V48, P2122, DOI 10.1002/art.11137; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306; Hultgren O, 1998, J IMMUNOL, V161, P5937; Jarvis B, 1999, DRUGS, V57, P945, DOI 10.2165/00003495-199957060-00014; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MIOSSEC P, 1992, BAILLIERE CLIN RHEUM, V6, P373, DOI 10.1016/S0950-3579(05)80180-3; Mori L, 1996, J IMMUNOL, V157, P3178; Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281-200305000-00016; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P372, DOI 10.1002/art.20009; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311; Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620	34	105	117	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1066	1072		10.1038/nm1304	http://dx.doi.org/10.1038/nm1304			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16170321				2022-12-27	WOS:000232492500027
J	Kirsch, DG; Dinulescu, DM; Miller, JB; Grimm, J; Santiago, PM; Young, NP; Nielsen, GP; Quade, BJ; Chaber, CJ; Schultz, CP; Takeuchi, O; Bronson, RT; Crowley, D; Korsmeyer, SJ; Yoon, SS; Hornicek, FJ; Weissleder, R; Jacks, T				Kirsch, David G.; Dinulescu, Daniela M.; Miller, John B.; Grimm, Jan; Santiago, Philip M.; Young, Nathan P.; Nielsen, G. Petur; Quade, Bradley J.; Chaber, Christopher J.; Schultz, Christian P.; Takeuchi, Osamu; Bronson, Roderick T.; Crowley, Denise; Korsmeyer, Stanley J.; Yoon, Sam S.; Hornicek, Francis J.; Weissleder, Ralph; Jacks, Tyler			A spatially and temporally restricted mouse model of soft tissue sarcoma	NATURE MEDICINE			English	Article							K-RAS; TUMOR SUPPRESSION; P53; APOPTOSIS; GENE; TUMORIGENESIS; DEFICIENCY; EXPRESSION; MUTATIONS; ABSENCE	Soft tissue sarcomas are mesenchymal tumors that are fatal in approximately one-third of patients. To explore mechanisms of sarcoma pathogenesis, we have generated a mouse model of soft tissue sarcoma. Intramuscular delivery of an adenovirus expressing Cre recombinase in mice with conditional mutations in Kras and Trp53 was sufficient to initiate high-grade sarcomas with myofibroblastic differentiation. Like human sarcomas, these tumors show a predilection for lung rather than lymph node metastasis. Using this model, we showed that a prototype handheld imaging device can identify residual tumor during intraoperative molecular imaging. Deletion of the Ink4a-Arf locus (Cdkn2a), but not Bak1 and Bax, could substitute for mutation of Trp53 in this model. Deletion of Bak1 and Bax, however, was able to substitute for mutation of Trp53 in the development of sinonasal adenocarcinoma. Therefore, the intrinsic pathway of apoptosis seems sufficient to mediate p53 tumor suppression in an epithelial cancer, but not in this model of soft tissue sarcoma.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Siemens Med Solut Inc, Charlestown, MA 02129 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Tufts Univ, Sch Med & Vet Med, North Grafton, MA 01536 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Siemens AG; Harvard University; Dana-Farber Cancer Institute; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	Jacks, T (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu	Miller, John J/GZG-5663-2022; Takeuchi, Osamu/AAG-9359-2019; Grimm, Jan/B-1937-2008	Takeuchi, Osamu/0000-0002-1260-6232; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R24CA092782, U54CA119349, P30CA014051, P50CA086355, K08CA114176] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA119349, K08 CA 114176, P30-CA14051, P50 CA86355, R24 CA92782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borden EC, 2003, CLIN CANCER RES, V9, P1941; CHIEN YH, 1979, J VIROL, V31, P752, DOI 10.1128/JVI.31.3.752-760.1979; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Grimm J, 2005, P NATL ACAD SCI USA, V102, P14404, DOI 10.1073/pnas.0503920102; Hill MA, 1997, CANCER EPIDEM BIOMAR, V6, P1095; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Marino S, 2000, GENE DEV, V14, P994; Matushansky I, 2005, HEMATOL ONCOL CLIN N, V19, P427, DOI 10.1016/j.hoc.2005.03.006; Montet X, 2005, CANCER RES, V65, P6330, DOI 10.1158/0008-5472.CAN-05-0382; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sakamoto A, 2001, HUM PATHOL, V32, P1225, DOI 10.1053/hupa.2001.28953; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takeuchi O, 2005, P NATL ACAD SCI USA, V102, P11272, DOI 10.1073/pnas.0504783102; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weihrauch M, 2002, ENVIRON MOL MUTAGEN, V40, P36, DOI 10.1002/em.10084; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; White LM, 2005, INT J RADIAT ONCOL, V61, P1439, DOI 10.1016/j.ijrobp.2004.08.036; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	30	218	222	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					992	997		10.1038/nm1602	http://dx.doi.org/10.1038/nm1602			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17676052				2022-12-27	WOS:000248674600032
J	Walker, MJ; Hollands, A; Sanderson-Smith, ML; Cole, JN; Kirk, JK; Henningham, A; McArthur, JD; Dinkla, K; Aziz, RK; Kansal, RG; Simpson, AJ; Buchanan, JT; Chhatwal, GS; Kotb, M; Nizet, V				Walker, Mark J.; Hollands, Andrew; Sanderson-Smith, Martina L.; Cole, Jason N.; Kirk, Joshua K.; Henningham, Anna; McArthur, Jason D.; Dinkla, Katrin; Aziz, Ramy K.; Kansal, Rita G.; Simpson, Amelia J.; Buchanan, John T.; Chhatwal, Gursharan S.; Kotb, Malak; Nizet, Victor			DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection	NATURE MEDICINE			English	Article							CYSTEINE PROTEASE; BINDING; PATHOGENESIS; PLASMINOGEN; EXPRESSION; PHAGOCYTOSIS; EMERGENCE; SURFACE; CLONE; SPEB	Most invasive bacterial infections are caused by species that more commonly colonize the human host with minimal symptoms. Although phenotypic or genetic correlates underlying a bacterium's shift to enhanced virulence have been studied, the in vivo selection pressures governing such shifts are poorly understood. The globally disseminated M1T1 clone of group A Streptococcus (GAS) is linked with the rare but life-threatening syndromes of necrotizing fasciitis and toxic shock syndrome(1). Mutations in the GAS control of virulence regulatory sensor kinase (covRS) operon are associated with severe invasive disease, abolishing expression of a broad-spectrum cysteine protease (SpeB) 2,3 and allowing the recruitment and activation of host plasminogen on the bacterial surface(4). Here we describe how bacteriophage-encoded GAS DNase (Sda1), which facilitates the pathogen's escape from neutrophil extracellular traps(5,6),serves as a selective force for covRS mutation. The results provide a paradigm whereby natural selection exerted by the innate immune system generates hypervirulent bacterial variants with increased risk of systemic dissemination.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis & Vaccine Dev, D-38124 Braunschweig, Germany; Cairo Univ, Dept Microbiol & Immunol, Cairo, Egypt; Vet Affairs Med Ctr, Memphis, TN 38163 USA; MidS Ctr Biodef & Secur, Memphis, TN 38163 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of Wollongong; Helmholtz Association; Helmholtz-Center for Infection Research; Egyptian Knowledge Bank (EKB); Cairo University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of California System; University of California San Diego; University of California System; University of California San Diego	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Sanderson-Smith, Martina L/H-9614-2013; Simpson, Amelia/HGB-1823-2022; Sanderson-Smith, Martina/O-9387-2019; Henningham, Anna/C-7355-2017; Walker, Mark J./F-6940-2011; Nizet, Victor/AAF-3190-2019; Aziz, Ramy/B-2918-2009	Sanderson-Smith, Martina L/0000-0002-6366-4993; Henningham, Anna/0000-0002-0554-6593; Nizet, Victor/0000-0003-3847-0422; Walker, Mark/0000-0001-7423-2769; Aziz, Ramy/0000-0002-4448-7100	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048176] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Aziz RK, 2005, J BACTERIOL, V187, P3311, DOI 10.1128/JB.187.10.3311-3318.2005; Aziz RK, 2004, MOL MICROBIOL, V54, P184, DOI 10.1111/j.1365-2958.2004.04255.x; Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Collin M, 2000, MOL MICROBIOL, V36, P1306, DOI 10.1046/j.1365-2958.2000.01942.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Kansal RG, 2000, INFECT IMMUN, V68, P6362, DOI 10.1128/IAI.68.11.6362-6369.2000; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; Ochman H, 2001, SCIENCE, V292, P1096, DOI 10.1126/science.1058543; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Ringdahl U, 2000, MOL MICROBIOL, V37, P1318, DOI 10.1046/j.1365-2958.2000.02062.x; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Sumby P, 2005, P NATL ACAD SCI USA, V102, P1679, DOI 10.1073/pnas.0406641102; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006	26	304	307	0	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					981	985		10.1038/nm1612	http://dx.doi.org/10.1038/nm1612			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17632528	Green Submitted, Bronze			2022-12-27	WOS:000248674600030
J	Kishimoto, H; Kojima, T; Watanabe, Y; Kagawa, S; Fujiwara, T; Uno, F; Teraishi, F; Kyo, S; Mizuguchi, H; Hashimoto, Y; Urata, Y; Tanaka, N; Fujiwara, T				Kishimoto, Hiroyuki; Kojima, Toru; Watanabe, Yuichi; Kagawa, Shunsuke; Fujiwara, Toshiya; Uno, Futoshi; Teraishi, Fuminori; Kyo, Satoru; Mizuguchi, Hiroyuki; Hashimoto, Yuuri; Urata, Yasuo; Tanaka, Noriaki; Fujiwara, Toshiyoshi			In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus	NATURE MEDICINE			English	Article							GREEN FLUORESCENT PROTEIN; VISUALIZING GENE-EXPRESSION; FROZEN-SECTION ANALYSIS; CELL LUNG-CANCER; BREAST-CANCER; SENTINEL NODE; BIOPSY; MELANOMA; MICE; DELIVERY	Currently available methods for detection of tumors in vivo such as computed tomography and magnetic resonance imaging are not specific for tumors. Here we describe a new approach for visualizing tumors whose fluorescence can be detected using telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 contains the replication cassette, in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of E1 genes, and the GFP gene for monitoring viral replication. When OBP-401 was intratumorally injected into HT29 tumors orthotopically implanted into the rectum in BALB/c nu/nu mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. Our results indicate that OBP-401 causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes. This technology is adaptable to detect lymph node metastasis in vivo as a preclinical model of surgical navigation.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Div Surg Oncol, Dept Surg, Okayama 7008558, Japan; Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama, Japan; Oncolys BioPharma, Minato Ku, Tokyo 1060032, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Inst Biomed Innovat, Lab Gene Transfer & Regulat, Ibaraki, Osaka 5670085, Japan	Okayama University; Okayama University; Oncolys BioPharma; Kanazawa University; National Institute of Health Sciences - Japan	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Div Surg Oncol, Dept Surg, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Chao C, 2001, AM J SURG, V182, P609, DOI 10.1016/S0002-9610(01)00794-2; Coello Michael C, 2004, Clin Lung Cancer, V5, P214; Ehrhardt D, 2003, CURR OPIN PLANT BIOL, V6, P622, DOI 10.1016/j.pbi.2003.09.014; Fujiwara T, 2006, J CLIN ONCOL, V24, P1689, DOI 10.1200/JCO.2005.03.4116; Fujiwara T, 2006, INT J CANCER, V119, P432, DOI 10.1002/ijc.21846; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gulec SA, 2001, AM SURGEON, V67, P529; Hasegawa S, 2000, CANCER GENE THER, V7, P1336, DOI 10.1038/sj.cgt.0237; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626; Koopal SA, 2000, CANCER, V89, P1720, DOI 10.1002/1097-0142(20001015)89:8<1720::AID-CNCR11>3.3.CO;2-6; Kuerer HM, 2005, J CLIN ONCOL, V23, P1698, DOI 10.1200/JCO.2005.09.047; MacDonald SLS, 2003, EUR J RADIOL, V45, P18, DOI 10.1016/S0720-048X(02)00300-5; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; McMasters KM, 2001, J CLIN ONCOL, V19, P2851, DOI 10.1200/JCO.2001.19.11.2851; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Ohtani S, 2004, MOL CANCER THER, V3, P93; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Tanis PJ, 2001, ANN SURG ONCOL, V8, P222, DOI 10.1007/s10434-001-0222-2; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Tsutsumi S, 2001, CANCER LETT, V169, P77, DOI 10.1016/S0304-3835(00)00622-4; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; van Roessel P, 2002, NAT CELL BIOL, V4, pE15, DOI 10.1038/ncb0102-e15; Watanabe T, 2006, EXP CELL RES, V312, P256, DOI 10.1016/j.yexcr.2005.10.026; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yang M, 2005, BIOTECHNIQUES, V39, P170, DOI 10.2144/05392BM02	28	142	151	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1213	1219		10.1038/nm1404	http://dx.doi.org/10.1038/nm1404			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013385	Green Submitted			2022-12-27	WOS:000241102200041
J	Yoshioka, M; Yuasa, S; Matsumura, K; Kimura, K; Shiomi, T; Kimura, N; Shukunami, C; Okada, Y; Mukai, M; Shin, H; Yozu, R; Sata, M; Ogawa, S; Hiraki, Y; Fukuda, K				Yoshioka, Masatoyo; Yuasa, Shinsuke; Matsumura, Keisuke; Kimura, Kensuke; Shiomi, Takayuki; Kimura, Naritaka; Shukunami, Chisa; Okada, Yasunori; Mukai, Makio; Shin, Hankei; Yozu, Ryohei; sata, Maka Sata; Ogawa, Satoshi; Hiraki, Yuji; Fukuda, Keiichi			Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis	NATURE MEDICINE			English	Article							AORTIC-VALVE CALCIFICATION; GROWTH-PLATE CHONDROCYTES; INTERSTITIAL-CELLS; ENDOTHELIAL-CELLS; MESSENGER-RNA; EXPRESSION; CARTILAGE; HEART; LOCALIZATION; INHIBITOR	The avascularity of cardiac valves is abrogated in several valvular heart diseases (VHDs). This study investigated the molecular mechanisms underlying valvular avascularity and its correlation with VHD. Chondromodulin-l, an antiangiogenic factor isolated from cartilage, is abundantly expressed in cardiac valves. Gene targeting of chondromodulin-l resulted in enhanced Vegf-A expression, angiogenesis, lipid deposition and calcification in the cardiac valves of aged mice. Echocardiography showed aortic valve thickening, calcification and turbulent flow, indicative of early changes in aortic stenosis. Conditioned medium obtained from cultured valvular interstitial cells strongly inhibited tube formation and mobilization of endothelial cells and induced their apoptosis; these effects were partially inhibited by chondromodulin-l small interfering RNA. In human VHD, including cases associated with infective endocarditis, rheumatic heart disease and atherosclerosis, VEGF-A expression, neovascularization and calcification were observed in areas of chondromodulin-l downregulation. These findings provide evidence that chondromodulin-l has a pivotal role in maintaining valvular normal function by preventing angiogenesis that may lead to VHD.	Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Cardiopulm Div, Dept Internal Med,Shinjiku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Cardiovasc Surg, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Dept Cellular Differentiat, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Keio Univ, Sch Med, Div Diagnost Pathol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	Keio University; Keio University; Keio University; Keio University; Kyoto University; Keio University; University of Tokyo	Fukuda, K (corresponding author), Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kfukuda@sc.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014; Shukunami, Chisa/G-2887-2019; Yuasa, Shinsuke/L-8310-2013; Shiomi, Takayuki/A-2228-2014; Fukuda, Keiichi/L-3777-2013	Okada, Yasunori/0000-0001-9208-4755; Shukunami, Chisa/0000-0001-5616-6761; Shiomi, Takayuki/0000-0002-4250-1204; Yuasa, Shinsuke/0000-0001-5593-7552				Agmon Y, 2001, J AM COLL CARDIOL, V38, P827, DOI 10.1016/S0735-1097(01)01422-X; Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Azizan A, 2001, J BIOL CHEM, V276, P23632, DOI 10.1074/jbc.M009967200; Camenisch TD, 2002, DEV BIOL, V248, P170, DOI 10.1006/dbio.2002.0731; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; CHANTHOMAS PS, 1993, DEV DYNAM, V197, P203, DOI 10.1002/aja.1001970305; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dietz UH, 1999, DEV DYNAM, V216, P233, DOI 10.1002/(SICI)1097-0177(199911)216:3<233::AID-DVDY2>3.0.CO;2-G; Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002-9440(10)63808-4; FILIP DA, 1986, CIRC RES, V59, P310, DOI 10.1161/01.RES.59.3.310; Fondard O, 2005, EUR HEART J, V26, P1333, DOI 10.1093/eurheartj/ehi248; Fujimoto N, 2000, METH MOL B, V151, P347, DOI 10.1385/1-59259-046-2:347; Funaki H, 2001, INVEST OPHTH VIS SCI, V42, P1193; Gotlieb AI, 2002, J THORAC CARDIOV SUR, V124, P591, DOI 10.1067/mtc.2002.123812; HAMMON JW, 1974, J THORAC CARDIOV SUR, V68, P352; Hiraki Y, 1997, FEBS LETT, V415, P321, DOI 10.1016/S0014-5793(97)01151-4; Hiraki Y, 1999, EUR J BIOCHEM, V260, P869, DOI 10.1046/j.1432-1327.1999.00227.x; Hiraki Y, 1991, Seikagaku, V63, P1449; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Ikeda T, 2004, ARTHRITIS RHEUM-US, V50, P3561, DOI 10.1002/art.20611; Inoue H, 1997, BIOCHEM BIOPH RES CO, V241, P395, DOI 10.1006/bbrc.1997.7820; Kyuwa S, 1997, EXP ANIM TOKYO, V46, P11, DOI 10.1538/expanim.46.11; LESTER W, 1988, LAB INVEST, V59, P710; LITWIN SE, 1994, CIRCULATION, V89, P345, DOI 10.1161/01.CIR.89.1.345; Mazzone A, 2004, J AM COLL CARDIOL, V43, P1670, DOI 10.1016/j.jacc.2003.12.041; Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Nakamichi Y, 2003, MOL CELL BIOL, V23, P636, DOI 10.1128/MCB.23.2.636-644.2003; O'Brien KD, 2002, CIRCULATION, V106, P2224, DOI 10.1161/01.CIR.0000035655.45453.D2; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Pohle K, 2004, MAYO CLIN PROC, V79, P1242, DOI 10.4065/79.10.1242; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Sachdev SW, 2001, MECH DEVELOP, V105, P157, DOI 10.1016/S0925-4773(01)00417-8; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1998, BIOCHEM BIOPH RES CO, V249, P885, DOI 10.1006/bbrc.1998.9233; Shukunami C, 1999, FEBS LETT, V456, P165, DOI 10.1016/S0014-5793(99)00931-X; Shworak NW, 2004, CURR OPIN CARDIOL, V19, P140, DOI 10.1097/00001573-200403000-00013; Soini Y, 2003, HUM PATHOL, V34, P756, DOI 10.1016/S0046-8177(03)00245-4; Sugi Y, 2004, DEV BIOL, V269, P505, DOI 10.1016/j.ydbio.2004.01.045; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tanaka K, 2005, J AM COLL CARDIOL, V46, P134, DOI 10.1016/j.jacc.2005.03.058; Yamauchi R, 2004, ARTERIOSCL THROM VAS, V24, P282, DOI 10.1161/01.ATV.0000114565.42679.c6; ZACKS S, 1991, ARCH PATHOL LAB MED, V115, P774	48	115	123	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1151	1159		10.1038/nm1476	http://dx.doi.org/10.1038/nm1476			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980969				2022-12-27	WOS:000241102200031
J	Bence, KK; Delibegovic, M; Xue, B; Gorgun, CZ; Hotamisligil, GS; Neel, BG; Kahn, BB				Bence, Kendra K.; Delibegovic, Mirela; Xue, Bingzhong; Gorgun, Cem Z.; Hotamisligil, Gokhan S.; Neel, Benjamin G.; Kahn, Barbara B.			Neuronal PTP1B regulates body weight, adiposity and leptin action	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE-PHOSPHATASE 1B; INSULIN SENSITIVITY; GLUCOSE-HOMEOSTASIS; METABOLIC SYNDROME; ENERGY-BALANCE; FOOD-INTAKE; PROTEIN; OBESITY; MICE	Obesity is a major health problem and a risk factor for type 2 diabetes. Leptin, an adipocyte-secreted hormone, acts on the hypothalamus to inhibit food intake and increase energy expenditure. Most obese individuals develop hyperleptinemia and leptin resistance, limiting the therapeutic efficacy of exogenously administered leptin. Mice lacking the tyrosine phosphatase PTP1B are protected from diet-induced obesity and are hypersensitive to leptin, but the site and mechanism for these effects remain controversial. We generated tissue-specific PTP1B knockout (Ptpn1(-/-)) mice. Neuronal Ptpn1(-/-) mice have reduced weight and adiposity, and increased activity and energy expenditure. In contrast, adipose PTP1B deficiency increases body weight, whereas PTP1B deletion in muscle or liver does not affect weight. Neuronal Ptpn1(-/-) mice are hypersensitive to leptin, despite paradoxically elevated leptin levels, and show improved glucose homeostasis. Thus, PTP1B regulates body mass and adiposity primarily through actions in the brain. Furthermore, neuronal PTP1B regulates adipocyte leptin production and probably is essential for the development of leptin resistance.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Res N 380C,99 Brookline Ave, Boston, MA 02215 USA.	kbence@vet.upenn.edu; bneel@bidmc.harvard.edu; bkahn@bidmc.harvard.edu		Delibegovic, Mirela/0000-0001-6193-3152; Bence, Kendra/0000-0002-5879-4726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK064360, R01DK060839, R01DK064360, P30DK046200, P01DK056116, R01DK060838, P30DK057521] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57521, DK56116, DK60839, DK64360, DK046200, DK60838] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Bamshad M, 1998, AM J PHYSIOL-REG I, V275, pR291, DOI 10.1152/ajpregu.1998.275.1.R291; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Carvalho E, 2004, J BIOL CHEM, V279, P21598, DOI 10.1074/jbc.M312269200; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Dhillon H, 2006, NEURON, V49, P191, DOI 10.1016/j.neuron.2005.12.021; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Elmquist JK, 2004, SCIENCE, V304, P63, DOI 10.1126/science.1096746; Elmquist JK, 2003, NAT MED, V9, P645, DOI 10.1038/nm0603-645; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Fliers E, 2003, J NEUROENDOCRINOL, V15, P1005, DOI 10.1046/j.1365-2826.2003.01096.x; Gil-Campos M, 2004, CLIN NUTR, V23, P963, DOI 10.1016/j.clnu.2004.04.010; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Kreier F, 2002, J CLIN INVEST, V110, P1243, DOI 10.1172/JCI200215736; Lafontan M, 2005, ANNU REV PHARMACOL, V45, P119, DOI 10.1146/annurev.pharmtox.45.120403.095843; Liu G, 2003, CURR MED CHEM, V10, P1407, DOI 10.2174/0929867033457296; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Mensah GA, 2004, CARDIOL CLIN, V22, P485, DOI 10.1016/j.ccl.2004.06.005; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Munzberg H, 2005, CELL MOL LIFE SCI, V62, P642, DOI 10.1007/s00018-004-4432-1; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Ogus S, 2003, ENDOCRINOLOGY, V144, P2865, DOI 10.1210/en.2002-0178; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Porte D, 2005, DIABETES, V54, P1264, DOI 10.2337/diabetes.54.5.1264; Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Steppan CM, 2004, J INTERN MED, V255, P439, DOI 10.1111/j.1365-2796.2004.01306.x; SUTHERLAND TM, 1974, GENETICS, V78, P525; Takeda S, 2005, BIOCHEM BIOPH RES CO, V328, P697, DOI 10.1016/j.bbrc.2004.11.071; VanPatten S, 2004, BIOCHEM J, V379, P229, DOI 10.1042/BJ20040134; Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI200524301; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	45	466	486	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					917	924		10.1038/nm1435	http://dx.doi.org/10.1038/nm1435			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16845389				2022-12-27	WOS:000239626200022
J	Gregorevic, P; Allen, JM; Minami, E; Blankinship, MJ; Haraguchi, M; Meuse, L; Finn, E; Adams, ME; Froehner, SC; Murry, CE; Chamberlain, JS				Gregorevic, Paul; Allen, James M.; Minami, Elina; Blankinship, Michael J.; Haraguchi, Miki; Meuse, Leonard; Finn, Eric; Adams, Marvin E.; Froehner, Stanley C.; Murry, Charles E.; Chamberlain, Jeffrey S.			rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MICE; GENE-THERAPY; UTROPHIN; MOUSE; MDX; SARCOLEMMA; SKELETAL; COMPLEX; MODEL	Mice carrying mutations in both the dystrophin and utrophin genes die prematurely as a consequence of severe muscular dystrophy. Here, we show that intravascular administration of recombinant adeno-associated viral (rAAV) vectors carrying a microdystrophin gene restores expression of dystrophin in the respiratory, cardiac and limb musculature of these mice, considerably reducing skeletal muscle pathology and extending lifespan. These findings suggest rAAV vector-mediated systemic gene transfer may be useful for treatment of serious neuromuscular disorders such as Duchenne muscular dystrophy.	Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Ctr Cardiovasc Biol & Regenerat Med, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chamberlain, JS (corresponding author), Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, 1959 NE Pacific St, Seattle, WA 98195 USA.	jsc5@u.washington.edu	Gregorevic, Paul/AAH-6040-2021	Gregorevic, Paul/0000-0002-7418-8945; Chamberlain, Jeffrey/0000-0001-5299-0059	NIAMS NIH HHS [R37 AR040864] Funding Source: Medline; NINDS NIH HHS [P01 NS046788] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS046788] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Collins KA, 2003, PHYSIOL GENOMICS, V13, P227, DOI 10.1152/physiolgenomics.00005.2003; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Gozal D, 2000, PEDIATR PULM, V29, P141, DOI 10.1002/(SICI)1099-0496(200002)29:2<141::AID-PPUL9>3.0.CO;2-Y; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hawkins D, 1997, J BIOMECH, V30, P63, DOI 10.1016/S0021-9290(96)00094-2; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27	13	225	241	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					787	789		10.1038/nm1439	http://dx.doi.org/10.1038/nm1439			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819550	Green Accepted			2022-12-27	WOS:000238862800064
J	Hayashi, M; Imanaka-Yoshida, K; Yoshida, T; Wood, M; Fearns, C; Tatake, RJ; Lee, JD				Hayashi, M; Imanaka-Yoshida, K; Yoshida, T; Wood, M; Fearns, C; Tatake, RJ; Lee, JD			A crucial role of mitochondrial Hsp40 in preventing dilated cardiomyopathy	NATURE MEDICINE			English	Article							DROSOPHILA TUMOR-SUPPRESSOR; ADENINE-NUCLEOTIDE TRANSLOCATOR; MOLECULAR CHAPERONES; CARDIAC-HYPERTROPHY; INTEGRATIVE BIOLOGY; DNA-POLYMERASE; HUMAN HOMOLOG; PROTEIN; HEART; DISEASES	Many heat-shock proteins (Hsp) are members of evolutionarily conserved families of chaperone proteins that inhibit the aggregation of unfolded polypeptides and refold denatured proteins, thereby remedying phenotypic effects that may result from protein aggregation or protein instability(1,2). Here we report that the mitochondrial chaperone Hsp40, also known as Dnaja3 or Tid1, is differentially expressed during cardiac development and pathological hypertrophy. Mice deficient in Dnaja3 developed dilated cardiomyopathy (DCM) and died before 10 weeks of age. Progressive respiratory chain deficiency and decreased copy number of mitochondrial DNA were evident in cardiomyocytes lacking Dnaja3. Profiling of Dnaja3-interacting proteins identified the alpha-subunit of DNA polymerase gamma (Polga) as a client protein. These findings suggest that Dnaja3 is crucial for mitochondrial biogenesis, at least in part, through its chaperone activity on Polga and provide genetic evidence of the necessity for mitochondrial Hsp40 in preventing DCM.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Mie Univ, Grad Sch Med, Dept Pathol & Matrix Biol, Tsu, Mie 5148507, Japan; Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, Ridgefield, CT 06877 USA	Scripps Research Institute; Mie University; Boehringer Ingelheim	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217	NATIONAL CANCER INSTITUTE [R01CA079871] Funding Source: NIH RePORTER; NCI NIH HHS [CA079871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Duchniewicz M, 1999, MOL CELL BIOL, V19, P8201; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Marin-Garcia J, 2004, J MOL MED, V82, P565, DOI 10.1007/s00109-004-0567-7; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	31	69	73	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					128	132		10.1038/nm1327	http://dx.doi.org/10.1038/nm1327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16327803				2022-12-27	WOS:000234419000062
J	Ito, M; Liu, YP; Yang, ZX; Nguyen, J; Liang, F; Morris, RJ; Cotsarelis, G				Ito, M; Liu, YP; Yang, ZX; Nguyen, J; Liang, F; Morris, RJ; Cotsarelis, G			Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis	NATURE MEDICINE			English	Article							LABEL-RETAINING CELLS; SKIN; EXPRESSION; EPITHELIUM; CAPACITY; RENEWAL; ONSET; CYCLE; UNIT	The discovery of long-lived epithelial stem cells in the bulge region of the hair follicle led to the hypothesis that epidermal renewal and epidermal repair after wounding both depend on these cells(1). To determine whether bulge cells are necessary for epidermal renewal, here we have ablated these cells by targeting them with a suicide gene encoding herpes simplex virus thymidine kinase (HSV-TK) using a Keratin 1-15 (Krt115) promoter(2). We show that ablation leads to complete loss of hair follicles but survival of the epidermis. Through fate-mapping experiments, we find that stem cells in the hair follicle bulge do not normally contribute cells to the epidermis which is organized into epidermal proliferative units, as previously predicted(3,4). After epidermal injury, however, cells from the bulge are recruited into the epidermis and migrate in a linear manner toward the center of the wound, ultimately forming a marked radial pattern. Notably, although the bulgederived cells acquire an epidermal phenotype, most are eliminated from the epidermis over several weeks, indicating that bulge stem cells respond rapidly to epidermal wounding by generating short-lived 'transient amplifying' cells responsible for acute wound repair. Our findings have implications for both gene therapy and developing treatments for wounds because it will be necessary to consider epidermal and hair follicle stem cells as distinct populations.	Univ Penn, Sch Med, Kligman Labs, Dept Dermatol, Philadelphia, PA 19104 USA; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10031 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10031 USA	University of Pennsylvania; Columbia University; Columbia University	Cotsarelis, G (corresponding author), Univ Penn, Sch Med, Kligman Labs, Dept Dermatol, M8 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.	cotsarel@mail.med.upenn.edu			NCI NIH HHS [CA97957] Funding Source: Medline; NIAMS NIH HHS [AR46837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARGYRIS TS, 1976, AM J PATHOL, V83, P329; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Domashenko A, 2000, NAT BIOTECHNOL, V18, P420, DOI 10.1038/74480; Ferraris C, 2000, DEVELOPMENT, V127, P5487; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Ito M, 2004, DIFFERENTIATION, V72, P548, DOI 10.1111/j.1432-0436.2004.07209008.x; Ito M, 2001, J INVEST DERMATOL, V116, P956, DOI 10.1046/j.0022-202x.2001.01369.x; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Li A, 2004, J CLIN INVEST, V113, P390, DOI 10.1172/JCI.200419140; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Lyle S, 1998, J CELL SCI, V111, P3179; Mackenzie IC, 1997, J INVEST DERMATOL, V109, P377, DOI 10.1111/1523-1747.ep12336255; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Miller SJ, 1998, J INVEST DERMATOL, V110, P13, DOI 10.1046/j.1523-1747.1998.00087.x; Morasso MI, 2005, BIOL CELL, V97, P173; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427	28	943	991	4	83	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1351	1354		10.1038/nm1328	http://dx.doi.org/10.1038/nm1328			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16288281				2022-12-27	WOS:000233774400035
J	Zhang, H; Chua, KS; Guimond, M; Kapoor, V; Brown, MV; Fleisher, TA; Long, LM; Bernstein, D; Hill, BJ; Douek, DC; Berzofsky, JA; Carter, CS; Read, EJ; Helman, LJ; Mackall, CL				Zhang, H; Chua, KS; Guimond, M; Kapoor, V; Brown, MV; Fleisher, TA; Long, LM; Bernstein, D; Hill, BJ; Douek, DC; Berzofsky, JA; Carter, CS; Read, EJ; Helman, LJ; Mackall, CL			Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+) CD25(+) regulatory T cells	NATURE MEDICINE			English	Article							HIV-INFECTED PATIENTS; TUMOR-IMMUNITY; AUTOIMMUNITY; MICE; TOLERANCE; FOXP3; SELF; TRANSPLANTATION; RECONSTITUTION; EXPANSION	CD4(+)CD25(+) regulatory T ( T-reg) cells have a crucial role in maintaining immune tolerance. Mice and humans born lacking Treg cells develop severe autoimmune disease(1,2), and depletion of Treg cells in lymphopenic mice induces autoimmunity(3,4). Interleukin ( IL)-2 signaling is required for thymic development(5), peripheral expansion(6) and suppressive activity of T(reg)cells(7). Animals lacking IL-2 die of autoimmunity(8,9), which is prevented by administration of IL-2-responsive T(reg)cells(5). In light of the emerging evidence that one of the primary physiologic roles of IL-2 is to generate and maintain T-reg cells(10), the question arises as to the effects of IL-2 therapy on them. We monitored Treg cells during immune reconstitution in individuals with cancer who did or did not receive IL-2 therapy. CD4(+)CD25(hi) cells underwent homeostatic peripheral expansion during immune reconstitution, and in lymphopenic individuals receiving IL-2, the T-reg cell compartment was markedly increased. Mouse studies showed that IL-2 therapy induced expansion of existent T-reg cells in normal hosts, and IL-2 induced T-reg cell expansion was further augmented by lymphopenia. On a per-cell basis, T-reg cells generated by IL-2 therapy expressed similar levels of FOXP3 and had similar potency for suppression compared to Treg cells present in normal hosts. These studies suggest that IL-2 and lymphopenia are primary modulators of CD4(+)CD25(+) T-reg cell homeostasis.	NIH, Pediat Oncol Branch, Bethesda, MD 20892 USA; NIH, Expt Transplantat & Immunol Branch, Canc Res Ctr, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA; NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA; NIH, Vaccine Branch, Canc Res Ctr, Bethesda, MD 20892 USA; NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Mackall, CL (corresponding author), NIH, Pediat Oncol Branch, 10 Ctr Dr, Bethesda, MD 20892 USA.	cm35c@nih.gov			NATIONAL CANCER INSTITUTE [ZIASC006891, Z01SC006891, Z01SC004020, ZIASC004020, Z01SC010281] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Atkins MB, 2002, SEMIN ONCOL, V29, P12, DOI 10.1053/sonc.2002.33077; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bayer AL, 2005, J EXP MED, V201, P769, DOI 10.1084/jem.20041179; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Cozzo C, 2003, J IMMUNOL, V171, P5678, DOI 10.4049/jimmunol.171.11.5678; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Hakim FT, 2005, J CLIN INVEST, V115, P930, DOI 10.1172/JCI200522492; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Itoh M, 1999, J IMMUNOL, V162, P5317; Katlama C, 2002, AIDS, V16, P2027, DOI 10.1097/00002030-200210180-00007; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Murakami M, 2002, P NATL ACAD SCI USA, V99, P8832, DOI 10.1073/pnas.132254399; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Sereti I, 2005, J CLIN INVEST, V115, P1839, DOI 10.1172/JCI24307; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Yu P, 2005, J EXP MED, V201, P779, DOI 10.1084/jem.20041684	31	316	339	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1238	1243		10.1038/nm1312	http://dx.doi.org/10.1038/nm1312			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227988				2022-12-27	WOS:000233115400037
J	Brinker, NG				Brinker, NG			When society meets science	NATURE MEDICINE			English	Editorial Material									Susan G Komen Breast Canc Fdn, Dallas, TX 75244 USA		Brinker, NG (corresponding author), Susan G Komen Breast Canc Fdn, Dallas, TX 75244 USA.								0	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2005	11	10					1040	1042		10.1038/nm1005-1040	http://dx.doi.org/10.1038/nm1005-1040			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211030				2022-12-27	WOS:000232492500016
J	Castilla, J; Saa, P; Soto, C				Castilla, J; Saa, P; Soto, C			Detection of prions in blood	NATURE MEDICINE			English	Article							CYCLIC AMPLIFICATION; PROTEIN; TRANSMISSION; PROPAGATION; TRANSFUSION; INFECTIVITY; BSE; CJD	Prion diseases are caused by an unconventional infectious agent termed prion, composed mainly of the misfolded prion protein ( PrPSc)(1). The development of highly sensitive assays for biochemical detection of PrPSc in blood is a top priority for minimizing the spread of the disease(2). Here we show that the protein misfolding cyclic amplification ( PMCA) technology(3) can be automated and optimized for high- efficiency amplification of PrPSc. We show that 140 PMCA cycles leads to a 6,600- fold increase in sensitivity over standard detection methods. Two successive rounds of PMCA cycles resulted in a 10 million - fold increase in sensitivity and a capability to detect as little as 8,000 equivalent molecules of PrPSc. Notably, serial PMCA enables detection of PrPSc in blood samples of scrapie- afflicted hamsters with 89% sensitivity and 100% specificity. These findings represent the first time that PrPSc has been detected biochemically in blood, offering promise for developing a noninvasive method for early diagnosis of prion diseases.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Autonoma Madrid, Ctr Mol Biol, E-28049 Madrid, Spain	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Autonomous University of Madrid	Soto, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	clsoto@utmb.edu	Castilla, Joaquín/J-8414-2019; Castilla, Joaquin/D-5261-2011; Saa, Paula/AAB-6607-2019	Castilla, Joaquín/0000-0002-2216-1361; Castilla, Joaquin/0000-0002-2216-1361; Saa, Paula/0000-0001-6077-4532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002246] Funding Source: NIH RePORTER; NIA NIH HHS [AG0224642] Funding Source: Medline; NINDS NIH HHS [NS049173] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; Bieschke J, 2004, P NATL ACAD SCI USA, V101, P12207, DOI 10.1073/pnas.0404650101; Bradley Ray, 2004, Folia Neuropathol, V42 Suppl A, P55; Brown P, 2001, J LAB CLIN MED, V137, P5, DOI 10.1067/mlc.2001.111951; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2004, TECHNIQUES PRION RES, P198, DOI [10.1007/978-3-0348-7949-1_14, DOI 10.1007/978-3-0348-7949-1_14]; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Ingrosso L, 2002, TRENDS MOL MED, V8, P273, DOI 10.1016/S1471-4914(02)02358-4; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Piening N, 2005, BIOCHEM BIOPH RES CO, V326, P339, DOI 10.1016/j.bbrc.2004.11.039; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saa Paula, 2004, V299, P53; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Soto C, 2004, NAT REV MICROBIOL, V2, P809, DOI 10.1038/nrmicro1003; Soto C, 2005, FEBS LETT, V579, P638, DOI 10.1016/j.febslet.2004.12.035; Soto C, 2002, TRENDS NEUROSCI, V25, P390, DOI 10.1016/S0166-2236(02)02195-1	24	237	260	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					982	985		10.1038/nm1286	http://dx.doi.org/10.1038/nm1286			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16127436				2022-12-27	WOS:000231724700026
J	Plotkin, SA				Plotkin, SA			Vaccines: past, present and future	NATURE MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; HEPATITIS-B VACCINE; CANCER VACCINES; INFLUENZA; IMMUNIZATION; IMMUNOGENICITY; TRIAL; PROTECTION; INFECTION; RESPONSES	The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.	Univ Penn, Doylestown, PA 18901 USA	University of Pennsylvania	Plotkin, SA (corresponding author), Univ Penn, 4550 Wismer Rd, Doylestown, PA 18901 USA.	Stanley.Plotkin@sanofipasteur.com						Amara RR, 2002, VACCINE, V20, P1949, DOI 10.1016/S0264-410X(02)00076-2; Arvin AM, 2004, CLIN INFECT DIS, V39, P233, DOI 10.1086/421999; ASSAAD F, 1982, B WORLD HEALTH ORGAN, V60, P231; AUTRAN B, 2002, PRACTICAL GUIDELINES, P65; Baker CJ, 2004, J INFECT DIS, V189, P1103, DOI 10.1086/382193; Belshe RB, 2000, J PEDIATR-US, V136, P168, DOI 10.1016/S0022-3476(00)70097-7; BenMohamed L, 2002, LANCET INFECT DIS, V2, P425, DOI 10.1016/S1473-3099(02)00318-3; Bernstein DI, 1998, VACCINE, V16, P381, DOI 10.1016/S0264-410X(97)00210-7; Buckner C, 2004, VIROLOGY, V320, P167, DOI 10.1016/j.virol.2003.12.003; Calmette A, 1907, ANN I PASTEUR PARIS, V21, P401; Chen DX, 2003, VACCINE, V21, P2830, DOI 10.1016/S0264-410X(03)00175-0; CLARK HF, 2004, VACCINES, P1327; DECKER MD, 2004, VACCINES, P825, DOI DOI 10.1016/S0264-410X(02)00770-3; Dhiman N, 2001, VACCINE, V20, P22, DOI 10.1016/S0264-410X(01)00319-X; Durbin AP, 2003, CLIN INFECT DIS, V37, P1668, DOI 10.1086/379775; Excler JL, 1997, AIDS, V11, pS127; Fattom AI, 2004, VACCINE, V22, P880, DOI 10.1016/j.vaccine.2003.11.034; FENN EA, 2001, POX AM GREAT SMALLPO, V1; FENNER F, 1988, HIST INT PUBLIC HLTH, V6, P245; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Forsyth KD, 2004, CLIN INFECT DIS, V39, P1802, DOI 10.1086/426020; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Glenn Gregory M, 2003, Expert Rev Vaccines, V2, P253, DOI 10.1586/14760584.2.2.253; Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004; Hallez S, 2004, CANCER IMMUNOL IMMUN, V53, P642, DOI 10.1007/s00262-004-0501-4; Hammond SA, 2001, VACCINE, V19, P2701, DOI 10.1016/S0264-410X(00)00506-5; Hassani M, 2004, CLIN IMMUNOL, V111, P1, DOI 10.1016/j.clim.2003.09.010; Hoft DF, 1999, CLIN INFECT DIS, V28, P785, DOI 10.1086/515201; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Horwitz MA, 2003, INFECT IMMUN, V71, P1672, DOI 10.1128/IAI.71.4.1672-1679.2003; Huang Y, 2004, J VIROL, V78, P12557, DOI 10.1128/JVI.78.22.12557-12565.2004; Jones T, 2003, VACCINE, V21, P3706, DOI 10.1016/S0264-410X(03)00387-6; Kantak KN, 2000, PSYCHOPHARMACOLOGY, V148, P251, DOI 10.1007/s002130050049; KILBOURNE ED, 1960, J EXP MED, V111, P387, DOI 10.1084/jem.111.3.387; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Lewis JJ, 2004, P NATL ACAD SCI USA, V101, P14653, DOI 10.1073/pnas.0404839101; Markowitz M, 2002, J INFECT DIS, V186, P634, DOI 10.1086/342559; Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040; Matyas GR, 2004, INFECT IMMUN, V72, P1181, DOI 10.1128/IAI.72.2.1181-1183.2004; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; McCurdy LH, 2004, CLIN INFECT DIS, V38, P1749, DOI 10.1086/421266; Mettens P, 2002, BRIT MED BULL, V62, P175, DOI 10.1093/bmb/62.1.175; Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415; Moingeon P, 2001, VACCINE, V19, P4363, DOI 10.1016/S0264-410X(01)00193-1; Moingeon P, 2001, VACCINE, V19, P1305, DOI 10.1016/S0264-410X(00)00372-8; Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x; Mora M, 2003, DRUG DISCOV TODAY, V8, P459, DOI 10.1016/S1359-6446(03)02689-8; Morse Stephen S., 1994, P325; Munoz FM, 2003, VACCINE, V21, P3465, DOI 10.1016/S0264-410X(03)00352-9; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Palese P, 2002, J CLIN INVEST, V110, P9, DOI 10.1172/JCI200215999; Pasteur L., 1881, CR HEBD ACAD SCI, V92, P1378; Pasteur L, 1880, CR HEBD ACAD SCI, V91, P673; Petrovsky Nikolai, 2003, Paediatr Drugs, V5, P575, DOI 10.2165/00148581-200305090-00001; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; Plotkin S.L., 2004, VACCINES-BASEL, V5, P1; Plotkin SA, 2005, PEDIATR INFECT DIS J, V24, P1, DOI 10.1097/01.inf.0000148933.08301.02; Plotkin SA, 2001, PEDIATR INFECT DIS J, V20, P63, DOI 10.1097/00006454-200101000-00013; RAMON G., 1926, COMPT REND ACAD SCI [PARIS], V182, P245; Ramon G, 1923, CR HEBD ACAD SCI, V177, P1338; Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360; Reddy ST, 1999, CURR OPIN MOL THER, V1, P22; Robinson HL, 1997, VACCINE, V15, P785, DOI 10.1016/S0264-410X(96)00249-6; Schiller JT, 2004, NAT REV MICROBIOL, V2, P343, DOI 10.1038/nrmicro867; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; Sela M, 2004, P NATL ACAD SCI USA, V101, P14559, DOI 10.1073/pnas.0405924101; Sepulveda-Amor J, 2002, VACCINE, V20, P2790, DOI 10.1016/S0264-410X(02)00179-2; Serruto D, 2004, J BIOTECHNOL, V113, P15, DOI 10.1016/j.jbiotec.2004.03.024; Singh M, 1998, AM J REPROD IMMUNOL, V39, P395; Smith T., 1886, AM VET REV, V10, P63; SPAETE RR, 1991, TRANSPLANT P, V23, P90; Stanberry Lawrence R, 2004, Herpes, V11 Suppl 3, p161A; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; Tacket Carol O, 2004, Expert Rev Vaccines, V3, P529, DOI 10.1586/14760584.3.5.529; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Vandepapeliere P, 2002, LANCET INFECT DIS, V2, P353, DOI 10.1016/S1473-3099(02)00289-X; Webster DE, 2002, J VIROL, V76, P7910, DOI 10.1128/JVI.76.15.7910-7912.2002; WELLER TH, 1949, P SOC EXP BIOL MED, V72, P153, DOI 10.3181/00379727-72-17359; Wood JM, 2004, NAT REV MICROBIOL, V2, P842, DOI 10.1038/nrmicro979	87	320	345	2	78	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S5	S11		10.1038/nm1209	http://dx.doi.org/10.1038/nm1209			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812490	Green Published			2022-12-27	WOS:000228339600004
J	Palomero, T; Sulis, ML; Cortina, M; Real, PJ; Barnes, K; Ciofani, M; Caparros, E; Buteau, J; Brown, K; Perkins, SL; Bhagat, G; Agarwal, AM; Basso, G; Castillo, M; Nagase, S; Cordon-Cardo, C; Parsons, R; Zuniga-Pflucker, JC; Dominguez, M; Ferrando, AA				Palomero, Teresa; Sulis, Maria Luisa; Cortina, Maria; Real, Pedro J.; Barnes, Kelly; Ciofani, Maria; Caparros, Esther; Buteau, Jean; Brown, Kristy; Perkins, Sherrie L.; Bhagat, Govind; Agarwal, Archana M.; Basso, Giuseppe; Castillo, Mireia; Nagase, Satoru; Cordon-Cardo, Carlos; Parsons, Ramon; Zuniga-Pflucker, Juan Carlos; Dominguez, Maria; Ferrando, Adolfo A.			Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia	NATURE MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-SECRETASE INHIBITORS; HEMATOPOIETIC STEM-CELLS; TUMOR-SUPPRESSOR; C-MYC; EPIGENETIC SILENCERS; DROSOPHILA EYE; BREAST-CANCER; PRE-TCR; EXPRESSION	Gain-of-function mutations in NOTCH1 are common in T- cell lymphoblastic leukemias and lymphomas ( T- ALL), making this receptor a promising target for drugs such as gamma-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation. However, the enthusiasm for these therapies has been tempered by tumor resistance and the paucity of information on the oncogenic programs regulated by oncogenic NOTCH1. Here we show that NOTCH1 regulates the expression of PTEN ( encoding phosphatase and tensin homolog) and the activity of the phosphoinositol- 3 kinase ( PI3K)-AKT signaling pathway in normal and leukemic T cells. Notch signaling and the PI3K-AKT pathway synergize in vivo in a Drosophila melanogaster model of Notch- induced tumorigenesis, and mutational loss of PTEN is associated with human T- ALL resistance to pharmacological inhibition of NOTCH1. Overall, these findings identify transcriptional control of PTEN and regulation of the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the basis for the design of new therapeutic strategies for T- ALL.	Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA; Univ Toronto, Sunnybrook Res Inst, Dept Immunol, Toronto, ON M4N 3M5, Canada; Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Endocrinol, New York, NY 10032 USA; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Padua, Dept Pediat, Hematooncol Lab, I-35128 Padua, Italy; Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA; Inst Neurociencias Alicante, Alicante 03550, Spain	Columbia University; Columbia University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Columbia University; Columbia University; Utah System of Higher Education; University of Utah; University of Padua; Tohoku University; Columbia University; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Dominguez, M (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.	m.dominguez@umh.es; af2196@columbia.edu	Zuniga-Pflucker, Juan C/H-1295-2012; Castillo-Martin, Mireia/H-6152-2013; Real, Pedro J./ABH-3493-2021; Caparrós, Esther/AHD-3233-2022; Dominguez, Maria/G-2171-2014; Real, Pedro J./K-2994-2014; Bhagat, Govind/AAE-9493-2021; Ferrando, Adolfo A/Q-7026-2016	Caparrós, Esther/0000-0002-9681-0408; Dominguez, Maria/0000-0002-3329-7862; Real, Pedro J./0000-0001-7968-5353; Bhagat, Govind/0000-0001-6250-048X; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178; Ciofani, Maria/0000-0001-6472-5260; Nagase, Satoru/0000-0001-5212-1128; BASSO, GIUSEPPE/0000-0002-2634-9302; Parsons, Ramon/0000-0002-6656-3514; Cortina, Maria/0000-0001-7684-3424	NCI NIH HHS [R01 CA082783, R01 CA082783-06, R01 CA082783-07, R01 CA120196-02, CA120196, R01 CA082783-08, R01 CA120196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082783, R01CA120196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Chang H, 2006, LEUKEMIA RES, V30, P262, DOI 10.1016/j.leukres.2005.07.008; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; DE SB, 1999, NATURE, V398, P518; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Dominguez M, 2006, CANCER RES, V66, P8931, DOI 10.1158/0008-5472.CAN-06-1858; Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Pahlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; She QB, 2003, CLIN CANCER RES, V9, P4340; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Swainson L, 2005, P NATL ACAD SCI USA, V102, P12867, DOI 10.1073/pnas.0503603102; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703	49	678	726	0	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1203	1210		10.1038/nm1636	http://dx.doi.org/10.1038/nm1636			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17873882	Green Accepted			2022-12-27	WOS:000249980200036
J	Patil, ST; Zhang, L; Martenyi, F; Lowe, SL; Jackson, KA; Andreev, BV; Avedisova, AS; Bardenstein, LM; Gurovich, IY; Morozova, MA; Mosolov, SN; Neznanov, NG; Reznik, AM; Smulevich, AB; Tochilov, VA; Johnson, BG; Monn, JA; Schoepp, DD				Patil, Sandeep T.; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D.			Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial	NATURE MEDICINE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; PLACEBO-CONTROLLED TRIAL; MODULATION; AGONIST; DRUGS; ANTIPSYCHOTICS; LAMOTRIGINE; OLANZAPINE; LY379268; CORTEX	Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions and thought disorder), negative symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathological symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control)(1). Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors(2). LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors(3) and has shown antipsychotic potential in animal studies. With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine. To clinically test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study. Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both positive and negative symptoms of schizophrenia compared to placebo (P < 0.001 at week 4). Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or weight gain. These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.	Lilly Med Ctr, A-1030 Vienna, Austria; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Lily Natl Univ, Singapore Ctr Clin Pharmacol, Singapore 117597, Singapore; Lilly Erl Wood Manor, Windlesham GU20 6PH, Surrey, England; Gatchinskiy Reg Psychiat Hosp, Nikolskoe 188357, Russia; St Petersburg State Univ, St Petersburg, Russia; Moscow State Univ Med & Dent, Moscow Psychiat Hosp, Moscow 115522, Russia; Moscow Res Inst Psychiat, Moscow 107076, Russia; Russian Acad Med Sci, State Inst Mental Hlth Sci Res Ctr, Moscow 115522, Russia; VM Bekhterev Psychoneurol Res Inst, St Petersburg 192019, Russia; Moscow Reg Psychiat Hosp, Khotkovo 142601, Moscow Region, Russia; Mechnikov State Med Acad, St Petersburg 190121, Russia	Eli Lilly; Saint Petersburg State University; Moscow State University of Medicine & Dentistry; Russian Academy of Medical Sciences; V.M. Bekhterev National Research Medical Center Psychiatry & Neurology	Martenyi, F (corresponding author), Lilly Med Ctr, Kolblgasse 8-10, A-1030 Vienna, Austria.	Martenyi_Ferenc@lilly.com; Monn_James_A@lilly.com	Morozova, Margarita Alekseevna/D-9098-2015; Andreev, Boris V./G-5743-2015; Mosolov, Sergey N./B-1779-2013; Bardenshteyn, Leonid M/F-7198-2013; Neznanov, Nikolai/U-1562-2017; Gurovich, Isaak Ya/A-5444-2013; Smulevich, Anatoly/B-4458-2016; Mosolov, Sergey/A-9563-2013	Morozova, Margarita Alekseevna/0000-0002-7847-2716; Andreev, Boris V./0000-0001-5982-5523; Mosolov, Sergey N./0000-0002-5749-3964; Bardenshteyn, Leonid M/0000-0002-1171-5517; Smulevich, Anatoly/0000-0003-2737-3432; Reznik, Aleksandr/0000-0002-7076-5901; Patil, Sandeep/0000-0002-0283-7678				Aghajanian GK, 1997, NEUROPHARMACOLOGY, V36, P589, DOI 10.1016/S0028-3908(97)00051-8; Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6; ANDREASEN NC, 1993, SCHIZOPHRENIA BULL, V19, P199, DOI 10.1093/schbul/19.2.199; Cartmell J, 1999, J PHARMACOL EXP THER, V291, P161; Crawford AMK, 1997, SCHIZOPHR RES, V26, P41, DOI 10.1016/S0920-9964(97)00036-4; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; FLEISCHHACKER WW, 1994, ACTA PSYCHIAT SCAND, V89, P11; Flor PJ, 2002, ADV EXP MED BIOL, V513, P197; Gewirtz JC, 2000, NEUROPSYCHOPHARMACOL, V23, P569, DOI 10.1016/S0893-133X(00)00136-6; Goff DC, 2005, PSYCHOPHARMACOLOGY, V179, P144, DOI 10.1007/s00213-004-2032-2; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; Heresco-Levy U, 2005, BIOL PSYCHIAT, V57, P577, DOI 10.1016/j.biopsych.2004.12.037; Hu G, 1999, J PHARMACOL EXP THER, V289, P412; Johnson MP, 2002, NEUROPHARMACOLOGY, V43, P799, DOI 10.1016/S0028-3908(02)00142-9; Kay SR, 1986, POSITIVE NEGATIVE SY; Kremer I, 2004, BIOL PSYCHIAT, V56, P441, DOI 10.1016/j.biopsych.2004.06.029; Large CH, 2005, PSYCHOPHARMACOLOGY, V181, P415, DOI 10.1007/s00213-005-0020-9; Marek GJ, 2000, J PHARMACOL EXP THER, V292, P76; Marek GJ, 2001, NEUROSCIENCE, V105, P379, DOI 10.1016/S0306-4522(01)00199-3; Meltzer H.Y., 2002, NEUROPSYCHOPHARMACOL, P819; Rorick-Kehn LM, 2007, J PHARMACOL EXP THER, V321, P308, DOI 10.1124/jpet.106.110809; Schoepp Darryle D., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P215, DOI 10.2174/1568007024606177; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SVENSSON L, 1994, BRAIN RES, V643, P155, DOI 10.1016/0006-8993(94)90021-3; Swanson CJ, 2002, J PHARMACOL EXP THER, V303, P919, DOI 10.1124/jpet.102.038422; Tamminga CA, 1996, INT CLIN PSYCHOPHARM, V11, P73, DOI 10.1097/00004850-199605002-00012; Tuominen HJ, 2005, SCHIZOPHR RES, V72, P225, DOI 10.1016/j.schres.2004.05.005; Xi ZX, 2002, J PHARMACOL EXP THER, V303, P608, DOI 10.1124/jpet.102.039735; Zhai Y, 2003, NEUROPSYCHOPHARMACOL, V28, P45, DOI 10.1038/sj.npp.1300013	30	866	911	0	97	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1102	1107		10.1038/nm1632	http://dx.doi.org/10.1038/nm1632			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17767166				2022-12-27	WOS:000249353100038
J	Sagare, A; Deane, R; Bell, RD; Johnson, B; Hamm, K; Pendu, R; Marky, A; Lenting, PJ; Wu, ZH; Zarcone, T; Goate, A; Mayo, K; Perlmutter, D; Coma, M; Zhong, ZH; Zlokovic, BV				Sagare, Abhay; Deane, Rashid; Bell, Robert D.; Johnson, Bradley; Hamm, Katie; Pendu, Ronan; Marky, Andrew; Lenting, Peter J.; Wu, Zhenhua; Zarcone, Troy; Goate, Alison; Mayo, Kevin; Perlmutter, David; Coma, Mireia; Zhong, Zhihui; Zlokovic, Berislav V.			Clearance of amyloid-beta by circulating lipoprotein receptors	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; PROTEIN LRP; PEPTIDE; TRANSPORT; PLAQUES; COMPLEX; PLASMA	Low-density lipoprotein receptor-related protein-1 (LRP) on brain capillaries clears amyloid beta-peptide (Ab) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Ab in humans. Recombinant LRP cluster IV (LRP-IV) bound Ab in plasma in mice and Alzheimer's disease-affected humans with compromised sLRP-mediated Ab binding, and reduced Ab-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Ab.	Univ Rochester, Sch Med, Dept Neurosurg, Frank P Smith Lab Neurosci & Neurosurg Res, Rochester, NY 14642 USA; Univ Med Ctr Utrecht, Dept Hematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands; Univ Rochester, Sch Med, Dept Environm Med, Neurobehav Facil Lab, Rochester, NY USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	University of Rochester; Utrecht University; Utrecht University Medical Center; University of Rochester; Washington University (WUSTL)	Zlokovic, BV (corresponding author), Univ Rochester, Sch Med, Dept Neurosurg, Frank P Smith Lab Neurosci & Neurosurg Res, Rochester, NY 14642 USA.	Berislav_Zlokovic@urmc.rochester.edu	Sagare, Abhay/Y-3273-2019; Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Sagare, Abhay/0000-0002-8178-3785; Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [R37 AG023084, P50 AG005681, P50 AG05681, R37 AG023084-02] Funding Source: Medline; NINDS NIH HHS [R37 NS034467, R37 NS34467, R01 NS034467, R01 NS034467-07] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034467, R01NS034467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG023084, P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bell RD, 2007, J CEREBR BLOOD F MET, V27, P909, DOI 10.1038/sj.jcbfm.9600419; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jensen GA, 2006, J MOL BIOL, V362, P700, DOI 10.1016/j.jmb.2006.07.013; Kumar-Singh S, 2005, AM J PATHOL, V167, P527, DOI 10.1016/S0002-9440(10)62995-1; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Tamaki C, 2006, PHARM RES-DORDR, V23, P1407, DOI 10.1007/s11095-006-0208-7; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Westein E, 2002, J BIOL CHEM, V277, P2511, DOI 10.1074/jbc.M102293200; Zerbinatti CV, 2005, REV NEUROSCIENCE, V16, P123	15	333	344	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1029	1031		10.1038/nm1635	http://dx.doi.org/10.1038/nm1635			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17694066	Green Accepted			2022-12-27	WOS:000249353100028
J	Zou, CB; Ma, JH; Wang, X; Guo, L; Zhu, ZQ; Stoops, J; Eaker, AE; Johnson, CJ; Strom, S; Michalopoulos, GK; DeFrances, MC; Zarnegar, R				Zou, Chunbin; Ma, Jihong; Wang, Xue; Guo, Lida; Zhu, Zhenqi; Stoops, John; Eaker, Amanda E.; Johnson, Carla J.; Strom, Stephen; Michalopoulos, George K.; DeFrances, Marie C.; Zarnegar, Reza			Lack of Fas antagonism by Met in human fatty liver disease	NATURE MEDICINE			English	Article							NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; HEPATOCYTE APOPTOSIS; RECEPTOR; MICE; INJURY; REGENERATION; MECHANISM; THERAPY; GROWTH	Hepatocytes in fatty livers are hypersensitive to apoptosis and undergo escalated apoptotic activity via death receptor-mediated pathways, particularly that of Fas-FasL, causing hepatic injury that can eventually proceed to cirrhosis and end-stage liver disease. Here we report that the hepatocyte growth factor receptor, Met, plays an important part in preventing Fas-mediated apoptosis of hepatocytes by sequestering Fas. We also show that Fas antagonism by Met is abrogated in human fatty liver disease (FLD). Through structure-function studies, we found that a YLGA amino-acid motif located near the extracellular N terminus of the Met alpha-subunit is necessary and sufficient to specifically bind the extracellular portion of Fas and to act as a potent FasL antagonist and inhibitor of Fas trimerization. Using mouse models of FLD, we show that synthetic YLGA peptide tempers hepatocyte apoptosis and liver damage and therefore has therapeutic potential.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, S411A Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	rezazar@pitt.edu	Zou, Chunbin/L-7488-2019	Zou, Chunbin/0000-0003-1355-4726; Strom, Stephen/0000-0002-2889-3387	NCI NIH HHS [R01CA095782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anstee QM, 2006, INT J EXP PATHOL, V87, P1, DOI 10.1111/j.0959-9673.2006.00465.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Canbay A, 2004, HEPATOLOGY, V39, P273, DOI 10.1002/hep.20051; Connolly K, 2001, J PHARMACOL EXP THER, V298, P25; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Diehl AM, 2005, GUT, V54, P303, DOI 10.1136/gut.2003.024935; Ding XK, 2006, HEPATOLOGY, V43, P173, DOI 10.1002/hep.21006; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Feldstein A, 2004, AM J GASTROENTEROL, V99, P1718, DOI 10.1111/j.1572-0241.2004.40573.x; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feldstein AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4; Gomez-Lechon MJ, 2007, CHEM-BIOL INTERACT, V165, P106, DOI 10.1016/j.cbi.2006.11.004; Guicciardi ME, 2004, NAT MED, V10, P587, DOI 10.1038/nm0604-587; Hasegawa A, 2004, P NATL ACAD SCI USA, V101, P6599, DOI 10.1073/pnas.0401597101; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Kirsch R, 2003, J GASTROEN HEPATOL, V18, P1272, DOI 10.1046/j.1440-1746.2003.03198.x; LEON LDA, 1985, J HISTOCHEM CYTOCHEM, V33, P737; Li ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/jhep.2003.50048; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MEAGAN J, 2004, HEPATOLOGY, V39, P1230; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Moriya K, 2001, BIOCHEM BIOPH RES CO, V281, P1207, DOI 10.1006/bbrc.2001.4523; Nakamoto Y, 2002, J EXP MED, V196, P1105, DOI 10.1084/jem.20020633; Nehra V, 2001, DIGEST DIS SCI, V46, P2347, DOI 10.1023/A:1012338828418; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Takeda K, 2000, P NATL ACAD SCI USA, V97, P5498, DOI 10.1073/pnas.040566697; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Yin XM, 2003, CURR MOL MED, V3, P491, DOI 10.2174/1566524033479555; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	35	66	71	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1078	1085		10.1038/nm1625	http://dx.doi.org/10.1038/nm1625			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17704785				2022-12-27	WOS:000249353100035
J	Hyafil, F; Cornily, JC; Feig, JE; Gordon, R; Vucic, E; Amirbekian, V; Fisher, EA; Fuster, V; Feldman, LJ; Fayad, ZA				Hyafil, Fabien; Cornily, Jean-Christophe; Feig, Jonathan E.; Gordon, Ronald; Vucic, Esad; Amirbekian, Vardan; Fisher, Edward A.; Fuster, Valentin; Feldman, Laurent J.; Fayad, Zahi A.			Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography	NATURE MEDICINE			English	Article							ULTRASMALL SUPERPARAMAGNETIC PARTICLES; CORONARY ATHEROSCLEROTIC PLAQUE; INTRAVASCULAR ULTRASOUND; IRON-OXIDE; HIGH-RISK; VULNERABLE PLAQUE; PART I; CT; INFLAMMATION; ACCURACY	Sudden fibrous cap disruption of 'high-risk' atherosclerotic plaques can trigger the formation of an occlusive thrombus in coronary arteries, causing acute coronary syndromes. High-risk atherosclerotic plaques are characterized by their specific cellular and biological content (in particular, a high density of macrophages), rather than by their impact on the vessel lumen. Early identification of high-risk plaques may be useful for preventing ischemic events. One major hurdle in detecting high-risk atherosclerotic plaques in coronary arteries is the lack of an imaging modality that allows for the identification of atherosclerotic plaque composition with high spatial and temporal resolutions. Here we show that macrophages in atherosclerotic plaques of rabbits can be detected with a clinical X-ray computed tomography (CT) scanner after the intravenous injection of a contrast agent formed of iodinated nanoparticles dispersed with surfactant. This contrast agent may become an important adjunct to the clinical evaluation of coronary arteries with CT.	Mt Sinai Sch Med, Sinai Translat & Mol Imaging Inst, New York, NY 10029 USA; Mt Sinai Sch Med, Imaging Sci Labs, New York, NY 10029 USA; INSERM U698, F-75018 Paris, France; Hop Bichat, Dept Cardiol, APHP, F-75018 Paris, France; NYU, Sch Med, Dept Med, Marc & Ruti Bell Vasc Biol Program, New York, NY 10016 USA; Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA; Mt Sinai Hosp, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; Mt Sinai Hosp, Marie Josee & Henry R Kravis Cardiovasc Hlth Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; New York University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Fayad, ZA (corresponding author), Mt Sinai Sch Med, Sinai Translat & Mol Imaging Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zahi.fayad@mssm.edu	Fayad, Zahi/Z-3272-2019; Fuster, Valentin/H-4319-2015; Fisher, Edward/ABE-7469-2020	Fayad, Zahi/0000-0002-3439-7347; Fuster, Valentin/0000-0002-9043-9986; Fisher, Edward/0000-0001-9802-143X; Hyafil, Fabien/0000-0002-9600-0376	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078667] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL78667] Funding Source: Medline; PHITPO CDC HHS [R01 HK71021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHITPO CDC HHS		Achenbach S, 2004, CIRCULATION, V109, P14, DOI 10.1161/01.CIR.0000111517.69230.0F; Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; Boll DT, 2006, J COMPUT ASSIST TOMO, V30, P804, DOI 10.1097/01.rct.0000228162.70849.26; Dunphy MPS, 2005, J NUCL MED, V46, P1278; Fayad ZA, 2001, CIRC RES, V89, P305, DOI 10.1161/hh1601.095596; Flohr TG, 2006, EUR RADIOL, V16, P256, DOI 10.1007/s00330-005-2919-2; Fu YJ, 2006, BIOCONJUGATE CHEM, V17, P1043, DOI 10.1021/bc060019c; Fuster V, 2005, J AM COLL CARDIOL, V46, P937, DOI 10.1016/j.jacc.2005.03.074; Gupta R, 2006, EUR RADIOL, V16, P1191, DOI 10.1007/s00330-006-0156-y; Helft G, 2002, CIRCULATION, V105, P993, DOI 10.1161/hc0802.104325; Hoffmann U, 2004, CIRCULATION, V110, P2638, DOI 10.1161/01.CIR.0000145614.07427.9F; Hyafil F, 2006, ARTERIOSCL THROM VAS, V26, P176, DOI 10.1161/01.ATV.0000194098.82677.57; Kooi ME, 2003, CIRCULATION, V107, P2453, DOI 10.1161/01.CIR.0000068315.98705.CC; Krause W, 1999, ADV DRUG DELIVER REV, V37, P159, DOI 10.1016/S0169-409X(98)00105-7; Leber AW, 2006, J AM COLL CARDIOL, V47, P672, DOI 10.1016/j.jacc.2005.10.058; Leber AW, 2004, J AM COLL CARDIOL, V43, P1241, DOI 10.1016/j.jacc.2003.10.059; Leber AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/j.jacc.2005.03.071; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mauriello A, 2005, J AM COLL CARDIOL, V45, P1585, DOI 10.1016/j.jacc.2005.01.054; McIntire GL, 2000, INVEST RADIOL, V35, P91, DOI 10.1097/00004424-200002000-00001; Mukundan S, 2006, AM J ROENTGENOL, V186, P300, DOI 10.2214/AJR.05.0523; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Pohle K, 2007, ATHEROSCLEROSIS, V190, P174, DOI 10.1016/j.atherosclerosis.2006.01.013; Rabin O, 2006, NAT MATER, V5, P118, DOI 10.1038/nmat1571; Rudd JHF, 2002, CIRCULATION, V105, P2708, DOI 10.1161/01.CIR.0000020548.60110.76; Ruehm SG, 2001, CIRCULATION, V103, P415; Schroeder S, 2001, CLIN RADIOL, V56, P466, DOI 10.1053/crad.2001.0687; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Trivedi RA, 2004, STROKE, V35, P1631, DOI 10.1161/01.STR.0000131268.50418.b7; Viles-Gonzalez JF, 2004, CIRCULATION, V110, P1467, DOI 10.1161/01.CIR.0000141732.28175.2A; Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065; Wisner E R, 1994, Acad Radiol, V1, P377; Zhang Zhuangyu, 2006, BMC Nucl Med, V6, P3, DOI 10.1186/1471-2385-6-3; Zheng JZ, 2006, INVEST RADIOL, V41, P339, DOI 10.1097/01.rli.0000186568.50265.64	35	342	359	2	77	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2007	13	5					636	641		10.1038/nm1571	http://dx.doi.org/10.1038/nm1571			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17417649				2022-12-27	WOS:000246302800033
J	Lee, JP; Jeyakumar, M; Gonzalez, R; Takahashi, H; Lee, PJ; Baek, RC; Clark, D; Rose, H; Fu, G; Clarke, J; McKercher, S; Meerloo, J; Muller, FJ; Park, KI; Butters, TD; Dwek, RA; Schwartz, P; Tong, G; Wenger, D; Lipton, SA; Seyfried, TN; Platt, FM; Snyder, EY				Lee, Jean-Pyo; Jeyakumar, Mylvaganam; Gonzalez, Rodolfo; Takahashi, Hiroto; Lee, Pei-Jen; Baek, Rena C.; Clark, Dan; Rose, Heather; Fu, Gerald; Clarke, Jonathan; McKercher, Scott; Meerloo, Jennifer; Muller, Franz-Josef; Park, Kook In; Butters, Terry D.; Dwek, Raymond A.; Schwartz, Philip; Tong, Gang; Wenger, David; Lipton, Stuart A.; Seyfried, Thomas N.; Platt, Frances M.; Snyder, Evan Y.			Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease	NATURE MEDICINE			English	Article							SANDHOFF-DISEASE; PROGENITOR CELLS; TAY-SACHS; N-BUTYLDEOXYNOJIRIMYCIN; NEURAL PROGENITORS; LYSOSOMAL STORAGE; MOUSE-BRAIN; IN-VITRO; NEURONS; MODEL	Intracranial transplantation of neural stem cells (NSCs) delayed disease onset, preserved motor function, reduced pathology and prolonged survival in a mouse model of Sandhoff disease, a lethal gangliosidosis. Although donor-derived neurons were electrophysiologically active within chimeric regions, the small degree of neuronal replacement alone could not account for the improvement. NSCs also increased brain beta-hexosaminidase levels, reduced ganglioside storage and diminished activated microgliosis. Additionally, when oral glycosphingolipid biosynthesis inhibitors (beta-hexosaminidase substrate inhibitors) were combined with NSC transplantation, substantial synergy resulted. Efficacy extended to human NSCs, both to those isolated directly from the central nervous system (CNS) and to those derived secondarily from embryonic stem cells. Appreciating that NSCs exhibit a broad repertoire of potentially therapeutic actions, of which neuronal replacement is but one, may help in formulating rational multimodal strategies for the treatment of neurodegenerative diseases.	Burnham Inst Med Res, Ctr Neurosci & Aging Res, Stem Cell & Regenerat Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Zentrum Integrat Psychiat, D-24105 Kiel, Germany; Yonsei Univ, Coll Med, Dept Pediat, Seoul 120749, South Korea; Childrens Hosp Orange Cty, Res Inst, Orange, CA 92826 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA; San Diego Consortium Regenerat Med, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of Oxford; Boston College; Yonsei University; Yonsei University Health System; Childrens Hospital of Orange County; University of California System; University of California San Diego; Jefferson University	Snyder, EY (corresponding author), Burnham Inst Med Res, Ctr Neurosci & Aging Res, Stem Cell & Regenerat Program, La Jolla, CA 92037 USA.	frances.platt@pharm.ox.ac.uk; esnyder@burnham.org	Platt, Frances/G-1004-2010; Müller, Franz-Josef/E-3336-2010	Müller, Franz-Josef/0000-0001-9478-8430; Platt, Frances/0000-0001-7614-0403; Lipton, Stuart/0000-0002-3490-1259; Seyfried, Thomas/0000-0003-1491-3989	Medical Research Council [G0400834] Funding Source: Medline; MRC [G0400834] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersson U, 2004, NEUROBIOL DIS, V16, P506, DOI 10.1016/j.nbd.2004.04.012; Cachon-Gonzalez MB, 2006, P NATL ACAD SCI USA, V103, P10373, DOI 10.1073/pnas.0603765103; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Givogri MI, 2006, J NEUROSCI, V26, P3109, DOI 10.1523/JNEUROSCI.4366-05.2006; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; HULTBERG B, 1993, CLIN CHIM ACTA, V216, P73, DOI 10.1016/0009-8981(93)90140-Y; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jeyakumar M, 2004, ANN NEUROL, V56, P642, DOI 10.1002/ana.20242; Jeyakumar M, 2003, BRAIN, V126, P974, DOI 10.1093/brain/awg089; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; Jones, 2017, J S CAROLINA WATER R, V4, P21, DOI [10.34068/JSCWR.04.03, DOI 10.34068/JSCWR.04.03]; Kasperzyk JL, 2004, J NEUROCHEM, V89, P645, DOI 10.1046/j.1471-4159.2004.02381.x; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Kondo Y, 2005, P NATL ACAD SCI USA, V102, P18670, DOI 10.1073/pnas.0506473102; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Light W, 2005, DEVELOPMENT, V132, P1831, DOI 10.1242/dev.01734; Maragakis NJ, 2005, GLIA, V50, P145, DOI 10.1002/glia.20161; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; Muotri AR, 2005, P NATL ACAD SCI USA, V102, P18644, DOI 10.1073/pnas.0509315102; Murphy MJ, 2005, TRENDS CELL BIOL, V15, P128, DOI 10.1016/j.tcb.2005.01.008; Myerowitz R, 2002, HUM MOL GENET, V11, P1343, DOI 10.1093/hmg/11.11.1343; Neville DCA, 2004, ANAL BIOCHEM, V331, P275, DOI 10.1016/j.ab.2004.03.051; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Park KI, 2006, EXP NEUROL, V199, P156, DOI 10.1016/j.expneurol.2006.04.002; Parker MA, 2005, EXP NEUROL, V194, P320, DOI 10.1016/j.expneurol.2005.04.018; Pellegatta S, 2006, NEUROBIOL DIS, V21, P314, DOI 10.1016/j.nbd.2005.07.016; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Rosario CM, 1997, DEVELOPMENT, V124, P4213; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tifft CJ, 2000, GLYCOBIOLOGY, V10, P1249, DOI 10.1093/glycob/10.12.1249; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; WENGER DA, 1991, TECHNIQUES DIAGNOSTI, P587; Wu YP, 2004, P NATL ACAD SCI USA, V101, P8425, DOI 10.1073/pnas.0400625101; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	50	236	250	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					439	447		10.1038/nm1548	http://dx.doi.org/10.1038/nm1548			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17351625				2022-12-27	WOS:000245543900032
J	Nicholls, JM; Chan, MCW; Chan, WY; Wong, HK; Cheung, CY; Kwong, DLW; Wong, MP; Chui, WH; Poon, LLM; Tsao, SW; Guan, Y; Peiris, JSM				Nicholls, J. M.; Chan, M. C. W.; Chan, W. Y.; Wong, H. K.; Cheung, C. Y.; Kwong, D. L. W.; Wong, M. P.; Chui, W. H.; Poon, L. L. M.; Tsao, S. W.; Guan, Y.; Peiris, J. S. M.			Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract	NATURE MEDICINE			English	Article							SIALIC-ACID; RECEPTOR SPECIFICITY; HUMAN AIRWAY; VIRUSES; HEMAGGLUTININ; AFFINITY	Poor human-to-human transmission of influenza A H5N1 virus has been attributed to the paucity of putative sialic acid alpha 2-3 virus receptors in the epithelium of the human upper respiratory tract, and thus to the presumed inability of the virus to replicate efficiently at this site. We now demonstrate that ex vivo cultures of human nasopharyngeal, adenoid and tonsillar tissues can be infected with H5N1 viruses in spite of an apparent lack of these receptors.	Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Grantham Hosp, Dept Cardiothorac Surg, Aberdeen, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Nicholls, JM (corresponding author), Univ Hong Kong, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	nicholls@pathology.hku.hk; malik@hkucc.hku.hk	Kwong, Dora/C-4295-2009; Poon, Leo Lit Man/C-4382-2009; Poon, Leo/AAP-6887-2020; Tsao, George/C-4422-2009; Chan, Renee/D-4799-2012; Chan, Michael Chi Wai/C-4212-2009; Cheung, Chung Yan/C-4233-2009; Peiris, Joseph/C-4380-2009; Chan, Renee Wan Yi/AAA-6598-2020; Nicholls, John Malcolm/C-4375-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Chan, Michael Chi Wai/0000-0001-8174-8405; Chan, Renee Wan Yi/0000-0001-6485-0926; Guan, Yi/0000-0001-6057-9243; Nicholls, John Malcolm/0000-0001-7217-7444	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Gambaryan A, 2005, VIROLOGY, V334, P276, DOI 10.1016/j.virol.2005.02.003; Gambaryan AS, 2004, VIROLOGY, V326, P310, DOI 10.1016/j.virol.2004.06.002; Helander A, 2003, J VIROL, V77, P7964, DOI 10.1128/JVI.77.14.7964-7977.2003; Imberty A, 2000, J BIOL CHEM, V275, P17541, DOI 10.1074/jbc.M000560200; KONAMI Y, 1994, FEBS LETT, V342, P334, DOI 10.1016/0014-5793(94)80527-X; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548	11	256	285	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					147	149		10.1038/nm1529	http://dx.doi.org/10.1038/nm1529			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17206149				2022-12-27	WOS:000244031700022
J	Kim, SJ; Doudet, DJ; Studenov, AR; Nian, C; Ruth, TJ; Gambhir, SS; McIntosh, CHS				Kim, Su-Jin; Doudet, Doris J.; Studenov, Andrei R.; Nian, Cuilan; Ruth, Thomas J.; Gambhir, Sanjiv Sam; McIntosh, Christopher H. S.			Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival	NATURE MEDICINE			English	Article							REPORTER GENE-EXPRESSION; TRANSPLANTATION; CELLS; MASS	Islet transplantation is an attractive approach for treating type-1 diabetes, but there is a massive loss of transplanted islets. It is currently only possible to estimate islet mass indirectly, through measurement of circulating C-peptide and insulin levels. This type of estimation, however, is not sufficiently sensitive or reproducible for follow-up of individuals who have undergone islet transplantation. Here we show that islet graft survival could be assessed for 1 month in diabetic NOD mice using 9-(4-[F-18]-fluoro-3-hydroxymethylbutyl) guanine ([F-18]FHBG) positron emission tomography ( PET) technology, the PET signal reflecting insulin secretory capacity of transplanted islets. Expression of the gene encoding viral interleukin-10 (vIL-10), was measurable in real time with PET scanning. Additionally, we addressed the clinical potential of this approach by visualizing transplanted islets in the liver, the preferred clinical transplantation site. We conclude that quantitative in vivo PET imaging is a valid method for facilitating the development of protocols for prolonging islet survival, with the potential for tracking human transplants.	Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Diabet Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC V6T 2B5, Canada; TRIUMF, TRI Univ Meson Facil, Vancouver, BC V6T 2A3, Canada; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Dept Bioengn, BioX Program, Mol Imaging Program Stanford,James H Clark Ctr, Stanford, CA 94305 USA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Stanford University; Stanford University	McIntosh, CHS (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	è-, ä/F-9947-2012					BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Carter JD, 2005, MOL THER, V12, P360, DOI 10.1016/j.ymthe.2005.02.030; Chatziioannou A, 2000, IEEE T MED IMAGING, V19, P507, DOI 10.1109/42.870260; CHWALINSKI S, 1989, AM J ANAT, V186, P397, DOI 10.1002/aja.1001860409; Evgenov NV, 2006, NAT MED, V12, P144, DOI 10.1038/nm1316; Fowler M, 2005, TRANSPLANTATION, V79, P768, DOI 10.1097/01.TP.0000152798.03204.5C; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Hathout E, 2003, ARCH DIS CHILD, V88, P591, DOI 10.1136/adc.88.7.591; Herschman HR, 2003, CURR OPIN IMMUNOL, V15, P378, DOI 10.1016/S0952-7915(03)00066-9; Jirak D, 2004, MAGN RESON MED, V52, P1228, DOI 10.1002/mrm.20282; Lu YX, 2004, MOL THER, V9, P428, DOI 10.1016/j.ymthe.2004.01.008; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Oca-Cossio J, 2004, BIOCHEM BIOPH RES CO, V319, P569, DOI 10.1016/j.bbrc.2004.04.195; Paty BW, 2004, TRANSPLANTATION, V77, P1133, DOI 10.1097/01.TP.0000113231.90613.0E; Ponde DE, 2004, NUCL MED BIOL, V31, P133, DOI 10.1016/S0969-8051(03)00096-9; Qi JY, 1998, IEEE T NUCL SCI, V45, P1096, DOI 10.1109/23.681985; Robertson RP, 2004, NEW ENGL J MED, V350, P694, DOI 10.1056/NEJMra032425; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; Salvalaggio PRO, 2002, TRANSPLANTATION, V74, P877, DOI 10.1097/00007890-200209270-00023; Shapiro AMJ, 2001, TRANSPLANTATION, V71, P1709, DOI 10.1097/00007890-200106270-00002; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Stock PG, 2004, ANNU REV MED, V55, P133, DOI 10.1146/annurev.med.55.091902.103539; Yang ZD, 2002, J IMMUNOL, V168, P6479, DOI 10.4049/jimmunol.168.12.6479; Yu YJ, 2000, NAT MED, V6, P933, DOI 10.1038/78704	24	63	68	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1423	1428		10.1038/nm1458	http://dx.doi.org/10.1038/nm1458			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17143277				2022-12-27	WOS:000242618200024
J	Hanna, J; Goldman-Wohl, D; Hamani, Y; Avraham, I; Greenfield, C; Natanson-Yaron, S; Prus, D; Cohen-Daniel, L; Arnon, TI; Manaster, I; Gazit, R; Yutkin, V; Benharroch, D; Porgador, A; Keshet, E; Yagel, S; Mandelboim, O				Hanna, Jacob; Goldman-Wohl, Debra; Hamani, Yaron; Avraham, Inbal; Greenfield, Caryn; Natanson-Yaron, Shira; Prus, Diana; Cohen-Daniel, Leonor; Arnon, Tal I.; Manaster, Irit; Gazit, Roi; Yutkin, Vladimir; Benharroch, Daniel; Porgador, Angel; Keshet, Eli; Yagel, Simcha; Mandelboim, Ofer			Decidual NK cells regulate key developmental processes at the human fetal-maternal interface	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; HLA-G EXPRESSION; ACTIVATING RECEPTOR; GENE-EXPRESSION; RECOGNITION; TROPHOBLASTS; DIFFERENTIATION; PREGNANCY; HEMAGGLUTININS; ENDOMETRIUM	Human CD56(bright) NK cells accumulate in the maternal decidua during pregnancy and are found in direct contact with fetal trophoblasts. Several mechanisms have been proposed to explain the inability of NK cells to kill the semiallogeneic fetal cells. However, the actual functions of decidual NK (dNK) cells during pregnancy are mostly unknown. Here we show that dNK cells, but not peripheral blood - derived NK subsets, regulate trophoblast invasion both in vitro and in vivo by production of the interleukin-8 and interferon-inducible protein - 10 chemokines. Furthermore, dNK cells are potent secretors of an array of angiogenic factors and induce vascular growth in the decidua. Notably, such functions are regulated by specific interactions between dNK-activating and dNK-inhibitory receptors and their ligands, uniquely expressed at the fetal-maternal interface. The overall results support a 'peaceful' model for reproductive immunology, in which elements of innate immunity have been incorporated in a constructive manner to support reproductive tissue development.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Urol, IL-91120 Jerusalem, Israel; Ben Gurion Univ Negev, Dept Microbiol & Immunol, IL-92865 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Pathol, IL-92865 Beer Sheva, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University	Mandelboim, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	syagel@hadassah.org.il; oferman@md2.huji.ac.il	Keshet, Eli/GQR-0445-2022; Gazit, Roi/J-3352-2017; Hanna, Jacob/K-1339-2012	Hanna, Jacob/0000-0003-2042-9974; Gazit, Roi/0000-0002-0548-2147; Mandelboim, Ofer/0000-0002-9354-1855; Porgador, Angel/0000-0003-1540-4449				Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Ashkar AA, 2001, SEMIN IMMUNOL, V13, P235, DOI 10.1006/smim.2000.0319; Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; Bulmer JN, 2005, MOL IMMUNOL, V42, P511, DOI 10.1016/j.molimm.2004.07.035; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Drake PM, 2001, J EXP MED, V193, P1199, DOI 10.1084/jem.193.10.1199; Faust Z, 1999, AM J REPROD IMMUNOL, V42, P71; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Fisher Susan J, 2004, Reprod Biol Endocrinol, V2, P53, DOI 10.1186/1477-7827-2-53; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P535, DOI 10.1093/molehr/6.6.535; Gonen-Gross T, 2003, J IMMUNOL, V171, P1343, DOI 10.4049/jimmunol.171.3.1343; Guimond MJ, 1997, BIOL REPROD, V56, P169, DOI 10.1095/biolreprod56.1.169; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Hanna J, 2004, J IMMUNOL, V173, P6547, DOI 10.4049/jimmunol.173.11.6547; Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517; Henderson TA, 2003, J CLIN ENDOCR METAB, V88, P440, DOI 10.1210/jc.2002-021174; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214; Katz G, 2004, J IMMUNOL, V173, P1819, DOI 10.4049/jimmunol.173.3.1819; Katz G, 2001, J IMMUNOL, V166, P7260, DOI 10.4049/jimmunol.166.12.7260; King A, 1996, AM J REPROD IMMUNOL, V35, P258; Kitaya K, 2000, BIOL REPROD, V63, P683, DOI 10.1095/biolreprod63.3.683; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Kopcow HD, 2005, P NATL ACAD SCI USA, V102, P15563, DOI 10.1073/pnas.0507835102; Langer N, 1999, AM J REPROD IMMUNOL, V42, P263; Lanier LL, 2005, ADV EXP MED BIOL, V560, P51; Leonard S, 2006, PLACENTA, V27, pS40, DOI 10.1016/j.placenta.2005.11.007; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; Moffett A, 2004, PLACENTA, V25, P1, DOI 10.1016/S0143-4004(03)00167-X; Monk JM, 2005, PLACENTA, V26, P835, DOI 10.1016/j.placenta.2004.10.016; Moretta A, 2002, NAT IMMUNOL, V3, P6, DOI 10.1038/ni0102-6; Parham P, 2004, IMMUNOL LETT, V92, P11, DOI 10.1016/j.imlet.2003.11.016; Parham P, 2004, J EXP MED, V200, P951, DOI 10.1084/jem.20041783; Pazmany L, 1999, J REPROD IMMUNOL, V43, P127, DOI 10.1016/S0165-0378(99)00028-5; Rajagopalan S, 2006, PLOS BIOL, V4, P70, DOI 10.1371/journal.pbio.0040009; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Tabiasco J, 2006, PLACENTA, V27, pS34, DOI 10.1016/j.placenta.2006.01.009; Tayade C, 2006, J IMMUNOL, V176, P148, DOI 10.4049/jimmunol.176.1.148; Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; Verma S, 2000, BIOL REPROD, V62, P959, DOI 10.1095/biolreprod62.4.959; Zhang LL, 2000, CANCER RES, V60, P3655; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1998, J REPROD IMMUNOL, V39, P197, DOI 10.1016/S0165-0378(98)00022-9	49	1160	1205	4	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1065	1074		10.1038/nm1452	http://dx.doi.org/10.1038/nm1452			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892062				2022-12-27	WOS:000240373900031
J	Ito, K; Hirao, A; Arai, F; Takubo, K; Matsuoka, S; Miyamoto, K; Ohmura, M; Naka, K; Hosokawa, K; Ikeda, Y; Suda, T				Ito, K; Hirao, A; Arai, F; Takubo, K; Matsuoka, S; Miyamoto, K; Ohmura, M; Naka, K; Hosokawa, K; Ikeda, Y; Suda, T			Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells	NATURE MEDICINE			English	Article							SIGNALING PATHWAY; OXIDATIVE STRESS; AGED MICE; TRANSPLANTATION; MITOCHONDRIA; QUIESCENCE; ACTIVATION; EXPRESSION; APOPTOSIS	Hematopoietic stem cells (HSCs) undergo self-renewing cell divisions and maintain blood production for their lifetime(1). Appropriate control of HSC self-renewal is crucial for the maintenance of hematopoietic homeostasis. Here we show that activation of p38 MAPK in response to increasing levels of reactive oxygen species (ROS) limits the lifespan of HSCs in vivo. In Atm(-/-) mice, elevation of ROS levels induces HSC-specific phosphorylation of p38 MAPK accompanied by a defect in the maintenance of HSC quiescence. Inhibition of p38 MAPK rescued ROS-induced defects in HSC repopulating capacity and in the maintenance of HSC quiescence, indicating that the ROS- p38 MAPK pathway contributes to exhaustion of the stem cell population. Furthermore, prolonged treatment with an antioxidant or an inhibitor of p38 MAPK extended the lifespan of HSCs from wild-type mice in serial transplantation experiments. These data show that inactivation of p38 MAPK protects HSCs against loss of self-renewal capacity. Our characterization of molecular mechanisms that limit HSC lifespan may lead to beneficial therapies for human disease.	Keio Univ, Sch Med, Dept Cell Differentiat, Sakaguchi Lab Dev Biol,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Div Hematol, Dept Internal Med,Shinjuku Ku, Tokyo 1608582, Japan; Kanazawa Univ, Div Mol Genet, Dept Mol Oncol, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Keio University; Keio University; Kanazawa University; Japan Science & Technology Agency (JST)	Hirao, A (corresponding author), Keio Univ, Sch Med, Dept Cell Differentiat, Sakaguchi Lab Dev Biol,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	ahirao@kenroku.kanazawa-u.ac.jp; sudato@sc.itc.keio.ac.jp	Takubo, Keiyo/AAX-5546-2020; Arai, Fumio/J-5241-2013; Naka, Kazuhito/X-3756-2019; Suda, Toshio/H-6761-2013	Takubo, Keiyo/0000-0002-1736-7592; Arai, Fumio/0000-0003-1936-4907; Naka, Kazuhito/0000-0001-6646-6004; Suda, Toshio/0000-0001-7540-1771				Allsopp RC, 2003, NAT MED, V9, P369, DOI 10.1038/nm0403-369; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Griffith O W, 1981, Methods Enzymol, V77, P59; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARRISON DE, 1975, J IMMUNOL, V114, P1314; HARRISON DE, 1975, J GERONTOL, V30, P279, DOI 10.1093/geronj/30.3.279; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Wu WS, 2003, ONCOGENE, V22, P955, DOI 10.1038/sj.onc.1206237	20	1017	1082	13	107	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					446	451		10.1038/nm1388	http://dx.doi.org/10.1038/nm1388			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16565722				2022-12-27	WOS:000236581300034
J	Zhao, BQ; Wang, S; Kim, HY; Storrie, H; Rosen, BR; Mooney, DJ; Wang, XY; Lo, EH				Zhao, BQ; Wang, S; Kim, HY; Storrie, H; Rosen, BR; Mooney, DJ; Wang, XY; Lo, EH			Role of matrix metalloproteinases in delayed cortical responses after stroke	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; PLASMINOGEN ACTIVATOR; MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS; INDUCTION; RECOVERY; REGENERATION; PROTEOLYSIS; EXPRESSION	Matrix metalloproteinases ( MMPs) are zinc-endopeptidases with multifactorial actions in central nervous system (CNS) physiology and pathology(1). Accumulating data suggest that MMPs have a deleterious role in stroke. By degrading neurovascular matrix, MMPs promote injury of the blood-brain barrier, edema and hemorrhage(2-4). By disrupting cell-matrix signaling and homeostasis, MMPs trigger brain cell death(5,6). Hence, there is a movement toward the development of MMP inhibitors for acute stroke therapy. But MMPs may have a different role during delayed phases after stroke. Because MMPs modulate brain matrix, they may mediate beneficial plasticity and remodeling during stroke recovery. Here, we show that MMPs participate in delayed cortical responses after focal cerebral ischemia in rats. MMP-9 is upregulated in peri-infarct cortex at 7-14 days after stroke and is colocalized with markers of neurovascular remodeling. Treatment with MMP inhibitors at 7 days after stroke suppresses neurovascular remodeling, increases ischemic brain injury and impairs functional recovery at 14 days. MMP processing of bioavailable VEGF may be involved because inhibition of MMPs reduces endogenous VEGF signals, whereas additional treatment with exogenous VEGF prevents MMP inhibitor-induced worsening of infarction. These data suggest that, contrary to MMP inhibitor therapies for acute stroke, strategies that modulate MMPs may be needed for promoting stroke recovery.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; Massachusetts Gen Hosp, Aninthoula Martinos Ctr Biomed Imaging, MGH E 2, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu		Mooney, David/0000-0001-6299-1194	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048422, R01NS037074, R01NS040529, P50NS010828] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01-EB02066] Funding Source: Medline; NINDS NIH HHS [R01-NS48422, P50-NS10828, R01-NS37074, R01-NS40529] Funding Source: Medline; PHS HHS [R01-EBO2066] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Chmielnicki E, 2002, PROG BRAIN RES, V138, P451, DOI 10.1016/S0079-6123(02)38093-2; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kim YR, 2005, J CEREBR BLOOD F MET, V25, P820, DOI 10.1038/sj.jcbfm.9600084; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Manoonkitiwongsa PS, 2001, J CEREBR BLOOD F MET, V21, P1223, DOI 10.1097/00004647-200110000-00011; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P1759, DOI 10.1161/01.STR.32.8.1759; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Omura K, 2004, BRAIN RES, V1001, P13, DOI 10.1016/j.brainres.2003.10.067; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Reeves TM, 2003, J NEUROSCI, V23, P10182; Silva EA, 2004, CURR TOP DEV BIOL, V64, P181, DOI 10.1016/S0070-2153(04)64008-7; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; WALLACE CS, 1995, MOL BRAIN RES, V32, P211, DOI 10.1016/0169-328X(95)00076-5; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	30	552	586	2	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					441	445		10.1038/nm1387	http://dx.doi.org/10.1038/nm1387			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16565723				2022-12-27	WOS:000236581300033
J	Chan, CW; Crafton, E; Fan, HN; Flook, J; Yoshimura, K; Skarica, M; Brockstedt, D; Dubensky, TW; Stins, MF; Lanier, LL; Pardoll, DM; Housseau, F				Chan, CW; Crafton, E; Fan, HN; Flook, J; Yoshimura, K; Skarica, M; Brockstedt, D; Dubensky, TW; Stins, MF; Lanier, LL; Pardoll, DM; Housseau, F			Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity	NATURE MEDICINE			English	Article							HUMAN NK CELLS; IFN-GAMMA; ACTIVATION; RECEPTOR; NKG2D; BETA; EXPRESSION; INFECTION	Natural killer (NK) cells and dendritic cells (DCs) are, respectively, central components of innate and adaptive immune responses(1,2). We describe here a third DC lineage, termed interferon-producing killer DCs (IKDCs), distinct from conventional DCs and plasmacytoid DCs and with the molecular expression profile of both NK cells and DCs. They produce substantial amounts of type I interferons (IFN) and interleukin (IL)-12 or IFN-c, depending on activation stimuli. Upon stimulation with CpG oligodeoxynucleotides, ligands for Toll-like receptor (TLR)-9, IKDCs kill typical NK target cells using NK-activating receptors. Their cytolytic capacity subsequently diminishes, associated with the loss of NKG2D receptor (also known as Klrk1) and its adaptors, Dap10 and Dap12. As cytotoxicity is lost, DC-like antigen-presenting activity is gained, associated with upregulation of surface major histocompatibility complex class II (MHC II) and costimulatory molecules, which formally distinguish them from classical NK cells. In vivo, splenic IKDCs preferentially show NK function and, upon systemic infection, migrate to lymph nodes, where they primarily show antigen-presenting cell activity. By virtue of their capacity to kill target cells, followed by antigen presentation, IKDCs provide a link between innate and adaptive immunity.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Cerus Corp, Concord, CA 94520 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Infect Dis, Baltimore, MD 21205 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Johns Hopkins University; Johns Hopkins Medicine; Cerus Corporation; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Housseau, F (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, CRB-440,1650 Orleans St, Baltimore, MD 21231 USA.	dmpardol@jhmi.edu; fhousse1@jhmi.edu	Stins, Monique/W-2621-2018; Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952; Skarica, Mario/0000-0002-2478-014X	NATIONAL CANCER INSTITUTE [R01CA089294, R01CA089189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064826] Funding Source: NIH RePORTER; NCI NIH HHS [CA89294, CA89189, R01 CA089189, R01 CA089294] Funding Source: Medline; NIAID NIH HHS [R01 AI064826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Arase H, 2001, J IMMUNOL, V167, P1141, DOI 10.4049/jimmunol.167.3.1141; Ardavin C, 2003, NAT REV IMMUNOL, V3, P582, DOI 10.1038/nri1127; Asselin-Paturel C, 2005, J EXP MED, V201, P1157, DOI 10.1084/jem.20041930; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Kamath AT, 2005, J IMMUNOL, V174, P767, DOI 10.4049/jimmunol.174.2.767; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Ortaldo JR, 1999, J LEUKOCYTE BIOL, V66, P512, DOI 10.1002/jlb.66.3.512; Pelayo R, 2005, BLOOD, V105, P4407, DOI 10.1182/blood-2004-07-2529; Pillarisetty VG, 2005, J IMMUNOL, V174, P2612, DOI 10.4049/jimmunol.174.5.2612; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Walzer T, 2005, BLOOD; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zingoni A, 2004, J IMMUNOL, V173, P3716, DOI 10.4049/jimmunol.173.6.3716	30	324	355	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					207	213		10.1038/nm1352	http://dx.doi.org/10.1038/nm1352			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444266				2022-12-27	WOS:000235160600025
J	Novak, K				Novak, K			Janet Rowley	NATURE MEDICINE			English	Biographical-Item														Novak, Kristine/0000-0001-9314-1803				ROWLEY JD, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					10	10		10.1038/nm0106-10	http://dx.doi.org/10.1038/nm0106-10			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397540				2022-12-27	WOS:000234419000011
J	Wakita, T; Pietschmann, T; Kato, T; Date, T; Miyamoto, M; Zhao, ZJ; Murthy, K; Habermann, A; Krausslich, HG; Mizokami, M; Bartenschlager, R; Liang, TJ				Wakita, T; Pietschmann, T; Kato, T; Date, T; Miyamoto, M; Zhao, ZJ; Murthy, K; Habermann, A; Krausslich, HG; Mizokami, M; Bartenschlager, R; Liang, TJ			Production of infectious hepatitis C virus in tissue culture from a cloned viral genome	NATURE MEDICINE			English	Article							NON-B HEPATITIS; EFFICIENT REPLICATION; GENOTYPE 2A; NON-A; ENVELOPE PROTEIN; MOLECULAR CLONE; CDNA-CLONE; CHIMPANZEES; PERSISTENT	Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem. Detailed analyses of HCV have been hampered by the lack of viral culture systems. Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture. Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7). Particles have a density of about 1.15 - 1.17 g/ml and a spherical morphology with an average diameter of about 55 nm. Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by immunoglobulins from chronically infected individuals. The cell culture - generated HCV is infectious for chimpanzee. This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.	Tokyo Metropolitan Inst Neurosci, Dept Microbiol, Tokyo 1838526, Japan; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany; Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi 4678601, Japan; NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA; SW Fdn Biomed Res, San Antonio, TX 78227 USA; Heidelberg Univ, Dept Virol, D-69120 Heidelberg, Germany	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Ruprecht Karls University Heidelberg; Nagoya City University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Texas Biomedical Research Institute; Ruprecht Karls University Heidelberg	Wakita, T (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Microbiol, Tokyo 1838526, Japan.	wakita@tmin.ac.jp	Pietschmann, Thomas/E-9241-2015; Bartenschlager, Ralf/L-2582-2015	Pietschmann, Thomas/0000-0001-5138-6239; Bartenschlager, Ralf/0000-0001-5601-9307; Habermann, Anja/0000-0003-3686-9050	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB027091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054505, Z01DK054504, Z01DK054503] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK054504-11] Funding Source: Medline; NHLBI NIH HHS [N01-HB-27091, N01HB27091] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoyagi K, 1999, J CLIN MICROBIOL, V37, P1802, DOI 10.1128/JCM.37.6.1802-1808.1999; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Date T, 2004, J BIOL CHEM, V279, P22371, DOI 10.1074/jbc.M311120200; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Hadlock KG, 2000, J VIROL, V74, P10407, DOI 10.1128/JVI.74.22.10407-10416.2000; HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; KAITO M, 1994, J GEN VIROL, V75, P1755, DOI 10.1099/0022-1317-75-7-1755; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kato T, 2005, J VIROL, V79, P592, DOI 10.1128/JVI.79.1.592-596.2005; Kato T, 2003, J MED VIROL, V69, P357, DOI 10.1002/jmv.10297; Kato T, 2001, J MED VIROL, V64, P334, DOI 10.1002/jmv.1055; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Major ME, 2002, J VIROL, V76, P6586, DOI 10.1128/JVI.76.13.6586-6595.2002; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Shimizu YK, 1996, HEPATOLOGY, V23, P205; TAKAHASHI K, 1992, VIROLOGY, V191, P431, DOI 10.1016/0042-6822(92)90204-3; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; Thomson M, 2003, J VIROL, V77, P862, DOI 10.1128/JVI.77.2.862-870.2003; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	29	2258	2460	3	160	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					791	796		10.1038/nm1268	http://dx.doi.org/10.1038/nm1268			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15951748	Green Accepted			2022-12-27	WOS:000230304200037
J	Steinman, RM				Steinman, Ralph M.			Dendritic cells: versatile controllers of the immune system	NATURE MEDICINE			English	Editorial Material							REGULATORY T-CELLS; PERIPHERAL LYMPHOID ORGANS; EPIDERMAL LANGERHANS CELLS; MIXED LEUKOCYTE REACTION; MACROPHAGES IN-VITRO; ANTIGEN PRESENTATION; ACCESSORY CELLS; LYMPHOCYTIC CHORIOMENINGITIS; HORSERADISH-PEROXIDASE; ANTIBODY-RESPONSES		Rockefeller Univ, New York, NY 10065 USA	Rockefeller University	Steinman, RM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA.	steinma@rockefeller.edu	Steinman, Ralph/F-7729-2012					Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Badovinac VP, 2005, NAT MED, V11, P748, DOI 10.1038/nm1257; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; BRACK C, 1978, CELL, V15, P1, DOI 10.1016/0092-8674(78)90078-8; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; COHN ZA, 1983, HARVEY LECT, V77, P63; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; DOHERTY PC, 1975, J EXP MED, V141, P502, DOI 10.1084/jem.141.2.502; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; INABA K, 1985, SCIENCE, V229, P475, DOI 10.1126/science.3160115; INABA K, 1983, P NATL ACAD SCI-BIOL, V80, P6041, DOI 10.1073/pnas.80.19.6041; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Luo XR, 2007, P NATL ACAD SCI USA, V104, P2821, DOI 10.1073/pnas.0611646104; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236; MISHELL RI, 1967, J EXP MED, V126, P423, DOI 10.1084/jem.126.3.423; Moser M, 2003, IMMUNITY, V19, P5, DOI 10.1016/S1074-7613(03)00182-1; MOSIER DE, 1967, SCIENCE, V158, P1573, DOI 10.1126/science.158.3808.1573; Munz C, 2005, J EXP MED, V202, P203, DOI 10.1084/jem.20050810; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; NUSSENZWEIG MC, 1980, J EXP MED, V152, P1070, DOI 10.1084/jem.152.4.1070; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; PALADE GE, 1975, LES PRIX NOBEL 1974, P36; Probst HC, 2003, IMMUNITY, V18, P713, DOI 10.1016/S1074-7613(03)00120-1; Pulendran B, 2005, J IMMUNOL, V174, P2457, DOI 10.4049/jimmunol.174.5.2457; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; Steinman RM, 2004, CLIN INVEST MED, V27, P231; STEINMAN RM, 1974, J EXP MED, V139, P380, DOI 10.1084/jem.139.2.380; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; STEINMAN RM, 1972, J CELL BIOL, V55, P616, DOI 10.1083/jcb.55.3.616; STEINMAN RM, 1972, J CELL BIOL, V55, P186, DOI 10.1083/jcb.55.1.186; STEINMAN RM, IN PRESS EUR J IMMUN; Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005; UNANUE ER, 1970, J EXP MED, V131, P711, DOI 10.1084/jem.131.4.711; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Zammit DJ, 2005, IMMUNITY, V22, P561, DOI 10.1016/j.immuni.2005.03.005; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	73	233	239	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1155	1159		10.1038/nm1643	http://dx.doi.org/10.1038/nm1643			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17917664				2022-12-27	WOS:000249980200028
J	Mandavilli, A				Mandavilli, Apoorva			Straight talk from... James Love	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1010	1010		10.1038/nm0907-1010	http://dx.doi.org/10.1038/nm0907-1010			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17828212	Bronze			2022-12-27	WOS:000249353100009
J	Micu, I; Ridsdale, A; Zhang, LQ; Woulfe, J; McClintock, J; Brantner, CA; Andrews, SB; Stys, PK				Micu, Ileana; Ridsdale, Andrew; Zhang, Lingqing; Woulfe, John; McClintock, Jeff; Brantner, Christine A.; Andrews, S. Brian; Stys, Peter K.			Real-time measurement of free Ca2+ changes in CNS myelin by two-photon microscopy	NATURE MEDICINE			English	Article							CORD WHITE-MATTER; SHEATH THICKNESS; ION CHANNELS; OPTIC-NERVE; CALCIUM; MECHANISMS; ACTIVATION; RECEPTORS; GLYCINE; CELLS	Here we describe a technique for measuring changes in Ca2+ in the cytosolic domain of mature compact myelin of live axons in the central nervous system (CNS). We label the myelin sheath of optic nerve and dorsal column axons by using the Ca2+ indicator X-rhod-1 coupled with DiOC(6)(3) to produce bright myelin counterstaining, thereby providing unambiguous identification of the myelin sheath for analysis of two-photon excited fluorescence. We present evidence for localization of the Ca2+ reporter to the cytosolic domain of myelin, obtained by using fluorescence lifetime, spectral measurements and Mn2+ quenching. Chemical ischemia increased myelinic X-rhod-1 fluorescence (similar to 50% after 30 min) in a manner dependent on extracellular Ca2+. Inhibiting Na+-dependent glutamate transporters (with TBOA) or glycine transporters (with sarcosine and ALX-1393) reduced the ischemia-induced increase in Ca2+. We show that myelinic N-methyl-D-aspartate (NMDA) receptors are activated by the two conventional coagonists glutamate and glycine, which are released by specific transporters under conditions of cellular Na+ loading and depolarization in injured white matter. This new technique facilitates detailed studies of living myelin, a vital component of the mammalian CNS.	Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; NINDS, Neurobiol Lab, NIH, Bethesda, MD 20892 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Stys, PK (corresponding author), Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada.	pstys@ucalgary.ca	Micu, Ileana/M-9468-2016	Micu, Ileana/0000-0001-7112-0075; Brantner, Christine/0000-0001-8172-901X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002610, Z01NS002610] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER SPH, 2006, BRIT J PHARMACOL, V147, pS148; Aragon C, 2003, EUR J PHARMACOL, V479, P249, DOI 10.1016/j.ejphar.2003.08.074; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; CHERKSEY B, 1994, NEUROCHEM RES, V19, P1101, DOI 10.1007/BF00968722; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dingledine R, 1999, PHARMACOL REV, V51, P7; ELLISMAN M H, 1979, Scanning Electron Microscopy, P793; HILDEBRAND C, 1978, J NEUROL SCI, V38, P421, DOI 10.1016/0022-510X(78)90147-8; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lazzarini R. A., 2004, MYELIN BIOL DISORDER; LEVRAM V, 1995, J NEUROSCI, V15, P2628; Li S, 1999, J Neurosci, V19, pRC16; MARTENSON RE, 1992, MYELIN BIOL CHEM; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; MINTA A, 1989, J BIOL CHEM, V264, P8171; MRSULJA BJ, 1985, BRAIN RES, V343, P154, DOI 10.1016/0006-8993(85)91170-9; Ness JK, 2005, GLIA, V50, P321, DOI 10.1002/glia.20206; Ouardouz M, 2003, NEURON, V40, P53, DOI 10.1016/j.neuron.2003.08.016; RANVIER L, 1878, LECONS HIST SYTEME N; Ren Y, 2000, J NEUROSCI METH, V102, P165, DOI 10.1016/S0165-0270(00)00304-6; ROPTE S, 1990, J NEUROCYTOL, V19, P242, DOI 10.1007/BF01217302; SCHLAEPFER WW, 1977, NATURE, V265, P734, DOI 10.1038/265734a0; SIMPSON PB, 1995, EUR J NEUROSCI, V7, P831, DOI 10.1111/j.1460-9568.1995.tb01070.x; Spike RC, 1997, NEUROSCIENCE, V77, P543, DOI 10.1016/S0306-4522(96)00501-5; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Taylor CM, 2004, P NATL ACAD SCI USA, V101, P4643, DOI 10.1073/pnas.0400922101; Verbny Y, 2002, J NEUROPHYSIOL, V88, P802, DOI 10.1152/jn.2002.88.2.802; VIRCHOW RLK, 1854, ALLGEMEINE STORUNGEN	30	56	57	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2007	13	7					874	879		10.1038/nm1568	http://dx.doi.org/10.1038/nm1568			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17603496				2022-12-27	WOS:000247902800036
J	Bishop, BL; Duncan, MJ; Song, J; Li, GJ; Zaas, D; Abraham, SN				Bishop, Brian L.; Duncan, Mathew J.; Song, Jeongmin; Li, Guojie; Zaas, David; Abraham, Soman N.			Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells	NATURE MEDICINE			English	Article							UNIQUE DITERPENE ACTIVATOR; BACTERIAL INVASION; FORSKOLIN; INDUCTION; MEMBRANES; GROWTH	The superficial bladder epithelium is a powerful barrier to urine and also serves as a regulator of bladder volume, which is achieved by apical exocytosis of specialized fusiform vesicles during distension of the bladder. We report that type 1 fimbriated uropathogenic Escherichia coli (UPEC) circumvents the bladder barrier by harboring in these Rab27b/ CD63-positive and cAMP-regulatable fusiform vesicles within bladder epithelial cells (BECs). Incorporation of UPEC into BEC fusiform compartments enabled bacteria to escape elimination during voiding and to re-emerge in the urine as the bladder distended. Notably, treatment of UPEC-infected mice with a drug that increases intracellular cAMP and induces exocytosis of fusiform vesicles reduced the number of intracellular E. coli.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Bishop, BL (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	blb7@duke.edu; soman.abraham@duke.edu		Song, Jeongmin/0000-0002-6777-3505	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056101, R01AI035678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050814] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-35678, R21 AI056101] Funding Source: Medline; NIDDK NIH HHS [R37DK50814] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1985, INFECT IMMUN, V48, P625, DOI 10.1128/IAI.48.3.625-628.1985; Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550; ANDERSON JD, 1979, J CLIN MICROBIOL, V10, P766, DOI 10.1128/JCM.10.6.766-771.1979; Andrews Norma W., 1993, Biological Research, V26, P65; Apodaca G, 2001, Urology, V57, P103, DOI 10.1016/S0090-4295(01)01026-3; Apodaca G, 2004, TRAFFIC, V5, P117, DOI 10.1046/j.1600-0854.2003.00156.x; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Carbone M, 2002, ANN NY ACAD SCI, V963, P332; Chen YR, 2003, P NATL ACAD SCI USA, V100, P14012, DOI 10.1073/pnas.2436350100; Drewes SE, 2003, PHYTOCHEMISTRY, V62, P1019, DOI 10.1016/S0031-9422(02)00621-0; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; Eto DS, 2006, CELL MICROBIOL, V8, P704, DOI 10.1111/j.1462-5822.2006.00691.x; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; Lewis SA, 2000, AM J PHYSIOL-RENAL, V278, pF867; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; MEYER BH, 1987, S AFR MED J, V71, P570; Min GW, 2002, J MOL BIOL, V317, P697, DOI 10.1006/jmbi.2002.5442; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Styczynski J, 2006, BRIT J HAEMATOL, V133, P397, DOI 10.1111/j.1365-2141.2006.06032.x; Svanborg C, 1997, INFECT DIS CLIN N AM, V11, P513, DOI 10.1016/S0891-5520(05)70371-8; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Truschel ST, 2002, MOL BIOL CELL, V13, P830, DOI 10.1091/mbc.01-09-0435; Uehling DT, 1999, WORLD J UROL, V17, P351, DOI 10.1007/s003450050160; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; Wajima Z, 2002, CRIT CARE MED, V30, P820, DOI 10.1097/00003246-200204000-00017; Wang E, 2003, METHODS, V30, P207, DOI 10.1016/S1046-2023(03)00027-6	32	149	157	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					625	630		10.1038/nm1572	http://dx.doi.org/10.1038/nm1572			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17417648				2022-12-27	WOS:000246302800031
J	Ludwiczek, S; Theurl, I; Muckenthaler, MU; Jakab, M; Mair, SM; Theurl, M; Kiss, J; Paulmichl, M; Hentze, MW; Ritter, M; Weiss, G				Ludwiczek, Susanne; Theurl, Igor; Muckenthaler, Martina U.; Jakab, Martin; Mair, Sabine M.; Theurl, Milan; Kiss, Judit; Paulmichl, Markus; Hentze, Matthias W.; Ritter, Markus; Weiss, Guenter			Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1	NATURE MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; MICROCYTIC ANEMIA; DIETARY IRON; ION TRANSPORTER; DMT1; ABSORPTION; EXPRESSION; GENE; METABOLISM; HEPCIDIN	Hereditary hemochromatosis and transfusional iron overload are frequent clinical conditions associated with progressive iron accumulation in parenchymal tissues, leading to eventual organ failure. We have discovered a new mechanism to reverse iron overload-pharmacological modulation of the divalent metal transporter-1 (DMT-1). DMT-1 mediates intracellular iron transport during the transferrin cycle and apical iron absorption in the duodenum. Its additional functions in iron handling in the kidney and liver are less well understood. We show that the L-type calcium channel blocker nifedipine increases DMT-1-mediated cellular iron transport 10- to 100-fold at concentrations between 1 and 100 mu M. Mechanistically, nifedipine causes this effect by prolonging the iron-transporting activity of DMT-1. We show that nifedipine mobilizes iron from the liver of mice with primary and secondary iron overload and enhances urinary iron excretion. Modulation of DMT-1 function by L-type calcium channel blockers emerges as a new pharmacological therapy for the treatment of iron overload disorders.	Innsbruck Med Univ, Dept Gen Internal Med, Clin Immunol & Infect Dis, A-6020 Innsbruck, Austria; Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; Innsbruck Med Univ, Dept Physiol & Med Phys, A-6020 Innsbruck, Austria; Paracelsus Med Univ, Inst Physiol, A-5020 Salzburg, Austria; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany	Medical University of Innsbruck; Ruprecht Karls University Heidelberg; Medical University of Innsbruck; Paracelsus Private Medical University; University of Milan; European Molecular Biology Laboratory (EMBL)	Weiss, G (corresponding author), Innsbruck Med Univ, Dept Gen Internal Med, Clin Immunol & Infect Dis, Anichstr 35, A-6020 Innsbruck, Austria.	hentze@embl.de; guenter.weiss@i-med.ac.at	Hentze, Matthias W/V-3980-2017; Ritter, Markus/AAG-4987-2020	Hentze, Matthias W/0000-0002-4023-7876; Ritter, Markus/0000-0001-7346-7750; Theurl, Igor/0000-0003-3180-4784; Weiss, Guenter/0000-0003-0709-2158; Muckenthaler, Martina/0000-0002-3778-510X				Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Abouhamed M, 2006, AM J PHYSIOL-RENAL, V290, pF1525, DOI 10.1152/ajprenal.00359.2005; Anderson GJ, 2002, INT J HEMATOL, V76, P203, DOI 10.1007/BF02982788; Andrews NC, 1999, INT J BIOCHEM CELL B, V31, P991, DOI 10.1016/S1357-2725(99)00065-5; Bahram S, 1999, P NATL ACAD SCI USA, V96, P13312, DOI 10.1073/pnas.96.23.13312; Beaumont C, 2006, BLOOD, V107, P4168, DOI 10.1182/blood-2005-10-4269; Canonne-Hergaux FS, 2002, KIDNEY INT, V62, P147, DOI 10.1046/j.1523-1755.2002.00405.x; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Ferguson CJ, 2001, AM J PHYSIOL-RENAL, V280, pF803, DOI 10.1152/ajprenal.2001.280.5.F803; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Fleming RE, 2002, ANNU REV PHYSIOL, V64, P663, DOI 10.1146/annurev.physiol.64.081501.155838; Frazer DM, 2003, BLOOD CELL MOL DIS, V30, P288, DOI 10.1016/S1079-9796(03)00039-1; Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020; Gruen AB, 2001, J INVEST DERMATOL, V116, P774, DOI 10.1046/j.1523-1747.2001.01318.x; Gunshin H, 2005, J CLIN INVEST, V115, P1258, DOI [10.1172/JCI200524356, 10.1172/JCI24356]; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hershko C, 1998, ANN NY ACAD SCI, V850, P191, DOI 10.1111/j.1749-6632.1998.tb10475.x; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hubert N, 2002, P NATL ACAD SCI USA, V99, P12345, DOI 10.1073/pnas.192423399; Iolascon A, 2006, BLOOD, V107, P349, DOI 10.1182/blood-2005-06-2477; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kushner J P, 2001, Hematology Am Soc Hematol Educ Program, P47; Lam-Yuk-Tseung S, 2006, BIOCHEMISTRY-US, V45, P2294, DOI 10.1021/bi052307m; Ludwiczek S, 2004, J MOL MED, V82, P373, DOI 10.1007/s00109-004-0542-3; Ludwiczek S, 2003, BLOOD, V101, P4148, DOI 10.1182/blood-2002-08-2459; Mackenzie B, 2006, PFLUG ARCH EUR J PHY, V451, P544, DOI 10.1007/s00424-005-1494-3; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Mims MP, 2005, BLOOD, V105, P1337, DOI 10.1182/blood-2004-07-2966; Mims MP, 2005, HEMATOLOGY, V10, P339, DOI 10.1080/10245330500093419; Morgan EH, 2002, BLOOD CELL MOL DIS, V29, P384, DOI 10.1006/bcmd.2002.0578; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; Musilkova J, 2001, BBA-BIOMEMBRANES, V1514, P117, DOI 10.1016/S0005-2736(01)00367-4; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Oudit GY, 2003, NAT MED, V9, P1187, DOI 10.1038/nm920; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; RUSSELL ES, 1970, TRANSPLANT P, V2, P144; Savigni DL, 2003, BIOCHEM PHARMACOL, V65, P1215, DOI 10.1016/S0006-2952(03)00045-5; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Wareing M, 2003, AM J PHYSIOL-RENAL, V285, pF1050, DOI 10.1152/ajprenal.00064.2003; Xu HX, 2004, PLOS BIOL, V2, P378, DOI 10.1371/journal.pbio.0020050; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492; Zoller H, 1999, LANCET, V353, P2120, DOI 10.1016/S0140-6736(98)11179-0	47	124	131	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					448	454		10.1038/nm1542	http://dx.doi.org/10.1038/nm1542			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17293870				2022-12-27	WOS:000245543900033
J	de Witte, L; Nabatov, A; Pion, M; Fluitsma, D; de Jong, MAWP; de Gruijl, T; Piguet, V; van Kooyk, Y; Geijtenbeek, TBH				de Witte, Lot; Nabatov, Alexey; Pion, Marjorie; Fluitsma, Donna; de Jong, Marein A. W. P.; de Gruijl, Tanja; Piguet, Vincent; van Kooyk, Yvette; Geijtenbeek, Teunis B. H.			Langerin is a natural barrier to HIV-1 transmission by Langerhans cells	NATURE MEDICINE			English	Article							EPIDERMAL DENDRITIC CELLS; INFECTION; BINDING; MICROBICIDES; RECEPTORS; MODEL	Human immunodeficiency virus-1 (HIV-1) is primarily transmitted sexually. Dendritic cells (DCs) in the subepithelium transmit HIV-1 to T cells through the C- type lectin DC-specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin (DC-SIGN). However, the epithelial Langerhans cells (LCs) are the first DC subset to encounter HIV-1. It has generally been assumed that LCs mediate the transmission of HIV-1 to T cells through the C- type lectin Langerin, similarly to transmission by DC-SIGN on dendritic cells (DCs). Here we show that in stark contrast to DC-SIGN, Langerin prevents HIV-1 transmission by LCs. HIV-1 captured by Langerin was internalized into Birbeck granules and degraded. Langerin inhibited LC infection and this mechanism kept LCs refractory to HIV-1 transmission; inhibition of Langerin allowed LC infection and subsequent HIV-1 transmission. Notably, LCs also inhibited T-cell infection by viral clearance through Langerin. Thus Langerin is a natural barrier to HIV-1 infection, and strategies to combat infection must enhance, preserve or, at the very least, not interfere with Langerin expression and function.	Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; Univ Hosp Geneva, Dept Dermatol & Venerol, CH-1211 Geneva, Switzerland; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Geneva; Vrije Universiteit Amsterdam	Geijtenbeek, TBH (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Van De Boechorstr 7, NL-1081 BT Amsterdam, Netherlands.	t.geijtenbeek@vumc.nl	Nabatov, Alexey/R-5291-2016; Geijtenbeek, Teunis/C-2229-2009; Pion, Marjorie/D-8139-2012; Pion, Marjorie/AAB-5812-2022; de Witte, Lot/H-1499-2011; Pion, Marjorie/D-8139-2012	Nabatov, Alexey/0000-0001-7932-1445; Pion, Marjorie/0000-0003-1828-4745; Van Kooyk, Yvette/0000-0001-5997-3665; Pion, Marjorie/0000-0002-6406-747X				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Cohn MA, 2001, J INFECT DIS, V184, P410, DOI 10.1086/322780; Collins KB, 2000, NAT MED, V6, P475, DOI 10.1038/74743; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Hunger RE, 2004, J CLIN INVEST, V113, P701, DOI 10.1172/JCI200419655; Kawamura T, 2000, J EXP MED, V192, P1491, DOI 10.1084/jem.192.10.1491; Kawamura T, 2005, J DERMATOL SCI, V40, P147, DOI 10.1016/j.jdermsci.2005.08.009; Kawamura T, 2003, P NATL ACAD SCI USA, V100, P8401, DOI 10.1073/pnas.1432450100; Kawamura T, 2001, EUR J IMMUNOL, V31, P360, DOI 10.1002/1521-4141(200102)31:2<360::AID-IMMU360>3.0.CO;2-X; Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848; Masterson AJ, 2002, BLOOD, V100, P701, DOI 10.1182/blood.V100.2.701; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795; Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024; Patterson BK, 2002, AM J PATHOL, V161, P867, DOI 10.1016/S0002-9440(10)64247-2; PICUT CA, 1987, J HISTOCHEM CYTOCHEM, V35, P745, DOI 10.1177/35.7.2884251; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623; RICHTERS CD, 1994, CLIN EXP IMMUNOL, V98, P330; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055; Ward EM, 2006, J BIOL CHEM, V281, P15450, DOI 10.1074/jbc.M511502200	25	450	464	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					367	371		10.1038/nm1541	http://dx.doi.org/10.1038/nm1541			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17334373				2022-12-27	WOS:000244715700051
J	Brisbare-Roch, C; Dingemanse, J; Koberstein, R; Hoever, P; Aissaoui, H; Flores, S; Mueller, C; Nayler, O; van Gerven, J; de Haas, SL; Hess, P; Qiu, CB; Buchmann, S; Scherz, M; Weller, T; Fischli, W; Clozel, M; Jenck, F				Brisbare-Roch, Catherine; Dingemanse, Jasper; Koberstein, Ralf; Hoever, Petra; Aissaoui, Hamed; Flores, Susan; Mueller, Celia; Nayler, Oliver; van Gerven, Joop; de Haas, Sanne L.; Hess, Patrick; Qiu, Changbin; Buchmann, Stephan; Scherz, Michael; Weller, Thomas; Fischli, Walter; Clozel, Martine; Jenck, Francois			Promotion of sleep by targeting the orexin system in rats, dogs and humans	NATURE MEDICINE			English	Article							HYPOCRETIN OREXIN; LOCUS-COERULEUS; DIURNAL-VARIATION; LATENCY TEST; A LEVELS; NARCOLEPSY; NEURONS; WAKEFULNESS; MICE; PEPTIDES	Orexins are hypothalamic peptides that play an important role in maintaining wakefulness in mammals. Permanent deficit in orexinergic function is a pathophysiological hallmark of rodent, canine and human narcolepsy. Here we report that in rats, dogs and humans, somnolence is induced by pharmacological blockade of both orexin OX1 and OX2 receptors. When administered orally during the active period of the circadian cycle, a dual antagonist increased, in rats, electrophysiological indices of both non-REM and, particularly, REM sleep, in contrast to GABA(A) receptor modulators; in dogs, it caused somnolence and increased surrogate markers of REM sleep; and in humans, it caused subjective and objective electrophysiological signs of sleep. No signs of cataplexy were observed, in contrast to the rodent, dog or human narcolepsy syndromes. These results open new perspectives for investigating the role of endogenous orexins in sleep-wake regulation.	Actel Pharmaceut Ltd, Res & Dev, CH-4123 Allschwil, Switzerland; Ctr Human Drug Res, NL-2333 CL Leiden, Netherlands; Chinese Acad Sci, Inst Biol Sci, Actel Joint Labs, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	Actelion Pharmaceuticals Ltd; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Jenck, F (corresponding author), Actel Pharmaceut Ltd, Res & Dev, Gewerbestr 16, CH-4123 Allschwil, Switzerland.	francois.jenck@actelion.com						ANSTEVENINCK F, 1993, THESIS LEIDEN U; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; Borbely AA, 2001, ARCH ITAL BIOL, V139, P53; Bourgin P, 2000, J NEUROSCI, V20, P7760; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Crocker A, 2005, NEUROLOGY, V65, P1184, DOI 10.1212/01.WNL.0000168173.71940.ab; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Desarnaud F, 2004, SLEEP, V27, P851, DOI 10.1093/sleep/27.5.851; Espana RA, 2001, NEUROSCIENCE, V106, P699, DOI 10.1016/S0306-4522(01)00319-0; Estabrooke IV, 2001, J NEUROSCI, V21, P1656, DOI 10.1523/JNEUROSCI.21-05-01656.2001; Gerashchenko D, 2001, J NEUROSCI, V21, P7273, DOI 10.1523/JNEUROSCI.21-18-07273.2001; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Ishibashi M, 2005, PEPTIDES, V26, P471, DOI 10.1016/j.peptides.2004.10.014; Kilduff TS, 2000, TRENDS NEUROSCI, V23, P359, DOI 10.1016/S0166-2236(00)01594-0; KIMOFF RJ, 1994, J APPL PHYSIOL, V76, P1810, DOI 10.1152/jappl.1994.76.4.1810; Kiyashchenko LI, 2002, J NEUROSCI, V22, P5282; Kiyashchenko LI, 2001, J NEUROPHYSIOL, V85, P2008, DOI 10.1152/jn.2001.85.5.2008; Lambe EK, 2005, J NEUROSCI, V25, P5225, DOI 10.1523/JNEUROSCI.0719-05.2005; Lee MG, 2005, J NEUROSCI, V25, P6716, DOI 10.1523/JNEUROSCI.1887-05.2005; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Martinez GS, 2002, BRAIN RES, V955, P1, DOI 10.1016/S0006-8993(02)03264-X; Methippara MM, 2000, NEUROREPORT, V11, P3423, DOI 10.1097/00001756-200011090-00004; Mieda M, 2004, P NATL ACAD SCI USA, V101, P4649, DOI 10.1073/pnas.0400590101; Mileykovskiy BY, 2005, NEURON, V46, P787, DOI 10.1016/j.neuron.2005.04.035; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Piper DC, 2000, EUR J NEUROSCI, V12, P726, DOI 10.1046/j.1460-9568.2000.00919.x; ROEHRS T, 1992, J CLIN NEUROPHYSIOL, V9, P63, DOI 10.1097/00004691-199201000-00007; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Salomon RM, 2003, BIOL PSYCHIAT, V54, P96, DOI 10.1016/S0006-3223(02)01740-7; Smith MI, 2003, NEUROSCI LETT, V341, P256, DOI 10.1016/S0304-3940(03)00066-1; Taheri S, 2000, NEUROSCI LETT, V279, P109, DOI 10.1016/S0304-3940(99)00955-6; Thakkar M M, 1999, Sleep Res Online, V2, P112; THORPY MJ, 1992, SLEEP, V15, P268; Willie JT, 2003, NEURON, V38, P715, DOI 10.1016/S0896-6273(03)00330-1; Xi MC, 2001, BRAIN RES, V901, P259, DOI 10.1016/S0006-8993(01)02317-4; Yoshida Y, 2001, EUR J NEUROSCI, V14, P1075, DOI 10.1046/j.0953-816x.2001.01725.x; Zeitzer JM, 2003, J NEUROSCI, V23, P3555	42	450	519	2	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					150	155		10.1038/nm1544	http://dx.doi.org/10.1038/nm1544			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17259994				2022-12-27	WOS:000244031700023
J	Leiper, J; Nandi, M; Torondel, B; Murray-Rust, J; Malaki, M; O'Hara, B; Rossiter, S; Anthony, S; Madhani, M; Selwood, D; Smith, C; Wojciak-Stothard, B; Rudiger, A; Stidwill, R; McDonald, NQ; Vallance, P				Leiper, James; Nandi, Manasi; Torondel, Belen; Murray-Rust, Judith; Malaki, Mohammed; O'Hara, Bernard; Rossiter, Sharon; Anthony, Shelagh; Madhani, Melanie; Selwood, David; Smith, Caroline; Wojciak-Stothard, Beata; Rudiger, Alain; Stidwill, Ray; McDonald, Neil Q.; Vallance, Patrick			Disruption of methylarginine metabolism impairs vascular homeostasis	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE; ASYMMETRICAL DIMETHYLARGININE; PULMONARY-HYPERTENSION; INHIBITORS; EXPRESSION; ARGININE; DISEASE; PLASMA; DEATH	Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA) are endogenously produced amino acids that inhibit all three isoforms of nitric oxide synthase (NOS)(1). ADMA accumulates in various disease states, including renal failure, diabetes and pulmonary hypertension, and its concentration in plasma is strongly predictive of premature cardiovascular disease and death(2-4). Both L-NMMA and ADMA are eliminated largely through active metabolism by dimethylarginine dimethylaminohydrolase (DDAH)(5) and thus DDAH dysfunction may be a crucial unifying feature of increased cardiovascular risk. However, despite considerable interest in this pathway and in the role of ADMA as a cardiovascular risk factor, there is little evidence to support a causal role of ADMA in pathophysiology. Here we reveal the structure of human DDAH-1 and probe the function of DDAH-1 both by deleting the Ddah1 gene in mice and by using DDAH-specific inhibitors which, as we demonstrate by crystallography, bind to the active site of human DDAH-1. We show that loss of DDAH-1 activity leads to accumulation of ADMA and reduction in NO signaling. This in turn causes vascular pathophysiology, including endothelial dysfunction, increased systemic vascular resistance and elevated systemic and pulmonary blood pressure. Our results also suggest that DDAH inhibition could be harnessed therapeutically to reduce the vascular collapse associated with sepsis.	UCL, Div Med, Ctr Clin Pharmacol, London WC1E 6JJ, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England; Canc Res UK, London Res Inst, Struct Biol Lab, London WC2A 3PX, England; UCL, Wolfson Inst Biomed Res, London WC1E 6JJ, England	University of London; University College London; University of London; Birkbeck University London; Cancer Research UK; University of London; University College London	Vallance, P (corresponding author), GlaxoSmithKline, Greenford Rd, Greenford UB6 0HE, Middx, England.	patrick.5.vallance@gsk.com	Madhani, Melanie/I-4342-2014; Selwood, David/C-1571-2008	Madhani, Melanie/0000-0001-8596-763X; Rossiter, Sharon/0000-0003-3822-0028; nandi, manasi/0000-0001-8585-5363; Rudiger, Alain/0000-0001-7943-7624; Selwood, David/0000-0002-6817-5064; Leiper, James/0000-0003-4656-519X; Smith, Caroline Louise/0000-0002-5217-6812	Medical Research Council [MC_U120097118, G0500712] Funding Source: Medline; Wellcome Trust [065612/Z/01] Funding Source: Medline; MRC [G0500712] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Hollenberg SM, 2001, AM J RESP CRIT CARE, V164, P891, DOI 10.1164/ajrccm.164.5.2010073; Ichinose F, 2004, CIRCULATION, V109, P3106, DOI 10.1161/01.CIR.0000134595.80170.62; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Leiper J, 2002, P NATL ACAD SCI USA, V99, P13527, DOI 10.1073/pnas.212269799; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Millatt LJ, 2003, CIRCULATION, V108, P1493, DOI 10.1161/01.CIR.0000089087.25930.FF; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Nandi M, 2005, CIRCULATION, V111, P2086, DOI 10.1161/01.CIR.0000163268.32638.F4; Pullamsetti S, 2005, FASEB J, V19, P1175, DOI 10.1096/fj.04-3223fje; Ravani P, 2005, J AM SOC NEPHROL, V16, P2449, DOI 10.1681/ASN.2005010076; Rossiter S, 2005, J MED CHEM, V48, P4670, DOI 10.1021/jm050187a; Schnabel R, 2005, CIRC RES, V97, P53, DOI 10.1161/01.RES.0000181286.44222.61; Smith CL, 2005, PLOS MED, V2, P1031, DOI 10.1371/journal.pmed.0020264; Teerlink T, 2002, ANAL BIOCHEM, V303, P131, DOI 10.1006/abio.2001.5575; Tran CTL, 2000, GENOMICS, V68, P101, DOI 10.1006/geno.2000.6262; VALLANCE P, 1992, LANCET, V339, P572; Vallance P, 2002, NAT REV DRUG DISCOV, V1, P939, DOI 10.1038/nrd960	21	327	344	2	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					198	203		10.1038/nm1543	http://dx.doi.org/10.1038/nm1543			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17273169				2022-12-27	WOS:000244031700029
J	Kiepiela, P; Ngumbela, K; Thobakgale, C; Ramduth, D; Honeyborne, I; Moodley, E; Reddy, S; de Pierres, C; Mncube, Z; Mkhwanazi, N; Bishop, K; van der Stok, M; Nair, K; Khan, N; Crawford, H; Payne, R; Leslie, A; Prado, J; Prendergast, A; Frater, J; McCarthy, N; Brander, C; Learn, GH; Nickle, D; Rousseau, C; Coovadia, H; Mullins, JI; Heckerman, D; Walker, BD; Goulder, P				Kiepiela, Photini; Ngumbela, Kholiswa; Thobakgale, Christina; Ramduth, Dhanwanthie; Honeyborne, Isobella; Moodley, Eshia; Reddy, Shabashini; de Pierres, Chantal; Mncube, Zenele; Mkhwanazi, Nompumelelo; Bishop, Karen; van der Stok, Mary; Nair, Kriebashnie; Khan, Nasreen; Crawford, Hayley; Payne, Rebecca; Leslie, Alasdair; Prado, Julia; Prendergast, Andrew; Frater, John; McCarthy, Noel; Brander, Christian; Learn, Gerald H.; Nickle, David; Rousseau, Christine; Coovadia, Hoosen; Mullins, James I.; Heckerman, David; Walker, Bruce D.; Goulder, Philip			CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMARY INFECTION; ESCAPE VARIANTS; LYMPHOCYTE RESPONSES; ACUTE SEROCONVERSION; IMMUNE-RESPONSES; TYPE-1 INFECTION; AUTOLOGOUS VIRUS; SIV REPLICATION; VACCINE DESIGN	Selection of T-cell vaccine antigens for chronic persistent viral infections has been largely empirical. To define the relationship, at the population level, between the specificity of the cellular immune response and viral control for a relevant human pathogen, we performed a comprehensive analysis of the 160 dominant CD8(+) T-cell responses in 578 untreated HIV-infected individuals from KwaZulu-Natal, South Africa. Of the HIV proteins targeted, only Gag-specific responses were associated with lowering viremia. Env-specific and Accessory/Regulatory protein-specific responses were associated with higher viremia. Increasing breadth of Gag-specific responses was associated with decreasing viremia and increasing Env breadth with increasing viremia. Association of the specific CD8(+) T-cell response with low viremia was independent of HLA type and unrelated to epitope sequence conservation. These population-based data, suggesting the existence of both effective immune responses and responses lacking demonstrable biological impact in chronic HIV infection, are of relevance to HIV vaccine design and evaluation.	Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa; Nuffield Dept Med, Dept Paediat, Oxford OX1 3SY, England; Dept Zool, Oxford OX1 3SY, England; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02129 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Microsoft Res, Redmond, WA 98052 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	University of Kwazulu Natal; University of Oxford; Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; Microsoft; Howard Hughes Medical Institute	Goulder, P (corresponding author), Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa.	philip.goulder@paediatrics.ox.ac.uk	Learn, Gerald H/B-6934-2011; Prado, Julia Garcia/R-7177-2019; Bishop, Karen/G-7073-2015; McCarthy, Noel D/K-3314-2012; Payne, Rebecca/AAC-4783-2022; Learn, Jerry/E-3356-2012; Nickle, David/ABF-2727-2020	Learn, Gerald H/0000-0003-0434-7733; Prado, Julia Garcia/0000-0002-5439-4645; Bishop, Karen/0000-0003-4935-7708; Payne, Rebecca/0000-0002-9037-7367; Brander, Christian/0000-0002-0548-5778; Thobakgale-Tshabalala, Christina/0000-0001-5619-8894; Prendergast, Andrew/0000-0001-7904-7992; leslie, alasdair/0000-0003-2538-6467; McCarthy, Noel/0000-0003-1113-1017; Frater, John/0000-0001-7163-7277	Medical Research Council [G0500384, G108/626] Funding Source: Medline; NIAID NIH HHS [2R01AI46995-06, R01AI067073, P30 AI027757] Funding Source: Medline; PHS HHS [N01-A1-15422] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G108/626, G0500384] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067073, P30AI027757, R01AI046995] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; Draenert R, 2004, J VIROL, V78, P630, DOI 10.1128/JVI.78.2.630-641.2004; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Kobayashi M, 2005, J VIROL, V79, P11529, DOI 10.1128/JVI.79.17.11529-11532.2005; Leslie A, 2005, J EXP MED, V201, P891, DOI 10.1084/jem.20041455; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MADDISON WP, 1989, FOLIA PRIMATOL, V53, P190, DOI 10.1159/000156416; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Matano T, 2004, J EXP MED, V199, P1709, DOI 10.1084/jem.20040432; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894; Reimann KA, 2005, J VIROL, V79, P8878, DOI 10.1128/JVI.79.14.8878-8885.2005; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; Rousseau CM, 2006, J VIROL METHODS, V136, P118, DOI 10.1016/j.jviromet.2006.04.009; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	48	818	851	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					46	53		10.1038/nm1520	http://dx.doi.org/10.1038/nm1520			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17173051				2022-12-27	WOS:000243301800035
J	Liu, TX; Becker, MW; Jelinek, J; Wu, WS; Deng, M; Mikhalkevich, N; Hsu, K; Bloomfield, CD; Stone, RM; DeAngelo, DJ; Galinsky, IA; Issa, JP; Clarke, MF; Look, AT				Liu, Ting Xi; Becker, Michael W.; Jelinek, Jaroslav; Wu, Wen-Shu; Deng, Min; Mikhalkevich, Natallia; Hsu, Karl; Bloomfield, Clara D.; Stone, Richard M.; DeAngelo, Daniel J.; Galinsky, Ilene A.; Issa, Jean-Pierre; Clarke, Michael F.; Look, A. Thomas			Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation	NATURE MEDICINE			English	Article							MOLECULAR DELINEATION; TUMOR-SUPPRESSOR; REGION; LEUKEMIA; IDENTIFICATION; LINE; DIVISION; DISEASES; DNA	m Interstitial loss of all or part of the long arm of chromosome 5, or del(5q), is a frequent clonal chromosomal abnormality in human myelodysplastic syndrome (MDS, a preleukemic disorder) and acute myeloid leukemia (AML)(1), and is thought to contribute to the pathogenesis of these diseases by deleting one or more tumor-suppressor genes(2). Although a major commonly deleted region (CDR) has been delineated on chromosome band 5q31.1 (refs.3-7), attempts to identify tumor suppressors within this band have been unsuccessful. We focused our analysis of gene expression on RNA from primitive leukemia-initiating cells, which harbor 5q deletions(8,9), and analyzed 12 genes within the CDR that are expressed by normal hematopoietic stem cells. Here we show that the gene encoding alpha-catenin (CTNNA1) is expressed at a much lower level in leukemia-initiating stem cells from individuals with AML or MDS with a 5q deletion than in individuals with MDS or AML lacking a 5q deletion or in normal hematopoietic stem cells. Analysis of HL-60 cells, a myeloid leukemia line with deletion of the 5q31 region(10,11), showed that the CTNNA1 promoter of the retained allele is suppressed by both methylation and histone deacetylation. Restoration of CTNNA1 expression in HL-60 cells resulted in reduced proliferation and apoptotic cell death. Thus, loss of expression of the alpha-catenin tumor suppressor in hematopoietic stem cells may provide a growth advantage that contributes to human MDS or AML with del(5q).	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Lab Dev & Dis, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Univ Rochester, Div Hematol Oncol, Rochester, NY 14642 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Chicago, Canc & Leukemia Grp, Chicago, IL 60606 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Stanford Univ, Inst Stem Cell & Regenerat Med, Palo Alto, CA 94304 USA; Stanford Univ, Div Hematol Oncol, Palo Alto, CA 94304 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Chicago; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Stanford University; Stanford University	Look, AT (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Jelinek, Jaroslav/O-6876-2019; Jelinek, Jaroslav/A-8476-2008; Wu, Wen-Shu/I-1258-2014; Jelinek, Jaroslav/D-2282-2012	Wu, Wen-Shu/0000-0002-0225-2522; Jelinek, Jaroslav/0000-0002-2533-0220; Becker, Michael/0000-0001-9890-8815; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [CA101140, CA104987, CA108631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA108631, R01CA104987, U10CA101140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dick JE, 2003, NATURE, V423, P231, DOI 10.1038/423231a; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Lai F, 2001, GENOMICS, V71, P235, DOI 10.1006/geno.2000.6414; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lee JY, 2002, CANCER GENET CYTOGEN, V137, P124, DOI 10.1016/S0165-4608(02)00565-4; Liang JC, 1999, CANCER GENET CYTOGEN, V113, P105, DOI 10.1016/S0165-4608(99)00030-8; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Mrozek K, 2003, GENE CHROMOSOME CANC, V38, P249, DOI 10.1002/gcc.10274; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; NIMER SD, 1987, BLOOD, V70, P1705; Shipley J, 1996, GENE CHROMOSOME CANC, V15, P182, DOI 10.1002/(SICI)1098-2264(199603)15:3<182::AID-GCC7>3.0.CO;2-Z; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Ulger C, 2003, CANCER GENET CYTOGEN, V147, P28, DOI 10.1016/S0165-4608(03)00155-9; VandenBerghe H, 1997, CANCER GENET CYTOGEN, V94, P1, DOI 10.1016/S0165-4608(96)00350-0; Vanpoucke G, 2002, BBA-GENE STRUCT EXPR, V1574, P262, DOI 10.1016/S0167-4781(01)00378-5; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	27	155	161	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					78	83		10.1038/nm1512	http://dx.doi.org/10.1038/nm1512			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159988				2022-12-27	WOS:000243301800039
J	Sasano, T; McDonald, AD; Kikuchi, K; Donahue, JK				Sasano, Tetsuo; McDonald, Amy D.; Kikuchi, Kan; Donahue, J. Kevin			Molecular ablation of ventricular tachycardia after myocardial infarction	NATURE MEDICINE			English	Article							ACTION-POTENTIAL DURATION; GENE-TRANSFER; BIOLOGICAL PACEMAKER; EXPRESSION; VECTORS; HEART; MICE	Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel ( KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.	Case Western Reserve Univ, Heart & Vasc Res Ctr, Metrohlth Hosp, Sch Med, Cleveland, OH 44109 USA; Kyushu Kosei Nenkin Hosp, Div Cardiol, Kitakyushu, Fukuoka 8078555, Japan	Case Western Reserve University; MetroHealth System	Kikuchi, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21205 USA.	kdonahue@metrohealth.org			NHLBI NIH HHS [R01 HL067148] Funding Source: Medline; NIBIB NIH HHS [R01 EB002846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		*AM HEART ASS, 2002, 2001 HEART STROK STA; Brunner M, 2003, AM J PHYSIOL-HEART C, V285, pH194, DOI 10.1152/ajpheart.00971.2002; Donahue JK, 2000, NAT MED, V6, P1395; Gould PA, 2006, JAMA-J AM MED ASSOC, V295, P1907, DOI 10.1001/jama.295.16.1907; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; LESH MD, 1989, CIRC RES, V65, P1426, DOI 10.1161/01.RES.65.5.1426; Maisel WH, 2006, JAMA-J AM MED ASSOC, V295, P1901, DOI 10.1001/jama.295.16.1901; Miake J, 2002, NATURE, V419, P132, DOI 10.1038/419132b; Qu JH, 2003, CIRCULATION, V107, P1106, DOI 10.1161/01.CIR.0000059939.97249.2C; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Rothman SA, 1997, CIRCULATION, V96, P3499; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270	13	87	96	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1256	1258		10.1038/nm1503	http://dx.doi.org/10.1038/nm1503			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072309	Green Accepted			2022-12-27	WOS:000241844900022
J	King, CG; Kobayashi, T; Cejas, PJ; Kim, T; Yoon, K; Kim, GK; Chiffoleau, E; Hickman, SP; Walsh, PT; Turka, LA; Choi, Y				King, Carolyn G.; Kobayashi, Takashi; Cejas, Pedro J.; Kim, Taesoo; Yoon, Kwiyeom; Kim, Gregory K.; Chiffoleau, Elise; Hickman, Somia P.; Walsh, Patrick T.; Turka, Laurence A.; Choi, Yongwon			TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis	NATURE MEDICINE			English	Article							INTESTINAL INFLAMMATION; INTERLEUKIN-1; AUTOIMMUNITY; DEFICIENCY; ACTIVATION; MATURATION; PATHWAYS; CTLA-4; FOXP3; CD28	TRAF6 has a key role in the regulation of innate immune responses by mediating signals from both TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies. Here we show that T cell - specific deletion of TRAF6 unexpectedly results in multiorgan inflammatory disease. TRAF6-deficient T cells exhibit hyperactivation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway compared with wild-type T cells and, as a result, become resistant to suppression by CD4(+)CD25(+) regulatory T cells. These data identify a previously unrecognized role for TRAF6 in the maintenance of peripheral tolerance, and suggest the presence of a T cell - intrinsic control mechanism to render responder T cells susceptible to tolerizing signals.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Choi, Y (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, 421 Curie Blvd, Philadelphia, PA 19104 USA.	ychoi3@mail.med.upenn.edu	Chiffoleau, Elise/N-2982-2018; Walsh, Patrick/I-7909-2014	Chiffoleau, Elise/0000-0001-6167-682X; Walsh, Patrick/0000-0002-0130-8766; King, Carolyn G./0000-0001-6059-323X				Akiyama T, 2005, SCIENCE, V308, P248, DOI 10.1126/science.1105677; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chiffoleau E, 2003, J IMMUNOL, V171, P5751, DOI 10.4049/jimmunol.171.11.5751; Chung JY, 2002, J CELL SCI, V115, P679; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074-7613(03)00230-9; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mackey MF, 2003, EUR J IMMUNOL, V33, P779, DOI 10.1002/eji.200323729; Parsons MJ, 2001, J IMMUNOL, V167, P42, DOI 10.4049/jimmunol.167.1.42; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	25	169	178	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1088	1092		10.1038/nm1449	http://dx.doi.org/10.1038/nm1449			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16921377				2022-12-27	WOS:000240373900034
J	Wunder, C; Churin, Y; Winau, F; Warnecke, D; Vieth, M; Lindner, B; Zahringer, U; Mollenkopf, HJ; Heinz, E; Meyer, TF				Wunder, Christian; Churin, Yuri; Winau, Florian; Warnecke, Dirk; Vieth, Michael; Lindner, Buko; Zaehringer, Ulrich; Mollenkopf, Hans-Joachim; Heinz, Ernst; Meyer, Thomas F.			Cholesterol glucosylation promotes immune evasion by Helicobacter pylori	NATURE MEDICINE			English	Article							CAG PATHOGENICITY ISLAND; LIPID RAFTS; STEROL BIOSYNTHESIS; PROFILES; PHAGOCYTOSIS; GLUCOSIDES; STRAINS; GROWTH; MICE	Helicobacter pylori infection causes gastric pathology such as ulcer and carcinoma. Because H. pylori is auxotrophic for cholesterol, we have explored the assimilation of cholesterol by H. pylori in infection. Here we show that H. pylori follows a cholesterol gradient and extracts the lipid from plasma membranes of epithelial cells for subsequent glucosylation. Excessive cholesterol promotes phagocytosis of H. pylori by antigen-presenting cells, such as macrophages and dendritic cells, and enhances antigen-specific T cell responses. A cholesterol-rich diet during bacterial challenge leads to T cell-dependent reduction of the H. pylori burden in the stomach. Intrinsic alpha-glucosylation of cholesterol abrogates phagocytosis of H. pylori and subsequent T cell activation. We identify the gene hp0421 as encoding the enzyme cholesterol-alpha-glucosyltransferase responsible for cholesterol glucosylation. Generation of knockout mutants lacking hp0421 corroborates the importance of cholesteryl glucosides for escaping phagocytosis, T cell activation and bacterial clearance in vivo. Thus, we propose a mechanism regulating the host - pathogen interaction whereby glucosylation of a lipid tips the scales towards immune evasion or response.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; Univ Hamburg, Biozentrum Klein Flottbeck, D-22609 Hamburg, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Max Planck Inst Infect Biol, Core Facil Microarray, D-10117 Berlin, Germany; Max Planck Inst Infect Biol, Dept Biol Mol, D-10117 Berlin, Germany	Max Planck Society; University of Hamburg; Otto von Guericke University; Forschungszentrum Borstel; Max Planck Society; Max Planck Society	Wunder, C (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	wunderc@mail.nih.gov; meyer@mpiib-berlin.mpg.de	Meyer, Thomas F. F/J-2485-2013; Mollenkopf, Hans-Joachim/AAH-2500-2019; Wunder, Christian/K-8542-2017; Lindner, Buko/G-9731-2014	Meyer, Thomas F. F/0000-0002-6120-8679; Wunder, Christian/0000-0001-9091-0080; Mollenkopf, Hans-Joachim/0000-0003-1167-4783				Allen LAH, 2000, J EXP MED, V191, P115, DOI 10.1084/jem.191.1.115; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Ben-Menachem G, 2003, P NATL ACAD SCI USA, V100, P7913, DOI 10.1073/pnas.1232451100; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Dixon MF, 1997, HELICOBACTER, V2, pS17; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gomez-Duarte OG, 1998, VACCINE, V16, P460, DOI 10.1016/S0264-410X(97)00247-8; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HAQUE M, 1995, ACTA MED OKAYAMA, V49, P205; HAQUE M, 1995, J BACTERIOL, V177, P5334, DOI 10.1128/jb.177.18.5334-5337.1995; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; HIRAI Y, 1995, J BACTERIOL, V177, P5327, DOI 10.1128/jb.177.18.5327-5333.1995; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250; LEBRUN AH, 2006, J BIOL CHEM; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Li JW, 2005, CELL CYCLE, V4, P1599, DOI 10.4161/cc.4.11.2117; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAYBERRY WR, 1983, BIOCHIM BIOPHYS ACTA, V752, P434, DOI 10.1016/0005-2760(83)90273-4; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Montecucco C, 2001, NAT REV MOL CELL BIO, V2, P457, DOI 10.1038/35073084; Odenbreit S, 2001, CELL MICROBIOL, V3, P21, DOI 10.1046/j.1462-5822.2001.00088.x; Oku M, 2003, EMBO J, V22, P3231, DOI 10.1093/emboj/cdg331; OTOOLE PW, 1994, MOL MICROBIOL, V14, P691, DOI 10.1111/j.1365-2958.1994.tb01307.x; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; Schaible UE, 1999, J CELL SCI, V112, P681; Schaller H, 2004, PLANT PHYSIOL BIOCH, V42, P465, DOI 10.1016/j.plaphy.2004.05.012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shimomura H, 2004, FEMS MICROBIOL LETT, V237, P407, DOI 10.1016/j.femsle.2004.07.004; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slonczewski JL, 2000, HELICOBACTER, V5, P240, DOI 10.1046/j.1523-5378.2000.00037.x; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tannaes T, 2005, FEMS MICROBIOL LETT, V244, P117, DOI 10.1016/j.femsle.2005.01.030; Testerman TL, 2001, J CLIN MICROBIOL, V39, P3842, DOI 10.1128/JCM.39.11.3842-3850.2001; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x	47	208	212	2	36	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1030	1038		10.1038/nm1480	http://dx.doi.org/10.1038/nm1480			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16951684				2022-12-27	WOS:000240373900027
J	Check, E				Check, Erika			Amir Attaran	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					872	872		10.1038/nm0806-872	http://dx.doi.org/10.1038/nm0806-872			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892022	Bronze			2022-12-27	WOS:000239626200008
J	Freund, P; Schmidlin, E; Wannier, T; Bloch, J; Mir, A; Schwab, ME; Rouiller, EM				Freund, Patrick; Schmidlin, Eric; Wannier, Thierry; Bloch, Jocelyne; Mir, Anis; Schwab, Martin E.; Rouiller, Eric M.			Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates	NATURE MEDICINE			English	Article							SPINAL-CORD; UNILATERAL SECTION; HAND REPRESENTATION; CORTICOSPINAL TRACT; MACAQUE MONKEY; REGENERATION; INHIBITORS; LEVEL	In rodents, after spinal lesion, neutralizing the neurite growth inhibitor Nogo-A promotes axonal sprouting and functional recovery. To evaluate this treatment in primates, 12 monkeys were subjected to cervical lesion. Recovery of manual dexterity and sprouting of corticospinal axons were enhanced in monkeys treated with Nogo-A-specific antibody as compared to monkeys treated with control antibody.	Univ Fribourg, Fac Sci, Dept Med, Univ Physiol, CH-1700 Fribourg, Switzerland; Univ Fribourg, Fac Sci, Dept Med, Program Neurosci, CH-1700 Fribourg, Switzerland; Univ Zurich, ETH Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Univ Lausanne Hosp, Neurosurg Clin, Dept Neurosurg, CH-1011 Lausanne, Switzerland; Novartis Inst BioMed Res, Neurosci Res, CH-4002 Basel, Switzerland	University of Fribourg; University of Fribourg; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Novartis	Rouiller, EM (corresponding author), Univ Fribourg, Fac Sci, Dept Med, Univ Physiol, CH-1700 Fribourg, Switzerland.	Eric.Rouiller@unifr.ch	Schwab, Martin E/B-6818-2016; Bloch, Jocelyne/A-9668-2017; Freund, Patrick/D-4193-2013	Bloch, Jocelyne/0000-0002-6405-1590; Freund, Patrick/0000-0002-4851-2246; Rouiller, Eric/0000-0003-1355-6019				BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fouad K, 2004, EUR J NEUROSCI, V20, P2479, DOI 10.1111/j.1460-9568.2004.03716.x; Galea MP, 1997, J COMP NEUROL, V381, P282; Galea MP, 1997, J COMP NEUROL, V381, P307; JENNY AB, 1983, J NEUROSCI, V3, P567; LAWRENCE DG, 1976, BRAIN, V99, P235, DOI 10.1093/brain/99.2.235; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; NUDO RJ, 2006, EVOLUTION NERVOUS SY, V4; PORTER R, 1990, ELECTROEN CLIN NEURO, V76, P282, DOI 10.1016/0013-4694(90)90029-J; Sasaki S, 2004, J NEUROPHYSIOL, V92, P3142, DOI 10.1152/jn.00342.2004; Schmidlin E, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-56; Schmidlin E, 2004, BRAIN RES, V1017, P172, DOI 10.1016/j.brainres.2004.05.036; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004	15	244	250	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					790	792		10.1038/nm1436	http://dx.doi.org/10.1038/nm1436			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819551	Green Submitted			2022-12-27	WOS:000238862800065
J	Iwatsubo, T; Ihara, Y; Kanazawa, I				Iwatsubo, Takeshi; Ihara, Yasuo; Kanazawa, Ichiro			Alzheimer disease research in Japan: public funding	NATURE MEDICINE			English	Editorial Material									Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878551, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo	Kanazawa, I (corresponding author), Natl Ctr Neurol & Psychiat, 4-1-1 Ogawa Higashimachi, Kodaira, Tokyo 1878551, Japan.	ichiro@ncnp.go.jp							0	3	3	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					778	779		10.1038/nm0706-778	http://dx.doi.org/10.1038/nm0706-778			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829946				2022-12-27	WOS:000238862800062
J	Arumugam, TV; Chan, SL; Jo, DG; Yilmaz, G; Tang, SC; Cheng, AW; Gleichmann, M; Okun, E; Dixit, VD; Chigurupati, S; Mughal, MR; Ouyang, X; Miele, L; Magnus, T; Poosala, S; Granger, DN; Mattson, MP				Arumugam, TV; Chan, SL; Jo, DG; Yilmaz, G; Tang, SC; Cheng, AW; Gleichmann, M; Okun, E; Dixit, VD; Chigurupati, S; Mughal, MR; Ouyang, X; Miele, L; Magnus, T; Poosala, S; Granger, DN; Mattson, MP			Gamma secretase-mediated notch signaling worsens brain damage and functional outcome in ischemic stroke	NATURE MEDICINE			English	Article							ACTIVATION; DISEASE		NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Natl Taiwan Univ Hosp, Dept Neurol, Stroke Ctr, Taipei, Taiwan; NIA, Immunol Lab, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Intramural Res Program, Baltimore, MD 21224 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA; Johns Hopkins Med Inst, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Taiwan University; National Taiwan University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Johns Hopkins Medicine	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	okun, eitan/AAC-9571-2019; Mattson, Mark P/F-6038-2012; Jo, Dong-Gyu/AAN-9278-2021; Arumugam, Thiruma Valavan/B-4898-2011; Arumugam, Thiruma/C-7969-2009; Arumugam, Thiruma/AAG-6958-2019	okun, eitan/0000-0001-8474-1487; Jo, Dong-Gyu/0000-0003-2271-1076; Miele, Lucio/0000-0002-5853-7287; Arumugam, Thiruma/0000-0002-3377-0939; Tang, Sung-Chun/0000-0003-3731-5973	NATIONAL INSTITUTE ON AGING [Z01AG000314, ZIAAG000317, Z01AG000317, Z01AG000313, ZIAAG000313, ZIAAG000314] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Costa RM, 2005, TRENDS NEUROSCI, V28, P429, DOI 10.1016/j.tins.2005.05.003; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eagar TN, 2004, IMMUNITY, V20, P407, DOI 10.1016/S1074-7613(04)00081-0; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Ishikura N, 2005, P NATL ACAD SCI USA, V102, P886, DOI 10.1073/pnas.0408612101; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Pollack Scott J, 2005, Curr Opin Investig Drugs, V6, P35; Prunell GF, 2005, CNS NEUROL DISORD-DR, V4, P51, DOI 10.2174/1568007053005082; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sugawara Taku, 2004, NeuroRx, V1, P17, DOI 10.1602/neurorx.1.1.17; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475	15	207	230	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					621	623		10.1038/nm1403	http://dx.doi.org/10.1038/nm1403			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680150				2022-12-27	WOS:000238149200021
J	Simard, JM; Chen, M; Tarasov, KV; Bhatta, S; Ivanova, S; Melnitchenko, L; Tsymbalyuk, N; West, GA; Gerzanich, V				Simard, JM; Chen, M; Tarasov, KV; Bhatta, S; Ivanova, S; Melnitchenko, L; Tsymbalyuk, N; West, GA; Gerzanich, V			Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke	NATURE MEDICINE			English	Article							ADULT-RAT BRAIN; SENSITIVE POTASSIUM CHANNELS; NONSELECTIVE CATION CHANNEL; REACTIVE ASTROCYTES; K+ CHANNELS; ARTERY OCCLUSION; SULFONYLUREA; RECEPTOR; PH; IDENTIFICATION	Pathological conditions in the central nervous system, including stroke and trauma, are often exacerbated by cerebral edema. We recently identified a nonselective cation channel, the NCCa-ATP channel, in ischemic astrocytes that is regulated by sulfonylurea receptor 1 (SUR1), is opened by depletion of ATP and, when opened, causes cytotoxic edema. Here, we evaluated involvement of this channel in rodent models of stroke. SUR1 protein and mRNA were newly expressed in ischemic neurons, astrocytes and capillaries. Upregulation of SUR1 was linked to activation of the transcription factor Sp1 and was associated with expression of functional NCCa-ATP but not K-ATP channels. Block of SUR1 with low-dose glibenclamide reduced cerebral edema, infarct volume and mortality by 50%, with the reduction in infarct volume being associated with cortical sparing. Our findings indicate that the NCCa-ATP channel is crucially involved in development of cerebral edema, and that targeting SUR1 may provide a new therapeutic approach to stroke.	Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Oregon Hlth Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Oregon Health & Science University	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite 12SD, Baltimore, MD 21201 USA.	msimard@surgery1.umaryland.edu		Tarasov, Kirill/0000-0001-7799-4670	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048260] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL082517, R01 HL082517-01, R01 HL082517] Funding Source: Medline; NINDS NIH HHS [R01 NS048260, NS048260] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anisimov SV, 2002, MECH DEVELOP, V117, P25, DOI 10.1016/S0925-4773(02)00177-6; Ashfield R, 1998, DIABETES, V47, P1274, DOI 10.2337/diabetes.47.8.1274; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Doerfler A, 2001, STROKE, V32, P2675, DOI 10.1161/hs1101.098369; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; FINDLAY I, 1992, J PHARMACOL EXP THER, V262, P71; Fujita A, 2000, PHARMACOL THERAPEUT, V85, P39, DOI 10.1016/S0163-7258(99)00050-9; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Hainsworth AH, 2001, NEUROPHARMACOLOGY, V40, P784, DOI 10.1016/S0028-3908(01)00004-1; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; Hua Y, 2003, J CEREBR BLOOD F MET, V23, P1448, DOI 10.1097/01.WCB.0000090621.86921.D5; Kaluz S, 2003, CANCER RES, V63, P917; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; KAWAMURA S, 1991, ACTA NEUROCHIR, V109, P126, DOI 10.1007/BF01403007; LI PA, 1994, NEUROSCI LETT, V177, P63, DOI 10.1016/0304-3940(94)90045-0; Lindauer U, 2003, J CEREBR BLOOD F MET, V23, P1227, DOI 10.1097/01.WCB.0000088764.02615.B7; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; Nakabayashi K, 1997, AM J NEURORADIOL, V18, P485; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Proks P, 2002, DIABETES, V51, pS368, DOI 10.2337/diabetes.51.2007.S368; SCHWANSTECHER M, 1994, J NEUROCHEM, V63, P698; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Tomiyama Y, 1999, STROKE, V30, P1942, DOI 10.1161/01.STR.30.9.1942; Toomey JR, 2002, STROKE, V33, P578, DOI 10.1161/hs0202.102950; TREHERNE JM, 1991, NEUROSCIENCE, V40, P523, DOI 10.1016/0306-4522(91)90138-E; Tsankova NM, 2004, J NEUROSCI, V24, P5603, DOI 10.1523/JNEUROSCI.0589-04.2004; Wang Y, 2000, STROKE, V31, P1386, DOI 10.1161/01.STR.31.6.1386; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; YOUNG W, 1994, NEUROBIOLOGY CENTRAL; ZUNKLER BJ, 1989, N-S ARCH PHARMACOL, V340, P328	36	290	322	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2006	12	4					433	440		10.1038/nm1390	http://dx.doi.org/10.1038/nm1390			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550187	Green Accepted			2022-12-27	WOS:000236581300032
J	Zhang, HT; Cheng, X; Richter, M; Greene, MI				Zhang, HT; Cheng, X; Richter, M; Greene, MI			A sensitive and high-throughput assay to detect low-abundance proteins in serum	NATURE MEDICINE			English	Article							METASTATIC BREAST-CANCER; T7 RNA-POLYMERASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; IN-VITRO; C-ERBB-2; EXPRESSION; QUANTIFICATION; AMPLIFICATION; IMMUNOASSAYS	The ability to detect antigens immunologically is limited by the affinity of the antibodies and the amount of antigens. We have now succeeded in creating a modular, facile amplification system, termed fluorescent amplification catalyzed by T7 polymerase technique (FACTT). Such a system can detect protein targets specifically at subfemtomolar levels (similar to 0.08 fM). We describe here the detection of Her2 ( also known as Neu) from rodent and human sera. FACTT is adaptable to highthroughput screening and automation and provides a practical method to enhance current ELISAs in medical practice.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049				Arnold S, 2001, BIOTECHNOL BIOENG, V72, P548, DOI 10.1002/1097-0290(20010305)72:5<548::AID-BIT1019>3.0.CO;2-2; COHEN JA, 1989, ONCOGENE, V4, P81; Di Leo A, 2002, ONCOLOGY-BASEL, V63, P25, DOI 10.1159/000066204; Fehm T, 1998, ONCOLOGY-BASEL, V55, P33, DOI 10.1159/000011832; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Jones LJ, 1998, ANAL BIOCHEM, V265, P368, DOI 10.1006/abio.1998.2914; KANDL H, 1994, BRIT J CANCER, V70, P739, DOI 10.1038/bjc.1994.387; Li P, 2003, CANCER LETT, V193, P139, DOI 10.1016/S0304-3835(03)00017-X; LODATO RF, 1990, MODERN PATHOL, V3, P449; Lubec G, 2003, PROG NEUROBIOL, V69, P193, DOI 10.1016/S0301-0082(03)00036-4; Luftner D, 2004, INT J BIOL MARKER, V19, P1; MAGUIRE HC, 1990, PATHOBIOLOGY, V58, P297; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PORSTMANN B, 1985, J IMMUNOL METHODS, V79, P27, DOI 10.1016/0022-1759(85)90388-6; PORSTMANN T, 1992, J IMMUNOL METHODS, V150, P5, DOI 10.1016/0022-1759(92)90061-W; Saghatchian M, 2004, INT J BIOL MARKER, V19, P14, DOI 10.1177/172460080401900102; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tannous BA, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf140; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; Zhang HT, 1999, EXP MOL PATHOL, V67, P15, DOI 10.1006/exmp.1999.2266; Zhang HT, 2001, P NATL ACAD SCI USA, V98, P5497, DOI 10.1073/pnas.101124598	26	57	70	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					473	477		10.1038/nm1378	http://dx.doi.org/10.1038/nm1378			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16532003				2022-12-27	WOS:000236581300038
J	Engelhorn, ME; Guevara-Patino, JA; Noffz, G; Hooper, AT; Lou, O; Gold, JS; Kappel, BJ; Houghton, AN				Engelhorn, ME; Guevara-Patino, JA; Noffz, G; Hooper, AT; Lou, O; Gold, JS; Kappel, BJ; Houghton, AN			Autoimmunity and tumor immunity induced by immune responses to mutations in self	NATURE MEDICINE			English	Article							CYTOLYTIC T-LYMPHOCYTES; SYNGENEIC MICE; IMMUNIZATION; TYROSINASE; PEPTIDE; ANTIGEN; REJECTION; VARIANTS; RECOGNITION; EXPRESSION	Little is known about the consequences of immune recognition of mutated gene products, despite their potential relevance to autoimmunity and tumor immunity. To identify mutations that induce immunity, here we have developed a systematic approach in which combinatorial DNA libraries encoding large numbers of random mutations in two syngeneic tyrosinase-related proteins are used to immunize black mice. We show that the libraries of mutated DNA induce autoimmune hypopigmentation and tumor immunity through cross-recognition of nonmutated gene products. Truncations are present in all immunogenic clones and are sufficient to elicit immunity to self, triggering recognition of normally silent epitopes. Immunity is further enhanced by specific amino acid substitutions that promote T helper cell responses. Thus, presentation of a vast repertoire of antigen variants to the immune system can enhance the generation of adaptive immune responses to self.	Mem Sloan Kettering Canc Ctr, Swim Across Amer Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Sch, New York, NY 10021 USA; Cornell Univ, Grad Sch, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Houghton, AN (corresponding author), Mem Sloan Kettering Canc Ctr, Swim Across Amer Lab, 1275 York Ave, New York, NY 10021 USA.	engelho1@mskcc.org; a-houghton@ski.mskcc.org	Gold, Jason S./O-5112-2014; Guevara, Jose/AAD-6707-2020	Gold, Jason S./0000-0002-2925-4755; 	NCI NIH HHS [CA33049, CA56821, CA59350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA033049, R01CA056821, P01CA059350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BOON T, 1977, P NATL ACAD SCI USA, V74, P272, DOI 10.1073/pnas.74.1.272; BOON T, 1978, P NATL ACAD SCI USA, V75, P1519, DOI 10.1073/pnas.75.3.1519; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Brandle D, 1996, J EXP MED, V183, P2501, DOI 10.1084/jem.183.6.2501; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Chiari R, 1999, CANCER RES, V59, P5785; COULIE PG, 1995, P NATL ACAD SCI USA, V92, P7976, DOI 10.1073/pnas.92.17.7976; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; Effros RB, 2003, IMMUNOL ALLERGY CLIN, V23, P41, DOI 10.1016/S0889-8561(02)00055-3; Gaudin C, 1999, J IMMUNOL, V162, P1730; Gold JS, 2003, J IMMUNOL, V170, P5188, DOI 10.4049/jimmunol.170.10.5188; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; Hogan KT, 1998, CANCER RES, V58, P5144; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; LeFur N, 1997, P NATL ACAD SCI USA, V94, P5332, DOI 10.1073/pnas.94.10.5332; Leitner WW, 2003, NAT MED, V9, P33, DOI 10.1038/nm813; Lewis JJ, 2000, INT J CANCER, V87, P391, DOI 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K; MAKELA O, 1965, J IMMUNOL, V95, P378; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Negroiu G, 2005, BIOCHEM BIOPH RES CO, V328, P914, DOI 10.1016/j.bbrc.2005.01.040; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; PREHN RT, 1957, J NATL CANCER I, V18, P769; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Ross HM, 1997, CLIN CANCER RES, V3, P2191; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Turk MJ, 2002, IMMUNOL REV, V188, P122, DOI 10.1034/j.1600-065X.2002.18811.x; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131; Watahiki A, 2004, NAT METHODS, V1, P233, DOI 10.1038/NMETH719; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zhu YR, 2003, J MOL BIOL, V326, P1157, DOI 10.1016/S0022-2836(02)01437-7; Zorn E, 1999, EUR J IMMUNOL, V29, P592, DOI 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2	40	70	75	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					198	206		10.1038/nm1363	http://dx.doi.org/10.1038/nm1363			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444264				2022-12-27	WOS:000235160600024
J	Evgenov, NV; Medarova, Z; Dai, GP; Bonner-Weir, S; Moore, A				Evgenov, NV; Medarova, Z; Dai, GP; Bonner-Weir, S; Moore, A			In vivo imaging of islet transplantation	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE TRACKING; BETA-CELL MASS; T-CELLS; MRI; NANOPARTICLES; MACROPHAGES	Type 1 diabetes mellitus is characterized by the selective destruction of insulin-producing beta cells, which leads to a deficiency in insulin secretion and, as a result, to hyperglycemia. At present, transplantation of pancreatic islets is an emerging and promising clinical modality, which can render individuals with type 1 diabetes insulin independent without increasing the incidence of hypoglycemic events. To monitor transplantation efficiency and graft survival, reliable noninvasive imaging methods are needed. If such methods were introduced into the clinic, essential information could be obtained repeatedly and noninvasively. Here we report on the in vivo detection of transplanted human pancreatic islets using magnetic resonance imaging (MRI) that allowed noninvasive monitoring of islet grafts in diabetic mice in real time. We anticipate that the information obtained in this study would ultimately result in the ability to detect and monitor islet engraftment in humans, which would greatly aid the clinical management of this disease.	Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Moore, A (corresponding author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Massachusetts Gen Hosp,Mol Imaging Lab,MGH,MIT,HM, Room 2301,Bldg 149,13th St, Charlestown, MA 02129 USA.	amoore@helix.mgh.harvard.edu		Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [DK071225] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071225] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbab AS, 2003, RADIOLOGY, V229, P838, DOI 10.1148/radiol.2293021215; Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Fowler M, 2005, TRANSPLANTATION, V79, P768, DOI 10.1097/01.TP.0000152798.03204.5C; Jirak D, 2004, MAGN RESON MED, V52, P1228, DOI 10.1002/mrm.20282; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Ladriere L, 2001, AM J PHYSIOL-ENDOC M, V281, pE298, DOI 10.1152/ajpendo.2001.281.2.E298; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lu YX, 2004, MOL THER, V9, P428, DOI 10.1016/j.ymthe.2004.01.008; Malaisse WJ, 2001, INT J MOL MED, V7, P405; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Moore A, 2004, DIABETES, V53, P1459, DOI 10.2337/diabetes.53.6.1459; Moore A, 2004, CANCER RES, V64, P1821, DOI 10.1158/0008-5472.CAN-03-3230; Moore A, 2002, MAGNET RESON MED, V47, P751, DOI 10.1002/mrm.10110; Moore A, 1997, J MAGN RESON IMAGING, V7, P1140, DOI 10.1002/jmri.1880070629; Moore A, 2001, DIABETES, V50, P2231, DOI 10.2337/diabetes.50.10.2231; Schmitz A, 2004, NUCL MED BIOL, V31, P483, DOI 10.1016/j.nucmedbio.2003.12.003; Shapiro AMJ, 2003, LANCET, V362, P1242, DOI 10.1016/S0140-6736(03)14526-6; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Zhan YF, 2003, IMMUNOL CELL BIOL, V81, P451, DOI 10.1046/j.1440-1711.2003..x	23	217	227	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					144	148		10.1038/nm1316	http://dx.doi.org/10.1038/nm1316			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16380717				2022-12-27	WOS:000234419000065
J	Gao, XJ; Bashirova, A; Iversen, AKN; Phair, J; Goedert, JJ; Buchbinder, S; Hoots, K; Vlahov, D; Altfeld, M; O'Brien, SJ; Carrington, M				Gao, XJ; Bashirova, A; Iversen, AKN; Phair, J; Goedert, JJ; Buchbinder, S; Hoots, K; Vlahov, D; Altfeld, M; O'Brien, SJ; Carrington, M			AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis	NATURE MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; T-LYMPHOCYTE RESPONSE; ESCAPE MUTATION; TRANSMISSION; GAG; REVERSION; EVOLUTION	An effective acquired immune response to infectious agents mediated by HLA-restricted T-cell recognition can target different stages of disease pathogenesis. We show here that three distinct HLA alleles known to alter the overall rate of AIDS progression act during distinct intervals after HIV-1 infection. The discrete timing of HLA allele influence suggests alternative functional mechanisms in immune defense against this dynamic and chronic immunosuppressive disease.	NCI, Lab Genom Divers, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21231 USA; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England; Northwestern Univ, Howard Brown Hlth Ctr, Chicago, IL 60611 USA; Northwestern Univ, Fineberg Sch Med, Chicago, IL 60611 USA; NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; Univ Texas, Hlth Sci Ctr, Gulf States Hemophilia Ctr, Houston, TX 77030 USA; New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; NCI, Lab Genom Divers, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Johns Hopkins University; University of Oxford; Northwestern University; Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); San Francisco Department of Public Health; University of Texas System; University of Texas Health Science Center Houston; New York Academy of Medicine; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Carrington, M (corresponding author), NCI, Lab Genom Divers, SAIC Frederick, Basic Res Program, POB B, Frederick, MD 21702 USA.	carringt@ncifcrf.gov	Altfeld, Marcus/AAE-7306-2019; OBRIEN, STEPHEN/ABD-1346-2020	Altfeld, Marcus/0000-0001-5972-2997; OBRIEN, STEPHEN/0000-0001-7857-0757	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NIDA NIH HHS [DA 04334] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Centers for Disease Control and Prevention, 1992, MORB MORTAL WKLY REP, V41, P1; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Jin X, 2002, J VIROL, V76, P12603, DOI 10.1128/JVI.76.24.12603-12610.2002; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; Pillay T, 2005, J VIROL, V79, P12100, DOI 10.1128/JVI.79.18.12100-12105.2005; 1987, MORB MORTAL WKLY REP, V36, pS3	15	161	165	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1290	1292		10.1038/nm1333	http://dx.doi.org/10.1038/nm1333			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16288280				2022-12-27	WOS:000233774400025
J	Idris, AI; Hof, RJV; Greig, IR; Ridge, SA; Baker, D; Ross, RA; Ralston, SH				Idris, AI; Hof, RJV; Greig, IR; Ridge, SA; Baker, D; Ross, RA; Ralston, SH			Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; MICE; INHIBITION; RESORPTION; ACTIVATION; DISEASES		Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; UCL, Inst Neurol, London WC1N 1PJ, England; Univ Edinburgh, Rheumat Dis Unit, Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Aberdeen; University of London; University College London; University of Edinburgh	Ralston, SH (corresponding author), Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	stuart.ralston@ed.ac.uk	Idris, Aymen I/AAX-1138-2020; Ross, R./AAG-7468-2019	Idris, Aymen I/0000-0003-4327-5306; van 't Hof, Rob/0000-0002-8193-6788; Greig, Iain/0000-0003-0603-3383	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009789] Funding Source: NIH RePORTER; Multiple Sclerosis Society [541] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Multiple Sclerosis Society(National Multiple Sclerosis Society)		Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; GRIORGADIS AE, 1994, SCIENCE, V266, P443; Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375; Hildebrandt AL, 2003, EUR J PHARMACOL, V462, P125, DOI 10.1016/S0014-2999(03)01343-8; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Howlett AC, 1998, MOL PHARMACOL, V53, P504, DOI 10.1124/mol.53.3.504; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; RAVINET TC, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI DOI 10.1152/AJPREGU.00545.2002; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Shearman LP, 2003, BEHAV PHARMACOL, V14, P573, DOI 10.1097/00008877-200312000-00001; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Takahashi N, 2003, METH MOLEC MED, V80, P129; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004-0205; van't Hof RJ, 2004, J BONE MINER RES, V19, P1651, DOI 10.1359/jbmr.2004.19.10.1651	24	259	300	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2005	11	7					774	779		10.1038/nm1255	http://dx.doi.org/10.1038/nm1255			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15908955	Green Accepted			2022-12-27	WOS:000230304200034
J	Pajvani, UB; Trujillo, ME; Combs, TP; Iyengar, P; Jelicks, L; Roth, KA; Kitsis, RN; Scherer, PE				Pajvani, UB; Trujillo, ME; Combs, TP; Iyengar, P; Jelicks, L; Roth, KA; Kitsis, RN; Scherer, PE			Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy	NATURE MEDICINE			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; LEPTIN; MICE; EXPRESSION; ADIPOCYTE; AGONIST; WHITE; GENE	We describe the generation and characterization of the first inducible 'fatless' model system, the FAT-ATTAC mouse (fat apoptosis through targeted activation of caspase 8). This transgenic mouse develops identically to wild- type littermates. Apoptosis of adipocytes can be induced at any developmental stage by administration of a FK1012 analog leading to the dimerization of a membrane-bound, adipocyte- specific caspase 8 - FKBP fusion protein. Within 2 weeks of dimerizer administration, FAT-ATTAC mice show near- knockout levels of circulating adipokines and markedly reduced levels of adipose tissue. FAT-ATTAC mice are glucose intolerant, have diminished basal and endotoxin-stimulated systemic inflammation, are less responsive to glucose-stimulated insulin secretion and show increased food intake independent of the effects of leptin. Most importantly, we show that functional adipocytes can be recovered upon cessation of treatment, allowing the study of adipogenesis in vivo, as well as a detailed examination of the importance of the adipocyte in the regulation of multiple physiological functions and pathological states.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012; Trujillo, Martha E./L-1763-2014; Jelicks, Linda/L-9740-2019	Scherer, Philipp E/0000-0003-0680-3392; Trujillo, Martha E./0000-0002-9193-1673; Jelicks, Linda/0000-0002-6438-1792; Roth, Kevin/0000-0002-0643-995X	NEI NIH HHS [R03 EYO14935] Funding Source: Medline; NHLBI NIH HHS [1R01HL073163-01] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758, DK61228] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY014935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758, F32DK061228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berg AH, 2004, AM J PHYSIOL-ENDOC M, V287, pE1178, DOI 10.1152/ajpendo.00002.2004; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Colombo C, 2002, DIABETES, V51, P2727, DOI 10.2337/diabetes.51.9.2727; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Gavrilova O, 2000, DIABETES, V49, P1910, DOI 10.2337/diabetes.49.11.1910; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Grujic D, 1997, J BIOL CHEM, V272, P17686, DOI 10.1074/jbc.272.28.17686; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Mallet VO, 2002, NAT BIOTECHNOL, V20, P1234, DOI 10.1038/nbt762; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; ROTH KA, NEUROMETHODS, V37, P205; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664	18	220	240	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					797	803		10.1038/nm1262	http://dx.doi.org/10.1038/nm1262			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	15965483				2022-12-27	WOS:000230304200038
J	Cheng, WJ; Liu, JS; Yoshida, H; Rosen, D; Naora, H				Cheng, WJ; Liu, JS; Yoshida, H; Rosen, D; Naora, H			Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract	NATURE MEDICINE			English	Article							HOMEOBOX GENE; MOUSE MODEL; SURFACE EPITHELIUM; CLEAR-CELL; K-RAS; EXPRESSION; DIFFERENTIATION; CARCINOMA; PTEN; TUMORIGENESIS	Although epithelial ovarian cancers (EOCs) have been thought to arise from the simple epithelium lining the ovarian surface or inclusion cysts, the major subtypes of EOCs show morphologic features that resemble those of the mullerian duct-derived epithelia of the reproductive tract. We found that HOX genes, which normally regulate mullerian duct differentiation, are not expressed in normal ovarian surface epithelium (OSE), but are expressed in different EOC subtypes according to the pattern of mullerian-like differentiation of these cancers. Ectopic expression of Hoxa9 in tumorigenic mouse OSE cells gave rise to papillary tumors resembling serous EOCs. In contrast, Hoxa10 and Hoxa11 induced morphogenesis of endometrioid-like and mucinous-like EOCs, respectively. Hoxa7 showed no lineage specificity, but promoted the abilities of Hoxa9, Hoxa10 and Hoxa11 to induce differentiation along their respective pathways. Therefore, inappropriate activation of a molecular program that controls patterning of the reproductive tract could explain the morphologic heterogeneity of EOCs and their assumption of mullerian-like features.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Naora, H (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 1515 Holcombe Blvd,Box 184, Houston, TX 77030 USA.	hnaora@mdanderson.org		cheng, wenjun/0000-0003-3101-8476	NCI NIH HHS [R01 CA101826, R21 CA102108, P01 CA64602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101826, R21CA102108, P01CA064602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Albarracin CT, 2000, HUM PATHOL, V31, P672, DOI 10.1053/hupa.2000.6799; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Benson GV, 1996, DEVELOPMENT, V122, P2687; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; BRADGATE MG, 1989, BRIT J OBSTET GYNAEC, V96, P854, DOI 10.1111/j.1471-0528.1989.tb03328.x; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Connolly DC, 2003, CANCER RES, V63, P1389; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Hough CD, 2000, CANCER RES, V60, P6281; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Korkolopoulou P, 2002, GYNECOL ONCOL, V85, P404, DOI 10.1006/gyno.2002.6627; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Naora H, 2001, P NATL ACAD SCI USA, V98, P15209, DOI 10.1073/pnas.011503998; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1418, DOI 10.1097/00000478-200311000-00003; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Sato N, 2000, CANCER RES, V60, P7052; Schwartz DR, 2002, CANCER RES, V62, P4722; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495	40	205	224	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					531	537		10.1038/nm1230	http://dx.doi.org/10.1038/nm1230			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15821746				2022-12-27	WOS:000228915000025
J	Fauci, AS				Fauci, Anthony S.			The expanding global health agenda: a welcome development	NATURE MEDICINE			English	Editorial Material							INFECTIOUS-DISEASES; AIDS		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike,Bldg 31,Room 7A-03, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839; Folkers GK, 2001, JAMA-J AM MED ASSOC, V286, P458, DOI 10.1001/jama.286.4.458; IGLEHART JK, 2004, HLTH AFF MILLWOOD, P262; Institute of Medicine, 1997, AM VIT INT GLOB HLTH; *J HOPK U SCH HYG, 1992, INT DECL HLTH RIGHTS; *JOINT UN PROGR HI, 2006, AIDS EP UPD SPEC RE; *LASK FDN FUND FIR, 2000, EXC RET EC VAL AM IN; *OFF US GOLB AIDS, 2007, 3 ANN REP C PEPFAR; *US AG INT DEV, 2007, PRES MAL IN; *WHO, 2007, WHO STAT INF SYST; *WHO UNAIDS UNICEF, 2007, TOW UN ACC SCAL UP P; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	13	19	19	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1169	1171		10.1038/nm1646	http://dx.doi.org/10.1038/nm1646			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17917667				2022-12-27	WOS:000249980200031
J	Nakai, A; Yamaguchi, O; Takeda, T; Higuchi, Y; Hikoso, S; Taniike, M; Omiya, S; Mizote, I; Matsumura, Y; Asahi, M; Nishida, K; Hori, M; Mizushima, N; Otsu, K				Nakai, Atsuko; Yamaguchi, Osamu; Takeda, Toshihiro; Higuchi, Yoshiharu; Hikoso, Shungo; Taniike, Masayuki; Omiya, Shigemiki; Mizote, Isamu; Matsumura, Yasushi; Asahi, Michio; Nishida, Kazuhiko; Hori, Masatsugu; Mizushima, Noboru; Otsu, Kinya			The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress	NATURE MEDICINE			English	Article							CELLULAR AUTOPHAGY; APOPTOSIS; MICE; DEATH; CARDIOMYOPATHY; INHIBITION; PROTEIN; CELLS; HYPERTROPHY; DISEASE	Autophagy, an evolutionarily conserved process for the bulk degradation of cytoplasmic components, serves as a cell survival mechanism in starving cells(1,2). Although altered autophagy has been observed in various heart diseases, including cardiac hypertrophy(3,4) and heart failure(5,6), it remains unclear whether autophagy plays a beneficial or detrimental role in the heart. Here, we report that the cardiac-specific loss of autophagy causes cardiomyopathy in mice. In adult mice, temporally controlled cardiac-specific deficiency of Atg5 (autophagy-related 5), a protein required for autophagy, led to cardiac hypertrophy, left ventricular dilatation and contractile dysfunction, accompanied by increased levels of ubiquitination. Furthermore, Atg5-deficient hearts showed disorganized sarcomere structure and mitochondrial misalignment and aggregation. On the other hand, cardiac-specific deficiency of Atg5 early in cardiogenesis showed no such cardiac phenotypes under baseline conditions, but developed cardiac dysfunction and left ventricular dilatation one week after treatment with pressure overload. These results indicate that constitutive autophagy in the heart under baseline conditions is a homeostatic mechanism for maintaining cardiomyocyte size and global cardiac structure and function, and that upregulation of autophagy in failing hearts is an adaptive response for protecting cells from hemodynamic stress.	Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Med Informat Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Bunkyo Ku, Tokyo 1138519, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; Osaka University; Tokyo Metropolitan Institute of Medical Science; Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST)	Otsu, K (corresponding author), Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kotsu@medone.med.osaka-u.ac.jp	Hikoso, Shungo/R-4281-2018; Mizushima, Noboru/C-3635-2009	Mizushima, Noboru/0000-0002-6258-6444; Yamaguchi, Osamu/0000-0002-7461-369X; Hikoso, Shungo/0000-0003-2284-1970				Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; DAMMRICH J, 1983, VIRCHOWS ARCH B, V43, P287, DOI 10.1007/BF02932962; DECKER RS, 1980, AM J PATHOL, V98, P425; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Hosokawa N, 2006, FEBS LETT, V580, P2623, DOI 10.1016/j.febslet.2006.04.008; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Miyata S, 2006, AM J PATHOL, V168, P386, DOI 10.2353/ajpath.2006.050137; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; PFEIFER U, 1987, J MOL CELL CARDIOL, V19, P1179, DOI 10.1016/S0022-2828(87)80528-X; Shimomura H, 2001, JPN CIRC J, V65, P965, DOI 10.1253/jcj.65.965; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100; Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	30	1168	1226	2	121	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2007	13	5					619	624		10.1038/nm1574	http://dx.doi.org/10.1038/nm1574			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17450150				2022-12-27	WOS:000246302800030
J	Loser, K; Mehling, A; Loeser, S; Apelt, J; Kuhn, A; Grabbe, S; Schwarz, T; Penninger, JM; Beissert, S				Loser, Karin; Mehling, Annette; Loeser, Stefanie; Apelt, Jenny; Kuhn, Annegret; Grabbe, Stephan; Schwarz, Thomas; Penninger, Josef M.; Beissert, Stefan			Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells	NATURE MEDICINE			English	Article							IMMUNOLOGICAL SELF-TOLERANCE; CONTACT HYPERSENSITIVITY; SYSTEMIC AUTOIMMUNITY; LYMPH-NODE; INTESTINAL INFLAMMATION; TUMOR-IMMUNITY; CD25(+); INDUCTION; LIGAND; MICE	Regulatory CD4(+)CD25(+) T cells are important in suppressing immune responses. The requirements for the maintenance of peripheral CD4(+)CD25(+) T cells remain incompletely understood. Receptor activator of NF-kappa B ( RANK) and its ligand (RANKL; also known as CD254, OPGL and TRANCE) are key regulators of bone remodeling, mammary gland formation, lymph node development and T-cell/dendritic cell communication. Here we report that RANKL is expressed in keratinocytes of the inflamed skin. RANKL overexpression in keratinocytes resulted in functional alterations of epidermal dendritic cells and systemic increases of regulatory CD4(+)CD25(+) T cells. Thus, epidermal RANKL expression can change dendritic cell functions to maintain the number of peripheral CD4(+)CD25(+) regulatory T cells. Epidermal RANKL mediated ultraviolet-induced immunosuppression and overexpression of epidermal RANKL suppressed allergic contact hypersensitivity responses and the development of systemic autoimmunity. Therefore, environmental stimuli at the skin can rewire the local and systemic immune system by means of RANKL.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; German Canc Res Ctr, Tumor Immunol Program, Div Immunogenet, D-69120 Heidelberg, Germany; Univ Essen Gesamthsch, Dept Dermatol, D-45122 Essen, Germany; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Munster; University of Munster; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Kiel	Beissert, S (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.	beisser@uni-muenster.de	Penninger, Josef M/I-6860-2013; Grabe, Stephan/AAJ-4578-2021; Schwarz, Thomas/A-9148-2010	Penninger, Josef M/0000-0002-8194-3777; Grabe, Stephan/0000-0002-6863-8719; 				ALUFER TM, 2006, NATURE, V383, P81; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074-7613(03)00326-1; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Bynoe MS, 2003, IMMUNITY, V19, P317, DOI 10.1016/S1074-7613(03)00239-5; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Cremer I, 2002, BLOOD, V100, P3646, DOI 10.1182/blood-2002-01-0312; Dombrecht EJ, 2006, CLIN EXP RHEUMATOL, V24, P31; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074-7613(02)00279-0; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Itoh M, 1999, J IMMUNOL, V162, P5317; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KRAGBALLE K, 1992, J CELL BIOCHEM, V49, P46, DOI 10.1002/jcb.240490109; Kuhn A, 2001, J AM ACAD DERMATOL, V45, P86, DOI 10.1067/mjd.2001.114589; Labeur MS, 1999, J IMMUNOL, V162, P168; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Loser K, 2005, GENE THER, V12, P1294, DOI 10.1038/sj.gt.3302567; Loser K, 2004, EUR J IMMUNOL, V34, P2022, DOI 10.1002/eji.200324785; Loser K, 2006, J INVEST DERMATOL, V126, P1307, DOI 10.1038/sj.jid.5700185; Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Papiernik M, 1998, INT IMMUNOL, V10, P371, DOI 10.1093/intimm/10.4.371; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422	46	307	324	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1372	1379		10.1038/nm1518	http://dx.doi.org/10.1038/nm1518			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17143276				2022-12-27	WOS:000242618200017
J	Anthony, RM; Urban, JF; Alem, F; Hamed, HA; Rozo, CT; Boucher, JL; Van Rooijen, N; Gause, WC				Anthony, Robert M.; Urban, Joseph F., Jr.; Alem, Farhang; Hamed, Hossein A.; Rozo, Cristina T.; Boucher, Jean-Luc; Van Rooijen, Nico; Gause, William C.			Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites	NATURE MEDICINE			English	Article							HELIGMOSOMOIDES-POLYGYRUS; IMMUNE-RESPONSES; T-CELLS; INFECTION; CHITINASE; MUSCLE; LARVAE; IL-13	Although primary and memory responses against bacteria and viruses have been studied extensively, T helper type 2 (T(H)2) effector mechanisms leading to host protection against helminthic parasites remain elusive(1). Examination of the intestinal epithelial submucosa of mice after primary and secondary infections by a natural gastrointestinal parasite revealed a distinct immune-cell infiltrate after challenge, featuring interleukin-4-expressing memory CD4(+) T cells that induced IL-4 receptor(hi) (IL-4R(hi)) CD206(+) alternatively activated macrophages(2). In turn, these alternatively activated macrophages (AAMacs) functioned as important effector cells of the protective memory response contributing to parasite elimination, demonstrating a previously unknown mechanism for host protection against intestinal helminths.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol, Bethesda, MD 20814 USA; USDA, Beltsville Human Nutr Res Ctr, Nutr Requirements & Funct Lab, Beltsville, MD 20705 USA; Univ Paris 05, CNRS, Lab Chim & Biochim Pharmacol, UMR 8601, F-75270 Paris, France; Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands	Rutgers State University New Brunswick; Rutgers State University Medical Center; Uniformed Services University of the Health Sciences - USA; United States Department of Agriculture (USDA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Vrije Universiteit Amsterdam	Gause, WC (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, 185 S Orange Ave, Newark, NJ 07103 USA.	gausewc@umdnj.edu	Van Rooijen, Nico/Z-1578-2019	Urban, Joseph/0000-0002-1590-8869	NIAID NIH HHS [R01 AI031678-09, R01 AI031678-12, R01 AI031678-07, R01 AI031678-10, R01 AI031678-11, R01 AI031678-13, R01 AI031678, R01 AI031678-06, R01 AI031678-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031678] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ben-Smith A, 2003, J HELMINTHOL, V77, P133, DOI 10.1079/JOH2003173; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cliffe LJ, 2005, SCIENCE, V308, P1463, DOI 10.1126/science.1108661; Gause WC, 2003, TRENDS IMMUNOL, V24, P269, DOI 10.1016/S1471-4906(03)00101-7; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Kuwano K, 2003, EUR RESPIR J, V21, P232, DOI 10.1183/09031936.03.00063203; Liu ZG, 2004, IMMUNOL REV, V201, P57, DOI 10.1111/j.0105-2896.2004.00186.x; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Madden KB, 2004, J IMMUNOL, V172, P5616, DOI 10.4049/jimmunol.172.9.5616; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mei BS, 1997, J PARASITOL, V83, P760, DOI 10.2307/3284260; Morimoto M, 2004, J IMMUNOL, V172, P2424, DOI 10.4049/jimmunol.172.4.2424; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murakami H, 2000, KIDNEY INT, V58, P1346, DOI 10.1046/j.1523-1755.2000.00295.x; Nair MG, 2005, INFECT IMMUN, V73, P385, DOI 10.1128/IAI.73.1.385-394.2005; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; Pennock JL, 2006, CHEM IMMUNOL ALLERGY, V90, P128, DOI 10.1159/000088885; PERSSON L, 1974, ZBL VET MED B, V21, P483; Shea-Donohue T, 2001, J IMMUNOL, V167, P2234, DOI 10.4049/jimmunol.167.4.2234; Takamiya S, 1996, MOL BIOCHEM PARASIT, V79, P61, DOI 10.1016/0166-6851(96)02650-3; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; vanRooijen N, 1997, TRENDS BIOTECHNOL, V15, P178, DOI 10.1016/S0167-7799(97)01019-6; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zhao AP, 2003, J IMMUNOL, V171, P948, DOI 10.4049/jimmunol.171.2.948; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	30	395	409	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					955	960		10.1038/nm1451	http://dx.doi.org/10.1038/nm1451			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892038	Green Accepted			2022-12-27	WOS:000239626200028
J	Kitamura, T; Feng, Y; Kitamura, YI; Chua, SC; Xu, AW; Barsh, GS; Rossetti, L; Accili, D				Kitamura, Tadahiro; Feng, Yun; Kitamura, Yukari Ido; Chua, Streamson C., Jr.; Xu, Allison W.; Barsh, Gregory S.; Rossetti, Luciano; Accili, Domenico			Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR FOXO1; PROOPIOMELANOCORTIN MESSENGER-RNA; CENTRAL-NERVOUS-SYSTEM; BETA-CELL FUNCTION; HYPOTHALAMIC NEURONS; INSULIN SENSITIVITY; GLUCOSE-PRODUCTION; SIGNAL TRANSDUCER; INDUCED ANOREXIA; GENE-EXPRESSION	Leptin controls food intake by regulating the transcription of key neuropeptides in the hypothalamus. The mechanism by which leptin regulates gene expression is unclear, however. Here we show that delivery of adenovirus encoding a constitutively nuclear mutant FoxO1, a transcription factor known to control liver metabolism and pancreatic beta-cell function, to the hypothalamic arcuate nucleus of rodents results in a loss of the ability of leptin to curtail food intake and suppress expression of Agrp. Conversely, a transactivation-deficient FoxO1 mutant prevents induction of Agrp by fasting. We also find that FoxO1 and the transcription factor Stat3 exert opposing actions on the expression of Agrp and Pomc through transcriptional squelching. FoxO1 promotes opposite patterns of coactivator-corepressor exchange at the Pomc and Agrp promoters, resulting in activation of Agrp and inhibition of Pomc. Thus, FoxO1 represents a shared component of pathways integrating food intake and peripheral metabolism.	Columbia Univ, Ctr Med, Dept Med, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Diabet Res & Training Ctr, Bronx, NY 10461 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Columbia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stanford University; Stanford University	Accili, D (corresponding author), Columbia Univ, Ctr Med, Dept Med, 1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK048321, R01DK057539, P30DK063608, R37DK048321, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654] Funding Source: NIH RePORTER; NIA NIH HHS [AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK20541, DK48321, DK63608, DK57539] Funding Source: Medline; PHS HHS [AK45024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Barsh GS, 2002, NAT REV GENET, V3, P589, DOI [10.1038/nrn902, 10.1038/nrg862]; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Figlewicz DP, 2003, BRAIN RES, V964, P107, DOI 10.1016/S0006-8993(02)04087-8; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; He W, 2006, NAT NEUROSCI, V9, P227, DOI 10.1038/nn1626; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Lam TKT, 2005, SCIENCE, V309, P943, DOI 10.1126/science.1112085; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Morton GJ, 2005, CELL METAB, V2, P411, DOI 10.1016/j.cmet.2005.10.009; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Schwartz MW, 2003, DIABETES, V52, P232, DOI 10.2337/diabetes.52.2.232; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI200524301	40	329	345	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					534	540		10.1038/nm1392	http://dx.doi.org/10.1038/nm1392			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604086				2022-12-27	WOS:000238149100037
J	Robicsek, A; Strahilevitz, J; Jacoby, GA; Macielag, M; Abbanat, D; Park, CH; Bush, K; Hooper, DC				Robicsek, A; Strahilevitz, J; Jacoby, GA; Macielag, M; Abbanat, D; Park, CH; Bush, K; Hooper, DC			Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase	NATURE MEDICINE			English	Article							MEDIATED QUINOLONE RESISTANCE; CHLORAMPHENICOL ACETYLTRANSFERASE; UNITED-STATES; FUSIDIC ACID; PLASMID; BINDING	Antimicrobial-modifying resistance enzymes have traditionally been class specific, having coevolved with the antibiotics they inactivate. Fluoroquinolones, antimicrobial agents used extensively in medicine and agriculture, are synthetic and have been considered safe from naturally occurring antimicrobial-modifying enzymes. We describe reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase AAC(6')-lb. This enzyme reduces the activity of ciprofloxacin by N-acetylation at the amino nitrogen on its piperazinyl substituent. Although approximately 30 variants of this gene have been reported since 1986, the two base-pair changes responsible for the ciprofloxacin modification phenotype are unique to this variant, first reported in 2003 and now widely disseminated. An intense increase in the medical use of ciprofloxacin seems to have been accompanied by a notable development: a single-function resistance enzyme has crossed class boundaries, and is now capable of enzymatically undermining two unrelated antimicrobial agents, one of them fully synthetic.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Lahey Clin Fdn, Burlington, MA 01805 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Lahey Hospital & Medical Center; Johnson & Johnson; Johnson & Johnson USA	Hooper, DC (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GRJ 512, Boston, MA 02114 USA.	dhooper@partners.org	Jacoby, George A/G-2604-2011; Bush, Karen/O-2820-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043312, R01AI057576] Funding Source: NIH RePORTER; NIAID NIH HHS [AI57576, R01 AI057576, AI43312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT AD, 1983, BIOCHEM J, V215, P29, DOI 10.1042/bj2150029; Boyd DA, 2004, ANTIMICROB AGENTS CH, V48, P3758, DOI 10.1128/AAC.48.10.3758-3764.2004; Davies J. E., 1986, ANTIBIOTICS LABORATO, P790; DOMAGALA JM, 1994, J ANTIMICROB CHEMOTH, V33, P685, DOI 10.1093/jac/33.4.685; HEISIG P, 1994, ANTIMICROB AGENTS CH, V38, P1284, DOI 10.1128/AAC.38.6.1284; Martinez-Freijo P, 1998, J ANTIMICROB CHEMOTH, V42, P689, DOI 10.1093/jac/42.6.689; MURRAY IA, 1995, J MOL BIOL, V254, P993, DOI 10.1006/jmbi.1995.0671; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Pechere JC, 2001, INT J ANTIMICROB AG, V18, pS25; Robicsek A, 2005, ANTIMICROB AGENTS CH, V49, P3001, DOI 10.1128/AAC.49.7.3001-3003.2005; TOLMASKY ME, 1986, ANTIMICROB AGENTS CH, V30, P315, DOI 10.1128/AAC.30.2.315; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Wang F, 2001, J Infect Chemother, V7, P117, DOI 10.1007/s101560100019; Wang MG, 2004, ANTIMICROB AGENTS CH, V48, P1295, DOI 10.1128/AAC.48.4.1295-1299.2004; Wang MG, 2003, ANTIMICROB AGENTS CH, V47, P2242, DOI 10.1128/AAC.47.7.2242-2248.2003; Wetzstein HG, 1997, APPL ENVIRON MICROB, V63, P4272, DOI 10.1128/AEM.63.11.4272-4281.1997	17	688	807	4	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					83	88		10.1038/nm1347	http://dx.doi.org/10.1038/nm1347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16369542				2022-12-27	WOS:000234419000056
J	Thomas, GV; Tran, C; Mellinghoff, IK; Welsbie, DS; Chan, E; Fueger, B; Czernin, J; Sawyers, CL				Thomas, GV; Tran, C; Mellinghoff, IK; Welsbie, DS; Chan, E; Fueger, B; Czernin, J; Sawyers, CL			Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; MAMMALIAN TARGET; RAPAMYCIN; EXPRESSION; GENE; TUMORS; HIF; SUPPRESSION; THERAPY	Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity in cancer trials, leading to confusion about the appropriate clinical setting for their use. Here we show that loss of the Von Hippel-Lindau tumor suppressor gene (VHL) sensitizes kidney cancer cells to the mTOR inhibitor CCI-779 in vitro and in mouse models. Growth arrest caused by CCI-779 correlates with a block in translation of mRNA encoding hypoxia-inducible factor (HIF1A), and is rescued by expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region. VHL-deficient tumors show increased uptake of the positron emission tomography (PET) tracer fluorodeoxyglucose (FDG) in an mTOR-dependent manner. Our findings provide preclinical rationale for prospective, biomarker-driven clinical studies of mTOR inhibitors in kidney cancer and suggest that FDG-PET scans may have use as a pharmacodynamic marker in this setting.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016; Tran, Chau/GRX-4633-2022	Thomas, George V/0000-0001-7416-8840				Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; CHEN F, 1995, CANCER RES, V55, P4804; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Gayed I, 2004, J NUCL MED, V45, P17; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hain SF, 2003, BJU INT, V92, P159, DOI 10.1046/j.1464-410X.2003.04284.x; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Joensuu H, 2002, MED KLIN, V97, P28; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Satyamurthy N, 2002, Mol Imaging Biol, V4, P65, DOI 10.1016/S1095-0397(01)00068-1; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Zhong H, 2000, CANCER RES, V60, P1541	24	491	509	0	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					122	127		10.1038/nm1337	http://dx.doi.org/10.1038/nm1337			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341243				2022-12-27	WOS:000234419000061
J	Meunier, MC; Delisle, JS; Bergeron, J; Rineau, V; Baron, C; Perreault, C				Meunier, MC; Delisle, JS; Bergeron, J; Rineau, V; Baron, C; Perreault, C			T cells targeted against a single minor histocompatibility antigen can cure solid tumors	NATURE MEDICINE			English	Article							TISSUE DISTRIBUTION; CANCER-IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; RECOGNITION; MECHANISMS; IMMUNODOMINANCE; ELIMINATION; ACTIVATION; MOLECULES	T cells responsive to minor histocompatibility ( H) antigens are extremely effective in curing leukemia but it remains unknown whether they can eradicate solid tumors. We report that injection of CD8(+) T cells primed against the immunodominant H7(a) minor H antigen can cure established melanomas in mice. Tumor rejection was initiated by preferential extravasation at the tumor site of interferon ( IFN)-gamma-producing H7(a)-specific T cells. Intratumoral release of IFN-gamma had two crucial effects: inhibition of tumor angiogenesis and upregulation of major histocompatibility complex ( MHC) class I expression on tumor cells. Despite ubiquitous expression of H7(a), dissemination of a few H7(a)-specific T cells in extralymphoid organs caused neither graft-versus-host disease ( GVHD) nor vitiligo because host nonhematopoietic cells were protected by their low expression of MHC class I. Our preclinical model yields unique insights into how minor H antigen-based immunotherapy could be used to treat human solid tumors.	Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; Hop Maison Neuve Rosemont, Guy Bernier Res Ctr, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Perreault, C (corresponding author), Univ Montreal, Inst Res Immunol & Canc, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	c.perreault@videotron.ca	Perreault, Claude/A-7220-2008	Perreault, Claude/0000-0001-9453-7383; Delisle, Jean-Sebastien/0000-0003-1460-7287				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; Dienst A, 2005, JNCI-J NATL CANCER I, V97, P733, DOI 10.1093/jnci/dji130; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eden PA, 1999, J IMMUNOL, V162, P4502; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Gervois N, 1996, J EXP MED, V183, P2403, DOI 10.1084/jem.183.5.2403; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; Hernandez J, 2000, J IMMUNOL, V164, P596, DOI 10.4049/jimmunol.164.2.596; Issekutz AC, 2002, J IMMUNOL, V168, P1934, DOI 10.4049/jimmunol.168.4.1934; Klein CA, 2002, J EXP MED, V196, P359, DOI 10.1084/jem.20011838; Korngold R, 1997, Biol Blood Marrow Transplant, V3, P57; KUZU I, 1993, LAB INVEST, V69, P322; Li Y, 2005, NAT BIOTECHNOL, V23, P349, DOI 10.1038/nbt1070; Liu LZ, 2002, NAT MED, V8, P185, DOI 10.1038/nm0202-185; Meunier MC, 2003, BLOOD, V101, P766, DOI 10.1182/blood-2002-04-1032; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; Morgan RA, 2003, J IMMUNOL, V171, P3287, DOI 10.4049/jimmunol.171.6.3287; Nandi A, 2004, IMMUNITY, V20, P455, DOI 10.1016/S1074-7613(04)00077-9; Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008; Perreault C, 2002, J MOL MED, V80, P212, DOI 10.1007/s00109-001-0315-1; Pion S, 1997, EUR J IMMUNOL, V27, P421, DOI 10.1002/eji.1830270212; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Roy-Proulx G, 2001, EUR J IMMUNOL, V31, P2284, DOI 10.1002/1521-4141(200108)31:8<2284::AID-IMMU2284>3.0.CO;2-E; Rubio V, 2003, NAT MED, V9, P1377, DOI 10.1038/nm942; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schuler T, 2003, J IMMUNOL, V170, P4427, DOI 10.4049/jimmunol.170.9.4427; Siegelman MH, 2000, J CLIN INVEST, V105, P683, DOI 10.1172/JCI8692; Spierings E, 2004, TRENDS IMMUNOL, V25, P56, DOI 10.1016/j.it.2003.12.002; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Thatte J, 2003, BLOOD, V101, P4916, DOI 10.1182/blood-2002-10-3159; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Yoshimura Y, 2004, J IMMUNOL, V172, P6666, DOI 10.4049/jimmunol.172.11.6666	40	61	65	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1222	1229		10.1038/nm1311	http://dx.doi.org/10.1038/nm1311			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227989				2022-12-27	WOS:000233115400035
J	Reddy, P; Maeda, Y; Liu, C; Krijanovski, OI; Korngold, R; Ferrara, JLM				Reddy, P; Maeda, Y; Liu, C; Krijanovski, OI; Korngold, R; Ferrara, JLM			A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses	NATURE MEDICINE			English	Article							HOST DENDRITIC CELLS; MARROW-TRANSPLANTATION; DISEASE; CANCER; IMMUNOTHERAPY; IMMUNOBIOLOGY; MECHANISMS; LYMPHOMA; BLOOD	Graft-versus-leukemia ( GVL) response after allogeneic bone marrow transplantation ( BMT) represents one of the most potent forms of immunotherapy against malignant diseases(1). Antigen-presenting cells ( APCs) are crucial for the induction of graft-versus-host disease ( GVHD)(2-6), the most serious complication of allogeneic BMT, but their role in GVL responses is unclear. Using a series of clinically relevant mouse GVL tumor models, we found that APCs and alloantigen expression on tumors are crucial for GVL. Moreover, APCs of host origin predominated in GVL responses although donor APCs contributed as the acuity of tumor burden decreased.	Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA; Univ Michigan, Ctr Canc, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida; Hackensack University Medical Center; University of Michigan System; University of Michigan	Reddy, P (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, 1500 E Mem Ctr Dr, Ann Arbor, MI 48109 USA.	reddypr@umich.edu	Korngold, Robert/AAF-2686-2020	Reddy, Pavan/0000-0001-7264-8429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI052863] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 49542] Funding Source: Medline; NHLBI NIH HHS [R01 HL55593] Funding Source: Medline; NIAID NIH HHS [K08 AI052863-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Auffermann-Gretzinger S, 2002, BLOOD, V99, P1442, DOI 10.1182/blood.V99.4.1442; Bierman PJ, 2003, J CLIN ONCOL, V21, P3744, DOI 10.1200/JCO.2003.08.054; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Duffner UA, 2004, J IMMUNOL, V172, P7393, DOI 10.4049/jimmunol.172.12.7393; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eibl B, 1997, GENE CHROMOSOME CANC, V20, P215, DOI 10.1002/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO;2-5; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Gatza E, 2002, J IMMUNOL, V169, P5227, DOI 10.4049/jimmunol.169.9.5227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a; Jones SC, 2003, J CLIN INVEST, V112, P1880, DOI 10.1172/JCI200319427; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; Li JM, 2004, BIOL BLOOD MARROW TR, V10, P540, DOI 10.1016/j.bbmt.2004.05.007; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Merad M, 2004, NAT MED, V10, P510, DOI 10.1038/nm1038; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Patterson AE, 2000, BIOL BLOOD MARROW TR, V6, P537, DOI 10.1016/S1083-8791(00)70063-2; Patterson AE, 2001, BIOL BLOOD MARROW TR, V7, P187, DOI 10.1053/bbmt.2001.v7.pm11349805; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Reddy P, 2003, BLOOD REV, V17, P187, DOI 10.1016/S0268-960X(03)00009-2; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stelljes M, 2004, BLOOD, V104, P1210, DOI 10.1182/blood-2003-10-3387; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	30	185	190	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2005	11	11					1244	1249		10.1038/nm1309	http://dx.doi.org/10.1038/nm1309			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227991				2022-12-27	WOS:000233115400038
J	Tiede, S; Storch, S; Lubke, T; Henrissat, B; Bargal, R; Raas-Rothschild, A; Braulke, T				Tiede, S; Storch, S; Lubke, T; Henrissat, B; Bargal, R; Raas-Rothschild, A; Braulke, T			Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase	NATURE MEDICINE			English	Article							LYSOSOMAL-ENZYMES; COMPLEMENTATION; BIOSYNTHESIS; CLONING	Mucolipidosis II (ML II) is a fatal lysosomal storage disorder resulting from defects in the multimeric GlcNAc-1-phosphotransferase responsible for the initial step in the generation of the mannose 6-phosphate (M6P) recognition marker(1). M6P residues on oligosaccharides of newly synthesized lysosomal enzymes are essential for efficient receptor-mediated transport to lysosomes(2). We used the recombinant GlcNAc-1-phosphotransferase c subunit as an affinity matrix to purify an unknown protein identified as the product of GNPTA (encoding GNPTA, previously known as MGC4170). The cDNA encodes a protein of 1,256 amino acids with two putative transmembrane domains and a complex preserved modular structure comprising at least six domains. The N-terminal domain of GNPTA, interrupted by a long insertion, shows similarities to bacterial capsule biosynthesis proteins. We identified seven mutations in GNPTA that lead to premature translational termination in six individuals with ML II. Retroviral transduction of fibroblasts from an individual with ML II resulted in the expression and localization of GNPTA in the Golgi apparatus, accompanied by the correction of hypersecretion of lysosomal enzymes. Our results provide evidence that GNPTA encodes a subunit of GlcNAc-1-phosphotransferase defective in individuals with ML II.	Univ Hamburg, Dept Biochem, Childrens Hosp, D-20246 Hamburg, Germany; Univ Gottingen, Dept Biochem, D-37073 Gottingen, Germany; Univ Aix Marseille 1, UMR6098, CNRS, F-13288 Marseille, France; Univ Aix Marseille 2, UMR6098, CNRS, F-13288 Marseille, France; Hadassah Univ, Hosp Med, Dept Human Genet, IL-91120 Jerusalem, Israel	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Hebrew University of Jerusalem; Hadassah University Medical Center	Braulke, T (corresponding author), Univ Hamburg, Dept Biochem, Childrens Hosp, Martinistr 52, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Braulke, Thomas/AAV-9121-2020; Lübke, Torben/B-6019-2012; Henrissat, Bernard/J-2475-2012	Braulke, Thomas/0000-0002-2336-8532; Henrissat, Bernard/0000-0002-3434-8588; Lubke, Torben/0000-0002-3342-0090; Storch, Stephan/0000-0002-8807-5917; Tiede, Stephan/0000-0002-6045-3736				Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Eckert V, 1998, GLYCOBIOLOGY, V8, P77, DOI 10.1093/glycob/8.1.77; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Kornfeld S., 2001, METABOLIC MOL BASES, P3421; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Muschol N, 2002, BIOCHEM J, V368, P845, DOI 10.1042/BJ20020249; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Storch S, 2004, J BIOL CHEM, V279, P53625, DOI 10.1074/jbc.M410930200; Storch Stephan, 2005, P17; Tiede Stephan, 2004, Hum Mutat, V24, P535, DOI 10.1002/humu.9293; Tzeng YL, 2003, INFECT IMMUN, V71, P6712, DOI 10.1128/IAI.71.12.6712-6720.2003	15	144	152	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1109	1112		10.1038/nm1305	http://dx.doi.org/10.1038/nm1305			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16200072				2022-12-27	WOS:000232492500033
J	Poola, I; DeWitty, RL; Marshalleck, JJ; Bhatnagar, R; Abraham, J; Leffall, LD				Poola, I; DeWitty, RL; Marshalleck, JJ; Bhatnagar, R; Abraham, J; Leffall, LD			Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis	NATURE MEDICINE			English	Article							MATRIX METALLOPROTEINASES	Breast cancer is the second leading cause of cancer death for women in the United States. In 2005, about 215,000 cases of invasive breast cancer (IBC) and 50,000 cases of ductal carcinoma in situ will be diagnosed and 40,000 women will die of IBC in the US1. Yet there is presently no molecular marker that can be used to detect a precancerous state or identify which premalignant lesions will develop into invasive breast cancer. Here we report the gene expression analysis of atypical ductal hyperplastic tissues from patients with and without a history of breast cancer. We identify MMP-1 as a candidate marker that may be useful for identification of breast lesions that can develop into cancer.	Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Howard Univ Hosp, Washington, DC 20060 USA; Univ Alberta, Dept Biol, Edmonton, AB T6G 2E9, Canada	Howard University; Howard University; University of Alberta	Poola, I (corresponding author), Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA.	ipoola@howard.edu	Abraham, Jessy/AAC-3337-2022	Abraham, Jessy/0000-0003-1983-9415	NATIONAL CANCER INSTITUTE [R33CA088347] Funding Source: NIH RePORTER; NCI NIH HHS [R33 CA88347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Krishnamurthy S, 2002, ADV ANAT PATHOL, V9, P185, DOI 10.1097/00125480-200205000-00002; Lacroix M, 2002, INT J BIOL MARKER, V17, P5, DOI 10.1177/172460080201700102; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Migita T, 1999, INT J CANCER, V84, P74, DOI 10.1002/(SICI)1097-0215(19990219)84:1<74::AID-IJC14>3.0.CO;2-I; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400	10	138	144	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					481	483		10.1038/nm1243	http://dx.doi.org/10.1038/nm1243			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15864312				2022-12-27	WOS:000228915000018
J	Dove, A				Dove, A			Maurice Hilleman	NATURE MEDICINE			English	Biographical-Item																			0	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4		S			S2	S2		10.1038/nm1223	http://dx.doi.org/10.1038/nm1223			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812484	Bronze			2022-12-27	WOS:000228339600002
J	Seki, E; De Minicis, S; Osterreicher, CH; Kluwe, J; Osawa, Y; Brenner, DA; Schwabe, RF				Seki, Ekihiro; De Minicis, Samuele; Oesterreicher, Christoph H.; Kluwe, Johannes; Osawa, Yosuke; Brenner, David A.; Schwabe, Robert F.			TLR4 enhances TGF-beta signaling and hepatic fibrosis	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTOR-4; DIFFERENTIATION FACTOR-88; GENE-EXPRESSION; STELLATE CELLS; KUPFFER CELLS; CUTTING EDGE; LIVER-INJURY; ACTIVATION; LIPOPOLYSACCHARIDE; IDENTIFICATION	Hepatic injury is associated with a defective intestinal barrier and increased hepatic exposure to bacterial products. Here we report that the intestinal bacterial microflora and a functional Toll-like receptor 4 (TLR4), but not TLR2, are required for hepatic fibrogenesis. Using Tlr4-chimeric mice and in vivo lipopolysaccharide (LPS) challenge, we demonstrate that quiescent hepatic stellate cells (HSCs), the main precursors for myofibroblasts in the liver, are the predominant target through which TLR4 ligands promote fibrogenesis. In quiescent HSCs, TLR4 activation not only upregulates chemokine secretion and induces chemotaxis of Kupffer cells, but also downregulates the transforming growth factor (TGF)-beta pseudoreceptor Bambi to sensitize HSCs to TGF-beta induced signals and allow for unrestricted activation by Kupffer cells. LPS-induced Bambi downregulation and sensitization to TGF-beta is mediated by a MyD88-NF-kappa B-dependent pathway. Accordingly, Myd88-deficient mice have decreased hepatic fibrosis. Thus, modulation of TGF-beta signaling by a TLR4-MyD88-NF-kappa B axis provides a novel link between proinflammatory and profibrogenic signals.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Columbia University; University of California System; University of California San Diego	Schwabe, RF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021; Seki, Ekihiro/K-2481-2016; Kluwe, Johannes/CAF-7810-2022	Seki, Ekihiro/0000-0002-9472-6085; Brenner, David/0000-0003-2573-525X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM041804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Brun P, 2005, AM J PHYSIOL-GASTR L, V289, pG571, DOI 10.1152/ajpgi.00537.2004; Campbell JS, 2006, J IMMUNOL, V176, P2522, DOI 10.4049/jimmunol.176.4.2522; De Minicis S, 2007, GASTROENTEROLOGY, V132, P1937, DOI 10.1053/j.gastro.2007.02.033; Diehl AM, 2005, GUT, V54, P303, DOI 10.1136/gut.2003.024935; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Huang HJ, 2007, HEPATOLOGY, V46, P297, DOI 10.1002/hep.21695; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Isayama F, 2006, AM J PHYSIOL-GASTR L, V290, pG1318, DOI 10.1152/ajpgi.00405.2005; Isogawa M, 2005, J VIROL, V79, P7269, DOI 10.1128/JVI.79.11.7269-7272.2005; Izuishi K, 2006, J IMMUNOL, V176, P7154, DOI 10.4049/jimmunol.176.12.7154; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kisseleva T, 2006, J HEPATOL, V45, P429, DOI 10.1016/j.jhep.2006.04.014; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; MAGILAVY DB, 1988, J EXP MED, V168, P789, DOI 10.1084/jem.168.2.789; Muhlbauer M, 2004, BIOCHEM BIOPH RES CO, V325, P191, DOI 10.1016/j.bbrc.2004.10.020; Oakley F, 2005, GASTROENTEROLOGY, V128, P108, DOI 10.1053/j.gastro.2004.10.003; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Paik YH, 2003, HEPATOLOGY, V37, P1043, DOI 10.1053/jhep.2003.50182; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200, DOI 10.1152/ajpgi.2001.281.1.G200; Sasaki T, 2004, ONCOL REP, V11, P1219; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; Seki E, 2005, HEPATOLOGY, V41, P443, DOI 10.1002/hep.20603; Seki E, 2001, J IMMUNOL, V166, P2651, DOI 10.4049/jimmunol.166.4.2651; Sekiya T, 2004, BIOCHEM BIOPH RES CO, V320, P680, DOI 10.1016/j.bbrc.2004.06.017; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thurman RG, 1998, J GASTROEN HEPATOL, V13, pS39, DOI 10.1111/jgh.1998.13.s1.39; Tsang M, 2000, GENESIS, V28, P47, DOI 10.1002/1526-968X(200010)28:2<47::AID-GENE20>3.0.CO;2-S; Tsung A, 2005, J IMMUNOL, V175, P7661, DOI 10.4049/jimmunol.175.11.7661; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Uesugi T, 2001, HEPATOLOGY, V34, P101, DOI 10.1053/jhep.2001.25350; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Yata Y, 2003, HEPATOLOGY, V37, P267, DOI 10.1053/jhep.2003.50067; Zhai Y, 2004, J IMMUNOL, V173, P7115, DOI 10.4049/jimmunol.173.12.7115	47	1375	1451	6	197	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2007	13	11					1324	1332		10.1038/nm1663	http://dx.doi.org/10.1038/nm1663			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17952090				2022-12-27	WOS:000250736900025
J	Bi, YM; Ehirchiou, D; Kilts, TM; Inkson, CA; Embree, MC; Sonoyama, W; Li, L; Leet, AI; Seo, BM; Zhang, L; Shi, ST; Young, MF				Bi, Yanming; Ehirchiou, Driss; Kilts, Tina M.; Inkson, Colette A.; Embree, Mildred C.; Sonoyama, Wataru; Li, Li; Leet, Arabella I.; Seo, Byoung-Moo; Zhang, Li; Shi, Songtao; Young, Marian F.			Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche	NATURE MEDICINE			English	Article							MARROW STROMAL FIBROBLASTS; MESENCHYMAL STEM-CELLS; LABEL-RETAINING CELLS; HUMAN BONE-MARROW; IN-VITRO; PROGENITOR CELLS; MONOCLONAL-ANTIBODY; DEFICIENT MICE; TENASCIN-C; MOUSE	The repair of injured tendons remains a great challenge, largely owing to a lack of in- depth characterization of tendon cells and their precursors. We show that human and mouse tendons harbor a unique cell population, termed tendon stem/ progenitor cells ( TSPCs), that has universal stem cell characteristics such as clonogenicity, multipotency and self- renewal capacity. The isolated TSPCs could regenerate tendon- like tissues after extended expansion in vitro and transplantation in vivo. Moreover, we show that TSPCs reside within a unique niche predominantly comprised of an extracellular matrix, and we identify biglycan ( Bgn) and fibromodulin ( Fmod) as two critical components that organize this niche. Depletion of Bgn and Fmod affects the differentiation of TSPCs by modulating bone morphogenetic protein signaling and impairs tendon formation in vivo. Our results, while offering new insights into the biology of tendon cells, may assist in future strategies to treat tendon diseases.	Natl Inst Dental & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Dept Physiol, Baltimore, MD 21201 USA; Johns Hopkins Univ, Div Pediat Orthopaed, Baltimore, MD 21287 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of Southern California	Young, MF (corresponding author), Natl Inst Dental & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, 30 Convent Dr 30-225 MSC 4320, Bethesda, MD 20892 USA.	songtaos@usc.edu; myoung@dir.nidcr.nih.gov	Mordwinkin, Nicholas M/A-4347-2010; Sonoyama, Wataru/B-2160-2011	Inkson, Colette/0000-0003-1215-312X; Young, Marian F/0000-0003-0929-8854	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R01 HL61589-01, R01 HL061589] Funding Source: Medline; NIAID NIH HHS [R21 AI078365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267; Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Brandau O, 2001, DEV DYNAM, V221, P72, DOI 10.1002/dvdy.1126; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DEMOS M, 2007, DISORD, V8, P16; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828; Fenwick S, 2002, RHEUMATOLOGY, V41, pA474, DOI 10.1093/rheumatology/41.4.474; Filshie RJA, 1998, LEUKEMIA, V12, P414, DOI 10.1038/sj.leu.2400922; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hoffmann A, 2006, J CLIN INVEST, V116, P940, DOI 10.1172/JCI22689; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kannus P, 2000, SCAND J MED SCI SPOR, V10, P312, DOI 10.1034/j.1600-0838.2000.010006312.x; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Kuznetsov SA, 1997, BRIT J HAEMATOL, V97, P561, DOI 10.1046/j.1365-2141.1997.902904.x; Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; MORRIS RJ, 1994, CELL PROLIFERAT, V27, P279, DOI 10.1111/j.1365-2184.1994.tb01425.x; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Ohta M, 1998, BLOOD, V91, P4074; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Sharma P., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P181; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; SIMMONS PJ, 1991, BLOOD, V78, P55; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; VANVLASSELAER P, 1994, BLOOD, V84, P753, DOI 10.1182/blood.V84.3.753.bloodjournal843753; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Yoon J. H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P22; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	50	928	1002	10	123	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1219	1227		10.1038/nm1630	http://dx.doi.org/10.1038/nm1630			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17828274				2022-12-27	WOS:000249980200038
J	Mi, S; Hu, B; Hahm, KM; Luo, Y; Hui, ESK; Yuan, QJ; Wong, WM; Wang, L; Su, HX; Chu, TH; Guo, JS; Zhang, WM; So, KF; Pepinsky, B; Shao, ZH; Graff, C; Garber, E; Jung, V; Wu, EX; Wu, W				Mi, Sha; Hu, Bing; Hahm, Kyungmin; Luo, Yi; Hui, Edward Sai Kam; Yuan, Qiuju; Wong, Wai Man; Wang, Li; Su, Huanxing; Chu, Tak-Ho; Guo, Jiasong; Zhang, Wenming; So, Kwok-Fai; Pepinsky, Blake; Shao, Zhaohui; Graff, Christilyn; Garber, Ellen; Jung, Vincent; Wu, Ed Xuekui; Wu, Wutian			LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis	NATURE MEDICINE			English	Article							DIFFUSION-TENSOR MRI; MULTIPLE-SCLEROSIS; MODEL; DEMYELINATION; MYELINATION; RECOVERY; LESIONS	Demyelinating diseases, such as multiple sclerosis, are characterized by the loss of the myelin sheath around neurons, owing to inflammation and gliosis in the central nervous system ( CNS). Current treatments therefore target anti- inflammatory mechanisms to impede or slow disease progression. The identification of a means to enhance axon myelination would present new therapeutic approaches to inhibit and possibly reverse disease progression. Previously, LRR and Ig domain - containing, Nogo receptor interacting protein ( LINGO- 1) has been identified as an in vitro and in vivo negative regulator of oligodendrocyte differentiation and myelination. Here we show that loss of LINGO- 1 function by Lingo1 gene knockout or by treatment with an antibody antagonist of LINGO- 1 function leads to functional recovery from experimental autoimmune encephalomyelitis. This is reflected biologically by improved axonal integrity, as confirmed by magnetic resonance diffusion tensor imaging, and by newly formed myelin sheaths, as determined by electron microscopy. Antagonism of LINGO- 1 or its pathway is therefore a promising approach for the treatment of demyelinating diseases of the CNS.	Biogen Idec Inc, Cambridge, MA 02142 USA; Univ Hong Kong, Dept Anat, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Res Ctr Heart Brain Hormone & Hlth Aging, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Reprod Dev & Growth, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Fac Engn, Dept Elect & Elect Engn, Pokfulam, Hong Kong, Peoples R China	Biogen; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Mi, S (corresponding author), Biogen Idec Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	sha.mi@biogenidec.com; wtwu@hkucc.hku.hk	Messier, Claude/A-2322-2008; Chu, Tak-Ho/AAB-4608-2021; Hui, Edward/GQO-9176-2022; Su, Huanxing/X-3954-2019; Wu, Ed/C-1579-2009; Chu, Tak Ho/C-4153-2009; hu, bing/B-1030-2010; Su, Huanxing/X-3980-2019; Yuan, Qiuju/AAJ-3101-2020; Guo, Jiasong/I-2206-2019	Messier, Claude/0000-0002-4791-1763; Chu, Tak-Ho/0000-0002-3123-207X; Su, Huanxing/0000-0003-3254-825X; Wu, Ed/0000-0001-5581-1546; hu, bing/0000-0001-8627-5272; Su, Huanxing/0000-0002-0513-4943; Guo, Jiasong/0000-0002-7885-2903; Hui, Sai Kam/0000-0002-1761-0169; So, Kwok-Fai/0000-0003-4039-4246				Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI [10.1006/jmrb.1996.0086, 10.1016/j.jmr.2011.09.022]; Ben-Hur T, 2003, GLIA, V41, P73, DOI 10.1002/glia.10159; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Dubois-Dalcq M, 2005, NEURON, V48, P9, DOI 10.1016/j.neuron.2005.09.004; EAGER KB, 1983, J IMMUNOL METHODS, V64, P157, DOI 10.1016/0022-1759(83)90394-0; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Lassmann H, 1997, GLIA, V19, P104, DOI 10.1002/(SICI)1098-1136(199702)19:2<104::AID-GLIA2>3.3.CO;2-R; Lee X, 2007, J NEUROSCI, V27, P220, DOI 10.1523/JNEUROSCI.4175-06.2007; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; Lubetzki C, 2005, CURR OPIN NEUROL, V18, P237, DOI 10.1097/01.wco.0000169739.83793.e0; LUDWIN SK, 1981, ANN NEUROL, V9, P301; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Noseworthy JH, 1999, CURR OPIN NEUROL, V12, P279, DOI 10.1097/00019052-199906000-00007; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; Reynolds R, 2002, J NEUROCYTOL, V31, P523, DOI 10.1023/A:1025747832215; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trapp BD, 1999, NEUROSCIENTIST, V5, P48, DOI 10.1177/107385849900500107; WEKERLE H, 1994, ANN NEUROL, V36, P47; WU WT, 1993, EXP NEUROL, V122, P88, DOI 10.1006/exnr.1993.1110; Zhao C, 2005, J NEUROL SCI, V233, P87, DOI 10.1016/j.jns.2005.03.008	24	389	416	2	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1228	1233		10.1038/nm1664	http://dx.doi.org/10.1038/nm1664			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17906634				2022-12-27	WOS:000249980200039
J	Tanno, T; Bhanu, NV; Oneal, PA; Goh, SH; Staker, P; Lee, YT; Moroney, JW; Reed, CH; Luban, NLC; Wang, RH; Eling, TE; Childs, R; Ganz, T; Leitman, SF; Fucharoen, S; Miller, JL				Tanno, Toshihiko; Bhanu, Natarajan V.; Oneal, Patricia A.; Goh, Sung-Ho; Staker, Pamela; Lee, Y. Terry; Moroney, John W.; Reed, Christopher H.; Luban, Naomi L. C.; Wang, Rui-Hong; Eling, Thomas E.; Childs, Richard; Ganz, Tomas; Leitman, Susan F.; Fucharoen, Suthat; Miller, Jeffery L.			High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin	NATURE MEDICINE			English	Article							MACROPHAGE INHIBITORY CYTOKINE-1; FACTOR-BETA SUPERFAMILY; SERUM; ERYTHROPOIESIS; METABOLISM; ABSORPTION	In thalassemia, deficient globin-chain production during erythropoiesis results in anemia(1-3). Thalassemia may be further complicated by iron overload (frequently exacerbated by blood transfusion), which induces numerous endocrine diseases, hepatic cirrhosis, cardiac failure and even death(4). Accumulation of iron in the absence of blood transfusions may result from inappropriate suppression of the iron-regulating peptide hepcidin by an erythropoietic mechanism(5). To test this hypothesis, we examined erythroblast transcriptome profiles from 15 healthy, nonthalassemic donors. Growth differentiation factor 15 (GDF15), a member of the transforming growth factor-beta superfamily, showed increased expression and secretion during erythroblast maturation. Healthy volunteers had mean GDF15 serum concentrations of 450 +/- 50 pg/ml. In comparison, individuals with beta-thalassemia syndromes had elevated GDF15 serum levels (mean 66,000 +/- 9,600 pg/ml; range 4,800-248,000 pg/ml; P < 0.05) that were positively correlated with the levels of soluble transferrin receptor, erythropoietin and ferritin. Serum from thalassemia patients suppressed hepcidin mRNA expression in primary human hepatocytes, and depletion of GDF15 reversed hepcidin suppression. These results suggest that GDF15 overexpression arising from an expanded erythroid compartment contributes to iron overload in thalassemia syndromes by inhibiting hepcidin expression.	NIDDK, Mol Med Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; Natl Naval Med Ctr, Dept Obstet & Gynecol, Bethesda, MD 20889 USA; Childrens Natl Med Ctr, Lab Med Pathol, Washington, DC 20010 USA; NIDDK, Genet Dev & Dis Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, Natl Inst Hlth, Res Triangle Pk, NC 27709 USA; NHLBI, Hematol Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Dept Pathol & Med, Los Angeles, CA 90095 USA; Natl Inst Hlth, Dept Transfus Med, Bethesda, MD 20892 USA; Mahidol Univ, Inst Sci & Technol Res & Dev, Thalassemia Res Ctr, Phuttamonthon 73170, Nakornpathom, Thailand	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Walter Reed National Military Medical Center; Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; Mahidol University	Miller, JL (corresponding author), NIDDK, Mol Med Branch, Natl Inst Hlth, 10 Ctr Dr, Bethesda, MD 20892 USA.	jm7f@nih.gov	Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002345, Z01HL002345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025094, Z01DK025100, ZIADK025095, ZIADK025100, ZIADK025094, Z01DK025095, Z01DK025099, ZIADK025099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016, ZIAES010016] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Donovan A, 2006, PHYSIOLOGY, V21, P115, DOI 10.1152/physiol.00052.2005; Eling TE, 2006, J BIOCHEM MOL BIOL, V39, P649; Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Inamura J, 2005, HEPATOL RES, V33, P198, DOI 10.1016/j.hepres.2005.08.005; Kattamis A, 2006, HAEMATOLOGICA, V91, P809; Kearney SL, 2007, PEDIATR BLOOD CANCER, V48, P57, DOI 10.1002/pbc.20616; Koopmann J, 2006, CLIN CANCER RES, V12, P442, DOI 10.1158/1078-0432.CCR-05-0564; Marjono AB, 2003, PLACENTA, V24, P100, DOI 10.1053/plac.2002.0881; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Millard KN, 2004, GUT, V53, P655, DOI 10.1136/gut.2003.031153; NATHAN DG, 1964, MEDICINE, V43, P779, DOI 10.1097/00005792-196411000-00021; Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303; Papanikolaou G, 2005, BLOOD, V105, P4103, DOI 10.1182/blood-2004-12-4844; Pootrakul P, 2000, BLOOD, V96, P2606, DOI 10.1182/blood.V96.7.2606.h8002606_2606_2612; RAO KRP, 1984, J LAB CLIN MED, V103, P792; Rund D, 2005, NEW ENGL J MED, V353, P1135, DOI 10.1056/NEJMra050436; Sritippayawan S, 2005, ASIAN PAC J ALLERGY, V23, P121; Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Weatherall D.J., 2001, THALASSAEMIA SYNDROM, Vfourth; Weizer-Stern O, 2006, BRIT J HAEMATOL, V135, P129, DOI 10.1111/j.1365-2141.2006.06258.x; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wojda U, 2002, BLOOD, V99, P3005, DOI 10.1182/blood.V99.8.3005.h8003005_3005_3013; Xu J, 2006, CIRC RES, V98, P342, DOI 10.1161/01.RES.0000202804.84885.d0; Yamamoto Y, 2004, NATURWISSENSCHAFTEN, V91, P519, DOI 10.1007/s00114-004-0575-z; Yang H, 2003, MOL CANCER THER, V2, P1023	30	624	655	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1096	1101		10.1038/nm1629	http://dx.doi.org/10.1038/nm1629			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17721544				2022-12-27	WOS:000249353100037
J	Mandavilli, A				Mandavilli, Apoorva			Wafaa El-Sadr	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					275	275		10.1038/nm0307-275	http://dx.doi.org/10.1038/nm0307-275			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342133				2022-12-27	WOS:000244715700031
J	Parsa, AT; Waldron, JS; Panner, A; Crane, CA; Parney, IF; Barry, JJ; Cachola, KE; Murray, JC; Tihan, T; Jensen, MC; Mischel, PS; Stokoe, D; Pieper, RO				Parsa, Andrew T.; Waldron, James S.; Panner, Amith; Crane, Courtney A.; Parney, Ian F.; Barry, Jeffrey J.; Cachola, Kristine E.; Murray, Joseph C.; Tihan, Tarik; Jensen, Michael C.; Mischel, Paul S.; Stokoe, David; Pieper, Russell O.			Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma	NATURE MEDICINE			English	Article							RENAL-CELL CARCINOMA; T-CELLS; IMMUNE EVASION; GLIOBLASTOMA-MULTIFORME; POTENTIAL MECHANISM; CANCER; BLOCKADE; IMMUNOTHERAPY; PATHWAY; PD-L1	Cancer immunoresistance and immune escape(1-3) may play important roles in tumor progression and pose obstacles for immunotherapy. Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer(4-10). Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3) K) pathway. Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN. These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA; Univ Calif Los Angeles, David Geffen Sch Med, Henry E Singleton Brain Canc Res Program, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Parsa, AT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	parsaa@neurosurg.ucsf.edu	Murray, Joseph C/J-8916-2014; Tihan, Tarik/AAU-6371-2021	Murray, Joseph C/0000-0001-6159-7814; Parney, Ian/0000-0002-9702-8047; Tihan, Tarik/0000-0003-4551-2555				Blank C, 2006, INT J CANCER, V119, P317, DOI 10.1002/ijc.21775; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015; Dong HD, 2003, J MOL MED, V81, P281, DOI 10.1007/s00109-003-0430-2; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hirano F, 2005, CANCER RES, V65, P1089; Iwai Y, 2005, INT IMMUNOL, V17, P133, DOI 10.1093/intimm/dxh194; Kahlon KS, 2004, CANCER RES, V64, P9160, DOI 10.1158/0008-5472.CAN-04-0454; Kaur S, 2005, J INTERF CYTOK RES, V25, P780, DOI 10.1089/jir.2005.25.780; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rich JN, 2004, NAT REV DRUG DISCOV, V3, P430, DOI 10.1038/nrd1380; Saudemont A, 2004, BLOOD, V104, P2124, DOI 10.1182/blood-2004-01-0064; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Thompson RH, 2005, UROLOGY, V66, P10, DOI 10.1016/j.urology.2005.06.010; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wilmotte R, 2005, NEUROREPORT, V16, P1081, DOI 10.1097/00001756-200507130-00010; Wintterle S, 2003, CANCER RES, V63, P7462	30	1013	1086	5	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					84	88		10.1038/nm1517	http://dx.doi.org/10.1038/nm1517			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159987				2022-12-27	WOS:000243301800040
J	Lewis, DA; Gonzalez-Burgos, G				Lewis, David A.; Gonzalez-Burgos, Guillermo			Pathophysiologically based treatment interventions in schizophrenia	NATURE MEDICINE			English	Review							DORSOLATERAL PREFRONTAL CORTEX; GLUTAMIC-ACID DECARBOXYLASE; ANTERIOR CINGULATE CORTEX; NMDA RECEPTOR SUBUNITS; DOPAMINE D1 RECEPTORS; WORKING-MEMORY; GENE-EXPRESSION; MESSENGER-RNA; SELECTIVE ALTERATIONS; COGNITIVE DEFICITS	Identifying the molecular alterations that underlie the pathophysiology of critical clinical features of schizophrenia is an essential step in the rational development of new therapeutic interventions for this devastating illness. Cognitive deficits, such as the impairments in working memory that arise from dysfunction of the dorsolateral prefrontal cortex, are a major determinant of functional outcome in schizophrenia. Here we consider the contributions of disturbances in glutamate, dopamine and GABA neurotransmission to the pathophysiology of working memory impairments in schizophrenia, suggest a cascade of molecular events that might link these disturbances, and argue that the molecular alterations most proximal to the pathophysiology of prefrontal dysfunction offer the most promise as targets for new drug development.	Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lewis, DA (corresponding author), Univ Pittsburgh, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	lewisda@upmc.edu	Lewis, David A/G-4053-2014	Lewis, David A/0000-0002-3225-6778; Gonzalez-Burgos, Guillermo/0000-0002-1650-8111	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH043784, R01MH043784, P50MH045156] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 045156, MH 043784, MH 051234] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abi-Dargham A, 2002, J NEUROSCI, V22, P3708, DOI 10.1523/jneurosci.22-09-03708.2002; Abi-Dargham A, 2003, NEUROSCIENTIST, V9, P404, DOI 10.1177/1073858403252674; Addington AM, 2005, MOL PSYCHIATR, V10, P581, DOI 10.1038/sj.mp.4001599; Adler CM, 1999, AM J PSYCHIAT, V156, P1646, DOI 10.1176/ajp.156.10.1646; Akbarian S, 1996, J NEUROSCI, V16, P19; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; Akbarian S, 2006, BRAIN RES REV, V52, P293, DOI 10.1016/j.brainresrev.2006.04.001; Akil M, 1999, AM J PSYCHIAT, V156, P1580, DOI 10.1176/ajp.156.10.1580; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barch DM, 2006, NEUROSCIENCE, V139, P73, DOI 10.1016/j.neuroscience.2005.09.013; Barch DM, 2003, BIOL PSYCHIAT, V53, P376, DOI 10.1016/S0006-3223(02)01674-8; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Callicott JH, 2003, AM J PSYCHIAT, V160, P2209, DOI 10.1176/appi.ajp.160.12.2209; Cannon TD, 2005, ARCH GEN PSYCHIAT, V62, P1071, DOI 10.1001/archpsyc.62.10.1071; Carlsson A, 2006, PHARMACOPSYCHIATRY, V39, pS10, DOI 10.1055/s-2006-931483; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Cho RY, 2005, SCHIZOPHRENIA BULL, V31, P450; Cochran SM, 2003, NEUROPSYCHOPHARMACOL, V28, P265, DOI 10.1038/sj.npp.1300031; Corfas G, 2004, NAT NEUROSCI, V7, P575, DOI 10.1038/nn1258; Coyle JT, 2004, BIOCHEM PHARMACOL, V68, P1507, DOI 10.1016/j.bcp.2004.07.034; Coyle JT, 2004, PSYCHOPHARMACOLOGY, V174, P32, DOI 10.1007/s00213-003-1709-2; Cunningham MO, 2006, J NEUROSCI, V26, P2767, DOI 10.1523/JNEUROSCI.5054-05.2006; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; Dracheva S, 2001, AM J PSYCHIAT, V158, P1400, DOI 10.1176/appi.ajp.158.9.1400; Dudkin K N, 2001, Neurosci Behav Physiol, V31, P207, DOI 10.1023/A:1005224610354; Durstewitz D, 2006, NEUROSCIENCE, V139, P119, DOI 10.1016/j.neuroscience.2005.06.094; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Elvevag B, 2000, CRIT REV NEUROBIOL, V14, P1; Flames N, 2004, NEURON, V44, P251, DOI 10.1016/j.neuron.2004.09.028; Gold JM, 2004, SCHIZOPHR RES, V72, P21, DOI 10.1016/j.schres.2004.09.008; Goldman-Rakic PS, 2004, PSYCHOPHARMACOLOGY, V174, P3, DOI 10.1007/s00213-004-1793-y; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; Gonzalez-Burgos G, 2005, J NEUROPHYSIOL, V94, P4168, DOI 10.1152/jn.00698.2005; Gonzalez-Burgos G, 2002, PHYSIOL BEHAV, V77, P537, DOI 10.1016/S0031-9384(02)00940-X; Green MF, 1996, AM J PSYCHIAT, V153, P321; Gulyas AI, 1999, J NEUROSCI, V19, P10082; Hahn CG, 2006, NAT MED, V12, P824, DOI 10.1038/nm1418; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Hashimoto T, 2003, J NEUROSCI, V23, P6315; Howard MW, 2003, CEREB CORTEX, V13, P1369, DOI 10.1093/cercor/bhg084; Huntley GW, 1997, BRAIN RES, V749, P245, DOI 10.1016/S0006-8993(96)00847-5; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; Hyman SE, 2003, SCIENCE, V299, P350, DOI 10.1126/science.1077141; Insel TR, 2006, MOL PSYCHIATR, V11, P11, DOI 10.1038/sj.mp.4001777; Jones EG, 1997, SCHIZOPHRENIA BULL, V23, P483, DOI 10.1093/schbul/23.3.483; Keefe RSE, 2005, BIOL PSYCHIAT, V57, P688, DOI 10.1016/j.biopsych.2005.01.003; Keilhoff G, 2004, NEUROSCIENCE, V126, P591, DOI 10.1016/j.neuroscience.2004.03.039; Kellendonk C, 2006, NEURON, V49, P603, DOI 10.1016/j.neuron.2006.01.023; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Konradi C, 2003, PHARMACOL THERAPEUT, V97, P153, DOI 10.1016/S0163-7258(02)00328-5; Kristiansen LV, 2006, MOL PSYCHIATR, V11, P737, DOI 10.1038/sj.mp.4001844; Kroner S, 2007, CEREB CORTEX, V17, P1020, DOI 10.1093/cercor/bhl012; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; Laruelle M., 2003, SCHIZOPHRENIA, P365; Law AJ, 2006, P NATL ACAD SCI USA, V103, P6747, DOI 10.1073/pnas.0602002103; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; Lewis DA, 2002, NEUROPSYCHOPHARMACOL, V26, P143, DOI 10.1016/S0893-133X(01)00393-1; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lewis DA, 2001, J COMP NEUROL, V432, P119, DOI 10.1002/cne.1092; LEWIS DA, IN PRESS ARCH NEUROL; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; MacDonald AW, 2005, AM J PSYCHIAT, V162, P475, DOI 10.1176/appi.ajp.162.3.475; Mann EO, 2005, J PHYSIOL-LONDON, V562, P55, DOI 10.1113/jphysiol.2004.078758; Melchitzky DS, 2003, CEREB CORTEX, V13, P452, DOI 10.1093/cercor/13.5.452; Meyer-Lindenberg A, 2006, MOL PSYCHIATR, V11, P867, DOI 10.1038/sj.mp.4001860; Millar JK, 2005, SCIENCE, V310, P1187, DOI 10.1126/science.1112915; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mirnics K, 2006, BIOL PSYCHIAT, V60, P163, DOI 10.1016/j.biopsych.2006.02.003; Moghaddam B, 2003, NEURON, V40, P881, DOI 10.1016/S0896-6273(03)00757-8; Muly EC, 1998, J NEUROSCI, V18, P10553; Munafo MR, 2006, MOL PSYCHIATR, V11, P539, DOI 10.1038/sj.mp.4001817; Narendran R, 2005, AM J PSYCHIAT, V162, P2352, DOI 10.1176/appi.ajp.162.12.2352; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Rao SG, 2000, J NEUROSCI, V20, P485, DOI 10.1523/JNEUROSCI.20-01-00485.2000; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Sawaguchi T, 2001, NEUROSCI RES, V41, P115, DOI 10.1016/S0168-0102(01)00270-X; SAWAGUCHI T, 1989, EXP BRAIN RES, V75, P457; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; Scherzer CR, 1998, J COMP NEUROL, V390, P75, DOI 10.1002/(SICI)1096-9861(19980105)390:1<75::AID-CNE7>3.0.CO;2-N; Sesack SR, 1998, CEREB CORTEX, V8, P614, DOI 10.1093/cercor/8.7.614; Sesack SR, 2002, PHYSIOL BEHAV, V77, P513, DOI 10.1016/S0031-9384(02)00931-9; Spencer KM, 2004, P NATL ACAD SCI USA, V101, P17288, DOI 10.1073/pnas.0406074101; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Tan HY, 2005, AM J PSYCHIAT, V162, P1849, DOI 10.1176/appi.ajp.162.10.1849; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Tosato S, 2005, SCHIZOPHRENIA BULL, V31, P613, DOI 10.1093/schbul/sbi043; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; Tsukada H, 2005, NEUROPSYCHOPHARMACOL, V30, P1861, DOI 10.1038/sj.npp.1300732; Tunbridge EM, 2004, J NEUROSCI, V24, P5331, DOI 10.1523/JNEUROSCI.1124-04.2004; Verma A, 1996, J NEUROSCI, V16, P373; Volk DW, 2001, AM J PSYCHIAT, V158, P256, DOI 10.1176/appi.ajp.158.2.256; Volk DW, 2002, CEREB CORTEX, V12, P1063, DOI 10.1093/cercor/12.10.1063; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; Wang XJ, 2006, PHARMACOPSYCHIATRY, V39, pS80, DOI 10.1055/s-2006-931501; Weickert CS, 2004, ARCH GEN PSYCHIAT, V61, P544, DOI 10.1001/archpsyc.61.6.544; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Whittington MA, 2003, TRENDS NEUROSCI, V26, P676, DOI 10.1016/j.tins.2003.09.016; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Woo TU, 1998, P NATL ACAD SCI USA, V95, P5341, DOI 10.1073/pnas.95.9.5341; Woo TUW, 2004, ARCH GEN PSYCHIAT, V61, P649, DOI 10.1001/archpsyc.61.7.649; Yau HJ, 2003, CEREB CORTEX, V13, P252, DOI 10.1093/cercor/13.3.252; Zaitsev AV, 2005, CEREB CORTEX, V15, P1178, DOI 10.1093/cercor/bhh218	107	255	258	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1016	1022		10.1038/nm1478	http://dx.doi.org/10.1038/nm1478			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16960576				2022-12-27	WOS:000240373900024
J	Bandyopadhyay, S; Zhan, R; Chaudhuri, A; Watabe, M; Pai, SK; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Takano, Y; Saito, K; Pauza, ME; Hayashi, S; Wang, Y; Mohinta, S; Mashimo, T; Iiizumi, M; Furuta, E; Watabe, K				Bandyopadhyay, Sucharita; Zhan, Rui; Chaudhuri, Asok; Watabe, Misako; Pai, Sudha K.; Hirota, Shigeru; Hosobe, Sadahiro; Tsukada, Taisei; Miura, Kunio; Takano, Yukio; Saito, Ken; Pauza, Mary E.; Hayashi, Sunao; Wang, Ying; Mohinta, Sonia; Mashimo, Tomoyuki; Iiizumi, Megumi; Furuta, Eiji; Watabe, Kounosuke			Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression	NATURE MEDICINE			English	Article							PROSTATE-CANCER; CHEMOKINE RECEPTOR; SENESCENCE; ANTIGEN; GENE; IDENTIFICATION; ACTIVATION; DEFICIENT; PROTEIN; SYSTEM	CD82, also known as KAI1, was recently identified as a prostate cancer metastasis suppressor gene on human chromosome 11p1.2 (ref. 1). The product of CD82 is KAI1, a 40- to 75-kDa tetraspanin cell-surface protein also known as the leukocyte cell-surface marker CD82 (refs. 1,2). Downregulation of KAI1 has been found to be clinically associated with metastatic progression in a variety of cancers, whereas overexpression of CD82 specifically suppresses tumor metastasis in various animal models(3). To define the mechanism of action of KAI1, we used a yeast two-hybrid screen and identified an endothelial cell-surface protein, DARC (also known as gp-Fy), as an interacting partner of KAI1. Our results indicate that the cancer cells expressing KAI1 attach to vascular endothelial cells through direct interaction between KAI1 and DARC, and that this interaction leads to inhibition of tumor cell proliferation and induction of senescence by modulating the expression of TBX2 and p21. Furthermore, the metastasis-suppression activity of KAI1 was significantly compromised in DARC knockout mice, whereas KAI1 completely abrogated pulmonary metastasis in wild-type and heterozygous littermates. These results provide direct evidence that DARC is essential for the function of CD82 as a suppressor of metastasis.	So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Akita Red Cross Hosp, Akita 0101495, Japan	Southern Illinois University System; Southern Illinois University; New York Blood Center; Akita Red Cross Hospital	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 801 N Rutledge St,POB 19626, Springfield, IL 62794 USA.	kwatabe@siumed.edu			NCI NIH HHS [5R01CA89438-03] Funding Source: Medline; PHS HHS [R15VS079473] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; AUSUBEL F, 2004, CURRENT PROTOCOLS MO, pCH13, DOI UNSP 13.6.1; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; IWAMOTO S, 1995, BLOOD, V85, P622, DOI 10.1182/blood.V85.3.622.bloodjournal853622; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; Luo H, 2000, MOL CELL BIOL, V20, P3097, DOI 10.1128/MCB.20.9.3097-3101.2000; Mannion BA, 1996, J IMMUNOL, V157, P2039; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Schwarze SR, 2005, NEOPLASIA, V7, P816, DOI 10.1593/neo.05250; Sigala S, 1999, CLIN CANCER RES, V5, P1211; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717	22	173	189	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					933	938		10.1038/nm1444	http://dx.doi.org/10.1038/nm1444			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862154				2022-12-27	WOS:000239626200024
J	Chattopadhyay, PK; Price, DA; Harper, TF; Betts, MR; Yu, J; Gostick, E; Perfetto, SP; Goepfert, P; Koup, RA; De Rosa, SC; Bruchez, MP; Roederer, M				Chattopadhyay, Pratip K.; Price, David A.; Harper, Theresa F.; Betts, Michael R.; Yu, Joanne; Gostick, Emma; Perfetto, Stephen P.; Goepfert, Paul; Koup, Richard A.; De Rosa, Stephen C.; Bruchez, Marcel P.; Roederer, Mario			Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; T-CELLS; LIVE CELLS; MEMORY; COMPENSATION; LYMPHOCYTES; ACTIVATION; EXPRESSION; PHENOTYPE; BLOOD	Immune responses arise from a wide variety of cells expressing unique combinations of multiple cell-surface proteins. Detailed characterization is hampered, however, by limitations in available probes and instrumentation. Here, we use the unique spectral properties of semiconductor nanocrystals (quantum dots) to extend the capabilities of polychromatic flow cytometry to resolve 17 fluorescence emissions. We show the need for this power by analyzing, in detail, the phenotype of multiple antigen-specific T-cell populations, revealing variations within complex phenotypic patterns that would otherwise remain obscure. For example, T cells specific for distinct epitopes from one pathogen, and even those specific for the same epitope, can have markedly different phenotypes. The technology we describe, encompassing the detection of eight quantum dots in conjunction with conventional fluorophores, should expand the horizons of flow cytometry, as well as our ability to characterize the intricacies of both adaptive and innate cellular immune responses.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Solus Biosyst, Palo Alto, CA 94303 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Carnegie Mellon Univ, Dept Chem & Technol, Ctr Networks & Pathways, Pittsburgh, PA 15213 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania; University of Oxford; University of Alabama System; University of Alabama Birmingham; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Carnegie Mellon University	Roederer, M (corresponding author), NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.	Roederer@nih.gov	Price, David A/C-7876-2013; Bruchez, Marcel P/C-2271-2009; Chattopadhyay, Pratip/B-9227-2008; Roederer, Mario/G-1887-2011	Price, David A/0000-0001-9416-2737; Bruchez, Marcel P/0000-0002-7370-4848; Chattopadhyay, Pratip/0000-0002-5457-9666	MRC [G108/441] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005013, Z01AI005020, Z01AI005021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000364] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; Medical Research Council [G108/441] Funding Source: Medline; NIBIB NIH HHS [R01 EB 000364] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amlot PL, 1996, CLIN EXP IMMUNOL, V105, P176, DOI 10.1046/j.1365-2249.1996.d01-722.x; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; CHATTOPADHYAY PK, 2005, CURRENT PROTOCOLS IM; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; Diamond DJ, 1997, BLOOD, V90, P1751, DOI 10.1182/blood.V90.5.1751; Goldman ER, 2005, METH MOL B, V303, P19; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hotz CZ, 2005, METH MOL B, V303, P1; Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Perfetto Stephen P, 2004, Methods Mol Biol, V263, P419; PLAEGERMARSHALL S, 1993, J ACQ IMMUN DEF SYND, V6, P984; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Rieger S, 2005, DEV DYNAM, V234, P670, DOI 10.1002/dvdy.20524; Roederer M, 2001, CYTOMETRY, V46, P357, DOI 10.1002/cyto.10008; Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C; ROWLANDJONES SL, 1993, EUR J IMMUNOL, V23, P1999, DOI 10.1002/eji.1830230841; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Scotet E, 1996, J EXP MED, V184, P1791, DOI 10.1084/jem.184.5.1791; Sing G, 1998, J VIRAL HEPATITIS, V5, P83, DOI 10.1046/j.1365-2893.1998.00088.x	29	290	310	0	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					972	977		10.1038/nm1371	http://dx.doi.org/10.1038/nm1371			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862156				2022-12-27	WOS:000239626200031
J	Machado, FS; Johndrow, JE; Esper, L; Dias, A; Bafica, A; Serhan, CN; Aliberti, J				Machado, FS; Johndrow, JE; Esper, L; Dias, A; Bafica, A; Serhan, CN; Aliberti, J			Anti-inflammatory actions of lipoxin A(4) and aspirin-triggered lipoxin are SOCS-2 dependent	NATURE MEDICINE			English	Article							IL-12 PRODUCTION; NEUTROPHIL RECRUITMENT; INFLAMMATION; RECEPTOR; IMMUNOPATHOLOGY; TRAFFICKING; RESOLUTION; MEDIATORS; INFECTION; ANALOG	Control of inflammation is crucial to prevent damage to the host during infection. Lipoxins and aspirin-triggered lipoxins are crucial modulators of proinflammatory responses; however, their intracellular mechanisms have not been completely elucidated. We previously showed that lipoxin A(4) (LXA(4)) controls migration of dendritic cells (DCs) and production of interleukin (IL)-12 in vivo(1). In the absence of LXA(4) biosynthetic pathways, the resulting uncontrolled inflammation during infection is lethal, despite pathogen clearance(2). Here we show that lipoxins activate two receptors in DCs, AhR and LXAR, and that this activation triggers expression of suppressor of cytokine signaling (SOCS)-2. SOCS-2-deficient DCs are hyper-responsive to microbial stimuli, as well as refractory to the inhibitory actions of LXA(4), but not to IL-10. Upon infection with an intracellular pathogen, SOCS-2-deficient mice had uncontrolled production of proinflammatory cytokines, decreased microbial proliferation, aberrant leukocyte infiltration and elevated mortality. We also show that SOCS-2 is a crucial intracellular mediator of the anti-inflammatory actions of aspirin-induced lipoxins in vivo.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27705 USA; NIAID, Lab Parasit Dis, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Inst, Seattle, WA 98109 USA; Fd Osvaldo Cruz, Lab Imunorregulacao, BR-40295 Salvador, BA, Brazil; Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut, Boston, MA 02115 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital	Aliberti, J (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27705 USA.	fabiana.machado@duke.edu; julio.aliberti@duke.edu	Aliberti, Julio/I-7354-2013; Aliberti, Julio/G-4565-2012; Bafica, Andre/ABF-5986-2020	Aliberti, Julio/0000-0003-3420-8478; Bafica, Andre/0000-0002-5148-600X; Simao Machado, Fabiana/0000-0001-9272-5209	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NIDCR NIH HHS [P50-DE0161912] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; Goh J, 2003, GASTROENTEROLOGY, V124, P1043, DOI 10.1053/gast.2003.50154; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091; Qiu FH, 2001, FASEB J, V15, P2736, DOI 10.1096/fj.01-0576fje; RAMSTEDT U, 1985, J IMMUNOL, V135, P3434; SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Sousa CRE, 1999, IMMUNITY, V11, P637, DOI 10.1016/S1074-7613(00)80138-7; Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202	23	245	255	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					330	334		10.1038/nm1355	http://dx.doi.org/10.1038/nm1355			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16415877				2022-12-27	WOS:000235802900033
J	Teague, RM; Sather, BD; Sacks, JA; Huang, MZ; Dossett, ML; Morimoto, J; Tan, XX; Sutton, SE; Cooke, MP; Ohlen, C; Greenberg, PD				Teague, RM; Sather, BD; Sacks, JA; Huang, MZ; Dossett, ML; Morimoto, J; Tan, XX; Sutton, SE; Cooke, MP; Ohlen, C; Greenberg, PD			Interleukin-15 rescues tolerant CD8(+) T cells for use in adoptive immunotherapy of established tumors	NATURE MEDICINE			English	Article							HEPATITIS-B-VIRUS; IMMUNOLOGICAL SYNAPSE; CANCER-IMMUNOTHERAPY; BETA-CHAIN; IN-VIVO; MEMORY; ANTIGEN; EFFECTOR; EXPRESSION; IL-15	CD8(+) T cells can mediate eradication of established tumors, and strategies to amplify tumor-reactive T-cell numbers by immunization or ex vivo expansion followed by adoptive transfer are currently being explored in individuals with cancer(1-3). Generating effective CD8(+) T cell-mediated responses to tumors is often impeded by T-cell tolerance to relevant tumor antigens, as most of these antigens are also expressed in normal tissues. We examined whether such tolerant T cells could be rescued and functionally restored for use in therapy of established tumors. We used a transgenic T-cell receptor (TCR) mouse model in which peripheral CD8(+) T cells specific for a candidate tumor antigen also expressed in liver are tolerant, failing to proliferate or secrete interleukin (IL)-2 in response to antigen(4). Molecular and cellular analysis showed that these tolerant T cells expressed the IL-15 receptor alpha chain, and could be induced to proliferate in vitro in response to exogenous IL-15. Such proliferation abrogated tolerance and the rescued cells became effective in treating leukemia. Therefore, high-affinity CD8(+) T cells are not necessarily deleted by encounter with self-antigen in the periphery, and can potentially be rescued and expanded for use in tumor immunotherapy.	Univ Washington, Sch Med, Dept Immunol, HSC Off H 564, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Immunol, Seattle, WA 98109 USA; Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Novartis	Greenberg, PD (corresponding author), Univ Washington, Sch Med, Dept Immunol, HSC Off H 564, Box 357650, Seattle, WA 98195 USA.	pgreen@washington.edu	Dossett, Michelle/U-1166-2019	Teague, Ryan/0000-0002-8426-2870; Huang, Maria/0000-0001-6881-4754	NATIONAL CANCER INSTITUTE [R01CA033084, R37CA033084, P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA33084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; DESILVA DR, 1991, J IMMUNOL, V147, P3261; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Dumortier H, 2005, J IMMUNOL, V175, P855, DOI 10.4049/jimmunol.175.2.855; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; GREENBERG PD, 1984, J IMMUNOL, V133, P3401; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Kershaw MH, 2005, NAT REV IMMUNOL, V5, P928, DOI 10.1038/nri1729; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Oh S, 2004, P NATL ACAD SCI USA, V101, P15154, DOI 10.1073/pnas.0406649101; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Ohlen C, 2001, J IMMUNOL, V166, P2863, DOI 10.4049/jimmunol.166.4.2863; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Redmond WL, 2005, IMMUNITY, V22, P275, DOI 10.1016/j.immuni.2005.01.010; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rosenberg SA, 2004, P NATL ACAD SCI USA, V101, P14639, DOI 10.1073/pnas.0405730101; Scherer A, 2003, BIOTECHNIQUES, V34, P546, DOI 10.2144/03343rr01; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Vamosi G, 2004, P NATL ACAD SCI USA, V101, P11082, DOI 10.1073/pnas.0403916101; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; WIRTH S, 1995, J IMMUNOL, V154, P2504; Wolint P, 2004, J EXP MED, V199, P925, DOI 10.1084/jem.20031799; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zippelius A, 2004, CANCER RES, V64, P2865, DOI 10.1158/0008-5472.CAN-03-3066	35	189	208	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					335	341		10.1038/nm1359	http://dx.doi.org/10.1038/nm1359			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474399				2022-12-27	WOS:000235802900034
J	Folgori, A; Capone, S; Ruggeri, L; Meola, A; Sporeno, E; Ercole, BB; Pezzanera, M; Tafi, R; Arcuri, M; Fattori, E; Lahm, A; Luzzago, A; Vitelli, A; Colloca, S; Cortese, R; Nicosia, A				Folgori, A; Capone, S; Ruggeri, L; Meola, A; Sporeno, E; Ercole, BB; Pezzanera, M; Tafi, R; Arcuri, M; Fattori, E; Lahm, A; Luzzago, A; Vitelli, A; Colloca, S; Cortese, R; Nicosia, A			A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; VIRAL CLEARANCE; INFECTION; RESPONSES; PERSISTENCE; ADENOVIRUS; GENE; DETERMINANTS; IMMUNIZATION; PREVALENCE	Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus. Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8(+) T lymphocytes that cross-reacted with vaccine and virus epitopes. These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Merck & Company	Nicosia, A (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30,600, I-00040 Rome, Italy.	alfredo_nicasia@merck.com	Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Capone, Stefania/0000-0002-2272-120X				Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X; Aste-Amezaga M, 2004, HUM GENE THER, V15, P293, DOI 10.1089/104303404322886147; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Bassett SE, 1998, J VIROL, V72, P2589, DOI 10.1128/JVI.72.4.2589-2599.1998; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; CAPONE S, IN PRESS J VIROL; Casimiro DR, 2004, J VIROL, V78, P11434, DOI 10.1128/JVI.78.20.11434-11438.2004; Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Forns X, 2000, HEPATOLOGY, V32, P618, DOI 10.1053/jhep.2000.9877; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Guglietta S, 2005, EUR J IMMUNOL, V35, P2627, DOI 10.1002/eji.200526067; Houghton M, 2005, NATURE, V436, P961, DOI 10.1038/nature04081; Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Lanford RE, 2004, J VIROL, V78, P1575, DOI 10.1128/JVI.78.3.1575-1581.2004; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Major ME, 2004, HEPATOLOGY, V39, P1709, DOI 10.1002/hep.20239; Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Palitzsch KD, 1999, EUR J GASTROEN HEPAT, V11, P1215, DOI 10.1097/00042737-199911000-00005; Post JJ, 2004, J INFECT DIS, V189, P1846, DOI 10.1086/383279; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Puig M, 2004, VACCINE, V22, P991, DOI 10.1016/j.vaccine.2003.09.010; Riestra S, 2001, EUR J GASTROEN HEPAT, V13, P477, DOI 10.1097/00042737-200105000-00003; Rollier C, 2004, J VIROL, V78, P187, DOI 10.1128/JVI.78.1.187-196.2004; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239; Spada E, 2004, GUT, V53, P1673, DOI 10.1136/gut.2003.037788; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447; Zampaglione I, 2005, J GENE MED, V7, P1475, DOI 10.1002/jgm.774; Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000	45	243	269	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					190	197		10.1038/nm1353	http://dx.doi.org/10.1038/nm1353			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462801				2022-12-27	WOS:000235160600023
J	LaVoie, MJ; Ostaszewski, BL; Weihofen, A; Schlossmacher, MG; Selkoe, DJ				LaVoie, MJ; Ostaszewski, BL; Weihofen, A; Schlossmacher, MG; Selkoe, DJ			Dopamine covalently modifies and functionally inactivates parkin	NATURE MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; REDOX-CYCLING QUINOPROTEIN; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; TYROSINE-HYDROXYLASE; SYNAPTIC VESICLES; UBIQUITIN LIGASE; S-NITROSYLATION; DISEASE; MUTATIONS	Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease.	Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	LaVoie, MJ (corresponding author), Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, 77 Ave Louis Pasteur,HIM 7th Floor, Boston, MA 02115 USA.	mlavoie@rics.bwh.harvard.edu	Weihofen, Andreas/A-1566-2011	Schlossmacher, Michael/0000-0002-0394-0300; LaVoie, Matthew/0000-0002-2583-1578; Weihofen, Andreas/0000-0001-6265-9087	NINDS NIH HHS [NS38375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Berman SB, 1996, J NEUROCHEM, V67, P593; Berman SB, 1997, J NEUROCHEM, V69, P1185; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Cheng FC, 1996, J NEURAL TRANSM, V103, P433, DOI 10.1007/BF01276419; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2003, HUM MOL GENET, V12, P2957, DOI 10.1093/hmg/ddg328; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dong ZZ, 2003, P NATL ACAD SCI USA, V100, P12438, DOI 10.1073/pnas.2132992100; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; Hilker R, 2002, NEUROSCI LETT, V323, P50, DOI 10.1016/S0304-3940(01)02529-0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; JIANG H, 2004, HUM MOL GENET; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kuhn DM, 1998, J NEUROSCI, V18, P7111; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LaVoie MJ, 1999, J NEUROCHEM, V73, P2546, DOI 10.1046/j.1471-4159.1999.0732546.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Pramstaller PP, 2005, ANN NEUROL, V58, P411, DOI 10.1002/ana.20587; ROSENGREN E, 1985, J NEURAL TRANSM, V63, P247, DOI 10.1007/BF01252029; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; SRIRAM SR, 2005, HUM MOL GENET; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; SULZER D, 1995, J NEUROSCI, V15, P4102; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Wilson MA, 2004, P NATL ACAD SCI USA, V101, P1531, DOI 10.1073/pnas.0308089100; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Xu YM, 1998, J NEUROSCI RES, V54, P691, DOI 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F; Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zucca FA, 2004, PIGM CELL RES, V17, P610, DOI 10.1111/j.1600-0749.2004.00201.x	50	553	573	2	195	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2005	11	11					1214	1221		10.1038/nm1314	http://dx.doi.org/10.1038/nm1314			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227987				2022-12-27	WOS:000233115400034
J	Jeffreys, AJ				Jeffreys, AJ			Genetic fingerprinting	NATURE MEDICINE			English	Editorial Material							DNA; GLOBIN; REPEAT; MINISATELLITES; IDENTIFICATION; AMPLIFICATION; REGIONS		Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Leicester	Jeffreys, AJ (corresponding author), Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England.	ajj@le.ac.uk	Schneider, Peter M./A-6661-2011					BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; Dubrova YE, 2002, ADV EXP MED BIOL, V518, P115; EDWARDS A, 1991, AM J HUM GENET, V49, P746; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; GOODBOURN SEY, 1983, P NATL ACAD SCI-BIOL, V80, P5022, DOI 10.1073/pnas.80.16.5022; Jeffreys A, 1999, ELECTROPHORESIS, V20, P1665, DOI 10.1002/(SICI)1522-2683(19990101)20:8<1665::AID-ELPS1665>3.0.CO;2-L; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; JEFFREYS AJ, 1985, NATURE, V317, P818, DOI 10.1038/317818a0; JEFFREYS AJ, 1992, FORENSIC SCI INT, V56, P65, DOI 10.1016/0379-0738(92)90148-P; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Jobling MA, 2004, NAT REV GENET, V5, P739, DOI 10.1038/nrg1455; Jobling MA, 2001, TRENDS GENET, V17, P353, DOI 10.1016/S0168-9525(01)02284-3; Kauppi L, 2004, NAT REV GENET, V5, P413, DOI 10.1038/nrg1346; KIMPTON CP, 1993, PCR METH APPL, V3, P13; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LITT M, 1989, AM J HUM GENET, V44, P397; SIGNER EN, 1994, MOL ECOL, V3, P291, DOI 10.1111/j.1365-294X.1994.tb00069.x; Signer EN, 1998, NATURE, V394, P329, DOI 10.1038/28524; vanOorschot RAH, 1997, NATURE, V387, P767, DOI 10.1038/42838; Wambaugh J., 1989, BLOODING; WEBER JL, 1989, AM J HUM GENET, V44, P388; WETTON JH, 1987, NATURE, V327, P147, DOI 10.1038/327147a0; Williamson R, 2002, NATURE, V418, P585, DOI 10.1038/418585a; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754	28	20	22	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1035	1039		10.1038/nm1005-1035	http://dx.doi.org/10.1038/nm1005-1035			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211029				2022-12-27	WOS:000232492500015
J	Buitrago, M; Lorenz, K; Maass, AH; Maass, SO; Keller, U; Schmitteckert, EM; Ivashchenko, Y; Lohse, MJ; Engelhardt, S				Buitrago, M; Lorenz, K; Maass, AH; Maass, SO; Keller, U; Schmitteckert, EM; Ivashchenko, Y; Lohse, MJ; Engelhardt, S			The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy	NATURE MEDICINE			English	Article							NGFI-A EGR-1; IN-VIVO; THERAPEUTIC TARGET; SIGNALING PATHWAYS; HEART-FAILURE; CALCINEURIN; GENE; MICE; INHIBITION; PROTEIN	Hypertrophy represents the major physiological response of the heart to adapt to chronically enhanced workload, but is also crucial in the development of heart failure. Although we know of numerous inducers of cardiac hypertrophy, little is known about mechanisms that limit cardiac hypertrophy. Here, we describe the transcriptional repressor NAB1 as an endogenous regulator of cardiac growth. We identified NAB1 as being upregulated in both mouse and human heart failure. Nab1 is highly expressed in mammalian cardiac myocytes and it inhibited cardiomyocyte hypertrophy through repression of its targets, transcription factor Egr. Transgenic mice with cardiac-specific overexpression of Nab1 showed that Nab1 is a potent inhibitor of cardiac growth in response to pathological stimuli in vivo. Nab1 overexpression suppressed adrenergically induced and pressure overload-induced hypertrophy, whereas physiological growth during development and in response to exercise was not affected. These findings implicate the Nab1-Egr1 axis as a crucial regulator of pathological cardiac growth.	Univ Wurzburg, Rudolf Virchow Ctr, DFG, Res Ctr Expt Biomed, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany; Sanofi Aventis, Div Cardiovasc, D-65926 Frankfurt, Germany	German Research Foundation (DFG); University of Wurzburg; University of Wurzburg; University of Wurzburg; Sanofi-Aventis	Engelhardt, S (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr, DFG, Res Ctr Expt Biomed, Versbacher Str 9, D-97078 Wurzburg, Germany.	stefan.engelhardt@virchow.uni-wuerzburg.de	Engelhardt, Stefan/AAA-9329-2019; Lohse, Martin J/A-7160-2012; Maass, Alexander/B-8534-2008; Lorenz, Kristina/F-3522-2016	Engelhardt, Stefan/0000-0001-5378-8661; Lohse, Martin J/0000-0002-0599-3510; Maass, Alexander/0000-0002-7936-360X; Lorenz, Kristina/0000-0002-5747-2207				Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Buvoli M, 2002, METHOD ENZYMOL, V346, P134; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NEYSES L, 1991, BIOCHEM BIOPH RES CO, V181, P22, DOI 10.1016/S0006-291X(05)81376-2; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Rapacciuolo A, 2001, J AM COLL CARDIOL, V38, P876, DOI 10.1016/S0735-1097(01)01433-4; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Yasukawa H, 2003, J CLIN INVEST, V111, P469, DOI 10.1172/JCI200316491; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	35	95	104	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					837	844		10.1038/nm1272	http://dx.doi.org/10.1038/nm1272			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16025126				2022-12-27	WOS:000230964700028
J	Schubert, C				Schubert, C			Healing brain hemorrhage	NATURE MEDICINE			English	News Item								Investigators introduce a targeted treatment for intracerebral hemorrhage, a recombinant form of a molecule that promotes clotting. Recombinant activated factor VIIa (rFVIIa), which is used to treat hemophilia improved survival of patients. The investigators report that the area affected by bleeding was smallerin the patients treated with the drug.										Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-27	WOS:000228180500025
J	Zhu, DC; Kepley, CL; Zhang, K; Terada, T; Yamada, T; Saxon, A				Zhu, DC; Kepley, CL; Zhang, K; Terada, T; Yamada, T; Saxon, A			A chimeric human-cat fusion protein blocks cat-induced allergy	NATURE MEDICINE			English	Article							FC-EPSILON-RI; MAST-CELL ACTIVATION; AFFINITY IGE RECEPTOR; GAMMA-RII; NEGATIVE REGULATION; PHOSPHATASE SHIP; BASOPHILS; IDENTIFICATION; DEGRANULATION; ANAPHYLAXIS	Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a chimeric human-cat fusion protein composed of a truncated human IgG Fc gamma 1 and the major cat allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fc gamma-Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. Such inhibition was associated with altered Syk and ERK signaling. The Fc gamma-Fel d1 protein also blocked in vivo reactivity in Fc epsilon RI alpha transgenic mice passively sensitized with human IgE antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fc gamma-Fel d1 protein alone did not induce mediator release. Chimeric human Fc gamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.	Univ Calif Los Angeles, Sch Med, Dept Med,Div Clin Immunol Allergy, Hart & Louise Lyon Lab, Los Angeles, CA 90095 USA; Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Virginia Commonwealth University	Zhu, DC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med,Div Clin Immunol Allergy, Hart & Louise Lyon Lab, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	dczhu@ucla.edu; asaxon@mednet.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, R01AI015251] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15251, R01 AI015251-24, R01 AI015251-25, R01 AI015251-26] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Malbec O, 1998, J IMMUNOL, V160, P1647; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; Suzuki H, 1997, J IMMUNOL, V159, P5881; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; Wedi B, 1996, ARCH DERMATOL RES, V289, P21, DOI 10.1007/s004030050147; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	28	163	175	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					446	449		10.1038/nm1219	http://dx.doi.org/10.1038/nm1219			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793580				2022-12-27	WOS:000228180500038
J	Conrad, C; Boyman, O; Tonel, G; Tun-Kyi, A; Laggner, U; de Fougerolles, A; Kotelianski, V; Gardner, H; Nestle, FO				Conrad, Curdin; Boyman, Onur; Tonel, Giulia; Tun-Kyi, Adrian; Laggner, Ute; de Fougerolles, Antonin; Kotelianski, Victor; Gardner, Humphrey; Nestle, Frank O.			alpha(1)beta(1) integrin is crucial for accumulation of epidermal T cells and the development of psoriasis	NATURE MEDICINE			English	Article							ALPHA-1-BETA-1 INTEGRIN; EXPRESSION; RESIDENT; LYMPHOCYTES; INDUCTION; MAJORITY; LESIONS; MEMORY; ALPHA; VLA-1	Psoriasis is a common T cell-mediated autoimmune inflammatory disease. We show that blocking the interaction of alpha(1)beta(1) integrin (VLA-1) with collagen prevented accumulation of epidermal T cells and immunopathology of psoriasis. alpha(1)beta(1) integrin, a major collagen-binding surface receptor, was exclusively expressed by epidermal but not dermal T cells. alpha(1)beta(1)-positive T cells showed characteristic surface markers of effector memory cells and contained high levels of interferon-gamma but not interleukin-4. Blockade of alpha(1)beta(1) inhibited migration of T cells into the epidermis in a clinically relevant xenotransplantation model. This was paralleled by a complete inhibition of psoriasis development, comparable to that caused by tumor necrosis factor-alpha blockers. These results define a crucial role for alpha(1)beta(1) in controlling the accumulation of epidermal type 1 polarized effector memory T cells in a common human immunopathology and provide the basis for new strategies in psoriasis treatment focusing on T cell-extracellular matrix interactions.	Kings Coll London, Sch Med, Guys Hosp, St Johns Inst Dermatol,Div Genet & Mol Med, London SE1 9RT, England; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Biogen Inc, Cambridge Ctr, Cambridge, MA 02142 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Zurich; University Zurich Hospital; Biogen	Nestle, FO (corresponding author), Kings Coll London, Sch Med, Guys Hosp, St Johns Inst Dermatol,Div Genet & Mol Med, Floor 8 Guys Tower,St Thomas St, London SE1 9RT, England.	curdin.conrad@usz.ch; frank.nestle@kcl.ac.uk		Boyman, Onur/0000-0001-8279-5545; Conrad, Curdin/0000-0002-2547-3440	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; BAKER BS, 1984, BRIT J DERMATOL, V110, P555; Ben-Horin S, 2004, CLIN IMMUNOL, V113, P119, DOI 10.1016/j.clim.2004.06.007; BOEHNCKE WH, 1992, J AM ACAD DERMATOL, V26, P907, DOI 10.1016/0190-9622(92)70131-X; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Boyman O, 2005, BRIT J DERMATOL, V152, P1211, DOI 10.1111/j.1365-2133.2005.06701.x; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Boyman O, 2007, TRENDS IMMUNOL, V28, P51, DOI 10.1016/j.it.2006.12.005; Chamian F, 2005, P NATL ACAD SCI USA, V102, P2075, DOI 10.1073/pnas.0409569102; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; CHRISTOPHERS E, 1973, BRIT J DERMATOL, V89, P327; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; de Fougerolles AR, 2003, MOL B INT U, P165; Fiorucci S, 2002, IMMUNITY, V17, P769, DOI 10.1016/S1074-7613(02)00476-4; FRAKI JE, 1983, J INVEST DERMATOL, V80, pS31, DOI 10.1111/1523-1747.ep12537053; Ghohestani RF, 2001, CLIN DERMATOL, V19, P551, DOI 10.1016/S0738-081X(00)00175-9; Goldstein I, 2003, J CLIN INVEST, V112, P1444, DOI 10.1172/JCI200319607; Gotwals PJ, 1999, BIOCHEMISTRY-US, V38, P8280, DOI 10.1021/bi982860m; Griffiths CEM, 1996, J ROY SOC MED, V89, P315, DOI 10.1177/014107689608900604; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Krueger JG, 2005, ANN RHEUM DIS, V64, P30, DOI 10.1136/ard.2004.031120; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Nestle FO, 2005, J INVEST DERMATOL, V125, pXIV, DOI 10.1111/j.0022-202X.2005.23923.x; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; Ragaz A, 1979, Am J Dermatopathol, V1, P199, DOI 10.1097/00000372-197900130-00002; Ray SJ, 2004, IMMUNITY, V20, P167, DOI 10.1016/S1074-7613(04)00021-4; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Selin LK, 2004, NAT MED, V10, P343, DOI 10.1038/nm0404-343; Teraki Y, 2002, BRIT J DERMATOL, V147, P1118, DOI 10.1046/j.1365-2133.2002.05005.x	39	187	193	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					836	842		10.1038/nm1605	http://dx.doi.org/10.1038/nm1605			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17603494				2022-12-27	WOS:000247902800030
J	Rakhit, R; Robertson, J; Vande Velde, C; Horne, P; Ruth, DM; Griffin, J; Cleveland, DW; Cashman, NR; Chakrabartty, A				Rakhit, Rishi; Robertson, Janice; Vande Velde, Christine; Horne, Patrick; Ruth, Deborah M.; Griffin, Jennifer; Cleveland, Don W.; Cashman, Neil R.; Chakrabartty, Avijit			An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MUTANT SUPEROXIDE DISMUTASE-1; MOTOR-NEURON DEGENERATION; CU,ZN-SUPEROXIDE DISMUTASE; MITOCHONDRIA; SUPEROXIDE-DISMUTASE-1; INDUCTION; DISEASE; ACCUMULATION; AGGREGATION	Misfolding of Cu/Zn-superoxide dismutase (SOD1) is emerging as a mechanism underlying motor neuron degeneration in individuals with amyotrophic lateral sclerosis (ALS) who carry a mutant SOD1 gene (SOD1 ALS). Here we describe a structure-guided approach to developing an antibody that specifically recognizes monomer-misfolded forms of SOD1. We raised this antibody to an epitope that is normally buried in the SOD1 native homodimer interface. The SOD1 exposed dimer interface (SEDI) antibody recognizes only those SOD1 conformations in which the native dimer is disrupted or misfolded and thereby exposes the hydrophobic dimer interface. Using the SEDI antibody, we established the presence of monomer-misfolded SOD1 in three ALS mouse models, with G37R, G85R and G93A SOD1 mutations, and in a human individual with an A4V SOD1 mutation. Despite ubiquitous expression, misfolded SOD1 was found primarily within degenerating motor neurons. Misfolded SOD1 appeared before the onset of symptoms and decreased at the end stage of the disease, concomitant with motor neuron loss.	Univ Toronto, Dept Biochem, Toronto, ON M5G 1L7, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada; Ontario Canc Inst, Toronto, ON M5G 1L7, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 3H2, Canada; Univ Calif San Diego, La Jolla, CA 92093 USA; Ludwig Inst Canc Res, La Jolla, CA 92093 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of California System; University of California San Diego; Ludwig Institute for Cancer Research	Chakrabartty, A (corresponding author), Univ Toronto, Dept Biochem, 101 Coll St, Toronto, ON M5G 1L7, Canada.	chakrab@uhnres.utoronto.ca	Vande Velde, Christine/F-2721-2016; Velde, Christine Vande/AAB-8828-2020; Cleveland, Don/AAN-9783-2021	Vande Velde, Christine/0000-0001-5926-1529; Cleveland, Don/0000-0002-1934-3682; Chakrabartty, Avi/0000-0001-7002-8381				Atkin JD, 2006, J BIOL CHEM, V281, P30152, DOI 10.1074/jbc.M603393200; Batulan Z, 2003, J NEUROSCI, V23, P5789; Bergemalm D, 2006, J NEUROSCI, V26, P4147, DOI 10.1523/JNEUROSCI.5461-05.2006; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Higgins CMJ, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-16; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Majoor-Krakauer D, 2003, CLIN GENET, V63, P83, DOI 10.1046/j.0009-9163.2002.00001.x; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Tiwari A, 2005, J BIOL CHEM, V280, P29771, DOI 10.1074/jbc.M504039200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x	30	179	191	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2007	13	6					754	759		10.1038/nm1559	http://dx.doi.org/10.1038/nm1559			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17486090				2022-12-27	WOS:000247084300041
J	Kanzler, H; Barrat, FJ; Hessel, EM; Coffman, RL				Kanzler, Holger; Barrat, Franck J.; Hessel, Edith M.; Coffman, Robert L.			Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists	NATURE MEDICINE			English	Review							PLASMACYTOID DENDRITIC CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEPATITIS-B-VACCINE; NF-KAPPA-B; CPG-OLIGODEOXYNUCLEOTIDES; AIRWAY INFLAMMATION; TRANSLATING INNATE; MURINE MODEL; T-CELLS; RECOGNITION	The identification of the antigen recognition receptors for innate immunity, most notably the Toll-like receptors, has sparked great interest in therapeutic manipulation of the innate immune system. Toll-like receptor agonists are being developed for the treatment of cancer, allergies and viral infections, and as adjuvants for potent new vaccines to prevent or treat cancer and infectious diseases. As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well.	Dynavax Technol, Albany, CA 94710 USA		Kanzler, H (corresponding author), Dynavax Technol, 2929 7th St,Suite 100, Albany, CA 94710 USA.	rcoffman@dynavax.com	Hessel, Edith M/AAB-6002-2021	Hessel, Edith M/0000-0002-2339-4482				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Amlie-Lefond C, 2005, J ALLERGY CLIN IMMUN, V116, P1334, DOI 10.1016/j.jaci.2005.08.048; Baccala R, 2007, NAT MED, V13, P543, DOI 10.1038/nm1590; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029; Boasso A, 2007, BLOOD, V109, P3351, DOI 10.1182/blood-2006-07-034785; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011; Chang YC, 2005, SOUTH MED J, V98, P914, DOI 10.1097/01.SMJ.0000176712.01491.98; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Coffman RL, 2005, J EXP MED, V201, P1875, DOI 10.1084/jem.20050901; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Datta SK, 2004, IMMUNOL REV, V199, P217, DOI 10.1111/j.0105-2896.2004.00149.x; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dupont J, 2006, VACCINE, V24, P7167, DOI 10.1016/j.vaccine.2006.06.053; Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219; Fanucchi MV, 2004, AM J RESP CRIT CARE, V170, P1153, DOI 10.1164/rccm.200404-533OC; Fletcher S, 2006, CURR OPIN INVESTIG D, V7, P702; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; Gekeler V, 2006, OLIGONUCLEOTIDES, V16, P83, DOI 10.1089/oli.2006.16.83; Halperin SA, 2006, VACCINE, V24, P20, DOI 10.1016/j.vaccine.2005.08.095; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; Hodi FS, 2006, ADV IMMUNOL, V90, P341, DOI 10.1016/S0065-2776(06)90009-1; Hoebe K, 2006, CURR PHARM DESIGN, V12, P4123, DOI 10.2174/138161206778743466; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; Hornef MW, 2005, J ENDOTOXIN RES, V11, P124, DOI 10.1179/096805105X35224; Horner AA, 2004, CURR OPIN ALLERGY CL, V4, P555, DOI 10.1097/00130832-200412000-00014; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jahrsdorfer B, 2005, J LEUKOCYTE BIOL, V77, P378, DOI 10.1189/jlb.0604373; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Janeway CA, 2001, P NATL ACAD SCI USA, V98, P7461, DOI 10.1073/pnas.131202998; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Krieg AM, 2004, J IMMUNOTHER, V27, P460, DOI 10.1097/00002371-200411000-00006; Krieg Arthur M, 2004, Curr Oncol Rep, V6, P88, DOI 10.1007/s11912-004-0019-0; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Larche M, 2006, CURR OPIN IMMUNOL, V18, P745, DOI 10.1016/j.coi.2006.09.013; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lenert PS, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1888; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Marshall JD, 2004, CELL IMMUNOL, V229, P93, DOI 10.1016/j.cellimm.2004.04.009; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Moisan J, 2006, AM J PHYSIOL-LUNG C, V290, pL987, DOI 10.1152/ajplung.00440.2005; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rast JP, 2006, SCIENCE, V314, P952, DOI 10.1126/science.1134301; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; Ronnblom L, 2003, ARTHRITIS RES THER, V5, P68, DOI 10.1186/ar625; Rossignol Daniel P, 2005, Curr Opin Investig Drugs, V6, P496; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Sansonetti PJ, 2006, NAT IMMUNOL, V7, P1237, DOI 10.1038/ni1420; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880; Tayyari F, 2005, EUR RESPIR J, V25, P295, DOI 10.1183/09031936.05.00016304; TOMAI MA, 2006, DRUG DISCOV TODAY TH, V3, P342; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Van Ghelue M, 2003, J AUTOIMMUN, V20, P171, DOI 10.1016/S0896-8411(02)00110-5; Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Yarovinsky F, 2006, IMMUNITY, V25, P655, DOI 10.1016/j.immuni.2006.07.015; Zaks K, 2006, J IMMUNOL, V176, P7335, DOI 10.4049/jimmunol.176.12.7335	96	676	802	2	93	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					552	559		10.1038/nm1589	http://dx.doi.org/10.1038/nm1589			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17479101				2022-12-27	WOS:000246302800021
J	Ginsberg, AM; Spigelman, M				Ginsberg, Ann M.; Spigelman, Melvin			Challenges in tuberculosis drug research and development	NATURE MEDICINE			English	Editorial Material							PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; IDENTIFICATION; MOXIFLOXACIN; CANDIDATE; THERAPY; SQ109		Global Alliance TB Drug Dev, New York, NY USA		Ginsberg, AM (corresponding author), Global Alliance TB Drug Dev, New York, NY USA.	ann.ginsberg@tballiance.org						Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; [Anonymous], 1948, BMJ-BRIT MED J, V2, P769; ARORA S, 2004, INT UN TB LUNG DIS N; Barry C, 2001, TUBERCULOSIS, V81, P1, DOI 10.1054/tube.2001.0288; Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8; Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC; Chen P, 2006, J ANTIMICROB CHEMOTH, V58, P332, DOI 10.1093/jac/dkl227; DANIELS M, 1952, BRIT MED J, V1, P1162, DOI 10.1136/bmj.1.4769.1162; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; Donald PR, 1997, AM J RESP CRIT CARE, V156, P895, DOI 10.1164/ajrccm.156.3.9609132; Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Grosset J, 1998, MYCOBACTERIA, VII, P51; HITTEL N, 2006, OP FOR 2 KEY ISS TB; Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103; MCNEELEY D, 2006, OP FOR 2 KEY ISS TB; Mitchison DA, 2006, J ANTIMICROB CHEMOTH, V58, P494, DOI 10.1093/jac/dkl260; NACY C, 2006, OP FOR 2 KEY ISS TB; Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885OC; Park-Wyllie LY, 2006, NEW ENGL J MED, V354, P1352, DOI 10.1056/NEJMoa055191; Protopopova M, 2005, J ANTIMICROB CHEMOTH, V56, P968, DOI 10.1093/jac/dki319; PYLE MM, 1947, P STAFF M MAYO CLIN, V22, P465; SELKON JB, 1964, B WORLD HEALTH ORGAN, V31, P273; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Wright A., 2006, Morbidity and Mortality Weekly Report, V55, P301; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877	26	203	213	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					290	294		10.1038/nm0307-290	http://dx.doi.org/10.1038/nm0307-290			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342142				2022-12-27	WOS:000244715700039
J	Diarra, D; Stolina, M; Polzer, K; Zwerina, J; Ominsky, MS; Dwyer, D; Korb, A; Smolen, J; Hoffmann, M; Scheinecker, C; van der Heide, D; Landewe, R; Lacey, D; Richards, WG; Schett, G				Diarra, Danielle; Stolina, Marina; Polzer, Karin; Zwerina, Jochen; Ominsky, Michael S.; Dwyer, Denise; Korb, Adelheid; Smolen, Josef; Hoffmann, Markus; Scheinecker, Clemens; van der Heide, Desiree; Landewe, Robert; Lacey, Dave; Richards, William G.; Schett, Georg			Dickkopf-1 is a master regulator of joint remodeling	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; BONE-RESORPTION; INFLAMMATION; INHIBITION; CRITERIA; MICE; OSTEOCLASTOGENESIS; STIMULATION	Degenerative and inflammatory joint diseases lead to a destruction of the joint architecture. Whereas degenerative osteoarthritis results in the formation of new bone, rheumatoid arthritis leads to bone resorption. The molecular basis of these different patterns of joint disease is unknown. By inhibiting Dickkopf-1 (DKK-1), a regulatory molecule of the Wnt pathway, we were able to reverse the bone-destructive pattern of a mouse model of rheumatoid arthritis to the bone-forming pattern of osteoarthritis. In this way, no overall bone erosion resulted, although bony nodules, so-called osteophytes, did form. We identified tumor necrosis factor-alpha (TNF) as a key inducer of DKK-1 in the mouse inflammatory arthritis model and in human rheumatoid arthritis. These results suggest that the Wnt pathway is a key regulator of joint remodeling.	Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Clin Immunol, D-91054 Erlangen, Germany; Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria; Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA; Univ Hosp Maastricht, Dept Internal Med & Rheumatol, NL-6229 HX Maastricht, Netherlands	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Medical University of Vienna; Amgen; Maastricht University; Maastricht University Medical Centre (MUMC)	Schett, G (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med 3, Krankenhausstr 12, D-91054 Erlangen, Germany.	georg.schett@med3.med.uni-erlangen.de	LANDEWE, ROBERT B.M./ABD-7388-2021	LANDEWE, ROBERT B.M./0000-0002-0577-6620; Diarra, Danielle/0000-0001-9298-7233				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Feldmann M, 2005, J AUTOIMMUN, V25, P26, DOI 10.1016/j.jaut.2005.09.006; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; GARRETT S, 1994, J RHEUMATOL, V21, P2286; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gortz B, 2004, J BONE MINER RES, V19, P990, DOI 10.1359/JBMR.040205; Gravallese EM, 1998, AM J PATHOL, V152, P943; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KLIPPEL JH, 2001, PRIMER RHEUMATIC DIS; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Millar JBA, 2002, GENOME BIOL, V3; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Scharstuhl A, 2003, ARTHRITIS RHEUM-US, V48, P3442, DOI 10.1002/art.11328; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Beuningen HM, 2000, OSTEOARTHR CARTILAGE, V8, P25, DOI 10.1053/joca.1999.0267; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105; Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105-2896.2005.00338.x; Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487	32	983	1076	1	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2007	13	2					156	163		10.1038/nm1538	http://dx.doi.org/10.1038/nm1538			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17237793				2022-12-27	WOS:000244031700024
J	Avila, J				Avila, Jesus			The Spanish experience	NATURE MEDICINE			English	Editorial Material													Avila, Jesus/I-2610-2015	Avila, Jesus/0000-0002-6288-0571					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					776	776						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829945				2022-12-27	WOS:000238862800058
J	Siragam, V; Crow, AR; Brinc, D; Song, S; Freedman, J; Lazarus, AH				Siragam, Vinayakumar; Crow, Andrew R.; Brinc, Davor; Song, Seng; Freedman, John; Lazarus, Alan H.			Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells	NATURE MEDICINE			English	Article							IDIOPATHIC THROMBOCYTOPENIC PURPURA; RETICULOENDOTHELIAL SYSTEM FUNCTION; IMMUNE THROMBOCYTOPENIA; AUTOIMMUNE-DISEASE; MURINE ITP; ANTI-D; IVIG; IGG; MACROPHAGES; ANTIBODIES	Despite a more than 20-year experience of therapeutic benefit, the relevant molecular and cellular targets of intravenous immunoglobulin ( IVIg) in autoimmune disease remain unclear. Contrary to the prevailing theories of IVIg action in autoimmunity, we show that IVIg drives signaling through activating Fc gamma receptors ( Fc gamma R) in the amelioration of mouse immune thrombocytopenic purpura ( ITP). The actual administration of IVIg was unnecessary because as few as 105 IVIg-treated cells could, upon adoptive transfer, ameliorate ITP. IVIg did not interact with the inhibitory Fc gamma RIIB on the initiator cell, although Fc gamma RIIB does have a role in the late phase of IVIg action. Notably, only IVIg-treated CD11c(+) dendritic cells could mediate these effects. We hypothesize that IVIg forms soluble immune complexes in vivo that prime dendritic-cell regulatory activity. In conclusion, the clinical effects of IVIg in ameliorating ITP seem to involve the acute interaction of IVIg with activating Fc gamma R on dendritic cells.	Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada; St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Platelet Immunobiol Grp, Toronto, ON, Canada	Canadian Blood Services; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Lazarus, AH (corresponding author), Canadian Blood Serv, 1800 Alta Vista Dr, Ottawa, ON K1G 4J5, Canada.	lazarusa@smh.toronto.on.ca	Brinc, Davor/AAF-1771-2021	Crow, Andrew R/0000-0001-6978-4999; Brinc, Davor/0000-0003-4471-8965; Lazarus, Alan/0000-0002-5051-6916				Arnal C, 2002, J RHEUMATOL, V29, P75; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Braun-Moscovici Y, 2003, CURR OPIN RHEUMATOL, V15, P237, DOI 10.1097/00002281-200305000-00010; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Bussel JB, 2000, SEMIN HEMATOL, V37, P261, DOI 10.1053/shem.2000.8957; Cao XH, 2004, J IMMUNOL, V172, P4851, DOI 10.4049/jimmunol.172.8.4851; Crow AR, 2003, BLOOD, V102, P558, DOI 10.1182/blood-2003-01-0023; Crow AR, 2001, BRIT J HAEMATOL, V115, P679, DOI 10.1046/j.1365-2141.2001.03136.x; DEANDRES B, 1991, J IMMUNOL, V146, P1566; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X; Knezevic-Maramica I, 2003, TRANSFUSION, V43, P1460, DOI 10.1046/j.1537-2995.2003.00519.x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; LATOUR S, 1992, J IMMUNOL, V149, P2155; Lazarus AH, 2003, TRANSFUS APHER SCI, V28, P249, DOI 10.1016/S1473-0502(03)00043-0; MCMILLAN R, 1974, NEW ENGL J MED, V291, P812, DOI 10.1056/NEJM197410172911602; SALAMA A, 1984, BLUT, V49, P29, DOI 10.1007/BF00320381; SALAMA A, 1983, LANCET, V2, P193; SALEH MN, 1989, BLOOD, V74, P1328; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Semple JW, 2002, BLOOD REV, V16, P9, DOI 10.1054/blre.2001.0172; Siragam V, 2005, J CLIN INVEST, V115, P155, DOI 10.1172/JCI200522753; Song S, 2005, BLOOD, V105, P1546, DOI 10.1182/blood-2004-05-1886; Song S, 2003, BLOOD, V101, P3708, DOI 10.1182/blood-2002-10-3078; Spisek R, 2006, TRANSFUSION, V46, P55, DOI 10.1111/j.1537-2995.2005.00670.x; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838	27	199	204	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					688	692		10.1038/nm1416	http://dx.doi.org/10.1038/nm1416			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715090				2022-12-27	WOS:000238149200032
J	Uno, T; Takeda, K; Kojima, Y; Yoshizawa, H; Akiba, H; Mittler, RS; Gejyo, F; Okumura, K; Yagita, H; Smyth, MJ				Uno, Tomoyasu; Takeda, Kazuyoshi; Kojima, Yuko; Yoshizawa, Hirohisa; Akiba, Hisaya; Mittler, Robert S.; Gejyo, Fumitake; Okumura, Ko; Yagita, Hideo; Smyth, Mark J.			Eradication of established tumors in mice by a combination antibody-based therapy	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; T-CELL IMMUNITY; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; TUMORICIDAL ACTIVITY; IN-VIVO; INDUCTION; FAMILY; INTERLEUKIN-12; CHEMOTHERAPY	Tumor-cell apoptosis is the basis of many cancer therapies(1-3), and tumor-specific T cells are the principal effectors of successful antitumor immunotherapies(4-7). Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand ( TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8(+) T cells capable of eradicating preestablished tumors. Primary fibrosarcomas initiated with the carcinogen 3-methylcholanthrene ( MCA), multiorgan metastases and a primary tumor containing as many as 90% tumor cells resistant to DR5-specific monoclonal antibody were rejected without apparent toxicity or induction of autoimmunity. This combination therapy of three monoclonal antibodies ( trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon ( IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process. These results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Homeostat Regulat & Dev, Div Resp Med, Niigata 9518510, Japan; Peter MacCallum Canc Inst, Canc Immunol Program, Melbourne, Vic 3002, Australia; Juntendo Univ, Sch Med, Biomed Res Ctr, Div Biomed Imaging Res,Bunkyo Ku, Tokyo 1138421, Japan; Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata 9518510, Japan; Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30329 USA	Juntendo University; Niigata University; Peter Maccallum Cancer Center; Juntendo University; Niigata University; Emory University; Emory University	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; HAMANN U, 1983, J IMMUNOL, V130, P7; Hayakawa Y, 2003, P NATL ACAD SCI USA, V100, P9464, DOI 10.1073/pnas.1630663100; Hixon JA, 2002, BIOL BLOOD MARROW TR, V8, P316, DOI 10.1053/bbmt.2002.v8.pm12108917; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Noguchi Y, 1996, P NATL ACAD SCI USA, V93, P11798, DOI 10.1073/pnas.93.21.11798; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Selenko N, 2001, LEUKEMIA, V15, P1619, DOI 10.1038/sj.leu.2402226; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	30	206	231	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					693	698		10.1038/nm1405	http://dx.doi.org/10.1038/nm1405			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680149				2022-12-27	WOS:000238149200033
J	Mandavilli, A				Mandavilli, A			Thomas Frieden	NATURE MEDICINE			English	Biographical-Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2006	12	4					378	378		10.1038/nm0406-378	http://dx.doi.org/10.1038/nm0406-378			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16598275	Bronze			2022-12-27	WOS:000236581300010
J	Wu, ZH; Guo, H; Chow, NW; Sallstrom, J; Bell, RD; Deane, R; Brooks, AI; Kanagala, S; Rubio, A; Sagare, A; Liu, D; Li, F; Armstrong, D; Gasiewicz, T; Zidovetzki, R; Song, XM; Hofman, F; Zlokovic, BV				Wu, ZH; Guo, H; Chow, NW; Sallstrom, J; Bell, RD; Deane, R; Brooks, AI; Kanagala, S; Rubio, A; Sagare, A; Liu, D; Li, F; Armstrong, D; Gasiewicz, T; Zidovetzki, R; Song, XM; Hofman, F; Zlokovic, BV			Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; MICROVASCULAR PATHOLOGY; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; RECEPTOR FAMILY; BETA-PEPTIDE; GAX; EXPRESSION	Neurovascular dysfunction substantially contributes to Alzheimer disease. Here, we show that transcriptional profiling of human brain endothelial cells ( BECs) defines a subset of genes whose expression is age- independent but is considerably altered in Alzheimer disease, including the homeobox gene MEOX2 ( also known as GAX), a regulator of vascular differentiation, whose expression is low in Alzheimer disease. By using viral- mediated MEOX2 gene silencing and transfer, we show that restoring expression of the protein it encodes, GAX, in BECs from individuals with Alzheimer disease stimulates angiogenesis, transcriptionally suppresses AFX1 forkhead transcription factor - mediated apoptosis and increases the levels of a major amyloid- beta peptide ( Ab) clearance receptor, the low- density lipoprotein receptor - related protein 1 ( LRP), at the blood- brain barrier. In mice, deletion of Meox2 ( also known as Gax) results in reductions in brain capillary density and resting cerebral blood flow, loss of the angiogenic response to hypoxia in the brain and an impaired Ab efflux from brain caused by reduced LRP levels. The link of MEOX2 to neurovascular dysfunction in Alzheimer disease provides new mechanistic and therapeutic insights into this illness.	Univ Rochester, Med Ctr, Frank P Smith Labs Neurosci & Neurosurg Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Genom Ctr, Rochester, NY 14642 USA; Socratech Res Labs, Rochester, NY 14620 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; Univ So Calif, Hoffman Med Res Ctr, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA	University of Rochester; University of Rochester; University of California System; University of California Riverside; University of Rochester; University of Southern California	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Labs Neurosci & Neurosurg Res, Arthur Kornberg Med Res Bldg,601 Elmwood Ave,Box, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu	Sagare, Abhay/Y-3273-2019	Sagare, Abhay/0000-0002-8178-3785; Armstrong, Don/0000-0002-4904-638X	NATIONAL INSTITUTE ON AGING [R43AG024002, R37AG023084, R43AG023993] Funding Source: NIH RePORTER; NIA NIH HHS [R43 AG24002, R43 AG23993, R37 AG023084] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ANDRES V, 1995, MOL CELL BIOL, V15, P4272; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Bailey TL, 2004, NEUROL RES, V26, P573, DOI 10.1179/016164104225016272; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Davis GE, 2001, J CELL SCI, V114, P917; de la Torre JC, 2004, NEUROL RES, V26, P517, DOI 10.1179/016164104225016254; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Fryer JD, 2003, J NEUROSCI, V23, P7889; Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47; Gorski DH, 2003, TRENDS CARDIOVAS MED, V13, P213, DOI 10.1016/S1050-1738(03)00081-1; Gorski DH, 2003, J SURG RES, V111, P91, DOI 10.1016/S0022-4804(03)00042-8; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; Greenberg SA, 2004, STROKE, V35, P2616, DOI 10.1161/01.str.0000143224.36527.44; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Iscove NN, 2002, NAT BIOTECHNOL, V20, P940, DOI 10.1038/nbt729; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; LaRue B, 2004, J NEUROSCI METH, V138, P233, DOI 10.1016/j.jneumeth.2004.04.026; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Paris D, 2004, NEUROSCI LETT, V366, P80, DOI 10.1016/j.neulet.2004.05.017; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Patel S, 2005, CANCER RES, V65, P1414, DOI 10.1158/0008-5472.CAN-04-3431; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Roher AE, 2004, STROKE, V35, P2623, DOI 10.1161/01.STR.0000143317.70478.b3; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Saito T, 2005, REGUL PEPTIDES, V127, P159, DOI 10.1016/j.regpep.2004.11.006; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001	49	233	240	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					959	965		10.1038/nm1287	http://dx.doi.org/10.1038/nm1287			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116430				2022-12-27	WOS:000231724700023
J	Bard-Chapeau, EA; Hevener, AL; Long, SN; Zhang, EE; Olefsky, JM; Feng, GS				Bard-Chapeau, EA; Hevener, AL; Long, SN; Zhang, EE; Olefsky, JM; Feng, GS			Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action	NATURE MEDICINE			English	Article							SUBSTRATE-1 TYROSINE PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; MICE LACKING; RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; SKELETAL-MUSCLE; SENSITIVITY; RESISTANCE; GENE; P85-ALPHA	Insulin receptor substrate-1 (IRS-1) and IRS-2 are known to transduce and amplify signals emanating from the insulin receptor(1-3). Here we show that Grb2-associated binder 1 (Gab1), despite its structural similarity to IRS proteins(4), is a negative modulator of hepatic insulin action. Liver-specific Gab1 knockout (LGKO) mice showed enhanced hepatic insulin sensitivity with reduced glycemia and improved glucose tolerance. In LGKO liver, basal and insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-2 was elevated, accompanied by enhanced Akt/PKB activation. Conversely, Erk activation by insulin was suppressed in LGKO liver, leading to defective IRS-1 Ser612 phosphorylation. Thus, Gab1 acts to attenuate, through promotion of the Erk pathway, insulin-elicited signals flowing through IRS and Akt proteins, which represents a novel balancing mechanism for control of insulin signal strength in the liver.	Burnham Inst, Signal Transduct Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, Mol Pathol Grad Program, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Feng, GS (corresponding author), Burnham Inst, Signal Transduct Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org	Bard-Chapeau, Emilie/H-6091-2011	Zhang, Eric/0000-0002-4472-7493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060484, R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660, R01GM053660] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60484, DK33651] Funding Source: Medline; NIGMS NIH HHS [GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRAYN KN, 1980, J LIPID RES, V21, P139; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	30	69	72	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					567	571		10.1038/nm1227	http://dx.doi.org/10.1038/nm1227			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15821749				2022-12-27	WOS:000228915000031
J	Buckland, BC				Buckland, BC			The process development challenge for a new vaccine	NATURE MEDICINE			English	Editorial Material								The challenges of vaccine development are not limited to identification of suitable antigens, adjuvants and delivery methods, but include regulatory, technical and manufacturing hurdles in translating a vaccine candidate to the clinic. Process development is the technological foundation that underlies the manufacture of new vaccines and is central to successful commercialization.	Merck Res Labs, West Point, PA 19486 USA	Merck & Company	Buckland, BC (corresponding author), Merck Res Labs, West Point, PA 19486 USA.	barry_buckland@merck.com						Brown DR, 2004, VACCINE, V22, P2936, DOI 10.1016/j.vaccine.2003.11.059; Clark HF, 2004, J PEDIATR-US, V144, P184, DOI 10.1016/j.jpeds.2003.10.054; Clark HF, 2003, PEDIATR INFECT DIS J, V22, P914, DOI 10.1097/01.inf.0000091887.48999.77; Fife KH, 2004, VACCINE, V22, P2943, DOI 10.1016/j.vaccine.2003.11.058; JANSEN KU, 1995, VACCINE, V13, P1509, DOI 10.1016/0264-410X(95)00103-8; KNICKSEN PJ, 1992, VACCINES NEW APPROAC, P177; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; PISANO GP, 1997, DEV FACTORY	8	65	67	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S16	S19		10.1038/nm1218	http://dx.doi.org/10.1038/nm1218			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812483	Bronze			2022-12-27	WOS:000228339600006
J	Lambert, PH; Liu, M; Siegrist, CA				Lambert, PH; Liu, M; Siegrist, CA			Can successful vaccines teach us how to induce efficient protective immune responses?	NATURE MEDICINE			English	Review							INFLUENZAE TYPE-B; HYPERIMMUNE GAMMA-GLOBULIN; BACILLUS-CALMETTE-GUERIN; ANTIBODY-RESPONSES; BONE-MARROW; MONOCLONAL-ANTIBODIES; TOXIN-NEUTRALIZATION; IMMUNOLOGICAL MEMORY; CONJUGATE VACCINES; CELL RESPONSES	Some recently introduced vaccines that have excellent efficacy records have been developed without a clear understanding of their mechanism of protection. In fact, successful vaccines have often emerged out of empirical observations and have only rarely been the result of a rational use of the continuously increasing immunological knowledge available to scientists. However, a posteriori deciphering of the biological bases for the efficacy of successful vaccines should be an essential component of research efforts directed at the development of new vaccines for the most challenging infectious diseases.	Univ Geneva, CMU, Ctr Vaccinol, Dept Immunol Pathol, CH-1211 Geneva, Switzerland; Univ Geneva, CMU, Ctr Vaccinol, Dept Pediat, CH-1211 Geneva, Switzerland; Transgene SA, F-67082 Strasbourg, France	University of Geneva; University of Geneva; Transgene SA	Lambert, PH (corresponding author), Univ Geneva, CMU, Ctr Vaccinol, Dept Immunol Pathol, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	paul.lambert@medecine.unige.ch						Ahman H, 1999, VACCINE, V17, P2726, DOI 10.1016/S0264-410X(99)00048-1; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; *AM AC PED, 2003, RED BOOK 2003 REP CO, P309; *AM AC PED, 2003, RED BOOK 2003 REP CO, P419; *AM AC PED, 2003, RED BOOK 2003 REP CO, P263; *AM AC PED, 2003, RED BOOK 2003 REP CO, P611; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Ballou WR, 2004, AM J TROP MED HYG, V71, P239; Banatvala J, 2000, LANCET, V356, P337, DOI 10.1016/S0140-6736(05)73618-7; Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323; BELSHE RB, 2004, VACCINES, P371; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bjorkholm B, 2000, EUR J CLIN MICROBIOL, V19, P195, DOI 10.1007/s100960050458; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Bosnak M, 2002, PEDIATR INT, V44, P663, DOI 10.1046/j.1442-200X.2002.01621.x; BRESEE JS, 2003, VACCINE BOOK, P225; Cassidy WM, 2001, PEDIATRICS, V107, P626, DOI 10.1542/peds.107.4.626; *CDCP, 1984, MMWR-MORBID MORTAL W, V33, P398; Dagan R, 2000, PEDIATR INFECT DIS J, V19, P1045, DOI 10.1097/00006454-200011000-00004; Davidkin I, 2000, VACCINE, V18, P3106, DOI 10.1016/S0264-410X(00)00139-0; DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; De Wit D, 2004, BLOOD, V103, P1030, DOI 10.1182/blood-2003-04-1216; Deloye Florence, 1997, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V191, P433; DEQUADROS CA, 2003, VACCINE BOOK, P189; Edwards KM, 2003, VACCINE, V21, P3483, DOI 10.1016/S0264-410X(03)00356-6; Fisher R G, 1998, Pediatr Rev, V19, P62, DOI 10.1542/pir.19-2-62; FOX JP, 1984, REV INFECT DIS, V6, pS352; Fukuda K, 2004, VACCINES, P339; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; Gans HA, 1999, J IMMUNOL, V162, P5569; GERSHON AA, 1995, PRINCIPLES PRACTICE, P1519; Giuliano M, 1998, J PEDIATR-US, V132, P983, DOI 10.1016/S0022-3476(98)70395-6; Givner LB, 1999, PEDIATR INFECT DIS J, V18, P541, DOI 10.1097/00006454-199906000-00014; Golaz A, 2000, J INFECT DIS, V181, pS203, DOI 10.1086/315558; Goldblatt D, 1998, BMJ-BRIT MED J, V316, P1570, DOI 10.1136/bmj.316.7144.1569; Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407; Gomez I, 2004, EXP GERONTOL, V39, P597, DOI 10.1016/j.exger.2003.11.018; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; GUPTA PS, 1980, LANCET, V2, P439; GUPTA RK, 1994, BIOLOGICALS, V22, P215, DOI 10.1006/biol.1994.1031; HACKELL JG, 2003, VACCINE, P257; Hankins DG, 2004, MAYO CLIN PROC, V79, P671, DOI 10.4065/79.5.671; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; HOSKINS TW, 1979, LANCET, V1, P33; JANEWAY CA, 1945, B NEW YORK ACAD MED, V21, P202; Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443; Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221; Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000; Kelly DF, 2004, IMMUNOLOGY, V113, P163, DOI 10.1111/j.1365-2567.2004.01971.x; KEMPE CH, 1961, B WORLD HEALTH ORGAN, V25, P41; LAMPE RM, 1985, AM J DIS CHILD, V139, P33, DOI 10.1001/archpedi.1985.02140030035022; MANZ RA, IN PRESS ANN REV IMM; Marchant A, 1999, J IMMUNOL, V163, P2249; MATSUDA M, 1992, EUR J EPIDEMIOL, V8, P1, DOI 10.1007/BF02427384; MCHEYZERWILLIAM.LJ, IN PRESS ANN REV IMM; McVernon J, 2003, ARCH DIS CHILD, V88, P379, DOI 10.1136/adc.88.5.379; MORRIS D, 1957, ARCH DIS CHILD, V32, P236, DOI 10.1136/adc.32.163.236; Nicol M, 2002, PEDIATR INFECT DIS J, V21, P138, DOI 10.1097/00006454-200202000-00010; Obukhanych TV, 2006, J EXP MED, V203, P305, DOI 10.1084/jem.20052036; Ota MOC, 2004, VACCINE, V22, P511, DOI 10.1016/j.vaccine.2003.07.020; Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919; Pawelec G, 2004, TRENDS IMMUNOL, V25, P406, DOI 10.1016/j.it.2004.05.006; Pihlgren M, 2003, VACCINE, V21, P2492, DOI 10.1016/S0264-410X(03)00052-5; Pihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824; Pihlgren M, 2001, EUR J IMMUNOL, V31, P939, DOI 10.1002/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I; Pinschewer DD, 2004, J CLIN INVEST, V114, P988, DOI 10.1172/JCI200422374; POWERS DC, 1994, J INFECT DIS, V169, P1125, DOI 10.1093/infdis/169.5.1125; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; ROBBINS FC, 2004, VACCINES, P17; Salmaso S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e81; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIBER GR, 1992, J INFECT DIS, V165, pS129, DOI 10.1093/infdis/165-Supplement_1-S129; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Siegrist CA, 2004, VACCINE, V23, P615, DOI 10.1016/j.vaccine.2004.07.014; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001; Storch GA, 1998, PEDIATRICS, V102, P648, DOI 10.1542/peds.102.3.648; STREBEL PM, 2004, VACCINES, P389; Terrault NA, 1996, HEPATOLOGY, V24, P1327, DOI 10.1053/jhep.1996.v24.pm0008938155; Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Treanor JJ, 1999, VACCINE, V18, P899, DOI 10.1016/S0264-410X(99)00334-5; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Turton K, 2002, TRENDS BIOCHEM SCI, V27, P552, DOI 10.1016/S0968-0004(02)02177-1; Usinger WR, 1999, INFECT IMMUN, V67, P2366, DOI 10.1128/IAI.67.5.2366-2370.1999; Vazquez M, 2004, JAMA-J AM MED ASSOC, V291, P851, DOI 10.1001/jama.291.7.851; Voordouw ACG, 2004, JAMA-J AM MED ASSOC, V292, P2089, DOI 10.1001/jama.292.17.2089; Zinkernagel RM, 2002, CURR OPIN IMMUNOL, V14, P523, DOI 10.1016/S0952-7915(02)00367-9; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	91	122	134	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S54	S62		10.1038/nm1216	http://dx.doi.org/10.1038/nm1216			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812491				2022-12-27	WOS:000228339600011
J	Chakravarty, S; Cockburn, IA; Kuk, S; Overstreet, MG; Sacci, JB; Zavala, F				Chakravarty, Sumana; Cockburn, Ian A.; Kuk, Salih; Overstreet, Michael G.; Sacci, John B.; Zavala, Fidel			CD8(+) T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes	NATURE MEDICINE			English	Article							MARROW-DERIVED CELLS; CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-YOELII; DENDRITIC CELLS; SPOROZOITE INFECTION; ANTIGEN PRESENTATION; KUPFFER CELLS; IMMUNITY; RESPONSES; MICE	The success of immunization with irradiated sporozoites is unparalleled among the current vaccination approaches against malaria, but its mechanistic underpinnings have yet to be fully elucidated. Using a model mimicking natural infection by Plasmodium yoelii, we delineated early events governing the development of protective CD8(+) T-cell responses to the circumsporozoite protein. We demonstrate that dendritic cells in cutaneous lymph nodes prime the first cohort of CD8+ T cells after an infectious mosquito bite. Ablation of these lymphoid sites greatly impairs subsequent development of protective immunity. Activated CD8+ T cells then travel to systemic sites, including the liver, in a sphingosine-1-phosphate(S1P)-dependent fashion. These effector cells, however, no longer require bone marrow-derived antigen-presenting cells for protection; instead, they recognize antigen on parenchymal cells-presumably parasitized hepatocytes. Therefore, we report an unexpected dichotomy in the tissue restriction of host responses during the development and execution of protective immunity to Plasmodium.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Malaria Res Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore	Zavala, F (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Malaria Res Inst, Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	fzavala@jhsph.edu	Kuk, Salih/ABA-7923-2020	Cockburn, Ian/0000-0001-8220-9294; Overstreet, Michael/0000-0001-7450-7929	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044375, R21AI044375] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44375] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Baba S, 2004, J HEPATOL, V40, P255, DOI 10.1016/j.jhep.2003.10.012; Baer K, 2007, CELL MICROBIOL, V9, P397, DOI 10.1111/j.1462-5822.2006.00798.x; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X; Cantz T, 2004, CELL TRANSPLANT, V13, P659, DOI 10.3727/000000004783983521; Carvalho LH, 2001, J IMMUNOL METHODS, V252, P207, DOI 10.1016/S0022-1759(01)00331-3; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; Crispe IN, 2006, IMMUNOL REV, V213, P101, DOI 10.1111/j.1600-065X.2006.00435.x; Frevert U, 2005, PLOS BIOL, V3, P1034, DOI 10.1371/journal.pbio.0030192; Frevert U, 2006, CELL MICROBIOL, V8, P1537, DOI 10.1111/j.1462-5822.2006.00777.x; Hafalla JCR, 2003, J IMMUNOL, V171, P964, DOI 10.4049/jimmunol.171.2.964; Hafalla JCR, 2002, P NATL ACAD SCI USA, V99, P11819, DOI 10.1073/pnas.182189999; Hafalla JCR, 2006, EUR J IMMUNOL, V36, P1179, DOI 10.1002/eji.200535712; HAMILTON AJ, 1988, CELL BIOL INT REP, V12, P123, DOI 10.1016/0309-1651(88)90126-9; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Krzych U, 2005, CURR TOP MICROBIOL, V297, P1; Krzych U, 2000, IMMUNOL REV, V174, P123, DOI 10.1034/j.1600-0528.2002.00013h.x; Kumar KA, 2006, NATURE, V444, P937, DOI 10.1038/nature05361; Leiriao P, 2005, J INFECT DIS, V191, P1576, DOI 10.1086/429635; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Medica DL, 2005, INFECT IMMUN, V73, P4363, DOI 10.1128/IAI.73.7.4363-4369.2005; Mehal WZ, 2001, J IMMUNOL, V167, P667, DOI 10.4049/jimmunol.167.2.667; Milling SWF, 2006, NAT PROTOC, V1, P2263, DOI 10.1038/nprot.2006.315; Morrot A, 2005, J EXP MED, V202, P551, DOI 10.1084/jem.20042463; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; PARADIS K, 1990, J PEDIATR GASTR NUTR, V11, P525, DOI 10.1097/00005176-199011000-00014; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102; Rodrigues EG, 2000, PARASITE IMMUNOL, V22, P157, DOI 10.1046/j.1365-3024.2000.00289.x; Rodrigues EG, 1997, J IMMUNOL, V158, P1268; RODRIGUES M, 1993, IMMUNOLOGY, V80, P1; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; Sano G, 2001, J EXP MED, V194, P173, DOI 10.1084/jem.194.2.173; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Waters AP, 2005, SCIENCE, V307, P528, DOI 10.1126/science.1108598; WEISS WR, 1992, J IMMUNOL, V149, P2103; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; Wilson NS, 2006, NAT IMMUNOL, V7, P165, DOI 10.1038/ni1300; Yamauchi LM, 2007, CELL MICROBIOL, V9, P1215, DOI 10.1111/j.1462-5822.2006.00861.x; Yrlid U, 2003, APMIS, V111, P756, DOI 10.1034/j.1600-0463.2003.11107807.x	48	196	205	1	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1035	1041		10.1038/nm1628	http://dx.doi.org/10.1038/nm1628			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17704784				2022-12-27	WOS:000249353100030
J	Chen, CJ; Kono, H; Golenbock, D; Reed, G; Akira, S; Rock, KL				Chen, Chun-Jen; Kono, Hajime; Golenbock, Douglas; Reed, George; Akira, Shizuo; Rock, Kenneth L.			Identification of a key pathway required for the sterile inflammatory response triggered by dying cells	NATURE MEDICINE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HEPATIC ISCHEMIA-REPERFUSION; TUMOR-NECROSIS-FACTOR; ACTIVATE B-CELLS; NEUTROPHIL DEPLETION; INJURY; MECHANISMS; BLOCKADE; ANTIBODY; HMGB1	Dying cells stimulate inflammation, and this response is thought to contribute to the pathogenesis of many diseases. Very little has been known, however, about how cell death triggers inflammation. We found here that the acute neutrophilic inflammatory response to cell injury requires the signaling protein myeloid differentiation primary response gene 88 (Myd88). Analysis of the contribution of Myd88-dependent receptors to this response revealed only a minor reduction in mice doubly deficient in Toll-like receptor 2 (Tlr2) and Tlr4 and normal responses in mice lacking Tlr1, Tlr3, Tlr6, Tlr7, Tlr9, Tlr11 or the interleukin-18 receptor (IL-18R). However, mice lacking IL-1R showed a markedly reduced neutrophilic inflammatory response to dead cells and tissue injury in vivo as well as greatly decreased collateral damage from inflammation. This inflammatory response required IL-1 alpha, and IL-1R function was required on non-bone-marrow-derived cells. Notably, the acute monocyte response to cell death, which is thought to be important for tissue repair, was much less dependent on the IL-1R-Myd88 pathway. Also, this pathway was not required for the neutrophil response to a microbial stimulus. These findings suggest that inhibiting the IL-1R-Myd88 pathway in vivo could block the damage from acute inflammation that occurs in response to sterile cell death, and do so in a way that might not compromise tissue repair or host defense against pathogens.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Natl Taiwan Univ, Inst Microbiol & Biochem, Taipei 10617, Taiwan; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA; Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	University of Massachusetts System; University of Massachusetts Worcester; National Taiwan University; University of Massachusetts System; University of Massachusetts Worcester; Osaka University	Rock, KL (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, 55 Lake Ave N,Room S2-109, Worcester, MA 01655 USA.	kenneth.rock@umassmed.edu	Hsiao, Wei-Hung/B-9931-2013; Akira, Shizuo/C-3134-2009; Chen, Chun-Jen/D-9647-2013	Chen, Chun-Jen/0000-0002-9211-8641; Kono, Hajime/0000-0002-4578-8677	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; ANTMAN EM, 2001, ACUTE MYOCARDIAL INF, P1114; Balding DJ, 2004, APPL LONGITUDINAL AN; Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075; Dovi JV, 2003, J LEUKOCYTE BIOL, V73, P448, DOI 10.1189/jlb.0802406; FISHER CJ, 1994, CIRC SHOCK, V44, P1; FISHER TC, 1994, THROMB RES, V74, pS21, DOI 10.1016/S0049-3848(10)80004-0; Jaeschke H, 2006, AM J PHYSIOL-GASTR L, V290, pG1083, DOI 10.1152/ajpgi.00568.2005; Jaeschke Hartmut, 2005, Expert Opin Drug Metab Toxicol, V1, P389, DOI 10.1517/17425255.1.3.389; Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Liu ZX, 2006, HEPATOLOGY, V43, P1220, DOI 10.1002/hep.21175; MAJNO G, 1960, VIRCHOWS ARCH A, V333, P421, DOI 10.1007/BF00955327; Palmer G, 2003, EUR J IMMUNOL, V33, P434, DOI 10.1002/immu.200310018; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Sawa Y, 1996, CIRCULATION, V93, P1640, DOI 10.1161/01.CIR.93.9.1640; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Shito M, 1997, TRANSPLANTATION, V63, P143, DOI 10.1097/00007890-199701150-00026; Suzuki K, 2001, CIRCULATION, V104, pI308; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zingarelli B, 1999, GASTROENTEROLOGY, V116, P335, DOI 10.1016/S0016-5085(99)70130-7	30	650	685	0	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					851	856		10.1038/nm1603	http://dx.doi.org/10.1038/nm1603			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17572686	Green Published			2022-12-27	WOS:000247902800032
J	Fischer, W; Perkins, S; Theiler, J; Bhattacharya, T; Yusim, K; Funkhouser, R; Kuiken, C; Haynes, B; Letvin, NL; Walker, BD; Hahn, BH; Korber, BT				Fischer, Will; Perkins, Simon; Theiler, James; Bhattacharya, Tanmoy; Yusim, Karina; Funkhouser, Robert; Kuiken, Carla; Haynes, Barton; Letvin, Norman L.; Walker, Bruce D.; Hahn, Beatrice H.; Korber, Bette T.			Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RHESUS-MONKEYS; LYMPHOCYTE ESCAPE; VIRAL ESCAPE; TYPE-1; RESPONSES; INFECTION; IMMUNOGENICITY; ENVELOPE; AIDS	HIV-1/AIDS vaccines must address the extreme diversity of HIV-1. We have designed new polyvalent vaccine antigens comprised of sets of 'mosaic' proteins, assembled from fragments of natural sequences via a computational optimization method. Mosaic proteins resemble natural proteins, and a mosaic set maximizes the coverage of potential T-cell epitopes (peptides of nine amino acids) for a viral population. We found that coverage of viral diversity using mosaics was greatly increased compared to coverage by natural-sequence vaccine candidates, for both variable and conserved proteins; for conserved HIV-1 proteins, global coverage may be feasible. For example, four mosaic proteins perfectly matched 74% of 9-amino-acid potential epitopes in global Gag sequences; 87% of potential epitopes matched at least 8 of 9 positions. In contrast, a single natural Gag protein covered only 37% (9 of 9) and 67% (8 of 9). Mosaics provide diversity coverage comparable to that afforded by thousands of separate peptides, but, because the fragments of natural proteins are compressed into a small number of native-like proteins, they are tractable for vaccines.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Univ Alabama, Birmingham, AL 35294 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham	Korber, BT (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	btk@lanl.gov	Bhattacharya, Tanmoy/J-8956-2013; Fischer, Will/AAD-2807-2019; Fischer, Will/B-1323-2013	Bhattacharya, Tanmoy/0000-0002-1060-652X; Fischer, Will/0000-0003-4579-4062; Fischer, Will/0000-0003-4579-4062; Hahn, Beatrice/0000-0002-9400-9887; Korber, Bette/0000-0002-2026-5757	NIAID NIH HHS [P01 AI061734-01, R21 AI055421-01-A1] Funding Source: Medline; PHS HHS [N01-15442] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI055421, P01AI061734] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003; Ammaranond P, 2005, AIDS RES HUM RETROV, V21, P395, DOI 10.1089/aid.2005.21.395; Bansal A, 2005, AIDS, V19, P241; Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Doria-Rose NA, 2005, J VIROL, V79, P11214, DOI 10.1128/JVI.79.17.11214-11224.2005; Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Hanke T, 1998, VACCINE, V16, P426, DOI 10.1016/S0264-410X(97)00296-X; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Holland J. H., 1992, ADAPTATION NATURAL A; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Killian MS, 2005, AIDS, V19, P887, DOI 10.1097/01.aids.0000171402.00372.c2; Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Milicic A, 2005, J IMMUNOL, V175, P4618, DOI 10.4049/jimmunol.175.7.4618; Moore JP, 2004, NAT MED, V10, P769, DOI 10.1038/nm0804-769; Nabel GJ, 2002, VACCINE, V20, P1945, DOI 10.1016/S0264-410X(02)00074-9; Oxenius A, 2004, J INFECT DIS, V189, P1199, DOI 10.1086/382028; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seaman MS, 2005, J VIROL, V79, P2956, DOI 10.1128/JVI.79.5.2956-2963.2005; Singh RAK, 2002, J IMMUNOL, V169, P6779, DOI 10.4049/jimmunol.169.12.6779; Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05; Williamson C, 2003, AIDS RES HUM RETROV, V19, P133, DOI 10.1089/088922203762688649	32	328	364	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					100	106		10.1038/nm1461	http://dx.doi.org/10.1038/nm1461			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17187074				2022-12-27	WOS:000243301800043
J	Lee, JH; Huh, YM; Jun, Y; Seo, J; Jang, J; Song, HT; Kim, S; Cho, EJ; Yoon, HG; Suh, JS; Cheon, J				Lee, Jae-Hyun; Huh, Yong-Min; Jun, Young-wook; Seo, Jung-wook; Jang, Jung-tak; Song, Ho-Taek; Kim, Sungjun; Cho, Eun-Jin; Yoon, Ho-Geun; Suh, Jin-Suck; Cheon, Jinwoo			Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging	NATURE MEDICINE			English	Article							CONTRAST AGENTS; QUANTUM DOTS; CANCER; BREAST; FUTURE; CELLS	Successful development of ultra-sensitive molecular imaging nanoprobes for the detection of targeted biological objects is a challenging task. Although magnetic nanoprobes have the potential to perform such a role, the results from probes that are currently available have been far from optimal. Here we used artificial engineering approaches to develop innovative magnetic nanoprobes, through a process that involved the systematic evaluation of the magnetic spin, size and type of spinel metal ferrites. These magnetism-engineered iron oxide (MEIO) nanoprobes, when conjugated with antibodies, showed enhanced magnetic resonance imaging (MRI) sensitivity for the detection of cancer markers compared with probes currently available. Also, we successfully visualized small tumors implanted in a mouse. Such high-performance, nanotechnology-based molecular probes could enhance the ability to visualize other biological events critical to diagnostics and therapeutics.	Yonsei Univ, Coll Med, Dept Radiol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Res Inst Radiol Sci, Seoul 120752, South Korea; Yonsei Univ, Dept Chem, Seoul 120749, South Korea; Yonsei Univ, Nanomed Natl Core Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University; Yonsei University Health System	Suh, JS (corresponding author), Yonsei Univ, Coll Med, Dept Radiol, Seoul 120752, South Korea.	jss@yumc.yonsei.ac.kr; jcheon@yonsei.ac.kr	Jun, Young-wook/A-4141-2008; suh, jin-suck/B-1196-2008; Song, Ho-Taek/K-3807-2014; Jang, Jung-tak/B-3317-2009	Song, Ho-Taek/0000-0002-6655-2575; Kim, Sungjun/0000-0002-7876-7901; Yoon, Ho-Geun Yoon/0000-0003-2718-3372; Huh, Yong-Min/0000-0002-9831-4475; Jun, Young-wook/0000-0003-3182-5366; Suh, jin-suck/0000-0001-9455-9240				Allen MJ, 2004, MET IONS BIOL SYST, V42, P1; Artemov D, 2003, MAGNET RESON MED, V49, P403, DOI 10.1002/mrm.10406; Benaron DA, 2002, CANCER METAST REV, V21, P45, DOI 10.1023/A:1020131208786; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; CHEON J, 2004, Patent No. 2006052042; Czernin J, 2002, ANNU REV MED, V53, P89, DOI 10.1146/annurev.med.53.082901.104028; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Graves EE, 2004, CURR MOL MED, V4, P419, DOI 10.2174/1566524043360555; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P235; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Huh YM, 2005, J AM CHEM SOC, V127, P12387, DOI 10.1021/ja052337c; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Jun YW, 2005, J AM CHEM SOC, V127, P5732, DOI 10.1021/ja0422155; Kang HW, 2002, BIOCONJUGATE CHEM, V13, P122, DOI 10.1021/bc0155521; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; KOENIG SH, 1995, MAGNET RESON MED, V34, P227, DOI 10.1002/mrm.1910340214; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Marx V, 2005, CHEM ENG NEWS, V83, P25, DOI 10.1021/cen-v083n030.p025; MCCURRIE RA, 1994, FERROMAGNETIC MAT ST, P123; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Sharkey RM, 2005, NAT MED, V11, P1250, DOI 10.1038/nm1322; Vernimmen D, 2003, BRIT J CANCER, V89, P899, DOI 10.1038/sj.bjc.6601200; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241	25	1565	1638	14	768	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					95	99		10.1038/nm1467	http://dx.doi.org/10.1038/nm1467			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17187073				2022-12-27	WOS:000243301800042
J	Brenchley, JM; Price, DA; Schacker, TW; Asher, TE; Silvestri, G; Rao, S; Kazzaz, Z; Bornstein, E; Lambotte, O; Altmann, D; Blazar, BR; Rodriguez, B; Teixeira-Johnson, L; Landay, A; Martin, JN; Hecht, FM; Picker, LJ; Lederman, MM; Deeks, SG; Douek, DC				Brenchley, Jason M.; Price, David A.; Schacker, Timothy W.; Asher, Tedi E.; Silvestri, Guido; Rao, Srinivas; Kazzaz, Zachary; Bornstein, Ethan; Lambotte, Olivier; Altmann, Daniel; Blazar, Bruce R.; Rodriguez, Benigno; Teixeira-Johnson, Leia; Landay, Alan; Martin, Jeffrey N.; Hecht, Frederick M.; Picker, Louis J.; Lederman, Michael M.; Deeks, Steven G.; Douek, Daniel C.			Microbial translocation is a cause of systemic immune activation in chronic HIV infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; T-CELL DEPLETION; COMBINATION ANTIRETROVIRAL THERAPY; INFLAMMATORY-BOWEL-DISEASE; VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; GASTROINTESTINAL-TRACT; TYPE-1 INFECTION; SIV INFECTION; INTESTINAL PERMEABILITY	Chronic activation of the immune system is a hallmark of progressive HIV infection and better predicts disease outcome than plasma viral load, yet its etiology remains obscure. Here we show that circulating microbial products, probably derived from the gastrointestinal tract, are a cause of HIV-related systemic immune activation. Circulating lipopolysaccharide, which we used as an indicator of microbial translocation, was significantly increased in chronically HIV-infected individuals and in simian immunodeficiency virus (SIV)-infected rhesus macaques (P <= 0.002). We show that increased lipopolysaccharide is bioactive in vivo and correlates with measures of innate and adaptive immune activation. Effective antiretroviral therapy seemed to reduce microbial translocation partially. Furthermore, in nonpathogenic SIV infection of sooty mangabeys, microbial translocation did not seem to occur. These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection.	NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; NIAID, Lab Anim Med, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Infect Dis, London W12 0NN, England; Univ Minnesota, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Minneapolis, MN 55455 USA; Case Western Reserve Univ, Cleveland, OH 44016 USA; Univ Hosp Cleveland, Cleveland, OH 44016 USA; Rush Med Coll, Dept Immunol & Microbiol, Chicago, IL 60612 USA; Univ Calif San Francisco, San Francisco, CA 90210 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97006 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Imperial College London; University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University; University Hospitals of Cleveland; Rush University; University of California System; University of California San Francisco; Oregon Health & Science University	Douek, DC (corresponding author), NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.	ddouek@mail.nih.gov	Rodriguez, Benigno/C-3365-2009; Lambotte, Olivier/GRT-0160-2022; Brenchley, Jason/AAC-5085-2019; Eckhardt, Erik/G-1567-2010; Price, David A/C-7876-2013	Rodriguez, Benigno/0000-0001-9736-7957; Price, David A/0000-0001-9416-2737; Altmann, Daniel/0000-0002-2436-6192; Brenchley, Jason/0000-0001-8357-2984; Hecht, Frederick/0000-0002-5782-1171	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165, M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879, R01AI052755, R01AI066998, P30AI027763, R01AI052745, R37AI066998, U01AI041531, P30AI036219, U01AI038858, Z01AI005034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER; MRC [G108/441] Funding Source: UKRI; Intramural NIH HHS Funding Source: Medline; Medical Research Council [G108/441] Funding Source: Medline; NCRR NIH HHS [M01-RR0083-37, RR-00165] Funding Source: Medline; NIAID NIH HHS [AI066998, AI 36219, AI41531, AI 25879, AI 38858, AI052745, R0I AI052755, P30 AI27763] Funding Source: Medline; NIMH NIH HHS [P30 MH62246] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aziz N, 1999, J INFECT DIS, V179, P843, DOI 10.1086/314673; Bafica A, 2004, J IMMUNOL, V172, P7229, DOI 10.4049/jimmunol.172.12.7229; Barclay G R, 1995, Prog Clin Biol Res, V392, P263; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; COHEN IR, 1966, SCIENCE, V152, P1257, DOI 10.1126/science.152.3726.1257; Cooke KR, 2002, J ENDOTOXIN RES, V8, P441, DOI 10.1179/096805102125001046; Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005; Fort MM, 2005, J IMMUNOL, V174, P6416, DOI 10.4049/jimmunol.174.10.6416; George MD, 2005, J VIROL, V79, P2709, DOI 10.1128/JVI.79.5.2709-2719.2005; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Haas DW, 1998, J INFECT DIS, V177, P1746, DOI 10.1086/517437; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Holmes CL, 2003, CHEST, V124, P1103, DOI 10.1378/chest.124.3.1103; Ito T, 2006, BLOOD, V107, P2423, DOI 10.1182/blood-2005-07-2709; Kitchens RL, 2005, J ENDOTOXIN RES, V11, P225, DOI 10.1179/096805105X46565; Kotler DP, 2005, AIDS, V19, P107, DOI 10.1097/00002030-200501280-00002; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; MacArthur RD, 2000, J INFECT DIS, V181, P1486, DOI 10.1086/315370; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Sankaran S, 2005, P NATL ACAD SCI USA, V102, P9860, DOI 10.1073/pnas.0503463102; Schietroma M, 2006, ANN SURG, V243, P359, DOI 10.1097/01.sla.0000201455.89037.f6; Schietroma Mario, 2006, Chir Ital, V58, P171; Sharpstone D, 1999, GUT, V45, P70, DOI 10.1136/gut.45.1.70; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Skoner DP, 1999, J INFECT DIS, V180, P10, DOI 10.1086/314823; Strutz F, 1999, INTENS CARE MED, V25, P435, DOI 10.1007/s001340050877; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383; Valdez H, 1997, AIDS Clin Rev, P187; Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WELLMANN W, 1986, GUT, V27, P814, DOI 10.1136/gut.27.7.814; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Zaunders JJ, 2001, J INFECT DIS, V183, P736, DOI 10.1086/318827	50	2518	2613	1	180	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1365	1371		10.1038/nm1511	http://dx.doi.org/10.1038/nm1511			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115046	Green Published			2022-12-27	WOS:000242618200016
J	Clarke, MCH; Figg, N; Maguire, JJ; Davenport, AP; Goddard, M; Littlewood, TD; Bennett, MR				Clarke, Murray C. H.; Figg, Nichola; Maguire, Janet J.; Davenport, Anthony P.; Goddard, Martin; Littlewood, Trevor D.; Bennett, Martin R.			Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis	NATURE MEDICINE			English	Article							DIPHTHERIA-TOXIN; CELLULAR PROLIFERATION; ARTERIAL INJURY; TRANSGENIC MICE; FAS LIGAND; DEATH; EXPRESSION; RECEPTOR; MACROPHAGES; DEPLETION	Vascular smooth muscle cell (VSMC) apoptosis occurs in many arterial diseases, including aneurysm formation, angioplasty restenosis and atherosclerosis. Although VSMC apoptosis promotes vessel remodeling, coagulation and inflammation, its precise contribution to these diseases is unknown, given that apoptosis frequently accompanies vessel injury or alterations to flow. To study the direct consequences of VSMC apoptosis, we generated transgenic mice expressing the human diphtheria toxin receptor (hDTR, encoded by HBEGF) from a minimal Tagln (also known as SM22 alpha) promoter. Despite apoptosis inducing loss of 50 - 70% of VSMCs, normal arteries showed no inflammation, reactive proliferation, thrombosis, remodeling or aneurysm formation. In contrast, VSMC apoptosis in atherosclerotic plaques of SM22 alpha-hDTR Apoe(-/-) mice induced marked thinning of fibrous cap, loss of collagen and matrix, accumulation of cell debris and intense intimal inflammation. We conclude that VSMC apoptosis is 'silent' in normal arteries, which have a large capacity to withstand cell loss. In contrast, VSMC apoptosis alone is sufficient to induce features of plaque vulnerability in atherosclerosis. SM22 alpha-hDTR Apoe(-/-) mice may represent an important new model to test agents proposed to stabilize atherosclerotic plaques.	Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Pharmacol, ACCI, Cambridge CB2 2QQ, England; Papworth Hosp, Dept Pathol, Cambridge CB3 8RE, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; Papworth Hospital	Bennett, MR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI, Box 110, Cambridge CB2 2QQ, England.	mrb@mole.bio.cam.ac.uk	Davenport, Anthony P./A-5773-2008; Maguire, Janet J/Z-2180-2019	Davenport, Anthony P./0000-0002-2096-3117; Maguire, Janet J/0000-0002-9254-7040; Bennett, Martin/0000-0002-2565-1825; Clarke, Murray/0000-0002-8215-8885				Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; CHO A, 1995, CIRC RES, V76, P168, DOI 10.1161/01.RES.76.2.168; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; CHUNG DW, 1977, BIOCHIM BIOPHYS ACTA, V483, P248, DOI 10.1016/0005-2744(77)90053-5; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1986, LAB INVEST, V54, P295; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; GENG YJ, 1995, AM J PATHOL, V147, P251; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; KEEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P2912, DOI 10.1073/pnas.79.9.2912; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Littlewood TD, 2003, CURR OPIN LIPIDOL, V14, P469, DOI 10.1097/00041433-200310000-00007; LopezCandales A, 1997, AM J PATHOL, V150, P993; Lutgens E, 1999, CARDIOVASC RES, V41, P473, DOI 10.1016/S0008-6363(98)00311-3; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Mitamura T, 1997, J BIOL CHEM, V272, P27084, DOI 10.1074/jbc.272.43.27084; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schaub FJ, 2003, CIRC RES, V93, P515, DOI 10.1161/01.RES.0000093205.42313.7C; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; XU W, 1996, BLOOD	30	508	529	2	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1075	1080		10.1038/nm1459	http://dx.doi.org/10.1038/nm1459			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892061				2022-12-27	WOS:000240373900032
J	Almeida, AM; Murakami, Y; Layton, DM; Hillmen, P; Sellick, GS; Maeda, Y; Richards, S; Patterson, S; Kotsianidis, I; Mollica, L; Crawford, DH; Baker, A; Ferguson, M; Roberts, I; Houlston, R; Kinoshita, T; Karadimitris, A				Almeida, Antonio M.; Murakami, Yoshiko; Layton, D. Mark; Hillmen, Peter; Sellick, Gabrielle S.; Maeda, Yusuke; Richards, Stephen; Patterson, Scott; Kotsianidis, Ioannis; Mollica, Luigina; Crawford, Dorothy H.; Baker, Alastair; Ferguson, Michael; Roberts, Irene; Houlston, Richard; Kinoshita, Taroh; Karadimitris, Anastasios			Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency	NATURE MEDICINE			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHOR; MEMBRANE-PROTEIN; 3RD MANNOSE; GLYCOSYLATION; CELLS; BIOSYNTHESIS; PATHOGENESIS; SURFACE; LYSIS	Attachment to the plasma membrane by linkage to a glycosylphosphatidylinositol (GPI) anchor(1) is a mode of protein expression highly conserved from protozoa to mammals(2). As a clinical entity, deficiency of GPI has been recognized as paroxysmal nocturnal hemoglobinuria, an acquired clonal disorder associated with somatic mutations of the X-linked PIGA gene in hematopoietic cells(3,4). We have identified a novel disease characterized by a propensity to venous thrombosis and seizures in which deficiency of GPI is inherited in an autosomal recessive manner. In two unrelated kindreds, a point mutation (c -> g) at position -270 from the start codon of PIGM, a mannosyltransferase-encoding gene, disrupts binding of the transcription factor Sp1 to its cognate promoter motif. This mutation substantially reduces transcription of PIGM and blocks mannosylation of GPI, leading to partial but severe deficiency of GPI. These findings indicate that biosynthesis of GPI is essential to maintain homeostasis of blood coagulation and neurological function.	Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London W12 0NN, England; Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 565, Japan; Gen Infirm, Haematol Malignancy Diagnost Serv Lab, Leeds Teaching Hosp NHS Trust, Leeds LS1 3EX, W Yorkshire, England; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Edinburgh, Clin & Basic Virol Lab, Sch Biomed Sci, Edinburgh EH9 1HQ, Midlothian, Scotland; Kings Coll Hosp London, Paediat Liver Ctr, London SE5 9RS, England; Univ Dundee, Div Biol Chem & Mol Microbiol, Dundee DD1 4HN, Scotland	Imperial College London; Osaka University; Leeds General Infirmary; University of Leeds; University of London; Institute of Cancer Research - UK; University of Edinburgh; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Dundee	Karadimitris, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, Du Cane Rd, London W12 0NN, England.	a.karadimitris@imperial.ac.uk	Kotsianidis, Ioannis/AGH-1791-2022; KOTSIANIDIS, IOANNIS/ABH-1436-2021; KARADIMITRIS, ANASTASIOS/B-4353-2009; Kinoshita, Taroh/C-7353-2009; Ferguson, Michael A. J./F-7829-2010	KOTSIANIDIS, IOANNIS/0000-0001-7668-0186; Ferguson, Michael A. J./0000-0003-1321-8714; Richards, Stephen/0000-0002-8421-5353; Karadimitris, Anastasios/0000-0002-9566-9780; Houlston, Richard/0000-0002-5268-0242; Almeida, Antonio/0000-0003-4361-0928				Ashida H, 2005, MOL BIOL CELL, V16, P1439, DOI 10.1091/mbc.E04-09-0802; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hugel B, 1999, BLOOD, V93, P3451, DOI 10.1182/blood.V93.10.3451.410k27_3451_3456; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Jaeken J, 2001, METABOLIC MOL BASES, P1601; Karadimitris A, 2001, LEUKEMIA, V15, P1148, DOI 10.1038/sj.leu.2402180; Karadimitris A, 2000, BRIT J HAEMATOL, V111, P1158, DOI 10.1046/j.1365-2141.2000.02494.x; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Luzzatto L, 1997, CELL, V88, P1, DOI 10.1016/S0092-8674(00)81850-4; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Nozaki M, 1999, LAB INVEST, V79, P293; Orlean P, 2000, J CLIN INVEST, V105, P131, DOI 10.1172/JCI9157; Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Sellick GS, 2005, HUM GENET, V117, P207, DOI 10.1007/s00439-005-1301-4; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; Zhang J, 2003, CIRCULATION, V108, P623, DOI 10.1161/01.CIR.0000078642.45127.7B	30	160	162	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					846	851		10.1038/nm1410	http://dx.doi.org/10.1038/nm1410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767100				2022-12-27	WOS:000238862800074
J	Sheng, GQ; Chang, GQ; Lin, JY; Yu, ZX; Fang, ZH; Rong, J; Lipton, SA; Li, SH; Tong, G; Leibowitz, SF; Li, XJ				Sheng, Guoqing; Chang, Guo-Qing; Lin, John Y.; Yu, Zhao-Xue; Fang, Zhi-Hui; Rong, Juan; Lipton, Stuart A.; Li, Shi-Hua; Tong, Gang; Leibowitz, Sarah F.; Li, Xiao-Jiang			Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior	NATURE MEDICINE			English	Article							GAMMA-AMINOBUTYRIC-ACID; BODY-WEIGHT; INTRACELLULAR TRAFFICKING; GENETICALLY-OBESE; GABA(A) RECEPTORS; ZUCKER RATS; INSULIN; DISEASE; HAP1; BRAIN	The hypothalamus responds to circulating leptin and insulin in the control of food intake and body weight. A number of neurotransmitters in the hypothalamus, including gamma-aminobutyric acid ( GABA), also have key roles in feeding. Huntingtin-associated protein 1 (Hap1) is expressed more abundantly in the hypothalamus than in other brain regions, and lack of Hap1 in mice leads to early postnatal death. Hap1 is also involved in intracellular trafficking of the GABA(A) receptor. Here, we report that fasting upregulates the expression of Hap1 in the rodent hypothalamus, whereas intracerebroventricular administration of insulin downregulates Hap1 by increasing its degradation through ubiquitination. Decreasing the expression of mouse hypothalamic Hap1 by siRNA reduces the level and activity of hypothalamic GABAA receptors and causes a decrease in food intake and body weight. These findings provide evidence linking hypothalamic Hap1 to GABA in the stimulation of feeding and suggest that this mechanism is involved in the feeding-inhibitory actions of insulin in the brain.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Rockefeller Univ, Lab Behav Neurobiol, New York, NY 10021 USA; Burnham Inst Med Res, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Emory University; Rockefeller University; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu		Lin, John/0000-0002-1723-4597; Lipton, Stuart/0000-0002-3490-1259	NIA NIH HHS [AG00975, AG19206] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NIMH NIH HHS [MH43422] Funding Source: Medline; NINDS NIH HHS [NS36232, NS045016] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036232, R01NS045016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benoit SC, 2004, RECENT PROG HORM RES, V59, P267, DOI 10.1210/rp.59.1.267; Carvalheira JBC, 2003, DIABETOLOGIA, V46, P1629, DOI 10.1007/s00125-003-1246-x; Chan EYW, 2002, HUM MOL GENET, V11, P945, DOI 10.1093/hmg/11.8.945; Chang GQ, 2005, MOL BRAIN RES, V135, P69, DOI 10.1016/j.molbrainres.2004.12.017; COSCINA DV, 1992, INT J OBESITY, V16, P425; DECAVEL C, 1990, J COMP NEUROL, V302, P1019, DOI 10.1002/cne.903020423; Dragatsis I, 2004, HUM MOL GENET, V13, P3115, DOI 10.1093/hmg/ddh328; Emmerson PJ, 1999, J PHYSIOL-LONDON, V517, P431, DOI 10.1111/j.1469-7793.1999.0431t.x; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fujinaga R, 2004, J COMP NEUROL, V478, P88, DOI 10.1002/cne.20277; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Herring D, 2003, J BIOL CHEM, V278, P24046, DOI 10.1074/jbc.M301420200; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; KREMER HPH, 1990, J NEUROPATH EXP NEUR, V49, P371, DOI 10.1097/00005072-199007000-00002; Leibowitz SF, 2004, PEPTIDES, V25, P473, DOI 10.1016/j.peptides.2004.02.006; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; Li XJ, 2005, TRENDS PHARMACOL SCI, V26, P1, DOI 10.1016/j.tips.2004.11.001; MacDonald PE, 2004, ENDOCRINOLOGY, V145, P4078, DOI 10.1210/en.2004-0028; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; McGuire JR, 2006, J BIOL CHEM, V281, P3552, DOI 10.1074/jbc.M509806200; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OLGIATI VR, 1980, PSYCHOPHARMACOLOGY, V68, P163, DOI 10.1007/BF00432135; Page KJ, 1998, EUR J NEUROSCI, V10, P1835, DOI 10.1046/j.1460-9568.1998.00185.x; Petersen A, 2005, HUM MOL GENET, V14, P39, DOI 10.1093/hmg/ddi004; Pratley RE, 2000, ANN NEUROL, V47, P64, DOI 10.1002/1531-8249(200001)47:1<64::AID-ANA11>3.3.CO;2-J; Pu SY, 1999, ENDOCRINOLOGY, V140, P933, DOI 10.1210/en.140.2.933; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; SANBERG PR, 1981, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1981.tb135681.x; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Stratford TR, 1997, J NEUROSCI, V17, P4434; TSUJII S, 1991, BRAIN RES, V540, P48, DOI 10.1016/0006-8993(91)90491-D; van den Pol AN, 2003, NEURON, V40, P1059, DOI 10.1016/S0896-6273(03)00809-2; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763	45	75	81	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					526	533		10.1038/nm1382	http://dx.doi.org/10.1038/nm1382			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604089				2022-12-27	WOS:000238149100036
J	Smyth, S; Heron, A				Smyth, S; Heron, A			Diabetes and obesity: the twin epidemics	NATURE MEDICINE			English	Article									Int Finance Ctr, London EC2N 1HN, England		Smyth, S (corresponding author), Int Finance Ctr, 25 Old Broad St,5th Floor,Tower 42, London EC2N 1HN, England.	andrew.heron@woodmac.com							0	388	399	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					75	80		10.1038/nm0106-75	http://dx.doi.org/10.1038/nm0106-75			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397575				2022-12-27	WOS:000234419000055
J	Goldstein, JL				Goldstein, JL			60 years of winged victories for biomedical research	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2005	11	10					1023	1025		10.1038/nm1005-1023	http://dx.doi.org/10.1038/nm1005-1023			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211026				2022-12-27	WOS:000232492500012
J	Jonsson, H; Allen, P; Peng, SL				Jonsson, H; Allen, P; Peng, SL			Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis	NATURE MEDICINE			English	Article							FORKHEAD TRANSCRIPTION FACTORS; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; CELL-SURVIVAL; INTERLEUKIN-1; ACTIVATION; WITHDRAWAL; REGULATORS; SYNOVITIS; PATHWAYS	In inflammatory arthridities such as rheumatoid arthritis, cognate lymphocytes have long been considered instigators of autoimmunity, but accumulating evidence indicates that innate immune cells such as neutrophils and mast cells are responsible for a vast majority of acute and ongoing inflammation(1-3); however, the molecular mechanisms that govern them remain largely unknown. Here we show that such inflammation requires the forkhead transcription factor Foxo3a: Foxo3a-deficient mice are resistant to two models of neutrophilic inflammation, immune complex - mediated inflammatory arthritis and thioglycollate-induced peritonitis. This reflects a need for Foxo3a to maintain neutrophil vitality during inflammation by suppressing Fas ligand; because Foxo3a can bind and suppress the Fasl promoter, Foxo3a-deficient neutrophils upregulate Fas ligand and undergo apoptosis in response to TNF-alpha and IL-1, and Fas ligand blockade renders Foxo3a-deficient mice susceptible to both arthritis and peritonitis. Thus, Foxo3a ensures neutrophil survival during inflammation, identifying Foxo3a as therapeutic target in inflammation.	Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Peng, SL (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, 660 S Euclid Ave, St Louis, MO 63110 USA.	speng@im.wustl.edu	Peng, Stanford/S-6723-2019	Jonsson, Anna Helena/0000-0002-9558-2474	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061478, R01AI057471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 061478, AI 057471] Funding Source: Medline; NIDDK NIH HHS [DK 52574] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; Crossley LJ, 2003, J LEUKOCYTE BIOL, V74, P583, DOI 10.1189/jlb.0103020; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Firestein GS, 2002, ARTHRITIS RHEUM, V46, P298, DOI 10.1002/art.502; Gerth AJ, 2004, ARTHRITIS RHEUM, V50, P3392, DOI 10.1002/art.20579; Gerth AJ, 2003, INT IMMUNOL, V15, P937, DOI 10.1093/intimm/dxg093; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; LUO Y, 1997, CURRENT PROTOCOLS IM; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Norris J. S., 2001, Current Gene Therapy, V1, P123, DOI 10.2174/1566523013348977; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Villunger A, 2000, J EXP MED, V192, P647, DOI 10.1084/jem.192.5.647; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3	30	166	174	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					666	671		10.1038/nm1248	http://dx.doi.org/10.1038/nm1248			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15895074				2022-12-27	WOS:000229589800034
J	Hiraoka, S; Furuichi, T; Nishimura, G; Shibata, S; Yanagishita, M; Rimoin, DL; Superti-Furga, A; Nikkels, PG; Ogawa, M; Katsuyama, K; Toyoda, H; Kinoshita-Toyoda, A; Ishida, N; Isono, K; Sanai, Y; Cohn, DH; Koseki, H; Ikegawa, S				Hiraoka, Shuichi; Furuichi, Tatsuya; Nishimura, Gen; Shibata, Shunichi; Yanagishita, Masaki; Rimoin, David L.; Superti-Furga, Andrea; Nikkels, Peter G.; Ogawa, Minako; Katsuyama, Kayoko; Toyoda, Hidenao; Kinoshita-Toyoda, Akiko; Ishida, Nobuhiro; Isono, Kyoichi; Sanai, Yutaka; Cohn, Daniel H.; Koseki, Haruhiko; Ikegawa, Shiro			Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human	NATURE MEDICINE			English	Article							SCHNECKENBECKEN DYSPLASIA; GENE; MUTATIONS; GLYCOSAMINOGLYCANS; CHONDRODYSPLASIAS; BIOSYNTHESIS; PROTEOGLYCAN; AGGRECAN; PROTEIN	Proteoglycans are a family of extracellular macromolecules comprised of glycosaminoglycan chains of a repeated disaccharide linked to a central core protein(1,2). Proteoglycans have critical roles in chondrogenesis and skeletal development. The glycosaminoglycan chains found in cartilage proteoglycans are primarily composed of chondroitin sulfate(3). The integrity of chondroitin sulfate chains is important to cartilage proteoglycan function; however, chondroitin sulfate metabolism in mammals remains poorly understood. The solute carrier-35 D1 (SLC35D1) gene (SLC35D1) encodes an endoplasmic reticulum nucleotide-sugar transporter (NST) that might transport substrates needed for chondroitin sulfate biosynthesis(4,5). Here we created Slc35d1-deficient mice that develop a lethal form of skeletal dysplasia with severe shortening of limbs and facial structures. Epiphyseal cartilage in homozygous mutant mice showed a decreased proliferating zone with round chondrocytes, scarce matrices and reduced proteoglycan aggregates. These mice had short, sparse chondroitin sulfate chains caused by a defect in chondroitin sulfate biosynthesis. We also identified that loss-of-function mutations in human SLC35D1 cause Schneckenbecken dysplasia, a severe skeletal dysplasia. Our findings highlight the crucial role of NSTs in proteoglycan function and cartilage metabolism, thus revealing a new paradigm for skeletal disease and glycobiology.	RIKEN, Res Ctr Allergy & Immunol, Lab Dev Genet, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN, Single Nucleotide Polymorphism Res Ctr, Lab Bone & Joint Dis, Minato Ku, Tokyo 1088639, Japan; Tokyo Metropolitan Kiyose Childrens Hosp, Dept Radiol, Kiyose 2048567, Japan; Tokyo Med & Dent Univ, Dept Maxillofacial Biol, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Grad Sch, Div Biomatrix,Bunkyo Ku, Tokyo 1138549, Japan; Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90048 USA; Freiburg Univ Hosp, Ctr Paediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan	RIKEN; RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Freiburg; Utrecht University; Utrecht University Medical Center; Chiba University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Koseki, H (corresponding author), RIKEN, Res Ctr Allergy & Immunol, Lab Dev Genet, Tsurumi Ku, 1-7-22 Suehirocho, Kanagawa 2300045, Japan.	koseki@rcai.riken.jp; sikegawa@ims.u-tokyo.ac.jp	Koseki, Haruhiko/I-3825-2014; superti-furga, andrea/E-9162-2015; Shibata, Shunichi/AAQ-7252-2021; Ikegawa, Shiro/N-6895-2015	Koseki, Haruhiko/0000-0001-8424-5854; superti-furga, andrea/0000-0002-3543-7531; Ikegawa, Shiro/0000-0003-0316-2147; Isono, Kyoichi/0000-0002-4609-8985	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NICHD NIH HHS [HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOROCHOWITZ Z, 1986, AM J MED GENET, V25, P47, DOI 10.1002/ajmg.1320250107; GIEDION A, 1991, SKELETAL RADIOL, V20, P534; Hastbacka J, 1996, AM J HUM GENET, V58, P255; Ishida N, 2004, PFLUG ARCH EUR J PHY, V447, P768, DOI 10.1007/s00424-003-1093-0; JOYNER AL, 1992, GENE TARGETING; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Kesselman MA, 2004, BOOK LIB IN, V67, P89; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Muraoka M, 2007, J BIOL CHEM, V282, P24615, DOI 10.1074/jbc.M611358200; Nikkels PG, 2001, PEDIATR RADIOL, V31, P27, DOI 10.1007/s002470000357; Ogihara Y, 2001, J BONE MINER METAB, V19, P4, DOI 10.1007/s007740170054; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Shibata S, 2003, J ANAT, V203, P425, DOI 10.1046/j.1469-7580.2003.00226.x; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Superti-Furga A, 2007, AM J MED GENET A, V143A, P1, DOI 10.1002/ajmg.a.31483; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101; Thomsen B, 2006, GENOME RES, V16, P97, DOI 10.1101/gr.3690506; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; WALLIN J, 1994, DEVELOPMENT, V120, P1109	24	82	85	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1363	1367		10.1038/nm1655	http://dx.doi.org/10.1038/nm1655			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17952091				2022-12-27	WOS:000250736900030
J	Johnen, H; Lin, S; Kuffner, T; Brown, DA; Tsai, VWW; Bauskin, AR; Wu, L; Pankhurst, G; Jiang, LL; Junankar, S; Hunter, M; Fairlie, WD; Lee, NJ; Enriquez, RF; Baldock, PA; Corey, E; Apple, FS; Murakami, MM; Lin, EJ; Wang, C; During, MJ; Sainsbury, A; Herzog, H; Breit, SN				Johnen, Heiko; Lin, Shu; Kuffner, Tamara; Brown, David A.; Tsai, Vicky Wang-Wei; Bauskin, Asne R.; Wu, Liyun; Pankhurst, Greg; Jiang, Lele; Junankar, Simon; Hunter, Mark; Fairlie, W. Douglas; Lee, Nicola J.; Enriquez, Ronaldo F.; Baldock, Paul A.; Corey, Eva; Apple, Fred S.; Murakami, MaryAnn M.; Lin, En-Ju; Wang, Chuansong; During, Matthew J.; Sainsbury, Amanda; Herzog, Herbert; Breit, Samuel N.			Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1	NATURE MEDICINE			English	Article							MACROPHAGE INHIBITORY CYTOKINE-1; CACHEXIA; CANCER; SERUM; PATHWAYS; BEHAVIOR; MEMBER; MEN	Anorexia and weight loss are part of the wasting syndrome of late-stage cancer, are a major cause of morbidity and mortality in cancer, and are thought to be cytokine mediated. Macrophage inhibitory cytokine-1 (MIC-1) is produced by many cancers. Examination of sera from individuals with advanced prostate cancer showed a direct relationship between MIC-1 abundance and cancer-associated weight loss. In mice with xenografted prostate tumors, elevated MIC-1 levels were also associated with marked weight, fat and lean tissue loss that was mediated by decreased food intake and was reversed by administration of antibody to MIC-1. Additionally, normal mice given systemic MIC-1 and transgenic mice overexpressing MIC-1 showed hypophagia and reduced body weight. MIC-1 mediates its effects by central mechanisms that implicate the hypothalamic transforming growth factor-beta receptor II, extracellular signal-regulated kinases 1 and 2, signal transducer and activator of transcription-3, neuropeptide Y and pro-opiomelanocortin. Thus, MIC-1 is a newly defined central regulator of appetite and a potential target for the treatment of both cancer anorexia and weight loss, as well as of obesity.	St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Program Neurosci, Sydney, NSW 2010, Australia; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Hennepin Cty Med Ctr, Clin Labs, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55415 USA; Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA	St Vincents Hospital Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; University of Washington; University of Washington Seattle; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University	Breit, SN (corresponding author), St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia.	s.breit@cfi.unsw.edu.au	/A-4361-2010; During, Matthew/AAC-1388-2020; Fairlie, Walter/M-8401-2015; Salis, Amanda/A-3187-2011; Herzog, Herbert/B-8294-2008; /B-2038-2013; Junankar, Simon/O-2009-2019; Baldock, Paul/B-3840-2012; /E-2900-2010; Junankar, Simon/B-7677-2019	Fairlie, Walter/0000-0002-2498-1160; Salis, Amanda/0000-0001-9176-1574; /0000-0001-7766-6095; Junankar, Simon/0000-0002-3965-8278; Brown, David/0000-0003-1382-9419; lin, shu/0000-0002-4239-2028; Jiang, Lele/0000-0002-1326-5871				Anker SD, 2002, INT J CARDIOL, V85, P51, DOI 10.1016/S0167-5273(02)00233-4; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; Bauskin AR, 2005, CANCER RES, V65, P2330, DOI 10.1158/0008-5472.CAN-04-3827; Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008-5472.CAN-05-4067; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bouret SG, 2004, J NEUROSCI, V24, P2797, DOI 10.1523/JNEUROSCI.5369-03.2004; Buckhaults P, 2001, CANCER RES, V61, P6996; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Huhmann MB, 2005, LANCET ONCOL, V6, P334, DOI 10.1016/S1470-2045(05)70170-4; Kamel HK, 2002, DRUG AGING, V19, P865, DOI 10.2165/00002512-200219110-00004; Karl T, 2004, P NATL ACAD SCI USA, V101, P12742, DOI 10.1073/pnas.0404085101; Koopmann J, 2004, CLIN CANCER RES, V10, P2386, DOI 10.1158/1078-0432.CCR-03-0165; Kovesdy CP, 2007, J AM SOC NEPHROL, V18, P304, DOI 10.1681/ASN.2006060674; Lin EJD, 2006, ENDOCRINOLOGY, V147, P5094, DOI 10.1210/en.2006-0097; Marks DL, 2001, CANCER RES, V61, P1432; NAYLOR JL, 1995, HUM EXP TOXICOL, V14, P587, DOI 10.1177/096032719501400706; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pfitzenmaier J, 2003, CANCER, V97, P1211, DOI 10.1002/cncr.11178; Rall LC, 2004, RHEUMATOLOGY, V43, P1219, DOI 10.1093/rheumatology/keh321; Rosen CJ, 2004, BONE, V35, P1046, DOI 10.1016/j.bone.2004.07.008; Rubin H, 2003, P NATL ACAD SCI USA, V100, P5384, DOI 10.1073/pnas.0931260100; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Thompson IM, 2005, JAMA-J AM MED ASSOC, V294, P66, DOI 10.1001/jama.294.1.66; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100	25	374	422	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1333	1340		10.1038/nm1677	http://dx.doi.org/10.1038/nm1677			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17982462				2022-12-27	WOS:000250736900026
J	Zhang, LM; Lee, KC; Bhojani, MS; Khan, AP; Shilman, A; Holland, EC; Ross, BD; Rehemtulla, A				Zhang, Limin; Lee, Kuei C.; Bhojani, Mahaveer S.; Khan, Amjad P.; Shilman, Alla; Holland, Eric C.; Ross, Brian D.; Rehemtulla, Alnawaz			Molecular imaging of Akt kinase activity	NATURE MEDICINE			English	Article							PHOSPHOINOSITIDE 3-KINASE INHIBITORS; ENCODED FLUORESCENT REPORTER; PROTEIN-PROTEIN INTERACTIONS; NF-KAPPA-B; CANCER; CELLS; TUMOR; PHOSPHORYLATION; LY294002; PATHWAY	The serine/threonine kinase Akt mediates mitogenic and antiapoptotic responses that result from activation of multiple signaling cascades. It is considered a key determinant of tumor aggressiveness and is a major target for anticancer drug development. Here, we describe a new reporter molecule whose bioluminescence activity within live cells and in mice can be used to measure Akt activity. Akt activity in cultured cells and tumor xenografts was monitored quantitatively and dynamically in response to activation or inhibition of receptor tyrosine kinase, inhibition of phosphoinositide 3-kinase, or direct inhibition of Akt. The results provide unique insights into the pharmacokinetics and pharmacodynamics of agents that modulate Akt activity, revealing the usefulness of this reporter for rapid dose and schedule optimization in the drug development process.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Michigan, Ctr Mol Imaging, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; University of Michigan System; University of Michigan	Rehemtulla, A (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.	alnawaz@umich.edu	Lee, Kuei/AAF-9272-2021		NATIONAL CANCER INSTITUTE [P01CA085878, R24CA083099, P50CA093990] Funding Source: NIH RePORTER; NCI NIH HHS [R24CA83099, P50CA01014, P01CA85878, P50 CA093990, R24 CA083099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Beckmann N, 2001, ANAT RECORD, V265, P85, DOI 10.1002/ar.1059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chenevert TL, 2000, JNCI-J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hu LM, 2000, CLIN CANCER RES, V6, P880; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moffat BA, 2004, MAGN RESON MATER PHY, V17, P249, DOI 10.1007/s10334-004-0079-z; Ozawa T, 2001, ANAL CHEM, V73, P2516, DOI 10.1021/ac0013296; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Vink SR, 2005, INVEST NEW DRUG, V23, P279, DOI 10.1007/s10637-005-1436-0; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	30	107	112	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1114	1119		10.1038/nm1608	http://dx.doi.org/10.1038/nm1608			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17694068				2022-12-27	WOS:000249353100040
J	Orinska, Z; Maurer, M; Mirghomizadeh, F; Bulanova, E; Metz, M; Nashkevich, N; Schiemann, F; Schulmistrat, J; Budagian, V; Giron-Michel, J; Brandt, E; Paus, R; Bulfone-Paus, S				Orinska, Zane; Maurer, Marcus; Mirghomizadeh, Farhad; Bulanova, Elena; Metz, Martin; Nashkevich, Natalia; Schiemann, Florian; Schulmistrat, Jan; Budagian, Vadim; Giron-Michel, Julien; Brandt, Ernst; Paus, Ralf; Bulfone-Paus, Silvia			IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities	NATURE MEDICINE			English	Article							INTERLEUKIN-15 PROTECTS; BACTERIAL CLEARANCE; SEPTIC PERITONITIS; PROTEASES; RECEPTOR; EXPRESSION; GRANULE; ALPHA; ACTIVATION; MODEL	Sepsis remains a global clinical problem. By using the mouse cecal ligation and puncture model of sepsis, here we identify an important aspect of mast cell (MC)-dependent, innate immune defenses against Gram-negative bacteria by demonstrating that MC protease activity is regulated by interleukin- 15 (IL-15). Mouse MCs express both constitutive and lipopolysaccharide-inducible IL-15 and store it intracellularly. Deletion of parallel to 15 in mice markedly increases chymase activities, leading to greater MC bactericidal responses, increased processing and activation of neutrophil-recruiting chemokines, and significantly higher survival rates of mice after septic peritonitis. By showing that intracellular IL-15 acts as a specific negative transcriptional regulator of a mouse MC chymase (mast cell protease-2), we provide evidence that defined MC protease activity is transcriptionally regulated by an intracellularly retained cytokine. Our results identify an unexpected breach in MC-dependent innate immune defenses against sepsis and suggest that inhibiting intracellular IL-15 in MCs may improve survival from sepsis.	Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, D-10117 Berlin, Germany; Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany	Forschungszentrum Borstel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Kiel; Schleswig Holstein University Hospital	Bulfone-Paus, S (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Pk Allee 22, D-23845 Borstel, Germany.	sbulfone@fz-borstel.de	Giron-michel, Julien/GNP-7299-2022; Giron-Michel, Julien/Q-4503-2018; Metz, Martin/B-8799-2009; Metz, Martin/M-5237-2013; Paus, Ralf/F-6243-2011; Maurer, Marcus/ABG-2174-2020	Giron-michel, Julien/0000-0001-6613-6099; Giron-Michel, Julien/0000-0001-6613-6099; Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X				Abu Nabah YN, 2004, CIRCULATION, V110, P3581, DOI 10.1161/01.CIR.0000148824.93600.F3; Bone-Larson CL, 2000, AM J PATHOL, V157, P1177, DOI 10.1016/S0002-9440(10)64633-0; Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001; Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045; Bulfone-Paus S, 2006, BIOESSAYS, V28, P362, DOI 10.1002/bies.20380; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cao J, 2005, J IMMUNOL, V174, P7665, DOI 10.4049/jimmunol.174.12.7665; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Colucci F, 2003, NAT REV IMMUNOL, V3, P413, DOI 10.1038/nri1088; de Garavilla L, 2005, J BIOL CHEM, V280, P18001, DOI 10.1074/jbc.M501302200; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P72; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Feger F, 2002, TRENDS IMMUNOL, V23, P151, DOI 10.1016/S1471-4906(01)02156-1; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Feyerabend TB, 2005, MOL CELL BIOL, V25, P6199, DOI 10.1128/MCB.25.14.6199-6210.2005; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; Hiromatsu T, 2003, J INFECT DIS, V187, P1442, DOI 10.1086/374643; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Ilangumaran S, 2003, J BIOL CHEM, V278, P41871, DOI 10.1074/jbc.M308382200; Kandere-Grzybowska K, 2003, J IMMUNOL, V171, P4830, DOI 10.4049/jimmunol.171.9.4830; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; KINGHT PA, 2000, MAST CELLS BASOPHILS, P257; Kunori Y, 2002, EUR J BIOCHEM, V269, P5921, DOI 10.1046/j.1432-1033.2002.03316.x; Lindstedt KA, 2001, FASEB J, V15, P1377, DOI 10.1096/fj.00-0273com; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Malaviya R, 2000, J LEUKOCYTE BIOL, V67, P841, DOI 10.1002/jlb.67.6.841; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Miller HRP, 1999, BLOOD, V93, P3473, DOI 10.1182/blood.V93.10.3473.410k01_3473_3486; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; Moreno SE, 2006, J IMMUNOL, V177, P3218, DOI 10.4049/jimmunol.177.5.3218; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Schiemann F, 2006, BLOOD, V107, P2234, DOI 10.1182/blood-2005-06-2424; Solivan S, 2002, FEBS LETT, V512, P133, DOI 10.1016/S0014-5793(02)02242-1; Strik MCM, 2004, BLOOD, V103, P2710, DOI 10.1182/blood-2003-08-2981; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wirtz S, 2006, J EXP MED, V203, P1875, DOI 10.1084/jem.20060471; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	49	93	97	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2007	13	8					927	934		10.1038/nm1615	http://dx.doi.org/10.1038/nm1615			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	199CU	17643110				2022-12-27	WOS:000248674600023
J	Ieda, M; Kanazawa, H; Kimura, K; Hattori, F; Ieda, Y; Taniguchi, M; Lee, JK; Matsumura, K; Tomita, Y; Miyoshi, S; Shimoda, K; Makino, S; Sano, M; Kodama, I; Ogawa, S; Fukuda, K				Ieda, Masaki; Kanazawa, Hideaki; Kimura, Kensuke; Hattori, Fumiyuki; Ieda, Yasuyo; Taniguchi, Masahiko; Lee, Jong-Kook; Matsumura, Keisuke; Tomita, Yuichi; Miyoshi, Shunichiro; Shimoda, Kouji; Makino, Shinji; Sano, Motoaki; Kodama, Itsuo; Ogawa, Satoshi; Fukuda, Keiichi			Sema3a maintains normal heart rhythm through sympathetic innervation patterning	NATURE MEDICINE			English	Article							CARDIAC CONDUCTION SYSTEM; SEMAPHORIN-III; SUDDEN; EXPRESSION; GENE; ARRHYTHMIA; GROWTH; RAT; SUSCEPTIBILITY; AFFERENTS	Sympathetic innervation is critical for effective cardiac function. However, the developmental and regulatory mechanisms determining the density and patterning of cardiac sympathetic innervation remain unclear, as does the role of this innervation in arrhythmogenesis. Here we show that a neural chemorepellent, Sema3a, establishes cardiac sympathetic innervation patterning. Sema3a is abundantly expressed in the trabecular layer in early-stage embryos but is restricted to Purkinje fibers after birth, forming an epicardial-to-endocardial transmural sympathetic innervation patterning. Sema3a(-/-) mice lacked a cardiac sympathetic innervation gradient and exhibited stellate ganglia malformation, which led to marked sinus bradycardia due to sympathetic dysfunction. Cardiac-specific overexpression of Sema3a in transgenic mice (SemaTG) was associated with reduced sympathetic innervation and attenuation of the epicardial-to-endocardial innervation gradient. SemaTG mice demonstrated sudden death and susceptibility to ventricular tachycardia, due to catecholamine supersensitivity and prolongation of the action potential duration. We conclude that appropriate cardiac Sema3a expression is needed for sympathetic innervation patterning and is critical for heart rate control.	Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Med, Cardiol Div,Shinjuku Ku, Tokyo 1608582, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Biochem,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Nagoya Univ, Environm Med Res Inst, Dept Cardiovasc Res, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Keio Univ, Sch Med, Lab Anim Ctr, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Sapporo Medical University; Nagoya University; Keio University	Fukuda, K (corresponding author), Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kfukuda@sc.itc.keio.ac.jp	Shimoda, Kouji/V-2280-2017; Kanazawa, Hideaki/A-2874-2014; Sano, Motoaki/L-3405-2013; Fukuda, Keiichi/L-3777-2013					Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Brunet S, 2004, J PHYSIOL-LONDON, V559, P103, DOI 10.1113/jphysiol.2004.063347; Cao JM, 2000, CIRC RES, V86, P816, DOI 10.1161/01.RES.86.7.816; Cao JM, 2000, CIRCULATION, V101, P1960, DOI 10.1161/01.CIR.101.16.1960; Chantranuwat C, 2004, J HEART LUNG TRANSPL, V23, P683, DOI 10.1016/S1053-2498(03)00295-X; CHOW LTC, 1993, BRIT HEART J, V69, P430; Costantini DL, 2005, CELL, V123, P347, DOI 10.1016/j.cell.2005.08.004; Crick SJ, 1999, J ANAT, V195, P341, DOI 10.1046/j.1469-7580.1999.19530341.x; CRICK SJ, 1994, CIRCULATION, V89, P1697, DOI 10.1161/01.CIR.89.4.1697; Dae MW, 1997, CIRCULATION, V96, P1337, DOI 10.1161/01.CIR.96.4.1337; Ecker PM, 2006, AM J PHYSIOL-HEART C, V290, pH192, DOI 10.1152/ajpheart.00032.2005; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hansson M, 1998, J MOL CELL CARDIOL, V30, P2047, DOI 10.1006/jmcc.1998.0767; Heart rate variability: standards of measurement physiological interpretation and clinical use, 1996, AQUACULTURE, V93, P1043, DOI [10.1111/j.1542-474X.1996.tb00275.x, DOI 10.1161/STR.0b013e3182587839]; Ieda M, 2004, J CLIN INVEST, V113, P876, DOI 10.1172/JCI200419480; ITO M, 1994, CIRCULATION, V90, P1459, DOI 10.1161/01.CIR.90.3.1459; Kannankeril PJ, 2006, P NATL ACAD SCI USA, V103, P12179, DOI 10.1073/pnas.0600268103; Kawasaki T, 2002, DEVELOPMENT, V129, P671; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Kuruvilla R, 2004, CELL, V118, P243, DOI 10.1016/j.cell.2004.06.021; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; OPTHOF T, 1991, CIRC RES, V68, P1204, DOI 10.1161/01.RES.68.5.1204; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; PRIORI SG, 1990, AM J PHYSIOL, V258, pH1796, DOI 10.1152/ajpheart.1990.258.6.H1796; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Qu JH, 2004, J MOL CELL CARDIOL, V37, P439, DOI 10.1016/j.yjmcc.2004.05.009; RANDALL WC, 1968, CIRC RES, V22, P315, DOI 10.1161/01.RES.22.3.315; Saba S, 2003, J CARDIOVASC ELECTR, V14, P191, DOI 10.1046/j.1540-8167.2003.02454.x; Shusterman V, 2002, AM J PHYSIOL-HEART C, V282, pH2076, DOI 10.1152/ajpheart.00917.2001; Sosunov EA, 2001, CARDIOVASC RES, V51, P659, DOI 10.1016/S0008-6363(01)00333-9; STRAMBABADIALE M, 1992, AM J PHYSIOL, V263, pH1514, DOI 10.1152/ajpheart.1992.263.5.H1514; TAGO H, 1986, J HISTOCHEM CYTOCHEM, V34, P1431, DOI 10.1177/34.11.2430009; Takahashi T, 2006, CIRCULATION, V114, P388, DOI 10.1161/CIRCULATIONAHA.106.632513; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; Tang XQ, 2004, J NEUROSCI, V24, P819, DOI 10.1523/JNEUROSCI.1263-03.2004; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Xu XM, 2000, J NEUROSCI, V20, P2638	44	141	149	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					604	612		10.1038/nm1570	http://dx.doi.org/10.1038/nm1570			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17417650				2022-12-27	WOS:000246302800028
J	Wong, CW; Christen, T; Roth, I; Chadjichristos, CE; Derouette, JP; Foglia, BF; Chanson, M; Goodenough, DA; Kwak, BR				Wong, Cindy W.; Christen, Thomas; Roth, Isabelle; Chadjichristos, Christos E.; Derouette, Jean-Paul; Foglia, Bernard F.; Chanson, Marc; Goodenough, Daniel A.; Kwak, Brenda R.			Connexin37 protects against atherosclerosis by regulating monocyte adhesion	NATURE MEDICINE			English	Article							GAP-JUNCTIONS; LEUKOCYTE RECRUITMENT; MYOCARDIAL-INFARCTION; MIMETIC PEPTIDES; DEFICIENT MICE; BLOOD-CELLS; CHANNELS; EXPRESSION; RECEPTORS; COMMUNICATION	A genetic polymorphism in the human gene encoding connexin37 (CX37, encoded by GJA4, also known as CX37) has been reported as a potential prognostic marker for atherosclerosis(1). The expression of this gap-junction protein is altered in mouse and human atherosclerotic lesions(2): it disappears from the endothelium of advanced plaques but is detected in macrophages recruited to the lesions. The role of CX37 in atherogenesis, however, remains unknown. Here we have investigated the effect of deleting the mouse connexin37 (Cx37) gene (Gja4, also known as Cx37) on atherosclerosis in apolipoprotein E-deficient (Apoe(-/-)) mice, an animal model of this disease(3). We find that Gja4(-/-) Apoe(-/-) mice develop more aortic lesions than Gja4(+/+) Apoe(-/-) mice that express Cx37. Using in vivo adoptive transfer, we show that monocyte and macrophage recruitment is enhanced by eliminating expression of Cx37 in these leukocytes but not by eliminating its expression in the endothelium. We further show that Cx37 hemichannel activity in primary monocytes, macrophages and a macrophage cell line (H36.12j) inhibits leukocyte adhesion. This antiadhesive effect is mediated by release of ATP into the extracellular space. Thus, Cx37 hemichannels may control initiation of the development of atherosclerotic plaques by regulating monocyte adhesion. H36.12j macrophages expressing either of the two CX37 proteins encoded by a polymorphism in the human GJA4 gene show differential ATP-dependent adhesion. These results provide a potential mechanism by which a polymorphism in CX37 protects against atherosclerosis.	Univ Hosp Geneva, Div Cardiol, Dept Internal Med, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva, Switzerland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Geneva; University of Geneva; Harvard University; Harvard Medical School	Kwak, BR (corresponding author), Univ Hosp Geneva, Div Cardiol, Dept Internal Med, CH-1211 Geneva, Switzerland.	Brenda.KwakChanson@medecine.unige.ch	Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Chanson, Marc/0000-0001-8104-2090	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018974, R01GM018974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18974] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker HM, 2004, J IMMUNOL METHODS, V286, P69, DOI 10.1016/j.jim.2003.11.016; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Eriksson EE, 2004, CURR OPIN LIPIDOL, V15, P553, DOI 10.1097/00041433-200410000-00009; Evans WH, 2001, BIOCHEM SOC T, V29, P606, DOI 10.1042/BST0290606; Fortes FSA, 2004, J CELL SCI, V117, P4717, DOI 10.1242/jcs.01345; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Henttinen T, 2003, J BIOL CHEM, V278, P24888, DOI 10.1074/jbc.M300779200; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Kwak BR, 2003, CIRCULATION, V107, P1033, DOI 10.1161/01.CIR.0000051364.70064.D1; Kwak BR, 2002, ARTERIOSCL THROM VAS, V22, P225, DOI 10.1161/hq0102.104125; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4; Merhi-Soussi F, 2005, CARDIOVASC RES, V66, P583, DOI 10.1016/j.cardiores.2005.01.008; Osterud B, 2003, PHYSIOL REV, V83, P1069, DOI 10.1152/physrev.00005.2003; PATEL MN, 1981, ANGEW MAKROMOL CHEM, V97, P75; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Puljung MC, 2004, J GEN PHYSIOL, V124, P587, DOI 10.1085/jgp.200409023; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Scemes E, 2003, J NEUROSCI, V23, P11444; Simon AM, 1997, NATURE, V385, P525, DOI 10.1038/385525a0; Van Nhieu GT, 2003, NAT CELL BIOL, V5, P720, DOI 10.1038/ncb1021; Wang Q, 2004, AM J HUM GENET, V74, P262, DOI 10.1086/381560; Wong CW, 2004, CARDIOVASC RES, V62, P357, DOI 10.1016/j.cardiores.2003.12.015; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	29	241	256	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					950	954		10.1038/nm1441	http://dx.doi.org/10.1038/nm1441			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862155				2022-12-27	WOS:000239626200027
J	Schuchmann, S; Schmitz, D; Rivera, C; Vanhatalo, S; Salmen, B; Mackie, K; Sipila, ST; Voipio, J; Kaila, K				Schuchmann, Sebastian; Schmitz, Dietmar; Rivera, Claudio; Vanhatalo, Sampsa; Salmen, Benedikt; Mackie, Ken; Sipila, Sampsa T.; Voipio, Juha; Kaila, Kai			Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; IMMATURE RAT MODEL; LONG-TERM; VENTILATORY RESPONSES; AMBIENT-TEMPERATURE; HIPPOCAMPAL SLICES; CARBON-DIOXIDE; NEWBORN RATS; PH; CHILDREN	Febrile seizures are frequent during early childhood, and prolonged ( complex) febrile seizures are associated with an increased susceptibility to temporal lobe epilepsy. The pathophysiological consequences of febrile seizures have been extensively studied in rat pups exposed to hyperthermia. The mechanisms that trigger these seizures are unknown, however. A rise in brain pH is known to enhance neuronal excitability. Here we show that hyperthermia causes respiratory alkalosis in the immature brain, with a threshold of 0.2-0.3 pH units for seizure induction. Suppressing alkalosis with 5% ambient CO2 abolished seizures within 20 s. CO2 also prevented two long-term effects of hyperthermic seizures in the hippocampus: the upregulation of the I-h current and the upregulation of CB1 receptor expression. The effects of hyperthermia were closely mimicked by intraperitoneal injection of bicarbonate. Our work indicates a mechanism for triggering hyperthermic seizures and suggests new strategies in the research and therapy of fever-related epileptic syndromes.	Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland; Univ Med Berlin, Neurosci Res Ctr, Charite, D-10119 Berlin, Germany; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Neurophysiol, Childrens Hosp, Helsinki 00029, Finland; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	University of Helsinki; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Washington; University of Washington Seattle; University of Helsinki	Kaila, K (corresponding author), Univ Helsinki, Dept Biol & Environm Sci, Viikinkaari 1 POB 65, FIN-00014 Helsinki, Finland.	kai.kaila@helsinki.fi	Vanhatalo, Sampsa/B-1393-2013; Rivera, Claudio/ABE-2499-2021; Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Kaila, Kai K/R-8528-2016	Rivera, Claudio/0000-0003-2462-6561; Mackie, Ken/0000-0001-8501-6199; Kaila, Kai K/0000-0003-0668-5955; Voipio, Juha/0000-0001-7096-1286; Schmitz, Dietmar/0000-0003-2741-5241	NIDA NIH HHS [K02 DA000286, R01 DA011322] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011322, K02DA000286] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAM JA, 1987, NEUROSCI LETT, V83, P345, DOI 10.1016/0304-3940(87)90112-1; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; Banke TG, 2005, J NEUROSCI, V25, P42, DOI 10.1523/JNEUROSCI.3154-04.2005; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Baulac S, 2004, LANCET NEUROL, V3, P421, DOI 10.1016/S1474-4422(04)00808-7; Bender RA, 2004, ADV EXP MED BIOL, V548, P213; Berg AT, 1996, EPILEPSIA, V37, P126, DOI 10.1111/j.1528-1157.1996.tb00003.x; Brewster A, 2002, J NEUROSCI, V22, P4591, DOI 10.1523/JNEUROSCI.22-11-04591.2002; Cameron YL, 2000, PEDIATR RES, V47, P813, DOI 10.1203/00006450-200006000-00022; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Chen K, 2003, NEURON, V39, P599, DOI 10.1016/S0896-6273(03)00499-9; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; CURTIS M, 1998, J NEUROSCI, V178, P7543; Dube C, 2006, BRAIN, V129, P911, DOI 10.1093/brain/awl018; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; GADOMSKI AM, 1994, J CLIN EPIDEMIOL, V47, P1043, DOI 10.1016/0895-4356(94)90120-1; Hajos N, 2000, EUR J NEUROSCI, V12, P3239, DOI 10.1046/j.1460-9568.2000.00217.x; HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x; Haut SR, 2004, LANCET NEUROL, V3, P608, DOI 10.1016/S1474-4422(04)00881-6; HOLTZMAN D, 1981, SCIENCE, V213, P1034, DOI 10.1126/science.7268407; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; KAILA K, 1998, PH BRAIN FUNCTION, P1; Kang JQ, 2006, J NEUROSCI, V26, P2590, DOI 10.1523/JNEUROSCI.4243-05.2006; Lahtinen H, 2002, J NEUROPHYSIOL, V88, P1469, DOI 10.1152/jn.2002.88.3.1469; Lee J, 1996, BRAIN RES, V706, P210, DOI 10.1016/0006-8993(95)01214-1; Mantegazza M, 2005, P NATL ACAD SCI USA, V102, P18177, DOI 10.1073/pnas.0506818102; Mariak Z, 1999, J APPL PHYSIOL, V87, P1609, DOI 10.1152/jappl.1999.87.5.1609; Mortola JP, 2000, ANNU REV PHYSIOL, V62, P847, DOI 10.1146/annurev.physiol.62.1.847; Mulley JC, 2005, HUM MOL GENET, V14, pR243, DOI 10.1093/hmg/ddi355; ODEMPSEY TJD, 1993, ARCH DIS CHILD, V68, P492, DOI 10.1136/adc.68.4.492; Prole DL, 2003, J GEN PHYSIOL, V122, P775, DOI 10.1085/jgp.200308897; Putnam RW, 2005, RESP PHYSIOL NEUROBI, V149, P165, DOI 10.1016/j.resp.2005.03.004; Putnam RW, 2004, AM J PHYSIOL-CELL PH, V287, pC1493, DOI 10.1152/ajpcell.00282.2004; Richerson GB, 2004, NAT REV NEUROSCI, V5, P449, DOI 10.1038/nrn1409; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Saiki C, 1996, J PHYSIOL-LONDON, V491, P261, DOI 10.1113/jphysiol.1996.sp021213; Schmitz D, 2003, NAT NEUROSCI, V6, P1058, DOI 10.1038/nn1116; Singh R, 1999, ANN NEUROL, V45, P75, DOI 10.1002/1531-8249(199901)45:1<75::AID-ART13>3.0.CO;2-W; TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011; Toth Z, 1998, J NEUROSCI, V18, P4285; TSUBOI T, 1984, NEUROLOGY, V34, P175, DOI 10.1212/WNL.34.2.175; Vanhatalo S, 2005, CLIN EEG NEUROSCI, V36, P311, DOI 10.1177/155005940503600411; VAUGHANJONES RD, 1986, PFLUG ARCH EUR J PHY, V406, P641, DOI 10.1007/BF00584033; Voipio J, 2003, J NEUROPHYSIOL, V89, P2208, DOI 10.1152/jn.00915.2002; VOIPIO J, 1993, PFLUG ARCH EUR J PHY, V423, P193, DOI 10.1007/BF00374394; Wirrell EC, 1996, EPILEPSIA, V37, P459, DOI 10.1111/j.1528-1157.1996.tb00592.x; Xiong ZQ, 2000, J NEUROSCI, V20, P1290; Yi DK, 1996, DEV PSYCHOBIOL, V29, P497, DOI 10.1002/(SICI)1098-2302(199609)29:6<497::AID-DEV2>3.0.CO;2-H	50	193	203	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					817	823		10.1038/nm1422	http://dx.doi.org/10.1038/nm1422			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819552	Green Accepted			2022-12-27	WOS:000238862800069
J	Yaniv, K; Isogai, S; Castranova, D; Dye, L; Hitomi, J; Weinstein, BM				Yaniv, Karina; Isogai, Sumio; Castranova, Daniel; Dye, Louis; Hitomi, Jiro; Weinstein, Brant M.			Live imaging of lymphatic development in the zebrafish	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; EMBRYONIC VASCULAR DEVELOPMENT; TRANSGENIC ZEBRAFISH; MOUSE EMBRYOS; FACTOR-C; IN-VIVO; EXPRESSION; SYSTEM; PROX1; GENE	The lymphatic system has become the subject of great interest in recent years because of its important role in normal and pathological processes. Progress in understanding the origins and early development of this system, however, has been hampered by difficulties in observing lymphatic cells in vivo and in performing defined genetic and experimental manipulation of the lymphatic system in currently available model organisms. Here, we show that the optically clear developing zebrafish provides a useful model for imaging and studying lymphatic development, with a lymphatic system that shares many of the morphological, molecular and functional characteristics of the lymphatic vessels found in other vertebrates. Using two-photon time-lapse imaging of transgenic zebrafish, we trace the migration and lineage of individual cells incorporating into the lymphatic endothelium. Our results show lymphatic endothelial cells of the thoracic duct arise from primitive veins through a novel and unexpected pathway.	NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Iwate Med Univ, Sch Med, Dept Anat, Morioka, Iwate 0208505, Japan; NICHHD, Microscopy & Imaging Core, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Iwate Medical University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Weinstein, BM (corresponding author), NICHHD, Mol Genet Lab, NIH, 6B-309,6 Ctr Dr, Bethesda, MD 20892 USA.	bw96w@nih.gov			Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008808, ZIAHD001011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008808, Z01HD001011] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bovenkamp DE, 2004, GENE EXPR PATTERNS, V4, P361, DOI 10.1016/j.modgep.2004.01.014; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Glasgow E, 1998, MECH DEVELOP, V76, P175, DOI 10.1016/S0925-4773(98)00121-X; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Huntington GS, 1910, AM J ANAT, V10, P177, DOI 10.1002/aja.1000100108; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kampmeier O.F, 1969, EVOLUTION COMP MORPH; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; Long QM, 1997, DEVELOPMENT, V124, P4105; Martyn U, 2004, DEV DYNAM, V231, P33, DOI 10.1002/dvdy.20048; Ny A, 2005, NAT MED, V11, P998, DOI 10.1038/nm1285; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; Oliver G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI 10.1146/annurev.cellbio.21.012704.132338; Pepper MS, 2003, J CELL BIOL, V163, P209, DOI 10.1083/jcb.200308082; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; TILNEY NL, 1971, J ANAT, V109, P369; van der Putte S C, 1975, Adv Anat Embryol Cell Biol, V51, P3; VANDERPUTTE SCJ, 1975, ACTA MORPHOL NEER SC, V13, P245; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wilting J, 2006, DEV BIOL, V292, P165, DOI 10.1016/j.ydbio.2005.12.043; Yu HH, 2004, GENE EXPR PATTERNS, V4, P371, DOI 10.1016/j.modgep.2004.01.011; Yuan L, 2002, DEVELOPMENT, V129, P4797	31	340	347	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					711	716		10.1038/nm1427	http://dx.doi.org/10.1038/nm1427			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732279				2022-12-27	WOS:000238149200036
J	Scortti, M; Lacharme-Lora, L; Wagner, M; Chico-Calero, I; Losito, P; Vazquez-Boland, JA				Scortti, Mariela; Lacharme-Lora, Lizeth; Wagner, Martin; Chico-Calero, Isabel; Losito, Patrizia; Vazquez-Boland, Jose Ava			Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox	NATURE MEDICINE			English	Article							MONOCYTOGENES; PENETRATION; PRFA	Discrepancies between resistance in vitro and therapeutic efficacy in vivo are generally attributed to failure of laboratory susceptibility tests to reflect an antibiotic's pharmacokinetic or pharmacodynamic properties. We show here that this phenomenon can result from differential in vitro-in vivo expression of bacterial determinants of antibiotic susceptibility. We found that an in vivo-induced virulence factor, Hpt, also mediates uptake of fosfomycin in Listeria monocytogenes. These bacteria therefore seem resistant to fosfomycin in vitro, although they are in fact susceptible to the antibiotic during infection.	Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Langford BS40 5DU, England; Univ Complutense Madrid, Fac Vet, Grp Patogenesis Mol Bacteriana, E-28040 Madrid, Spain; Univ Leon, Grp Patogenesis Mol & Genom Bacteriana, Fac Vet, E-24071 Leon, Spain	University of Bristol; Complutense University of Madrid; Universidad de Leon	Vazquez-Boland, JA (corresponding author), Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Langford BS40 5DU, England.	v.boland@bristol.ac.uk		Vazquez-Boland, Jose A/0000-0003-4521-5972	Wellcome Trust [074020] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bishai W, 2002, J ANTIMICROB CHEMOTH, V49, P433, DOI 10.1093/jac/49.3.433; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Ermolaeva S, 2004, MOL MICROBIOL, V52, P601, DOI 10.1111/j.1365-2958.2004.04003.x; Freitag NE, 1999, INFECT IMMUN, V67, P1844; Gobernado M, 2003, Rev Esp Quimioter, V16, P15; Hof H, 1997, CLIN MICROBIOL REV, V10, P345, DOI 10.1128/CMR.10.2.345; Joukhadar C, 2003, J ANTIMICROB CHEMOTH, V51, P1247, DOI 10.1093/jac/dkg187; KADNER RJ, 1983, J BACTERIOL, V155, P1052, DOI 10.1128/JB.155.3.1052-1061.1983; MICHELET C, 1994, ANTIMICROB AGENTS CH, V38, P438, DOI 10.1128/AAC.38.3.438; Ripio MT, 1997, J BACTERIOL, V179, P7174, DOI 10.1128/jb.179.22.7174-7180.1997; Sauermann R, 2005, ANTIMICROB AGENTS CH, V49, P4448, DOI 10.1128/AAC.49.11.4448-4454.2005; Troxler R, 2000, CLIN MICROBIOL INFEC, V6, P525, DOI 10.1046/j.1469-0691.2000.00168.x; Varaldo PE, 2002, J ANTIMICROB CHEMOTH, V50, P1, DOI 10.1093/jac/dkf093; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Vega Y, 2004, MOL MICROBIOL, V52, P1553, DOI 10.1111/j.1365-2958.2004.04052.x	15	54	61	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					515	517		10.1038/nm1396	http://dx.doi.org/10.1038/nm1396			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633349				2022-12-27	WOS:000238149100034
J	van Hall, T; Wolpert, EZ; van Veelen, P; Laban, S; van der Veer, M; Roseboom, M; Bres, S; Grufman, P; de Ru, A; Meiring, H; de Jong, A; Franken, K; Teixeira, A; Valentijn, R; Drijfhout, JW; Koning, F; Camps, M; Ossendorp, F; Karre, K; Ljunggren, HG; Melief, CJM; Offringa, R				van Hall, T; Wolpert, EZ; van Veelen, P; Laban, S; van der Veer, M; Roseboom, M; Bres, S; Grufman, P; de Ru, A; Meiring, H; de Jong, A; Franken, K; Teixeira, A; Valentijn, R; Drijfhout, JW; Koning, F; Camps, M; Ossendorp, F; Karre, K; Ljunggren, HG; Melief, CJM; Offringa, R			Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants	NATURE MEDICINE			English	Article							I ANTIGEN PRESENTATION; RMA-S CELLS; CTL EPITOPE; PEPTIDES; TRANSPORTER; DEFICIENT; TAP; EXPRESSION; MOLECULES; COMPLEX	Defects in major histocompatibility complex (MHC) class I-restricted antigen presentation are frequently observed in human cancers and result in escape of tumors from cytotoxic T lymphocyte (CTL) immune surveillance in mice. Here, we show the existence of a unique category of CTLs that can prevent this escape. The CTLs target an alternative repertoire of peptide epitopes that emerge in MHC class I at the surface of cells with impaired function of transporter associated with antigen processing (TAP), tapasin or the proteasome. These peptides, although derived from self antigens such as the commonly expressed Lass5 protein (also known as Trh4), are not presented by normal cells. This explains why they act as immunogenic neoantigens. The newly discovered epitopes can be exploited for immune intervention against processing-deficient tumors through adoptive T-cell transfer or peptide vaccination.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Leiden Univ, Med Ctr, Ctr Med Syst Biol, NL-2300 RC Leiden, Netherlands; Accuro Immunol, S-17177 Stockholm, Sweden; Netherlands Vaccine Inst, Unit Res & Dev, NL-3720 AL Bilthoven, Netherlands; Karolinska Inst, Strateg Res Ctr IRIS, S-17177 Stockholm, Sweden; Karolinska Univ Hosp Huddinge F59, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Huddinge, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Swedish Foundation for Strategic Research; Karolinska Institutet; Karolinska University Hospital	van Hall, T (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, POB 9600, NL-2300 RC Leiden, Netherlands.	t.van_hall@lumc.nl	Drijfhout, Jan Wouter/ABA-6318-2021; Franken, Kees/ABA-7095-2021; van Hall, Thorbald/Y-5651-2018	Drijfhout, Jan Wouter/0000-0003-4808-5296; Franken, Kees/0000-0002-4747-6060; Koning, Frits/0000-0002-4007-5715; van Veelen, Peter/0000-0002-7898-9408; Laban, Sandra/0000-0003-2710-4531; van Hall, Thorbald/0000-0002-9115-558X				Alimonti J, 2000, NAT BIOTECHNOL, V18, P515, DOI 10.1038/75373; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Chiang EY, 2003, J IMMUNOL, V170, P4515, DOI 10.4049/jimmunol.170.9.4515; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; De Silva AD, 1999, J IMMUNOL, V163, P4413; Evans M, 2001, J IMMUNOL, V167, P5420, DOI 10.4049/jimmunol.167.9.5420; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; GLAS R, 1992, J EXP MED, V175, P843, DOI 10.1084/jem.175.3.843; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Howell D, 2000, IMMUNOGENETICS, V52, P150, DOI 10.1007/s002510000254; Jensen PE, 2004, IMMUNOL RES, V29, P81, DOI 10.1385/IR:29:1-3:081; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Qin ZH, 2002, CANCER RES, V62, P2856; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Snyder HL, 1998, EUR J IMMUNOL, V28, P1339; Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Toomey JA, 1999, J IMMUNOL, V163, P3176; van Hall T, 1998, CANCER RES, V58, P3087; van Hall T, 2000, J IMMUNOL, V165, P869, DOI 10.4049/jimmunol.165.2.869; van Hall T, 2000, J EXP MED, V192, P483, DOI 10.1084/jem.192.4.483; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vivier E, 2004, NAT REV IMMUNOL, V4, P190, DOI 10.1038/nri1306; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Wolpert EZ, 1997, P NATL ACAD SCI USA, V94, P11496, DOI 10.1073/pnas.94.21.11496; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	38	113	122	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2006	12	4					417	424		10.1038/nm1381	http://dx.doi.org/10.1038/nm1381			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16550190				2022-12-27	WOS:000236581300030
J	Carpentier, A				Carpentier, Alain			The surprising rise of nonthrombogenic valvular surgery	NATURE MEDICINE			English	Editorial Material							VALVE; REPLACEMENT; CALCIFICATION; BIOPROSTHESES; HETEROGRAFTS; IMPLANTATION		Univ Paris 05, F-75270 Paris 06, France; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, F-75015 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Carpentier, A (corresponding author), Univ Paris 05, F-75270 Paris 06, France.							BINET JP, 1965, CR HEBD ACAD SCI, V261, P5733; BRAUNBERGER E, 2001, CIRCULATION S1, V104, P8; CARPENTIER A, 1984, CIRCULATION, V70, P165; CARPENTIER A, 1969, J THORAC CARDIOV SUR, V58, P467, DOI 10.1016/S0022-5223(19)42561-0; CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; CARPENTIER A, 1968, J THORAC CARDIOV SUR, V56, P388, DOI 10.1016/S0022-5223(19)42831-6; Carpentier SM, 1998, ANN THORAC SURG, V66, pS264, DOI 10.1016/S0003-4975(98)01101-1; GIBBON J H Jr, 1954, Minn Med, V37, P171; Khambadkone S, 2005, CIRCULATION, V112, P1189, DOI 10.1161/CIRCULATIONAHA.104.523266; MAGILLIGAN DJ, 1985, J THORAC CARDIOV SUR, V89, P499; Nageotte J, 1917, CR SOC BIOL, V80, P925; ROSS DN, 1962, LANCET, V2, P487; STARR A, 1961, ANN SURG, V154, P726, DOI 10.1097/00000658-196110000-00017	13	22	22	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1165	1168		10.1038/nm1645	http://dx.doi.org/10.1038/nm1645			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17917666				2022-12-27	WOS:000249980200030
J	Zhang, L; Anglesio, MS; O'Sullivan, M; Zhang, F; Yang, G; Sarao, R; Nghiem, MP; Cronin, S; Hara, H; Melnyk, N; Li, LH; Wada, T; Liu, PP; Farrar, J; Arceci, RJ; Sorensen, PH; Penninger, JM				Zhang, Liyong; Anglesio, Michael S.; O'Sullivan, Maureen; Zhang, Fan; Yang, Ge; Sarao, Renu; Nghiem, Mai P.; Cronin, Shane; Hara, Hiromitsu; Melnyk, Nataliya; Li, Liheng; Wada, Teiji; Liu, Peter P.; Farrar, Jason; Arceci, Robert J.; Sorensen, Poul H.; Penninger, Josef M.			The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers	NATURE MEDICINE			English	Article							UBIQUITIN-PROTEIN LIGASE; WILMS-TUMOR; ALLELIC LOSS; OVARIAN-TUMORS; BREAST-CANCER; CYCLIN D1; IN-SITU; TUMORIGENESIS; CARCINOMA; MICE	Transformation and cancer growth are regulated by the coordinate actions of oncogenes and tumor suppressors. Here, we show that the novel E3 ubiquitin ligase HACE1 is frequently downregulated in human tumors and maps to a region of chromosome 6q21 implicated in multiple human cancers. Genetic inactivation of HACE1 in mice results in the development of spontaneous, late-onset cancer. A second hit from either environmental triggers or genetic heterozygosity of another tumor suppressor, p53, markedly increased tumor incidence in a Hace1-deficient background. Re-expression of HACE1 in human tumor cells directly abrogates in vitro and in vivo tumor growth, whereas downregulation of HACE1 via siRNA allows non-tumorigenic human cells to form tumors in vivo. Mechanistically, the tumor-suppressor function of HACE1 is dependent on its E3 ligase activity and HACE1 controls adhesion-dependent growth and cell cycle progression during cell stress through degradation of cyclin D1. Thus, HACE1 is a candidate chromosome 6q21 tumor-suppressor gene involved in multiple cancers.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 2C4, Canada; Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON M5G 2C4, Canada; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Lab Med, Vancouver, BC V5Z 1L3, Canada; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Johns Hopkins University; Johns Hopkins Medicine	Sorensen, PH (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3, A-1030 Vienna, Austria.	psor@interchange.ubc.ca; josef.penninger@imba.oeaw.ac.at	Farrar, Jason/G-8451-2017; Penninger, Josef M/I-6860-2013	Farrar, Jason/0000-0003-2148-5839; Penninger, Josef M/0000-0002-8194-3777; O'Sullivan, Maureen/0000-0001-5838-1609; Anglesio, Michael/0000-0003-1639-5003				Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Bruce CK, 2003, CANCER GENET CYTOGEN, V141, P106, DOI 10.1016/S0165-4608(02)00669-6; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fernandez CV, 2001, CANCER GENET CYTOGEN, V129, P165, DOI 10.1016/S0165-4608(01)00445-9; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Fujii H, 2002, BREAST CANCER RES TR, V76, P255, DOI 10.1023/A:1020808020873; Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; Hoban PR, 1997, J MED GENET, V34, P343, DOI 10.1136/jmg.34.4.343; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hyytinen ER, 2002, GENE CHROMOSOME CANC, V34, P306, DOI 10.1002/gcc.10065; Inoue M, 2002, AM J PATHOL, V161, P1507, DOI 10.1016/S0002-9440(10)64426-4; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Konishi N, 2003, CANCER SCI, V94, P764, DOI 10.1111/j.1349-7006.2003.tb01516.x; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Li BCY, 2003, DIAGN MOL PATHOL, V12, P193, DOI 10.1097/00019606-200312000-00003; Lovvorn HN, 2000, J PEDIATR SURG, V35, P1070, DOI 10.1053/jpsu.2000.7774; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Nakamura M, 2003, CANCER RES, V63, P737; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Smeds J, 2005, ACTA ONCOL, V44, P41, DOI 10.1080/02841860410002842; SOLIS V, 1988, CANCER GENET CYTOGEN, V34, P223, DOI 10.1016/0165-4608(88)90264-6; Takeuchi S, 2003, ONCOGENE, V22, P6970, DOI 10.1038/sj.onc.1206974; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Thomas NA, 2003, INT J CANCER, V105, P499, DOI 10.1002/ijc.11107; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Trink B, 1998, ONCOGENE, V16, P2815, DOI 10.1038/sj.onc.1201795; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080; Yoon J, 2003, LEUKEMIA LYMPHOMA, V44, P2077, DOI 10.1080/1042819031000123410; Zhang YM, 2000, GENE CHROMOSOME CANC, V27, P52, DOI 10.1002/(SICI)1098-2264(200001)27:1<52::AID-GCC7>3.0.CO;2-X	45	106	109	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2007	13	9					1060	1069		10.1038/nm1621	http://dx.doi.org/10.1038/nm1621			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17694067				2022-12-27	WOS:000249353100033
J	Courtine, G; Bunge, MB; Fawcett, JW; Grossman, RG; Kaas, JH; Lemon, R; Maier, I; Martin, J; Nudo, RJ; Ramon-Cueto, A; Rouiller, EM; Schnell, L; Wannier, T; Schwab, ME; Edgerton, VR				Courtine, Gregoire; Bunge, Mary Bartlett; Fawcett, James W.; Grossman, Robert G.; Kaas, Jon H.; Lemon, Roger; Maier, Irin; Martin, John; Nudo, Randolph J.; Ramon-Cueto, Almudena; Rouiller, Eric M.; Schnell, Lisa; Wannier, Thierry; Schwab, Martin E.; Edgerton, V. Reggie			Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?	NATURE MEDICINE			English	Editorial Material							UPPER-LIMB MOTONEURONS; CORTICOSPINAL TRACT; UNILATERAL SECTION; CERVICAL LEVEL; MOTOR CORTEX; HAND REPRESENTATION; PYRAMIDAL TRACT; CELL GRAFTS; RECOVERY; LOCOMOTION		Univ Calif Los Angeles, Dept Physiol Sci & Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Cambridge, Brain Repair Ctr, Cambridge CB2 2PY, England; Methodist Hosp, Inst Neurol, Dept Neurosurg, Houston, TX 77030 USA; Vanderbilt Univ, Dept Psychol, Nashville, TN 37203 USA; UCL, Inst Neurol, London WC1N 3BG, England; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ Kansas, Med Ctr, Landon Ctr Aging, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Spanish Council Sci Res, Lab Neural Regenerat, Inst Biomed, Valencia 46010, Spain; Univ Fribourg, Inst Physiol, CH-1700 Fribourg, Switzerland	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Miami; University of Miami; University of Cambridge; The Methodist Hospital System; The Methodist Hospital - Houston; Vanderbilt University; University of London; University College London; University of Zurich; Columbia University; University of Kansas; University of Kansas Medical Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of Fribourg	Edgerton, VR (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci & Neurobiol, Los Angeles, CA 90095 USA.	vre@ucla.edu	Schwab, Martin E/B-6818-2016; Nudo, Randolph/B-1623-2009; courtine, gregoire/AAJ-1694-2020	courtine, gregoire/0000-0002-5744-4142; Rouiller, Eric/0000-0003-1355-6019; Fawcett, James/0000-0002-7990-4568	NINDS NIH HHS [R01 NS016446, R37 NS030853-16A1, R37 NS030853] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030853, R01NS016446] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Belci M, 2004, SPINAL CORD, V42, P417, DOI 10.1038/sj.sc.3101613; BORTOFF GA, 1993, J NEUROSCI, V13, P5105, DOI 10.1523/JNEUROSCI.13-12-05105.1993; Courtine G, 2005, BRAIN, V128, P2338, DOI 10.1093/brain/awh604; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Darian-Smith C, 2005, J COMP NEUROL, V491, P27, DOI 10.1002/cne.20686; Fawcett J, 2002, SPINAL CORD, V40, P615, DOI 10.1038/sj.sc.3101328; Fouad K, 2004, EUR J NEUROSCI, V20, P2479, DOI 10.1111/j.1460-9568.2004.03716.x; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; Friel KM, 2000, NEUROREHAB NEURAL RE, V14, P187, DOI 10.1177/154596830001400304; HEFFNER R, 1975, BRAIN BEHAV EVOLUT, V12, P161, DOI 10.1159/000124401; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; KUYPERS H. G. J. M., 1964, PROGR BRAIN RES, V11, P178; LAWRENCE DG, 1968, BRAIN, V91, P1, DOI 10.1093/brain/91.1.1; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Lemon RN, 2004, PROG BRAIN RES, V143, P263, DOI 10.1016/S0079-6123(03)43026-4; *MED RES COUNC, 2006, PRIM MED RES; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Nakajima K, 2004, PROG BRAIN RES, V143, P183, DOI 10.1016/S0079-6123(03)43018-5; Nakajima K, 2000, J NEUROPHYSIOL, V84, P698, DOI 10.1152/jn.2000.84.2.698; NATHAN PW, 1994, BRAIN, V117, P337, DOI 10.1093/brain/117.2.337; Rouiller EM, 1996, EUR J NEUROSCI, V8, P1055, DOI 10.1111/j.1460-9568.1996.tb01592.x; Schmidlin E, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-56; Schmidlin E, 2004, BRAIN RES, V1017, P172, DOI 10.1016/j.brainres.2004.05.036; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tuszynski MH, 2002, J COMP NEUROL, V449, P88, DOI 10.1002/cne.10266; Wannier T, 2005, J NEUROTRAUM, V22, P703, DOI 10.1089/neu.2005.22.703; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6	31	271	281	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2007	13	5					561	566		10.1038/nm1595	http://dx.doi.org/10.1038/nm1595			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	165JW	17479102	Green Published, Green Submitted, Green Accepted			2022-12-27	WOS:000246302800022
J	Yang, BF; Lin, HX; Xiao, JN; Lu, YJ; Luo, XB; Li, BX; Zhang, Y; Xu, CQ; Bai, YL; Wang, HZ; Chen, GH; Wang, ZG				Yang, Baofeng; Lin, Huixian; Xiao, Jiening; Lu, Yanjie; Luo, Xiaobin; Li, Baoxin; Zhang, Ying; Xu, Chaoqian; Bai, Yunlong; Wang, Huizhen; Chen, Guohao; Wang, Zhiguo			The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2	NATURE MEDICINE			English	Article							RAT-HEART; IN-VIVO; VENTRICULAR-ARRHYTHMIAS; EXPRESSION; ISCHEMIA; DISEASE; CARDIOMYOCYTES; HYPERTROPHY; INHIBITION; CONNEXIN43	MicroRNAs (miRNAs) are endogenous noncoding RNAs, about 22 nucleotides in length, that mediate post-transcriptional gene silencing by annealing to inexactly complementary sequences in the 3'-untranslated regions of target mRNAs1-3. Our current understanding of the functions of miRNAs relies mainly on their tissue-specific or developmental stage-dependent expression and their evolutionary conservation, and therefore is primarily limited to their involvement in developmental regulation and oncogenesis(2). Of more than 300 miRNAs that have been identified, miR-1 and miR-133 are considered to be muscle specific(4-6). Here we show that miR-1 is overexpressed in individuals with coronary artery disease, and that when overexpressed in normal or infarcted rat hearts, it exacerbates arrhythmogenesis. Elimination of miR-1 by an antisense inhibitor in infarcted rat hearts relieved arrhythmogenesis. miR-1 overexpression slowed conduction and depolarized the cytoplasmic membrane by post-transcriptionally repressing KCNJ2 (which encodes the K+ channel subunit Kir2.1) and GJA1 (which encodes connexin 43), and this likely accounts at least in part for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in the heart, and is a potential antiarrhythmic target.	Harbin Med Coll, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Harbin 150086, Heilongjiang, Peoples R China; Harbin Med Coll, Cardiovasc Res Inst, Harbin 150086, Heilongjiang, Peoples R China; Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Harbin Medical University; Harbin Medical University; Universite de Montreal; Universite de Montreal	Wang, ZG (corresponding author), Harbin Med Coll, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Harbin 150086, Heilongjiang, Peoples R China.	yangbf@ems.hrbmu.edu.cn; wz.email@gmail.com	wang, zhiguo/AAN-4182-2021; Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045				Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Clements-Jewery H, 2005, BRIT J PHARMACOL, V145, P551, DOI 10.1038/sj.bjp.0706231; CURTIS MJ, 1988, CARDIOVASC RES, V22, P656, DOI 10.1093/cvr/22.9.656; Diaz RJ, 2004, CIRC RES, V95, P325, DOI 10.1161/01.RES.0000137727.34938.35; Ghuran AV, 2001, BRIT MED BULL, V59, P193, DOI 10.1093/bmb/59.1.193; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; Jongsma HJ, 2000, CIRC RES, V86, P1193, DOI 10.1161/01.RES.86.12.1193; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lerner DL, 2000, CIRCULATION, V101, P547, DOI 10.1161/01.CIR.101.5.547; McLerie M, 2003, J MOL CELL CARDIOL, V35, P367, DOI 10.1016/S0022-2828(03)00014-2; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Rajan S, 2003, BASIC RES CARDIOL, V98, P39, DOI 10.1007/s00395-003-0382-2; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Salameh A, 2004, EUR J PHARMACOL, V503, P9, DOI 10.1016/j.ejphar.2004.09.024; Sarkar N, 2002, J CARDIOVASC PHARM, V39, P215, DOI 10.1097/00005344-200202000-00008; SAYED D, 2007, CIRC RES; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Yang BF, 2005, CELL PHYSIOL BIOCHEM, V16, P163, DOI 10.1159/000089842; Yue P, 2006, CELL PHYSIOL BIOCHEM, V17, P129, DOI 10.1159/000092074; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	24	892	1041	4	122	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					486	491		10.1038/nm1569	http://dx.doi.org/10.1038/nm1569			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17401374				2022-12-27	WOS:000245543900038
J	Gramaglia, I; Sobolewski, P; Meays, D; Contreras, R; Nolan, JP; Frangos, JA; Intaglietta, M; van der Heyde, HC				Gramaglia, Irene; Sobolewski, Peter; Meays, Diana; Contreras, Ramiro; Nolan, John P.; Frangos, John A.; Intaglietta, Marcos; van der Heyde, Henri C.			Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria	NATURE MEDICINE			English	Article							SICKLE-CELL-DISEASE; TANZANIAN CHILDREN; FALCIPARUM-MALARIA; HEMOGLOBIN; MICE; PATHOPHYSIOLOGY; METHEMOGLOBIN; INHIBITION; DEPLETION; HEMOLYSIS	The role of nitric oxide ( NO) in the genesis of cerebral malaria is controversial. Most investigators propose that the unfortunate consequence of the high concentrations of NO produced to kill the parasite is the development of cerebral malaria. Here we have tested this high NO bioavailability hypothesis in the setting of experimental cerebral malaria (ECM), but find instead that low NO bioavailability contributes to the genesis of ECM. Specifically, mice deficient in vascular NO synthase showed parasitemia and mortality similar to that observed in control mice. Exogenous NO did not affect parasitemia but provided marked protection against ECM; in fact, mice treated with exogenous NO were clinically indistinguishable from uninfected mice at a stage when control infected mice were moribund. Administration of exogenous NO restored NO-mediated signaling in the brain, decreased proinflammatory biomarkers in the blood, and markedly reduced vascular leak and petechial hemorrhage into the brain. Low NO bioavailability in the vasculature during ECM was caused in part by an increase in NO-scavenging free hemoglobin in the blood, by hypoargininemia, and by low blood and erythrocyte nitrite concentrations. Exogenous NO inactivated NO-scavenging free hemoglobin in the plasma and restored nitrite to concentrations observed in uninfected mice. We therefore conclude that low rather than high NO bioavailability contributes to the genesis of ECM.	La Jolla Bioengn Inst, La Jolla, CA 92037 USA	La Jolla Bioengineering Institute	van der Heyde, HC (corresponding author), La Jolla Bioengn Inst, 505 Coast Blvd, La Jolla, CA 92037 USA.	hvande@ljbi.org	Sobolewski, Peter/I-7177-2013	Sobolewski, Peter/0000-0002-2097-0990	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL040696, R29HL040696, R01HL040696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003824] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40696, R01 HL040696, R24 HL643952] Funding Source: Medline; NIAID NIH HHS [AI40667] Funding Source: Medline; NIBIB NIH HHS [EB003824, R01 EB003824-03, R01 EB003824] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; Anstey NM, 1996, T ROY SOC TROP MED H, V90, P147, DOI 10.1016/S0035-9203(96)90118-2; Astrand A, 2004, AM J PHYSIOL-REG I, V287, pR749, DOI 10.1152/ajpregu.00134.2004; Chang WL, 2001, INFECT IMMUN, V69, P7341, DOI 10.1128/IAI.69.12.7341-7348.2001; Clark CJ, 2005, INFECT IMMUN, V73, P5249, DOI 10.1128/IAI.73.8.5249-5251.2005; Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3; Combes V, 2004, AM J PATHOL, V164, P781, DOI 10.1016/S0002-9440(10)63166-5; Combes V., 2005, DRUG DISCOVERY TODAY, V2, P141, DOI [10.1016/j.ddmod.2005.05.015, DOI 10.1016/J.DDMOD.2005.05.015]; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Favre N, 1999, PARASITOLOGY, V118, P135, DOI 10.1017/S0031182098003606; Lopansri BK, 2003, LANCET, V361, P676, DOI 10.1016/S0140-6736(03)12564-0; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001/jama.294.1.81; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; ODONNELL A, 2006, T R SOC TROP MED HYG; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rivers EP, 2006, CHEST, V129, P217, DOI 10.1378/chest.129.2.217; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Serirom S, 2003, AM J PATHOL, V162, P1651, DOI 10.1016/S0002-9440(10)64299-X; Sobolewski P, 2005, TRENDS PARASITOL, V21, P415, DOI 10.1016/j.pt.2005.07.002; Sobolewski P, 2005, J INVEST MED, V53, P246, DOI 10.2310/6650.2005.53507; Srivastava S, 2000, IN VIVO, V14, P547; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Sun G, 2003, INFECT IMMUN, V71, P6553, DOI 10.1128/IAI.71.11.6553-6561.2003; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; van der Heyde HC, 2005, BLOOD, V105, P1956, DOI 10.1182/blood-2004-06-2206; van der Heyde HC, 2001, INFECT IMMUN, V69, P3460, DOI 10.1128/IAI.69.5.3460-3465.2001; VANDERHEYDE HC, 2006, TRENDS PARASITOL; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265	30	168	170	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1417	1422		10.1038/nm1499	http://dx.doi.org/10.1038/nm1499			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17099710				2022-12-27	WOS:000242618200023
J	Bhandari, V; Choo-Wing, R; Lee, CG; Zhu, Z; Nedrelow, JH; Chupp, GL; Zhang, XC; Matthay, MA; Ware, LB; Homer, RJ; Lee, PJ; Geick, A; de Fougerolles, AR; Elias, JA				Bhandari, Vineet; Choo-Wing, Rayman; Lee, Chun G.; Zhu, Zhou; Nedrelow, Jonathan H.; Chupp, Geoffrey L.; Zhang, Xucher; Matthay, Michael A.; Ware, Lorraine B.; Homer, Robert J.; Lee, Patty J.; Geick, Anke; de Fougerolles, Antonin R.; Elias, Jack A.			Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TIE-2; EXPRESSION; NECROSIS; ANGIOGENESIS; APOPTOSIS; OXYGEN; VEGF; PATHOPHYSIOLOGY; PATHOGENESIS	The angiogenic growth factor angiopoietin 2 (Ang2) destabilizes blood vessels, enhances vascular leak and induces vascular regression and endothelial cell apoptosis. We considered that Ang2 might be important in hyperoxic acute lung injury (ALI). Here we have characterized the responses in lungs induced by hyperoxia in wild-type and Ang2(-/-) mice or those given either recombinant Ang2 or short interfering RNA (siRNA) targeted to Ang2. During hyperoxia Ang2 expression is induced in lung epithelial cells, while hyperoxia-induced oxidant injury, cell death, inflammation, permeability alterations and mortality are ameliorated in Ang2(-/-) and siRNA-treated mice. Hyperoxia induces and activates the extrinsic and mitochondrial cell death pathways and activates initiator and effector caspases through Ang2-dependent pathways in vivo. Ang2 increases inflammation and cell death during hyperoxia in vivo and stimulates epithelial necrosis in hyperoxia in vitro. Ang2 in plasma and alveolar edema fluid is increased in adults with ALI and pulmonary edema. Tracheal Ang2 is also increased in neonates that develop bronchopulmonary dysplasia. Ang2 is thus a mediator of epithelial necrosis with an important role in hyperoxic ALI and pulmonary edema.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Div Perinatal Med, Dept Pediat, New Haven, CT 06520 USA; Univ Calif San Francisco, Sch Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; VACT Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA; Alnylam Pharmaceut, Cambridge, MA 02142 USA	Yale University; Yale University; University of California System; University of California San Francisco; Vanderbilt University; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St, New Haven, CT 06520 USA.	jack.elias@yale.edu	Bhandari, Vineet/AAS-3365-2020; Ware, Lorraine/AAJ-9307-2021; homer, robert/P-3884-2019; Lee, Chun Geun/AAC-2838-2021	Ware, Lorraine/0000-0002-9429-4702; homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, P01HL056389, R01HL061904, K08HL074195, R01HL064242, R37HL051856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64242, HL-61904, HL-56389, HL-74195, P50 HL056389, R01 HL064242, P01 HL056389, R37 HL051856, K08 HL074195, R37 HL051856-14] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anandarajah AP, 2004, CURR OPIN RHEUMATOL, V16, P338, DOI 10.1097/01.bor.0000129718.13939.81<; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Bhandari A, 2003, FRONT BIOSCI-LANDMRK, V8, pE370, DOI 10.2741/1060; Bloch W, 2000, FASEB J, V14, P2373; Brat DJ, 2004, LAB INVEST, V84, P397, DOI 10.1038/labinvest.3700070; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; Fearon U, 2003, J RHEUMATOL, V30, P260; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Horowitz S, 1999, CHEST, V116, p64S, DOI 10.1378/chest.116.suppl_1.64S; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Joza N, 2002, TRENDS GENET, V18, P142, DOI 10.1016/S0168-9525(01)02618-X; Karmpaliotis D, 2002, AM J PHYSIOL-LUNG C, V283, pL585, DOI 10.1152/ajplung.00048.2002; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Kimura H, 2004, HEPATOL RES, V29, P51, DOI 10.1016/j.hepres.2004.02.004; Koga K, 2001, CANCER RES, V61, P6248; LIN EY, 1993, J IMMUNOL, V151, P1979; Lip PL, 2004, BRIT J OPHTHALMOL, V88, P1543, DOI 10.1136/bjo.2004.048587; Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Mitsutake N, 2002, THYROID, V12, P95, DOI 10.1089/105072502753522310; Nakayama T, 2004, HISTOPATHOLOGY, V44, P232, DOI 10.1111/j.0309-0167.2004.01817.x; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Reilly MA, 1998, AM J RESP CELL MOL, V19, P777, DOI 10.1165/ajrcmb.19.5.3200; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; Ohashi H, 2004, MOL VIS, V10, P608; Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Richard C, 2002, PROSTATE, V50, P83; Sandhu R, 2004, CARDIOVASC RES, V64, P115, DOI 10.1016/j.cardiores.2004.05.013; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsigkos S, 2003, EXPERT OPIN INV DRUG, V12, P933, DOI 10.1517/eoid.12.6.933.21790; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wurmbach JH, 2000, ANTICANCER RES, V20, P5217; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068	50	261	277	2	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1286	1293		10.1038/nm1494	http://dx.doi.org/10.1038/nm1494			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17086189	Green Accepted			2022-12-27	WOS:000241844900026
J	Choi, M; Moschetta, A; Bookout, AL; Peng, L; Umetani, M; Holmstrom, SR; Suino-Powell, K; Xu, HE; Richardson, JA; Gerard, RD; Mangelsdorf, DJ; Kliewer, SA				Choi, Mihwa; Moschetta, Antonio; Bookout, Angie L.; Peng, Li; Umetani, Michihisa; Holmstrom, Sam R.; Suino-Powell, Kelly; Xu, H. Eric; Richardson, James A.; Gerard, Robert D.; Mangelsdorf, David J.; Kliewer, Steven A.			Identification of a hormonal basis for gallbladder filling	NATURE MEDICINE			English	Article							MOTOR FUNCTION; CYCLIC-AMP; PATHOGENESIS; GALLSTONES; ARTICLE	The cycle of gallbladder filling and emptying controls the flow of bile into the intestine for digestion. Here we show that fibroblast growth factor-15, a hormone made by the distal small intestine in response to bile acids, is required for gallbladder filling. These studies demonstrate that gallbladder filling is actively regulated by an endocrine pathway and suggest a postprandial timing mechanism that controls gallbladder motility.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA; Consorzio Mario Negri Sud, I-66030 Chieti, Italy; Univ Bari, Clin Med Murri, Policlin Bari, I-70124 Bari, Italy; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Van Andel Res Inst, Lab Struct Sci, Grand Rapids, MI 49503 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Consorzio Mario Negri Sud; Universita degli Studi di Bari Aldo Moro; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Van Andel Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kliewer, SA (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	steven.kliewer@utsouthwestern.edu	Umetani, Michi/AAP-3964-2020; Moschetta, Antonio/K-6211-2016; Moschetta, Antonio/AAC-5295-2022; Xu, H. Eric/ABD-7487-2021	Umetani, Michi/0000-0001-8474-7088; Mangelsdorf, David/0000-0002-4355-0796; Xu, H. Eric/0000-0002-6829-8144; Moschetta, Antonio/0000-0003-2123-6074	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434, R01DK067158] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19DK62434, DK067158] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON KE, 1972, ACTA PHYSIOL SCAND, V85, P511; CAREY MC, 1993, AM J SURG, V165, P410, DOI 10.1016/S0002-9610(05)80932-8; GOMEZ G, 1988, GASTROENTEROLOGY, V94, P1036, DOI 10.1016/0016-5085(88)90564-1; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Kline LW, 1997, J EXP BIOL, V200, P2669; LAMORTE WW, 1981, SURG CLIN N AM, V61, P765; Li JL, 2005, J BIOL CHEM, V280, P7427, DOI 10.1074/jbc.M411473200; MALAGELADA JR, 1973, J CLIN INVEST, V52, P2160, DOI 10.1172/JCI107400; MASCLEE AA, 2003, DIG LIVER DIS S3, V35, P35; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pauletzki J, 2000, ALIMENT PHARM THERAP, V14, P32, DOI 10.1046/j.1365-2036.2000.014s2032.x; Pozo MJ, 2004, CURR MED CHEM, V11, P1801, DOI 10.2174/0929867043364955; Shaffer EA, 2000, ALIMENT PHARM THER, V14, P2, DOI 10.1046/j.1365-2036.2000.014s2002.x; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	15	222	229	3	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1253	1255		10.1038/nm1501	http://dx.doi.org/10.1038/nm1501			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072310				2022-12-27	WOS:000241844900021
J	Minetti, GC; Colussi, C; Adami, R; Serra, C; Mozzetta, C; Parente, V; Fortuni, S; Straino, S; Sampaolesi, M; Di Padova, M; Illi, B; Gallinari, P; Steinkuhler, C; Capogrossi, MC; Sartorelli, V; Bottinelli, R; Gaetano, C; Puri, PL				Minetti, G. C.; Colussi, C.; Adami, R.; Serra, C.; Mozzetta, C.; Parente, V.; Fortuni, S.; Straino, S.; Sampaolesi, M.; Di Padova, M.; Illi, B.; Gallinari, P.; Steinkuehler, C.; Capogrossi, M. C.; Sartorelli, V.; Bottinelli, R.; Gaetano, C.; Puri, P. L.			Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors	NATURE MEDICINE			English	Article							MUSCULAR-DYSTROPHY; SKELETAL MYOGENESIS; MYOSTATIN BLOCKADE; DEFICIENT MICE; MDX MICE; EXPRESSION; SEVERITY	Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles(1,2). We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and alpha-sarcoglycan (alpha-SG)-deficient mice by inducing the expression of the myostatin antagonist follistatin(3) in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.	Fdn A Cesalpino, Dulbecco Telethon Inst, Inst Cell Biol & Tissue Engn, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; IRCCS, Ist Dermatopat Immacolata, Lab Vasc Pathol, I-00167 Rome, Italy; Univ Pavia, Dept Expt Med, Human Physiol Unit, I-27100 Pavia, Italy; Univ Pavia, Interuniv Inst Mycol, I-27100 Pavia, Italy; Burnham Inst, La Jolla, CA 92037 USA; Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; NIAMSD, Muscle Gene Express Grp, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA; IRCCS, Lab Vasc Biol & Gene Therapy, Ctr Cardiol Monzino, I-20138 Milan, Italy; Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Pavia; University of Pavia; Sanford Burnham Prebys Medical Discovery Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); IRCCS Centro Cardiologico Monzino; Merck & Company	Puri, PL (corresponding author), Fdn A Cesalpino, Dulbecco Telethon Inst, Inst Cell Biol & Tissue Engn, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.	plpuri@dti.telethon.it	Mozzetta, Chiara/Q-2786-2019; Bottinelli, Roberto/AAC-1904-2020; Gaetano, Carlo/P-9997-2019; Gallinari, Paola/ABE-8238-2021; Mozzetta, Chiara/K-9947-2018; Parente, Valeria/H-7817-2016; Sampaolesi, Maurilio/H-6509-2013; Illi, Barbara/AAY-8650-2020; canepari, Monica MC/D-7677-2015; Colussi, Claudia/H-8609-2019	Mozzetta, Chiara/0000-0002-7147-7266; Bottinelli, Roberto/0000-0002-4960-7490; Gaetano, Carlo/0000-0002-5238-1832; Mozzetta, Chiara/0000-0002-7147-7266; Parente, Valeria/0000-0001-6559-9817; Sampaolesi, Maurilio/0000-0002-2422-3757; Puri, Pier Lorenzo/0000-0003-4964-0095; Adami, Raffaella/0000-0001-9656-3219; Sartorelli, Vittorio/0000-0002-9284-3675; Colussi, Claudia/0000-0002-7727-8911; DI PADOVA, Monica/0000-0003-3808-7159	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041126, Z01AR041126] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Telethon [GGP02284] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Telethon(Fondazione Telethon)		Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Zammit PS, 2002, NAT MED, V8, P1355, DOI 10.1038/nm1202-1355	15	239	250	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1147	1150		10.1038/nm1479	http://dx.doi.org/10.1038/nm1479			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980968	Green Published			2022-12-27	WOS:000241102200030
J	Okada, S; Nakamura, M; Katoh, H; Miyao, T; Shimazaki, T; Ishii, K; Yamane, J; Yoshimura, A; Iwamoto, Y; Toyama, Y; Okano, H				Okada, Seiji; Nakamura, Masaya; Katoh, Hiroyuki; Miyao, Tamaki; Shimazaki, Takuya; Ishii, Ken; Yamane, Junichi; Yoshimura, Akihiko; Iwamoto, Yukihide; Toyama, Yoshiaki; Okano, Hideyuki			Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury	NATURE MEDICINE			English	Article							FIBRILLARY ACIDIC PROTEIN; MEDIATED RECOMBINATION; DEFICIENT MICE; GLIAL SCAR; ACTIVATION; CNS; INDUCTION; CELLS; INFILTRATION; EXPRESSION	In the injured central nervous system (CNS), reactive astrocytes form a glial scar and are considered to be detrimental for axonal regeneration, but their function remains elusive. Here we show that reactive astrocytes have a crucial role in wound healing and functional recovery by using mice with a selective deletion of the protein signal transducer and activator of transcription 3 (Stat3) or the protein suppressor of cytokine signaling 3 (Socs3) under the control of the Nes promoter-enhancer (Nes-Stat3(-/-), Nes-Socs3(-/-)). Reactive astrocytes in Nes-Stat(3-/-) mice showed limited migration and resulted in markedly widespread infiltration of inflammatory cells, neural disruption and demyelination with severe motor deficits after contusive spinal cord injury (SCI). On the contrary, we observed rapid migration of reactive astrocytes to seclude inflammatory cells, enhanced contraction of lesion area and notable improvement in functional recovery in Nes-Socs3(-/-) mice. These results suggest that Stat3 is a key regulator of reactive astrocytes in the healing process after SCI, providing a potential target for intervention in the treatment of CNS injury.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, Core Res Evoluat Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608562, Japan; Kyushu Univ, Grad Sch Med Sci, Div Mol & Cellular Immunol, Med Inst Bioregulat,Higashi Ku, Fukuoka 8128582, Japan	Keio University; Kyushu University; Japan Science & Technology Agency (JST); Keio University; Kyushu University	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Shimazaki, Takuya/L-1159-2013; Nakamura, Masaya/K-4111-2013; Yoshimura, Akihiko/K-5515-2013; Ishii, Ken J/B-1685-2012; Okano, Hideyuki/I-7584-2019; Toyama, Yoshiaki/K-5743-2013	Shimazaki, Takuya/0000-0002-3936-2098; Ishii, Ken J/0000-0002-6728-3872; Okada, Seiji/0000-0002-5107-8209; ISHII, KEN/0000-0003-0094-7918				Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Johansson CB, 2002, J NEUROSCI RES, V69, P784, DOI 10.1002/jnr.10376; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Kerr BJ, 2004, EXP NEUROL, V188, P391, DOI 10.1016/j.expneurol.2004.04.012; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Okano HJ, 1997, J NEUROSCI, V17, P3024; Ozawa Y, 2004, MOL CELL NEUROSCI, V26, P258, DOI 10.1016/j.mcn.2004.02.001; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Takeda K, 1998, J IMMUNOL, V161, P4652; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Xia XG, 2002, MOL CELL NEUROSCI, V21, P379, DOI 10.1006/mcne.2002.1180; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545	30	680	706	0	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					829	834		10.1038/nm1425	http://dx.doi.org/10.1038/nm1425			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16783372				2022-12-27	WOS:000238862800071
J	Teixeira-Clerc, F; Julien, B; Grenard, P; Van Nhieu, JT; Deveaux, V; Li, LY; Serriere-Lanneau, V; Ledent, C; Mallat, A; Lotersztajn, S				Teixeira-Clerc, Fatima; Julien, Boris; Grenard, Pascale; Van Nhieu, Jeanne Tran; Deveaux, Vanessa; Li, Liying; Serriere-Lanneau, Valerie; Ledent, Catherine; Mallat, Ariane; Lotersztajn, Sophie			CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis	NATURE MEDICINE			English	Article							HUMAN HEPATIC MYOFIBROBLASTS; SPHINGOSINE 1-PHOSPHATE; ENDOCANNABINOID SYSTEM; ANTIFIBROGENIC PROTEIN; MOLECULAR-MECHANISMS; OVERWEIGHT PATIENTS; STELLATE CELLS; RISK-FACTORS; MICE; CIRRHOSIS	Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide(1). We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of experimental liver fibrosis(2). We also found that during the course of chronic hepatitis C, daily cannabis use is an independent predictor of fibrosis progression(3). Overall, these results suggest that endocannabinoids may drive both CB2-mediated antifibrogenic effects and CB2-independent profibrogenic effects. Here we investigated whether activation of cannabinoid CB1 receptors ( encoded by Cnr1) promotes progression of fibrosis. CB1 receptors were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with the CB1 receptor antagonist SR141716A decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three models of chronic liver injury. We saw similar changes in Cnr1(-/-) mice as compared to wildtype mice. Genetic or pharmacological inactivation of CB1 receptors decreased fibrogenesis by lowering hepatic transforming growth factor ( TGF)-beta 1 and reducing accumulation of fibrogenic cells in the liver after apoptosis and growth inhibition of hepatic myofibroblasts. In conclusion, our study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis.	Hop Henri Mondor, INSERM, U581, F-94000 Creteil, France; Univ Paris 12, Fac Med, F-94000 Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, F-94000 Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, F-94000 Creteil, France; Univ Libre Bruxelles, IRIBHN, Brussels, Belgium	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Libre de Bruxelles	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U581, F-94000 Creteil, France.	sophie.lotersztajn@creteil.inserm.fr	Lotersztajn, Sophie/K-9160-2017; VAN NHIEU, Jeanne TRAN/R-5235-2018; Teixeira-Clerc, Fatima/C-9884-2009; Julien, Boris/E-2374-2012; Teixeira-Clerc, Fatima/AAB-5499-2021	Teixeira-Clerc, Fatima/0000-0003-1098-9222; lotersztajn, Sophie/0000-0002-0053-7807				Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Biecker E, 2004, EUR J CLIN INVEST, V34, P283, DOI 10.1111/j.1365-2362.2004.01331.x; Bilkei-Gorzo A, 2005, P NATL ACAD SCI USA, V102, P15670, DOI 10.1073/pnas.0504640102; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hezode C, 2005, HEPATOLOGY, V42, P63, DOI 10.1002/hep.20733; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Li LY, 2004, J HEPATOL, V41, P407, DOI 10.1016/j.jhep.2004.05.016; Li LY, 2003, GASTROENTEROLOGY, V125, P460, DOI 10.1016/S0016-5085(03)00906-5; Li LY, 2001, J BIOL CHEM, V276, P38152; Li XN, 2002, J HEPATOL, V36, P488, DOI 10.1016/S0168-8278(02)00011-9; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; MALLAT A, IN PRESS J ENDOCRINO; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; Ros J, 2002, GASTROENTEROLOGY, V122, P85, DOI 10.1053/gast.2002.30305; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Vrochides D, 1996, HEPATOLOGY, V23, P1650, DOI 10.1053/jhep.1996.v23.pm0008675189; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100	32	400	431	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					671	676		10.1038/nm1421	http://dx.doi.org/10.1038/nm1421			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715087				2022-12-27	WOS:000238149200029
J	Grossman, Z; Meier-Schellersheim, M; Paul, WE; Picker, LJ				Grossman, Z; Meier-Schellersheim, M; Paul, WE; Picker, LJ			Pathogenesis of HIV infection: what the virus spares is as important as what it destroys	NATURE MEDICINE			English	Review							T-CELL DEPLETION; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-SYSTEM ACTIVATION; AFRICAN-GREEN MONKEYS; NECROSIS-FACTOR-ALPHA; IN-VIVO ACTIVATION; TYPE-1 INFECTION; SIV INFECTION; MACROPHAGE ACTIVATION; LYMPHOCYTE ACTIVATION	Upon transmission to a new host, HIV targets CCR5(+)CD4(+) effector memory T cells, resulting in acute, massive depletion of these cells from mucosal effector sites. This depletion does not initially compromise the regenerative capacity of the immune system because naive and most central memory T cells are spared. Here, we discuss evidence suggesting that frequent activation of these spared cells during the chronic phase of HIV infection supplies mucosal tissues with short-lived CCR5(+)CD4(+) effector cells that prevent life-threatening infections. This immune activation also facilitates continued viral replication, but infection and killing of target T cells by HIV are selective and the impact on effector-cell lifespan is limited. We propose, however, that persistent activation progressively disrupts the functional organization of the immune system, reducing its regenerative capacity and facilitating viral evolution that leads to loss of the exquisite target cell-sparing selectivity of viral replication, ultimately resulting in AIDS.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Oregon Hlth & Sci Univ, Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tel Aviv University; Sackler Faculty of Medicine; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Grossman, Z (corresponding author), NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.	grossman@helix.nih.gov	Grossman, Zvi/A-9643-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000926, Z01AI000974, R01AI054292, R37AI054292] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI054292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; ASCHER MS, 1988, CLIN EXP IMMUNOL, V73, P165; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; Bentwich Z, 1998, CLIN EXP IMMUNOL, V111, P1; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; BRENCHLEY JM, IN PRESS NAT IMMUNOL; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Campbell JJ, 2001, J IMMUNOL, V166, P877, DOI 10.4049/jimmunol.166.2.877; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Evans MRW, 1996, J INFECTION, V33, P91, DOI 10.1016/S0163-4453(96)92967-9; Feinberg MB, 2002, NAT MED, V8, P537, DOI 10.1038/nm0602-537a; Feinberg MB, 2002, NAT MED, V8, P207, DOI 10.1038/nm0302-207; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Freitas AA, 2000, ANNU REV IMMUNOL, V18, P83, DOI 10.1146/annurev.immunol.18.1.83; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; Grossman Z, 2004, NAT REV IMMUNOL, V4, P387, DOI 10.1038/nri1355; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Hayashi N, 2002, P NATL ACAD SCI USA, V99, P6187, DOI 10.1073/pnas.092129899; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hellerstein MK, 2003, J CLIN INVEST, V112, P956, DOI 10.1172/JCI200317533; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hosmalin A, 2001, BLOOD, V97, P2695, DOI 10.1182/blood.V97.9.2695; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001; Lee C, 2003, J LEUKOCYTE BIOL, V74, P676, DOI 10.1189/jlb.0503206; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Li QJ, 2004, NAT IMMUNOL, V5, P791, DOI 10.1038/ni1095; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Newberry RD, 2005, IMMUNOL REV, V206, P6, DOI 10.1111/j.0105-2896.2005.00282.x; Picker L.J., 1999, FUNDAMENTAL IMMUNOLO, P479; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Picker LJ, 2005, NAT IMMUNOL, V6, P430, DOI 10.1038/ni0505-430; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; Roederer M, 1997, Semin Immunol, V9, P389, DOI 10.1006/smim.1997.0097; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Salmi M, 2005, IMMUNOL REV, V206, P100, DOI 10.1111/j.0105-2896.2005.00285.x; Schacker TW, 2002, J CLIN INVEST, V110, P1133, DOI [10.1172/JCI200216413, 10.1172/JCI0216413]; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2003, J CLIN INVEST, V112, P821, DOI 10.1172/JCI200319799; Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400; Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203, DOI 10.1097/00126334-200011010-00001; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; Veazey RS, 2003, J INFECT DIS, V187, P769, DOI 10.1086/368386; Veazey RS, 2000, J VIROL, V74, P11001, DOI 10.1128/JVI.74.23.11001-11007.2000; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101	101	302	326	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					289	295		10.1038/nm1380	http://dx.doi.org/10.1038/nm1380			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16520776				2022-12-27	WOS:000235802900025
J	Polyak, K; Hahn, WC				Polyak, K; Hahn, WC			Roots and stems: stem cells in cancer	NATURE MEDICINE			English	Review							BREAST-CANCER; SELF-RENEWAL; SIDE POPULATION; THERAPEUTIC IMPLICATIONS; COLORECTAL-CANCER; TELOMERASE; IDENTIFICATION; PROLIFERATION; LINES; TRANSPLANTATION	Cancer develops from normal tissues through the accumulation of genetic alterations that act in concert to confer malignant phenotypes. Although we have now identified some of the genes that when mutated initiate tumor formation and drive cancer progression, the identity of the cell population(s) susceptible to such transforming events remains undefined for the majority of human cancers. Recent work indicates that a small population of cells endowed with unique self-renewal properties and tumorigenic potential is present in some, and perhaps all, tumors. Although our understanding of the biology of these putative cancer stem cells remains rudimentary, the existence of such cells has implications for current conceptualizations of malignant transformation and therapeutic approaches to cancer.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Broad Inst Harvard, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Polyak, K (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P50CA089393, R01CA094074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA94074, P50 CA89393] Funding Source: Medline; NIA NIH HHS [R01 AG23145] Funding Source: Medline; PHS HHS [K01 94223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Bates RC, 2005, CANCER BIOL THER, V4, P365; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; CAUSSINUS E, 2005, NAT GENET; Cohnheim J., 1875, VIRCHOWS ARCH, V65, P64, DOI DOI 10.1007/BF01978936; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crowe DL, 2004, HISTOL HISTOPATHOL, V19, P505, DOI 10.14670/HH-19.505; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goodell MA, 2002, CYTOTHERAPY, V4, P507, DOI 10.1080/146532402761624638; Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lininger RA, 1998, MODERN PATHOL, V11, P1151; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; MAKINO S, 1956, ANN NY ACAD SCI, V63, P818, DOI 10.1111/j.1749-6632.1956.tb50894.x; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Miller SJ, 2005, BBA-REV CANCER, V1756, P25, DOI 10.1016/j.bbcan.2005.07.003; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Prindull G, 2005, EXP HEMATOL, V33, P738, DOI 10.1016/j.exphem.2005.03.002; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Setoguchi T, 2004, CELL CYCLE, V3, P414; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Singh SK, 2003, CANCER RES, V63, P5821; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Tsai RYL, 2004, INT J BIOCHEM CELL B, V36, P684, DOI 10.1016/j.biocel.2003.10.016; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Young HE, 2004, CELL BIOCHEM BIOPHYS, V40, P1, DOI 10.1385/CBB:40:1:1	63	284	306	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2006	12	3					296	300		10.1038/nm1379	http://dx.doi.org/10.1038/nm1379			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16520777				2022-12-27	WOS:000235802900026
J	Horig, H; Marincola, E; Marincola, FM				Horig, H; Marincola, E; Marincola, FM			Obstacles and opportunities in translational research	NATURE MEDICINE			English	Editorial Material							TUMOR-MARKERS; END-POINTS; CANCER; PRINCIPLES; DESIGN	Traditional boundaries among basic research, clinical research and patient- oriented research are yielding to a single, continuous, bidirectional spectrum commonly termed 'translational research' or 'translational medicine.' These encompass ( i) the definition of guidelines for drug development or for the identification and validation of clinically relevant biomarkers; ( ii) experimental nonhuman and nonclinical studies conducted with the intent of developing principles for the discovery of new therapeutic strategies; ( iii) clinical investigations that provide a biological foundation for the development of improved therapies; ( iv) any clinical trial initiated in accordance with the above goals; and ( v) basic science studies that define the biological effects of therapeutics in humans. Although these goals are essentially no different from those of traditional academic clinical research, translational research emphasizes strategies to expedite their successful implementation. Unfortunately, several barriers that delay this process need to be surmounted to make translational research more than just an interesting concept.	NIH, Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA; Columbia Univ, Ctr Med, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Sci Serv, Washington, DC 20036 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Columbia University	Marincola, FM (corresponding author), NIH, Immunogenet Sect, Dept Transfus Med, Ctr Clin, 9000 Rockville Pike, Bethesda, MD 20892 USA.	fmarincola@cc.nih.gov			CLINICAL CENTER [Z01CL002115] Funding Source: NIH RePORTER	CLINICAL CENTER		Arteaga CL, 2003, CLIN CANCER RES, V9, P1579; Atkins M, 2005, CLIN CANCER RES, V11, P3714, DOI 10.1158/1078-0432.CCR-04-2019; BERG P, 2004, ASCB NEWSLETTER, V27, P6; Bialek W, 2004, SCIENCE, V303, P788, DOI 10.1126/science.1095480; Conley BA, 2004, DIS MARKERS, V20, P35, DOI 10.1155/2004/202031; Danforth W, 2003, ACAD MED, V78, P237; Glass AG, 2001, CLIN CANCER RES, V7, P1843; Hammond MEH, 2002, SEMIN ONCOL, V29, P213, DOI 10.1053/sonc.2002.32896; HEFFLER S, 2005, HLTH AFF MILLWOOD; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Joiner KA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-19; Kluft C, 2004, MATURITAS, V47, P293, DOI 10.1016/j.maturitas.2003.11.011; Lehmann Frederic, 2003, J Transl Med, V1, P2, DOI 10.1186/1479-5876-1-2; Mankoff Stacey P, 2004, J Transl Med, V2, P14, DOI 10.1186/1479-5876-2-14; Martin JB, 2000, NEW ENGL J MED, V343, P1646, DOI 10.1056/NEJM200011303432213; MINTZBERG H, 1981, HARVARD BUS REV, V59, P103; Monsurro V, 2003, SEMIN CANCER BIOL, V13, P473, DOI 10.1016/j.semcancer.2003.09.011; Parks Malcolm R, 2004, J Transl Med, V2, P28, DOI 10.1186/1479-5876-2-28; Rees J, 2002, SCIENCE, V296, P698, DOI 10.1126/science.296.5568.698; Schechter AN, 2004, PERSPECT BIOL MED, V47, P476, DOI 10.1353/pbm.2004.0070; Snyderman R, 2004, JAMA-J AM MED ASSOC, V291, P882, DOI 10.1001/jama.291.7.882; Snyderman Ralph, 2004, J Clin Invest, V114, P1169, DOI 10.1172/JCI23463; Wadman M, 2004, NATURE, V431, P886, DOI 10.1038/431886b; Zeh HJ, 2005, J IMMUNOTHER, V28, P1, DOI 10.1097/00002371-200501000-00001; 2004, NAT MED, V10, P1003	25	74	79	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2005	11	7					705	708		10.1038/nm0705-705	http://dx.doi.org/10.1038/nm0705-705			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	942TB	16015353				2022-12-27	WOS:000230304200013
J	Kaneider, NC; Agarwal, A; Leger, AJ; Kuliopulos, A				Kaneider, NC; Agarwal, A; Leger, AJ; Kuliopulos, A			Reversing systemic inflammatory response syndrome with chemokine receptor pepducins	NATURE MEDICINE			English	Article							INTERLEUKIN-8; ACTIVATION; CXCR2; NEUTROPHIL; SEPSIS; PLASMA; COAGULATION; INHIBITION; STRATEGIES; INFECTION	We describe a new therapeutic approach for the treatment of lethal sepsis using cell-penetrating lipopeptides - termed pepducins - that target either individual or multiple chemokine receptors. Interleukin-8 (IL-8), a ligand for the CXCR1 and CXCR2 receptors, is the most potent endogenous proinflammatory chemokine in sepsis. IL-8 levels rise in blood and lung fluids to activate neutrophils and other cells, and correlate with shock, lung injury and high mortality(1-5). We show that pepducins derived from either the i1 or i3 intracellular loops of CXCR1 and CXCR2 prevent the IL-8 response of both receptors and reverse the lethal sequelae of sepsis, including disseminated intravascular coagulation and multi-organ failure in mice. Conversely, pepducins selective for CXCR4 cause a massive leukocytosis that does not affect survival. CXCR1 and CXCR2 pepducins conferred nearly 100% survival even when treatment was postponed, suggesting that our approach might be beneficial in the setting of advanced disease.	Tufts Univ, New England Med Ctr, Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064701] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 64701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; Bonecchi R, 2000, J IMMUNOL, V164, P3862, DOI 10.4049/jimmunol.164.7.3862; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; ENDO S, 1995, J INFLAMM, V45, P136; FRIEDLAND JS, 1992, INFECT IMMUN, V60, P2402, DOI 10.1128/IAI.60.6.2402-2408.1992; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943, DOI 10.1055/s-0037-1613338; HACK CE, 1992, INFECT IMMUN, V60, P2835, DOI 10.1128/IAI.60.7.2835-2842.1992; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Lomas-Neira JL, 2004, J LEUKOCYTE BIOL, V76, P58, DOI 10.1189/jlb.1103541; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Matsukawa A, 2000, Rev Immunogenet, V2, P339; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; Ness TL, 2003, J IMMUNOL, V171, P3775, DOI 10.4049/jimmunol.171.7.3775; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; REDL H, 1991, J INFECT DIS, V164, P383, DOI 10.1093/infdis/164.2.383; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Suratt BT, 2004, BLOOD, V104, P565, DOI 10.1182/blood-2003-10-3638; Taub Dennis D., 1996, Cytokine and Growth Factor Reviews, V7, P355, DOI 10.1016/S1359-6101(97)89237-4; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; WIEDERMANN CJ, 1992, J CLIN INVEST, V89, P1580, DOI 10.1172/JCI115752	30	101	109	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					661	665		10.1038/nm1245	http://dx.doi.org/10.1038/nm1245			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880119				2022-12-27	WOS:000229589800033
J	Krutzik, SR; Tan, B; Li, HY; Ochoa, MT; Liu, PT; Sharfstein, SE; Graeber, TG; Sieling, PA; Liu, YJ; Rea, TH; Bloom, BR; Modlin, RL				Krutzik, SR; Tan, B; Li, HY; Ochoa, MT; Liu, PT; Sharfstein, SE; Graeber, TG; Sieling, PA; Liu, YJ; Rea, TH; Bloom, BR; Modlin, RL			TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; LECTIN DC-SIGN; T-CELLS; CUTTING EDGE; ANTIMICROBIAL ACTIVITY; INDUCED EXPRESSION; HOST-DEFENSE; ANTIGEN; CD209; GENE	Leprosy enables investigation of mechanisms by which the innate immune system contributes to host defense against infection, because in one form, the disease progresses, and in the other, the infection is limited. We report that Toll-like receptor (TLR) activation of human monocytes induces rapid differentiation into two distinct subsets: DC-SIGN(+)CD16(+) macrophages and CD1b(+) DC-SIGN(-) dendritic cells. DC-SIGN(+) phagocytic macrophages were expanded by TLR-mediated upregulation of interleukin ( IL)-15 and IL-15 receptor. CD1b(+) dendritic cells were expanded by TLR-mediated upregulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor, promoted T cell activation and secreted proinflammatory cytokines. Whereas DC-SIGN(+) macrophages were detected in lesions and after TLR activation in all leprosy patients, CD1b(+) dendritic cells were not detected in lesions or after TLR activation of peripheral monocytes in individuals with the progressive lepromatous form, except during reversal reactions in which bacilli were cleared by T helper type 1 ( T(H)1) responses. In tuberculoid lepromatous lesions, DC-SIGN(+) cells were positive for macrophage markers, but negative for dendritic cell markers. Thus, TLR-induced differentiation of monocytes into either macrophages or dendritic cells seems to crucially influence effective host defenses in human infectious disease.	Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Immunol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Div Dermatol, 611 Charles Young Dr E,536 Boyer Hall, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Modlin, Robert L/M-7941-2014; Liu, Philip/C-9638-2011; Liu, Philip/C-2524-2009	Modlin, Robert L/0000-0003-4720-031X; Liu, Philip/0000-0002-6144-0304; Ochoa, Maria T/0000-0001-6550-5008; Graeber, Thomas/0000-0001-8574-9181	NIAID NIH HHS [R01 AI022553, AI 07126, R37 AI047868, AI 47866, R01 AI047866, AI 22553, T32 AI007126, N01 AI 75320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI022553, R01AI047866, N01AI075320, R37AI047868] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029; Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Doyle SE, 2004, J EXP MED, V199, P81, DOI 10.1084/jem.20031237; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Giordano D, 2003, J IMMUNOL, V171, P6421, DOI 10.4049/jimmunol.171.12.6421; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Judge AD, 2002, J EXP MED, V196, P935, DOI 10.1084/jem.20020772; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kim J, 1997, J IMMUNOL, V159, P335; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Ochoa MT, 2001, NAT MED, V7, P174, DOI 10.1038/84620; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Schluns KS, 2002, J IMMUNOL, V168, P4827, DOI 10.4049/jimmunol.168.10.4827; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; van Lent PLEM, 2003, ARTHRITIS RHEUM, V48, P360, DOI 10.1002/art.10786; WEMAMBU SNC, 1969, LANCET, V2, P933; YAMAMURA M, 1992, J IMMUNOL, V149, P1470; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	43	309	328	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					653	660		10.1038/nm1246	http://dx.doi.org/10.1038/nm1246			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15880118	Green Accepted			2022-12-27	WOS:000229589800032
J	Petrache, I; Natarajan, V; Zhen, LJ; Medler, TR; Richter, AT; Cho, C; Hubbard, WC; Berdyshev, EV; Tuder, RM				Petrache, I; Natarajan, V; Zhen, LJ; Medler, TR; Richter, AT; Cho, C; Hubbard, WC; Berdyshev, EV; Tuder, RM			Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NIEMANN-PICK-DISEASE; SPHINGOMYELINASE-DEFICIENT MICE; LUNG ADENOCARCINOMA CELLS; ACTIVATED PROTEIN-KINASE; SMOKE-INDUCED EMPHYSEMA; ACID SPHINGOMYELINASE; LIQUID-CHROMATOGRAPHY; GENE-EXPRESSION; STRESS	Alveolar cell apoptosis is involved in the pathogenesis of emphysema, a prevalent disease primarily caused by cigarette smoking. We report that ceramide, a second messenger lipid, is a crucial mediator of alveolar destruction in emphysema. Inhibition of enzymes controlling de novo ceramide synthesis prevented alveolar cell apoptosis, oxidative stress and emphysema caused by blockade of the vascular endothelial growth factor ( VEGF) receptors in both rats and mice. Emphysema was reproduced with intratracheal instillation of ceramide in naive mice. Excessive ceramide triggers a feed-forward mechanism mediated by activation of secretory acid sphingomyelinase, as suggested by experiments with neutralizing ceramide antibody in mice and with acid sphingomyelinase-deficient fibroblasts. Concomitant augmentation of signaling initiated by a prosurvival metabolite, sphingosine-1-phosphate, prevented lung apoptosis, implying that a balance between ceramide and sphingosine-1-phosphate is required for maintenance of alveolar septal integrity. Finally, increased lung ceramides in individuals with smoking-induced emphysema suggests that ceramide upregulation may be a crucial pathogenic element and a promising target in this disease that currently lacks effective therapies.	Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, JHAAC, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Pathol, Div Cardiopulm Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Med, Div Allergy & Immunol, JHAAC, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Petrache, I (corresponding author), Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, JHAAC, 5501 Hopkins Bayview Circle,4B-65, Baltimore, MD 21224 USA.	ipetra@jhmi.edu		Cho, Chung/0000-0002-3718-9332	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016798] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152, K08HL004396, R01HL105772, R01HL066554] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10 RR16798] Funding Source: Medline; NHLBI NIH HHS [R01 HL105772, K08 HL04396, K08 HL004396, R01 HL71152, R01 HL071152, R01HL66554, R01 HL066554] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berdyshev EV, 2005, ANAL BIOCHEM, V339, P129, DOI 10.1016/j.ab.2004.12.006; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dobrowsky RT, 2001, METHOD CELL BIOL, V66, P135; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Heinrich M, 2000, ADV EXP MED BIOL, V477, P305; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Ikegami M, 2003, AM J PHYSIOL-LUNG C, V284, pL518, DOI 10.1152/ajplung.00258.2002; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Luberto C, 2002, NEUROCHEM RES, V27, P609, DOI 10.1023/A:1020267831851; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Morita Y, 2000, ANN NY ACAD SCI, V905, P209; Norred WP, 1996, ADV EXP MED BIOL, V392, P225; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Pautz A, 2002, KIDNEY INT, V61, P790, DOI 10.1046/j.1523-1755.2002.00222.x; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Ravid T, 2003, AM J PHYSIOL-LUNG C, V284, pL1082, DOI 10.1152/ajplung.00172.2002; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Shapiro SD, 2000, J CLIN INVEST, V106, P1309, DOI 10.1172/JCI11344; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Sullards M C, 2001, Sci STKE, V2001, ppl1; Taraseviciene-Stewart L, 2005, AM J RESP CRIT CARE, V171, P734, DOI 10.1164/rccm.200409-1275OC; Tepper AD, 2000, METHOD ENZYMOL, V312, P16; Tilly JL, 2002, BBA-MOL CELL BIOL L, V1585, P135, DOI 10.1016/S1388-1981(02)00333-5; Tuder RM, 2000, CHEST, V117, p241S, DOI 10.1378/chest.117.5_suppl_1.241S; Tuder RM, 2003, AM J RESP CELL MOL, V29, P88, DOI 10.1165/rcmb.2002-0228OC; Tuder RM, 2003, AM J RESP CELL MOL, V28, P551, DOI 10.1165/rcmb.F269; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	50	385	403	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					491	498		10.1038/nm1238	http://dx.doi.org/10.1038/nm1238			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15852018	Green Accepted			2022-12-27	WOS:000228915000020
J	Tuszynski, MH; Thal, L; Pay, M; Salmon, DP; Sang, UH; Bakay, R; Patel, P; Blesch, A; Vahlsing, HL; Ho, G; Tong, G; Potkin, SG; Fallon, J; Hansen, L; Mufson, EJ; Kordower, JH; Gall, C; Conner, J				Tuszynski, MH; Thal, L; Pay, M; Salmon, DP; Sang, UH; Bakay, R; Patel, P; Blesch, A; Vahlsing, HL; Ho, G; Tong, G; Potkin, SG; Fallon, J; Hansen, L; Mufson, EJ; Kordower, JH; Gall, C; Conner, J			A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease	NATURE MEDICINE			English	Article							CHOLINERGIC NEURONAL DEGENERATION; PRIMATE BRAIN; NEUROTROPHIC FACTOR; PARKINSON-DISEASE; INFUSION; NGF; CELLS; AMELIORATION; INNERVATION; PLASTICITY	Cholinergic neuron loss is a cardinal feature of Alzheimer disease. Nerve growth factor (NGF) stimulates cholinergic function, improves memory and prevents cholinergic degeneration in animal models of injury, amyloid overexpression and aging. We performed a phase 1 trial of ex vivo NGF gene delivery in eight individuals with mild Alzheimer disease, implanting autologous fibroblasts genetically modified to express human NGF into the forebrain. After mean follow-up of 22 months in six subjects, no long-term adverse effects of NGF occurred. Evaluation of the Mini-Mental Status Examination and Alzheimer Disease Assessment Scale-Cognitive subcomponent suggested improvement in the rate of cognitive decline. Serial PET scans showed significant (P < 0.05) increases in cortical 18-fluorodeoxyglucose after treatment. Brain autopsy from one subject suggested robust growth responses to NGF. Additional clinical trials of NGF for Alzheimer disease are warranted.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Rush Univ, Med Ctr, Dept Surg, Chicago, IL 60612 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Rush Univ, Med Ctr, Dept Neurosci, Chicago, IL 60612 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Rush University; University of California System; University of California San Diego; University of California System; University of California Irvine; University of California System; University of California Irvine; Rush University	Tuszynski, MH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	mtuszynski@ucsd.edu	Potkin, Steven G/A-2021-2013	Potkin, Steven/0000-0003-1028-1013; Blesch, Armin/0000-0003-1133-1174				BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; CHEN KS, 1995, J NEUROSCI, V15, P2819; Conner JM, 2001, P NATL ACAD SCI USA, V98, P1941, DOI 10.1073/pnas.98.4.1941; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Cooper JD, 2001, P NATL ACAD SCI USA, V98, P10439, DOI 10.1073/pnas.181219298; EMERICH DF, 1994, J COMP NEUROL, V349, P148, DOI 10.1002/cne.903490110; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Gottwald B, 2003, NEUROPSYCHOLOGIA, V41, P1452, DOI 10.1016/S0028-3932(03)00090-3; HEFTI F, 1986, J NEUROSCI, V6, P2155; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lyons KE, 2004, NEUROLOGY, V63, P612, DOI 10.1212/01.WNL.0000134650.91974.1A; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; Mayeux R, 1999, NEW ENGL J MED, V341, P1670, DOI 10.1056/NEJM199911253412207; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mesulam M, 2004, LEARN MEMORY, V11, P43, DOI 10.1101/lm.69204; MESULAM MM, 1988, J COMP NEUROL, V275, P216, DOI 10.1002/cne.902750205; Molinari M, 2002, NEUROSCIENCE, V111, P863, DOI 10.1016/S0306-4522(02)00024-6; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; Potkin SG, 2001, INT J NEUROPSYCHOPH, V4, P223, DOI 10.1017/S1461145701002528; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; STERN RG, 1994, AM J PSYCHIAT, V151, P390; Thal LJ, 2003, NEUROLOGY, V61, P1498, DOI 10.1212/01.WNL.0000096376.03678.C1; Tuszynski MH, 1996, GENE THER, V3, P305; Tuszynski MH, 2002, LANCET NEUROL, V1, P51, DOI 10.1016/S1474-4422(02)00006-6; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604	35	755	811	2	80	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2005	11	5					551	555		10.1038/nm1239	http://dx.doi.org/10.1038/nm1239			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15852017				2022-12-27	WOS:000228915000028
J	Robinson, HL; Amara, RR				Robinson, HL; Amara, RR			T cell vaccines for microbial infections	NATURE MEDICINE			English	Review							VIRUS 89.6P CHALLENGE; IMMUNE-RESPONSES; ANTIVIRAL IMMUNITY; IN-VIVO; IMMUNOLOGICAL MEMORY; MALARIA VACCINATION; PROTECTIVE IMMUNITY; MUCOSAL CHALLENGE; DENDRITIC CELLS; DNA/MVA VACCINE	Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease(1). Historically, most vaccines have worked by eliciting long-lived plasma cells. These cells produce antibodies that limit disease by neutralizing a toxin or blocking the spread of the infectious agent. For these 'B cell vaccines,' the immunological marker, or correlate, for protection is the titer of protective antibodies. With the discovery of HIV/AIDS, vaccine development has been confronted by an agent that is not easily blocked by antibody(2). To overcome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular immunity, or 'T cell vaccines,' which recognize and kill infected cells(3,4).	Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30329 USA; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	Emory University; Emory University	Robinson, HL (corresponding author), Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30329 USA.	hrobins@rmy.emory.edu	Amara, Rama/AAO-8136-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI049364, P01AI043045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA012121] Funding Source: NIH RePORTER; NCRR NIH HHS [P51 RR000165] Funding Source: Medline; NIAID NIH HHS [P01-AI43045, P01-AI49364] Funding Source: Medline; NIDA NIH HHS [P30 DA 12121] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Amara RR, 2004, J VIROL, V78, P3811, DOI 10.1128/JVI.78.8.3811-3816.2004; Amara RR, 2002, J VIROL, V76, P6138, DOI 10.1128/JVI.76.12.6138-6146.2002; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Badovinac VP, 2003, J IMMUNOL, V170, P4933, DOI 10.4049/jimmunol.170.10.4933; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 1998, J IMMUNOL, V161, P1875; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Faint JM, 2001, J IMMUNOL, V167, P212, DOI 10.4049/jimmunol.167.1.212; Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Grayson JM, 2002, J IMMUNOL, V169, P3760, DOI 10.4049/jimmunol.169.7.3760; Gruener NH, 2001, J VIROL, V75, P5550, DOI 10.1128/JVI.75.12.5550-5558.2001; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kagi D, 1999, EUR J IMMUNOL, V29, P3262, DOI 10.1002/(SICI)1521-4141(199910)29:10<3262::AID-IMMU3262>3.0.CO;2-A; KAHN P, 2003, IAVI, V7, P10; Khan IA, 1999, J IMMUNOL, V163, P4503; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Lai Ching-Juh, 2003, Adv Virus Res, V61, P469, DOI 10.1016/S0065-3527(03)61013-4; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Letvin NL, 2005, ANNU REV MED, V56, P213, DOI 10.1146/annurev.med.54.101601.152349; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; MACGREGOR RR, 1996, INT C AIDS, V11, P23; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; McKay PF, 2002, J IMMUNOL, V168, P332, DOI 10.4049/jimmunol.168.1.332; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x; Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118; Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515; Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5; Nossal GJV, 2000, NAT IMMUNOL, V1, P5, DOI 10.1038/76852; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Pardigon N, 1998, INT IMMUNOL, V10, P619, DOI 10.1093/intimm/10.5.619; Prlic M, 2002, J EXP MED, V195, pF49, DOI 10.1084/jem.20020767; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Ravkov EV, 2003, J IMMUNOL, V170, P2461, DOI 10.4049/jimmunol.170.5.2461; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Reyes-Sandoval A, 2004, J VIROL, V78, P7392, DOI 10.1128/JVI.78.14.7392-7399.2004; Robinson HL, 2002, NAT REV IMMUNOL, V2, P239, DOI 10.1038/nri776; Robinson R, 2000, J GEOPHYS RES-SOL EA, V105, P16139, DOI 10.1029/2000JB900012; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; Sadagopal S, 2005, J VIROL, V79, P3243, DOI 10.1128/JVI.79.6.3243-3253.2005; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Santra S, 2004, P NATL ACAD SCI USA, V101, P11088, DOI 10.1073/pnas.0401954101; Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Smith JM, 2004, AIDS RES HUM RETROV, V20, P1335, DOI 10.1089/aid.2004.20.1335; Smith JM, 2004, AIDS RES HUM RETROV, V20, P654, DOI 10.1089/0889222041217419; Sprent J, 2000, PHILOS T R SOC B, V355, P317, DOI 10.1098/rstb.2000.0568; Sumida SM, 2004, J VIROL, V78, P2666, DOI 10.1128/JVI.78.6.2666-2673.2004; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066; van Leeuwen EM, 2002, J IMMUNOL, V169, P5838, DOI 10.4049/jimmunol.169.10.5838; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Waldrop SL, 1998, J IMMUNOL, V161, P5284; Welsh RM, 2004, ANNU REV IMMUNOL, V22, P711, DOI 10.1146/annurev.immunol.22.012703.104527; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wherry EJ, 1999, J IMMUNOL, V163, P3735; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Yajima T, 2002, J IMMUNOL, V168, P1198, DOI 10.4049/jimmunol.168.3.1198; Yang ZY, 2003, J VIROL, V77, P799, DOI 10.1128/JVI.77.1.799-803.2003	92	154	163	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S25	S32		10.1038/nm1212	http://dx.doi.org/10.1038/nm1212			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812486	Bronze			2022-12-27	WOS:000228339600008
J	Schubert, C				Schubert, C			Gene variant thickens arteries	NATURE MEDICINE			English	News Item								Loss-of-function polymorphism in the gene encoding for tissue kallikrein has been found to cause narrowing of the arterial lumen.										Azizi M, 2005, J CLIN INVEST, V115, P780, DOI 10.1172/JCI200523669	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-27	WOS:000228180500028
J	Tao, R; de Zoeten, EF; Ozkaynak, E; Chen, CX; Wang, LQ; Porrett, PM; Li, B; Turka, LA; Olson, EN; Greene, MI; Wells, AD; Hancock, WW				Tao, Ran; de Zoeten, Edwin F.; Oezkaynak, Engin; Chen, Chunxia; Wang, Liqing; Porrett, Paige M.; Li, Bin; Turka, Laurence A.; Olson, Eric N.; Greene, Mark I.; Wells, Andrew D.; Hancock, Wayne W.			Deacetylase inhibition promotes the generation and function of regulatory T cells	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR FOXP3; HISTONE-DEACETYLASE; TRICHOSTATIN-A; EXPERIMENTAL COLITIS; CHEMOKINE RECEPTOR; PROGRAMMED DEATH-1; PERMANENT SURVIVAL; ISLET ALLOGRAFTS; GENE-EXPRESSION; DNA-BINDING	Histone/protein deacetylases (HDACs) regulate chromatin remodeling and gene expression as well as the functions of more than 50 transcription factors and nonhistone proteins. We found that administration of an HDAC inhibitor (HDACi) in vivo increased Foxp3 gene expression, as well as the production and suppressive function of regulatory T cells (T-reg cells). Although T-reg cells express multiple HDACs, HDAC9 proved particularly important in regulating Foxp3-dependent suppression. Optimal Treg function required acetylation of several lysines in the forkhead domain of Foxp3, and Foxp3 acetylation enhanced binding of Foxp3 to the II2 promoter and suppressed endogenous IL-2 production. HDACi therapy in vivo enhanced T-reg-mediated suppression of homeostatic proliferation, decreased inflammatory bowel disease through T-reg-dependent effects, and, in conjunction with a short course of low-dose rapamycin, induced permanent, Treg-dependent cardiac and islet allograft survival and donor-specific allograft tolerance. Our data show that use of HDACi allows the beneficial pharmacologic enhancement of both the numbers and suppressive function of Foxp3+ T-reg cells.	Childrens Hosp Philadelphia, Div Transplantat Immunol, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Biesecker Ctr Studies Pediat Liver Dis, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hancock, WW (corresponding author), Childrens Hosp Philadelphia, Div Transplantat Immunol, Dept Pathol & Lab Med, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	whancock@mail.med.upenn.edu	Porrett, Paige/AAU-8992-2020; lI, Bin/AAR-4966-2021	lI, Bin/0000-0002-7640-8884; de Zoeten, Edwin/0000-0002-0946-9759	NIAID NIH HHS [R01 AI 54720] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almeida ARM, 2006, INT IMMUNOL, V18, P1607, DOI 10.1093/intimm/dxl093; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Elson CO, 2005, IMMUNOL REV, V206, P260, DOI 10.1111/j.0105-2896.2005.00291.x; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fukuzaki T, 1998, TRANSPLANTATION, V65, P1036, DOI 10.1097/00007890-199804270-00005; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hricik DE, 2003, AM J TRANSPLANT, V3, P878, DOI 10.1034/j.1600-6143.2003.00132.x; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Lam AL, 2005, CHROMOSOMA, V114, P242, DOI 10.1007/s00412-005-0001-0; Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709; Lee I, 2003, J IMMUNOL, V171, P6929, DOI 10.4049/jimmunol.171.12.6929; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Liang S, 2005, J EXP MED, V201, P127, DOI 10.1084/jem.20041201; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002; Melgar S, 2005, AM J PHYSIOL-GASTR L, V288, pG1328, DOI 10.1152/ajpgi.00467.2004; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreira JMA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-30; Nusinzon Inna, 2005, Sci STKE, V2005, pre11, DOI 10.1126/stke.2962005re11; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Shintani N, 1998, GEN PHARMACOL-VASC S, V31, P477, DOI 10.1016/S0306-3623(98)00004-4; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Tao R, 2005, J IMMUNOL, V175, P5774, DOI 10.4049/jimmunol.175.9.5774; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Tian L, 2005, GENETICS, V169, P337, DOI 10.1534/genetics.104.033142; Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x; Wang LQ, 2005, J IMMUNOL, V175, P6311, DOI 10.4049/jimmunol.175.10.6311; Wang LQ, 2005, EUR J IMMUNOL, V35, P428, DOI 10.1002/eji.200425518; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Workman CJ, 2005, J IMMUNOL, V174, P688, DOI 10.4049/jimmunol.174.2.688; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	50	682	726	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1299	1307		10.1038/nm1652	http://dx.doi.org/10.1038/nm1652			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17922010				2022-12-27	WOS:000250736900022
J	Podrez, EA; Byzova, TV; Febbraio, M; Salomon, RG; Ma, Y; Valiyaveettil, M; Poliakov, E; Sun, M; Finton, PJ; Curtis, BR; Chen, J; Zhang, R; Silverstein, RL; Hazen, SL				Podrez, Eugene A.; Byzova, Tatiana V.; Febbraio, Maria; Salomon, Robert G.; Ma, Yi; Valiyaveettil, Manojkumar; Poliakov, Eugenia; Sun, Mingjiang; Finton, Paula J.; Curtis, Brian R.; Chen, Juhua; Zhang, Renliang; Silverstein, Roy L.; Hazen, Stanley L.			Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype	NATURE MEDICINE			English	Article							SCAVENGER RECEPTOR CD36; LOW-DENSITY-LIPOPROTEIN; GLYCOPROTEIN-IV CD36; PERCUTANEOUS CORONARY INTERVENTION; OXIDIZED PHOSPHOLIPIDS; ANTIOXIDANT STATUS; TYROSINE KINASES; APOLIPOPROTEIN-E; MICE; ATHEROSCLEROSIS	Dyslipidemia is associated with a prothrombotic phenotype; however, the mechanisms responsible for enhanced platelet reactivity remain unclear. Proatherosclerotic lipid abnormalities are associated with both enhanced oxidant stress and the generation of biologically active oxidized lipids, including potential ligands for the scavenger receptor CD36, a major platelet glycoprotein. Using multiple mouse in vivo thrombosis models, we now demonstrate that genetic deletion of Cd36 protects mice from hyperlipidemia-associated enhanced platelet reactivity and the accompanying prothrombotic phenotype. Structurally defined oxidized choline glycerophospholipids that serve as high-affinity ligands for CD36 were at markedly increased levels in the plasma of hyperlipidemic mice and in the plasma of humans with low HDL levels, were able to bind platelets via CD36 and, at pathophysiological levels, promoted platelet activation via CD36. Thus, interactions of platelet CD36 with specific endogenous oxidized lipids play a crucial role in the well-known clinical associations between dyslipidemia, oxidant stress and a prothrombotic phenotype.	Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Blood Ctr SE Wisconsin Inc, Platelet & Neutrophil Immunol Lab, Milwaukee, WI 53233 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Versiti Blood Center of Wisconsin; Cleveland Clinic Foundation	Podrez, EA (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	podreze@ccf.org	Salomon, Robert G/C-3463-2008; Curtis, Brian R/AAT-7861-2020; Hazen, Stanley L/ABD-5845-2021	Byzova, Tatiana/0000-0002-2615-875X; Salomon, Robert/0000-0001-9456-3557	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [P01 HL072942, R01 HL070621, HL072942, HL46403, HL053315, R01 HL071625-05, R01 HL071625, P01 HL046403, P50 HL81011, P01 HL077107, P50 HL077107, HL077107, HL073311, R01 HL077213, HL071625, P50 HL081011, P01 HL073311, R01 HL070083, HL077213, P01 HL073311-050004, R01 HL077213-05, P01 HL076491, HL70621, HL076491, R01 HL053315, HL 70083] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070083, P01HL076491, R01HL070621, R01HL053315, P01HL072942, P01HL046403, R01HL071625, R01HL077213, P50HL081011, P01HL073311, P50HL077107] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Berliner JA, 2005, NEW ENGL J MED, V353, P9, DOI 10.1056/NEJMp058118; Bodart V, 2002, CIRC RES, V90, P844, DOI 10.1161/01.RES.0000016164.02525.B4; Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200; CARVALHO AC, 1974, NEW ENGL J MED, V290, P434, DOI 10.1056/NEJM197402212900805; Cipollone F, 2002, CIRCULATION, V106, P399, DOI 10.1161/01.CIR.0000025419.95769.F0; DAVI G, 1992, CIRCULATION, V85, P1792, DOI 10.1161/01.CIR.85.5.1792; Davi G, 1998, CIRCULATION, V97, P953; Eitzman DT, 2000, ARTERIOSCL THROM VAS, V20, P1831, DOI 10.1161/01.ATV.20.7.1831; Englyst NA, 2003, DIABETES, V52, P1248, DOI 10.2337/diabetes.52.5.1248; Febbraio M, 2004, ARTERIOSCL THROM VAS, V24, P2333, DOI 10.1161/01.ATV.0000148007.06370.68; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; Kabbani SS, 2003, AM J CARDIOL, V91, P876, DOI 10.1016/S0002-9149(03)00025-0; Kabbani SS, 2001, CIRCULATION, V104, P181, DOI 10.1161/01.CIR.104.2.181; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; Maschberger P, 2000, J BIOL CHEM, V275, P19159, DOI 10.1074/jbc.M910257199; MORITOKI H, 1994, J MATER PROCESS TECH, V45, P589, DOI 10.1016/0924-0136(94)90403-0; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; Philips JA, 2005, SCIENCE, V309, P1251, DOI 10.1126/science.1116006; PLOW EF, 1985, BLOOD, V66, P724; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Prevost N, 2005, P NATL ACAD SCI USA, V102, P9820, DOI 10.1073/pnas.0404065102; SALONEN JT, 1991, AM J CLIN NUTR, V53, P1222, DOI 10.1093/ajcn/53.5.1222; Sarma J, 2002, CIRCULATION, V105, P2166, DOI 10.1161/01.CIR.0000015700.27754.6F; Schafer K, 2003, ARTERIOSCL THROM VAS, V23, P2097, DOI 10.1161/01.ATV.0000097766.36623.DF; Simon DI, 2000, J CLIN INVEST, V105, P293, DOI 10.1172/JCI7811; STUART MJ, 1980, NEW ENGL J MED, V302, P6, DOI 10.1056/NEJM198001033020102; Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1991, BLOOD, V78, P2809; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; Vanschoonbeek K, 2002, THROMB HAEMOSTASIS, V88, P931, DOI 10.1055/s-0037-1613336; Vericel E, 2004, DIABETES, V53, P1046, DOI 10.2337/diabetes.53.4.1046; WANG TH, 2005, EUR HEART J; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	45	337	347	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1086	1095		10.1038/nm1626	http://dx.doi.org/10.1038/nm1626			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17721545	Green Accepted			2022-12-27	WOS:000249353100036
J	Cohn, RD; van Erp, C; Habashi, JP; Soleimani, AA; Klein, EC; Lisi, MT; Gamradt, M; Rhys, CMA; Holm, TM; Loeys, BL; Ramirez, F; Judge, DP; Ward, CW; Dietz, HC				Cohn, Ronald D.; van Erp, Christel; Habashi, Jennifer P.; Soleimani, Arshia A.; Klein, Erin C.; Lisi, Matthew T.; Gamradt, Matthew; Rhys, Colette M. ap; Holm, Tammy M.; Loeys, Bart L.; Ramirez, Francesco; Judge, Daniel P.; Ward, Christopher W.; Dietz, Harry C.			Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states	NATURE MEDICINE			English	Article							TRANSFORMING-GROWTH-FACTOR; MARFAN-SYNDROME; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MOUSE MODEL; MDX MICE; EXPRESSION; MYOSTATIN; DIFFERENTIATION; PATHOGENESIS	Skeletal muscle has the ability to achieve rapid repair in response to injury or disease(1). Many individuals with Marfan syndrome (MFS), caused by a deficiency of extracellular fibrillin-1, exhibit myopathy and often are unable to increase muscle mass despite physical exercise. Evidence suggests that selected manifestations of MFS reflect excessive signaling by transforming growth factor (TGF)-beta (refs. 2,3). TGF-beta is a known inhibitor of terminal differentiation of cultured myoblasts; however, the functional contribution of TGF-beta signaling to disease pathogenesis in various inherited myopathic states in vivo remains unknown(4,5). Here we show that increased TGF-beta activity leads to failed muscle regeneration in fibrillin-1 deficient mice. Systemic antagonism of TGF-beta through administration of TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and function in vivo. Moreover, we show TGF-beta-induced failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Cardiol, Baltimore, MD 21205 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21202 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, 733 N Broadway, Baltimore, MD 21205 USA.	hdietz@jhmi.edu	Cohn, Ronald/AAC-5835-2021; Loeys, Bart/B-3236-2017	Loeys, Bart/0000-0003-3703-9518; Steinbach, Erin/0000-0002-6165-8928; Judge, Daniel/0000-0002-3407-0248	NIAMS NIH HHS [R01 AR041135-07, R01 AR041135, R01 AR041135-08] Funding Source: Medline; NIGMS NIH HHS [T32 GM007814] Funding Source: Medline; NINDS NIH HHS [K08 NS055879-02, K08 NS055879-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS055879] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN RE, 1987, J CELL PHYSIOL, V133, P567, DOI 10.1002/jcp.1041330319; Assereto S, 2006, AM J PHYSIOL-CELL PH, V290, pC577, DOI 10.1152/ajpcell.00434.2005; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Delafontaine P, 2006, CURR OPIN CLIN NUTR, V9, P220, DOI 10.1097/01.mco.0000222103.29009.70; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Goetsch SC, 2003, PHYSIOL GENOMICS, V14, P261, DOI 10.1152/physiolgenomics.00056.2003; Gosselin LE, 2004, MUSCLE NERVE, V30, P645, DOI 10.1002/mus.20150; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jin Y, 2000, ACTA NEUROPATHOL, V99, P619, DOI 10.1007/s004010051172; Judge DP, 2004, J CLIN INVEST, V114, P172, DOI 10.1172/JCI200420641; Lavoie P, 2005, J HYPERTENS, V23, P1895, DOI 10.1097/01.hjh.0000182521.44440.c5; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; Lim DS, 2001, CIRCULATION, V103, P789, DOI 10.1161/01.CIR.103.6.789; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Ng CM, 2004, J CLIN INVEST, V114, P1586, DOI 10.1172/JCI22715; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Reimann J, 2000, NEUROMUSCULAR DISORD, V10, P276, DOI 10.1016/S0960-8966(99)00118-2; Sato K, 2003, MUSCLE NERVE, V28, P365, DOI 10.1002/mus.10436; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; YAMAZAKI M, 1994, AM J PATHOL, V144, P221; Zhou Y, 2006, BIOCHEM BIOPH RES CO, V339, P633, DOI 10.1016/j.bbrc.2005.11.060; Zhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007	30	518	538	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					204	210		10.1038/nm1536	http://dx.doi.org/10.1038/nm1536			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17237794	Green Accepted			2022-12-27	WOS:000244031700030
J	Krause, DS; Lazarides, K; von Andrian, UH; Van Etten, RA				Krause, Daniela S.; Lazarides, Katherine; von Andrian, Ulrich H.; Van Etten, Richard A.			Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; BONE-MARROW; HEMATOPOIETIC PROGENITORS; ADHESION MOLECULES; SELECTIN LIGAND; MICE; BCR/ABL; TRANSPLANTATION; PROLIFERATION; INHIBITION	In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the graft contribute to leukemic relapse(1), but the mechanisms of homing and engraftment of leukemic CML stem cells are unknown. Here we show that CD44 expression is increased on mouse stem-progenitor cells expressing BCR-ABL and that CD44 contributes functional E-selectin ligands. In a mouse retroviral transplantation model of CML, BCR-ABL1-transduced progenitors from CD44-mutant donors are defective in homing to recipient marrow, resulting in decreased engraftment and impaired induction of CML-like myeloproliferative disease. By contrast, CD44-deficient stem cells transduced with empty retrovirus engraft as efficiently as do wild-type HSCs. CD44 is dispensable for induction of acute B-lymphoblastic leukemia by BCR-ABL, indicating that CD44 is specifically required on leukemic cells that initiate CML. The requirement for donor CD44 is bypassed by direct intrafemoral injection of BCR-ABL1-transduced CD44-deficient stem cells or by coexpression of human CD44. Antibody to CD44 attenuates induction of CML-like leukemia in recipients. These results show that BCR-ABL-expressing leukemic stem cells depend to a greater extent on CD44 for homing and engraftment than do normal HSCs, and argue that CD44 blockade may be beneficial in autologous transplantation in CML.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA	Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	rvanetten@tufts-nemc.org	von Andrian, Ulrich H/A-5775-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56949, P01 HL056949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; BARNETT MJ, 1994, BLOOD, V84, P724; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; GHAFFARI S, 1995, BLOOD, V86, P2976; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014; Khaldoyanidi S, 1996, J LEUKOCYTE BIOL, V60, P579, DOI 10.1002/jlb.60.5.579; Krause DS, 2005, BLOOD, V106, p206A; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Oostendorp RAJ, 2000, BONE MARROW TRANSPL, V26, P559, DOI 10.1038/sj.bmt.1702536; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Protin U, 1999, J IMMUNOL, V163, P4917; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Salgia R, 1999, BLOOD, V94, P4233; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Verfaillie CM, 1996, BLOOD, V87, P4770, DOI 10.1182/blood.V87.11.4770.bloodjournal87114770; Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953	30	322	336	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1175	1180		10.1038/nm1489	http://dx.doi.org/10.1038/nm1489			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998483	Green Published			2022-12-27	WOS:000241102200034
J	Zakrzewski, JL; Kochman, AA; Lu, SX; Terwey, TH; Kim, TD; Hubbard, VM; Muriglan, SJ; Suh, D; Smith, OM; Grubin, J; Patel, N; Chow, A; Cabrera-Perez, J; Radhakrishnan, R; Diab, A; Perales, MA; Rizzuto, G; Menet, E; Pamer, EG; Heller, G; Zuniga-Pflucker, JC; Alpdogan, O; van den Brink, MRM				Zakrzewski, Johannes L.; Kochman, Adam A.; Lu, Sydney X.; Terwey, Theis H.; Kim, Theo D.; Hubbard, Vanessa M.; Muriglan, Stephanie J.; Suh, David; Smith, Odette M.; Grubin, Jeremy; Patel, Neel; Chow, Andrew; Cabrera-Perez, Javier; Radhakrishnan, Radhika; Diab, Adi; Perales, Miguel-Angel; Rizzuto, Gabrielle; Menet, Ewa; Pamer, Eric G.; Heller, Glen; Zuniga-Pflucker, Juan Carlos; Alpdogan, Onder; van den Brink, Marcel R. M.			Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation	NATURE MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; KERATINOCYTE GROWTH-FACTOR; DELTA-LIKE-1 IN-VITRO; NOTCH LIGAND DELTA1; IMMUNE RECONSTITUTION; LYMPHOID PROGENITORS; UNRELATED DONORS; THYMUS; LEUKEMIA	Immunoincompetence after allogeneic hematopoietic stem cell transplantation (HSCT) affects in particular the T-cell lineage and is associated with an increased risk for infections, graft failure and malignant relapse. To generate large numbers of T-cell precursors for adoptive therapy, we cultured mouse hematopoietic stem cells (HSCs) in vitro on OP9 mouse stromal cells expressing the Notch-1 ligand Delta-like-1 (OP9-DL1). We infused these cells, together with T-cell-depleted mouse bone marrow or purified HSCs, into lethally irradiated allogeneic recipients and determined their effect on T-cell reconstitution after transplantation. Recipients of OP9-DL1-derived T-cell precursors showed increased thymic cellularity and substantially improved donor T-cell chimerism (versus recipients of bone marrow or HSCs only). OP9-DL1-derived T-cell precursors gave rise to host-tolerant CD4(+) and CD8(+) populations with normal T-cell antigen receptor repertoires, cytokine secretion and proliferative responses to antigen. Administration of OP9-DL1-derived T-cell precursors increased resistance to infection with Listeria monocytogenes and mediated significant graft-versustumor (GVT) activity but not graft-versus-host disease (GVHD). We conclude that the adoptive transfer of OP9-DL1-derived T-cell precursors markedly enhances T-cell reconstitution after transplantation, resulting in GVT activity without GVHD.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Immunol, Toronto, ON M4N 3M5, Canada	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	van den Brink, MRM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Zuckerman Res Ctr 1404,Mailbox 111, New York, NY 10021 USA.	m-van-den-brink@ski.mskcc.org	Rizzuto, Gabrielle/GWR-2224-2022; Zuniga-Pflucker, Juan C/H-1295-2012; van den Brink, Marcel R. M./HGB-9434-2022	Lu, Sydney/0000-0002-2217-1674; Chow, Andrew/0000-0003-1151-2450; PERALES, MIGUEL-ANGEL/0000-0002-5910-4571; Rizzuto, Gabrielle/0000-0003-3052-0253; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178	NCI NIH HHS [CA33049, P20-CA103694, CA107096, P30 CA008748] Funding Source: Medline; NHLBI NIH HHS [HL69929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA103694, R01CA107096, P01CA033049, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpdogan O, 2006, BLOOD, V107, P2453, DOI 10.1182/blood-2005-07-2831; Arber C, 2003, BLOOD, V102, P421, DOI 10.1182/blood-2002-12-3834; Balciunaite G, 2005, EUR J IMMUNOL, V35, P1292, DOI 10.1002/eji.200425822; BitMansour A, 2002, BLOOD, V100, P4660, DOI 10.1182/blood-2002-05-1552; Chen BJ, 2004, BLOOD, V103, P4344, DOI 10.1182/blood-2003-07-2534; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Dallas MH, 2005, J EXP MED, V201, P1361, DOI 10.1084/jem.20042450; Danilenko DM, 1999, TOXICOL PATHOL, V27, P64, DOI 10.1177/019262339902700113; DANILENKO DM, 1996, FASEB J, V10, P1148; De Smedt M, 2004, BLOOD CELL MOL DIS, V33, P227, DOI 10.1016/j.bcmd.2004.08.007; Delaney C, 2005, BLOOD, V106, P2693, DOI 10.1182/blood-2005-03-1131; Foss DL, 2001, J EXP MED, V193, P365, DOI 10.1084/jem.193.3.365; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Harman BC, 2003, SEMIN IMMUNOL, V15, P91, DOI 10.1016/S1044-5323(03)00005-8; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; Huang JX, 2005, J IMMUNOL, V175, P4858, DOI 10.4049/jimmunol.175.8.4858; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; KEEVER CA, 1989, BLOOD, V73, P1340; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; La Motte-Mohs RN, 2005, BLOOD, V105, P1431, DOI 10.1182/blood-2004-04-1293; Lambolez F, 2006, NAT IMMUNOL, V7, P76, DOI 10.1038/ni1293; Min DL, 2002, BLOOD, V99, P4592, DOI 10.1182/blood.V99.12.4592; OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979; PERALES MA, IN PRESS J IMMUNOL; Petrovic A, 2004, BLOOD, V103, P1542, DOI 10.1182/blood-2003-03-0957; Porter DL, 1999, ANNU REV MED, V50, P369; Prockop SE, 2004, J IMMUNOL, V173, P1604, DOI 10.4049/jimmunol.173.3.1604; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Rossi S, 2002, BLOOD, V100, P682, DOI 10.1182/blood.V100.2.682; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; STOREK J, 1995, BONE MARROW TRANSPL, V16, P413; Terszowski G, 2006, SCIENCE, V312, P284, DOI 10.1126/science.1123497; Terwey TH, 2005, BLOOD, V106, P3322, DOI 10.1182/blood-2005-05-1860; van den Brink MRM, 2004, NAT REV IMMUNOL, V4, P856, DOI 10.1038/nri1484; Yang YG, 2002, BLOOD, V99, P4207, DOI 10.1182/blood.V99.11.4207; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	41	137	148	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1039	1047		10.1038/nm1463	http://dx.doi.org/10.1038/nm1463			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16936725				2022-12-27	WOS:000240373900028
J	Steeg, PS				Steeg, Patricia S.			Tumor metastasis: mechanistic insights and clinical challenges	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; HUMAN PANCREATIC-CANCER; MATRIX-METALLOPROTEINASE INHIBITORS; MAMMARY-CARCINOMA CELLS; FOCAL-ADHESION KINASE; IN-VIVO; COLORECTAL-CANCER; NUDE-MICE; LIVER METASTASIS	Metastatic disease is the primary cause of death for most cancer patients. Complex and redundant pathways involving the tumor cell and the microenvironment mediate tumor invasion at the primary site, survival and arrest in the bloodstream, and progressive outgrowth at a distant site. Understanding these pathways and their dynamic interactions will help identify promising molecular targets for cancer therapy and key obstacles to their clinical development.	NCI, Ctr Canc Res, Lab Mol Pharmacol, Womens Canc Sect,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Steeg, PS (corresponding author), NCI, Ctr Canc Res, Lab Mol Pharmacol, Womens Canc Sect,NIH, Bldg 37,Room 1122, Bethesda, MD 20892 USA.	steegp@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIASC000892, Z01SC000892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Arao T, 2006, INT J CANCER, V118, P483, DOI 10.1002/ijc.21340; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6; Barlesi F, 2005, FUND CLIN PHARMACOL, V19, P385, DOI 10.1111/j.1472-8206.2005.00323.x; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078-0432.CCR-05-1933; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Bruns CJ, 2002, INT J CANCER, V102, P101, DOI 10.1002/ijc.10681; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chang E, 2005, BIOCHEM BIOPH RES CO, V334, P1317, DOI 10.1016/j.bbrc.2005.07.028; Chekmareva MA, 1998, CANCER RES, V58, P4963; Chen YL, 2002, BRIT J CANCER, V87, P359, DOI 10.1038/sj.bjc.6600461; Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; Clifford CA, 2000, J VET INTERN MED, V14, P479, DOI 10.1892/0891-6640(2000)014&lt;0479:TOCHAB&gt;2.3.CO;2; Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053/j.seminoncol.2003.08.013; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; CROWLEY NJ, 1992, ARCH SURG-CHICAGO, V127, P1303; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; de Vos FYFL, 2004, CANCER TREAT REV, V30, P495, DOI 10.1016/j.ctrv.2004.05.003; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Demicheli R, 1996, BREAST CANCER RES TR, V41, P177, DOI 10.1007/BF01807163; DeWald DB, 2005, CANCER RES, V65, P713; Engel M, 2004, J BIOL CHEM, V279, P35803, DOI 10.1074/jbc.M402768200; Entschladen F, 2005, CURR PHARM DESIGN, V11, P403, DOI 10.2174/1381612053382197; Epstein RJ, 2005, CLIN CANCER RES, V11, P5337, DOI 10.1158/1078-0432.CCR-05-0437; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fournier HN, 2002, J BIOL CHEM, V277, P20895, DOI 10.1074/jbc.M200200200; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Funovics MA, 2004, RADIOLOGY, V231, P659, DOI 10.1148/radiol.2313030831; Gao CF, 2005, P NATL ACAD SCI USA, V102, P10528, DOI 10.1073/pnas.0504367102; Goldberg SF, 1999, CLIN EXP METASTAS, V17, P601, DOI 10.1023/A:1006718800891; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; Griend DJV, 2005, CANCER RES, V65, P10984, DOI 10.1158/0008-5472.CAN-05-2382; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hartsough MT, 2002, J BIOL CHEM, V277, P32389, DOI 10.1074/jbc.M203115200; Herlevsen M, 2003, J CELL SCI, V116, P4373, DOI 10.1242/jcs.00760; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hunter K, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23b; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Kim LS, 2004, CLIN EXP METASTAS, V21, P107, DOI 10.1023/B:CLIN.0000024761.00373.55; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Knapp DW, 2000, UROL ONCOL, V5, P47, DOI 10.1016/S1078-1439(99)00006-X; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Ladeda V, 2001, BREAST CANCER RES TR, V69, P39, DOI 10.1023/A:1012201805486; Lang JY, 2005, CLIN CANCER RES, V11, P3455, DOI 10.1158/1078-0432.CCR-04-2026; Lassman AB, 2003, NEUROL CLIN, V21, P1, DOI 10.1016/S0733-8619(02)00035-X; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lev DC, 2005, CLIN CANCER RES, V11, P306; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lovey J, 2003, STRAHLENTHER ONKOL, V179, P812, DOI 10.1007/s00066-003-1051-y; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Manni A, 2003, CLIN EXP METASTAS, V20, P321, DOI 10.1023/A:1024055522067; Mannori G, 1997, AM J PATHOL, V151, P233; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Messerli SM, 2004, NEOPLASIA, V6, P95, DOI 10.1593/neo.03214; Miller JC, 2005, JNCI-J NATL CANCER I, V97, P172, DOI 10.1093/jnci/dji023; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyamoto S, 2005, CLIN CANCER RES, V11, P3494, DOI 10.1158/1078-0432.CCR-04-1701; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nagle JA, 2004, MOL CELL BIOL, V24, P9726, DOI 10.1128/MCB.24.22.9726-9735.2004; Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013; Nasulewicz A, 2004, BBA-MOL BASIS DIS, V1739, P26, DOI 10.1016/j.bbadis.2004.08.003; Naumov GN, 2003, BREAST CANCER RES TR, V82, P199, DOI 10.1023/B:BREA.0000004377.12288.3c; Naumov GN, 2002, CANCER RES, V62, P2162; Neville-Webbe HL, 2004, BREAST CANCER RES TR, V86, P269; Omuro AMP, 2005, CANCER-AM CANCER SOC, V103, P2344, DOI 10.1002/cncr.21033; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palmieri D, 2005, JNCI-J NATL CANCER I, V97, P632, DOI 10.1093/jnci/dji111; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635; Parulekar WR, 2004, JNCI-J NATL CANCER I, V96, P990, DOI 10.1093/jnci/djh182; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Pinkas J, 2004, MOL CANCER RES, V2, P551; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008-5472.CAN-04-4458; Raghunand N, 2003, BRIT J RADIOL, V76, pS11, DOI 10.1259/bjr/12913493; Rak J, 2004, SEMIN CANCER BIOL, V14, P93, DOI 10.1016/j.semcancer.2003.09.014; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Roodman GD, 2003, CANCER-AM CANCER SOC, V97, P733, DOI 10.1002/cncr.11148; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Saunders MM, 2001, CANCER RES, V61, P1765; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Seymour L, 2002, CURR PHARM DESIGN, V8, P2279, DOI 10.2174/1381612023393099; Shannon KE, 2004, CLIN EXP METASTAS, V21, P129, DOI 10.1023/B:CLIN.0000024764.93092.5f; Sharma V, 2005, J NUCL MED, V46, P354; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; Solorzano CC, 2001, CANCER BIOTHER RADIO, V16, P359, DOI 10.1089/108497801753354267; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Stephan S, 2004, CLIN CANCER RES, V10, P6993, DOI 10.1158/1078-0432.CCR-04-0808; Stessels F, 2004, BRIT J CANCER, V90, P1429, DOI 10.1038/sj.bjc.6601727; Streck CJ, 2004, J AM COLL SURGEONS, V199, P78, DOI 10.1016/j.jamcollsurg.2004.02.011; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Sweeney CJ, 2005, MOL CANCER THER, V4, P1004, DOI 10.1158/1535-7163.MCT-05-0030; Takeda A, 2002, ANN SURG ONCOL, V9, P610, DOI 10.1245/aso.2002.9.7.610; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Wang Z, 2005, ANTICANCER RES, V25, P2367; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Winding B, 2002, CLIN CANCER RES, V8, P1932; Wong CW, 2001, CANCER RES, V61, P333; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yano S, 2000, CANCER RES, V60, P4959; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621; Yu Q, 2004, CLIN EXP METASTAS, V21, P235, DOI 10.1023/B:CLIN.0000037705.25256.d3; Zeng Q, 2003, CANCER RES, V63, P2716; Zvibel I, 1998, EXP CELL RES, V245, P123, DOI 10.1006/excr.1998.4229	163	1573	1673	7	407	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					895	904		10.1038/nm1469	http://dx.doi.org/10.1038/nm1469			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892035				2022-12-27	WOS:000239626200019
J	Ait-Oufella, H; Salomon, BL; Potteaux, S; Robertson, AKL; Gourdy, P; Zoll, J; Merval, R; Esposito, B; Cohen, JL; Fisson, S; Flavell, RA; Hansson, GK; Klatzmann, D; Tedgui, A; Mallat, Z				Ait-Oufella, H; Salomon, BL; Potteaux, S; Robertson, AKL; Gourdy, P; Zoll, J; Merval, R; Esposito, B; Cohen, JL; Fisson, S; Flavell, RA; Hansson, GK; Klatzmann, D; Tedgui, A; Mallat, Z			Natural regulatory T cells control the development of atherosclerosis in mice	NATURE MEDICINE			English	Article							HOMEOSTASIS; INTERLEUKIN-4; COSTIMULATION; MECHANISMS; IMMUNITY; LDL	Atherosclerosis is an immunoinflammatory disease elicited by accumulation of lipids in the artery wall and leads to myocardial infarction and stroke(1,2). Here, we show that naturally arising CD4(+)CD25(+) regulatory T cells, which actively maintain immunological tolerance to self and nonself antigens(3,4), are powerful inhibitors of atherosclerosis in several mouse models. These results provide new insights into the immunopathogenesis of atherosclerosis and could lead to new therapeutic approaches that involve immune modulation using regulatory T cells.	Ctr Rech Cardiovasc Lariboisiere, INSERM, U689, F-75010 Paris, France; Grp Hosp Pitie Salpetriere, CNRS, UMR 7087, F-75013 Paris, France; Karolinska Inst, Karolinska Hosp, Dept Med, Ctr Mol Med, SE-17176 Stockholm, Sweden; Inst L Bugnard, INSERM, U589, F-31432 Toulouse 4, France; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Karolinska Institutet; Karolinska University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University; Howard Hughes Medical Institute; Yale University	Mallat, Z (corresponding author), Ctr Rech Cardiovasc Lariboisiere, INSERM, U689, 41 Bd Chapelle, F-75010 Paris, France.	mallat@larib.inserm.fr	Salomon, Benoit/AAP-5209-2021; Mallat, Ziad/D-4041-2012; FISSON, Sylvain/J-8003-2013; Salomon, Benoit L/M-2421-2017; Cohen, José/Q-4816-2018; Hansson, Goran K/B-7423-2012	Salomon, Benoit/0000-0001-9673-5578; Mallat, Ziad/0000-0003-0443-7878; FISSON, Sylvain/0000-0002-0057-363X; Salomon, Benoit L/0000-0001-9673-5578; Cohen, José/0000-0002-5077-6726; Potteaux, Stephane/0000-0003-3068-8769; Klatzmann, David/0000-0002-0054-3422; Gourdy, Pierre/0000-0002-5362-3813; Hansson, Goran/0000-0003-4148-5190				Almeida ARM, 2002, J IMMUNOL, V169, P4850, DOI 10.4049/jimmunol.169.9.4850; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479; Buono C, 2004, CIRCULATION, V109, P2009, DOI 10.1161/01.CIR.0000127121.16815.F1; Daugherty A, 2002, CIRC RES, V90, P1039, DOI 10.1161/01.RES.0000021397.28936.F9; Davenport P, 2003, AM J PATHOL, V163, P1117, DOI 10.1016/S0002-9440(10)63471-2; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; King VL, 2002, ARTERIOSCL THROM VAS, V22, P456, DOI 10.1161/hq0302.104905; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mallat Z, 2003, CIRCULATION, V108, P1232, DOI 10.1161/01.CIR.0000089083.61317.A1; Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180	15	791	837	2	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					178	180		10.1038/nm1343	http://dx.doi.org/10.1038/nm1343			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462800				2022-12-27	WOS:000235160600021
J	Kanter, JL; Narayana, S; Ho, PP; Catz, I; Warren, KG; Sobel, RA; Steinman, L; Robinson, WH				Kanter, JL; Narayana, S; Ho, PP; Catz, I; Warren, KG; Sobel, RA; Steinman, L; Robinson, WH			Lipid microarrays identify key mediators of autoimmune brain inflammation	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; CIRCULATING ANTIGANGLIOSIDE ANTIBODIES; PROGRESSIVE MULTIPLE-SCLEROSIS; ENCEPHALOMYELITIS; DEMYELINATION; DISEASE; EXPRESSION; SULFATIDE; PROTEIN; LESIONS	Recent studies suggest that increased T-cell and autoantibody reactivity to lipids may be present in the autoimmune demyelinating disease multiple sclerosis. To perform large-scale multiplex analysis of antibody responses to lipids in multiple sclerosis, we developed microarrays composed of lipids present in the myelin sheath, including ganglioside, sulfatide, cerebroside, sphingomyelin and total brain lipid fractions. Lipid-array analysis showed lipid-specific antibodies against sulfatide, sphingomyelin and oxidized lipids in cerebrospinal fluid (CSF) derived from individuals with multiple sclerosis. Sulfatide-specific antibodies were also detected in SJL/J mice with acute experimental autoimmune encephalomyelitis (EAE). Immunization of mice with sulfatide plus myelin peptide resulted in a more severe disease course of EAE, and administration of sulfatide-specific antibody exacerbated EAE. Thus, autoimmune responses to sulfatide and other lipids are present in individuals with multiple sclerosis and in EAE, and may contribute to the pathogenesis of autoimmune demyelination.	Stanford Univ, Sch Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Alberta, Dept Med, Edmonton, AB, Canada; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Palo Alto VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; University of Alberta; Stanford University; Geriatric Research Education & Clinical Center	Robinson, WH (corresponding author), Stanford Univ, Sch Med, Div Rheumatol & Immunol, 269 Campus Dr, Stanford, CA 94305 USA.	wrobins@stanford.edu		Sobel, Raymond/0000-0002-0477-9002; Steinman, Lawrence/0000-0002-2437-2250; Robinson, William/0000-0003-4385-704X; /0000-0002-6848-318X	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018235] Funding Source: NIH RePORTER; Multiple Sclerosis Society [835] Funding Source: Medline; NHLBI NIH HHS [N01 HV 28183] Funding Source: Medline; NIAMS NIH HHS [K08 AR02133] Funding Source: Medline; NIDDK NIH HHS [U19 DK61934] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07276] Funding Source: Medline; NINDS NIH HHS [5R01NS18235] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Multiple Sclerosis Society(National Multiple Sclerosis Society); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLING C, 1971, BRAIN RES, V35, P325, DOI 10.1016/0006-8993(71)90478-1; Battistini L, 1996, J NEUROIMMUNOL, V67, P145; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Busshoff U, 2001, J NEUROIMMUNOL, V113, P220, DOI 10.1016/S0165-5728(00)00450-1; Cipriani B, 2003, BRAIN PATHOL, V13, P1; CUMINGS JN, 1955, BRAIN, V78, P554, DOI 10.1093/brain/78.4.554; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fredman P, 1998, ANN NY ACAD SCI, V845, P341, DOI 10.1111/j.1749-6632.1998.tb09686.x; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GERSTL B, 1961, BRAIN, V84, P310, DOI 10.1093/brain/84.2.310; Giovannoni G, 2000, ANN NEUROL, V47, P684, DOI 10.1002/1531-8249(200005)47:5<684::AID-ANA27>3.3.CO;2-F; Ilyas AA, 2003, J NEUROIMMUNOL, V139, P76, DOI 10.1016/S0165-5728(03)00131-0; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Mazzanti B, 1998, J NEUROIMMUNOL, V82, P96, DOI 10.1016/S0165-5728(97)00194-X; Moody DB, 2005, NAT REV IMMUNOL, V5, P387, DOI 10.1038/nri1605; MOORE GRW, 1984, LAB INVEST, V51, P416; Morell P, 1999, MYELIN FORMATION STR; Pender MP, 2003, J CLIN NEUROSCI, V10, P63, DOI 10.1016/S0967-5868(02)00270-9; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Rosenbluth J, 2003, J NEUROCYTOL, V32, P265, DOI 10.1023/B:NEUR.0000010085.91976.a6; Sadatipour BT, 1998, ANN NEUROL, V44, P980, DOI 10.1002/ana.410440621; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; Tettamanti G, 1980, Adv Exp Med Biol, V125, P263; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UHLIG H, 1989, AUTOIMMUNITY, V5, P87, DOI 10.3109/08916938909029146	30	242	254	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					138	143		10.1038/nm1344	http://dx.doi.org/10.1038/nm1344			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341241				2022-12-27	WOS:000234419000064
J	Zhang, Y; Joe, G; Hexner, E; Zhu, J; Emerson, SG				Zhang, Y; Joe, G; Hexner, E; Zhu, J; Emerson, SG			Host-reactive CD8(+) memory stem cells in graft-versus-host disease	NATURE MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; T-CELLS; IN-VIVO; IMMUNE-RESPONSE; VIRAL-INFECTION; DENDRITIC CELLS; DIFFERENTIATION; PHENOTYPE; EFFECTOR; IL-15	Graft-versus-host disease (GVHD) is caused by alloreactive donor T cells that trigger host tissue injury. GVHD develops over weeks or months, but how this immune response is maintained over time is unknown. In mouse models of human GVHD, we identify a new subset of postmitotic CD44(lo)CD62L(hi)CD8(+) T cells that generate and sustain all allogeneic T-cell subsets in GVHD reactions, including central memory, effector memory and effector CD8(+) T cells, while self-renewing. These cells express Sca-1, CD122 and Bc1-2, and induce GVHD upon transfer into secondary recipients. The postmitotic CD44loCD62LhiCD8+ T cells persist throughout the course of GVHD, are generated in the initial phase in response to alloantigens and dendritic cells and require interleukin-15. Thus, their long life, ability to self-renew and multipotentiality define these cells as candidate memory stem cells. Memory stem cells will be important targets for understanding and influencing diverse chronic immune reactions, including GVHD.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Emerson, SG (corresponding author), Univ Penn, Sch Med, Room 510,Maloney,3600 Spruce St, Philadelphia, PA 19104 USA.	emersons@mail.med.upenn.edu	Hexner, Elizabeth/AAC-1442-2020	Hexner, Elizabeth/0000-0002-1125-4060	NCI NIH HHS [R01 CA102464-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Berard M, 2003, J IMMUNOL, V170, P5018, DOI 10.4049/jimmunol.170.10.5018; Blaser BW, 2005, BLOOD, V105, P894, DOI 10.1182/blood-2004-05-1687; Blazar BR, 1997, IMMUNOL REV, V157, P79, DOI 10.1111/j.1600-065X.1997.tb00976.x; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chen BJ, 2004, BLOOD, V103, P1534, DOI 10.1182/blood-2003-08-2987; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; del Rosario MLU, 1999, BLOOD, V93, P3558, DOI 10.1182/blood.V93.10.3558.410k31_3558_3564; DIAMOND DJ, 1995, TRANSPLANTATION, V59, P1436, DOI 10.1097/00007890-199505270-00014; Duffner UA, 2004, J IMMUNOL, V172, P7393, DOI 10.4049/jimmunol.172.12.7393; Favre A, 1997, AM J SURG PATHOL, V21, P23, DOI 10.1097/00000478-199701000-00003; Fearon DT, 2001, SCIENCE, V293, P248, DOI 10.1126/science.1062589; Ferrara JLM, 2003, INT J HEMATOL, V78, P181, DOI 10.1007/BF02983793; Foster AE, 2004, BLOOD, V104, P2403, DOI 10.1182/blood-2003-12-4431; Gattorno M, 2005, ARTHRITIS RES THER, V7, pR256, DOI 10.1186/ar1485; Giver CR, 2004, IMMUNOL RES, V29, P269, DOI 10.1385/IR:29:1-3:269; Goker H, 2001, EXP HEMATOL, V29, P259, DOI 10.1016/S0301-472X(00)00677-9; Higman MA, 2004, BRIT J HAEMATOL, V125, P435, DOI 10.1111/j.1365-2141.2004.04945.x; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; Lauvau G, 2001, SCIENCE, V294, P1735, DOI 10.1126/science.1064571; Lodolce J, 2002, MOL IMMUNOL, V39, P537, DOI 10.1016/S0161-5890(02)00211-0; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI13296; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; Monsurro V, 2004, BLOOD, V104, P1970, DOI 10.1182/blood-2004-02-0525; Oehen S, 1998, J IMMUNOL, V161, P5338; Opferman JT, 1999, SCIENCE, V283, P1745, DOI 10.1126/science.283.5408.1745; Schluns KS, 2002, J IMMUNOL, V168, P4827, DOI 10.4049/jimmunol.168.10.4827; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Sprent J, 2003, MICROBES INFECT, V5, P227, DOI 10.1016/S1286-4579(03)00015-7; Sprent J, 2001, SCIENCE, V293, P245, DOI 10.1126/science.1062416; Walzer T, 2002, J IMMUNOL, V168, P2704, DOI 10.4049/jimmunol.168.6.2704; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weng NP, 2002, ANN NY ACAD SCI, V975, P46, DOI 10.1111/j.1749-6632.2002.tb05940.x; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Wherry EJ, 2004, J VIROL, V78, P5535, DOI 10.1128/JVI.78.11.5535-5545.2004; Yamashita K, 2004, BLOOD, V103, P3986, DOI 10.1182/blood-2003-09-3286; Zhang Y, 2005, J IMMUNOL, V174, P3051, DOI 10.4049/jimmunol.174.5.3051; Zhang Y, 1998, BLOOD, V92, P118, DOI 10.1182/blood.V92.1.118.413a01_118_128; Zhang Y, 2004, BLOOD, V103, P3970, DOI 10.1182/blood-2003-09-3135; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	49	267	282	2	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1299	1305		10.1038/nm1326	http://dx.doi.org/10.1038/nm1326			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16288282				2022-12-27	WOS:000233774400028
J	Cancelas, JA; Lee, AW; Prabhakar, R; Stringer, KF; Zheng, Y; Williams, DA				Cancelas, JA; Lee, AW; Prabhakar, R; Stringer, KF; Zheng, Y; Williams, DA			Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; ADHESION MOLECULES; PROGENITOR CELLS; MOBILIZATION; MARROW; CHEMOTHERAPY; ENGRAFTMENT; POLARITY; FAMILY; ROLES	The molecular events that regulate engraftment and mobilization of hematopoietic stem cells and progenitors (HSC/Ps) are still incompletely defined(1,2). We have examined the role of the Rho GTPases Rac1 and Rac2 in HSC engraftment and mobilization. Rac1, but not the hematopoietic-specific Rac2, is required for the engraftment phase of hematopoietic reconstitution, because Rac1(-/-) HSCs did not rescue in vivo hematopoiesis after transplantation, but deletion of Rac1 after engraftment did not impair steady-state hematopoiesis. Rac1(-/-) HSC/Ps showed impaired spatial localization to the endosteum but near-normal homing to the medullary cavity in vivo. Interaction with the bone marrow microenvironment in vitro was markedly altered. Whereas post-engraftment deletion of Rac1 alone did not impair hematopoiesis, deficiency of both Rac1 and Rac2 led to massive mobilization of HSCs from the marrow associated with ineffective hematopoiesis and intense selection for Rac-expressing HSCs. This mobilization was reversible by re-expression of Rac1. In addition, a rationally designed, reversible small-molecule inhibitor of Rac activation led to transient mobilization of engraftable HSC/Ps. Rac proteins thus differentially regulate engraftment and mobilization phenotypes, suggesting that these biological processes and steady-state hematopoiesis are biochemically separable and that Rac proteins may be important molecular targets for stem cell modification.	Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Cincinnati Childrens Res Fdn, Div Pathol, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Hoxworth Blood Ctr, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Williams, DA (corresponding author), Cincinnati Childrens Res Fdn, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	david.williams@cchmc.org	Cancelas, Jose/AAR-9324-2020; Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIDDK NIH HHS [R01 DK62752] Funding Source: Medline; NIGMS NIH HHS [R01 GM60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Cancelas JA, 1998, TRANSFUSION, V38, P1063, DOI 10.1046/j.1537-2995.1998.38111299056318.x; Christopherson KW, 2003, EXP HEMATOL, V31, P1126, DOI 10.1016/j.exphem.2003.07.002; Conca A, 2004, NEUROPSYCHIATRIE, V18, P1; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Driessen RL, 2003, EXP HEMATOL, V31, P1284, DOI 10.1016/j.exphem.2003.08.015; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Jansen M, 2005, STEM CELLS, V23, P335, DOI 10.1634/stemcells.2004-0216; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Levesque JP, 2003, EXP HEMATOL, V31, P109, DOI 10.1016/S0301-472X(02)01028-7; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; PAPAYANNOPOULOU T, 1977, P NATL ACAD SCI USA, V74, P2923, DOI 10.1073/pnas.74.7.2923; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; PLOEMACHER RE, 1991, BLOOD, V78, P2527; Roberts AW, 1997, BLOOD, V89, P2736, DOI 10.1182/blood.V89.8.2736; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349-9360.2003; Simmons PJ, 1997, BAILLIERE CLIN HAEM, V10, P485, DOI 10.1016/S0950-3536(97)80022-4; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	31	220	227	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					886	891		10.1038/nm1274	http://dx.doi.org/10.1038/nm1274			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16025125				2022-12-27	WOS:000230964700035
J	Ritvo, P; Wilson, K; Willms, D; Upshur, R				Ritvo, P; Wilson, K; Willms, D; Upshur, R		CANVAC Sociobehavioural Study Grp	Vaccines in the public eye	NATURE MEDICINE			English	Editorial Material							HEPATITIS-B VACCINATION; HIV IMMUNIZATION; HIGH-RISK; INFLUENZA VACCINATION; ATTITUDES; ACCEPTABILITY; PERCEPTION; INFECTION; KNOWLEDGE; CHILDREN	Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.	York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada; York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 2C4, Canada; McMaster Univ, Dept Anthropol, Hamilton, ON L8S 4L9, Canada; Sunnybrook Hlth Sci Ctr, Primary Care Res Unit, Toronto, ON M4N 3M5, Canada	York University - Canada; York University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ritvo, P (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.	pritvo@yorku.ca		Krahn, Murray/0000-0001-5836-397X; Upshur, Ross/0000-0003-1128-0557				Abraham J, 2002, LANCET, V360, P1498, DOI 10.1016/S0140-6736(02)11477-2; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; CAGE S, 2004, ASS PRESS       0630; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504; Diamond J, 1999, GUNS GERMS STEEL; Donnelly CA, 2004, LANCET INFECT DIS, V4, P672, DOI 10.1016/S1473-3099(04)01173-9; FIEBACH NH, 1991, AM J MED, V91, P393, DOI 10.1016/0002-9343(91)90157-S; Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097; Greenberg SB, 2000, SOUTHERN MED J, V93, P763; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hennock EP, 1998, SOC HIST MED, V11, P49, DOI 10.1093/shm/11.1.49; Hernan MA, 2004, NEUROLOGY, V63, P838, DOI 10.1212/01.WNL.0000138433.61870.82; HIRSCHLER B, 2005, TORONTO STAR    0127; Honkanen PO, 1996, PUBLIC HEALTH, V110, P163, DOI 10.1016/S0033-3506(96)80070-9; Horton R, 2004, LANCET, V364, P2071, DOI 10.1016/S0140-6736(04)17560-0; *IMM SAF COMM, 2002, IMM SAF REV HEP B VA; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Keller-Stanislawski B, 2001, VACCINE, V20, pS45, DOI 10.1016/S0264-410X(01)00298-5; KNOBLER SL, 2004, THREAT PANDEMIC INFL; Krahn MD, 2005, VACCINE, V23, P1549, DOI 10.1016/j.vaccine.2004.09.023; Kremer M, 2002, Global Public Goods Financing: New Tools for New Challenges, P37; Levy-Bruhl D, 2002, VACCINE, V20, P2065, DOI 10.1016/S0264-410X(02)00053-1; Liau A, 2000, INT J STD AIDS, V11, P445, DOI 10.1258/0956462001916227; Liau A, 1998, SEX TRANSM DIS, V25, P76, DOI 10.1097/00007435-199802000-00004; Liau A, 2001, AIDS CARE, V13, P643, DOI 10.1080/09540120120075275; McPhillips HA, 2001, ARCH PEDIAT ADOL MED, V155, P1051, DOI 10.1001/archpedi.155.9.1051; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; Mieczkowski TA, 2002, VACCINE, V20, P1383, DOI 10.1016/S0264-410X(01)00463-7; MURASKIN W, 2001, VACCINES DEV EC WHO; Murch SH, 2004, LANCET, V363, P750, DOI 10.1016/S0140-6736(04)15715-2; Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702; NICHOL KL, 1992, ARCH INTERN MED, V152, P106, DOI 10.1001/archinte.152.1.106; POTTER CW, 1998, TXB INFLUENZA, P3; POWELL D, 1997, MAD COWS MOTHERS MIL; QADIR A, 2004, ASS PRESS       0828; Renn O., 1991, COMMUN RISKS PUBLIC, P175, DOI DOI 10.1007/978-94-009-1952-5_10; Ritvo Paul, 2003, J Immune Based Ther Vaccines, V1, P3, DOI 10.1186/1476-8518-1-3; Sadovnick AD, 2000, LANCET, V355, P549, DOI 10.1016/S0140-6736(99)02991-8; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Sturkenboom MC, 1999, PHARMACOEPIDEM DR S, V8, pS170; Touze E, 2000, REV NEUROL, V156, P242; Touze E, 2002, NEUROEPIDEMIOLOGY, V21, P180, DOI 10.1159/000059520; *UK DEP HLTH, 2004, STAT B NHS IMM STAT; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Vidor E, 1999, COMBINATION VACCINES, P1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WARD L, 2002, GUARDIAN        0221; Webb PM, 1999, J ADOLESCENT HEALTH, V25, P320, DOI 10.1016/S1054-139X(99)00066-X; Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150; *WHO, 2004, NEUROLOGY       0914; WHO, 2003, SUMM TABL SARS CAS C; Zimet GD, 2000, INT J STD AIDS, V11, P143, DOI 10.1258/0956462001915570; Zimet GD, 1999, J PEDIATR PSYCHOL, V24, P67, DOI 10.1093/jpepsy/24.1.67	55	23	23	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4		S			S20	S24		10.1038/nm1220	http://dx.doi.org/10.1038/nm1220			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812485				2022-12-27	WOS:000228339600007
J	Wilkinson, IR; Ferrandis, E; Artymiuk, PJ; Teillot, M; Soulard, C; Touvay, C; Pradhananga, SL; Justice, S; Wu, Z; Leung, KC; Strasburger, CJ; Sayers, JR; Ross, RJ				Wilkinson, Ian R.; Ferrandis, Eric; Artymiuk, Peter J.; Teillot, Marc; Soulard, Chantal; Touvay, Caroline; Pradhananga, Sarbendra L.; Justice, Sue; Wu, Zida; Leung, Kin C.; Strasburger, Christian J.; Sayers, Jon R.; Ross, Richard J.			A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist	NATURE MEDICINE			English	Article							GH-DEFICIENT ADULTS; BINDING-PROTEIN; EXTRACELLULAR DOMAIN; METABOLIC-CLEARANCE; INJECTIONS; INFUSION; KINETICS; COMPLEX; HEALTH; SAFETY	Cytokine hormones have a short plasma half-life and require frequent administration. For example, growth hormone replacement involves daily injections. In common with other cytokines, the extracellular domain of the growth hormone receptor circulates as a binding protein, which naturally prolongs the biological half-life of growth hormone. Here we have studied the biological actions of a ligand-receptor fusion of growth hormone and the extracellular domain of its receptor. The genetically engineered ligand-receptor fusion protein was purified from mammalian cell culture. In rats, the ligandreceptor fusion had a 300-times reduced clearance as compared to native growth hormone, and a single injection promoted growth for 10 d, far exceeding the growth seen after administration of native growth hormone. The ligand-receptor fusion forms a reciprocal, head-to-tail dimer that provides a reservoir of inactive hormone similar to the natural reservoir of growth hormone and its binding protein. In conclusion, a ligand-receptor fusion of cytokine to its extracellular receptor generates a potent, long-acting agonist with exceptionally slow absorption and elimination. This approach could be easily applied to other cytokines.	Univ Sheffield, Royal Hallamshire Hosp, Sch Med & Biomed Sci, Sheffield S10 2JF, S Yorkshire, England; Inst Henri Beaufour, Ipsen, F-91966 Les Ulis, France; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2JF, S Yorkshire, England; Campus Mitte Charite Univ Med, Dept Med, D-10117 Berlin, Germany; Garvan Inst Med Res, Pituitary Res Unit, Sydney, NSW 2010, Australia; Univ Sheffield, Royal Hallamshire Hosp, Unit Infect & Immun, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Garvan Institute of Medical Research; University of Sheffield	Ross, RJ (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Sch Med & Biomed Sci, Sheffield S10 2JF, S Yorkshire, England.	r.j.ross@sheffield.ac.uk	Ross, Richard/B-2672-2012; Sayers, Jon R/I-8974-2012; Sayers, Jon R/AAP-6179-2020	Ross, Richard/0000-0001-9222-9678; Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443; Wilkinson, Ian/0000-0001-6236-2419				Ayling RM, 1997, NAT GENET, V16, P13, DOI 10.1038/ng0597-13; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BAUMANN G, 1995, ENDOCRINOLOGY, V136, P377, DOI 10.1210/en.136.2.377; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1989, METABOLISM, V38, P330, DOI 10.1016/0026-0495(89)90119-4; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; Cook DM, 2002, J CLIN ENDOCR METAB, V87, P4508, DOI 10.1210/jc.2002-020480; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Frick GP, 1998, ENDOCRINOLOGY, V139, P2824, DOI 10.1210/en.139.6.2824; HAFFNER D, 1994, J CLIN INVEST, V93, P1163, DOI 10.1172/JCI117069; HERINGTON AC, 1987, MOL CELL ENDOCRINOL, V53, P203, DOI 10.1016/0303-7207(87)90175-4; Huston J S, 1993, Cell Biophys, V22, P189; JOHNSON V, 1977, AM J PHYSIOL, V233, P185; Jostel A, 2005, CLIN ENDOCRINOL, V62, P623, DOI 10.1111/j.1365-2265.2005.02271.x; LAURSEN T, 1995, J CLIN ENDOCR METAB, V80, P2410, DOI 10.1210/jc.80.8.2410; Laursen T, 2001, J CLIN ENDOCR METAB, V86, P1222, DOI 10.1210/jc.86.3.1222; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MullerNewen G, 1996, INT ARCH ALLERGY IMM, V111, P99, DOI 10.1159/000237353; Osborn BL, 2002, EUR J PHARMACOL, V456, P149, DOI 10.1016/S0014-2999(02)02644-4; Reiter EO, 2001, J CLIN ENDOCR METAB, V86, P4700, DOI 10.1210/jc.86.10.4700; Ross RJM, 2001, J CLIN ENDOCR METAB, V86, P1716, DOI 10.1210/jc.86.4.1716; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; Veldhuis JD, 2002, J CLIN ENDOCR METAB, V87, P5737, DOI 10.1210/jc.2001-011885; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022	27	26	43	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2007	13	9					1108	1113		10.1038/nm1610	http://dx.doi.org/10.1038/nm1610			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	208XS	17721547				2022-12-27	WOS:000249353100039
J	Clark, SR; Ma, AC; Tavener, SA; McDonald, B; Goodarzi, Z; Kelly, MM; Patel, KD; Chakrabarti, S; McAvoy, E; Sinclair, GD; Keys, EM; Allen-Vercoe, E; DeVinney, R; Doig, CJ; Green, FHY; Kubes, P				Clark, Stephen R.; Ma, Adrienne C.; Tavener, Samantha A.; McDonald, Braedon; Goodarzi, Zahra; Kelly, Margaret M.; Patel, Kamala D.; Chakrabarti, Subhadeep; McAvoy, Erin; Sinclair, Gary D.; Keys, Elizabeth M.; Allen-Vercoe, Emma; DeVinney, Rebekah; Doig, Christopher J.; Green, Francis H. Y.; Kubes, Paul			Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood	NATURE MEDICINE			English	Article							LEUKOCYTE RECRUITMENT; ADHESION MOLECULES; INFLAMED LIVER; IN-VIVO; ENDOTOXIN; SELECTINS; STREPTOCOCCUS; DYSFUNCTION; INHIBITION; ESCAPE	It has been known for many years that neutrophils and platelets participate in the pathogenesis of severe sepsis, but the interrelationship between these players is completely unknown. We report several cellular events that led to enhanced trapping of bacteria in blood vessels: platelet TLR4 detected TLR4 ligands in blood and induced platelet binding to adherent neutrophils. This led to robust neutrophil activation and formation of neutrophil extracellular traps (NETs). Plasma from severely septic humans also induced TLR4-dependent platelet-neutrophil interactions, leading to the production of NETs. The NETs retained their integrity under flow conditions and ensnared bacteria within the vasculature. The entire event occurred primarily in the liver sinusoids and pulmonary capillaries, where NETs have the greatest capacity for bacterial trapping. We propose that platelet TLR4 is a threshold switch for this new bacterial trapping mechanism in severe sepsis.	Univ Calgary, Fac Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pathol & Lab Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Foothills Prov Gen Hosp, Dept Med & Community Hlth, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kubes, P (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pkubes@ucalgary.ca	Patel, Kamala D/AAX-1245-2021; Clark, Stephen/N-6242-2014; Kelly, Margaret M/G-4128-2012; Chakrabarti, Subhadeep/AAD-1078-2022; Doig, Christopher/AAC-7949-2020	Clark, Stephen/0000-0001-5907-9671; Kelly, Margaret M/0000-0002-1629-3210; Doig, Christopher/0000-0002-8576-9139; Goodarzi, Zahra/0000-0002-8858-4076				Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Alghamdi AS, 2005, BIOL REPROD, V73, P1174, DOI 10.1095/biolreprod.105.045666; Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916; Aslam R, 2006, BLOOD, V107, P637, DOI 10.1182/blood-2005-06-2202; Beiter K, 2006, CURR BIOL, V16, P401, DOI 10.1016/j.cub.2006.01.056; Bonder CS, 2005, IMMUNITY, V23, P153, DOI 10.1016/j.immuni.2005.06.007; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Gill V, 2005, CIRCULATION, V112, P2031, DOI 10.1161/CIRCULATIONAHA.105.546150; GROSS K, 1985, J PEDIATR SURG, V20, P320, DOI 10.1016/S0022-3468(85)80211-6; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Ibbotson GC, 2001, NAT MED, V7, P465, DOI 10.1038/86539; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; Li Y, 2002, EUR J IMMUNOL, V32, P3443, DOI 10.1002/1521-4141(200212)32:12<3443::AID-IMMU3443>3.0.CO;2-F; Lloyd KL, 2006, AM J PHYSIOL-HEART C, V291, pH473, DOI 10.1152/ajpheart.01234.2005; Lynn M, 2004, J PHARMACOL EXP THER, V308, P175, DOI 10.1124/jpet.103.056531; Mavrommatis AC, 2000, CRIT CARE MED, V28, P451, DOI 10.1097/00003246-200002000-00027; Mercer KW, 2006, SEMIN RESP CRIT CARE, V27, P286, DOI 10.1055/s-2006-945529; Moraes TJ, 2006, CURR OPIN HEMATOL, V13, P21, DOI 10.1097/01.moh.0000190113.31027.d5; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; NISHIDA J, 1994, AM J PHYSIOL-GASTR L, V267, pG1135, DOI 10.1152/ajpgi.1994.267.6.G1135; Reinhardt PH, 1998, BLOOD, V92, P4691, DOI 10.1182/blood.V92.12.4691.424k18_4691_4699; RUF A, 1995, BRIT J HAEMATOL, V90, P791, DOI 10.1111/j.1365-2141.1995.tb05197.x; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Sheridan BC, 1997, J TRAUMA, V42, P391, DOI 10.1097/00005373-199703000-00005; Singer G, 2006, MICROCIRCULATION, V13, P89, DOI 10.1080/10739680500466343; Stohlawetz P, 1999, THROMB HAEMOSTASIS, V81, P613; Vincent JL, 2002, CRIT CARE MED, V30, pS313, DOI 10.1097/00003246-200205001-00022; Ward JR, 2005, THROMB HAEMOSTASIS, V94, P831, DOI 10.1160/TH05-01-0009; WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006; Wong J, 1997, J CLIN INVEST, V99, P2782, DOI 10.1172/JCI119468	38	1489	1571	6	160	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2007	13	4					463	469		10.1038/nm1565	http://dx.doi.org/10.1038/nm1565			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17384648				2022-12-27	WOS:000245543900035
J	Korn, T; Reddy, J; Gao, WD; Bettelli, E; Awasthi, A; Petersen, TR; Backstrom, BT; Sobel, RA; Wucherpfennig, KW; Strom, TB; Oukka, M; Kuchroo, VK				Korn, Thomas; Reddy, Jayagopala; Gao, Wenda; Bettelli, Estelle; Awasthi, Amit; Petersen, Troels R.; Backstrom, B. Thomas; Sobel, Raymond A.; Wucherpfennig, Kai W.; Strom, Terry B.; Oukka, Mohamed; Kuchroo, Vijay K.			Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; RECEPTOR TRANSGENIC MICE; IN-VIVO; MULTIPLE-SCLEROSIS; DENDRITIC CELLS; OLIGODENDROCYTE GLYCOPROTEIN; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; ENCEPHALOMYELITIS; FOXP3	Treatment with ex vivo-generated regulatory T cells (T-reg) has been regarded as a potentially attractive therapeutic approach for autoimmune diseases. However, the dynamics and function of T-reg in autoimmunity are not well understood. Thus, we developed Foxp3gfp knock-in (Foxp3gfp.KI) mice and myelin oligodendrocyte glycoprotein (MOG)(35-55)/IA(b) (MHC class II) tetramers to track autoantigen-specific effector T cells (T-eff) and T-reg in vivo during experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. MOG tetramer-reactive, Foxp3(+) T-reg expanded in the peripheral lymphoid compartment and readily accumulated in the central nervous system (CNS), but did not prevent the onset of disease. Foxp3(+) T cells isolated from the CNS were effective in suppressing naive MOG-specific T cells, but failed to control CNS-derived encephalitogenic T-eff that secreted interleukin (IL)-6 and tumor necrosis factor (TNF). Our data suggest that in order for CD4(+)Foxp3(+) T-reg to effectively control autoimmune reactions in the target organ, it may also be necessary to control tissue inflammation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Res Ctr, Boston, MA 02115 USA; Malaghan Inst Med Res, Wellington, New Zealand; Vet Affairs Hlth Care Syst, Lab Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Malaghan Institute; Victoria University Wellington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Oukka, M (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.	moukka@rics.bwh.harvard.edu; vkuchroo@rics.bwh.harvard.edu	Strom, Terry B./E-9268-2010; Reddy, Jay/K-7200-2014; Korn, Thomas/AAE-6960-2019	Strom, Terry B./0000-0002-7570-0736; Reddy, Jay/0000-0003-4082-9254; Korn, Thomas/0000-0002-3633-0955; Petersen, Troels/0000-0002-6378-352X; Sobel, Raymond/0000-0002-0477-9002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039671, R01AI044880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035685, P01NS038037, R37NS030843, R01NS045937, R01NS046414] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI044880, P01 AI039671] Funding Source: Medline; NINDS NIH HHS [R37 NS030843, R01 NS045937, P01 NS038037, 1R01NS046414, R01 NS035685, 2R37NS30843-11, 2R01NS35685-06, 1R01NS045937-01, R01 NS046414, 1P01NS38037-04] Funding Source: Medline; PHS HHS [1R01A144880-03, 2P01A139671-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alvarado-Sanchez B, 2006, J AUTOIMMUN, V27, P110, DOI 10.1016/j.jaut.2006.06.005; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bagaeva LV, 2003, J NEUROIMMUNOL, V137, P109, DOI 10.1016/S0165-5728(03)00079-1; Bailey SL, 2007, NAT IMMUNOL, V8, P172, DOI 10.1038/ni1430; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Cao D, 2006, SCAND J IMMUNOL, V63, P444, DOI 10.1111/j.1365-3083.2006.001755.x; Crispin JC, 2003, J AUTOIMMUN, V21, P273, DOI 10.1016/S0896-8411(03)00121-5; Di Marco R, 2001, J NEUROIMMUNOL, V116, P168, DOI 10.1016/S0165-5728(01)00301-0; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; Glabinski AR, 2002, J AUTOIMMUN, V19, P175, DOI 10.1006/jaut.2002.0613; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Haas J, 2005, EUR J IMMUNOL, V35, P3343, DOI 10.1002/eji.200526065; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Hori S, 2002, P NATL ACAD SCI USA, V99, P8213, DOI 10.1073/pnas.122224799; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Kohm AP, 2002, J IMMUNOL, V169, P4712, DOI 10.4049/jimmunol.169.9.4712; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liu YW, 2006, NAT MED, V12, P518, DOI 10.1038/nm1402; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; Morgan ME, 2003, ARTHRITIS RHEUM, V48, P1452, DOI 10.1002/art.11063; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Piccirillo CA, 2005, ANN NY ACAD SCI, V1051, P72, DOI 10.1196/annals.1361.048; Reddy J, 2004, P NATL ACAD SCI USA, V101, P15434, DOI 10.1073/pnas.0404444101; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Tanchot C, 2004, J IMMUNOL, V172, P4285, DOI 10.4049/jimmunol.172.7.4285; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	47	636	662	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					423	431		10.1038/nm1564	http://dx.doi.org/10.1038/nm1564			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17384649	Green Accepted			2022-12-27	WOS:000245543900030
J	Mingozzi, F; Maus, MV; Hui, DJ; Sabatino, DE; Murphy, SL; Rasko, JEJ; Ragni, MV; Manno, CS; Sommer, J; Jiang, HY; Pierce, GF; Ertl, HCJ; High, KA				Mingozzi, Federico; Maus, Marcela V.; Hui, Daniel J.; Sabatino, Denise E.; Murphy, Samuel L.; Rasko, John E. J.; Ragni, Margaret V.; Manno, Catherine S.; Sommer, Jurg; Jiang, Haiyan; Pierce, Glenn F.; Ertl, Hildegund C. J.; High, Katherine A.			CD8+ T-cell responses to adeno-associated virus capsid in humans	NATURE MEDICINE			English	Article							HEMOPHILIA-B DOGS; GENE-THERAPY; FACTOR-IX; LIVER; VECTORS	Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Sydney, Centenary Inst Canc Med & Cell Biol, Gene & Stem Cell Therapy Program, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; Univ Pittsburgh, Med Ctr, Hemophilia Ctr Western Penn, Pittsburgh, PA 15213 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Avigen Inc, Alameda, CA 94502 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Sydney; Centenary Institute; University of Sydney; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; The Wistar Institute; Howard Hughes Medical Institute	High, KA (corresponding author), Childrens Hosp Philadelphia, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	high@email.chop.edu	Rasko, John EJ/F-5754-2013; Hui, Daniel J/H-8855-2013; High, Katherine A./AAB-9322-2020	Hui, Daniel J/0000-0003-0294-3582; Manno, Catherine/0000-0001-8029-0391; rasko, John/0000-0003-2975-807X; Jiang, Haiyan/0000-0002-5778-4008; Maus, Marcela/0000-0002-7578-0393	NCRR NIH HHS [M01-RR000056, M01-RR00240] Funding Source: Medline; NHLBI NIH HHS [F32 HL69647, T32 HL07439, P01 HL078810] Funding Source: Medline; NIAID NIH HHS [P30 AI045008] Funding Source: Medline; NIDDK NIH HHS [T32 DK07748] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240, M01RR000056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078810, T32HL007439, F32HL069647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007748] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Mount JD, 2002, BLOOD, V99, P2670, DOI 10.1182/blood.V99.8.2670; MUZYCZKA N, 2001, PARVOVIRIDAE VIRUSES, P2327; Sabatino DE, 2005, MOL THER, V12, P1023, DOI 10.1016/j.ymthe.2005.09.009; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; Vandenberghe LH, 2006, NAT MED, V12, P967, DOI 10.1038/nm1445; Wang LL, 2000, MOL THER, V1, P154, DOI 10.1006/mthe.2000.0031	9	499	537	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2007	13	4					419	422		10.1038/nm1549	http://dx.doi.org/10.1038/nm1549			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154YG	17369837				2022-12-27	WOS:000245543900029
J	Lang, PA; Schenck, M; Nicolay, JP; Becker, JU; Kempe, DS; Lupescu, A; Koka, S; Eisele, K; Klarl, BA; Rubben, H; Schmid, KW; Mann, K; Hildenbrand, S; Hefter, H; Huber, SM; Wieder, T; Erhardt, A; Haussinger, D; Hefter, H; Huber, SM; Wieder, T; Erhardt, A; Haussinger, D; Gulbins, E; Lang, F				Lang, Philipp A.; Schenck, Marcus; Nicolay, Jan P.; Becker, Jan Ulrich; Kempe, Daniela S.; Lupescu, Adrian; Koka, Saisudha; Eisele, Kerstin; Klarl, Barbara A.; Ruebben, Herbert; Schmid, Kurt W.; Mann, Klaus; Hildenbrand, Sibylle; Hefter, Harald; Huber, Stephan M.; Wieder, Thomas; Erhardt, Andreas; Haeussinger, Dieter; Hefter, Harald; Huber, Stephan M.; Wieder, Thomas; Erhardt, Andreas; Haeussinger, Dieter; Gulbins, Erich; Lang, Florian			Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide	NATURE MEDICINE			English	Article							COPPER-TRANSPORTING ATPASE; RICH MEMBRANE RAFTS; FUNCTIONAL EXPRESSION; HEMOLYTIC-ANEMIA; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-MECHANISMS; INDUCED APOPTOSIS; HUMAN GENE; IN-VIVO; ACTIVATION	Wilson disease is caused by accumulation of Cu2+ in cells, which results in liver cirrhosis and, occasionally, anemia. Here, we show that Cu2+ triggers hepatocyte apoptosis through activation of acid sphingomyelinase (Asm) and release of ceramide. Genetic deficiency or pharmacological inhibition of Asm prevented Cu2+-induced hepatocyte apoptosis and protected rats, genetically prone to develop Wilson disease, from acute hepatocyte death, liver failure and early death. Cu2+ induced the secretion of activated Asm from leukocytes, leading to ceramide release in and phosphatidylserine exposure on erythrocytes, events also prevented by inhibition of Asm. Phosphatidylserine exposure resulted in immediate clearance of affected erythrocytes from the blood in mice. Accordingly, individuals with Wilson disease showed elevated plasma levels of Asm, and displayed a constitutive increase of ceramide- and phosphatidylserine-positive erythrocytes. Our data suggest a previously unidentified mechanism for liver cirrhosis and anemia in Wilson disease.	Univ Tubingen, Inst Physiol, D-72076 Tubingen, Germany; Univ Essen Gesamthsch, Univ Clin, Inst Mol Biol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Univ Clin, Dept Urol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Univ Clin, Inst Pathol & Neuropathol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Univ Clin, Dept Internal Med, D-45122 Essen, Germany; Univ Tubingen, Dept Occupat & Social Med, D-72076 Tubingen, Germany; Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Eberhard Karls University of Tubingen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Eberhard Karls University of Tubingen; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Lang, F (corresponding author), Univ Tubingen, Inst Physiol, D-72076 Tubingen, Germany.	erich.gulbins@uni-due.de; florian.lang@uni-tuebingen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342; Huber, Stephan/0000-0002-9430-8334; Becker, Jan Ulrich/0000-0003-2929-8085				BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Compston A., 1912, BRAIN, V34, P295, DOI DOI 10.1093/BRAIN/34.4.295; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CUMINGS JN, 1948, BRAIN, V71, P410, DOI 10.1093/brain/71.4.410; DEISS A, 1970, ANN INTERN MED, V73, P413, DOI 10.7326/0003-4819-73-3-413; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; FORMAN SJ, 1980, AM J HEMATOL, V9, P269, DOI 10.1002/ajh.2830090305; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GOLDMAN M, 1991, CAN MED ASSOC J, V145, P971; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KERR JFR, 1979, LANCET, V2, P827; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Krumschnabel G, 2005, TOXICOL APPL PHARM, V209, P62, DOI 10.1016/j.taap.2005.03.016; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lang PA, 2005, CELL DEATH DIFFER, V12, P415, DOI 10.1038/sj.cdd.4401561; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; Pourahmad J, 2001, FREE RADICAL BIO MED, V30, P89, DOI 10.1016/S0891-5849(00)00450-0; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Reinehr R, 2005, GASTROENTEROLOGY, V129, P2009, DOI 10.1053/j.gastro.2005.09.023; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Seth R, 2004, TOXICOL IN VITRO, V18, P501, DOI 10.1016/j.tiv.2004.01.006; SOKOL RJ, 1994, GASTROENTEROLOGY, V107, P1788, DOI 10.1016/0016-5085(94)90822-2; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	45	363	373	4	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					164	170		10.1038/nm1539	http://dx.doi.org/10.1038/nm1539			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17259995				2022-12-27	WOS:000244031700025
J	Sato, K; Suematsu, A; Nakashima, T; Takemoto-Kimura, S; Aoki, K; Morishita, Y; Asahara, H; Ohya, K; Yamaguchi, A; Takai, T; Kodama, T; Chatila, TA; Bito, H; Takayanagi, H				Sato, Kojiro; Suematsu, Ayako; Nakashima, Tomoki; Takemoto-Kimura, Sayaka; Aoki, Kazuhiro; Morishita, Yasuyuki; Asahara, Hiroshi; Ohya, Keiichi; Yamaguchi, Akira; Takai, Toshiyuki; Kodama, Tatsuhiko; Chatila, Talal A.; Bito, Haruhiko; Takayanagi, Hiroshi			Regulation of osteoclast differentiation and function by the CaMK-CREB pathway	NATURE MEDICINE			English	Article							PROTEIN-KINASE-IV; T-CELLS; C-FOS; BONE HOMEOSTASIS; NUCLEAR FACTOR; TRANSCRIPTION; CALMODULIN; RANKL; EXPRESSION; INHIBITOR	Calcium (Ca2+) signaling is essential for a variety of cellular responses and higher biological functions. Ca2+/calmodulin-dependent kinases (CaMKs) and the phosphatase calcineurin activate distinct downstream pathways that are mediated by the transcription factors cAMP response element (CRE)-binding protein ( CREB) and nuclear factor of activated T cells ( NFAT), respectively(1). The importance of the calcineurin-NFAT pathway in bone metabolism has been demonstrated in osteoclasts, osteoblasts and chondrocytes(2-5). However, the contribution of the CaMK-CREB pathway is poorly understood, partly because of the difficulty of dissecting the functions of homologous family members(6-8). Here we show that the CaMKIV-CREB pathway is crucial for osteoclast differentiation and function. Pharmacological inhibition of CaMKs as well as the genetic ablation of Camk4 reduced CREB phosphorylation and downregulated the expression of c-Fos, which is required for the induction of NFATc1 ( the master transcription factor for osteoclastogenesis(2,3)) that is activated by receptor activator of NF-kappa B ligand ( RANKL). Furthermore, CREB together with NFATc1 induced the expression of specific genes expressed by differentiated osteoclasts. Thus, the CaMK-CREB pathway biphasically functions to regulate the transcriptional program of osteoclastic bone resorption, by not only enhancing induction of NFATc1 but also facilitating NFATc1-dependent gene regulation once its expression is induced. This provides a molecular basis for a new therapeutic strategy for bone diseases.	Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan; Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1138549, Japan; Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Pharmacol Sect, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan; Univ Tokyo, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Natl Ctr Child Hlth & Dev, Dept Innovat Surg, Setagaya Ku, Tokyo 1578535, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Oral Pathol, Bunkyo Ku, Tokyo 1138549, Japan; Tohoku Univ, Dept Expt Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Dept Mol Biol & Med, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Los Angeles, CA 90095 USA; Japan Sci & Technol Agcy JST, SORST, Kawaguchi, Saitama 3320012, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; Tokyo Medical & Dental University (TMDU); University of Tokyo; National Center for Child Health & Development - Japan; Tokyo Medical & Dental University (TMDU); Tohoku University; University of Tokyo; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST)	Takayanagi, H (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138549, Japan.	taka.csi@tmd.ac.jp	Bito, Haruhiko/A-8635-2008; AOKI, Kazuhiro/GRO-6475-2022; Yamaguchi, Akira/AAX-9286-2020	AOKI, Kazuhiro/0000-0001-6643-6315; Bito, Haruhiko/0000-0001-6315-9594; Chatila, Talal/0000-0001-7439-2762; Sato, Kojiro/0000-0003-4105-3726				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200; Kitsos CM, 2005, J BIOL CHEM, V280, P33101, DOI 10.1074/jbc.M505208200; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Long FX, 2001, DEVELOPMENT, V128, P541; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200	30	264	282	7	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1410	1416		10.1038/nm1515	http://dx.doi.org/10.1038/nm1515			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17128269				2022-12-27	WOS:000242618200022
J	Kirschenlohr, HL; Griffin, JL; Clarke, SC; Rhydwen, R; Grace, AA; Schofield, PM; Brindle, KM; Metcalfe, JC				Kirschenlohr, Heide L.; Griffin, Julian L.; Clarke, Sarah C.; Rhydwen, Ranyl; Grace, Andrew A.; Schofield, Peter M.; Brindle, Kevin M.; Metcalfe, James C.			Proton NMR analysis of plasma is a weak predictor of coronary artery disease	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CARDIOVASCULAR RISK-FACTORS; HEART-DISEASE; PRIOR KNOWLEDGE; H-1-NMR; WOMEN; ATHEROSCLEROSIS; QUANTIFICATION; LIPOPROTEINS; INVESTIGATE	Multivariate analysis of H-1-NMR spectra of blood sera was reported previously to predict angiographically defined advanced coronary artery disease ( CAD) with > 90% accuracy and specificity. The analysis depended mainly on the major lipid regions of the spectra, but many variables, including gender and drug treatment, affect lipid composition and are potential confounders. We have determined the predictive power of the same methodology for angiographically defined CAD using plasma samples from groups of male patients, classified by statin treatment, who had normal coronary arteries ( NCAs) or CAD. Predictions for NCA and CAD groups were only 80.3% correct for patients not treated with statins and 61.3% for treated patients, compared with random correct predictions of 50%. A confidence limit of > 99% was achieved for 36.2% of predictions for untreated groups and 6.2% for treated groups. Detection of CAD by H-1-NMR with > 99% confidence was therefore very weak compared with angiography.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Papworth Hosp, NHS Trust, Dept Cardiol, Cambridge CB3 8RE, England	University of Cambridge; Papworth Hospital	Metcalfe, JC (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Downing Site,Tennis Court Rd, Cambridge CB2 1QW, England.	jcm@mole.bio.cam.ac.uk			Biotechnology and Biological Sciences Research Council [E17880] Funding Source: Medline; Medical Research Council [G0100186] Funding Source: Medline; MRC [G0100186] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANTHONY ML, 1994, MOL PHARMACOL, V46, P199; BELL JD, 1987, FEBS LETT, V219, P239, DOI 10.1016/0014-5793(87)81224-3; Bittner V, 2002, AM J CARDIOL, V90, p77I, DOI 10.1016/S0002-9149(02)02637-1; Blake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Brindle JT, 2003, ANALYST, V128, P32, DOI 10.1039/b209155k; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Clarke SC, 2001, CIRCULATION, V103, P1497; CRAIG WY, 1992, CLIN CHEM, V38, P550; Eriksson L, 2001, MULTI MEGAVARIATE DA, P43; Freedman DS, 2004, CLIN CHEM, V50, P1189, DOI 10.1373/clinchem.2004.032763; Gavaghan CL, 2000, FEBS LETT, V484, P169, DOI 10.1016/S0014-5793(00)02147-5; Jousilahti P, 1999, CIRCULATION, V99, P1165, DOI 10.1161/01.cir.99.9.1165; Le Moyec L, 2005, NMR BIOMED, V18, P421, DOI 10.1002/nbm.974; Legato MJ, 2000, AM J CARDIOL, V86, p15L; LIM HM, 1991, YALE J BIOL MED, V64, P63; Mierisova S, 2001, NMR BIOMED, V14, P247, DOI 10.1002/nbm.697; PEDERSEN TR, 1994, LANCET, V344, P1383; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Ransohoff DF, 2005, NAT REV CANCER, V5, P142, DOI 10.1038/nrc1550; VANDERVEEN JWC, 1988, MAGNET RESON MED, V6, P92, DOI 10.1002/mrm.1910060111; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244	23	137	147	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					705	710		10.1038/nm1432	http://dx.doi.org/10.1038/nm1432			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732278				2022-12-27	WOS:000238149200035
J	Halban, PA; Ferrannini, E; Nerup, J				Halban, PA; Ferrannini, E; Nerup, J			Diabetes research investment in the European union	NATURE MEDICINE			English	Editorial Material									Univ Geneva, Med Ctr, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; Univ Pisa, Metabol Unit, Dept Internal Med, Sch Med, I-56100 Pisa, Italy; Univ Pisa, Sch Med, CNR, Inst Clin Physiol, I-56100 Pisa, Italy; Steno Diabet Ctr, DK-2820 Gentofte, Denmark	University of Geneva; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa; Steno Diabetes Center	Halban, PA (corresponding author), Univ Geneva, Med Ctr, Dept Genet Med & Dev, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	philippe.halban@medecine.unige.ch							0	9	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2006	12	1					70	72		10.1038/nm0106-70	http://dx.doi.org/10.1038/nm0106-70			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397573				2022-12-27	WOS:000234419000053
J	Trowbridge, JJ; Xenocostas, A; Moon, RT; Bhatia, M				Trowbridge, JJ; Xenocostas, A; Moon, RT; Bhatia, M			Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation	NATURE MEDICINE			English	Article							UMBILICAL-CORD BLOOD; SONIC HEDGEHOG; SELF-RENEWAL; BETA-CATENIN; BONE-MARROW; GLUCOSE-METABOLISM; UNRELATED DONORS; SKELETAL-MUSCLE; PROTO-ONCOGENE; GENE-THERAPY	The in vivo regulation of hematopoietic stem cell (HSC) function is poorly understood. Here, we show that hematopoietic repopulation can be augmented by administration of a glycogen synthase kinase-3 (GSK-3) inhibitor to recipient mice transplanted with mouse or human HSCs. GSK-3 inhibitor treatment improved neutrophil and megakaryocyte recovery, recipient survival and resulted in enhanced sustained long-term repopulation. The output of primitive Lin(-)c-Kit(+)Sca-1(+) cells and progenitors from HSCs increased upon GSK-3 inhibitor treatment without altering secondary repopulating ability, suggesting that the HSC pool is maintained while overall hematopoietic reconstitution is increased. GSK-3 inhibitors were found to modulate gene targets of Wnt, Hedgehog and Notch pathways in cells comprising the primitive hematopoietic compartment without affecting mature cells. Our study establishes GSK-3 as a specific in vivo modulator of HSC activity, and suggests that administration of GSK-3 inhibitors may provide a clinical means to directly enhance the repopulating capacity of transplanted HSCs.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5B8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5B8, Canada; London Hlth Sci Ctr, London, ON N6A 5W9, Canada; Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA; Krembil Ctr Stem Cell Biol, Robarts Res Inst, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Western University (University of Western Ontario)	Bhatia, M (corresponding author), McMaster Univ, Fac Hlth Sci, 1200 Main St W,MDCL 5029, Hamilton, ON, Canada.	mbhatia@mcmaster.ca	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014; Xenocostas, Anargyros/G-3358-2011	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; 	NIGMS NIH HHS [P01 GM069983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM069983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker JN, 2005, BLOOD, V105, P1343, DOI 10.1182/blood-2004-07-2717; Baron F, 2003, ARCH MED RES, V34, P528, DOI 10.1016/j.arcmed.2003.09.010; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen P, 1979, BIOCHEM SOC T, V7, P459, DOI 10.1042/bst0070459; Cohen Y, 2003, LEUKEMIA LYMPHOMA, V44, P1287, DOI 10.1080/1042819031000077016; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Devine SM, 2003, BONE MARROW TRANSPL, V31, P241, DOI 10.1038/sj.bmt.1703813; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Giralt Sergio, 2004, Curr Hematol Rep, V3, P165; Gluckman E, 2000, EXP HEMATOL, V28, P1197, DOI 10.1016/S0301-472X(00)00540-3; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Laughlin MJ, 2004, NEW ENGL J MED, V351, P2265, DOI 10.1056/NEJMoa041276; Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood-2004-08-3207; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Moscardo F, 2004, LEUKEMIA LYMPHOMA, V45, P11, DOI 10.1080/1042819031000146992; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shojaei F, 2005, DEV CELL, V8, P651, DOI 10.1016/j.devcel.2005.03.004; Srour EF, 1999, J HEMATOTHER, V8, P93, DOI 10.1089/106161299320370; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Vollweiler JL, 2003, BONE MARROW TRANSPL, V32, P1, DOI 10.1038/sj.bmt.1704081; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	48	206	226	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					89	98		10.1038/nm1339	http://dx.doi.org/10.1038/nm1339			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16341242				2022-12-27	WOS:000234419000057
J	Herrmann, O; Baumann, B; de Lorenzi, R; Muhammad, S; Zhang, W; Kleesiek, J; Malfertheiner, M; Kohrmann, M; Potrovita, I; Maegele, I; Beyer, C; Burke, JR; Hasan, MT; Bujard, H; Wirth, T; Pasparakis, M; Schwaninger, M				Herrmann, O; Baumann, B; de Lorenzi, R; Muhammad, S; Zhang, W; Kleesiek, J; Malfertheiner, M; Kohrmann, M; Potrovita, I; Maegele, I; Beyer, C; Burke, JR; Hasan, MT; Bujard, H; Wirth, T; Pasparakis, M; Schwaninger, M			IKK mediates ischemia-induced neuronal death	NATURE MEDICINE			English	Article							NF-KAPPA-B; FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; BRAIN-INJURY; KINASE COMPLEX; CELL-DEATH; SIGNALING PATHWAY; ACTIVATION; MICE; TRANSCRIPTION	The I kappa B kinase complex IKK is a central component of the signaling cascade that controls NF-kappa B-dependent gene transcription. So far, its function in the brain is largely unknown. Here, we show that IKK is activated in a mouse model of stroke. To investigate the function of IKK in brain ischemia we generated mice that contain a targeted deletion of Ikbkb (which encodes IKK2) in mouse neurons and mice that express a dominant inhibitor of IKK in neurons. In both lines, inhibition of IKK activity markedly reduced infarct size. In contrast, constitutive activation of IKK2 enlarged the infarct size. A selective small-molecule inhibitor of IKK mimicked the effect of genetic IKK inhibition in neurons, reducing the infarct volume and cell death in a therapeutic time window of 4.5 h. These data indicate a key function of IKK in ischemic brain damage and suggest a potential role for IKK inhibitors in stroke therapy.	Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; European Mol Biol Lab, Mouse Biol Unit, I-00016 Monterotondo, Italy; Rhein Westfal TH Aachen, Med Clin, Inst Neuroanat, D-52075 Aachen, Germany; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA; Max Planck Inst Med Res, Dept Biomed Opt, D-69120 Heidelberg, Germany; Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ulm University; European Molecular Biology Laboratory (EMBL); RWTH Aachen University; Bristol-Myers Squibb; Max Planck Society; Ruprecht Karls University Heidelberg	Schwaninger, M (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	markus.schwaninger@med.uni-heidelberg.de	Pasparakis, Manolis/H-9292-2017; Malfertheiner, Maximilian/AAA-8986-2020; Wirth, Thomas/X-7172-2019; Pasparakis, Manolis/N-4350-2019; Hasan, Mazahir/L-3679-2017	Pasparakis, Manolis/0000-0002-9870-0966; Malfertheiner, Maximilian/0000-0002-6245-2614; Pasparakis, Manolis/0000-0002-9870-0966; Muhammad, Sajjad/0000-0002-6734-7979; Schwaninger, Markus/0000-0002-4510-9718; Hasan, Mazahir/0000-0001-9985-7271				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Azoitei N, 2005, J NEUROCHEM, V93, P1487, DOI 10.1111/j.1471-4159.2005.03148.x; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; CHAN PH, 1993, NEUROREPORT, V5, P293, DOI 10.1097/00001756-199312000-00028; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Khoshnan A, 2004, J NEUROSCI, V24, P7999, DOI 10.1523/JNEUROSCI.2675-04.2004; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Ma JY, 2001, BRIT J PHARMACOL, V133, P345, DOI 10.1038/sj.bjp.0704075; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Nurmi A, 2004, STROKE, V35, P987, DOI 10.1161/01.STR.0000120732.45951.26; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Qin ZH, 1999, J NEUROSCI, V19, P4023; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Scholzke MN, 2003, EUR J NEUROSCI, V18, P3305, DOI 10.1111/j.1460-9568.2003.03079.x; Song YS, 2005, J CEREBR BLOOD F MET, V25, P1301, DOI 10.1038/sj.jcbfm.9600123; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vartiainen N, 2003, STROKE, V34, P752, DOI 10.1161/01.STR.0000057813.31798.1F; Wang XK, 2004, MOL PHARMACOL, V65, P890, DOI 10.1124/mol.65.4.890; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Williams AJ, 2003, J CEREBR BLOOD F MET, V23, P75, DOI 10.1097/01.WCB.0000039285.37737.C2; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004	48	220	232	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1322	1329		10.1038/nm1323	http://dx.doi.org/10.1038/nm1323			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16286924				2022-12-27	WOS:000233774400031
J	Diamond, B				Diamond, B			Marie Filbin	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2005	11	11					1134	1134		10.1038/nm1105-1134	http://dx.doi.org/10.1038/nm1105-1134			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16270058				2022-12-27	WOS:000233115400011
J	Tyner, JW; Uchida, O; Kajiwara, N; Kim, EY; Patel, AC; O'Sullivan, MP; Walter, MJ; Schwendener, RA; Cook, DN; Danoff, TM; Holtzman, MJ				Tyner, JW; Uchida, O; Kajiwara, N; Kim, EY; Patel, AC; O'Sullivan, MP; Walter, MJ; Schwendener, RA; Cook, DN; Danoff, TM; Holtzman, MJ			CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection	NATURE MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; CD8(+) T-CELLS; INFLAMMATORY RESPONSE; AIRWAY INFLAMMATION; CHEMOKINE RECEPTORS; EXPRESSION; RANTES; MICE; RECRUITMENT; REPLICATION	Host defense against viruses probably depends on targeted death of infected host cells and then clearance of cellular corpses by macrophages. For this process to be effective, the macrophage must presumably avoid its own virus-induced death. Here we identify one such mechanism. We show that mice lacking the chemokine Ccl5 are immune compromised to the point of delayed viral clearance, excessive airway inflammation and respiratory death after mouse parainfluenza or human influenza virus infection. Virus-inducible levels of Ccl5 are required to prevent apoptosis of virus-infected mouse macrophages in vivo and mouse and human macrophages ex vivo. The protective effect of Ccl5 requires activation of the Ccr5 chemokine receptor and consequent bilateral activation of G(alpha i)-Pl3K-AKT and G(alpha i)-MEK-ERK signaling pathways. The antiapoptotic action of chemokine signaling may therefore allow scavengers to finally stop the host cell-to-cell infectious process.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Paul Scherrer Inst, Dept Mol Cell Biol, CH-5232 Villigen, Switzerland; Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Duke University; University of Pennsylvania; Washington University (WUSTL)	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	holtzman@im.wustl.edu	Schwendener, Reto A/F-6373-2011; Cook, Donald/E-5079-2019; Patel, Anand/B-1441-2009; O'Sullivan, Mary P/C-9413-2012	Cook, Donald/0000-0002-0052-3755; Patel, Anand/0000-0002-6570-8582; O'Sullivan, Mary P/0000-0002-6104-8943; Tyner, Jeffrey/0000-0002-2133-0960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES102025] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; Chen YJ, 2003, PHYSIOL GENOMICS, V14, P251, DOI 10.1152/physiolgenomics.00022.2003; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Domachowske JB, 1999, CLIN MICROBIOL REV, V12, P298, DOI 10.1128/CMR.12.2.298; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Hull J, 2003, J INFECT DIS, V188, P904, DOI 10.1086/377587; Koga T, 1999, P NATL ACAD SCI USA, V96, P5680, DOI 10.1073/pnas.96.10.5680; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Lang R, 2002, J IMMUNOL, V168, P3402, DOI 10.4049/jimmunol.168.7.3402; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lillard JW, 2001, J IMMUNOL, V166, P162, DOI 10.4049/jimmunol.166.1.162; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x; Roscic-Mrkic B, 2001, J VIROL, V75, P3343, DOI 10.1128/JVI.75.7.3343-3351.2001; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SAUNDERS BM, 1995, INFECT IMMUN, V63, P2282, DOI 10.1128/IAI.63.6.2282-2287.1995; Smyth G.K., 2004, STAT APPL GENET MOL; Stephens R, 2002, J IMMUNOL, V169, P5458, DOI 10.4049/jimmunol.169.10.5458; Sumino KC, 2005, J INFECT DIS, V192, P1052, DOI 10.1086/432728; Taguchi M, 1998, J EXP MED, V187, P1927, DOI 10.1084/jem.187.12.1927; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Topham DJ, 1997, J IMMUNOL, V159, P5197; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683	40	221	232	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1180	1187		10.1038/nm1303	http://dx.doi.org/10.1038/nm1303			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16208318	Green Accepted			2022-12-27	WOS:000233115400030
J	Brotz-Oesterhelt, H; Beyer, D; Kroll, HP; Endermann, R; Ladel, C; Schroeder, W; Hinzen, B; Raddatz, S; Paulsen, H; Henninger, K; Bandow, JE; Sahl, HG; Labischinski, H				Brotz-Oesterhelt, H; Beyer, D; Kroll, HP; Endermann, R; Ladel, C; Schroeder, W; Hinzen, B; Raddatz, S; Paulsen, H; Henninger, K; Bandow, JE; Sahl, HG; Labischinski, H			Dysregulation of bacterial proteolytic machinery by a new class of antibiotics	NATURE MEDICINE			English	Article							DEPENDENT CLP PROTEASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; ATP HYDROLYSIS; HEAT-SHOCK; RESISTANCE; EXPRESSION; SELECTION	Here we show that a new class of antibiotics-acyldepsipeptides-has antibacterial activity against Gram-positive bacteria in vitro and in several rodent models of bacterial infection. The acyldepsipeptides are active against isolates that are resistant to antibiotics in clinical application, implying a new target, which we identify as ClpP, the core unit of a major bacterial protease complex. ClpP is usually tightly regulated and strictly requires a member of the family of Clp-ATPases and often further accessory proteins for proteolytic activation. Binding of acyldepsipeptides to ClpP eliminates these safeguards. The acyldepsipeptide-activated ClpP core is capable of proteolytic degradation in the absence of the regulatory Clp-ATPases. Such uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death.	Bayer HealthCare AG, Pharma Res, Dept Antiinfect, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Enabling Technol, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Chem, D-42096 Wuppertal, Germany; Bayer HealthCare AG, Pharma Res, Dept Pharmacokinet, D-42096 Wuppertal, Germany; Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany; Univ Bonn, Inst Med Microbiol, D-53105 Bonn, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Ernst Moritz Arndt Universitat Greifswald; University of Bonn	Brotz-Oesterhelt, H (corresponding author), Bayer HealthCare AG, Pharma Res, Dept Antiinfect, Aprather Weg 18a, D-42096 Wuppertal, Germany.	heike.broetz-oesterhelt@bayerhealthcare.com	Ladel, Christoph/ABG-3165-2021; Bandow, Julia/K-8854-2012	Bandow, Julia/0000-0003-4100-8829; Ladel, Christoph/0000-0001-8657-6219				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400; Bandow JE, 2003, ANTIMICROB AGENTS CH, V47, P948, DOI 10.1128/AAC.47.3.948-955.2003; Fritsche TR, 2005, ANTIMICROB AGENTS CH, V49, P1468, DOI 10.1128/AAC.49.4.1468-1476.2005; Gerth U, 2004, J BACTERIOL, V186, P179, DOI 10.1128/JB.186.1.179-191.2004; Hardy CD, 2003, ANTIMICROB AGENTS CH, V47, P941, DOI 10.1128/AAC.47.3.941-947.2003; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; *INF DIS SOC AM, BAD BUGS NO DRUGS; Kock H, 2004, MOL MICROBIOL, V51, P1087, DOI 10.1046/j.1365-2958.2003.03875.x; Kwon HY, 2004, INFECT IMMUN, V72, P5646, DOI 10.1128/IAI.72.10.5646-5653.2004; Kwon HY, 2003, INFECT IMMUN, V71, P3757, DOI 10.1128/IAI.71.7.3757-3765.2003; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Michel K.H., 1985, US Pat., Patent No. [4492650, 4,492,650]; Msadek T, 1998, MOL MICROBIOL, V27, P899, DOI 10.1046/j.1365-2958.1998.00735.x; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Schlothauer T, 2003, P NATL ACAD SCI USA, V100, P2306, DOI 10.1073/pnas.0535717100; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Tsubery H, 2002, MOL PHARMACOL, V62, P1036, DOI 10.1124/mol.62.5.1036; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; WOO KM, 1989, J BIOL CHEM, V264, P2088	24	352	367	2	42	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2005	11	10					1082	1087		10.1038/nm1306	http://dx.doi.org/10.1038/nm1306			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16200071				2022-12-27	WOS:000232492500029
J	Li, BJ; Tang, QQ; Cheng, D; Qin, C; Xie, FY; Wei, Q; Xu, J; Liu, YJ; Zheng, BJ; Woodle, MC; Zhong, NS; Lu, PY				Li, BJ; Tang, QQ; Cheng, D; Qin, C; Xie, FY; Wei, Q; Xu, J; Liu, YJ; Zheng, BJ; Woodle, MC; Zhong, NS; Lu, PY			Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; SMALL INTERFERING RNAS; SPIKE PROTEIN; GENE-TRANSFER; VIRUS; MICE; REPLICATION; INFECTION; SEQUENCE; EXPRESSION	Development of therapeutic agents for severe acute respiratory syndrome ( SARS) viral infection using short interfering RNA ( siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus ( SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque ( Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS- like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA- mediated anti- SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection - induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10 - 40 mg/ kg accumulated dosages of siRNA did not show any sign of siRNA- induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.	Intradigm Corp, Rockville, MD 20852 USA; Sun Yatsen Univ, Biotechnol Res Ctr, Guangzhou, Peoples R China; Minist Educ State, Key Lab Gene Engn, Guangzhou, Peoples R China; Guangzhou Top Genom Ltd, Guangzhou, Peoples R China; Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China	Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Hong Kong	Lu, PY (corresponding author), Intradigm Corp, 12115 K Parklawn Dr, Rockville, MD 20852 USA.	nanshan@vip.163.com; patricklu@intradigm.com	cheng, du/GPK-2264-2022	cheng, du/0000-0001-5105-7777				Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598; Bonnard E, 2002, PEPTIDES, V23, P1107, DOI 10.1016/S0196-9781(02)00034-7; Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X; Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Delepine P, 2003, J GENE MED, V5, P600, DOI 10.1002/jgm.385; Elmen J., 2004, PRECLINICA, V2, P135; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Ghanayem N S, 2001, Pediatr Crit Care Med, V2, P315, DOI 10.1097/00130478-200110000-00005; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001; Haasnoot J, 2003, J BIOMED SCI, V10, P607, DOI 10.1007/BF02256311; He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002; Heidel JD, 2004, NAT BIOTECHNOL, V22, P1579, DOI 10.1038/nbt1038; Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482; Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; LU PY, 2000, Patent No. 20030148975; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769; Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004; Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Thomas Neal J, 2005, Pediatr Crit Care Med, V6, P160, DOI 10.1097/01.PCC.0000154965.08432.16; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhang RL, 2003, CHINESE MED J-PEKING, V116, P1262; Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0; Zheng BJ, 2004, ANTIVIR THER, V9, P365; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	50	361	413	2	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					944	951		10.1038/nm1280	http://dx.doi.org/10.1038/nm1280			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116432	Green Published, Bronze			2022-12-27	WOS:000231724700021
J	Kukar, T; Murphy, MP; Eriksen, JL; Sagi, SA; Weggen, S; Smith, TE; Ladd, T; Khan, MA; Kache, R; Beard, J; Dodson, M; Merit, S; Ozols, VV; Anastasiadis, PZ; Das, P; Fauq, A; Koo, EH; Golde, TE				Kukar, T; Murphy, MP; Eriksen, JL; Sagi, SA; Weggen, S; Smith, TE; Ladd, T; Khan, MA; Kache, R; Beard, J; Dodson, M; Merit, S; Ozols, VV; Anastasiadis, PZ; Das, P; Fauq, A; Koo, EH; Golde, TE			Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A beta 42 production	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GAMMA-SECRETASE ACTIVITY; AMYLOID-BETA-PROTEIN; PROLIFERATOR-ACTIVATED RECEPTOR; TRANSGENIC MOUSE MODEL; IN-VIVO; COX-2 INHIBITORS; RAT-LIVER; PRESENILIN-1; RHO	Increased A beta 42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise A beta 42. Among the more potent A beta 42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised A beta 42, including multiple COX-2-selective derivatives of two A beta 42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised A beta 42. These compounds seem to target the gamma-secretase complex, increasing gamma-secretase-catalyzed production of A beta 42 in vitro. Short-term in vivo studies show that two A beta 42-raising compounds increase A beta 42 levels in the brains of mice. The elevations in A beta 42 by these compounds are comparable to the increases in A beta 42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid beta protein precursor and presenilins, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase A beta 42 production in humans.	Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Mayo Clin, Coll Med, Ctr Comprehens Canc, Jacksonville, FL 32224 USA	Mayo Clinic; University of California System; University of California San Diego; Mayo Clinic	Golde, TE (corresponding author), Mayo Clin, Coll Med, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu	Kukar, Thomas/AAW-2612-2021; Khan, Murad Ali/H-7094-2016; Eriksen, Jason/A-8054-2008	Khan, Murad Ali/0000-0002-8286-5504; Eriksen, Jason/0000-0003-1549-4165; Kukar, Thomas/0000-0002-3750-6262	NIA NIH HHS [P01 AG20206, T 32 AG00216] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG020206, T32AG000216] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Berger J, 1999, EUR J BIOCHEM, V265, P719, DOI 10.1046/j.1432-1327.1999.00772.x; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Gan XD, 2001, J BIOL CHEM, V276, P48702, DOI 10.1074/jbc.M109402200; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kalgutkar AS, 2000, J MED CHEM, V43, P2860, DOI 10.1021/jm000004e; Kammerl MC, 2004, LANCET, V364, P1486, DOI 10.1016/S0140-6736(04)17265-6; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Keller RK, 1996, BBA-LIPID LIPID MET, V1303, P169, DOI 10.1016/0005-2760(96)00081-1; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Martin BK, 2002, CONTROL CLIN TRIALS, V23, P93, DOI 10.1016/S0197-2456(01)00189-1; MCGOWAN E, 2003, ABSTR SOC NEUR; McLendon C, 2000, FASEB J, V14, P2383; Miyata K, 2000, ARTERIOSCL THROM VAS, V20, P2351, DOI 10.1161/01.ATV.20.11.2351; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Najib J, 2002, CLIN THER, V24, P2022, DOI 10.1016/S0149-2918(02)80095-9; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	48	233	265	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					545	550		10.1038/nm1235	http://dx.doi.org/10.1038/nm1235			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15834426				2022-12-27	WOS:000228915000027
J	Schubert, C				Schubert, C			Natural plaque-buster	NATURE MEDICINE			English	News Item								Researchers examined mice with transgenes expressing deviant forms of 2 proteins implicated in Alzheimer disease, APP (amyloid precursor protein) and presenilin, and found that these mice developed amyloid-beta plaques in the brain. When some of the mice were placed in an environment providing mental stimulation, fewer plaques were found to develop than in mice in ''boring'' environments. These findings help support the theory that Alzheimer disease can be staved off by keeping mentally alert.										Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-27	WOS:000228180500027
J	Ray, S; Britschgi, M; Herbert, C; Takeda-Uchimura, Y; Boxer, A; Blennow, K; Friedman, LF; Galasko, DR; Jutel, M; Karydas, A; Kaye, JA; Leszek, J; Miller, BL; Minthon, L; Quinn, JF; Rabinovici, GD; Robinson, WH; Sabbagh, MN; So, YT; Sparks, DL; Tabaton, M; Tinklenberg, J; Yesavage, JA; Tibshirani, R; Wyss-Coray, T				Ray, Sandip; Britschgi, Markus; Herbert, Charles; Takeda-Uchimura, Yoshiko; Boxer, Adam; Blennow, Kaj; Friedman, Leah F.; Galasko, Douglas R.; Jutel, Marek; Karydas, Anna; Kaye, Jeffrey A.; Leszek, Jerzy; Miller, Bruce L.; Minthon, Lennart; Quinn, Joseph F.; Rabinovici, Gil D.; Robinson, William H.; Sabbagh, Marwan N.; So, Yuen T.; Sparks, D. Larry; Tabaton, Massimo; Tinklenberg, Jared; Yesavage, Jerome A.; Tibshirani, Robert; Wyss-Coray, Tony			Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins	NATURE MEDICINE			English	Article							MILD COGNITIVE IMPAIRMENT; GENE-EXPRESSION; DISEASE; RESPONSES; IMMUNE	A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Satoris Inc, Redwood City, CA 94063 USA; Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94117 USA; Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Expt Neurosci, Inst Clin Neurosci, S-43180 Molndal, Sweden; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Wroclaw Med Univ, Dept Internal Med & Allergol, PL-50417 Wroclaw, Poland; Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA; Wroclaw Med Univ, Dept Psychiat, PL-51622 Wroclaw, Poland; Lund Univ, Dept Clin Sci Malmo, Clin Mem Res Unit, Univ Sjukhuset MAS, SE-20502 Malmo, Sweden; Stanford Univ, Sch Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Sun Hlth Res Inst, Sun City, AZ 85351 USA; Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA	Stanford University; Sahlgrenska University Hospital; University of Gothenburg; Stanford University; University of California System; University of California San Diego; Wroclaw Medical University; Oregon Health & Science University; Wroclaw Medical University; Lund University; Stanford University; Banner Research; Banner Health; Banner Sun Health Research Institute; University of Genoa; Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Wyss-Coray, T (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, 300 Pasteur Dr, Stanford, CA 94305 USA.	twc@stanford.edu	Abrams, William R/A-5782-2008; Wyss-Coray, Tony/AAF-3380-2019; Rabinovici, Gil/AAA-2495-2020	Wyss-Coray, Tony/0000-0001-5893-0831; Britschgi, Markus/0000-0001-6151-4257; Quinn, Joseph/0000-0001-7305-2256; Kaye, Jeffrey/0000-0002-9971-3478	NATIONAL INSTITUTE ON AGING [R01AG020603, P30AG008017, P50AG005131] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Assini A, 2004, NEUROLOGY, V63, P828, DOI 10.1212/01.WNL.0000137040.64252.ED; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Britschgi M, 2007, INT REV NEUROBIOL, V82, P205, DOI 10.1016/S0074-7742(07)82011-3; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Huang Ruo-Pan, 2004, Methods Mol Biol, V264, P215; LeBlanc Andrea C., 2005, Current Alzheimer Research, V2, P389, DOI 10.2174/156720505774330573; MAES OC, 2006, NEUROBIOL AGING 0918; Scherzer CR, 2007, P NATL ACAD SCI USA, V104, P955, DOI 10.1073/pnas.0610204104; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Storandt M, 2002, NEUROLOGY, V59, P1034, DOI 10.1212/WNL.59.7.1034; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484	15	780	841	3	137	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2007	13	11					1359	1362		10.1038/nm1653	http://dx.doi.org/10.1038/nm1653			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17934472				2022-12-27	WOS:000250736900029
J	Kuo, LE; Kitlinska, JB; Tilan, JU; Li, LJ; Baker, SB; Johnson, MD; Lee, EW; Burnett, MS; Fricke, ST; Kvetnansky, R; Herzog, H; Zukowska, Z				Kuo, Lydia E.; Kitlinska, Joanna B.; Tilan, Jason U.; Li, Lijun; Baker, Stephen B.; Johnson, Michael D.; Lee, Edward W.; Burnett, Mary Susan; Fricke, Stanley T.; Kvetnansky, Richard; Herzog, Herbert; Zukowska, Zofia			Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome	NATURE MEDICINE			English	Article							WHITE ADIPOSE-TISSUE; RAT CAROTID-ARTERY; SYMPATHETIC ACTIVATION; ISCHEMIC ANGIOGENESIS; GENE-EXPRESSION; OB/OB MICE; NPY; RESPONSES; EXERCISE; DIET	The relationship between stress and obesity remains elusive. In response to stress, some people lose weight, whereas others gain. Here we report that stress exaggerates diet-induced obesity through a peripheral mechanism in the abdominal white adipose tissue that is mediated by neuropeptide Y (NPY). Stressors such as exposure to cold or aggression lead to the release of NPY from sympathetic nerves, which in turn upregulates NPY and its Y2 receptors (NPY2R) in a glucocorticoid-dependent manner in the abdominal fat. This positive feedback response by NPY leads to the growth of abdominal fat. Release of NPY and activation of NPY2R stimulates fat angiogenesis, macrophage infiltration, and the proliferation and differentiation of new adipocytes, resulting in abdominal obesity and a metabolic syndrome-like condition. NPY, like stress, stimulates mouse and human fat growth, whereas pharmacological inhibition or fat-targeted knockdown of NPY2R is anti-angiogenic and anti-adipogenic, while reducing abdominal obesity and metabolic abnormalities. Thus, manipulations of NPY2R activity within fat tissue offer new ways to remodel fat and treat obesity and metabolic syndrome.	Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Plast Surg, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; MedStar Res Inst, Cardiovasc Res Inst, Washington, DC 20010 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Slovak Acad Sci, Inst Expt Endocrinol, Bratislava 83306, Slovakia; Gaven Inst Med Res, Sydney, NSW 2010, Australia	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Slovak Academy of Sciences	Zukowska, Z (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Biophys, 3900 Reservoir Rd NW,BSB 234, Washington, DC 20057 USA.	zzukow01@georgetown.edu	Herzog, Herbert/B-8294-2008	, Herbert/0000-0002-1713-1029; Lee, Edward/0000-0003-0418-1454	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357, R37HL055310, R01HL055310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE016050] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL067357, HL055310] Funding Source: Medline; NIDCR NIH HHS [DE016050] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN JM, 1987, MOL BRAIN RES, V3, P39, DOI 10.1016/0169-328X(87)90042-8; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bartness TJ, 2005, P NUTR SOC, V64, P53, DOI 10.1079/PNS2004409; Boehm S, 1997, PROG NEUROBIOL, V51, P225, DOI 10.1016/S0301-0082(96)00056-1; BOSWELL T, 1993, BRAIN RES BULL, V32, P379, DOI 10.1016/0361-9230(93)90203-N; Bowers RR, 2004, AM J PHYSIOL-REG I, V286, pR1167, DOI 10.1152/ajpregu.00558.2003; Bradley RL, 2005, OBES RES, V13, P653, DOI 10.1038/oby.2005.73; Brakenhielm E, 2004, CIRC RES, V94, P1579, DOI 10.1161/01.RES.0000132745.76882.70; BRAY GA, 1993, ANN NY ACAD SCI, V676, P223; Bujalska IJ, 2002, ENDOCR RES, V28, P449, DOI 10.1081/ERC-120016822; Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI 10.1073/pnas.1934666100; Dodt C, 2003, ACTA PHYSIOL SCAND, V177, P351, DOI 10.1046/j.1365-201X.2003.01077.x; Ghersi G, 2001, PEPTIDES, V22, P453, DOI 10.1016/S0196-9781(01)00340-0; Guzik TJ, 2006, J PHYSIOL PHARMACOL, V57, P505; Hjemdahl P, 2002, CIRCULATION, V106, P2634, DOI 10.1161/01.CIR.0000041502.43564.79; Jimenez M, 2002, FEBS LETT, V530, P37, DOI 10.1016/S0014-5793(02)03387-2; Kallio J, 2001, J CLIN ENDOCR METAB, V86, P5348, DOI 10.1210/jc.86.11.5348; Kalra SP, 2004, NEUROPEPTIDES, V38, P201, DOI 10.1016/j.npep.2004.06.003; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; KOZLOWSKI S, 1983, PFLUG ARCH EUR J PHY, V399, P63, DOI 10.1007/BF00652523; Lavebratt C, 2006, INT J OBESITY, V30, P453, DOI 10.1038/sj.ijo.0803188; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Levenson CW, 1998, NEUROSCI LETT, V242, P177, DOI 10.1016/S0304-3940(98)00064-0; Li LJ, 2005, ARTERIOSCL THROM VAS, V25, P2075, DOI 10.1161/01.ATV.0000179601.19888.19; Li LJ, 2003, ARTERIOSCL THROM VAS, V23, P1204, DOI 10.1161/01.ATV.0000071349.30914.25; Mark AL, 2002, J HYPERTENS, V20, P1245, DOI 10.1097/00004872-200207000-00001; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Mikurube Hajime, 2005, Nihon Koshu Eisei Zasshi, V52, P987; MORRIS MJ, 1986, J AUTONOM NERV SYST, V17, P143, DOI 10.1016/0165-1838(86)90089-5; Nankova B, 1996, ENDOCRINOLOGY, V137, P5597, DOI 10.1210/en.137.12.5597; Naveilhan P, 2002, PEPTIDES, V23, P1087, DOI 10.1016/S0196-9781(02)00042-6; Prod'homme T, 2006, TRENDS IMMUNOL, V27, P164, DOI 10.1016/J.IT.2006.02.003; Rosmond R, 1998, J CLIN ENDOCR METAB, V83, P1853, DOI 10.1210/jc.83.6.1853; Rotunda AM, 2006, DERMATOL SURG, V32, P465, DOI 10.1111/j.1524-4725.2006.32100.x; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420; SCHWARZ H, 1994, J NEUROIMMUNOL, V51, P53, DOI 10.1016/0165-5728(94)90128-7; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; TROISI RJ, 1991, HYPERTENSION, V17, P669, DOI 10.1161/01.HYP.17.5.669; Turtzo LC, 2002, HORM METAB RES, V34, P607, DOI 10.1055/s-2002-38245; van Rossum CTM, 2006, INT J OBESITY, V30, P1522, DOI 10.1038/sj.ijo.0803314; Yamada T, 2006, CELL METAB, V3, P223, DOI 10.1016/j.cmet.2006.02.001; Zukowska Z, 2003, TRENDS CARDIOVAS MED, V13, P86, DOI 10.1016/S1050-1738(02)00232-3; ZUKOWSKAGROJEC Z, 1988, LIFE SCI, V42, P1615, DOI 10.1016/0024-3205(88)90440-7; ZUKOWSKAGROJEC Z, 1987, AM J PHYSIOL, V253, pH1234, DOI 10.1152/ajpheart.1987.253.5.H1234; ZUKOWSKAGROJEC Z, 1988, SYNAPSE, V2, P293, DOI 10.1002/syn.890020319; ZukowskaGrojec Z, 1995, ANN NY ACAD SCI, V771, P219, DOI 10.1111/j.1749-6632.1995.tb44683.x	49	461	485	3	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					803	811		10.1038/nm1611	http://dx.doi.org/10.1038/nm1611			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17603492				2022-12-27	WOS:000247902800026
J	Roberts, JN; Buck, CB; Thompson, CD; Kines, R; Bernardo, M; Choyke, PL; Lowy, DR; Schiller, JT				Roberts, Jeffrey N.; Buck, Christopher B.; Thompson, Cynthia D.; Kines, Rhonda; Bernardo, Marcelino; Choyke, Peter L.; Lowy, Douglas R.; Schiller, John T.			Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan	NATURE MEDICINE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; MINOR CAPSID PROTEIN; PREVENTION; NEUTRALIZATION; SPERMICIDE; EFFICACY; SERA; HIV; L2	Genital human papillomavirus (HPV) infection is the most common sexually transmitted infection, and virtually all cases of cervical cancer are attributable to infection by a subset of HPVs (reviewed in ref. 1). Despite the high incidence of HPV infection and the recent development of a prophylactic vaccine that confers protection against some HPV types, many features of HPV infection are poorly understood. It remains worthwhile to consider other interventions against genital HPVs, particularly those that target infections not prevented by the current vaccine. However, productive papillomavirus infection is species- and tissue-restricted, and traditional models use animal papillomaviruses that infect the skin or oral mucosa. Here we report the development of a mouse model of cervicovaginal infection with HPV16 that recapitulates the establishment phase of papillomavirus infection. Transduction of a reporter gene by an HPV16 pseudovirus was characterized by histology and quantified by whole-organ, multispectral imaging. Disruption of the integrity of the stratified or columnar genital epithelium was required for infection, which occurred after deposition of the virus on the basement membrane underlying basal keratinocytes. A widely used vaginal spermicide, nonoxynol-9 (N-9), greatly increased susceptibility to infection. In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; SAIC Frederick, Frederick, MD 21702 USA; NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schiller, JT (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.	schillej@mail.nih.gov	Buck, Christopher/G-8358-2017; Schiller, John/ABK-8287-2022	Buck, Christopher/0000-0003-3165-8094; 	NATIONAL CANCER INSTITUTE [ZIABC010657, Z01BC009052, ZIABC010579, Z01BC010657, ZIABC009052, Z01BC010579] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Buck CB, 2005, J VIROL, V79, P2839, DOI 10.1128/JVI.79.5.2839-2846.2005; Buck CB, 2004, J VIROL, V78, P751, DOI 10.1128/JVI.78.2.751-757.2004; Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069; Campo MS, 2002, VIRUS RES, V89, P249, DOI 10.1016/S0168-1702(02)00193-4; Coggins C, 2000, SEX TRANSM INFECT, V76, P480, DOI 10.1136/sti.76.6.480; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; GIMENEZCONTI IB, 1994, DIFFERENTIATION, V56, P143, DOI 10.1007/s002580050031; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; HERMONAT PL, 1992, SEX TRANSM DIS, V19, P203, DOI 10.1097/00007435-199207000-00004; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607; Maguire RA, 1998, SEX TRANSM DIS, V25, P494, DOI 10.1097/00007435-199810000-00010; NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010; Pastrana DV, 2005, VIROLOGY, V337, P365, DOI 10.1016/j.virol.2005.04.011; Pastrana DV, 2004, VIROLOGY, V321, P205, DOI 10.1016/j.virol.2003.12.027; Patton DL, 1999, AM J OBSTET GYNECOL, V180, P1080, DOI 10.1016/S0002-9378(99)70598-3; Pyeon D, 2005, P NATL ACAD SCI USA, V102, P9311, DOI 10.1073/pnas.0504020102; Reuter JD, 2001, J VIROL METHODS, V98, P127, DOI 10.1016/S0166-0934(01)00370-6; Richards RM, 2006, P NATL ACAD SCI USA, V103, P1522, DOI 10.1073/pnas.0508815103; Roberts J.N, 2007, NAT PROTOC, DOI [10.1038/nprot.2007.235, DOI 10.1038/NPROT.2007.235]; Roden RBS, 2001, J VIROL, V75, P10493, DOI 10.1128/JVI.75.21.10493-10497.2001; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Spieler R, 2002, LANCET, V359, P1675, DOI 10.1016/S0140-6736(02)08605-1; TROTTIER H, 2005, VACCINE; Wilkinson D, 2002, LANCET INFECT DIS, V2, P613, DOI 10.1016/S1473-3099(02)00396-1	26	369	399	3	35	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					857	861		10.1038/nm1598	http://dx.doi.org/10.1038/nm1598			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17603495	Green Published			2022-12-27	WOS:000247902800033
J	Kaufmann, SHE; Parida, SK				Kaufmann, Stefan H. E.; Parida, Shreemanta K.			Changing funding patterns in tuberculosis	NATURE MEDICINE			English	Editorial Material									Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany	Max Planck Society	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Charitepl 1, D-10117 Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	; Kaufmann, Stefan HE/I-5454-2014	Parida, Shreemanta K/0000-0003-2129-6691; Kaufmann, Stefan HE/0000-0001-9866-8268				[Anonymous], 1882, BERLINER KLIN WOCHEN, V19, P221; FEUER C, 2006, TUBERCULOSIS RES DEV; FINE PEM, 1989, REV INFECT DIS, V11, pS353; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; KRAMER M, 2004, STRONG MED CREATING; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120	8	41	43	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					299	303		10.1038/nm0307-299	http://dx.doi.org/10.1038/nm0307-299			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342144	Bronze			2022-12-27	WOS:000244715700041
J	Keim, B				Keim, Brandon			Vikram Kumar	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2007	13	2					113	113		10.1038/nm0207-113	http://dx.doi.org/10.1038/nm0207-113			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	133RW	17290258	Bronze			2022-12-27	WOS:000244031700010
J	Dagia, NM; Gadhoum, SZ; Knoblauch, CA; Spencer, JA; Zamiri, P; Lin, CP; Sackstein, R				Dagia, Nilesh M.; Gadhoum, Samah Z.; Knoblauch, Christine A.; Spencer, Joel A.; Zamiri, Parisa; Lin, Charles P.; Sackstein, Robert			G-CSF induces E-selectin ligand expression on human myeloid cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; GRANULOCYTE-COLONY; IN-VIVO; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; BONE-MARROW; ADHESION; PSGL-1; BLOOD	Clinical use of G-CSF can result in vascular and inflammatory complications(1-7). To investigate the molecular basis of these effects, we analyzed the adherence of G-CSF-mobilized human peripheral blood leukocytes (ML) to inflamed (TNF-alpha - stimulated) vascular endothelium. Studies using parallel plate assays under physiologic flow conditions and intravital microscopy in a mouse inflammation model each showed that ML take part in heightened adhesive interactions with endothelium compared to unmobilized (native) blood leukocytes, mediated by markedly increased E-selectin receptor-ligand interactions. Biochemical studies showed that ML express the potent E-selectin ligand HCELL (ref. 8) and another, previously unrecognized similar to 65-kDa E-selectin ligand, and possess enhanced levels of transcripts encoding glycosyltransferases (ST3GaIIIV, FucT-IV and FucT-VII) conferring glycan modifications associated with E-selectin ligand activity. Enzymatic treatments and physiologic binding assays showed that HCELL and the similar to 65-kDa E-selectin ligand contribute prominently to the observed G-CSF-induced myeloid cell adhesion to inflamed endothelium. Treatment of normal human bone marrow cells with a pharmacokinetically relevant concentration of G-CSF in vitro(9,10) resulted in increased expression of these two molecules, coincident with increased transcripts encoding pertinent glycosyltransferases and heightened E-selectin binding. These findings provide direct evidence for a role of G-CSF in the induction of E-selectin ligands on myeloid cells, thus providing mechanistic insight into the pathobiology of G-CSF complications.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Sackstein, R (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, 77 Ave Louis Pasteur,Room 671, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu	Spencer, Joel/GLT-9687-2022; Spencer, Joel/A-4590-2013	Spencer, Joel/0000-0002-4013-8763; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000664] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060528, R01 HL073714] Funding Source: Medline; NIBIB NIH HHS [R01 EB000664] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adler BK, 2001, BLOOD, V97, P3313, DOI 10.1182/blood.V97.10.3313; ALBERT RK, 1995, THORAX, V50, pS49, DOI 10.1136/thx.50.Suppl_1.S49; Arimura Kosei, 2005, Haematologica, V90, pECR10; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Cowland JB, 1999, J IMMUNOL METHODS, V232, P191, DOI 10.1016/S0022-1759(99)00176-3; Dereure O, 2004, BRIT J DERMATOL, V150, P1228, DOI 10.1111/j.1365-2133.2004.06007.x; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Elfenbein GJ, 2004, EXP HEMATOL, V32, P327, DOI 10.1016/j.exphem.2004.01.010; Faulkner LB, 1998, BONE MARROW TRANSPL, V21, P1091, DOI 10.1038/sj.bmt.1701241; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fukumoto Y, 1997, BRIT J HAEMATOL, V97, P666, DOI 10.1046/j.1365-2141.1997.842724.x; Fuste B, 2004, HAEMATOLOGICA, V89, P578; Glass LF, 1996, J AM ACAD DERMATOL, V34, P455, DOI 10.1016/S0190-9622(96)90439-9; Hakansson L, 1997, BRIT J HAEMATOL, V98, P603, DOI 10.1046/j.1365-2141.1997.2723093.x; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Jilma B, 2002, TRANSFUSION, V42, P328, DOI 10.1046/j.1537-2995.2002.00045.x; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kieffer JD, 2001, BIOCHEM BIOPH RES CO, V285, P577, DOI 10.1006/bbrc.2001.5230; KRIEGSMANN J, 1995, ARTHRITIS RHEUM, V38, P750, DOI 10.1002/art.1780380606; LINDEMANN A, 1993, EUR J CANCER, V29A, P2338, DOI 10.1016/0959-8049(93)90236-9; OHSAKA A, 1993, BRIT J HAEMATOL, V84, P574, DOI 10.1111/j.1365-2141.1993.tb03130.x; Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Smith ML, 2004, J EXP MED, V200, P935, DOI 10.1084/jem.20040424; Stricker RB, 1996, AM J MED, V100, P665; van der Auwera P, 2001, AM J HEMATOL, V66, P245, DOI 10.1002/ajh.1052; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Xia LJ, 2002, J CLIN INVEST, V109, P939; Zollner O, 1997, J CELL BIOL, V136, P707, DOI 10.1083/jcb.136.3.707; Zou XY, 2005, AM J PHYSIOL-CELL PH, V289, pC415, DOI 10.1152/ajpcell.00289.2004	30	44	52	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1185	1190		10.1038/nm1470	http://dx.doi.org/10.1038/nm1470			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980970				2022-12-27	WOS:000241102200036
J	Ding, M; Cui, SY; Li, CJ; Jothy, S; Haase, V; Steer, BM; Marsden, PA; Pippin, J; Shankland, S; Rastaldi, MP; Cohen, CD; Kretzler, M; Quaggin, SE				Ding, Mei; Cui, Shiying; Li, Chengjin; Jothy, Serge; Haase, Volker; Steer, Brent M.; Marsden, Philip A.; Pippin, Jeffrey; Shankland, Stuart; Rastaldi, Maria Pia; Cohen, Clemens D.; Kretzler, Matthias; Quaggin, Susan E.			Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice	NATURE MEDICINE			English	Article							RENAL-CELL-CARCINOMA; CRESCENTIC GLOMERULONEPHRITIS; EXPRESSION; PROTEIN; EXCISION; RECEPTOR; KIDNEY; CANCER; VEGF	Rapidly progressive glomerulonephritis (RPGN) is a clinical syndrome characterized by loss of renal function within days to weeks and by glomerular crescents on biopsy. The pathogenesis of this disease is unclear, but circulating factors are believed to have a major role(1,2). Here, we show that deletion of the Von Hippel - Lindau gene (Vhlh) from intrinsic glomerular cells of mice is sufficient to initiate a necrotizing crescentic glomerulonephritis and the clinical features that accompany RPGN. Loss of Vhlh leads to stabilization of hypoxia-inducible factor alpha subunits (HIFs). Using gene expression profiling, we identified de novo expression of the HIF target gene Cxcr4 (ref. 3) in glomeruli from both mice and humans with RPGN. The course of RPGN is markedly improved in mice treated with a blocking antibody to Cxcr4, whereas overexpression of Cxcr4 alone in podocytes of transgenic mice is sufficient to cause glomerular disease. Collectively, these results indicate an alternative mechanism for the pathogenesis of RPGN and glomerular disease in an animal model and suggest novel molecular pathways for intervention in this disease.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; Univ Penn, Dept Med, Program Cell Growth & Canc, Philadelphia, PA 19104 USA; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada; Univ Washington, Div Nephrol, Seattle, WA 98195 USA; San Carlo Hosp, Fdn Damico Ric Malattie Renali, Renal Immunopathol Lab, I-20153 Milan, Italy; Univ Munich, Med Poliklin, Nephrol Zentrum, D-80336 Munich, Germany	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Washington; University of Washington Seattle; San Carlo Borromeo Hospital; University of Munich	Quaggin, SE (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	quaggin@mshri.on.ca	Cui, Steve W./D-4909-2013; Marsden, Philip A/B-1441-2012; Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013	Cui, Steve W./0000-0001-5864-4544; Haase, Volker Hans/0000-0002-7051-8994	NCI NIH HHS [R01 CA100787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Cui SY, 2005, J AM SOC NEPHROL, V16, P3247, DOI 10.1681/ASN.2005030278; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Eremina V, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133788; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Galban S, 2003, MOL CELL BIOL, V23, P2316, DOI 10.1128/MCB.23.7.2316-2328.2003; Grone HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134957; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hedger N, 2000, NEPHROL DIAL TRANSPL, V15, P1593, DOI 10.1093/ndt/15.10.1593; KAGAN A, 1993, NEPHRON, V65, P642, DOI 10.1159/000187581; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Li CG, 1998, BRIT J RHEUMATOL, V37, P1303; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Moeller MJ, 2004, J AM SOC NEPHROL, V15, P61, DOI 10.1097/01.ASN.0000102468.37809.C6; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Sommer M, 1998, NEPHROL DIAL TRANSPL, V13, P2107, DOI 10.1093/ndt/13.8.2107; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Timoshanko JR, 2003, J AM SOC NEPHROL, V14, P1785, DOI 10.1097/01.ASN.0000073902.38428.33; Wada T, 2005, KIDNEY INT, V68, P1618, DOI 10.1111/j.1523-1755.2005.00574.x; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	26	166	173	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1081	1087		10.1038/nm1460	http://dx.doi.org/10.1038/nm1460			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906157				2022-12-27	WOS:000240373900033
J	Tam, BYY; Wei, K; Rudge, JS; Hoffman, J; Holash, J; Park, SK; Yuan, J; Hefner, C; Chartier, C; Lee, JS; Jiang, S; Niyak, NR; Kuypers, FA; Ma, L; Sundram, U; Wu, G; Garcia, JA; Schrier, SL; Maher, JJ; Johnson, RS; Yancopoulos, GD; Mulligan, RC; Kuo, CJ				Tam, Betty Y. Y.; Wei, Kevin; Rudge, John S.; Hoffman, Jana; Holash, Joceyln; Park, Sang-ki; Yuan, Jenny; Hefner, Colleen; Chartier, Cecile; Lee, Jeng-Shin; Jiang, Shelly; Niyak, Nihar R.; Kuypers, Frans A.; Ma, Lisa; Sundram, Uma; Wu, Grace; Garcia, Joseph A.; Schrier, Stanley L.; Maher, Jacquelyn J.; Johnson, Randall S.; Yancopoulos, George D.; Mulligan, Richard C.; Kuo, Calvin J.			VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LIVER; RECEPTOR; CELLS; HIF-1-ALPHA; HYPOXIA; HIF-2-ALPHA; EXPRESSION; SURVIVAL; GENE	Vascular endothelial growth factor ( VEGF) exerts crucial functions during pathological angiogenesis and normal physiology. We observed increased hematocrit (60-75%) after high-grade inhibition of VEGF by diverse methods, including adenoviral expression of soluble VEGF receptor ( VEGFR) ectodomains, recombinant VEGF Trap protein and the VEGFR2-selective antibody DC101. Increased production of red blood cells ( erythrocytosis) occurred in both mouse and primate models, and was associated with near-complete neutralization of VEGF corneal micropocket angiogenesis. High-grade inhibition of VEGF induced hepatic synthesis of erythropoietin ( Epo, encoded by Epo) > 40-fold through a HIF-1 alpha-independent mechanism, in parallel with suppression of renal Epo mRNA. Studies using hepatocyte-specific deletion of the Vegfa gene and hepatocyte-endothelial cell cocultures indicated that blockade of VEGF induced hepatic Epo by interfering with homeostatic VEGFR2-dependent paracrine signaling involving interactions between hepatocytes and endothelial cells. These data indicate that VEGF is a previously unsuspected negative regulator of hepatic Epo synthesis and erythropoiesis and suggest that levels of Epo and erythrocytosis could represent noninvasive surrogate markers for stringent blockade of VEGF in vivo.	Stanford Univ, Div Hematol, Sch Med, Stanford, CA 94305 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Childrens Hosp, Dept Genet, Sch Med,Div Mol Med, Boston, MA 02115 USA; Stanford Univ, Div Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Stanford Univ, Div Pathol, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Div Cardiol, Dallas, TX USA	Stanford University; Regeneron; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard Medical School; Stanford University; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kuo, CJ (corresponding author), Stanford Univ, Div Hematol, Sch Med, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.	cjkuo@stanford.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Garcia, Joseph/0000-0002-5621-7538; Kuo, Calvin/0000-0002-7427-5985	NCI NIH HHS [1 R01 CA95654-01] Funding Source: Medline; NHLBI NIH HHS [K08 HL067154, 1 R01 HL074267-01] Funding Source: Medline; NIDDK NIH HHS [P30 DK026743, P30 DK26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095654] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154, R01HL074267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Ebert BL, 1999, BLOOD, V94, P1864; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hegenbarth S, 2000, HUM GENE THER, V11, P481, DOI 10.1089/10430340050015941; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; IRVING MG, 1984, GASTROENTEROLOGY, V87, P1233; Jacobi J, 2004, GENE THER, V11, P302, DOI 10.1038/sj.gt.3302162; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KONNER J, 2004, CLIN COLORECTAL CANC, V2, pS81; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; KUO CJ, 2002, GENE THERAPY CANC; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lau SC, 2005, CURR OPIN MOL THER, V7, P493; Laughlin KM, 1996, J PHARMACOL EXP THER, V277, P1049; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834; Mahasreshti PJ, 2003, CLIN CANCER RES, V9, P2701; Malik AK, 2006, BLOOD, V107, P550, DOI 10.1182/blood-2005-05-2047; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Prewett M, 1999, CANCER RES, V59, P5209; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Richard S, 2002, BLOOD, V99, P3851, DOI 10.1182/blood.V99.10.3851; Rinaudo D, 2000, BIOTECHNIQUES, V29, P218, DOI 10.2144/00292bm03; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schipani E, 2001, GENE DEV, V15, P2865; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wedge SR, 2000, CANCER RES, V60, P970; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; YAMANE A, 1994, ONCOGENE, V9, P2683; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	49	135	143	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					793	800		10.1038/nm1428	http://dx.doi.org/10.1038/nm1428			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799557				2022-12-27	WOS:000238862800066
J	Thomas, RK; Nickerson, E; Simons, JF; Janne, PA; Tengs, T; Yuza, Y; Garraway, LA; LaFramboise, T; Lee, JC; Shah, K; O'Neill, K; Sasaki, H; Lindeman, N; Wong, KK; Borras, AM; Gutmann, EJ; Dragnev, KH; DeBiasi, R; Chen, TH; Glatt, KA; Greulich, H; Desany, B; Lubeski, CK; Brockman, W; Alvarez, P; Hutchison, SK; Leamon, JH; Ronan, MT; Turenchalk, GS; Egholm, M; Sellers, WR; Rothberg, JM; Meyerson, M				Thomas, Roman K.; Nickerson, Elizabeth; Simons, Jan F.; Janne, Pasi A.; Tengs, Torstein; Yuza, Yuki; Garraway, Levi A.; LaFramboise, Thomas; Lee, Jeffrey C.; Shah, Kinjal; O'Neill, Keith; Sasaki, Hidefumi; Lindeman, Neal; Wong, Kwok-Kin; Borras, Ana M.; Gutmann, Edward J.; Dragnev, Konstantin H.; DeBiasi, Ralph; Chen, Tzu-Hsiu; Glatt, Karen A.; Greulich, Heidi; Desany, Brian; Lubeski, Christine K.; Brockman, William; Alvarez, Pablo; Hutchison, Stephen K.; Leamon, J. H.; Ronan, Michael T.; Turenchalk, Gregory S.; Egholm, Michael; Sellers, William R.; Rothberg, Jonathan M.; Meyerson, Matthew			Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; KINASE INHIBITOR; EGF RECEPTOR; GEFITINIB; ERLOTINIB; THERAPY; DOMAIN	The sensitivity of conventional DNA sequencing in tumor biopsies is limited by stromal contamination and by genetic heterogeneity within the cancer. Here, we show that microreactor-based pyrosequencing can detect rare cancer-associated sequence variations by independent and parallel sampling of multiple representatives of a given DNA fragment. This technology can thereby facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Harvard Univ, Cambridge Ctr 7, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Melanoma Program Med Oncol, Boston, MA 02115 USA; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Translat Res Lab, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Dana-Farber Cancer Institute; Nagoya City University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Meyerson, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012	wong, kwok kin/0000-0001-6323-235X	NCI NIH HHS [T32 CA009172, R01CA098185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009172, R01CA098185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Janne PA, 2006, CLIN CANCER RES, V12, P751, DOI 10.1158/1078-0432.CCR-05-2047; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; VANOMMEN GJ, 1999, LANCET S1, V354, pS15	19	274	303	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					852	855		10.1038/nm1437	http://dx.doi.org/10.1038/nm1437			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799556				2022-12-27	WOS:000238862800075
J	Taieb, J; Chaput, N; Menard, C; Apetoh, L; Ullrich, E; Bonmort, M; Pequignot, M; Casares, N; Terme, M; Flament, C; Opolon, P; Lecluse, Y; Metivier, D; Tomasello, E; Vivier, E; Ghiringhelli, F; Martin, F; Klatzmann, D; Poynard, T; Tursz, T; Raposo, G; Yagita, H; Ryffel, B; Kroemer, G; Zitvogel, L				Taieb, J; Chaput, N; Menard, C; Apetoh, L; Ullrich, E; Bonmort, M; Pequignot, M; Casares, N; Terme, M; Flament, C; Opolon, P; Lecluse, Y; Metivier, D; Tomasello, E; Vivier, E; Ghiringhelli, F; Martin, F; Klatzmann, D; Poynard, T; Tursz, T; Raposo, G; Yagita, H; Ryffel, B; Kroemer, G; Zitvogel, L			A novel dendritic cell subset involved in tumor immunosurveillance	NATURE MEDICINE			English	Article							INTERFERON-GAMMA; IFN-GAMMA; TRAIL; CANCER; IMMUNOTHERAPY; MACROPHAGES; RECEPTORS; APOPTOSIS; IMATINIB; PATHWAY	The interferon (IFN)-gamma-induced TRAIL effector mechanism is a vital component of cancer immunosurveillance by natural killer (NK) cells in mice(1,2). Here we show that the main source of IFN-gamma is not the conventional NK cell but a subset of B220(+)Ly6C(-) dendritic cells, which are atypical insofar as they express NK cell-surface molecules. Upon contact with a variety of tumor cells that are poorly recognized by NK cells, B220(+)NK1.1(+) dendritic cells secrete high levels of IFN-gamma and mediate TRAIL-dependent lysis of tumor cells. Adoptive transfer of these IFN-producing killer dendritic cells (IKDCs) into tumor-bearing Rag2(-/-)Il2rg(-/-) mice prevented tumor outgrowth, whereas transfer of conventional NK cells did not. In conclusion, we identified IKDCs as pivotal sensors and effectors of the innate antitumor immune response.	Inst Gustave Roussy, Fac Med Kremlin Bicetre, INSERM, ERM0208, Villejuif, France; Inst Gustave Roussy, CNRS, UMR8125, Villejuif, France; Inst Gustave Roussy, IFR54, Flow Cytometry Core Facil, Villejuif, France; Univ Mediterranee, Ctr Immunol Marseille Luminy, CNRS, INSERM, Marseille, France; Fac Med, INSERM, U517, Dijon, France; Grp Hosp Pitie Salpetriere, CERVI, UPMC, CNRS,UMR7087, F-75634 Paris, France; Hop La Pitie Salpetriere, AH HP, Dept Gastroenterol, Paris, France; Inst Curie, CNRS, UMR144, F-75231 Paris, France; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Inst Transgenose, CNRS, IEM 2815, Orleans, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Juntendo University; Centre National de la Recherche Scientifique (CNRS)	Zitvogel, L (corresponding author), Inst Gustave Roussy, Fac Med Kremlin Bicetre, INSERM, ERM0208, Villejuif, France.	zitvogel@igr.fr	Poynard, Thierry/C-1355-2010; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Vivier, Eric/F-8939-2010; Apetoh, Lionel/G-3310-2014; TERME, Magali/GZK-9661-2022; Serei, Virian D/B-4616-2015; Casares, Noelia/AAA-5568-2019; Pequignot, Marie O/P-1994-2017; Ménard, Cédric/AAB-3180-2020	Poynard, Thierry/0000-0002-3726-7230; KROEMER, Guido/0000-0002-9334-4405; Vivier, Eric/0000-0001-7022-8287; Apetoh, Lionel/0000-0002-2774-438X; TERME, Magali/0000-0003-0857-7237; Casares, Noelia/0000-0003-3817-6434; Ménard, Cédric/0000-0002-2207-361X; Raposo, graca/0000-0001-9590-1298; ghiringhelli, francois/0000-0002-5465-8305; Klatzmann, David/0000-0002-0054-3422; Tomasello, Elena/0000-0002-6839-5219; Ullrich, Evelyn/0000-0001-8530-1192; ZITVOGEL, laurence/0000-0003-1596-0998; Poynard, Thierry/0000-0002-2050-640X; Pequignot, Marie/0000-0002-8866-3778				Bonnotte B, 2001, J IMMUNOL, V167, P5077, DOI 10.4049/jimmunol.167.9.5077; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; CHAN CW, IN PRESS NAT MED; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Mohty M, 2004, BLOOD, V103, P4666, DOI 10.1182/blood-2003-09-3220; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Pelayo R, 2005, BLOOD, V105, P4407, DOI 10.1182/blood-2004-07-2529; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; Smyth MJ, 2004, J EXP MED, V200, P1325, DOI 10.1084/jem.20041522; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Wang HW, 2005, BLOOD, V105, P1135, DOI 10.1182/blood-2004-01-0027; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x	26	320	347	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					214	219		10.1038/nm1356	http://dx.doi.org/10.1038/nm1356			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16444265				2022-12-27	WOS:000235160600026
J	Toebes, M; Coccoris, M; Bins, A; Rodenko, B; Gomez, R; Nieuwkoop, NJ; van de Kasteele, W; Rimmelzwaan, GF; Haanen, JBAG; Ovaa, H; Schumacher, TNM				Toebes, M; Coccoris, M; Bins, A; Rodenko, B; Gomez, R; Nieuwkoop, NJ; van de Kasteele, W; Rimmelzwaan, GF; Haanen, JBAG; Ovaa, H; Schumacher, TNM			Design and use of conditional MHC class I ligands	NATURE MEDICINE			English	Article							STEM-CELL TRANSPLANTATION; T-LYMPHOCYTES; REACTIVE CTL; PEPTIDE; MOLECULES; CYTOMEGALOVIRUS; TETRAMERS; INFECTION; RESPONSES; SELECTION	Major histocompatibility complex (MHC) class I molecules associate with a variety of peptide ligands during biosynthesis and present these ligands on the cell surface for recognition by cytotoxic T cells. We have designed conditional MHC ligands that form stable complexes with MHC molecules but degrade on command, by exposure to a defined photostimulus. 'Empty MHC molecules' generated in this manner can be loaded with arrays of peptide ligands to determine MHC binding properties and to monitor antigen-specific T-cell responses in a high-throughput manner. We document the value of this approach by identifying cytotoxic T-cell epitopes within the H5N1 influenza A/Vietnam/1194/04 genome.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Erasmus MC, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, WHO, Natl Influenza Ctr, NL-3000 DR Rotterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; World Health Organization	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.ovaa@nki.nl; t.schumacher@nki.nl	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019; Rodenko, Boris/E-5492-2010; ovaa, huib/M-2334-2016	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804; Rodenko, Boris/0000-0001-5223-4296; ovaa, huib/0000-0002-0068-054X; Bins, Adriaan/0000-0002-9794-6526				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bins AD, 2005, NAT MED, V11, P899, DOI 10.1038/nm1264; Bosques CJ, 2003, J AM CHEM SOC, V125, P7530, DOI 10.1021/ja035360b; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Choi EM, 2002, J IMMUNOL METHODS, V268, P35, DOI 10.1016/S0022-1759(02)00198-9; Cobbold M, 2005, J EXP MED, V202, P379, DOI 10.1084/jem.20040613; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Falkenburg JHF, 2003, EXP HEMATOL, V31, P743, DOI 10.1016/S0301-472X(03)00190-5; Firat H, 1999, EUR J IMMUNOL, V29, P3112, DOI 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Moss P, 2005, NAT REV IMMUNOL, V5, P9, DOI 10.1038/nri1526; Oelke M, 2004, CLIN IMMUNOL, V110, P243, DOI 10.1016/j.clim.2003.11.014; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065; Stone JD, 2005, P NATL ACAD SCI USA, V102, P3744, DOI 10.1073/pnas.0407019102; Sulyok GAG, 2001, J MED CHEM, V44, P1938, DOI 10.1021/jm0004953; Valmori D, 1998, J IMMUNOL, V160, P1750; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wieboldt R, 2002, J ORG CHEM, V67, P8827, DOI 10.1021/jo0201373; Yee C, 1999, J IMMUNOL, V162, P2227	30	249	275	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2006	12	2					246	251		10.1038/nm1360	http://dx.doi.org/10.1038/nm1360			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16462803				2022-12-27	WOS:000235160600032
J	Han, BY; Serra, P; Amrani, A; Yamanouchi, J; Maree, AFM; Edelstein-Keshet, L; Santamaria, P				Han, BY; Serra, P; Amrani, A; Yamanouchi, J; Maree, AFM; Edelstein-Keshet, L; Santamaria, P			Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide	NATURE MEDICINE			English	Article							T-CELL-RECEPTOR; MULTIPLE-SCLEROSIS; II COLLAGEN; MICE; ENCEPHALOMYELITIS; TOLERANCE; LYMPHOCYTES; VACCINATION; DETERMINES; EXPANSION	Antigen therapy may hold great promise for the prevention of autoimmunity; however, most clinical trials have failed, suggesting that the principles guiding the choice of treatment remain ill defined. Here, we examine the antidiabetogenic properties of altered peptide ligands of CD8(+) T cells recognizing an epitope of islet-specific glucose-6-phosphatase catalytic subunit - related protein (IGRP(206-214)), a prevalent population of autoreactive T cells in autoimmune diabetes. We show that islet-associated CD8(+) T cells in nonobese diabetic mice recognize numerous IGRP epitopes, and that these cells have a role in the outcome of protocols designed to induce IGRP(206-214)-specific tolerance. Ligands targeting IGRP(206-214)-reactive T cells prevented disease, but only at doses that spared low-avidity clonotypes. Notably, near complete depletion of the IGRP(206-214)-reactive T-cell pool enhanced the recruitment of subdominant specificities and did not blunt diabetogenesis. Thus, peptide therapy in autoimmunity is most effective under conditions that foster occupation of the target organ lymphocyte niche by nonpathogenic, low-avidity clonotypes.	Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Calgary, AB T2N 4N1, Canada; Univ Utrecht, Dept Theoret Biol, NL-3584 CH Utrecht, Netherlands; Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z2, Canada	University of Calgary; Utrecht University; University of British Columbia	Santamaria, P (corresponding author), Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	psantama@ucalgary.ca	Santamaria, Pere/ABF-6823-2021	Maree, Athanasius F. M./0000-0003-2689-2484				AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Amrani A, 2000, NATURE, V406, P739, DOI 10.1038/35021081; Amrani A, 2001, J IMMUNOL, V167, P655, DOI 10.4049/jimmunol.167.2.655; Anderson B, 1999, P NATL ACAD SCI USA, V96, P9311, DOI 10.1073/pnas.96.16.9311; Anderton SM, 1998, EUR J IMMUNOL, V28, P1251, DOI 10.1002/(SICI)1521-4141(199804)28:04<1251::AID-IMMU1251>3.0.CO;2-O; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; Gross DA, 2004, J CLIN INVEST, V113, P425, DOI 10.1172/JCI200419418; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Lieberman SM, 2003, P NATL ACAD SCI USA, V100, P8384, DOI 10.1073/pnas.0932778100; Lieberman SM, 2003, TISSUE ANTIGENS, V62, P359, DOI 10.1034/j.1399-0039.2003.00152.x; LIU GY, 1995, INT IMMUNOL, V7, P1255, DOI 10.1093/intimm/7.8.1255; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; McKown KM, 1999, ARTHRITIS RHEUM, V42, P1204, DOI 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U; Metzler B, 2000, IMMUNOL INVEST, V29, P61, DOI 10.3109/08820130009105145; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; Perez-Diez A, 2002, J IMMUNOL, V168, P338, DOI 10.4049/jimmunol.168.1.338; Pociot F, 2002, GENES IMMUN, V3, P235, DOI 10.1038/sj.gene.6363875; Pozzilli P, 2000, DIABETOLOGIA, V43, P1000, DOI 10.1007/s001250051482; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; Trudeau JD, 2003, J CLIN INVEST, V111, P217, DOI 10.1172/JCI200316409; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; Verdaguer J, 1996, J IMMUNOL, V157, P4726; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; Zeh HJ, 1999, J IMMUNOL, V162, P989	36	116	122	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2005	11	6					645	652		10.1038/nm1250	http://dx.doi.org/10.1038/nm1250			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15908957				2022-12-27	WOS:000229589800031
J	Schubert, C				Schubert, C			HIV unbound	NATURE MEDICINE			English	News Item								A new study cracks the structure of unbound gp120. The structure of a core region of the molecule with a few loops hacked off shows that receptor binding induces a massive change in protein shape. The refolding mechanism of gp120 alsomay create vulnerabilities, leaving many empty cavities in the structure. Researchers found that one such cavity serves as the binding site for a recently discovered class of viral-entry inhibitors.										Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385		10.1038/nm0405-385	http://dx.doi.org/10.1038/nm0405-385			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-27	WOS:000228180500024
J	Piontek, K; Menezes, LF; Garcia-Gonzalez, MA; Huso, DL; Germino, GG				Piontek, Klaus; Menezes, Luis F.; Garcia-Gonzalez, Miguel A.; Huso, David L.; Germino, Gregory G.			A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1	NATURE MEDICINE			English	Article							PLANAR CELL POLARITY; DISEASE; PROLIFERATION; POLYCYSTIN-1; MORPHOGENESIS; INHIBITION; APOPTOSIS; TISSUES; MICE	Autosomal dominant polycystic kidney disease is an important cause of end-stage renal disease, for which there is no proven therapy(1). Mutations in PKD1 (the gene encoding polycystin-1) are the principal cause of this disease. The disease begins in utero(2) and is slowly progressive, but it is not known whether cystogenesis is an ongoing process during adult life. We now show that inactivation of Pkd1 in mice before postnatal day 13 results in severely cystic kidneys within 3 weeks, whereas inactivation at day 14 and later results in cysts only after 5 months. We found that cellular proliferation was not appreciably higher in cystic specimens than in age-matched controls, but the abrupt change in response to Pkd1 inactivation corresponded to a previously unrecognized brake point during renal growth and significant changes in gene expression. These findings suggest that the effects of Pkd1 inactivation are defined by a developmental switch that signals the end of the terminal renal maturation process. Our studies show that Pkd1 regulates tubular morphology in both developing and adult kidney, but the pathologic consequences of inactivation are defined by the organ's developmental status. These results have important implications for clinical understanding of the disease and therapeutic approaches.	Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Germino, GG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Ross 958,720 Rutland Ave, Baltimore, MD 21205 USA.	ggermino@jhmi.edu	Gonzalez, Miguel Garcia/ABF-9880-2020; Menezes, Luis Fernando/C-7286-2015; Garcia-Gonzalez, Miguel A/G-6920-2011	Gonzalez, Miguel Garcia/0000-0002-4330-7200; Germino, Gregory/0000-0002-3609-5588; Menezes, Luis Fernando/0000-0003-2225-168X	NIDDK NIH HHS [R01 DK051259, R37 DK048006-13, R01 DK048006, R01 DK051259-11, DK51259, R37 DK048006-14, R37 DK048006, DK48006, R01 DK051259-12] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048006, R01DK048006, R01DK051259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; Boucher C, 2004, EUR J HUM GENET, V12, P347, DOI 10.1038/sj.ejhg.5201162; Bukanov NO, 2006, NATURE, V444, P949, DOI 10.1038/nature05348; Calvet J P, 1994, Curr Opin Nephrol Hypertens, V3, P340, DOI 10.1097/00041552-199405000-00017; Chang MY, 2006, NEPHROL DIAL TRANSPL, V21, P2078, DOI 10.1093/ndt/gfl150; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; Ciruna B, 2006, NATURE, V439, P220, DOI 10.1038/nature04375; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fischer E, 2006, NAT GENET, V38, P21, DOI 10.1038/ng1701; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; HEGG O, 1966, J PATHOL BACTERIOL, V91, P311, DOI 10.1002/path.1700910204; Lanoix J, 1996, ONCOGENE, V13, P1153; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681, DOI 10.1177/002215540305101212; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; OSATHANONDH V, 1964, ARCH PATHOL, V77, P459; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; PRETORIUS DH, 1987, J ULTRAS MED, V6, P249; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stegmann A, 2006, PHYSIOL GENOMICS, V27, P141, DOI 10.1152/physiolgenomics.00314.2005; Sweeney WE, 2003, KIDNEY INT, V64, P1310, DOI 10.1046/j.1523-1755.2003.00232.x; Torres VE, 2004, NAT MED, V10, P363, DOI 10.1038/nm1004; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	30	294	297	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1490	1495		10.1038/nm1675	http://dx.doi.org/10.1038/nm1675			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	17965720	Green Accepted			2022-12-27	WOS:000251445400024
J	Liu, CY; Noorchashm, H; Sutter, JA; Naji, M; Prak, EL; Boyer, J; Green, T; Rickels, MR; Tomaszewski, JE; Koeberlein, B; Wang, ZL; Paessler, ME; Velidedeoglu, E; Rostami, SY; Yu, M; Barker, CF; Naji, A				Liu, Chengyang; Noorchashm, Hooman; Sutter, Jennifer A.; Naji, Mina; Prak, Eline Luning; Boyer, Jean; Green, Taryn; Rickels, Michael R.; Tomaszewski, John E.; Koeberlein, Brigitte; Wang, Zhonglin; Paessler, Michelle E.; Velidedeoglu, Ergun; Rostami, Susan Y.; Yu, Ming; Barker, Clyde F.; Naji, Ali			B lymphocyte - directed immunotherapy promotes long-term islet allograft survival in nonhuman primates	NATURE MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; ANTIGEN PRESENTATION; CELL SUBSETS; TRANSPLANTATION; REJECTION; BLOOD	We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitution after rituximab-mediated depletion was characterized by a preponderance of immature and transitional cells, whose persistence was associated with long-term islet allograft survival. Development of donor-specific alloantibodies was abrogated only in the setting of continued rapamycin monotherapy.	Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Naji, A (corresponding author), Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA.	Ali.Naji@uphs.upenn.edu	Rickels, Michael/D-1380-2009	Rickels, Michael/0000-0002-9253-838X	NIAID NIH HHS [AI065356] Funding Source: Medline; NIDDK NIH HHS [DK64603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI065356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P723, DOI 10.1002/art.21650; Colvin RB, 2005, NAT REV IMMUNOL, V5, P807, DOI 10.1038/nri1702; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Martin F, 2006, ANNU REV IMMUNOL, V24, P467, DOI 10.1146/annurev.immunol.24.021605.090517; MCCULLOCH DK, 1991, DIABETES, V40, P673, DOI 10.2337/diabetes.40.6.673; Miller JP, 2006, J IMMUNOL, V176, P6405, DOI 10.4049/jimmunol.176.11.6405; Noorchashm H, 2006, J IMMUNOL, V177, P7715, DOI 10.4049/jimmunol.177.11.7715; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Preville X, 2001, TRANSPLANTATION, V71, P460, DOI 10.1097/00007890-200102150-00021; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; Schroder C, 2003, TRANSPL IMMUNOL, V12, P19, DOI 10.1016/S0966-3274(03)00059-5; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Vugmeyster Y, 2004, CYTOM PART A, V61A, P69, DOI 10.1002/cyto.a.20039	15	125	130	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1295	1298		10.1038/nm1673	http://dx.doi.org/10.1038/nm1673			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17965721				2022-12-27	WOS:000250736900021
J	Mullican, SE; Zhang, S; Konopleva, M; Ruvolo, V; Andreeff, M; Milbrandt, J; Conneely, OM				Mullican, Shannon E.; Zhang, Shuo; Konopleva, Marina; Ruvolo, Vivian; Andreeff, Michael; Milbrandt, Jeffrey; Conneely, Orla M.			Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia	NATURE MEDICINE			English	Article							STEM-CELLS; TRANSCRIPTION FACTOR; ORPHAN RECEPTOR; MICE LACKING; C/EBP-ALPHA; NGFI-B; NUR77; IDENTIFICATION; PROGENITORS; EXPRESSION	Nur77 (NR4A1) and Nor-1 (NR4A3) are highly homologous orphan nuclear receptors(1,2) that regulate the transcription of overlapping target genes(2),(3). The transcriptional activity of both proteins is regulated in a ligand-independent manner by cell-and stimulus-specific gene induction and protein phosphorylation(4,5). Nor-1 and Nur77 have been implicated in a variety of cellular processes, including the transduction of hormonal, inflammatory, mitogenic, apoptotic and differentiative signals(4,6,7). Cellular responses to these proteins suggest that they may function as homeostatic regulators of proliferation, apoptosis and differentiation, and thus may regulate cellular susceptibility to tumorigenesis. Their physiological functions, however, remain poorly understood. Here we describe a previously unsuspected function of Nor-1 and Nur77-as critical tumor suppressors of myeloid leukemogenesis. The abrogation of these proteins in mice led to rapidly lethal acute myeloid leukemia (AML), involving abnormal expansion of hematopoietic stem cells (HSCs) and myeloid progenitors, decreased expression of the AP-1 transcription factors JunB and c-Jun and defective extrinsic apoptotic (Fas-L and TRAIL) signaling. We found that downregulation of NR4A3 (NOR-1) and NR4A1 (NUR77) was a common feature in leukemic blasts from human AML patients, irrespective of karyotype. Thus Nor-1 and Nur77 may provide potential targets for therapeutic intervention in AML.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)	Conneely, OM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	orlac@bcm.tmc.edu		Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA111411, P01CA055164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA55164, CA16672, CA111411] Funding Source: Medline; NIDDK NIH HHS [U19DK62434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; Martinez-Gonzalez J, 2003, CIRC RES, V92, P96, DOI 10.1161/01.ES.0000050921.53008.47; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; NUCIFORA G, 1993, BLOOD, V81, P883; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Ponnio T, 2002, MOL CELL BIOL, V22, P935, DOI 10.1128/MCB.22.3.935-945.2002; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	30	229	238	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					730	735		10.1038/nm1579	http://dx.doi.org/10.1038/nm1579			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17515897				2022-12-27	WOS:000247084300037
J	Mavilio, F; Pellegrini, G; Ferrari, S; Di Nunzio, F; Di Iorio, E; Recchia, A; Maruggi, G; Ferrari, G; Provasi, E; Bonini, C; Capurro, S; Conti, A; Magnoni, C; Giannetti, A; De Luca, M				Mavilio, Fulvio; Pellegrini, Graziella; Ferrari, Stefano; Di Nunzio, Francesca; Di Iorio, Enzo; Recchia, Alessandra; Maruggi, Giulietta; Ferrari, Giuliana; Provasi, Elena; Bonini, Chiara; Capurro, Sergio; Conti, Andrea; Magnoni, Cristina; Giannetti, Alberto; De Luca, Michele			Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells	NATURE MEDICINE			English	Article							GENE-THERAPY; CLONAL ANALYSIS; RETROVIRAL VECTOR; T-CELLS; EPITHELIUM; P63; PROLIFERATION; KERATINOCYTES; ASSOCIATION; INTEGRATION	The continuous renewal of human epidermis is sustained by stem cells contained in the epidermal basal layer and in hair follicles(1,2). Cultured keratinocyte stem cells, known as holoclones(3-6), generate sheets of epithelium used to restore severe skin, mucosal and corneal defects(7-9). Mutations in genes encoding the basement membrane component laminin 5 (LAM5) cause junctional epidermolysis bullosa (JEB), a devastating and often fatal skin adhesion disorder(10). Epidermal stem cells from an adult patient affected by LAM5-beta 3-deficient JEB were transduced with a retroviral vector expressing LAMB3 cDNA ( encoding LAM5-beta 3), and used to prepare genetically corrected cultured epidermal grafts. Nine grafts were transplanted onto surgically prepared regions of the patient's legs. Engraftment was complete after 8 d. Synthesis and proper assembly of normal levels of functional LAM5 were observed, together with the development of a firmly adherent epidermis that remained stable for the duration of the follow-up ( 1 year) in the absence of blisters, infections, inflammation or immune response. Retroviral integration site analysis indicated that the regenerated epidermis is maintained by a defined repertoire of transduced stem cells. These data show that ex vivo gene therapy of JEB is feasible and leads to full functional correction of the disease.	Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; Veneto Eye Bank Fdn, Epithelial Stem Cell Res Ctr, I-30100 Venice, Italy; Ist Sci San Raffaele, Telethon Inst Gene Therapy, HSR TIGET, I-20132 Milan, Italy; Vita Salute Univ, I-20132 Milan, Italy; Ist Sci H San Raffaele, Canc Immunotherapy & Gene Therapy Program, I-20132 Milan, Italy; H San Martino, Div Plast Surg, I-16132 Genoa, Italy; Univ Modena & Reggio Emilia, Dept Internal Med, I-41100 Modena, Italy	Universita di Modena e Reggio Emilia; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Universita di Modena e Reggio Emilia	Mavilio, F (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Sci, Via Campi 287, I-41100 Modena, Italy.	fulvio.mavilio@unimore.it; michele.deluca@unimore.it	De Luca, Michele/N-5883-2014; bonini, chiara/I-9202-2012; Recchia, Alessandra/B-7954-2015; Magnoni, Cristina/F-5367-2017; Pellegrini, Graziella/E-1189-2015; Di Nunzio, Francesca/A-6153-2014; Ferrari, Giuliana/AAB-5546-2019; Conti, Andrea/K-8793-2013	De Luca, Michele/0000-0002-0850-8445; Recchia, Alessandra/0000-0002-3467-1094; Magnoni, Cristina/0000-0002-6081-4925; Pellegrini, Graziella/0000-0001-9861-0736; Di Nunzio, Francesca/0000-0003-2879-3164; Ferrari, Giuliana/0000-0003-0790-3133; Conti, Andrea/0000-0003-4848-3817; Mavilio, Fulvio/0000-0003-0459-4320; Ferrari, Stefano/0000-0003-3983-3328; BONINI, Maria Chiara/0000-0002-0772-1674	Telethon [GAT0201] Funding Source: Medline	Telethon(Fondazione Telethon)		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bushman F, 2005, NAT REV MICROBIOL, V3, P848, DOI 10.1038/nrmicro1263; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; De Luca M, 2006, REGEN MED, V1, P45, DOI 10.2217/17460751.1.1.45; Dellambra E, 1998, HUM GENE THER, V9, P1359, DOI 10.1089/hum.1998.9.9-1359; Di Iorio E, 2005, P NATL ACAD SCI USA, V102, P9523, DOI 10.1073/pnas.0503437102; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Guerra L, 2000, ARCH DERMATOL, V136, P1380, DOI 10.1001/archderm.136.11.1380; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Krall WJ, 1996, GENE THER, V3, P37; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; PARKER KC, 1994, J IMMUNOL, V152, P163; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769; Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021; Posteraro P, 1998, BIOCHEM BIOPH RES CO, V243, P758, DOI 10.1006/bbrc.1998.8180; Recchia A, 2006, P NATL ACAD SCI USA, V103, P1457, DOI 10.1073/pnas.0507496103; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	30	446	472	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1397	1402		10.1038/nm1504	http://dx.doi.org/10.1038/nm1504			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115047				2022-12-27	WOS:000242618200020
J	Moghaddam, A; Olszewska, W; Wang, B; Tregoning, JS; Helson, R; Sattentau, QJ; Openshaw, PJM				Moghaddam, Amin; Olszewska, Wieslawa; Wang, Belinda; Tregoning, John S.; Helson, Rebecca; Sattentau, Quentin J.; Openshaw, Peter J. M.			A potential molecular mechanism for hypersensitivity caused by formalin- inactivated vaccines	NATURE MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; PROTEINS; IMMUNIZATION	Heat, oxidation and exposure to aldehydes create reactive carbonyl groups on proteins, targeting antigens to scavenger receptors. Formaldehyde is widely used in making vaccines, but has been associated with atypical enhanced disease during subsequent infection with paramyxoviruses. We show that carbonyl groups on formaldehyde-treated vaccine antigens boost T helper type 2 (T(H)2) responses and enhance respiratory syncytial virus (RSV) disease in mice, an effect partially reversible by chemical reduction of carbonyl groups.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ London Imperial Coll Sci & Technol, Wright Fleming Inst, Dept Resp Med, London W2 1PG, England	University of Oxford; Imperial College London	Openshaw, PJM (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, South Parks Rd, Oxford OX1 3RE, England.	p.openshaw@imperial.ac.uk	Moghaddam, Amin/N-2300-2014; Openshaw, Peter/AAL-9442-2020	Moghaddam, Amin/0000-0001-8668-1609; Openshaw, Peter/0000-0002-7220-2555; Tregoning, John/0000-0001-8093-8741; Wang, Belinda Lei/0000-0002-6963-4963	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust [G0000635] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		ACHARYA AS, 1983, P NATL ACAD SCI-BIOL, V80, P3590, DOI 10.1073/pnas.80.12.3590; Adams S, 2001, FRONT BIOSCI, V6, pA17, DOI 10.2741/Adams; Allison MED, 2000, EUR J IMMUNOL, V30, P2881, DOI 10.1002/1521-4141(200010)30:10<2881::AID-IMMU2881>3.0.CO;2-9; Cederna JB, 1999, VACCINE, V18, P892, DOI 10.1016/S0264-410X(99)00342-4; de Swart RL, 2002, J VIROL, V76, P11561, DOI 10.1128/JVI.76.22.11561-11569.2002; Dean RT, 1997, BIOCHEM J, V324, P1; Flyvholm MA, 2005, CONTACT DERMATITIS, V53, P27, DOI 10.1111/j.0105-1873.2005.00629.x; GALEMBECK F, 1977, J AGR FOOD CHEM, V25, P238, DOI 10.1021/jf60210a019; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; Nagai K, 2006, THORAX, V61, P496, DOI 10.1136/thx.2005.049148; Openshaw PJM, 2001, VACCINE, V20, pS27, DOI 10.1016/S0264-410X(01)00301-2; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Willis MS, 2002, ALCOHOL CLIN EXP RES, V26, P94, DOI 10.1097/00000374-200201000-00013	15	160	164	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					905	907		10.1038/nm1456	http://dx.doi.org/10.1038/nm1456			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862151				2022-12-27	WOS:000239626200020
J	Thaker, PH; Han, LY; Kamat, AA; Arevalo, JM; Takahashi, R; Lu, CH; Jennings, NB; Armaiz-Pena, G; Bankson, JA; Ravoori, M; Merritt, WM; Lin, YG; Mangala, LS; Kim, TJ; Coleman, RL; Landen, CN; Li, Y; Felix, E; Sanguino, AM; Newman, RA; Lloyd, M; Gershenson, DM; Kundra, V; Lopez-Berestein, G; Lutgendorf, SK; Cole, SW; Sood, AK				Thaker, Premal H.; Han, Liz Y.; Kamat, Aparna A.; Arevalo, Jesusa M.; Takahashi, Rie; Lu, Chunhua; Jennings, Nicholas B.; Armaiz-Pena, Guillermo; Bankson, James A.; Ravoori, Murali; Merritt, William M.; Lin, Yvonne G.; Mangala, Lingegowda S.; Kim, Tae Jin; Coleman, Robert L.; Landen, Charles N.; Li, Yang; Felix, Edward; Sanguino, Angela M.; Newman, Robert A.; Lloyd, Mary; Gershenson, David M.; Kundra, Vikas; Lopez-Berestein, Gabriel; Lutgendorf, Susan K.; Cole, Steven W.; Sood, Anil K.			Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma	NATURE MEDICINE			English	Article							SOCIAL SUPPORT; FACTOR RECEPTOR; CELL-LINES; CANCER; METASTASIS; MEDIATORS; DISTRESS; CORTISOL; SURVIVAL; ASCITES	Stress can alter immunological, neurochemical and endocrinological functions, but its role in cancer progression is not well understood. Here, we show that chronic behavioral stress results in higher levels of tissue catecholamines, greater tumor burden and more invasive growth of ovarian carcinoma cells in an orthotopic mouse model. These effects are mediated primarily through activation of the tumor cell cyclic AMP (cAMP)-protein kinase A (PKA) signaling pathway by the beta(2) adrenergic receptor (encoded by ADRB2). Tumors in stressed animals showed markedly increased vascularization and enhanced expression of VEGF, MMP2 and MMP9, and we found that angiogenic processes mediated the effects of stress on tumor growth in vivo. These data identify beta-adrenergic activation of the cAMP-PKA signaling pathway as a major mechanism by which behavioral stress can enhance tumor angiogenesis in vivo and thereby promote malignant cell growth. These data also suggest that blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Texas, MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; Univ Iowa, Dept Psychol, Iowa City, IA 52241 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Iowa	Sood, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, 1155 Herman Pressler,Unit 1362, Houston, TX 77030 USA.	asood@mdanderson.org	Bankson, James A./J-9798-2014; Ibrahim, Essam Hassan/G-1960-2018; Coleman, Robert/E-4346-2019	Bankson, James A./0000-0002-8574-154X; Ibrahim, Essam Hassan/0000-0003-0130-2257; Armaiz-Pena, Guillermo N/0000-0002-9081-5339	NCI NIH HHS [CA-104825, CA-10929801, CA-11079301, 2P50 CA083639-06A1] Funding Source: Medline; NIAID NIH HHS [AI52737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083639, R01CA104825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONS RD, 1982, J PHARMACOL EXP THER, V221, P439; Antoni MH, 2000, ANN BEHAV MED, V22, P29, DOI 10.1007/BF02895165; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Ben-Eliyahu S, 2003, BRAIN BEHAV IMMUN, V17, pS27; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Costanzo ES, 2005, CANCER-AM CANCER SOC, V104, P305, DOI 10.1002/cncr.21147; Daldrup H, 1998, AM J ROENTGENOL, V171, P941, DOI 10.2214/ajr.171.4.9762973; Exton MS, 2002, J NEUROIMMUNOL, V131, P21, DOI 10.1016/S0165-5728(02)00249-7; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; HALDER J, IN PRESS CLIN CANC R; Hu LM, 2005, CLIN CANCER RES, V11, P6966, DOI 10.1158/1078-0432.CCR-05-0910; JUSTICE A, 1985, PSYCHOL BULL, V98, P108, DOI 10.1037/0033-2909.98.1.108; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Langley RR, 2003, CANCER RES, V63, P2971; Lutgendorf SK, 2005, J CLIN ONCOL, V23, P7105, DOI 10.1200/JCO.2005.10.015; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; Lutgendorf SK, 2002, CANCER-AM CANCER SOC, V95, P808, DOI 10.1002/cncr.10739; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Paredes A, 1998, ENDOCRINE, V8, P309, DOI 10.1385/ENDO:8:3:309; PASSANITI A, 1992, LAB INVEST, V67, P519; RADINSKY R, 1993, CANCER RES, V53, P937; Reiche EMV, 2004, LANCET ONCOL, V5, P617, DOI 10.1016/S1470-2045(04)01597-9; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; Rowe J.W., 1994, ANN BEHAV MED, V16, P95, DOI DOI 10.1093/abm/16.2.95; SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A; Teunis MAT, 2002, FASEB J, V16, P1465, DOI 10.1096/fj.02-0145fje; Thaker PH, 2005, CLIN CANCER RES, V11, P4923, DOI 10.1158/1078-0432.CCR-04-2060; Turner-Cobb JM, 2000, PSYCHOSOM MED, V62, P337, DOI 10.1097/00006842-200005000-00007; Xu L, 2000, INT J ONCOL, V16, P445	30	822	866	2	124	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2006	12	8					939	944		10.1038/nm1447	http://dx.doi.org/10.1038/nm1447			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16862152				2022-12-27	WOS:000239626200025
J	Takeda, H; Lyle, S; Lazar, AJF; Zouboulis, CC; Smyth, I; Watt, FM				Takeda, H; Lyle, S; Lazar, AJF; Zouboulis, CC; Smyth, I; Watt, FM			Human sebaceous tumors harbor inactivating mutations in LEF1	NATURE MEDICINE			English	Article							BETA-CATENIN; STEM-CELLS; INDIAN HEDGEHOG; HAIR-FOLLICLES; EPIDERMIS; SKIN; WNT; MOUSE; DIFFERENTIATION; ADIPOGENESIS	We found that one-third of human sebaceous tumors examined had double-nucleotide substitutions in the same LEF1 allele, irrespective of DNA mismatch repair status. The mutations impaired both LEF1 binding to beta-catenin and transcriptional activation, and are the first tumor-associated mutations that inactivate Wnt signaling. Mutant LEF1 not only inhibited expression of beta-catenin target genes but also stimulated expression of sebocyte markers, suggesting that it may determine the differentiated characteristics of sebaceous tumors.	Canc Res UK London Res Inst, London WC2A 3PX, England; Univ Massachusetts, Sch Med, Worcester, MA 01605 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Dessau Med Ctr, Dept Dermatol, D-06847 Dessau, Germany; Dessau Med Ctr, Dept Immunol, D-06847 Dessau, Germany	Cancer Research UK; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; Dessau Medical Center; Dessau Medical Center	Watt, FM (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	fiona.watt@cancer.org.uk	Zouboulis, Christos C./I-4493-2013; Lazar, Alexander J/A-3416-2008; Watt, Fiona/AHB-0226-2022	Zouboulis, Christos C./0000-0003-1646-2608; Lazar, Alexander J/0000-0002-6395-4499; Watt, Fiona/0000-0001-9151-5154; Smyth, Ian/0000-0002-1727-7829	NIAMS NIH HHS [P30AR042689, AR02179] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042689, K08AR002179] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; Kruse R, 2001, J INVEST DERMATOL, V116, P463, DOI 10.1046/j.1523-1747.2001.01265.x; Liu JJ, 2004, J BIOL CHEM, V279, P45020, DOI 10.1074/jbc.M407050200; Niemann C, 2003, P NATL ACAD SCI USA, V100, P11873, DOI 10.1073/pnas.1834202100; Niemann C, 2002, DEVELOPMENT, V129, P95; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Queille S, 1998, MOL CARCINOGEN, V22, P167, DOI 10.1002/(SICI)1098-2744(199807)22:3<167::AID-MC4>3.0.CO;2-I; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; TROY JL, 1984, AM J DERMATOPATH, V6, P7, DOI 10.1097/00000372-198402000-00006; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087	15	106	125	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2006	12	4					395	397		10.1038/nm1386	http://dx.doi.org/10.1038/nm1386			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	029RE	16565724				2022-12-27	WOS:000236581300026
J	Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X				Ji, SP; Zhang, Y; Van Cleemput, J; Jiang, W; Liao, MX; Li, L; Wan, Q; Backstrom, JR; Zhang, X			Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse	NATURE MEDICINE			English	Article							SEROTONIN; PROTEIN; INHIBITION; NEURONS; REWARD; CELLS; RATS	The widespread distribution of the tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) in the adult brain(1) suggests its role in a broad range of brain functions. Here we show evidence supporting a physical interaction of PTEN with a region in the third intracellular loop (3L4F) of the serotonin 5-HT2C receptor (5-HT2cR, formerly 5-HT1c receptor(2)) in cell cultures. PTEN limits agonist-induced phosphorylation of 5-HT2cR through its protein phosphatase activity. We showed the probable existence of PTEN:5-HT2cR complexes in putative dopaminergic neurons in the rat ventral tegmental area (VTA), a brain region in which virtually all abused drugs exert rewarding effects by activating its dopamine neurons(3,4). We synthesized the interfering peptide Tat-3L4F, which is able to disrupt PTEN coupling with 5-HT2cR. Systemic application of Tat-3L4F or the 5-HT2cR agonist Ro600175 suppressed the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana. Using behavioral tests, we found that Tat-3L4F or Ro600175 blocks conditioned place preference of THC or nicotine, and that Ro600175, but not Tat-3L4F, produces anxiogenic effects, penile erection, hypophagia and motor functional suppression. These results suggest a potential strategy for treating drug addiction with the Tat-3L4F peptide.	Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, Saskatoon, SK S7N 5E4, Canada; Toronto Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Toronto Hosp, Dept Physiol, Toronto, ON M5T 2S8, Canada; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	University of Saskatchewan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Vanderbilt University	Zhang, X (corresponding author), Univ Saskatchewan, Neuropsychiat Res Unit, Dept Psychiat, 103 Wiggins Rd, Saskatoon, SK S7N 5E4, Canada.	zhangxia@duke.usask.ca		Zhang, Xia/0000-0002-4811-3229				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Alves SH, 2004, BEHAV PHARMACOL, V15, P37, DOI 10.1097/00008877-200402000-00005; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Braida D, 2004, EUR J PHARMACOL, V506, P63, DOI 10.1016/j.ejphar.2004.10.043; BUNNEY BS, 1973, J PHARMACOL EXP THER, V185, P560; Cheer JF, 2000, NEUROSCIENCE, V99, P661, DOI 10.1016/S0306-4522(00)00241-4; Clifton PG, 2000, PSYCHOPHARMACOLOGY, V152, P256, DOI 10.1007/s002130000504; Di Matteo V, 2002, PHARMACOL BIOCHEM BE, V71, P727, DOI 10.1016/S0091-3057(01)00705-5; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Grottick AJ, 2000, J PHARMACOL EXP THER, V295, P1183; Hannesson DK, 2001, J NEUROSCI, V21, P4443, DOI 10.1523/JNEUROSCI.21-12-04443.2001; Higgins GA, 2003, EUR J PHARMACOL, V480, P151, DOI 10.1016/j.ejphar.2003.08.102; JOHNSON SW, 1992, J NEUROSCI, V12, P483; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li L, 2003, J CELL BIOCHEM, V88, P24, DOI 10.1002/jcb.10312; Lupica CR, 2004, BRIT J PHARMACOL, V143, P227, DOI 10.1038/sj.bjp.0705931; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; Ning K, 2004, J NEUROSCI, V24, P4052, DOI 10.1523/JNEUROSCI.5449-03.2004; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; Rice HB, 2002, PHARMACOL BIOCHEM BE, V73, P545, DOI 10.1016/S0091-3057(02)00839-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Steelman LS, 2004, EXPERT OPIN THER TAR, V8, P537, DOI 10.1517/14728222.8.6.537; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wood MD, 2003, CNS NEUROL DISORD-DR, V2, P383, DOI 10.2174/1568007033482698; Zhang X, 2001, J NEUROSCI, V21, P3674, DOI 10.1523/JNEUROSCI.21-10-03674.2001	30	123	126	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					324	329		10.1038/nm1349	http://dx.doi.org/10.1038/nm1349			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16474401				2022-12-27	WOS:000235802900032
J	Yach, D; Stuckler, D; Brownell, KD				Yach, D; Stuckler, D; Brownell, KD			Epidemiologic and economic consequences of the global epidemics of obesity and diabetes	NATURE MEDICINE			English	Editorial Material							CHRONIC DISEASES; CARE; PERFORMANCE; OVERWEIGHT; EMPLOYMENT; MELLITUS; CHILDREN; CANADA; GROWTH; RISKS		Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Dept Psychol, New Haven, CT 06520 USA; Yale Univ, Rudd Ctr Food Policy & Obes, New Haven, CT 06520 USA	Yale University; Yale University; Yale University		derek.yach@yale.edu	Stuckler, David/H-2261-2012	Stuckler, David/0000-0002-1288-8401				Anderson PM, 2003, J HEALTH ECON, V22, P477, DOI 10.1016/S0167-6296(03)00022-5; [Anonymous], 2000, Pediatrics, V105, P671; [Anonymous], 2005, PREV CHRON DIS VIT I; Barcelo A, 2003, B WORLD HEALTH ORGAN, V81, P19; Bloomgarden ZT, 2004, DIABETES CARE, V27, P998, DOI 10.2337/diacare.27.4.998; Cawley J, 2004, J HUM RESOUR, V39, P451, DOI 10.2307/3559022; CAWLEY J, 2004, NATL BUREAU EC RES W; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P80; CHALE SS, 1992, BRIT MED J, V304, P1215, DOI 10.1136/bmj.304.6836.1215; Chou SY, 2004, J HEALTH ECON, V23, P565, DOI 10.1016/j.jhealeco.2003.10.003; Cockram C. S., 2000, Hong Kong Medical Journal, V6, P43; Cutler DM, 2003, J ECON PERSPECT, V17, P93, DOI 10.1257/089533003769204371; Datar A, 2004, OBES RES, V12, P58, DOI 10.1038/oby.2004.9; Dawson KG, 2002, DIABETES CARE, V25, P1303, DOI 10.2337/diacare.25.8.1303; Drewnowski A, 2004, AM J PREV MED, V27, P154, DOI 10.1016/j.amepre.2004.06.011; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Finkelstein EA, 2005, ANNU REV PUBL HEALTH, V26, P239, DOI 10.1146/annurev.publhealth.26.021304.144628; Goetzel RZ, 2005, J OCCUP ENVIRON MED, V47, P759, DOI 10.1097/01.jom.0000172868.05935.67; Gura T, 2003, SCIENCE, V299, P849, DOI 10.1126/science.299.5608.849; HENRYLEE A, 1999, SMALL APPL RES, V6; James WPT, 2003, COMP QUANTIFICATION; Katzmarzyk PT, 2004, CAN J APPL PHYSIOL, V29, P90, DOI 10.1139/h04-008; Kibriya MG, 1999, DIABETES RES CLIN PR, V46, P253, DOI 10.1016/S0168-8227(99)00093-5; Kraut A, 2001, DIABETES CARE, V24, P64, DOI 10.2337/diacare.24.1.64; Kuchler F., 2002, FoodReview, V25, P33; LAKDAWALLA D, 2005, J AM EC REV, V95; Lee WJ, 2005, OBES SURG, V15, P751, DOI 10.1381/0960892054222614; Leeder S, 2004, RACE TIME CHALLENGE; Lin T, 2001, DIABETES RES CLIN PR, V54, pS43; MACKINTOSH M, 2003, RUIG RES U INT GENEV; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mete C., 2002, 846 YAL U EC GROWTH; Mo-Suwan L, 1999, INT J OBESITY, V23, P272, DOI 10.1038/sj.ijo.0800808; Neuhann HF, 2002, DIABETIC MED, V19, P509, DOI 10.1046/j.1464-5491.2002.00673.x; Niefeld MR, 2003, DIABETES CARE, V26, P1344, DOI 10.2337/diacare.26.5.1344; Nielsen Samara Joy, 2003, JAMA (Journal of the American Medical Association), V289, P450, DOI 10.1001/jama.289.4.450; *OXF HLTH ALL WORK, 2005, EC COSTS CHRON DIS E; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Petersen M, 2003, DIABETES CARE, V26, P917; Philipson T, 2001, HEALTH ECON, V10, P1, DOI 10.1002/1099-1050(200101)10:1<1::AID-HEC586>3.0.CO;2-1; Philipson TJ, 2003, PERSPECT BIOL MED, V46, pS87; Pinhas-Hamiel O, 2005, J PEDIATR-US, V146, P693, DOI 10.1016/j.jpeds.2004.12.042; Popkin BM, 2001, J NUTR, V131, p871S, DOI 10.1093/jn/131.3.871S; Putnam J., 2002, FoodReview, V25, P2; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130; Sander Beate, 2003, Eur J Health Econ, V4, P248; Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909; Sarlio-Lahteenkorva S, 1999, INT J EPIDEMIOL, V28, P445, DOI 10.1093/ije/28.3.445; Schmid A, 2005, SOZ PRAVENTIV MED, V50, P87, DOI 10.1007/s00038-004-4067-x; Shobhana R, 2000, DIABETES RES CLIN PR, V48, P37, DOI 10.1016/S0168-8227(99)00130-8; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; TSHABALALAMSIMA.M, 2005, COMMUNICATION   0915; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; Uauy R., 2004, OBES REV S1, V5, P4, DOI [10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]; Variyam JN, 2005, NUTR LABELING FOOD A; Wang LD, 2005, LANCET, V366, P1821, DOI 10.1016/S0140-6736(05)67344-8; *WHO FOOD AGR ORG, 2003, 916 WHO	58	548	563	3	67	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2006	12	1					62	66		10.1038/nm0106-62	http://dx.doi.org/10.1038/nm0106-62			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	999VO	16397571				2022-12-27	WOS:000234419000051
J	Bareyre, FM; Kerschensteiner, M; Misgeld, T; Sanes, JR				Bareyre, FM; Kerschensteiner, M; Misgeld, T; Sanes, JR			Transgenic labeling of the corticospinal tract for monitoring axonal responses to spinal cord injury	NATURE MEDICINE			English	Article							FUNCTIONAL RECOVERY; RAT; REGENERATION; PLASTICITY; ORIGIN; SYSTEM; GROWTH; REPAIR; MICE	The rodent corticospinal tract (CST) has been used extensively to investigate regeneration and remodeling of central axons after injury. CST axons are currently visualized after injection of tracer dye, which is invasive, incomplete and prone to variation, and often does not show functionally crucial but numerically minor tract components. Here, we characterize transgenic mice in which CST fibers are specifically and completely labeled by yellow fluorescent protein (YFP). Using these CST-YFP mice, we show that minor CST components are responsible for most monosynaptic contacts onto motoneurons. Lesions of the main dorsal CST lead to extension of new collaterals, some of them originating from large, heavily myelinated axons within the minor dorsolateral and ventral CST components. Some of these new collaterals form additional direct synapses onto motoneurons. We propose that CST-YFP mice will be useful for evaluating strategies designed to maximize such remodeling and to promote regeneration.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Sanes, JR (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Sherman Fairchild Bldg,Room 143,7 Divin Ave, Cambridge, MA 02138 USA.	sanesj@mcb.harvard.edu						Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Bareyre FM, 2002, J NEUROSCI, V22, P7097; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brosamle C, 1997, J COMP NEUROL, V386, P293, DOI 10.1002/(SICI)1096-9861(19970922)386:2<293::AID-CNE9>3.0.CO;2-X; Buffelli M, 2003, NATURE, V424, P430, DOI 10.1038/nature01844; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Daston MM, 1996, J NEUROSCI, V16, P5488; DeLuca GC, 2004, BRAIN, V127, P1009, DOI 10.1093/brain/awh118; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gianino S, 1999, DEV BRAIN RES, V112, P189, DOI 10.1016/S0165-3806(98)00168-0; Gorski JA, 2002, J NEUROSCI, V22, P6309; Joosten E A, 1987, Brain Res, V433, P121; KALIL K, 1982, J COMP NEUROL, V211, P265, DOI 10.1002/cne.902110305; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; KUANG RZ, 1990, J COMP NEUROL, V302, P461, DOI 10.1002/cne.903020304; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Lichtman JW, 2003, J NEUROCYTOL, V32, P767, DOI 10.1023/B:NEUR.0000020622.58471.37; Martin JH, 2005, NEUROSCIENTIST, V11, P161, DOI 10.1177/1073858404270843; NUDO RJ, 1990, J COMP NEUROL, V296, P559, DOI 10.1002/cne.902960405; Pan YA, 2003, J NEUROSCI, V23, P11479; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; STANFIELD BB, 1992, PROG NEUROBIOL, V38, P169, DOI 10.1016/0301-0082(92)90039-H; Steward O, 2004, J COMP NEUROL, V472, P463, DOI 10.1002/cne.20090; Steward O, 2003, J COMP NEUROL, V459, P1, DOI 10.1002/cne.10593; TERASHIMA T, 1995, NEUROSCI RES, V22, P139, DOI 10.1016/0168-0102(95)00895-9; TERASHIMA T, 1994, J COMP NEUROL, V340, P469, DOI 10.1002/cne.903400403; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Yin H, 2004, J NEUROL, V251, P1249, DOI 10.1007/s00415-004-0526-9	30	148	151	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1355	1360		10.1038/nm1331	http://dx.doi.org/10.1038/nm1331			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16286922				2022-12-27	WOS:000233774400036
J	Chattopadhyay, PK; Yu, J; Roederer, M				Chattopadhyay, PK; Yu, J; Roederer, M			A live-cell assay to detect antigen-specific CD4(+) T cells with diverse cytokine profiles	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; FLOW-CYTOMETRY; CD40 LIGAND; IDENTIFICATION; EXPRESSION; MOLECULES; MICE	Recently activated, but not resting, CD4(+) T cells express CD154, providing costimulatory signals to B cells and antigen-presenting cells (APCs). Therefore, de novo CD154 expression after stimulation identifies antigen-specific CD4+ T cells. Previous assays were limited by the transient nature of surface CD154 expression; we overcame this by including fluorescently conjugated CD154-specific antibody during stimulation. Our assay is fully compatible with intracellular cytokine staining, and can be used for stimulations as long as 24 h. Notably, it is nonlethal, providing a means to purify viable antigen-specific CD4+ T cells for further analysis. Using this assay, we found that stimulated cells expressing tumor necrosis factor (TNF)-alpha, interleukin (IL)-2 or interferon (IFN)-alpha were predominantly CD154(+). Furthermore, some cells expressing none of these cytokines also expressed CD154, suggesting that CD154 marks cells with other effector functions. For vaccine- or pathogen-specific responses, we found substantial heterogeneity in expression of CD154 and cytokines, suggesting previously unrecognized diversity in abilities of responding cells to stimulate APCs through CD40.	NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Roederer, M (corresponding author), NIAID, ImmunoTechnol Sect, Vaccine Res Ctr, NIH, 40 Convent Dr,Room 5509, Bethesda, MD 20892 USA.	roederer@nih.gov	Roederer, Mario/G-1887-2011; Chattopadhyay, Pratip/B-9227-2008	Chattopadhyay, Pratip/0000-0002-5457-9666	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005021, Z01AI005020] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berhanu D, 2003, J IMMUNOL METHODS, V279, P199, DOI 10.1016/S0022-1759(03)00186-8; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Betts MR, 2001, IMMUNOL LETT, V79, P117, DOI 10.1016/S0165-2478(01)00273-5; BRINES RD, 1993, INT IMMUNOL, V5, P1445, DOI 10.1093/intimm/5.11.1445; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; Klenerman P, 2002, NAT REV IMMUNOL, V2, P263, DOI 10.1038/nri777; Lyerly HK, 2003, SEMIN ONCOL, V30, P9, DOI 10.1016/S0093-7754(03)00230-6; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROY M, 1993, J IMMUNOL, V151, P2497; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Skov S, 2000, J IMMUNOL, V164, P3500, DOI 10.4049/jimmunol.164.7.3500; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1994, J IMMUNOL, V152, P598	21	254	280	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1113	1117		10.1038/nm1293	http://dx.doi.org/10.1038/nm1293			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16186817				2022-12-27	WOS:000232492500034
J	McCulloch, EA; Till, JE				McCulloch, EA; Till, JE			Perspectives on the properties of stem cells	NATURE MEDICINE			English	Editorial Material							COLONY-FORMING CELLS; BONE MARROW CELLS; RADIATION SENSITIVITY; HEMATOPOIETIC STEM; IRRADIATED MICE; SPLEEN COLONIES; TRANSPLANTATION		Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	McCulloch, EA (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.	mcculloc@uhnres.utoronto.ca; till@uhnres.utoronto.ca		Till, James/0000-0002-6532-6023				BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; FINKEL E, 2005, STEM CELLS CONTROVER, P17; GRECO FA, 1992, CA-CANCER J CLIN, V42, P96, DOI 10.3322/canjclin.42.2.96; Jackson KA, 2002, J CELL BIOCHEM, P1, DOI 10.1002/jcb.10045; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; McCulloch E. A., 2003, ONTARIO CANC I SUCCE, P46; MCCULLOCH EA, 1960, RADIAT RES, V13, P115, DOI 10.2307/3570877; McCulloch EA, 2003, LEUKEMIA, V17, P1042, DOI 10.1038/sj.leu.2402948; MCCULLOCH EA, 2003, STEM CELLS HDB, P119; PARSON A, 2004, PROTEUS EFFECT STEM; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; SIMINOVITCH L, 1964, J CELL COMPAR PHYSL, V64, P23, DOI 10.1002/jcp.1030640104; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VOGEL H, 1969, J THEOR BIOL, V22, P249, DOI 10.1016/0022-5193(69)90004-6; Wulf GG, 2001, EXP HEMATOL, V29, P1361, DOI 10.1016/S0301-472X(01)00752-4	18	99	104	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2005	11	10					1026	1028		10.1038/nm1005-1026	http://dx.doi.org/10.1038/nm1005-1026			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	972ZM	16211027				2022-12-27	WOS:000232492500013
J	Ny, A; Koch, M; Schneider, M; Neven, E; Tong, RT; Maity, S; Fischer, C; Plaisance, S; Lambrechts, D; Heligon, C; Terclavers, S; Ciesiolka, M; Kalin, R; Man, WY; Senn, I; Wyns, S; Lupu, F; Brandli, A; Vleminckx, K; Collen, D; Dewerchin, M; Conway, EM; Moons, L; Jain, RK; Carmeliet, P				Ny, A; Koch, M; Schneider, M; Neven, E; Tong, RT; Maity, S; Fischer, C; Plaisance, S; Lambrechts, D; Heligon, C; Terclavers, S; Ciesiolka, M; Kalin, R; Man, WY; Senn, I; Wyns, S; Lupu, F; Brandli, A; Vleminckx, K; Collen, D; Dewerchin, M; Conway, EM; Moons, L; Jain, RK; Carmeliet, P			A genetic Xenopus laevis tadpole model to study lymphangiogenesis	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LYMPHATIC-SYSTEM; VASCULAR DEVELOPMENT; TYROSINE KINASES; VEGF-C; VEINS; ANGIOGENESIS; METASTASIS; ZEBRAFISH; EMBRYOS	Lymph vessels control fluid homeostasis, immunity and metastasis. Unraveling the molecular basis of lymphangiogenesis has been hampered by the lack of a small animal model that can be genetically manipulated. Here, we show that Xenopus tadpoles develop lymph vessels from lymphangioblasts or, through transdifferentiation, from venous endothelial cells. Lymphangiography showed that these lymph vessels drain lymph, through the lymph heart, to the venous circulation. Morpholino- mediated knockdown of the lymphangiogenic factor Prox1 caused lymph vessel defects and lymphedema by impairing lymphatic commitment. Knockdown of vascular endothelial growth factor C ( VEGF- C) also induced lymph vessel defects and lymphedema, but primarily by affecting migration of lymphatic endothelial cells. Knockdown of VEGF- C also resulted in aberrant blood vessel formation in tadpoles. This tadpole model offers opportunities for the discovery of new regulators of lymphangiogenesis.	Katholieke Univ Leuven VIB, Ctr Trasgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Ghent, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Harvard Univ, Sch Med, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol,Massachusetts Gen Hosp, Boston, MA 02114 USA; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; Ghent University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Oklahoma Medical Research Foundation	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Trasgene Technol & Gene Therapy, Campus Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.be	Brandli, Andre/N-1620-2013; Lupu, Florea/AAV-3257-2021; Lambrechts, Diether/AAJ-3167-2020; Lupu, Florea/C-3162-2009; Jain, Rakesh K/I-1384-2017; Kälin, Roland/AAG-9161-2020; Plaisance, Stephane/ABI-6307-2020; Schneider, Martin/H-3745-2011; Plaisance, Stephane/B-3488-2009; Verdrengh, Evelien/H-4571-2012; Vleminckx, Kris/J-5699-2013; Carmeliet, Peter/AAQ-5140-2020; Ny, Annelii/R-7712-2018	Brandli, Andre/0000-0002-8932-3644; Lupu, Florea/0000-0003-1249-9278; Lambrechts, Diether/0000-0002-3429-302X; Lupu, Florea/0000-0003-1249-9278; Jain, Rakesh K/0000-0001-7571-3548; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X; Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411; HELIGON, Christophe/0000-0001-7557-3565; Maity, Sunit/0000-0001-6667-3249; Ny, Annelii/0000-0002-3678-5941; Conway, Edward/0000-0003-0081-0305	NCI NIH HHS [CA-85140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA085140, R01CA085140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Asellius G, 1627, LACTEIBUS SIVE LACTE; Baldwin ME, 2005, MOL CELL BIOL, V25, P2441, DOI 10.1128/MCB.25.6.2441-2449.2005; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Cleaver O, 1997, DEV DYNAM, V210, P66, DOI 10.1002/(SICI)1097-0177(199709)210:1<66::AID-AJA7>3.3.CO;2-S; Daniels CB, 2003, FASEB J, V17, P479, DOI 10.1096/fj.02-0579fje; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Faber J., 1994, NORMAL TABLE XENOPUS, P2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HOYER M, 2005, B ACAD CRACOV 2, P451; Jain RK, 2002, COLD SPRING HARB SYM, V67, P239, DOI 10.1101/sqb.2002.67.239; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Levine AJ, 2003, DEV BIOL, V254, P50, DOI 10.1016/S0012-1606(02)00029-5; LIU ZY, 1989, LYMPHOLOGY, V22, P31; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; OLSZEWSKI W, 1993, LYMPHOLOGY, V26, P154; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wilting J, 2000, LYMPHOLOGY, V33, P81; Wilting J, 2001, MICROSC RES TECHNIQ, V55, P81, DOI 10.1002/jemt.1159	28	176	186	1	9	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2005	11	9					998	1004		10.1038/nm1285	http://dx.doi.org/10.1038/nm1285			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16116431				2022-12-27	WOS:000231724700029
J	Sato, S; Hanada, R; Kimura, A; Abe, T; Matsumoto, T; Iwasaki, M; Inose, H; Ida, T; Mieda, M; Takeuchi, Y; Fukumoto, S; Fujita, T; Kato, S; Kangawa, K; Kojima, M; Shinomiya, K; Takeda, S				Sato, Shingo; Hanada, Reiko; Kimura, Ayako; Abe, Tomomi; Matsumoto, Takahiro; Iwasaki, Makiko; Inose, Hiroyuki; Ida, Takanori; Mieda, Michihiro; Takeuchi, Yasuhiro; Fukumoto, Seiji; Fujita, Toshiro; Kato, Shigeaki; Kangawa, Kenji; Kojima, Masayasu; Shinomiya, Ken-ichi; Takeda, Shu			Central control of bone remodeling by neuromedin U	NATURE MEDICINE			English	Article							SYMPATHETIC-NERVOUS-SYSTEM; LEPTIN; MASS; RECEPTORS; DEFICIENCY; EXPRESSION; CART	Bone remodeling, the function affected in osteoporosis, the most common of bone diseases, comprises two phases: bone formation by matrix- producing osteoblasts(1) and bone resorption by osteoclasts(2). The demonstration that the anorexigenic hormone leptin(3-5) inhibits bone formation through a hypothalamic relay(6,7) suggests that other molecules that affect energy metabolism in the hypothalamus could also modulate bone mass. Neuromedin U ( NMU) is an anorexigenic neuropeptide that acts independently of leptin through poorly defined mechanisms(8,9). Here we show that Nmu-deficient ( Nmu(-/-)) mice have high bone mass owing to an increase in bone formation; this is more prominent in male mice than female mice. Physiological and cell- based assays indicate that NMU acts in the central nervous system, rather than directly on bone cells, to regulate bone remodeling. Notably, leptin- or sympathetic nervous system - mediated inhibition of bone formation(6,7) was abolished in Nmu(-/-) mice, which show an altered bone expression of molecular clock genes ( mediators of the inhibition of bone formation by leptin). Moreover, treatment of wild- type mice with a natural agonist for the NMU receptor decreased bone mass. Collectively, these results suggest that NMU may be the first central mediator of leptin- dependent regulation of bone mass identified to date. Given the existence of inhibitors and activators of NMU action(10), our results may influence the treatment of diseases involving low bone mass, such as osteoporosis.	Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed Surg,Bunkyo Ku, 21st Century Ctr Excellence Program, Tokyo 1138519, Japan; Kurume Univ, Inst Life Sci, Div Mol Genet, Fukuoka 8390842, Japan; Tokyo Med & Dent Univ, Dept Mol Neurosci, Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Agcy, Exploratory Res Adv Technol, Kawaguchi, Saitama 3320012, Japan; Toranomon Hosp Endocrine Ctr, Minato Ku, Tokyo 1058470, Japan; Tokyo Univ Hosp, Dept Internal Med, Div Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan	Tokyo Medical & Dental University (TMDU); Kurume University; Tokyo Medical & Dental University (TMDU); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; National Cerebral & Cardiovascular Center - Japan	Takeda, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed Surg,Bunkyo Ku, 21st Century Ctr Excellence Program, 1-5-45 Yushima, Tokyo 1138519, Japan.	shu-tky@umin.ac.jp	Ida, Takanori/GXG-2269-2022; Fukumoto, Seiji/B-7853-2015; takeda, shu/B-5195-2012	Fukumoto, Seiji/0000-0003-3610-3469; Mieda, Michihiro/0000-0002-2451-7034; INOSE, HIROYUKI/0000-0003-4195-2545; Sato, Shingo/0000-0002-6227-5910				Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahn JD, 2006, ENDOCRINOLOGY, V147, P3196, DOI 10.1210/en.2006-0281; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Chu CP, 2002, REGUL PEPTIDES, V105, P29, DOI 10.1016/S0167-0115(01)00381-0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Fang LY, 2006, NEUROSCI LETT, V404, P148, DOI 10.1016/j.neulet.2006.05.034; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Graham ES, 2003, J NEUROCHEM, V87, P1165, DOI 10.1046/j.1471-4159.2003.02079.x; Hanada R, 2004, NAT MED, V10, P1067, DOI 10.1038/nm1106; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Kalinova J, 2006, J AGR FOOD CHEM, V54, P5330, DOI 10.1021/jf060521r; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Parfitt AM., 1983, BONE HISTOMORPHOMETR, V1983, P143; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wren AM, 2002, ENDOCRINOLOGY, V143, P4227, DOI 10.1210/en.2002-220308; Zeng HK, 2006, MOL CELL BIOL, V26, P9352, DOI 10.1128/MCB.01148-06	27	139	145	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1234	1240		10.1038/nm1640	http://dx.doi.org/10.1038/nm1640			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17873881				2022-12-27	WOS:000249980200040
J	Soucek, L; Lawlor, ER; Soto, D; Shchors, K; Swigart, LB; Evan, GI				Soucek, Laura; Lawlor, Elizabeth R.; Soto, Darya; Shchors, Ksenya; Swigart, Lamorna Brown; Evan, Gerard I.			Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors	NATURE MEDICINE			English	Article							GASTROINTESTINAL STROMAL TUMORS; C-KIT CD117; BETA-CELLS; IN-VIVO; GENE-EXPRESSION; CANCER; INFLAMMATION; MICE; ACTIVATION; INDUCTION	An association between inflammation and cancer has long been recognized, but the cause and effect relationship linking the two remains unclear. Myc is a pleiotropic transcription factor that is overexpressed in many human cancers and instructs many extracellular aspects of the tumor tissue phenotype, including remodeling of tumor stroma and angiogenesis. Here we show in a beta-cell tumor model that activation of Myc in vivo triggers rapid recruitment of mast cells to the tumor site - a recruitment that is absolutely required for macroscopic tumor expansion. In addition, treatment of established beta-cell tumors with a mast cell inhibitor rapidly triggers hypoxia and cell death of tumor and endothelial cells. Inhibitors of mast cell function may therefore prove therapeutically useful in restraining expansion and survival of pancreatic and other cancers.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Evan, GI (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019	Soucek, Laura/0000-0002-4750-7971; 	NATIONAL CANCER INSTITUTE [F32CA106039, R01CA098018] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA106039, CA098018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann B, 1998, BRIT J UROL, V82, P118; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Belo AV, 2005, MICROCIRCULATION, V12, P597, DOI 10.1080/10739680500253535; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, ENDOCRINOLOGY, V141, P1926, DOI 10.1210/en.141.6.1926; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Bot I, 2007, CIRCULATION, V115, P2516, DOI 10.1161/CIRCULATIONAHA.106.660472; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Escribano L, 1998, LEUKEMIA LYMPHOMA, V30, P459, DOI 10.3109/10428199809057558; Fischer M, 2003, INT J CANCER, V107, P197, DOI 10.1002/ijc.11370; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Kanbe N, 1999, EUR J IMMUNOL, V29, P2645; Kaneto H, 2002, J BIOL CHEM, V277, P12998, DOI 10.1074/jbc.M111148200; Kopp HG, 2006, CURR OPIN HEMATOL, V13, P175, DOI 10.1097/01.moh.0000219664.26528.da; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Laybutt DR, 2002, DIABETES, V51, P1793, DOI 10.2337/diabetes.51.6.1793; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Michalec L, 2002, J IMMUNOL, V168, P846, DOI 10.4049/jimmunol.168.2.846; NAGLE DL, 1995, HUM MOL GENET, V4, P2073, DOI 10.1093/hmg/4.11.2073; Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Robinson SC, 2005, ADV CANCER RES, V93, P159, DOI 10.1016/S0065-230X(05)93005-4; Rubin BP, 2001, CANCER RES, V61, P8118; Sawatsubashi M, 2000, VIRCHOWS ARCH, V436, P243, DOI 10.1007/s004280050037; Scapini P, 2004, J IMMUNOL, V172, P5034, DOI 10.4049/jimmunol.172.8.5034; Shchors K, 2006, GENE DEV, V20, P2527, DOI 10.1101/gad.1455706; Sperling C, 1997, HAEMATOLOGICA, V82, P617; THOMPSON PJ, 1983, LANCET, V2, P848; Toth T, 2000, MODERN PATHOL, V13, P1020, DOI 10.1038/modpathol.3880184; Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359-6101(01)00033-8; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957	41	376	393	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1211	1218		10.1038/nm1649	http://dx.doi.org/10.1038/nm1649			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17906636				2022-12-27	WOS:000249980200037
J	Xiang, YY; Wang, SH; Liu, MY; Hirota, JA; Li, JX; Ju, W; Fan, YJ; Kelly, MM; Ye, B; Orser, B; O'Byrne, PM; Inman, MD; Yang, X; Lu, WY				Xiang, Yun-Yan; Wang, Shuhe; Liu, Mingyao; Hirota, Jeremy A.; Li, Jingxin; Ju, William; Fan, Yijun; Kelly, Margaret M.; Ye, Bin; Orser, Beverley; O'Byrne, Paul M.; Inman, Mark D.; Yang, Xi; Lu, Wei-Yang			A GABAergic system in airway epithelium is essential for mucus overproduction in asthma	NATURE MEDICINE			English	Article							HIPPOCAMPAL-NEURONS; GOBLET CELL; MOUSE MODEL; RECEPTOR; EXPRESSION; INFLAMMATION; INHIBITION; RESPONSES; GROWTH; MICE	gamma-aminobutyric acid (GABA) is an important neurotransmitter that, through the subtype A GABA receptor (GABA(A)R), induces inhibition in the adult brain. Here we show that an excitatory, rather than inhibitory, GABAergic system exists in airway epithelial cells. Both GABA(A)Rs and the GABA synthetic enzyme glutamic acid decarboxylase (GAD) are expressed in pulmonary epithelial cells. Activation of GABA(A)Rs depolarized these cells. The expression of GAD in the cytosol and GABA(A)Rs in the apical membranes of airway epithelial cells increased markedly when mice were sensitized and then challenged with ovalbumin, an approach for inducing allergic asthmatic reactions. Similarly, GAD and GABA(A)Rs in airway epithelial cells of humans with asthma increased after allergen inhalation challenge. Intranasal application of selective GABA(A)R inhibitors suppressed the hyperplasia of goblet cells and the overproduction of mucus induced by ovalbumin or interleukin-13 in mice. These findings show that a previously unknown epithelial GABAergic system has an essential role in asthma.	Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Manitoba, Dept Med Microbiol, Immune Regulat Allergy Grp, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Microbiol & Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Michael G DeGroot Sch Med, Hamilton, ON L8N 3Z5, Canada; Shandong Univ, Sch Med, Inst Physiol, Jinan 250012, Shandong, Peoples R China; Univ Toronto, Dept Anesthesia, Toronto, ON M5S 3E2, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; University of Manitoba; University of Toronto; University of Toronto; McMaster University; Shandong University; University of Toronto	Lu, WY (corresponding author), Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	yangxi@cc.umanitoba.ca; wlu@sten.sunnybrook.utoronto.ca	Kelly, Margaret M/G-4128-2012; Lu, Wei-Yang/K-4404-2013	Kelly, Margaret M/0000-0002-1629-3210; O'Byrne, Paul/0000-0003-0979-281X; Yang, Xi/0000-0002-8831-7488; Liu, Mingyao/0000-0002-9188-8417				Baufreton J, 2005, J NEUROSCI, V25, P8505, DOI 10.1523/JNEUROSCI.1163-05.2005; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; Dong HH, 2004, J NEUROSCI, V24, P8950, DOI 10.1523/JNEUROSCI.2106-04.2004; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Han XB, 2006, J IMMUNOL, V176, P5232, DOI 10.4049/jimmunol.176.9.5232; Hirota JA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-120; Hocking DC, 2003, AM J PHYSIOL-LUNG C, V285, pL169, DOI 10.1152/ajplung.00371.2002; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Jin N, 2005, CELL TISSUE RES, V321, P173, DOI 10.1007/s00441-005-1130-8; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Represa A, 2005, TRENDS NEUROSCI, V28, P278, DOI 10.1016/j.tins.2005.03.010; Rogers DF, 2002, CLIN EXP ALLERGY, V32, P1124, DOI 10.1046/j.1365-2745.2002.01474.x; Serantes R, 2006, J BIOL CHEM, V281, P14632, DOI 10.1074/jbc.M512489200; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Treiman DM, 2001, EPILEPSIA, V42, P8, DOI 10.1046/j.1528-1157.2001.042suppl.3008.x; Wang SH, 2001, J IMMUNOL, V166, P2741, DOI 10.4049/jimmunol.166.4.2741; Ware LB, 2003, AM J PHYSIOL-LUNG C, V285, pL514, DOI 10.1152/ajplung.00442.2002; Whiting PJ, 2003, CURR OPIN DRUG DISC, V6, P648; Xiang YY, 2006, J BIOL CHEM, V281, P19358, DOI 10.1074/jbc.M512980200; YANG X, 1993, J EXP MED, V178, P349, DOI 10.1084/jem.178.1.349	29	147	158	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					862	867		10.1038/nm1604	http://dx.doi.org/10.1038/nm1604			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17589520				2022-12-27	WOS:000247902800034
J	Zaidi, M				Zaidi, Mone			Skeletal remodeling in health and disease	NATURE MEDICINE			English	Review							BONE-MINERAL DENSITY; T-CELLS; UP-REGULATION; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; OSTEOCLAST FUNCTION; DEFICIENT MICE; NUCLEAR FACTOR; IN-VIVO; RECEPTOR	The use of genetically manipulated mouse models, gene and protein discovery and the cataloguing of genetic mutations have each allowed us to obtain new insights into skeletal morphogenesis and remodeling. These techniques have made it possible to identify molecules that are obligatory for specific cellular functions, and to exploit these molecules for therapeutic purposes. New insights into the pathophysiology of diseases have also enabled us to understand molecular defects in a way that was not possible a decade ago. This review summarizes our current understanding of the carefully orchestrated cross-talk between cells of the bone marrow and between bone cells and the brain through which bone is constantly remodeled during adult life. It also highlights molecular aberrations that cause bone cells to become dysfunctional, as well as therapeutic options and opportunities to counteract skeletal loss.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Zaidi, M (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1055, New York, NY 10029 USA.	mone.zaidi@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023176, R03AG014907] Funding Source: NIH RePORTER; NIA NIH HHS [AG14907, AG23176] Funding Source: Medline; NIDDK NIH HHS [DK70526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Bassett JHD, 2007, MOL ENDOCRINOL, V21, P1095, DOI 10.1210/me.2007-0033; Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; Bekker PJ, 2005, J BONE MINER RES, V20, P2274, DOI 10.1359/jbmr.2005.20.12.2274; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boisvert CA, 2005, NATURE, V438, P1145, DOI 10.1038/nature04119; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Buchinsky FJ, 1996, ENDOCRINOLOGY, V137, P2278, DOI 10.1210/en.137.6.2278; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; CHRITENSEN C, IN PRESS P NY AC SCI; Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood-2004-02-0474; Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135; Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616; DATTA HK, 1989, BIOCHEM BIOPH RES CO, V162, P876, DOI 10.1016/0006-291X(89)92391-7; Devleta B, 2004, J BONE MINER METAB, V22, P360, DOI 10.1007/s00774-004-0495-1; Doecke JD, 2006, J BONE MINER RES, V21, P265, DOI 10.1359/JBMR; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Elefteriou F, 2003, ENDOCRINOLOGY, V144, P3842, DOI 10.1210/en.2003-0369; Epstein S, 2003, J BONE MINER RES, V18, P2083, DOI 10.1359/jbmr.2003.18.12.2083; Ermakov S, 2006, BONE, V38, P199, DOI 10.1016/j.bone.2005.08.008; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Gao JJ, 2007, ENDOCRINOLOGY, V148, P2613, DOI 10.1210/en.2006-1404; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101; Hase H, 2006, P NATL ACAD SCI USA, V103, P12849, DOI 10.1073/pnas.0600427103; Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218; Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004; Iqbal J, 2006, P NATL ACAD SCI USA, V103, P14925, DOI 10.1073/pnas.0606805103; Iqbal J, 2006, AM J PHYSIOL-RENAL, V291, pF557, DOI 10.1152/ajprenal.00066.2006; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Jono S, 2002, CIRCULATION, V106, P1192, DOI 10.1161/01.CIR.0000031524.49139.29; Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200; Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kawaguchi H, 1999, J CLIN INVEST, V104, P229, DOI 10.1172/JCI5705; Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009; Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084; Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313; Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614; Lindsay R, 2001, JAMA-J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126; McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459; Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003-1097; Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Miyaura C, 2001, BIOCHEM BIOPH RES CO, V280, P1062, DOI 10.1006/bbrc.2001.4246; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mohan S, 2005, J ENDOCRINOL, V185, P415, DOI 10.1677/joe.1.06141; Moonga BS, 2002, AM J PHYSIOL-RENAL, V282, pF921, DOI 10.1152/ajprenal.00045.2000; Mundy GR, 1999, CLIN CHEM, V45, P1347; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Pazianas M, 2006, ANN NY ACAD SCI, V1068, P543, DOI 10.1196/annals.1346.055; Qvist P, 2002, BONE, V31, P57, DOI 10.1016/S8756-3282(02)00791-3; Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Ryan MR, 2005, P NATL ACAD SCI USA, V102, P16735, DOI 10.1073/pnas.0505168102; Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302; Schmitt CP, 2005, PEDIATR NEPHROL, V20, P346, DOI 10.1007/s00467-004-1767-7; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Schwarz EM, 2006, ANN NY ACAD SCI, V1068, P275, DOI 10.1196/annals.1346.031; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756-3282(01)00643-3; Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509; Sowers MR, 2006, J CLIN ENDOCR METAB, V91, P1261, DOI 10.1210/jc.2005-1836; STEPNICK LS, 2004, BONE HLTH OSTEOPOROS, P68; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102; Sun L, 2003, FASEB J, V17, P369, DOI 10.1096/fj.02-0205com; Sun L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0705com; Sun L, 2006, ANN NY ACAD SCI, V1068, P309, DOI 10.1196/annals.1346.033; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; THORNDYKE MC, 1979, CELL TISSUE RES, V203, P301; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Towler DA, 2006, ANN NY ACAD SCI, V1068, P327, DOI 10.1196/annals.1346.036; Tozum TF, 2004, CALCIFIED TISSUE INT, V75, P60, DOI 10.1007/s00223-004-0119-8; Ueland T, 2005, CIRCULATION, V111, P2461, DOI 10.1161/01.CIR.0000165119.62099.14; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; Whyte MP, 2006, ANN NY ACAD SCI, V1068, P143, DOI 10.1196/annals.1346.016; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zaidi M, 2005, CELL METAB, V1, P219, DOI 10.1016/j.cmet.2005.03.006; ZAIDI M, 1987, CALCIFIED TISSUE INT, V40, P149, DOI 10.1007/BF02555699; Zaidi M, 2004, BIOL REV, V79, P79, DOI 10.1017/S1464793103006262; Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599; Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1; Zaidi M, 2006, CELL, V127, P1080, DOI 10.1016/j.cell.2006.12.003; Zaidi M, 2006, THYROID, V16, P1075, DOI 10.1089/thy.2006.16.1075; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	124	728	760	1	68	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2007	13	7					791	801		10.1038/nm1593	http://dx.doi.org/10.1038/nm1593			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	188EU	17618270				2022-12-27	WOS:000247902800025
J	Dorman, SE; Chaisson, RE				Dorman, Susan E.; Chaisson, Richard E.			From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; HIV; SURVEILLANCE; INFECTION; PROJECT		Johns Hopkins Univ, Ctr Tuberculosis Res, Baltimore, MD 21231 USA	Johns Hopkins University	Dorman, SE (corresponding author), Johns Hopkins Univ, Ctr Tuberculosis Res, 1550 Orleans St,Room 1M-08, Baltimore, MD 21231 USA.	rchaiss@jhmi.edu			NIAID NIH HHS [AI01637, AI51528] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001637, K23AI051528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2; *BRIT MED RES COUN, 1948, BMJ-BRIT MED J, V2, P769; Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P301; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; *CTR DIS CONTR PRE, 2006, MMWR-MORBID MORTAL W, V55, P305; Currie CSM, 2003, AIDS, V17, P2501, DOI 10.1097/00002030-200311210-00013; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; FEUER C, 2006, TUBERCULOSIS RES DEV; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GANDHI N, 2006, 16 INT AIDS C 13 18; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Heifets LB, 1999, INT J TUBERC LUNG D, V3, P564; Kang'ombe CT, 2004, INT J TUBERC LUNG D, V8, P829; Nardell Edward A, 2003, Semin Respir Infect, V18, P307; Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704; Ryan F., 1993, GLOTTA; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; *WHO, 2005, WHOHTMTB2005349; *WHO, 2006, WHOHTMTB2006375; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877; 1999, GUIDELINES PREVENTIO	24	151	160	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					295	298		10.1038/nm0307-295	http://dx.doi.org/10.1038/nm0307-295			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342143				2022-12-27	WOS:000244715700040
J	Medarova, Z; Pham, W; Farrar, C; Petkova, V; Moore, A				Medarova, Zdravka; Pham, Wellington; Farrar, Christian; Petkova, Victoria; Moore, Anna			In vivo imaging of siRNA delivery and silencing in tumors	NATURE MEDICINE			English	Article							SMALL INTERFERING RNA; FAS PROTECTS MICE; GENE-EXPRESSION; EFFICIENT DELIVERY; LENTIVIRAL VECTORS; SEQUENCE; MODEL; INHIBITION; KNOCKDOWN; POTENT	With the increased potential of RNA interference (RNAi) as a therapeutic strategy, new noninvasive methods for detection of siRNA delivery and silencing are urgently needed. Here we describe the development of dual-purpose probes for in vivo transfer of siRNA and the simultaneous imaging of its accumulation in tumors by high-resolution magnetic resonance imaging (MRI) and near-infrared in vivo optical imaging (NIRF). These probes consisted of magnetic nanoparticles labeled with a near-infrared dye and covalently linked to siRNA molecules specific for model or therapeutic targets. Additionally, these nanoparticles were modified with a membrane translocation peptide for intracellular delivery. We show the feasibility of in vivo tracking of tumor uptake of these probes by MRI and optical imaging in two separate tumor models. We also used proof-of-principle optical imaging to corroborate the efficiency of the silencing process. These studies represent the first step toward the advancement of siRNA delivery and imaging strategies, essential for cancer therapeutic product development and optimization.	Harvard Univ, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Moore, A (corresponding author), Harvard Univ, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Room 2301,Bldg 149,13th St, Boston, MA 02129 USA.	amoore@helix.mgh.harvard.edu		Pham, Wellington/0000-0002-8408-7611; Farrar, Christian/0000-0001-6623-8220	NATIONAL INSTITUTE ON AGING [K25AG029415] Funding Source: NIH RePORTER; NIA NIH HHS [K25 AG029415-03, K25 AG029415-02, K25 AG029415-04, K25 AG029415, K25 AG029415-05, K25 AG029415-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Bourrinet P, 2006, INVEST RADIOL, V41, P313, DOI 10.1097/01.rli.0000197669.80475.dd; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; Harborth J, 2003, ANTISENSE NUCLEIC A, V13, P83, DOI 10.1089/108729003321629638; Hassani Z, 2005, J GENE MED, V7, P198, DOI 10.1002/jgm.659; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Moore A, 2004, CANCER RES, V64, P1821, DOI 10.1158/0008-5472.CAN-03-3230; Moore A, 1998, MICROVASC RES, V56, P145, DOI 10.1006/mvre.1998.2102; Moore A, 2000, RADIOLOGY, V214, P568, DOI 10.1148/radiology.214.2.r00fe19568; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Tiscornia G, 2004, P NATL ACAD SCI USA, V101, P7347, DOI 10.1073/pnas.0402107101; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yano J, 2004, CLIN CANCER RES, V10, P7721, DOI 10.1158/1078-0432.CCR-04-1049; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x; Zimmer C, 1997, EXP NEUROL, V143, P61, DOI 10.1006/exnr.1996.6350; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	35	565	619	2	162	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					372	377		10.1038/nm1486	http://dx.doi.org/10.1038/nm1486			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17322898				2022-12-27	WOS:000244715700052
J	Yamauchi, T; Nio, Y; Maki, T; Kobayashi, M; Takazawa, T; Iwabu, M; Okada-Iwabu, M; Kawamoto, S; Kubota, N; Kubota, T; Ito, Y; Kamon, J; Tsuchida, A; Kumagai, K; Kozono, H; Hada, Y; Ogata, H; Tokuyama, K; Tsunoda, M; Ide, T; Murakami, K; Awazawa, M; Takamoto, I; Froguel, P; Hara, K; Tobe, K; Nagai, R; Ueki, K; Kadowaki, T				Yamauchi, Toshimasa; Nio, Yasunori; Maki, Toshiyuki; Kobayashi, Masaki; Takazawa, Takeshi; Iwabu, Masato; Okada-Iwabu, Miki; Kawamoto, Sachiko; Kubota, Naoto; Kubota, Tetsuya; Ito, Yusuke; Kamon, Junji; Tsuchida, Atsushi; Kumagai, Katsuyoshi; Kozono, Hideki; Hada, Yusuke; Ogata, Hitomi; Tokuyama, Kumpei; Tsunoda, Masaki; Ide, Tomohiro; Murakami, Kouji; Awazawa, Motoharu; Takamoto, Iseki; Froguel, Philippe; Hara, Kazuo; Tobe, Kazuyuki; Nagai, Ryozo; Ueki, Kohjiro; Kadowaki, Takashi			Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED INSULIN-RESISTANCE; FATTY-ACID OXIDATION; PPAR-ALPHA; HORMONE ADIPONECTIN; MUSCLE-CELLS; WEIGHT-LOSS; OBESITY; RECEPTOR; EXPRESSION	Adiponectin plays a central role as an antidiabetic and antiatherogenic adipokine. AdipoR1 and AdipoR2 serve as receptors for adiponectin in vitro, and their reduction in obesity seems to be correlated with reduced adiponectin sensitivity. Here we show that adenovirus-mediated expression of AdipoR1 and R2 in the liver of Lepr(-/-) mice increased AMP-activated protein kinase (AMPK) activation and peroxisome proliferator-activated receptor (PPAR)-alpha signaling pathways, respectively. Activation of AMPK reduced gluconeogenesis, whereas expression of the receptors in both cases increased fatty acid oxidation and lead to an amelioration of diabetes. Alternatively, targeted disruption of AdipoR1 resulted in the abrogation of adiponectin-induced AMPK activation, whereas that of AdipoR2 resulted in decreased activity of PPAR-alpha signaling pathways. Simultaneous disruption of both AdipoR1 and R2 abolished adiponectin binding and actions, resulting in increased tissue triglyceride content, inflammation and oxidative stress, and thus leading to insulin resistance and marked glucose intolerance. Therefore, AdipoR1 and R2 serve as the predominant receptors for adiponectin in vivo and play important roles in the regulation of glucose and lipid metabolism, inflammation and oxidative stress in vivo.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, 22nd Century Med & Res Ctr, Dept Integrated Mol Sci Metab Dis, Tokyo 1138655, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Tokyo 3320012, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Kyorin Pharmaceut Co Ltd, Biosci Div 1, Metab Discovery Res Labs, Shimotsuga 3290114, Japan; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sect Genom Med, London W12 0NN, England	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tsukuba; Imperial College London	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Nio, Yasunori/AFE-2456-2022; FROGUEL, Philippe/O-6799-2017; Kubota, Naoto/N-7892-2015	FROGUEL, Philippe/0000-0003-2972-0784; Kumagai, Katsuyoshi/0000-0003-4072-9907				Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Hug C, 2005, CURR OPIN PHARMACOL, V5, P129, DOI 10.1016/j.coph.2005.01.001; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kubota N, 2006, J BIOL CHEM, V281, P8748, DOI 10.1074/jbc.M505649200; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Maddux BA, 2001, DIABETES, V50, P404, DOI 10.2337/diabetes.50.2.404; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matschinsky FM, 2006, DIABETES, V55, P1; Matsuzawa Y, 2006, FEBS LETT, V580, P2917, DOI 10.1016/j.febslet.2006.04.028; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Toyama T, 2004, BIOCHEM BIOPH RES CO, V324, P697, DOI 10.1016/j.bbrc.2004.09.110; Tsuchida A, 2005, DIABETES, V54, P3358, DOI 10.2337/diabetes.54.12.3358; Tsuchida A, 2004, J BIOL CHEM, V279, P30817, DOI 10.1074/jbc.M402367200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	40	986	1049	1	85	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2007	13	3					332	339		10.1038/nm1557	http://dx.doi.org/10.1038/nm1557			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17268472				2022-12-27	WOS:000244715700046
J	Kaneko, S; Iwanami, A; Nakamura, M; Kishino, A; Kikuchi, K; Shibata, S; Okano, HJ; Ikegami, T; Moriya, A; Konishi, O; Nakayama, C; Kumagai, K; Kimura, T; Sato, Y; Goshima, Y; Taniguchi, M; Ito, M; He, ZG; Toyama, Y; Okano, H				Kaneko, Shinjiro; Iwanami, Akio; Nakamura, Masaya; Kishino, Akiyoshi; Kikuchi, Kaoru; Shibata, Shinsuke; Okano, Hirotaka J.; Ikegami, Takeshi; Moriya, Ayako; Konishi, Osamu; Nakayama, Chikao; Kumagai, Kazuo; Kimura, Toru; Sato, Yasufumi; Goshima, Yoshio; Taniguchi, Masahiko; Ito, Mamoru; He, Zhigang; Toyama, Yoshiaki; Okano, Hideyuki			A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord	NATURE MEDICINE			English	Article							OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CHEMOREPELLENT SEMAPHORIN-III; PERIPHERAL-NERVE PROJECTION; IN-VIVO; NEURITE OUTGROWTH; AXON REGENERATION; CELL-MIGRATION; SENSORY AFFERENTS; NOGO RECEPTOR; GROWTH	Axons in the adult mammalian central nervous system (CNS) exhibit little regeneration after injury. It has been suggested that several axonal growth inhibitors prevent CNS axonal regeneration. Recent research has demonstrated that semaphorin3A (Sema3A) is one of the major inhibitors of axonal regeneration. We identified a strong and selective inhibitor of Sema3A, SM-216289, from the fermentation broth of a fungal strain. To examine the effect of SM-216289 in vivo, we transected the spinal cord of adult rats and administered SM-216289 into the lesion site for 4 weeks. Rats treated with SM-216289 showed substantially enhanced regeneration and/or preservation of injured axons, robust Schwann cell-mediated myelination and axonal regeneration in the lesion site, appreciable decreases in apoptotic cell number and marked enhancement of angiogenesis, resulting in considerably better functional recovery. Thus, Sema3A is essential for the inhibition of axonal regeneration and other regenerative responses after spinal cord injury (SCI). These results support the possibility of using Sema3A inhibitors in the treatment of human SCI.	Keio Univ, Sch Med, Dept Physiol, Shinjyuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjyuku Ku, Tokyo 1608582, Japan; Harvard Univ, Sch Med, Childrens Hosp Boston, Div Neurosci, Boston, MA 02115 USA; Natl Hosp Org, Clin Res Ctr, Murayama Med Ctr, Tokyo 2080011, Japan; Dainippon Sumitomo Pharma Co Ltd, Konohana Ku, Osaka 5540022, Japan; Yokohama City Univ, Sch Med, Dept Mol Pharmacol & Neurobiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Tokyo, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa 2160001, Japan	Keio University; Keio University; Harvard University; Boston Children's Hospital; Harvard Medical School; Dainippon Sumitomo Pharmaceutical Company; Yokohama City University; University of Tokyo	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjyuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Nakamura, Masaya/K-4111-2013; Toyama, Yoshiaki/K-5743-2013; Shibata, Shinsuke/AAM-6620-2020; Kumagai, Kazuo/D-7676-2016	Kumagai, Kazuo/0000-0003-2312-5765; Okano, Hirotaka James/0000-0003-4611-7098				ARCHELOS JJ, 1993, J NEUROSCI RES, V35, P46, DOI 10.1002/jnr.490350107; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Christensen MD, 1997, EXP NEUROL, V147, P463, DOI 10.1006/exnr.1997.6608; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GUTHRIE S, 1994, NEUROPROTOCOLS, V4, P116; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Kikuchi K, 2003, J BIOL CHEM, V278, P42985, DOI 10.1074/jbc.M302395200; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumagai K, 2003, J ANTIBIOT, V56, P610, DOI 10.7164/antibiotics.56.610; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Mikami Y, 2002, J NEUROSURG, V97, P142, DOI 10.3171/spi.2002.97.1.0142; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Olson L, 2002, NATURE, V416, P589, DOI 10.1038/416589a; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Romero MI, 2001, J NEUROSCI, V21, P8408, DOI 10.1523/JNEUROSCI.21-21-08408.2001; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yaron A, 2005, NEURON, V45, P513, DOI 10.1016/j.neuron.2005.01.013; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	50	297	311	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1380	1389		10.1038/nm1505	http://dx.doi.org/10.1038/nm1505			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17099709				2022-12-27	WOS:000242618200018
J	Beadling, C; Slifka, MK				Beadling, Carol; Slifka, Mark K.			Quantifying viable virus-specific T cells without a priori knowledge of fine epitope specificity	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; MHC CLASS-II; INTERCELLULAR TRANSFER; CYTOKINE RESPONSES; VIRAL-INFECTIONS; CUTTING EDGE; PEPTIDE; COMPLEXES; CD4(+); ACQUISITION	Identification of pathogen-specific T cells has been greatly facilitated by the advent of synthetic peptide-major histocompatibility complex (MHC) tetramers. In many cases, however, specific epitopes have not been defined, necessitating detection methods that function independently of exact peptide-MHC specificity. Lymphocytes acquire surface proteins from antigen-presenting cells (APCs), and we have exploited this phenomenon to develop the T-cell recognition of APCs by protein transfer (TRAP) assay. This method is based on biotinylation and streptavidin-fluorochrome labeling of APCs, followed by subsequent acquisition of this label by antigen-specific T cells. The TRAP procedure detects MHC class l-restricted T cells regardless of their cytokine profiles or peptide-MHC affinities, and provides a versatile tool for monitoring the phenomenon of APC membrane acquisition by antigen-specific T cells.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu			NCRR NIH HHS [RR000163, P51 RR000163] Funding Source: Medline; NIAID NIH HHS [AI054458, R01 AI054458] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054458] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arnold PY, 1997, EUR J IMMUNOL, V27, P3198, DOI 10.1002/eji.1830271217; Beadling C, 2005, BLOOD, V105, P1179, DOI 10.1182/blood-2004-07-2833; Becker C, 2001, NAT MED, V7, P1159, DOI 10.1038/nm1001-1159; Belz GT, 2001, J IMMUNOL, V166, P4627, DOI 10.4049/jimmunol.166.7.4627; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Chang J, 2002, NAT MED, V8, P54, DOI 10.1038/nm0102-54; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372; Harrington LE, 2002, J VIROL, V76, P3329, DOI 10.1128/JVI.76.7.3329-3337.2002; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hudrisier D, 2001, J IMMUNOL, V166, P3645, DOI 10.4049/jimmunol.166.6.3645; Hudrisier D, 2002, FASEB J, V16, P477, DOI 10.1096/fj.01-0933rev; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Liu F, 2005, J IMMUNOL, V174, P5936, DOI 10.4049/jimmunol.174.10.5936; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Marten NW, 2003, J VIROL, V77, P2775, DOI 10.1128/JVI.77.4.2775-2778.2003; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NEPOM JT, 1981, J IMMUNOL, V127, P888; Patel DM, 1999, J IMMUNOL, V163, P5201; Raue HP, 2004, J IMMUNOL, V173, P6873, DOI 10.4049/jimmunol.173.11.6873; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Tomaru U, 2003, NAT MED, V9, P469, DOI 10.1038/nm845; Tsang JYS, 2003, BLOOD, V101, P2704, DOI 10.1182/blood-2002-04-1230; Wetzel SA, 2005, J IMMUNOL, V174, P80, DOI 10.4049/jimmunol.174.1.80; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003	30	28	30	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1208	1212		10.1038/nm1413	http://dx.doi.org/10.1038/nm1413			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013384				2022-12-27	WOS:000241102200040
J	Huber-Lang, M; Sarma, JV; Zetoune, FS; Rittirsch, D; Neff, TA; McGuire, SR; Lambris, JD; Warner, RL; Flierl, MA; Hoesel, LM; Gebhard, F; Younger, JG; Drouin, SM; Wetsel, RA; Ward, PA				Huber-Lang, Markus; Sarma, J. Vidya; Zetoune, Firas S.; Rittirsch, Daniel; Neff, Thomas A.; McGuire, Stephanie R.; Lambris, John D.; Warner, Roscoe L.; Flierl, Michael A.; Hoesel, Laszlo M.; Gebhard, Florian; Younger, John G.; Drouin, Scott M.; Wetsel, Rick A.; Ward, Peter A.			Generation of C5a in the absence of C3: a new complement activation pathway	NATURE MEDICINE			English	Article							REVERSE ARTHUS REACTION; DEFICIENT MICE; INFLAMMATORY RESPONSES; RECEPTOR ANTAGONIST; PULMONARY RESPONSE; REPERFUSION INJURY; COMPONENT C5; IN-VIVO; EXPRESSION; NEUTROPHILS	Complement-mediated tissue injury in humans occurs upon deposition of immune complexes, such as in autoimmune diseases and acute respiratory distress syndrome. Acute lung inflammatory injury in wild-type and C3(-/-) mice after deposition of IgG immune complexes was of equivalent intensity and was C5a dependent, but injury was greatly attenuated in Hc(-/-) mice ( Hc encodes C5). Injury in lungs of C3(-/-) mice and C5a levels in bronchoalveolar lavage ( BAL) fluids from these mice were greatly reduced in the presence of antithrombin III ( ATIII) or hirudin but were not reduced in similarly treated C3(+/+) mice. Plasma from C3(-/-) mice contained threefold higher levels of thrombin activity compared to plasma from C3(+/+) mice. There were higher levels of F2 mRNA ( encoding prothrombin) as well as prothrombin and thrombin protein in liver of C3(-/-) mice compared to C3(+/+) mice. A potent solid- phase C5 convertase was generated using plasma from either C3(+/+) or C3(-/-) mice. Human C5 incubated with thrombin generated C5a that was biologically active. These data suggest that, in the genetic absence of C3, thrombin substitutes for the C3-dependent C5 convertase. This linkage between the complement and coagulation pathways may represent a new pathway of complement activation.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Ulm, Sch Med, Dept Traumatol Hand & Reconstruct Surg, D-89075 Ulm, Germany; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA	University of Michigan System; University of Michigan; Ulm University; University of Pennsylvania; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health Science Center Houston	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Lambris, John/Q-5633-2018; Huber-Lang, Markus/AAJ-2209-2020	Lambris, John/0000-0002-9370-5776; Younger, John/0000-0002-0820-0635; Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069438, R01GM029507, R37GM029507, R24GM069736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31963] Funding Source: Medline; NIAID NIH HHS [AI-30040] Funding Source: Medline; NIDDK NIH HHS [DK-59422] Funding Source: Medline; NIGMS NIH HHS [GM-069438, GM-069736, GM-29507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS AK, 1999, ROBBINS PATHOLOGIC B, P188; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; BARTON PA, 1993, INFECT IMMUN, V61, P1474, DOI 10.1128/IAI.61.4.1474-1481.1993; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Czermak BJ, 1999, J IMMUNOL, V162, P2321; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Heller T, 1999, J IMMUNOL, V163, P985; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Huber-Lang M, 2002, AM J PATHOL, V161, P1849, DOI 10.1016/S0002-9440(10)64461-6; HUGLI TE, 1977, CHEM BIOL THROMBIN, P345; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Kyriakides C, 1999, J APPL PHYSIOL, V87, P2357, DOI 10.1152/jappl.1999.87.6.2357; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; LARSEN GL, 1982, AM REV RESPIR DIS, V126, P306; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; POLLEY MJ, 1978, J EXP MED, V147, P1713, DOI 10.1084/jem.147.6.1713; Rawal N, 2003, J BIOL CHEM, V278, P38476, DOI 10.1074/jbc.M307017200; Strachan AJ, 2001, BRIT J PHARMACOL, V134, P1778, DOI 10.1038/sj.bjp.0704417; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WARD PA, 1970, J IMMUNOL, V104, P535; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WETSEL RA, 1983, J EXP MED, V157, P2029, DOI 10.1084/jem.157.6.2029; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326	30	707	752	3	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					682	687		10.1038/nm1419	http://dx.doi.org/10.1038/nm1419			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715088				2022-12-27	WOS:000238149200031
J	Dubois, MJ; Bergeron, S; Kim, HJ; Dombrowski, L; Perreault, M; Fournes, B; Faure, R; Olivier, M; Beauchemin, N; Shulman, GI; Siminovitch, KA; Kim, JK; Marette, A				Dubois, Marie-Julie; Bergeron, Sebastien; Kim, Hyo-Jeong; Dombrowski, Luce; Perreault, Mylene; Fournes, Benedicte; Faure, Robert; Olivier, Martin; Beauchemin, Nicole; Shulman, Gerald I.; Siminovitch, Katherine A.; Kim, Jason K.; Marette, Andre			The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; SH2 DOMAIN; REGULATORY SUBUNIT; EPITHELIAL-CELLS; TRANSGENIC MICE; IN-VIVO; PHOSPHORYLATION; ACTIVATION	The protein tyrosine phosphatase SHP-1 is a well-known inhibitor of activation-promoting signaling cascades in hematopoietic cells but its potential role in insulin target tissues is unknown. Here we show that Ptpn6(me-v/me-v) (also known as viable motheaten) mice bearing a functionally deficient SHP-1 protein are markedly glucose tolerant and insulin sensitive as compared to wild-type littermates, as a result of enhanced insulin receptor signaling to IRS-PI3K-Akt in liver and muscle. Downregulation of SHP-1 activity in liver of normal mice by adenoviral expression of a catalytically inert mutant of SHP-1, or after small hairpin RNA mediated SHP-1 silencing, further confirmed this phenotype. Tyrosine phosphorylation of CEACAM1, a modulator of hepatic insulin clearance, and clearance of serum [I-125]-insulin were markedly increased in SHP-1-deficient mice or SHP-1-deficient hepatic cells in vitro. These findings show a novel role for SHP-1 in the regulation of glucose homeostasis through modulation of insulin signaling in liver and muscle as well as hepatic insulin clearance.	Univ Laval Hosp, Res Ctr, Dept Anat Physiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval Hosp, Res Ctr, Lipid Res Unit, Quebec City, PQ G1V 4G2, Canada; Yale Univ, Sch Med, Yale Mouse Metabol Phenotyping Ctr, Dept Internal Med,Sect Endocrinol & Metab, New Haven, CT 06520 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Laval Hosp, Res Ctr, Dept Pediat, Quebec City, PQ G1V 4G2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Immunol, Toronto, ON M5G 1X5, Canada	Laval University; Laval University; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; McGill University; Laval University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Marette, A (corresponding author), Univ Laval Hosp, Res Ctr, Dept Anat Physiol, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013; Shulman, Gerald I./P-7176-2019; Siminovitch, Katherine/K-1475-2013	Shulman, Gerald I./0000-0003-1529-5668; Marette, Andre/0000-0003-3950-5973; Kim, Jason/0000-0002-7185-042X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059635, R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, U24 DK-59635] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, J BIOL CHEM, V272, P448; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Choice CV, 1998, J BIOL CHEM, V273, P22194, DOI 10.1074/jbc.273.35.22194; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dai T, 2004, J BIOL CHEM, V279, P45155, DOI 10.1074/jbc.M404764200; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Dustin LB, 1999, J IMMUNOL, V162, P2717; Elchebly M, 2000, J MOL MED-JMM, V78, P473, DOI 10.1007/s001090000141; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt;3185::AID-IMMU3185&gt;3.0.CO;2-J; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; Furnari FB, 1998, CANCER RES, V58, P5002; Goldstein BJ, 2002, J CLIN ENDOCR METAB, V87, P2474, DOI 10.1210/jc.87.6.2474; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Najjar SM, 2005, CELL METAB, V2, P43, DOI 10.1016/j.cmet.2005.06.001; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; Nakajima A, 2002, J IMMUNOL, V168, P1028, DOI 10.4049/jimmunol.168.3.1028; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	50	104	107	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					549	556		10.1038/nm1397	http://dx.doi.org/10.1038/nm1397			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16617349				2022-12-27	WOS:000238149100039
J	Jin, DK; Shido, K; Kopp, HG; Petit, I; Shmelkov, SV; Young, LM; Hooper, AT; Amano, H; Avecilla, ST; Heissig, B; Hattori, K; Zhang, F; Hicklin, DJ; Wu, Y; Zhu, ZP; Dunn, A; Salari, H; Werb, Z; Hackett, NR; Crystal, RG; Lyden, D; Rafii, S				Jin, David K.; Shido, Koji; Kopp, Hans-Georg; Petit, Isabelle; Shmelkov, Sergey V.; Young, Lauren M.; Hooper, Andrea T.; Amano, Hideki; Avecilla, Scott T.; Heissig, Beate; Hattori, Koichi; Zhang, Fan; Hicklin, Daniel J.; Wu, Yan; Zhu, Zhenping; Dunn, Ashley; Salari, Hassan; Werb, Zena; Hackett, Neil R.; Crystal, Ronald G.; Lyden, David; Rafii, Shahin			Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4(+) hemangiocytes	NATURE MEDICINE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; STEM-CELLS; TUMOR ANGIOGENESIS; GROWTH-FACTOR; FACTOR-I; ISCHEMIC TISSUES; CHEMOKINE SDF-1; DEFICIENT MICE; KIT-LIGAND; VEGF-A	The mechanisms through which hematopoietic cytokines accelerate revascularization are unknown. Here, we show that the magnitude of cytokine-mediated release of SDF-1 from platelets and the recruitment of nonendothelial CXCR4(+)VEGFR1(+) hematopoietic progenitors, 'hemangiocytes,' constitute the major determinant of revascularization. Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser extent, erythropoietin (EPO) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induced the release of SDF-1 from platelets, enhancing neovascularization through mobilization of CXCR4(+)VEGFR1(+) hemangiocytes. Although revascularization of ischemic hindlimbs was partially diminished in mice deficient in both GM-CSF and G-CSF (Csf2(-/-)Csf3(-/-)), profound impairment in neovascularization was detected in sKitL-deficient Mmp9(-/-) as well as thrombocytopenic Thpo(-/-) and TPO receptor-deficient (Mpl(-/-)) mice. SDF-1-mediated mobilization and incorporation of hemangiocytes into ischemic limbs were impaired in Thpo(-/-), Mpl(-/-) and Mmp9(-/-) mice. Transplantation of CXCR4(+)VEGFR1(+) hemangiocytes into Mmp9(-/-) mice restored revascularization, whereas inhibition of CXCR4 abrogated cytokine- and VEGF-A-mediated mobilization of CXCR4(+)VEGFR1(+) cells and suppressed angiogenesis. In conclusion, hematopoietic cytokines, through graded deployment of SDF-1 from platelets, support mobilization and recruitment of CXCR4(+)VEGFR1(+) hemangiocytes, whereas VEGFR1 is essential for their angiogenic competency for augmenting revascularization. Delivery of SDF- 1 may be effective in restoring angiogenesis in individuals with vasculopathies.	Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Med Oncol, New York, NY 10021 USA; ImClone Syst Inc, New York, NY 10014 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumor Biol Branch, Melbourne, Vic 3050, Australia; Chemokine Therapeut Corp, Vancouver, BC V6T 1Z3, Canada; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Cornell Univ, Weill Med Coll, Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Childrens Blood Fdn Labs, New York, NY 10021 USA	Cornell University; Cornell University; Eli Lilly; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of California System; University of California San Francisco; Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, 1300 York Ave, New York, NY 10021 USA.	srafii@med.cornell.edu	Hattori, Koichi/AAF-6862-2021; Petit, isabelle/AAF-5620-2020; Heissig, Beate/AAF-6771-2021; Avecilla, Scott/AAR-5873-2021	Petit, isabelle/0000-0002-9782-0683; Heissig, Beate/0000-0002-0348-5934; Avecilla, Scott/0000-0003-0661-9704; Kopp, Hans-Georg/0000-0002-0825-8888	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [U01 CA105379-04, U01 CA105379] Funding Source: Medline; NHLBI NIH HHS [R01 HL075234-04, P01 HL067839-020004, R01 HL061849, P01 HL067839-050004, R01 HL061849-04, R01 HL058707-04, HL67839, P01 HL067839, R01 HL058707-03, R01 HL061849-03S1, R01 HL061849-05, HL59312, P01 HL067839-010004, P01 HL067839-02, R01 HL061849-02, P01 HL067839-030004, HL66592, R01-HL075234, P01 HL067839-040004, P01 HL059312, R01 HL061849-03, R01 HL075234, P01 HL059312-10] Funding Source: Medline; NIA NIH HHS [R01 AG023218, R01 AG023218-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA105379] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059312, P01HL067839, R01HL058707, R01HL061849, P50HL059312, R01HL075234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023218] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; AVRAHAM H, 1992, BLOOD, V79, P365; Basu S, 2000, BLOOD, V95, P3725; Brizzi MF, 1999, CIRC RES, V84, P785; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Forster R, 1998, J IMMUNOL, V160, P1522; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kirito K, 2005, CELL CYCLE, V4, P1729, DOI 10.4161/cc.4.12.2197; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li JJ, 2001, THROMB HAEMOSTASIS, V85, P204, DOI 10.1055/s-0037-1615677; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Losordo DW, 2004, CIRCULATION, V109, P2692, DOI 10.1161/01.CIR.0000128596.49339.05; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; Pelus LM, 2005, EXP HEMATOL, V33, P295, DOI 10.1016/j.exphem.2004.11.008; Perez LE, 2004, EXP HEMATOL, V32, P300, DOI 10.1016/j.exphem.2003.12.005; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Walter DH, 2005, CIRC RES, V97, P1142, DOI 10.1161/01.RES.0000193596.94936.2c; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	50	535	561	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					557	567		10.1038/nm1400	http://dx.doi.org/10.1038/nm1400			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16648859	Green Published, Green Accepted			2022-12-27	WOS:000238149100040
J	Cardona, K; Korbutt, GS; Milas, Z; Lyon, J; Cano, J; Jiang, W; Bello-Laborn, H; Hacquoil, B; Strobert, E; Gangappa, S; Weber, CJ; Pearson, TC; Rajotte, RV; Larsen, CP				Cardona, K; Korbutt, GS; Milas, Z; Lyon, J; Cano, J; Jiang, W; Bello-Laborn, H; Hacquoil, B; Strobert, E; Gangappa, S; Weber, CJ; Pearson, TC; Rajotte, RV; Larsen, CP			Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; VASCULAR REJECTION; XENOGRAFTS; CELLS; XENOTRANSPLANTATION; TRANSPLANTATION; BLOCKADE; REVERSAL; ANTIGENS	We evaluated the ability of neonatal porcine islets to engraft and restore glucose control in pancreatectomized rhesus macaques. Although porcine islets transplanted into nonimmunosuppressed macaques were rapidly rejected by a process consistent with cellular rejection, recipients treated with a CD28-CD154 costimulation blockade regimen achieved sustained insulin independence ( median survival, > 140 days) without evidence of porcine endogenous retrovirus dissemination. Thus, neonatal porcine islets represent a promising solution to the crucial supply problem in clinical islet transplantation.	Univ Alberta, Surg Med Res Inst, Dent Pharm Ctr 1074, Edmonton, AB T6G 2N8, Canada; Emory Univ, Sch Med, Emory Transplant Ctr, Dept Surg, Atlanta, GA 30322 USA; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	University of Alberta; Emory University; Emory University	Rajotte, RV (corresponding author), Univ Alberta, Surg Med Res Inst, Dent Pharm Ctr 1074, Edmonton, AB T6G 2N8, Canada.	rrajotte@ualberta.ca; clarsen@emoryhealthcare.org	Sano, Michael/E-1715-2011; Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649	NCRR NIH HHS [P51-RR000165-45] Funding Source: Medline; NIAID NIH HHS [U19-AI51731] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051731] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams AB, 2005, J IMMUNOL, V174, P542, DOI 10.4049/jimmunol.174.1.542; Adams AB, 2001, J IMMUNOL, V167, P1103, DOI 10.4049/jimmunol.167.2.1103; Adams AB, 2002, DIABETES, V51, P265, DOI 10.2337/diabetes.51.2.265; Chen G, 2005, NAT MED, V11, P1295, DOI 10.1038/nm1330; COLLINS BH, 1995, J IMMUNOL, V154, P5500; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kin T, 2005, DIABETES, V54, P1032, DOI 10.2337/diabetes.54.4.1032; Kirchhof N, 2004, XENOTRANSPLANTATION, V11, P396, DOI 10.1111/j.1399-3089.2004.00157.x; Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Trivedi N, 2001, ENDOCRINOLOGY, V142, P2115, DOI 10.1210/en.142.5.2115; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014	14	362	376	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2006	12	3					304	306		10.1038/nm1375	http://dx.doi.org/10.1038/nm1375			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	018ZA	16501570				2022-12-27	WOS:000235802900028
J	Zhang, CC; Kaba, M; Ge, GT; Xie, K; Tong, W; Hug, C; Lodish, HF				Zhang, CC; Kaba, M; Ge, GT; Xie, K; Tong, W; Hug, C; Lodish, HF			Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells	NATURE MEDICINE			English	Article							IN-VITRO; MOLECULAR-CLONING; GROWTH-FACTOR; SIGNAL PEPTIDES; SELF-RENEWAL; GENE; IDENTIFICATION; DIFFERENTIATION; PREDICTION; LIVER	Successful ex vivo expansion of hematopoietic stem cells (HSCs) would greatly benefit the treatment of disease and the understanding of crucial questions of stem cell biology. Here we show, using microarray studies, that the HSC-supportive mouse fetal liver CD3(+) cells specifically express the proteins angiopoietin-like 2 (Angptl2) and angiopoietin-like 3 (Angptl3). We observed a 24- or 30-fold net expansion of long- term HSCs by reconstitution analysis when we cultured highly enriched HSCs for 10 days in the presence of Angptl2 or Angptl3 together with saturating levels of other growth factors. The coiled-coil domain of Angptl2 was capable of stimulating expansion of HSCs. Furthermore, angiopoietin-like 5, angiopoietin-like 7 and microfibril-associated glycoprotein 4 also supported expansion of HSCs in culture.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu		Xie, Kathleen/0000-0002-3178-8959; Tong, Wei/0000-0001-9951-2273	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067356] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 067356, R01 DK067356-04, R01 DK067356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; FRASER CC, 1990, BLOOD, V76, P1071; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oike Y, 2005, NAT MED, V11, P400, DOI 10.1038/nm1214; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Sauvageau G, 2004, ONCOGENE, V23, P7223, DOI 10.1038/sj.onc.1207942; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zeng L, 2003, J HUM GENET, V48, P159, DOI 10.1007/s100380300025; Zhang CC, 2005, BLOOD, V105, P4314, DOI 10.1182/blood-2004-11-4418; Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood-2003-08-2955; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	30	281	301	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2006	12	2					240	245		10.1038/nm1342	http://dx.doi.org/10.1038/nm1342			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	010BY	16429146	Green Accepted			2022-12-27	WOS:000235160600031
J	Ch'ang, HJ; Maj, JG; Paris, F; Xing, HR; Zhang, JJ; Truman, JP; Cardon-Cardo, C; Haimovitz-Friedman, A; Kolesnick, R; Fuks, Z				Ch'ang, HJ; Maj, JG; Paris, F; Xing, HR; Zhang, JJ; Truman, JP; Cardon-Cardo, C; Haimovitz-Friedman, A; Kolesnick, R; Fuks, Z			ATM regulates target switching to escalating doses of radiation in the intestines	NATURE MEDICINE			English	Article							STEM-CELLS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; INDUCED APOPTOSIS; MICE; IRRADIATION; EPITHELIUM; PARADIGM; DAMAGE; DEATH	Although stem cells succumbing to reproductive death are assumed to be the single relevant targets in radiation tissue damage, recent studies showed intestinal stem cell damage is conditionally linked to crypt endothelial apoptosis, defining a two-target model. Here we report that when mouse intestines were protected against microvascular apoptosis, radiation switched as the dose escalated to a previously unrecognized crypt stem cell target, activating ceramide synthase-mediated apoptosis to initiate intestinal damage. Whereas ataxia telangiectasia-mutated (ATM) kinase normally represses ceramide synthase, its derepression in Atm(-/-) mice increased crypt stem cell radiosensitivity 3.7-fold without sensitizing the microvascular response. Discovery of this intestinal radiosensitivity mechanism allowed design of an antisense Atm oligonucleotide treatment which phenocopied the Atm(-/-) mouse, reordering ceramide synthase-mediated stem cell death to become the first-line gastrointestinal response of wild-type littermates. These experiments indicate that tissues operate multiple potential targets activated consecutively according to their inherent radiosensitivities that may be reordered therapeutically to control radiation tissue responses.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Natl Taiwan Univ Hosp, Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; Inst Biol, INSERM, U463, F-44093 Nantes, France; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org	Paris, francois E/L-4915-2015; Ch'ang, Hui-Ju/E-3826-2010	Paris, francois E/0000-0002-0176-7348; 	NATIONAL CANCER INSTITUTE [R01CA085704] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA85704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEDFORD JS, 1978, RADIAT RES, V76, P573, DOI 10.2307/3574806; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; BUDACH W, 1993, J NATL CANCER I, V85, P988, DOI 10.1093/jnci/85.12.988; Chu K, 2002, RADIAT RES, V158, P667, DOI 10.1667/0033-7587(2002)158[0667:CVTLCA]2.0.CO;2; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Maj JG, 2003, CANCER RES, V63, P4338; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOORE J V, 1983, Radiotherapy and Oncology, V1, P143, DOI 10.1016/S0167-8140(83)80017-6; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; TROTT KR, 1994, RADIOTHER ONCOL, V30, P1, DOI 10.1016/0167-8140(94)90002-7; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WITHERS HR, 1985, CANCER, V55, P2086, DOI 10.1002/1097-0142(19850501)55:9+<2086::AID-CNCR2820551409>3.0.CO;2-1; WITHERS HR, 1969, RADIAT RES, V38, P598, DOI 10.2307/3572619; WITHERS HR, 1971, CANCER, V28, P75, DOI 10.1002/1097-0142(197107)28:1<75::AID-CNCR2820280115>3.0.CO;2-8	35	108	112	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					484	490		10.1038/nm1237	http://dx.doi.org/10.1038/nm1237			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15864314				2022-12-27	WOS:000228915000019
J	Clemens, J; Jodar, L				Clemens, J; Jodar, L			Introducing new vaccines into developing countries: obstacles, opportunities and complexities	NATURE MEDICINE			English	Editorial Material							TRANSLATIONAL RESEARCH; IMMUNIZATION; VACCINATION; FUTURE; INFECTION; EFFICACY; CHILDREN; TRIAL	Infectious diseases are thought to account for nearly 25% of all deaths worldwide, and extract a disproportionate toll in developing countries(1). Moreover, infectious diseases are now appreciated to be major causes of the poverty and economic underdevelopment that characterize the world's poorest countries(2). Development and deployment of new vaccines to prevent infectious diseases in developing countries have therefore become high priorities in the global health agenda.	Intl Vaccine Inst, Seoul, South Korea		Clemens, J (corresponding author), Intl Vaccine Inst, Seoul, South Korea.	jclemens@ivi.int						Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; [Anonymous], 2002, B WORLD HEALTH ORGAN, V80, P167; Batson A, 2003, VACCINE BOOK, P345; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Clemens JD, 2004, J HEALTH POPUL NUTR, V22, P223; Clements CJ, 2004, VACCINE, V22, P2822, DOI 10.1016/j.vaccine.2004.01.002; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Esparza J, 2003, CURR MOL MED, V3, P183, DOI 10.2174/1566524033479825; Glass RI, 2004, LANCET, V363, P1547, DOI 10.1016/S0140-6736(04)16155-2; GOTUZZO E, 1993, INFECT IMMUN, V61, P3994, DOI 10.1128/IAI.61.9.3994-3997.1993; HANLON P, 1987, LANCET, V1, P1342; Hardon A, 2005, SOC SCI MED, V60, P345, DOI 10.1016/j.socscimed.2004.05.008; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; Levine OS, 2004, J HEALTH POPUL NUTR, V22, P268; Mahoney R, 2004, J HEALTH POPUL NUTR, V22, P331; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Martin JF, 2003, VACCINE, V21, P587, DOI 10.1016/S0264-410X(02)00564-9; Milstien J, 2004, B WORLD HEALTH ORGAN, V82, P128; *NIH NAT I ALL INF, 2002, JORD REP 20 ANN ACC, P261; Salisbury DM, 1998, PEDIATR INFECT DIS J, V17, pS93, DOI 10.1097/00006454-199809001-00002; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Webber D, 2001, B WORLD HEALTH ORGAN, V79, P735; WHO, 2003, WORLD HLTH REP; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713	24	44	45	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4		S			S12	S15		10.1038/nm1225	http://dx.doi.org/10.1038/nm1225			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	915VO	15812482				2022-12-27	WOS:000228339600005
J	Schubert, C				Schubert, C			Oxygen sensor damages DNA	NATURE MEDICINE			English	News Item								Cancer cells often overexpress HIF 1-alpha (hypoxia inducible factor 1-alpha),a transcription factor that regulates responses to low oxygen and inhibits a complex of proteins that repair DNA, MutS-alpha. MutS-alpha consists of two proteins, MSH2 and MSH6. Expression studies have hinted that in sporadic colon cancer, HIF 1-alpha overexpression was associated with the loss of MSH2 expression.										Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015	1	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2005	11	4					385	385						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15812519				2022-12-27	WOS:000228180500026
J	Zhang, R; Khoo, MSC; Wu, YJ; Yang, YB; Grueter, CE; Ni, GM; Price, EE; Thiel, W; Guatimosim, S; Song, LS; Madu, EC; Shah, AN; Vishnivetskaya, TA; Atkinson, JB; Gurevich, VV; Salama, G; Lederer, WJ; Colbran, RJ; Anderson, ME				Zhang, R; Khoo, MSC; Wu, YJ; Yang, YB; Grueter, CE; Ni, GM; Price, EE; Thiel, W; Guatimosim, S; Song, LS; Madu, EC; Shah, AN; Vishnivetskaya, TA; Atkinson, JB; Gurevich, VV; Salama, G; Lederer, WJ; Colbran, RJ; Anderson, ME			Calmodulin kinase II inhibition protects against structural heart disease	NATURE MEDICINE			English	Article							CARDIAC RYANODINE RECEPTOR; VENTRICULAR MYOCYTES; SER(16) PHOSPHORYLATION; DILATED CARDIOMYOPATHY; DEPENDENT FACILITATION; CALCIUM-CHANNELS; ANGIOTENSIN-II; CA2+ CURRENT; EXCITATION; FAILURE	beta-Adrenergic receptor (beta AR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive beta AR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II ( CaMKII) is a recently identified downstream element of the beta AR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in beta AR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive beta AR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and beta AR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to beta AR signaling.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21021 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil; Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University System of Maryland; University of Maryland Baltimore; Universidade Federal de Minas Gerais; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University	Anderson, ME (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 2220 Pierce Ave, Nashville, TN 37232 USA.	mark.anderson@vanderbilt.edu	Salama, Guy/GWQ-9862-2022; Guatimosim, Silvia/AAN-7441-2021; Vishnivetskaya, Tatiana/A-4488-2008; Song, Long-Sheng/D-5899-2012; Gurevich, Vsevolod/A-3236-2008; Colbran, Roger/AAU-7708-2021; Lederer, William/B-1285-2010	Guatimosim, Silvia/0000-0001-8386-3722; Vishnivetskaya, Tatiana/0000-0002-0660-023X; Gurevich, Vsevolod/0000-0002-3950-5351; Colbran, Roger/0000-0001-7401-8244; MADU, ERNEST/0000-0001-5739-2816; Grueter, Chad/0000-0001-8950-742X; Song, Long-Sheng/0000-0002-6035-8106; Thiel, William/0000-0002-2372-2925	NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL070250, HL046681, HL70709, HL70511, HL67849, HL25675, HL36974] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NIMH NIH HHS [MH63232] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL070250, R01HL025675, R01HL070511, P01HL067849, R01HL036974, P01HL070709, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alseikhan BA, 2002, P NATL ACAD SCI USA, V99, P17185, DOI 10.1073/pnas.262372999; ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; Benitah JP, 1999, CIRC RES, V85, P1139; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; Cannon WB, 1911, AM J PHYSIOL, V28, P64, DOI 10.1152/ajplegacy.1911.28.1.64; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Choi BR, 1998, AM J PHYSIOL-HEART C, V274, pH829, DOI 10.1152/ajpheart.1998.274.3.H829; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; Chu L, 2003, CIRC RES, V92, P1024, DOI 10.1161/01.RES.0000070595.10196.CF; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Currie S, 2004, BIOCHEM J, V377, P357, DOI 10.1042/BJ20031043; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HADLEY RW, 1991, J GEN PHYSIOL, V98, P265, DOI 10.1085/jgp.98.2.265; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hjalmarson A, 1999, LANCET, V353, P2001; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Ichihara S, 2002, CIRCULATION, V106, P2244, DOI 10.1161/01.CIR.0000033826.52681.37; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kudej RK, 1997, J MOL CELL CARDIOL, V29, P2735, DOI 10.1006/jmcc.1997.0508; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Muth JN, 2001, CIRCULATION, V103, P140; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Patberg KW, 2003, CIRC RES, V93, P472, DOI 10.1161/01.RES.0000088785.24381.2F; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Rottman JN, 2003, J AM SOC ECHOCARDIOG, V16, P1150, DOI 10.1067/S0894-7317(03)00471-1; Sah R, 2001, J PHYSIOL-LONDON, V533, P201, DOI 10.1111/j.1469-7793.2001.0201b.x; Vinogradova TM, 2000, CIRC RES, V87, P760, DOI 10.1161/01.RES.87.9.760; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wu YJ, 2002, CIRCULATION, V106, P1288, DOI 10.1161/01.CIR.0000027583.73268.E7; Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	50	445	471	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2005	11	4					409	417		10.1038/nm1215	http://dx.doi.org/10.1038/nm1215			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	913UU	15793582				2022-12-27	WOS:000228180500032
J	Day, SE; Kettunen, MI; Gallagher, FA; Hu, DE; Lerche, M; Wolber, J; Golman, K; Ardenkjaer-Larsen, JH; Brindle, KM				Day, Sam E.; Kettunen, Mikko I.; Gallagher, Ferdia A.; Hu, De-En; Lerche, Mathilde; Wolber, Jan; Golman, Klaes; Ardenkjaer-Larsen, Jan Henrik; Brindle, Kevin M.			Detecting tumor response to treatment using hyperpolarized C-13 magnetic resonance imaging and spectroscopy	NATURE MEDICINE			English	Article							EMISSION-TOMOGRAPHY; APOPTOSIS; THERAPY; INHIBITION; INDUCTION; CELLS; P-31	Measurements of early tumor responses to therapy have been shown, in some cases, to predict treatment outcome. We show in lymphoma-bearing mice injected intravenously with hyperpolarized [1-C-13] pyruvate that the lactate dehydrogenase-catalyzed flux of C-13 label between the carboxyl groups of pyruvate and lactate in the tumor can be measured using 13C magnetic resonance spectroscopy and spectroscopic imaging, and that this flux is inhibited within 24 h of chemotherapy. The reduction in the measured flux after drug treatment and the induction of tumor cell death can be explained by loss of the coenzyme NAD(H) and decreases in concentrations of lactate and enzyme in the tumors. The technique could provide a new way to assess tumor responses to treatment in the clinic.	Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; Imagnia AB, S-20041 Malmo, Sweden; GE Healthcare, Grove Ctr, Amersham HP7 9LL, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; General Electric	Brindle, KM (corresponding author), Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	kmb@mole.bio.cam.ac.uk	Kettunen, Mikko I/K-2299-2012; Ardenkjær-Larsen, Jan Henrik/B-5765-2017; Lerche, Mathilde Hauge/J-5487-2017	Kettunen, Mikko I/0000-0002-2004-660X; Ardenkjær-Larsen, Jan Henrik/0000-0001-6167-6926; Gallagher, Ferdia Aidan/0000-0003-4784-5230; Lerche, Mathilde Hauge/0000-0002-5899-2781				Aboagye EO, 1998, CANCER RES, V58, P1063; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; BRINDLE KM, 1986, EUR J BIOCHEM, V158, P299, DOI 10.1111/j.1432-1033.1986.tb09751.x; BRINDLE KM, 1988, PROG NUCL MAG RES SP, V20, P257, DOI 10.1016/0079-6565(88)80003-7; Czernin J, 2006, ANNU REV MED, V57, P99, DOI 10.1146/annurev.med.57.080904.190431; Filipovic DM, 1999, AM J PHYSIOL-RENAL, V277, pF428, DOI 10.1152/ajprenal.1999.277.3.F428; Golman K, 2003, P NATL ACAD SCI USA, V100, P10435, DOI 10.1073/pnas.1733836100; Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564; Golman K, 2006, ACAD RADIOL, V13, P932, DOI 10.1016/j.acra.2006.06.001; Golman K, 2006, P NATL ACAD SCI USA, V103, P11270, DOI 10.1073/pnas.0601319103; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Kettunen MI, 2005, PROG NUCL MAG RES SP, V47, P175, DOI 10.1016/j.pnmrs.2005.08.005; Moffat BA, 2005, P NATL ACAD SCI USA, V102, P5524, DOI 10.1073/pnas.0501532102; Neves AA, 2006, BBA-REV CANCER, V1766, P242, DOI 10.1016/j.bbcan.2006.10.002; Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5; Poptani H, 2003, NMR BIOMED, V16, P102, DOI 10.1002/nbm.816; Ross BD, 2003, MOL CANCER THER, V2, P581; Schmitz JE, 2005, MAGN RESON MED, V54, P43, DOI 10.1002/mrm.20529; SHULMAN RG, 1979, SCIENCE, V205, P160, DOI 10.1126/science.36664; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Stroobants S, 2003, EUR J CANCER, V39, P2012, DOI 10.1016/S0959-8049(03)00073-X; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Weber WA, 2006, J CLIN ONCOL, V24, P3282, DOI 10.1200/JCO.2006.06.6068; Williams SNO, 1998, MAGNET RESON MED, V40, P411, DOI 10.1002/mrm.1910400311; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241	26	690	705	1	117	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2007	13	11					1382	1387		10.1038/nm1650	http://dx.doi.org/10.1038/nm1650			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17965722				2022-12-27	WOS:000250736900033
J	Huang, JL; Wang, FX; Argyris, E; Chen, KY; Liang, ZH; Tian, H; Huang, WL; Squires, K; Verlinghieri, G; Zhang, H				Huang, Jialing; Wang, Fengxiang; Argyris, Elias; Chen, Keyang; Liang, Zhihui; Tian, Heng; Huang, Wenlin; Squires, Kathleen; Verlinghieri, Gwen; Zhang, Hui			Cellular microRNAs contribute to HIV-1 latency in resting primary CD4(+) T lymphocytes	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; IN-VIVO; RNA; CELLS; REPLICATION; IDENTIFICATION; RECRUITMENT; SUPPRESSION	The latency of human immunodeficiency virus type 1 ( HIV- 1) in resting primary CD4(+) T cells is the major barrier for the eradication of the virus in patients on suppressive highly active antiretroviral therapy ( HAART). Even with optimal HAART treatment, replication- competent HIV- 1 still exists in resting primary CD4(+) T cells(1-4). Multiple restriction factors that act upon various steps of the viral life cycle could contribute to viral latency. Here we show that cellular microRNAs ( miRNAs) potently inhibit HIV- 1 production in resting primary CD4(+) T cells. We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR- 28, miR-125b, miR- 150, miR- 223 and miR- 382, which are enriched in resting CD4(+) T cells as compared to activated CD4(+) T cells. Specific inhibitors of these miRNAs substantially counteracted their effects on the target mRNAs, measured either as HIV- 1 protein translation in resting CD4(+) T cells transfected with HIV- 1 infectious clones, or as HIV- 1 virus production from resting CD4(+) T cells isolated from HIV-1 infected individuals on suppressive HAART. Our data indicate that cellular miRNAs are pivotal in HIV-1 latency and suggest that manipulation of cellular miRNAs could be a novel approach for purging the HIV-1 reservoir.	Thomas Jefferson Univ, Dept Med, Div Infect Dis, Ctr Human Virol, Philadelphia, PA 19107 USA; Sun Yat Sen Univ, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Jefferson University; Sun Yat Sen University	Zhang, H (corresponding author), Thomas Jefferson Univ, Dept Med, Div Infect Dis, Ctr Human Virol, Philadelphia, PA 19107 USA.	hui.zhang@jefferson.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052732, R01AI058798] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen KY, 2006, J VIROL, V80, P7645, DOI 10.1128/JVI.00206-06; Chun TW, 2003, P NATL ACAD SCI USA, V100, P1908, DOI 10.1073/pnas.0437640100; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kim YK, 2006, EMBO J, V25, P3596, DOI 10.1038/sj.emboj.7601248; Lassen KG, 2006, PLOS PATHOG, V2, P650, DOI 10.1371/journal.ppat.0020068; Lassen KG, 2004, J VIROL, V78, P9105, DOI 10.1128/JVI.78.17.9105-9114.2004; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Patterson BK, 2001, AIDS, V15, P1635, DOI 10.1097/00002030-200109070-00005; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319; Wang FX, 2005, J CLIN INVEST, V115, P128, DOI 10.1172/JCI200522574; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	29	595	640	0	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2007	13	10					1241	1247		10.1038/nm1639	http://dx.doi.org/10.1038/nm1639			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17906637				2022-12-27	WOS:000249980200041
J	McAteer, MA; Sibson, NR; von zur Muhlen, C; Schneider, JE; Lowe, AS; Warrick, N; Channon, KM; Anthony, DC; Choudhury, RP				McAteer, Martina A.; Sibson, Nicola R.; von zur Muhlen, Constantin; Schneider, Jurgen E.; Lowe, Andrew S.; Warrick, Nicholas; Channon, Keith M.; Anthony, Daniel C.; Choudhury, Robin P.			In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; DIAGNOSTIC-CRITERIA; ADHESION MOLECULES; ENDOTHELIAL-CELLS; MRI DETECTION; VCAM-1; ICAM-1; ATHEROSCLEROSIS; ACTIVATION	Multiple sclerosis is a disease of the central nervous system that is associated with leukocyte recruitment and subsequent inflammation, demyelination and axonal loss. Endothelial vascular cell adhesion molecule- 1 ( VCAM- 1) and its ligand, alpha(4)beta(1) integrin, are key mediators of leukocyte recruitment, and selective inhibitors that bind to the alpha(4) subunit of alpha(4)beta(1) substantially reduce clinical relapse in multiple sclerosis. Urgently needed is a molecular imaging technique to accelerate diagnosis, to quantify disease activity and to guide specific therapy. Here we report in vivo detection of VCAM- 1 in acute brain inflammation, by magnetic resonance imaging in a mouse model, at a time when pathology is otherwise undetectable. Antibody- conjugated microparticles carrying a large amount of iron oxide provide potent, quantifiable contrast effects that delineate the architecture of activated cerebral blood vessels. Their rapid clearance from blood results in minimal background contrast. This technology is adaptable to monitor the expression of endovascular molecules in vivo in various pathologies.	Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Dept Physiol Anat & Genet, Expt Neuroimaging Grp, Oxford OX1 3PT, England; Dept Pharmacol, Oxford OX1 3QX, England	University of Oxford; University of Oxford	Choudhury, RP (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	robin.choudhury@cardiov.ox.ac.uk	McAteer, Martina/AAD-8628-2022; Lowe, Andrew S/J-4801-2013; Anthony, Daniel/F-7765-2010	Lowe, Andrew S/0000-0001-6650-7486; Anthony, Daniel/0000-0003-1380-6655; McAteer (Duric), Martina/0000-0002-7350-4651; channon, keith/0000-0002-1043-4342	MRC [G0300456, G9900989] Funding Source: UKRI; Medical Research Council [G9900989, G0300456] Funding Source: Medline; Wellcome Trust [076994, 088291] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aime S, 2002, J MAGN RESON IMAGING, V16, P394, DOI 10.1002/jmri.10180; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Briley-Saebo K, 2004, CELL TISSUE RES, V316, P315, DOI 10.1007/s00441-004-0884-8; CARLOS TM, 1990, BLOOD, V76, P965; Chen HH, 2005, MAGN RESON MED, V53, P614, DOI 10.1002/mrm.20395; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Dedrick RL, 2003, EXPERT OPIN BIOL TH, V3, P85, DOI 10.1517/eobt.3.1.85.20954; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Goldberg-Zimring D, 2005, J NEUROIMAGING, V15, p68S, DOI 10.1177/1051228405283363; Gosk S, 2005, Int J Clin Pharmacol Ther, V43, P581; Guttmann CRG, 2006, MAGN RESON IMAGING, V24, P475, DOI 10.1016/j.mri.2005.12.038; Maurer CA, 1998, INT J CANCER, V79, P76, DOI 10.1002/(SICI)1097-0215(19980220)79:1<76::AID-IJC15>3.0.CO;2-F; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Nahrendorf M, 2006, CIRCULATION, V114, P1504, DOI 10.1161/CIRCULATIONAHA.106.646380; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OROSZ CG, 1992, IMMUNOL LETT, V32, P7, DOI 10.1016/0165-2478(92)90191-P; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Reinhardt M, 2005, NEUROIMAGE, V27, P267, DOI 10.1016/j.neuroimage.2005.04.019; Ropele S, 2000, AM J NEURORADIOL, V21, P1885; Sakhalkar HS, 2003, P NATL ACAD SCI USA, V100, P15895, DOI 10.1073/pnas.2631433100; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Sibson NR, 2004, MAGN RESON MED, V51, P248, DOI 10.1002/mrm.10723; Sipkins DA, 2000, J NEUROIMMUNOL, V104, P1, DOI 10.1016/S0165-5728(99)00248-9; Villanueva FS, 1998, CIRCULATION, V98, P1, DOI 10.1161/01.CIR.98.1.1; Will O, 2006, LANCET ONCOL, V7, P52, DOI 10.1016/S1470-2045(05)70537-4; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	28	220	225	3	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2007	13	10					1253	1258		10.1038/nm1631	http://dx.doi.org/10.1038/nm1631			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217XI	17891147	Green Accepted			2022-12-27	WOS:000249980200043
J	Medyouf, H; Alcalde, H; Berthier, C; Guillemin, MC; dos Santos, NR; Janin, A; Decaudin, D; de The, H; Ghysdael, J				Medyouf, Hind; Alcalde, Helene; Berthier, Caroline; Guillemin, Marie Claude; dos Santos, Nuno R.; Janin, Anne; Decaudin, Didier; de The, Hugues; Ghysdael, Jacques			Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; DEFICIENT MICE; NFAT; LYMPHOMA; TEL-JAK2; INDUCTION; PROTEINS; NOTCH1; VIRUS; MYC	Calcineurin is a calcium-activated serine/threonine phosphatase critical to a number of developmental processes in the cardiovascular, nervous and immune systems. In the T-cell lineage, calcineurin activation is important for pre-T-cell receptor (TCR) signaling, TCR-mediated positive selection of thymocytes into mature T cells, and many aspects of the immune response 1,2. The critical role of calcineurin in the immune response is underscored by the fact that calcineurin inhibitors, such as cyclosporin A (CsA) and FK506, are powerful immunosuppressants in wide clinical use. We observed sustained calcineurin activation in human B-and T-cell lymphomas and in all mouse models of lymphoid malignancies analyzed. In intracellular NOTCH1 (ICN1)-and TEL-JAK2-induced T-cell lymphoblastic leukemia3-5, two mouse models relevant to human malignancies6-8, in vivo inhibition of calcineurin activity by CsA or FK506 induced apoptosis of leukemic cells and rapid tumor clearance, and substantially prolonged mouse survival. In contrast, ectopic expression of a constitutively activated mutant of calcineurin favored leukemia progression. Moreover, CsA treatment induced apoptosis in human lymphoma and leukemia cell lines. Thus, calcineurin activation is critical for the maintenance of the leukemic phenotype in vivo, identifying this pathway as a relevant therapeutic target in lymphoid malignancies.	Ctr Univ Orsay, Inst Curie, F-91405 Orsay, France; Ctr Univ, Unite Mixt Rech 146, CNRS, F-91405 Orsay, France; Univ Paris 07, CNRS, Unite Mixte Rech 7151, Hop St Louis, F-75475 Paris, France; Univ Paris 07, Inst Natl Sante & Rech Med, Unite 728, Hop St Louis, F-75475 Paris, France; Inst Curie, Dept Clin Hematol, F-75248 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ghysdael, J (corresponding author), Ctr Univ Orsay, Inst Curie, Batiment 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013; dos Santos, Nuno Rodrigues/F-4411-2012	dos Santos, Nuno Rodrigues/0000-0001-7347-2592; Medyouf, Hind/0000-0003-4652-9455				Abramson JS, 2005, BLOOD, V106, P1164, DOI 10.1182/blood-2005-02-0687; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Carron C, 2000, BLOOD, V95, P3891; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Decaudin D, 2006, ANTI-CANCER DRUG, V17, P685, DOI 10.1097/01.cad.0000215061.78189.4e; dos Santos NR, 2007, BLOOD, V109, P3972, DOI 10.1182/blood-2006-09-048801; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glud SZ, 2005, BLOOD, V106, P3546, DOI 10.1182/blood-2005-02-0493; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ke HM, 2003, BIOCHEM BIOPH RES CO, V311, P1095, DOI 10.1016/S0006-291X(03)01537-7; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Marafiot T, 2005, BRIT J HAEMATOL, V128, P333, DOI 10.1111/j.1365-2141.2004.05313.x; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zhao WL, 2004, LAB INVEST, V84, P1512, DOI 10.1038/labinvest.3700145	30	120	126	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2007	13	6					736	741		10.1038/nm1588	http://dx.doi.org/10.1038/nm1588			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	176KQ	17515895				2022-12-27	WOS:000247084300038
J	Pei, LM; Waki, H; Vaitheesvaran, B; Wilpitz, DC; Kurland, IJ; Tontonoz, P				Pei, Liming; Waki, Hironori; Vaitheesvaran, Bhavapriya; Wilpitz, Damien C.; Kurland, Irwin J.; Tontonoz, Peter			NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism	NATURE MEDICINE			English	Article							MASS ISOTOPOMER ANALYSIS; INSULIN-RESISTANCE; PPAR-GAMMA; NGFI-B; GLUCONEOGENESIS; INDUCTION; LIVER; GENE; IDENTIFICATION; REQUIREMENT	Hepatic glucose production is crucial for glucose homeostasis, and its dysregulation contributes to the pathogenesis of diabetes. Here, we show that members of the NR4A family of ligand-independent orphan nuclear receptors are downstream mediators of cAMP action in the hormonal control of gluconeogenesis. Hepatic expression of Nur77, Nurr1 and NOR1 is induced by the cAMP axis in response to glucagon and fasting in vivo and is increased in diabetic mice that exhibit elevated gluconeogenesis. Adenoviral expression of Nur77 induces genes involved in gluconeogenesis, stimulates glucose production both in vitro and in vivo, and raises blood glucose levels. Conversely, expression of an inhibitory mutant Nur77 receptor antagonizes gluconeogenic gene expression and lowers blood glucose levels in db/db mice. These results outline a previously unrecognized role for orphan nuclear receptors in the transcriptional control of glucose homeostasis.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu	Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793; Pei, Liming/0000-0002-1924-0333	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK058132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568] Funding Source: Medline; NIDDK NIH HHS [DK58132, R01 DK058132-06, P30 DK041301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Erion MD, 2005, P NATL ACAD SCI USA, V102, P7970, DOI 10.1073/pnas.0502983102; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; KATZ J, 1989, J BIOL CHEM, V264, P12994; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Montminy M, 2004, ANN ENDOCRINOL-PARIS, V65, P73, DOI 10.1016/S0003-4266(04)95634-X; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; SZAFRANECK J, 1974, CARBOHYD RES, V38, P97, DOI 10.1016/S0008-6215(00)82341-1; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002	49	251	258	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1048	1055		10.1038/nm1471	http://dx.doi.org/10.1038/nm1471			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906154				2022-12-27	WOS:000240373900029
J	Chen, G; Qian, H; Starz, T; Sun, HT; Garcia, B; Wang, XM; Wise, Y; Liu, YQ; Xiang, Y; Copeman, L; Liu, WH; Jevnikar, A; Wall, W; Cooper, DKC; Murase, N; Dai, YF; Wang, WY; Xiong, YL; White, DJ; Zhong, R				Chen, G; Qian, H; Starz, T; Sun, HT; Garcia, B; Wang, XM; Wise, Y; Liu, YQ; Xiang, Y; Copeman, L; Liu, WH; Jevnikar, A; Wall, W; Cooper, DKC; Murase, N; Dai, YF; Wang, WY; Xiong, YL; White, DJ; Zhong, R			Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys	NATURE MEDICINE			English	Article							NATURAL ANTIBODIES; VASCULAR REJECTION; TRANSPLANTATION; SURVIVAL; DONORS; HEARTS	We transplanted kidneys from alpha 1,3-galactosyltransferase knockout (GalT-KO) pigs into six baboons using two different immunosuppressive regimens, but most of the baboons died from severe acute humoral xenograft rejection. Circulating induced antibodies to non-Gal antigens were markedly elevated at rejection, which mediated strong complement-dependent cytotoxicity against GaIT-KO porcine target cells. These data suggest that antibodies to non-Gal antigens will present an additional barrier to transplantation of organs from GaIT-KO pigs to humans.	Univ Western Ontario, Dept Surg, London, ON N6A 5C1, Canada; Univ Pittsburgh, Ctr Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA; Univ Western Ontario, Dept Pathol, London, ON N6A 5A5, Canada; Robarts Res Inst, Transplantat Grp, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5A5, Canada; London Hlth Sci Ctr, Lawson Hlth Res Inst, London, ON N6A 5A5, Canada; London Hlth Sci Ctr, Multi Organ Transplant Program, London, ON N6A 5A5, Canada; Revivcor Inc, Blacksburg, VA 24060 USA; Chinese Acad Sci, Kunming Inst Zool, Anim Toxicol Lab, Kunming, Peoples R China; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; United Therapeutics Corporation; Revivicor Inc.; Chinese Academy of Sciences; Kunming Institute of Zoology; Western University (University of Western Ontario)	Zhong, R (corresponding author), Univ Western Ontario, Dept Surg, London, ON N6A 5C1, Canada.	mangantl@upmc.edu; zzhong@uwo.ca	Jevnikar, Anthony M./G-3309-2011	Yang, Haiyuan/0000-0001-5253-0079	NIAID NIH HHS [AI38899] Funding Source: Medline; NIDDK NIH HHS [R01DK64207, R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064207, R01DK029961] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhatti FNK, 1999, TRANSPLANT P, V31, P958, DOI 10.1016/S0041-1345(98)01855-7; CHEN G, IN PRESS TRANSPLANTA; Collins Braldey H., 1994, Xenotransplantation, V1, P36, DOI 10.1111/j.1399-3089.1994.tb00048.x; Cooper D K, 1993, Transpl Immunol, V1, P198, DOI 10.1016/0966-3274(93)90047-C; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; Knechtle SJ, 2003, IMMUNOL REV, V196, P237, DOI 10.1046/j.1600-065X.2003.00086.x; Kuwaki K, 2005, NAT MED, V11, P29, DOI 10.1038/nm1171; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Starzl TE, 2003, LANCET, V361, P1502, DOI 10.1016/S0140-6736(03)13175-3; Xu Y, 1998, TRANSPLANTATION, V65, P172; Yamada K, 2005, NAT MED, V11, P32, DOI 10.1038/nm1172; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014	15	271	289	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1295	1298		10.1038/nm1330	http://dx.doi.org/10.1038/nm1330			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16311604	Green Accepted			2022-12-27	WOS:000233774400027
J	Kermorvant-Duchemin, E; Sennlaub, F; Sirinyan, M; Brault, S; Andelfinger, G; Kooli, A; Germain, S; Ong, H; d'Orleans-Juste, P; Gobeil, F; Zhu, T; Boisvert, C; Hardy, P; Jain, K; Falck, JR; Balazy, M; Chemtob, S				Kermorvant-Duchemin, E; Sennlaub, F; Sirinyan, M; Brault, S; Andelfinger, G; Kooli, A; Germain, S; Ong, H; d'Orleans-Juste, P; Gobeil, F; Zhu, T; Boisvert, C; Hardy, P; Jain, K; Falck, JR; Balazy, M; Chemtob, S			Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RETINAL VASCULAR DEVELOPMENT; OXYGEN-INDUCED RETINOPATHY; NITRIC-OXIDE; VITAMIN-E; TYROSINE NITRATION; REGULATED KINASE; NITROGEN-DIOXIDE; CELL APOPTOSIS; NEOVASCULARIZATION	Nitrative stress has an important role in microvascular degeneration leading to ischemia in conditions such as diabetic retinopathy and retinopathy of prematurity. Thus far, mediators of nitrative stress have been poorly characterized. We recently described that trans-arachidonic acids are major products of NO2 center dot-mediated isomerization of arachidonic acid within the cell membrane, but their biological relevance is unknown. Here we show that trans-arachidonic acids are generated in a model of retinal microangiopathy in vivo in a NO center dot-dependent manner. They induce a selective time- and concentration-dependent apoptosis of microvascular endothelial cells in vitro, and result in retinal microvascular degeneration ex vivo and in vivo. These effects are mediated by an upregulation of the antiangiogenic factor thrombospondin-1, independently of classical arachidonic acid metabolism. Our findings provide new insight into the molecular mechanisms of nitrative stress in microvascular injury and suggest new therapeutic avenues in the management of disorders involving nitrative stress, such as ischemic retinopathies and encephalopathies.	Hop St Justine, Res Ctr, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ H3T 1C5, Canada; Inst Biomed Cordeliers, INSERM, Unite 598, F-75006 Paris, France; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Coll France, F-75006 Paris, France; INSERM, Unite 36, F-75006 Paris, France; Univ Montreal, Dept Pharm, Montreal, PQ H3C 3J7, Canada; Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; McGill University; UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; University of Sherbrooke; New York Medical College; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chemtob, S (corresponding author), Hop St Justine, Res Ctr, Dept Pediat Ophthalmol & Pharmacol, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	michael_balazy@nymc.edu; sylvain.chemtob@umontreal.ca	Sennlaub, Florian/F-2756-2017; Germain, Stephane/E-2301-2016	Sennlaub, Florian/0000-0003-4412-1341; Germain, Stephane/0000-0001-5992-1275; Balazy, Ph.D., Michael/0000-0003-0218-8820; Falck, John/0000-0002-9219-7845; Boisvert, Chantal/0000-0002-7642-1843	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062453] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62453, R01 GM062453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; Balazy M, 2000, J PHYSIOL PHARMACOL, V51, P597; Balazy Michael, 2004, Current Vascular Pharmacology, V2, P81, DOI 10.2174/1570161043476465; Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008; Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279; Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222; Caffe AR, 2001, J CHEM NEUROANAT, V22, P263; Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H; CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022; El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5; FLYNN JT, 1992, NEW ENGL J MED, V326, P1050, DOI 10.1056/NEJM199204163261603; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002; Guo NH, 1997, CANCER RES, V57, P1735; Hardy P, 2000, CARDIOVASC RES, V47, P489, DOI 10.1016/S0008-6363(00)00084-5; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jiang HL, 1999, J BIOL CHEM, V274, P16235, DOI 10.1074/jbc.274.23.16235; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kirsch M, 2002, BIOL CHEM, V383, P389, DOI 10.1515/BC.2002.043; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; Kroncke KD, 2003, BIOL CHEM, V384, P1341; Lahaie I, 1998, AM J PHYSIOL-REG I, V274, pR1406, DOI 10.1152/ajpregu.1998.274.5.R1406; Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Llorens Silvia, 2003, Current Vascular Pharmacology, V1, P335, DOI 10.2174/1570161033476637; MANN RM, 1995, INVEST OPHTH VIS SCI, V36, P925; NIELSEN JC, 1988, INVEST OPHTH VIS SCI, V29, P22; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Okuno M, 2002, FEBS LETT, V519, P108, DOI 10.1016/S0014-5793(02)02720-5; Penn JS, 1997, FREE RADICAL BIO MED, V22, P977, DOI 10.1016/S0891-5849(96)00479-0; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Raju TNK, 1997, J PEDIATR-US, V131, P844, DOI 10.1016/S0022-3476(97)70031-3; Roy U, 2004, BIOORG MED CHEM LETT, V14, P1019, DOI 10.1016/j.bmcl.2003.11.054; Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00; Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030; Spierer A, 2005, EYE, V19, P86, DOI 10.1038/sj.eye.6701424; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; SWERLICK RA, 1992, J IMMUNOL, V148, P78; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412; Zghibeh CM, 2004, ANAL BIOCHEM, V332, P137, DOI 10.1016/j.ab.2004.04.030	50	81	83	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2005	11	12					1339	1345		10.1038/nm1336	http://dx.doi.org/10.1038/nm1336			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	990WR	16311602	Green Accepted, Green Published			2022-12-27	WOS:000233774400033
J	Chen, JH; Somanath, PR; Razorenova, O; Chen, WS; Hay, N; Bornstein, P; Byzova, TV				Chen, JH; Somanath, PR; Razorenova, O; Chen, WS; Hay, N; Bornstein, P; Byzova, TV			Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; TUMOR-GROWTH; EXTRACELLULAR-MATRIX; PROGENITOR CELLS; MICE; ACTIVATION; BONE; THROMBOSPONDIN-1; MOBILIZATION	Akt kinases control essential cellular functions, including proliferation, apoptosis, metabolism and transcription, and have been proposed as promising targets for treatment of angiogenesis-dependent pathologies, such as cancer and ischemic injury. But their precise roles in neovascularization remain elusive. Here we show that Akt1 is the predominant isoform in vascular cells and describe the unexpected consequences of Akt1 knockout on vascular integrity and pathological angiogenesis. Angiogenic responses in three distinct in vivo models were enhanced in Akt1(-/-) mice; these enhanced responses were associated with impairment of blood vessel maturation and increased vascular permeability. Although impaired vascular maturation in Akt1(-/-) mice may be attributed to reduced activation of endothelial nitric oxide synthase ( eNOS), the major phenotypic changes in vascular permeability and angiogenesis were linked to reduced expression of two endogenous vascular regulators, thrombospondins 1 ( TSP-1) and 2 ( TSP-2). Re-expression of TSP-1 and TSP-2 in mice transplanted with wild-type bone marrow corrected the angiogenic abnormalities in Akt1(-/-) mice. These findings establish a crucial role of an Akt-thrombospondin axis in angiogenesis.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle	Byzova, TV (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org	Razorenova, Olga V/A-6400-2014	Byzova, Tatiana/0000-0002-2615-875X; Rammohan Shenoy, Somanath/0000-0003-3017-0230	NATIONAL CANCER INSTITUTE [R01CA090764] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER; NCI NIH HHS [CA90764, R01 CA090764] Funding Source: Medline; NHLBI NIH HHS [HL071625, R01 HL071625] Funding Source: Medline; NIDDK NIH HHS [R01 DK060933, DK060933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Armstrong LC, 2002, MOL BIOL CELL, V13, P1893, DOI 10.1091/mbc.E01-09-0066; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Bornstein P, 2004, INT J BIOCHEM CELL B, V36, P1115, DOI 10.1016/j.biocel.2004.01.012; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Lange-Asschenfeldt B, 2002, BLOOD, V99, P538, DOI 10.1182/blood.V99.2.538; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nagoshi T, 2005, J CLIN INVEST, V115, P2128, DOI 10.1172/JCI23073; Narizhneva NV, 2005, FASEB J, V19, P1158, DOI 10.1096/fj.04-3310fje; O'Neill BT, 2005, J CLIN INVEST, V115, P2059, DOI 10.1172/JCI25900; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Simantov R, 2003, FRONT BIOSCI-LANDMRK, V8, pS874, DOI 10.2741/1168; Soula-Rothhut M, 2005, EXP CELL RES, V304, P187, DOI 10.1016/j.yexcr.2004.10.026; Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102	45	328	346	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2005	11	11					1188	1196		10.1038/nm1307	http://dx.doi.org/10.1038/nm1307			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	981VF	16227992	Green Accepted			2022-12-27	WOS:000233115400031
J	Hammarlund, E; Lewis, MW; Carter, SV; Amanna, I; Hansen, SG; Strelow, LI; Wong, SW; Yoshihara, P; Hanifin, JM; Slifka, MK				Hammarlund, E; Lewis, MW; Carter, SV; Amanna, I; Hansen, SG; Strelow, LI; Wong, SW; Yoshihara, P; Hanifin, JM; Slifka, MK			Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox	NATURE MEDICINE			English	Article							EMERGING INFECTIONS; SMALLPOX; DISEASE; VARIOLA; COWPOX; CONGO	Approximately 50% of the US population received smallpox vaccinations before routine immunization ceased in 1972 for civilians and in 1990 for military personnel. Several studies have shown long- term immunity after smallpox vaccination, but skepticism remains as to whether this will translate into full protection against the onset of orthopoxvirus- induced disease. The US monkeypox outbreak of 2003 provided the opportunity to examine this issue. Using independent and internally validated diagnostic approaches with >= 95% sensitivity and >= 90% specificity for detecting clinical monkeypox infection, we identified three previously unreported cases of monkeypox in preimmune individuals at 13, 29 and 48 years after smallpox vaccination. These individuals were unaware that they had been infected because they were spared any recognizable disease symptoms. Together, this shows that the US monkeypox outbreak was larger than previously realized and, more importantly, shows that cross- protective antiviral immunity against West African monkeypox can potentially be maintained for decades after smallpox vaccination.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu		Amanna, Ian/0000-0001-7545-4013; Lewis, Matthew/0000-0002-6241-3690	NCRR NIH HHS [M01 RR000334, RR00163, P51 RR000163, 5 M01 RR00334] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334, P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amara RR, 2004, J VIROL, V78, P3811, DOI 10.1128/JVI.78.8.3811-3816.2004; Anderson MG, 2003, PEDIATR INFECT DIS J, V22, P1093, DOI 10.1097/01.inf.0000101821.61387.a5; BAXBY D, 1994, BRIT J DERMATOL, V131, P598, DOI 10.1111/j.1365-2133.1994.tb04969.x; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P537; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P642; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; ESPOSITO JJ, 1977, J MED VIROL, V1, P35, DOI 10.1002/jmv.1890010107; Gross E, 2003, ANN EMERG MED, V42, P660, DOI 10.1016/S0196-0644(03)00819-9; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hawranek T, 2003, J AM ACAD DERMATOL, V49, P513, DOI 10.1067/S0190-9622(03)00762-X; HEINER GG, 1971, AM J EPIDEMIOL, V94, P252, DOI 10.1093/oxfordjournals.aje.a121319; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; HUTCHINSON HD, 1977, B WORLD HEALTH ORGAN, V55, P613; Hutin YJF, 2001, EMERG INFECT DIS, V7, P434; Ibrahim MS, 2003, J CLIN MICROBIOL, V41, P3835, DOI 10.1128/JCM.41.8.3835-3839.2003; JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551; JEZEK Z, 1987, J INFECT DIS, V156, P293, DOI 10.1093/infdis/156.2.293; JEZEK Z, 1988, TROP GEOGR MED, V40, P73; JEZEK Z, 1987, J TROP MED HYG, V90, P31; Klein Kelly R, 2004, Prehosp Disaster Med, V19, P256; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; Meyer H, 2002, J CLIN MICROBIOL, V40, P2919, DOI 10.1128/JCM.40.8.2919-2921.2002; Pelkonen PM, 2003, EMERG INFECT DIS, V9, P1458, DOI 10.3201/eid0911.020814; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307; Seward JF, 2004, CLIN INFECT DIS, V39, P1477, DOI 10.1086/425500; Shchelkunov SN, 2002, VIROLOGY, V297, P172, DOI 10.1006/viro.2002.1446; Slifka MK, 2004, CURR OPIN IMMUNOL, V16, P443, DOI 10.1016/j.coi.2004.05.013; Smith GL, 2002, NAT REV IMMUNOL, V2, P521, DOI 10.1038/nri845; 2003, MMWR MORB MORTAL WKL, V52, P561	30	107	112	4	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2005	11	9					1005	1011		10.1038/nm1273	http://dx.doi.org/10.1038/nm1273			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	962IL	16086024				2022-12-27	WOS:000231724700030
J	Koga, T; Matsui, Y; Asagiri, M; Kodama, T; de Crombrugghe, B; Nakashima, K; Takayanagi, H				Koga, T; Matsui, Y; Asagiri, M; Kodama, T; de Crombrugghe, B; Nakashima, K; Takayanagi, H			NFAT and Osterix cooperatively regulate bone formation	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CYCLOSPORINE-A; OSTEOCLAST DIFFERENTIATION; CELLS; FK506; CALCINEURIN; RANKL; TRANSPLANTATION; CHONDROGENESIS	Immunosuppressants are crucial in the prevention of detrimental immune reactions associated with allogenic organ transplantation, but they often cause adverse effects in a number of biological systems, including the skeletal system(1,2). Calcineurin inhibitors FK506 and cyclosporin A inhibit nuclear factor of activated T cells (NFAT) activity and induce strong immunosuppression(3-5). Among NFAT proteins, NFATc1 is crucial for the differentiation of bone-resorbing osteoclasts(6,7). Here we show FK506 administration induces the reduction of bone mass despite a blockade of osteoclast differentiation. This reduction is caused by severe impairment of bone formation, suggesting that NFAT transcription factors also have an important role in the transcriptional program of osteoblasts. In fact, bone formation is inhibited in Nfatc1- and Nfatc2-deficient cells as well as in FK506-treated osteoblasts. Overexpression of NFATc1 stimulates Osterix(8)-dependent activation of the Col1a1 (encoding type I collagen) promoter, but not Runx2-dependent activation of the Bglap1 (encoding osteocalcin) promoter(9). NFAT and Osterix form a complex that binds to DNA, and this interaction is important for the transcriptional activity of Osterix. Thus, NFAT and Osterix cooperatively control osteoblastic bone formation. These results may provide important insight into the management of post-transplantation osteoporosis as well as a new strategy for promoting bone regeneration in osteopenic disease.	Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Med, Dept Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Meguro Ku, Tokyo 1538904, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Texas System; UTMD Anderson Cancer Center; Tokyo Medical & Dental University (TMDU)	Takayanagi, H (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138549, Japan.	taka.csi@tmd.ac.jp		Nakashima, Kazuhisa/0000-0003-0491-2149				BLACKHAM A, 1991, CLIN EXP IMMUNOL, V86, P224; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CVETKOVIC M, 1994, TRANSPLANTATION, V57, P1231, DOI 10.1097/00007890-199404270-00016; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukunaga J, 2004, BONE, V34, P425, DOI 10.1016/j.bone.2003.05.003; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Leidig-Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140-6736(00)03641-2; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rodino MA, 1998, AM J MED, V104, P459, DOI 10.1016/S0002-9343(98)00081-3; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812; Tomita M, 2002, J BIOL CHEM, V277, P42214, DOI 10.1074/jbc.C200504200; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Yocum DE, 2003, ARTHRITIS RHEUM-US, V48, P3328, DOI 10.1002/art.11363; Zhou SH, 2004, J BONE MINER RES, V19, P1732, DOI 10.1359/JBMR.040702	30	358	382	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2005	11	8					880	885		10.1038/nm1270	http://dx.doi.org/10.1038/nm1270			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	951XC	16041384				2022-12-27	WOS:000230964700034
J	Stech, J; Garn, H; Wegmann, M; Wagner, R; Klenk, HD				Stech, J; Garn, H; Wegmann, M; Wagner, R; Klenk, HD			A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin	NATURE MEDICINE			English	Article							FUSION PEPTIDE MUTANTS; A-VIRUS; PROTEOLYTIC CLEAVAGE; INACTIVATED VIRUS; ANTIBODY-RESPONSE; ACTIVATION; MICE; PATHOGENICITY; PROTECTION; INFECTION	A promising approach to reduce the impact of influenza is the use of an attenuated, live virus as a vaccine. Using reverse genetics, we generated a mutant of strain A/WSN/33 with a modified cleavage site within its hemagglutinin, which depends on proteolytic activation by elastase. Unlike the wildtype, which requires trypsin, this mutant is strictly dependent on elastase. Both viruses grow equally well in cell culture. In contrast to the lethal wild-type virus, the mutant is entirely attenuated in mice. At a dose of 10(5) plaque-forming units, it induced complete protection against lethal challenge. This approach allows the conversion of any epidemic strain into a genetically homologous attenuated virus.	Klinikum Philipps Univ Marburg, Inst Virol, D-35011 Marburg, Germany; Klinikum Philipps Univ Marburg, Inst Klin Chem & Mol Diagnost, Biomed Forschungszentrum, D-35033 Marburg, Germany; Paul Ehrlich Inst, Bundesamt Sera & Impfstoffe, D-63225 Langen, Germany	Philipps University Marburg; Philipps University Marburg; Paul Ehrlich Institute	Stech, J (corresponding author), Klinikum Philipps Univ Marburg, Inst Virol, Postfach 2360, D-35011 Marburg, Germany.	stech@med.uni-marburg.de		Garn, Holger/0000-0002-5178-4023; Stech, Juergen/0000-0002-3187-702X; Wegmann, Michael/0000-0002-1658-1554				BELSHE RB, 1992, J INFECT DIS, V165, P727, DOI 10.1093/infdis/165.4.727; Beyer WEP, 2002, VACCINE, V20, P1340, DOI 10.1016/S0264-410X(01)00471-6; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; Cross KJ, 2001, EMBO J, V20, P4432, DOI 10.1093/emboj/20.16.4432; GARTEN W, 1981, VIROLOGY, V115, P361, DOI 10.1016/0042-6822(81)90117-3; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; GRUBER WC, 1998, TXB INFLUENZA, P435; GUNTHER I, 1993, VIRUS RES, V27, P147, DOI 10.1016/0168-1702(93)90078-2; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; HUANG RTC, 1980, VIROLOGY, V104, P294, DOI 10.1016/0042-6822(80)90334-7; Jin H, 2003, VIROLOGY, V306, P18, DOI 10.1016/S0042-6822(02)00035-1; KAWAOKA Y, 1990, VIROLOGY, V179, P759, DOI 10.1016/0042-6822(90)90143-F; KENDAL AP, 1982, CONCEPTS PROCEDURE B, V17, P17; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LAZAROWITZ SG, 1973, VIROLOGY, V56, P172, DOI 10.1016/0042-6822(73)90296-1; MAASSAB HF, 1967, NATURE, V213, P612, DOI 10.1038/213612a0; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MURPHY BR, 1979, INFECT IMMUN, V23, P253, DOI 10.1128/IAI.23.2.253-259.1979; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; O'Neill E, 2000, J GEN VIROL, V81, P2689, DOI 10.1099/0022-1317-81-11-2689; ORLICH M, 1995, J GEN VIROL, V76, P625, DOI 10.1099/0022-1317-76-3-625; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; Ribeiro RM, 1998, AIDS, V12, P461, DOI 10.1097/00002030-199805000-00006; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SCHEIBLAUER H, 1995, ARCH VIROL, V140, P341, DOI 10.1007/BF01309867; SCHERLE PA, 1988, P NATL ACAD SCI USA, V85, P4446, DOI 10.1073/pnas.85.12.4446; SCHOLTISSEK C, 1979, VIROLOGY, V95, P492, DOI 10.1016/0042-6822(79)90503-8; Stech J, 1999, J VIROL, V73, P1878, DOI 10.1128/JVI.73.3.1878-1884.1999; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; Suarez DL, 1998, J VIROL, V72, P6678, DOI 10.1128/JVI.72.8.6678-6688.1998; Takada A, 2003, VACCINE, V21, P3212, DOI 10.1016/S0264-410X(03)00234-2; TAKADA A, 1994, J VET MED SCI, V56, P633, DOI 10.1292/jvms.56.633; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WRIGHT PF, 1975, J PEDIATR-US, V87, P1109, DOI 10.1016/S0022-3476(75)80123-5; YAMNIKOVA SS, 1993, VIROLOGY, V197, P558, DOI 10.1006/viro.1993.1629	39	64	97	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2005	11	6					683	689		10.1038/nm1256	http://dx.doi.org/10.1038/nm1256			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	932YD	15924146	Bronze			2022-12-27	WOS:000229589800037
J	Oliphant, T; Engle, M; Nybakken, GE; Doane, C; Johnson, S; Huang, L; Gorlatov, S; Mehlhop, E; Marri, A; Chung, KM; Ebel, GD; Kramer, LD; Fremont, DH; Diamond, MS				Oliphant, T; Engle, M; Nybakken, GE; Doane, C; Johnson, S; Huang, L; Gorlatov, S; Mehlhop, E; Marri, A; Chung, KM; Ebel, GD; Kramer, LD; Fremont, DH; Diamond, MS			Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus	NATURE MEDICINE			English	Article							JAPANESE ENCEPHALITIS-VIRUS; ENVELOPE PROTEIN; DENGUE VIRUS; DOMAIN-III; DISSEMINATED INFECTION; POLYPEPTIDE LIBRARIES; NUCLEOTIDE-SEQUENCE; IMMUNE-RESPONSE; NEW-YORK; IMMUNOGLOBULIN	Neutralization of West Nile virus (WNV) in vivo correlates with the development of an antibody response against the viral envelope ( E) protein. Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Monoclonal antibodies that strongly neutralized WNV localized to a surface patch on the lateral face of domain III. Convalescent antibodies from individuals who had recovered from WNV infection also detected this epitope. One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when administered as a single dose 5 d after infection. A humanized version of E16 was generated that retained antigen specificity, avidity and neutralizing activity. In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; MacroGenics, Rockville, MD 20850 USA; New York State Dept Hlth, Wadsworth Ctr, Slingerlands, NY 12159 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Wadsworth Center	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8051, St Louis, MO 63110 USA.	diamond@borcim.wustl.edu	Ebel, Gregory/D-8324-2017; Diamond, Michael/AAH-1733-2019; Ebel, Gregory/ABG-1052-2021	Diamond, Michael/0000-0002-8791-3165; Fremont, Daved/0000-0002-8544-2689	NIAID NIH HHS [U01 AI061373, U54 AI057160] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061373, U54AI057160] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Beasley DWC, 2001, VIROLOGY, V279, P447, DOI 10.1006/viro.2000.0721; Ben-Nathan D, 2003, J INFECT DIS, V188, P5, DOI 10.1086/376870; Bhardwaj S, 2001, J VIROL, V75, P4002, DOI 10.1128/JVI.75.8.4002-4007.2001; Boder ET, 1998, BIOTECHNOL PROGR, V14, P55, DOI 10.1021/bp970144q; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; Chambers TJ, 1998, J GEN VIROL, V79, P2375, DOI 10.1099/0022-1317-79-10-2375; Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; DELENDA C, 1994, J GEN VIROL, V75, P1569, DOI 10.1099/0022-1317-75-7-1569; Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Ebel GD, 2004, AM J TROP MED HYG, V71, P493, DOI 10.4269/ajtmh.2004.71.493; Engle MJ, 2003, J VIROL, V77, P12941, DOI 10.1128/JVI.77.24.12941-12949.2003; Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P714; HIETER PA, 1982, J BIOL CHEM, V257, P1516; KABAT E, 1991, SEEQUENCES PROTEINS, P3242; Karabatsos N., 1985, INT CATALOGUE ARBOVI; KIMURAKURODA J, 1988, J IMMUNOL, V141, P3606; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6515, DOI 10.1093/nar/13.18.6515; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6499, DOI 10.1093/nar/13.18.6499; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; LIN B, 1994, VIROLOGY, V202, P885, DOI 10.1006/viro.1994.1410; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Matsuda F, 1998, J EXP MED, V188, P2151, DOI 10.1084/jem.188.11.2151; MEREDITH RF, 1991, J NUCL MED, V32, P1162; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200; Roehrig JT, 2001, ANN NY ACAD SCI, V951, P286; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; TAO MH, 1989, J IMMUNOL, V143, P2595; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Volk DE, 2004, J BIOL CHEM, V279, P38755, DOI 10.1074/jbc.M402385200; Wang T, 2004, CURR OPIN IMMUNOL, V16, P519, DOI 10.1016/j.coi.2004.05.008; Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200; Wu SC, 1997, VIRUS RES, V51, P173, DOI 10.1016/S0168-1702(97)00098-1; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990	47	408	443	2	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2005	11	5					522	530		10.1038/nm1240	http://dx.doi.org/10.1038/nm1240			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923MW	15852016	Green Accepted, Green Published			2022-12-27	WOS:000228915000024
